
@article{ ISI:000288364100005,
Author = {Coutinho, Henrique D. M. and Rodrigues, Fabiola F. G. and Nascimento,
   Eidla M. M. and Costa, Jose G. M. and Falcao-Silva, Vivyanne S. and
   Siqueira-Junior, Jose P.},
Title = {{Synergism of Gentamicin and Norfloxacin with the Volatile Compounds of
   Lippia microphylla Cham. (Verbenaceae)}},
Journal = {{JOURNAL OF ESSENTIAL OIL RESEARCH}},
Year = {{2011}},
Volume = {{23}},
Number = {{2}},
Pages = {{24-28}},
Month = {{MAR-APR}},
Abstract = {{This is the first report of antibiotic modifying activity by the
   volatile compounds from essential oils of Lippia microphylla Cham.
   (Verbenaceae). The leaves of Lip pia microphylla Chain. (Verbenaceae)
   were extracted by hydrodistillation, and the essential oil obtained was
   examined with respect to its effects on the antibiotic activity of
   gentamicin, tetracycline and norfloxacin by minimal inhibitory dose
   method and gaseous contact. The gaseous component of the oil inhibited
   the bacterial growth of the strains of Staphylococcus aureus with a MID
   of 0.5 mg/L air. The activity of gentamicin against Pseudomonas
   aerugionosa and norfloxacin against Staphylococcus aureus 1199B was
   increased by 47\% and 225\%, whereas no effect or an increased
   resistance to tetracycline was observed with an inhibition zone 14.3\%
   smaller after contact with the gaseous component of the essential oil.
   These results show that the volatile compounds of this oil can enhance
   antibiotic activity, which may lead to the development of an adjuvant in
   the antibiotic therapy of multidrug resistant pathogens (MDR) such as
   the respiratory tract bacterial pathogens.}},
Publisher = {{ALLURED PUBL CORP}},
Address = {{362 S SCHMALE RD, CAROL STREAM, IL 60188-2787 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Coutinho, HDM (Reprint Author), Univ Reg Carl, Lab Microbiol \& Biol Mol, Ctr Ciencias Biol \& Saude, Crato, Ceara, Brazil.
   Coutinho, Henrique D. M., Univ Reg Carl, Lab Microbiol \& Biol Mol, Ctr Ciencias Biol \& Saude, Crato, Ceara, Brazil.
   Rodrigues, Fabiola F. G.; Nascimento, Eidla M. M.; Costa, Jose G. M., Univ Reg Carl, Lab Pesquisa Prod Naturais, Ctr Ciencias Biol \& Saude, Crato, Ceara, Brazil.
   Falcao-Silva, Vivyanne S.; Siqueira-Junior, Jose P., Univ Fed Paraiba, Lab Genet Microrganismos, Ctr Ciencias Exatas \& Natureza, BR-58059900 Joao Pessoa, Paraiba, Brazil.}},
ISSN = {{1041-2905}},
Keywords = {{Lippia microphylla; gaseous contact; minimal inhibitory dose;
   Staphylococcus aureus; Pseudomonas aeruginosa}},
Keywords-Plus = {{GRAM-NEGATIVE BACTERIA; ESSENTIAL OILS; ANTIMICROBIAL ACTIVITY;
   STAPHYLOCOCCUS-AUREUS; CHEMICAL-COMPOSITION; CYSTIC-FIBROSIS; EFFLUX
   PUMPS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC-ACTIVITY; PLANT-EXTRACTS}},
Research-Areas = {{Chemistry; Food Science \& Technology}},
Web-of-Science-Categories  = {{Chemistry, Applied; Food Science \& Technology}},
Author-Email = {{hdmcoutinho@gmail.com}},
ResearcherID-Numbers = {{Coutinho, Henrique/E-1046-2013
   Costa, Jose Galberto/L-6022-2016}},
ORCID-Numbers = {{Coutinho, Henrique/0000-0002-6634-4207
   Costa, Jose Galberto/0000-0002-0730-7246}},
Funding-Acknowledgement = {{FUNCAP; FAPESQ; CNPQ}},
Funding-Text = {{Tje authors are grateful to the Brazilian research agencies FUNCAP,
   FAPESQ and CNPQ.}},
Cited-References = {{Abad MJ, 1997, PHYTOTHER RES, V11, P198, DOI 10.1002/(SICI)1099-1573(199705)11:3<198::AID-PTR78>3.0.CO;2-L.
   Adams R. P., 2007, IDENTIFICATION ESSEN.
   Alencar J. W., 1990, QUIM NOVA, V13, P282.
   Bassole IHN, 2003, PHYTOCHEMISTRY, V62, P209, DOI 10.1016/S0031-9422(02)00477-6.
   Burt S, 2004, INT J FOOD MICROBIOL, V94, P223, DOI 10.1016/j.ijfoodmicro.2004.03.022.
   Campana Silvia, 2004, J Cyst Fibros, V3, P159, DOI 10.1016/j.jcf.2004.03.010.
   Cegiela-Carlioz P, 2005, FLAVOUR FRAG J, V20, P671, DOI 10.1002/ffj.1584.
   CHANH RH, 1998, PLANTA MED, V54, P294.
   Costa SMO, 2005, J ESSENT OIL RES, V17, P378, DOI 10.1080/10412905.2005.9698935.
   Costa SMO, 2001, J NAT PROD, V64, P792, DOI 10.1021/np0005917.
   Costa VCO, 2008, REV BRAS FARMACOGN, V18, P245, DOI 10.1590/S0102-695X2008000200019.
   Coutinho HDM, 2010, J YOUNG PHARM, V2, P362, DOI 10.4103/0975-1483.71625.
   COUTINHO HD, 2009, IN VIVO, V23, P289.
   Coutinho HDM, 2008, CHEMOTHERAPY, V54, P328, DOI 10.1159/000151267.
   Coutinho HDM, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-13.
   Coutinho Henrique Douglas M, 2008, Int Arch Med, V1, P24, DOI 10.1186/1755-7682-1-24.
   Edris AE, 2007, PHYTOTHER RES, V21, P308, DOI 10.1002/ptr.2072.
   Ferreira FS, 2009, J ETHNOPHARMACOL, V126, P233, DOI 10.1016/j.jep.2009.08.038.
   FONTENELLE RO, 2008, J APPL MICROBIOL, V104, P1363.
   Forestieri AM, 1996, PHYTOTHER RES, V10, P100, DOI 10.1002/(SICI)1099-1573(199603)10:2<100::AID-PTR724>3.0.CO;2-I.
   Gibbons S, 2003, J ANTIMICROB CHEMOTH, V51, P13, DOI 10.1093/jac/dkg044.
   Gibbons Simon, 2005, Phytochemistry Reviews, V4, P63, DOI 10.1007/s11101-005-2494-9.
   Granowitz EV, 2008, CRIT CARE CLIN, V24, P421, DOI 10.1016/j.ccc.2007.12.011.
   Helander IM, 1998, J AGR FOOD CHEM, V46, P3590, DOI 10.1021/jf980154m.
   Hemaiswarya S, 2008, PHYTOMEDICINE, V15, P639, DOI 10.1016/j.phymed.2008.06.008.
   Hendry ER, 2009, J ANTIMICROB CHEMOTH, V64, P1219, DOI 10.1093/jac/dkp362.
   Inouye S, 2001, J ANTIMICROB CHEMOTH, V47, P565, DOI 10.1093/jac/47.5.565.
   Jana S, 2006, APPL MICROBIOL BIOT, V70, P140, DOI 10.1007/s00253-005-0279-0.
   Jedlickova Z, 1992, J Hyg Epidemiol Microbiol Immunol, V36, P303.
   Juven J., 1994, J APPL BACTERIOL, V76, P626.
   LEMOS TLG, 1990, PHYTOTHER RES, V4, P82, DOI 10.1002/ptr.2650040210.
   Mann CM, 2000, LETT APPL MICROBIOL, V30, P294, DOI 10.1046/j.1472-765x.2000.00712.x.
   Marquez B, 2005, BIOCHIMIE, V87, P1137, DOI 10.1016/j.biochi.2005.04.012.
   MARTIN DW, 1993, P NATL ACAD SCI USA, V90, P8377, DOI 10.1073/pnas.90.18.8377.
   Matos F.J.A., 1998, REV BRAS FARM, V79, P84.
   MOLEYAR V, 1986, Food Microbiology (London), V3, P331, DOI 10.1016/0740-0020(86)90017-1.
   Nguefack J, 2004, LETT APPL MICROBIOL, V39, P395, DOI 10.1111/j.1472-765X.2004.01587.x.
   Nicolson K, 1999, FEMS MICROBIOL LETT, V179, P233, DOI 10.1016/S0378-1097(99)00417-6.
   Pascual ME, 2001, J ETHNOPHARMACOL, V76, P201, DOI 10.1016/S0378-8741(01)00234-3.
   Piddock LJV, 2006, CLIN MICROBIOL REV, V19, P382, DOI 10.1128/CMR.19.2.382-402.2006.
   Poole K, 2005, J ANTIMICROB CHEMOTH, V56, P20, DOI 10.1093/jac/dki171.
   Rodrigues FFG, 2010, INDIAN J MED RES, V131, P833.
   Rodrigues FFG, 2009, PHYTOMEDICINE, V16, P1052, DOI 10.1016/j.phymed.2009.04.004.
   Saiman L, 1996, CLIN INFECT DIS, V23, P532, DOI 10.1093/clinids/23.3.532.
   Santos NKA, 2011, MED CHEM RES, V20, P637, DOI 10.1007/s00044-010-9372-8.
   Schmidt E., 2005, Journal of Essential Oil-Bearing Plants, V8, P99.
   SoutoBachiller FA, 1997, PHYTOCHEMISTRY, V44, P1077, DOI 10.1016/S0031-9422(96)00691-7.
   Tassou CC, 1995, INT BIODETER BIODEGR, V36, P411, DOI 10.1016/0964-8305(95)00103-4.
   VALENTIN A, 1995, PHYTOCHEMISTRY, V40, P1439, DOI 10.1016/0031-9422(95)00522-9.
   Valenza G, 2008, J CYST FIBROS, V7, P123, DOI 10.1016/j.jcf.2007.06.006.
   Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018.
   Waikedre J, 2010, CHEM BIODIVERS, V7, P871, DOI 10.1002/cbdv.200900196.
   WENDAKOON CN, 1995, J FOOD PROTECT, V58, P280, DOI 10.4315/0362-028X-58.3.280.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Essent. Oil Res.}},
Doc-Delivery-Number = {{734UD}},
Unique-ID = {{ISI:000288364100005}},
DA = {{2018-08-13}},
}

@article{ ISI:000287702500009,
Author = {Cho, Hyun-Jong and Choi, Min-Koo and Lin, Hongxia and Kim, Jung Sun and
   Chung, Suk-Jae and Shim, Chang-Koo and Kim, Dae-Duk},
Title = {{Expression and functional activity of P-glycoprotein in passaged primary
   human nasal epithelial cell monolayers cultured by the air-liquid
   interface method for nasal drug transport study}},
Journal = {{JOURNAL OF PHARMACY AND PHARMACOLOGY}},
Year = {{2011}},
Volume = {{63}},
Number = {{3}},
Pages = {{385-391}},
Month = {{MAR}},
Abstract = {{Objectives
   P-glycoprotein (P-gp) is an efflux transporter encoded by the multidrug
   resistance gene (MDR1), which is also known as the human ABCB1 gene
   (ATP-binding cassette, subfamily-B). The objectives of this study were
   to investigate the expression of P-gp in passaged primary human nasal
   epithelial (HNE) cell monolayer, cultured by the air-liquid interface
   (ALI) method, and to evaluate its feasibility as an in-vitro model for
   cellular uptake and transport studies of P-gp substrates.
   Methods
   Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed
   to verify the expression of the MDR1 gene. Transport and cellular uptake
   studies with P-gp substrate (rhodamine123) and P-gp inhibitors
   (verapamil and cyclosporin A) were conducted to assess the functional
   activity of P-gp in HNE cell monolayers cultured by the ALI method.
   Key findings
   MDR1 gene expression in primary HNE cell monolayers cultured by ALI
   method was confirmed by RT-PCR. The apparent permeability coefficient
   (P-app) of the P-gp substrate (rhodamine123) in the basolateral to
   apical (B to A) direction was 6.9 times higher than that in the apical
   to basolateral (A to B) direction. B to A transport was saturated at
   high rhodamine123 concentration, and the treatment of P-gp inhibitors
   increased cellular uptake of rhodamine123 in a time- and
   concentration-dependent manner.
   Conclusions
   These results support the MDR1 gene expression and the functional
   activity of P-gp in primary HNE cell monolayers cultured by the ALI
   method.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kim, DD (Reprint Author), Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   Cho, Hyun-Jong; Lin, Hongxia; Chung, Suk-Jae; Shim, Chang-Koo; Kim, Dae-Duk, Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   Cho, Hyun-Jong; Lin, Hongxia; Chung, Suk-Jae; Shim, Chang-Koo; Kim, Dae-Duk, Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul, South Korea.
   Choi, Min-Koo, Dankook Univ, Coll Pharm, Cheonan, South Korea.
   Kim, Jung Sun, Dongseo Univ, Div Hlth Sci, Pusan, South Korea.}},
DOI = {{10.1111/j.2042-7158.2010.01221.x}},
ISSN = {{0022-3573}},
Keywords = {{P-glycoprotein; human nasal epithelial cell monolayer; in-vitro models;
   nasal drug delivery}},
Keywords-Plus = {{INTRANASAL DELIVERY; RHODAMINE-123; RESISTANCE; CACO-2; MDR1;
   HYDROCHLORIDE; SUBSTRATE; CALU-3; RATS; PUMP}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{ddkim@snu.ac.kr}},
ResearcherID-Numbers = {{Kim, Dae Duk/D-8864-2013}},
Funding-Acknowledgement = {{Ministry of Commerce, Industry and Energy (MOCIE) in Korea {[}10031825];
   Korean government (MEST) {[}20090083533]}},
Funding-Text = {{This work was supported by the Industrial Source Technology Development
   Program funded by the Ministry of Commerce, Industry and Energy (MOCIE)
   in Korea (Grant no. 10031825) and by the National Research Foundation
   (NRF) grant funded by the Korean government (MEST) (No. 20090083533).}},
Cited-References = {{Agu RU, 2009, J PHARM PHARMACOL, V61, P599, DOI 10.1211/jpp/61.05.0008.
   BATES DA, 1985, CANCER RES, V45, P4895.
   Brouillard F, 2001, CANCER RES, V61, P1693.
   Costantino HR, 2007, INT J PHARMACEUT, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025.
   Ehrhardt C, 2003, PHARMACEUT RES, V20, P545, DOI 10.1023/A:1023230328687.
   Endter S, 2007, CELL TISSUE RES, V328, P77, DOI 10.1007/s00441-006-0346-6.
   Florea BI, 2001, BRIT J PHARMACOL, V134, P1555, DOI 10.1038/sj.bjp.0704390.
   Graff CL, 2005, PHARM RES, V22, P86, DOI 10.1007/s11095-004-9013-3.
   Graff CL, 2003, PHARMACEUT RES, V20, P1225, DOI 10.1023/A:1025053115583.
   Hamilton KO, 2001, J PHARM SCI, V90, P647, DOI 10.1002/1520-6017(200105)90:5<647::AID-JPS1021>3.0.CO;2-G.
   Huh Y, 2010, EUR J PHARM SCI, V40, P9, DOI 10.1016/j.ejps.2010.02.002.
   Itagaki F, 2004, BIOL PHARM BULL, V27, P1694, DOI 10.1248/bpb.27.1694.
   Jintapattanakit A, 2010, J PHARM PHARMACOL, V62, P583, DOI {[}10.1211/jpp.62.05.0004, 10.1211/jpp/62.05.0004].
   Khan S, 2009, J PHARM PHARMACOL, V61, P669, DOI 10.1211/jpp/61.05.0017.
   LechaptZalcman E, 1997, EUR RESPIR J, V10, P1837, DOI 10.1183/09031936.97.10081837.
   Lee MJ, 2005, J SOC GYNECOL INVEST, V12, p299A.
   Lin HX, 2007, J PHARM SCI-US, V96, P341, DOI 10.1002/jps.20803.
   Lin HX, 2005, EUR J PHARM SCI, V26, P203, DOI 10.1016/j.ejps.2005.06.003.
   Mallants R, 2009, J PHARM PHARMACOL, V61, P883, DOI 10.1211/jpp/61.07.0007.
   Merkle HP, 1998, ADV DRUG DELIV REV, V29, P51.
   O'Connor R, 2007, ANTICANCER RES, V27, P1267.
   Seeger MA, 2009, BBA-PROTEINS PROTEOM, V1794, P725, DOI 10.1016/j.bbapap.2008.12.004.
   Shilling RA, 2006, TRENDS PHARMACOL SCI, V27, P195, DOI 10.1016/j.tips.2006.02.008.
   Shyeilla V D, 2010, J PHARM SCI, V99, P1654.
   THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735.
   Troutman MD, 2003, PHARMACEUT RES, V20, P1192, DOI 10.1023/A:1025096930604.
   Ugwoke MI, 2005, ADV DRUG DELIVER REV, V57, P1640, DOI 10.1016/j.addr.2005.07.009.
   van der Sandt ICJ, 2000, EUR J PHARM SCI, V11, P207, DOI 10.1016/S0928-0987(00)00097-X.
   Wioland MA, 2000, J HISTOCHEM CYTOCHEM, V48, P1215, DOI 10.1177/002215540004800905.
   Yoo JW, 2003, PHARMACEUT RES, V20, P1690, DOI 10.1023/A:1026112107100.
   Yumoto R, 1999, J PHARMACOL EXP THER, V289, P149.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Pharm. Pharmacol.}},
Doc-Delivery-Number = {{726ES}},
Unique-ID = {{ISI:000287702500009}},
DA = {{2018-08-13}},
}

@article{ ISI:000287114400005,
Author = {Perez, Hernando R. and Johnson, Rachel and Gurian, Patrick L. and Gibbs,
   Shawn G. and Taylor, Jennifer and Burstyn, Igor},
Title = {{Isolation of Airborne Oxacillin-Resistant Staphylococcus aureus from
   Culturable Air Samples of Urban Residences}},
Journal = {{JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE}},
Year = {{2011}},
Volume = {{8}},
Number = {{2}},
Pages = {{80-85}},
Month = {{FEB}},
Abstract = {{Culturable single-stage impactor samples were collected onto nutrient
   agar in kitchen and bedroom areas of eight urban and four suburban
   residences in Philadelphia, Pennsylvania. Staphylococcus aureus colonies
   were identified by replica plating of the original impactor samples onto
   Chapman Stone medium followed by isolation of up to eight colonies for
   coagulase testing. Kirby-Bauer disk diffusion method was utilized to
   evaluate S. aureus resistance to both oxacillin and cefaclor The median
   concentrations of total culturable bacteria observed in bedrooms and
   trash areas were 300 CFU/m(3) and 253 CFU/m(3), respectively. Median
   culturable Staphylococcus spp. concentrations in bedrooms and trash
   areas were 142 CFU/m(3) and 204 CFU/m(3), respectively. A total of 148
   individual S. aureus colonies were isolated and tested for antibiotic
   resistance. Cefaclor resistance was encountered among only 6 of the 148
   (4\%) colonies. Nearly one-quarter of all S. aureus isolates tested
   displayed resistance (n = 30) or intermediate resistance (n = 5) to
   oxacillin. Twenty-six percent (n = 20) of trash area isolates and 21\%
   (n = 15) of bedroom isolates displayed resistance or intermediate
   resistance to oxacillin. The median difference in percent resistance
   between trash and bedroom areas was 10\% (p = 0.1). Results suggest that
   there may be a systematic difference in bacterial populations between
   downtown and suburban residences. Storage of household waste and
   handling of food may contribute to presence of the organism in the air
   of residences.}},
Publisher = {{TAYLOR \& FRANCIS INC}},
Address = {{325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Perez, HR (Reprint Author), Drexel Univ, Sch Publ Hlth, Dept Environm \& Occupat Hlth, 1505 Race St,Bellet Bldg,13th Floor, Philadelphia, PA 19102 USA.
   Perez, Hernando R.; Johnson, Rachel; Taylor, Jennifer; Burstyn, Igor, Drexel Univ, Sch Publ Hlth, Dept Environm \& Occupat Hlth, Philadelphia, PA 19102 USA.
   Gurian, Patrick L., Drexel Univ, Coll Engn, Dept Civil Architectural \& Environm Engn, Philadelphia, PA 19102 USA.
   Gibbs, Shawn G., Univ Nebraska Med Ctr, Coll Publ Hlth, Dept Environm Agr \& Occupat Hlth, Omaha, NE USA.}},
DOI = {{10.1080/15459624.2010.515552}},
ISSN = {{1545-9624}},
Keywords = {{antibiotic resistance; bioaerosols; indoor air; MRSA; residential;
   Staphylococcus aureus}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; FOOD ANIMALS; ANTIBIOTIC-RESISTANCE; ORGANIC
   DUST; HUMAN HEALTH; TRANSMISSION; HUMANS; INFECTIONS; EXPOSURE; BACTERIA}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Author-Email = {{hrp22@drexel.edu}},
ResearcherID-Numbers = {{Gurian, Patrick/A-8365-2013}},
ORCID-Numbers = {{Gurian, Patrick/0000-0001-7456-9740}},
Funding-Acknowledgement = {{Department of Homeland Security {[}2007-ST-104-000004]}},
Funding-Text = {{A This work was supported by Department of Homeland Security Grant
   2007-ST-104-000004. The views and conclusions contained in this document
   are those of the authors and should not be interpreted as necessarily
   representing the official policies, either expressed or implied, of the
   U.S. Department of Homeland Security.}},
Cited-References = {{Aarestrup FM, 1999, MICROBES INFECT, V1, P639, DOI 10.1016/S1286-4579(99)80064-1.
   COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050.
   Conly J, 2002, CAN MED ASSOC J, V167, P885.
   Dansby W, 2008, J BURN CARE RES, V29, P331, DOI 10.1097/BCR.0b013e3181667583.
   Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184.
   EFSA (European Food Safety Authority), 2009, EFSAQ200900612.
   Elston DM, 2007, J AM ACAD DERMATOL, V56, P1, DOI 10.1016/j.jaad.2006.04.018.
   Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252.
   Gandara A, 2006, ENVIRON HEALTH PERSP, V114, P1859, DOI 10.1289/ehp.9585.
   GORAK EJ, 1999, CLIN INFECT DIS, V29.
   Guardabassi L, 2004, J ANTIMICROB CHEMOTH, V54, P321, DOI 10.1093/jac/dkh332.
   Herr CEW, 2004, INT ARCH OCC ENV HEA, V77, P90, DOI 10.1007/s00420-003-0489-7.
   Herr CEW, 2004, AM J IND MED, V46, P381, DOI 10.1002/ajim.20073.
   Kourbatova EV, 2005, AM J INFECT CONTROL, V33, P385, DOI 10.1016/j.ajic.2005.06.006.
   LEDERBERG J, 1952, J BACTERIOL, V63, P399.
   Lee JH, 2003, APPL ENVIRON MICROB, V69, P6489, DOI {[}10.1128/AEM.69.11.6489-6494.2003, 10.1128/AEM.69.11.6489-6496.2003].
   Lis DO, 2009, AM J INFECT CONTROL, V37, P177, DOI 10.1016/j.ajic.2008.09.013.
   McEwen SA, 2002, CLIN INFECT DIS, V34, pS93, DOI 10.1086/340246.
   Moschandreas DJ, 2003, AEROSOL SCI TECH, V37, P899, DOI 10.1080/02786820390229039.
   Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976.
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064.
   Nienhoff U, 2009, J ANTIMICROB CHEMOTH, V64, P660, DOI 10.1093/jac/dkp243.
   Normanno G, 2007, INT J FOOD MICROBIOL, V117, P219, DOI 10.1016/j.ijfoodmicro.2007.04.006.
   Perez HR, 2006, INDOOR BUILT ENVIRON, V15, P207, DOI 10.1177/1420326X06066427.
   Phillips I, 2004, J ANTIMICROB CHEMOTH, V53, P28, DOI 10.1093/jac/dkg483.
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051.
   Shiomori T, 2001, ARCH OTOLARYNGOL, V127, P644, DOI 10.1001/archotol.127.6.644.
   Silbergeld EK, 2008, ANNU REV PUBL HEALTH, V29, P151, DOI 10.1146/annurev.publhealth.29.020907.090904.
   Smith RD, 2002, B WORLD HEALTH ORGAN, V80, P126.
   Van Loo IHM, 2007, EMERG INFECT DIS, V13, P1753, DOI 10.3201/eid1311.070358.
   Virk A, 2000, MAYO CLIN PROC, V75, P200.
   Woodford N, 2005, CLIN MICROBIOL INFEC, V11, P2, DOI 10.1111/j.1469-0691.2005.01140.x.
   Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016/S1473-3099(05)70112-2.
   LAB DETECTION OXACIL.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{17}},
Journal-ISO = {{J. Occup. Environ. Hyg.}},
Doc-Delivery-Number = {{718IL}},
Unique-ID = {{ISI:000287114400005}},
DA = {{2018-08-13}},
}

@article{ ISI:000287288300003,
Author = {Zheng, Zirui and Li, Junyan and Sun, Jing and Song, Ting and Wei,
   Congwen and Zhang, Yanhong and Rao, Guirong and Chen, Guangming and Li,
   DeChao and Yang, Gongming and Han, Bao and Wei, Shi and Cao, Cheng and
   Zhong, Hui},
Title = {{Inhibition of HBV replication by theophylline}},
Journal = {{ANTIVIRAL RESEARCH}},
Year = {{2011}},
Volume = {{89}},
Number = {{2}},
Pages = {{149-155}},
Month = {{FEB}},
Abstract = {{We have suggested recently that ATM-Rad3-Related (AIR) DNA damage
   signaling pathway, which responds to single-strand breaks in DNA, was
   activated in response to HBV infection. ATR knockdown cells showed
   decreased HBV DNA yields, implying HBV infection and replication
   activate and exploit the activated DNA damage response. Host cell
   proteins may constitute an attractive target for anti-HBV-1
   therapeutics, since development of drug resistance against compounds
   targeting these cellular cofactor proteins is unlikely. In this study,
   we show that one of the clinically used compounds of AIR and ataxia
   telangiectasia-mutated (ATM) kinases inhibitor, theophylline (Tp),
   significantly reduced the yield of HBV DNA, HBsAg and HBeAg in HepG2215
   cell culture system, furthermore, Tp could also suppress serum HBV DNA
   and HBsAg levels in the HBV-transgenic mice. Consistent with this
   result, immunohistology also showed reduced intensity of HBsAg staining
   on livers from Tp-treatment group. Taken together, these data indicated
   the feasibility of therapeutic approaches that target host cell proteins
   by inhibiting a cellular gene that was required for HBV replication and
   provided a potential approach for the prevention and treatment of HBV
   infection. Crown Copyright (C) 2010 Published by Elsevier B.V. All
   rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Wei, S (Reprint Author), Jilin Univ, Key Lab Mol Enzymol \& Engn, Changchun 130021, Peoples R China.
   Zheng, Zirui; Wei, Shi, Jilin Univ, Key Lab Mol Enzymol \& Engn, Changchun 130021, Peoples R China.
   Zheng, Zirui; Song, Ting; Wei, Congwen; Zhang, Yanhong; Cao, Cheng; Zhong, Hui, Beijing Inst Biotechnol, State Key Lab Pathogen \& Biosecur, Beijing 100850, Peoples R China.
   Rao, Guirong; Chen, Guangming, 458 Hosp PLA, PLA Liver Dis Res Ctr, Guangzhou 510600, Guangdong, Peoples R China.
   Li, Junyan; Li, DeChao, Jiamusi Univ, Jiamusi 154007, Peoples R China.
   Sun, Jing; Yang, Gongming; Han, Bao, Beijing Publ Secur Hosp, Beijing 100121, Peoples R China.}},
DOI = {{10.1016/j.antiviral.2010.12.004}},
ISSN = {{0166-3542}},
Keywords = {{Theophylline; DNA damage signaling pathway; HBV transgenic mice}},
Keywords-Plus = {{HEPATITIS-B-VIRUS; DNA-DAMAGE RESPONSE; INFECTION; REPAIR; ATM; COMPLEX}},
Research-Areas = {{Pharmacology \& Pharmacy; Virology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Virology}},
Author-Email = {{shiw@jlu.edu.cn
   cao\_c@yahoo.com
   towall@yahoo.com}},
Funding-Acknowledgement = {{NSFC {[}30772605, 30700413, 30870500, 30871276]; Beijing Natural Science
   Foundation {[}7092081]}},
Funding-Text = {{This work was supported in part by NSFC Grant 30772605, 30700413,
   30870500 and 30871276 and was supported in part by Beijing Natural
   Science Foundation 7092081.}},
Cited-References = {{BAKKENIST, 2004, CELL, V118, P9.
   BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532.
   Chou YC, 2005, J VIROL, V79, P1813, DOI 10.1128/JVI.79.3.1813-1823.2005.
   Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100.
   Gao LF, 2004, WORLD J GASTROENTERO, V10, P841.
   Gaspar M, 2006, P NATL ACAD SCI USA, V103, P2821, DOI 10.1073/pnas.0511148103.
   Kar P, 2009, ANTIVIR RES, V84, P249, DOI 10.1016/j.antiviral.2009.09.013.
   Kudoh A, 2005, J BIOL CHEM, V280, P8156, DOI 10.1074/jbc.M411405200.
   Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250.
   Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x.
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406.
   Li D, 2005, J MED VIROL, V76, P203, DOI 10.1002/jmv.20353.
   Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005.
   Locarnini S, 2004, SEMIN LIVER DIS, V24, P3, DOI 10.1055/s-2004-828672.
   Nunnari G, 2005, VIROLOGY, V335, P177, DOI 10.1016/j.virol.2005.02.015.
   Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200.
   Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723.
   SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005.
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011.
   Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863.
   Wilkinson DE, 2006, J CELL SCI, V119, P2695, DOI 10.1242/jcs.02981.
   Wong SN, 2006, CURR OPIN GASTROEN, V22, P241.
   Zhao F, 2008, WORLD J GASTROENTERO, V14, P6163, DOI 10.3748/wjg.14.6163.
   Zhao F, 2008, WORLD J GASTROENTERO, V14, P5059, DOI 10.3748/wjg.14.5059.
   Zimmerman ES, 2006, J VIROL, V80, P10407, DOI 10.1128/JVI.01212-06.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Antiviral Res.}},
Doc-Delivery-Number = {{720NV}},
Unique-ID = {{ISI:000287288300003}},
DA = {{2018-08-13}},
}

@article{ ISI:000286470800017,
Author = {Sun, Peng and Sun, Yi and Wu, Haiyan and Zhu, Weidong and Lopez, Jose L.
   and Liu, Wei and Zhang, Jue and Li, Ruoyu and Fang, Jing},
Title = {{Atmospheric pressure cold plasma as an antifungal therapy}},
Journal = {{APPLIED PHYSICS LETTERS}},
Year = {{2011}},
Volume = {{98}},
Number = {{2}},
Month = {{JAN 10}},
Abstract = {{A microhollow cathode based, direct-current, atmospheric pressure,
   He/O(2) (2\%) cold plasma microjet was used to inactive antifungal
   resistants Candida albicans, Candida krusei, and Candida glabrata in air
   and in water. Effective inactivation (>90\%) was achieved in 10 min in
   air and 1 min in water. Antifungal susceptibility tests showed drastic
   reduction of the minimum inhibitory concentration after plasma
   treatment. The inactivation was attributed to the reactive oxygen
   species generated in plasma or in water. Hydroxyl and singlet molecular
   oxygen radicals were detected in plasma-water system by electron spin
   resonance spectroscopy. This approach proposed a promising clinical
   dermatology therapy. (C) 2011 American Institute of Physics.
   {[}doi:10.1063/1.3530434]}},
Publisher = {{AMER INST PHYSICS}},
Address = {{CIRCULATION \& FULFILLMENT DIV, 2 HUNTINGTON QUADRANGLE, STE 1 N O 1,
   MELVILLE, NY 11747-4501 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Liu, W (Reprint Author), Peking Univ, Dept Dermatol \& Venerol, Hosp 1, Beijing 100034, Peoples R China.
   Sun, Yi; Liu, Wei; Li, Ruoyu, Peking Univ, Dept Dermatol \& Venerol, Hosp 1, Beijing 100034, Peoples R China.
   Sun, Yi; Liu, Wei; Li, Ruoyu, Peking Univ, Res Ctr Med Mycol, Beijing 100034, Peoples R China.
   Sun, Peng; Wu, Haiyan; Zhang, Jue; Fang, Jing, Peking Univ, Coll Engn, Beijing 100871, Peoples R China.
   Zhang, Jue; Fang, Jing, Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.
   Zhu, Weidong; Lopez, Jose L., St Peters Coll, Dept Appl Sci \& Technol, Jersey City, NJ 07306 USA.
   Zhu, Weidong; Lopez, Jose L., St Peters Coll, Ctr Microplasma Sci \& Technol, Jersey City, NJ 07306 USA.}},
DOI = {{10.1063/1.3530434}},
Article-Number = {{021501}},
ISSN = {{0003-6951}},
Keywords-Plus = {{BACILLUS-SUBTILIS SPORES; AIR PLASMA; DIAPER DERMATITIS; INACTIVATION;
   TEMPERATURE; BACTERIA; CANDIDA; MICROJET}},
Research-Areas = {{Physics}},
Web-of-Science-Categories  = {{Physics, Applied}},
Author-Email = {{liuw90@yahoo.com
   zhangjue@pku.edu.cn}},
ResearcherID-Numbers = {{Zhang, Jue/E-2067-2014
   Sun, Peter/H-8154-2013}},
ORCID-Numbers = {{Sun, Peter/0000-0001-5681-6621}},
Funding-Acknowledgement = {{Bioelectrics Inc. (U.S.A.) {[}2007CB935602]; China International Science
   and Technology Cooperation {[}2008KR1330]; U.S. Air Force Office of
   Scientific Research (AFOSR) {[}FA9550-08-1-0332]}},
Funding-Text = {{P.S. and Y.S. contributed equally to this work. This research was
   sponsored by the Bioelectrics Inc. (U.S.A.), National Basic Research
   Program (Grant No. 2007CB935602, and the China International Science and
   Technology Cooperation (Grant No. 2008KR1330). The development of the
   PMJ device was funded in part by the Electro-Energetic Physics Program
   of the U.S. Air Force Office of Scientific Research (AFOSR) under Grant
   No. FA9550-08-1-0332. The acknowledgment is also made to the donors of
   the American Chemical Society Petroleum Research Fund for the partial
   support of this research.}},
Cited-References = {{BAI N, PLASMA PROC IN PRESS.
   Choi Hee Kyoung, 2009, Korean Journal of Internal Medicine, V24, P263, DOI 10.3904/kjim.2009.24.3.263.
   Cuellar-Cruz M, 2008, EUKARYOT CELL, V7, P814, DOI 10.1128/EC.00011-08.
   Deng XT, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2103394.
   Deng XT, 2006, IEEE T PLASMA SCI, V34, P1310, DOI 10.1109/TPS.2006.877739.
   Dorko E, 2003, FOLIA MICROBIOL, V48, P385, DOI 10.1007/BF02931371.
   Feng HQ, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3491180.
   Feng HQ, 2009, IEEE T PLASMA SCI, V37, P121, DOI 10.1109/TPS.2008.2008438.
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090-006-9024-4.
   FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525.
   Hawser SP, 1998, J CLIN MICROBIOL, V36, P1450.
   HIDEG E, 1994, PHOTOSYNTH RES, V39, P191, DOI 10.1007/BF00029386.
   Ikawa S, 2010, PLASMA PROCESS POLYM, V7, P33, DOI 10.1002/ppap.200900090.
   Jiang CQ, 2009, PLASMA PROCESS POLYM, V6, P479, DOI 10.1002/ppap.200800133.
   Kolb JF, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2940325.
   Laroussi M, 2002, APPL PHYS LETT, V81, P772, DOI 10.1063/1.1494863.
   Laroussi M, 2002, IEEE T PLASMA SCI, V30, P1409, DOI 10.1109/TPS.2002.804220.
   Lee HW, 2009, J ENDODONT, V35, P587, DOI 10.1016/j.joen.2009.01.008.
   Liu FX, 2010, PLASMA PROCESS POLYM, V7, P231, DOI 10.1002/ppap.200900070.
   Lu XP, 2009, IEEE T PLASMA SCI, V37, P668, DOI 10.1109/TPS.2009.2015454.
   Mann PA, 2009, ANTIMICROB AGENTS CH, V53, P5026, DOI 10.1128/AAC.01031-09.
   National Committee for Clinical Laboratory Standards, 2008, M27A3 NCCLS.
   Nield LS, 2007, CLIN PEDIATR, V46, P480, DOI 10.1177/0009922806292409.
   Noda Y, 2009, NEUROCHEM RES, V34, P734, DOI 10.1007/s11064-008-9811-9.
   Nosenko T, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115013.
   Shi XM, 2008, IEEE T PLASMA SCI, V36, P498, DOI 10.1109/TPS.2008.917515.
   Sun P, 2010, IEEE T PLASMA SCI, V38, P1892, DOI 10.1109/TPS.2009.2039585.
   Zaoutis TE, 2005, CLIN INFECT DIS, V41, P1232, DOI 10.1086/496922.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{38}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{19}},
Journal-ISO = {{Appl. Phys. Lett.}},
Doc-Delivery-Number = {{709VZ}},
Unique-ID = {{ISI:000286470800017}},
DA = {{2018-08-13}},
}

@article{ ISI:000294642700050,
Author = {Fox, Gregory J. and Dobler, Claudia C. and Marks, Guy B.},
Title = {{Active case finding in contacts of people with tuberculosis}},
Journal = {{COCHRANE DATABASE OF SYSTEMATIC REVIEWS}},
Year = {{2011}},
Number = {{9}},
Abstract = {{Background
   Tuberculosis is a major global health challenge that is caused by a
   bacteria which is spread by airborne droplets. Mostly patients are
   identified in high- burden countries when they visit health care
   facilities ('passive case finding'). Contacts of tuberculosis patients
   are a high- risk group for developing the disease. Actively screening
   contacts of people with confirmed tuberculosis may improve case
   detection rates and control of the disease.
   Objectives
   This study aims to compare whether active case finding among contacts of
   people with confirmed tuberculosis increases case detection compared to
   usual practice.
   Search strategy
   In April 2011 we searched CENTRAL ( T h e Cochrane Library 2011, Issue
   2), MEDLINE, EMBASE, LILACS and mRCT. We also checked article reference
   lists, the International Journal of Tuberculosis and Lung Disease and
   contacted relevant researchers and organizations.
   Selection criteria
   Randomized and quasi- randomized trials of active case finding to detect
   tuberculosis disease among close and casual contacts of patients with
   microbiologically proven pulmonary tuberculosis ( by sputum smear and/or
   culture).
   Data collection and analysis
   Two authors independently assessed eligibility and the methodological
   quality of the trials that were extracted using a search method that was
   outlined previously.
   Main results
   No trials met the inclusion criteria for this review. One RCT did test
   the effect of active case finding in contacts, but the intervention in
   that trial also included screening for, and treatment of, LTBI in
   contacts; and the separate effect of active case finding could not be
   estimated.
   Authors' conclusions
   There are currently insufficient data from randomized controlled trials
   or quasi-randomized controlled trials to evaluate the effect of active
   case finding for tuberculosis among contacts of patients with confirmed
   disease. While observational studies show that contacts have a higher
   risk of developing tuberculosis than the general population, further
   research is needed to determine whether active case finding among
   contacts significantly increases case detection rates.}},
Publisher = {{WILEY}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Fox, GJ (Reprint Author), Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2050, Australia.
   Fox, Gregory J.; Dobler, Claudia C.; Marks, Guy B., Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2050, Australia.}},
DOI = {{10.1002/14651858.CD008477.pub2}},
Article-Number = {{CD008477}},
ISSN = {{1469-493X}},
EISSN = {{1361-6137}},
Keywords-Plus = {{RANDOMIZED CONTROLLED-TRIAL; RESOURCE-LIMITED SETTINGS; PULMONARY
   TUBERCULOSIS; LATENT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS;
   INFECTIOUS TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY; EDUCATIONAL OUTREACH;
   MULTIDRUG-RESISTANT; HOUSEHOLD CONTACTS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{greg.fox@sydney.edu.au}},
ORCID-Numbers = {{Dobler, Claudia/0000-0002-5460-0189}},
Funding-Acknowledgement = {{National Health and Medical Research Council (NHMRC); NHMRC, Australia;
   Department for International Development (DFID), UK}},
Funding-Text = {{External sources; Greg Fox is supported by a National Health and Medical
   Research Council (NH\&MRC) Postgraduate Research Scholarship and an
   NH\&MRC Project Grant, Australia.; The authors are grateful to our
   affiliated Institutions and Organizations, and thank the referees and
   editors for their comments and encouragement. The editorial base for the
   Cochrane Infectious Disease Group is funded by the Department for
   International Development (DFID), UK, for the benefit of low-and
   middle-income countries.}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   Anthony RM, 2009, INT J TUBERC LUNG D, V13, P1051.
   Aparicio JP, 2000, J THEOR BIOL, V206, P327, DOI 10.1006/jtbi.2000.2129.
   Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236.
   Bauer J, 1998, J CLIN MICROBIOL, V36, P305.
   Becerra MC, 2005, PUBLIC HEALTH REP, V120, P271, DOI 10.1177/003335490512000309.
   Becerra MC, 2011, LANCET, V377, P147, DOI 10.1016/S0140-6736(10)61972-1.
   Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847.
   Breen RAM, 2008, INT J TUBERC LUNG D, V12, P44.
   Cavalcante SC, 2010, INT J TUBERC LUNG D, V14, P203.
   CHAN W, 1971, B WORLD HEALTH ORGAN, V45, P551.
   Churchyard GJ, 2011, THORAX, V66, P134, DOI 10.1136/thx.2010.139048.
   Claessens NJM, 2002, INT J TUBERC LUNG D, V6, P266.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Corbett EL, 2010, LANCET, V376, P1244, DOI 10.1016/S0140-6736(10)61425-0.
   Daitko DG, 2009, PLOS ONE, V4, pe5443.
   Diel R, 2002, J CLIN MICROBIOL, V40, P532, DOI 10.1128/JCM.40.2.532-539.2002.
   Diel R, 2006, EUR RESPIR J, V28, P35, DOI 10.1183/09031936.06.00011806.
   Etkind S, 2000, TUBERCULOSIS COMPREH.
   Fairall L, 2010, TROP MED INT HEALTH, V15, P277, DOI 10.1111/j.1365-3156.2009.02455.x.
   Fairall LR, 2005, BRIT MED J, V331, P750, DOI 10.1136/bmj.331.7519.750.
   Fok A, 2008, INT J TUBERC LUNG D, V12, P480.
   Greenaway C, 2003, INT J TUBERC LUNG D, V7, pS479.
   Griffiths C, 2007, LANCET, V369, P1528, DOI 10.1016/S0140-6736(07)60707-7.
   Gutierrez MC, 1998, J CLIN MICROBIOL, V36, P486.
   Houben RMGJ, 2009, INT J TUBERC LUNG D, V13, P275.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   Khan MS, 2007, LANCET, V369, P1955, DOI 10.1016/S0140-6736(07)60916-7.
   Kranzer K, 2010, LANCET INFECT DIS, V10, P93, DOI 10.1016/S1473-3099(09)70326-3.
   Kruk A, 2008, PEDIATRICS, V121, pE1646, DOI 10.1542/peds.2007-3138.
   Lemos Antonio Carlos, 2004, Braz J Infect Dis, V8, P424, DOI 10.1590/S1413-86702004000600006.
   LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193.
   Long NH, 2001, HEALTH POLICY, V58, P69, DOI 10.1016/S0168-8510(01)00143-9.
   Magkanas E, 2005, INT J TUBERC LUNG D, V9, P865.
   Marks GB, 2000, AM J RESP CRIT CARE, V162, P1851, DOI 10.1164/ajrccm.162.5.2004154.
   Marks SM, 2000, AM J RESP CRIT CARE, V162, P2033, DOI 10.1164/ajrccm.162.6.2004022.
   Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006.
   Miller AC, 2010, INT J TUBERC LUNG D, V14, P720.
   Monkongdee P, 2009, AM J RESP CRIT CARE, V180, P903, DOI 10.1164/rccm.200905-0692OC.
   Morrison J, 2008, LANCET INFECT DIS, V8, P359, DOI 10.1016/S1473-3099(08)70071-9.
   Noertjojo K, 2002, INT J TUBERC LUNG D, V6, P19.
   Ormerod P, 2000, THORAX, V55, P887.
   Steingart K, 2006, LANCET INFECT DIS, V6, P570, DOI 10.1016/S1473-3099(06)70578-3.
   Rieder H L, 2003, Int J Tuberc Lung Dis, V7, P333.
   Sekandi JN, 2009, INT J TUBERC LUNG D, V13, P508.
   Shargie EB, 2006, B WORLD HEALTH ORGAN, V84, P112, DOI 10.2471/BLT.05.024489.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   STYBLO K, 1984, TUBERCLE, V65, P237, DOI 10.1016/0041-3879(84)90034-5.
   Taylor Zachary, 2005, Morbidity and Mortality Weekly Report, V54, P1.
   Tsukishima Eri, 2007, Kekkaku, V82, P459.
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930.
   VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R.
   Verver S, 2004, LANCET, V363, P212, DOI 10.1016/S0140-6736(03)15332-9.
   Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2.
   Wallis RS, 2010, LANCET, V375, P1920, DOI 10.1016/S0140-6736(10)60359-5.
   Ward HA, 2004, INT J TUBERC LUNG D, V8, P593.
   {*}WHO, 2004, GUID HIV SURV TUB PA.
   WHO, GLOB TUB CONTR 2010.
   {*}WHO, STOP TB STRAT BUILD.
   World Health Organization, 2008, WHO 3 IS M REP JOINT.
   World Health Organization, GLOB TUB CONTR SHORT.
   World Health Organization, 2006, INT STAND TUB CAR DI.
   World Health Organization. Regional office for Europe, 2001, TB MAN NAT TUB PROGR, P6.
   Wrighton-Smith P, 2006, EUR RESPIR J, V28, P45, DOI 10.1183/09031936.06.00005906.
   Yimer S, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-454.
   Zachariah R, 2003, INT J TUBERC LUNG D, V7, P1033.}},
Number-of-Cited-References = {{66}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Cochrane Database Syst Rev.}},
Doc-Delivery-Number = {{817AH}},
Unique-ID = {{ISI:000294642700050}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000283221800001,
Author = {Naidoo, Kogieleum and Naidoo, Kasavan and Padayatchi, Nesri and Karim,
   Quarraisha Abdool},
Title = {{HIV-Associated Tuberculosis}},
Journal = {{CLINICAL \& DEVELOPMENTAL IMMUNOLOGY}},
Year = {{2011}},
Abstract = {{The intersecting HIV and Tuberculosis epidemics in countries with a high
   disease burden of both infections pose many challenges and
   opportunities. For patients infected with HIV in high TB burden
   countries, the diagnosis of TB, ARV drug choices in treating HIV-TB
   coinfected patients, when to initiate ARV treatment in relation to TB
   treatment, managing immune reconstitution, minimising risk of getting
   infected with TB and/or managing recurrent TB, minimizing airborne
   transmission, and infection control are key issues. In addition, given
   the disproportionate burden of HIV in women in these settings, sexual
   reproductive health issues and particular high mortality rates
   associated with TB during pregnancy are important. The scaleup and
   resource allocation to access antiretroviral treatment in these high HIV
   and TB settings provide a unique opportunity to strengthen both services
   and impact positively in meeting Millennium Development Goal 6.}},
Publisher = {{HINDAWI LTD}},
Address = {{ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Naidoo, K (Reprint Author), Univ KwaZulu Natal, CAPRISA Treatment Res Program, Ctr AIDS Programme Res S Africa CAPRISA, ZA-4013 Durban, South Africa.
   Naidoo, Kogieleum; Naidoo, Kasavan; Padayatchi, Nesri; Karim, Quarraisha Abdool, Univ KwaZulu Natal, CAPRISA Treatment Res Program, Ctr AIDS Programme Res S Africa CAPRISA, ZA-4013 Durban, South Africa.
   Padayatchi, Nesri; Karim, Quarraisha Abdool, Univ KwaZulu Natal, Dept Publ Hlth \& Family Med, ZA-4013 Durban, South Africa.
   Karim, Quarraisha Abdool, Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.}},
DOI = {{10.1155/2011/585919}},
Article-Number = {{585919}},
ISSN = {{1740-2522}},
EISSN = {{1740-2530}},
Keywords-Plus = {{RECONSTITUTION INFLAMMATORY SYNDROME; ISONIAZID PREVENTIVE THERAPY;
   ACTIVE ANTIRETROVIRAL THERAPY; RESOURCE-LIMITED SETTINGS;
   MULTIDRUG-RESISTANT TUBERCULOSIS; HEALTH-CARE WORKERS; SUB-SAHARAN
   AFRICA; INFECTED PATIENTS; PULMONARY TUBERCULOSIS; SOUTH-AFRICA}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{naidook45@ukzn.ac.za}},
ORCID-Numbers = {{Abdool Karim, Quarraisha/0000-0002-0985-477X
   padayatchi, nesri/0000-0003-2543-9071
   Naidoo, Kogieleum/0000-0002-8874-6661}},
Cited-References = {{Ait-Khaled N, 2009, INT J TUBERC LUNG D, V13, P927.
   Akolo C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000171.pub3.
   Albert H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-41.
   BASSETT ICS, 2009, INTENSIVE TB SCREENI.
   BHAT GJ, 1993, J TROP PEDIATRICS, V39, P219, DOI 10.1093/tropej/39.4.219.
   BOCK NN, 1996, J INFECT DIS S1, V196, pS108.
   Breen RAM, 2005, AIDS, V19, P1201, DOI 10.1097/01.aids.0000176221.33237.67.
   Breton G, 2004, CLIN INFECT DIS, V39, P1709, DOI 10.1086/425742.
   CHURCHYARD GJ, 1996, J INFECT DIS S1, V196, pS52.
   CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770.
   Dautremer J, 2007, AIDS, V21, P381, DOI 10.1097/QAD.0b013e328011981a.
   de Pinho AMF, 2001, AIDS, V15, P2129, DOI 10.1097/00002030-200111090-00008.
   Dhasmana DJ, 2008, DRUGS, V68, P191, DOI 10.2165/00003495-200868020-00004.
   Dheda K, 2010, LANCET, V375, P1798, DOI 10.1016/S0140-6736(10)60492-8.
   Dheda K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009848.
   {*}DOH, 2010, PROV LAUNCH THEIR HI.
   EDWARDS DVM, 2009, BASELINE SCREENING T.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Escombe AR, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000043.
   Eshun-Wilson Ingrid, 2010, J Int Assoc Physicians AIDS Care (Chic), V9, P104, DOI 10.1177/1545109710361537.
   First MW, 2005, J OCCUP ENVIRON HYG, V2, P285, DOI 10.1080/1545962059095224.
   Fitzgerald DW, 2000, LANCET, V356, P1470, DOI 10.1016/S0140-6736(00)02870-1.
   Foster S, 1997, AIDS, V11, P919, DOI 10.1097/00002030-199707000-00012.
   FRANCIS J, 2007, CURRY NATL TUBERCULO.
   French MA, 2004, AIDS, V18, P1615, DOI 10.1097/01.aids.0000131375.21070.06.
   Gamage B, 2005, AM J INFECT CONTROL, V33, P114, DOI 10.1016/j.ajic.2004.12.002.
   Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC.
   Golub JE, 2007, AIDS, V21, P1441, DOI 10.1097/QAD.0b013e328216f441.
   Golub JE, 2009, AIDS, V23, P631, DOI 10.1097/QAD.0b013e328327964f.
   Grange J, 2010, INT J GYNECOL OBSTET, V108, P181, DOI 10.1016/j.ijgo.2009.12.005.
   GREENBERG SD, 1994, RADIOLOGY, V193, P115, DOI 10.1148/radiology.193.1.7916467.
   HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537.
   Helb D, 2010, J CLIN MICROBIOL, V48, P229, DOI 10.1128/JCM.01463-09.
   Howard AA, 2010, CLIN INFECT DIS, V50, pS238, DOI 10.1086/651497.
   Humphreys H, 2007, J HOSP INFECT, V66, P1, DOI 10.1016/j.jhin.2007.01.007.
   {*}IUAT, 1982, B WORLD HEALTH ORGAN, V60, P555.
   John L, 2005, AIDS, V19, P2049, DOI 10.1097/01.aids.0000191922.08938.12.
   Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848.
   Khan M, 2001, AIDS, V15, P1857, DOI 10.1097/00002030-200109280-00016.
   Kirk O, 2000, AM J RESP CRIT CARE, V162, P865, DOI 10.1164/ajrccm.162.3.9908018.
   Korenromp EL, 2003, CLIN INFECT DIS, V37, P101, DOI 10.1086/375220.
   Kumarasamy N, 2004, JAIDS-J ACQ IMM DEF, V37, P1574, DOI 10.1097/00126334-200412150-00007.
   Lawn SD, 2005, LANCET INFECT DIS, V5, P361, DOI 10.1016/S1473-3099(05)70140-7.
   Lawn SD, 2005, AIDS, V19, P1113, DOI 10.1097/01.aids.0000176211.08581.5a.
   Lawn SD, 2007, AIDS, V21, P335, DOI 10.1097/QAD.0b013e328011efac.
   LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005.
   Maher D, 2005, TROP MED INT HEALTH, V10, P734, DOI 10.1111/j.1365-3156.2005.01456.x.
   Mallory KF, 2000, INT J TUBERC LUNG D, V4, P455.
   MCILLERON H, 1996, J INFECT DIS S1, V196, pS63.
   Meintjes G, 2008, LANCET INFECT DIS, V8, P516, DOI 10.1016/S1473-3099(08)70184-1.
   Migliori GB, 2008, CAN J INFECT DIS MED, V19, P169, DOI 10.1155/2008/857901.
   Moore D, 2005, AM J INFECT CONTROL, V33, P88, DOI 10.1016/j.ajic.2004.11.003.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Mosimaneotsile B, 2010, JAIDS-J ACQ IMM DEF, V54, P71, DOI 10.1097/QAI.0b013e3181c3cbf0.
   Muller M, 2010, LANCET INFECT DIS, V10, P251, DOI 10.1016/S1473-3099(10)70026-8.
   Mutetwa R, 2009, INT J TUBERC LUNG D, V13, P1253.
   Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014.
   Narita M, 1998, AM J RESP CRIT CARE, V158, P157, DOI 10.1164/ajrccm.158.1.9712001.
   O'Donnell MR, 2009, INT J TUBERC LUNG D, V13, P855.
   Onyebujoh PC, 2007, J INFECT DIS, V196, pS35, DOI 10.1086/518657.
   PADAYATCHI N, 2010, UNPUB.
   Pepper T, 2008, INT J TUBERC LUNG D, V12, P397.
   Perlman DC, 1997, CLIN INFECT DIS, V25, P242, DOI 10.1086/514546.
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204.
   Ramogale MR, 2007, SAMJ S AFR MED J, V97, P363.
   Reid MJA, 2009, LANCET INFECT DIS, V9, P173, DOI 10.1016/S1473-3099(09)70043-X.
   ROSCIGNO G, 2009, DRUG RESISTANT TB NE.
   Samb B, 1999, INT J TUBERC LUNG D, V3, P330.
   SCAAF H, 2009, TUBERCULOSIS COMPREH, P179.
   Shelburne Samuel A. III, 2003, AIDS Reviews, V5, P67.
   Sonnenberg P, 2001, LANCET, V358, P1687, DOI 10.1016/S0140-6736(01)06712-5.
   {*}UNAIDS, 2008, 2008 REP GLOB AIDS E.
   Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8.
   Walters E, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-1.
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665.
   WHO, 2008, GLOB TUB CONTR SURV.
   WHO, 2004, INT POL COLL TB HIV.
   {*}WHO, 1998, POL STAT PREV THER T.
   {*}WHO, 2006, GUID NAT TB PROGR NT.
   WOLDEHANNA S, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000171.PUB2.
   World Health Organization, 2009, WHO POL TB INF CONTR.
   World Health Organization, 2007, GUID PROV IN HIV TES.
   World Health Organization, 2009, GLOB TUB CONTR EP ST.
   Zar HJ, 2007, BRIT MED J, V334, P136, DOI 10.1136/bmj.39000.486400.55.
   Zumla A, 2009, LANCET INFECT DIS, V9, P197, DOI 10.1016/S1473-3099(09)70045-3.
   1999, WEEKLY EPIDEMIOLOGIC, V74, P385.}},
Number-of-Cited-References = {{86}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Dev. Immunol.}},
Doc-Delivery-Number = {{667UT}},
Unique-ID = {{ISI:000283221800001}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000287529600005,
Author = {Sarma, J. B. and Bhattacharya, P. K. and Kalita, D. and Rajbangshi, M.},
Title = {{Multidrug-resistant Enterobacteriaceae including metallo-beta-lactamase
   producers are predominant pathogens of healthcare-associated infections
   in an Indian teaching hospital}},
Journal = {{INDIAN JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{2011}},
Volume = {{29}},
Number = {{1}},
Pages = {{22-27}},
Month = {{JAN-MAR}},
Abstract = {{Purpose: A study was carried out in an Indian teaching hospital in 2009
   to detect the rate of surgical site infections (SSI) and peripheral
   vascular access site infections. Materials and Methods: The study was a
   point-prevalence study involving over 300 patients. The presence of
   infection was determined according to the CDC criteria. Swabs were taken
   from the infected sites and identification and sensitivity were carried
   out using VITEK (R) 2 automated system. Characterisation of
   beta-lactamase was carried out at ARRML, Colindale, London. Results: The
   rate of SSI was 15\% for the clean and clean-contaminated categories
   while that for the dirty contaminated category was 85\% (NNIS risk index
   0). Cultures yielded definite or probable pathogens from 64\% (9/14) of
   the patients with SSI. In 1/3(rd) of the cultures, Staphylococcus aureus
   was grown and the rest had Enterobacteriaceae, either extended-spectrum
   beta-lactamase (ESBL) producers or Amp-C hyperproducers and, alarmingly,
   three isolates were positive for newly recognised New Delhi
   metallo-beta-lactamase-1 (NDM-1). In medicine, 87\% (n = 99) of the
   patients had a peripheral IV access device, 55\% developed associated
   phlebitis/infection and, in seven, probable pathogens were isolated
   (Candida species and Escherichia coli producing ESBL and NDM-1,
   respectively, Staphylococcus aureus and Enterococcus faecium). All ESBL
   and metallo-beta-lactamase producers were resistant to multiple classes
   of antimicrobials, the latter being sensitive only to colistin and
   tigecycline. The study also found that all post-operative patients were
   on antibiotics, 92\% on IV {[}213 defined daily doses (DDD)/100 post-op
   patients] limited mainly to the third-generation cephalosporins (26\%)
   and aminoglycosides (24\%) and imidazole derivatives (30\%). In
   medicine, 83\% (n = 82) were on IV antibiotics (123 DDD/100 bed-days),
   limited mainly to the third-generation cephalosporins (74\%).
   Conclusion: Indiscriminate use of antibiotics is a major problem
   predisposing patients to harm by multi-resistant pathogens. Carbapenems
   were in little use in this hospital, but the selection pressure exerted
   by cephalosporins and other unrelated classes was sufficient to select
   NDM-1-producing strains due to co-selection, suggesting a role of single
   plasmid carrying resistance genes to multiple classes.}},
Publisher = {{MEDKNOW PUBLICATIONS \& MEDIA PVT LTD}},
Address = {{B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bhattacharya, P. K.; Kalita, D.; Rajbangshi, M., Guwahati Med Coll, Bhangagarh 781032, Guwahati, India.}},
DOI = {{10.4103/0255-0857.76519}},
ISSN = {{0255-0857}},
EISSN = {{1998-3646}},
Keywords = {{healthcare-associated infections; surgical site infections;
   extended-spectrum beta-lactamase; metallo-beta-lactamase;
   meticillin-resistant S. aureus}},
Keywords-Plus = {{SURGICAL WOUND-INFECTION; CTX-M; RISK; ENVIRONMENT; PREVALENCE;
   AIRBORNE; RATES}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Author-Email = {{jayanta.sarma@nhs.net}},
Funding-Acknowledgement = {{North East Clinical Excellence Foundation, Guwahati, Assam}},
Funding-Text = {{Source of Support: North East Clinical Excellence Foundation, Guwahati,
   Assam.}},
Cited-References = {{Anderson DJ, 2008, INFECT CONT HOSP EP, V29, pS51, DOI 10.1086/591064.
   AYLIFFE GAJ, 1991, REV INFECT DIS, V13, pS800.
   Boyce John M, 2002, MMWR Recomm Rep, V51, P1.
   Canton R, 2006, CURR OPIN MICROBIOL, V9, P466, DOI 10.1016/j.mib.2006.08.011.
   CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z.
   Dharan S, 2002, J HOSP INFECT, V51, P79, DOI 10.1053/jhin.2002.1217.
   DRAKE CT, 1977, ANN SURG, V185, P219, DOI 10.1097/00000658-197702000-00015.
   Gaynes RP, 2001, CLIN INFECT DIS, V33, pS69, DOI 10.1086/321860.
   Hawkey PM, 2008, CLIN MICROBIOL INFEC, V14, P159, DOI 10.1111/j.1469-0691.2007.01855.x.
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002.
   Humphreys H, 2002, J HOSP INFECT, V50, P85, DOI 10.1053/jhin.2001.1126.
   Kumarasamy KK, 2010, LANCET INFECT DIS, V10, P597, DOI 10.1016/S1473-3099(10)70143-2.
   Livermore DM, 2007, J ANTIMICROB CHEMOTH, V59, P165, DOI 10.1093/jac/dkl483.
   Livermore DM, 2009, J ANTIMICROB CHEMOTH, V64, P29, DOI 10.1093/jac/dkp255.
   Madeo M, 1996, Br J Theatre Nurs, V6, P29.
   {*}NAT I HLTH CLIN E, 2008, NAT I HLTH CLIN EX C, V74.
   Sarma JB, 2010, INDIAN J MED MICROBI, V28, P217, DOI 10.4103/0255-0857.66476.
   Sarma JB, 2010, INDIAN J MED MICROBI, V28, P127, DOI 10.4103/0255-0857.62489.
   Sarma JB, 2010, INDIAN J MED MICROBI, V28, P11, DOI 10.4103/0255-0857.58721.
   {*}SCOTT INT GUID NE, 2008, SCOTT INT GUID NETW, V104.
   Tarrant F, 2007, J ANTIMICROB CHEMOTH, V59, P815, DOI 10.1093/jac/dkl559.
   Walsh TR, 2007, J ANTIMICROB CHEMOTH, V59, P799, DOI 10.1093/jac/dkl532.
   WHYTE W, 1992, J HOSP INFECT, V22, P41, DOI 10.1016/0195-6701(92)90129-A.
   2009, ARMRL NEWS, V23, P1.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Indian J. Med. Microbiol.}},
Doc-Delivery-Number = {{723TJ}},
Unique-ID = {{ISI:000287529600005}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000289182200004,
Author = {Hankiewicz-Ziolkowska, Karolina and Gospodarek, Eugenia},
Title = {{Stenotrophomonas maltophilia - characteristics and the pathogenesis of
   infection}},
Journal = {{POSTEPY MIKROBIOLOGII}},
Year = {{2011}},
Volume = {{50}},
Number = {{1}},
Pages = {{43-50}},
Month = {{JAN-MAR}},
Abstract = {{Stenotrophomonas maltophilia an opportunistic Gram-negative bacillus,
   which is becoming increasingly recognized as an important nosocomial
   pathogen especially in debilitated or immune suppressed patients. S.
   maltophilia is found in a wide variety of environments. It has been
   isolated from water sources, soil, variety of plants, including wheat,
   corn, bananas, tobacco, and food such as milk, eggs and frozen fish. S.
   maltophilia can form biofilm on synthetic materials for temporary or
   permanent implantats i.e., central venous catheters, urinary catheters
   and prosthetic heart valves.
   In hospitals, the micro-organism has been isolated from wet environments
   such as antiseptic fluids containing chlorhexsidine, respiratory therapy
   equipment and air nebulizers.
   Little is known of the virulence factors of S. maltophilia. S.
   maltophilia is naturally resistant to many currently available
   broad-spectrum antimicrobial agents. Particularly noteworthy is the
   resistance to carbapenems mediated by beta-lactamase L1 and multidrug
   resistance mediated by efflux pumps.
   Treatment of infections caused by this microorganism is difficult as the
   bacterium is resistant to a wide range of commonly used antibiotics.
   Trimethoprim-sulphamethoxazole is recommended as the agent of choice for
   the treatment of S. maltophilia infections. However, the development of
   resistance to this antibiotic represents a challenge to clinicians.}},
Publisher = {{POLSKIE TOWARZYSTWO MIKROBIOLOGOW-POLISH SOCIETY OF MICROBIOLOGISTS}},
Address = {{CHELMSKA STR 30-34, WARSAW, 00-725, POLAND}},
Type = {{Article}},
Language = {{Polish}},
Affiliation = {{Hankiewicz-Ziolkowska, K (Reprint Author), Uniwersytetu Mikolaja Kopernika Toruniu, Coll Med Luclwika Rydygiera Bydgoszczy, Katedra \& Zaklad Mikrobiol, Ul M Sklodowskiej Curie 9, PL-80094 Bydgoszcz, Poland.
   Hankiewicz-Ziolkowska, Karolina; Gospodarek, Eugenia, Uniwersytetu Mikolaja Kopernika Toruniu, Coll Med Luclwika Rydygiera Bydgoszczy, Katedra \& Zaklad Mikrobiol, PL-80094 Bydgoszcz, Poland.}},
ISSN = {{0079-4252}},
Keywords = {{infections; resistance to antibiotics; Stenotrophomonas maltophilia;
   trimethoprim-sulphametoxazole}},
Keywords-Plus = {{MULTIPLE ANTIBIOTIC-RESISTANCE; BETA-LACTAMASE EXPRESSION; GRAM-NEGATIVE
   BACILLI; CARE-UNIT PATIENTS; XANTHOMONAS-MALTOPHILIA;
   PSEUDOMONAS-MALTOPHILIA; ANTIMICROBIAL SUSCEPTIBILITY;
   PERITONEAL-DIALYSIS; RISK-FACTORS; HUGH 1981}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{kizmikrob@cm.umk.pl}},
ResearcherID-Numbers = {{Gospodarek, Eugenia/H-2511-2014}},
Cited-References = {{Alonso A, 1997, ANTIMICROB AGENTS CH, V41, P1140.
   ARELLA M, 1979, CAN J MICROBIOL, V25, P321, DOI 10.1139/m79-051.
   Aznar R., 1992, Systematic and Applied Microbiology, V14, P235.
   Barbolla R, 2004, ANTIMICROB AGENTS CH, V48, P666, DOI 10.1128/AAC.48.2.666-669.2004.
   BOLLET C, 1995, APPL ENVIRON MICROB, V61, P1653.
   Coenye T, 2004, INT J SYST EVOL MICR, V54, P1235, DOI 10.1099/ijs.0.63093-0.
   Crossman LC, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r74.
   Denton M, 1998, CLIN MICROBIOL REV, V11, P57.
   DENTON M, 20 EUR CYST FIBR C 1.
   Drancourt M, 1997, INT J SYST BACTERIOL, V47, P160, DOI 10.1099/00207713-47-1-160.
   ELTING LS, 1990, MEDICINE, V69, P296, DOI 10.1097/00005792-199009000-00003.
   Falagas ME, 2009, EUR J CLIN MICROBIOL, V28, P719, DOI 10.1007/s10096-009-0709-5.
   Falagas ME, 2008, J ANTIMICROB CHEMOTH, V62, P889, DOI 10.1093/jac/dkn301.
   Fedler KA, 2006, DIAGN MICR INFEC DIS, V56, P427, DOI 10.1016/j.diagmicrobio.2006.07.003.
   FREDERIKSEN B, 1995, PEDIAT PULMON S, V12, P287.
   Gould VC, 2006, J ANTIMICROB CHEMOTH, V57, P199, DOI 10.1093/jac/dki453.
   GUERZONI ME, 1994, MICROBIOL RES, V149, P115, DOI 10.1016/S0944-5013(11)80105-9.
   Gutierrez F, 1996, CLIN INFECT DIS, V23, P1261.
   Hanes SD, 2002, CLIN INFECT DIS, V35, P228, DOI 10.1086/341022.
   HEATH T, 1995, J HOSP INFECT, V30, P309, DOI 10.1016/0195-6701(95)90266-X.
   Horster S, 2009, INFECTION, V37, P117, DOI 10.1007/s15010-008-8150-8.
   HUGH R, 1961, J GEN MICROBIOL, V26, P123.
   HUGH R, 1963, INT B BACT NOMENCL T, V13, P133, DOI 10.1099/0096266X-13-3-133.
   IOSIFIDIS E, 2010, EUR J PEDIATR, V196, P867.
   Jang Tsrang-Neng, 1992, Journal of the Formosan Medical Association, V91, P1170.
   Jucker BA, 1996, J BACTERIOL, V178, P5472, DOI 10.1128/jb.178.18.5472-5479.1996.
   JUFFS HS, 1973, J APPL BACTERIOL, V36, P585, DOI 10.1111/j.1365-2672.1973.tb04145.x.
   JUHNKE ME, 1989, APPL ENVIRON MICROB, V55, P747.
   JUHNKE ME, 1987, APPL ENVIRON MICROB, V53, P2793.
   Kerr KG, 1996, EUR J CLIN MICROBIOL, V15, P607, DOI 10.1007/BF01709373.
   KERR KG, 1994, 94 GEN M A S M WASH.
   KING BA, 1978, J ANTIMICROB CHEMOTH, V4, P467, DOI 10.1093/jac/4.5.467-a.
   KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655.
   Lai CH, 2006, CLIN MICROBIOL INFEC, V12, P986, DOI 10.1111/j.1469-0691.2006.01511.x.
   LESCOBORNET M, 1992, ANTIMICROB AGENTS CH, V36, P669.
   Liaw SJ, 2010, INT J ANTIMICROB AG, V35, P126, DOI 10.1016/j.ijantimicag.2009.09.015.
   Lockhart SR, 2007, J CLIN MICROBIOL, V45, P3352, DOI 10.1128/JCM.01284-07.
   Muder RR, 1996, CLIN INFECT DIS, V22, P508, DOI 10.1093/clinids/22.3.508.
   NARASIMHAN SL, 1977, AM J CLIN PATHOL, V68, P304, DOI 10.1093/ajcp/68.2.304.
   Nicodemo AC, 2007, EUR J CLIN MICROBIOL, V26, P229, DOI 10.1007/s10096-007-0279-3.
   NORD CE, 1975, MED MICROBIOL IMMUN, V161, P79, DOI 10.1007/BF02121748.
   O'BRIEN M, 1981, Microbios Letters, V16, P41.
   OBRIEN M, 1982, J CLIN MICROBIOL, V16, P417.
   PALLERONI NJ, 1993, INT J SYST BACTERIOL, V43, P606, DOI 10.1099/00207713-43-3-606.
   PAPAPETROPOULOU M, 1994, J CHEMOTHERAPY, V6, P111.
   ROSENTHAL SL, 1974, AM J CLIN PATHOL, V62, P807.
   ROSTA S, 1989, J BACTERIOL, V171, P483, DOI 10.1128/jb.171.1.483-487.1989.
   RYAN PR, 2009, NATURE, V7, P514.
   Sader HS, 2005, INT J ANTIMICROB AG, V25, P95, DOI 10.1016/j.ijantimicag.2004.10.002.
   SADER HS, 1994, J ANTIMICROB CHEMOTH, V33, P615, DOI 10.1093/jac/33.3.615.
   SAINO Y, 1982, ANTIMICROB AGENTS CH, V22, P564, DOI 10.1128/AAC.22.4.564.
   SAINO Y, 1984, ANTIMICROB AGENTS CH, V25, P362, DOI 10.1128/AAC.25.3.362.
   Sanchez P, 2004, ANTIMICROB AGENTS CH, V48, P2274, DOI 10.1128/AAC.48.6.2274-2276.2004.
   Shimizu K, 2008, ANTIMICROB AGENTS CH, V52, P3823, DOI 10.1128/AAC.00026-08.
   SIERRA M, 1995, ARCH LEBENSMITTELHYG, V46, P20.
   SWINGS J, 1983, INT J SYST BACTERIOL, V33, P409, DOI 10.1099/00207713-33-2-409.
   Szeto CC, 1997, AM J KIDNEY DIS, V29, P91, DOI 10.1016/S0272-6386(97)90013-5.
   TABER TE, 1991, PERITON DIALYSIS INT, V11, P213.
   Toleman MA, 2007, EMERG INFECT DIS, V13, P559, DOI 10.3201/eid1304.061378.
   VANHOOF R, 1995, J ANTIMICROB CHEMOTH, V35, P167, DOI 10.1093/jac/35.1.167.
   VARTIVARIAN SE, 1994, ANN INTERN MED, V121, P969, DOI 10.7326/0003-4819-121-12-199412150-00011.
   VICTOR MA, 1994, SCAND J INFECT DIS, V26, P163, DOI 10.3109/00365549409011780.
   VILLARINO ME, 1992, INFECT CONT HOSP EP, V13, P201.
   Wasaznik A, 2009, POSTEP HIG MED DOSW, V63, P123.
   WILCOX MH, 1994, J ANTIMICROB CHEMOTH, V33, P663, DOI 10.1093/jac/33.3.663.
   WISHART MM, 1976, MED J AUSTRALIA, V2, P710.
   Zhang L, 2000, ANTIMICROB AGENTS CH, V44, P287, DOI 10.1128/AAC.44.2.287-293.2000.
   ZURAVLEFF JJ, 1982, REV INFECT DIS, V4, P1236.}},
Number-of-Cited-References = {{68}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Postep. Mikrobiol.}},
Doc-Delivery-Number = {{745RB}},
Unique-ID = {{ISI:000289182200004}},
DA = {{2018-08-13}},
}

@article{ ISI:000285763000002,
Author = {Jamrozik, Euzebiusz and Musk, Arthur William},
Title = {{Respiratory health issues in the Asia-Pacific region: An overview}},
Journal = {{RESPIROLOGY}},
Year = {{2011}},
Volume = {{16}},
Number = {{1}},
Pages = {{3-12}},
Month = {{JAN}},
Abstract = {{The Asia-Pacific region is home to a large heterogeneous population
   whose respiratory health is influenced by diverse social, economic and
   environmental factors. Despite this variability, the most prevalent
   causes of respiratory morbidity and mortality are tobacco smoking,
   infection, and air pollution. This review aims to summarize current
   respiratory health issues in the region including smoking-related
   diseases especially COPD, lung cancer and infectious problems such as
   pandemic influenza, the severe acute respiratory syndrome coronavirus,
   bacterial pneumonia and tuberculosis, as well as the contribution of air
   pollution to respiratory disease. Published data on trends in the
   epidemiology and management of respiratory diseases and are summarized;
   finally, the limitations of available data and projections for the
   future of respiratory health in the region are discussed.}},
Publisher = {{WILEY}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Jamrozik, E (Reprint Author), Sir Charles Gairdner Hosp, Busselton Hlth Study, Dept Resp Med, B Block,Hosp Ave, Perth, WA 6009, Australia.
   Jamrozik, Euzebiusz, Sir Charles Gairdner Hosp, Busselton Hlth Study, Dept Resp Med, Perth, WA 6009, Australia.
   Jamrozik, Euzebiusz; Musk, Arthur William, Univ Western Australia, Fac Med \& Dent, Perth, WA 6009, Australia.
   Jamrozik, Euzebiusz; Musk, Arthur William, Busselton Populat Med Res Fdn, Busselton, WA, Australia.}},
DOI = {{10.1111/j.1440-1843.2010.01844.x}},
ISSN = {{1323-7799}},
EISSN = {{1440-1843}},
Keywords = {{air pollution; Asia-Pacific; environmental and occupational health and
   epidemiology; tobacco; tuberculosis; viral infection}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; COMMUNITY-ACQUIRED PNEUMONIA; RANDOMIZED
   CONTROLLED-TRIAL; PANDEMIC INFLUENZA VACCINE; LUNG-CANCER;
   AIR-POLLUTION; SMOKING-CESSATION; GLOBAL BURDEN; HYGIENE HYPOTHESIS;
   SOUTHEAST-ASIA}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{zeb.jamrozik@gmail.com}},
ORCID-Numbers = {{Jamrozik, Euzebiusz/0000-0001-5940-602X}},
Cited-References = {{Abu-Raddad LJ, 2009, P NATL ACAD SCI USA, V106, P13980, DOI 10.1073/pnas.0901720106.
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211.
   Andersen P, 2007, NAT REV MICROBIOL, V5, P484, DOI 10.1038/nrmicro1703.
   Barzi F, 2008, TOB CONTROL, V17, P166, DOI 10.1136/tc.2007.023457.
   Becklake MR, 2007, INT J TUBERC LUNG D, V11, P356.
   Bell ML, 2005, EPIDEMIOLOGY, V16, P436, DOI 10.1097/01.ede.0000165817.40152.85.
   Bishop JF, 2009, NEW ENGL J MED, V361, P2591, DOI 10.1056/NEJMp0910445.
   Blanc RD, 2007, INT J TUBERC LUNG D, V11, P251.
   Braman SS, 2006, CHEST, V130, p1S, DOI 10.1378/chest.130.1\_suppl.1S.
   Bremner PR, 1998, AM J RESP CRIT CARE, V158, P1724, DOI 10.1164/ajrccm.158.6.9702068.
   Cain KR, 2007, INT J TUBERC LUNG D, V11, P1008.
   Cheng YW, 2001, CANCER RES, V61, P2799.
   Chiang CY, 2010, RESPIROLOGY, V15, P413, DOI 10.1111/j.1440-1843.2010.01738.x.
   Cohen AJ, 2005, J TOXICOL ENV HEAL A, V68, P1301, DOI 10.1080/15287390590936166.
   Cohen D, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c2912.
   Cohen T, 2008, AM J RESP CRIT CARE, V177, P1302, DOI 10.1164/rccm.200801-175PP.
   Coker R, 2006, LANCET, V368, P886, DOI 10.1016/S0140-6736(06)69209-X.
   Costelloe C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2096.
   Cotes J.E., 2006, LUNG FUNCTION.
   De Klerk NH, 2002, MESOTHELIOMA, P339.
   Dennekamp M, 2011, RESPIROLOGY, V16, P198, DOI 10.1111/j.1440-1843.2010.01868.x.
   Dheda K, 2010, RESPIROLOGY, V15, P433, DOI 10.1111/j.1440-1843.2010.01739.x.
   Doshi P, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b5164.
   Driscoll T, 2005, AM J IND MED, V48, P419, DOI 10.1002/ajim.20209.
   Emanuel EJ, 2003, ANN INTERN MED, V139, P589, DOI 10.7326/0003-4819-139-7-200310070-00011.
   Espinal MA, 2001, INT J TUBERC LUNG D, V5, P887.
   Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017.
   Fletcher CM, 1976, NATURAL HIST CHRONIC.
   Fok AOL, 2009, CURR OPIN ALLERGY CL, V9, P116, DOI 10.1097/ACI.0b013e3283292256.
   Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4.
   Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605.
   Higuchi K, 2008, RESPIROLOGY, V13, P468, DOI 10.1111/j.1440-1843.2008.01244.x.
   Huxley R, 2007, AM J EPIDEMIOL, V165, P1280, DOI 10.1093/aje/kwm002.
   Ip MSM, 2011, RESPIROLOGY, V16, P190, DOI 10.1111/j.1440-1843.2010.01850.x.
   Jeebhay MF, 2007, INT J TUBERC LUNG D, V11, P122.
   Katz MA, 2007, VACCINE, V25, P3827, DOI 10.1016/j.vaccine.2007.01.109.
   Ko YC, 2000, AM J EPIDEMIOL, V151, P140.
   Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30.
   Lam KC, 2011, RESPIROLOGY, V16, P13, DOI 10.1111/j.1440-1843.2010.01821.x.
   Lam WK, 2005, RESPIROLOGY, V10, P408, DOI 10.1111/j.1440-1843.2005.00723.x.
   Lan Q, 2002, J NATL CANCER I, V94, P826, DOI 10.1093/jnci/94.11.826.
   Lange C, 2010, RESPIROLOGY, V15, P220, DOI 10.1111/j.1440-1843.2009.01692.x.
   Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5.
   Liam CK, 2007, RESPIROLOGY, V12, P162, DOI 10.1111/j.1440-1843.2006.01013.x.
   Liam CK, 2006, RESPIROLOGY, V11, P786, DOI 10.1111/j.1400-1843.2006.00947.x.
   Light RW, 2010, RESPIROLOGY, V15, P451, DOI 10.1111/j.1440-1843.2010.01723.x.
   Lin HH, 2008, LANCET, V372, P1473, DOI 10.1016/S0140-6736(08)61345-8.
   Lobue P, 2010, RESPIROLOGY, V15, P603, DOI 10.1111/j.1440-1843.2010.01751.x.
   Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4.
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442.
   Mathers CD, 2009, BRIT MED BULL, V92, P7, DOI 10.1093/bmb/ldp028.
   Metayer C, 2002, LUNG CANCER-J IASLC, V35, P111, DOI 10.1016/S0169-5002(01)00412-3.
   MUMFORD JL, 1987, SCIENCE, V235, P217, DOI 10.1126/science.3798109.
   Mylius SD, 2008, VACCINE, V26, P3742, DOI 10.1016/j.vaccine.2008.04.043.
   Nakachi K, 1999, JPN J CANCER RES, V90, P1187, DOI 10.1111/j.1349-7006.1999.tb00694.x.
   Nuermberger EL, 2010, RESPIROLOGY, V15, P764, DOI 10.1111/j.1440-1843.2010.01775.x.
   Nys S, 2004, J ANTIMICROB CHEMOTH, V54, P952, DOI 10.1093/jac/dkh448.
   Onozaki I, 2010, RESPIROLOGY, V15, P32, DOI 10.1111/j.1440-1843.2009.01673.x.
   Park AW, 2007, LANCET INFECT DIS, V7, P543, DOI 10.1016/S1473-3099(07)70186-X.
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74.
   Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x.
   Prieto-Lara E, 2010, VACCINE, V28, P4328, DOI 10.1016/j.vaccine.2010.03.068.
   Quah E., 2003, J ASIAN EC, V14, P73, DOI DOI 10.1016/S1049-0078(02)00240-3.
   Ramsey CD, 2005, CURR OPIN PULM MED, V11, P14, DOI 10.1097/01.mcp.0000145791.13714.ae.
   Rees D, 2007, INT J TUBERC LUNG D, V11, P474.
   Russell CA, 2008, VACCINE, V26, pD31, DOI 10.1016/j.vaccine.2008.07.078.
   Schaaf HS, 2010, RESPIROLOGY, V15, P747, DOI 10.1111/j.1440-1843.2010.01784.x.
   Sellwood C, 2007, POSTGRAD MED J, V83, P445, DOI 10.1136/pgmj.2007.059253.
   Shann F, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c809.
   Shimouchi A, 2001, Respirology, V6, P75, DOI 10.1046/j.1440-1843.2001.00301.x.
   Song JH, 2004, ANTIMICROB AGENTS CH, V48, P2101, DOI 10.1128/AAC.48.6.2101-2107.2004.
   Stieb DM, 2002, J AIR WASTE MANAGE, V52, P470, DOI 10.1080/10473289.2002.10470794.
   Streefland PH, 1999, B WORLD HEALTH ORGAN, V77, P722.
   Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190.
   Tam JS, 2007, PEDIATR INFECT DIS J, V26, P619, DOI 10.1097/INF.0b013e31806166f8.
   Tan WC, 2009, RESPIROLOGY, V14, P90, DOI 10.1111/j.1440-1843.2008.01415.x.
   Tan WC, 2005, RESPIROLOGY, V10, P9.
   Thiam S, 2007, JAMA-J AM MED ASSOC, V297, P380, DOI 10.1001/jama.297.4.380.
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3.
   Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736.
   Tsuhako K, 1998, J CLIN PATHOL, V51, P741, DOI 10.1136/jcp.51.10.741.
   Virta R, 2009, MINERALS YB 2008 ASB.
   Wang TJ, 1996, LUNG CANCER-J IASLC, V14, pS93, DOI 10.1016/S0169-5002(96)90214-7.
   Wardlow H, 2007, AM J PUBLIC HEALTH, V97, P1006, DOI 10.2105/AJPH.2006.088559.
   Waterer GW, 2010, RESPIROLOGY, V15, P51, DOI 10.1111/j.1440-1843.2009.01675.x.
   Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9.
   WHO, 2008, GLOB BURD DIS REP 20.
   Wong G W K, 2004, Paediatr Respir Rev, V5 Suppl A, pS163, DOI 10.1016/S1526-0542(04)90032-2.
   Wong TW, 1999, OCCUP ENVIRON MED, V56, P679, DOI 10.1136/oem.56.10.679.
   WOO J, 1988, THORAX, V43, P617, DOI 10.1136/thx.43.8.617.
   World Health Organization (WHO), 2010, PAND H1N1 2009 UPD 1.
   WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421.
   XU ZY, 1989, J NATL CANCER I, V81, P1800, DOI 10.1093/jnci/81.23.1800.
   Yang GH, 2001, TOB CONTROL, V10, P170, DOI 10.1136/tc.10.2.170.
   Yew WW, 2008, RESPIROLOGY, V13, P21, DOI 10.1111/j.1440-1843.2007.01180.x.
   Yim JJ, 2010, RESPIROLOGY, V15, P241, DOI 10.1111/j.1440-1843.2009.01690.x.
   Zheng W, 1992, J EPIDEMIOL S, V2, pS82.
   Zhong L, 2000, LUNG CANCER, V12, P797.
   Zhong NS, 2008, RESPIROLOGY, V13, pS33, DOI 10.1111/j.1440-1843.2008.01255.x.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.}},
Number-of-Cited-References = {{100}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Respirology}},
Doc-Delivery-Number = {{700RW}},
Unique-ID = {{ISI:000285763000002}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000284939600013,
Author = {Coulon, Charlene and Vinogradov, Evgeny and Filloux, Alain and
   Sadovskaya, Irina},
Title = {{Chemical Analysis of Cellular and Extracellular Carbohydrates of a
   Biofilm-Forming Strain Pseudomonas aeruginosa PA14}},
Journal = {{PLOS ONE}},
Year = {{2010}},
Volume = {{5}},
Number = {{12}},
Month = {{DEC 3}},
Abstract = {{Background: Pseudomonas aeruginosa is a Gram-negative bacterium and an
   opportunistic pathogen, which causes persisting life-threatening
   infections in cystic fibrosis (CF) patients. Biofilm mode of growth
   facilitates its survival in a variety of environments. Most P.
   aeruginosa isolates, including the non-mucoid laboratory strain PA14,
   are able to form a thick pellicle, which results in a surface-associated
   biofilm at the air-liquid (A-L) interface in standing liquid cultures.
   Exopolysaccharides (EPS) are considered as key components in the
   formation of this biofilm pellicle. In the non-mucoid P. aeruginosa
   strain PA14, the ``scaffolding{''} polysaccharides of the biofilm
   matrix, and the molecules responsible for the structural integrity of
   rigid A-L biofilm have not been identified. Moreover, the role of LPS in
   this process is unclear, and the chemical structure of the LPS O-antigen
   of PA14 has not yet been elucidated.
   Principal Findings: In the present work we carried out a systematic
   analysis of cellular and extracellular (EC) carbohydrates of P.
   aeruginosa PA14. We also elucidated the chemical structure of the LPS
   O-antigen by chemical methods and 2-D NMR spectroscopy. Our results
   showed that it is composed of linear trisaccharide repeating units,
   identical to those described for P. aeruginosa Lanyi type O:2a,c
   (Lanyi-Bergman O-serogroup 10a, 10c; IATS serotype 19) and having the
   following structure:
   -4)-alpha-L-GalNAcA-(1-3)-alpha-D-QuiNAc-(1-3)-alpha-L-Rha-(1-.
   Furthermore, an EC O-antigen polysaccharide (EC O-PS) and the
   glycerol-phosphorylated cyclic beta-(1,3)-glucans were identified in the
   culture supernatant of PA14, grown statically in minimal medium.
   Finally, the extracellular matrix of the thick biofilm formed at the A-L
   interface contained, in addition to eDNA, important quantities (at least
   similar to 20\% of dry weight) of LPS-like material.
   Conclusions: We characterized the chemical structure of the LPS
   O-antigen and showed that the O-antigen polysaccharide is an abundant
   extracellular carbohydrate of PA14. We present evidence that LPS-like
   material is found as a component of a biofilm matrix of P. aeruginosa.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Coulon, C (Reprint Author), Univ Lille Nord France, Lille, France.
   Coulon, Charlene; Sadovskaya, Irina, Univ Lille Nord France, Lille, France.
   Vinogradov, Evgeny, Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
   Coulon, Charlene, Univ Littoral Cote dOpale, LR2B, Bassin Napoleon, Boulogne Mer, France.
   Filloux, Alain, Univ London Imperial Coll Sci Technol \& Med, Ctr Mol Microbiol \& Infect, Fac Nat Sci, Div Cell \& Mol Biol, London, England.
   Sadovskaya, Irina, Univ Littoral Cote dOpale, UMT 08, Boulogne Sur Mer, France.}},
DOI = {{10.1371/journal.pone.0014220}},
Article-Number = {{e14220}},
ISSN = {{1932-6203}},
Keywords-Plus = {{MOLECULAR-WEIGHT POLYSACCHARIDE; AIR-LIQUID INTERFACE; ESCHERICHIA-COLI;
   ANTIBIOTIC-RESISTANCE; SPONTANEOUS RELEASE; O-ANTIGEN;
   LIPOPOLYSACCHARIDE; GENES; EXPRESSION; MATRIX}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{Irina.Sadovskaya@univ-littoral.fr}},
ORCID-Numbers = {{Vinogradov, Evgeny/0000-0002-5364-1376}},
Funding-Acknowledgement = {{le Ministere de l'Enseignement Superieur et de la Recherche; Arcir
   {[}54R01]; Royal Society; ERA-NET Pathogenomics}},
Funding-Text = {{This study was supported by le Ministere de l'Enseignement Superieur et
   de la Recherche to CC and by Arcir 54R01 to IS. AF is supported by the
   Royal Society and the ERA-NET Pathogenomics grant EPS-MATRIX. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.}},
Cited-References = {{Abraham T, 2008, BIOMACROMOLECULES, V9, P2799, DOI 10.1021/bm800562r.
   Al-Tahhan RA, 2000, APPL ENVIRON MICROB, V66, P3262, DOI 10.1128/AEM.66.8.3262-3268.2000.
   Allesen-Holm M, 2006, MOL MICROBIOL, V59, P1114, DOI 10.1111/j.1365-2958.2005.05008.x.
   Apicella MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011060.
   Bordi C, 2010, MOL MICROBIOL.
   Buchanan PJ, 2009, BIOCHEM SOC T, V37, P863, DOI 10.1042/BST0370863.
   Byrd MS, 2009, MOL MICROBIOL, V73, P622, DOI 10.1111/j.1365-2958.2009.06795.x.
   CADIEUX JE, 1983, J BACTERIOL, V155, P817.
   CRUTCHLE.MJ, 1967, NATURE, V214, P1052, DOI 10.1038/2141052a0.
   DAVIES DG, 1993, APPL ENVIRON MICROB, V59, P1181.
   DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0.
   Filloux A, 2003, M S-MED SCI, V19, P77, DOI 10.1051/medsci/200319177.
   Friedman L, 2004, MOL MICROBIOL, V51, P675, DOI 10.1046/j.1365-2958.2003.03877.x.
   Fujise O, 2008, ORAL MICROBIOL IMMUN, V23, P226, DOI 10.1111/j.1399-302X.2007.00416.x.
   Gibson DL, 2006, J BACTERIOL, V188, P7722, DOI 10.1128/JB.00809-06.
   GOLDMAN RC, 1982, J BACTERIOL, V151, P1210.
   Goodman AL, 2009, GENE DEV, V23, P249, DOI 10.1101/gad.1739009.
   Govan JRW, 1996, MICROBIOL REV, V60, P539.
   ISHIGURO EE, 1986, J BACTERIOL, V168, P328, DOI 10.1128/jb.168.1.328-333.1986.
   JOHNSON KG, 1975, CAN J MICROBIOL, V21, P1969, DOI 10.1139/m75-285.
   KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9.
   KNIREL YA, 1982, EUR J BIOCHEM, V125, P221, DOI 10.1111/j.1432-1033.1982.tb06672.x.
   Knirel YA, 2006, J ENDOTOXIN RES, V12, P324, DOI 10.1179/096805106X118906.
   KOCHAROVA NA, 1988, BIOORG KHIM+, V14, P701.
   Lau PCY, 2009, J BACTERIOL, V191, P6618, DOI 10.1128/JB.00698-09.
   Lee YW, 2010, LETT APPL MICROBIOL, V50, P452, DOI 10.1111/j.1472-765X.2010.02813.x.
   Lequette Y, 2007, MICROBIOL-SGM, V153, P3255, DOI 10.1099/mic.0.2007/008953-0.
   Mah TF, 2003, NATURE, V426, P306, DOI 10.1038/nature02122.
   Matsukawa M, 2004, J BACTERIOL, V186, P4449, DOI 10.1128/JB.186.14.4449-4456.2004.
   Mulcahy H, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000213.
   Nakamura S, 2008, JPN J INFECT DIS, V61, P375.
   PIER GB, 1984, INFECT IMMUN, V45, P309.
   PIER GB, 1989, INFECT IMMUN, V57, P426.
   PIER GB, 1981, INFECT IMMUN, V34, P461.
   PIER GB, 1978, INFECT IMMUN, V22, P908.
   PIKE RM, 1974, J GEN MICROBIOL, V81, P59, DOI 10.1099/00221287-81-1-59.
   Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930.
   Ryder C, 2007, CURR OPIN MICROBIOL, V10, P644, DOI 10.1016/j.mib.2007.09.010.
   Sadovskaya I, 2010, GLYCOBIOLOGY, V20, P895, DOI 10.1093/glycob/cwq047.
   Sakuragi Y, 2007, J BACTERIOL, V189, P5383, DOI 10.1128/JB.00137-07.
   Scher K, 2005, APPL ENVIRON MICROB, V71, P1163, DOI 10.1128/AEM.71.3.1163-1168.2005.
   Schwudke D, 2003, J BIOL CHEM, V278, P27502, DOI 10.1074/jbc.M303012200.
   Snyder DS, 2006, CARBOHYD RES, V341, P2388, DOI 10.1016/j.carres.2006.06.010.
   Spiers AJ, 2003, MOL MICROBIOL, V50, P15, DOI 10.1046/j.1365-2958.2003.03670.x.
   Spiers AJ, 2005, MICROBIOL-SGM, V151, P2829, DOI {[}10.1099/mic.0.27984-0, 10.1099/mic.027984-0].
   Sutherland IW, 2001, MICROBIOL-UK, V147, P3, DOI 10.1099/00221287-147-1-3.
   Vasseur P, 2005, MICROBIOL-SGM, V151, P985, DOI 10.1099/mic.0.27410-0.
   Vasseur P, 2007, BIOCHIMIE, V89, P903, DOI 10.1016/j.niochi.2007.04.002.
   Ventre I, 2006, P NATL ACAD SCI USA, V103, P171, DOI 10.1073/pnas.0507407103.
   Vincent F, 2010, ENVIRON MICROBIOL, V12, P1775, DOI 10.1111/j.1462-2920.2010.02264.x.
   WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83.
   White AP, 2003, J BACTERIOL, V185, P5398, DOI 10.1128/JB.185.18.5398-5407.2003.
   Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x.
   Wozniak DJ, 2003, P NATL ACAD SCI USA, V100, P7907, DOI 10.1073/pnas.1231792100.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{PLoS One}},
Doc-Delivery-Number = {{689PF}},
Unique-ID = {{ISI:000284939600013}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000285676100001,
Author = {Imam, F. and Anwer, M. K. and Iqbal, M. and Alam, S. and Khayyam, K. U.
   and Sharma, M.},
Title = {{Tuberculosis: Brief Overview and its Shifting Paradigm for Management in
   India}},
Journal = {{INTERNATIONAL JOURNAL OF PHARMACOLOGY}},
Year = {{2010}},
Volume = {{6}},
Number = {{6}},
Pages = {{755-783}},
Month = {{NOV-DEC}},
Abstract = {{Tuberculosis, or TB, is one of the most ancient infectious bacterial
   disease caused by Mycobacterium tuberculosis. On the basis of site of
   tuberculosis it is mainly divided in to two categories: pulmonary and
   extra-pulmonary which is further divided into 5 and 7 different
   category, respectively. The TB is a highly contagious disease that is
   usually transmitted by coughing and sneezing. It is mainly diagnosed by
   detecting the presence of Mycobacterium tuberculosis bacteria, abnormal
   chest x-ray and surgical biopsy in the patient. In 1998, World Health
   Organization has declared this disease a global emergency and
   established a new strategy for treating patients, called Directly
   Observed Treatment, Short-course (DOTS). India is the highest TB burden
   country accounting for one fifth of the global incidence. There has been
   significant change in management of tuberculosis never since
   pre-chemotherapeutic era to the present day RNTCP protocol based on
   specific disease categories. Its initial management in an organized way
   was started in late 1930 when the main line of treatment was good food,
   open air and dry climate. Effective drugs against TB began available
   around the time India gained Independence and District Tuberculosis
   Programme (DTP) was started to reduce the TB problem across the country.
   But major problem raised was that of keeping the patients on continuous
   treatment as only 66\% of the patients were taking drugs regularly. In
   seventies, availability of two highly effective drugs-rifampicin and
   pyrazimamide enabled to cut down the duration of treatment and Short
   Course Chemotherapy (SCC) policy was implemented. Inspite of the
   introduction of SCC, a high rate of defaulters and the disturbing trends
   of low compliance in SCC districts were reported. In 1992, the
   Government of India designed the Revised National Tuberculosis Control
   Programme based on DOTS strategy. Phase 11 of the RNTCP started from
   October 2005, which is a step towards achieving the TB-related targets
   of the Millennium Development Goals. By March 2006, the programme was
   implemented nationwide in 633 districts, covering 1114 million (100\%)
   population. In 2008, 1.51 million patients have already been placed on
   treatment and NSP treatment success rate was 86\%.}},
Publisher = {{ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET}},
Address = {{308-LASANI TOWN, SARGODHA RD, FAISALABAD, 38090, PAKISTAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Imam, F (Reprint Author), Fac Pharm, Dept Pharmacol, New Delhi, India.
   Imam, F.; Sharma, M., Fac Pharm, Dept Pharmacol, New Delhi, India.
   Anwer, M. K., Al Kharj Univ, Dept Pharmaceut, Coll Pharm Al Kharj, Al Kharj, Saudi Arabia.
   Iqbal, M., King Saud Univ, Coll Pharm, Riyadh 11451, Saudi Arabia.
   Alam, S., Integral Univ, Dept Pharmaceut, Fac Pharm, Lucknow, Uttar Pradesh, India.
   Khayyam, K. U., Lala Ram Sarup Inst TB \& Resp Dis, Dept Epidemiol \& Publ Hlth, New Delhi, India.}},
ISSN = {{1811-7775}},
EISSN = {{1812-5700}},
Keywords = {{Tuberculosis; management; symptoms; diagnosis; short course chemotherapy}},
Keywords-Plus = {{PATIENTS RECEIVING AMINOGLYCOSIDES; LIGHT-CHAIN PROTEINURIA; PULMONARY
   TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; RISK-FACTORS; ANTITUBERCULOSIS
   TREATMENT; GENTAMICIN-NEPHROTOXICITY; MILIARY TUBERCULOSIS; AUDITORY
   TOXICITY; DRUG-RESISTANCE}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{AHUJA SS, 1992, CRIT CARE MED, V20, P901, DOI 10.1097/00003246-199206000-00031.
   ALVAREZ S, 1987, AM J MED, V82, P602, DOI 10.1016/0002-9343(87)90106-9.
   ALVAREZ S, 1984, MEDICINE, V63, P25, DOI 10.1097/00005792-198401000-00003.
   ANDERSON DG, 1945, NEW ENGL J MED, V233, P485, DOI 10.1056/NEJM194510252331701.
   Aneja K.S., 1952, NTI NEWSLETT, V19, P58.
   {[}Anonymous], 2009, TREATM TUB GUID NAT.
   Antony VB, 2003, EUR RESPIR J, V21, P539, DOI 10.1183/09031936.03.00403902.
   Appel G.B., 1982, AMINOGLYCOSIDES MICR, P269.
   AQIL M, 2006, INT J PHARM PRACT, V14, P311, DOI DOI 10.1211/ijpp.14.4.0012.
   ARONOFF GR, 1983, ANTIMICROB AGENTS CH, V23, P74, DOI 10.1128/AAC.23.1.74.
   Arora V K, 1989, J Assoc Physicians India, V37, P205.
   AVERY GS, 1980, DRUG TREATMENT PRINC.
   Baciewicz AM, 2003, ANN PHARMACOTHER, V37, P182.
   BAILEY CM, 1981, LARYNGOSCOPE, V91, P93.
   BAILEY WC, 1974, ANN INTERN MED, V81, P200, DOI 10.7326/0003-4819-81-2-200.
   Balasubramanian VN, 2000, INT J TUBERC LUNG D, V4, P409.
   BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779.
   Bates DE, 2003, DRUGS TODAY, V39, P277, DOI 10.1358/dot.2003.39.4.799404.
   Battaglia A, 2003, NEUROSCIENCE, V122, P1025, DOI 10.1016/j.neuroscience.2003.08.041.
   BAYLIS C, 1977, KIDNEY INT, V12, P344, DOI 10.1038/ki.1977.121.
   BCG Conference, 1962, P 6 ALL IND BCG C BA, P20.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919.
   Benjamin P.V., 1973, INDIAN J TUBERC, V20, P33.
   BENNETT WM, 1982, ANTIMICROB AGENTS CH, V22, P508, DOI 10.1128/AAC.22.3.508.
   Bhore S., 1946, MINISTRY HLTH REPORT, P157.
   Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243.
   Brown W.G.S., 1965, DIS EAR NOSE THROAT, P539.
   Brummett RE, 1983, REV INFECT DIS, V5, P294.
   BUDAVARI S, 1989, MERCK INDEX ENCY CHE.
   BYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239, DOI 10.1001/jama.241.12.1239.
   CAUTHEN G M, 1988, American Review of Respiratory Disease, V137, P260.
   Cavalcanti Zilda do Rego, 2006, J. bras. pneumol., V32, P535, DOI 10.1590/S1806-37132006000600011.
   Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P1.
   Chaudhuri K, 1993, IND J TUB, V40, P83.
   CHOW AW, 1985, REV INFECT DIS, V7, P287.
   Chung CL, 2005, CHEST, V128, P690, DOI 10.1378/chest.128.2.690.
   de Jager P, 2002, INT J TUBERC LUNG D, V6, P622.
   De la Iglesia A. I., 2006, Rev. argent. microbiol., V38, P97.
   Dollery C., 1991, THERAPEUTIC DRUGS C, P100.
   ELIAS WF, 1945, SCIENCE, V101, P589, DOI 10.1126/science.101.2632.589.
   Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN.
   Farivar T. N., 2008, Journal of Applied Sciences, V8, P719.
   Farr B.F., 2000, PRINCIPLES PRACTICE, P348.
   FONG IW, 1981, J ANTIMICROB CHEMOTH, V7, P81, DOI 10.1093/jac/7.1.81.
   FOX HH, 1952, J ORG CHEM, V17, P542, DOI 10.1021/jo01138a005.
   FOX W, 1962, Bull Int Union Tuberc, V32, P307.
   FOX W, 1981, BRIT J DIS CHEST, V75, P331, DOI 10.1016/0007-0971(81)90022-X.
   Frimodt Moller J., 1952, P 9 TUB WORK C TWC 5, P133.
   FURESZ S, 1970, ANTIBIOT CHEMOTHER, V16, P316.
   GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357, DOI 10.1164/arrd.1972.106.3.357.
   GDF, 2005, AM REV RESPIR DIS, V133, P963.
   Gholami Kheirollah, 2006, Pharmacy Pract (Granada), V4, P134, DOI 10.4321/s1885-642x2006000300006.
   Gilman A.G., 1990, GOODMAN GILMANS PHAR, P1317.
   Gothi GD, 1974, INDIAN J TUBERC, V21, P90.
   GRABER CD, 1973, AM REV RESPIR DIS, V107, P713.
   GROSSET J, 1983, REV INFECT DIS, V5, pS440.
   Gumbo T, 2007, ANTIMICROB AGENTS CH, V51, P2329, DOI 10.1128/AAC.00185-07.
   HADDAD L, 1983, CLIN MANAGEMENT POIS.
   Hall RG, 2009, PHARMACOTHERAPY, V29, P1468, DOI 10.1592/phco.29.12.1468.
   HOLDINESS MR, 1985, CLIN PHARMACOKINET, V10, P532, DOI 10.2165/00003088-198510060-00006.
   Huber W.G., 1966, VET PHARM THERAPEUTI, P519.
   HUMES HD, 1984, J CLIN INVEST, V73, P134, DOI 10.1172/JCI111184.
   ICMR, 1959, TUB IND NAT SAMPL SU, P1.
   ICMR, 1976, REV NAT TUB PROGR.
   ICORCI, 1988, DEPTH STUD NAT TUB P.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Iseman MD, 2000, CLIN GUIDE TUBERCULO, P51.
   Jacobs Jr W.R., 2000, MOL GENETICS MYCOBAC.
   Jayaram R, 2004, ANTIMICROB AGENTS CH, V48, P2951, DOI 10.1128/AAC.48.8.2951-2957.2004.
   KARNIK AM, 1985, POSTGRAD MED J, V61, P811, DOI 10.1136/pgmj.61.719.811.
   KEATING MJ, 1979, MEDICINE, V58, P159, DOI 10.1097/00005792-197903000-00004.
   Keers RY, 1978, PULMONARY TUBERCULOS.
   KEYS TF, 1981, MAYO CLIN PROC, V56, P556.
   Khatri GR, 2000, INT J TUBERC LUNG D, V4, P193.
   Khayyam U.K., 2010, INDIAN J DERMATOL.
   Kinzig-Schippers M, 2005, ANTIMICROB AGENTS CH, V49, P1733, DOI 10.1128/AAC.49.5.1733-1738.2005.
   Koch R., 1938, MED CLASSICS, V2, P853.
   KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M.
   Lee BH, 2005, CHEST, V127, P1304, DOI 10.1378/chest.127.4.1304.
   Li B, 2007, WORLD J GASTROENTERO, V13, P628, DOI 10.3748/wjg.v13.i4.628.
   Lietman P.S., 1983, REV INFECT DIS S2, V5, P284.
   LIGHT RW, 2001, PLEURAL DIS, P182.
   LUFT FC, 1980, J INFECT DIS, V142, P910, DOI 10.1093/infdis/142.6.910.
   Mandell G.L., 1985, PHARMACOL BASIS THER, P1115.
   MARSHALL EK, 1948, J PHARMACOL EXP THER, V92, P43.
   Marynowski A, 1972, Ginekol Pol, V43, P713.
   MCGLYNN KA, 1986, AM REV RESPIR DIS, V134, P666.
   Meisel P, 2002, PHARMACOGENOMICS, V3, P349, DOI 10.1517/14622416.3.3.349.
   Merck, 1989, MERCK IND ENC CHEM D.
   MILLER RR, 1979, CHEST, V75, P356, DOI 10.1378/chest.75.3.356.
   MITCHELL CJ, 1977, J ANTIMICROB CHEMOTH, V3, P593, DOI 10.1093/jac/3.6.593.
   Mohan A, 1996, Indian J Chest Dis Allied Sci, V38, P157.
   Molavi A., 1990, BASIC PHARM MED.
   MOORE RD, 1984, ANN INTERN MED, V100, P352, DOI 10.7326/0003-4819-100-3-352.
   MOORE RD, 1984, J INFECT DIS, V149, P23, DOI 10.1093/infdis/149.1.23.
   Nagpaul D.R., 1968, B INT UNION TUBERC, V61, P148.
   Nardell E.A., 2000, LUNG BIOL HEALTH DIS, P215.
   National Tuberculosis Institute, 1993, YB NTP IND.
   NEU HC, 1976, J INFECT DIS, V134, pS206, DOI 10.1093/infdis/134.Supplement\_1.S206.
   Nyboe J, 1968, Bull Int Union Tuberc, V41, P115.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   PATEL V, 1975, ANTIMICROB AGENTS CH, V7, P364, DOI 10.1128/AAC.7.3.364.
   Peloquin CA, 2002, DRUGS, V62, P2169, DOI 10.2165/00003495-200262150-00001.
   Perez-Guzman C, 1999, CHEST, V116, P961, DOI 10.1378/chest.116.4.961.
   Pinet G, 2001, GOOD PRACTICE LEGISL.
   PIQUERAS AR, 1987, INTENS CARE MED, V13, P175.
   POSTLETHWAITE AE, 1972, NEW ENGL J MED, V286, P761, DOI 10.1056/NEJM197204062861407.
   POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918.
   Prahlad Kumar, 2005, Indian Journal of Tuberculosis, V52, P63.
   Pratt W.B., 1986, BACTERICIDAL INHIBIT, P153.
   Puri M M, 2010, Indian J Tuberc, V57, P41.
   QUEENER SF, 1983, ANTIMICROB AGENTS CH, V24, P815, DOI 10.1128/AAC.24.5.815.
   Rao K.P., 1971, IND J TUB, V18, P10.
   Reynolds J.E.F., 1982, MARTINDALE EXTRA PHA, P1569.
   Reynolds J.E.F., 1989, MARTINDALE EXTRA PHA, P1249.
   Reynolds J.E.F., 1993, MARTINDALE EXTRA PHA, P164.
   Rifater\&REG;, 2009, PROD MON.
   Ryan Frank, 1992, TUBERCULOSIS GREATES.
   Schaberg T, 1996, EUR RESPIR J, V9, P2026, DOI 10.1183/09031936.96.09102026.
   SCHENTAG JJ, 1979, ANTIMICROB AGENTS CH, V16, P468, DOI 10.1128/AAC.16.4.468.
   Sharma Himanshu, 2007, Pharm Pract (Granada), V5, P46.
   Sharma M., 2008, CONT J PHARM TOXICOL, V2, P6.
   Sharma S.K., 2002, AM J RESP, V166, P907.
   Sharma SK, 2005, LANCET INFECT DIS, V5, P415, DOI 10.1016/S1473-3099(05)70163-8.
   Sikand B.K., 1951, P 8 TB WORK C TBWC 5, P90.
   Sikand BK, 1956, P 13 TB WORK C TB AS, P179.
   SINGHAL K C, 1990, Indian Journal of Pharmacology, V22, P231.
   Smink F, 2006, NETH J MED, V64, P377.
   SMITH CR, 1980, NEW ENGL J MED, V302, P1106, DOI 10.1056/NEJM198005153022002.
   SNIDER DE, 1980, TUBERCLE, V61, P191, DOI 10.1016/0041-3879(80)90038-0.
   SOKOLL MD, 1981, ANESTHESIOLOGY, V55, P148, DOI 10.1097/00000542-198108000-00011.
   Stout JE, 2003, AM J RESP CRIT CARE, V167, P824, DOI 10.1164/rccm.200209-998OC.
   Swan SK, 1997, SEMIN NEPHROL, V17, P27.
   SYDOW M, 1992, RESP MED, V86, P517, DOI 10.1016/S0954-6111(96)80014-X.
   Taki Reiko, 2008, Kekkaku, V83, P87.
   TCC, 1964, B WORLD HEALTH ORGAN, V31, P247.
   Telzak EE, 1997, CLIN INFECT DIS, V25, P666, DOI 10.1086/513772.
   Tuberculosis Association of India New Delhi, 1939, P TUB ASS IND NEW DE, P171.
   VANDIJK JM, 1993, NETH J MED, V42, P12.
   VANSCOY RE, 1987, MAYO CLIN PROC, V62, P1129, DOI 10.1016/S0025-6196(12)62507-5.
   Verma S. K., 2008, Indian Journal of Chest Diseases and Allied Sciences, V50, P195.
   Vernon A.A., 2004, TUBERCULOSIS, P759.
   Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000.
   WARRINGTON RJ, 1977, ARCH INTERN MED, V137, P927, DOI 10.1001/archinte.137.7.927.
   {*}WHO, 2008, WHOHTMTB2008393.
   WHO, 2004, HLTH AC AV TUB SELF, P5.
   WHO, 1998, WHO GLOB TUB PROGR G.
   WHO, 1994, FRAM WORK EFF TUB CO.
   WILSON WR, 1984, ANN INTERN MED, V100, P816, DOI 10.7326/0003-4819-100-6-816.
   Windholz M., 1983, MERCK INDEX ENCY CHE.
   Wobeser W, 1999, CAN MED ASSOC J, V160, P789.
   WONG PC, 1995, EUR RESPIR J, V8, P866.
   WOOD CA, 1986, ANTIMICROB AGENTS CH, V30, P20, DOI 10.1128/AAC.30.1.20.
   World Health Organization, 1992, TUB PROGR REV IND.
   World Health Organization, 2009, GLOB TUB CONTR EP ST.
   Yee D, 2003, AM J RESP CRIT CARE, V167, P1472, DOI 10.1164/rccm.200206-626OC.
   Zhang Y., 2004, TUBERCULOSIS, P739.
   Zimhony O, 2000, NAT MED, V6, P1043.}},
Number-of-Cited-References = {{159}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Int. J. Pharmacol.}},
Doc-Delivery-Number = {{699PU}},
Unique-ID = {{ISI:000285676100001}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000283979900012,
Author = {Milanowski, Bartlomiej and Lulek, Janina and Lehmler, Hans-Joachim and
   Kania-Korwel, Izabela},
Title = {{Assessment of the disposition of chiral polychlorinated biphenyls in
   female mdr 1a/b knockout versus wild-type mice using multivariate
   analyses}},
Journal = {{ENVIRONMENT INTERNATIONAL}},
Year = {{2010}},
Volume = {{36}},
Number = {{8, SI}},
Pages = {{884-892}},
Month = {{NOV}},
Note = {{5th PCB Workshop on New Knowledge Gained from Old Pollutants, Iowa City,
   IA, MAY 18-22, 2008}},
Abstract = {{Polychlorinated biphenyls (PCBs) are present in the environment as
   complex mixtures, which make it challenging to identify PCB congeners
   that may be subject to active transport processes. Here we employ a
   transgenic mouse model in combination with multivariate analyses to
   investigate if chiral PCBs 91, 95, 132, 136, 149, 174, 176 and 183 are
   subject to active (enantioselective) transport by multidrug resistance
   (MDR) transporters. A synthetic PCB mixture containing these congeners
   was administered orally to female FVB or mdr1a/1b knockout mice. Due to
   the short half-life of chiral PCB congeners, mice were euthanized after
   24h and PCB concentrations and enantiomeric fractions were determined in
   selected tissues and excreta. Principal component analysis did not
   reveal differences between wild-type and mdr1a/1b knockout mice.
   However, Hotelling T(2)-test revealed significantly lower PCB
   concentrations and a more pronounced enantiomeric enrichment in the
   adipose tissue of mdr1a/1b knockout mice. These differences are due to
   higher body weights and higher fecal fat contents of mdr1a/1b knockout
   mice. Analysis of the enantiomeric fractions of PCBs 91, 95, 136, 149
   and 174 showed a significant enantiomeric enrichment for all five
   congeners in wild-type and mdr1a/1b knockout mice. Overall, by studying
   a PCB mixture in a transgenic mouse model in combination with a
   multivariate data reduction approach, PCBs 91, 95, 136, 149 and 174
   could be excluded as substrates of multidrug resistance transporters
   1a/b. (C) 2009 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Lehmler, HJ (Reprint Author), 100 Oakdale Campus,221 IREH, Iowa City, IA USA.
   Milanowski, Bartlomiej; Lulek, Janina, Karol Marcinkowski Univ Med Sci, Dept Pharmaceut Technol, PL-60780 Poznan, Poland.
   Milanowski, Bartlomiej; Lehmler, Hans-Joachim; Kania-Korwel, Izabela, Univ Iowa, Coll Publ Hlth, Dept Occupat \& Environm Hlth, Iowa City, IA 52242 USA.}},
DOI = {{10.1016/j.envint.2009.10.007}},
ISSN = {{0160-4120}},
Keywords = {{Polychlorinated biphenyls; Enantiomeric fraction; Atropisomers; Fecal
   fat content; Multivariate analysis; Chemometrics; Principal component
   analysis; Hotelling T(2)-test; Transgenic mice; Active transport;
   Multidrug resistance transporters}},
Keywords-Plus = {{2,2',3,3',6,6'-HEXACHLOROBIPHENYL PCB-136; INTESTINAL-ABSORPTION; TISSUE
   DISTRIBUTION; P-GLYCOPROTEIN; C57BL/6 MICE; PCB MIXTURE; INDOOR AIR;
   ATROPISOMERS; SIGNATURES; FISH}},
Research-Areas = {{Environmental Sciences \& Ecology}},
Web-of-Science-Categories  = {{Environmental Sciences}},
Author-Email = {{hans-joachim-lehmler@uiowa.edu}},
ResearcherID-Numbers = {{Korwel, Izabela/D-6315-2013
   }},
ORCID-Numbers = {{Korwel, Izabela/0000-0002-5747-1925
   Lehmler, Hans-Joachim/0000-0001-9163-927X
   Lulek, Janina/0000-0002-5567-9909
   Milanowski, Bartlomiej/0000-0002-6450-174X}},
Funding-Acknowledgement = {{NIEHS NIH HHS {[}K25 ES012475, ES012475, P42 ES013661, ES05605,
   ES013661, P30 ES005605]}},
Cited-References = {{Abu-Qare AW, 2003, J TOXICOL ENV HEAL B, V6, P279, DOI 10.1080/15287390390155562.
   AGUILAR A, 1985, RESIDUE REV, V95, P91.
   Asher BJ, 2007, ENVIRON SCI TECHNOL, V41, P6163, DOI 10.1021/es070763n.
   Bachour G, 1998, ARCH ENVIRON CON TOX, V35, P666, DOI 10.1007/s002449900429.
   Bain LJ, 1997, ENVIRON HEALTH PERSP, V105, P812, DOI 10.2307/3433698.
   BIRNBAUM LS, 1983, TOXICOL APPL PHARM, V3, P262.
   Bordajandi LR, 2008, CHEMOSPHERE, V70, P567, DOI 10.1016/j.chemosphere.2007.07.019.
   BROWN JF, 1994, ENVIRON SCI TECHNOL, V28, P2295, DOI 10.1021/es00062a013.
   BUNACIU PR, 2007, TOXICOLOGY, V239, P147.
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866.
   Chu SG, 2003, ENVIRON RES, V93, P167, DOI 10.1016/S0013-9351(03)00016-1.
   Drouillard KG, 2003, ARCH ENVIRON CON TOX, V44, P97, DOI 10.1007/s00244-002-1199-y.
   Frame GM, 1996, CHEMOSPHERE, V33, P603, DOI 10.1016/0045-6535(96)00214-7.
   GOBAS FAPC, 1993, ENVIRON TOXICOL CHEM, V12, P567, DOI 10.1897/1552-8618(1993)12{[}567:IAABOO]2.0.CO;2.
   Haglund P, 1996, HRC-J HIGH RES CHROM, V19, P373.
   HANSEN LG, 1977, ARCH ENVIRON CON TOX, V5, P257, DOI 10.1007/BF02220909.
   Harner T, 2000, ENVIRON SCI TECHNOL, V34, P218, DOI 10.1021/es9906958.
   Harrad S, 2006, CHEMOSPHERE, V63, P1368, DOI 10.1016/j.chemosphere.2005.09.027.
   Hayes Jr W. J., 1975, TOXICOLOGY PESTICIDE.
   Hovander L, 2006, ENVIRON SCI TECHNOL, V40, P3696, DOI 10.1021/es0525657.
   Jamshidi A, 2007, ENVIRON SCI TECHNOL, V41, P2153, DOI 10.1021/es062218c.
   Jensen S, 2003, J AGR FOOD CHEM, V51, P5607, DOI 10.1021/jf0301201.
   KAMINSKY LS, 1981, BIOCHEMISTRY-US, V20, P7379, DOI 10.1021/bi00529a009.
   Kania-Korwel I, 2008, FOOD CHEM TOXICOL, V46, P637, DOI 10.1016/j.fct.2007.09.072.
   Kania-Korwel I, 2005, ENVIRON SCI TECHNOL, V39, P3513, DOI 10.1021/es047987f.
   Kania-Korwel I, 2006, ENVIRON SCI TECHNOL, V40, P3704, DOI 10.1021/es0602086.
   Kania-Korwel I, 2008, J CHROMATOGR A, V1207, P146, DOI 10.1016/j.chroma.2008.08.044.
   Kania-Korwel I, 2008, ARCH ENVIRON CON TOX, V55, P510, DOI 10.1007/s00244-007-9111-4.
   Kania-Korwel I, 2008, CHEM RES TOXICOL, V21, P1295, DOI 10.1021/tx800059j.
   Kania-Korwel I, 2007, CHIRALITY, V19, P56, DOI 10.1002/chir.20342.
   Kania-Korwel I, 2008, J CHROMATOGR A, V1214, P37, DOI 10.1016/j.chroma.2008.10.089.
   KANIAKORWEL I, 2007, ENVIRON TOXICOL CHEM, V27, P299.
   KANNAN N, 1995, ENVIRON SCI TECHNOL, V29, P1851, DOI 10.1021/es00007a024.
   Kelly BC, 2004, ENVIRON TOXICOL CHEM, V23, P2324, DOI 10.1897/03-545.
   Klaassen CD, 2008, TOXICOL SCI, V101, P186, DOI 10.1093/toxsci/kfm214.
   Kostyniak PJ, 2005, TOXICOL SCI, V88, P400, DOI 10.1093/toxsci/kfi338.
   Lehmler HJ, 2003, FRESEN ENVIRON BULL, V12, P254.
   Magar VS, 2005, ENVIRON SCI TECHNOL, V39, P3538, DOI 10.1021/es048622y.
   Mankowski DC, 2000, XENOBIOTICA, V30, P745, DOI 10.1080/00498250050119817.
   MATTHEWS HB, 1984, ANNU REV PHARMACOL, V24, P85.
   MATTHEWS HB, 1980, TOXICOL APPL PHARM, V53, P377, DOI 10.1016/0041-008X(80)90351-8.
   NESS DK, 1994, J TOXICOL ENV HEALTH, V43, P453, DOI 10.1080/15287399409531934.
   Norstrom K, 2006, ENVIRON SCI TECHNOL, V40, P7649, DOI 10.1021/es061584t.
   PUTTMANN M, 1989, BIOCHEM PHARMACOL, V38, P1345, DOI 10.1016/0006-2952(89)90342-0.
   Robertson LW, 2001, PCBS RECENT ADV ENV.
   Saghir SA, 2000, TOXICOL SCI, V54, P60, DOI 10.1093/toxsci/54.1.60.
   Schuetz EG, 2000, MOL PHARMACOL, V57, P188.
   Shaikh NS, 2006, ORGANOMETALLICS, V25, P4207, DOI 10.1021/om060456a.
   SIPES IG, 1982, TOXICOL APPL PHARM, V65, P264, DOI 10.1016/0041-008X(82)90009-6.
   Tampal NM, 2003, TOXICOL APPL PHARM, V187, P168, DOI 10.1016/S0041-008X(02)00069-8.
   Warner NA, 2009, ENVIRON SCI TECHNOL, V43, P114, DOI 10.1021/es802237u.
   Wong CS, 2000, J CHROMATOGR A, V866, P213, DOI 10.1016/S0021-9673(99)01104-8.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{15}},
Journal-ISO = {{Environ. Int.}},
Doc-Delivery-Number = {{677HO}},
Unique-ID = {{ISI:000283979900012}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000208216700006,
Author = {Letourneau, Valerie and Nehme, Benjamin and Meriaux, Anne and Masse,
   Daniel and Cormier, Yvon and Duchaine, Caroline},
Title = {{Human pathogens and tetracycline-resistant bacteria in bioaerosols of
   swine confinement buildings and in nasal flora of hog producers}},
Journal = {{INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH}},
Year = {{2010}},
Volume = {{213}},
Number = {{6}},
Pages = {{444-449}},
Month = {{NOV}},
Abstract = {{Swine confinement buildings in eastern Canada are enclosed and equipped
   with modern production systems to manage waste. Bioaerosols of these
   swine confinement buildings could be contaminated by human pathogens and
   antimicrobial resistant bacteria which could colonize exposed workers.
   We therefore wanted to analyze bioaerosols of swine confinement
   buildings and nasal flora of Canadian hog producers to evaluate possible
   colonization with human pathogens and tetracycline-resistant bacteria.
   Culturable and non-culturable human pathogens and tet genes were
   investigated in the bioaerosols of 18 barns. The nasal passages of 35
   hog producers were sampled and total DNA was extracted from the
   calcium-alginate swabs to detect, by PCR, Campylobacter, C. perfringens,
   Enterococcus, E. coli, Y. enterocolitica, tetA/tetC, tetG and ribosomal
   protection protein genes. Airborne culturable C. perfringens,
   Enterococcus, E. call, and Y. enterocolitica were present in the
   bioaerosols of 16, 17, 11 and 6 of the 18 facilities. Aerosolized total
   (culturable/non culturable) Campylobacter, C. perfringens, Enterococcus,
   E. coli and Y. enterocolitica were detected in 10, 6, 15, 18 and 2
   barns, respectively. Tet genes were found in isolates of culturable
   human pathogens. TetA/tetC, tetG and ribosomal protection protein genes
   were detected in the bioaerosols of all 18 studied buildings.
   Campylobacter, C. perfringens, Enterococcus, E. coli, and Y.
   enterocolitica were found respectively in 4, 9, 17, 14 and one nasal
   flora of workers. One and 10 workers were positive for tetA/tetC and
   tetG genes, respectively. In swine confinement buildings, hog producers
   are exposed to aerosolized human pathogens and tetracycline-resistant
   bacteria that can contaminate the nasal flora. (C) 2010 Elsevier GmbH.
   All rights reserved.}},
Publisher = {{ELSEVIER GMBH, URBAN \& FISCHER VERLAG}},
Address = {{OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Duchaine, C (Reprint Author), Hop Laval, Inst Univ Cardiol \& Pneumol Quebec, 2725 Chemin St Foy, Quebec City, PQ G1V 4G5, Canada.
   Letourneau, Valerie; Nehme, Benjamin; Meriaux, Anne; Cormier, Yvon; Duchaine, Caroline, Hop Laval, Inst Univ Cardiol \& Pneumol Quebec, Quebec City, PQ G1V 4G5, Canada.
   Masse, Daniel, Agr \& Agri Food Canada, Dairy \& Swine Res \& Dev Ctr, Lennoxville, PQ J1M 1Z3, Canada.
   Cormier, Yvon, Univ Laval, Fac Med, Dept Med, Quebec City, PQ G1V 0A6, Canada.
   Duchaine, Caroline, Univ Laval, Fac Sci \& Genie, Dept Biochim \& Microbiol, Quebec City, PQ G1V 0A6, Canada.}},
DOI = {{10.1016/j.ijheh.2010.09.008}},
ISSN = {{1438-4639}},
Keywords = {{Aerobiology; Air sampling; Nasal swab; Airborne pathogens; tet genes}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{caroline.duchaine@bcm.ulaval.ca}},
Funding-Acknowledgement = {{Agriculture and Agri-Food Canada; FQRNT; IRSST; CCHSA}},
Funding-Text = {{Agriculture and Agri-Food Canada and FQRNT. VL received scholarships
   from IRSST and FQRNT. VL and BN were CIHR strategic training fellows in
   PHARE. CD is a Junior 2 FRSQ scholar and recipient of CCHSA time release
   support. Thanks to Serge Simard (biostatistics) and Jakob Bonlokke,
   Gaetane Racine and Odette Gingras (nasal sampling).}},
Cited-References = {{Albrich WC, 2008, LANCET INFECT DIS, V8, P289, DOI 10.1016/S1473-3099(08)70097-5.
   Aminov RI, 2001, APPL ENVIRON MICROB, V67, P22, DOI 10.1128/AEM.67.1.22-32.2001.
   ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   Aubry-Damon H, 2004, EMERG INFECT DIS, V10, P873, DOI 10.3201/eid1005.030735.
   Cormier Y, 2000, EUR RESPIR J, V15, P560, DOI 10.1034/j.1399-3003.2000.15.22.x.
   D'Allaire S., 1999, S HOG ENV MAN STRAT.
   Duchaine C, 2000, AM IND HYG ASSOC J, V61, P56, DOI 10.1202/0002-8894(2000)061<0056:IOBMEF>2.0.CO;2.
   Gast RK, 1998, AVIAN DIS, V42, P315, DOI 10.2307/1592482.
   Gast RK, 2004, POULTRY SCI, V83, P1106, DOI 10.1093/ps/83.7.1106.
   Klappenbach JA, 2001, NUCLEIC ACIDS RES, V29, P181, DOI 10.1093/nar/29.1.181.
   Kristensen CS, 2004, VET MICROBIOL, V99, P197, DOI 10.1016/j.vetmic.2004.01.005.
   Lee ZMP, 2009, NUCLEIC ACIDS RES, V37, pD489, DOI 10.1093/nar/gkn689.
   LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103.
   Lipsitcht M, 2002, P NATL ACAD SCI USA, V99, P5752, DOI 10.1073/pnas.09214299.
   Malinen E, 2003, MICROBIOL-SGM, V149, P269, DOI 10.1099/mic.0.25975-0.
   McEwen S., 2002, USES ANTIMICROBIALS.
   McGeer AJ, 1998, CAN MED ASSOC J, V159, P1119.
   Morris A, 1998, CURR OPIN MICROBIOL, V1, P524, DOI 10.1016/S1369-5274(98)80084-2.
   Nehme B, 2008, ENVIRON MICROBIOL, V10, P665, DOI 10.1111/j.1462-2920.2007.01489.x.
   Neubauer H, 2000, SYST APPL MICROBIOL, V23, P58, DOI 10.1016/S0723-2020(00)80046-6.
   Proux K, 2001, VET RES, V32, P591, DOI 10.1051/vetres:2001148.
   Rinttila T, 2004, J APPL MICROBIOL, V97, P1166, DOI 10.1111/j.1365-2672.2004.02409.x.
   Roberts MC, 1996, FEMS MICROBIOL REV, V19, P1, DOI 10.1111/j.1574-6976.1996.tb00251.x.
   Salyers AA, 1997, ANTIMICROB AGENTS CH, V41, P2321.
   Solberg CO, 2000, SCAND J INFECT DIS, V32, P587, DOI 10.1080/003655400459478.
   TSCHAPE H, 1995, EPIDEMIOL INFECT, V114, P441, DOI 10.1017/S0950268800052158.
   Wilson I G, 2004, Commun Dis Public Health, V7, P349.
   Wise MG, 2005, APPL ENVIRON MICROB, V71, P3911, DOI 10.1128/AEM.71.7.3911-3916.2005.
   Yu ZT, 2005, APPL ENVIRON MICROB, V71, P6926, DOI 10.1128/AEM.71.11.6926-6933.2005.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{27}},
Journal-ISO = {{Int. J. Hyg. Environ. Health.}},
Doc-Delivery-Number = {{V21OK}},
Unique-ID = {{ISI:000208216700006}},
DA = {{2018-08-13}},
}

@article{ ISI:000284250000007,
Author = {Iwabuchi, Eriko and Maruyama, Noriko and Hara, Ayumi and Nishimura,
   Masaaki and Muramatsu, Masatake and Ochiai, Tameichi and Hirai, Katsuya},
Title = {{Nationwide Survey of Salmonella Prevalence in Environmental Dust from
   Layer Farms in Japan}},
Journal = {{JOURNAL OF FOOD PROTECTION}},
Year = {{2010}},
Volume = {{73}},
Number = {{11}},
Pages = {{1993-2000}},
Month = {{NOV}},
Abstract = {{A nationwide survey was conducted to determine Salmonella prevalence in
   airborne dust from layer farms. Of the 4,090 layer farm; in Japan, 203
   were surveyed and 48 (23.6\%) of these were positive for Salmonella.
   Salmonella isolation rates were higher in the eastern (24.3\%), central
   (25.6\%), western (23.9\%), and southern (27.5\%) prefectures than they
   were in the northern (13.3\%) prefecture. We recovered 380 Salmonella
   isolates and identified 34 different Salmonella serovars. Salmonella
   Infantis was the most prevalent serovar (42 {[}11.1\%] of 380), followed
   by Salmonella Agona (39 {[}10.3\%] of 380), Salmonella Mbandaka (37
   {[}9.7\%] of 380), Salmonella Cerro (32 {[}8.4\%] of 380). Salmonella
   Thompson (29 {[}7.6\%] of 380), and Salmonella Braenderup (27 {[}7.1\%]
   of 380). Of the 380 isolates, 273 (71.8\%) were resistant to more than
   one antibiotic. Salmonella Infantis (41 {[}97.6\%] of 42), Salmonella
   Agona (38 {[}97.4\%] of 39), and Salmonella Mbandaka (34 {[}91.9\%] of
   37) showed the highest resistance rates. We found 18 different
   resistance patterns and the most common (179 {[}47.1\%] of 273) was
   resistant to dihydrostreptomycin. One of the 13 Salmonella Hadar
   isolates was resistant to eight antibiotics. To investigate
   characteristics of Salmonella Agona, Salmonella Infantis, and Salmonella
   Mbandaka isolates across different prefectures, we performed
   pulsed-field gel electrophresis by using Xbal and Blnl. The Salmonella
   Agona and Salmonella Mbandaka dendrograms were grouped into seven
   clusters, with 80 and 70\% similarity, respectively. Because the
   Salmonella Infantis dendrogram showed low similarity, there is a
   possibility of genetic diffusion of this serovar across Japan. This
   report is the first to describe Salmonella contamination in airborne
   dust from layer farms in Japan. Our findings should be useful for future
   Salmonella infection monitoring and control.}},
Publisher = {{INT ASSOC FOOD PROTECTION}},
Address = {{6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Iwabuchi, E (Reprint Author), Tenshi Coll, Dept Nutr, Sch Nursing \& Nutr, Higashi Ku, Sapporo, Hokkaido 0650013, Japan.
   Iwabuchi, Eriko; Hirai, Katsuya, Tenshi Coll, Dept Nutr, Sch Nursing \& Nutr, Higashi Ku, Sapporo, Hokkaido 0650013, Japan.
   Maruyama, Noriko; Hara, Ayumi; Nishimura, Masaaki; Muramatsu, Masatake, Res Inst Anim Sci Biochem \& Toxicol, Midori Ku, Kanagawa 2520132, Japan.
   Ochiai, Tameichi, Univ E Asia, Grad Sch Integrated Sci \& Art, Yamaguchi 7518503, Japan.}},
DOI = {{10.4315/0362-028X-73.11.1993}},
ISSN = {{0362-028X}},
EISSN = {{1944-9097}},
Keywords-Plus = {{CONTAMINATION; BROILER; FLOCKS; ENTERITIDIS; SURVEILLANCE; INFECTIONS;
   OUTBREAKS; CHICKENS; ENTERICA; FACILITY}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Author-Email = {{iwabuti@tenshi.ac.jp}},
Funding-Acknowledgement = {{Japan Racing Association Foundation}},
Funding-Text = {{This study was supported by Japan Racing Association Foundation. We are
   grateful to the owners of the layer farms for their cooperation on this
   project. In addition, the authors acknowledge many technical assistants
   and graduates of Tenshi College.}},
Cited-References = {{Adak GK, 2002, GUT, V51, P832, DOI 10.1136/gut.51.6.832.
   Adeline HS, 2009, PREV VET MED, V89, P51, DOI 10.1016/j.prevetmed.2009.01.006.
   Byrd JA, 1999, AVIAN DIS, V43, P39, DOI 10.2307/1592760.
   Cardinale E, 2005, J APPL MICROBIOL, V99, P968, DOI 10.1111/j.1365-2672.2005.02618.x.
   Chemaly M, 2009, J FOOD PROTECT, V72, P2071, DOI 10.4315/0362-028X-72.10.2071.
   Chittick P, 2006, J FOOD PROTECT, V69, P1150, DOI 10.4315/0362-028X-69.5.1150.
   Djuretic T, 1996, Commun Dis Rep CDR Rev, V6, pR57.
   GAST KR, 2007, DIS POULTRY, P583.
   HENZLER DJ, 1992, AVIAN DIS, V36, P625, DOI 10.2307/1591757.
   Herikstad H, 2002, EPIDEMIOL INFECT, V129, P1, DOI 10.1017/S0950268802006842.
   HIGGINS R, 1982, AVIAN DIS, V26, P26, DOI 10.2307/1590021.
   IRWIN RJ, 1994, CAN J VET RES, V58, P263.
   Jansen A, 2005, Z GASTROENTEROL, V43, P707, DOI 10.1055/s-2005-858256.
   JONES FT, 1991, J FOOD PROTECT, V54, P502, DOI 10.4315/0362-028X-54.7.502.
   JONES FT, 1995, POULTRY SCI, V74, P753, DOI 10.3382/ps.0740753.
   Limawongpranee S, 1999, AVIAN DIS, V43, P302, DOI 10.2307/1592621.
   Marin C, 2009, POULTRY SCI, V88, P424, DOI 10.3382/ps.2008-00241.
   Murase T, 2001, J FOOD PROTECT, V64, P1912, DOI 10.4315/0362-028X-64.12.1912.
   Nakamura M, 1997, AVIAN DIS, V41, P354, DOI 10.2307/1592189.
   {*}NAT COMM CLIN LAB, 2002, M32A2 NAT COMM CLIN.
   Palmer S, 2000, EPIDEMIOL INFECT, V125, P467, DOI 10.1017/S0950268800004659.
   Pieskus J, 2008, J POULT SCI, V45, P227, DOI 10.2141/jpsa.45.227.
   Poppe C., 2000, Salmonella in domestic animals., P107, DOI 10.1079/9780851992617.0107.
   POPPE C, 1991, EPIDEMIOL INFECT, V106, P259, DOI 10.1017/S0950268800048408.
   POPPE C, 1991, EPIDEMIOL INFECT, V107, P201, DOI 10.1017/S0950268800048822.
   POY P, 2002, AVIAN DIS, V46, P17.
   RENWICK SA, 1992, CAN VET J, V33, P449.
   Santos FBO, 2007, J FOOD PROTECT, V70, P1328, DOI 10.4315/0362-028X-70.6.1328.
   Sasipreeyajan J, 1996, TROP ANIM HEALTH PRO, V28, P174, DOI 10.1007/BF02299571.
   Shirota K, 2001, J FOOD PROTECT, V64, P734, DOI 10.4315/0362-028X-64.5.734.
   Vaillant V, 2005, FOODBORNE PATHOG DIS, V2, P221, DOI 10.1089/fpd.2005.2.221.
   2004, STAT SURVEY LIVESTOC.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Food Prot.}},
Doc-Delivery-Number = {{680QR}},
Unique-ID = {{ISI:000284250000007}},
DA = {{2018-08-13}},
}

@article{ ISI:000285513300036,
Author = {Goveia, Vania Regina and Cunha Pinheiro Ribeiro, Silma Maria and Servolo
   de Medeiros, Eduardo Alexandrino and Campos Pignatari, Antonio Carlos},
Title = {{How to implement the airborne infection isolation room in health-care
   settings with occupational risk for Mycobacterium tuberculosis
   transmission?}},
Journal = {{REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL}},
Year = {{2010}},
Volume = {{43}},
Number = {{6}},
Pages = {{756-757}},
Month = {{NOV-DEC}},
Publisher = {{SOC BRASILEIRA MEDICINA TROPICAL}},
Address = {{UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL}},
Type = {{Letter}},
Language = {{Portuguese}},
Affiliation = {{Goveia, VR (Reprint Author), Univ Fed Minas Gerais, Dept Enfermagem Basica, Escola Enfermagem, ENB EE UFMG, Av Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil.
   Goveia, Vania Regina; Cunha Pinheiro Ribeiro, Silma Maria, Univ Fed Minas Gerais, Dept Enfermagem Basica, Escola Enfermagem, ENB EE UFMG, BR-30130100 Belo Horizonte, MG, Brazil.
   Servolo de Medeiros, Eduardo Alexandrino; Campos Pignatari, Antonio Carlos, Univ Fed Sao Paulo, Disciplina Infectol, Dept Doencas Infecciosas Parasitarias, Escola Paulista Med, Sao Paulo, Brazil.}},
DOI = {{10.1590/S0037-86822010000600036}},
ISSN = {{0037-8682}},
Keywords-Plus = {{ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MULTIDRUG-RESISTANT TUBERCULOSIS;
   NOSOCOMIAL TRANSMISSION; OUTBREAK; WORKERS}},
Research-Areas = {{Parasitology; Tropical Medicine}},
Web-of-Science-Categories  = {{Parasitology; Tropical Medicine}},
Author-Email = {{vaniagoveia@uol.com.br}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P1.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Haas DW, 1998, INFECT CONT HOSP EP, V19, P635.
   Joshi R, 2006, PLOS MED, V3, P494, DOI DOI 10.1371/J0URNAL.PMED.0030494.
   {*}MIN SAUD, 2006, MAN REC CONTR TUB BR.
   PARENTI CF, 2006, DIAGNOSTICO SITUACAO.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   Ridzon R, 1997, INFECT CONT HOSP EP, V18, P422.
   Roth VR, 2005, INT J TUBERC LUNG D, V9, P1335.
   {*}SOC BRAS PNEUM TI, 2004, J BRAS PNEUMOL, V30, P1.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Rev. Soc. Bras. Med. Trop.}},
Doc-Delivery-Number = {{697KU}},
Unique-ID = {{ISI:000285513300036}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000282523500008,
Author = {Haghi, Mehra and Young, Paul M. and Traini, Daniela and Jaiswal, Ritu
   and Gong, Joyce and Bebawy, Mary},
Title = {{Time- and passage-dependent characteristics of a Calu-3 respiratory
   epithelial cell model}},
Journal = {{DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY}},
Year = {{2010}},
Volume = {{36}},
Number = {{10}},
Pages = {{1207-1214}},
Month = {{OCT}},
Abstract = {{Background: Although standard protocols for the study of drug delivery
   in the upper airways using the sub-bronchial epithelial cell line Calu-3
   model, particularly that of the air-liquid interface configuration, are
   readily available, the model remains un-validated with respect to
   culture conditions, barrier integrity, mucous secretion, and transporter
   function. With respect to the latter, the significance of functional
   P-glycoprotein (P-gp) activity in Calu-3 cells has recently been
   questioned, despite previous reports demonstrating a significant
   contribution by the same transporter in limiting drug uptake across the
   pulmonary epithelium. Therefore, the aim of this study was the
   standardization of this model as a tool for drug discovery. Methods:
   Calu-3 cells were grown using air-interfaced condition (AIC) on
   polyester cell culture supports. Monolayers were evaluated for
   transepithelial electrical resistance (TEER), permeability to the
   paracellular marker fluorescein sodium (flu-Na), surface P-gp
   expression, and functionality. Mucous secretion was also identified by
   alcian blue staining. Results: TEER and permeability values obtained for
   Calu-3 monolayers were shown to plateau between day 5 and day 21 in
   culture with values reaching 474 +/- 44 Omega cm(2) and 2.33 +/- 0.36 x
   10(-7) cm/s, respectively, irrespective of the passage number examined.
   32.7 +/- 1.49\% of Calu-3 cells cultured under these conditions detected
   positive for cell surface P-gp expression from day 7 onwards. Functional
   cell surface expression was established by rhodamine 123 drug extrusion
   assays. Conclusion: This study establishes a clear dependence on culture
   time and passage number for optimal barrier integrity, mucous secretion,
   and cell-surface P-gp expression and function in Calu-3 cells.
   Furthermore it provides initial guidelines for the optimization of this
   model for high throughput screening applications.}},
Publisher = {{INFORMA HEALTHCARE}},
Address = {{TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bebawy, M (Reprint Author), Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.
   Haghi, Mehra; Young, Paul M.; Traini, Daniela; Jaiswal, Ritu; Gong, Joyce; Bebawy, Mary, Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.}},
DOI = {{10.3109/03639041003695113}},
ISSN = {{0363-9045}},
Keywords = {{Calu-3; culture conditions; P-glycoprotein; P-gp; respiratory epithelium}},
Keywords-Plus = {{PULMONARY DRUG-DELIVERY; P-GLYCOPROTEIN; LINE CALU-3;
   MULTIDRUG-RESISTANCE; CULTURE; ABSORPTION; TRANSPORT; MONOLAYERS;
   PROTEIN; METABOLISM}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Pharmacology \& Pharmacy}},
Author-Email = {{mary.bebauy@sydney.edu.au}},
ResearcherID-Numbers = {{Traini, Daniela/N-3272-2013
   }},
ORCID-Numbers = {{Traini, Daniela/0000-0002-7173-017X
   Jaiswal, Ritu/0000-0002-8691-1352
   Haghi, Mehra/0000-0002-3362-1845
   Bebawy, Mary/0000-0003-2606-921X}},
Cited-References = {{Babu PBR, 2004, BIOCHEM BIOPH RES CO, V319, P1132, DOI 10.1016/j.bbrc.2004.05.101.
   Bebawy M, 2001, BRIT J CANCER, V85, P1998, DOI 10.1054/bjoc.2001.2184.
   Behrens I, 2003, EUR J PHARM SCI, V19, P433, DOI 10.1016/S0928-0987(03)00146-5.
   Borchard G, 2002, J PHARM SCI, V91, P1561, DOI 10.1002/jps.10151.
   BUTLER M, 1982, IN VITRO CELL DEV B, V18, P213.
   Chen XM, 2008, ANAL BIOCHEM, V381, P185, DOI 10.1016/j.ab.2008.07.013.
   Crivellato E, 1997, HISTOCHEM J, V29, P193, DOI 10.1023/A:1026445724699.
   Ehrhardt C, 2002, J AEROSOL MED, V15, P131, DOI 10.1089/089426802320282257.
   Elbert KJ, 1999, PHARMACEUT RES, V16, P601, DOI 10.1023/A:1018887501927.
   Fenneteau F, 2009, THEOR BIOL MED MODEL, V6, DOI 10.1186/1742-4682-6-2.
   Fiegel J, 2003, PHARMACEUT RES, V20, P788, DOI 10.1023/A:1023441804464.
   Florea BI, 2003, J CONTROL RELEASE, V87, P131, DOI 10.1016/S0168-3659(02)00356-5.
   Forbes B, 2003, INT J PHARM, V257, P161, DOI 10.1016/S0378-5173(03)00129-7.
   Forbes B, 2005, EUR J PHARM BIOPHARM, V60, P193, DOI 10.1016/j.ejpb.2005.02.010.
   Foster KA, 2000, INT J PHARM, V208, P1, DOI 10.1016/S0378-5173(00)00452-X.
   Fromm MF, 2003, EUR J CLIN INVEST, V33, P6, DOI 10.1046/j.1365-2362.33.s2.4.x.
   Fu D, 2004, INT J CANCER, V109, P174, DOI 10.1002/ijc.11659.
   Gonda I, 2006, J AEROSOL MED, V19, P47, DOI 10.1089/jam.2006.19.47.
   Gonda I, 2000, J PHARM SCI, V89, P940, DOI 10.1002/1520-6017(200007)89:7<940::AID-JPS11>3.3.CO;2-2.
   Grainger CI, 2006, PHARM RES, V23, P1482, DOI 10.1007/s11095-006-0255-0.
   GROBSTEIN C, 1953, NATURE, V172, P869, DOI 10.1038/172869a0.
   Hamilton KO, 2001, J PHARM SCI, V90, P647, DOI 10.1002/1520-6017(200105)90:5<647::AID-JPS1021>3.0.CO;2-G.
   Hamilton KO, 2001, J PHARMACOL EXP THER, V298, P1199.
   Inglis SK, 1998, AM J PHYSIOL-LUNG C, V274, pL762, DOI 10.1152/ajplung.1998.274.5.L762.
   Madlova M, 2009, J PHARM PHARMACOL, V61, P293, DOI 10.1211/jpp/61.03.0003.
   Mathias NR, 2002, J DRUG TARGET, V10, P31, DOI 10.1080/10611860290007504.
   Ng YL, 2008, BIOPROC BIOSYST ENG, V31, P393, DOI 10.1007/s00449-007-0174-4.
   Sullivan Vincent J, 2006, Expert Opin Drug Deliv, V3, P87, DOI 10.1517/17425247.3.1.87.
   Toropainen E, 2001, INVEST OPHTH VIS SCI, V42, P2942.
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943.
   Widdicombe JH, 2003, IN VITRO CELL DEV-AN, V39, P51.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{62}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Drug Dev. Ind. Pharm.}},
Doc-Delivery-Number = {{658WK}},
Unique-ID = {{ISI:000282523500008}},
DA = {{2018-08-13}},
}

@article{ ISI:000282473700036,
Author = {Erkens, C. G. M. and Kamphorst, M. and Abubakar, I. and Bothamley, G. H.
   and Chemtob, D. and Haas, W. and Migliori, G. B. and Rieder, H. L. and
   Zellweger, J-P. and Lange, C.},
Title = {{Tuberculosis contact investigation in low prevalence countries: a
   European consensus}},
Journal = {{EUROPEAN RESPIRATORY JOURNAL}},
Year = {{2010}},
Volume = {{36}},
Number = {{4}},
Pages = {{925-949}},
Month = {{OCT}},
Abstract = {{Contact investigation to identify individuals with tuberculosis and
   latent infection with Mycobacterium tuberculosis is an important
   component of tuberculosis control in low tuberculosis incidence
   countries. This document provides evidence-based and best-practice
   policy recommendations for contact tracing among high-and
   medium-priority contacts in a variety of settings. It provides a basis
   for national guidelines on contact investigation and tuberculosis
   outbreak management, and should support countries and tuberculosis
   control managers in evaluating and revising national policies. A review
   of existing guidelines, a literature search, several meetings and
   consultation with experts were used to formulate and grade
   recommendations for action during contact investigation.
   Available tests to identify individuals with latent infection with M.
   tuberculosis are designed to identify immune response against
   mycobacterial antigens and have variable predictive value for the
   likelihood to develop active tuberculosis in different populations.
   Contact investigation should therefore be limited to situations with a
   clear likelihood of transmission or to those with a higher probability
   of developing active tuberculosis, for instance, young children and
   immunocompromised persons. A risk assessment-based approach is
   recommended, where the need to screen contacts is prioritised on the
   basis of the infectiousness of the index case, intensity of exposure and
   susceptibility of contacts.}},
Publisher = {{EUROPEAN RESPIRATORY SOC JOURNALS LTD}},
Address = {{442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Erkens, CGM (Reprint Author), KNCV TB Fdn, Parkstr 17,POB 146, NL-2501 CC The Hague, Netherlands.
   Erkens, C. G. M.; Kamphorst, M., KNCV TB Fdn, NL-2501 CC The Hague, Netherlands.
   Kamphorst, M., Municipal Publ Hlth Serv Rotterdam Rijnmond, Dept TB Control, Rotterdam, Netherlands.
   Abubakar, I., Hlth Protect Agcy Ctr Infect, TB Sect, London, England.
   Bothamley, G. H., Homerton Univ Hosp, N E London TB Network, London, England.
   Chemtob, D., Dept TB \& AIDS, Jerusalem, Israel.
   Haas, W., Robert Koch Inst, D-1000 Berlin, Germany.
   Lange, C., Res Ctr Borstel, Borstel, Germany.
   Lange, C., Univ Lubeck, Lubeck, Germany.
   Migliori, G. B., Fdn S Maugeri, Care \& Res Inst, WHO Collaborating Ctr TB \& Lung Dis, Tradate, Italy.
   Rieder, H. L., Int Union TB \& Lung Dis, Paris, France.
   Rieder, H. L., Univ Zurich, Inst Social \& Prevent Med, CH-8006 Zurich, Switzerland.
   Zellweger, J-P., Swiss Lung Assoc, Bern, Switzerland.}},
DOI = {{10.1183/09031936.00201609}},
ISSN = {{0903-1936}},
Keywords = {{Active case finding; contact investigation; consensus statement; latent
   tuberculosis infection; preventive chemotherapy; tuberculosis}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-BOVIS INFECTION; GAMMA
   RELEASE ASSAYS; ISONIAZID PREVENTIVE THERAPY; CALMETTE-GUERIN
   VACCINATION; WORLD-HEALTH-ORGANIZATION; LUNG-DISEASE IUATLD; AIR-BORNE
   INFECTION; LATENT TUBERCULOSIS; SKIN-TEST}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{erkensc@kncvtbc.nl}},
ResearcherID-Numbers = {{Lange, Christoph/J-6289-2012
   }},
ORCID-Numbers = {{Lange, Christoph/0000-0002-9691-4741
   Abubakar, Ibrahim/0000-0002-0370-1430
   Migliori, Giovanni Battista/0000-0002-2597-574X}},
Cited-References = {{Abubakar I, 2010, LANCET INFECT DIS, V10, P176, DOI 10.1016/S1473-3099(10)70028-1.
   Adetifa IMO, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-122.
   Allix-Beguec C, 2008, J CLIN MICROBIOL, V46, P1398, DOI 10.1128/JCM.02089-07.
   {*}AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT\_.
   ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143.
   Arend SM, 2007, AM J RESP CRIT CARE, V175, P618, DOI 10.1164/rccm.200608-1099OC.
   Arend SM, 2002, J INFECT DIS, V186, P1797, DOI 10.1086/345760.
   Arnadottir T, 1996, TUBERCLE LUNG DIS, V77, P1, DOI 10.1016/S0962-8479(96)90127-6.
   Attamna A, 2009, THORAX, V64, P271, DOI 10.1136/thx.2008.100974.
   Bahammam A, 1999, INT J TUBERC LUNG D, V3, P62.
   Bailey WC, 2002, JAMA-J AM MED ASSOC, V287, P996, DOI 10.1001/jama.287.8.996.
   Baily G V, 1980, Indian J Med Res, V72 Suppl, P1.
   Bakari M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-32.
   Bakir M, 2008, ANN INTERN MED, V149, P777, DOI 10.7326/0003-4819-149-11-200812020-00248.
   BARNES PF, 1988, CHEST, V94, P316, DOI 10.1378/chest.94.2.316.
   BEFFA P, 2008, EUR RESPIR J, V31, P31.
   Beglinger C, 2007, SWISS MED WKLY, V137, P621.
   Behr MA, 1998, AM J RESP CRIT CARE, V158, P465, DOI 10.1164/ajrccm.158.2.9801062.
   BENTZON JOHANNE WEIS, 1953, TUBERCLE, V34, P34, DOI 10.1016/S0041-3879(53)80013-9.
   Bergamini BM, 2009, PEDIATRICS, V123, pe419, DOI 10.1542/peds.2008-1722.
   Berkel GM, 2005, INT J TUBERC LUNG D, V9, P310.
   Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195.
   Borgen K, 2008, EUR RESPIR J, V32, P419, DOI 10.1183/09031936.00136607.
   Bothamley GH, 2008, EUR RESPIR J, V32, P1023, DOI 10.1183/09031936.00011708.
   Bothamley Graham H, 2007, Expert Rev Respir Med, V1, P365, DOI 10.1586/17476348.1.3.365.
   BOUCOT KR, 1952, AM REV TUBERC PULM, V65, P1.
   BOUROS D, 1991, CHEST, V99, P416, DOI 10.1378/chest.99.2.416.
   {*}BRIT TUB ASS, 1966, TUBERCLE, V47, P305.
   Brock L, 2004, AM J RESP CRIT CARE, V170, P65, DOI 10.1164/rccm.200402-232OC.
   BRODY JA, 1964, NEW ENGL J MED, V271, P1294, DOI 10.1056/NEJM196412172712505.
   Broekmans JF, 2002, EUR RESPIR J, V19, P765, DOI 10.1183/09031936.02.00261402.
   BROOKS RW, 1984, AM REV RESPIR DIS, V130, P630.
   BROOKS SM, 1973, AM REV RESPIR DIS, V108, P799.
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299.
   BRUCE RM, 1977, ANN INTERN MED, V87, P574, DOI 10.7326/0003-4819-87-5-574.
   Burgos M, 2003, J INFECT DIS, V188, P1878, DOI 10.1086/379895.
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P1.
   Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P1.
   Chia S, 1998, INT J TUBERC LUNG D, V2, P989.
   Chiang CY, 2005, LANCET INFECT DIS, V5, P629, DOI 10.1016/S1473-3099(05)70240-1.
   Christie LJ, 2008, EMERG INFECT DIS, V14, P1473, DOI 10.3201/eid1409.070264.
   CLANCY L, 1991, EUR RESPIR J, V4, P1288.
   Cobelens FG, 2006, CLIN INFECT DIS, V43, P634, DOI 10.1086/506432.
   COMSTOCK GW, 1975, CHEST, V68, P465, DOI 10.1378/chest.68.3\_Supplement.465.
   COMSTOCK GW, 1974, AM J EPIDEMIOL, V99, P131, DOI 10.1093/oxfordjournals.aje.a121593.
   Comstock GW, 1999, INT J TUBERC LUNG D, V3, P847.
   COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479.
   COMSTOCK GW, 1975, AM REV RESPIR DIS, V111, P573.
   COMSTOCK GW, 1964, B WORLD HEALTH ORGAN, V31, P161.
   Conde MB, 2000, AM J RESP CRIT CARE, V162, P2238, DOI 10.1164/ajrccm.162.6.2003125.
   Conde MB, 2003, AM J RESP CRIT CARE, V167, P723, DOI 10.1164/rccm.2111019.
   Cook VJ, 2008, INT J TUBERC LUNG D, V12, P903.
   COWIE RL, 1994, AM J RESP CRIT CARE, V150, P1460, DOI 10.1164/ajrccm.150.5.7952577.
   Curtis AB, 2000, INT J TUBERC LUNG D, V4, P308.
   DARCY HP, 1977, BRIT MED J, V2, P293.
   de Jong BC, 2008, J INFECT DIS, V198, P1037, DOI 10.1086/591504.
   de la Rua-Domenech R, 2006, TUBERCULOSIS, V86, P77, DOI 10.1016/j.tube.2005.05.002.
   de Vries G, 2007, AM J RESP CRIT CARE, V176, P201, DOI 10.1164/rccm.200612-1877OC.
   DEVADATT.S, 1970, B WORLD HEALTH ORGAN, V42, P337.
   Diel R, 2007, Pneumologie, V61, P440, DOI 10.1055/s-2007-959219.
   Diel R, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-77.
   Diel R, 2006, EUR RESPIR J, V28, P16, DOI 10.1183/09031936.06.00107005.
   Diel R, 2008, AM J RESP CRIT CARE, V177, P1164, DOI 10.1164/rccm.200711-1613OC.
   Doherty TM, 2002, J CLIN MICROBIOL, V40, P704, DOI 10.1128/JCM.40.2.704-706.2002.
   Dosanjh DPS, 2008, ANN INTERN MED, V148, P325, DOI 10.7326/0003-4819-148-5-200803040-00003.
   DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031.
   Driver CR, 2002, PUBLIC HEALTH REP, V117, P366, DOI 10.1093/phr/117.4.366.
   DROBNIEWSKI F, 2007, EUROSURVEILLANCE, V12, P260.
   Drobniewski FA, 2006, EUR RESPIR J, V28, P903, DOI 10.1183/09031936.06.00084906.
   EDWARDS J H, 1957, Br J Prev Soc Med, V11, P10.
   EDWARDS L B, 1952, Bull World Health Organ, V5, P245.
   EDWARDS L B, 1952, Bull World Health Organ, V5, P333.
   EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1.
   Ena J, 2005, CLIN INFECT DIS, V40, P670, DOI 10.1086/427802.
   {*}EUR CTR DIS PREV, RISK ASS GUID DIS 2.
   European Centre for Disease Prevention and Control, FRAM ACT PLAN FIGHT.
   Evans JT, 2007, LANCET, V369, P1270, DOI 10.1016/S0140-6736(07)60598-4.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   FELD R, 1976, ARCH INTERN MED, V136, P67, DOI 10.1001/archinte.136.1.67.
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC.
   Ferebee SH, 1969, ADV TUBERC RES, V17, P28.
   Fraser A, 2006, INT J TUBERC LUNG D, V10, P19.
   Gagneux S, 2006, PLOS PATHOG, V2, P603, DOI 10.1371/journal.ppat.0020061.
   Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8.
   Gerald LB, 2002, AM J RESP CRIT CARE, V166, P1122, DOI 10.1164/rccm.200202-124OC.
   Gey van Pittius N. C., 2006, BMC EVOL BIOL, V6, P95.
   Girardi E, 1997, ARCH INTERN MED, V157, P797, DOI 10.1001/archinte.157.7.797.
   GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36.
   Goletti D., 2008, PLos One, pe3417.
   Grange JM, 2001, TUBERCULOSIS, V81, P71, DOI 10.1054/tube.2000.0263.
   GREGG MB, 1985, OXFORD TXB PUBLIC HL, P284.
   Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST.
   GROOTHUIS DG, 1991, MANUAL DIAGNOSTIC PU.
   GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90.
   GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007.
   GULD J, 1958, Bull World Health Organ, V19, P845.
   GUNNELS JJ, 1974, AM REV RESPIR DIS, V109, P323.
   Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227.
   Harboe M, 1996, INFECT IMMUN, V64, P16.
   HERTZBERG GERH, 1957, AN EPIDEMIOLOGICAL INVESTIGATION ACTA TUBERC SCAND SUPPL, V38, P1.
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286.
   {*}INT COMM RED CROS, 2009, GUID CONTR TUB PRIS.
   Jereb J, 2003, INT J TUBERC LUNG D, V7, pS384.
   Jick SS, 2006, ARTHRIT RHEUM-ARTHR, V55, P19, DOI 10.1002/art.21705.
   Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC.
   Jochem K, 1997, CAN J PUBLIC HEALTH, V88, P202.
   Kampmann B, 2009, EUR RESPIR J, V33, P1374, DOI 10.1183/09031936.00153408.
   KAPLAN MH, 1974, CANCER-AM CANCER SOC, V33, P850, DOI 10.1002/1097-0142(197403)33:3<850::AID-CNCR2820330334>3.0.CO;2-H.
   Kaufmann SHE, 2005, J EXP MED, V201, P1693, DOI 10.1084/jem.20050842.
   Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   Kik SV, 2010, EUR RESPIR J, V35, P1346, DOI 10.1183/09031936.00098509.
   Kik SV, 2008, AM J RESP CRIT CARE, V178, P96, DOI 10.1164/rccm.200708-1256OC.
   Kim HA, 1998, CLIN EXP RHEUMATOL, V16, P9.
   Kim SJ, 1995, TUBERCLE LUNG DIS, V76, P529, DOI 10.1016/0962-8479(95)90529-4.
   KNCV Tuberculosis Foundation, 2007, LAND COORD INF RICHT.
   Korner MM, 1997, CHEST, V111, P365, DOI 10.1378/chest.111.2.365.
   Lalvani A, 2006, INT J TUBERC LUNG D, V10, P826.
   Landry J, 2008, INT J TUBERC LUNG D, V12, P1352.
   Lange C, 2010, RESPIROLOGY, V15, P220, DOI 10.1111/j.1440-1843.2009.01692.x.
   Lauzardo M, 2001, CHEST, V119, P640, DOI 10.1378/chest.119.2.640.
   Lawn SD, 1999, BRIT J RADIOL, V72, P339, DOI 10.1259/bjr.72.856.10474493.
   Leyten EMS, 2007, EUR RESPIR J, V29, P1212, DOI 10.1183/09031936.00117506.
   LICHTENSTEIN IH, 1983, REV INFECT DIS, V5, P216.
   LIIPPO KK, 1993, AM REV RESPIR DIS, V148, P235, DOI 10.1164/ajrccm/148.1.235.
   Lin HH, 2007, PLOS MED, V4, P173, DOI 10.1371/journal.pmed.0040020.
   Lonnroth K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-289.
   LONG R, 1991, CHEST, V99, P123, DOI 10.1378/chest.99.1.123.
   LOUDON RG, 1967, AM REV RESPIR DIS, V95, P435.
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109.
   LOUDON RG, 1968, AM REV RESPIR DIS, V98, P297.
   LOUDON RG, 1958, AM REV TUBERC PULM, V77, P623.
   LUNDIN AP, 1979, AM J MED, V67, P597, DOI 10.1016/0002-9343(79)90240-7.
   Maartens G, 2007, LANCET, V370, P2030, DOI 10.1016/S0140-6736(07)61262-8.
   Mack U, 2009, EUR RESPIR J, V33, P956, DOI 10.1183/09031936.00120908.
   Madhi F, 2002, PEDIATR PULM, V34, P159, DOI 10.1002/ppul.10153.
   Malakmadze N, 2005, CLIN INFECT DIS, V40, P366, DOI 10.1086/427112.
   Marais BJ, 2007, PAEDIATR RESPIR REV, V8, P124, DOI 10.1016/j.prrv.2007.04.002.
   Marais BJ, 2004, INT J TUBERC LUNG D, V8, P392.
   Marciniuk DD, 1999, CHEST, V115, P445, DOI 10.1378/chest.115.2.445.
   Marks SM, 2000, AM J RESP CRIT CARE, V162, P2033, DOI 10.1164/ajrccm.162.6.2004022.
   Matulis G, 2008, ANN RHEUM DIS, V67, P84, DOI 10.1136/ard.2007.070789.
   Meijer J, 1971, Bull Int Union Tuberc, V45, P5.
   MELLMAN WJ, 1963, J LAB CLIN MED, V61, P453.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120.
   MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003.
   MITCHISON DA, 1984, BRIT MED BULL, V40, P84, DOI 10.1093/oxfordjournals.bmb.a071952.
   Mohammed A, 2004, INT J TUBERC LUNG D, V8, P792.
   Moonan PK, 2006, AM J RESP CRIT CARE, V174, P599, DOI 10.1164/rccm.200512-1977OC.
   Moonan PK, 2005, INT J TUBERC LUNG D, V9, P322.
   MORI T, 1985, AM REV RESPIR DIS, V131, P886.
   Mori T, 2009, J INFECT CHEMOTHER, V15, P143, DOI 10.1007/s10156-009-0686-8.
   Nardell EA, 2004, AM J RESP CRIT CARE, V169, P553, DOI 10.1164/rccm.2401003.
   Nava-Aguilera E, 2009, INT J TUBERC LUNG D, V13, P17.
   Neuenschwander BE, 2002, AM J EPIDEMIOL, V155, P654, DOI 10.1093/aje/155.7.654.
   ORMEROD LP, 1992, ARCH DIS CHILD, V67, P530, DOI 10.1136/adc.67.4.530.
   OSCARSSON PN, 1958, ACTA MED SCAND, V161, P335.
   PablosMendez A, 1997, AM J PUBLIC HEALTH, V87, P574, DOI 10.2105/AJPH.87.4.574.
   Page KR, 2006, ARCH INTERN MED, V166, P1863, DOI 10.1001/archinte.166.17.1863.
   Pai M, 2008, ANN INTERN MED, V149, P177, DOI 10.7326/0003-4819-149-3-200808050-00241.
   Pai M, 2007, EXPERT REV ANTI-INFE, V5, P385, DOI 10.1586/14787210.5.3.385.
   Pai M, 2006, EXPERT REV MOL DIAGN, V6, P423, DOI 10.1586/14737159.6.3.423.
   PALMER CE, 1957, AM REV TUBERC PULM, V76, P517.
   PALMER JE, 1969, J TOWN PLANN I, V55, P413.
   Papastavros T, 2002, CAN MED ASSOC J, V167, P131.
   Paranjothy S, 2008, BRIT MED J, V337, P573.
   PAUL R, 1961, ARCH ENVIRON HEALTH, V2, P96, DOI 10.1080/00039896.1961.10662823.
   Pelly TF, 2005, INT J TUBERC LUNG D, V9, P977.
   PICKLEMAN JR, 1975, JAMA-J AM MED ASSOC, V234, P744, DOI 10.1001/jama.234.7.744.
   PINTO M R M, 1972, Tubercle, V53, P182, DOI 10.1016/0041-3879(72)90015-3.
   Pollock JM, 1997, J INFECT DIS, V175, P1251, DOI 10.1086/593686.
   Poulsen A, 1950, ACTA TUBERC SCAND, V24, P311.
   Public Health Agency of Canada, 2007, CAN TUB STAND.
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC.
   Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X.
   Reed C, 2006, AM J EPIDEMIOL, V164, P32, DOI 10.1093/aje/kwj159.
   Rehm J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-450.
   Reichman LB, 2004, AM J RESP CRIT CARE, V170, P832, DOI 10.1164/rccm.200405.584PP.
   Rennie TW, 2007, EUR RESPIR J, V30, P728, DOI 10.1183/09031936.00034007.
   Rieder H, 2007, PRIORITIES TUBERCULO.
   Rieder H. L., 2002, INTERVENTIONS TUBERC.
   Rieder HL, 2008, AM J RESP CRIT CARE, V178, P651, DOI 10.1164/ajrccm.178.6.651.
   Rieder HL, 1996, EUR RESPIR J, V9, P1097, DOI 10.1183/09031936.96.09051097.
   RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9.
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046.
   RIEDER HL, 1994, EUR RESPIR J, V7, P1545, DOI 10.1183/09031936.94.07081545.
   RILEY RL, 1974, AM J MED, V57, P466, DOI 10.1016/0002-9343(74)90140-5.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   ROONEY JJ, 1976, AM J MED, V60, P517, DOI 10.1016/0002-9343(76)90718-X.
   RUST P, 1975, AM J EPIDEMIOL, V101, P311, DOI 10.1093/oxfordjournals.aje.a112099.
   SARASIN FP, 1995, TUBERCLE LUNG DIS, V76, P394, DOI 10.1016/0962-8479(95)90004-7.
   Sarmiento OL, 2003, J CLIN MICROBIOL, V41, P3233, DOI 10.1128/JCM.41.7.3233-3240.2003.
   Schwoebel V, 2000, EUR RESPIR J, V16, P364, DOI 10.1183/09031936.00.16236400.
   Seaworth BJ, 2002, INFECT DIS CLIN N AM, V16, P73, DOI 10.1016/S0891-5520(03)00047-3.
   Seidler A, 2005, RESPIRATION, V72, P431, DOI 10.1159/000086261.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Sester M, 2004, KIDNEY INT, V65, P1826, DOI 10.1111/j.1523-1755.2004.00586.x.
   Sester U, 2006, NEPHROL DIAL TRANSPL, V21, P3258, DOI 10.1093/ndt/gfl416.
   Shams H, 2005, AM J RESP CRIT CARE, V172, P1161, DOI 10.1164/rccm.200505-748OC.
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724.
   Shrikrishna D, 2009, THORAX, V64, P89, DOI 10.1136/thx.2008.106302.
   Slam K, 2007, INT J TUBERC LUNG D, V11, P1049.
   SMIEJA MJ, 1999, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001363.
   Smith RMM, 2004, EMERG INFECT DIS, V10, P539, DOI 10.3201/eid1003.020819.
   SMITHROHRBERG D, 2008, SARCOIDOSIS VASC DIF, V33, P130.
   SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125.
   SORENSEN AL, 1995, INFECT IMMUN, V63, P1710.
   STANFORD JL, 1988, TUBERCLE, V69, P293, DOI 10.1016/0041-3879(88)90052-9.
   STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837.
   STEIGER Z, 1976, AM J SURG, V131, P68.
   STEINER P, 1980, AM J DIS CHILD, V134, P747, DOI 10.1001/archpedi.1980.02130200017007.
   STEPHAN C, 2008, AIDS, V22, P2417.
   Sterling TR, 2000, NEW ENGL J MED, V342, P246, DOI 10.1056/NEJM200001273420404.
   Story A, 2007, THORAX, V62, P667, DOI 10.1136/thx.2006.065409.
   Strauss OJ, 2008, J CLIN MICROBIOL, V46, P1514, DOI 10.1128/JCM.01938-07.
   Sutherland I, 1968, TUBERCULOSIS SURVEIL, V1, P61.
   TALA E, 1991, EUR RESPIR J, V4, P1159.
   TAMASHIRO VG, 1987, PEDIATR INFECT DIS J, V6, P451, DOI 10.1097/00006454-198705000-00007.
   TEMPLETON GL, 1995, ANN INTERN MED, V122, P922, DOI 10.7326/0003-4819-122-12-199506150-00005.
   The National Collaborating Centre for Chronic Conditions (UK), 2006, CLIN DIAGN MAN TUB M.
   THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555.
   THORN PA, 1956, BMJ-BRIT MED J, V1, P603, DOI 10.1136/bmj.1.4967.603.
   Tissot F, 2005, CLIN INFECT DIS, V40, P211, DOI 10.1086/426434.
   Toman K, 1979, TUBERCULOSIS CASE FI.
   Torre-Cisneros J, 2009, CLIN INFECT DIS, V48, P1657, DOI 10.1086/599035.
   TOSTMANN A, 2009, CLIN INFECT DIS, V47, P1135.
   Trebucq A, 2005, INT J TUBERC LUNG D, V9, P1097.
   Tubach F, 2009, ARTHRITIS RHEUM-US, V60, P1884, DOI 10.1002/art.24632.
   TVERDAL A, 1986, EUR J RESPIR DIS, V69, P355.
   URBANCZIK R, 2009, INT J TUBERC LUNG D, V13, P801.
   van Geuns H A, 1975, Bull Int Union Tuberc, V50, P107.
   van Zyl Smit RN, 2009, PLOS ONE, V4, pe8517.
   VANZYLSMIT, 2009, AM J RESP CRIT CARE, V180, P49.
   Veen J, 1998, EUR RESPIR J, V12, P505, DOI 10.1183/09031936.98.12020505.
   VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R.
   Veerapathran A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001850.
   Villarino ME, 1997, AM J RESP CRIT CARE, V155, P1735, DOI 10.1164/ajrccm.155.5.9154885.
   Vordermeier HM, 2007, CLIN VACCINE IMMUNOL, V14, P1203, DOI 10.1128/CVI.00116-07.
   Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247.
   WALLGREN A, 1948, Tubercle, V29, P245, DOI 10.1016/S0041-3879(48)80033-4.
   Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804.
   WASZHOCKERT O, 1947, ANN MED FENN, V96, P764.
   Wells WF, 1934, AM J HYG, V20, P619, DOI 10.1093/oxfordjournals.aje.a118098.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   WESSELS G, 1992, ANN TROP PAEDIATR, V12, P277, DOI 10.1080/02724936.1992.11747585.
   WESTERHOLM P, 1986, ENVIRON RES, V41, P339, DOI 10.1016/S0013-9351(86)80195-5.
   {*}WHO, TUB INF CONTR ER EXP.
   {*}WHO, 1955, B WORLD HEALTH ORGAN, V22, P63.
   {*}WHO, FRAM EFF TUB CONTR.
   {*}WHO, TUB CONTR PRIS MAN P.
   {*}WHO, ALL TUB.
   Wolfe F, 2004, ARTHRITIS RHEUM, V50, P372, DOI 10.1002/art.20009.
   Wood R, 2000, J ACQ IMMUN DEF SYND, V23, P75.
   World Health Organization, 2002, INT J TUBERC LUNG D, V6, P378.
   World Health Organization, GUID PROGR MAN DRUG.
   World Health Organization, TUB AIR TRAV GUID PR.
   Wurtz R, 1996, J CLIN MICROBIOL, V34, P1017.
   Younossian AB, 2005, EUR RESPIR J, V26, P462, DOI 10.1183/09031936.05.00006205.
   Yun LWH, 2003, INT J TUBERC LUNG D, V7, pS405.
   2009, LANCET, V373, P1145.
   WOLFHEZE 2008 TUBERC.}},
Number-of-Cited-References = {{264}},
Times-Cited = {{140}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Eur. Resp. J.}},
Doc-Delivery-Number = {{658ER}},
Unique-ID = {{ISI:000282473700036}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000282710700003,
Author = {LoBue, P. A. and Enarson, D. A. and Thoen, T. C.},
Title = {{Tuberculosis in humans and its epidemiology, diagnosis and treatment in
   the United States}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2010}},
Volume = {{14}},
Number = {{10}},
Pages = {{1226-1232}},
Month = {{OCT}},
Abstract = {{Tuberculosis (TB) is a pulmonary and systemic disease caused by
   Mycobacterium tuberculosis complex species. TB is spread from person to
   person by airborne transmission. Several factors determine the
   probability of transmission, including the infectiousness of the source
   patient and the nature of the environment where exposure occurs. This
   initial infection (primary TB) rapidly progresses to disease in some
   persons (especially children and immunocompromised persons), but
   resolves spontaneously in most individuals. This condition in which the
   organism lies dormant is known as latent TB infection (LTBI). In the
   United States, the diagnosis of LTBI is made with either the tuberculin
   skin test or an interferon-gamma release assay. LTBI is treated with
   isoniazid (INH; usually for 9 months) to prevent progression to TB
   disease. Up to 5\% of immunocompetent persons will progress to TB
   disease at some time in the future, even decades after infection, if
   they are not treated for LTBI. Pulmonary TB disease is diagnosed using a
   combination of chest radiography and microscopic examination, culture
   and nucleic acid amplification testing of sputum. Treatment of
   drug-susceptible TB consists of at least 6 months of an INH and
   rifampin-containing regimen (with ethambutol and pyrazinamide for the
   first 2 months). In the United States, drug-resistant TB is relatively
   rare (approximately 1\% of all patients), and is treated with an 18-24
   month individualized regimen based on drug susceptibility test results.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Enarson, DA (Reprint Author), Int Union TB \& Lung Dis, 68 Bd St Michel, F-75006 Paris, France.
   Enarson, D. A., Int Union TB \& Lung Dis, F-75006 Paris, France.
   LoBue, P. A., Ctr Dis Control \& Prevent, Atlanta, GA USA.
   Thoen, T. C., Iowa State Univ, Ames, IA USA.}},
ISSN = {{1027-3719}},
EISSN = {{1815-7920}},
Keywords = {{tuberculosis; treatment; epidemiology}},
Keywords-Plus = {{IMMUNODEFICIENCY-VIRUS-INFECTION; MANIFESTATIONS; ASSAY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{denarson@theunion.org}},
Cited-References = {{{*}AM THOR SOC, 2000, MMWR RECOMM REP, V49, P1.
   {*}AM THOR SOC CDCP, 2003, AM J RESP CRIT CARE, V167, P603.
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Catanzaro A, 2000, JAMA-J AM MED ASSOC, V283, P639, DOI 10.1001/jama.283.5.639.
   {*}CDCP, 2008, MMWR-MORBID MORTAL W, V57, P281.
   {*}CDCP, 2008, REP TUB US 2007.
   Centers for Disease Control and Prevention, 2007, MAN DRUG INT TREATM.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28.
   FRANCIS J, 2004, DRUG RESISTANT TUBER.
   Goble Marian, 1994, P259.
   Havlir DV, 1999, NEW ENGL J MED, V340, P367, DOI 10.1056/NEJM199902043400507.
   {*}I MED, 2000, END NEGL EL TUB US, P27.
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292.
   KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991.
   LoBue PA, 2003, AM J RESP CRIT CARE, V168, P443, DOI 10.1164/rccm.200303-390OC.
   LoBue PA, 2005, INT J TUBERC LUNG D, V9, P501.
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   MCADAMS HP, 1995, RADIOL CLIN N AM, V33, P655.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014.
   Pai M, 2008, ANN INTERN MED, V149, P177, DOI 10.7326/0003-4819-149-3-200808050-00241.
   Parsons LM, 2002, J CLIN MICROBIOL, V40, P2339, DOI 10.1128/JCM.40.7.2339-2345.2002.
   Thoen C, 2006, VET MICROBIOL, V112, P339, DOI 10.1016/j.vetmic.2005.11.047.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{42}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{661FR}},
Unique-ID = {{ISI:000282710700003}},
DA = {{2018-08-13}},
}

@article{ ISI:000282710700004,
Author = {Nardell, E. and Dharmadhikari, A.},
Title = {{Turning off the spigot: reducing drug-resistant tuberculosis
   transmission in resource-limited settings}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2010}},
Volume = {{14}},
Number = {{10}},
Pages = {{1233-1243}},
Month = {{OCT}},
Abstract = {{Ongoing transmission and re-infection, primarily in congregate settings,
   is a key factor fueling the global multidrug-resistant/extensively
   drug-resistant tuberculosis (MDR/XDR-TB) epidemic, especially in
   association with the human immunodeficiency virus. Even as efforts to
   broadly implement conventional TB transmission control measures begin,
   current strategies may be incompletely effective under the overcrowded
   conditions extant in high-burden, resource-limited settings.
   Longstanding evidence suggesting that TB patients on effective therapy
   rapidly become non-infectious and that unsuspected, untreated TB cases
   account for the most transmission makes a strong case for the
   implementation of rapid point-of-care diagnostics coupled with fully
   supervised effective treatment. Among the most important decisions
   affecting transmission, the choice of an MDR-TB treatment model that
   includes community-based treatment may offer important advantages over
   hospital or clinic-based care, not only in cost and effectiveness, but
   also in transmission control. In the community, too, rapid
   identification of infectious cases, especially drug-resistant cases,
   followed by effective, fully supervised treatment, is critical to
   stopping transmission. Among the conventional interventions available,
   we present a simple triage and separation strategy, point out that
   separation is intimately linked to the design and engineering of
   clinical space and call attention to the pros and cons of natural
   ventilation, simple mechanical ventilation systems, germicidal
   ultraviolet air disinfection, fit-tested respirators on health care
   workers and short-term use of masks on patients before treatment is
   initiated.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nardell, E (Reprint Author), Harvard Univ, Brigham \& Womens Hosp, Div Global Hlth Equ, Sch Med, F\&B Bldg,7th Floor,651 Huntington Ave, Boston, MA 02115 USA.
   Nardell, E., Harvard Univ, Brigham \& Womens Hosp, Div Global Hlth Equ, Sch Med, Boston, MA 02115 USA.
   Dharmadhikari, A., Harvard Univ, Brigham \& Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.}},
ISSN = {{1027-3719}},
EISSN = {{1815-7920}},
Keywords = {{nosocomial; resistance; drug; tuberculosis}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; AIR DISINFECTION; ULTRAVIOLET-IRRADIATION; RURAL
   HAITI; MDR-TB; COMMUNITY; HIV; PERU; LIMA; CHEMOTHERAPY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Author-Email = {{enardell@pih.org}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}K23 AI084548]}},
Cited-References = {{ACCINELLI R, 2002, AM J RESP CRIT CARE, V165, pA439.
   BALASUBRAMANIAN V, 1994, TUBERCLE LUNG DIS, V75, P168, DOI 10.1016/0962-8479(94)90002-7.
   BROOKS SM, 1973, AM REV RESPIR DIS, V108, P799.
   BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x.
   CIE, 2010, 1872010 CIE.
   Desvarieux M, 2001, AM J PUBLIC HEALTH, V91, P138.
   DHARMADHIKARI A, 2009, INT J TUBERC LUNG S1, V13, pS364.
   Dumyahn T, 1999, AM IND HYG ASSOC J, V60, P219, DOI 10.1202/0002-8894(1999)060<0219:COUURA>2.0.CO;2.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Escombe AR, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000043.
   Escombe AR, 2008, PLOS MED, V5, P1387, DOI 10.1371/journal.pmed.0050188.
   Farmer P, 1999, INT J TUBERC LUNG D, V3, P643.
   Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671.
   Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8.
   Figueroa-Munoz J, 2005, HUM RESOUR HEALTH, V3, P2.
   Fine PEM, 1998, NOVART FDN SYMP, V217, P57, DOI 10.1002/0470846526.ch5.
   Fine PEM, 1996, INT J LEPROSY, V64, P448.
   FINE PEM, 1998, NOVART FDN SYMP, V217, P69.
   First M., 1999, ASHRAE T, V105, P877.
   First MW, 2005, J OCCUP ENVIRON HYG, V2, P285, DOI 10.1080/1545962059095224.
   FIRST MW, 1999, ASHRAE T, V105, P869.
   Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Gelmanova IY, 2007, B WORLD HEALTH ORGAN, V85, P703, DOI 10.2471/BLT.06.038331.
   GUNNELS JJ, 1977, HOSPITALS, V51, P133.
   HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   KAMAT SR, 1966, B WORLD HEALTH ORGAN, V34, P517.
   Kangovi S, 2009, J COMMUN HEALTH, V34, P506, DOI 10.1007/s10900-009-9174-4.
   KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5.
   Koenig SP, 2004, AIDS, V18, pS21, DOI 10.1097/01.aids.0000131308.62828.45.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   NARDELL EA, 1993, INFECT CONT HOSP EP, V14, P681.
   Nardell EA, 2002, INT J TUBERC LUNG D, V6, P647.
   Nardell EA, 2008, PUBLIC HEALTH REP, V123, P52, DOI 10.1177/003335490812300108.
   Nardell Edward A, 2003, Semin Respir Infect, V18, P307.
   {*}NAT AC I MED, 2009, ADDR THREAT DRUG RES.
   National Institute for Occupational Safety and Health, 2009, ENV CONTR TUB BAS UP.
   RILEY RL, 1974, AM REV RESPIR DIS, V110, P810.
   RILEY RL, 1995, AM J EPIDEMIOL, V142, P3, DOI 10.1093/oxfordjournals.aje.a117542.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2.
   Rudnick SN, 2007, J OCCUP ENVIRON HYG, V4, P352, DOI 10.1080/15459620701298167.
   Seung KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007186.
   Shen GM, 2006, EMERG INFECT DIS, V12, P1776, DOI 10.3201/eid1211.051207.
   Shin S, 2004, SOC SCI MED, V59, P1529, DOI 10.1016/j.socscimed.2004.01.027.
   Sonnenberg P, 2004, AIDS, V18, P657, DOI 10.1097/01.aids.0000111404.02002ce.
   Walton DA, 2004, J PUBLIC HEALTH POL, V25, P137, DOI 10.1057/palgrave.jphp.3190013.
   Wandwalo E, 2004, INT J TUBERC LUNG D, V8, P1248.
   Wandwalo E, 2006, HEALTH POLICY, V78, P284, DOI 10.1016/j.healthpol.2005.11.010.
   Wandwalo Eliud, 2005, Cost Eff Resour Alloc, V3, P6, DOI 10.1186/1478-7547-3-6.
   WHO, 2006, WHOHTMSTB200635.
   {*}WHO, 1999, WHOTB99269.
   WHO, 2009, NAT VENT INF CONTR H.
   WHO, 2009, MIN M HIGH M XDR TB.
   Willingham FF, 2001, EMERG INFECT DIS, V7, P123, DOI 10.3201/eid0701.010117.
   World Health Organization, 2009, WHOHTMTB2009419.
   World Health Organization, 2010, MULT EXT DRUG RES TU.}},
Number-of-Cited-References = {{59}},
Times-Cited = {{46}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{661FR}},
Unique-ID = {{ISI:000282710700004}},
DA = {{2018-08-13}},
}

@article{ ISI:000285226600071,
Author = {Kumar, Sandeep and Benjamin, Jane C. and Lawrence, Rubina and Kumar,
   Kaushalendra},
Title = {{Evaluation of Selected Nosocomial Bacterial Pathogens Isolated from
   Hospital Aerosol and their Antibiotic Susceptibility Pattern}},
Journal = {{JOURNAL OF PURE AND APPLIED MICROBIOLOGY}},
Year = {{2010}},
Volume = {{4}},
Number = {{2}},
Pages = {{903-906}},
Month = {{OCT}},
Abstract = {{Air sample from various wards of different hospitals of Allahabad city
   were analyzed for the incidence of pathogenic microorganisms. Evaluation
   of isolates for detection of selected pathogen in various samples.
   Staphylococcus aureus (43.85\%) gave highest incidence, which causes
   major microbial infection. Least incidence was found to be of
   Pseudomonas aeruginosa (8.9\%). Antibiotic susceptibility pattern of the
   isolated pathogen showed highest resistance against Gentamycin and
   Methicillin. Imipenem was found to be most effective against all the
   isolates. There is a pressing need for a continued surveillance that
   must be applied periodically to detect possible changes in the level of
   microorganism. Monitoring of multidrug resistance pattern is also
   required for these bioaerosols, along with adequate ventilation control
   and the occupant density.}},
Publisher = {{DR M N KHAN}},
Address = {{54, NEAR POST OFFICE, THANA ST, BHOPAL, SHAHJAHANABAD 462 001, INDIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kumar, S (Reprint Author), Deemed Univ, Dept Microbiol, Allahabad Agr Inst, Allahabad, Uttar Pradesh, India.
   Kumar, Sandeep; Benjamin, Jane C.; Lawrence, Rubina, Deemed Univ, Dept Microbiol, Allahabad Agr Inst, Allahabad, Uttar Pradesh, India.
   Kumar, Kaushalendra, Indian Vet Res Inst, Anim Nutr Div, Rumen Microbiol Lab, Izatnagar 243122, Bareilly, India.}},
ISSN = {{0973-7510}},
Keywords = {{Air sample; Hospital environment; Nosocomial infection; Antibiotic
   resistance pattern}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{sandeep\_ritwik@hotmail.com}},
Cited-References = {{BABAY HAH, 2006, JAPANESE J INFECT DI, V60, P123.
   BAUER RW, 1966, AM J CLIN PATHOL, V45, P493.
   BROOKS SM, 1995, MOSBY YEAR BOOK, P9.
   FAVERO MS, 1968, APPL MICROBIOL, V16, P480.
   Holt J, 1984, BERGEYS MANUAL SYSTE, V1.
   KOWALSKI WJ, 2007, HAPC ENG, P1.
   KUMAR A, 2006, PULMON, V3, P84.
   LOLEKHA S, 1981, PHILIPPIAN J MICROBI, P103.
   Mathur P, 2005, INDIAN J MED RES, V122, P305.
   Sobotova L, 2006, INDOOR BUILT ENVIRON, V15, P73, DOI 10.1177/1420326X06062370.
   SRIKANTH P, 2007, HISICON, V11, P3.
   Wayne P.A., 2003, MIWS13M2 CLSI, P1.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Pure Appl. Microbiol.}},
Doc-Delivery-Number = {{693LW}},
Unique-ID = {{ISI:000285226600071}},
DA = {{2018-08-13}},
}

@article{ ISI:000281705500047,
Author = {Kong, Weijun and Li, Zulun and Xiao, Xiaohe and Zhao, Yanling and Zhang,
   Ping},
Title = {{Activity of berberine on Shigella dysenteriae investigated by
   microcalorimetry and multivariate analysis}},
Journal = {{JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY}},
Year = {{2010}},
Volume = {{102}},
Number = {{1}},
Pages = {{331-336}},
Month = {{OCT}},
Abstract = {{In this study, the microcalorimetric method was applied to investigate
   the activity of berberine on Shigella dysenteriae (S. dysenteriae). Heat
   flow power (HFP)-time curves of the growth metabolism of S. dysenteriae
   affected by berberine were determined using the thermal activity monitor
   (TAM) air isothermal microcalorimeter, ampoule mode, at 37 A degrees C.
   By analyzing these curves and some quantitative parameters using
   multivariate analytical methods, similarity analysis (SA) and principal
   component analysis (PCA), the antibacterial activity of berberine on S.
   dysenteriae could be accurately evaluated from the change of the two
   main parameters, the maximum heat flow power P (m) (2) and total heat
   output Q (t): berberine at low concentration (25 mu g mL(-1)) began to
   inhibit the growth of S. dysenteriae, high concentrations (50-200 mu g
   mL(-1)) of berberine had strong antibacterial activity on S.
   dysenteriae, when the concentration of berberine was higher (250-300 mu
   g mL(-1)), this antibacterial activity was stronger. All these
   illustrated that the antibacterial activity of berberine on S.
   dysenteriae was enhanced with the increase of the concentration of this
   compound. Berberine can be used as potential novel antibacterial agent
   for treating multidrug-resistant Shigella. This work provided a useful
   idea of the combination of microcalorimetry and multivariate analysis
   for studying the activity of other compounds or drugs on organisms.}},
Publisher = {{SPRINGER}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Li, ZL (Reprint Author), Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 611137, Sichuan, Peoples R China.
   Kong, Weijun; Li, Zulun, Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 611137, Sichuan, Peoples R China.
   Kong, Weijun; Xiao, Xiaohe; Zhao, Yanling; Zhang, Ping, 302 Mil Hosp China, China Mil Inst Chinese Mat Med, Beijing 100039, Peoples R China.}},
DOI = {{10.1007/s10973-010-0778-9}},
ISSN = {{1388-6150}},
Keywords = {{Berberine; S. dysenteriae; Microcalorimetry; Multivariate analysis}},
Keywords-Plus = {{PRINCIPAL COMPONENT ANALYSIS; INFECTIOUS-DISEASES; STRATEGIES;
   RESISTANCE; ALKALOIDS; GROWTH}},
Research-Areas = {{Thermodynamics; Chemistry}},
Web-of-Science-Categories  = {{Thermodynamics; Chemistry, Analytical; Chemistry, Physical}},
Author-Email = {{kongwj302@126.com}},
Funding-Acknowledgement = {{National Basic Research Program of China {[}2007CB512607]; Foundation of
   State Youth Science {[}30625042]; National Natural Science Fond
   {[}30772740]}},
Funding-Text = {{We are grateful to the support of National Basic Research Program of
   China (973 project) (2007CB512607); Foundation of State Youth Science
   (30625042) and National Natural Science Fond (No. 30772740). We thank
   the reviewers for their critical comments on the manuscript.}},
Cited-References = {{Alekshun MN, 2007, CELL, V128, P1037, DOI 10.1016/j.cell.2007.03.004.
   Antonelli ML, 2008, J THERM ANAL CALORIM, V91, P113, DOI 10.1007/s10973-007-8366-3.
   Bellavia G, 2009, J THERM ANAL CALORIM, V95, P699, DOI 10.1007/s10973-008-9490-4.
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536.
   Kong WJ, 2009, J APPL MICROBIOL, V107, P1072, DOI 10.1111/j.1365-2672.2009.04292.x.
   Kong WJ, 2008, J CHROMATOGR B, V871, P109, DOI 10.1016/j.jchromb.2008.06.053.
   Kong WJ, 2009, PHYTOMEDICINE, V16, P950, DOI 10.1016/j.phymed.2009.03.016.
   Kong WJ, 2009, J HAZARD MATER, V168, P609, DOI 10.1016/j.jhazmat.2009.02.071.
   Kong WJ, 2009, CHINESE J CHEM, V27, P1186, DOI 10.1002/cjoc.200990199.
   Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651.
   LINDBERG AA, 1993, VACCINE, V11, P168, DOI 10.1016/0264-410X(93)90014-O.
   Matos CRS, 2007, ANAL CHEM, V79, P2091, DOI 10.1021/ac061991n.
   Montanari MLC, 2004, THERMOCHIM ACTA, V417, P283, DOI 10.1016/j.tca.2003.07.024.
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759.
   ROKAR R, 2008, J THERM ANAL CALORIM, V92, P791.
   Ruan L, 2007, J THERM ANAL CALORIM, V89, P953, DOI 10.1007/s10973-005-7278-3.
   Sommer MOA, 2009, SCIENCE, V325, P1128, DOI 10.1126/science.1176950.
   Sur D, 2004, INDIAN J MED RES, V120, P454.
   Wadso I, 2002, THERMOCHIM ACTA, V394, P305, DOI 10.1016/S0040-6031(02)00263-0.
   World Health Organization, 2005, GUID CONTR SHIG INCL, V1.
   Xie P S., 2005, CHROMATOGRAPHIC FING.
   Yan D, 2009, J THERM ANAL CALORIM, V95, P495, DOI 10.1007/s10973-008-9273-y.
   Yang Y, 2007, LISHIZHEN MED MAT ME, V18, P3013.
   Zhao YL, 2010, J THERM ANAL CALORIM, V102, P49, DOI 10.1007/s10973-009-0565-7.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{23}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Therm. Anal. Calorim.}},
Doc-Delivery-Number = {{648PD}},
Unique-ID = {{ISI:000281705500047}},
DA = {{2018-08-13}},
}

@article{ ISI:000281931500057,
Author = {Brooks, J. P. and McLaughlin, M. R. and Scheffler, B. and Miles, D. M.},
Title = {{Microbial and antibiotic resistant constituents associated with
   biological aerosols and poultry litter within a commercial poultry house}},
Journal = {{SCIENCE OF THE TOTAL ENVIRONMENT}},
Year = {{2010}},
Volume = {{408}},
Number = {{20}},
Pages = {{4770-4777}},
Month = {{SEP 15}},
Abstract = {{Poultry are known to harbor antibiotic resistant and pathogenic
   bacteria, and as such poultry litter and poultry house air can be
   contaminated with these bacteria. However, the presence of antibiotic
   resistant bacteria in biological aerosols and litter is largely not
   understood. The purpose of this study was to determine the amount of
   aerosolized bacteria and endotoxin, particularly fecal indicators,
   staphylococci, and enterococci, associated with poultry house and
   outdoor air. Aerosol samples were collected at multiple locations on the
   farm and in the house. Antibiotic resistance was investigated using the
   Kirby Bauer method on selected isolates using twelve different
   antibiotics spanning both narrow to broad spectrums of effectiveness.
   Overall there was a cyclical increase in bacterial concentrations as
   flocks progressed from pre-flock to late-flock, with >2 orders magnitude
   lower concentration during pre-flock periods (no chickens), in both the
   litter and aerosol samples. The house environment provided for
   significantly concentrated bacterial and endotoxin levels. It was
   estimated that Staphylococcus bacteria accounted for at least 90\% of
   cultured aerobic bacteria and culture-independent 165 rRNA analyses
   demonstrated that significant population changes occurred from pre- to
   late-flock. Rarely was an isolate resistant to more than 4 antibiotic
   classes; however there was a trend upwards in overall resistance of
   enterococci as the flock cycle progressed. It appears that although
   levels of antibiotic resistant bacteria were highly concentrated within
   the house, levels were much lower outside of the house, and very little
   house escape occurred. Published by Elsevier B.V.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Brooks, JP (Reprint Author), 810 Hwy 12 E, Mississippi State, MS 39762 USA.
   Brooks, J. P.; McLaughlin, M. R.; Miles, D. M., ARS, USDA, Genet \& Precis Agr Unit, Mississippi State, MS 39762 USA.
   Scheffler, B., ARS, USDA, Genet \& Bioinformat Res Unit, Stoneville, MS 38776 USA.}},
DOI = {{10.1016/j.scitotenv.2010.06.038}},
ISSN = {{0048-9697}},
Keywords = {{Poultry; Aerosol; Bacteria; Antibiotic resistant; 16S rRNA}},
Keywords-Plus = {{RISK-FACTORS; SALMONELLA; BIOSOLIDS; PATHOGENS; INDICATORS; REGROWTH;
   BROILERS; BACTERIA}},
Research-Areas = {{Environmental Sciences \& Ecology}},
Web-of-Science-Categories  = {{Environmental Sciences}},
Author-Email = {{john.brooks@ars.usda.gov}},
ORCID-Numbers = {{Scheffler, Brian/0000-0003-1968-8952}},
Cited-References = {{Al-Zenki SF, 2009, J APPL POULTRY RES, V18, P23, DOI 10.3382/japr.2008-00036.
   {[}Anonymous], ADWEEK.
   Associated Press, ASS PRESS.
   Bakutis B, 2004, ACTA VET BRNO, V73, P283, DOI 10.2754/avb200473020283.
   Banhazi TM, 2008, BIOSYST ENG, V101, P100, DOI 10.1016/j.biosystemseng.2008.06.007.
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493.
   Baykov B, 1999, FEMS MICROBIOL ECOL, V29, P389, DOI 10.1111/j.1574-6941.1999.tb00629.x.
   Brooks JP, 2009, J ENVIRON QUAL, V38, P2431, DOI 10.2134/jeq2008.0471.
   Brooks J.P., 2004, J RESIDUALS SCI TECH, V1, P13.
   Brooks JP, 2005, J APPL MICROBIOL, V99, P310, DOI 10.1111/j.1365-2672.2005.02604.x.
   Cole JR, 2003, NUCLEIC ACIDS RES, V31, P442, DOI 10.1093/nar/gkg039.
   FELSENSTEIN J, 2004, PHYLIP PHYLOGENY INF.
   HARTUNG J, RISKS CAUSED BIOAERO.
   Heidelberg JF, 1997, APPL ENVIRON MICROB, V63, P3585.
   Just N., 2009, J OCCUP MED TOXICOL, V4, P1.
   Kelley TR, 1998, POULTRY SCI, V77, P243, DOI 10.1093/ps/77.2.243.
   KELLEY TR, 1994, J APPL POULTRY RES, V3, P279, DOI DOI 10.1093/JAPR/3.3.279.
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150.
   Lieberman JM, 2003, PEDIATR INFECT DIS J, V22, P1143, DOI 10.1097/01.inf.0000101851.57263.63.
   Liu TR, 2002, J FOOD PROTECT, V65, P1227, DOI 10.4315/0362-028X-65.8.1227.
   Lu Jingrang, 2003, Applied and Environmental Microbiology, V69, P901, DOI 10.1128/AEM.69.2.901-908.2003.
   Miles DM, 2006, POULTRY SCI, V85, P167, DOI 10.1093/ps/85.2.167.
   MONTROSE MS, 1985, AVIAN DIS, V29, P392, DOI 10.2307/1590500.
   Nather G, 2009, POULTRY SCI, V88, P1299, DOI 10.3382/ps.2008-00389.
   Oppliger A, 2008, ANN OCCUP HYG, V52, P405, DOI 10.1093/annhyg/men021.
   Pope MJ, 2000, POULTRY SCI, V79, P1351, DOI 10.1093/ps/79.9.1351.
   {*}POULTR EGG ASS, FREQ ASK QUEST.
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09.
   Sidhu J, 2001, WATER RES, V35, P913, DOI 10.1016/S0043-1354(00)00352-3.
   Taylor NM, 2008, J APPL MICROBIOL, V105, P1421, DOI 10.1111/j.1365-2672.2008.03877.x.
   Terzich M, 2000, J APPL POULTRY RES, V9, P287, DOI 10.1093/japr/9.3.287.
   Zaleski KJ, 2005, APPL ENVIRON MICROB, V71, P3701, DOI 10.1128/AEM.71.7.3701-3708.2005.
   Zucker BA, 2000, J VET MED B, V47, P37, DOI 10.1046/j.1439-0450.2000.00308.x.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{8}},
Usage-Count-Since-2013 = {{31}},
Journal-ISO = {{Sci. Total Environ.}},
Doc-Delivery-Number = {{651MJ}},
Unique-ID = {{ISI:000281931500057}},
DA = {{2018-08-13}},
}

@article{ ISI:000280593800002,
Author = {Gilbert, Yan and Veillette, Marc and Duchaine, Caroline},
Title = {{Airborne bacteria and antibiotic resistance genes in hospital rooms}},
Journal = {{AEROBIOLOGIA}},
Year = {{2010}},
Volume = {{26}},
Number = {{3}},
Pages = {{185-194}},
Month = {{SEP}},
Abstract = {{The microbial biodiversity of bioaerosols in recently occupied hospital
   rooms was assessed in a pulmonology unit. Environmental samples and
   isolates were also screened for antibiotics resistance genes. Biofilms
   from sink drains were also studied to evaluate whether sink drains
   constitute a potential source of bioaerosols in this environment and a
   reservoir for opportunistic bacteria and antibiotic resistance genes.
   Stenotrophomonas maltophilia was by far the most frequently isolated
   microorganisms from the biofilm, followed by Enterobacter cloacae.
   Airborne bacterial concentration ranged from 14 to 74 CFU m(-3) and
   fungi ranged from 50 to 600 CFU m(-3). Biofilm bacteria were outnumbered
   in aerosols by microorganisms affiliated with human skin flora.
   Nonetheless, they were recovered from air samples in low concentrations.
   Erythromycin resistance genes were detected in all air samples collected
   from hospital rooms, and tetracycline resistance genes were detected
   sporadically. Antibiotic resistance genes were found in a single drain
   suggesting that genes present in DNA extracts from air samples were not
   aerosolized from sink drains, but rather from an unknown source. Results
   obtained in this study suggest that bacteria from sink drains were not
   aerosolized in significant concentration. They still remain a concern
   because of the risk of aerial transmission associated with their
   presence.}},
Publisher = {{SPRINGER}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Duchaine, C (Reprint Author), Inst Univ Cardiol \& Pneumol Quebec, Ctr Rech, 2725 Chemin, Ste Foy, PQ G1V 4G5, Canada.
   Gilbert, Yan; Veillette, Marc; Duchaine, Caroline, Inst Univ Cardiol \& Pneumol Quebec, Ctr Rech, Ste Foy, PQ G1V 4G5, Canada.}},
DOI = {{10.1007/s10453-010-9155-1}},
ISSN = {{0393-5965}},
Keywords = {{Biofilm; Bioaerosols; Antibiotic resistance; Biodiversity; Hospital;
   Stenotrophomonas maltophilia}},
Keywords-Plus = {{INTENSIVE-CARE-UNIT; BLOOD-STREAM INFECTIONS; 16S RIBOSOMAL-RNA; TIME
   PCR ASSAYS; PSEUDOMONAS-AERUGINOSA; SPHINGOMONAS-PAUCIMOBILIS;
   STENOTROPHOMONAS-MALTOPHILIA; SERRATIA-MARCESCENS; SINK DRAINS; OUTBREAK}},
Research-Areas = {{Life Sciences \& Biomedicine - Other Topics; Environmental Sciences \&
   Ecology}},
Web-of-Science-Categories  = {{Biology; Environmental Sciences}},
Author-Email = {{caroline.duchaine@bcm.ulaval.ca}},
Funding-Acknowledgement = {{Institute of Circulatory and Respiratory Health of Canadian Institutes
   of Health Research (CIHR); Health Respiratory Network of the Fonds de la
   Recherche en Sante du Quebec (FRSQ)}},
Funding-Text = {{Gilbert Y. was a Quebec Respiratory Health training fellow, sponsored by
   the Institute of Circulatory and Respiratory Health of Canadian
   Institutes of Health Research (CIHR) and the Health Respiratory Network
   of the Fonds de la Recherche en Sante du Quebec (FRSQ). Duchaine C.
   acknowledges FRSQ Junior 2 Scholarship and is a member of the FRSQ
   Respiratory Health Network.}},
Cited-References = {{Adams WE, 2006, J CATARACT REFR SURG, V32, P1238, DOI 10.1016/j.jcrs.2006.01.094.
   AGER BP, 1983, ANN OCCUP HYG, V27, P341, DOI 10.1093/annhyg/27.4.341.
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999.
   Anaissie EJ, 2001, CLIN INFECT DIS, V33, P1871, DOI 10.1086/324501.
   ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   Appelbaum PC, 2006, CLIN MICROBIOL INFEC, V12, P3, DOI 10.1111/j.1469-0691.2006.01402.x.
   Augustowska M, 2006, ANN AGR ENV MED, V13, P99.
   AYLIFFE GAJ, 1974, LANCET, V2, P578.
   Beggs CB, 2003, INDOOR BUILT ENVIRON, V12, P9, DOI 10.1177/142032603032201.
   Beggs CB, 2008, AM J INFECT CONTROL, V36, P250, DOI 10.1016/j.ajic.2007.07.012.
   BROWN DG, 1977, J PEDIATR-US, V90, P453, DOI 10.1016/S0022-3476(77)80715-4.
   Chen J, 2007, APPL ENVIRON MICROB, V73, P4407, DOI 10.1128/AEM.02799-06.
   Curtis L, 2005, J HOSP INFECT, V59, P188, DOI 10.1016/j.jhin.2004.05.017.
   Dalben M, 2008, J HOSP INFECT, V70, P7, DOI 10.1016/j.jhin.2008.05.003.
   DORING G, 1991, ZBL HYG UMWELTMED, V191, P494.
   Driscoll JA, 2007, DRUGS, V67, P351, DOI 10.2165/00003495-200767030-00003.
   DUTKAMALEN S, 1995, J CLIN MICROBIOL, V33, P1434.
   Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192.
   Eggleston PA, 2003, CURR ALLERGY ASTHM R, V3, P424, DOI 10.1007/s11882-003-0079-5.
   Elliott B, 2007, INTERN MED J, V37, P561, DOI 10.1111/j.1445-5994.2007.01403.x.
   Fridkin SK, 1996, CLIN MICROBIOL REV, V9, P499.
   Friedman ND, 2002, J INFECTION, V45, P47, DOI 10.1053/jinf.2002.0978.
   Groll AH, 2001, CLIN MICROBIOL INFEC, V7, P8, DOI 10.1111/j.1469-0691.2001.tb00005.x.
   HALL RA, 1982, PARASITOLOGY, V84, P205, DOI 10.1017/S0031182000053658.
   Hota B, 2004, CLIN INFECT DIS, V39, P1182, DOI 10.1086/424667.
   Hota S, 2009, INFECT CONT HOSP EP, V30, P25, DOI 10.1086/592700.
   Hsueh PR, 1998, CLIN INFECT DIS, V26, P676, DOI 10.1086/514595.
   Jong S. C., 1988, ADV APPL MICROBIOL, V34, P183.
   Kilic A, 2007, JPN J INFECT DIS, V60, P394.
   Labriola L, 2009, CLIN NEPHROL, V71, P355.
   LEVIN MH, 1984, J CLIN PATHOL, V37, P424, DOI 10.1136/jcp.37.4.424.
   Li CS, 2003, SCI TOTAL ENVIRON, V305, P169, DOI 10.1016/S0048-9697(02)00500-4.
   Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795.
   McBain AJ, 2003, APPL ENVIRON MICROB, V69, P177, DOI 10.1128/AEM.69.1.177-185.2003.
   McDonald LC, 1998, PEDIATR INFECT DIS J, V17, P716, DOI 10.1097/00006454-199808000-00011.
   MCGEER A, 1990, J CLIN MICROBIOL, V28, P55.
   Moore JE, 2002, J HOSP INFECT, V50, P235, DOI 10.1053/jhin.2001.1175.
   Muder RR, 1996, CLIN INFECT DIS, V22, P508, DOI 10.1093/clinids/22.3.508.
   MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695.
   PERRYMAN FA, 1980, J CLIN MICROBIOL, V12, P79.
   RISER E, 1978, J HYG-CAMBRIDGE, V80, P43, DOI 10.1017/S0022172400053389.
   Roberts K, 2006, INDOOR BUILT ENVIRON, V15, P35, DOI 10.1177/1420326X06062562.
   Sarica S, 2002, INDOOR BUILT ENVIRON, V11, P285, DOI 10.1159/000066523.
   Senol E, 2004, J HOSP INFECT, V57, P1, DOI 10.1016/j.jhin.2004.01.033.
   Shiomori T, 2001, ARCH OTOLARYNGOL, V127, P644, DOI 10.1001/archotol.127.6.644.
   Sisti M., 2000, Igiene Moderna, V113, P147.
   Squier, 2000, Curr Infect Dis Rep, V2, P490, DOI 10.1007/s11908-000-0049-1.
   STREIFEL AJ, 1987, J CLIN MICROBIOL, V25, P1.
   Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022.
   Thorne PS, 2007, MANUAL OF ENVIRONMENTAL MICROBIOLOGY, 3RD ED, P989.
   TRAUTMANN M, 2005, AM J INFECT CONTROL, V33, P41, DOI DOI 10.1016/J.AJIC.2005.03.006.
   Uduman SA, 2002, J HOSP INFECT, V52, P175, DOI 10.1053/jhin.2002.1308.
   VANSAENE HKF, 1989, EPIDEMIOL INFECT, V102, P231, DOI 10.1017/S0950268800029903.
   Walsh T J, 1999, Transpl Infect Dis, V1, P247, DOI 10.1034/j.1399-3062.1999.010404.x.
   Yu ZT, 2005, APPL ENVIRON MICROB, V71, P6926, DOI 10.1128/AEM.71.11.6926-6933.2005.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{8}},
Usage-Count-Since-2013 = {{53}},
Journal-ISO = {{Aerobiologia}},
Doc-Delivery-Number = {{634OW}},
Unique-ID = {{ISI:000280593800002}},
DA = {{2018-08-13}},
}

@article{ ISI:000281284800002,
Author = {Millet, Coralie O. M. and Cable, Joanne and Lloyd, David},
Title = {{The Diplomonad Fish Parasite Spironucleus vortens Produces Hydrogen}},
Journal = {{JOURNAL OF EUKARYOTIC MICROBIOLOGY}},
Year = {{2010}},
Volume = {{57}},
Number = {{5}},
Pages = {{400-404}},
Month = {{SEP-OCT}},
Abstract = {{The diplomonad fish parasite Spironucleus vortens causes major problems
   in aquaculture of ornamental fish, resulting in severe economic losses
   in the fish farming industry. The strain of S. vortens studied here was
   isolated from an angelfish and grown in Keister's modified TY-I-S33
   medium. A membrane-inlet mass spectrometer was employed to monitor, in a
   closed system, O(2), CO(2), and H(2). When introduced into air-saturated
   buffer, S. vortens rapidly consumed O(2) at the average rate of 62 +/- 4
   nmol/min/107 cells and CO(2) was produced at 75 +/- 11 nmol/min/107
   cells. Hydrogen production began under microaerophilic conditions
   ({[}O(2)]=33.+/- 15 mu M) at a rate of 77 +/- 7 nmol/min/107 cells.
   Hydrogen production was inhibited by 62\% immediately after adding 150
   mu M KCN to the reaction vessel, and by 50\% at 0.24 mu M CO, suggesting
   that an Fe-only hydrogenase is responsible for H(2) production.
   Metronidazole (1 mM) inhibited H(2) production by 50\%, while CO(2)
   production was not affected. This suggests that metronidazole may be
   reduced by an enzyme of the H(2) pathway, thus competing for electrons
   with H+.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Millet, COM (Reprint Author), Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales.
   Millet, Coralie O. M.; Cable, Joanne; Lloyd, David, Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales.}},
DOI = {{10.1111/j.1550-7408.2010.00499.x}},
ISSN = {{1066-5234}},
Keywords = {{Diplmonad fish parasite; Hexamitidae; hydrogenase; mass spectrometry;
   metronidazole; Spironucleus vortens}},
Keywords-Plus = {{FRESH-WATER ANGELFISH; TRICHOMONAS-VAGINALIS; ENTAMOEBA-HISTOLYTICA;
   DRUG-RESISTANT; THIOREDOXIN REDUCTASE; ANAEROBIC EUKARYOTES;
   GIARDIA-INTESTINALIS; TREPOMONAS-AGILIS; IRON-HYDROGENASES; IN-VIVO}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{milletCO@gmail.com}},
ResearcherID-Numbers = {{Cable, Joanne/A-4360-2010}},
ORCID-Numbers = {{Cable, Joanne/0000-0002-8510-7055}},
Funding-Acknowledgement = {{William E. Morgan Scholarship; Natural Environment Research Council, UK
   {[}NER/J/S/2002/00706]; Natural Environment Research Council
   {[}NER/J/S/2002/00706]}},
Funding-Text = {{The authors are deeply indebted to Prof. Jaroslav Kulda for his expert
   advice and guidance in the culture of the organism. This work was funded
   by the William E. Morgan Scholarship to COM and a Natural Environment
   Research Council, UK, Research Fellowship to JC (NER/J/S/2002/00706).}},
Cited-References = {{ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5.
   Biagini GA, 1997, FEMS MICROBIOL LETT, V155, P133, DOI 10.1111/j.1574-6968.1997.tb13869.x.
   Brugerolle G, 2003, PARASITOL RES, V90, P249, DOI 10.1007/s00436-003-0832-7.
   BRUGEROLLE G, 1980, Z PARASITENKD, V62, P47, DOI 10.1007/BF00925366.
   BRUGEROLLE G, 1973, Protistologica, V9, P495.
   BRUGEROLLE G, 2000, FLAGELLATES UNITY DI, V9, P166.
   CAMMACK R, 2003, BIOCH PHYSL ANAEROBI, V9, P113.
   CavalierSmith T, 1996, J MOL EVOL, V43, P551, DOI 10.1007/BF02202103.
   Cooper GL, 2004, AVIAN DIS, V48, P706, DOI 10.1637/7160-012904.
   Cudmore SL, 2004, CLIN MICROBIOL REV, V17, P783, DOI 10.1128/CMR.17.4.783-793.2004.
   Czeizel AE, 1998, BRIT J OBSTET GYNAEC, V105, P322, DOI 10.1111/j.1471-0528.1998.tb10094.x.
   ELLIS JE, 1992, MOL BIOCHEM PARASIT, V56, P79, DOI 10.1016/0166-6851(92)90156-E.
   Embley TM, 2006, NATURE, V440, P623, DOI 10.1038/nature04546.
   Embley TM, 2003, IUBMB LIFE, V55, P387, DOI 10.1080/15216540310001592834.
   Embley TM, 2003, PHILOS T R SOC B, V358, P191, DOI 10.1098/rstb.2002.1190.
   EMBLEY TM, 1995, P ROY SOC B-BIOL SCI, V262, P87, DOI 10.1098/rspb.1995.0180.
   Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4.
   Embley TM, 2003, PHILOS T R SOC LON B, V358, P201.
   Fauque G., 1988, FEMS MICROBIOL REV, V4, P299.
   Hackstein JHP, 1999, TRENDS MICROBIOL, V7, P441, DOI 10.1016/S0966-842X(99)01613-3.
   Happe T, 2002, EUR J BIOCHEM, V269, P1022, DOI 10.1046/j.0014-2956.2001.02743.x.
   HARPER FDW, 1991, VET REC, V128, P130, DOI 10.1136/vr.128.6.130-a.
   Harris JC, 2001, APPL MICROBIOL BIOT, V57, P614, DOI 10.1007/s002530100720.
   Horner DS, 2000, MOL BIOL EVOL, V17, P1695, DOI 10.1093/oxfordjournals.molbev.a026268.
   Horner DS, 1999, MOL BIOL EVOL, V16, P1280, DOI 10.1093/oxfordjournals.molbev.a026218.
   Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155.
   Hrdy I, 2004, NATURE, V432, P618, DOI 10.1038/nature03149.
   KULDA J, 1993, J EUKARYOT MICROBIOL, V40, P262, DOI 10.1111/j.1550-7408.1993.tb04915.x.
   Land KM, 2002, MOL BIOCHEM PARASIT, V121, P153, DOI 10.1016/S0166-6851(02)00025-7.
   Lantsman Y, 2008, MICROBIOL-SGM, V154, P2757, DOI 10.1099/mic.0.2008/017897-0.
   Leitsch D, 2007, PLOS BIOL, V5, P1820, DOI 10.1371/journal.pbio.0050211.
   Leitsch D, 2009, MOL MICROBIOL, V72, P518, DOI 10.1111/j.1365-2958.2009.06675.x.
   LINDMARK DG, 1973, J BIOL CHEM, V248, P7724.
   LLOYD D, 1985, J GEN MICROBIOL, V131, P87.
   Lloyd D, 2002, TRENDS MICROBIOL, V10, P122, DOI 10.1016/S0966-842X(02)02306-5.
   Lloyd D, 2002, MICROBIOL-SGM, V148, P727, DOI 10.1099/00221287-148-3-727.
   LLOYD D, 1985, J GEN MICROBIOL, V131, P849.
   Lloyd D, 1992, Soc Appl Bacteriol Symp Ser, V21, p155S.
   LLOYD D, 1982, BIOCHEM J, V206, P367, DOI 10.1042/bj2060367.
   McKeon T, 1997, AUST VET J, V75, P652, DOI 10.1111/j.1751-0813.1997.tb15363.x.
   Morin L, 2000, J EUKARYOT MICROBIOL, V47, P167, DOI 10.1111/j.1550-7408.2000.tb00028.x.
   Mukherjee M, 2006, EUKARYOT CELL, V5, P2062, DOI 10.1128/EC.00205-06.
   Nixon JEJ, 2003, BIOL BULL-US, V204, P1, DOI 10.2307/1543490.
   Ozbilgin Ahmet, 1994, Journal of the Egyptian Society of Parasitology, V24, P621.
   PAUL RG, 1990, J GEN MICROBIOL, V136, P1981, DOI 10.1099/00221287-136-10-1981.
   Paull GC, 2001, DIS AQUAT ORGAN, V45, P197, DOI 10.3354/dao045197.
   Philbey AW, 2002, AUST VET J, V80, P154, DOI 10.1111/j.1751-0813.2002.tb11381.x.
   Poynton SL, 2004, DIS AQUAT ORGAN, V60, P49, DOI 10.3354/dao060049.
   Poynton SL, 2002, J FISH DIS, V25, P15, DOI 10.1046/j.1365-2761.2002.00331.x.
   POYNTON SL, 1995, J EUKARYOT MICROBIOL, V42, P731, DOI 10.1111/j.1550-7408.1995.tb01625.x.
   Price MA, 2006, JAIDS-J ACQ IMM DEF, V43, P202, DOI 10.1097/01.qai.0000229014.39451.33.
   Rasoloson D, 2002, MICROBIOL-SGM, V148, P2467, DOI 10.1099/00221287-148-8-2467.
   SAMOUR JH, 1995, VET REC, V136, P358, DOI 10.1136/vr.136.14.358.
   Sangmaneedet S, 1999, DIS AQUAT ORGAN, V38, P47, DOI 10.3354/dao038047.
   SCHNEIDER K, 1979, BIOCHIM BIOPHYS ACTA, V578, P445, DOI 10.1016/0005-2795(79)90175-2.
   SEBESTENY A, 1979, LAB ANIM, V13, P189, DOI 10.1258/002367779780937780.
   Sterud E, 1997, J EUKARYOT MICROBIOL, V44, P399, DOI 10.1111/j.1550-7408.1997.tb05715.x.
   van Grinsven KWA, 2008, J BIOL CHEM, V283, P1411, DOI 10.1074/jbc.M702528200.
   Vanacova S, 2003, INT J PARASITOL, V33, P235, DOI 10.1016/S0020-7519(02)00267-9.
   Vidakovic M, 2003, ANTIMICROB AGENTS CH, V47, P302, DOI 10.1128/AAC.47.1.302-308.2003.
   WHITEHOUSE A, 1993, AUST VET J, V70, P193, DOI 10.1111/j.1751-0813.1993.tb06134.x.
   WILHELM E, 1977, CHEM REV, V77, P219, DOI 10.1021/cr60306a003.
   Wood AM, 2005, AVIAN DIS, V49, P138, DOI 10.1637/7250-080204R.
   YARLETT N, 1986, BIOCHEM PHARMACOL, V35, P1703, DOI 10.1016/0006-2952(86)90327-8.
   ZIMMER JF, 1987, CORNELL VET, V77, P383.}},
Number-of-Cited-References = {{65}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Eukaryot. Microbiol.}},
Doc-Delivery-Number = {{643GY}},
Unique-ID = {{ISI:000281284800002}},
DA = {{2018-08-13}},
}

@article{ ISI:000280854400008,
Author = {Singer, Darrell E. and Bautista, Christian T. and O'Connell, Robert J.
   and Sanders-Buell, Eric and Agan, Brian K. and Kijak, Gustavo H. and
   Hakre, Shilpa and Sanchez, Jose L. and Sateren, Warren B. and McCutchan,
   Francine E. and Michael, Nelson L. and Scott, Paul T.},
Title = {{HIV Infection Among US Army and Air Force Military Personnel:
   Sociodemographic and Genotyping Analysis}},
Journal = {{AIDS RESEARCH AND HUMAN RETROVIRUSES}},
Year = {{2010}},
Volume = {{26}},
Number = {{8}},
Pages = {{889-894}},
Month = {{AUG}},
Abstract = {{Since 1985, the U. S. Department of Defense has periodically screened
   all military personnel for HIV allowing for the monitoring of the
   infection in this dynamic cohort population. A nested case-control study
   was performed to study sociodemographics, overseas assignment, and
   molecular analysis of HIV. Cases were newly identified HIV infections
   among U. S. Army and Air Force military personnel from 2000 to 2004.
   Controls were frequency matched to cases by gender and date of case
   first positive HIV screening test. Genotyping analysis was performed
   using high-throughput screening assays and partial genome sequencing.
   HIV was significantly associated with black race {[}odds ratio (OR) =
   6.65], single marital status (OR = 4.45), and age (OR per year = 1.07).
   Ninety-seven percent were subtype B and 3\% were non-B subtypes (A3,
   CRF01\_AE, A/C recombinant, G, CRF02\_AG). Among cases, overseas
   assignment in the period at risk prior to their first HIV-positive test
   was associated with non-B HIV subtype infection (OR = 8.44). Black and
   single military personnel remain disproportionately affected by HIV
   infection. Most non-B HIV subtypes were associated with overseas
   assignment. Given the increased frequency and length of assignments, and
   the expanding HIV genetic diversity observed in this population, there
   is a need for active HIV genotyping surveillance and a need to reinforce
   primary HIV prevention efforts.}},
Publisher = {{MARY ANN LIEBERT INC}},
Address = {{140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Scott, PT (Reprint Author), Walter Reed Army Inst Res, Div Retrovirol, Dept Epidemiol \& Threat Assessment, Rockville, MD 20850 USA.
   Scott, Paul T., Walter Reed Army Inst Res, Div Retrovirol, Dept Epidemiol \& Threat Assessment, Rockville, MD 20850 USA.
   Bautista, Christian T.; Sanders-Buell, Eric; Kijak, Gustavo H.; Hakre, Shilpa, Henry Jackson Fdn Adv Mil Med, US Mil HIV Res Program, Rockville, MD USA.
   Singer, Darrell E., Dept Def HIV Program Nigeria, Abuja, Nigeria.
   O'Connell, Robert J.; Agan, Brian K., Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA.
   Sanchez, Jose L., Armed Forces Hlth Surveillance Ctr, Dept Def Global Emerging Surveillance \& Response, Silver Spring, MD USA.
   McCutchan, Francine E., Bill \& Melinda Gates Fdn, Seattle, WA USA.}},
DOI = {{10.1089/aid.2009.0289}},
ISSN = {{0889-2229}},
Keywords-Plus = {{IMMUNODEFICIENCY-VIRUS TYPE-1; NON-B SUBTYPES; UNITED-STATES; GENETIC
   SUBTYPES; DRUG-RESISTANCE; DIVERSITY; SEROCONVERSION; PREVALENCE;
   SURVEILLANCE; TRENDS}},
Research-Areas = {{Immunology; Infectious Diseases; Virology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Virology}},
Author-Email = {{pscott@hivresearch.org}},
ResearcherID-Numbers = {{Bautista, Christian/B-2812-2011
   }},
ORCID-Numbers = {{Agan, Brian/0000-0002-5114-1669
   Bautista, Christian/0000-0002-1228-0754}},
Funding-Acknowledgement = {{Henry M. Jackson Foundation for the Advancement of Military Medicine,
   Inc. {[}W8IXWH-07-2-0067]; U.S. Department of Defense (DOD)
   {[}W8IXWH-07-2-0067]}},
Funding-Text = {{We thank the Armed Forces Health Surveillance Center for providing data
   and specimens for analysis and Sebastian-Santiago B. for technical
   assistance. This research study (WRAIR \#1169/RV161) was approved and
   reviewed by the Walter Reed Army Institute of Research, Rockville,
   Maryland. This work was supported by a cooperative agreement
   (W8IXWH-07-2-0067) between the Henry M. Jackson Foundation for the
   Advancement of Military Medicine, Inc., and the U.S. Department of
   Defense (DOD). The views expressed are those of the authors and should
   not be of the U.S. Army or DOD.}},
Cited-References = {{Armed Forces Health Surveillance Center, 2008, MED SURV MONTHL REP, V15.
   Bautista CT, 2006, JAIDS-J ACQ IMM DEF, V43, P351, DOI 10.1097/01.qai.0000243051.35204.d0.
   Bautista CT, 2006, JAIDS-J ACQ IMM DEF, V42, P68, DOI 10.1097/01.qai.0000218362.13465.33.
   Brodine SK, 1999, ANN INTERN MED, V131, P502, DOI 10.7326/0003-4819-131-7-199910050-00004.
   Brodine SK, 2003, AIDS, V17, P2521, DOI 10.1097/00002030-200311210-00016.
   BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0.
   Brown BK, 2005, J VIROL, V79, P6089, DOI 10.1128/JVI.79.10.6089-6101.2005.
   de Oliveira CF, 2000, TRANSFUSION, V40, P1399, DOI 10.1046/j.1537-2995.2000.40111399.x.
   {*}DEP DEF, 2006, ACT DUT MIL PERS STR.
   DONGHUN L, 2003, J MICROBIOL, V41, P232.
   Fang GW, 2004, AIDS, V18, P153, DOI 10.1097/01.aids.0000104372.21567.31.
   GAIL MH, 2001, ENCY EPIDEMIOLOGIC M, P155.
   GAO F, 1994, AIDS RES HUM RETROV, V10, P625, DOI 10.1089/aid.1994.10.625.
   {*}GLOB RES, 2007, GLOB DEPL US MIL PER.
   {*}HER CTR DAT AN, 2004, GLOB US TROOP DEPL 1.
   Irwin KL, 1997, J INFECT DIS, V176, P1629, DOI 10.1086/517343.
   KANE T, 2006, CDA06A09 HER FDN.
   Kijak GH, 2007, VIROLOGY, V358, P178, DOI 10.1016/j.virol.2006.07.055.
   Krogstad P, 2002, AIDS RES HUM RETROV, V18, P413, DOI 10.1089/088922202753614173.
   Lasky M, 1997, AIDS, V11, P43, DOI 10.1097/00002030-199701000-00007.
   LEVIN LI, 1995, AM J PUBLIC HEALTH, V85, P1500, DOI 10.2105/AJPH.85.11.1500.
   LIN H, 2000, 7 C RETR OPP INF AL, P107.
   Martinez-Cajas JL, 2008, AIDS REV, V10, P212.
   McCutchan FE, 1999, EVOLUTION OF HIV, P41.
   Meloni ST, 2004, J VIROL, V78, P12455, DOI 10.1128/JVI.78.22.12455-12461.2004.
   Paraskevis D, 2007, J INFECT DIS, V196, P1167, DOI 10.1086/521677.
   Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5.
   PUFAL SL, 2001, ENHANCING WELLNESS R.
   Rayfield MA, 1996, EMERG INFECT DIS, V2, P209, DOI 10.3201/eid0203.960307.
   Renzullo PO, 2001, AIDS, V15, P1569, DOI 10.1097/00002030-200108170-00015.
   Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900.
   Shafer MA, 2002, MIL MED, V167, P496.
   Sides TL, 2005, J INFECT DIS, V192, P37, DOI 10.1086/430322.
   Sullivan P S, 1997, JAMA, V278, P292, DOI 10.1001/jama.278.4.292.
   Taylor BS, 2008, NEW ENGL J MED, V358, P1590, DOI 10.1056/NEJMra0706737.
   Thomson MM, 2001, CLIN INFECT DIS, V32, P1732, DOI 10.1086/320764.
   Tovanabutra S, 2005, AIDS RES HUM RETROV, V21, P424, DOI 10.1089/aid.2005.21.424.
   Womack C, 2001, J INFECT DIS, V183, P138, DOI 10.1086/317649.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Aids Res. Hum. Retrovir.}},
Doc-Delivery-Number = {{637YK}},
Unique-ID = {{ISI:000280854400008}},
DA = {{2018-08-13}},
}

@article{ ISI:000281215300001,
Author = {Sarkar-Tyson, Mitali and Titball, Richard W.},
Title = {{Progress Toward Development of Vaccines Against Melioidosis: A Review}},
Journal = {{CLINICAL THERAPEUTICS}},
Year = {{2010}},
Volume = {{32}},
Number = {{8}},
Pages = {{1437-1445}},
Month = {{AUG}},
Abstract = {{Background: Melioidosis is a serious and often fatal disease that is
   prevalent in subtropical and tropical climates, primarily in at-risk
   groups (eg, those with diabetes, alcoholism, or other cause of
   immunosuppression). Treatment is often unsuccessful, with infection
   frequently relapsing. Burkholderia pseudomallei, the etiologic agent of
   melioidosis, is inherently resistant to many antibiotics.
   Objective: This article reviews available evidence on the development of
   vaccines against melioidosis, including live attenuated vaccines,
   inactivated whole cell vaccines, and recombinant subunit vaccines.
   Methods: Web of Science and PubMed (1950 February 2010) were searched
   for relevant reports using the term Burkholderia pseudomallei alone and
   combined with live attenuated vaccine, inactivated vaccine, animal
   models, and immunity. The reference lists of identified articles were
   reviewed for additional relevant publications.
   Results: Studies in murine models suggest that protective immunity
   against B pseudomallei may be induced by a range of living and nonliving
   immunogens. The strongest protective immunity was induced by live
   attenuated immunogens, although concerns about latency make it unlikely
   that such vaccines will be appropriate for use in humans.
   Heat-inactivated immunogens have shown promise, and several candidates
   for subunit vaccines have been tested. However, in all cases, it has
   been difficult to achieve induction of sterile immunity and protection
   against airborne infection.
   Conclusions: Live attenuated mutants of B pseudomallei have been found
   to be the most effective immunogens in mice, although it is unlikely
   that such mutants would be appropriate for a vaccine against melioidosis
   in humans. The ongoing challenge is to identify nonliving formulations
   that are able to induce good protective immunity. Both humoral and
   cell-mediated immunity are likely to be required. In this respect, naked
   DNA vaccines have the potential to provide high-level protection. (Clin
   Then 2010;32:1437-1445) (C) 2010 Excerpta Medica Inc}},
Publisher = {{ELSEVIER}},
Address = {{685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Sarkar-Tyson, M (Reprint Author), Def Sci \& Technol Lab, Salisbury SP4 0JQ, Wilts, England.
   Sarkar-Tyson, Mitali, Def Sci \& Technol Lab, Salisbury SP4 0JQ, Wilts, England.
   Titball, Richard W., Univ Exeter, Sch Biosci, Exeter, Devon, England.}},
DOI = {{10.1016/j.clinthera.2010.07.020}},
ISSN = {{0149-2918}},
EISSN = {{1879-114X}},
Keywords = {{melioidosis; vaccines; live vaccines; inactivated vaccines; subunit
   vaccines}},
Keywords-Plus = {{BURKHOLDERIA-PSEUDOMALLEI INFECTION; SIGNATURE-TAGGED MUTAGENESIS;
   CELL-MEDIATED-IMMUNITY; T-CELLS; CAPSULAR POLYSACCHARIDE;
   GENE-EXPRESSION; MURINE MODEL; SEPTICEMIC MELIOIDOSIS; PROTECTIVE
   EFFICACY; ADAPTIVE IMMUNITY}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{MSTYSON@mail.dstl.gov.uk}},
Cited-References = {{Arya SC, 2008, VACCINE, V26, P291, DOI 10.1016/j.vaccine.2007.11.017.
   Atkins T, 2002, J MED MICROBIOL, V51, P539, DOI 10.1099/0022-1317-51-7-539.
   Bambini S, 2009, DRUG DISCOV TODAY, V14, P252, DOI 10.1016/j.drudis.2008.12.007.
   Barnes JL, 2004, CLIN IMMUNOL, V113, P22, DOI 10.1016/j.clim.2004.06.006.
   Barnes JL, 2007, IMMUNOL CELL BIOL, V85, P551, DOI 10.1038/sj.icb.7100084.
   Bottex C, 2005, IMMUNOPHARM IMMUNOT, V27, P565, DOI 10.1080/08923970500493995.
   Breitbach Katrin, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS89, DOI 10.1016/S0035-9203(08)70022-1.
   Brett PJ, 1996, INFECT IMMUN, V64, P2824.
   BROWN AE, 1991, J INFECT DIS, V163, P1145, DOI 10.1093/infdis/163.5.1145.
   Bryan L E, 1994, Can J Infect Dis, V5, P170.
   Charoenwong Punthip, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P698.
   Chen YS, 2006, VACCINE, V24, P750, DOI 10.1016/j.vaccine.2005.08.069.
   Cheng AC, 2005, CLIN MICROBIOL REV, V18, P383, DOI 10.1128/CMR.18.2.383-416.2005.
   Cuccui J, 2007, INFECT IMMUN, V75, P1186, DOI 10.1128/IAI.01240-06.
   Currie Bart J, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS1, DOI 10.1016/S0035-9203(08)70002-6.
   Currie BJ, 2003, EUR RESPIR J, V22, P542, DOI 10.1183/09031936.03.00006203.
   DANCE DAB, 1991, CLIN MICROBIOL REV, V4, P52.
   DeShazer D, 1998, MOL MICROBIOL, V30, P1081, DOI 10.1046/j.1365-2958.1998.01139.x.
   Elvin SJ, 2006, INFECT IMMUN, V74, P1706, DOI 10.1128/IAI.74.3.1706-1711.2006.
   Felgner PL, 2009, P NATL ACAD SCI USA, V106, P13499, DOI 10.1073/pnas.0812080106.
   Haque A, 2006, J INFECT DIS, V193, P370, DOI 10.1086/498983.
   Haque A, 2006, J INFECT DIS, V194, P1241, DOI 10.1086/508217.
   Hara Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006496.
   Harding SV, 2007, VACCINE, V25, P2664, DOI 10.1016/j.vaccine.2006.12.006.
   Harland DN, 2007, INFECT IMMUN, V75, P4173, DOI 10.1128/IAI.00404-07.
   Hawkridge A, 2009, HUM VACCINES, V5, P773, DOI 10.4161/hv.5.11.9310.
   Ho M, 1997, INFECT IMMUN, V65, P3648.
   Holden MTG, 2004, P NATL ACAD SCI USA, V101, P14240, DOI 10.1073/pnas.0403302101.
   Jitsurong Siroj, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P810.
   Jones C, 2005, AN ACAD BRAS CIENC, V77, P293, DOI 10.1590/S0001-37652005000200009.
   Jones SM, 2002, J MED MICROBIOL, V51, P1055, DOI 10.1099/0022-1317-51-12-1055.
   Klinman DM, 2006, INT REV IMMUNOL, V25, P135, DOI 10.1080/08830180600743057.
   Lauw FN, 2000, J INFECT DIS, V182, P206, DOI 10.1086/315642.
   Leakey AK, 1998, MICROB PATHOGENESIS, V24, P269, DOI 10.1006/mpat.1997.0179.
   Lertmemongkolchai G, 2001, J IMMUNOL, V166, P1097, DOI 10.4049/jimmunol.166.2.1097.
   LeVine AM, 1999, J CLIN INVEST, V103, P563, DOI 10.1172/JCI5212.
   MACKOWIAK PA, 1978, JAMA-J AM MED ASSOC, V240, P764, DOI 10.1001/jama.240.8.764.
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166.
   Nelson M, 2004, J MED MICROBIOL, V53, P1177, DOI 10.1099/jmm.0.45766-0.
   Ngauy V, 2005, J CLIN MICROBIOL, V43, P970, DOI 10.1128/JCM.43.2.970-972.2005.
   Nimtz M, 1997, EUR J BIOCHEM, V250, P608, DOI 10.1111/j.1432-1033.1997.0608a.x.
   Plotkin SA, 2009, CLIN VACCINE IMMUNOL, V16, P1709, DOI 10.1128/CVI.00290-09.
   Razak CE, 1986, MALAYS APPL BIOL, V15, P105.
   Reckseidler SL, 2001, INFECT IMMUN, V69, P34, DOI 10.1128/IAI.69.1.34-44.2001.
   Reckseidler-Zenteno SL, 2009, MINI-REV MED CHEM, V9, P265, DOI 10.2174/138955709787316047.
   Rodrigues F, 2006, J BACTERIOL, V188, P8178, DOI 10.1128/JB.01006-06.
   Santanirand P, 1999, INFECT IMMUN, V67, P3593.
   Sarkar-Tyson M, 2007, J MED MICROBIOL, V56, P1005, DOI 10.1099/jmm.0.47043-0.
   Sarkar-Tyson M, 2009, VACCINE, V27, P4447, DOI 10.1016/j.vaccine.2009.05.040.
   Srilunchang T, 2009, SE ASIAN J TROP MED, V40, P123.
   STEINMETZ I, 1995, INFECT IMMUN, V63, P3959.
   Steinmetz I, 2000, ACTA TROP, V74, P211, DOI 10.1016/S0001-706X(99)00072-8.
   Stevens MP, 2004, MICROBIOL-SGM, V150, P2669, DOI 10.1099/mic.0.27146-0.
   SUPUTTAMONGKOL Y, 1992, J INFECT DIS, V165, P561, DOI 10.1093/infdis/165.3.561.
   Suputtamongkol Y, 1999, CLIN INFECT DIS, V29, P408, DOI 10.1086/520223.
   Tan GYG, 2008, J MED MICROBIOL, V57, P508, DOI 10.1099/jmm.0.47595-0.
   Tippayawat P, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000407.
   Titball Richard W, 2008, Trans R Soc Trop Med Hyg, V102 Suppl 1, pS111, DOI 10.1016/S0035-9203(08)70026-9.
   Ulett GC, 2005, MICROBES INFECT, V7, P1263, DOI 10.1016/j.micinf.2005.04.013.
   Ulett GC, 2000, ACTA TROP, V74, P229, DOI 10.1016/S0001-706X(99)00075-3.
   Ulett GC, 2000, INFECT IMMUN, V68, P2034, DOI 10.1128/IAI.68.4.2034-2042.2000.
   White NJ, 2003, LANCET, V361, P1715, DOI 10.1016/S0140-6736(03)13374-0.
   Wiersinga WJ, 2008, MICROBES INFECT, V10, P868, DOI 10.1016/j.micinf.2008.04.019.
   Wiersinga WJ, 2008, CELL MICROBIOL, V10, P81, DOI 10.1111/j.1462-5822.2007.01016.x.
   Wiersinga WJ, 2006, NAT REV MICROBIOL, V4, P272, DOI 10.1038/nrmicro1385.
   Wuorimaa T, 2001, SCAND J IMMUNOL, V53, P422, DOI 10.1046/j.1365-3083.2001.00882.x.
   Wuthiekanun Vanaporn, 2006, Expert Rev Anti Infect Ther, V4, P445, DOI 10.1586/14787210.4.3.445.}},
Number-of-Cited-References = {{67}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Clin. Ther.}},
Doc-Delivery-Number = {{642LO}},
Unique-ID = {{ISI:000281215300001}},
DA = {{2018-08-13}},
}

@article{ ISI:000281907700007,
Author = {Kim, Min Su and Ko, Young-Joon and Maeng, Shinae and Floyd, Anna and
   Heitman, Joseph and Bahn, Yong-Sun},
Title = {{Comparative Transcriptome Analysis of the CO2 Sensing Pathway Via
   Differential Expression of Carbonic Anhydrase in Cryptococcus neoformans}},
Journal = {{GENETICS}},
Year = {{2010}},
Volume = {{185}},
Number = {{4}},
Pages = {{1207-U124}},
Month = {{AUG}},
Abstract = {{Carbon dioxide (CO2) sensing and metabolism via carbonic anhydrases
   (CAs) play pivotal roles in survival and proliferation of pathogenic
   fungi infecting human hosts from natural environments due to the drastic
   difference in CO2 levels. In Cryptococcus neoformans, which causes fatal
   fungal meningoencephalitis, the Can2 CA plays essential roles during
   both cellular growth in air and sexual differentiation of the pathogen.
   However the signaling networks downstream of Can2 are largely unknown.
   To address this question, the present study employed comparative
   transcriptome DNA microarray analysis of a C. neoformans strain in which
   CAN2 expression is artificially controlled by the CTR4 (copper
   transporter) promoter. The P-CTR4::CAN2 strain showed growth defects in
   a CO2-dependent manner when CAN2 was repressed but resumed normal growth
   when CAN2 was overexpressed. The Can2-dependent genes identified by the
   transcriptome analysis include FAS1 (fatty acid synthase 1) and GPB1
   (G-protein beta subunit), supporting the roles of Can2 in fatty acid
   biosynthesis and sexual differentiation. Cas3, a capsular structure
   designer protein, was also discovered to be Can2-dependent and yet was
   not involved in CO2-mediated capsule induction. Most notably, a majority
   of Can2-dependent genes were environmental stress-regulated (ESR) genes.
   Supporting this, the CAN2 overexpression strain was hypersensitive to
   oxidative and genotoxic stress as well as antifungal drugs, such as
   polyene and azole drugs, potentially due to defective membrane
   integrity. Finally, an oxidative stress-responsive Atf1 transcription
   factor was also found to be Can2-dependent. Atf1 not only plays an
   important role in diverse stress responses, including thermotolerance
   and antifungal drug resistance, but also represses melanin and capsule
   production in C. neoformans. In conclusion, this study provides insights
   into the comprehensive signaling networks orchestrated by CA/CO2-sensing
   pathways in pathogenic fungi.}},
Publisher = {{GENETICS SOC AM}},
Address = {{9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bahn, YS (Reprint Author), Yonsei Univ, Dept Biotechnol, Ctr Fungal Pathogenesis, 134 Shinchon Dong, Seoul 120749, South Korea.
   Kim, Min Su; Ko, Young-Joon; Maeng, Shinae; Bahn, Yong-Sun, Yonsei Univ, Dept Biotechnol, Ctr Fungal Pathogenesis, Seoul 120749, South Korea.
   Floyd, Anna; Heitman, Joseph, Duke Univ, Med Ctr, Dept Mol Genet \& Microbiol, Durham, NC 27710 USA.
   Floyd, Anna; Heitman, Joseph, Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
   Floyd, Anna; Heitman, Joseph, Duke Univ, Med Ctr, Dept Pharmacol \& Canc Biol, Durham, NC 27710 USA.}},
DOI = {{10.1534/genetics.110.118315}},
ISSN = {{0016-6731}},
Keywords-Plus = {{CANDIDA-ALBICANS; FISSION YEAST; SPC1 KINASE; GENE NCE103; VIRULENCE;
   STRESS; DIOXIDE; GROWTH; ROLES; METABOLISM}},
Research-Areas = {{Genetics \& Heredity}},
Web-of-Science-Categories  = {{Genetics \& Heredity}},
Author-Email = {{ysbahn@yonsei.ac.kr}},
ResearcherID-Numbers = {{Bahn, Yong-Sun/C-1211-2012}},
ORCID-Numbers = {{Bahn, Yong-Sun/0000-0001-9573-5752}},
Funding-Acknowledgement = {{Ministry of Education, Science and Technology {[}2009-0081512]; Korean
   government (MEST) {[}2009-0063344]; Yonsei University {[}2008-7-0285];
   National Institutes of Health/National Institute of Allergy and
   Infectious Diseases {[}AI50438, AI70230]}},
Funding-Text = {{This work was supported by the Pioneer Research Center Program through
   the National Research Foundation of Korea, funded by the Ministry of
   Education, Science and Technology (no. 2009-0081512), the National
   Research Foundation of Korea grant, funded by the Korean government
   (MEST) (2009-0063344), and Yonsei University Research Fund of 2008
   (2008-7-0285) (to Y.S.B). This work was also supported in part by RO1
   grant AI50438 and R21 grant AI70230 from the National Institutes of
   Health/National Institute of Allergy and Infectious Diseases (to J.H.).}},
Cited-References = {{Alspaugh JA, 1997, GENE DEV, V11, P3206, DOI 10.1101/gad.11.23.3206.
   Amoroso G, 2005, MOL MICROBIOL, V56, P549, DOI 10.1111/j.1365-2958.2005.04560.x.
   Ausubel FM, 1994, CURRENT PROTOCOLS MO.
   Bahn YS, 2007, EUKARYOT CELL, V6, P2278, DOI 10.1128/EC.00349-07.
   Bahn YS, 2006, CURR OPIN MICROBIOL, V9, P572, DOI 10.1016/j.mib.2006.09.003.
   Bahn YS, 2006, MOL BIOL CELL, V17, P3122, DOI 10.1091/mbc.E06-02-0113.
   Bahn YS, 2005, MOL BIOL CELL, V16, P2285, DOI 10.1091/mbc.E04-11-0987.
   Bahn YS, 2005, CURR BIOL, V15, P2013, DOI 10.1016/j.cub.2005.09.047.
   Chayakulkeeree M, 2007, ANTIMICROB AGENTS CH, V51, P3537, DOI 10.1128/AAC.00442-07.
   Clark D, 2004, BIOCHEM J, V379, P609, DOI 10.1042/BJ20031711.
   CULOTTA VC, 1995, J BIOL CHEM, V270, P29991.
   Davidson RC, 2002, MICROBIOL-SGM, V148, P2607, DOI 10.1099/00221287-148-8-2607.
   Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356.
   Gotz R, 1999, YEAST, V15, P855, DOI 10.1002/(SICI)1097-0061(199907)15:10A<855::AID-YEA425>3.0.CO;2-C.
   GRANGER DL, 1985, J CLIN INVEST, V76, P508, DOI 10.1172/JCI112000.
   Henry RP, 1996, ANNU REV PHYSIOL, V58, P523, DOI 10.1146/annurev.ph.58.030196.002515.
   Hicks JK, 2004, EUKARYOT CELL, V3, P14, DOI 10.1128/EC.3.1.14-26.2004.
   Idnurm A, 2009, EUKARYOT CELL, V8, P315, DOI 10.1128/EC.00375-08.
   Kim MS, 2009, BIOCHEM BIOPH RES CO, V390, P983, DOI 10.1016/j.bbrc.2009.10.089.
   Klengel T, 2005, CURR BIOL, V15, P2021, DOI 10.1016/j.cub.2005.10.040.
   KWONCHUNG KJ, 1992, INFECT IMMUN, V60, P602.
   Liu OW, 2008, CELL, V135, P174, DOI 10.1016/j.cell.2008.07.046.
   Missall TA, 2005, MOL MICROBIOL, V57, P847, DOI 10.1111/j.1365-2958.2005.04735.x.
   MOCK RC, 1990, CAN J MICROBIOL, V36, P249, DOI 10.1139/m90-043.
   Mogensen EG, 2006, EUKARYOT CELL, V5, P103, DOI 10.1128/EC.5.1.103-111.2006.
   Moyrand F, 2004, EUKARYOT CELL, V3, P1513, DOI 10.1128/EC.3.6.1513-1524.2004.
   Ory JJ, 2004, YEAST, V21, P919, DOI 10.1002/yea.1139.
   Parkkila S, 2001, P NATL ACAD SCI USA, V98, P1918, DOI 10.1073/pnas.98.4.1918.
   PERFECT JR, 1993, J CLIN MICROBIOL, V31, P3305.
   Schlicker C, 2009, J MOL BIOL, V385, P1207, DOI 10.1016/j.jmb.2008.11.037.
   Sheth CC, 2008, FUNGAL GENET BIOL, V45, P1075, DOI 10.1016/j.fgb.2008.04.004.
   Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276.
   SIMS W, 1986, J MED MICROBIOL, V22, P203, DOI 10.1099/00222615-22-3-203.
   Subhi AL, 2003, J BIOL CHEM, V278, P49868, DOI 10.1074/jbc.M308451200.
   Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200.
   VARTIVARIAN SE, 1993, J INFECT DIS, V167, P186, DOI 10.1093/infdis/167.1.186.
   Wang L, 1997, ACTA PHYSIOL SCAND, V160, P75, DOI 10.1046/j.1365-201X.1997.00131.x.
   Wang P, 2000, MOL CELL BIOL, V20, P352, DOI 10.1128/MCB.20.1.352-362.2000.
   Watson PH, 2003, BRIT J CANCER, V88, P1065, DOI 10.1038/sj.bjc.6600796.
   Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Genetics}},
Doc-Delivery-Number = {{651EM}},
Unique-ID = {{ISI:000281907700007}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000281374400014,
Author = {Heo, Yongju and Park, Jiyeon and Lim, Sung-il and Hur, Hor-gil and Kim,
   Daesung and Park, Kihong},
Title = {{Size-resolved culturable airborne bacteria sampled in rice field,
   sanitary landfill, and waste incineration sites}},
Journal = {{JOURNAL OF ENVIRONMENTAL MONITORING}},
Year = {{2010}},
Volume = {{12}},
Number = {{8}},
Pages = {{1619-1624}},
Month = {{AUG}},
Abstract = {{Size-resolved bacterial concentrations in atmospheric aerosols sampled
   by using a six stage viable impactor at rice field, sanitary landfill,
   and waste incinerator sites were determined. Culture-based and
   Polymerase Chain Reaction (PCR) methods were used to identify the
   airborne bacteria. The culturable bacteria concentration in total
   suspended particles (TSP) was found to be the highest (848 Colony
   Forming Unit (CFU)/m(3)) at the sanitary landfill sampling site, while
   the rice field sampling site has the lowest (125 CFU/m(3)). The closed
   landfill would be the main source of the observed bacteria concentration
   at the sanitary landfill. The rice field sampling site was fully covered
   by rice grain with wetted conditions before harvest and had no
   significant contribution to the airborne bacteria concentration. This
   might occur because the dry conditions favor suspension of soil
   particles and this area had limited personnel and vehicle flow. The
   respirable fraction calculated by particles less than 3.3 mu m was
   highest (26\%) at the sanitary landfill sampling site followed by waste
   incinerator (19\%) and rice field (10\%), which showed a lower level of
   respiratory fraction compared to previous literature values. We
   identified 58 species in 23 genera of culturable bacteria, and the
   Microbacterium, Staphylococcus, and Micrococcus were the most abundant
   genera at the sanitary landfill, waste incinerator, and rice field
   sites, respectively. An antibiotic resistant test for the above bacteria
   (Micrococcus sp., Microbacterium sp., and Staphylococcus sp.) showed
   that the Staphylococcus sp. had the strongest resistance to both
   antibiotics (25.0\% resistance for 32 mu g ml(-1) of Chloramphenicol and
   62.5\% resistance for 4 mu g ml(-1) of Gentamicin).}},
Publisher = {{ROYAL SOC CHEMISTRY}},
Address = {{THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Park, K (Reprint Author), Gwangju Inst Sci \& Technol, Dept Environm Sci \& Engn, Res Ctr Biomol Nanotechnol, 1 Oryong Dong, Kwangju 500712, South Korea.
   Heo, Yongju; Park, Jiyeon; Lim, Sung-il; Hur, Hor-gil; Kim, Daesung; Park, Kihong, Gwangju Inst Sci \& Technol, Dept Environm Sci \& Engn, Res Ctr Biomol Nanotechnol, Kwangju 500712, South Korea.}},
DOI = {{10.1039/c0em00004c}},
ISSN = {{1464-0325}},
Keywords-Plus = {{OUTDOOR ENVIRONMENTS; MICROORGANISMS; BIOAEROSOLS; INDOOR;
   IDENTIFICATION; ENUMERATION; BUILDINGS; EXPOSURE; AEROSOL; FUNGI}},
Research-Areas = {{Chemistry; Environmental Sciences \& Ecology}},
Web-of-Science-Categories  = {{Chemistry, Analytical; Environmental Sciences}},
Author-Email = {{kpark@gist.ac.kr}},
ResearcherID-Numbers = {{Park, Kihong/F-8366-2011}},
Funding-Acknowledgement = {{Korea Science and Engineering Foundation (KOSEF)
   {[}R01-2007-000-10391-0]; Desalination project {[}B01-05-03]}},
Funding-Text = {{The research described in this article was supported by Korea Science
   and Engineering Foundation (KOSEF) (No. R01-2007-000-10391-0) and was
   partially supported by desalination project (B01-05-03).}},
Cited-References = {{AMANN RI, 1995, MICROBIOL REV, V59, P143.
   Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl\_1.5.
   Che F, 2004, PRINCIPLE APPL AIRBO, P1.
   DiGiorgio C, 1996, ATMOS ENVIRON, V30, P155, DOI 10.1016/1352-2310(95)00143-M.
   Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032.
   Fang ZG, 2008, AEROSOL SCI TECH, V42, P325, DOI 10.1080/02786820802068657.
   Fang ZG, 2007, MICROB ECOL, V54, P487, DOI 10.1007/s00248-007-9216-3.
   HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161.
   Huang CY, 2002, ATMOS ENVIRON, V36, P4385, DOI 10.1016/S1352-2310(02)00322-9.
   Jimenez E, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-143.
   Jo WK, 2005, CHEMOSPHERE, V61, P1570, DOI 10.1016/j.chemosphere.2005.04.103.
   Kummer V, 2008, INT J HYG ENVIR HEAL, V211, P299, DOI 10.1016/j.ijheh.2007.06.006.
   Lee JH, 2006, ENVIRON RES, V101, P11, DOI 10.1016/j.envres.2005.08.009.
   Lee SA, 2006, J OCCUP ENVIRON HYG, V3, P118, DOI 10.1080/15459620500524607.
   Lis DO, 2008, CLEAN-SOIL AIR WATER, V36, P551, DOI 10.1002/clen.200800003.
   MACHER JM, 1989, AM IND HYG ASSOC J, V50, P561, DOI 10.1202/0002-8894(1989)050<0561:PCOMIF>2.0.CO;2.
   Negrin MM, 2007, AEROBIOLOGIA, V23, P249, DOI 10.1007/s10453-007-9069-8.
   Nicholson WL, 2002, CELL MOL LIFE SCI, V59, P410, DOI 10.1007/s00018-002-8433-7.
   Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734.
   Pastuszka JS, 2000, ATMOS ENVIRON, V34, P3833, DOI 10.1016/S1352-2310(99)00527-0.
   Peccia J, 2006, ATMOS ENVIRON, V40, P3941, DOI 10.1016/j.atmosenv.2006.02.029.
   Polymenakou PN, 2008, ENVIRON HEALTH PERSP, V116, P292, DOI 10.1289/ehp.10684.
   Pourcher AM, 2001, FEMS MICROBIOL ECOL, V34, P229, DOI 10.1016/S0168-6496(00)00101-X.
   Predicala BZ, 2002, CURR MICROBIOL, V44, P136, DOI 10.1007/s00284-001-0064-y.
   RAHKONEN P, 1992, WASTE MANAGE RES, V10, P411, DOI 10.1016/0734-242X(92)90115-2.
   Sarica S, 2002, INDOOR BUILT ENVIRON, V11, P285, DOI 10.1159/000066523.
   Seino K, 2005, ATMOS ENVIRON, V39, P337, DOI 10.1016/j.atmosenv.2004.09.030.
   Shaffer BT, 1997, MICROBIAL ECOL, V34, P167, DOI 10.1007/s002489900046.
   Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002.
   Stetzenbach LD, 2004, CURR OPIN BIOTECH, V15, P170, DOI 10.1016/j.copbio.2004.04.009.
   Swan JRM, 1998, ANN AGR ENV MED, V5, P7.
   Wang CC, 2007, TOXICOL IND HEALTH, V23, P133, DOI 10.1177/0748233707078741.
   Zhu Hong, 2003, Aerobiologia, V19, P201, DOI 10.1023/B:AERO.0000006571.23160.8a.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{15}},
Journal-ISO = {{J. Environ. Monit.}},
Doc-Delivery-Number = {{644KH}},
Unique-ID = {{ISI:000281374400014}},
DA = {{2018-08-13}},
}

@article{ ISI:000278087600004,
Author = {Steinstraesser, Lars and Sorkin, M. and Niederbichler, A. D. and
   Becerikli, M. and Stupka, J. and Daigeler, A. and Kesting, M. R. and
   Stricker, I. and Jacobsen, F. and Schulte, M.},
Title = {{A novel human skin chamber model to study wound infection ex vivo}},
Journal = {{ARCHIVES OF DERMATOLOGICAL RESEARCH}},
Year = {{2010}},
Volume = {{302}},
Number = {{5}},
Pages = {{357-365}},
Month = {{JUL}},
Abstract = {{Wound infections with multi-drug resistant bacteria increase morbidity
   and mortality and have considerable socioeconomic impact. They can lead
   to impaired wound healing, resulting in rising treatment costs. The aim
   of this study was to investigate an ex vivo human wound infection model.
   Human full-thickness skin from the operating room (OR) was placed into
   the Bo-Drum(A (R)) and cultivated for 7 days in an air-liquid
   interphase. On day 8, the skin was inoculated with either (1)
   Pseudomonas aeruginosa, (2) Staphylococcus aureus (10(5) CFU, n = 3) or
   (3) carrier control. 1, 3 and 7 days after inoculation colony forming
   units in the tissue/media were determined and cytokine expression was
   quantified. A reliable and reproducible wound infection could be
   established for 7 days. At this timepoint, 1.8 x 10(8) CFU/g tissue of
   P. aeruginosa and 2 x 10(7) CFU/g tissue of S. aureus were detected.
   Immunohistochemical analysis demonstrated bacterial infection and
   epidermolysis in infected skin. RT-PCR analysis exhibited a significant
   induction of proinflammatory cytokines after infection. The BO-drum(A
   (R)) is a robust, easy-to-use, sterilizable and reusable ex vivo
   full-skin culture system. For investigation of wound infection,
   treatment and healing, the BO-drum(A (R)) presents a convenient model
   and may help to standardize wound research.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Steinstraesser, L (Reprint Author), Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Plast Surg, Bochum, Germany.
   Steinstraesser, Lars; Sorkin, M.; Becerikli, M.; Stupka, J.; Daigeler, A.; Jacobsen, F.; Schulte, M., Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Plast Surg, Bochum, Germany.
   Stricker, I., Ruhr Univ Bochum, Sch Med, Dept Pathol, Bochum, Germany.
   Niederbichler, A. D., Hannover Med Sch, Burn Ctr, Dept Plast Hand \& Reconstruct Surg, D-30623 Hannover, Germany.
   Kesting, M. R., Tech Univ Munich, Klinikum Rechts Isar, Dept Oral \& Maxillofacial Surg, D-8000 Munich, Germany.}},
DOI = {{10.1007/s00403-009-1009-8}},
ISSN = {{0340-3696}},
Keywords = {{Ex vivo; Infection; Human; Skin; Staphylococcus aureus; Pseudomonas
   aeruginosa}},
Keywords-Plus = {{IN-VITRO; ORGAN-CULTURE; BURN WOUNDS; TISSUE; CELLS; KERATINOCYTES;
   FIBROBLASTS; REORGANIZATION; MAINTENANCE; EPIDERMIS}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Author-Email = {{lars.steinstraesser@ruhr-uni-bochum.de}},
ResearcherID-Numbers = {{Daigeler, Adrien/C-9417-2016}},
ORCID-Numbers = {{Daigeler, Adrien/0000-0002-0012-9870}},
Funding-Acknowledgement = {{Deutsche Forschungsgemeinschaft (DFG)}},
Funding-Text = {{This study was Wnancially supported by the Deutsche
   Forschungsgemeinschaft (DFG). We sincerely thank Ms. Andrea Rittig for
   expert technical assistance.}},
Cited-References = {{Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127.
   Damour O, 1998, MED BIOL ENG COMPUT, V36, P825, DOI 10.1007/BF02518890.
   Davidson JM, 1998, ARCH DERMATOL RES, V290, pS1, DOI 10.1007/PL00007448.
   de Brugerolle A, 2007, ALTEX-ALTERN TIEREXP, V24, P167.
   Emanuelsson P, 1997, BURNS, V23, P32, DOI 10.1016/S0305-4179(96)00073-3.
   GILLERY P, 1989, J CELL PHYSIOL, V140, P483, DOI 10.1002/jcp.1041400312.
   Gottrup F, 2000, WOUND REPAIR REGEN, V8, P83, DOI 10.1046/j.1524-475x.2000.00083.x.
   GREENWALD DP, 1992, PLAST RECONSTR SURG, V90, P289, DOI 10.1097/00006534-199290020-00019.
   GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401.
   HENTZER B, 1979, ACTA DERM-VENEREOL, V59, P389.
   Jacobsen F, 2005, J ANTIMICROB CHEMOTH, V55, P735, DOI 10.1093/jac/dki067.
   Khetani SR, 2006, CURR OPIN BIOTECH, V17, P524, DOI 10.1016/j.copbio.2006.08.009.
   Kirkpatrick CJ, 2002, BIOMOL ENG, V19, P211, DOI 10.1016/S1389-0344(02)00019-9.
   Krugluger W, 2005, EXP DERMATOL, V14, P580, DOI 10.1111/j.0906-6705.2005.00330.x.
   Megyeri K, 2002, CYTOKINE, V19, P206, DOI 10.1006/cyto.2002.0876.
   Moll I, 2003, METH MOLEC MED, V78, P305.
   Moll I, 1998, J INVEST DERMATOL, V111, P251, DOI 10.1046/j.1523-1747.1998.00265.x.
   Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381.
   PRUNEIRAS M, 1983, J INVEST DERMATOL, V81, P28.
   Puissant A, 1976, Rev Stomatol Chir Maxillofac, V77, P735.
   REGNIER M, 1993, J PHARM SCI, V82, P404, DOI 10.1002/jps.2600820414.
   Regnier M, 1998, MED BIOL ENG COMPUT, V36, P821, DOI 10.1007/BF02518889.
   Robson MC, 1999, AM J SURG, V178, P399, DOI 10.1016/S0002-9610(99)00208-1.
   Roupe KM, 2010, J INVEST DERMATOL, V130, P1167, DOI 10.1038/jid.2009.284.
   Schindler M, 2006, CELL BIOCHEM BIOPHYS, V45, P215, DOI 10.1385/CBB:45:2:215.
   SEILER WO, 1989, AM J CLIN PATHOL, V92, P430, DOI 10.1093/ajcp/92.4.430.
   Steinstraesser L, 2007, J GENE MED, V9, P949, DOI 10.1002/jgm.1099.
   Steinstraesser Lars, 2009, Eplasty, V9, pe5.
   Tavakkol A, 1999, ARCH DERMATOL RES, V291, P643, DOI 10.1007/s004030050469.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Arch. Dermatol. Res.}},
Doc-Delivery-Number = {{601TO}},
Unique-ID = {{ISI:000278087600004}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000285703200001,
Author = {Blasi, F. and Concia, E. and Mazzei, T. and Moretti, A. M. and
   Nicoletti, G. and Novelli, A. and Tempera, G. and GIARIR},
Title = {{Role of the Oral Beta-Lactams in the Treatment of Exacerbations of
   Chronic Bronchitis: Critical Analysis and Therapeutic Recommendations}},
Journal = {{JOURNAL OF CHEMOTHERAPY}},
Year = {{2010}},
Volume = {{22}},
Number = {{1}},
Pages = {{3-28}},
Month = {{JUL}},
Abstract = {{The GIARIR study group has made a critical analysis of the most recent
   scientific literature on acute bacterial exacerbations of chronic
   bronchitis (ABECB) with the aim of proposing therapeutic recommendations
   applicable to the current epidemiological situation in Italy. The
   international literature has indicated the scarcity of studies on the
   treatment of ABECB compared to an abundance of information regarding
   chronic obstructive pulmonary disease (COPD), of which ABECB is often
   considered the initial ore predisposing stage, even though a precise
   evolutionary correlation between these pathologies has not yet been
   demonstrated.
   ABECB is the principle cause of doctor visits, hospitalization and death
   in COPD patients. The natural course of the disease is characterized by
   the appearance of exacerbation episodes (a mean of two yearly). For this
   reason it is indispensable to prevent exacerbations, to treat them as
   quickly as possible, in order to minimize their negative effects on the
   respiratory tract and the patient's general health.
   The routine use of antibiotic therapy is controversial because at least
   20\% of exacerbations do not have an infectious origin and about 30\%
   are viral. In most cases the choice of antibiotic is empiric, in both
   ABECB patients without risk factors (mild form) and in those with risk
   factors such as cigarette smoking or constant exposure to air pollutants
   (moderate form). For these reasons it is necessary to keep up to date on
   the local and regional bacteria etiological situation and to be aware of
   antibiotic resistance patterns for the most commonly involved pathogens.
   An analysis of the most recent information in Italy has confirmed the
   involvement of the terrible three bacterial species Haemophilus
   influenzae, Moraxella catarrhalis and Streptococcus pneumoniae as the
   cause of 85-95\% of ABECB cases, as well as an increase in resistance to
   various classes of molecules by all the respiratory pathogens. On the
   basis of the known resistance patterns in Italy, some antibiotics are no
   longer considered first choice for empiric therapy such as the
   unprotected beta-lactams, tetracycline, trimethoprim/sulfamethoxazole
   and the macrolides) which should be used only after antibiotic
   susceptibility testing indicates they are still active against the
   pathogens. The epidemiological picture of bacterial resistance in Italy
   has greatly restricted the choice of antibiotics which can be used for
   this type of infection, justifying interest in the oral beta-lactams
   which have the highest therapeutic index and are first choice therapy
   against bacterial exacerbations of chronic bronchitis. Included in this
   group are amoxicillin-clavulanate and the new cephem molecule,
   cefditoren, which has been available in Italy since 2008. Thanks to its
   good pharmacokinetics and pharmacodynamics as well as clinical
   performance, cefditoren may be considered a drug of choice against
   exacerbations of chronic bronchitis.}},
Publisher = {{MANEY PUBLISHING}},
Address = {{STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Novelli, A (Reprint Author), Univ Florence, Dept Pharmacol, Viale Pieraccini 6, I-50139 Florence, Italy.
   Blasi, F.; GIARIR, Univ Milan, Dept Lung \& Heart Dis, I-20122 Milan, Italy.
   Concia, E., GB Rossi Polyclin Borgo Roma, Verona, Italy.
   Mazzei, T.; Novelli, A., Univ Florence, Dept Preclin \& Clin Pharmacol, I-50139 Florence, Italy.
   Moretti, A. M., Gen Hosp, Dept Pneumol, Bari, Italy.
   Nicoletti, G.; Tempera, G., Univ Catania, Dept Microbiol \& Gynecol, I-95124 Catania, Italy.}},
DOI = {{10.1179/joc.2010.22.Supplement-1.3}},
ISSN = {{1120-009X}},
EISSN = {{1973-9478}},
Keywords = {{Beta-lactams; chronic obstructive pulmonary disease (COPD);
   amoxicillin-clavulanate; cefditoren; ABECB}},
Keywords-Plus = {{OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-TRACT INFECTIONS; RANDOMIZED
   CONTROLLED-TRIAL; CLINICAL PHARMACOKINETIC PROPERTIES;
   STREPTOCOCCUS-PNEUMONIAE STRAINS; ANTIBIOTIC TISSUE PENETRATION;
   IN-VITRO; ANTIMICROBIAL SUSCEPTIBILITY; PHARMACOECONOMIC EVALUATION;
   PATHOPHYSIOLOGICAL STATES}},
Research-Areas = {{Oncology; Infectious Diseases; Pathology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Oncology; Infectious Diseases; Pathology; Pharmacology \& Pharmacy}},
Author-Email = {{andrea.novelli@unifi.it}},
ResearcherID-Numbers = {{BLASI, FRANCESCO/O-5885-2017}},
ORCID-Numbers = {{BLASI, FRANCESCO/0000-0002-2285-9970}},
Cited-References = {{Alpuche C, 2007, INT J ANTIMICROB AG, V30, pS135, DOI 10.1016/j.ijantimicag.2007.07.035.
   {[}Anonymous], 2008, GLOB STRAT DIAGN MAN.
   Biedenbach DJ, 2009, DIAGN MICR INFEC DIS, V64, P202, DOI 10.1016/j.diagmicrobio.2009.01.017.
   Blasi F, 2009, CLIN MICROBIOL INFEC, V15, P29, DOI 10.1111/j.1469-0691.2008.02130.x.
   Blasi F, 2009, DIAGN MICR INFEC DIS, V63, P302, DOI 10.1016/j.diagmicrobio.2008.11.012.
   Boccia D, 2004, EUR J CLIN PHARMACOL, V60, P115, DOI 10.1007/s00228-003-0724-x.
   BRYSKIER A, 1994, PRESSE MED, V23, P1762.
   Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4.
   Burge S, 2003, Eur Respir J Suppl, V41, p46s.
   BURK RH, 1973, ARCH INTERN MED, V132, P865, DOI 10.1001/archinte.132.6.865.
   Burley CJ, 2007, J INFECTION, V55, P226, DOI 10.1016/j.jinf.2007.05.181.
   BURROWS B, 1969, NEW ENGL J MED, V280, P397, DOI 10.1056/NEJM196902202800801.
   Cao ZY, 2006, RESPIROLOGY, V11, P188, DOI 10.1111/j.1440-1843.2006.00819.x.
   Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304.
   Cizman M, 2001, J ANTIMICROB CHEMOTH, V47, P475, DOI 10.1093/jac/47.4.475.
   Clark CL, 2002, J ANTIMICROB CHEMOTH, V50, P33, DOI 10.1093/jac/dkf076.
   Clinical and Laboratory Standards Institute, 2008, M100S18 CLSI.
   COCUZZA CE, 1994, MICROBIOLOGIA MED, V9, P21.
   Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592.
   COOK PJ, 1994, THORAX, V49, P1134, DOI 10.1136/thx.49.11.1134.
   CRAIG WA, 1995, DIAGN MICR INFEC DIS, V22, P89, DOI 10.1016/0732-8893(95)00053-D.
   Craig WA, 1998, CLIN INFECT DIS, V26, P1, DOI 10.1086/516284.
   CRAIG WA, 1993, J ANTIMICROB CHEMOTH, V31, P149, DOI 10.1093/jac/31.suppl\_D.149.
   CRAIG WA, 1991, ANTIBIOTICS LAB MED, P403.
   Dal Negro R, 2003, RESP MED, V97, pS43, DOI 10.1016/S0954-6111(03)80024-0.
   Dal Negro Roberto W, 2005, COPD, V2, P7.
   DALNEGRO R, 2002, MONALDI ARCH CHEST D, V57, P1.
   Davies L, 2000, BRIT MED J, V321, P1265, DOI 10.1136/bmj.321.7271.1265.
   Deshpande LM, 2006, DIAGN MICR INFEC DIS, V54, P157, DOI 10.1016/j.diagmicrobio.2005.08.012.
   Detournay B, 2004, VALUE HEALTH, V7, P168, DOI 10.1111/j.1524-4733.2004.72329.x.
   Diekema DJ, 2000, EMERG INFECT DIS, V6, P552, DOI 10.3201/eid0605.000519.
   DOMAGALA JM, 1994, J ANTIMICROB CHEMOTH, V33, P685, DOI 10.1093/jac/33.4.685.
   Dubois J, 2000, DIAGN MICR INFEC DIS, V37, P187, DOI 10.1016/S0732-8893(00)00141-3.
   {*}EUR RESP SOC, 2003, EUR LUNG WHIT BOOK, P34.
   FALLANI S, 2003, FARMACI TERAPIA, V20, P9.
   FELMINGHAM D, 1994, DRUG EXP CLIN RES, V20, P127.
   Felmingham D, 2004, CHEMOTHERAPY, V50, P3, DOI 10.1159/000079816.
   Felmingham D, 1996, J ANTIMICROB CHEMOTH, V38, P1.
   Fenoll A, 2008, EUR J CLIN MICROBIOL, V27, P75, DOI 10.1007/s10096-007-0402-5.
   Firsov AA, 2002, J ANTIMICROB CHEMOTH, V50, P533, DOI 10.1093/jac/dkf177.
   FORREST A, 1993, ANTIMICROB AGENTS CH, V37, P1073, DOI 10.1128/AAC.37.5.1073.
   FUSO L, 1995, AM J MED, V98, P272, DOI 10.1016/S0002-9343(99)80374-X.
   Garcia-Rey C, 2002, J CLIN MICROBIOL, V40, P159, DOI 10.1128/JCM.40.1.159-164.2002.
   Gherardi G, 2009, EUR J CLIN MICROBIOL, V28, P99, DOI 10.1007/s10096-008-0581-8.
   GOULD IM, 1994, THORAX, V49, P999, DOI 10.1136/thx.49.10.999.
   Gunen H, 2005, EUR RESPIR J, V26, P234, DOI 10.1183/09031936.05.00024804.
   Hernandez C, 2003, EUR RESPIR J, V21, P58, DOI 10.1183/09031936.03.00015603.
   Higgins K, 2008, CLIN INFECT DIS, V47, pS150, DOI 10.1086/591397.
   Hilleman DE, 2000, CHEST, V118, P1278, DOI 10.1378/chest.118.5.1278.
   Hurst JR, 2009, AM J RESP CRIT CARE, V179, P369, DOI 10.1164/rccm.200807-1067OC.
   Jones RN, 1998, DIAGN MICR INFEC DIS, V31, P573, DOI 10.1016/S0732-8893(98)00044-3.
   Jones RN, 2001, DIAGN MICR INFEC DIS, V41, P1, DOI 10.1016/S0732-8893(01)00274-7.
   JUMBE NL, 2000, 40 ICAAC TOR CAN SEP.
   Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017.
   KINZIGSCHIPPERS M, 2001, 41 INT C ANT AG CHEM.
   Kong GK, 1997, CHEST, V111, P89, DOI 10.1378/chest.111.1.89.
   Lucioni C, 2005, PHARMACOECONOMICS IT, V7, P119.
   Macgowan AP, 1997, J CHEMOTHERAPY, V9, P64.
   Marchese A, 2005, INT J ANTIMICROB AG, V26, P8, DOI 10.1016/j.ijantimicag.2005.02.01.
   MARCHESE A, 1995, J ANTIMICROB CHEMOTH, V36, P833, DOI 10.1093/jac/36.5.833.
   MAZZEI T, 2008, FARMACI TERAPIA, V25, P1.
   MAZZEI T, 2005, TRATTATO FARMACOLOGI.
   MAZZEI T, 2006, FARMACI TERAPIA, V23, P3.
   Miravitlles M, 2002, CHEST, V121, P1449, DOI 10.1378/chest.121.5.1449.
   Montagnani F, 2006, J CHEMOTHERAPY, V18, P389, DOI 10.1179/joc.2006.18.4.389.
   Monte SV, 2008, AM J MANAG CARE, V14, P190.
   Morris S, 2002, PHARMACOECONOMICS, V20, P153, DOI 10.2165/00019053-200220030-00002.
   Morrissey I, 2007, INT J ANTIMICROB AG, V30, P345, DOI 10.1016/j.ijantimicag.2007.05.021.
   {*}NAT I PUBL HLTH E, 2009, REPORT EARSS 2008 EA.
   Navarro AS, 2005, CLIN PHARMACOKINET, V44, P1097.
   Nicolau D P, 1994, Pharmacoeconomics, V5, P34, DOI 10.2165/00019053-199400052-00007.
   Niewoehner DE, 2006, AM J MED, V119, pS38, DOI 10.1016/j.amjmed.2006.08.006.
   Nightingale CH, 2000, CHEMOTHERAPY, V46, P6, DOI 10.1159/000048487.
   NIX DE, 1991, ANTIMICROB AGENTS CH, V35, P1953, DOI 10.1128/AAC.35.10.1953.
   NIX DE, 1991, ANTIMICROB AGENTS CH, V35, P1947, DOI 10.1128/AAC.35.10.1947.
   Novelli A, 2002, J CHEMOTHERAPY, V14, P584, DOI 10.1179/joc.2002.14.6.584.
   NOVELLI A, 2005, FARMACOLOGIA PRINCIP, P600.
   NOVELLI A, 2000, INT J ANTIMICROB AG, P501.
   NOVELLI A, 2004, EUR RESP MON, V9, P229.
   O'Donnell DE, 2007, CAN RESPIR J, V14, p5B, DOI 10.1155/2007/830570.
   Ojoo JC, 2002, THORAX, V57, P167, DOI 10.1136/thorax.57.2.167.
   Oliphant CM, 2002, AM FAM PHYSICIAN, V65, P455.
   Osman IM, 1997, THORAX, V52, P67.
   Ott S R, 2010, Pneumologie, V64, P18, DOI 10.1055/s-0029-1215197.
   Owens RC, 1997, PHARMACOTHERAPY, V17, P707.
   PERITI P, 1989, CLIN PHARMACOKINET, V16, P193, DOI 10.2165/00003088-198916040-00001.
   PERITI P, 1993, DRUG SAFETY, V9, P346, DOI 10.2165/00002018-199309050-00004.
   PERITI P, 1989, CLIN PHARMACOKINET, V16, P261, DOI 10.2165/00003088-198916050-00001.
   PERITI P, 1988, ATTUALITA CEFALOSPOR.
   PETRI WA, 2006, PHARMACOL BASIS THER, P1127.
   Petrosillo N, 2002, EUR J CLIN MICROBIOL, V21, P181, DOI 10.1007/s10096-001-0689-6.
   Pickerill KE, 2000, PHARMACOTHERAPY, V20, P417, DOI 10.1592/phco.20.5.417.35062.
   PORTIER F, 1992, CHEST, V101, P204, DOI 10.1378/chest.101.1.204.
   Preston SL, 1998, JAMA-J AM MED ASSOC, V279, P125, DOI 10.1001/jama.279.2.125.
   Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO.
   Rodriguez-Roisin R, 2000, CHEST, V117, p398S, DOI 10.1378/chest.117.5\_suppl\_2.398S.
   Rubinstein E, 2001, INT J ANTIMICROB AG, V18, pS71.
   Sadaba B, 2007, REV ESP QUIM, V20, P51.
   SCAGLIONE F, 2005, GIMMOC, V9, P39.
   Schentag J. J., 2002, Journal of Chemotherapy, V14, P13.
   Schentag JJ, 1998, CLIN INFECT DIS, V27, P40, DOI 10.1086/514621.
   SCHITO G, 1999, GIORNALE ITALIANO MI, V3, P11.
   Schito GC, 1997, J CHEMOTHERAPY, V9, P18.
   Schito GC, 2000, GIMMOC, V4, P13.
   SCHITO GC, 1999, GIMMOC, V3, P43.
   SCHITO GC, 1994, MICROB MED, V9, P532.
   Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032.
   Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022.
   SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852.
   Sethi S, 1999, J ANTIMICROB CHEMOTH, V43, P97, DOI 10.1093/jac/43.suppl\_1.97.
   Sethi S, 2005, SEM RESP CRIT CARE M, V26, P192, DOI 10.1055/s-2005-869538.
   Sethi S, 2000, CHEST, V118, P1557, DOI 10.1378/chest.118.6.1557.
   Sethi S, 2000, CHEST, V117, p380S, DOI 10.1378/chest.117.5\_suppl\_2.380S.
   Skwarska E, 2000, THORAX, V55, P907, DOI 10.1136/thorax.55.11.907.
   Stefani S, 2008, J CHEMOTHERAPY, V20, P561, DOI 10.1179/joc.2008.20.5.561.
   Tempera G, 2010, J CHEMOTHERAPY, V22, P153, DOI 10.1179/joc.2010.22.3.153.
   TEMPERA G, 2010, J CHEMOTHER IN PRESS.
   Tristram S, 2007, CLIN MICROBIOL REV, V20, P368, DOI 10.1128/CMR.00040-06.
   Verduin CM, 2002, CLIN MICROBIOL REV, V15, P125, DOI 10.1128/CMR.15.1.125-144.2002.
   Viegi G, 2007, EUR RESPIR J, V30, P993, DOI 10.1183/09031936.00082507.
   White AJ, 2003, THORAX, V58, P680, DOI 10.1136/thorax.58.8.680.
   White AJ, 2003, THORAX, V58, P73, DOI 10.1136/thorax.58.1.73.
   White AR, 2004, J ANTIMICROB CHEMOTH, V53, pI3, DOI 10.1093/jac/dkh050.
   Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC.}},
Number-of-Cited-References = {{124}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Chemother.}},
Doc-Delivery-Number = {{699ZZ}},
Unique-ID = {{ISI:000285703200001}},
DA = {{2018-08-13}},
}

@article{ ISI:000279897100002,
Author = {McNerney, Ruth and Wondafrash, Beyene A. and Amena, Kebede and Tesfaye,
   Ato and McCash, Elaine M. and Murray, Nicol J.},
Title = {{Field test of a novel detection device for Mycobacterium tuberculosis
   antigen in cough}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2010}},
Volume = {{10}},
Month = {{JUN 8}},
Abstract = {{Background: Tuberculosis is a highly infectious disease that is spread
   from person to person by infected aerosols emitted by patients with
   respiratory forms of the disease. We describe a novel device that
   utilizes immunosensor and bio-optical technology to detect M.
   tuberculosis antigen (Ag85B) in cough and demonstrate its use under
   field conditions during a pilot study in an area of high TB incidence.
   Methods: The TB Breathalyzer device (Rapid Biosensor Systems Ltd) was
   field tested in the outpatient clinic of Adama Hospital, Ethiopia.
   Adults seeking diagnosis for respiratory complaints were tested.
   Following nebulization with 0.9\% saline patients were asked to cough
   into a disposable collection device where cough aerosols were deposited.
   Devices were then inserted into a portable instrument to assess whether
   antigen was present in the sample. Demographic and clinical data were
   recorded and all patients were subjected to chest radiogram and
   examination of sputum by Ziehl-Nielsen microscopy. In the absence of
   culture treatment decisions were based on smear microscopy, chest x-ray
   and clinical assessment. Breathalyzer testing was undertaken by a
   separate physician to triage and diagnostic assessment.
   Results: Sixty individuals were each subjected to a breathalyzer test.
   The procedure was well tolerated and for each patient the testing was
   completed in less than 10 min. Positive breath test results were
   recorded for 29 (48\%) patients. Of 31 patients with a diagnosis of
   tuberculosis 23 (74\%; 95\% CI 55-87) were found positive for antigen in
   their breath and 20 (64\%; 95\% CI 45-80) were smear positive for acid
   fast bacilli in their sputum. Six patients provided apparent false
   positive breathalyzer results that did not correlate with a diagnosis of
   tuberculosis.
   Conclusions: We propose that the breathalyzer device described warrants
   further investigation as a tool for studying exhalation of M.
   tuberculosis. The portability, simplicity of use and speed of the test
   device suggest it may also find use as a tool to aid early
   identification of infectious cases. We recommend studies be undertaken
   to determine the diagnostic sensitivity and specificity of the device
   when compared to microbiological and clinical indicators of tuberculosis
   disease.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{McNerney, R (Reprint Author), Univ London London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, Keppel St, London WC1E 7HT, England.
   McNerney, Ruth; Wondafrash, Beyene A., Univ London London Sch Hyg \& Trop Med, Dept Infect \& Trop Dis, London WC1E 7HT, England.
   Wondafrash, Beyene A.; Amena, Kebede; Tesfaye, Ato, Adama Hosp, Nazareth, Oromia, Ethiopia.
   McCash, Elaine M.; Murray, Nicol J., Rapid Biosensor Syst Ltd, Cambridge CB22 3AT, England.}},
DOI = {{10.1186/1471-2334-10-161}},
Article-Number = {{161}},
ISSN = {{1471-2334}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; AIRBORNE TRANSMISSION; HIV ERA}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{Ruth.Mcnerney@lshtm.ac.uk}},
ORCID-Numbers = {{MCNERNEY, Ruth/0000-0002-1957-443X}},
Funding-Acknowledgement = {{Department for International Development, UK; World Health Organisation;
   UK Department of Trade and Industry SMART Feasibility and Development}},
Funding-Text = {{The study received financial support from the TARGETS Communicable
   Diseases Research Consortium funded by Department for International
   Development, UK. Breathalyzer test devices and training in their use
   were supplied by Rapid Biosensor Systems Ltd.; Elaine McCash and Nicol
   Murray (RBS) received financial support for development of the test
   device from the World Health Organisation and UK Department of Trade and
   Industry SMART Feasibility and Development awards.}},
Cited-References = {{Banwell CN, 1994, FUNDAMENTALS MOL SPE.
   Chen PS, 2008, AEROSOL SCI TECH, V42, P194, DOI 10.1080/02786820801922953.
   Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9.
   Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397.
   Fennelly KP, 2007, CLIN INFECT DIS, V44, P1358, DOI 10.1086/516617.
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC.
   HATCH TF, 1961, BACTERIOL REV, V25, P237.
   KAMAT SR, 1966, B WORLD HEALTH ORGAN, V34, P517.
   Kato-Maeda M, 2000, WESTERN J MED, V172, P256, DOI 10.1136/ewjm.172.4.256.
   Marks SM, 2000, AM J RESP CRIT CARE, V162, P2033, DOI 10.1164/ajrccm.162.6.2004022.
   MCCASH E, 2008, BIOL MEASUREMENT SYS.
   Mustafa AS, 2000, INFECT IMMUN, V68, P3933, DOI 10.1128/IAI.68.7.3933-3940.2000.
   Perkins MD, 2007, J INFECT DIS, V196, pS15, DOI 10.1086/518656.
   RILEY RL, 1959, AM J EPIDEMIOL, V142, P3.
   Schafer MP, 1998, AM IND HYG ASSOC J, V59, P540, DOI 10.1202/0002-8894(1998)059<0540:SAAMDF>2.0.CO;2.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   World Health Organization, 2009, GLOB TUB CONTR SURV.
   Zager EM, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-10.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{625LP}},
Unique-ID = {{ISI:000279897100002}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000277913800022,
Author = {Tanaka, Naritaka and Kimura, Hitoshi and Faried, Ahmad and Sakai, Makoto
   and Sano, Akihiko and Inose, Takanori and Sohda, Makoto and Okada, Koji
   and Nakajima, Masanobu and Miyazaki, Tatsuya and Fukuchi, Minoru and
   Kato, Hiroyuki and Asao, Takayuki and Kuwano, Hiroyuki and Satoh,
   Takahiro and Oikawa, Masakazu and Kamiya, Tomihiro and Arakawa, Kazuo},
Title = {{Quantitative analysis of cisplatin sensitivity of human esophageal
   squamous cancer cell lines using in-air micro-PIXE}},
Journal = {{CANCER SCIENCE}},
Year = {{2010}},
Volume = {{101}},
Number = {{6}},
Pages = {{1487-1492}},
Month = {{JUN}},
Abstract = {{Cisplatin is a key chemotherapeutic agent for the treatment of
   esophageal cancer. We examined the intracellular localization of
   cisplatin in esophageal cancer cell lines and determined their
   sensitivity to cisplatin using in-air micro-PIXE (particle induced X-ray
   emission). Two human esophageal squamous cell carcinoma (ESCC) cell
   lines, TE-2 and TE-13, were examined for their response to cisplatin
   using MTT assay, flow cytometry, and DNA fragmentation assays. Real-time
   reverse transcription-polymerase chain reaction was also used to
   evaluate the mRNA expression of multidrug resistance protein 2 (MRP2) in
   both cell lines. Platinum localizations of intracellular and
   intranuclear were measured using in-air micro-PIXE. TE-2 cells were more
   sensitive to cisplatin than TE-13 cells (IC(50): 37.5 mu m and 56.3 mu
   m, respectively). Flow cytometry analysis confirmed that more TE-2 than
   TE-13 cells were in the sub-G1 phase. DNA fragmentation assay was
   analyzed to confirm the MTT assay and flow cytometry results. The
   expression of MRP2 mRNA in TE-13 cells was stronger than in TE-2 cells.
   In-air micro-PIXE showed that TE-2 cells had higher intracellular
   cisplatin concentrations than TE-13 cells and the ratio of intranuclear
   to intracellular cisplatin in individual cells was not significantly
   different. We observed the intracellular and intranuclear localization
   of cisplatin using in-air micro-PIXE. The results of this study suggest
   that in-air micro-PIXE could be a useful quantitative method for
   evaluating the cisplatin sensitivity of individual cells. Finally, we
   speculate that MRP2 in the cell membrane may play an important role in
   regulating the cisplatin sensitivity of ESCC cells. (Cancer Sci 2010).}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tanaka, N (Reprint Author), Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gumma 371, Japan.
   Tanaka, Naritaka; Kimura, Hitoshi; Faried, Ahmad; Sakai, Makoto; Sano, Akihiko; Inose, Takanori; Okada, Koji; Nakajima, Masanobu; Miyazaki, Tatsuya; Fukuchi, Minoru; Kato, Hiroyuki; Asao, Takayuki; Kuwano, Hiroyuki, Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi, Gumma 371, Japan.
   Tanaka, Naritaka; Kimura, Hitoshi; Faried, Ahmad; Sakai, Makoto; Sano, Akihiko; Inose, Takanori; Sohda, Makoto; Okada, Koji; Nakajima, Masanobu; Miyazaki, Tatsuya; Fukuchi, Minoru; Kato, Hiroyuki; Asao, Takayuki; Kuwano, Hiroyuki, Gunma Univ, Grad Sch Med, Century COE Program 21, Maebashi, Gumma 371, Japan.
   Kato, Hiroyuki, Dokkyo Med Univ, Dept Surg Oncol, Mibu, Tochigi, Japan.
   Satoh, Takahiro; Oikawa, Masakazu; Kamiya, Tomihiro; Arakawa, Kazuo, Japan Atom Energy Agcy, Takasaki Adv Radiat Res Inst, Takasaki, Gumma 3701292, Japan.}},
DOI = {{10.1111/j.1349-7006.2010.01542.x}},
ISSN = {{1347-9032}},
Keywords-Plus = {{RAY-EMISSION ANALYSIS; MULTIDRUG-RESISTANCE; INCREASED EXPRESSION;
   ELEMENTAL ANALYSIS; LUNG-CANCER; TRANSPORTER; PROTEINS; CHEMOTHERAPY;
   RADIOSENSITIVITY; SUPERFAMILY}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{ntanaka@showa.gunma-u.ac.jp}},
Funding-Acknowledgement = {{Ministry of Education, Culture, Sports Science and Technology of Japan}},
Funding-Text = {{This work was supported in party by a Grant-in-Aid for Scientific
   Research and the 21st Century Center of Excellence (COE) Program from
   the Ministry of Education, Culture, Sports Science and Technology of
   Japan.}},
Cited-References = {{Akimoto T, 2001, INT J RADIAT ONCOL, V50, P195, DOI 10.1016/S0360-3016(00)01560-1.
   Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095.
   Barnas C, 1997, INT J CANCER, V71, P79, DOI 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4.
   Borst P, 2000, J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295.
   Cholewa M, 1996, CELL MOL BIOL, V42, P69.
   Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R.
   Fan W., 1996, Cellular Pharmacology, V3, P343.
   Filipits M, 2007, CLIN CANCER RES, V13, P3892, DOI 10.1158/1078-0432.CCR-06-2446.
   Furuya M, 2004, J PATHOL, V203, P551, DOI 10.1002/path.1543.
   Garman EF, 2005, PROG BIOPHYS MOL BIO, V89, P173, DOI 10.1016/j.pbiomolbio.2004.09.005.
   Ghazvini PTM, 2009, BIORESOURCE TECHNOL, V100, P2361, DOI 10.1016/j.biortech.2008.11.025.
   Gibb RK, 1997, GYNECOL ONCOL, V65, P13, DOI 10.1006/gyno.1997.4637.
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706.
   Hinoshita E, 2000, CLIN CANCER RES, V6, P2401.
   Ishii K, 2001, NUCL INSTRUM METH B, V181, P448, DOI 10.1016/S0168-583X(01)00623-1.
   Kozai N, 2005, NUCL INSTRUM METH B, V231, P530, DOI 10.1016/j.nimb.2005.01.112.
   Kusakabe T, 2008, TOXICOL IN VITRO, V22, P1469, DOI 10.1016/j.tiv.2008.04.021.
   MCILWRATH AJ, 1994, CANCER RES, V54, P3718.
   Nagamine T, 2007, BIOL TRACE ELEM RES, V117, P115, DOI 10.1007/BF02698088.
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O.
   NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923.
   Noma B, 2008, INT J ONCOL, V33, P1187, DOI 10.3892/ijo\_00000108.
   Pascolo L, 2003, BIOCHEM BIOPH RES CO, V303, P259, DOI 10.1016/S0006-291X(03)00327-9.
   Sakai T, 2005, NUCL INSTRUM METH B, V231, P112, DOI 10.1016/j.nimb.2005.01.043.
   Sakai T, 2002, NUCL INSTRUM METH B, V190, P271, DOI 10.1016/S0168-583X(02)00469-X.
   Sakurai H, 2008, CANCER SCI, V99, P901, DOI 10.1111/j.1349-7006.2008.00755.x.
   Samimi G, 2004, CLIN CANCER RES, V10, P4661, DOI 10.1158/1078-0432.CCR-04-0137.
   Shimizu Y, 2008, INT J IMMUNOPATH PH, V21, P567, DOI 10.1177/039463200802100309.
   Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026.
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Cancer Sci.}},
Doc-Delivery-Number = {{599LJ}},
Unique-ID = {{ISI:000277913800022}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000277120300004,
Author = {Lucio, M. and Lima, J. L. F. C. and Reis, S.},
Title = {{Drug-Membrane Interactions: Significance for Medicinal Chemistry}},
Journal = {{CURRENT MEDICINAL CHEMISTRY}},
Year = {{2010}},
Volume = {{17}},
Number = {{17}},
Pages = {{1795-1809}},
Month = {{JUN}},
Abstract = {{Generally drugs can act on the level of different biological membranes
   as well as inside the cells that are limited by membranes. Even in the
   latter situation, drugs must still interact with the membrane in order
   to cross it and reach their targets. For this reason, the efficiency of
   drugs to interact with the membranes constitutes one of the most
   important pharmacological features playing an essential role in their
   biological activity.
   Membranes are the gathering place of many proteins and lipids, and are
   the structures where most cellular activities occur. Although drugs bind
   to proteins and regulate their activity, the membrane lipid phase is no
   less important. Great part of compounds studied induces structural
   changes in the lipid phase resulting structural defects, which in turn
   disturb membrane function and indirectly modulate membrane proteins.
   This paper reviews the clinical significance of drug-membrane
   interaction studies with a special focus in the lipidic components of
   the membrane and reinforcing the importance of these studies in the
   field of medicinal chemistry since they constitute stimulating
   opportunities for understanding drugs mode of action and toxic effects
   and cannot be overlooked during drug design and synthesis.}},
Publisher = {{BENTHAM SCIENCE PUBL LTD}},
Address = {{EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Lucio, M (Reprint Author), Univ Porto, Fac Farm, Serv Quim Fis, REQUIMTE, Rua Anibal Cunha,164, P-4099030 Oporto, Portugal.
   Lucio, M.; Lima, J. L. F. C.; Reis, S., Univ Porto, Fac Farm, Serv Quim Fis, REQUIMTE, P-4099030 Oporto, Portugal.}},
DOI = {{10.2174/092986710791111233}},
ISSN = {{0929-8673}},
EISSN = {{1875-533X}},
Keywords = {{Drug-membrane interactions; lipid membrane; lipidomics; multidrug
   resistance}},
Keywords-Plus = {{DIFFERENTIAL SCANNING CALORIMETRY; ATOMIC-FORCE MICROSCOPY;
   1,2-DIMYRISTOYL-SN-GLYCERO-3-PHOSPHOCHOLINE DMPC LIPOSOMES; NONSTEROIDAL
   ANTIINFLAMMATORY DRUGS; AIR-WATER-INTERFACE; HUMAN SERUM-ALBUMIN;
   SOLID-STATE NMR; MULTIDRUG-RESISTANCE; LIPID-BILAYERS; AMPHOTERICIN-B}},
Research-Areas = {{Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Chemistry, Medicinal; Pharmacology \&
   Pharmacy}},
Author-Email = {{mlucio@ff.up.pt}},
ResearcherID-Numbers = {{REQUIMTE, ANALYSIS/M-4644-2013
   REQUIMTE, AL/H-9106-2013
   REQUIMTE, UCIBIO/N-9846-2013
   Hipolito Reis Dias Rodrigues, Maria de La Salette/A-9613-2013
   Lima, Jose/D-8208-2013
   Chaves, Pedro/K-1288-2013
   REQUIMTE, LAQV/N-9835-2013
   REQUIMTE, BBB/M-6212-2013
   }},
ORCID-Numbers = {{Hipolito Reis Dias Rodrigues, Maria de La Salette/0000-0002-0736-2835
   Lucio, Marlene/0000-0003-2593-1672
   Lima, Jose/0000-0002-8906-9826}},
Funding-Acknowledgement = {{Fundacao para a Ciencia e Tecnologia (FCT - Lisbon)
   {[}PTDC/SAU-FCF/67718/2006]}},
Funding-Text = {{Partial financial support for this work was provided by Fundacao para a
   Ciencia e Tecnologia (FCT - Lisbon), through the contract
   PTDC/SAU-FCF/67718/2006.}},
Cited-References = {{Agasosler AV, 2001, BIOCHEM PHARMACOL, V61, P817, DOI 10.1016/S0006-2952(01)00542-1.
   Agasoster AV, 2001, BIOPHYS CHEM, V91, P37.
   Alessenko A, 2002, BIOELECTROCHEMISTRY, V58, P13, DOI 10.1016/S1567-5394(02)00135-4.
   Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948.
   Avdeef A, 2007, J PHARM SCI-US, V96, P2893, DOI 10.1002/jps.21068.
   Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100.
   Baginski M, 2005, ACTA BIOCHIM POL, V52, P655.
   Baginski M, 1997, J MOL STRUC-THEOCHEM, V389, P139, DOI 10.1016/S0166-1280(96)04585-X.
   Barbato F, 2004, EUR J PHARM SCI, V22, P261, DOI 10.1016/j.ejps.2004.03.019.
   Barwicz J, 1997, CHEM PHYS LIPIDS, V85, P145, DOI 10.1016/S0009-3084(96)02652-7.
   BAUERLE HD, 1991, BIOCHEMISTRY-US, V30, P7203, DOI 10.1021/bi00243a023.
   BERGETHON PR, 1990, BIOPHYSICAL CHEM MOL.
   Bernsdorff C, 1999, J BIOMED MATER RES, V46, P141, DOI 10.1002/(SICI)1097-4636(199908)46:2<141::AID-JBM2>3.3.CO;2-L.
   Berquand A, 2005, PHARM RES, V22, P465, DOI 10.1007/s11095-004-1885-8.
   Berquand A, 2004, BBA-BIOMEMBRANES, V1664, P198, DOI 10.1016/j.bbamem.2004.05.010.
   Bittman R, 2004, CHEM PHYS LIPIDS, V129, P111, DOI 10.1016/j.chemphyslip.2004.01.004.
   BORGES CPF, 1995, J LUMIN, V65, P105, DOI 10.1016/0022-2313(95)00052-R.
   Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055.
   Bosch I, 1996, BIOCHIM BIOPHYS ACTA, V9, P37.
   Bouwstra JA, 2002, CELL MOL BIOL LETT, V7, P222.
   Bouwstra JA, 2002, ADV DRUG DELIVER REV, V54, pS41, DOI 10.1016/S0169-409X(02)00114-X.
   Brezesinski G, 2003, ADV COLLOID INTERFAC, V100, P563, DOI 10.1016/S0001-8686(02)00071-4.
   Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X.
   Brockman H, 2000, ACTA OPHTHALMOL SCAN, V78, P10, DOI 10.1034/j.1600-0420.2000.078s230010.x.
   Brockman HL, 2003, OCUL IMMUNOL INFLAMM, V11, P247, DOI 10.1076/ocii.11.4.247.18261.
   Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200.
   BUTLER MB, 2006, IEEE ULTRASONICS S P, V1, P1362.
   Caetano W, 2001, BIOPHYS CHEM, V91, P21, DOI 10.1016/S0301-4622(01)00145-4.
   Carrozzino JM, 2004, PHARM RES, V21, P2327, DOI 10.1007/s11095-004-7685-3.
   Castelli F, 2005, J COLLOID INTERF SCI, V285, P110, DOI 10.1016/j.jcis.2004.11.039.
   Castelli F, 2006, MOL PHARMACEUT, V3, P737, DOI 10.1021/mp060059y.
   Cavalcanti LP, 2006, EUR BIOPHYS J BIOPHY, V35, P431, DOI 10.1007/s00249-006-0050-1.
   Chakraborty H, 2005, CHEM PHYS LIPIDS, V138, P20, DOI 10.1016/j.chemphyslip.2005.07.005.
   Chakraborty H, 2004, LANGMUIR, V20, P3551, DOI 10.1021/la0361417.
   Chakraborty H, 2007, BBA-BIOMEMBRANES, V1768, P1138, DOI 10.1016/j.bbamem.2007.01.004.
   Cheng HY, 1996, BBA-BIOMEMBRANES, V1284, P20, DOI 10.1016/0005-2736(96)00097-1.
   Clausell A, 2004, BIOPOLYMERS, V75, P480, DOI 10.1002/bip.20165.
   Cocquyt J, 2007, LANGMUIR, V23, P1959, DOI 10.1021/la062139e.
   COHEN BE, 1992, BIOCHIM BIOPHYS ACTA, V1108, P49, DOI 10.1016/0005-2736(92)90113-Z.
   Cronier F, 2007, CHEM PHYS LIPIDS, V146, P125, DOI 10.1016/j.chemphyslip.2007.01.002.
   Cushion MT, 2009, CURR MED CHEM, V16, P2514, DOI 10.2174/092986709788682038.
   da Silva AMG, 2005, CHEM PHYS LIPIDS, V137, P62, DOI 10.1016/j.chemphyslip.2005.06.004.
   De Weer P, 2000, ANNU REV PHYSIOL, V62, P919, DOI 10.1146/annurev.physiol.62.1.919.
   dePaula E, 1996, BRAZ J MED BIOL RES, V29, P877.
   Di L, 2003, CURR OPIN CHEM BIOL, V7, P402, DOI 10.1016/S1367-5931(03)00055-3.
   Dimova R, 2006, J PHYS-CONDENS MAT, V18, pS1151, DOI 10.1088/0953-8984/18/28/S04.
   Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199.
   DRORI S, 1995, EUR J BIOCHEM, V228, P1020, DOI 10.1111/j.1432-1033.1995.1020m.x.
   El Maghraby GMM, 2005, INT J PHARMACEUT, V292, P179, DOI 10.1016/j.ijpharm.2004.11.037.
   Epand RM, 1997, BIOPOLYMERS, V43, P15, DOI 10.1002/(SICI)1097-0282(1997)43:1<15::AID-BIP3>3.0.CO;2-3.
   Escriba PV, 2008, J CELL MOL MED, V12, P829, DOI 10.1111/j.1582-4934.2008.00281.x.
   ESCRIBA PV, 1995, P NATL ACAD SCI USA, V92, P7595, DOI 10.1073/pnas.92.16.7595.
   Escriba PV, 2006, TRENDS MOL MED, V12, P34, DOI 10.1016/j.molmed.2005.11.004.
   ESCRIBA PV, 1990, BIOCHEMISTRY-US, V29, P7275, DOI 10.1021/bi00483a017.
   Fa N, 2007, BBA-BIOMEMBRANES, V1768, P1830, DOI 10.1016/j.bbamem.2007.04.013.
   Fa N, 2006, CHEM PHYS LIPIDS, V144, P108, DOI 10.1016/j.chemphyslip.2006.08.002.
   FENDLER JH, 1980, J PHYS CHEM-US, V84, P1485, DOI 10.1021/j100449a012.
   Ferreira H, 2005, ANAL BIOANAL CHEM, V382, P1256, DOI 10.1007/s00216-005-3251-z.
   Ferreira H, 2005, J PHARM SCI-US, V94, P1277, DOI 10.1002/jps.20351.
   Ferreira H, 2003, ANAL BIOANAL CHEM, V377, P293, DOI 10.1007/s00216-003-2089-5.
   FOLDVARI M, 1992, INT J DERMATOL, V31, P894, DOI 10.1111/j.1365-4362.1992.tb03556.x.
   FORD JM, 1990, PHARMACOL REV, V42, P155.
   FORD JM, 1990, CANCER RES, V50, P1748.
   FORD JM, 1989, MOL PHARMACOL, V35, P105.
   Frankel DJ, 2006, BIOPHYS J, V90, P2404, DOI 10.1529/biophysj.105.073692.
   Gao S, 1998, J CONTROL RELEASE, V51, P193, DOI 10.1016/S0168-3659(97)00168-5.
   Garcia ML, 1997, THIN SOLID FILMS, V301, P169, DOI 10.1016/S0040-6090(96)09589-2.
   Gicquaud C, 1996, ARCH BIOCHEM BIOPHYS, V334, P193, DOI 10.1006/abbi.1996.0446.
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125.
   Gouaux E, 2001, CURR OPIN STRUC BIOL, V11, P393, DOI 10.1016/S0959-440X(00)00222-0.
   Grancelli A, 2002, LANGMUIR, V18, P9177, DOI 10.1021/la025837h.
   Greenhall MH, 1998, LANGMUIR, V14, P2619, DOI 10.1021/la970458n.
   Gref R, 2003, BIOMATERIALS, V24, P4529, DOI 10.1016/S0142-9612(03)00348-X.
   Hac-Wydro K, 2005, BIOPHYS CHEM, V116, P77, DOI 10.1016/j.bpc.2005.03.001.
   Han XL, 2007, FRONT BIOSCI, V12, P2601, DOI 10.2741/2258.
   Hidalgo AA, 2004, BIOPHYS CHEM, V109, P85, DOI 10.1016/j.bpc.2003.10.020.
   Hilgemann DW, 2003, ANNU REV PHYSIOL, V65, P697, DOI 10.1146/annurev.physiol.65.092101.142453.
   HILLGREN KM, 1995, MED RES REV, V15, P83, DOI 10.1002/med.2610150202.
   Hong SP, 2006, BIOCONJUGATE CHEM, V17, P728, DOI 10.1021/bc060077y.
   Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7.
   Jelinek R, 2005, CURR PROTEIN PEPT SC, V6, P103, DOI 10.2174/1389203053027511.
   Jesorka A, 2008, ANNU REV ANAL CHEM, V1, P801, DOI 10.1146/annurev.anchem.1.031207.112747.
   JORGENSEN K, 1993, CHEM PHYS LIPIDS, V65, P205, DOI 10.1016/0009-3084(93)90018-X.
   JORGENSEN K, 1991, BIOCHIM BIOPHYS ACTA, V1067, P241, DOI 10.1016/0005-2736(91)90050-I.
   JORGENSEN K, 1991, BIOCHIM BIOPHYS ACTA, V1062, P227, DOI 10.1016/0005-2736(91)90397-Q.
   Jutila A, 2001, CHEM PHYS LIPIDS, V112, P151, DOI 10.1016/S0009-3084(01)00175-X.
   Kahya N, 2001, BIOPHYS J, V81, P1464, DOI 10.1016/S0006-3495(01)75801-8.
   KANSY M, 2001, HIGH THROUGHPUT ARTI.
   Kessel A, 2001, BIOPHYS J, V80, P2536, DOI 10.1016/S0006-3495(01)76225-X.
   Krill SL, 1998, J PHARM SCI, V87, P751, DOI 10.1021/js970374z.
   Kumar R, 1997, NEUROCHEM RES, V22, P1, DOI 10.1023/A:1027332000569.
   Lakowicz J.R., 2006, PRINCIPLES FLUORESCE.
   Lasic D. D., 1993, LIPOSOMES PHYS APPL.
   Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012.
   Leroueil PR, 2007, ACCOUNTS CHEM RES, V40, P335, DOI 10.1021/ar600012y.
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012.
   Lewis RNAH, 2001, BBA-BIOMEMBRANES, V1510, P70, DOI 10.1016/S0005-2736(00)00336-9.
   Liu J, 2005, LANGMUIR, V21, P9091, DOI 10.1021/la051500e.
   Liu Q, 2006, BIOCHEMISTRY-US, V45, P4248, DOI 10.1021/bi052517z.
   Lommerse PHM, 2004, BBA-BIOMEMBRANES, V1664, P119, DOI 10.1016/j.bbamem.2004.05.005.
   Lu PH, 2001, EUR J BIOCHEM, V268, P1687, DOI 10.1046/j.1432-1033.2001.02041.x.
   Lucio M, 2004, PHYS CHEM CHEM PHYS, V6, P1493, DOI 10.1039/b314551b.
   Lucio M, 2009, CHEM PHYS LETT, V471, P300, DOI 10.1016/j.cplett.2009.02.047.
   Lucio M, 2008, LANGMUIR, V24, P4132, DOI 10.1021/la703584s.
   Lucio M, 2007, ANAL CHIM ACTA, V597, P163, DOI 10.1016/j.aca.2007.06.039.
   Malheiros SVP, 2004, BIOPHYS CHEM, V110, P213, DOI 10.1016/j.bpc.2004.01.013.
   Mamelli L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006443.
   Marezak A, 2006, CELL BIOL INT, V30, P127, DOI 10.1016/j.cellbi.2005.09.001.
   Matsuda R, 1997, BIOCHEM BIOPH RES CO, V237, P499, DOI 10.1006/bbrc.1997.7177.
   Matsuoka S, 2003, BBA-BIOMEMBRANES, V1617, P109, DOI 10.1016/j.bbamem.2003.09.010.
   Matsuoka S, 2006, BIOORGAN MED CHEM, V14, P6608, DOI 10.1016/j.bmc.2006.06.001.
   Mecke A, 2005, LANGMUIR, V21, P10348, DOI 10.1021/la0506291.
   Meier M, 2006, BIOPHYS J, V91, P2943, DOI 10.1529/biophysj.106.089581.
   Merino S, 2003, LANGMUIR, V19, P6922, DOI 10.1021/la034232y.
   Michalak K, 2006, CURR DRUG TARGETS, V7, P1095, DOI 10.2174/138945006778226570.
   Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P1003.
   MOLITORIS BA, 1993, AM J PHYSIOL, V264, pF907.
   Mukherjee S, 2004, ANNU REV CELL DEV BI, V20, P839, DOI 10.1146/annurev.cellbio.20.010403.095451.
   MUSTONEN P, 1991, J BIOL CHEM, V266, P6302.
   NICOLAY K, 1987, BIOCHIM BIOPHYS ACTA, V892, P320, DOI 10.1016/0005-2728(87)90236-2.
   Nussio MR, 2009, LANGMUIR, V25, P1086, DOI 10.1021/la803288s.
   Omote H, 2006, BIOPHYS J, V90, P4046, DOI 10.1529/biophysj.105.077743.
   Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200.
   Osterberg T, 2001, EUR J PHARM SCI, V12, P427, DOI 10.1016/S0928-0987(00)00183-4.
   Pajeva IK, 1996, J CANCER RES CLIN, V122, P27, DOI 10.1007/BF01203070.
   Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788.
   Panicker L, 2006, BIOPHYS CHEM, V120, P15, DOI 10.1016/j.bpc.2005.09.017.
   Panicker L, 2008, PHASE TRANSIT, V81, P361, DOI 10.1080/01411590701689839.
   Pedros J, 1997, SPECTROCHIM ACTA A, V53, P421, DOI 10.1016/S1386-1425(96)01820-3.
   Porcar I, 2003, J PHARM SCI, V92, P45, DOI 10.1002/jps.10254.
   Przestalski S, 2000, ACTA BIOCHIM POL, V47, P627.
   Rakotomanga M, 2005, ANTIMICROB AGENTS CH, V49, P2677, DOI 10.1128/AAC.49.7.2677-2686.2005.
   Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P727, DOI 10.1007/s00018-002-8461-3.
   Rocha S, 2008, J PEPT SCI, V14, P436, DOI 10.1002/pse.935.
   Rog T, 2009, BBA-BIOMEMBRANES, V1788, P97, DOI 10.1016/j.bbamem.2008.08.022.
   Romanowski M, 1997, BBA-BIOMEMBRANES, V1329, P245, DOI 10.1016/S0005-2736(97)00115-6.
   Romsicki Y, 1997, BIOCHEMISTRY-US, V36, P9807, DOI 10.1021/bi963120l.
   Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q.
   Rosa SMLJ, 2000, BBA-MOL CELL BIOL L, V1487, P286, DOI 10.1016/S1388-1981(00)00122-0.
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X.
   Santos F, 2008, FREE RADICAL RES, V42, P639, DOI 10.1080/10715760802270326.
   Saveyn P, 2008, LANGMUIR, V24, P6007, DOI 10.1021/la800025y.
   Schreier S, 2000, BBA-BIOMEMBRANES, V1508, P210, DOI 10.1016/S0304-4157(00)00012-5.
   Seddon AM, 2009, CHEM SOC REV, V38, P2509, DOI 10.1039/b813853m.
   Seydel J.K., 2002, DRUG MEMBRANE INTERA.
   SEYDEL JK, 1994, ARCH PHARM, V327, P601, DOI 10.1002/ardp.19943271002.
   SEYDEL JK, 1992, QUANT STRUCT-ACT REL, V11, P205, DOI 10.1002/qsar.19920110216.
   Shah JC, 2001, ADV DRUG DELIVER REV, V47, P229, DOI 10.1016/S0169-409X(01)00108-9.
   Shaikh SR, 2006, CHEM PHYS LIPIDS, V144, P1, DOI 10.1016/j.chemphyslip.2006.06.017.
   Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803.
   Singer SJ, 2004, ANNU REV PHYSIOL, V66, P1, DOI 10.1146/annurev.physiol.66.032902.131835.
   Sousa C, 2008, J PHARM SCI-US, V97, P3195, DOI 10.1002/jps.21218.
   SUGANO K, 2007, COMPREHENSIVE MED CH.
   Sulkowska A, 2002, J MOL STRUCT, V614, P227, DOI 10.1016/S0022-2860(02)00256-9.
   Suwalsky M, 2008, MACROMOL SYMP, V269, P119, DOI 10.1002/masy.200850915.
   Tatulian SA, 2003, BIOCHEMISTRY-US, V42, P11898, DOI 10.1021/bi034235+.
   Theodoropoulou E, 1999, BBA-BIOMEMBRANES, V1461, P135, DOI 10.1016/S0005-2736(99)00155-8.
   Theumer MG, 2008, COLLOID SURFACE B, V64, P22, DOI 10.1016/j.colsurfb.2008.01.002.
   Thormann E, 2007, J MOL RECOGNIT, V20, P554, DOI 10.1002/jmr.850.
   Tumer YTA, 2007, ADV DRUG DELIVER REV, V59, P1453, DOI 10.1016/j.addr.2007.08.020.
   Ulrich AS, 2002, BIOSCIENCE REP, V22, P129, DOI 10.1023/A:1020178304031.
   Urban BW, 2006, PHARMACOL THERAPEUT, V111, P729, DOI 10.1016/j.pharmthera.2005.12.005.
   Vazquez JL, 2001, LANGMUIR, V17, P1009, DOI 10.1021/la0008582.
   Vigh L, 2005, PROG LIPID RES, V44, P303, DOI 10.1016/j.plipres.2005.08.001.
   Vogler O, 2004, J BIOL CHEM, V279, P36540, DOI 10.1074/jbc.M402061200.
   Watson AD, 2006, J LIPID RES, V47, P2101, DOI 10.1194/jlr.R600022-JLR200.
   Wenk MR, 2005, NAT REV DRUG DISCOV, V4, P594, DOI 10.1038/nrd1776.
   Wisniewska A, 2003, CELL MOL BIOL LETT, V8, P147.
   Yamane MA, 1995, J PHARM PHARMACOL, V47, P978, DOI 10.1111/j.2042-7158.1995.tb03282.x.
   Yun I, 2002, BBA-BIOMEMBRANES, V1564, P123, DOI 10.1016/S0005-2736(02)00409-1.
   Zhang JZ, 2007, BIOPHYS J, V92, P3988, DOI 10.1526/biophysj.106.102434.
   Zhang LX, 2008, BIOCHEM BIOPH RES CO, V373, P202, DOI 10.1016/j.bbrc.2008.05.187.
   Zhang YH, 2008, TALANTA, V76, P246, DOI 10.1016/j.talanta.2008.02.033.
   ZILVERSMIT DB, 1952, J LAB CLIN MED, V40, P255.
   Zoumpoulakis P, 2003, CHEM PHYS LIPIDS, V125, P13, DOI 10.1016/S0009-3084(03)00053-7.}},
Number-of-Cited-References = {{175}},
Times-Cited = {{59}},
Usage-Count-Last-180-days = {{5}},
Usage-Count-Since-2013 = {{56}},
Journal-ISO = {{Curr. Med. Chem.}},
Doc-Delivery-Number = {{589BU}},
Unique-ID = {{ISI:000277120300004}},
DA = {{2018-08-13}},
}

@article{ ISI:000276765600022,
Author = {Shenoi, Sheela V. and Escombe, A. Roderick and Friedland, Gerald},
Title = {{Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the
   Critical Importance of Airborne Infection Control in the Era of HIV
   Infection and Highly Active Antiretroviral Therapy Rollouts}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2010}},
Volume = {{50}},
Number = {{3}},
Pages = {{S231-S237}},
Month = {{MAY 15}},
Abstract = {{Comprehensive and successful tuberculosis (TB) care and treatment must
   incorporate effective airborne infection-control strategies. This is
   particularly and critically important for health care workers and all
   persons with or at risk of human immunodeficiency virus (HIV) infection.
   Past and current outbreaks and epidemics of drug-susceptible,
   multidrug-resistant, and extensively drug-resistant TB have been fueled
   by HIV infection, with high rates of morbidity and mortality and linked
   to the absence or limited application of airborne infection-control
   strategies in both resource-rich and resource-limited settings. Airborne
   infection-control strategies are available-grouped into administrative,
   environmental, and personal protection categories-and have been shown to
   be associated with decreases in nosocomial transmission of TB; their
   efficacy has not been fully demonstrated, and their implementation is
   extremely limited, particularly in resource-limited settings. New
   research and resources are required to fully realize the potential
   benefits of infection control in the era of TB and HIV epidemics.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Friedland, G (Reprint Author), Yale Univ, Sch Med, AIDS Program, Infect Dis Sect, 135 Coll St, New Haven, CT 06510 USA.
   Shenoi, Sheela V.; Friedland, Gerald, Yale Univ, Sch Med, AIDS Program, Infect Dis Sect, New Haven, CT 06510 USA.
   Escombe, A. Roderick, Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immun, London, England.
   Shenoi, Sheela V.; Friedland, Gerald, TF CARES, Tugela Ferry, Kwazulu Natal, South Africa.}},
DOI = {{10.1086/651496}},
ISSN = {{1058-4838}},
EISSN = {{1537-6591}},
Keywords-Plus = {{HEALTH-CARE WORKERS; NEW-YORK-CITY; MULTIDRUG-RESISTANT;
   ULTRAVIOLET-IRRADIATION; RESPIRATORY ISOLATION; SOUTH-AFRICA; AIR;
   VENTILATION; PREVENTION; HOSPITALS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{gerald.friedland@yale.edu}},
ORCID-Numbers = {{Shenoi, Sheela/0000-0001-7654-4344}},
Funding-Acknowledgement = {{Fogarty International Center; National Institutes of Health
   {[}R24TW007988]; Gilead Foundation; Doris Duke Charitable Foundation;
   Irene Diamond Fund; President's Emergency Program for AIDS Relief;
   Wellcome Trust; Center for Global Health Policy; Infectious Diseases
   Society of America; HIV Medicine Association, through the Bill \&
   Melinda Gates Foundation}},
Funding-Text = {{Financial support. Fogarty International Center, National Institutes of
   Health (R24TW007988, the Fogarty International Clinical Research
   Scholars Support Center), Gilead Foundation, The Doris Duke Charitable
   Foundation, The Irene Diamond Fund, the President's Emergency Program
   for AIDS Relief, and the Wellcome Trust.; Supplement sponsorship. This
   article is part of a supplement entitled ``Synergistic Pandemics:
   Confronting the Global HIV and Tuberculosis Epidemics,{''} which was
   sponsored by the Center for Global Health Policy, a project of the
   Infectious Diseases Society of America and the HIV Medicine Association,
   through a grant from the Bill \& Melinda Gates Foundation.}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   Andrews JR, 2008, J INFECT DIS, V198, P1582, DOI 10.1086/592991.
   Andrews JR, 2007, J INFECT DIS, V196, pS482, DOI 10.1086/521121.
   BABARIA P, 2009, 16 C RETR OPP INF MO.
   Basu S, 2007, LANCET, V370, P1500, DOI 10.1016/S0140-6736(07)61636-5.
   Basu S, 2009, P NATL ACAD SCI USA, V106, P7672, DOI 10.1073/pnas.0812472106.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191.
   CATTERICK K, 2009, S AFR AIDS C DURB S.
   {*}CDCP, 2009, MMWR MORB MORTAL WKL, V58.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Escombe AR, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000043.
   Escombe AR, 2008, PLOS MED, V5, P1387, DOI 10.1371/journal.pmed.0050188.
   First MW, 2005, J OCCUP ENVIRON HYG, V2, P285, DOI 10.1080/1545962059095224.
   FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623.
   FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801.
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406.
   Friedland G, 2008, INT J TUBERC LUNG D, V12, P585.
   GANDHI N, 2009, AM THOR SOC ANN C SA.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Harries AD, 1997, B WORLD HEALTH ORGAN, V75, P477.
   Harries AD, 2002, B WORLD HEALTH ORGAN, V80, P526.
   ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251.
   Jensen PA, 2005, INT J TUBERC LUNG D, V9, P825.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Jiamjarasrangsi W, 2009, INT J TUBERC LUNG D, V13, P454.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   KANJEE Z, 2008, 17 INT AIDS C MEX CI.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Menzies D, 2000, ANN INTERN MED, V133, P779, DOI 10.7326/0003-4819-133-10-200011210-00010.
   Nardell EA, 2008, PUBLIC HEALTH REP, V123, P52, DOI 10.1177/003335490812300108.
   Pavelchak N, 2000, INFECT CONT HOSP EP, V21, P191, DOI 10.1086/501742.
   Pittet D, 2004, J HOSP INFECT, V58, P1, DOI 10.1016/j.jhin.2004.06.002.
   RILEY RL, 1957, AM REV TUBERC PULM, V76, P931.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   Shenoi S, 2009, CURR OPIN INFECT DIS, V22, P11, DOI 10.1097/QCO.0b013e3283210020.
   Stead WW, 1996, INFECT CONT HOSP EP, V17, P11.
   {*}WHO, 2006, TUB INF CONTR ER EXP.
   {*}WHO, 2004, 3 WHO.
   World Health Organization, 2009, POL TB INF CONTR HLT.
   World Health Organization, 2008, 4 WHO.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{34}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{584PV}},
Unique-ID = {{ISI:000276765600022}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000276954000009,
Author = {Trajman, Anete and Menzies, Dick},
Title = {{Occupational respiratory infections}},
Journal = {{CURRENT OPINION IN PULMONARY MEDICINE}},
Year = {{2010}},
Volume = {{16}},
Number = {{3}},
Pages = {{226-234}},
Month = {{MAY}},
Abstract = {{Purpose of review
   In the last decade, descriptions of outbreaks of extensively
   drug-resistant strains of tuberculosis (TB) have increased concern about
   the nosocomial transmission of TB - a potentially life-threatening
   occupational respiratory infection. In addition, outbreaks of avian
   influenza caused by an H5N1 virus, severe acute respiratory syndrome
   caused by a coronavirus A and the recent pandemic caused by an H1N1
   influenza virus have heightened concern about occupational infectious
   illnesses among workers in healthcare and agriculture.
   Recent findings
   The last decade has witnessed extensive research into the modes,
   patterns, determinants and extent of transmission of these illnesses.
   The most important findings regarding risk, determinants and preventive
   measures of these occupational infections and recent guidelines are
   reviewed in this article.
   Summary
   Administrative, personal and engineering measures to control respiratory
   infection are effective and should be implemented in healthcare
   facilities. The use of N95 personal respirators by healthcare workers
   who are caring for pulmonary TB and viral respiratory infections
   patients is strongly recommended. Vaccination against influenza
   (including H1N1) is effective and strongly recommended for healthcare
   workers. Ultraviolet germicidal irradiation is underused at present,
   despite good evidence of safety and efficacy in elimination of airborne
   respiratory infectious agents including TB.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Menzies, D (Reprint Author), McGill Univ, Resp Epidemiol Unit, Montreal Chest Inst, 3650 St Urbain,Room K1-24, Montreal, PQ H2X 2P4, Canada.
   Trajman, Anete, Univ Gama Filho, Rio De Janeiro, Brazil.
   Menzies, Dick, McGill Univ, Montreal Chest Inst, Resp Epidemiol \& Clin Res Unit, Montreal, PQ H2X 2P4, Canada.}},
DOI = {{10.1097/MCP.0b013e328338639b}},
ISSN = {{1070-5287}},
EISSN = {{1531-6971}},
Keywords = {{avian influenza; H1N1; infection control; influenza; nosocomial
   transmission; occupational health; severe acute respiratory syndrome;
   swine origin influenza; tuberculosis}},
Keywords-Plus = {{HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS INFECTION; AVIAN
   INFLUENZA H5N1; INCREASED RISK; HONG-KONG; NOSOCOMIAL TRANSMISSION;
   HOSPITAL WORKERS; POULTRY WORKERS; UNITED-STATES; CHIANG-RAI}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{dick.menzies@mcgill.ca}},
ResearcherID-Numbers = {{Trajman, Anete/C-7679-2016}},
ORCID-Numbers = {{Trajman, Anete/0000-0002-4000-4984}},
Funding-Acknowledgement = {{Fundacao Carlos Chagas de Amparo a Pesquisa do Rio de Janeiro (FAPERJ)
   {[}E-26/102.712/2008]; ICOHRTA AIDS/TB {[}5 U2R TW006883-02]; Fonds de
   Recherche en Sante de Quebec (FRSQ)}},
Funding-Text = {{A.T. is supported by Fundacao Carlos Chagas de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ grant \# E-26/102.712/2008) and by ICOHRTA AIDS/TB
   (grant \# 5 U2R TW006883-02). D. M. is supported by a Chercheur National
   salary award from the Fonds de Recherche en Sante de Quebec (FRSQ).}},
Cited-References = {{Alonso-Echanove J, 2001, CLIN INFECT DIS, V33, P589, DOI 10.1086/321892.
   Babus V, 1997, INT J TUBERC LUNG D, V1, P254.
   Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964.
   Behrman AJ, 1998, ANN EMERG MED, V31, P370, DOI 10.1016/S0196-0644(98)70349-X.
   Beigel H, 2005, NEW ENGL J MED, V353, P1374.
   BERMAN J, 1981, AM J PUBLIC HEALTH, V71, P1217, DOI 10.2105/AJPH.71.11.1217.
   BOURDREAU AY, 1997, AM J IND MED, V32, P528.
   Burch J, 2009, LANCET INFECT DIS, V9, P537, DOI 10.1016/S1473-3099(09)70199-9.
   BUXTON BC, 2000, J INFECT DIS, V181, P344, DOI DOI 10.1086/315213.
   Calder R A, 1991, Bull Int Union Tuberc Lung Dis, V66, P103.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   {*}CDC, 2009, INT GUID WORK WHO AR.
   {*}CDC, 2005, MMWR-MORBID MORTAL W, V54, P1.
   CDC, 2009, INT GUID INF CONTR M.
   {*}CDC, 2009, INT BIOS GUID ALL IN.
   {*}CDCP, 1994, MMWR-MORBID MORTAL W, V43, P1.
   Cuhadaroglu C, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-14.
   da Costa PA, 2009, J HOSP INFECT, V72, P57, DOI 10.1016/j.jhin.2009.01.016.
   de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512.
   Diel R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-35.
   Dimitrova B, 2005, INT J TUBERC LUNG D, V9, P43.
   Do AN, 1999, INT J TUBERC LUNG D, V3, P377.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   Driver CR, 2005, AM J INFECT CONTROL, V33, P519, DOI 10.1016/j.ajic.2005.05.016.
   EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Eyob G, 2002, INT J TUBERC LUNG D, V6, P85.
   Garcia-Garcia MD, 2001, INFECT CONT HOSP EP, V22, P88.
   Gooskens J, 2009, JAMA-J AM MED ASSOC, V301, P1042, DOI 10.1001/jama.2009.297.
   Graham JP, 2008, PUBLIC HEALTH REP, V123, P282, DOI 10.1177/003335490812300309.
   Gray GC, 2007, CLIN PHARMACOL THER, V82, P638, DOI 10.1038/sj.clpt.2007.6100391.
   Gray GC, 2007, VACCINE, V25, P4376, DOI 10.1016/j.vaccine.2007.03.036.
   Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413.
   Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1.
   HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204.
   Hanshaoworakul W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006051.
   Harries AD, 1997, B WORLD HEALTH ORGAN, V75, P477.
   Harries AD, 1997, T ROY SOC TROP MED H, V91, P15, DOI 10.1016/S0035-9203(97)90376-X.
   Harries AD, 1999, T ROY SOC TROP MED H, V93, P32, DOI 10.1016/S0035-9203(99)90170-0.
   HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759.
   Hill A, 1997, THORAX, V52, P994, DOI 10.1136/thx.52.11.994.
   Ho AS, 2003, ANN INTERN MED, V139, P564, DOI 10.7326/0003-4819-139-7-200310070-00008.
   Ho PL, 2007, INT J TUBERC LUNG D, V11, P710.
   Hosoglu S, 2005, AM J INFECT CONTROL, V33, P23, DOI 10.1016/j.ajic.2004.07.013.
   {*}INT UN TUB LUNG D, 1994, TUBERCLE LUNG DIS, V75, P94.
   Jiamjarasrangsi W, 2005, INT J TUBERC LUNG D, V9, P1253.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5.
   Kanyerere HS, 2003, INT J TUBERC LUNG D, V7, P489.
   Kassim S, 2000, INT J TUBERC LUNG D, V4, P321.
   Kayanja HK, 2005, INT J TUBERC LUNG D, V9, P686.
   Keawcharoen J, 2004, EMERG INFECT DIS, V10, P2189, DOI 10.3201/eid1012.040759.
   Keskiner R, 2004, INFECT CONT HOSP EP, V25, P1067, DOI 10.1086/502345.
   Kilinc O, 2002, RESP MED, V96, P506, DOI 10.1053/rmed.2002.1315.
   Kruuner A, 2001, INT J TUBERC LUNG D, V5, P170.
   Lau JTF, 2004, EMERG INFECT DIS, V10, P280, DOI 10.3201/eid1002.030534.
   Lessler J, 2009, LANCET INFECT DIS, V9, P291, DOI 10.1016/S1473-3099(09)70069-6.
   Leung GM, 2004, ANN INTERN MED, V141, P662, DOI 10.7326/0003-4819-141-9-200411020-00006.
   Li YG, 2004, AM J EPIDEMIOL, V160, P719, DOI 10.1093/aje/kwh273.
   Liss GM, 1996, INFECT CONT HOSP EP, V17, P29.
   Liverman C. T., 2009, RESP PROTECTION HEAL.
   Loeb M, 2004, EMERG INFECT DIS, V10, P251, DOI 10.3201/eid1002.030838.
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466.
   LUNDGREN R, 1987, TUBERCLE, V68, P147, DOI 10.1016/0041-3879(87)90032-8.
   Maciel ELN, 2005, REV SOC BRAS MED TRO, V38, P469, DOI 10.1590/S0037-86822005000600004.
   Maltezou HC, 2008, CURR OPIN INFECT DIS, V21, P337, DOI 10.1097/QCO.0b013e3283013945.
   McKenna MT, 1996, AM J RESP CRIT CARE, V154, P587, DOI 10.1164/ajrccm.154.3.8810591.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Menzies D, 2003, INFECT CONT HOSP EP, V24, P483, DOI 10.1086/502242.
   Menzies D, 2003, AM J RESP CRIT CARE, V167, P599, DOI 10.1164/rccm.200208-873BC.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   Menzies D, 2000, ANN INTERN MED, V133, P779, DOI 10.7326/0003-4819-133-10-200011210-00010.
   MENZIES D, 2006, REICHMAN HERSHFIELDS, P215.
   MENZIES R, 1995, AM J RESP CRIT CARE, V152, P1992, DOI 10.1164/ajrccm.152.6.8520767.
   Meredith S, 1996, BRIT MED J, V313, P522.
   Moro ML, 2000, INT J TUBERC LUNG D, V4, P61.
   Myers KP, 2006, CLIN INFECT DIS, V42, P14, DOI 10.1086/498977.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Nardell Edward A, 2003, Semin Respir Infect, V18, P307.
   Nicas M, 1998, J OCCUP ENVIRON MED, V40, P648, DOI 10.1097/00043764-199807000-00011.
   NICAS M, 1995, AM J IND MED, V27, P317, DOI 10.1002/ajim.4700270302.
   Ofner-Agostini M, 2006, INFECT CONT HOSP EP, V27, P473, DOI 10.1086/504363.
   Orrett FA, 2000, CLIN MICROBIOL INFEC, V6, P45, DOI 10.1046/j.1469-0691.2000.00015-2.x.
   Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746.
   Palese P, 2004, NAT MED, V10, pS82, DOI 10.1038/nm1141.
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498.
   Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252.
   Pleszewski B, 1998, INT J TUBERC LUNG D, V2, P898.
   Raitio M, 2003, INT J TUBERC LUNG D, V7, P556.
   Roth VR, 2005, INT J TUBERC LUNG D, V9, P1335.
   Schwartzman K, 1996, AM J RESP CRIT CARE, V154, P1006, DOI 10.1164/ajrccm.154.4.8887599.
   SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012.
   SEPKOWITZ KA, 1995, CLIN INFECT DIS, V21, P1098, DOI 10.1093/clinids/21.5.1098.
   SUGITA M, 1990, ACTA PATHOL JAPON, V40, P116.
   Tan CC, 2006, ANN ACAD MED SINGAP, V35, P345.
   Tiensin T, 2005, EMERG INFECT DIS, V11, P1664, DOI 10.3201/eid1111.050608.
   Varia M, 2003, CAN MED ASSOC J, V169, P285.
   Voirin N, 2009, J HOSP INFECT, V71, P1, DOI 10.1016/j.jhin.2008.08.013.
   Warren DK, 2001, CLIN INFECT DIS, V32, P1331, DOI 10.1086/319993.
   {*}WHO, 2004, INF CONTR QUICK REF.
   {*}WHO, 2009, CLIN MAN HUM INF AV.
   {*}WHO, 2004, WHO GUID GLOB SURV S.
   {*}WHO, 2009, SUMM PROB SARS CAS O.
   World Health Organization (WHO), 2008, EP PAND PRON AC RESP.
   Yanai H, 2003, INT J TUBERC LUNG D, V7, P36.
   Yee KS, 2009, COMP IMMUNOL MICROB, V32, P325, DOI 10.1016/j.cimid.2008.01.005.
   Yu IT, 2007, CLIN INFECT DIS, V44, P1017, DOI 10.1086/512819.
   Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9.
   Zahnow K, 1998, INFECT CONT HOSP EP, V19, P829.
   2003, CONSENSUS DOCUMENT E.
   2009, MMWR MORB MORTAL WKL, V58, P614.
   2009, EXPERTS ADVISE WHO P.
   2003, MORB MORTAL WKLY REP, V52, P269.
   2009, MMWR MORB MORTAL WKL, V58, P1009.}},
Number-of-Cited-References = {{114}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Curr. Opin. Pulm. Med.}},
Doc-Delivery-Number = {{586ZE}},
Unique-ID = {{ISI:000276954000009}},
DA = {{2018-08-13}},
}

@article{ ISI:000278344700019,
Author = {Chuma, Takehisa and Kawamoto, Toshio and Shahada, Francis and Fujimoto,
   Hideki and Okamoto, Karoku},
Title = {{Antimicrobial Susceptibility of Erysipelothrix rhusiopathiae Isolated
   from Pigs in Southern Japan with a Modified Agar Dilution Method}},
Journal = {{JOURNAL OF VETERINARY MEDICAL SCIENCE}},
Year = {{2010}},
Volume = {{72}},
Number = {{5}},
Pages = {{643-645}},
Month = {{MAY}},
Abstract = {{The determination of antimicrobial minimum inhibitory concentration
   (MIC) in Erysipelothrix rhusiopathiae by using the agar dilution method
   has not been covered by the Clinical and Laboratory Institute (CLSI).
   Only the broth microdilution method has been outlined. This report
   describes a modification of the agar dilution procedure for E.
   rhusiopathiae using Trypto-soy agar supplemented with 0.1\% Tween 80 and
   incubation in ambient air at 37 degrees C for 24 hr. The MICs of the
   assay were in agreement with those of the broth microdilution method
   recommended by the CLSI. Antimicrobial susceptibility test was performed
   using this method for 149 E. rhusiopathiae isolates from 2 meat
   processing plants in Kagoshima Prefecture during the period of April
   2004 to March 2005. The number of strains resistant to oxytetracycline,
   erythromycin, lincomycin, ofloxacin and enrofloxacin were 56 (37.6\%), 4
   (2.7\%), 18 (12.1\%), 21 (14.1\%) and 19 (12.8\%), respectively. All
   strains were susceptible to ampicillin.}},
Publisher = {{JAPAN SOC VET SCI}},
Address = {{UNIV TOKYO, 1-1-1 YAYOI, BUNKYO-KU, TOKYO, 103, JAPAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chuma, T (Reprint Author), Kagoshima Univ, Fac Agr, Dept Vet Med, Lab Vet Publ Hlth, 1-21-24 Korimoto, Kagoshima 8900065, Japan.
   Chuma, Takehisa; Kawamoto, Toshio; Shahada, Francis; Okamoto, Karoku, Kagoshima Univ, Fac Agr, Dept Vet Med, Lab Vet Publ Hlth, Kagoshima 8900065, Japan.}},
DOI = {{10.1292/jvms.09-0448}},
ISSN = {{0916-7250}},
Keywords = {{antimicrobial resistance; Erysipelothrix rhusiopathiae; swine}},
Keywords-Plus = {{SWINE ERYSIPELAS; RESISTANCE}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{chuma@agri.kagoshima-u.ac.jp}},
Cited-References = {{Asai T, 2007, JPN J INFECT DIS, V60, P290.
   {*}CLIN LAB STAND I, 2006, M45A CLSI.
   Clinical and Laboratory Standards Institute, 2003, M7A6 CLSI.
   GORBY GL, 1988, REV INFECT DIS, V10, P317.
   Radostits OM, 2000, VET MED TXB DIS CATT, P742.
   REBOLI AC, 1989, CLIN MICROBIOL REV, V2, P354.
   TAKAHASHI T, 1984, ANTIMICROB AGENTS CH, V25, P385, DOI 10.1128/AAC.25.3.385.
   Takeshi K, 1999, J CLIN MICROBIOL, V37, P4093.
   VENDITTI M, 1990, ANTIMICROB AGENTS CH, V34, P2038, DOI 10.1128/AAC.34.10.2038.
   WOOD RL, 1997, DIS SWINE, P419.
   Yamamoto K, 2001, J VET MED B, V48, P115, DOI 10.1046/j.1439-0450.2001.00427.x.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Vet. Med. Sci.}},
Doc-Delivery-Number = {{605JU}},
Unique-ID = {{ISI:000278344700019}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000275419000024,
Author = {Sarva, Siva T. and Manjunath, Skantha K. and Baldwin, Heather S. and
   Robins, David B. and Freire, Amado X.},
Title = {{Lung Scedosporiosis in Human Immunodeficiency Virus/Acquired
   Immunodeficiency Syndrome}},
Journal = {{AMERICAN JOURNAL OF THE MEDICAL SCIENCES}},
Year = {{2010}},
Volume = {{339}},
Number = {{3}},
Pages = {{300-303}},
Month = {{MAR}},
Abstract = {{A 31-year-old African American woman with human immunodeficiency
   virus/acquired immunodeficiency syndrome (HIV/AIDS) (recent CD4 count of
   66/mm(3)) presented to the emergency room with a tension pneumothorax
   that required an emergent chest tube placement. Computed tomography scan
   showed fungus balls in multiple lung cavities and surrounding
   infiltrates. The patient showed remarkable improvement with voriconazole
   suggesting aspergillosis. However, the patient was serologically
   negative for Aspergillus and other common fungal infections. Because of
   a persistent air leak, surgical intervention was needed. The
   histological finding was consistent with invasive mycosis, and cultures
   were positive for Scedosporium apiospermum. Literature review showed
   that, among patients with HIV/AIDS, Scedosporium can present from focal
   localized to systemic disease, is resistant to traditional antifungal
   agents, and may respond to prompt management with voriconazole.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Freire, AX (Reprint Author), Univ Tennessee, Heath Sci Ctr, COM Memphis, 956 Court Ave,Room G-228, Memphis, TN 38163 USA.
   Sarva, Siva T., Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Med, Memphis, TN 38163 USA.
   Manjunath, Skantha K.; Freire, Amado X., Univ Tennessee, Hlth Sci Ctr, Coll Med, Div Pulm Crit Care \& Sleep Med, Memphis, TN 38163 USA.
   Baldwin, Heather S.; Robins, David B., Univ Tennessee, Coll Med, Dept Pathol, Memphis, TN 38163 USA.}},
DOI = {{10.1097/MAJ.0b013e3181cec4be}},
ISSN = {{0002-9629}},
Keywords = {{Scedosporium; Pseudoallescheria; Systemic mycoses; HIV; Lung cavity}},
Keywords-Plus = {{PSEUDALLESCHERIA-BOYDII INFECTION; IN-VITRO ACTIVITIES; TRANSPLANT
   RECIPIENTS; ANTIFUNGAL AGENTS; FUNGAL SINUSITIS; APIOSPERMUM; AIDS;
   PATIENT; VORICONAZOLE; PROLIFICANS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{afreire@uthsc.edu}},
ORCID-Numbers = {{Freire, Amado/0000-0001-7500-8291}},
Cited-References = {{Al Refai M, 2002, EUR J CARDIO-THORAC, V21, P938, DOI 10.1016/S1010-7940(02)00068-4.
   Busaba NY, 1997, OTOLARYNG HEAD NECK, V117, pS91, DOI 10.1016/S0194-5998(97)70067-6.
   Carrillo AJ, 2001, ANTIMICROB AGENTS CH, V45, P2151, DOI 10.1128/AAC.45.7.2151-2153.2001.
   Castiglioni B, 2002, MEDICINE, V81, P333, DOI 10.1097/01.md.0000030341.26556.e8.
   Cortez KJ, 2008, CLIN MICROBIOL REV, V21, P157, DOI 10.1128/CMR.00039-07.
   Cuenca-Estrella M, 1999, J ANTIMICROB CHEMOTH, V43, P149, DOI 10.1093/jac/43.1.149.
   Eckburg PB, 1999, CLIN INFECT DIS, V29, P212, DOI 10.1086/520164.
   Emmons C. W., 1944, MYCOLOGIA, V36, P188, DOI 10.2307/3754685.
   Garcia Jesus, 2003, Revista Iberoamericana de Micologia, V20, P64.
   Guarro J, 2006, MED MYCOL, V44, P295, DOI 10.1080/13693780600752507.
   Horton CK, 1999, J ACQ IMMUN DEF SYND, V20, P209, DOI 10.1097/00042560-199902010-00017.
   Husain S, 2005, CLIN INFECT DIS, V40, P89, DOI 10.1086/426445.
   Lamaris GA, 2006, CLIN INFECT DIS, V43, P1580, DOI 10.1086/509579.
   McGinnis M R, 1988, Infect Dis Clin North Am, V2, P939.
   Meletiadis J, 2002, ANTIMICROB AGENTS CH, V46, P62, DOI 10.1128/AAC.46.1.62-68.2002.
   MEYER RD, 1994, MEDICINE, V73, P69, DOI 10.1097/00005792-199403000-00001.
   Montero A, 1998, CLIN INFECT DIS, V26, P1476, DOI 10.1086/517674.
   RAFFANTI SP, 1990, REV INFECT DIS, V12, P993.
   REDDY PC, 1969, THORAX, V24, P722, DOI 10.1136/thx.24.6.722.
   Rollot F, 2000, SCAND J INFECT DIS, V32, P439, DOI 10.1080/003655400750045114.
   Sahi H, 2007, J HEART LUNG TRANSPL, V26, P350, DOI 10.1016/j./healun.2007.01.011.
   SCHERR GR, 1992, ARCH PATHOL LAB MED, V116, P535.
   Sheu R, 2009, J COMPUT ASSIST TOMO, V33, P247, DOI 10.1097/RCT.0b013e318172d629.
   Slack CL, 1999, ARCH OTOLARYNGOL, V125, P73, DOI 10.1001/archotol.125.1.73.
   Tadros TS, 1998, HUM PATHOL, V29, P1266, DOI 10.1016/S0046-8177(98)90255-6.
   TRAVIS LB, 1985, MAYO CLIN PROC, V60, P531, DOI 10.1016/S0025-6196(12)60571-0.
   Troke P, 2008, ANTIMICROB AGENTS CH, V52, P1743, DOI 10.1128/AAC.01388-07.
   Yao M, 2001, ANN OTO RHINOL LARYN, V110, P377, DOI 10.1177/000348940111000415.
   Zaas David, 2002, American Journal of Medicine, V113, P760, DOI 10.1016/S0002-9343(02)01456-0.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Med. Sci.}},
Doc-Delivery-Number = {{567CD}},
Unique-ID = {{ISI:000275419000024}},
DA = {{2018-08-13}},
}

@article{ ISI:000275633900017,
Author = {Abubakar, Ibrahim},
Title = {{Tuberculosis and air travel: a systematic review and analysis of policy}},
Journal = {{LANCET INFECTIOUS DISEASES}},
Year = {{2010}},
Volume = {{10}},
Number = {{3}},
Pages = {{176-183}},
Month = {{MAR}},
Abstract = {{WHO international guidelines for the control of tuberculosis in relation
   to air travel require after a risk assessment-tracing of passengers who
   sat for longer than 8 h in rows adjacent to people with pulmonary
   tuberculosis who are smear positive or smear negative. A further
   recommendation is that all commercial air travel should be prohibited
   until the person has two consecutive negative sputum smears for
   drug-susceptible tuberculosis or two consecutive cultures for
   multidrug-resistant tuberculosis. In this Review I examine the evidence
   put forward to support these recommendations and assess whether such an
   approach is justifiable. A systematic review identified 39 studies of
   which 13 were included. The majority of studies found no evidence of
   transmission. Only two studies reported reliable evidence of
   transmission. The analysis suggests that there is reason to doubt the
   value of actively screening air passengers for infection with
   Mycobacterium tuberculosis and that the resources used might be better
   spent addressing other priorities for the control of tuberculosis.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Abubakar, I (Reprint Author), Univ E Anglia, Sch Med Hlth Policy \& Practice, Norwich NR4 7TJ, Norfolk, England.
   Abubakar, Ibrahim, Univ E Anglia, Sch Med Hlth Policy \& Practice, Norwich NR4 7TJ, Norfolk, England.
   Abubakar, Ibrahim, Hlth Protect Agcy Ctr Infect, TB Sect, London, England.}},
DOI = {{10.1016/S1473-3099(10)70028-1}},
ISSN = {{1473-3099}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS;
   MULTIDRUG-RESISTANT; UNITED-STATES; LATENT TUBERCULOSIS;
   PREDICTIVE-VALUE; TRANSMISSION; GAMMA; RISK; PASSENGER}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
ORCID-Numbers = {{Abubakar, Ibrahim/0000-0002-0370-1430}},
Cited-References = {{Abubakar I, 2009, THORAX, V64, P512, DOI 10.1136/thx.2008.108712.
   Abubakar I., 2008, EURO SURVEILL, V13.
   Aichelburg MC, 2009, CLIN INFECT DIS, V48, P954, DOI 10.1086/597351.
   {[}Anonymous], 2008, TUB AIR TRAV GUID PR.
   Bakir M, 2008, ANN INTERN MED, V149, P777, DOI 10.7326/0003-4819-149-11-200812020-00248.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   BELLER M, 1996, STATE ALASKA EPIDEMI, V27.
   Byrne Neville, 2007, Travel Med Infect Dis, V5, P18, DOI 10.1016/j.tmaid.2006.03.003.
   {*}CDC, 1995, MMWR-MORBID MORTAL W, V44, P137.
   CHEMARDIN J, 2007, EURO SURVEILL, V12.
   Coker RJ, 2007, PUBLIC HEALTH, V121, P266, DOI 10.1016/j.puhe.2006.11.003.
   Diel R, 2008, AM J RESP CRIT CARE, V177, P1164, DOI 10.1164/rccm.200711-1613OC.
   DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031.
   Fraser A, 2006, INT J TUBERC LUNG D, V10, P19.
   Hill PC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001379.
   Hocking MB, 2000, CHEMOSPHERE, V41, P603, DOI 10.1016/S0045-6535(99)00537-8.
   Hong Kong Chest Service/Tuberculosis Research Centre Madras/British Medical Research Council, 1992, AM REV RESP DIS, V145, P36.
   Horsburgh CR, 2004, NEW ENGL J MED, V350, P2060, DOI 10.1056/NEJMsa031667.
   Jereb J, 2003, INT J TUBERC LUNG D, V7, pS384.
   Jones RM, 2009, RISK ANAL, V29, P355, DOI 10.1111/j.1539-6924.2008.01161.x.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   Ko G, 2004, RISK ANAL, V24, P379, DOI 10.1111/j.0272-4332.2004.00439.x.
   Mangili A, 2005, LANCET, V365, P989, DOI 10.1016/S0140-6736(05)71089-8.
   MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9.
   Migliori GB, 2008, EUR RESPIR J, V31, P1155, DOI 10.1183/09031936.00028708.
   Miller MA, 1996, TUBERCLE LUNG DIS, V77, P414, DOI 10.1016/S0962-8479(96)90113-6.
   Moore M, 1996, AVIAT SPACE ENVIR MD, V67, P1097.
   National Collaborating Centre for Chronic Conditions, 2006, TUB CLIN DIAGN MAN T.
   Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X.
   Parmet AJ, 1999, AVIAT SPACE ENVIR MD, V70, P817.
   Sampathkumar P, 2007, MAYO CLIN PROC, V82, P799, DOI 10.4065/82.7.799.
   Schenkel K, 2009, RISK ASSESSMENT GUID.
   Sehulster Lynne, 2003, MMWR Recomm Rep, V52, P1.
   SHAW JB, 1954, AM REV TUBERC PULM, V69, P724.
   STYBLO K, 1991, EPIDEMIOLOGY TUBERCU.
   THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555.
   Tostmann A, 2008, CLIN INFECT DIS, V47, P1135, DOI 10.1086/591974.
   VASSILOYANAKOPO.A, 1999, EURO SURVEILL, V4.
   VEEN J, 1992, TUBERCLE LUNG DIS, V73, P73, DOI 10.1016/0962-8479(92)90058-R.
   Wang PD, 2000, AM J INFECT CONTROL, V28, P233, DOI 10.1067/mic.2000.103555.
   Whitlock G, 2001, NEW ZEAL MED J, V114, P353.
   {*}WHO, 1998, TUB AIR TRAV GUID PR.
   Witlox F., 2004, GAWC RES B, V157.
   World Health Organisation, 2006, TUB AIR TRAV GUID PR.
   1992, AM REV RESP DIS, V146, P1623.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Lancet Infect. Dis.}},
Doc-Delivery-Number = {{569WQ}},
Unique-ID = {{ISI:000275633900017}},
DA = {{2018-08-13}},
}

@article{ ISI:000275273900010,
Author = {Cade, Christine E. and Dlouhy, Adrienne C. and Medzihradszky, Katalin F.
   and Salas-Castillo, Saida Patricia and Ghiladi, Reza A.},
Title = {{Isioniazid-resistance conferring mutations in Mycobacterium tuberculosis
   KatG: Catalase, peroxidase, and INH-NADH adduct formation activities}},
Journal = {{PROTEIN SCIENCE}},
Year = {{2010}},
Volume = {{19}},
Number = {{3}},
Pages = {{458-474}},
Month = {{MAR}},
Abstract = {{Mycobacterium tuberculosis catalase-peroxidase (KatG) is a bifunctional
   hemoprotein that has been shown to activate isoniazid (INH) a pro-drug
   that is integral to frontline antituberculosis treatments. The activated
   species, presumed to be an isonicotinoyl radical, couples to NAD(+)/NADH
   forming an isoniazid-NADH adduct that ultimately confers anti-tubercular
   activity. To better understand the mechanisms of isoniazid activation as
   well as the origins of KatG-derived INH-resistance, we have compared the
   catalytic properties (including the ability to form the INH-NADH adduct)
   of the wild-type enzyme to 23 KatG mutants which have been associated
   with isoniazid resistance in clinical M. tuberculosis, isolates. Neither
   catalase nor peroxidase activities, the two inherent enzymatic functions
   of KatG were found to correlate with isoniazid resistance. Furthermore,
   catalase function was lost in mutants which lacked the Met-Tyr-Trp
   crosslink, the biogenic cofactor in KatG which has been previously shown
   to be integral to this activity. The presence or absence of the
   crosslink itself, however, was also found to not correlate with INH
   resistance. The KatG resistance-conferring mutants were then assayed for
   their ability to generate the INH-NADH adduct in the presence of
   peroxide (t-BuOOH and H(2)O(2) superoxide, and no exogenous oxidant
   (air-only background control). The results demonstrate that residue
   location plays a critical role in determining INH-resistance mechanisms
   associated with INH activation; however, different mutations at the same
   location can produce vastly different reactivities that are
   oxidant-specific. Furthermore, the data can be interpreted to suggest
   the presence of a second mechanism of INH-resistance that is not
   correlated with the formation of the INH-NADH adduct.}},
Publisher = {{JOHN WILEY \& SONS INC}},
Address = {{111 RIVER ST, HOBOKEN, NJ 07030 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ghiladi, RA (Reprint Author), N Carolina State Univ, Dept Chem, Dabney Hall,Campus Box 8204, Raleigh, NC 27695 USA.
   Cade, Christine E.; Dlouhy, Adrienne C.; Ghiladi, Reza A., N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
   Medzihradszky, Katalin F.; Salas-Castillo, Saida Patricia, Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.}},
DOI = {{10.1002/pro.324}},
ISSN = {{0961-8368}},
Keywords = {{catalase-peroxidase; KatG; isoniazid; INH; heme; crosslink}},
Keywords-Plus = {{SITE-DIRECTED MUTAGENESIS; C-13 NMR CHARACTERIZATION; TRP CROSS-LINK;
   ISONIAZID RESISTANCE; BURKHOLDERIA-PSEUDOMALLEI; SUPEROXIDE REACTIVITY;
   ANTIBIOTIC-RESISTANCE; POSSIBLE INHIBITORS; MOLECULAR ANALYSIS; OXIDASE
   ACTIVITY}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{reza\_ghiladi@ncsu.edu}},
ResearcherID-Numbers = {{Ghiladi, Reza/J-8492-2017}},
ORCID-Numbers = {{Ghiladi, Reza/0000-0002-6450-9311}},
Funding-Acknowledgement = {{NIH/NAID {[}N01 Al-75320]}},
Funding-Text = {{Grant sponsor: NIH/NAID: Grant number N01 Al-75320.}},
Cited-References = {{Baker RD, 2004, BIOCHEM BIOPH RES CO, V320, P833, DOI 10.1016/j.bbre.2004.06.026.
   BEERS RF, 1952, J BIOL CHEM, V195, P133.
   Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200.
   Broussy S, 2005, ORG BIOMOL CHEM, V3, P670, DOI 10.1039/b417698g.
   Broussy S, 2003, CHEM-EUR J, V9, P2034, DOI 10.1002/chem.200204637.
   Carpena X, 2006, BIOCHEMISTRY-US, V45, P5171, DOI 10.1021/bi060017f.
   CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093.
   Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815.
   COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240.
   Deemagarn T, 2007, PROTEINS, V66, P219, DOI 10.1002/prot.21209.
   Doustdar F, 2008, MICROB DRUG RESIST, V14, P273, DOI 10.1089/mdr.2008.0842.
   Ducasse-Cabanot S, 2004, ANTIMICROB AGENTS CH, V48, P242, DOI 10.1128/AAC.48.1.242-249.2004.
   DUMARIEH R, CATALYTIC RELE UNPUB.
   Gagneux S, 2006, PLOS PATHOG, V2, P603, DOI 10.1371/journal.ppat.0020061.
   Ghiladi RA, 2005, BIOCHEMISTRY-US, V44, P15093, DOI 10.1021/bi051463q.
   Ghiladi RA, 2005, J AM CHEM SOC, V127, P13428, DOI 10.1021/ja054366t.
   Ghiladi RA, 2005, J BIOL CHEM, V280, P22651, DOI 10.1074/jbc.M502486200.
   Ghiladi RA, 2004, J AM CHEM SOC, V126, P4772, DOI 10.1021/ja031728t.
   Haas WH, 1997, ANTIMICROB AGENTS CH, V41, P1601.
   Halliwell B, 1999, FREE RADICALS BIOL M.
   HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x.
   HILL HAO, 1981, FEBS LETT, V125, P235, DOI 10.1016/0014-5793(81)80727-2.
   Jakopitsch C, 2005, J BIOL CHEM, V280, P9037, DOI 10.1074/jbc.M413317200.
   Jakopitsch C, 2003, FEBS LETT, V552, P135, DOI 10.1016/S0014-5793(03)00901-3.
   Jakopitsch C, 2004, J BIOL CHEM, V279, P46082, DOI 10.1074/jbc.M408399200.
   Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200.
   Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834.
   Kapetanaki SM, 2005, BIOCHEMISTRY-US, V44, P243, DOI 10.1021/bi048097f.
   Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520.
   Li YJ, 2004, BIOCHEM BIOPH RES CO, V318, P970, DOI 10.1016/j.bbrc.2004.04.130.
   LoBue Philip, 2009, Morbidity and Mortality Weekly Report, V58, P1.
   Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j.
   Magliozzo RS, 1997, J BIOL CHEM, V272, P8867.
   Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187.
   Mate M. J., 2001, HDB METALLOPROTEINS, P486.
   Metcalfe C, 2008, J BIOL CHEM, V283, P6193, DOI 10.1074/jbc.M707412200.
   MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954.
   Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196.
   MUSSER JM, 1995, CLIN MICROBIOL REV, V8, P496.
   Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265.
   Nguyen M, 2002, ANTIMICROB AGENTS CH, V46, P2137, DOI 10.1128/AAC.46.7.2137-2144.2002.
   Nguyen M, 2001, CHEMBIOCHEM, V2, P877, DOI 10.1002/1439-7633(20011203)2:12<877::AID-CBIC877>3.0.CO;2-V.
   Nicholls P, 2001, ADV INORG CHEM, V51, P51.
   Pym AS, 2002, INFECT IMMUN, V70, P4955, DOI 10.1128/IAI.70.9.4955-4960.2002.
   QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035.
   QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004.
   Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002.
   Ranguelova K, 2008, BIOCHEMISTRY-US, V47, P11377, DOI 10.1021/bi800952b.
   ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472.
   Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x.
   Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98.
   Saint-Joanis B, 1999, BIOCHEM J, V338, P753, DOI 10.1042/0264-6021:3380753.
   Sciora T, 2002, ARCH PHARM PHARM MED, V11, P511.
   Singh R, 2004, J BIOL CHEM, V279, P43098, DOI 10.1074/jbc.M406374200.
   Singh R, 2007, J AM CHEM SOC, V129, P15954, DOI 10.1021/ja075108u.
   Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2.
   Smulevich G, 2006, J INORG BIOCHEM, V100, P568, DOI 10.1016/j.jinorgbio.2006.01.033.
   Suarez J, 2009, J BIOL CHEM, V284, P7017, DOI 10.1074/jbc.M808106200.
   Suarez J, 2009, J BIOL CHEM, V284, P16146, DOI 10.1074/jbc.M109.005546.
   SUZUKI K, 2000, SUPEROXIDE GENERATIN.
   VANDERWALT BJ, 1994, INT J BIOCHEM, V26, P1081, DOI 10.1016/0020-711X(94)90130-9.
   Vidossich P, 2007, J AM CHEM SOC, V129, P13436, DOI 10.1021/ja072245i.
   Vilcheze C, 2007, ANNU REV MICROBIOL, V61, P35, DOI 10.1146/annurev.micro.61.111606.122346.
   Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003.
   WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215.
   Wengenack NL, 1997, J INFECT DIS, V176, P722, DOI 10.1086/514096.
   Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a.
   Wengenack NL, 1999, BIOCHEM BIOPH RES CO, V256, P485, DOI 10.1006/bbrc.1999.0358.
   Wengenack NL, 2004, PROTEIN EXPRES PURIF, V36, P232, DOI 10.1016/j.pep.2004.04.018.
   WINDER FG, 1959, BIOCHEM J, V73, P500, DOI 10.1042/bj0730500.
   Wojtyczka Robert D., 2004, Polish Journal of Microbiology, V53, P89.
   World Health Organization, 2008, 4 WHO.
   Yu SW, 2003, J BIOL CHEM, V278, P14769, DOI 10.1074/jbc.M300326200.
   Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1101/ps.09902.
   Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200.
   Zhao XB, 2006, BIOCHEMISTRY-US, V45, P4131, DOI 10.1021/bi051967o.
   Zhao XB, 2009, J BIOL CHEM, V284, P7030, DOI 10.1074/jbc.M808107200.}},
Number-of-Cited-References = {{77}},
Times-Cited = {{51}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{19}},
Journal-ISO = {{Protein Sci.}},
Doc-Delivery-Number = {{565FF}},
Unique-ID = {{ISI:000275273900010}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000290890700007,
Author = {Plotkin, Bruce J. and Hardiman, Maxwell C.},
Title = {{The international health regulations (2005), tuberculosis and air travel}},
Journal = {{TRAVEL MEDICINE AND INFECTIOUS DISEASE}},
Year = {{2010}},
Volume = {{8}},
Number = {{2, SI}},
Pages = {{90-95}},
Month = {{MAR}},
Abstract = {{In 2007, the World Health Organization's ({''}WHO{''}) revised
   International Health Regulations (2005) ({''}IHR{''} or
   ``Regulations{''}) entered into force across the globe. The IHR contain
   a range of binding and advisory provisions for reporting, health
   measures, capacity-building and further procedures to address the risks
   of international disease spread in international travel, transport and
   trade. While the prior versions of the Regulations were limited to a
   short list of infectious diseases (which did not include tuberculosis),
   the revised IHR cover virtually all serious internationally
   transmissible disease risks, whether biological/infectious, chemical or
   radionuclear in origin, that meet certain criteria. These revised
   Regulations are now generally applicable to transnational tuberculosis
   ({''}TB{''}) transmission, including through air travel. In light of the
   great numbers of persons undertaking international travel, the worldwide
   geographical coverage of the IHR, and the emergence of extremely drug
   resistant TB ({''}XDR TB{''}), these Regulations are an important
   element in addressing these (and other) serious international public
   health risks. This article describes the relevant provisions in the IHR,
   and their applicability in this context. (C) 2010 World Health
   Organization. Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Plotkin, BJ (Reprint Author), WHO, Int Hlth Regulat Coordinat Dept, Ave Appia 20, CH-1211 Geneva, Switzerland.
   Plotkin, Bruce J.; Hardiman, Maxwell C., WHO, Int Hlth Regulat Coordinat Dept, CH-1211 Geneva, Switzerland.}},
DOI = {{10.1016/j.tmaid.2009.11.003}},
ISSN = {{1477-8939}},
Keywords = {{Tuberculosis; Aircraft; WHO guideline; International Health Regulations;
   Travel}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{plotkinb@who.int
   hardimanm@who.int}},
Cited-References = {{{[}Anonymous], 2008, TUB AIR TRAV GUID PR.
   {*}INT CIV AV ORG, AIR NAV BUR AV MED S.
   PLOTKIN BJ, 1996, EMERG INFECT DIS, V3, P1.
   Plotkin BJ, 2007, INFECTIOUS DISEASE SURVEILLANCE, 1ST EDITION, P18, DOI 10.1002/9780470692097.ch2.
   {*}UN WORLD TOUR ORG, 2009, TOUR HIGHL 2009.
   WHO, 1996, WORLD HLTH REP 1996.
   {*}WHO, PUBL HLTH PASS LOC C.
   {*}WHO, 2009, GUID HYG SAN AIRCR.
   {*}WHO, 2005, STAT PART IHR.
   WHO (World Health Organization), 2007, WORLD HLTH REP 2007.
   World Health Organization, 2009, ASS TOOL COR CAP REQ.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Travel Med. Infect. Dis.}},
Doc-Delivery-Number = {{767WY}},
Unique-ID = {{ISI:000290890700007}},
DA = {{2018-08-13}},
}

@article{ ISI:000290890700011,
Author = {Kornylo-Duong, Krista and Kim, Curi and Cramer, Elaine H. and Buff, Ann
   M. and Rodriguez-Howell, Daniel and Doyle, June and Higashi, Julie and
   Fruthaler, Carolyn S. and Robertson, Carrie L. and Marienau, Karen J.},
Title = {{Three air travel-related contact investigations associated with
   infectious tuberculosis, 2007-2008}},
Journal = {{TRAVEL MEDICINE AND INFECTIOUS DISEASE}},
Year = {{2010}},
Volume = {{8}},
Number = {{2, SI}},
Pages = {{120-128}},
Month = {{MAR}},
Abstract = {{Background: The potential for transmission of Mycobacterium tuberculosis
   during air travel has garnered considerable attention in the media and
   among public health authorities due to high-profile cases of
   international travelers with infectious tuberculosis (TB).
   Methods: During 2007 and 2008, state and local health officials were
   asked to locate and conduct diagnostic follow-up for airline passengers
   considered contacts of three travelers, two with multidrug-resistant
   (MDR) TB and one considered highly contagious, who undertook air travel
   while infectious with TB disease.
   Results: Public health departments in 21 states located and evaluated 79
   (60\%) of the 131 passenger contacts identified; 52 (40\%) were lost to
   follow-up. Eight (10\%) contacts had a history of TB disease or latent
   TB infection and were not retested. Sixteen (23\%) of 71 contacts tested
   had positive TB test results suggesting latent TB infection, 15 of whom
   were from countries reporting estimated TB disease rates of greater than
   200 cases/100,000 persons.
   Conclusions: Passenger contacts' positive test results may represent
   prior TB infection acquired in their countries of residence or may be a
   result of new TB infection resulting from exposure during air travel.
   Published by Elsevier Ltd.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kornylo-Duong, K (Reprint Author), Ctr Dis Control \& Prevent, Natl Ctr Preparedness Detect \& Control Infect Dis, Div Global Migrat \& Quarantine, CDC Angeles Quarantine Stn,Quarantine \& Border Hl, 380 World Way,N-19, Los Angeles, CA 90045 USA.
   Kornylo-Duong, Krista, Ctr Dis Control \& Prevent, Natl Ctr Preparedness Detect \& Control Infect Dis, Div Global Migrat \& Quarantine, CDC Angeles Quarantine Stn,Quarantine \& Border Hl, Los Angeles, CA 90045 USA.
   Buff, Ann M., Ctr Dis Control \& Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD \& TB Preven, Div TB Eliminat, Atlanta, GA USA.
   Doyle, June, Wisconsin Dept Hlth Serv, Bur Communicable Dis \& Preparedness, Div Publ Hlth, Dept Hlth \& Family Serv, Madison, WI USA.
   Higashi, Julie, Santa Clara Publ Hlth Dept, TB Prevent \& Control Program, San Jose, CA USA.
   Fruthaler, Carolyn S.; Robertson, Carrie L., Harris Cty Publ Hlth \& Environm Serv, Div Dis Control \& Clin Prevent, Dis Control \& Med Epidemiol Sect, Houston, TX USA.}},
DOI = {{10.1016/j.tmaid.2009.08.001}},
ISSN = {{1477-8939}},
Keywords = {{Multidrug-resistant TB; Contact tracing; Airplane; Disease transmission;
   WHO guidelines}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; TRANSMISSION; FLIGHTS; CHILD}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{frl3@cdc.gov}},
Funding-Acknowledgement = {{Applied Epidemiology Fellowship; Centers for Disease Control and
   Prevention (CDC) Cooperative Agreement {[}U60/CCU007277]}},
Funding-Text = {{This study was supported in part by the Applied Epidemiology Fellowship
   Program administered by the Council of State and Territorial
   Epidemiologists (CSTE) and funded by the Centers for Disease Control and
   Prevention (CDC) Cooperative Agreement U60/CCU007277.}},
Cited-References = {{Abubakar I, 2008, EUROSURVEILLANCE, V13, P1.
   {[}Anonymous], STOP TB PARTN.
   Bayona J, 2003, INT J TUBERC LUNG D, V7, pS501.
   BUFF AM, 2008, 12 ANN N AM REG C IN.
   Byrne Neville, 2007, Travel Med Infect Dis, V5, P18, DOI 10.1016/j.tmaid.2006.03.003.
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P1.
   Centres for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V54, P49.
   CHEMARDIN J, 2006, EUROSURVEILL     OCT, P3325.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   {*}DEP HLTH HUM SERV, 2005, CDC NAT CTR HIV STD.
   FRANCIS J, 2008, DRUG RES TUB SURV GU.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968.
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120.
   Moore M, 1996, AVIAT SPACE ENVIR MD, V67, P1097.
   Poulsen A, 1950, ACTA TUBERC SCAND, V24, P311.
   Reichler MR, 2002, JAMA-J AM MED ASSOC, V287, P991, DOI 10.1001/jama.287.8.991.
   SCHOLTEN D, 2008, 39 WORLD C LUNG HLTH.
   Sneag DB, 2007, PEDIATR INFECT DIS J, V26, P1142, DOI 10.1097/INF.0b013e31814523e4.
   Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321.
   WALLGREN A, 1948, Tubercle, V29, P245, DOI 10.1016/S0041-3879(48)80033-4.
   WASZHOCKERT O, 1947, ANN MED FENN, V96, P764.
   Whitlock G, 2001, NEW ZEAL MED J, V114, P353.
   {*}WHO, 2008, WHOHTMTB2008393.
   World Health Organization, 2008, WHOHTMTB2006399.
   World Health Organization, 2006, WHOHTMTB2006361.
   2003, FED REG         0404, V68, P17244.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Travel Med. Infect. Dis.}},
Doc-Delivery-Number = {{767WY}},
Unique-ID = {{ISI:000290890700011}},
DA = {{2018-08-13}},
}

@article{ ISI:000272944900011,
Author = {Rosado, Helena and Doyle, Marie and Hinds, Jason and Taylor, Peter W.},
Title = {{Low-shear modelled microgravity alters expression of virulence
   determinants of Staphylococcus aureus}},
Journal = {{ACTA ASTRONAUTICA}},
Year = {{2010}},
Volume = {{66}},
Number = {{3-4}},
Pages = {{408-413}},
Month = {{FEB-MAR}},
Abstract = {{Microbiological monitoring of air and surfaces within the ISS indicate
   that bacteria of the genus Staphylococcus are found with high frequency.
   Staphylococcus aureus, an opportunistic pathogen with the capacity to
   cause severe debilitating infection, constitutes a significant
   proportion of these isolates. Experiments conducted during short-term
   night suggest that growth in microgravity leads to increases in
   bacterial antibiotic resistance and to cell wall changes. Growth under
   low-shear modelled microgravity (LSMMG) indicated that a reduced
   gravitational field acts as an environmental signal for expression of
   enhanced bacterial virulence in gram-negative pathogens. We therefore
   examined the effect of simulated microgravity on parameters of
   antibiotic susceptibility and virulence in methicillin-susceptible S.
   aureus isolates RF1, RF6 and RF11: these strains were grown in a high
   aspect ratio vessel under LSMMG and compared with cells grown under
   normal gravity (NG). There were no significant differences in antibiotic
   susceptibility of staphylococci grown under LSMMG compared to NG.
   LSMMG-induced reductions in synthesis of the pigment staphyloxanthin and
   the major virulence determinant alpha-toxin were noted. Significant
   changes in global gene expression were identified by DNA microarray
   analysis; with isolate RF6, the expression of hla and genes of the
   regulatory system saeR/saeS were reduced approximately two-fold. These
   data provide strong evidence that growth of S. aureus under modelled
   microgravity leads to a reduction in expression of virulence
   determinants. (C) 2009 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Taylor, PW (Reprint Author), Univ London, Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
   Rosado, Helena; Doyle, Marie; Taylor, Peter W., Univ London, Sch Pharm, London WC1N 1AX, England.
   Hinds, Jason, Univ London, Dept Cellular \& Mol Med, London SW17 0RE, England.}},
DOI = {{10.1016/j.actaastro.2009.06.007}},
ISSN = {{0094-5765}},
Keywords = {{Staphylococcus aureus; Microgravity; Bacterial microarrays; Bacterial
   virulence; Gene expression}},
Keywords-Plus = {{BACTERIAL GENE-EXPRESSION; ESCHERICHIA-COLI; SPACE-FLIGHT; GENOME;
   BIOSYNTHESIS; ANTIBIOTICS; MICROARRAY; RESISTANCE; EVOLUTION; STRESS}},
Research-Areas = {{Engineering}},
Web-of-Science-Categories  = {{Engineering, Aerospace}},
Author-Email = {{peter.taylor@pharmacy.ac.uk}},
Cited-References = {{Baba T, 2002, LANCET, V359, P1819, DOI 10.1016/S0140-6736(02)08713-5.
   Bohach G.A., 2006, GRAM POSITIVE PATHOG, P464, DOI 10.1128/9781555816513.ch38.
   Fang A, 1997, APPL ENVIRON MICROB, V63, P4090.
   Gill SR, 2005, J BACTERIOL, V187, P2426, DOI 10.1128/JB.187.7.2426-2438.2005.
   Guadarrama S, 2005, Gravit Space Biol Bull, V18, P85.
   HAMMOND TG, 2001, AM J PHYSIOL-RENAL, V281, P12.
   Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101.
   Kacena MA, 1999, APPL MICROBIOL BIOT, V51, P229, DOI 10.1007/s002530051386.
   Klaus D, 1997, MICROBIOL-SGM, V143, P449, DOI 10.1099/00221287-143-2-449.
   Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2.
   LAPCHINE L, 1986, DRUG EXP CLIN RES, V12, P933.
   Lui G.Y., 2005, J EXP MED, V202, P209.
   MARKS J, 1950, J PATHOL BACTERIOL, V62, P597, DOI 10.1002/path.1700620411.
   MENNIGMANN HD, 1988, ESA, P37.
   Nickerson CA, 2004, MICROBIOL MOL BIOL R, V68, P345, DOI 10.1128/MMBR.68.2.345-361.2004.
   Nickerson CA, 2003, J MICROBIOL METH, V54, P1, DOI 10.1016/S0167-7012(03)00018-6.
   Nickerson CA, 2000, INFECT IMMUN, V68, P3147, DOI 10.1128/IAI.68.6.3147-3152.2000.
   Novick RP, 2003, MOL MICROBIOL, V48, P1429, DOI 10.1046/j.1365-2958.2003.03526.x.
   Novikova N, 2006, RES MICROBIOL, V157, P5, DOI 10.1016/j.resmic.2005.07.010.
   Novikova ND, 2004, MICROBIAL ECOL, V47, P127, DOI 10.1007/s00248-003-1035-2.
   Pelz A, 2005, J BIOL CHEM, V280, P32493, DOI 10.1074/jbc.M505070200.
   Taylor PW, 2005, INT J ANTIMICROB AG, V26, P183, DOI 10.1016/j.ijantimicag.2005.06.002.
   Taylor PW, 2008, PLANET MARS RES FOCU, P165.
   TIXADOR R, 1985, AVIAT SPACE ENVIR MD, V56, P748.
   TIXADOR R, 1985, ACTA ASTRONAUT, V12, P131, DOI 10.1016/0094-5765(85)90082-7.
   TIXADOR R, 1994, AVIAT SPACE ENVIR MD, V65, P551.
   WIELAND B, 1994, J BACTERIOL, V176, P7719.
   Wilson JW, 2007, P NATL ACAD SCI USA, V104, P16299, DOI 10.1073/pnas.0707155104.
   Wilson JW, 2002, APPL ENVIRON MICROB, V68, P5408, DOI 10.1128/AEM.68.11.5408-5416.2002.
   Wilson JW, 2002, P NATL ACAD SCI USA, V99, P13807, DOI 10.1073/pnas.212387899.
   Witney AA, 2005, APPL ENVIRON MICROB, V71, P7504, DOI 10.1128/AEM.71.11.7504-7514.2005.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{14}},
Journal-ISO = {{Acta Astronaut.}},
Doc-Delivery-Number = {{535CT}},
Unique-ID = {{ISI:000272944900011}},
DA = {{2018-08-13}},
}

@article{ ISI:000274504200019,
Author = {Capo-chichi, Callinice D. and Yeasky, Toni M. and Heiber, Joshua F. and
   Wang, Ying and Barber, Glen N. and Xu, Xiang-Xi},
Title = {{Explicit targeting of transformed cells by VSV in ovarian epithelial
   tumor-bearing Wv mouse models}},
Journal = {{GYNECOLOGIC ONCOLOGY}},
Year = {{2010}},
Volume = {{116}},
Number = {{2, SI}},
Pages = {{269-275}},
Month = {{FEB}},
Abstract = {{Objective. Current treatment options for epithelial ovarian cancer are
   limited and therapeutic development for recurrent and drug-resistant
   ovarian cancer is an urgent agenda. We investigated the potential use of
   genetically engineered Vesicular Stomatitis Virus (VSV) to treat ovarian
   cancer patients who fail to respond to available therapies.
   Specifically, we examined the toxicity to hosts and specificity of
   targeting ovarian tumors using a Wv ovarian tumor model.
   Methods. We first tested recombinant VSV for oncolytic activity in a
   panel Of human ovarian epithelial cancer, immortalized, and primary
   ovarian surface epithelial cells in Culture. Then, we tested VSV
   oncolytic therapy using the immune competent Wv mice that develop
   tubular adenomas, benign turner lesions derived from Ovarian Surface
   epithelial cells.
   Results. The expression of GFP encoded by the recombinant VSV genome was
   detected in about 5\% of primary ovarian surface epithelial cells (3
   lines) up to 30 days Without Significantly altering the growth pattern
   of the cells, suggesting the lack of toxicity to the normal ovarian
   surface epithelial cells. However, VSV-GFP was detected in the majority
   (around 90\%) of cells that are either ``immortalized{''} by SV40
   antigen expression or cancer lines. Some variation in killing time
   courses was observed, but all the transformed cell lines were killed
   within 3 days. We found that regardless of the inoculation route (intra
   bursal, IP, or IV), VSV specifically infected and replicated in the in
   situ ovarian tumors in the Wv mice without significant activity in any
   other organs and tissues, and showed no detectable toxicity. The
   epithelial tumor lesions were greatly reduced in VSV-targeted ovarian
   tumors in the Wv mice.
   Conclusions. VSV oncolytic activity depends oil a cell autonomous
   property distinguishing primary and transformed cells. The efficient
   oncolytic activity of VSV for the ``immortalized{''} non-tumorigenic
   ovarian surface epithelial cells suggests that the selective specificity
   extends front pre-neoplastic to overt cancer cells. The results
   demonstrated the explicit targeting of ovarian epithelial tumors by VSV
   in immune competent, ovarian tumor-bearing mouse models, and further
   support the utility of VSV as air effective and safe anti-cancer agent.
   (C) 2009 Elsevier Inc. All rights reserved.}},
Publisher = {{ACADEMIC PRESS INC ELSEVIER SCIENCE}},
Address = {{525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Xu, XX (Reprint Author), Univ Miami, Miller Sch Med, UM Sylvester Comprehens Canc Ctr, Room 417,Papanicolaou Bldg,1550 NW 10th Ave M877, Miami, FL 33136 USA.
   Capo-chichi, Callinice D.; Yeasky, Toni M.; Heiber, Joshua F.; Wang, Ying; Barber, Glen N.; Xu, Xiang-Xi, Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.}},
DOI = {{10.1016/j.ygyno.2009.10.086}},
ISSN = {{0090-8258}},
Keywords = {{Ovarian Cancer; Therapy; Oncolytic virus; VSV; Tumor mouse models}},
Keywords-Plus = {{VESICULAR STOMATITIS-VIRUS; ONCOLYTIC ACTIVITY;
   HEPATOCELLULAR-CARCINOMA; SURFACE EPITHELIUM; CANCER; MICE; RESISTANCE;
   DEFECTS; ADENOVIRUSES; TRANSLATION}},
Research-Areas = {{Oncology; Obstetrics \& Gynecology}},
Web-of-Science-Categories  = {{Oncology; Obstetrics \& Gynecology}},
Author-Email = {{GBarber@med.miami.edu
   xxu2@med.miami.edu}},
ORCID-Numbers = {{CAPO-CHICHI, D. Callinice/0000-0003-4941-7301}},
Funding-Acknowledgement = {{NCI {[}R01 CA099471, R01 CA79716, R01 CA75389]; NIH {[}R01 CA095924,
   P01CA128115]; DOD {[}W81XWH-06-10095]}},
Funding-Text = {{File Studies were Supported by grants R01 CA099471, R01 CA79716, and R01
   CA75389 from NCI, NIH, and W81XWH-06-10095 from DOD to XX Xu, and by
   grants R01 CA095924 and P01CA128115 from NIH to G.N. Barber. We very
   much appreciate Dr. Andrew Godwin from Fox Chase Cancer Center
   (Philadelphia, PA) for providing HIO and HOSE cells used in this
   research work. We thank Dr. Elizabeth Smith for reading and commenting
   during the process of preparing the manuscript, and Dr. Marianna Nunez
   of the Histopathology Core in tissue analysis.}},
Cited-References = {{Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1.
   Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001.
   Baltzis D, 2004, J VIROL, V78, P12747, DOI 10.1128/JVI.78.23.12747-12761.2004.
   Barber GN, 2004, VIRAL IMMUNOL, V17, P516, DOI 10.1089/vim.2004.17.516.
   Barbosa NOE, 2005, J AM COLL NUTR, V24, P10, DOI 10.1080/07315724.2005.10719437.
   Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644.
   Capo-Chichi CD, 2009, MOL CELL BIOL, V29, P4766, DOI 10.1128/MCB.00087-09.
   Capo-Chichi CD, 2003, CANCER RES, V63, P4967.
   Cesaire R, 2006, ONCOGENE, V25, P349, DOI 10.1038/sj.onc.1209055.
   Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246.
   DIAZ RM, CANC RES, V67, P2840.
   Ebert O, 2005, CANCER GENE THER, V12, P350, DOI 10.1038/sj.cgt.7700794.
   Ebert O, 2003, CANCER RES, V63, P3605.
   Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002.
   Hadaschik BA, 2008, CANCER RES, V68, P4506, DOI 10.1158/0008-5472.CAN-08-0238.
   Hermiston T, 2006, CURR OPIN MOL THER, V8, P322.
   Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/mt.sj.6300108.
   KRUK PA, 1990, LAB INVEST, V63, P132.
   Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208.
   Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003.
   Lun X, 2006, J NATL CANCER I, V98, P1546, DOI 10.1093/jnci/djj413.
   Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238.
   Martin LP, 2009, SEMIN ONCOL, V36, P112, DOI 10.1053/j.seminoncol.2008.12.003.
   MURPHY ED, 1972, J NATL CANCER I, V48, P1283.
   Nettelbeck DM, 2008, J MOL MED-JMM, V86, P363, DOI 10.1007/s00109-007-0291-1.
   NOCKA K, 1990, EMBO J, V9, P1805.
   Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003.
   Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9.
   Parato KA, 2005, NAT REV CANCER, V5, P965, DOI 10.1038/nrc1750.
   REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390.
   Shinozaki K, 2005, HEPATOLOGY, V41, P196, DOI 10.1002/hep.20536.
   SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305.
   Stojdl DF, 2000, NAT MED, V6, P821.
   Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000.
   Wagner R. R., 1996, FIELDS VIROLOGY, V3, P1121.
   Yang WL, 2007, AM J PATHOL, V170, P1325, DOI 10.2353/ajpath.2007.060769.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Gynecol. Oncol.}},
Doc-Delivery-Number = {{555IV}},
Unique-ID = {{ISI:000274504200019}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000275139800003,
Author = {Manoharlal, Raman and Gorantala, Jyotsna and Sharma, Monika and
   Sanglard, Dominique and Prasad, Rajendra},
Title = {{PAP1 {[}poly(A) polymerase 1] homozygosity and hyperadenylation are
   major determinants of increased mRNA stability of CDR1 in
   azole-resistant clinical isolates of Candida albicans}},
Journal = {{MICROBIOLOGY-SGM}},
Year = {{2010}},
Volume = {{156}},
Number = {{2}},
Pages = {{313-326}},
Month = {{FEB}},
Abstract = {{Using genetically matched azole-susceptible (AS) and azole-resistant
   (AR) clinical isolates of Candida albicans, we recently demonstrated
   that CDRI overexpression in AR isolates is due to its enhanced
   transcriptional activation and mRNA stability. This study examines the
   molecular mechanisms underlying enhanced CDR1 mRNA stability in AIR
   isolates. Mapping of the 3' untranslated region (3' UTR) of CDRI
   revealed that it was rich in adenylate/uridylate (AU) elements,
   possessed heterogeneous polyadenylation sites, and had putative
   consensus sequences for RNA-binding proteins. Swapping of heterologous
   and chimeric lacZ-CDR1 3' UTR transcriptional reporter fusion constructs
   did not alter the reporter activity in AS and AR isolates, indicating
   that cis-acting sequences within the CDRI 3' UTR itself are not
   sufficient to confer the observed differential mRNA decay.
   Interestingly, the poly(A) tail of the CDRI mRNA of AIR isolates was
   similar to 35-50\% hyperadenylated as compared with AS isolates. C.
   albicans poly(A) polymerase (PAPI), responsible for mRNA adenylation,
   resides on chromosome 5 in close proximity to the mating type-like (MTL)
   locus. Two different PAPI alleles, PAP1-a/PAP1-alpha, were recovered
   from AS (MTL-a/MTL-alpha), while a single type of PAPI allele
   (PAP1-alpha.) was recovered from AR isolates (MTL-alpha/MTL-alpha).
   Among the heterozygous deletions of PAP1-a (Delta pap1-a/PAP1-alpha) and
   PAP1-alpha. (PAP1-a/Delta pap1-alpha), only the former led to relatively
   enhanced drug resistance, to polyadenylation and to transcript stability
   of CDR1 in the AS isolate. This suggests a dominant negative role of
   PAPI-a in CDR1 transcript polyadenylation and stability. Taken together,
   our study provides the first evidence, to our knowledge, that loss of
   heterozygosity at the PAP1 locus is linked to hyperadenylation and
   subsequent increased stability of CDR1 transcripts, thus contributing to
   enhanced drug resistance.}},
Publisher = {{SOC GENERAL MICROBIOLOGY}},
Address = {{MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Prasad, R (Reprint Author), Jawaharlal Nehru Univ, Sch Life Sci, Membrane Biol Lab, New Delhi 110067, India.
   Manoharlal, Raman; Sharma, Monika; Prasad, Rajendra, Jawaharlal Nehru Univ, Sch Life Sci, Membrane Biol Lab, New Delhi 110067, India.
   Gorantala, Jyotsna, Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
   Sanglard, Dominique, Univ Lausanne Hosp, Inst Microbiol, CH-1011 Lausanne, Switzerland.}},
DOI = {{10.1099/mic.0.035154-0}},
ISSN = {{1350-0872}},
Keywords-Plus = {{3' UNTRANSLATED REGIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIFUNGAL
   DRUG-RESISTANCE; ABC TRANSPORTERS CDR1; FLUCONAZOLE RESISTANCE;
   ENTAMOEBA-HISTOLYTICA; MOLECULAR-MECHANISMS; REGULATING CDR1;
   GENE-EXPRESSION; TRANSCRIPTION}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{rp47@mail.jnu.ac.in}},
ResearcherID-Numbers = {{Sanglard, Dominique/K-6032-2017}},
ORCID-Numbers = {{Sanglard, Dominique/0000-0002-5244-4178}},
Funding-Acknowledgement = {{Department of Science and Technology, Indo-Swiss
   {[}INT/SWISS/P-31/2009]; Department of Biotechnology
   {[}BT/PR9100/Med/29/ 03/2007, BT/PR9563/BRB/10/ 567/2007,
   BT/PR11158/BRB/10/640/2008]; Council of Scientific and Industrial
   Research (CSIR) {[}38(1122)/06/EMR-II]}},
Funding-Text = {{We are grateful to Joachim Morschhauser, Universitat Wurzburg, Germany,
   for providing the clinical isolates Gu4/Gu5. We thank Chinmay K.
   Mukhopadhyay, Special Centre for Molecular Medicine (SCMM), Jawaharlal
   Nehru University, New Delhi, India, for providing the valuable advice On
   the PAT assay. Thiolutin (CP-4092) and fluconazole were provided as
   generous gifts from Pfizer and Ranbaxy Laboratories, respectively. The
   work presented in this paper has been supported in part by grants to R.
   P. from the Department of Science and Technology, Indo-Swiss
   (INT/SWISS/P-31/2009), Department of Biotechnology (BT/PR9100/Med/29/
   03/2007, BT/PR9563/BRB/10/ 567/2007, BT/PR11158/BRB/10/640/2008) and the
   Council of Scientific and Industrial Research (CSIR)
   {[}38(1122)/06/EMR-II]. R. M. thanks CSIR for the award of a senior
   research fellowship.}},
Cited-References = {{Akins RA, 2005, MED MYCOL, V43, P285, DOI 10.1080/13693780500138971.
   Chen CG, 2004, ANTIMICROB AGENTS CH, V48, P4505, DOI 10.1128/AAC.48.12.4505-4512.2004.
   Coste A, 2006, GENETICS, V172, P2139, DOI 10.1534/genetics.105.054767.
   Coste AT, 2004, EUKARYOT CELL, V3, P1639, DOI 10.1128/EC.3.6.1639-1652.2004.
   de Micheli M, 2002, MOL MICROBIOL, V43, P1197, DOI 10.1046/j.1365-2958.2002.02814.x.
   EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547.
   FONZI WA, 1993, GENETICS, V134, P717.
   Franz R, 1999, MYCOSES, V42, P453, DOI 10.1046/j.1439-0507.1999.00498.x.
   Franz R, 1998, ANTIMICROB AGENTS CH, V42, P3065.
   Garcia-Vivas J, 2005, EXP PARASITOL, V110, P226, DOI 10.1016/j.exppara.2005.02.017.
   Gaur NA, 2004, FEMS YEAST RES, V4, P389, DOI 10.1016/S1567-1356(03)0204-6.
   Gerads M, 1998, NUCLEIC ACIDS RES, V26, P5061, DOI 10.1093/nar/26.22.5061.
   Higgins CF, 1991, CURR OPIN CELL BIOL, V3, P1013, DOI 10.1016/0955-0674(91)90122-F.
   HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4.
   HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596.
   Hull CM, 1999, SCIENCE, V285, P1271, DOI 10.1126/science.285.5431.1271.
   Jiang B, 2008, CHEM BIOL, V15, P363, DOI 10.1016/j.chembiol.2008.02.016.
   Karnani N, 2004, YEAST, V21, P219, DOI 10.1002/yea.1067.
   Kusov YY, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e57.
   Lopez-Camarillo C, 2003, J BIOL CHEM, V278, P11273, DOI 10.1074/jbc.M211757200.
   Lopez-Ribot JL, 1998, ANTIMICROB AGENTS CH, V42, P2932.
   Magee BB, 2000, SCIENCE, V289, P310, DOI 10.1126/science.289.5477.310.
   Manoharlal R, 2008, ANTIMICROB AGENTS CH, V52, P1481, DOI 10.1128/AAC.01106-07.
   McCarthy JEG, 1998, MICROBIOL MOL BIOL R, V62, P1492.
   Morschhauser J, 2007, PLOS PATHOG, V3, P1603, DOI 10.1371/journal.ppat.0030164.
   Murad AMA, 2000, YEAST, V16, P325, DOI 10.1002/1097-0061(20000315)16:4<325::AID-YEA538>3.0.CO;2-\#.
   Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3.
   Pesole G, 2002, NUCLEIC ACIDS RES, V30, P335, DOI 10.1093/nar/30.1.335.
   PRASAD R, 1995, CURR GENET, V27, P320, DOI 10.1007/BF00352101.
   Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101.
   Puri N, 1999, FEMS MICROBIOL LETT, V180, P213, DOI 10.1016/S0378-1097(99)00488-7.
   Reuss O, 2004, GENE, V341, P119, DOI 10.1016/j.gene.2004.06.021.
   Rognon B, 2006, MICROBIOL-SGM, V152, P3701, DOI 10.1099/mic.0.29277-0.
   Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0.
   Russell JE, 1998, MOL CELL BIOL, V18, P2173, DOI 10.1128/MCB.18.4.2173.
   Sanglard D, 1996, ANTIMICROB AGENTS CH, V40, P2300.
   Sanglard D, 2002, LANCET INFECT DIS, V2, P73, DOI 10.1016/S1473-3099(02)00181-0.
   SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378.
   Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405.
   Sparks KA, 1998, NUCLEIC ACIDS RES, V26, P4676, DOI 10.1093/nar/26.20.4676.
   Talibi D, 1999, J BACTERIOL, V181, P231.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Trzaska Dominika, 2005, Postepy Biochem, V51, P28.
   Uhl MA, 2001, MICROBIOL-SGM, V147, P1189, DOI 10.1099/00221287-147-5-1189.
   White T C, 1997, Oral Dis, V3 Suppl 1, pS102.
   White TC, 1997, ANTIMICROB AGENTS CH, V41, P1482.
   White TC, 1998, CLIN MICROBIOL REV, V11, P382.
   Wirsching S, 2000, J BACTERIOL, V182, P400, DOI 10.1128/JB.182.2.400-404.2000.
   Yang YL, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-22.
   Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405.
   Znaidi S, 2008, EUKARYOT CELL, V7, P836, DOI 10.1128/EC.00070-08.
   Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Microbiology-(UK)}},
Doc-Delivery-Number = {{563NR}},
Unique-ID = {{ISI:000275139800003}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000274647500006,
Author = {Alexander, T. W. and Inglis, G. D. and Yanke, L. J. and Topp, E. and
   Read, R. R. and Reuter, T. and McAllister, T. A.},
Title = {{Farm-to-fork characterization of Escherichia coli associated with
   feedlot cattle with a known history of antimicrobial use}},
Journal = {{INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY}},
Year = {{2010}},
Volume = {{137}},
Number = {{1}},
Pages = {{40-48}},
Month = {{JAN 31}},
Abstract = {{This study investigated antimicrobial-resistant (AR) Escherichia coli
   isolated from ``farm-to-fork{''} production of cattle fed diets
   containing the antimicrobial growth promoter (AGP) chlortetracycline
   plus sulfamethazine (44 ppm each, AS700) or no AGP (control). For each
   treatment, samples included: feces just prior to euthanization; hides
   after euthanization; intestinal digesta from the lower digestive tract;
   carcasses immediately after evisceration and after 24 h in the chiller;
   and ground beef stored at 5 degrees C for 1 and 8 days. Samples were
   also collected from the abattoir environment and from air during hide
   removal. Total, ampicillin (Amp(r))-, and tetracycline
   (Tet(r))-resistant E coli were isolated on MacConkey agar or MacConkey
   agar containing ampicillin or tetracycline, respectively. Amp(r) and
   Tet(r) E coli were isolated from the feces and hides of all cattle.
   Compared to the control, the prevalence of Amp(r) (26.5\% vs. 7.9\%) and
   Tet(r) (50.9\% vs. 12.6\%) E. coli was greater in feces from AS700
   treated animals (P<0.05), but was similar between treatments for hide
   samples (P>0.05). The prevalence of carcass or ground beef contamination
   with AR E. coli was not different between treatments. Resistant E. coli
   were isolated from the abattoir environment after processing of both
   groups of cattle. Susceptibilities to 11 antimicrobials and pulsed-field
   gel electrophoresis (PFGE) analyses were conducted on 360 Amp(r) and
   Tet(r) E. coli isolates. Twenty-five antibiogram profiles were detected,
   with isolates exhibiting resistance to up to 9 antimicrobials. Most
   (28.2\%) Amp(r) E coli were also resistant to streptomycin and
   tetracycline, whereas Tet(r) E. coli (53.5\%) were mainly resistant to
   only tetracycline. Thirty one genotypes were detected by PFGE with most
   isolates from meat and environmental samples having similar genetic
   profiles to isolates from hides or digesta. These data demonstrate that
   antimicrobial-resistant E coli can contaminate meat products during
   slaughter and enter the food chain regardless of whether or not cattle
   are administered AGP. The abundance of AR E. coli on the hides of
   animals is likely a key element for controlling end-product
   contamination. Crown Copyright (C) 2009 Published by Elsevier B.V, All
   rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{McAllister, TA (Reprint Author), Agr \& Agri Food Canada, Res Ctr, POB 3000 Ave S, Lethbridge, AB T1J 4B1, Canada.
   Alexander, T. W.; Inglis, G. D.; Yanke, L. J.; Reuter, T.; McAllister, T. A., Agr \& Agri Food Canada, Lethbridge Res Ctr, Lethbridge, AB T1J 4B1, Canada.
   Topp, E., Agr \& Agri Food Canada, So Crop Protect \& Food Res Ctr, London, ON N5V 4T3, Canada.
   Read, R. R., Univ Calgary, Fac Med, Calgary, AB T2N 4N1, Canada.}},
DOI = {{10.1016/j.ijfoodmicro.2009.11.008}},
ISSN = {{0168-1605}},
Keywords = {{Escherichia coli; Antimicrobial resistance; Growth promoter; Abattoir;
   Cattle}},
Keywords-Plus = {{RESISTANCE GENES; BEEF-CATTLE; ANTIBIOTIC-RESISTANCE; DRUG-RESISTANCE;
   HUMAN HEALTH; BACTERIA; CONTAMINATION; PREVALENCE; CARCASSES; HIDES}},
Research-Areas = {{Food Science \& Technology; Microbiology}},
Web-of-Science-Categories  = {{Food Science \& Technology; Microbiology}},
Author-Email = {{tim.mcallister@agr.gc.ca}},
ORCID-Numbers = {{McAllister, Tim A./0000-0002-8266-6513
   Topp, Ed/0000-0002-8273-9372}},
Funding-Acknowledgement = {{Canada-Alberta Beef Industry Development Fund (CABIDF); Agriculture and
   Agri-Food Canada; Natural Sciences and Engineering Research Council of
   Canada}},
Funding-Text = {{We wish to acknowledge the dedicated assistance of the following
   individuals at Agriculture and Agri-Food Canada, Lethbridge Research
   Centre: (1) Jennilee Jamison and Cindy Barkley for abattoir sampling:
   (2) jenny Gusse, Kathaleen House, Ryan Lammertsen, and Christa King for
   processing samples: (3) Wendi Smart, Brant Baker and Fred Van Herk for
   collection of fecal samples and for transporting cattle from the feedlot
   to the abattoir; and (4) Lorna Selinger, Ruth Barbieri, and Shaun Cook
   for isolate characterization. Financial support for this study was
   provided by grants from the Canada-Alberta Beef Industry Development
   Fund (CABIDF) and Agriculture and Agri-Food Canada Peer Review to GDI
   and TAM. Natural Sciences and Engineering Research Council of Canada
   fellowships to T.W.A. is gratefully acknowledged.}},
Cited-References = {{Alexander TW, 2008, APPL ENVIRON MICROB, V74, P4405, DOI 10.1128/AEM.00489-08.
   {[}Anonymous], 2008, M100S18 CLIN LAB STA.
   Aslam M, 2003, APPL ENVIRON MICROB, V69, P2794, DOI 10.1128/AEM.69.5.2794-2799.2003.
   Aslam M, 2006, J FOOD PROTECT, V69, P1508, DOI 10.4315/0362-028X-69.7.1508.
   Aslam M, 2009, J FOOD PROTECT, V72, P1089, DOI 10.4315/0362-028X-72.5.1089.
   Barton MD, 2000, NUTR RES REV, V13, P279, DOI 10.1079/095442200108729106.
   Bell RG, 1997, J APPL MICROBIOL, V82, P292, DOI 10.1046/j.1365-2672.1997.00356.x.
   Blake DP, 2003, J APPL MICROBIOL, V94, P1087, DOI 10.1046/j.1365-2672.2003.01937.x.
   Blanc V, 2006, VET MICROBIOL, V118, P299, DOI 10.1016/j.vetmic.2006.08.002.
   Brichta-Harhay DM, 2008, APPL ENVIRON MICROB, V74, P6289, DOI 10.1128/AEM.00700-08.
   {*}CAN FOOD INSP AG, 1994, AGR AGR CAN COMP MED.
   Casewell M, 2003, J ANTIMICROB CHEMOTH, V52, P159, DOI 10.1093/jac/dkg313.
   {*}CDCP, 1996, STAND MOL SUBT FOOD.
   Clinical and Laboratory Standards Institute, 2006, M7A7 CLSI.
   Davison J, 1999, PLASMID, V42, P73, DOI 10.1006/plas.1999.1421.
   Elder RO, 2000, P NATL ACAD SCI USA, V97, P2999, DOI 10.1073/pnas.060024897.
   Fluckey WM, 2007, J FOOD PROTECT, V70, P551, DOI 10.4315/0362-028X-70.3.551.
   Gill CO, 2001, J FOOD PROTECT, V64, P1824, DOI 10.4315/0362-028X-64.11.1824.
   Gu HW, 2003, J AM CHEM SOC, V125, P15702, DOI 10.1021/ja0359310.
   Hammerum AM, 2009, CLIN INFECT DIS, V48, P916, DOI 10.1086/597292.
   HUMMEL R, 1986, J BASIC MICROB, V26, P461, DOI 10.1002/jobm.3620260806.
   Jericho KWF, 2000, J FOOD PROTECT, V63, P1523, DOI 10.4315/0362-028X-63.11.1523.
   Khachatryan AR, 2006, APPL ENVIRON MICROB, V72, P443, DOI 10.1128/AEM.72.1.443-448.2006.
   Khachatryan AR, 2008, APPL ENVIRON MICROB, V74, P391, DOI 10.1128/AEM.01534-07.
   Larkin C, 2006, J FOOD PROTECT, V69, P22, DOI 10.4315/0362-028X-69.1.22.
   LeJeune JT, 2004, J FOOD PROTECT, V67, P1433, DOI 10.4315/0362-028X-67.7.1433.
   Namvar A, 2005, J FOOD PROTECT, V68, P2447, DOI 10.4315/0362-028X-68.11.2447.
   Olfert E. D., 1993, GUIDE CARE USE EXPT, V1.
   Salyers AA, 2004, TRENDS MICROBIOL, V12, P412, DOI 10.1016/j.tim.2004.07.004.
   Sawant AA, 2007, APPL ENVIRON MICROB, V73, P156, DOI 10.1128/AEM.01551-06.
   Schroeder CM, 2003, INT J FOOD MICROBIOL, V85, P197, DOI 10.1016/S0168-1605(02)00508-1.
   SHARMA R, 2009, FOODBORNE PATHOG DIS, V6, P1.
   Sharma R, 2008, APPL ENVIRON MICROB, V74, P6178, DOI 10.1128/AEM.00704-08.
   Shiferaw B, 2000, J FOOD PROTECT, V63, P1538, DOI 10.4315/0362-028X-63.11.1538.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   van den Bogaard AE, 2000, INT J ANTIMICROB AG, V14, P327, DOI 10.1016/S0924-8579(00)00145-X.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{28}},
Journal-ISO = {{Int. J. Food Microbiol.}},
Doc-Delivery-Number = {{557CY}},
Unique-ID = {{ISI:000274647500006}},
DA = {{2018-08-13}},
}

@article{ ISI:000208654600029,
Author = {Liguori, Giorgio and Bagattini, Maria and Galle, Francesca and Negrone,
   Mario and Di Onofrio, Valeria and Triassi, Maria},
Title = {{Automated cleaning of fan coil units with a natural
   detergent-disinfectant product}},
Journal = {{ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS}},
Year = {{2010}},
Volume = {{9}},
Abstract = {{Background: Air conditioning systems represent one important source of
   microbial pollutants for indoor air. In the past few years, numerous
   strategies have been conceived to reduce the contamination of air
   conditioners, mainly in hospital settings. The biocidal detergent BATT2
   represents a natural product obtained through extraction from brown
   seaweeds, that has been tested previously on multidrug-resistant
   microorganisms.
   Methods: BATT2 has been utilized for the disinfection of fan coil units
   from four air conditioning systems located in hospital environments with
   a mean degree of risk. Samples were collected from the air supplied by
   the conditioning systems and from the surfaces of fan coil units, before
   and after sanitization procedures. Total microbial counts at 37 degrees
   C and 22 degrees C and mycotic count at 32 degrees C were evaluated.
   Staphylococci and Pseudomonas aeruginosa were also detected on surfaces
   samples.
   Results: The biodetergent was able to reduce up 50\% of the microbial
   pollution of fan coil units surfaces and air supplied by the air
   conditioners.
   Conclusions: BATT2 could be considered for cleaning/disinfection of air
   conditioning systems, that should be performed on the basis of accurate
   and verifiable sanitization protocols.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bagattini, M (Reprint Author), Univ Naples Federico II, Dipartimento Sci Med Prevent, Sez Igiene, Naples, Italy.
   Liguori, Giorgio; Galle, Francesca; Di Onofrio, Valeria, Univ Napoli Parthenope, Cattedra Igiene \& Epidemiol, Naples, Italy.
   Bagattini, Maria; Triassi, Maria, Univ Naples Federico II, Dipartimento Sci Med Prevent, Sez Igiene, Naples, Italy.
   Negrone, Mario, Agenzia Sanita Pubbl, Dipartimento Med Prevent, Serv Igiene Alimenti \& Nutr, Potenza, Italy.}},
DOI = {{10.1186/1476-0711-9-29}},
Article-Number = {{29}},
ISSN = {{1476-0711}},
Keywords-Plus = {{SICK BUILDING SYNDROME; AIR-CONDITIONING SYSTEMS; US OFFICE BUILDINGS;
   RISK-FACTORS; EPA BASE; SYMPTOMS; VENTILATION; CONTAMINATION; SBS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{maria.bagattini@unina.it}},
ResearcherID-Numbers = {{Galle, Francesca/B-4520-2011
   }},
ORCID-Numbers = {{Galle, Francesca/0000-0002-0504-9562
   bagattini, maria/0000-0002-3658-7670
   Triassi, Maria/0000-0002-9420-9571}},
Cited-References = {{ABBRITTI G, 1992, ARCH ENVIRON HEALTH, V47, P16, DOI 10.1080/00039896.1992.9935939.
   Burge PS, 2004, OCCUP ENVIRON MED, V61, P185, DOI 10.1136/oem.2003.008813.
   Cecchini C, 2004, J APPL MICROBIOL, V97, P371, DOI 10.1111/j.1365-2672.2004.02308.x.
   Commission of the European Communities, 1993, 12 COMM EUR COMM.
   Critchley M, 2009, J APPL MICROBIOL, V106, P784, DOI 10.1111/j.1365-2672.2008.04044.x.
   Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032.
   Ente Nazionale Italiano di Unificazione, 2002, 130982002 UNI EN.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Istituto Nazionale Infortuni sul Lavoro, 2005, MON MICR NEGL AMB LA.
   Istituto Superiore Prevenzione e Sicurezza sul Lavoro, 2009, LIN GUID STAND SIC I.
   Jaakkola MS, 2007, OCCUP ENVIRON MED, V64, P178, DOI 10.1136/oem.2005.024596.
   Liguori G, 2009, ANN CLIN MICROB ANTI, V8, DOI 10.1186/1476-0711-8-35.
   Matuszewska Renata, 2008, Rocz Panstw Zakl Hig, V59, P445.
   Mendell MJ, 2008, INDOOR AIR, V18, P301, DOI 10.1111/j.1600-0668.2008.00531.x.
   Mendell MJ, 2006, J OCCUP ENVIRON HYG, V3, P225, DOI 10.1080/15459620600628589.
   MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193.
   Ministero della Salute, 2001, LIN GUID PROM TUT SA.
   Ministero della Salute - Direzione Generale della Prevenzione, 2001, REQ IG OP MAN IMPL C.
   Orlando P, 2008, J Prev Med Hyg, V49, P116.
   Pasquarella C, 2010, SCI TOTAL ENVIRON, V408, P4045, DOI 10.1016/j.scitotenv.2010.05.010.
   Pitzurra M, 1997, Ann Ig, V9, P439.
   Rizzetto R, 2008, J Prev Med Hyg, V49, P26.
   Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x.
   Uduman SA, 2002, J HOSP INFECT, V52, P175, DOI 10.1053/jhin.2002.1308.
   Weaver L, 2010, LETT APPL MICROBIOL, V50, P18, DOI 10.1111/j.1472-765X.2009.02753.x.
   WHO, 2009, WHO GUID IND AIR QUA.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Ann. Clin. Microbiol. Antimicrob.}},
Doc-Delivery-Number = {{V28AV}},
Unique-ID = {{ISI:000208654600029}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000282403300001,
Author = {Vandeplas, Sabrina and Dubois-Dauphin, Robin and Palm, Rodolphe and
   Beckers, Yves and Thonart, Philippe and Thewis, Andre},
Title = {{Prevalence and sources of Campylobacter spp. contamination in free-range
   broiler production in the southern part of Belgium}},
Journal = {{BIOTECHNOLOGIE AGRONOMIE SOCIETE ET ENVIRONNEMENT}},
Year = {{2010}},
Volume = {{14}},
Number = {{2}},
Pages = {{279-288}},
Abstract = {{A one year epidemiological study was carried out between February 2005
   and February 2006 in the southern part of Belgium to assess the
   Campylobacter prevalence in free-range broiler production. Three
   successive broiler flocks from six Belgian farms were investigated for
   the presence of Campylobacter spp. during the rearing period. Each flock
   was visited four times, before and after the outdoor rearing period.
   During each visit, samples were taken in the broiler house (litter,
   cecal droppings, water-lines, feed, anteroom) as well as from the outer
   rearing environment (open-air range). The Campylobacter detection in all
   samples was carried out according to the ISO 10272 standard.
   Identification was based on colonial morphology, microscopic
   examination, and biochemical tests. PCR multiplex was used for genetic
   confirmation. Campylobacter jejuni was the main species isolated from
   all contaminated samples. Overall, mixed infections C.
   jejuni/Campylobacter coli represented 40.6\%, while C. jejuni and C.
   coli represented 46.9\% and 12.5\% of chicken samples respectively. A
   100\% flock contamination was observed in the 6 farms during the
   summer-autumn period, whereas only 66.7\% and 33.3\% of the flocks
   became Campylobacter-positive in spring and winter respectively, at the
   end of the rearing period. Half of contaminated flocks were infected
   before chickens have access to the open-air range. Environmental
   samples, especially the open-air range soil, were found to be
   Campylobacter-positive before flock infection. The other potential
   sources of contamination were delivery tray, anteroom floor and
   water-lines. Other animal productions like cattle on the farm, no
   applied rodent control, no cleaning and disinfection of water-lines
   between flocks, no detergent used for cleaning and thinning were
   recorded as risk factors. In conclusion, the contact with the
   environment, particularly the access to an open-air range, appeared to
   be the major way of Campylobacter contamination of chickens in
   free-range broiler production.}},
Publisher = {{FAC UNIV SCIENCES AGRONOMIQUES GEMBLOUX}},
Address = {{BIBLIOTHEQUE, PASSAGE DES DEPORTES 2, GEMBLOUX, 00000, BELGIUM}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Vandeplas, S (Reprint Author), Univ Liege, Gembloux Agrobio Tech Anim Sci Unit, Passage Deportes 2, B-5030 Gembloux, Belgium.
   Vandeplas, Sabrina; Beckers, Yves; Thewis, Andre, Univ Liege, Gembloux Agrobio Tech Anim Sci Unit, B-5030 Gembloux, Belgium.
   Dubois-Dauphin, Robin; Thonart, Philippe, Univ Liege, Gembloux Agrobio Tech Bioind Unit, B-5030 Gembloux, Belgium.
   Palm, Rodolphe, Univ Liege, Gembloux Agrobio Tech Appl Stat Comp Sci \& Math U, B-5030 Gembloux, Belgium.}},
ISSN = {{1370-6233}},
Keywords = {{Campylobacter; epidemiology; free-range broiler flocks; open-air range;
   prevalence; risk factors}},
Keywords-Plus = {{RISK-FACTORS; THERMOPHILIC CAMPYLOBACTER; ANTIMICROBIAL RESISTANCE;
   REARING PERIOD; CHICKEN FLOCKS; JEJUNI; COLI; COLONIZATION; POULTRY;
   IDENTIFICATION}},
Research-Areas = {{Agriculture; Biotechnology \& Applied Microbiology; Environmental
   Sciences \& Ecology}},
Web-of-Science-Categories  = {{Agronomy; Biotechnology \& Applied Microbiology; Environmental Sciences}},
Author-Email = {{svandeplas@ulg.ac.be}},
ORCID-Numbers = {{Beckers, Yves/0000-0002-1649-1161}},
Funding-Acknowledgement = {{Ministry of the Walloon Region - General Direction of Agriculture,
   Natural Resources and Environment (DGARNE), Division for Research,
   Jambes, Belgium}},
Funding-Text = {{We would like to thank the poultry companies involved and their contract
   farmers for their participation. The technical assistance of Mrs Pascale
   Van Hal and the help in epidemiological protocol development from Mrs
   Valerie Decauwert are gratefully acknowledged. We are also grateful to
   Jean-Yves Zimmer, from the Department of functional and evolutionary
   Entomology of the ULg - Gembloux Agro-Bio Tech, for information about
   insects commonly found in broiler houses. Financial support was provided
   by the Ministry of the Walloon Region - General Direction of
   Agriculture, Natural Resources and Environment (DGARNE), Division for
   Research, Jambes, Belgium.}},
Cited-References = {{Allen V. M., 2005, EVIDENCE EFFECTIVENE.
   Arsenault J, 2007, PREV VET MED, V81, P250, DOI 10.1016/j.prevetmed.2007.04.016.
   Berndtson E, 1996, INT J FOOD MICROBIOL, V32, P35, DOI 10.1016/0168-1605(96)01102-6.
   Bouwknegt M, 2004, PREV VET MED, V62, P35, DOI 10.1016/j.prevetmed.2003.09.003.
   Bull SA, 2006, APPL ENVIRON MICROB, V72, P645, DOI 10.1128/AEM.72.1.645-652.2006.
   Butzler JP, 2004, CLIN MICROBIOL INFEC, V10, P868, DOI 10.1111/j.1469-0691.2004.00983.x.
   Denis M, 2008, POULTRY SCI, V87, P1662, DOI 10.3382/ps.2008-00010.
   Denis M, 1999, LETT APPL MICROBIOL, V29, P406, DOI 10.1046/j.1472-765X.1999.00658.x.
   {*}EUR FOOD SAF AUTH, 2007, EFSA J, V130, P1.
   Evans SJ, 2000, PREV VET MED, V46, P209, DOI 10.1016/S0167-5877(00)00143-4.
   Friedman CR, 2000, CAMPYLOBACTER, VII, P121.
   Hald B, 2008, POULTRY SCI, V87, P1428, DOI 10.3382/ps.2007-00301.
   Hansson I, 2007, J APPL MICROBIOL, V103, P640, DOI 10.1111/j.1365-2672.2007.03291.x.
   Herman L, 2003, EPIDEMIOL INFECT, V131, P1169, DOI 10.1017/S0950268803001183.
   Heuer OE, 2001, LETT APPL MICROBIOL, V33, P269, DOI 10.1046/j.1472-765X.2001.00994.x.
   Huneau-Salaun A, 2007, PREV VET MED, V80, P34, DOI 10.1016/j.prevetmed.2007.02.001.
   KAPPERUD G, 1993, EPIDEMIOL INFECT, V111, P245, DOI 10.1017/S0950268800056958.
   Kilonzo-Nthenge A, 2008, POULTRY SCI, V87, P1841, DOI 10.3382/ps.2007-00156.
   Luangtongkum T, 2006, APPL ENVIRON MICROB, V72, P3600, DOI 10.1128/AEM.72.5.3600-3607.2006.
   Moore JE, 2005, VET RES, V36, P351, DOI 10.1051/vetres:2005012.
   Nayak R, 2005, MOL CELL PROBE, V19, P187, DOI 10.1016/j.mcp.2004.11.005.
   Newell DG, 2003, APPL ENVIRON MICROB, V69, P4343, DOI 10.1128/AEM.69.8.4343-4351.2003.
   Patrick ME, 2004, APPL ENVIRON MICROB, V70, P7474, DOI 10.1128/AEM.70.12.7474-7480.2004.
   Ramabu SS, 2004, LETT APPL MICROBIOL, V39, P252, DOI 10.1111/j.1472-765X.2004.01573.x.
   Rasschaert G, 2006, J FOOD PROTECT, V69, P27, DOI 10.4315/0362-028X-69.1.27.
   RASSCHAERT G, 2007, THESIS GHENT U BELGI.
   Refregier-Petton J, 2001, PREV VET MED, V50, P89, DOI 10.1016/S0167-5877(01)00220-3.
   Rivoal K, 2005, APPL ENVIRON MICROB, V71, P6216, DOI 10.1128/AEM.71.10.6216-6227.2005.
   Rodenburg TB, 2004, NJAS-WAGEN J LIFE SC, V52, P101, DOI 10.1016/S1573-5214(04)80006-X.
   Rosenquist H, 2003, INT J FOOD MICROBIOL, V83, P87, DOI 10.1016/S0168-1605(02)00317-3.
   Sahin O, 2003, APPL ENVIRON MICROB, V69, P5372, DOI 10.1128/AEM.69.9.5372-5379.2003.
   Saleha A. A., 2004, International Journal of Poultry Science, V3, P129.
   Siemer BL, 2005, APPL ENVIRON MICROB, V71, P1953, DOI 10.1128/AEM.71.4.1953-1958.2005.
   Stern NJ, 2001, J FOOD PROTECT, V64, P1705, DOI 10.4315/0362-028X-64.11.1705.
   Van Looveren M, 2001, J ANTIMICROB CHEMOTH, V48, P235, DOI 10.1093/jac/48.2.235.
   VandeGiessen AW, 1996, EPIDEMIOL INFECT, V117, P245, DOI 10.1017/S0950268800001412.
   Wallace JS, 1997, J APPL MICROBIOL, V82, P219, DOI 10.1111/j.1365-2672.1997.tb03576.x.
   Zorman T, 2006, INT J FOOD MICROBIOL, V110, P24, DOI 10.1016/j.ijfoodmicro.2006.03.001.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Biotechnol. Agron. Soc.}},
Doc-Delivery-Number = {{657HH}},
Unique-ID = {{ISI:000282403300001}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000208443300003,
Author = {Scharfen, Jr., J. and Moravkova, M. and Buncek, M. and Hobza, V and
   Plisek, S. and Urbaskova, P. and Sedlacek, I and Zemlickova, H. and
   Starkova, H. and Paterova, P.},
Title = {{Nocardia farcinica as the Causative Agent of a Brain Abscess in a
   Patient with Interstitial Lung Disease}},
Journal = {{EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE}},
Year = {{2010}},
Volume = {{59}},
Number = {{1}},
Pages = {{13-20}},
Abstract = {{Scharfen J., Moravkova M., Buncek M., Hobza V., Plisek S., Urbaskova P.,
   Sedlacek I., Zemlickova H., Starkova H., Paterova P.: Nocardia farcinica
   as the Causative Agent of a Brain Abscess in a Patient with Interstitial
   Lung Disease
   This case report describes a two-step protocol for the identification of
   the causative agent of nocardiosis in a patient with brain abscess,
   antibiotic susceptibility testing and etiological treatment after
   neurosurgery. The patient treated with corticosteroids for pulmonary
   fibrosis and presenting with multiple neurological manifestations was
   admitted to a neurosurgery clinic. CT and contrast MRI revealed an
   expansive multilocular lesion 45 x 35 mm in size in the left parietal
   lobe, differentially diagnosed as malignant glioma. The lesion was
   biopsied and the histology showed a brain abscess containing white blood
   cells and dead tissue. The aspirated pus culture yielded bacteria of the
   genus Nocardia that were further identified, in the first step, by
   phenotypic methods (Gram positivity, partial acidoresistance, airborne
   mycelium detection, growth at 45 degrees C, lysozyme resistance and
   antibiotic resistance phenotype) as belonging to resistance phenotype
   V., v.s. N. farcinica (resistance to aminoglycosides except amikacin and
   to third-generation cephalosporins). In the second step of the
   polyphasic identification, rDNA was isolated and a 1000 bp part of the
   16S rRNA gene was sequenced. Sequence comparison with the GenBank
   database using BLAST software identified the agent as N. farcinica
   (100\%). The isolate was tested for susceptibility by the NCCLS / CLSI
   dilution method and showed good susceptibility to co-trimoxazole,
   amikacin and imipenem. The patient was treated with long-term
   intravenous cotrimoxazole acid in combination with amikacin and his
   clinical condition and laboratory parameters of inflammation improved.
   N. farcinica is among the three most frequently isolated Nocardia
   species in Europe as well as in the Czech Republic where it was
   repeatedly recovered from the lungs and respiratory tract of
   immunocompromised patients with systemic nocardiosis.}},
Publisher = {{CESKA LEKARSKA SPOLECNOST J  EV  PURKYNE}},
Address = {{SOKOLSKA 31, PRAGUE, 00000, CZECH REPUBLIC}},
Type = {{Article}},
Language = {{Czech}},
Affiliation = {{Scharfen, J (Reprint Author), Oblastni Nemocnice Trutnov As, Odd Lekarske Mikrobiolol \& Imunol, Narodni Referencni Lab, Trutnov 64121, Czech Republic.
   Scharfen, J., Jr.; Starkova, H., Oblastni Nemocnice Trutnov As, Oddeleni Lekarske Mikrobiolol \& Imunol, Narodni Referencni Lab Pro Patogenni Aktinomycety, Trutnov 64121, Czech Republic.
   Scharfen, J., Jr.; Moravkova, M.; Paterova, P., Ustav Klin Mikrobiol LF UK Hradci Kralove \& FN, Hradec Kralove, Czech Republic.
   Buncek, M., Generi Biotech As, Hradec Kralove, Czech Republic.
   Hobza, V, Neurochirugick Klin LF UK Hradci Kralove \& FN, Hradec Kralove, Czech Republic.
   Plisek, S., Infekcni Klin LF UK Hradci Kralove \& FN, Hradec Kralove, Czech Republic.
   Urbaskova, P.; Zemlickova, H., Statni Zdravotni Ustav Praze, Narodni Referencni Lab Pro Antibiotika, Prague, Czech Republic.
   Sedlacek, I, Masarykovy Univ Brne, Ceska Sbirka Mikroorg Prirodovedecke Fak, Brno, Czech Republic.
   Zemlickova, H., Statni Zdravotni Ustav Praha, Narodni Sbirka Typovych Kultur, Prague, Czech Republic.}},
ISSN = {{1210-7913}},
Keywords = {{Nocardia farcinica; brain abscess; polyphasic identification; 16S rRNA;
   resistance phenotype}},
Research-Areas = {{Immunology; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Microbiology}},
Author-Email = {{scharfen@nemtru.cz}},
ResearcherID-Numbers = {{Zemlickova, Helena/G-6105-2017
   }},
ORCID-Numbers = {{Zemlickova, Helena/0000-0002-3868-0545
   Paterova, Pavla/0000-0003-0192-7345}},
Cited-References = {{BOIRON P, 1993, LAB METHODS DIAGNOSI.
   Borchers M, 2006, DEUT MED WOCHENSCHR, V131, P1085, DOI 10.1055/s-2006-941724.
   Brown B. A., 1992, CLIN MICROBIOLOGY PR.
   Brown JM, 2003, MANUAL CLIN MICROBIO, P370.
   Brown-Elliott BA, 2006, CLIN MICROBIOL REV, V19, P259, DOI 10.1128/CMR.19.2.259-282.2006.
   Cibali Acikgo Z Z, 2004, NEUROCIRUGIA ASTUR, V6, P600.
   Conville PS, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P515.
   Djennane S, 2005, PRESSE MED, V34, P522, DOI 10.1016/S0755-4982(05)83964-8.
   Fellows GA, 2007, BRIT J NEUROSURG, V21, P301, DOI 10.1080/02688690701365770.
   Hope W, 2003, J INFECTION, V47, P256, DOI 10.1016/S0163-4453(03)00083-5.
   Iannotti C. A., 2008, SURG NEUROL.
   Jorgensen J. H., 2003, MANUAL CLIN MICROBIO, P1113.
   Kandasamy J, 2008, ACTA NEUROCHIR, V150, P505, DOI 10.1007/s00701-008-1578-x.
   Kilincer C, 2006, J CLIN NEUROSCI, V13, P481, DOI 10.1016/j.jocn.2005.04.031.
   Kostur Maria, 2002, J Miss State Med Assoc, V43, P111.
   Malincarne L, 2002, CLIN NEUROL NEUROSUR, V104, P132, DOI 10.1016/S0303-8467(01)00201-3.
   MCNEILL MM, 1994, CLIN MICROBIOL REV, V7, P357.
   Mellmann A, 2003, INT J MED MICROBIOL, V293, P359, DOI 10.1078/1438-4221-00271.
   {*}NCCLS, 2003, M24A NCCLS.
   Scharfen  jr J., 2007, ZPRAVY CEM SZU PRAHA, V3, P16.
   Scharfen jr J., 2008, NOKARDIOZA DOPORUCEN.
   Singh NP, 2003, ANN TROP PAEDIATR, V23, P75, DOI 10.1179/000349803125002904.
   Sorrell T. C, 2005, MANDELL DOUGLAS BENN, P2916.
   Urbaskova P., 1998, REZISTENCE BAKTERII.
   van Dam AP, 2005, EUR J CLIN MICROBIOL, V24, P61, DOI 10.1007/s10096-004-1263-9.
   WALLACE RJ, 1990, J CLIN MICROBIOL, V28, P2726.
   Wauters G, 2005, J CLIN MICROBIOL, V43, P2624, DOI 10.1128/JCM.43.6.2624-2628.2005.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Epidemiol. Mikrobiol. Imunol.}},
Doc-Delivery-Number = {{V24XO}},
Unique-ID = {{ISI:000208443300003}},
DA = {{2018-08-13}},
}

@article{ ISI:000272468400013,
Author = {Horne, David J. and Johnson, Catherine O. and Oren, Eyal and Spitters,
   Christopher and Narita, Masahiro},
Title = {{How Soon Should Patients with Smear-Positive Tuberculosis Be Released
   from Inpatient Isolation?}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{2010}},
Volume = {{31}},
Number = {{1}},
Pages = {{78-84}},
Month = {{JAN}},
Abstract = {{OBJECTIVE. In patients with smear-positive pulmonary tuberculosis who
   are hospitalized or reside in congregate settings, guidelines recommend
   airborne infection isolation until sputum smear results are negative.
   Studies have identified factors associated with delayed sputum smear and
   culture conversion in patients with tuberculosis. Because these studies
   did not use methods of survival analysis, estimates of time to sputum
   smear conversion that are based on initial patient characteristics are
   not available. The ability to predict time to sputum smear conversion
   could be useful for programmatic planning and patient counseling.
   METHODS. We performed a cohort study using survival analysis to identify
   factors associated with time to sputum smear and culture conversion. We
   defined the time to sputum smear conversion as the time elapsed from the
   start of treatment to the first date of sustained conversion.
   RESULTS. Ninety-eight patients had sputum smear samples positive for
   acid-fast bacilli. Lower initial smear grade (on 1+ to 4+ scale) and
   absence of cavitation on chest radiograph were associated with earlier
   sputum smear conversion in bivariate analysis. In multiple regression
   analysis, initial smear grade (hazard ratio, 0.45; 95\% confidence
   interval, 0.35-0.57) and drug resistance (hazard ratio, 2.30; 95\%
   confidence interval, 1.08-4.89) remained statistically significant; a
   model comprising only initial smear grade performed almost as well.
   Predictors of sputum culture conversion were similar.
   CONCLUSIONS. Initial smear grade was the strongest predictor of time to
   sputum smear and culture conversion in patients with pulmonary
   tuberculosis and may be a useful predictor for programmatic planning and
   patient counseling.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Horne, DJ (Reprint Author), Univ Washington, Harborview Med Ctr, Sch Med, Div Pulm \& Crit Care Med,Dept Med, 325 9th Ave,Box 359762, Seattle, WA 98104 USA.
   Horne, David J., Univ Washington, Harborview Med Ctr, Sch Med, Div Pulm \& Crit Care Med,Dept Med, Seattle, WA 98104 USA.
   Spitters, Christopher, Univ Washington, Sch Med, Dept Med, Div Allergy \& Infect Dis, Seattle, WA 98104 USA.
   Johnson, Catherine O.; Narita, Masahiro, Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98104 USA.
   Oren, Eyal; Spitters, Christopher; Narita, Masahiro, Publ Hlth Seattle \& King Cty, TB Control Program, Seattle, WA USA.}},
DOI = {{10.1086/649022}},
ISSN = {{0899-823X}},
Keywords-Plus = {{ACID-FAST BACILLI; PULMONARY TUBERCULOSIS; SPUTUM SMEAR; CONVERSION;
   TIME}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{dhorne@u.washington.edu}},
ORCID-Numbers = {{Oren, Eyal/0000-0001-7817-3516}},
Funding-Acknowledgement = {{Firland Foundation; National Institutes of Health, National Heart, Lung,
   and Blood Institute {[}F32HL094031]}},
Funding-Text = {{Firland Foundation and National Institutes of Health, National Heart,
   Lung, and Blood Institute (F32HL094031 to D. J. H.).}},
Cited-References = {{Al-Moamary MS, 1999, CHEST, V116, P726, DOI 10.1378/chest.116.3.726.
   {*}AM THOR SOC CDCP, 2005, AM J RESP CRIT CARE, V1169, P1227.
   {[}Anonymous], 2000, AM J RESP CRIT CARE, V161, P1376.
   Blumberg Henry M, 2003, Am J Respir Crit Care Med, V167, P603.
   Dominguez-Castellano A, 2003, INT J TUBERC LUNG D, V7, P432.
   Fortun J, 2007, J ANTIMICROB CHEMOTH, V59, P794, DOI 10.1093/jac/dkm025.
   Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630.
   Guler M, 2007, INT J CLIN PRACT, V61, P231, DOI 10.1111/j.1742-1241.2006.01131.x.
   HORNE DJ, 2008, AM J RESP CRIT CARE, V177, pA790.
   Hosmer DW, 2008, APPL SURVIVAL ANAL R.
   Iseman MD, 1997, CLIN INFECT DIS, V25, P671, DOI 10.1086/513774.
   KIM TC, 1984, AM REV RESPIR DIS, V129, P264.
   Lienhardt C, 1998, INT J TUBERC LUNG D, V2, P712.
   Mariam DH, 2004, ANTIMICROB AGENTS CH, V48, P1289, DOI 10.1128/AAC.48.4.1289-1294.2004.
   Rieder HL, 1996, TUBERCLE LUNG DIS, V77, P124, DOI 10.1016/S0962-8479(96)90026-X.
   Sepkowitz KA, 2001, EMERG INFECT DIS, V7, P259, DOI 10.3201/eid0702.010222.
   Singla R, 2003, INT J TUBERC LUNG D, V7, P58.
   Telzak EE, 1997, CLIN INFECT DIS, V25, P666, DOI 10.1086/513772.
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930.
   REPORT VERIFIED CASE.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{528SY}},
Unique-ID = {{ISI:000272468400013}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000275791800002,
Author = {Nahrevanian, H. and Esmaeili, B. and Kazemi, M. and Nazem, H. and Amini,
   M.},
Title = {{In Vivo Antimalarial Effects of Iranian Flora Artemisia khorassanica
   against Plasmodium berghei and Pharmacochemistry of its Natural
   Components}},
Journal = {{IRANIAN JOURNAL OF PARASITOLOGY}},
Year = {{2010}},
Volume = {{5}},
Number = {{1}},
Pages = {{6-19}},
Month = {{JAN-MAR}},
Abstract = {{Background: The aim of this study was to evaluate the antimalarial
   effects of Iranian flora Artemisia khorassanica against Plasmodium
   berghei in vivo and pharmacochemistry of its natural components.
   Methods: The aerial parts of Iranian flora A. khorasanica were collected
   at flowering stage from Khorassan Province, northeastern Iran in 2008.
   They were air-dried at room temperature; powder was macerated in
   methanol and the extract defatted in refrigerator, filtered, diluted
   with water, then eluted with n-hexane and finally non-polar components
   were identified through Gas Chromatography and Mass Spectroscopy
   (GC-MS). Toxicity of herbal extracts was assessed on naive NMRI mice,
   and its anti-malarial efficacy was investigated on infected Plasmodium
   berghei animals. This is the first application on A. khorssanica extract
   for treatment of murine malaria. The significance of differences was
   determined by Analysis of Variances (ANOVA) and Student's t-test using
   Graph Pad Prism Software.
   Results: The herbal extract was successfully tested in vivo for its
   anti-plasmodial activity through artemisin composition, which is widely
   used as a standard malaria treatment.
   Conclusion: Although, this study confirmed less anti-malarial effects of
   A. khorssanica against murine malaria in vivo, however there are some
   evidences on reducing pathophysiology by this medication. In
   complementary assay, major components were detected by GC-MS analysis in
   herbal extract including chrysanthenone (7.8\%), palmitic acid (7.4\%)
   and cis-thujone (5.8\%). The most retention indices of the component are
   given as n-eicosane, palmitic acid and n-octadecane.}},
Publisher = {{IRANIAN SCIENTIFIC SOCIETY MEDICAL ENTOMOLOGY}},
Address = {{SCHOOL PUBLIC HEALTH \& INST HEALTH RESEARCH, TEHRAN UNIV MEDICAL
   SCIENCES, P O BOX  6446-14155, TEHRAN, 00000, IRAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Nahrevanian, H (Reprint Author), Pasteur Inst Iran, Dept Parasitol, Tehran, Iran.
   Nahrevanian, H.; Amini, M., Pasteur Inst Iran, Dept Parasitol, Tehran, Iran.
   Esmaeili, B.; Nazem, H., Payame Nour Univ, Tehran Ctr, Tehran, Iran.
   Kazemi, M., Islamic Azad Univ, Dept Appl Chem, Qom Branch, Tehran, Iran.}},
ISSN = {{1735-7020}},
Keywords = {{Artemisia khorassanica; Iran; Malaria; Pharmacochemistry; Plasmodium
   berghei}},
Keywords-Plus = {{ESSENTIAL OIL COMPOSITION; NITRIC-OXIDE; DRUG-RESISTANCE; NONLETHAL
   STRAINS; MASS-SPECTROMETRY; MALARIA; ANNUA; FALCIPARUM; DERIVATIVES;
   EXPRESSION}},
Research-Areas = {{Parasitology}},
Web-of-Science-Categories  = {{Parasitology}},
Author-Email = {{mobcghn@pasteur.ac.ir}},
ResearcherID-Numbers = {{Nahrevanian, Hossein/J-3452-2012
   }},
ORCID-Numbers = {{Nahrevanian, Hossein/0000-0002-7657-7696
   Amini, Massoud/0000-0003-4134-0960}},
Funding-Acknowledgement = {{Department of Parasitology, Pasteur Institute of Iran}},
Funding-Text = {{This work was funded by Department of Parasitology, Pasteur Institute of
   Iran and collaboration with Department of Applied Chemistry, Islamic
   Azad University, Qom Branch, Qom, Iran and Payame Noor University of
   Tehran centre, Iran. We thank Department of Biochemistry, Pasteur
   Institute of Iran for assistance in methodology. The authors declare
   that they have no conflicts of interest.}},
Cited-References = {{Adams RP, 2001, IDENTIFICATION ESSEN, P61.
   Arab HA, 2006, TROP ANIM HEALTH PRO, V38, P497, DOI 10.1007/s11250-006-4390-8.
   Arsenault PR, 2008, CURR MED CHEM, V15, P2886, DOI 10.2174/092986708786242813.
   ASAWAMAHASAKDA W, 1994, J LAB CLIN MED, V123, P757.
   Asgary S, 2008, PHARMAZIE, V63, P394, DOI 10.1691/ph.2008.7742.
   Bagheri R, 2007, Pak J Biol Sci, V10, P810.
   Bhattacharya A, 2008, AM J TROP MED HYG, V78, P721.
   Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192.
   Castilho PC, 2008, PHYTOCHEM ANALYSIS, V19, P329, DOI 10.1002/pca.1053.
   Dascombe MJ, 2003, PARASITE IMMUNOL, V25, P149, DOI 10.1046/j.1365-3024.2003.00618.x.
   David AF, 2004, NAT REV, V3, P509.
   de Ridder S, 2008, J ETHNOPHARMACOL, V120, P302, DOI 10.1016/j.jep.2008.09.017.
   Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813.
   Farzaneh M, 2006, Commun Agric Appl Biol Sci, V71, P1327.
   GU J, 1999, MOL STRUCT THEOCHEM, V459, P103.
   Gu JD, 1999, J PHYS CHEM A, V103, P9364, DOI 10.1021/jp992577c.
   Hardman J.G, 2001, GOODMAN GILMANS PHAR, P1069.
   Haynes RK, 2006, CURR TOP MED CHEM, V6, P509, DOI 10.2174/156802606776743129.
   He SP, 2009, ANAL BIOANAL CHEM, V393, P1297, DOI 10.1007/s00216-008-2527-5.
   Heravi MJ, 2007, J CHROMATOGR A, V1160, P81, DOI 10.1016/j.chroma.2007.05.096.
   HEYWOOD VH, 1977, BIOL CHEM COMPOSITAE, P852.
   Khangholi S., 2008, J BIOL SCI, V11, P934.
   KLAYMAN DL, 1984, J NAT PROD, V47, P715, DOI 10.1021/np50034a027.
   Liu CZ, 2006, APPL MICROBIOL BIOT, V72, P11, DOI 10.1007/s00253-006-0452-0.
   Ma CF, 2007, J CHROMATOGR A, V1150, P50, DOI 10.1016/j.chroma.2006.08.080.
   Maleki Afshin, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P335.
   Martin S. A., 2004, AM J TROP MED HYG, V2, P268.
   Mercereau-Puijalon O, 2003, LANCET, V362, P2035, DOI 10.1016/S0140-6736(03)15146-X.
   Meschnick SR, 1996, MICROBIOL REV, V60, P301.
   Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7.
   MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217.
   MORE CM, 2002, PARASITOL TODAY, V16, P522.
   Morteza-Semnani K, 2005, FLAVOUR FRAG J, V20, P330, DOI 10.1002/ffj.1431.
   Nahrevanian H, 2002, PARASITE IMMUNOL, V24, P471, DOI 10.1046/j.1365-3024.2002.00490.x.
   Nahrevanian H, 2001, PARASITE IMMUNOL, V23, P491, DOI 10.1046/j.1365-3024.2001.00406.x.
   Nahrevanian H, 2007, EXP PARASITOL, V116, P233, DOI 10.1016/j.exppara.2007.01.002.
   Nematollahi F, 2006, J ESSENT OIL RES, V18, P339, DOI 10.1080/10412905.2006.9699106.
   Olliaro P, 1996, JAMA-J AM MED ASSOC, V275, P230, DOI 10.1001/jama.275.3.230.
   Peter I. T, 1998, CURRENT GLOBAL MALAR.
   RECHINGER KH, 1986, COMPOSITAE, P214.
   Rezaeinodehi A, 2008, Pak J Biol Sci, V11, P946.
   Ro DK, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-83.
   Romero MR, 2006, PLANTA MED, V72, P1169, DOI 10.1055/s-2006-947198.
   RUSTAIYAN A, 1989, PHYTOCHEMISTRY, V28, P1535, DOI 10.1016/S0031-9422(00)97784-7.
   Rustaiyan A, 2000, J ESSENT OIL RES, V12, P330, DOI 10.1080/10412905.2000.9699529.
   RUSTAIYAN A, 1987, PHYTOCHEMISTRY, V26, P2307, DOI 10.1016/S0031-9422(00)84708-1.
   RUSTAIYAN A, 1989, PHYTOCHEMISTRY, V28, P2723, DOI 10.1016/S0031-9422(00)98075-0.
   Rustaiyan A, 2000, IR IRAN, V11, P213.
   RUSTAIYAN A, 2009, PHARMACOGN MAG, V4, P1.
   SEFIDKON F, 2000, IRAN J FLAV FRAG, V17, P150.
   Turschner S, 2009, MINI-REV MED CHEM, V9, P206, DOI 10.2174/138955709787316074.
   van Agtmael MA, 1999, TRENDS PHARMACOL SCI, V20, P199, DOI 10.1016/S0165-6147(99)01302-4.
   Vyas N, 2002, ANTIMICROB AGENTS CH, V46, P105, DOI 10.1128/AAC.46.1.105-109.2002.
   Weyerstahl P, 1993, LIEBIGS ANN CHEM, V2, P111.
   Weyerstahl Peter, 1993, Flavour and Fragrance Journal, V8, P139, DOI 10.1002/ffj.2730080304.
   White NJ, 2008, SCIENCE, V320, P330, DOI 10.1126/science.1155165.
   White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7.
   Willoughby JA, 2009, J BIOL CHEM, V284, P2203, DOI 10.1074/jbc.M804491200.
   Yazdanparast R, 2008, VASC PHARMACOL, V48, P32, DOI 10.1016/j.vph.2007.11.003.}},
Number-of-Cited-References = {{59}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Iran. J. Parasitol.}},
Doc-Delivery-Number = {{571YG}},
Unique-ID = {{ISI:000275791800002}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000208403700003,
Author = {Velez-Montoya, Raul and Rascon-Vargas, Dulce and Mieler, William F. and
   Fromow-Guerra, Jans and Morales-Canton, Virgilio},
Title = {{Intravitreal Ampicillin Sodium for Antibiotic-Resistant Endophthalmitis:
   Streptococcus uberis First Human Intraocular Infection Report}},
Journal = {{JOURNAL OF OPHTHALMOLOGY}},
Year = {{2010}},
Abstract = {{Purpose. To describe the clinical characteristics, diagnosis, and
   treatment with intravitreal ampicillin sodium of a postoperative
   endophthalmitis case due to Streptococcus uberis; an environmental
   pathogen commonly seen in mastitis cases of lactating cows. Methods.
   Case Report. A 52-year-old, Hispanic diabetic patient who suddenly
   developed severe pain and severe loss of vision, following vitrectomy.
   Results. The patient was diagnosed with postoperative endophthalmitis
   secondary to a highly resistant strain of Streptococcus uberis that did
   not respond to intravitreal antibiotics. He was treated with an
   air-fluid interchange, anterior chamber washout, intravitreal ampicillin
   sodium (5mg/0.1mL), and silicon oil tamponade (5000 ck). The eye was
   anatomically stabilized, though there was no functional recovery.
   Conclusion. Streptococcus uberis is an uncommon pathogen to the human
   eye, which has unique features that help the strain in developing
   resistance to antibiotics. While treatment with intravitreal ampicillin
   is feasible, there are still concerns about its possible toxicity.}},
Publisher = {{HINDAWI PUBLISHING CORPORATION}},
Address = {{410 PARK AVENUE, 15TH FLOOR, \#287 PMB, NEW YORK, NY 10022 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Velez-Montoya, R (Reprint Author), Associacit Prevent Blindness Mexico IAP, Retina Dept, Mexico City, DF, Mexico.
   Velez-Montoya, Raul; Rascon-Vargas, Dulce; Fromow-Guerra, Jans; Morales-Canton, Virgilio, Associacit Prevent Blindness Mexico IAP, Retina Dept, Mexico City, DF, Mexico.
   Mieler, William F., Univ Illinois, Dept Ophthalmol \& Visual Sci, Chicago, IL 60607 USA.}},
DOI = {{10.1155/2010/169739}},
Article-Number = {{169739}},
ISSN = {{2090-004X}},
EISSN = {{2090-0058}},
Keywords-Plus = {{GENE}},
Research-Areas = {{Research \& Experimental Medicine; Ophthalmology}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental; Ophthalmology}},
Author-Email = {{rvelezmx@yahoo.com}},
ORCID-Numbers = {{Velez-Montoya, Raul/0000-0002-6457-4578
   Fromow-Guerra, Jans/0000-0001-5335-1275}},
Funding-Acknowledgement = {{Asociacion para Evitar la Ceguera Research Fund, in Mexico City}},
Funding-Text = {{The author thank Melanie Soberon for her help in the editing process and
   Virginia Vanzinni-Sago for her assistance in the microbiology
   laboratory. This paper has never been presented in any meeting. The
   authors do not have any economic, proprietary, or financial interest to
   disclose, in the publication of this paper. The paper has been fully
   sponsored and conducted by the Asociacion para Evitar la Ceguera
   Research Fund, in Mexico City. The authors states, that they have full
   control of all primary data, and they agree to allow Journal of
   Ophthalmology to review their data upon request.}},
Cited-References = {{Achard A, 2008, ANTIMICROB AGENTS CH, V52, P2767, DOI 10.1128/AAC.00481-08.
   Anand A R, 2000, Indian J Ophthalmol, V48, P123.
   Bertino JS, 2009, CLIN OPHTHALMOL, V3, P507.
   Duggirala Aparna, 2007, Indian Journal of Ophthalmology, V55, P15.
   Miller D, 2006, ARCH OPHTHALMOL-CHIC, V124, P479, DOI 10.1001/archopht.124.4.479.
   Peyman G. A., 1985, INTRAVITREAL SURG PR.
   Tang CW, 2007, CAN J OPHTHALMOL, V42, P477, DOI 10.3129/canjophthalmol.i07-057.
   Varhimo E, 2007, J BACTERIOL, V189, P5210, DOI 10.1128/JB.00473-07.
   VINE AK, 1995, ARCH OPHTHALMOL-CHIC, V113, P1479.
   West ES, 2005, OPHTHALMOLOGY, V112, P1388, DOI 10.1016/j.ophtha.2005.02.028.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Ophthalmol.}},
Doc-Delivery-Number = {{V24II}},
Unique-ID = {{ISI:000208403700003}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000284805300063,
Author = {Lou, Lin and Zhu, Xiaohang and Xu, Hongyan and Wang, Jianfang and Pei,
   Xinghai and Li, Jianliang},
Book-Group-Author = {{Zhejiang Sci-Tech Univ}},
Title = {{Functional Properties of Hemp Union Fabrics for Home Textiles}},
Booktitle = {{PROCEEDINGS OF THE SECOND INTERNATIONAL CONFERENCE ON ADVANCED TEXTILE
   MATERIALS \& MANUFACTURING TECHNOLOGY}},
Year = {{2010}},
Pages = {{293-297}},
Note = {{2nd International Conference on Advanced Textile Materials \&
   Manufacturing Technology, Zhejiang Sci-Tech Univ, Hangzhou, PEOPLES R
   CHINA, OCT 20-24, 2010}},
Organization = {{Minist Educ China, Key Lab Adv Textile Mat \& Mfg Technol; Zhejiang
   Provincial Key Lab Fiber Mat \& Mfg Technol; Minist Educ China, Engn Res
   Ctr eco-Dyeing \& Finishing Textiles; Textile Engn Inst Zhejiang
   Province}},
Abstract = {{By adjusting the yarn component, blend ratio and weave structure,
   fabrics with hemp fibers achieved good light stability, flexibility,
   pilling resistance, air permeability, antibacterial function, and flame
   retardant function. Those union fabrics were suitable for home textiles,
   such as curtains, sofa cloths, table cloths, etc. The existence of
   modacrylic fiber improved the light stability of the fabric. The fabric
   with sateen weave and with hemp/cotton blended weft yarn had a better
   flexibility. The fabrics with no less than 40\% of hemp fibers in the
   weft yarns had a better pilling resistance, especially when its
   structure was plain weave or twill weave. Hemp fiber contributed to the
   air permeability of the fabric. Sateen fabric had a better air
   permeability than plain or twill fabric. The fabric with hemp fibers had
   good antibacterial function. When its weft yarn had no less than 80\% of
   modacrylic fibers, the fabric met the requirements of flame retardancy.
   The flame retardant ability of the fabric was better when burnt in the
   direction perpendicular to the flame retardant yarns than when burnt
   along those yarns. The sateen fabrics provided a better flame retardant
   stability than plain or twill fabrics.}},
Publisher = {{ZHEJIANG UNIV PRESS}},
Address = {{YUGU ROAD 20,, HANGZHOU, ZHEJIANG 310027, PEOPLES R CHINA}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Zhu, XH (Reprint Author), Zhejiang Sci Tech Univ, 5 2nd St, Hangzhou 310018, Peoples R China.
   Lou, Lin; Zhu, Xiaohang; Xu, Hongyan; Wang, Jianfang; Pei, Xinghai; Li, Jianliang, Zhejiang Sci Tech Univ, Hangzhou 310018, Peoples R China.}},
ISBN = {{978-7-308-07958-7}},
Keywords = {{Hemp fiber; Home textile; Functional application; Aantibacterial; Flame
   retardant}},
Research-Areas = {{Materials Science}},
Web-of-Science-Categories  = {{Materials Science, Textiles}},
Cited-References = {{Yu weidong, 2006, TEXTILE MAT, P155.
   ZHANG JC, 2009, STRUCTURE PROPERTIES, P126.}},
Number-of-Cited-References = {{2}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Doc-Delivery-Number = {{BSL05}},
Unique-ID = {{ISI:000284805300063}},
DA = {{2018-08-13}},
}

@article{ ISI:000272961100005,
Author = {Reed, Nicholas G.},
Title = {{The History of Ultraviolet Germicidal Irradiation for Air Disinfection}},
Journal = {{PUBLIC HEALTH REPORTS}},
Year = {{2010}},
Volume = {{125}},
Number = {{1}},
Pages = {{15-27}},
Month = {{JAN-FEB}},
Abstract = {{Public health concerns such as multi- and extensive drug-resistant
   tuberculosis, bioterrorism, pandemic influenza, and severe acute
   respiratory syndrome have intensified efforts to prevent transmission of
   infections that are completely or partially airborne using environmental
   controls. One such control, ultraviolet germicidal irradiation (UVGI),
   has received renewed interest after decades of underutilization and
   neglect. With renewed interest, however, come renewed questions,
   especially regarding efficacy and safety. There is a long history of
   investigations concluding that, if used properly, UVGI can be safe and
   highly effective in disinfecting the air, thereby preventing
   transmission of a variety of airborne infections. Despite this long
   history, many infection control professionals are not familiar with the
   history of UVGI and how it has, and has not, been used safely and
   effectively. This article reviews that history of UVGI for air
   disinfection, starting with its biological basis, moving to its
   application in the real world, and ending with its current status.}},
Publisher = {{ASSOC SCHOOLS PUBLIC HEALTH}},
Address = {{1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Reed, NG (Reprint Author), MCHB TS OLO, 5158 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA.
   Reed, Nicholas G., USA, Ctr Hlth Promot \& Prevent Med, Laser Opt Radiat Program, Aberdeen Proving Ground, MD USA.}},
DOI = {{10.1177/003335491012500105}},
ISSN = {{0033-3549}},
Keywords-Plus = {{UPPER-ROOM AIR; ULTRA-VIOLET LIGHT; RURAL CENTRAL SCHOOLS; AIRBORNE
   MICROORGANISMS; SERRATIA-MARCESCENS; BACTERICIDAL ACTION;
   RELATIVE-HUMIDITY; BORNE INFECTION; OPERATING-ROOM;
   ENVIRONMENTAL-FACTORS}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{nick.g.reed@us.army.mil}},
Cited-References = {{Alani A, 2001, INT J ENVIRON HEAL R, V11, P219, DOI 10.1080/09603120020047000.
   {[}Anonymous], 2005, MMWR RECOMM REP, V54, P1.
   BAHLKE AM, 1949, AM J PUBLIC HLTH NAT, V39, P1321.
   BANG S, 1903, MITT FINSENS MED LYS, V3, P91.
   BANG S, 1901, MITT FINSENS MED LYS, V2, P1.
   BARENBERG LH, 1942, AEROBIOLOGY, V17, P233.
   Barnard JE, 1903, P R SOC LONDON, V72, P126, DOI 10.1098/rspl.1903.0028.
   Beggs CB, 2006, J AEROSOL SCI, V37, P885, DOI 10.1016/j.jaerosci.2005.08.002.
   Beggs CB, 2002, J AEROSOL SCI, V33, P1681, DOI 10.1016/S0021-8502(02)00117-9.
   Bernstein JA, 2006, J ASTHMA, V43, P255, DOI 10.1080/02770900600616887.
   BEUKERS R, 1960, BIOCHIM BIOPHYS ACTA, V41, P550, DOI 10.1016/0006-3002(60)90063-9.
   Brickner P. W., 2000, J HEALTHCARE SAFETY, V4, P123.
   BROOKS GL, 1942, PUBLICATION AM ASS A, V17, P228.
   BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x.
   BUCHNER H, 1892, CENTRALBLATT BAKTERI, V11, P781.
   Chang D, 2007, J ARCHIT ENG, V13, P152, DOI 10.1061/(ASCE)1076-0431(2007)13:3(152).
   {*}COMM INT ECL, 1935, COMPT REND P CIE SES.
   {*}COMM INT ECL, 2003, 1552003 CIE.
   Coohill Thomas P., 1997, Photochemistry and Photobiology, V65, p123S, DOI 10.1111/j.1751-1097.1997.tb07974.x.
   Council on Physical Therapy, 1943, JAMA-J AM MED ASSOC, V122, P503.
   del Mundo F, 1941, AM J DIS CHILD, V61, P213.
   DOWNES A, 1877, P ROY SOC LONDON, V26, P488, DOI DOI 10.1098/RSPL.1877.0068.
   Downes A, 1878, P ROY SOC LONDON, V28, P199.
   Downes A, 1877, NATURE, V16, P218.
   DUBUY HG, 1948, AM J HYG, V48, P207, DOI 10.1093/oxfordjournals.aje.a119236.
   DUCLAUX E, 1885, ANN CHIMIE PHYSIQU 6, V6, P5.
   DUCLAUX E, 1885, COMPT RENDUS HEBD SE, V37, P508.
   DUCLAUX E, 1885, COMPT RENDUS HEBD SE, V100, P119.
   Dumyahn T, 1999, AM IND HYG ASSOC J, V60, P219, DOI 10.1202/0002-8894(1999)060<0219:COUURA>2.0.CO;2.
   EHRISMANN O., 1932, ZEITSCHR HYG U INFEKTIONSKRANKH, V113, P597, DOI 10.1007/BF02177985.
   Emmons CW, 1939, AM J BOT, V26, P467, DOI 10.2307/2436570.
   Escombe AR, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000043.
   First M., 1999, ASHRAE T, V105, P877.
   First M., 2007, LEUKOS, V3, P181.
   First M, 2007, J OCCUP ENVIRON HYG, V4, P321, DOI 10.1080/15459620701271693.
   First MW, 2005, J OCCUP ENVIRON HYG, V2, P285, DOI 10.1080/1545962059095224.
   FIRST MW, 1999, ASHRAE T, V105, P869.
   FLUGGE C, 1897, Z HYG INFEKTIONSKR, V25, P179.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   Gates FL, 1930, J GEN PHYSIOL, V14, P31, DOI 10.1085/jgp.14.1.31.
   Gates FL, 1929, J GEN PHYSIOL, V13, P249, DOI 10.1085/jgp.13.2.249.
   Gates FL, 1929, J GEN PHYSIOL, V13, P231, DOI 10.1085/jgp.13.2.231.
   Geisler T., 1892, CENTRALBLATT BAKTERI, V11, P161.
   Goldner J L, 1980, Ann N Y Acad Sci, V353, P271, DOI 10.1111/j.1749-6632.1980.tb18930.x.
   Harris FI, 1917, SCIENCE, V46, P318, DOI 10.1126/science.46.1187.318.
   HARSTAD JB, 1954, APPL MICROBIOL, V2, P148.
   HART D, 1960, JAMA-J AM MED ASSOC, V172, P1019, DOI 10.1001/jama.1960.03020100027006.
   HART D, 1936, J THORACIC SURG, V6, P45.
   Henle W, 1942, J PEDIATR-US, V21, P577, DOI 10.1016/S0022-3476(42)80046-3.
   HENRI MME, 1914, C R SEANCES SOC BIOL, V73, P321.
   Hertel E., 1904, Z ALLGEM PHYSL, V4, P1.
   HERTEL E, 1905, Z ALLG PHYSL, V5, P95.
   HIGGONS RA, 1947, NEW YORK STATE J MED, V47, P707.
   Hockberger PE, 2002, PHOTOCHEM PHOTOBIOL, V76, P561, DOI 10.1562/0031-8655(2002)076<0561:AHOUPF>2.0.CO;2.
   Hockberger PE, 2000, J PHOTOCH PHOTOBIO B, V58, P185, DOI 10.1016/S1011-1344(00)00121-4.
   Hollaender A, 1936, J GEN PHYSIOL, V19, P753, DOI 10.1085/jgp.19.5.753.
   Hollaender A, 1944, J BACTERIOL, V48, P447.
   Hollaender A, 1939, J CELL COMPAR PHYSL, V13, P391, DOI 10.1002/jcp.1030130316.
   ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251.
   JARRETT ET, 1948, AM J HYG, V48, P233, DOI 10.1093/oxfordjournals.aje.a119238.
   KETHLEY TW, 1972, ARCH ENVIRON HEALTH, V25, P205, DOI 10.1080/00039896.1972.10666162.
   KINGSTON D, 1962, J HYG-CAMBRIDGE, V60, P341.
   Ko G, 2000, TUBERCLE LUNG DIS, V80, P217, DOI 10.1054/tuld.2000.0249.
   Ko G, 2002, ENVIRON HEALTH PERSP, V110, P95.
   Ko GP, 2001, RISK ANAL, V21, P657, DOI 10.1111/0272-4332.214142.
   KOCH R, 1890, UEBER BAKTERIOLOGISC.
   Kowalski W. J., 2000, QUANTITATIVE MICROBI, V2, P249, DOI DOI 10.1023/A:1013951313398.
   Kowalski W. J., 2000, ASHRAE T 2, V106, P1.
   Kowalski W. J, 2004, IUVA NEWS, V6, P20.
   Kowalski WJ, 2003, HVAC\&R RES, V9, P347, DOI 10.1080/10789669.2003.10391074.
   Kraissl CJ, 1940, ANN SURG, V111, P161, DOI 10.1097/00000658-194002000-00001.
   Kujundzic E, 2007, J ENVIRON ENG SCI, V6, P1, DOI 10.1139/S06-039.
   Lai KM, 2004, APPL ENVIRON MICROB, V70, P2021, DOI 10.1128/AEM.70.4.2021-2027.2004.
   LANGMUIR AD, 1948, AM J HYG, V48, P240, DOI 10.1093/oxfordjournals.aje.a119239.
   Levetin E, 2001, APPL ENVIRON MICROB, V67, P3712, DOI 10.1128/AEM.67.8.3712-3715.2001.
   LIDWELL OM, 1994, J HOSP INFECT, V28, P245, DOI 10.1016/0195-6701(94)90088-4.
   Lowell J D, 1980, Ann N Y Acad Sci, V353, P285, DOI 10.1111/j.1749-6632.1980.tb18931.x.
   Luckiesh M., 1946, APPL GERMICIDAL ERYT.
   Lurie MB, 1944, J EXP MED, V79, P559, DOI 10.1084/jem.79.6.559.
   MACHER JM, 1994, APPL OCCUP ENV HYG, V9, P462.
   Macher JM, 1992, APPL OCCUP ENV HYG, V7, P505.
   MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798.
   McDevitt JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003186.
   MCLEAN RL, 1961, AM REV RESPIR DIS, V83, P36.
   MEMARZEDEH F, 2000, ASSESSING EFFICACY U.
   Menzies D, 2003, LANCET, V362, P1785, DOI 10.1016/S0140-6736(03)14897-0.
   Miller OT, 1955, AM J PUBLIC HEALTH N, V45, P1420, DOI 10.2105/AJPH.45.11.1420.
   Miller SL, 2000, AEROSOL SCI TECH, V33, P274, DOI 10.1080/027868200416259.
   Miller SL, 2002, EFFICACY ULTRAVIOLET.
   MILLER WR, 1948, J INFECT DIS, V82, P86, DOI 10.1093/infdis/82.1.86.
   Nardell E. A., 1988, ARCHIT DESIGN, P296.
   NARDELL EA, 1995, AM J INFECT CONTROL, V23, P156, DOI 10.1016/0196-6553(95)90261-9.
   NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1.
   NARDELL EA, 1994, TUBERCULOSIS CURRENT, P5.
   Nardell EA, 2008, PUBLIC HEALTH REP, V123, P52, DOI 10.1177/003335490812300108.
   Nicas M, 1999, Appl Occup Environ Hyg, V14, P317.
   Noakes CJ, 2006, INDOOR BUILT ENVIRON, V15, P347, DOI 10.1177/1420356X0607353.
   Noakes CJ, 2004, INDOOR BUILT ENVIRON, V13, P477, DOI 10.1177/1420326X04049343.
   Noakes CJ, 2004, J AEROSOL SCI, V35, P489, DOI 10.1016/j.jaerosci.2003.10.011.
   Overholt RH, 1940, J THOR SURG, V9, P520.
   Peccia J, 2001, APPL ENVIRON MICROB, V67, P4225, DOI 10.1128/AEM.67.9.4225-4232.2001.
   Peccia J, 2001, AEROSOL SCI TECH, V35, P728, DOI 10.1080/02786820152546770.
   PERKINS JE, 1947, AM J PUBLIC HLTH NAT, V37, P529.
   PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303.
   Rahn RO, 1999, PHOTOCHEM PHOTOBIOL, V70, P314, DOI 10.1562/0031-8655(1999)070<0314:DORAGN>2.3.CO;2.
   Reed NG, 2009, J OCCUP ENVIRON HYG, V6, P289, DOI 10.1080/15459620902801041.
   RILEY RL, 1972, APPL MICROBIOL, V23, P1113.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P208, DOI 10.1080/00039896.1971.10665834.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1957, AM REV TUBERC PULM, V75, P420.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P551, DOI 10.1080/00039896.1971.10665899.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P200, DOI 10.1080/00039896.1971.10665833.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V23, P35, DOI 10.1080/00039896.1971.10665951.
   Riley RL, 1961, AIRBORNE INFECT TRAN.
   RILEY RL, 1993, PLANT TECHNOLOGY SAF, P25.
   Ritter MA, 2007, J BONE JOINT SURG AM, V89A, P1935, DOI 10.2106/JBJS.F.01037.
   Robertson EC, 1939, AM J DIS CHILD, V58, P1023.
   Robertson EC, 1943, J AMER MED ASSOC, V121, P908, DOI 10.1001/jama.1943.02840120010003.
   ROSENSTERN I, 1948, AM J DIS CHILD, V75, P193.
   Rudnick SN, 2001, AIHAJ, V62, P434, DOI 10.1080/15298660108984645.
   Rudnick SN, 2007, J OCCUP ENVIRON HYG, V4, P352, DOI 10.1080/15459620701298167.
   Sauer LW, 1942, J AMER MED ASSOC, V118, P1271, DOI 10.1001/jama.1942.02830150007003.
   Schafer MP, 2008, INFECT CONT HOSP EP, V29, P1042, DOI 10.1086/591856.
   SCHMARDA LK, 1845, OSTERREICHISCHEN STA, V54, P257.
   Schneiter R, 1944, AM J HYG, V40, P136, DOI 10.1093/oxfordjournals.aje.a118981.
   SETLOW RB, 1966, SCIENCE, V153, P379, DOI 10.1126/science.153.3734.379.
   Sharp DG, 1938, J BACTERIOL, V35, P589.
   Sharp DG, 1940, J BACTERIOL, V39, P535.
   Sommer HE, 1942, J PEDIATR-US, V21, P569, DOI 10.1016/S0022-3476(42)80045-1.
   Stead WW, 1996, INFECT CONT HOSP EP, V17, P11.
   TYNDALL J, 1881, SCIENCE, V2, P478.
   TYNDALL J, 1878, P R SOC LOND, V28, P212.
   {*}US CDCP, 2009, DHHS PUBL.
   VINCENT RL, 1998, MEASUREMENTS OPTICAL, P369.
   Ward HM, 1892, P ROY SOC LONDON, V52, P393.
   Ward HM, 1894, PHILOS T ROY SOC LON, V185, P961.
   WARD HM, 1893, P ROY SOC LONDON, V53, P23.
   WELLS A, 1944, J FRANKLIN I, V238, P185.
   WELLS MW, 1945, JAMA-J AM MED ASSOC, V129, P197, DOI 10.1001/jama.1945.02860370019006.
   WELLS MW, 1950, JAMA-J AM MED ASSOC, V142, P1337, DOI 10.1001/jama.1950.02910350007004.
   Wells W F, 1935, Science, V82, P280, DOI 10.1126/science.82.2125.280-a.
   Wells W. F., 1945, JOUR FRANKLIN INST, V240, P379, DOI 10.1016/0016-0032(45)90534-5.
   Wells W.F., 1955, AIRBORNE CONTAGION A.
   Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789.
   Wells WF, 1940, J FRANKL INST, V229, P347, DOI 10.1016/S0016-0032(40)90873-0.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   WELLS WF, 1936, JAMA-J AM MED ASSOC, V107, P1805.
   WHEELER SM, 1945, AM J PUBLIC HLTH NAT, V35, P457.
   WHISLER B, 1940, IOWA STATE COLL J SC, V14, P215.
   WILLMON TL, 1948, AM J HYG, V48, P227, DOI 10.1093/oxfordjournals.aje.a119237.
   WOODHALL B, 1949, ANN SURG, V129, P820, DOI 10.1097/00000658-194906000-00008.
   Xu P, 2005, ENVIRON SCI TECHNOL, V39, P9656, DOI 10.1021/es0504892.
   Xu P, 2003, ATMOS ENVIRON, V37, P405, DOI 10.1016/S1352-2310(02)00825-7.
   1954, SPEC REP SER MED RES, V283, P1.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{158}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{20}},
Journal-ISO = {{Public Health Rep.}},
Doc-Delivery-Number = {{535IN}},
Unique-ID = {{ISI:000272961100005}},
OA = {{green\_published}},
DA = {{2018-08-13}},
}

@article{ ISI:000272579200009,
Author = {Pinna, Antonio and Usai, Donatella and Sechi, Leonardo A. and Zanetti,
   Stefania and Jesudasan, Nelson C. A. and Thomas, Philip A. and
   Kaliamurthy, Jayaraman},
Title = {{An Outbreak of Post-Cataract Surgery Endophthalmitis Caused by
   Pseudomonas aeruginosa}},
Journal = {{OPHTHALMOLOGY}},
Year = {{2009}},
Volume = {{116}},
Number = {{12}},
Pages = {{2321-2326}},
Month = {{DEC}},
Abstract = {{Objective: Infectious endophthalmitis is among the most serious
   complications of cataract surgery. Gram-negative bacteria, including
   Pseudomonas aeruginosa, are responsible for less than 30\% of cases;
   however, their rapidity of infection and virulence often results in poor
   visual outcome despite prompt antibiotic treatment. The purpose of this
   study was to investigate an outbreak of post-cataract surgery P.
   aeruginosa endophthalmitis in India.
   Design: Hospital-based case series.
   Participants: Twenty patients with acute postoperative enclophthalmitis
   who underwent cataract surgery at one of the peripheral centers of
   Joseph Eye Hospital, Tiruchirapalli, Tamil Nadu, India, from February 23
   to April 2, 2008.
   Interventions: Vitreous aspirates and environmental surveillance
   specimens were inoculated for culture. Antibiotic susceptibility testing
   was performed by agar diffusion method. Polymerase chain reaction (PCR)
   with enterobacterial repetitive intergenic consensus (ERIC) primers
   (ERIC-PCR) was used to establish the clonal relationship between
   clinical and environmental isolates.
   Main Outcome Measures: Post-cataract surgery P. aeruginosa
   endophthalmitis.
   Results: Pseudomonas aeruginosa was isolated from 20 eyes with
   postoperative enclophthalmitis, the phacoemulsifier's internal tubes,
   the povidone-iodine solution, and the operating theater air-conditioning
   system. All strains were multidrug-resistant to cefazolin,
   chloramphenicol, tetracycline, aminoglycosides, and fluoro-quinolones;
   conversely, most of them were susceptible to polymyxin B. Polymerase
   chain reaction with enterobacterial repetitive intergenic consensus
   primers disclosed 2 major clusters: six genetically identical clinical
   isolates shared 94\% of similarity with the air-conditioning isolate; 11
   other clinical isolates had 88\% of similarity with the former strain.
   Despite the prompt use of intravitreal antibiotics, 10 patients had
   evisceration or phthisis of the affected eye.
   Conclusions: The outcome of cataract surgery-related P. aeruginosa
   endophthalmitis is poor. The detection of multidrug-resistant isolates
   is a serious problem, jeopardizing an appropriate choice of treatment.
   Polymerase chain reaction with enterobacterial repetitive intergenic
   consensus results strongly suggest that the main source of infection in
   this outbreak was the contaminated air-conditioning system. Polymerase
   chain reaction with enterobacterial repetitive intergenic consensus is
   an inexpensive, fast, reproducible, and discriminatory DNA typing tool
   for effective epidemiologic surveillance of clinical and environmental
   isolates of P. aeruginosa.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pinna, A (Reprint Author), Univ Sassari, Inst Ophthalmol, Viale San Pietro 43 A, I-07100 Sassari, Italy.
   Pinna, Antonio, Univ Sassari, Inst Ophthalmol, I-07100 Sassari, Italy.
   Usai, Donatella; Sechi, Leonardo A.; Zanetti, Stefania, Univ Sassari, Dept Biomed Sci, Sect Expt \& Clin Microbiol, I-07100 Sassari, Italy.
   Jesudasan, Nelson C. A.; Thomas, Philip A.; Kaliamurthy, Jayaraman, Joseph Eye Hosp, Inst Ophthalmol, Dept Microbiol, Tiruchchirappalli, Tamil Nadu, India.}},
DOI = {{10.1016/j.ophtha.2009.06.004}},
ISSN = {{0161-6420}},
Keywords-Plus = {{CONTACT-LENS WEAR; BACTERIAL ENDOPHTHALMITIS; CORNEAL ULCERS; KERATITIS;
   CIPROFLOXACIN; FLUOROQUINOLONES; PHACOEMULSIFIER; ASPERGILLOSIS;
   CONSTRUCTION; ANTIBIOTICS}},
Research-Areas = {{Ophthalmology}},
Web-of-Science-Categories  = {{Ophthalmology}},
Author-Email = {{apinna@uniss.it}},
ORCID-Numbers = {{Pinna, Antonio/0000-0003-3052-2662
   sechi, leonardo antonio/0000-0003-0566-2049}},
Cited-References = {{Aaberg TM, 1998, OPHTHALMOLOGY, V105, P1004, DOI 10.1016/S0161-6420(98)96000-6.
   Alexandrakis G, 2000, OPHTHALMOLOGY, V107, P1497, DOI 10.1016/S0161-6420(00)00179-2.
   American Institute of Architects Committee on Architecture for Health, 1993, GUID CONSTR EQ HOSP, P50.
   Arsan AK, 1996, J CATARACT REFR SURG, V22, P1116, DOI 10.1016/S0886-3350(96)80128-3.
   Boks T, 2006, BRIT J OPHTHALMOL, V90, P1094, DOI 10.1136/bjo.2006.094060.
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P491.
   Ciulla TA, 2002, OPHTHALMOLOGY, V109, P13, DOI 10.1016/S0161-6420(01)00899-5.
   CRAVEN DE, 1981, NEW ENGL J MED, V305, P621, DOI 10.1056/NEJM198109103051106.
   Cruciani M, 1998, CLIN INFECT DIS, V26, P330, DOI 10.1086/516292.
   Dharan S, 2002, J HOSP INFECT, V51, P79, DOI 10.1053/jhin.2002.1217.
   Eifrig CWG, 2003, OPHTHALMOLOGY, V110, P1714, DOI 10.1016/S0161-6420(03)00572-4.
   Fridkin SK, 1996, CLIN INFECT DIS, V22, P222, DOI 10.1093/clinids/22.2.222.
   Garg P, 1999, OPHTHALMOLOGY, V106, P1319, DOI 10.1016/S0161-6420(99)00717-4.
   Hoffmann KK, 2002, ARCH OPHTHALMOL-CHIC, V120, P90.
   IRVINE WD, 1992, ARCH OPHTHALMOL-CHIC, V110, P1450, DOI 10.1001/archopht.1992.01080220112031.
   Kenchappa Prashanth, 2005, Ann Clin Microbiol Antimicrob, V4, P19, DOI 10.1186/1476-0711-4-19.
   Kowalski RP, 2003, AM J OPHTHALMOL, V136, P500, DOI 10.1016/S002-9394(03)00294-0.
   Kresloff MS, 1998, SURV OPHTHALMOL, V43, P193, DOI 10.1016/S0039-6257(98)00036-8.
   LENTINO JR, 1982, AM J EPIDEMIOL, V116, P430, DOI 10.1093/oxfordjournals.aje.a113427.
   Lutz BD, 2003, CLIN INFECT DIS, V37, P786, DOI 10.1086/377537.
   Malhotra S, 2008, INDIAN J OPHTHALMOL, V56, P157, DOI 10.4103/0301-4738.39126.
   Mateos I, 2006, INFECT CONT HOSP EP, V27, P1249, DOI 10.1086/508838.
   Mather R, 2002, AM J OPHTHALMOL, V133, P463, DOI 10.1016/S0002-9394(02)01334-X.
   MAYO MS, 1986, J CLIN MICROBIOL, V24, P372.
   {*}NAT COMM CLIN LAB, 1988, M2T4 NAT COMM CLIN L.
   OBRIEN TP, 1996, OCULAR INFECT IMMUNI, P200.
   Obritsch MD, 2004, ANTIMICROB AGENTS CH, V48, P4606, DOI 10.1128/AAC.48.12.4606-4610.2004.
   Ohl CA, 2005, HARRISONS PRINCIPLES, P889.
   Pinna A, 2001, OPHTHALMOLOGY, V108, P1830, DOI 10.1016/S0161-6420(01)00723-0.
   Pinna A, 2008, CORNEA, V27, P320, DOI 10.1097/ICO.0b013e31815c5a3f.
   Rhee MK, 2004, AM J OPHTHALMOL, V138, P226, DOI 10.1016/j.ajo.2004.03.016.
   Streifel AJ, 2000, HEATING PIPING AIR C, V72, P28.
   SWADDIWUDHIPONG W, 1995, T ROY SOC TROP MED H, V89, P288, DOI 10.1016/0035-9203(95)90545-6.
   Syrmis MW, 2004, J MED MICROBIOL, V53, P1089, DOI 10.1099/jmm.0.45611-0.
   Tabbara KF, 1998, OPHTHALMOLOGY, V105, P522, DOI 10.1016/S0161-6420(98)93037-8.
   VINE AK, 1995, ARCH OPHTHALMOL-CHIC, V113, P1479.
   Zaluski S, 1999, J CATARACT REFR SURG, V25, P540, DOI 10.1016/S0886-3350(99)80052-2.
   Zavascki AP, 2007, J ANTIMICROB CHEMOTH, V60, P1206, DOI 10.1093/jac/dkm357.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ophthalmology}},
Doc-Delivery-Number = {{530HE}},
Unique-ID = {{ISI:000272579200009}},
DA = {{2018-08-13}},
}

@article{ ISI:000272153600001,
Author = {Morfill, G. E. and Kong, M. G. and Zimmermann, J. L.},
Title = {{Focus on Plasma Medicine}},
Journal = {{NEW JOURNAL OF PHYSICS}},
Year = {{2009}},
Volume = {{11}},
Month = {{NOV 26}},
Abstract = {{`Plasma Healthcare' is an emerging interdisciplinary research topic of
   rapidly growing importance, exploring considerable opportunities at the
   interface of plasma physics, chemistry and engineering with life
   sciences. Some of the scientific discoveries reported so far have
   already demonstrated clear benefits for healthcare in areas of medicine,
   food safety, environmental hygiene, and cosmetics. Examples include
   ongoing studies of prion inactivation, chronic wound treatment and
   plasma-mediated cancer therapy. Current research ranges from basic
   physical processes, plasma chemical design, to the interaction of
   plasmas with (i) eukaryotic (mammalian) cells; (ii) prokaryotic
   (bacteria) cells, viruses, spores and fungi; (iii) DNA, lipids, proteins
   and cell membranes; and (iv) living human, animal and plant tissues in
   the presence of biofluids. Of diverse interests in this new field is the
   need for hospital disinfection, in particular with respect to the
   alarming increase in bacterial resistance to antibiotics, the
   concomitant needs in private practices, nursing homes etc, the
   applications in personal hygiene-and the enticing possibility to
   `design' plasmas as possible pharmaceutical products, employing ionic as
   well as molecular agents for medical treatment. The `delivery' of the
   reactive plasma agents occurs at the gaseous level, which means that
   there is no need for a carrier medium and access to the treatment
   surface is optimal. This focus issue provides a close look at the
   current state of the art in Plasma Medicine with a number of forefront
   research articles as well as an introductory review.}},
Publisher = {{IOP PUBLISHING LTD}},
Address = {{DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Morfill, GE (Reprint Author), Max Planck Inst Extraterr Phys, Postfach 1312, D-85741 Garching, Germany.
   Morfill, G. E.; Zimmermann, J. L., Max Planck Inst Extraterr Phys, D-85741 Garching, Germany.
   Kong, M. G., Univ Loughborough, Ctr Biol Engn, Loughborough LE11 3TU, Leics, England.}},
DOI = {{10.1088/1367-2630/11/11/115011}},
Article-Number = {{115011}},
ISSN = {{1367-2630}},
Keywords-Plus = {{DIELECTRIC BARRIER DISCHARGE; ATMOSPHERIC-PRESSURE; INACTIVATION;
   STERILIZATION; SPORES; DECONTAMINATION; MECHANISMS; APOPTOSIS; TORCH;
   AIR}},
Research-Areas = {{Physics}},
Web-of-Science-Categories  = {{Physics, Multidisciplinary}},
Author-Email = {{gem@mpe.mpg.de
   m.g.kong@lboro.ac.uk}},
ResearcherID-Numbers = {{kong, michael/I-1574-2014}},
Cited-References = {{Abramzon N, 2006, IEEE T PLASMA SCI, V34, P1304, DOI 10.1109/TPS.2006.877515.
   Anderson KM, 1999, MED HYPOTHESES, V52, P451, DOI 10.1054/mehy.1997.0521.
   Baxter HC, 2006, IEEE T PLASMA SCI, V34, P1337, DOI 10.1109/TPS.2006.878387.
   Baxter HC, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115028.
   Bayliss DL, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115024.
   Boudam MK, 2006, J PHYS D APPL PHYS, V39, P3494, DOI 10.1088/0022-3727/39/16/S07.
   BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3.
   Cao Z, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3069276.
   Deng XT, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2103394.
   Deng XT, 2006, IEEE T PLASMA SCI, V34, P1310, DOI 10.1109/TPS.2006.877739.
   Dobrynin D, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115020.
   Foest R, 2005, PLASMA PHYS CONTR F, V47, pB525, DOI 10.1088/0741-3335/47/12B/S38.
   Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154.
   Fridman G, 2007, PLASMA CHEM PLASMA P, V27, P163, DOI 10.1007/s11090-007-9048-4.
   Fridman G, 2006, PLASMA CHEM PLASMA P, V26, P425, DOI 10.1007/s11090-006-9024-4.
   GRAVES DB, 2007, J APPL PHYS, V101, P7.
   Heise M, 2004, PLASMAS POLYM, V9, P23, DOI 10.1023/B:PAPO.0000039814.70172.c0.
   Helmke A, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115025.
   Iza F, 2008, PLASMA PROCESS POLYM, V5, P322, DOI 10.1002/ppap.200700162.
   Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004.
   Kampf G, 2006, INFECT CONT HOSP EP, V27, P996, DOI 10.1086/507293.
   Kong MG, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115012.
   Kudritzki RP, 2008, ASTROPHYS J, V681, P269, DOI 10.1086/588647.
   Kuo SP, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115016.
   Kylian O, 2009, PLASMA PROCESS POLYM, V6, P255, DOI 10.1002/ppap.200800199.
   Laroussi M, 2006, IEEE T PLASMA SCI, V34, P1253, DOI 10.1109/TPS.2006.876502.
   Leduc M, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115021.
   Lee HJ, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115026.
   Lee MH, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115022.
   Lu XP, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2912524.
   Martines E, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115014.
   Moisan M, 2002, PURE APPL CHEM, V74, P349, DOI 10.1351/pac200274030349.
   Morfill GE, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115019.
   {*}NAT RES COUNC, 2007, PLASM SCI ADV KNOWL.
   Nie QY, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115015.
   Nosenko T, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115013.
   Pompl R, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115023.
   Rossi F, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115017.
   Sato T, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115018.
   Shimizu T, 2008, PLASMA PROCESS POLYM, V5, P577, DOI 10.1002/ppap.200800021.
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304.
   Singh MK, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115027.
   Tarasenko O, 2006, IEEE T PLASMA SCI, V34, P1281, DOI 10.1109/TPS.2006.878378.
   Vleugels M, 2005, IEEE T PLASMA SCI, V33, P824, DOI 10.1109/TPS.2005.844524.
   Walsh JL, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2817965.
   Walsh JL, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2982497.
   Walsh JL, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2825576.
   {*}WHO, 2006, WHO GUID HAND HYG.
   Yu H, 2006, J APPL MICROBIOL, V101, P1323, DOI 10.1111/j.1365-2672.2006.03033.x.}},
Number-of-Cited-References = {{49}},
Times-Cited = {{131}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{69}},
Journal-ISO = {{New J. Phys.}},
Doc-Delivery-Number = {{524OW}},
Unique-ID = {{ISI:000272153600001}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000273203300028,
Author = {Rinner, Beate and Li, Zeng Xia and Haas, Helga and Siegl, Veronika and
   Sturm, Sonja and Stuppner, Hermann and Pfragner, Roswitha},
Title = {{Antiproliferative and Pro-apoptotic Effects of Uncaria tomentosa in
   Human Medullary Thyroid Carcinoma Cells}},
Journal = {{ANTICANCER RESEARCH}},
Year = {{2009}},
Volume = {{29}},
Number = {{11}},
Pages = {{4519-4528}},
Month = {{NOV}},
Abstract = {{Medullary thyroid carcinoma (MTC), a rare calcitonin-producing tumor, is
   derived from parafollicular cells of the thyroid and is characterized by
   constitutive Bcl-2 overexpression. The tumor is relatively insensitive
   to radiation therapy as well as conventional chemotherapy. To date, the
   only curative treatment is the early and complete surgical removal of
   all neoplastic tissue. In this study, the antiproliferative and
   pro-apoptotic effects of fractions obtained from Uncaria tomentosa
   (Willd.) DC, commonly known as una de gato or cat's claw were
   investigated. Cell growth of MTC cells as well as enzymatic activity of
   mitochondrial dehydrogenase was markedly inhibited after treatment with
   different fractions of the plant. Furthermore, there was air increase in
   the expressions of caspase-3 and -7 and poly(ADP-ribose) polymerase
   (PARP) fraction, while bcl-2 overexpression remained constant. In
   particular, the alkaloids isopterpodine and pteropodine of U. tomentosa
   exhibited a significant pro-apoptotic effect on MTC cells, whereas the
   alkaloid-poor fraction inhibited cell proliferation but did not show any
   pro-apoptotic effects. These promising results indicate the
   growth-restraining and apoptotic potential of plant extracts against
   neuroendocrine tumors, which may add to existing therapies for cancer.}},
Publisher = {{INT INST ANTICANCER RESEARCH}},
Address = {{EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pfragner, R (Reprint Author), Med Univ Graz, Dept Pathophysiol \& Immunol, Ctr Mol Med, Inst Pathophysiol \& Immunol, Heinrichstr 31, A-8010 Graz, Austria.
   Pfragner, Roswitha, Med Univ Graz, Dept Pathophysiol \& Immunol, Ctr Mol Med, Inst Pathophysiol \& Immunol, A-8010 Graz, Austria.
   Rinner, Beate, Med Univ Graz, Core Facil Flow Cytometry, Med Res Ctr, A-8010 Graz, Austria.
   Li, Zeng Xia, Fudan Univ, Shanghai Med Sch, Dept Biochem \& Mol Biol, Shanghai 200433, Peoples R China.
   Sturm, Sonja; Stuppner, Hermann, Univ Innsbruck, Inst Pharm, Ctr Mol Biosci, A-6020 Innsbruck, Austria.}},
ISSN = {{0250-7005}},
Keywords = {{Uncaria tomentosa; alkaloids; drug resistance; apoptosis; medullary
   thyroid carcinoma}},
Keywords-Plus = {{LEUKEMIA-CELLS; OXINDOLE ALKALOIDS; MISTLETOE EXTRACTS; CLINICAL-TRIALS;
   WILLD. DC; IN-VITRO; CANCER; LINES; PROLIFERATION; MANAGEMENT}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{roswitha.pfragner@medunigraz.at}},
Funding-Acknowledgement = {{Austrian Cancer Aid/Styria {[}EF01/2004]; Franz Lanyar Foundation
   {[}334]}},
Funding-Text = {{This research was supported by the Austrian Cancer Aid/Styria
   (EF01/2004) and the Franz Lanyar Foundation \#334.}},
Cited-References = {{Akesson C, 2003, INT IMMUNOPHARMACOL, V3, P1889, DOI 10.1016/j.intimp.2003.07.001.
   AQUINO R, 1991, J NAT PROD, V54, P453, DOI 10.1021/np50074a016.
   Bacher N, 2006, BRIT J HAEMATOL, V132, P615, DOI 10.1111/j.1365-2141.2005.05907.x.
   Beuth J, 2006, ANTICANCER RES, V26, P4451.
   Cheng AC, 2007, FOOD CHEM TOXICOL, V45, P2206, DOI 10.1016/j.fct.2007.05.016.
   De Martino L, 2006, J ETHNOPHARMACOL, V107, P91, DOI 10.1016/j.jep.2006.02.013.
   Efferth T, 2002, BLOOD CELL MOL DIS, V28, P160, DOI 10.1006/bcmd.2002.0492.
   Ernst E, 2003, INT J CANCER, V107, P262, DOI 10.1002/ijc.11386.
   Prado EG, 2007, PHYTOMEDICINE, V14, P280, DOI 10.1016/j.phymed.2006.12.023.
   Gonzales Gustavo F., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P429, DOI 10.2174/187152006778226486.
   Hardin Sonya R, 2007, Complement Ther Clin Pract, V13, P25, DOI 10.1016/j.ctcp.2006.10.003.
   Heitzman ME, 2005, PHYTOCHEMISTRY, V66, P5, DOI 10.1016/j.phytochem.2004.10.022.
   Horneber MA, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003297.PUB2.
   Kaczirek K, 2004, J CLIN ENDOCR METAB, V89, P2397, DOI 10.1210/jc.2003-031314.
   Keplinger K, 1999, J ETHNOPHARMACOL, V64, P23.
   Kienle GS, 2007, EUR J MED RES, V12, P103.
   Lampronti I, 2003, PHYTOMEDICINE, V10, P300, DOI 10.1078/094471103322004794.
   LEONG SS, 1981, FIELD ED ITALIA, P95.
   Li ZX, 2007, BIOL-TARGETS THER, V1, P455.
   Li ZX, 2008, ANTICANCER RES, V28, P2705.
   MARSH DJ, 1995, THYROID, V5, P407, DOI 10.1089/thy.1995.5.407.
   Moley JF, 2007, WORLD J SURG, V31, P946, DOI 10.1007/s00268-006-0846-2.
   Mur E, 2002, J RHEUMATOL, V29, P678.
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v.
   Orlandi F, 2001, ENDOCR-RELAT CANCER, V8, P135, DOI 10.1677/erc.0.0080135.
   Pfragner R, 1998, J NEUROCYTOL, V27, P175, DOI 10.1023/A:1006959625068.
   PFRAGNER R, 1990, CANCER RES, V50, P4160.
   Pfragner R, 2004, CULTURE HUMAN TUMOR, P373.
   Pryme IF, 2006, HISTOL HISTOPATHOL, V21, P285, DOI 10.14670/HH-21.285.
   Pusztai A, 2008, FRONT BIOSCI-LANDMRK, V13, P1130, DOI 10.2741/2750.
   Reinhard KH, 1999, J ALTERN COMPLEM MED, V5, P143, DOI 10.1089/acm.1999.5.143.
   Rinner B, 2004, ANTICANCER RES, V24, P495.
   Riva L, 2001, ANTICANCER RES, V21, P2457.
   Ruan Wen-jing, 2006, J Zhejiang Univ Sci B, V7, P1006, DOI 10.1631/jzus.2006.B1006.
   Stadler G, 2007, CYTOTHERAPY, V9, P488, DOI 10.1080/14653240701385836.
   STUPPNER H, 1992, CHROMATOGRAPHIA, V34, P597, DOI 10.1007/BF02269869.
   Tang W, 1992, CHINESE DRUGS PLANT, P613.
   TANSUWANWONG S, 2006, PAC J CANC PREV, V7, P641.
   Turan Nevruz, 2006, J Exp Ther Oncol, V6, P31.
   YANG KP, 1991, ANTICANCER RES, V11, P1065.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Anticancer Res.}},
Doc-Delivery-Number = {{538SC}},
Unique-ID = {{ISI:000273203300028}},
DA = {{2018-08-13}},
}

@article{ ISI:000269654500004,
Author = {Venglovsky, Jan and Sasakova, Nada and Placha, Iveta},
Title = {{Pathogens and antibiotic residues in animal manures and hygienic and
   ecological risks related to subsequent land application}},
Journal = {{BIORESOURCE TECHNOLOGY}},
Year = {{2009}},
Volume = {{100}},
Number = {{22}},
Pages = {{5386-5391}},
Month = {{NOV}},
Note = {{International Workshop on Livestock Waste Treatment Systems of the
   Future - A Challenge to Environment Quality, Food Safety and
   Sustainability, Florence, SC, APR 02-04, 2008}},
Organization = {{Org Econ Co-Operat \& Dev}},
Abstract = {{The practice of spreading of livestock wastes onto land used for the
   production of food or animal feeds is widely regarded as the least
   environmentally damaging disposal method, however, the practice is still
   fraught with pitfalls such as N pollution of air and water and
   significant microbiological risks. Therefore this paper focuses on some
   of the latest developments that provide new insights into the
   microbiological safety of animal manures, the related treatment options
   and the spreading the products onto land. In conclusion the paper
   stresses the need to fully address issues concerning environmental
   contamination and transmission of antimicrobial-resistant bacteria
   through livestock manure, improve current environmental regulations
   regarding manure management practice and coordination of research
   activities and dissemination of technical information. (C) 2009 Elsevier
   Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Venglovsky, J (Reprint Author), Univ Vet Med, Komenskeho 73, Kosice 04001, Slovakia.
   Venglovsky, Jan; Sasakova, Nada, Univ Vet Med, Kosice 04001, Slovakia.
   Placha, Iveta, Slovak Acad Sci, Inst Anim Physiol, Kosice 04001, Slovakia.}},
DOI = {{10.1016/j.biortech.2009.03.068}},
ISSN = {{0960-8524}},
Keywords = {{Animal manure; Pathogens; Survival; Antibiotics; Environmental risks}},
Keywords-Plus = {{CRYPTOSPORIDIUM-PARVUM OOCYSTS; ESCHERICHIA-COLI O157-H7; PIG SLURRY;
   SALMONELLA-TYPHIMURIUM; ASCARIS-SUUM; INDICATOR MICROORGANISMS;
   LIVESTOCK WASTES; BOVINE MANURE; SOIL; SURVIVAL}},
Research-Areas = {{Agriculture; Biotechnology \& Applied Microbiology; Energy \& Fuels}},
Web-of-Science-Categories  = {{Agricultural Engineering; Biotechnology \& Applied Microbiology; Energy
   \& Fuels}},
Author-Email = {{jan@venglovsky.com}},
ResearcherID-Numbers = {{Ducey, Thomas/A-6493-2011
   }},
ORCID-Numbers = {{Placha, Iveta/0000-0002-8724-0159}},
Cited-References = {{Aga DS, 2003, ANALYST, V128, P658, DOI 10.1039/b301630g.
   Albihn A, 2007, LIVEST SCI, V112, P232, DOI 10.1016/j.livsci.2007.09.015.
   Baguer AJ, 2000, CHEMOSPHERE, V40, P751, DOI 10.1016/S0045-6535(99)00449-X.
   BERNAL MP, 1993, BIORESOURCE TECHNOL, V43, P35, DOI 10.1016/0960-8524(93)90079-Q.
   Burton C. H., 2003, MANURE MANAGEMENT TR.
   Chantigny MH, 2004, SOIL SCI SOC AM J, V68, P306, DOI 10.2136/sssaj2004.3060.
   Christian T, 2003, ACTA HYDROCH HYDROB, V31, P36, DOI 10.1002/aheh.200390014.
   Cools D, 2001, APPL SOIL ECOL, V17, P53, DOI 10.1016/S0929-1393(00)00133-5.
   D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800.
   De Liguoro M, 2003, CHEMOSPHERE, V52, P203, DOI 10.1016/S0045-6535(03)00284-4.
   Duriez P, 2007, APPL ENVIRON MICROB, V73, P5486, DOI 10.1128/AEM.00218-07.
   Fayer R, 1996, APPL ENVIRON MICROB, V62, P1431.
   Gessel PD, 2004, APPL SOIL ECOL, V25, P237, DOI 10.1016/j.apsoil.2003.09.008.
   Himathongkham S, 1999, FEMS MICROBIOL LETT, V178, P251, DOI 10.1016/S0378-1097(99)00364-X.
   Hirsch R, 1999, SCI TOTAL ENVIRON, V225, P109, DOI 10.1016/S0048-9697(98)00337-4.
   Hutchison ML, 2005, J APPL MICROBIOL, V99, P58, DOI 10.1111/j.1365-2672.2005.02585.x.
   Islam M, 2004, APPL ENVIRON MICROB, V70, P2497, DOI 10.1128/AEM.70.4.2497-2502.2004.
   JAMIESON RC, 2002, CAN BIOSYS ENG, V44.
   Jenkins MB, 1998, APPL ENVIRON MICROB, V64, P784.
   Jenkins MB, 1999, APPL ENVIRON MICROB, V65, P1998.
   JONES PW, 1980, BRIT VET J, V136, P529.
   Kato S, 2002, J PARASITOL, V88, P718, DOI 10.1645/0022-3395(2002)088{[}0718:EOFTEO]2.0.CO;2.
   Khachatourians GG, 1998, CAN MED ASSOC J, V159, P1129.
   Kuczynska E, 2005, APPL ENVIRON MICROB, V71, P6394, DOI 10.1128/AEM.71.10.6394-6397.2005.
   Kudva IT, 1998, APPL ENVIRON MICROB, V64, P3166.
   Kumar K, 2004, J ENVIRON QUAL, V33, P250, DOI 10.2134/jeq2004.0250.
   Mawdsley JL, 1996, BIOL FERT SOILS, V23, P215.
   MAWDSLEY JL, 1995, APPL SOIL ECOL, V1, P1.
   McEwen SA, 2002, CLIN INFECT DIS, V34, pS93, DOI 10.1086/340246.
   McEwen SA, 2006, ANIM BIOTECHNOL, V17, P239, DOI 10.1080/10495390600957233.
   McGee P, 2001, LETT APPL MICROBIOL, V32, P152, DOI 10.1046/j.1472-765x.2001.00877.x.
   Mitscherlich E., 1984, MICROBIAL SURVIVAL E.
   Nicholson FA, 2005, BIORESOURCE TECHNOL, V96, P135, DOI {[}10.1016/j.biortech.2004.02.030, 10.1016/j.biotech.2004.02.030].
   NICHOLSON FA, 2007, WATER ENVIRON J, V3, P155.
   Olson ME, 2004, TRENDS PARASITOL, V20, P185, DOI 10.1016/j.pt.2004.01.015.
   OLSON ME, 2003, HUMAN ANIMAL PATHOGE.
   Paluszak Z, 2002, MED WETER, V58, P899.
   Papajova I, 2002, HELMINTHOLOGIA, V39, P77.
   Pecson BM, 2006, APPL ENVIRON MICROB, V72, P7864, DOI 10.1128/AEM.01983-06.
   Pell AN, 1997, J DAIRY SCI, V80, P2673, DOI 10.3168/jds.S0022-0302(97)76227-1.
   Placha I, 2001, J APPL MICROBIOL, V91, P1036, DOI 10.1046/j.1365-2672.2001.01471.x.
   Plachy P, 1996, VET MED-CZECH, V41, P255.
   POLPRASERT C, 1981, WATER RES, V15, P31, DOI 10.1016/0043-1354(81)90179-2.
   Sengelov G, 2003, ENVIRON INT, V28, P587, DOI 10.1016/S0160-4120(02)00084-3.
   Swartz MN, 2002, CLIN INFECT DIS, V34, pS111, DOI 10.1086/340248.
   {*}USDA, 1997, CONF AN MAN NUTR DAT.
   Vanotti MB, 2007, BIORESOURCE TECHNOL, V98, P3184, DOI 10.1016/j.biortech.2006.07.009.
   Vanotti MB, 2005, BIORESOURCE TECHNOL, V96, P209, DOI {[}10.1016/j.biortech.2004.05.010, 10.1016/j.biotech.2004.05.010].
   Varadyova Z, 2001, SMALL RUMINANT RES, V40, P155, DOI 10.1016/S0921-4488(01)00170-5.
   Venglovsky J, 2006, LIVEST SCI, V102, P197, DOI 10.1016/j.livsci.2006.03.017.
   Watabe M, 2003, LETT APPL MICROBIOL, V36, P208, DOI 10.1046/j.1472-765X.2003.01293.x.
   WHO, 2003, EM ISS WAT INF DIS.
   2005, HUMANURE HDB, pCH7.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{66}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{56}},
Journal-ISO = {{Bioresour. Technol.}},
Doc-Delivery-Number = {{492KM}},
Unique-ID = {{ISI:000269654500004}},
DA = {{2018-08-13}},
}

@article{ ISI:000269654500006,
Author = {Topp, E. and Scott, A. and Lapen, D. R. and Lyautey, E. and Duriez, P.},
Title = {{Livestock waste treatment systems for reducing environmental exposure to
   hazardous enteric pathogens: Some considerations}},
Journal = {{BIORESOURCE TECHNOLOGY}},
Year = {{2009}},
Volume = {{100}},
Number = {{22, SI}},
Pages = {{5395-5398}},
Month = {{NOV}},
Note = {{International Workshop on Livestock Waste Treatment Systems of the
   Future - A Challenge to Environment Quality, Food Safety and
   Sustainability, Florence, SC, APR 02-04, 2008}},
Organization = {{Org Econ Co-Operat \& Dev}},
Abstract = {{intensive livestock production systems produce significant quantities of
   excreted material that must be managed to protect water, air, and crop
   quality. Many jurisdictions mandate how livestock wastes are managed to
   protect adjacent water quality from microbial and chemical contaminants
   that pose an environmental and human health challenge. Here, we consider
   innovative livestock waste treatment systems in the context of
   multi-barrier strategies for protecting water quality from agricultural
   contamination. Specifically, we consider some aspects of how enteric
   bacterial populations can evolve during manure storage, how their fate
   following land application of manure can vary according to manure
   composition, and finally the challenge of distinguishing enteric
   pathogens of agricultural provenance from those of other sources of
   fecal pollution at a policy-relevant watershed scale. The beneficial
   impacts of livestock waste treatment on risk to humans via exposure to
   manured land are illustrated using quantitative microbial risk
   assessment (QMRA) scenarios. Overall, innovative livestock treatment
   systems offer a crucially important strategy for making livestock wastes
   more benign before they are released into the broader environment. Crown
   Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Topp, E (Reprint Author), Agr \& Agri Food Canada, 1391 Sandford St, London, ON N4V 4T3, Canada.
   Topp, E.; Scott, A.; Lyautey, E.; Duriez, P., Agr \& Agri Food Canada, London, ON N4V 4T3, Canada.
   Lapen, D. R., Agr \& Agri Food Canada, Cent Expt Farm, Ottawa, ON K1A 0C6, Canada.}},
DOI = {{10.1016/j.biortech.2008.11.001}},
ISSN = {{0960-8524}},
EISSN = {{1873-2976}},
Keywords = {{Water quality; Manure treatment; Escherichia coli; Pathogens;
   Agriculture}},
Keywords-Plus = {{ENTEROTOXIGENIC ESCHERICHIA-COLI; COMMERCIAL SWINE FARM; FECAL
   POLLUTION; ANTIBIOTIC-RESISTANCE; RISK-ASSESSMENT; ANAEROBIC-DIGESTION;
   LAND APPLICATION; SOURCE-TRACKING; MANURE STORAGE; AMENDED SOIL}},
Research-Areas = {{Agriculture; Biotechnology \& Applied Microbiology; Energy \& Fuels}},
Web-of-Science-Categories  = {{Agricultural Engineering; Biotechnology \& Applied Microbiology; Energy
   \& Fuels}},
Author-Email = {{toppe@agr.gc.ca}},
ORCID-Numbers = {{Topp, Ed/0000-0002-8273-9372
   Duriez, Patrick/0000-0001-5533-3353}},
Cited-References = {{Aitken MD, 2007, WATER RES, V41, P1659, DOI 10.1016/j.watres.2007.01.034.
   Bicudo JR, 2003, ENVIRON TECHNOL, V24, P115, DOI 10.1080/09593330309385542.
   {*}CAN HLTH, 2004, FED CONT SIT RISK 1.
   Cote C, 2006, BIORESOURCE TECHNOL, V97, P686, DOI 10.1016/j.biortech.2005.03.024.
   Domingo JWS, 2007, WATER RES, V41, P3539, DOI 10.1016/j.watres.2007.06.001.
   Duriez P, 2008, APPL ENVIRON MICROB, V74, P3935, DOI 10.1128/AEM.02710-07.
   Duriez P, 2007, APPL ENVIRON MICROB, V73, P5486, DOI 10.1128/AEM.00218-07.
   Edge TA, 2007, WATER RES, V41, P3585, DOI 10.1016/j.watres.2007.05.012.
   Eisenberg JNS, 2004, RISK ANAL, V24, P221, DOI 10.1111/j.0272-4332.2004.00425.x.
   Eisenberg JNS, 2008, ENVIRON HEALTH PERSP, V116, P727, DOI 10.1289/ehp.10994.
   Field Katharine G., 2003, Journal of Water and Health, V1, P181.
   Gerba CP, 2005, J ENVIRON QUAL, V34, P42.
   Gerba CP, 2002, WATER SCI TECHNOL, V46, P225.
   Graves AK, 2007, WATER RES, V41, P3729, DOI 10.1016/j.watres.2007.04.020.
   Haas C.N., 1999, QUANTITATIVE MICROBI.
   Haas CN, 1996, J AM WATER WORKS ASS, V88, P131.
   HARNETT NM, 1985, CAN J COMP MED, V49, P79.
   Harwood Valerie J., 2003, Journal of Water and Health, V1, P153.
   Holzel C, 2008, ZOONOSES PUBLIC HLTH, V55, P133, DOI 10.1111/j.1863-2378.2007.01102.x.
   Hutchison ML, 2004, LETT APPL MICROBIOL, V39, P207, DOI 10.1111/j.1472-765X.2004.01564.x.
   {*}INT JOINT COMM, 2004, 12 INT JOINT COMM.
   Islam M, 2004, J FOOD PROTECT, V67, P574, DOI 10.4315/0362-028X-67.3.574.
   Johnson LK, 2004, APPL ENVIRON MICROB, V70, P4478, DOI 10.1128/AEM.70.8.4478-4485.2004.
   Khatib LA, 2003, APPL MICROBIOL BIOT, V63, P231, DOI 10.1007/s00253-003-1373-9.
   Lamendella R, 2007, FEMS MICROBIOL ECOL, V59, P651, DOI 10.1111/j.1574-6941.2006.00211.x.
   Larney FJ, 2003, J ENVIRON QUAL, V32, P1508, DOI 10.2134/jeq2003.1508.
   Leung KT, 2004, FEMS MICROBIOL ECOL, V47, P111, DOI {[}10.1016/S0168-6496(03)00254-X, 10.1016/S0168-9496(03)00254-X].
   Lyautey E, 2007, CAN J MICROBIOL, V53, P1158, DOI 10.1139/W07-084.
   Lyautey E, 2007, APPL ENVIRON MICROB, V73, P5401, DOI 10.1128/AEM.00354-07.
   Maguire RO, 2006, J ENVIRON QUAL, V35, P849, DOI 10.2134/jeq2005.0339.
   McLellan SL, 2003, APPL ENVIRON MICROB, V69, P2587, DOI 10.1128/AEM.69.5.2587-2594.2003.
   Medema GJ, 1996, INT J FOOD MICROBIOL, V30, P101, DOI 10.1016/0168-1605(96)00994-4.
   Muirhead RW, 2005, APPL ENVIRON MICROB, V71, P2875, DOI 10.1128/AEM.71.6.2875-2879.2005.
   Myoda Samuel P., 2003, Journal of Water and Health, V1, P167.
   Ojha S, 2007, J FOOD PROTECT, V70, P2676, DOI 10.4315/0362-028X-70.11.2676.
   Olasz F, 2005, FEMS MICROBIOL LETT, V244, P281, DOI 10.1016/j.femsle.2005.01.057.
   Payne JB, 2007, POULTRY SCI, V86, P191, DOI 10.1093/ps/86.1.191.
   Rajic A, 2007, J FOOD PROTECT, V70, P1286, DOI 10.4315/0362-028X-70.5.1286.
   Ruecker NJ, 2007, APPL ENVIRON MICROB, V73, P3945, DOI 10.1128/AEM.02788-06.
   Scott A, 2006, CAN J SOIL SCI, V86, P841, DOI 10.4141/S06-011.
   Shanks OC, 2006, APPL ENVIRON MICROB, V72, P4054, DOI 10.1128/AEM.00023-06.
   SOBSEY MD, 2002, PATHOGENS ANIMAL WAS.
   SOLLER JA, 2006, 98REM113 WAT ENV RES.
   Stoeckel DM, 2004, ENVIRON SCI TECHNOL, V38, P6109, DOI 10.1021/es0354519.
   TEUNIS PF, 1996, 284550002 RIVM NAT I.
   Topp E, 2003, FEMS MICROBIOL ECOL, V44, P303, DOI 10.1016/S0168-6496(03)00055-2.
   Travis RM, 2006, J ANTIMICROB CHEMOTH, V58, P173, DOI 10.1093/jac/dkl207.
   Ufnar JA, 2007, APPL ENVIRON MICROB, V73, P5209, DOI 10.1128/AEM.00319-07.
   USEPA, 2005, EPA600R05064 OFF RES.
   Vanotti MB, 2005, BIORESOURCE TECHNOL, V96, P209, DOI {[}10.1016/j.biortech.2004.05.010, 10.1016/j.biotech.2004.05.010].
   Vogel JR, 2007, J ENVIRON QUAL, V36, P718, DOI 10.2134/jeq2006.0246.
   Whitlock JE, 2002, WATER RES, V36, P4273, DOI 10.1016/S0043-1354(02)00139-2.
   {*}WHO UN CHILDR FUN, 2000, WHO UNICEF JOINT MON.
   Zaleski KJ, 2005, APPL ENVIRON MICROB, V71, P3701, DOI 10.1128/AEM.71.7.3701-3708.2005.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{40}},
Journal-ISO = {{Bioresour. Technol.}},
Doc-Delivery-Number = {{492KM}},
Unique-ID = {{ISI:000269654500006}},
DA = {{2018-08-13}},
}

@article{ ISI:000270643700004,
Author = {Dopierala, Katarzyna and Luczynski, Jacek and Prochaska, Krystyna},
Title = {{Surface properties of the derivatives of lysosomotropic substances
   against other quaternary ammonium salts}},
Journal = {{ADVANCES IN COLLOID AND INTERFACE SCIENCE}},
Year = {{2009}},
Volume = {{151}},
Number = {{1-2}},
Pages = {{49-56}},
Month = {{OCT 30}},
Abstract = {{Equilibrium adsorption at the air/water interface of cationic
   surfactants belonging in the group of quaternary ammonium bromides was
   studied. Quaternary ammonium salts. derivatives of lysosomotropic
   substances with different alkyl chain numbers and hydrophobicities were
   investigated. Surface properties of considered compounds, were examined
   and presented against other quaternary ammonium bromides of different
   chemical structure and with different number of alkyl chains in the
   molecule. The Frumkin equation and reorientation model were used for a
   quantitative description of the process of their adsorption. It was
   found that considered biologically active derivatives reveal strong
   surface activity. Chemical structure-surface activity relationship was
   analyzed and referenced to biological activity. Symmetry of the
   molecules resulting from the number of alkyl chains is the factor
   determining the behavior of the surfactants at the air/water Interface
   as well as in the bulk. Surfactants with asymmetrical structure show a
   strong tendency to reorientation, in opposite to tetraalkylammonium
   bromides and double chain surfactants. Furthermore, the role of ester
   bond was emphasized. (C) 2009 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Prochaska, K (Reprint Author), Poznan Tech Univ, Inst Chem Engn \& Technol, Pl M Sklodowskiej Curie 2, PL-60965 Poznan, Poland.
   Dopierala, Katarzyna; Prochaska, Krystyna, Poznan Tech Univ, Inst Chem Engn \& Technol, PL-60965 Poznan, Poland.
   Luczynski, Jacek, Wroclaw Univ Technol, Inst Organ Technol, PL-50371 Wroclaw, Poland.}},
DOI = {{10.1016/j.cis.2009.07.006}},
ISSN = {{0001-8686}},
Keywords = {{Quaternary ammonium salts; Lysosomotropic substances; Chemical
   structure-surface activity relationship; Reorientation model}},
Keywords-Plus = {{YEAST SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; ADSORPTION
   BEHAVIOR; WATER/AIR INTERFACE; CYTOTOXICITY; MEMBRANE; AGENTS}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Physical}},
Author-Email = {{krystyna.prochaska@put.poznan.pl}},
ResearcherID-Numbers = {{Prochaska, Krystyna/F-7530-2014
   Dopierala, Katarzyna/F-2657-2015}},
ORCID-Numbers = {{Prochaska, Krystyna/0000-0002-1025-6726
   Dopierala, Katarzyna/0000-0002-6062-5390}},
Funding-Acknowledgement = {{SURUZ ``Scientific Network Surfactants and Dispersed Systems in Theory
   and Practice{''} {[}75/E-68/BWSN-01 19/2008];  {[}DS-067/2009]; 
   {[}323204/2009]}},
Funding-Text = {{This work was supported by DS-067/2009 and the research grant SURUZ
   ``Scientific Network Surfactants and Dispersed Systems in Theory and
   Practice{''} no. 75/E-68/BWSN-01 19/2008 (PUT no. 323204/2009). The
   authors wish to thank M. Kosla for her assistance in the realization of
   the part of experimental measurements.}},
Cited-References = {{DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9.
   Dopierala K, 2008, J COLLOID INTERF SCI, V321, P220, DOI 10.1016/j.jcis.2008.01.049.
   Fainerman B., 2001, STUDIES INTERFACE SC, V13.
   Fainerman VB, 2002, J PHYS CHEM B, V106, P809, DOI 10.1021/jp012672x.
   Fainerman VB, 1997, J PHYS CHEM B, V101, P6479, DOI 10.1021/jp970746s.
   Fainerman VB, 2000, J COLLOID INTERF SCI, V232, P254, DOI 10.1006/jcis.2000.7213.
   Fainerman VB, 2000, ADV COLLOID INTERFAC, V86, P83, DOI 10.1016/S0001-8686(00)00033-6.
   FIRESTONE RA, 1979, J MED CHEM, V22.
   JAFFREZOU JP, 1993, FEBS LETT, V323, P191, DOI 10.1016/0014-5793(93)81337-Y.
   Kleszczynska H, 2005, J FLUORESC, V15, P137, DOI 10.1007/s10895-005-2521-7.
   Lacave R, 1999, J CELL PHYSIOL, V178, P247, DOI 10.1002/(SICI)1097-4652(199902)178:2<247::AID-JCP14>3.0.CO;2-K.
   Luczynski J., 2000, THESIS WROCLAW.
   MILLER DK, 1983, J CELL BIOL, V97, P1841, DOI 10.1083/jcb.97.6.1841.
   Miller R, 2002, J SURFACTANTS DETERG, V5, P281, DOI 10.1007/s11743-002-0228-7.
   Oblak E, 2003, CELL MOL BIOL LETT, V8, P105.
   Oblak E, 2002, CELL MOL BIOL LETT, V7, P1121.
   Oblak E, 2001, CELL MOL BIOL LETT, V6, P871.
   Para G, 2006, ADV COLLOID INTERFAC, V122, P39, DOI 10.1016/j.cis.2006.06.017.
   Stubenrauch C, 2005, J PHYS CHEM B, V109, P1505, DOI 10.1021/jp0465251.
   WILSON PD, 1991, BIOCHEM BIOPH RES CO, V176, P1377, DOI 10.1016/0006-291X(91)90439-E.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Adv. Colloid Interface Sci.}},
Doc-Delivery-Number = {{504UR}},
Unique-ID = {{ISI:000270643700004}},
DA = {{2018-08-13}},
}

@article{ ISI:000269145100009,
Author = {Modi, Surbhi and Buff, Ann M. and Lawson, Carl J. and Rodriguez, Daniel
   and Kirking, Hannah L. and Lipman, Harvey and Fishbein, Daniel B.},
Title = {{Reporting Patterns and Characteristics of Tuberculosis among
   International Travelers, United States, June 2006 to May 2008}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2009}},
Volume = {{49}},
Number = {{6}},
Pages = {{885-891}},
Month = {{SEP 15}},
Abstract = {{Background. As part of efforts to prevent the introduction of
   communicable diseases into the United States, the Centers for Disease
   Control and Prevention (CDC) conducts surveillance for selected diseases
   in international travelers. One of these diseases, tuberculosis (TB),
   received substantial attention in May 2007 when the CDC issued travel
   restrictions and a federal isolation order for a person with
   drug-resistant TB who traveled internationally against public health
   recommendations.
   Methods. Reports of TB in international travelers in the CDC's
   Quarantine Activity Reporting System (QARS) from 1 June 2006 through 31
   May 2007 (year 1) were compared with reports from 1 June 2007 through 31
   May 2008 (year 2). These reports were classified using the CDC and
   American Thoracic Society guidelines and analyzed for epidemiologic
   characteristics and trends.
   Results. Among QARS reports, 4.6\% were classified as active TB disease
   and 1.7\% as no TB disease. Active TB disease reports increased from
   2.5\% of QARS reports in year 1 to 6.4\% in year 2 (P < .001). The
   proportion P < .001 of active TB disease reports leading to a federal
   travel restriction increased from 6.8\% in year 1 to 15.4\% in year 2 (P
   = .08).
   Conclusions. The significant increase in reports of international
   travelers with TB disease likely represents more attention to and a
   higher index of suspicion for TB. The increased use of federal travel
   restrictions was associated with the development of new procedures to
   limit travel for public health reasons. Continued efforts are needed to
   decrease the number of persons with TB who travel while potentially
   contagious.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Modi, S (Reprint Author), Ctr Dis Control \& Prevent, Div Global Migrat \& Quarantine, Natl Ctr Preparedness Detect \& Control Infect Dis, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA.
   Modi, Surbhi; Lawson, Carl J.; Rodriguez, Daniel; Kirking, Hannah L.; Lipman, Harvey; Fishbein, Daniel B., Ctr Dis Control \& Prevent, Div Global Migrat \& Quarantine, Natl Ctr Preparedness Detect \& Control Infect Dis, Atlanta, GA 30333 USA.
   Buff, Ann M., Ctr Dis Control \& Prevent, Epidem Intelligence Serv Program, Off Workforce \& Career Dev, Atlanta, GA 30333 USA.
   Kirking, Hannah L., Ctr Dis Control \& Prevent, Experience Appl Epidemiol Fellowship Program, Off Workforce \& Career Dev, Atlanta, GA 30333 USA.
   Buff, Ann M., Ctr Dis Control \& Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Hepatitis STD \& TB Prevent, Atlanta, GA 30333 USA.
   Modi, Surbhi, Emory Univ, Sch Med, Atlanta, GA USA.}},
DOI = {{10.1086/605437}},
ISSN = {{1058-4838}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; GLOBAL EPIDEMIOLOGY; AIR-TRAVEL; TRANSMISSION; ABOARD;
   SHIP; QUARANTINE; OUTBREAK}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{smodi@cdc.gov}},
Funding-Acknowledgement = {{CDC Experience Applied Epidemiology Fellowship Program; CDC Foundation
   from Pfizer}},
Funding-Text = {{S.M., A.M.B., C.J.L., D.R., H.L. K., H.L., and D. B. F. are all employed
   by the CDC. H. L. K. is a fellow in the CDC Experience Applied
   Epidemiology Fellowship Program, which is a public-private partnership
   supported jointly by the CDC and Pfizer via a grant to the CDC
   Foundation from Pfizer.}},
Cited-References = {{Al-Jahdali H, 2003, INT J ANTIMICROB AG, V21, P125, DOI 10.1016/S0924-8579(02)00283-2.
   {[}Anonymous], 2008, TUB AIR TRAV GUID PR.
   Buff AM, 2008, MIL MED, V173, P588, DOI 10.7205/MILMED.173.6.588.
   Byrne Neville, 2007, Travel Med Infect Dis, V5, P18, DOI 10.1016/j.tmaid.2006.03.003.
   {*}CDCP, 2008, BACKGR 2007 TECHN IN.
   {*}CDCP, 2008, TUB COMP INSTR MED E.
   {*}CDCP, 2007, LEG AUTH IS QUAR.
   Centers for Disease Control and Prevention (CDC), 1995, MMWR-MORBID MORTAL W, V44, P137.
   Centers for Disease Control and Prevention (CDC), 2008, MMWR-MORBID MORTAL W, V57, P1009.
   DISTASIO AJ, 1990, MIL MED, V155, P347.
   {*}DIV TUB EL, 2007, TUB INF INT TRAV.
   DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   Dye C, 2006, LANCET, V367, P938, DOI 10.1016/S0140-6736(06)68384-0.
   Fidler DP, 2007, J LAW MED ETHICS, V35, P616, DOI 10.1111/j.1748-720X.2007.00185.x.
   FITZGERALD D, 2005, DOUGLAS BENNETTS PRI, P2852.
   HARDY MA, 1968, J AMER MED ASSOC, V203, P175, DOI 10.1001/jama.203.3.175.
   Hollingsworth TD, 2007, EMERG INFECT DIS, V13, P1288, DOI 10.3201/eid1309.070081.
   Horna-Campos OJ, 2007, EMERG INFECT DIS, V13, P1491, DOI 10.3201/eid1310.060793.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   LaMar JE, 2003, MIL MED, V168, P523.
   MacPherson DW, 2006, PUBLIC HEALTH, V120, P712, DOI 10.1016/j.puhe.2006.05.002.
   Markel H, 2007, JAMA-J AM MED ASSOC, V298, P83, DOI 10.1001/jama.298.1.83.
   MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9.
   Miller MA, 1996, TUBERCLE LUNG DIS, V77, P414, DOI 10.1016/S0962-8479(96)90113-6.
   Moore M, 1999, CLIN INFECT DIS, V28, P52, DOI 10.1086/515089.
   Olowokure B, 2007, J EPIDEMIOL COMMUN H, V61, P385, DOI 10.1136/jech.2005.042598.
   Parmet WE, 2007, NEW ENGL J MED, V357, P433, DOI 10.1056/NEJMp078133.
   Rekha B, 2007, PAEDIATR RESPIR REV, V8, P99, DOI 10.1016/j.prrv.2007.04.010.
   Sampathkumar P, 2007, MAYO CLIN PROC, V82, P799, DOI 10.4065/82.7.799.
   Sivitz L.B., 2005, QUARANTINE STATIONS.
   VALENTINE V, 2007, TIMELINE ANDREW SPEA.
   World Health Organisation, 2006, TUB AIR TRAV GUID PR.
   Yusuf HR, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.3.e9.
   2008, WKLY EPIDEMIOL REC, V83, P209.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{485ST}},
Unique-ID = {{ISI:000269145100009}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000274700300007,
Author = {Cecilia Garcia-Sancho, Ma. and Garcia-Garcia, Lourdes and Baez-Saldana,
   Renata and Ponce-de-Leon, Alfredo and Sifuentes-Osornio, Jose and
   Bobadilla-del-Valle, Miriam and Ferreyra-Reyes, Leticia and
   Cano-Arellano, Bulmaro and Canizales-Quintero, Sergio and del Carmen
   Palacios-Merino, Luz and Juarez-Sandino, Luis and Ferreira-Guerrero,
   Elizabeth and Pablo Cruz-Hervert, Luis and Small, Peter M. and Rogelio
   Perez-Padilla, Jose},
Title = {{Indoor pollution as an occupational risk factor for tuberculosis among
   women: a population-based, gender oriented, case-control study in
   Southern Mexico}},
Journal = {{REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL
   INVESTIGATION}},
Year = {{2009}},
Volume = {{61}},
Number = {{5}},
Pages = {{392-398}},
Month = {{SEP-OCT}},
Abstract = {{Background. Indoor air pollution produced by biomass cooking fuels in
   developing countries has been associated with acute and chronic lower
   respiratory diseases, but has not been identified as an occupational
   exposure among women. Objective. To examine the relationship between the
   use of biomass cooking fuels (mainly wood) and tuberculosis (TB) among
   women living in rural areas in Southern Mexico. Methods. We conducted a
   population based case-control study in the health jurisdiction of
   Orizaba, Mexico. Cases were all incident female pulmonary TB patients,
   with Mycobacterium tuberculosis in sputum, living in communities with
   fewer than 15 000 inhabitants, diagnosed between March 1995 and April
   2003. Woodsmoke exposure was assessed by applying a standardized
   questionnaire (ATS-DLD-78 questionnaire). Controls were randomly
   selected from sex-matched neighbors. Appropriate IRB approval was
   obtained. Results. 42 TB cases and 84 community controls were recruited.
   Multivariate assessment showed that more than 20 years of exposure to
   smoke from biomass fuels was three times more frequent among cases than
   among controls {[}Odds ratio (OR): 3.3, 95\% confidence interval
   (CI):1.06-10.30, p = 0.03], after controlling for age, body mass,
   household crowding, years of formal education and tobacco use.
   Conclusions. We found a strong association between the use of biomass
   cooking fuels and tuberculosis among women in a community-based,
   case-control study. Results of this study are intended to provide
   evidence to policy makers, community leaders and the general public on
   the importance of implementing gender oriented interventions that
   decrease the use of biomass fuels in poor communities in developing
   countries.}},
Publisher = {{INST NACIONAL NUTRICION}},
Address = {{VASCO DE QUIROZA 15, COLONIA SECCION XVI, TLALPAN, MEXICO 14000 D F,
   MEXICO}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Garcia-Sancho, MC (Reprint Author), Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Av Univ 655,Col Sta Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.
   Cecilia Garcia-Sancho, Ma., Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca 62508, Morelos, Mexico.
   Small, Peter M., Bill \& Melinda Gates Fdn, Seattle, WA USA.}},
ISSN = {{2385-3956}},
Keywords = {{Tuberculosis; Woodsmoke; Biomass; Indoor pollution}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; CONTROL
   PROGRAM; AIR-POLLUTION; HEALTH; DISEASE; COMMUNITY; EXPOSURE; SMOKE}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{earcigarml@gmail.com}},
ResearcherID-Numbers = {{Mitchell, Ellen/H-5475-2013
   }},
ORCID-Numbers = {{Cruz-Hervert, Luis Pablo/0000-0002-6094-958X
   Ponce-de-Leon, Alfredo/0000-0003-2640-2916}},
Funding-Acknowledgement = {{NIH {[}A135969, K01TW000001]; Wellcome Trust {[}176W009]; HHMI
   {[}55000632]; Mexican CONACyT {[}G26264M, 30987-M]}},
Funding-Text = {{From the Mexican Secretariat of Health, the NIH (A135969 and
   K01TW000001), the Wellcome Trust (176W009), the HHMI (55000632) and the
   Mexican CONACyT (G26264M and 30987-M).}},
Cited-References = {{Bellia V, 2003, Eur Respir J Suppl, V40, p21s.
   BRAUER MBK, 1995, ENVIRON SCI TECHNOL, V30, P104.
   Bruce N, 1998, INT J EPIDEMIOL, V27, P454, DOI 10.1093/ije/27.3.454.
   Camp PG, 2004, CLIN CHEST MED, V25, P269, DOI 10.1016/j.ccm.2004.01.004.
   Crampin AC, 2004, INT J TUBERC LUNG D, V8, P194.
   DeRiemer K, 2005, LANCET, V365, P1239, DOI 10.1016/S0140-6736(05)74812-1.
   FICK RB, 1984, AM REV RESPIR DIS, V129, P76.
   Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630.
   Garcia-Garcia MD, 2000, INT J TUBERC LUNG D, V4, P12.
   Garcia-Garcia MD, 2002, EMERG INFECT DIS, V8, P1327.
   Garcia-Garcia ML, 2000, INT J TUBERC LUNG D, V4, pS168.
   Garcia-Sancho MC, 2006, INT J EPIDEMIOL, V35, P1447, DOI 10.1093/ije/dyl213.
   Gupta BN, 1997, ENERGY ENV REV, V13, P61.
   Houtmeyers E, 1999, EUR RESPIR J, V13, P1177, DOI 10.1034/j.1399-3003.1999.13e39.x.
   {*}I NAC EST, 2000, GEOGR INF EST UN MEX, P10.
   {*}INEGI, VIV PART HAB MUN COM.
   Jacobson LM, 2005, TROP MED INT HEALTH, V10, P305, DOI 10.1111/j.1365-3156.2005.01392.x.
   Jimenez-Corona ME, 2006, THORAX, V61, P348, DOI 10.1136/thx.2005.049452.
   Kennedy Susan M, 2007, Proc Am Thorac Soc, V4, P692, DOI 10.1513/pats.200707-094SD.
   Langer A, 2006, LANCET, V368, P1753, DOI 10.1016/S01400-6736(06)69527-5.
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9.
   Metchock B.G., 1999, MANUAL CLIN MICROBIO, P399.
   Mishra V K, 1999, Int J Infect Dis, V3, P119, DOI 10.1016/S1201-9712(99)90032-2.
   Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875.
   Perez-Padilla R, 2001, INT J TUBERC LUNG D, V5, P441.
   PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608.
   Ponce-De-Leon A, 2004, DIABETES CARE, V27, P1584, DOI 10.2337/diacare.27.7.1584.
   RODRIGUEZ BMJ, 2004, ARCH BRONCONEUMOL, V40, P463.
   Shetty N, 2006, INT J TUBERC LUNG D, V10, P80.
   SMITH KR, 1993, ANNU REV ENERG ENV, V18, P529, DOI 10.1146/annurev.eg.18.110193.002525.
   {*}SSA DIR GEN EP, 2005, SIST UN INF VIG EP.
   {*}WHO, 2005, 292 WHO.
   World Health Organization, 2007, WHOHTMTB2007376.
   1995, N0M006SSA2, P20.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Rev. Investig. Clin.}},
Doc-Delivery-Number = {{557WH}},
Unique-ID = {{ISI:000274700300007}},
DA = {{2018-08-13}},
}

@article{ ISI:000266030800050,
Author = {da Silva Pinto, Ana Cristina and Rocha Silva, Luis Francisco and
   Cavalcanti, Bruno Coelho and Silva Melo, Marcia Rubia and Maia Chaves,
   Francisco Celio and Costa Lotufo, Leticia Vera and de Moraes, Manoel
   Odorico and de Andrade-Neto, Valter Ferreira and Tadei, Wanderli Pedro
   and Pessoa, Claudia O. and Ribeiro Vieira, Pedro Paulo and Pohlit,
   Adrian Martin},
Title = {{New antimalarial and cytotoxic 4-nerolidylcatechol derivatives}},
Journal = {{EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY}},
Year = {{2009}},
Volume = {{44}},
Number = {{6}},
Pages = {{2731-2735}},
Month = {{JUN}},
Abstract = {{4-Nerolidylcatechol (1) was isolated from cultivated Pothomorphe peltata
   root on a multigram scale using straight-forward solvent
   extraction-column chromatography. New semi-synthetic derivatives of I
   were prepared and tested in vitro against multidrug-resistant Plasmodium
   falciparum K1 strain. Mono-O-methyl, mono-O-benzyl, O,O-dibenzyl and
   O,O-dibenzoyl derivatives 2-8 exhibited IC(50) in the 0.67-22.52 mu M
   range. Mono-O-methyl ethers 6 and 7 inhibited the in vitro growth of
   human tumor cell lines HCT-8 (colon carcinoma), SF-295 (central nervous
   system), LH-60 (human myeloblastic leukemia) and MDA/MB-435 (melanoma).
   in general, derivatives 2-8 are more stable to light, air and pH at
   ambient temperatures than their labile, natural precursor 1. These
   derivatives provide leads for the development of a novel class of
   antimalarial drugs with enhanced chemical and pharmacological
   properties. (C) 2008 Elsevier Masson SAS. All rights reserved.}},
Publisher = {{ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER}},
Address = {{23 RUE LINOIS, 75724 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pohlit, AM (Reprint Author), Inst Nacl de Pesquisas da Amazonia, Lab Principios Ativos Amazonia, BR-69060001 Manaus, Amazonas, Brazil.
   da Silva Pinto, Ana Cristina; Silva Melo, Marcia Rubia; Pohlit, Adrian Martin, Inst Nacl de Pesquisas da Amazonia, Lab Principios Ativos Amazonia, BR-69060001 Manaus, Amazonas, Brazil.
   da Silva Pinto, Ana Cristina, Univ Fed Amazonas, BR-69077000 Manaus, Amazonas, Brazil.
   Rocha Silva, Luis Francisco; Ribeiro Vieira, Pedro Paulo, Fundacao Med Trop Amazonas, Lab Gerencia Malaria, BR-69040000 Manaus, Amazonas, Brazil.
   Cavalcanti, Bruno Coelho; Costa Lotufo, Leticia Vera; de Moraes, Manoel Odorico; Pessoa, Claudia O., Univ Fed Ceara, Expt Oncol Lab, BR-60431970 Fortaleza, Ceara, Brazil.
   Maia Chaves, Francisco Celio, Embrapa Amazonia Ocidental, BR-69010970 Manaus, Amazonas, Brazil.
   de Andrade-Neto, Valter Ferreira, Univ Fed Rio Grande do Norte, Dept Microbiol \& Parasitol, BR-59072970 Natal, RN, Brazil.
   Tadei, Wanderli Pedro, Inst Nacl de Pesquisas da Amazonia, Lab Malaria \& Dengue, BR-69060001 Manaus, Amazonas, Brazil.}},
DOI = {{10.1016/j.ejmech.2008.10.025}},
ISSN = {{0223-5234}},
Keywords = {{Plasmodium falciparum; Human colon carcinoma; Human nervous system
   cancer; Melanoma; Human myeloblastic leukemia; Semi-synthetic
   4-nerolidylcatechol derivatives}},
Keywords-Plus = {{PLASMODIUM-FALCIPARUM; POTHOMORPHE; ANALOGS; GROWTH}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Chemistry, Medicinal}},
Author-Email = {{ampohlit@inpa.gov.br}},
ResearcherID-Numbers = {{Costa-Lotufo, Leticia/D-4998-2014
   Pohlit, Adrian/E-8125-2010
   Coelho Cavalcanti, Bruno/F-1555-2015
   Pohlit, Adrian/M-8122-2017
   }},
ORCID-Numbers = {{Costa-Lotufo, Leticia/0000-0003-1861-5153
   Pohlit, Adrian/0000-0002-6793-3759
   Pohlit, Adrian/0000-0002-6793-3759
   Andrade Neto, Valter/0000-0002-9986-0865}},
Funding-Acknowledgement = {{FAPEAM {[}PIPT 006/2003, CBA-UFAM 1577/2005]; POSGRAD; PIBIC/INPA;
   PPG-7/CNPq {[}557106/06]; MCT/CNPq/PPBio {[}48.0002/04-5]}},
Funding-Text = {{This work was supported by FAPEAM: (PIPT 006/2003, CBA-UFAM 1577/2005),
   and scholarships for study POSGRAD and PIBIC/INPA. PPG-7/CNPq (no.
   557106/06), MCT/CNPq/PPBio (no. 48.0002/04-5). The authors thank Dr.
   Massayoshi Yoshida (CBA) for NMR spectra, J.C. Tomaz and Prof Norberto
   Lopes (USP) for ESI-HRMS and Prof. Daniel Rettori (UNIBAN) for helpful
   comments on this manuscript.}},
Cited-References = {{ADAMI YL, 1995, ESTUDO VIVO VITRO PO.
   AMORIM CZ, 1986, BRAZ J MED BIOL RES, V19, pA569.
   AMORIM CZ, 1988, J ETHNOPHARMACOL, V24, P101.
   ANAND RC, 1985, B CHEM SOC JPN, V58, P791, DOI 10.1246/bcsj.58.791.
   Andrade-Neto V.F., 2007, MEM I O CRUZ, V102, P359.
   Bastos EL, 2003, J AGR FOOD CHEM, V51, P7481, DOI 10.1021/jf0345189.
   Bouktaib M, 2002, TETRAHEDRON, V58, P10001, DOI 10.1016/S0040-4020(02)01306-6.
   Ferreira-da-Cruz MD, 2000, EXP PARASITOL, V94, P243, DOI 10.1006/expr.2000.4494.
   Goulart HR, 2004, ANTIMICROB AGENTS CH, V48, P2502, DOI 10.1128/AAC.48.7.2502-2509.2004.
   Lopes NP, 1999, J ETHNOPHARMACOL, V67, P313, DOI 10.1016/S0378-8741(99)00072-0.
   Macedo C, 2002, FEMS MICROBIOL LETT, V207, P13.
   MILLIKEN W, 1997, PLANTS MALARIA PLANT, P83.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   MURAKAMI H, 2005, Patent No. 2005200332.
   Pinto A. C. S., 2006, REV BRAS PLANTAS MED, V8, P205.
   Pradines B, 2002, J ANTIMICROB CHEMOTH, V50, P177, DOI 10.1093/jac/dkf104.
   SALANETO F, 1992, REV SOC BRASILEIR S2, V25, P92.
   SHARMA SK, 1989, J MED CHEM, V32, P357, DOI 10.1021/jm00122a013.
   Simpson J, 2003, BIOORG MED CHEM LETT, V13, P2435, DOI 10.1016/S0960-894X(03)00528-6.
   TASSIGNON PSG, 1995, IND CROPS PROD, V3, P273.
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840.
   Yoo Ho, 2003, Farmaco (Lausanne), V58, P1243, DOI 10.1016/j.farmac.2003.08.001.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Eur. J. Med. Chem.}},
Doc-Delivery-Number = {{445DV}},
Unique-ID = {{ISI:000266030800050}},
DA = {{2018-08-13}},
}

@article{ ISI:000266877000003,
Author = {Gao, Xiaolei and Li, Yuguo and Leung, Gabriel M.},
Title = {{Ventilation Control of Indoor Transmission of Airborne Diseases in an
   Urban Community}},
Journal = {{INDOOR AND BUILT ENVIRONMENT}},
Year = {{2009}},
Volume = {{18}},
Number = {{3}},
Pages = {{205-218}},
Month = {{JUN}},
Abstract = {{Following the recent severe acute respiratory syndrome epidemics and
   worldwide concern about the next pandemic, whether influenza or multiple
   drug resistant tuberculosis, has underlined the importance of effective
   interventions into airborne disease transmission in indoor environments
   in a community. The engineering control measures available include
   ventilation dilution, use of high-efficiency particulate air filters in
   a room or in the heating, ventilation, and air-conditioning (HVAC)
   system, and use of ultraviolet germicidal irradiation devices in ceiling
   area of a room or in the HVAC system. These methods are known to be
   effective in controlling or delaying airborne disease transmission in a
   single enclosure in both healthcare facilities and the community.
   However, there have been no studies of their relative effectiveness at
   the community level. This paper presents mathematical modeling of some
   engineering control strategies with a focus on ventilation and
   corresponding analysis of their relative effectiveness compared with
   other public health interventions in disease control in indoor
   environments at the community level. The results should help us to
   determine the most effective intervention strategies. We conclude that
   the engineering intervention methods such as building ventilation can be
   as effective as public health interventions and the ventilation rates
   specified in the existing standards such as ASHRAE 62 may be too low for
   the purpose of preventing or controlling airborne infectious diseases in
   indoor environments.}},
Publisher = {{SAGE PUBLICATIONS LTD}},
Address = {{1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gao, XL (Reprint Author), Univ Hong Kong, Dept Mech Engn, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
   Gao, Xiaolei; Li, Yuguo, Univ Hong Kong, Dept Mech Engn, Hong Kong, Hong Kong, Peoples R China.
   Leung, Gabriel M., Univ Hong Kong, Dept Community Med, Pokfulam, Hong Kong, Peoples R China.}},
DOI = {{10.1177/1420326X09104141}},
ISSN = {{1420-326X}},
Keywords = {{Airborne disease; Engineering control; Ventilation; Wells-Riley
   equation; SEIR model; Influenza}},
Keywords-Plus = {{ULTRAVIOLET GERMICIDAL IRRADIATION; UPPER-ROOM AIR; MATHEMATICAL-THEORY;
   ROYAL SOCIETY; INFECTION TRANSMISSION; RESIDENTIAL BUILDINGS; PANDEMIC
   INFLUENZA; MODEL; RISK; TUBERCULOSIS}},
Research-Areas = {{Construction \& Building Technology; Engineering; Public, Environmental
   \& Occupational Health}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Engineering, Environmental; Public,
   Environmental \& Occupational Health}},
Author-Email = {{liyg@hku.hk}},
ResearcherID-Numbers = {{Li, Yuguo/A-9469-2010
   }},
ORCID-Numbers = {{Li, Yuguo/0000-0002-2281-4529
   Leung, Gabriel/0000-0002-2503-6283}},
Funding-Acknowledgement = {{Research Grants Council of the Hong Kong SAR Government {[}HKU 7150/06E]}},
Funding-Text = {{The work described in this paper was supported by a grant from the
   Research Grants Council of the Hong Kong SAR Government (Project No. HKU
   7150/06E).}},
Cited-References = {{ANDERSON RM, 1992, OXFORD SCI PUBLICATI, V8, P757.
   Beggs CB, 2003, INT J TUBERC LUNG D, V7, P1015.
   Beggs CB, 2002, J AEROSOL SCI, V33, P1681, DOI 10.1016/S0021-8502(02)00117-9.
   Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4.
   Chao CYH, 2001, BUILD ENVIRON, V36, P999, DOI 10.1016/S0360-1323(00)00057-3.
   Chao CYH, 2001, ATMOS ENVIRON, V35, P1585, DOI 10.1016/S1352-2310(00)00458-1.
   Chen SC, 2006, INDOOR AIR, V16, P469, DOI 10.1111/j.1600-0668.2006.00443.x.
   Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6.
   Dietz K, 2002, MATH BIOSCI, V180, P1, DOI 10.1016/S0025-5564(02)00122-0.
   EPD, 1995, CONS STUD IND AIR PO.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917.
   JENSEN MM, 1964, APPL MICROBIOL, V12, P418.
   KERMACK WO, 1991, B MATH BIOL, V53, P89, DOI 10.1016/S0092-8240(05)80042-4.
   KERMACK WO, 1991, B MATH BIOL, V53, P57, DOI 10.1016/S0092-8240(05)80041-2.
   KERMACK WO, 1991, B MATH BIOL, V53, P33, DOI 10.1016/S0092-8240(05)80040-0.
   Ko GP, 2001, RISK ANAL, V21, P657, DOI 10.1111/0272-4332.214142.
   Koopman J, 2004, ANNU REV PUBL HEALTH, V25, P303, DOI 10.1146/annurev.publhealth.25.102802.124353.
   Kowalski W.J., 1999, ASHRAE T, V105, P4.
   Kujundzic E, 2006, J OCCUP ENVIRON HYG, V3, P536, DOI 10.1080/15459620600909799.
   Li Y, 2007, INDOOR AIR, V17, P2, DOI 10.1111/j.1600-0668.2006.00445.x.
   Liao CM, 2008, EPIDEMIOL INFECT, V136, P299, DOI 10.1017/S0950268807008631.
   Lin ZP, 2003, BUILD ENVIRON, V38, P1389, DOI 10.1016/j.buildenv.2003.07.001.
   Longini IM, 2004, AM J EPIDEMIOL, V159, P623, DOI 10.1093/aje/kwh092.
   Miller SL, 2000, AEROSOL SCI TECH, V33, P274, DOI 10.1080/027868200416259.
   MOSER MR, 1979, AM J EPIDEMIOL, V110, P1.
   NICAS M, 1995, AM J IND MED, V27, P317, DOI 10.1002/ajim.4700270302.
   Noakes CJ, 2006, EPIDEMIOL INFECT, V134, P1082, DOI 10.1017/S0950268806005875.
   Noakes CJ, 2004, J AEROSOL SCI, V35, P489, DOI 10.1016/j.jaerosci.2003.10.011.
   PARZEN E, 1965, STOCHASTIC PROCESSES, V11, P324.
   RILEY EC, 1978, AM J EPIDEMIOL, V107, P421, DOI 10.1093/oxfordjournals.aje.a112560.
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051.
   Rudnick SN, 2003, INDOOR AIR, V13, P237, DOI 10.1034/j.1600-0668.2003.00189.x.
   TANG JW, 2007, LANCET INFECT DIS, V7, P761.
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426.
   Wallinga J, 2006, AM J EPIDEMIOL, V164, P936, DOI 10.1093/aje/kwj317.
   Weiss RA, 2004, NAT MED, V10, pS70, DOI 10.1038/nm1150.
   WELLS WF, 1955, AIRBORNE CONTAGION A, V29, P423.
   Wong TW, 2004, EMERG INFECT DIS, V10, P269, DOI 10.3201/eid1002.030452.
   Wu JT, 2006, PLOS MED, V3, P1532, DOI 10.1371/journal.pmed.0030361.
   Xu P, 2003, ATMOS ENVIRON, V37, P405, DOI 10.1016/S1352-2310(02)00825-7.
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{15}},
Journal-ISO = {{Indoor Built Environ.}},
Doc-Delivery-Number = {{456UN}},
Unique-ID = {{ISI:000266877000003}},
DA = {{2018-08-13}},
}

@article{ ISI:000267436900009,
Author = {Orki, A. and Kosar, A. and Demirhan, R. and Saygi, A. and Arman, B.},
Title = {{The Value of Surgical Resection in Patients with Multidrug Resistant
   Tuberculosis}},
Journal = {{THORACIC AND CARDIOVASCULAR SURGEON}},
Year = {{2009}},
Volume = {{57}},
Number = {{4}},
Pages = {{222-225}},
Month = {{JUN}},
Abstract = {{Background: Multidrug resistant tuberculosis (MDR-TB) still continues to
   be a serious health problem throughout the world. Although main
   treatment of MDR-TB is medical, Surgical resection with adjuvant medical
   therapy may increase the chance of cure in selected patients.
   Methods: We performed surgical resections in 55 patients between 1997
   and 2005; 36 were male and 19 were female with a median age of 34 years
   (range 13 to 66 years). Sputum was negative for 49 patients and positive
   for 6 patients in the preoperative period. Patients were treated
   according to a new therapy protocol for a mean of 3.7 months before the
   operation.
   Results: Lobectomy was performed in 37 patients, pneumonectomy in 17
   patients and lobectomy + segmentectomy in I patient. One patient with
   positive sputum preoperatively died in the early postoperative period
   (mortality: 1.81\%). Various complications occurred in 16 (29.09\%)
   patients. Prolonged air leak was the most common complication (n = 8).
   Bronchopleural fistula (BPF) + empyema occurred in 2 (3.63\%) patients.
   In the postoperative period, sputum negativity was achieved in all
   patients except three cases throughout the 57 months Of follow-up (Cure
   rate 94.5\%). Patients received drug therapy for 24 months
   postoperatively.
   Conclusions: Surgical resection with adjuvant drug therapy increases the
   chance of cure in patients with localized disease if they have an
   adequate cardiopulmonary reserve, favorable nutritional status and are
   treated with a new therapy protocol for at least 3 months.}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Orki, A (Reprint Author), Heybeliada Chest Dis \& Chest Surg Ctr, Camlica Plamiye Sitesi 11-3, TR-34692 Istanbul, Turkey.
   Orki, A.; Kosar, A.; Demirhan, R.; Saygi, A.; Arman, B., Heybeliada Chest Dis \& Chest Surg Ctr, TR-34692 Istanbul, Turkey.}},
DOI = {{10.1055/s-0029-1185458}},
ISSN = {{0171-6425}},
Keywords = {{MDR-TB; resection; cure chance}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; SURGERY; PNEUMONECTOMY; EXPERIENCE}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
Author-Email = {{alpayorki@yahoo.com}},
Cited-References = {{Kim YT, 2003, EUR J CARDIO-THORAC, V23, P833, DOI 10.1016/S1010-7940(03)00031-9.
   Leuvan M V, 1997, ANN THORAC SURG, V63, P1368.
   Mohsen T, 2007, J THORAC CARDIOV SUR, V134, P194, DOI 10.1016/j.jtcvs.2007.03.022.
   Naidoo Rishendran, 2007, Asian Cardiovasc Thorac Ann, V15, P134.
   Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339.
   RIZZI A, 1995, ANN THORAC SURG, V59, P896, DOI 10.1016/0003-4975(95)00011-9.
   Shiraishi Y, 2004, J THORAC CARDIOV SUR, V128, P523, DOI 10.1016/j.jtcvs.2004.06.012.
   Sung SW, 1999, EUR J CARDIO-THORAC, V16, P187, DOI 10.1016/S1010-7940(99)00158-X.
   Takeda S, 2005, ANN THORAC SURG, V79, P959, DOI 10.1016/j.athoracsur.2004.09.007.
   TREASURE RL, 1995, ANN THORAC SURG, V59, P1405, DOI 10.1016/0003-4975(95)00145-B.
   {*}WHO, 2004, 3 WHO.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Thorac. Cardiovasc. Surg.}},
Doc-Delivery-Number = {{463MS}},
Unique-ID = {{ISI:000267436900009}},
DA = {{2018-08-13}},
}

@article{ ISI:000265789000008,
Author = {Singleton, Rosalyn and Holve, Steve and Groom, Amy and McMahon, Brian J.
   and Santosham, Mathu and Brenneman, George and O'Brien, Katherine L.},
Title = {{Impact of Immunizations on the Disease Burden of American Indian and
   Alaska Native Children}},
Journal = {{ARCHIVES OF PEDIATRICS \& ADOLESCENT MEDICINE}},
Year = {{2009}},
Volume = {{163}},
Number = {{5}},
Pages = {{446-453}},
Month = {{MAY}},
Abstract = {{American Indian and Alaska Native (AI/AN) people have suffered
   disproportionately from infectious diseases compared with the general US
   population. As recently as 25 years ago, rates of hepatitis A and B
   virus, Haemophilus influenzae type b, and Streptococcus pneumoniae
   infections were as much as 10 times higher among AI/AN children compared
   with the general US child population. In the past quarter century,
   routine use of childhood immunizations for hepatitis A and B viruses has
   eliminated disease disparities for these pathogens in AI/AN children,
   and significant decreases have been demonstrated for H influenzae type
   b, S pneumoniae, and pertussis. Nevertheless, certain infectious
   diseases continue to occur at higher rates in AI/AN children. The reason
   for continued disparities is most likely related to adverse living
   conditions such as household crowding, lack of indoor plumbing, poverty,
   and poor indoor air quality. Although tremendous strides have been made
   in eliminating disparities in infectious disease among AI/AN children,
   further gains will require addressing disparities in adverse living
   conditions. Arch Pediatr Adolesc Med. 2009; 163(5):446-453}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60610-0946 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Singleton, R (Reprint Author), Ctr Dis Control \& Prevent, Arctic Invest Program, Natl Ctr Preparedness Detect \& Control Infect Dis, Coordinating Ctr Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA.
   Singleton, Rosalyn; McMahon, Brian J., Ctr Dis Control \& Prevent, Arctic Invest Program, Natl Ctr Preparedness Detect \& Control Infect Dis, Coordinating Ctr Infect Dis, Anchorage, AK 99508 USA.
   Singleton, Rosalyn, Ctr Dis Control \& Prevent, Alaska Native Tribal Consortium, Anchorage, AK 99508 USA.
   Holve, Steve, Tuba City Indian Med Ctr, Tuba City, AZ USA.
   Groom, Amy, Ctr Dis Control \& Prevent, Program Operat Branch, Immunizat Serv Div, Natl Ctr Immunizat \& Resp Dis, Atlanta, GA USA.
   Groom, Amy, Indian Hlth Serv, Div Epidemiol \& Dis Prevent, Albuquerque, NM USA.
   Santosham, Mathu; O'Brien, Katherine L., Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Amer Indian Hlth, Baltimore, MD USA.
   Brenneman, George, Indian Hlth Serv, Aberdeen Area, Aberdeen, SD USA.}},
DOI = {{10.1001/archpediatrics.2009.44}},
ISSN = {{1072-4710}},
Keywords-Plus = {{PNEUMOCOCCAL CONJUGATE VACCINE; DIARRHEA-ASSOCIATED HOSPITALIZATIONS;
   HEMOPHILUS-INFLUENZAE DISEASE; SYNCYTIAL VIRUS-INFECTION; MOUNTAIN
   APACHE CHILDREN; UNITED-STATES; HEPATITIS-B; HIGH-RISK; ANTIMICROBIAL
   RESISTANCE; ADVISORY-COMMITTEE}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{ris2@cdc.gov}},
ORCID-Numbers = {{O'Brien, Katherine/0000-0002-0164-4030}},
Cited-References = {{{[}Anonymous], 1996, MMWR Recomm Rep, V45, P1.
   Bell BP, 1998, J INFECT DIS, V178, P1579, DOI 10.1086/314518.
   Bialek SR, 2004, AM J PUBLIC HEALTH, V94, P996, DOI 10.2105/AJPH.94.6.996.
   Bockova J, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e20.
   Bulkow LR, 2002, PEDIATRICS, V109, P210, DOI 10.1542/peds.109.2.210.
   BULKOW LR, 1993, J INFECT DIS, V168, P1017, DOI 10.1093/infdis/168.4.1017.
   BULKOW LR, 1993, PEDIATR INFECT DIS J, V12, P484, DOI 10.1097/00006454-199306000-00006.
   Castor ML, 2006, AM J PUBLIC HEALTH, V96, P1478, DOI 10.2105/AJPH.2004.053942.
   {*}CDCP, 2005, MMWR-MORBID MORTAL W, V54, P893.
   {*}CDCP, 2002, MMWR-MORBID MORTAL W, V51, P234.
   Centers for Disease Control and Prevention, 1992, MMWR-MORBID MORTAL W, V41, P13.
   CHEN RT, 1985, AM J PUBLIC HEALTH, V75, P1393, DOI 10.2105/AJPH.75.12.1393.
   CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277.
   COULEHAN JL, 1984, PUBLIC HEALTH REP, V99, P404.
   Darling N., 2008, Morbidity and Mortality Weekly Report, V57, P961.
   DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675.
   DECKER JF, 1991, SOC SCI MED, V33, P381, DOI 10.1016/0277-9536(91)90319-8.
   Dentinger CM, 2005, PEDIATR INFECT DIS J, V24, P786, DOI 10.1097/01.inf.0000176617.63457.9f.
   Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1.
   FLESHMAN JK, 1968, ARCH ENVIRON HEALTH, V17, P517, DOI 10.1080/00039896.1968.10665274.
   Galil K, 1999, J INFECT DIS, V179, P101, DOI 10.1086/314569.
   GLASS RI, 1991, J PEDIATR-US, V118, pS27, DOI 10.1016/S0022-3476(05)81422-2.
   Golaz A, 2000, S D J Med, V53, P281.
   Groom AV, 2008, PEDIATRICS, V121, P938, DOI 10.1542/peds.2007-1794.
   Harpaz R, 2000, J INFECT DIS, V181, P413, DOI 10.1086/315259.
   Hennessy TW, 2008, AM J PUBLIC HEALTH, V98, P2072, DOI 10.2105/AJPH.2007.115618.
   Hennessy TW, 2005, VACCINE, V23, P5464, DOI 10.1016/j.vaccine.2005.08.100.
   HEYWARD WL, 1985, AM J EPIDEMIOL, V121, P914, DOI 10.1093/oxfordjournals.aje.a114061.
   Holman RC, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.2.e176.
   Holman RC, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.1.e11.
   {*}HOUS ASS COUNC, 2008, HOUS NAT AM LANDS.
   {*}IND HLTH SERV, 2002, TRENDS IND HLTH.
   {*}IND HLTH SERV DIV, Q IMM REP.
   Karron RA, 1999, J INFECT DIS, V180, P41, DOI 10.1086/314841.
   Lacapa R, 2008, CLIN INFECT DIS, V47, P476, DOI 10.1086/590001.
   LOSONSKY GA, 1984, PEDIATR INFECT DIS J, V3, P539, DOI 10.1097/00006454-198411000-00012.
   LUM MKW, 1986, PUBLIC HEALTH REP, V101, P309.
   MCCORMICK JB, 1977, J PEDIATR-US, V90, P13, DOI 10.1016/S0022-3476(77)80756-7.
   McMahon B J, 1998, Int J Circumpolar Health, V57 Suppl 1, P414.
   MCMAHON BJ, 1993, AM J EPIDEMIOL, V138, P544.
   MCMAHON BJ, 1987, LANCET, V2, P1134.
   Millar EV, 2000, AM J PUBLIC HEALTH, V90, P1550, DOI 10.2105/AJPH.90.10.1550.
   Millar EV, 2005, CLIN INFECT DIS, V40, P823, DOI 10.1086/428047.
   Murphy TV, 2008, J PEDIATR, V152, P839, DOI 10.1016/j.jpeds.2007.11.046.
   National American Indian Housing Council, 2001, TOO FEW ROOMS RES CR.
   O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6.
   OBRIEN KL, 2006, 5 ANN INT S PNEUM PN.
   Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1.
   Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91.
   Redd S. B., 2008, Morbidity and Mortality Weekly Report, V57, P494.
   Robin LF, 1996, PEDIATR INFECT DIS J, V15, P859, DOI 10.1097/00006454-199610000-00006.
   Rudolph KM, 2000, J INFECT DIS, V182, P490, DOI 10.1086/315716.
   Rynn L., 2008, Morbidity and Mortality Weekly Report, V57, P1.
   {*}S DAK DEP HLTH, REP DIS S DAK 1997 2.
   SANTOSHAM M, 1987, NEW ENGL J MED, V317, P923, DOI 10.1056/NEJM198710083171503.
   SANTOSHAM M, 1985, J INFECT DIS, V152, P778, DOI 10.1093/infdis/152.4.778.
   SANTOSHAM M, 1995, J DIARRHOEAL DIS RES, V13, P18.
   SANTOSHAM M, 1992, J INFECT DIS, V165, pS144, DOI 10.1093/infdis/165-Supplement\_1-S144.
   SANTOSHAM M, 1991, PEDIATR INFECT DIS J, V10, P113, DOI 10.1097/00006454-199102000-00007.
   SCHREEDER MT, 1983, AM J EPIDEMIOL, V118, P543, DOI 10.1093/oxfordjournals.aje.a113659.
   SHAW FE, 1990, AM J PUBLIC HEALTH, V80, P1091, DOI 10.2105/AJPH.80.9.1091.
   SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005.
   Singleton R, 2003, PEDIATR INFECT DIS J, V22, P540, DOI 10.1097/00006454-200306000-00010.
   Singleton R, 2000, J PEDIATR-US, V137, P313, DOI 10.1067/mpd.2000.107843.
   SINGLETON RJ, 1994, PEDIATR INFECT DIS J, V13, P362, DOI 10.1097/00006454-199405000-00006.
   Singleton R, 2006, PEDIATRICS, V118, pE421, DOI 10.1542/peds.2006-0287.
   Singleton RJ, 2007, PEDIATR INFECT DIS J, V26, P1006, DOI 10.1097/INF.0b013e3181256595.
   Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784.
   Staat A. M., 2008, Morbidity and Mortality Weekly Report, V57, P697.
   {*}US CENS BUR, 2000, CHAR AM IND AL NAT T.
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664.
   Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012.
   WARD JI, 1981, LANCET, V1, P1281.
   WARD JI, 1986, J INFECT DIS, V153, P17, DOI 10.1093/infdis/153.1.17.
   Wasley Annemarie, 2008, Morbidity and Mortality Weekly Report, V57, P1.
   Welty T K, 1996, S D J Med, V49, P317.
   WENGER J, 2008, 6 ANN INT S PNEUM PN.
   Zangwill KM, 1996, J INFECT DIS, V174, P752, DOI 10.1093/infdis/174.4.752.
   1997, MMWR MORB MORTAL WKL, V46, P588.}},
Number-of-Cited-References = {{79}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Arch. Pediatr. Adolesc. Med.}},
Doc-Delivery-Number = {{441RU}},
Unique-ID = {{ISI:000265789000008}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000265683700009,
Author = {Firestine, Steven M. and Paritala, Hanumantharao and Mcdonnell, Jane E.
   and Thoden, James B. and Holden, Hazel M.},
Title = {{Identification of inhibitors of N-5-carboxyaminoimidazole ribonucleotide
   synthetase by high-throughput screening}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY}},
Year = {{2009}},
Volume = {{17}},
Number = {{9}},
Pages = {{3317-3323}},
Month = {{MAY 1}},
Abstract = {{The increasing risk of drug-resistant bacterial infections indicates
   that there is a growing need for new and effective antimicrobial agents.
   One promising, but unexplored area in antimicrobial drug design is de
   novo purine biosynthesis. Recent research has shown that de novo purine
   biosynthesis in microbes is different from that in humans. The
   differences in the pathways are centered around the synthesis of
   4-carboxyaminoimidazole ribonucleotide (CAIR) which requires the enzyme
   N-5-carboxyaminoimidazole ribonucleotide (N-5-CAIR) synthetase. Humans
   do not require and have no homologs of this enzyme. Unfortunately, no
   studies aimed at identifying small-molecule inhibitors of N-5-CAIR
   synthetase have been published. To remedy this problem, we have
   conducted high-throughput screening (HTS) against Escherichia coli
   N-5-CAIR synthetase using a highly reproducible phosphate assay. HTS of
   48,000 compounds identified 14 compounds that inhibited the enzyme. The
   hits identified could be classified into three classes based on chemical
   structure. Class I contains compounds with an indenedione core. Class II
   contains an indolinedione group, and Class III contains compounds that
   are structurally unrelated to other inhibitors in the group. We
   determined the Michaelis-Menten kinetics for five compounds representing
   each of the classes. Examination of compounds belonging to Class I
   indicates that these compounds do not follow normal Michaelis-Menten
   kinetics. Instead, these compounds inhibit N-5-CAIR synthetase by
   reacting with the substrate AIR. Kinetic analysis indicates that the
   Class II family of compounds are non-competitive with both AIR and ATP.
   One compound in Class III is competitive with AIR but uncompetitive with
   ATP, whereas the other is non-competitive with both substrates. Finally,
   these compounds display no inhibition of human AIR carboxylase: SAICAR
   synthetase indicating that these agents are selective inhibitors of
   N-5-CAIR synthetase. (C) 2009 Elsevier Ltd. All rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Firestine, SM (Reprint Author), Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm \& Hlth Sci, Detroit, MI 48201 USA.
   Firestine, Steven M.; Paritala, Hanumantharao; Mcdonnell, Jane E., Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm \& Hlth Sci, Detroit, MI 48201 USA.
   Thoden, James B.; Holden, Hazel M., Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.}},
DOI = {{10.1016/j.bmc.2009.03.043}},
ISSN = {{0968-0896}},
Keywords = {{N-5-CAIR synthetase; High-throughput screening; Drug discovery; Enzyme
   inhibitors; Purine biosynthesis; Antimicrobial agents}},
Keywords-Plus = {{RESISTANT STAPHYLOCOCCUS-AUREUS; PURINE BIOSYNTHETIC-PATHWAY;
   ESCHERICHIA-COLI; CANDIDA-ALBICANS; CRYPTOCOCCUS-NEOFORMANS; VIRULENCE
   GENES; GALLUS-GALLUS; INFECTIONS; CARBOXYLASE; ENZYME}},
Research-Areas = {{Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic}},
Author-Email = {{sfirestine@wayne.edu}},
ResearcherID-Numbers = {{Paritala, Hanumantharao/K-1465-2013}},
Funding-Acknowledgement = {{Wayne State University; American Heart Association {[}AHA 0855712G]; NIH
   {[}DK47814]}},
Funding-Text = {{We thank Wayne State University, the American Heart Association (AHA
   0855712G to S. M. F.), and NIH (DK47814 to H. M. H.) for funding. We
   also thank Dr. W. W. Cleland for his help with the interpretation of the
   kinetic data for compounds 1 and 2. We thank Martha Larsen and Dr.
   Robert Neubig of the CCG at the University of Michigan for their help
   with this study.}},
Cited-References = {{Alekshun MN, 2005, EXPERT OPIN INV DRUG, V14, P117, DOI 10.1517/13543784.14.2.117.
   Appelbaum PC, 2006, CLIN MICROBIOL INFEC, V12, P3, DOI 10.1111/j.1469-0691.2006.01402.x.
   Arbeit RD, 2004, CLIN INFECT DIS, V38, P1673, DOI 10.1086/420818.
   BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8.
   Carleton HA, 2004, J INFECT DIS, V190, P1730, DOI 10.1086/425019.
   Cersini A, 2003, INFECT IMMUN, V71, P7002, DOI 10.1128/IAI.71.12.7002-7013.2003.
   Donovan M, 2001, INFECT IMMUN, V69, P2542, DOI 10.1128/IAI.69.4.2542-2548.2001.
   Eliopoulos GM, 2005, EUR J CLIN MICROBIOL, V24, P826, DOI 10.1007/s10096-005-0055-1.
   FIRESTINE SM, 1994, BIOCHEMISTRY-US, V33, P11927, DOI 10.1021/bi00205a031.
   FIRESTINE SM, 1994, BIOCHEMISTRY-US, V33, P11917, DOI 10.1021/bi00205a030.
   Firestine SM, 1998, ARCH BIOCHEM BIOPHYS, V351, P123, DOI 10.1006/abbi.1997.0512.
   Herrero IA, 2002, NEW ENGL J MED, V346, P867, DOI 10.1056/NEJM200203143461121.
   Hiramatsu K, 2001, Lancet Infect Dis, V1, P147, DOI 10.1016/S1473-3099(01)00091-3.
   KIRSCH DR, 1991, INFECT IMMUN, V59, P3297.
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763.
   Liu SP, 2006, P NATL ACAD SCI USA, V103, P15178, DOI 10.1073/pnas.0604905103.
   Lode H, 2005, CLIN MICROBIOL INFEC, V11, P778, DOI 10.1111/j.1469-0691.2005.01220.x.
   MAROLEWSKI A, 1994, BIOCHEMISTRY-US, V33, P2531, DOI 10.1021/bi00175a023.
   MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4.
   Meyer E, 1999, BIOCHEMISTRY-US, V38, P3012, DOI 10.1021/bi9827159.
   MEYER E, 1992, BIOCHEMISTRY-US, V31, P5022, DOI 10.1021/bi00136a016.
   MUELLER EJ, 1994, BIOCHEMISTRY-US, V33, P2269, DOI 10.1021/bi00174a038.
   Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976.
   PERFECT JR, 1993, INFECT IMMUN, V61, P4446.
   Polissi A, 1998, INFECT IMMUN, V66, P5620.
   Rodriguez-Suarez R, 2007, CHEM BIOL, V14, P1163, DOI 10.1016/j.chembiol.2007.09.009.
   Rowlands MG, 2004, ANAL BIOCHEM, V327, P176, DOI 10.1016/j.ab.2003.10.038.
   Samant S, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040037.
   Shen Y, 2004, MOL CELL, V16, P881, DOI 10.1016/j.molcel.2004.11.034.
   Spellberg B, 2004, CLIN INFECT DIS, V38, P1279, DOI 10.1086/420937.
   Stevens DL, 2002, CLIN INFECT DIS, V34, P1481, DOI 10.1086/340353.
   Thoden JB, 2000, BIOCHEMISTRY-US, V39, P8791, DOI 10.1021/bi000926j.
   Wang JY, 1996, P NATL ACAD SCI USA, V93, P10434, DOI 10.1073/pnas.93.19.10434.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Bioorg. Med. Chem.}},
Doc-Delivery-Number = {{440ES}},
Unique-ID = {{ISI:000265683700009}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000265249200005,
Author = {Shah, Rena H. and Frishman, William H.},
Title = {{Adenosine(1) Receptor Antagonism A New Therapeutic Approach for the
   Treatment of Decompensated Heart Failure}},
Journal = {{CARDIOLOGY IN REVIEW}},
Year = {{2009}},
Volume = {{17}},
Number = {{3}},
Pages = {{125-131}},
Month = {{MAY-JUN}},
Abstract = {{Heart failure (HF) remains a major cause of morbidity and mortality,
   even with the use of standard treatments in patients with chronic HF and
   acute decompensated. HF. Impaired renal function is an important
   prognostic indicator for adverse clinical outcome. Elevated plasma
   levels of adenosine have been observed in HF patients and stimulation of
   adenosine, receptors (A(1)R) in the kidney may be contributing to
   impaired renal function and treatment resistance. This observation has
   led to the development of AIR inhibitor drugs, both in oral and
   intravenous formulations, which in both animal and preliminary clinical
   trials have been shown to augment diuresis while preserving or improving
   renal function in HF patients. An extensive phase III clinical program
   using the AIR KW-3902 is now in progress in patients with symptomatic HF
   and renal dysfunction to evaluate the efficacy and safety of this
   treatment approach.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Frishman, WH (Reprint Author), New York Med Coll, Westchester Med Ctr, Dept Med, Munger Pavil 263, Valhalla, NY 10595 USA.
   Shah, Rena H.; Frishman, William H., New York Med Coll, Westchester Med Ctr, Dept Med, Valhalla, NY 10595 USA.}},
DOI = {{10.1097/CRD.0b013e31819f1a98}},
ISSN = {{1061-5377}},
Keywords = {{adenosine receptors; adenosine; A(1)R blockade; heart failure; drug
   resistant heart failure}},
Keywords-Plus = {{WORSENING RENAL-FUNCTION; HOSPITALIZED-PATIENTS; KW-3902; IMPAIRMENT;
   ROLOFYLLINE; MANAGEMENT; EPILEPSY; OUTCOMES; PROTECT; UPDATE}},
Research-Areas = {{Cardiovascular System \& Cardiology}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems}},
Author-Email = {{William\_Frishman@nymc.edu}},
Cited-References = {{Avsar E, 2004, NEUROPHARMACOLOGY, V47, P427, DOI 10.1016/j.neuropharm.2004.04.015.
   Boison D, 2005, NEUROSCIENTIST, V11, P25, DOI 10.1177/10738404269112.
   Butler J, 2004, AM HEART J, V147, P331, DOI 10.1016/j.ahj.2003.08.012.
   CHAPARRO S, 2008, DRUG EVA, V4, P117.
   Cleland JGF, 2007, EUR J HEART FAIL, V9, P850, DOI 10.1016/j.ejheart.2007.07.003.
   Cotter G, 2008, J CARD FAIL, V14, P631, DOI 10.1016/j.cardfail.2008.08.010.
   Degoma EM, 2006, J AM COLL CARDIOL, V48, P2397, DOI 10.1016/j.jacc.2006.08.039.
   Dittrich HC, 2007, J CARD FAIL, V13, P609, DOI 10.1016/j.cardfail.2007.08.006.
   ESHAGHIAN S, 2006, AM J CARDIOL, V37, P1216.
   Fonarow GC, 2007, ARCH INTERN MED, V167, P1493, DOI 10.1001/archinte.167.14.1493.
   Fonarow GC, 2007, AM HEART J, V153, P1021, DOI 10.1016/j.ahj.2007.03.012.
   Forman DE, 2004, J AM COLL CARDIOL, V43, P61, DOI 10.1016/j.jacc.2003.07.031.
   Forman MB, 2000, J PHARMACOL EXP THER, V292, P929.
   FRISHMAN WH, 2003, CARDIOVASC PHARMACOT, P545.
   Funaya H, 1997, CIRCULATION, V95, P1363.
   Givertz MM, 2007, J AM COLL CARDIOL, V50, P1551, DOI 10.1016/j.jacc.2007.07.019.
   Gottlieb SS, 2002, J CARD FAIL, V8, P136, DOI 10.1054/jcaf.2002.125289.
   Gottlieb SS, 2002, CIRCULATION, V105, P1348, DOI 10.1161/hc1102.105264.
   GOTTLIEB SS, 2001, DRUGS, V61, P1388.
   Greenberg B, 2007, J AM COLL CARDIOL, V50, P600, DOI 10.1016/j.jacc.2007.03.059.
   Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONHA.105.167586.
   Krumholz HM, 2000, AM J CARDIOL, V85, P1110, DOI 10.1016/S0002-9149(00)00705-0.
   Liang Kelly V, 2008, Crit Care Med, V36, pS75, DOI 10.1097/01.CCM.0000296270.41256.5C.
   Liao YL, 2003, CIRC RES, V93, P759, DOI 10.1161/01.RES.0000094744.88220.62.
   Metra M, 2008, EUR J HEART FAIL, V10, P188, DOI 10.1016/j.ejheart.2008.01.011.
   Miracle CM, 2007, KIDNEY BLOOD PRESS R, V30, P388, DOI 10.1159/000108625.
   Nonaka H, 1996, BRIT J PHARMACOL, V117, P1645, DOI 10.1111/j.1476-5381.1996.tb15335.x.
   Rieg T, 2005, J PHARMACOL EXP THER, V313, P403, DOI 10.1124/jpet.104.080432.
   Shin DD, 2007, AM J CARDIOL, V99, p4A, DOI 10.1016/j.amjcard.2006.11.025.
   Slawsky MT, 2009, EXPERT OPIN PHARMACO, V10, P311, DOI {[}10.1517/14656560802682213 , 10.1517/14656560802682213].
   Yao KZ, 2001, EUR J PHARMACOL, V414, P99, DOI 10.1016/S0014-2999(01)00764-6.
   Yao KZ, 2000, JPN J PHARMACOL, V84, P310, DOI 10.1254/jjp.84.310.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Cardiol. Rev.}},
Doc-Delivery-Number = {{434BC}},
Unique-ID = {{ISI:000265249200005}},
DA = {{2018-08-13}},
}

@article{ ISI:000265419400013,
Author = {Herzog, Torsten and Belyaev, Orlin and Muller, Christophe A. and
   Mittelkotter, Ultich and Seelig, Matthias H. and Weyhe, Dirk and
   Felderbauer, Peter and Schlottmann, Renate and Schrader, Henning and
   Schmidt, Wolfgang E. and Uhl, Waldemar},
Title = {{Bacteribilia After Preoperative Bile Duct Stenting A Prospective Study}},
Journal = {{JOURNAL OF CLINICAL GASTROENTEROLOGY}},
Year = {{2009}},
Volume = {{43}},
Number = {{5}},
Pages = {{457-462}},
Month = {{MAY-JUN}},
Abstract = {{Study Design: A prospective analysis of intraoperative bile duct
   cultures in patients undergoing surgery for both, malignant or benign
   periampullary diseases at the Department of Surgery, St Josef Hospital,
   Bochum, Germany, during a period of 18 months, between January 2004 and
   June 2005.
   Goals: The goals of the presented Study were to investigate the effects
   of preoperative bile duct stenting oil intraoperative bile duct cultures
   and postoperative outcome in patients undergoing pancreatic surgery.
   Background: In pancreatic surgery, bile duct stenting is often aimed at
   improving postoperative outcome. As implantation of xenograft material
   in the main bile duct facilitates bacterial contamination and
   cholangitis, a critical evaluation of stenting is mandatory.
   Study: In all patients with a hepaticojejunostomy (n = 80), a bile duct
   Culture was collected during the operation. All patients received
   antibiotic prophylaxis perioperatively and a retrograde flushing of bile
   ducts with warm saline after bile duct resection. Fifty-one percent
   (41/80) patients had biliary drainage before surgery, whereas 49\%
   (39/80) were operated without preoperative draining procedures.
   Results: After bile duct stenting, 98\% of patients had a positive bile
   culture, whereas only 21\% of infected bile was seen in patients Without
   drainage (P < 0.001). Despite infected bile, only 2\% stented patients
   developed acute cholangitis postoperatively, versus 13\% patients in the
   group without Stent (P = 0.231). After stenting. major complications
   occurred in 12\%, versus 8\% in patients without stent (P = 0.817).
   Conclusions: Preoperative biliary drainage leads to air almost 100\%
   bacterial contamination of bile ducts. With hospital-adjusted antibiotic
   prophylaxis and retrograde flushing of bile ducts, the postoperative
   rate of acute cholangitis and morbidity is riot elevated. A critical
   evaluation of benefits from preoperative biliary drainage for each
   patient is necessary.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Uhl, W (Reprint Author), Ruhr Univ Bochum, St Josef Hosp, Sch Med, Dept Surg, Gudrunstr 56, D-44791 Bochum, Germany.
   Herzog, Torsten; Belyaev, Orlin; Muller, Christophe A.; Mittelkotter, Ultich; Seelig, Matthias H.; Weyhe, Dirk; Uhl, Waldemar, Ruhr Univ Bochum, St Josef Hosp, Sch Med, Dept Surg, D-44791 Bochum, Germany.
   Felderbauer, Peter; Schlottmann, Renate; Schrader, Henning; Schmidt, Wolfgang E., Ruhr Univ Bochum, St Josef Hosp, Sch Med, Dept Internal Med 1, D-44791 Bochum, Germany.}},
DOI = {{10.1097/MCG.0b013e318186b19b}},
ISSN = {{0192-0790}},
EISSN = {{1539-2031}},
Keywords = {{bacteribilia; bile duct stenting; cholangitis; pancreatic surgery}},
Keywords-Plus = {{POSTOPERATIVE INFECTIOUS COMPLICATIONS; INTERNAL BILIARY DRAINAGE;
   OBSTRUCTIVE-JAUNDICE; PANCREATIC HEAD; ANTIBIOTIC-RESISTANCE;
   PANCREATICODUODENECTOMY; MORTALITY; RESECTION; TRACT; RATS}},
Research-Areas = {{Gastroenterology \& Hepatology}},
Web-of-Science-Categories  = {{Gastroenterology \& Hepatology}},
Author-Email = {{w.uhl@klinikum-bochum.de}},
ResearcherID-Numbers = {{Belyaev, Orlin/E-4429-2013}},
Cited-References = {{ARMSTRONG CP, 1984, BRIT J SURG, V71, P234, DOI 10.1002/bjs.1800710326.
   Brooks AD, 2000, ARCH SURG-CHICAGO, V135, P823, DOI 10.1001/archsurg.135.7.823.
   Buchler MW, 2000, BRIT J SURG, V87, P883, DOI 10.1046/j.1365-2168.2000.01465.x.
   CAMERON JL, 1993, ANN SURG, V217, P430, DOI 10.1097/00000658-199305010-00002.
   CRILE G, 1970, SURG GYNECOL OBSTETR, V130, P1049.
   Cybulski Z, 1994, Wiad Lek, V47, P619.
   Diener MK, 2005, WORLD J GASTROENTERO, V11, P1396, DOI 10.3748/wjg.v11.i9.1396.
   Freeman Martin L, 2003, Curr Gastroenterol Rep, V5, P145, DOI 10.1007/s11894-003-0084-9.
   GOUMA DJ, 1986, AM J CLIN NUTR, V44, P362.
   Gouma DJ, 2000, ANN SURG, V232, P786, DOI 10.1097/00000658-200012000-00007.
   GRACE PA, 1986, AM J SURG, V151, P141, DOI 10.1016/0002-9610(86)90024-3.
   GREENFIELD C, 1985, POSTGRAD MED J, V61, P213, DOI 10.1136/pgmj.61.713.213.
   Grizas Saulius, 2005, Medicina (Kaunas), V41, P386.
   Halloran CM, 2002, DIGEST SURG, V19, P138, DOI 10.1159/000052029.
   HATFIELD ARW, 1982, LANCET, V2, P896.
   Heslin MJ, 1998, ARCH SURG-CHICAGO, V133, P149, DOI 10.1001/archsurg.133.2.149.
   Hochwald SN, 1999, ARCH SURG-CHICAGO, V134, P261, DOI 10.1001/archsurg.134.3.261.
   Howard TJ, 2006, J GASTROINTEST SURG, V10, P523, DOI 10.1016/j.gassur.2005.08.011.
   Isenberg G, 2002, GASTROINTEST ENDOSC, V56, P310, DOI 10.1067/mge.2002.126146.
   Jagannath P, 2005, BRIT J SURG, V92, P356, DOI 10.1002/bjs.4864.
   Karsten TM, 1996, EUR J SURG, V162, P881.
   Karsten TM, 1998, J SURG RES, V74, P125, DOI 10.1006/jsre.1997.5192.
   Katsinelos P, 2002, SURG ENDOSC, V16, P1494, DOI 10.1007/s00464-002-4220-7.
   Kimmings AN, 2000, GUT, V46, P725, DOI 10.1136/gut.46.5.725.
   Kuzu MA, 1999, HEPATO-GASTROENTEROL, V46, P2159.
   LAI ECS, 1994, BRIT J SURG, V81, P1195, DOI 10.1002/bjs.1800810839.
   LYGIDAKIS NJ, 1987, ACTA CHIR SCAND, V153, P665.
   MCPHERSON GAD, 1984, BRIT J SURG, V71, P371, DOI 10.1002/bjs.1800710522.
   MCPHERSON GAD, 1982, BRIT J SURG, V69, P261, DOI 10.1002/bjs.1800690511.
   Neoptolemos JP, 1997, BRIT J SURG, V84, P1370.
   Padillo FJ, 2002, WORLD J SURG, V26, P1328, DOI 10.1007/s00268-002-6232-9.
   PITT HA, 1981, AM J SURG, V141, P66, DOI 10.1016/0002-9610(81)90014-3.
   Povoski SP, 1999, ANN SURG, V230, P131, DOI 10.1097/00000658-199908000-00001.
   Rerknimitr R, 2002, GASTROINTEST ENDOSC, V56, P885, DOI 10.1067/mge.2002.129604.
   ROBSON MC, 1970, SURGERY, V68, P471.
   ROUGHNEEN PT, 1986, J SURG RES, V41, P113, DOI 10.1016/0022-4804(86)90016-8.
   SAND J, 1992, AM SURGEON, V58, P324.
   Schlosser W, 2001, SCAND J GASTROENTERO, V36, P214, DOI 10.1080/003655201750065997.
   Sewnath ME, 2001, J AM COLL SURGEONS, V192, P726, DOI 10.1016/S1072-7515(01)00819-5.
   SHAPIRO TM, 1975, ANN SURG, V182, P715, DOI 10.1097/00000658-197512000-00010.
   Stewart PS, 2002, INT J MED MICROBIOL, V292, P107, DOI 10.1078/1438-4221-00196.
   Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1.
   TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097/00000658-199004000-00011.
   Wang DS, 2003, WORLD J GASTROENTERO, V9, P2737.
   Yu JL, 1996, J SURG RES, V62, P69, DOI 10.1006/jsre.1996.0175.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Clin. Gastroenterol.}},
Doc-Delivery-Number = {{436MY}},
Unique-ID = {{ISI:000265419400013}},
DA = {{2018-08-13}},
}

@article{ ISI:000265553700007,
Author = {Alvarado, Carla S. and Gandara, Angelina and Flores, Carissa and Perez,
   Hernando R. and Green, Christopher F. and Hurd, William W. and Gibbs,
   Shawn G.},
Title = {{Seasonal Changes in Airborne Fungi and Bacteria at a Dairy Cattle
   Concentrated Animal Feeding Operation in the Southwest United States}},
Journal = {{JOURNAL OF ENVIRONMENTAL HEALTH}},
Year = {{2009}},
Volume = {{71}},
Number = {{9}},
Pages = {{40-44}},
Month = {{MAY}},
Abstract = {{The objective of this study was to evaluate a dairy located in the and
   southwest United States to determine the concentrations and seasonal
   variation of airborne fungi and bacteria and to determine the percentage
   of antibiotic resistant Staphylococcus aureus. The authors used
   two-stage ambient air sampling systems to measure the culturable
   airborne fungal organisms and bacteria on a monthly basis. The authors
   recovered the most fungal, bacterial, and S. aureus organisms during the
   spring months. The most common fungi identified were Cladosporium,
   Aspergillus, and Stemphylium, which were most common in the spring and
   least common in the summer. S. aureus made up 4.2\% to 5.5\% of the
   total bacteria, and greater than 50\% of this bacteria were found to be
   resistant to ampicillin, penicillin, or cefaclor, with the greatest
   incidence of antibiotic resistance occuring in the fall. The incidence
   of S. aureus resistant to at least two antibiotics ranged from 14\% in
   the spring to 54\% in the fall.}},
Publisher = {{NATL ENVIRON HEALTH ASSOC}},
Address = {{720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gibbs, SG (Reprint Author), Univ Nebraska, Med Ctr, Coll Publ Hlth, Dept Environm Agr \& Occupat Hlth, 600 S 42nd St, Omaha, NE 68198 USA.
   Gibbs, Shawn G., Univ Nebraska, Med Ctr, Coll Publ Hlth, Dept Environm Agr \& Occupat Hlth, Omaha, NE 68198 USA.}},
ISSN = {{0022-0892}},
Keywords-Plus = {{STAPHYLOCOCCUS-AUREUS INFECTIONS; ANTIBIOTIC-RESISTANCE; SWINE; AIR;
   EXPOSURE; INDOOR; HEALTH}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Author-Email = {{sgibbs@unmc.edu}},
Funding-Acknowledgement = {{Center for Border Health Research; Center for Environmental Resource
   Management Environmental Protection Agency; University of Texas at El
   Paso; Susan Navarro and the Hispanic Health Disparities Research Center
   {[}P20 MD000548 NIH/NCMHD]}},
Funding-Text = {{Our research was partially funded by the Center for Border Health
   Research (an initiative of the Paso del Norte Health Foundation) and the
   Center for Environmental Resource Management Environmental Protection
   Agency Student Support at The University of Texas at El Paso. Editorial
   support was provided by Susan Navarro and the Hispanic Health
   Disparities Research Center (P20 MD000548 NIH/NCMHD). The authors do not
   have a competing financial interest in this work.}},
Cited-References = {{American Conference of Governmental Industrial Hygienists, 1999, BIOAER ASS CONTR.
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493.
   Brown KD, 2006, SCI TOTAL ENVIRON, V366, P772, DOI 10.1016/j.scitotenv.2005.10.007.
   Chapin A, 2005, ENVIRON HEALTH PERSP, V113, P137, DOI 10.1289/ehp.7473.
   Donham KJ, 2007, ENVIRON HEALTH PERSP, V115, P317, DOI 10.1289/ehp.8836.
   Gibbs SG, 2004, J OCCUP ENVIRON HYG, V1, P699, DOI 10.1080/15459620490515824.
   Gibbs SG, 2006, ENVIRON HEALTH PERSP, V114, P1032, DOI 10.1289/ehp.8910.
   Gilchrist MJ, 2007, ENVIRON HEALTH PERSP, V115, P313, DOI 10.1289/ehp.8837.
   Green CF, 2006, J OCCUP ENVIRON HYG, V3, P9, DOI 10.1080/15459620500430615.
   Heederik D, 2007, ENVIRON HEALTH PERSP, V115, P298, DOI 10.1289/ehp.8835.
   Jo WK, 2005, ARCH ENVIRON OCCUP H, V60, P140, DOI 10.3200/AEOH.60.3.140-146.
   Jo WK, 2005, CHEMOSPHERE, V61, P1570, DOI 10.1016/j.chemosphere.2005.04.103.
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763.
   Liao CM, 2005, SCI TOTAL ENVIRON, V347, P78, DOI 10.1016/j.scitotenv.2004.12.036.
   MALLOCH D, 1981, MOULDS THEIR ISOLATI.
   Menetrez MY, 2001, J AIR WASTE MANAGE, V51, P1436, DOI 10.1080/10473289.2001.10464365.
   Mirabelli MC, 2006, ENVIRON HEALTH PERSP, V114, P591, DOI 10.1289/ehp.8586.
   Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356.
   OKTEN SS, 2004, TRAKYA U J SCI, V6, P97.
   Radon K, 2001, OCCUP ENVIRON MED, V58, P405, DOI 10.1136/oem.58.6.405.
   Randrianirina Frederique, 2007, Ann Clin Microbiol Antimicrob, V6, P5, DOI 10.1186/1476-0711-6-5.
   Rule AM, 2005, ENVIRON SCI TECHNOL, V39, P9649, DOI 10.1021/es0501316.
   Sapkota AR, 2006, LETT APPL MICROBIOL, V43, P534, DOI 10.1111/j.1472-765X.2006.01996.x.
   {*}US EPA, 2007, REG DEF LARG CAFOS M.
   Von Essen Susanna G, 2005, J Agromedicine, V10, P55, DOI 10.1300/J096v10n04\_08.
   Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Environ. Health}},
Doc-Delivery-Number = {{438KG}},
Unique-ID = {{ISI:000265553700007}},
DA = {{2018-08-13}},
}

@article{ ISI:000265098700001,
Author = {Lis, Danuta O. and Pacha, Jerzy Z. and Idzik, Danuta},
Title = {{Methicillin resistance of airborne coagulase-negative staphylococci in
   homes of persons having contact with a hospital environment}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{2009}},
Volume = {{37}},
Number = {{3}},
Pages = {{177-182}},
Month = {{APR}},
Abstract = {{Background: The persons having contact with a hospital environment
   (hospital personnel workers and discharged patients) are highly exposed
   to colonization with multidrug-resistant bacteria. The aim of this study
   was to evaluate the airborne Staphylococcus genus features in homes in
   which inhabitants have had contact with the hospital environment.
   Methods: Airborne bacteria were collected using a 6-stage Anderson
   impactor. The Staphylococcus species composition and resistance to
   methicillin, and other antimicrobial agents among 3 coagulase-negative
   staphylococci (CNS) species (S cohnii spp cohnii, S epidermidis, S
   hominis), were determined. Antibiotic resistance of isolates was tested
   using the agar screen method with methicillin, the polymerase chain
   reaction technique to detect the mecA gene, and the disk diffusion
   method.
   Results: A higher prevalence of methicillin-resistant (MR) strains among
   the species isolated (40\% of Sepidermidis, 40\% of Shominis, and 60\%
   of S cohnii spp cohnii) was found in homes of persons who had contact
   with a hospital environment compared with the reference homes (only 12\%
   of S hominis). The mecA gene was revealed in all MR S epidermidis
   strains and in some MR S hominis (50\%) and S cohnii spp cohnii (33\%)
   strains. All isolated MR CNS strains were susceptible to vancomycin,
   rifampicin, and linezolid.
   Conclusion: High numbers of airborne multidrug-resistant MR CNS in the
   homes of persons having contact with a hospital environment indicates
   that such inhabitants pose a risk of intrafamilial spreading of MR
   strains via air. Copyright (c) 2009 by the Association for Professionals
   in Infection Control and Epidemiology, Inc.}},
Publisher = {{MOSBY-ELSEVIER}},
Address = {{360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lis, DO (Reprint Author), Inst Occupat Med \& Environm Hlth, Dept Biohazards, 13 Koscielna St, PL-41200 Sosnowiec, Poland.
   Lis, Danuta O., Inst Occupat Med \& Environm Hlth, Dept Biohazards, PL-41200 Sosnowiec, Poland.
   Pacha, Jerzy Z.; Idzik, Danuta, Med Univ Silesia, Dept Microbiol, Sosnowiec, Poland.}},
DOI = {{10.1016/j.ajic.2008.09.013}},
ISSN = {{0196-6553}},
Keywords-Plus = {{AUREUS; COMMUNITY; SUSCEPTIBILITY; IDENTIFICATION; BACTERIAL; CARRIAGE;
   STRAINS; MRSA; PCR}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
ResearcherID-Numbers = {{Lis, Danuta/H-9921-2013}},
ORCID-Numbers = {{Lis, Danuta/0000-0002-9657-7650}},
Funding-Acknowledgement = {{Polish Ministry of Education and Science Research Grant {[}2 P05D 024
   28]}},
Funding-Text = {{Supported by Polish Ministry of Education and Science Research Grant 2
   P05D 024 28, The authors report no conflicts of interest.}},
Cited-References = {{ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   Augustowska M, 2006, ANN AGR ENV MED, V13, P99.
   Bogado I, 2001, J APPL MICROBIOL, V91, P344, DOI 10.1046/j.1365-2672.2001.01400.x.
   Bouillard L, 2005, ANN AGR ENV MED, V12, P187.
   Calfee DP, 2003, INFECT CONT HOSP EP, V24, P422, DOI 10.1086/502225.
   Cespedes C, 2002, J CLIN MICROBIOL, V40, P2594, DOI 10.1128/JCM.40.7.2594-2597.2002.
   Chambers HF, 1997, CLIN MICROBIOL REV, V10, P781.
   {*}CLIN LAB STAND I, 2005, PERF STAND ANT TES S.
   DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632.
   Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184.
   Eveillard M, 2004, INFECT CONT HOSP EP, V25, P114, DOI 10.1086/502360.
   Gorny RL, 1999, ANN AGR ENV MED, V6, P105.
   Gorny RL, 2002, ANN AGR ENV MED, V9, P17.
   HAWKEY P, 2001, MICROBIOL TODAY, V28, P7.
   Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593.
   Jaffe RI, 2000, J CLIN MICROBIOL, V38, P3407.
   Kiss L, 1996, Acta Microbiol Immunol Hung, V43, P39.
   KLOOS WE, 1994, CLIN MICROBIOL REV, V7, P117.
   Kocagoz S, 1997, J CLIN MICROBIOL, V35, P2188.
   LARSON EL, 1986, J CLIN MICROBIOL, V23, P604.
   Livermore DM, 2000, INT J ANTIMICROB AG, V16, pS3.
   Lodise TP, 2005, DIAGN MICR INFEC DIS, V52, P113, DOI 10.1016/j.diagmicrobio.2005.02.007.
   MANDEL GL, 2005, MANDELL DOUGLAS BENN.
   Moschandreas DJ, 2003, AEROSOL SCI TECH, V37, P899, DOI 10.1080/02786820390229039.
   MURAKAMI K, 1991, J CLIN MICROBIOL, V29, P2240.
   NEVALAINEN A, 1989, THESIS U KUOPIO.
   OPAL SM, 1990, INFECT CONT HOSP EP, V11, P479, DOI 10.2307/30146980.
   Reponen T, 1992, INDOOR AIR, V2, P26, DOI DOI 10.1111/J.1600-0668.1992.03-21.X.
   Rybak MJ, 2005, PHARMACOTHERAPY, V25, P74, DOI 10.1592/phco.25.1.74.55620.
   Salmenlinna S, 2002, EMERG INFECT DIS, V8, P602, DOI 10.3201/eid0806.010313.
   Scudeller L, 2000, J HOSP INFECT, V46, P222, DOI 10.1053/jhin.2000.0806.
   Szewczyk Eligia M., 2000, Acta Microbiologica Polonica, V49, P121.
   Takashima M, 2004, AM J INFECT CONTROL, V32, P27, DOI 10.1016/j.ajic.2003.05.003.
   TOMASZ A, 1989, ANTIMICROB AGENTS CH, V33, P1869, DOI 10.1128/AAC.33.11.1869.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{16}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{431XS}},
Unique-ID = {{ISI:000265098700001}},
DA = {{2018-08-13}},
}

@article{ ISI:000264026000001,
Author = {Doran, A. L. and Morden, W. E. and Dunn, K. and Edwards-Jones, V.},
Title = {{Vapour-phase activities of essential oils against antibiotic sensitive
   and resistant bacteria including MRSA}},
Journal = {{LETTERS IN APPLIED MICROBIOLOGY}},
Year = {{2009}},
Volume = {{48}},
Number = {{4}},
Pages = {{387-392}},
Month = {{APR}},
Abstract = {{To determine whether essential oil (EO) vapours could reduce surface and
   airborne levels of bacteria including methicillin-resistant
   Staphylococcus aureus (MRSA).
   The antibacterial activity of geranium and lemongrass EO individually
   and blended were evaluated over a range of concentrations by direct
   contact and vapour diffusion. The EO were tested in vitro against a
   selection of antibiotic-sensitive and -resistant bacteria, including
   MRSA, vancomycin-resistant Enterococci (VRE), Acinetobacter baumanii and
   Clostridium difficile. An EO blend containing lemongrass and geranium
   was used to formulate BioScent(TM) that was dispersed into the
   environment using the ST Pro(TM) machine. The effects were variable
   depending on the methods used. In a sealed box environment, MRSA growth
   on seeded plates was reduced by 38\% after 20 h exposure to BioScent(TM)
   vapour. In an office environment, the ST Pro(TM) machine dispersing
   BioScent(TM) effected an 89\% reduction of airborne bacteria in 15 h,
   when operated at a constant output of 100\%.
   EO vapours inhibited growth of antibiotic-sensitive and -resistant
   bacteria in vitro and reduced surface and airborne levels of bacteria.
   Results suggest that EO vapours, particularly Bioscent(TM), could be
   used as a method of air disinfection.}},
Publisher = {{WILEY-BLACKWELL PUBLISHING, INC}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Edwards-Jones, V (Reprint Author), Manchester Metropolitan Univ, Sch Biol Chem \& Hlth Sci, Manchester M15 6BH, Lancs, England.
   Doran, A. L.; Edwards-Jones, V., Manchester Metropolitan Univ, Sch Biol Chem \& Hlth Sci, Manchester M15 6BH, Lancs, England.
   Dunn, K., Wythenshawe Hosp, Burns Ctr, Manchester M23 9LT, Lancs, England.}},
DOI = {{10.1111/j.1472-765X.2009.02552.x}},
ISSN = {{0266-8254}},
Keywords = {{antimicrobial; essential oils; MRSA; vapours}},
Keywords-Plus = {{TEA TREE; FOOD}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{v.e.jones@mmu.ac.uk}},
Funding-Acknowledgement = {{Scent Technologies}},
Funding-Text = {{The authors are grateful to Scent Technologies for funding this research
   and also to Helen Duxberry, Anne Leahy-Gilmartin and Alan Surrey for
   their technical assistance.}},
Cited-References = {{Carson CF, 2002, ANTIMICROB AGENTS CH, V46, P1914, DOI 10.1128/AAC.46.6.1914-1920.2002.
   Delaquis PJ, 2002, INT J FOOD MICROBIOL, V74, P101, DOI 10.1016/S0168-1605(01)00734-6.
   Edwards-Jones V, 2004, BURNS, V30, P772, DOI 10.1016/j.burns.2004.06.006.
   Fisher K, 2007, LETT APPL MICROBIOL, V44, P495, DOI 10.1111/j.1472-765X.2006.02106.x.
   Inouye S., 2003, International Journal of Aromatherapy, V13, P33, DOI 10.1016/S0962-4562(03)00057-2.
   Inouye Shigeharu, 2006, Journal of Infection and Chemotherapy, V12, P349, DOI 10.1007/s10156-006-0474-7.
   INOYUE S, 2001, J ANTIMICROB CHEMOTH, V47, P565.
   Otter JA, 2007, J HOSP INFECT, V67, P182, DOI 10.1016/j.jhin.2007.07.019.
   Schelz Z, 2006, FITOTERAPIA, V77, P279, DOI 10.1016/j.fitote.2006.03.013.
   Smith-Palmer A, 1998, LETT APPL MICROBIOL, V26, P118, DOI 10.1046/j.1472-765X.1998.00303.x.
   TISSERAND R, 1996, ESSENTIAL OIL SAFETY.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{16}},
Journal-ISO = {{Lett. Appl. Microbiol.}},
Doc-Delivery-Number = {{416SO}},
Unique-ID = {{ISI:000264026000001}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000260989100025,
Author = {Filiousis, George and Johansson, Anders and Frey, Joachim and Perreten,
   Vincent},
Title = {{Prevalence, genetic diversity and antimicrobial susceptibility of
   Listeria monocytogenes isolated from open-air food markets in Greece}},
Journal = {{FOOD CONTROL}},
Year = {{2009}},
Volume = {{20}},
Number = {{3}},
Pages = {{314-317}},
Month = {{MAR}},
Abstract = {{A total of 210 food samples originating from milk products, ready-to-eat
   salads, raw meat and raw meat products purchased in ten open-air market
   places in Thessaloniki, Greece, were analyzed for the presence of
   Listeria monocytogenes. Thirty (14.3\%) contained L. monocytogenes with
   the highest prevalence in raw meat (27.5\%), raw meat products (18\%)
   and cheese (8\%). The strains were susceptible to 16 antimicrobials as
   determined by microbroth dilution, except one strain which displayed
   resistance to tetracycline (MIC > 32 mu g/ml). This strain carried the
   tetracycline resistance gene tet(M). Pulsed-field gel electrophoresis
   (PFGE) revealed a low genetic diversity among the isolates, irrespective
   of their origin. This suggests that dominant L monocytogenes clones are
   widespread in different food product types in open-air food markets in
   Greece. The high prevalence of L monocytogenes in these products
   indicates that appropriate hygienic measures and periodic
   bacteriological controls are also necessary in open-air food markets to
   reduce contamination with food-borne pathogens. Greek specialties made
   with raw meat and raw milk may contain L monocytogenes and should not be
   consumed by persons at risk. (C) 2008 Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Perreten, V (Reprint Author), Univ Bern, Inst Vet Bacteriol, Langgass Str 122, CH-3001 Bern, Switzerland.
   Filiousis, George; Johansson, Anders; Frey, Joachim; Perreten, Vincent, Univ Bern, Inst Vet Bacteriol, CH-3001 Bern, Switzerland.
   Filiousis, George, Univ Thessaly, Sch Vet, Dept Med, Volos, Greece.}},
DOI = {{10.1016/j.foodcont.2008.05.018}},
ISSN = {{0956-7135}},
Keywords = {{Listeria monocytogenes; Food; Antimicrobial resistance; Hygiene;
   Pulsed-field gel electrophoresis (PFGE)}},
Keywords-Plus = {{ANTIBIOTIC-RESISTANCE; MEAT; PRODUCTS; CONTAMINATION; SPP.}},
Research-Areas = {{Food Science \& Technology}},
Web-of-Science-Categories  = {{Food Science \& Technology}},
Author-Email = {{vincent.perreten@vbi.unibe.ch}},
Funding-Acknowledgement = {{Institute of Veterinary Bacteriology, University of Berne}},
Funding-Text = {{This work was partially supported by the research Grant of the Institute
   of Veterinary Bacteriology, University of Berne.}},
Cited-References = {{Abrahim A, 1998, J FOOD PROTECT, V61, P1378, DOI 10.4315/0362-028X-61.10.1378.
   Angelidis AS, 2006, J FOOD PROTECT, V69, P938, DOI 10.4315/0362-028X-69.4.938.
   Autio T, 2002, INT J FOOD MICROBIOL, V77, P83, DOI 10.1016/S0168-1605(02)00055-7.
   Barbosa TM, 1999, ENVIRON MICROBIOL, V1, P53, DOI 10.1046/j.1462-2920.1999.00004.x.
   Bertrand S, 2005, J MED MICROBIOL, V54, P1151, DOI 10.1099/jmm.0.46142-0.
   CHARPENTIER E, 1995, J INFECT DIS, V172, P277, DOI 10.1093/infdis/172.1.277.
   Chasseignaux E, 2001, J APPL MICROBIOL, V91, P888, DOI 10.1046/j.1365-2672.2001.01445.x.
   {*}CLIN LAB STAND I, 2006, METH DIL ANT SUSC TE, V26.
   {*}CLIN LAB STAND I, 2006, METH ANT DIL DISK SU, V26.
   Corcoran D, 2006, INT J HYG ENVIR HEAL, V209, P527, DOI 10.1016/j.ijheh.2006.06.001.
   de Valk H, 2005, Euro Surveill, V10, P251.
   FARBER JM, 1991, MICROBIOL REV, V55, P476.
   Graves LM, 2001, INT J FOOD MICROBIOL, V65, P55, DOI 10.1016/S0168-1605(00)00501-8.
   Vitas AI, 2007, J FOOD PROTECT, V70, P2402, DOI 10.4315/0362-028X-70.10.2402.
   Liu DY, 2004, INT J FOOD MICROBIOL, V91, P297, DOI {[}10.1016/j.ijfoodmicro.2003.07.004, 10.1016/j.ijffodmicro.2003.07.004].
   LONCAREVIC S, 1995, INT J FOOD MICROBIOL, V26, P245, DOI 10.1016/0168-1605(95)00105-S.
   Peccio A, 2003, LETT APPL MICROBIOL, V37, P234, DOI 10.1046/j.1472-765X.2003.01384.x.
   Perreten V, 2005, FRONTIERS IN ANTIMICROBIAL RESISTANCE: A TRIBUTE TO STUART B. LEVY, P446.
   PINNER RW, 1992, JAMA-J AM MED ASSOC, V267, P2046, DOI 10.1001/jama.267.15.2046.
   Praakle-Amin K, 2006, J FOOD PROTECT, V69, P436, DOI 10.4315/0362-028X-69.2.436.
   Safdar A, 2003, J CLIN MICROBIOL, V41, P483, DOI 10.1128/JCM.41.1.483-485.2003.
   Samelis J, 1999, FOOD MICROBIOL, V16, P465, DOI 10.1006/fmic.1998.0263.
   Tsakris A, 1997, J ANTIMICROB CHEMOTH, V39, P553, DOI 10.1093/jac/39.4.553.
   Wagner M, 2007, ZOONOSES PUBLIC HLTH, V54, P16, DOI 10.1111/j.1863-2378.2007.00982.x.
   Zhang YF, 2007, INT J FOOD MICROBIOL, V113, P47, DOI 10.1016/j.ijfoodmicro.2006.07.010.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Food Control}},
Doc-Delivery-Number = {{373RF}},
Unique-ID = {{ISI:000260989100025}},
DA = {{2018-08-13}},
}

@article{ ISI:000263962200009,
Author = {Gehanno, J. F. and Louvel, A. and Nouvellon, M. and Caillard, J-F. and
   Pestel-Caron, M.},
Title = {{Aerial dispersal of meticillin-resistant Staphylococcus aureus in
   hospital rooms by infected or colonised patients}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{2009}},
Volume = {{71}},
Number = {{3}},
Pages = {{256-262}},
Month = {{MAR}},
Abstract = {{The aim of this study was to assess to what extent patients with
   meticillin-resistant Staphylococcus aureus (MRSA) at respiratory sites
   shed viable MRSA into the air of hospital rooms. We also evaluated
   whether the distance from the patient could influence the level of
   contamination. Air sampling was performed directly onto MRSA-selective
   agar in 24 hospital rooms containing patients with MRSA colonization or
   infection of the respiratory tract. Samplings were performed in
   duplicate at 0.5, 1 and 2-3 m from the patients' heads. Clinical and
   environmental isolates were compared using antimicrobial resistance
   patterns and pulsed-field get electrophoresis. MRSA strains were
   isolated from 21 out of 24 rooms, in quantities varying from between 1
   and 78 cfu/m(3). In each of the 21 rooms, at least one of the
   environmental isolates was identical to a clinical isolate from the
   patient in that room. There was no significant difference in MRSA counts
   between the distance from the patient's head and the sampler. This study
   demonstrates that most patients with MRSA infection or colonisation of
   the respiratory tract shed viable MRSA into the air of their room. The
   results emphasise the need to study MRSA in air in more detail in order
   to improve infection control recommendations. (C) 2008 The Hospital
   Infection Society. Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gehanno, JF (Reprint Author), Rouen Univ Hosp, Dept Occupat Hlth, 1 Rue Germont, F-76000 Rouen, France.
   Gehanno, J. F.; Louvel, A.; Caillard, J-F., Rouen Univ Hosp, Dept Occupat Med, F-76000 Rouen, France.
   Nouvellon, M.; Pestel-Caron, M., Rouen Univ Hosp, Microbiol Lab, F-76000 Rouen, France.}},
DOI = {{10.1016/j.jhin.2008.11.015}},
ISSN = {{0195-6701}},
Keywords = {{Air microbiology; Environmental monitoring; Infection control;
   Meticillin-resistant Staphylococcus aureus}},
Keywords-Plus = {{FIELD GEL-ELECTROPHORESIS; INFLUENZA-A; AIRBORNE; TRANSMISSION; SPREAD;
   CONTAMINATION; COLLECTION; PREVENTION; CARRIAGE; STRAINS}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{jean-francois.gehanno@chu-rouen.fr}},
ORCID-Numbers = {{Gehanno, jean-francois/0000-0002-2309-7322}},
Funding-Acknowledgement = {{Caisse Nationale de Retraite des Agents des Cottectivites Locates;
   Agence Fran aise de Securite Sanitaire de l'Environnement et du Travail}},
Funding-Text = {{This study was funded by grants from the Caisse Nationale de Retraite
   des Agents des Cottectivites Locates and the Agence Fran aise de
   Securite Sanitaire de l'Environnement et du Travail.}},
Cited-References = {{ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   Bischoff WE, 2007, INFECT CONT HOSP EP, V28, P1148, DOI 10.1086/520734.
   Bischoff WE, 2006, J INFECT DIS, V194, P1119, DOI 10.1086/507908.
   Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622.
   Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4.
   Cespedes C, 2005, J INFECT DIS, V191, P444, DOI 10.1086/427240.
   Cookson BD, 2007, J CLIN MICROBIOL, V45, P1830, DOI 10.1128/JCM.02402-06.
   Kramer A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-130.
   LIDWELL OM, 1975, J HYG-CAMBRIDGE, V75, P445, DOI 10.1017/S0022172400024505.
   Lim MSC, 2006, INFECT CONT HOSP EP, V27, P1063, DOI 10.1086/507959.
   Loveday HP, 2006, J HOSP INFECT, V63, pS45, DOI 10.1016/j.jhin.2006.01.002.
   MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319.
   Murchan S, 2003, J CLIN MICROBIOL, V41, P1574, DOI 10.1128/JCM.41.4.1574-1585.2003.
   Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976.
   Sexton T, 2006, J HOSP INFECT, V62, P187, DOI 10.1016/j.jhin.2005.07.017.
   Sherertz RJ, 1996, ANN INTERN MED, V124, P539, DOI 10.7326/0003-4819-124-6-199603150-00001.
   Shiomori T, 2002, J HOSP INFECT, V50, P30, DOI 10.1053/jhin.2001.1136.
   Siegel J. D., 2007, 2007 GUIDELINE ISOLA.
   Solberg CO, 2000, SCAND J INFECT DIS, V32, P587, DOI 10.1080/003655400459478.
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426.
   TENOVER FC, 1994, J CLIN MICROBIOL, V32, P407.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   WILLIAMS RE, 1966, BACTERIOL REV, V30, P660.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{415UW}},
Unique-ID = {{ISI:000263962200009}},
DA = {{2018-08-13}},
}

@article{ ISI:000266214700007,
Author = {Escombe, A. Roderick and Moore, David A. J. and Gilman, Robert H. and
   Navincopa, Marcos and Ticona, Eduardo and Mitchell, Bailey and Noakes,
   Catherine and Martinez, Carlos and Sheen, Patricia and Ramirez, Rocio
   and Quino, Willi and Gonzalez, Armando and Friedland, Jon S. and Evans,
   Carlton A.},
Title = {{Upper-Room Ultraviolet Light and Negative Air Ionization to Prevent
   Tuberculosis Transmission}},
Journal = {{PLOS MEDICINE}},
Year = {{2009}},
Volume = {{6}},
Number = {{3}},
Month = {{MAR}},
Abstract = {{Background
   Institutional tuberculosis (TB) transmission is an important public
   health problem highlighted by the HIV/AIDS pandemic and the emergence of
   multidrug- and extensively drug-resistant TB. Effective TB infection
   control measures are urgently needed. We evaluated the efficacy of
   upper-room ultraviolet (UV) lights and negative air ionization for
   preventing airborne TB transmission using a guinea pig air-sampling
   model to measure the TB infectiousness of ward air.
   Methods and Findings
   For 535 consecutive days, exhaust air from an HIV-TB ward in Lima, Peru,
   was passed through three guinea pig air-sampling enclosures each housing
   approximately 150 guinea pigs, using a 2-d cycle. On UV-off days, ward
   air passed in parallel through a control animal enclosure and a similar
   enclosure containing negative ionizers. On UV-on days, UV lights and
   mixing fans were turned on in the ward, and a third animal enclosure
   alone received ward air. TB infection in guinea pigs was defined by
   monthly tuberculin skin tests. All guinea pigs underwent autopsy to test
   for TB disease, defined by characteristic autopsy changes or by the
   culture of Mycobacterium tuberculosis from organs. 35\% (106/304) of
   guinea pigs in the control group developed TB infection, and this was
   reduced to 14\% (43/303) by ionizers, and to 9.5\% (29/307) by UV lights
   (both p < 0.0001 compared with the control group). TB disease was
   confirmed in 8.6\% (26/304) of control group animals, and this was
   reduced to 4.3\% (13/303) by ionizers, and to 3.6\% (11/307) by UV
   lights (both p < 0.03 compared with the control group). Time-to-event
   analysis demonstrated that TB infection was prevented by ionizers
   (log-rank 27; p < 0.0001) and by UV lights (log-rank 46; p < 0.0001).
   Time-to-event analysis also demonstrated that TB disease was prevented
   by ionizers (log-rank 3.7; p=0.055) and by UV lights (log-rank 5.4;
   p=0.02). An alternative analysis using an airborne infection model
   demonstrated that ionizers prevented 60\% of TB infection and 51\% of TB
   disease, and that UV lights prevented 70\% of TB infection and 54\% of
   TB disease. In all analysis strategies, UV lights tended to be more
   protective than ionizers.
   Conclusions
   Upper-room UV lights and negative air ionization each prevented most
   airborne TB transmission detectable by guinea pig air sampling. Provided
   there is adequate mixing of room air, upper-room UV light is an
   effective, low-cost intervention for use in TB infection control in
   high-risk clinical settings.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Escombe, AR (Reprint Author), Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immun, London, England.
   Escombe, A. Roderick; Moore, David A. J.; Friedland, Jon S.; Evans, Carlton A., Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immun, London, England.
   Escombe, A. Roderick; Moore, David A. J.; Friedland, Jon S.; Evans, Carlton A., Univ London Imperial Coll Sci Technol \& Med, Wellcome Ctr Clin Trop Med, London, England.
   Escombe, A. Roderick; Moore, David A. J.; Gilman, Robert H.; Evans, Carlton A., Asociac Benefica PRISMA, Lima, Peru.
   Moore, David A. J.; Gilman, Robert H.; Sheen, Patricia; Quino, Willi; Evans, Carlton A., Univ Peruana Cayetano Heredia, Lima, Peru.
   Moore, David A. J.; Gilman, Robert H.; Martinez, Carlos; Evans, Carlton A., Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   Navincopa, Marcos; Ticona, Eduardo, Hosp Nacl Dos Mayo, Lima, Peru.
   Navincopa, Marcos; Ramirez, Rocio; Gonzalez, Armando, Univ Nacl Mayor San Marcos, Lima 14, Peru.
   Mitchell, Bailey, ARS, USDA, Washington, DC USA.
   Noakes, Catherine, Univ Leeds, Sch Civil Engn, Leeds, W Yorkshire, England.}},
DOI = {{10.1371/journal.pmed.1000043}},
Article-Number = {{e1000043}},
ISSN = {{1549-1676}},
Keywords-Plus = {{ELECTROSTATIC SPACE-CHARGE; REDUCING AIRBORNE PATHOGENS; GERMICIDAL
   IRRADIATION; NOSOCOMIAL TUBERCULOSIS; SALMONELLA-ENTERITIDIS; RESISTANT
   TUBERCULOSIS; HATCHING CABINETS; INFECTED PATIENTS; DISINFECTION; RISK}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{rod.escombe@imperial.ac.uk}},
ORCID-Numbers = {{Evans, Carlton/0000-0002-6873-5447}},
Funding-Acknowledgement = {{The Wellcome Trust; The Halley Stewart Trust; Proyecto Vigia (U.S.
   Agency for International Development {[}USAID]); Innovation For Health
   And Development (IFHAD); Engineering and Physical Sciences Research
   Council (EPSRC)}},
Funding-Text = {{The authors would like to thank The Wellcome Trust, The Halley Stewart
   Trust, Proyecto Vigia (U.S. Agency for International Development
   {[}USAID]), Innovation For Health And Development (IFHAD), and the
   Engineering and Physical Sciences Research Council (EPSRC) for funding
   this work. The funding agencies and the donors of the UV lamps had no
   involvement in study design; in the collection, analysis, and
   interpretation of data; in the writing of the report; and in the
   decision to submit the article for publication. All researchers were
   independent of the funding agencies.}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   ALTMAN R, 2000, STAT GUIDELINES CONT.
   Arnold JW, 2002, J APPL POULTRY RES, V11, P179, DOI 10.1093/japr/11.2.179.
   BALASUBRAMANIAN V, 1992, INFECT IMMUN, V60, P4762.
   Basu S, 2007, LANCET, V370, P1500, DOI 10.1016/S0140-6736(07)61636-5.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   Brubacher J, 1996, CHEST, V109, P582, DOI 10.1378/chest.109.2.582-a.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490.
   Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Escombe AR, 2008, PLOS MED, V5, P1387, DOI 10.1371/journal.pmed.0050188.
   First M, 2007, J OCCUP ENVIRON HYG, V4, P321, DOI 10.1080/15459620701271693.
   First MW, 2006, LEUKOS, V3, P181, DOI 10.1582/LEUKOS.2007.03.03.005.
   First MW, 2005, J OCCUP ENVIRON HYG, V2, P285, DOI 10.1080/1545962059095224.
   Fletcher LA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-32.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Gast RK, 1999, POULTRY SCI, V78, P57, DOI 10.1093/ps/78.1.57.
   ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   Kerr KG, 2006, INTENS CARE MED, V32, P315, DOI 10.1007/s00134-005-0002-8.
   Ko G, 2002, ENVIRON HEALTH PERSP, V110, P95.
   Ko GP, 2001, RISK ANAL, V21, P657, DOI 10.1111/0272-4332.214142.
   Macher JM, 1992, APPL OCCUP ENV HYG, V7, P505.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Mitchell BW, 2002, POULTRY SCI, V81, P49, DOI 10.1093/ps/81.1.49.
   Mitchell BW, 2003, AVIAN DIS, V47, P247, DOI 10.1637/0005-2086(2003)047{[}0247:RAPADI]2.0.CO;2.
   Mohle-Boetani JC, 2002, CLIN INFECT DIS, V34, P668, DOI 10.1086/338815.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Nardell EA, 1999, CHEST, V116, P1143, DOI 10.1378/chest.116.4.1143.
   Nardell EA, 2008, PUBLIC HEALTH REP, V123, P52, DOI 10.1177/003335490812300108.
   Nardell EA, 2006, AM J RESP CRIT CARE, V174, P734, DOI 10.1164/rccm.200607-923ED.
   Nicas M, 1999, Appl Occup Environ Hyg, V14, P317.
   Noakes CJ, 2006, INDOOR BUILT ENVIRON, V15, P41, DOI 10.1177/1420326X06062364.
   Pai M, 2006, EMERG INFECT DIS, V12, P1311, DOI 10.3201/eid1209.051663.
   Richardson LJ, 2003, AVIAN DIS, V47, P1352, DOI 10.1637/7013.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P208, DOI 10.1080/00039896.1971.10665834.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P200, DOI 10.1080/00039896.1971.10665833.
   RILEY RL, 1957, AM REV TUBERC PULM, V76, P931.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   Rudnick SN, 2007, J OCCUP ENVIRON HYG, V4, P352, DOI 10.1080/15459620701298167.
   Seo KH, 2001, J FOOD PROTECT, V64, P113, DOI 10.4315/0362-028X-64.1.113.
   STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a.
   Talbot EA, 2002, INT J TUBERC LUNG D, V6, P738.
   VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151.
   {*}WHO, 1999, GUID PREV TUB HEALTH.
   Xu P, 2005, ENVIRON SCI TECHNOL, V39, P9656, DOI 10.1021/es0504892.
   Xu P, 2003, ATMOS ENVIRON, V37, P405, DOI 10.1016/S1352-2310(02)00825-7.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{70}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{PLos Med.}},
Doc-Delivery-Number = {{447TM}},
Unique-ID = {{ISI:000266214700007}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000262646500031,
Author = {Stroemstedt, Adam A. and Pasupuleti, Mukesh and Schmidtchen, Artur and
   Malmsten, Martin},
Title = {{Evaluation of Strategies for Improving Proteolytic Resistance of
   Antimicrobial Peptides by Using Variants of EFK17, an Internal Segment
   of LL-37}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2009}},
Volume = {{53}},
Number = {{2}},
Pages = {{593-602}},
Month = {{FEB}},
Abstract = {{Methods for increasing the proteolytic stability of EFK17
   (EFKRIVQRIKDFLRNLV), a new peptide sequence with antimicrobial
   properties derived from LL-37, were evaluated. EFK17 was modified by
   four d-enantiomer or tryptophan ( W) substitutions at known protease
   cleavage sites as well as by terminal amidation and acetylation. The
   peptide variants were studied in terms of proteolytic resistance,
   antibacterial potency, and cytotoxicity but also in terms their
   adsorption at model lipid membranes, liposomal leakage generation, and
   secondary-structure behavior. The W substitutions resulted in a marked
   reduction in the proteolytic degradation caused by human neutrophil
   elastase, Staphylococcus aureus aureolysin, and V8 protease but not in
   the degradation caused by Pseudomonas aeruginosa elastase. For the
   former two endoproteases, amidation and acetylation of the terminals
   also reduced proteolytic degradation but only when used in combination
   with W substitutions. The d-enantiomer substitutions rendered the
   peptides indigestible by all four proteases; however, those peptides
   displayed little antimicrobial potency. The W- and end-modified
   peptides, on the other hand, showed an increased bactericidal potency
   compared to that of the native peptide sequence, coupled with a moderate
   cytotoxicity that was largely absent in serum. The bactericidal,
   cytotoxic, and liposome lytic properties correlated with each other as
   well as with the amount of peptide adsorbed at the lipid membrane and
   the extent of helix formation associated with the adsorption. The lytic
   properties of the W- substituted peptides were less impaired by
   increased ionic strength, presumably by a combination of W- mediated
   stabilization of the largely amphiphilic helix conformation and a
   nonelectrostatic W affinity for the bilayer interface. Overall, W
   substitutions constitute an interesting means to reduce the proteolytic
   susceptibility of EFK17 while also improving antimicrobial performance.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Stromstedt, AA (Reprint Author), Uppsala Univ, Dept Pharm, Husargatan 3,Box 580, Uppsala, Sweden.
   Stroemstedt, Adam A.; Malmsten, Martin, Uppsala Univ, Dept Pharm, Uppsala, Sweden.
   Pasupuleti, Mukesh; Schmidtchen, Artur, Lund Univ, Dept Dermatol \& Venereol, Lund, Sweden.}},
DOI = {{10.1128/AAC.00477-08}},
ISSN = {{0066-4804}},
EISSN = {{1098-6596}},
Keywords-Plus = {{CATION-PI INTERACTIONS; HUMAN CATHELICIDIN LL-37; AMINO-ACID
   SUBSTITUTION; HELIX-COIL TRANSITION; AIR-WATER-INTERFACE;
   STAPHYLOCOCCUS-AUREUS; AROMATIC INTERACTIONS; DODECYL MALTOSIDE;
   TRYPTOPHAN-RICH; LIPID-BILAYERS}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{adam.stromstedt@farmaci.uu.se}},
ResearcherID-Numbers = {{Schmidtchen, Artur/F-9507-2015
   Pasupuleti, mukesh/H-7605-2013
   Stromstedt, Adam/I-8820-2018}},
ORCID-Numbers = {{Pasupuleti, mukesh/0000-0001-6337-6257
   Stromstedt, Adam/0000-0001-9070-6944}},
Funding-Acknowledgement = {{Swedish Research Council {[}13471, 2006-4469]; DermaGen AB}},
Funding-Text = {{We give our deepest gratitude to Mina Davoudi and Lotta Wahlberg for
   their expert technical assistance.; This work was financed by the
   Swedish Research Council ( projects 13471 and 2006-4469) and DermaGen
   AB.}},
Cited-References = {{Andrushchenko VV, 2007, BBA-BIOMEMBRANES, V1768, P2447, DOI 10.1016/j.bbamem.2007.05.015.
   Belas R, 2004, INFECT IMMUN, V72, P5159, DOI 10.1128/IAI.72.9.5159-5167.2004.
   BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N.
   Bjoorklind A, 1974, Biochim Biophys Acta, V370, P524.
   Butterfield SM, 2002, J AM CHEM SOC, V124, P9751, DOI 10.1021/ja026668q.
   Chan DI, 2006, BBA-BIOMEMBRANES, V1758, P1184, DOI 10.1016/j.bbamem.2006.04.006.
   CHEN RF, 1988, ANAL BIOCHEM, V172, P61, DOI 10.1016/0003-2697(88)90412-5.
   Ciornei CD, 2005, ANTIMICROB AGENTS CH, V49, P2845, DOI 10.1128/AAC.49.7.2845-2850.2005.
   de Kreij A, 2000, J BIOL CHEM, V275, P31115, DOI 10.1074/jbc.M003889200.
   DEFEIJTER JA, 1978, BIOPOLYMERS, V17, P1759, DOI 10.1002/bip.1978.360170711.
   Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163.
   DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720.
   Durr UHN, 2006, BBA-BIOMEMBRANES, V1758, P1408, DOI 10.1016/j.bbamem.2006.03.030.
   FAIRBROTHER WJ, 1989, PROTEIN ENG, V3, P5, DOI 10.1093/protein/3.1.5.
   Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459.
   Giangaspero A, 2001, EUR J BIOCHEM, V268, P5589, DOI 10.1046/j.0014-2956.2001.02494.x.
   GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031.
   Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x.
   Guina T, 2000, J BACTERIOL, V182, P4077, DOI 10.1128/JB.182.14.4077-4086.2000.
   Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x.
   Hong SY, 1999, BIOCHEM PHARMACOL, V58, P1775, DOI 10.1016/S0006-2952(99)00259-2.
   Hornef Mathias W., 2005, V86, P72.
   Kraus D, 2006, CURR TOP MICROBIOL, V306, P231.
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Maillere B, 1995, MOL IMMUNOL, V32, P1377, DOI 10.1016/0161-5890(95)00103-4.
   Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566.
   Nell MJ, 2006, PEPTIDES, V27, P649, DOI 10.1016/j.peptides.2005.09.016.
   Nizet V, 2006, CURR ISSUES MOL BIOL, V8, P11.
   Olson CA, 2001, PROTEINS, V44, P123, DOI 10.1002/prot.1079.
   Oren Z, 1999, BIOCHEM J, V341, P501, DOI 10.1042/0264-6021:3410501.
   PAUCHON V, 1993, BIOTECHNOL APPL BIOC, V17, P217.
   POWELL MF, 1993, PHARMACEUT RES, V10, P1268, DOI 10.1023/A:1018953309913.
   Reijmar K, 2007, J DRUG DELIV SCI TEC, V17, P293, DOI 10.1016/S1773-2247(07)50098-5.
   Ringstad L, 2006, LANGMUIR, V22, P5042, DOI 10.1021/la060317y.
   Ringstad L, 2008, LANGMUIR, V24, P208, DOI 10.1021/la702538k.
   Ringstad L, 2007, BBA-BIOMEMBRANES, V1768, P715, DOI 10.1016/j.bbamem.2006.11.016.
   Ringstad L, 2007, BIOPHYS J, V92, P87, DOI 10.1529/biophysj.106.088161.
   Ruissen ALA, 2003, BIOL CHEM, V384, P183, DOI 10.1515/BC.2003.020.
   Sal-Man N, 2007, J BIOL CHEM, V282, P19753, DOI 10.1074/jbc.M610368200.
   SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026.
   SCHELLENBERGER V, 1994, BIOCHEMISTRY-US, V33, P4251, DOI 10.1021/bi00180a020.
   Schmidtchen A, 2002, MOL MICROBIOL, V46, P157, DOI 10.1046/j.1365-2958.2002.03146.x.
   SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L.
   Shalev DE, 2002, BIOCHEMISTRY-US, V41, P7312, DOI 10.1021/bi016013m.
   Shi ZS, 2002, J AM CHEM SOC, V124, P3284, DOI 10.1021/ja0174938.
   Sieprawska-Lupa M, 2004, ANTIMICROB AGENTS CH, V48, P4673, DOI 10.1128/AAC.48.12.4673-4679.2004.
   Sigurdardottir T, 2006, ANTIMICROB AGENTS CH, V50, P2983, DOI 10.1128/AAC.01583-05.
   Sjogren H, 2005, BIOPHYS CHEM, V116, P11, DOI 10.1016/j.bpc.2005.01.007.
   Smith JS, 1998, BIOCHEMISTRY-US, V37, P33, DOI 10.1021/bi972026h.
   Sonesson A, 2007, BBA-BIOMEMBRANES, V1768, P346, DOI 10.1016/j.bbamem.2006.0.017.
   Sorensen O, 1997, BLOOD, V90, P2796.
   Stromstedt AA, 2007, J COLLOID INTERF SCI, V311, P59, DOI 10.1016/j.jcis.2007.02.070.
   Tiberg F, 2000, EUR BIOPHYS J BIOPHY, V29, P196, DOI 10.1007/PL00006646.
   Tossi A, 2002, PEPTIDES 2002, V27, P416.
   TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X.
   Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000.
   Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206.
   Vacklin HP, 2005, BBA-BIOMEMBRANES, V1668, P17, DOI 10.1016/j.bbamem.2004.11.001.
   WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761.
   Wang YQ, 1998, J BIOL CHEM, V273, P33115, DOI 10.1074/jbc.273.50.33115.
   Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521.
   Wieprecht T, 1999, J MOL BIOL, V294, P785, DOI 10.1006/jmbi.1999.3268.
   Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29.
   Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c.
   ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O.
   Zelezetsky I, 2005, BIOCHEM J, V390, P177, DOI 10.1042/BJ20042138.
   Zelezetsky I, 2006, BBA-BIOMEMBRANES, V1758, P1436, DOI 10.1016/j.bbamem.2006.03.021.}},
Number-of-Cited-References = {{68}},
Times-Cited = {{85}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{27}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{397EY}},
Unique-ID = {{ISI:000262646500031}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000263971200005,
Author = {Gehanno, J. -F. and Louvel, A. and Rysanek, E. and Pestel-Caron, M. and
   Nouvellon, M. and Kornabis, N. and Touche, S. and Ripault, B. and
   Buisson-Valles, I. and Sobaszek, A.},
Title = {{Biological risk assessment among healthcare workers}},
Journal = {{ARCHIVES DES MALADIES PROFESSIONNELLES ET DE L ENVIRONNEMENT}},
Year = {{2009}},
Volume = {{70}},
Number = {{1}},
Pages = {{36-42}},
Month = {{FEB}},
Abstract = {{Aim of the study. Healthcare workers are at occupational risk for a vast
   array of infections that cause Substantial Illness and occasional
   deaths. Nevertheless, risk assessment methods in this field are still
   scarce. This study had two main objectives. The first one was to
   elaborate a guide to help Occupational health professionals to assess
   those risks, on the basis of scientific literature and on local data
   concerning the incidence of the disease, for the most important
   biological agents. The second was to test the feasibility Of the use of
   a one-stage air sampler to assess the exposure in an inpatient setting.
   Material and method. two different strategies were followed. The first
   one was to collect and analyze available data on the circumstances
   during which healthcare workers (HCWs) may be exposed to the 20 selected
   biological agents and to elaborate and validate an exposure assessment
   guideline for those germs. The second one was to perform air samplings
   directly onto a MRSA selective agar in hospital rooms with patients
   infected or colonized with MRSA in their respiratory tract. The strains
   isolated from the patients' clinical isolates and front their
   environment were compared using antimicrobial resistance patterns.
   Results. The guidelines concerning exposure of HCWs to the selected
   agents, and the preventive measures that should be implemented, have
   been validated and posted on a specific web site:
   http://wwww.chu-rouen.fr/mtph. In the experimental part, we found that
   the one-stage air sampler had the ability to collect viable MRSA strains
   in the air. We demonstrated that the aerial contamination was linked to
   the infected patients. This provides useful insights into a future use
   of this sampler for occupational risk assessment purposes. (C) 2008
   Published by Elsevier Masson SAS.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{French}},
Affiliation = {{Gehanno, JF (Reprint Author), CHU Charles Nicolle, Serv Med Travail \& Malad Professionnelles, 1 Rue Germont, F-76031 Rouen, France.
   Gehanno, J. -F.; Louvel, A.; Rysanek, E., CHU Rouen, Med Serv, Rouen, France.
   Gehanno, J. -F.; Louvel, A.; Rysanek, E., CHU Rouen, Serv Sante Travail, Rouen, France.
   Kornabis, N.; Sobaszek, A., CHU Lille, Med Serv, F-59037 Lille, France.
   Kornabis, N.; Sobaszek, A., CHU Lille, Serv Sante Travail, F-59037 Lille, France.
   Touche, S., CHU Reims, Med Serv, Reims, France.
   Touche, S., CHU Reims, Serv Travail, Reims, France.
   Ripault, B., CHU Angers, Med Serv, Angers, France.
   Ripault, B., CHU Angers, Serv Sante Travail, Angers, France.
   Buisson-Valles, I., CHU Bordeaux, Med Serv, Bordeaux, France.
   Buisson-Valles, I., CHU Bordeaux, Serv Sante Travail, Bordeaux, France.}},
DOI = {{10.1016/j.admp.2008.10.021}},
ISSN = {{1775-8785}},
EISSN = {{1778-4190}},
Keywords = {{Healthcare workers; Occupational medicine; Biological risks; Disease
   transmission patient to professional}},
Keywords-Plus = {{RESISTANT STAPHYLOCOCCUS-AUREUS; INFECTION-CONTROL; CONTAMINATION;
   CARRIAGE}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{jean-francois.gehanno@chu-rouen.fr}},
ORCID-Numbers = {{Sobaszek, Annie/0000-0003-3975-1189}},
Cited-References = {{Bolyard EA, 1998, INFECT CONT HOSP EP, V19, P407.
   Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622.
   Cespedes C, 2005, J INFECT DIS, V191, P444, DOI 10.1086/427240.
   Crowcroft NS, 2006, LANCET, V367, P1926, DOI 10.1016/S0140-6736(06)68848-X.
   DUQUENNE P, 2005, HYGIENE SECURITE TRA, V198, P23.
   {*}EUR AG SAF HLTH W, 2007, EXP FOR EM BIOL RISK, P145.
   Karra S, 2007, WATER RES, V41, P1355, DOI 10.1016/j.watres.2006.12.014.
   Lim MSC, 2006, INFECT CONT HOSP EP, V27, P1063, DOI 10.1086/507959.
   Radon K, 2002, ANN AGR ENV MED, V9, P41.
   Sepkowitz KA, 1996, ANN INTERN MED, V125, P826, DOI 10.7326/0003-4819-125-10-199611150-00007.
   Sexton T, 2006, J HOSP INFECT, V62, P187, DOI 10.1016/j.jhin.2005.07.017.
   Shiomori T, 2002, J HOSP INFECT, V50, P30, DOI 10.1053/jhin.2001.1136.
   SIEGEL J, 2007, GUIDELINES ISOLATION.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Arch. Mal. Prof. Environ.}},
Doc-Delivery-Number = {{415YA}},
Unique-ID = {{ISI:000263971200005}},
DA = {{2018-08-13}},
}

@article{ ISI:000264894700015,
Author = {Smith, I, S. and Opere, B. and Goodluck, H. T. and Akindolire, O. T. and
   Folaranmi, A. and Odekeye, O. M. and Omonigbehin, E. A.},
Title = {{Antibiotic susceptibility pattern of Staphylococcus species isolated
   from telephone receivers}},
Journal = {{SINGAPORE MEDICAL JOURNAL}},
Year = {{2009}},
Volume = {{50}},
Number = {{2}},
Pages = {{208-211}},
Month = {{FEB}},
Abstract = {{Introduction: Microorganisms are transferred to everyday objects from
   the environment and infected individuals. Pathogenic microbes are
   transmissible from the air, skin, hands and other interpersonal contacts
   and cause diseases most of the time. This study centres on the microbial
   assessment of telephone receivers, their ability to transfer bacterial
   infections and the isolation of these microorganisms from receivers,
   with an emphasis on Staphylococcus aureus and its antibiotic
   susceptibility pattern.
   1,591 isolates were obtained from roadside telephone booths in 16
   different locations in the Lagos metropolis. They were all characterised
   using the Cowan and Steel's manual, after which the antimicrobial
   susceptibility pattern of the most frequently-occurring isolate was
   determined.
   Results: Of all the locations, Oshodi was found to have the largest
   number of microorganisms, with Akoka having the least. The organisms
   were Providencia, Klebsiella, Citrobacter, Enterobacter, Proteus,
   Escherichia, Staphylococcus, Bacillus, Streptococcus, Micrococcus and
   yeast. Staphylococcus spp. was the most frequently occurring, making up
   20.2 percent of the total number of isolated organisms, followed by
   Bacillus (18 percent), while Enterobacter and Citrobacter were the least
   common. 44 percent of the total Staphylococcus screened for an
   antimicrobial susceptibility pattern showed high resistance to most of
   the antibiotics used.
   Conclusion: This result could be related to the emergence of
   Staphylococcus-resistant strains, especially in a highly-populated area
   where there are health and hygiene problems and where drugs are abused.
   Precautions should be taken to prevent the spread of infectious diseases
   through the use of public telephones.}},
Publisher = {{SINGAPORE MEDICAL ASSOC}},
Address = {{LEVEL 2 ALUMNI MEDICAL CENTRE, 2 COLLEGE RD, SINGAPORE 169850, SINGAPORE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Smith, SI (Reprint Author), Nigerian Inst Med Res, Mol Biol \& Biotechnol Div, PMB 2013, Lagos, Nigeria.
   Smith, S., I; Goodluck, H. T.; Omonigbehin, E. A., Nigerian Inst Med Res, Mol Biol \& Biotechnol Div, Lagos, Nigeria.
   Opere, B.; Akindolire, O. T.; Folaranmi, A.; Odekeye, O. M., Lagos State Univ, Dept Bot, Lagos, Nigeria.}},
ISSN = {{0037-5675}},
Keywords = {{antibiotic resistance; antimicrobial susceptibility pattern;
   Staphylococcus aureus; telephone receivers}},
Keywords-Plus = {{AUREUS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{stellaismith@yahoo.com}},
Cited-References = {{Barrow G. I, 1993, COWAN STEELS MANUAL.
   BROOK GF, 1998, J MELNICK ADELBERGS, P177.
   CDC Centers for Disease Control and Prevention, 2003, MMWR-MORBID MORTAL W, V52, P88.
   {*}CLIN LAB STAND I, 2005, M100515 CLSI.
   COZANITIS DA, 1978, ANAESTHESIST, V27, P439.
   CRUICKSHANK R, 1973, MED MICROBIOLOGY GUI, P345.
   Gandara A, 2006, ENVIRON HEALTH PERSP, V114, P1859, DOI 10.1289/ehp.9585.
   Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7.
   Huys G, 2005, APPL ENVIRON MICROB, V71, P574, DOI 10.1128/AEM.71.1.574-579.2005.
   Lajunen HR, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-24.
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806.
   MERCOLA J, 2000, ANN M AM SOC MICR MA.
   O'Connor A, 2007, AM J INFECT CONTROL, V35, P285, DOI 10.1016/j.ajic.2006.09.015.
   Okesola A O, 1999, Afr J Med Med Sci, V28, P55.
   Okuma K, 2002, J CLIN MICROBIOL, V40, P4289, DOI 10.1128/JCM.40.11.4289-4294.2002.
   SALLE AJ, 1985, FUNDAMENTAL PRINCIPL, P649.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Singap. Med. J.}},
Doc-Delivery-Number = {{429BB}},
Unique-ID = {{ISI:000264894700015}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000292088300001,
Author = {Fortin, M. and Noiseux, I. and Mouslinkina, L. and Vernon, M. L. and
   Laflamme, C. and Filion, G. and Duchaine, C. and Ho, J.},
Editor = {{VoDinh, T and Lieberman, RA and Gauglitz, G}},
Title = {{System for rapid detection of antibiotic resistance of airborne
   pathogens}},
Booktitle = {{ADVANCED ENVIRONMENTAL, CHEMICAL, AND BIOLOGICAL SENSING TECHNOLOGIES VI}},
Series = {{Proceedings of SPIE}},
Year = {{2009}},
Volume = {{7312}},
Note = {{Conference on Advanced Environmental, Chemical, and Biological Sensing
   Technologies VI, Orlando, FL, APR 13-14, 2009}},
Organization = {{SPIE}},
Abstract = {{This project uses function-based detection via a fundamental
   understanding of the genetic markers of AR to distinguish harmful
   organisms from innocuous ones. This approach circumvents complex
   analyses to unravel the taxonomic details of 1399 pathogen species,
   enormously simplifying detection requirements. Laval Hospital's fast
   permeabilization strategy enables AR revelation in <1hr. Packaging the
   AR protocols in liquid-processing cartridges and coupling these to our
   in-house miniature fiber optic flow cell (FOFC) provides first
   responders with timely information on-site. INO's FOFC platform consists
   of a specialty optical fiber through which a hole is transversally bored
   by laser micromachining. The analyte solution is injected into the hole
   of the fiber and the particles are detected and counted. The advantage
   with respect to classic free space FC is that alignment occurs in the
   fabrication process only and complex excitation and collection optics
   are replaced by optical fibers. Moreover, we use a sheathless
   configuration which has the advantage of increase the portability of the
   system, to reduce excess biohazard material and the need for weekly
   maintenance. In this paper we present the principle of our FOFC along
   with a, demonstration of the basic capability of the platform for
   detection of bacillus cereus spores using permeabilized staining.}},
Publisher = {{SPIE-INT SOC OPTICAL ENGINEERING}},
Address = {{1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Fortin, M (Reprint Author), INO, 2740 Einstein St, Quebec City, PQ G1P 4S4, Canada.
   Fortin, M.; Noiseux, I.; Mouslinkina, L.; Vernon, M. L., INO, 2740 Einstein St, Quebec City, PQ G1P 4S4, Canada.
   Laflamme, C.; Filion, G.; Duchaine, C., Univ Laval, Ctr Recherche Hop Laval, Inst Univ Cardiol Pneumol, Quebec City, PQ, Canada.
   Ho, J., CFB Suffield, Def Res Establishment Suffield, Biol Detect Grp, Ralston, AB, Canada.
   Duchaine, C., Univ Laval, Fac Sci \& Genie, Dept Biochimie Microbiol, Quebec City, PQ, Canada.}},
DOI = {{10.1117/12.818783}},
Article-Number = {{731203}},
ISSN = {{0277-786X}},
ISBN = {{978-0-8194-7578-7}},
Keywords = {{Flow cytometry; sheathless; fiber optics; spores; FISH; Bacillus cereus;
   quantum dots}},
Keywords-Plus = {{IN-SITU HYBRIDIZATION}},
Research-Areas = {{Remote Sensing; Optics; Spectroscopy}},
Web-of-Science-Categories  = {{Remote Sensing; Optics; Spectroscopy}},
Cited-References = {{Boatman EM, 2005, J CHEM EDUC, V82, P1697.
   Cohen LY, 2008, ACTA ASTRONAUT, V63, P769, DOI 10.1016/j.actaastro.2007.12.024.
   Crucian B, 2005, CYTOM PART B-CLIN CY, V66B, P1, DOI 10.1002/cyto.b.20057.
   Edwards KA, 2006, ANAL BIOANAL CHEM, V384, P73, DOI 10.1007/s00216-005-0090-x.
   Filion G, 2009, J MICROBIOL METH, V77, P29, DOI 10.1016/j.mimet.2008.12.009.
   FISCHER K, 1995, SYST APPL MICROBIOL, V18, P265, DOI 10.1016/S0723-2020(11)80397-8.
   Ho J, 2002, ANAL CHIM ACTA, V457, P125, DOI 10.1016/S0003-2670(01)01592-6.
   Laflamme C, 2004, J APPL MICROBIOL, V96, P684, DOI 10.1111/j.1365-2672.2004.02184.x.
   LAFLAMME C, 2009, SYSTEMATIC IN PRESS.
   Lange JL, 1997, APPL ENVIRON MICROB, V63, P1557.
   MERMUT O, 2009, P SPIE IN PRESS.
   SHAPIRO HM, 2003, PRACTICAL FLOW CYTOM, P214.
   WU SM, CHEM PHYS CHEM, V7, P1062.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Doc-Delivery-Number = {{BVO55}},
Unique-ID = {{ISI:000292088300001}},
DA = {{2018-08-13}},
}

@article{ ISI:000261683900008,
Author = {Alam, Md. Suhail and Garg, Saurabh K. and Agrawal, Pushpa},
Title = {{Studies on structural and functional divergence among seven WhiB
   proteins of Mycobacterium tuberculosis H37Rv}},
Journal = {{FEBS JOURNAL}},
Year = {{2009}},
Volume = {{276}},
Number = {{1}},
Pages = {{76-93}},
Month = {{JAN}},
Abstract = {{The whiB-like genes (1-7) of Mycobacterium tuberculosis are involved in
   cell division, nutrient starvation, pathogenesis, antibiotic resistance
   and stress sensing. Although the biochemical properties of WhiB1, WhiB3
   and WhiB4 are known, there is no information about the other proteins.
   Here, we elucidate in detail the biochemical and biophysical properties
   of WhiB2, WhiB5, WhiB6 and WhiB7 of M. tuberculosis and present a
   comprehensive comparative study on the molecular properties of all WhiB
   proteins. UV-Vis spectroscopy has suggested the presence of a
   redox-sensitive {[}2Fe-2S] cluster in each of the WhiB proteins, which
   remains stably bound to the proteins in the presence of 8 m urea. The
   {[}2Fe-2S] cluster of each protein was oxidation labile but the rate of
   cluster loss decreased under reducing environments. The {[}2Fe-2S]
   cluster of each WhiB protein responded differently to the oxidative
   effect of air and oxidized glutathione. In all cases, disassembly of the
   {[}2Fe-2S] cluster was coupled with the oxidation of cysteine-thiols and
   the formation of two intramolecular disulfide bonds. Both CD and
   fluorescence spectroscopy revealed that WhiB proteins are structurally
   divergent members of the same family. Similar to WhiB1, WhiB3 and WhiB4,
   apo WhiB5, WhiB6 and WhiB7 also reduced the disulfide of insulin, a
   model substrate. However, the reduction efficiency varied significantly.
   Surprisingly, WhiB2 did not reduce the insulin disulfide, even though
   its basic properties were similar to those of others. The structural and
   functional divergence among WhiB proteins indicated that each WhiB
   protein is a distinguished member of the same family and together they
   may represent a novel redox system for M. tuberculosis.}},
Publisher = {{WILEY-BLACKWELL PUBLISHING, INC}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Agrawal, P (Reprint Author), CSIR, Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.
   Alam, Md. Suhail; Garg, Saurabh K.; Agrawal, Pushpa, CSIR, Inst Microbial Technol, Chandigarh 160036, India.}},
DOI = {{10.1111/j.1742-4658.2008.06755.x}},
ISSN = {{1742-464X}},
Keywords = {{iron-sulfur cluster; Mycobacterium tuberculosis; protein disulfide
   reductase; redox system; WhiB}},
Keywords-Plus = {{IRON-SULFUR CLUSTERS; 4FE-4S CLUSTER; DISULFIDE REDUCTASE; OXIDATIVE
   STRESS; REDOX PROPERTIES; GENOME SEQUENCE; CXXC-MOTIF; KAPPA-B;
   THIOREDOXIN; GENE}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{pushpa@imtech.res.in}},
Funding-Acknowledgement = {{`Council of Scientific and Industrial Research' (CSIR), Govt of India;
   `Department of Biotechnology' (DBT), Govt of India}},
Funding-Text = {{MSA and SKG are thankful to the `Council of Scientific and Industrial
   Research' (CSIR), Govt of India, for `Senior Research Fellowship'.
   Financial assistance by CSIR and `Department of Biotechnology' (DBT),
   Govt of India, is duly acknowledged. This report is IMTECH communication
   no. 08/2008. MSA, SKG and PA designed the experiments. SKG carried out
   some of the work on WhiB1. MSA carried out the rest of the work. MSA and
   PA wrote the manuscript.}},
Cited-References = {{Alam MS, 2008, PROTEIN EXPRES PURIF, V61, P83, DOI 10.1016/j.pep.2008.04.010.
   Alam MS, 2007, MOL MICROBIOL, V63, P1414, DOI 10.1111/j.1365-2958.2007.05589.x.
   Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x.
   Balmer Y, 2003, P NATL ACAD SCI USA, V100, P370, DOI 10.1073/pnas.232703799.
   Bao R, 2007, PROTEINS, V66, P246, DOI 10.1002/prot.21194.
   Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002.
   Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653.
   Berndt C, 2004, J BIOL CHEM, V279, P7850, DOI 10.1074/jbc.M309332200.
   Bertini I, 1997, BIOCHEMISTRY-US, V36, P9332, DOI 10.1021/bi970810w.
   Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x.
   Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967.
   Carroll KS, 2005, BIOCHEMISTRY-US, V44, P14647, DOI 10.1021/bi051344a.
   Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580.
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159.
   DAVIS NK, 1992, MOL GEN GENET, V232, P351.
   EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103.
   FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x.
   Garg SK, 2007, PROTEIN EXPRES PURIF, V52, P422, DOI 10.1016/j.pep.2006.10.015.
   Geiman DE, 2006, ANTIMICROB AGENTS CH, V50, P2836, DOI 10.1128/AAC.00295-06.
   Gomez JE, 2000, P NATL ACAD SCI USA, V97, P8554, DOI 10.1073/pnas.140225297.
   Hall G, 2006, ACTA CRYSTALLOGR D, V62, P1453, DOI 10.1107/s0907444906038212.
   HAYASHI T, 1993, J BIOL CHEM, V268, P11380.
   Hidalgo E, 1997, TRENDS BIOCHEM SCI, V22, P207, DOI 10.1016/S0968-0004(97)01068-2.
   HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237.
   HOLMGREN A, 1979, J BIOL CHEM, V254, P9627.
   HOLMGREN A, 1989, J BIOL CHEM, V264, P13963.
   Jakimowicz P, 2005, J BIOL CHEM, V280, P8309, DOI 10.1074/jbc.M412622200.
   Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518.
   Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0.
   Kiley PJ, 1998, FEMS MICROBIOL REV, V22, P341, DOI 10.1016/S0168-6445(98)00022-9.
   Kumar JK, 2004, P NATL ACAD SCI USA, V101, P3759, DOI 10.1073/pnas.0308701101.
   LEVINE H, 1993, PROTEIN SCI, V2, P404.
   Lewandowska A, 2007, J MOL BIOL, V371, P800, DOI 10.1016/j.jmb.2007.05.057.
   LOFERER H, 1995, J BIOL CHEM, V270, P26178, DOI 10.1074/jbc.270.44.26178.
   Mehrotra J, 2001, INT J MED MICROBIOL, V291, P171, DOI 10.1078/1438-4221-00113.
   Morris RP, 2005, P NATL ACAD SCI USA, V102, P12200, DOI 10.1073/pnas.0505446102.
   Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351.
   Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996.
   Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427.
   Orme-Johnson W. H., 1982, IRON SULFUR PROTEINS, P67.
   Paget MSB, 2003, ANNU REV GENET, V37, P91, DOI 10.1146/annurev.genet.37.110801.142538.
   Paraskevopoulou C, 2006, MOL MICROBIOL, V59, P795, DOI 10.1111/j.1365-2958.2005.04989..
   Patel MP, 1999, BIOCHEMISTRY-US, V38, P11827, DOI 10.1021/bi991025h.
   PLANK DW, 1989, J BIOL CHEM, V264, P20385.
   Quan S, 2007, J BIOL CHEM, V282, P28823, DOI 10.1074/jbc.M705291200.
   Raghava GPS, 2000, BIOTECHNIQUES, V29, P108.
   Raghunand TR, 2006, J BACTERIOL, V188, P6966, DOI 10.1128/JB.00384-06.
   Ramakrishnan L, 2000, SCIENCE, V288, P1436, DOI 10.1126/science.288.5470.1436.
   Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21.
   Romero-Isart N, 2002, J INORG BIOCHEM, V88, P388, DOI 10.1016/S0162-0134(01)00347-6.
   Sacchettini JC, 2008, NAT REV MICROBIOL, V6, P41, DOI 10.1038/nrmicro1816.
   Sambrook J, 2001, MOL CLONING LAB MANU.
   SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672.
   Shi YY, 2005, BIOCHEMISTRY-US, V44, P1683, DOI 10.1021/bi0480943.
   Singh A, 2007, P NATL ACAD SCI USA, V104, P11562, DOI 10.1073/pnas.0700490104.
   Smith I, 2003, CLIN MICROBIOL REV, V16, P463, DOI 10.1128/CMR.16.3.463-496.2003.
   SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827.
   Soliveri JA, 2000, MICROBIOL-UK, V146, P333, DOI 10.1099/00221287-146-2-333.
   Steyn AJC, 2002, P NATL ACAD SCI USA, V99, P3147, DOI 10.1073/pnas.052705399.
   Zahrt TC, 2002, ANTIOXID REDOX SIGN, V4, P141, DOI 10.1089/152308602753625924.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{47}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{FEBS J.}},
Doc-Delivery-Number = {{383OW}},
Unique-ID = {{ISI:000261683900008}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000265415800005,
Author = {Reed, Nicholas G. and Wengraitis, Stephen and Sliney, David H.},
Title = {{Intercomparison of Instruments Used for Safety and Performance
   Measurements of Ultraviolet Germicidal Irradiation Lamps}},
Journal = {{JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE}},
Year = {{2009}},
Volume = {{6}},
Number = {{5}},
Pages = {{289-297}},
Abstract = {{Public health concerns such as multidrug-resistant tuberculosis,
   bioterrorism, pandemic influenza, and sick building syndrome have
   brought about increased interest in the use of ultraviolet germicidal
   irradiation (UVGI) to prevent the spread of airborne infection. UVGI
   lamps require that radiometric measurements be performed to ensure their
   safe and effective use. This study evaluates 10 detectors that measure
   the ultraviolet radiation hazard of low-pressure mercury UVGI lamps,
   including a polychromator spectroradiometer, narrowband detectors
   designed to measure the ultraviolet radiation in a short range of
   wavelengths, and broadband detectors with a varying spectral response
   designed to follow the UV hazard action spectrum. The angular responses,
   spectral responses, and linearity of the detectors were measured and
   compared. The agreement between the measured angular responses and the
   ideal cosine responses varied widely among the detectors, and in
   general, the detectors with diffusing optics agreed significantly better
   with the ideal cosine response. The spectral responses at 254 nm also
   varied widely among the detectors, and, in general, the narrowband
   detectors agreed more closely with the 254 nm irradiances measured under
   the same conditions by a double monochromator spectroradiometer. All
   detectors displayed good linearity. The angular and spectral response
   data were then used to develop correction factors for the effective
   irradiance measurements of two UVGI sources, each measured at 10, 20,
   and 30 cm. The measured effective irradiances were compared with those
   measured by a double monochromator spectroradiometer with an integrating
   sphere input optic. Prior to correction, the effective irradiances
   measured by the detectors varied widely, ranging from 0.29 to 2.7 times
   those measured by the spectroradiometer. The application of cosine and
   spectral response correction factors significantly improved the
   agreement for the effective irradiances measured by all of the
   detectors, typically to within 10-20\%. Awareness of these detector
   characteristics can play a key role in ensuring the accuracy of health
   hazard measurements of UVGI lamps.}},
Publisher = {{TAYLOR \& FRANCIS INC}},
Address = {{325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Reed, NG (Reprint Author), 5158 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA.
   Reed, Nicholas G.; Wengraitis, Stephen, USA, Ctr Hlth Promot \& Prevent Med, Laser Opt Radiat Program, Aberdeen Proving Ground, MD USA.}},
DOI = {{10.1080/15459620902801041}},
ISSN = {{1545-9624}},
Keywords = {{measurement corrections; radiation safety; radiometers; ultraviolet
   meter; UV-C; UVGI}},
Keywords-Plus = {{DISINFECTION; AIR}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Author-Email = {{nick.g.reed@us.army.mil}},
Funding-Acknowledgement = {{U. S. Army Center for Health Promotion; Oak Ridge Institute for Science
   and Education}},
Funding-Text = {{This project was supported in part by an appointment to the
   Internship/Research Participation Program for the U. S. Army Center for
   Health Promotion and Preventive Medicine administered by the Oak Ridge
   Institute for Science and Education through an agreement between the U.
   S. Department of Energy and the USACHPPM. Use of trademarked name does
   not imply endorsement by the U. S. Army but is intended only to assist
   in identification of a specific product.}},
Cited-References = {{American Conference of Governmental Industrial Hygienists (ACGIH), 2008, TLVS AND BEIS.
   {*}ANSI IESNA, 2001, REC PRACT PHOT SAF L.
   {*}CIE, 1982, TECHN REP METH CHAR.
   Coleman AJ, 2000, RADIAT PROT DOSIM, V91, P153, DOI 10.1093/oxfordjournals.rpd.a033187.
   DIFFEY B. L., 1998, MEASUREMENTS OPTICAL, P63.
   Goldner J L, 1980, Ann N Y Acad Sci, V353, P271, DOI 10.1111/j.1749-6632.1980.tb18930.x.
   GOODMAN T, 1998, MEASUREMENTS OPTICAL, P589.
   GUGGHELMINGER A, 2004, P CIE S 04 LIGHT HLT, P86.
   Harm W., 1980, BIOL EFFECTS ULTRAVI.
   MARSHALL W, 1998, MEASUREMENTS OPTICAL, P465.
   Martin CJ, 1999, PHYS MED BIOL, V44, P843, DOI 10.1088/0031-9155/44/4/003.
   MASSCHELEIN WJ, 2002, ULTRAVIOLET LIGHT IN.
   Menzies D, 2003, LANCET, V362, P1785, DOI 10.1016/S0140-6736(03)14897-0.
   Miller OT, 1955, AM J PUBLIC HEALTH N, V45, P1420, DOI 10.2105/AJPH.45.11.1420.
   Nardell Edward A., 1994, P53.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RYER A, 1998, MEASUREMENTS OPTICAL, P493.
   Sliney DH, 2007, PHOTOCHEM PHOTOBIOL, V83, P425, DOI 10.1562/2006-11-14-RA-1081.
   Tseng CC, 2007, J OCCUP ENVIRON HYG, V4, P400, DOI 10.1080/15459620701329012.
   Wells W F, 1935, Science, V82, P280, DOI 10.1126/science.82.2125.280-a.
   Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789.
   Ylianttila L, 2005, PHOTOCHEM PHOTOBIOL, V81, P333, DOI 10.1562/2004-06-02-RA-184.1.
   Zuclich J. A., 1998, MEASUREMENTS OPTICAL, P143.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Occup. Environ. Hyg.}},
Doc-Delivery-Number = {{436LO}},
Unique-ID = {{ISI:000265415800005}},
DA = {{2018-08-13}},
}

@article{ ISI:000262593300006,
Author = {Cadena, Jose and Hartzler, Anthony and Hsue, Gunther and Longfield,
   Roben N.},
Title = {{Coccidioidomycosis and Tuberculosis Coinfection at a Tuberculosis
   Hospital Clinical Features and Literature Review}},
Journal = {{MEDICINE}},
Year = {{2009}},
Volume = {{88}},
Number = {{1}},
Pages = {{66-76}},
Month = {{JAN}},
Abstract = {{Tuberculosis (TB) and coccidioidomycosis can have similar clinical and
   radiologic presentations but require different treatments. Coinfection
   with TB and Coccidioides immitis is uncommonly reported and may be
   underdiagnosed in endemic areas.
   We performed a retrospective review of the medical records of all
   patients admitted to a TB referral hospital between 1995 and 2007, and
   selected all cases of TB and coccidioidomycosis coinfection in patients
   aged 18 years or older. All admitted patients had a diagnosis of TB and
   had sputum cultures for both pathogens. We reviewed clinical,
   laboratory, and radiologic features of the cases, and noted
   antimicrobial treatments received and outcomes.
   We identified 9 patients, of whom 7 (78\%) were Hispanic. Most patients
   were male (8/9, 89\%), and all were diagnosed with coccidioidomycosis
   after TB. Three (33\%) patients had drug-resistant TB. Six patients had
   culture-positive TB at the time of the double diagnosis, and 2 patients
   developed active coccidioidomycosis during their hospital stay. Only I
   had human immunodeficiency virus/acquired immunodeficiency syndrome
   (HIV-AIDS) (CD4 count, 20 cells/mm(3)). All but 2 patients were treated
   with antifungal agents. Two patients died, 1 of whom had AIDS.
   Radiologic studies were unable to distinguish between TB and
   coccidioidomycosis, except for a patient who developed a new air-fluid
   level in a previously stable cavity.
   TB and coccidioidomycosis coinfection should be suspected in
   coccidioidomycosis-endemic regions among patients with TB who fail to
   improve clinically or radiologically despite adequate, culture-directed
   therapy.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cadena, J (Reprint Author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, Mail Code 7881,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
   Cadena, Jose; Hartzler, Anthony, Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA.
   Hsue, Gunther, Tripler Army Med Ctr, Dept Med, Honolulu, HI 96859 USA.
   Longfield, Roben N., Univ Texas Tyler, Dept Specialty Care Serv, Texas Ctr Infect Dis, San Antonio, TX USA.}},
DOI = {{10.1097/MD.0b013e318194757a}},
ISSN = {{0025-7974}},
EISSN = {{1536-5964}},
Keywords-Plus = {{PULMONARY COCCIDIOIDOMYCOSIS; CASE SERIES; DISEASES; COEXISTENCE;
   POPULATION; INFECTION; DIAGNOSIS}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{cadenazuluag@utscsa.edu}},
Cited-References = {{Ampel NM, 2007, ANN NY ACAD SCI, V1111, P336, DOI 10.1196/annals.1406.033.
   Burrill J, 2007, RADIOGRAPHICS, V27, DOI 10.1148/rg.275065176.
   CASTANEDAGODOY R, 2002, REV I NAL ENF RESP M, V15, P98.
   CASTEN U, 1993, GEOPHYS PROSPECT, V41, P1, DOI 10.1111/j.1365-2478.1993.tb00562.x.
   {*}CDCP, 2003, MMWR-MORBID MORTAL W, V52, P1.
   Chong S, 2006, EUR J RADIOL, V59, P371, DOI 10.1016/j.ejrad.2006.04.017.
   COHEN IM, 1981, SABOURAUDIA, V19, P13.
   COHEN R, 1952, Arch Pediatr, V69, P267.
   Cordeiro RD, 2006, J ANTIMICROB CHEMOTH, V58, P575, DOI 10.1093/jac/dkl290.
   COTTON BH, 1954, AM REV TUBERC PULM, V70, P109.
   Crum-Cianflone NF, 2006, MEDICINE, V85, P263, DOI 10.1097/01.md.0000236953.95213.ac.
   DAVIS MV, 1960, DIS CHEST, V38, P214, DOI 10.1378/chest.38.2.214.
   Desai SA, 2001, RESP MED, V95, P305, DOI 10.1053/rmed.2000.1039.
   FIRESTONE GM, 1949, AM REV TUBERC PULM, V59, P415.
   FRASER CG, 1951, ANN SURG, V133, P116, DOI 10.1097/00000658-195101000-00012.
   Galgiani JN, 2005, CLIN INFECT DIS, V41, P1217, DOI 10.1086/496991.
   HYDE B, 1949, ARCH INTERN MED, V83, P505, DOI 10.1001/archinte.1949.00220340030003.
   KAHN M, 1950, AM REV TUBERC PULM, V61, P887.
   Laniado-Laborin Rafael, 2007, Revista Iberoamericana de Micologia, V24, P249.
   McNabb Scott J. N., 2006, Morbidity and Mortality Weekly Report, V55, P1.
   MELICK DW, 1968, DIS CHEST, VS 54, P278, DOI 10.1378/chest.54.Supplement\_1.278.
   Meya DB, 2007, J INTERN MED, V261, P309, DOI 10.1111/j.1365-2796.2007.01795.x.
   Niemi M, 2003, CLIN PHARMACOKINET, V42, P819, DOI 10.2165/00003088-200342090-00003.
   PALOMINO JC, 2007, TUBERCULOSIS 2007 BO.
   Pena-Ruiz MA, 2007, ANN NY ACAD SCI, V1111, P122, DOI 10.1196/annals.1406.038.
   REAMS GB, 1960, LANCET, V2, P1281.
   Restrepo BI, 2007, EPIDEMIOL INFECT, V135, P483, DOI 10.1017/S0950268806006935.
   RIFKIN H, 1947, ARCH INTERN MED, V79, P381, DOI 10.1001/archinte.1947.00220100031002.
   Saubolle MA, 2007, ANN NY ACAD SCI, V1111, P301, DOI 10.1196/annals.1406.049.
   Saubolle MA, 2007, J CLIN MICROBIOL, V45, P26, DOI 10.1128/JCM.02230-06.
   Spinello IM, 2008, SEMIN RESP CRIT CARE, V29, P166, DOI 10.1055/s-2008-1063855.
   STEIN HF, 1953, AM REV TUBERC PULM, V67, P477.
   STUDY RS, 1948, NEW ENGL J MED, V238, P837, DOI 10.1056/NEJM194806102382403.
   SWANSEY LK, 1974, ARIZ MED, V31, P94.
   TARASIDIS GC, 1966, AM REV RESPIR DIS, V94, P948.
   {*}US DEP HHS, 2007, CDC REP TUB US 2006.
   Valdivia L, 2006, EMERG INFECT DIS, V12, P958.
   Wallis RS, 2004, CLIN INFECT DIS, V38, P1261, DOI 10.1086/383317.
   Williams PL, 2007, ANN NY ACAD SCI, V1111, P377, DOI 10.1196/annals.1406.037.
   WINN RE, 1994, CHEST, V105, P412, DOI 10.1378/chest.105.2.412.
   WINN WA, 1967, AM REV RESPIR DIS, V96, P229.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Medicine (Baltimore)}},
Doc-Delivery-Number = {{396LN}},
Unique-ID = {{ISI:000262593300006}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000277196300085,
Author = {Tharannum, Seema and Nithya, J. and Manjula, T. S.},
Book-Group-Author = {{IEEE}},
Title = {{Prevalence of plasmid mediated multi drug resistant Enterobacteriaceae
   in Hospital environment at Bangalore, India}},
Booktitle = {{PROCEEDINGS OF THE SECOND INTERNATIONAL CONFERENCE ON ENVIRONMENTAL AND
   COMPUTER SCIENCE}},
Year = {{2009}},
Pages = {{398-402}},
Note = {{2nd International Conference on Environmental and Computer Science,
   Dubai, U ARAB EMIRATES, DEC 28-30, 2009}},
Organization = {{ESS; IACSIT; UPM; Ain Shams Univ}},
Abstract = {{Air being a major medium allows pathogens to disseminate and cause
   infections. An initial prevalence survey conducted in the air samples of
   the hospital environment especially in the out patient unit/ department
   (OPD) of 2 government and 2 private hospitals in Bangalore using a
   centrifugal air sampler system, when subjected to different standard
   morphological studies, staining procedures and biochemical techniques
   showed existence of nosochomial infection causing organisms in
   government hospital environment only.
   The highest frequency of nosochomial infection causing organisms in
   government hospitals are gram negative enterobacteriaceae and was
   recorded to be the dominant (81\%). The organisms thus isolated were
   subjected to multidrug antibiotic resistance test which include a group
   of beta-lactam antibiotics that are frequently used in the treatment.
   Susceptibility testing revealed that the isolates from government
   hospitals are resistant to old beta lactams penicillin (95\%),
   ampicillin (100\%) as well to the first and second generation
   cephalosporins (cephaloxin-40\%, cephalothin-60\%, cefoxitin-45\%).
   The plasmids were isolated from these resistant strains and were
   observed that around 90\% of the isolates had plasmid. The possible
   reason of antibiotic resistance in the organism being plasmid meditated.
   Incidences of these multidrug resistant enterobacteriaceae are serious
   threat to the hospital community. The organism can become endemic within
   the hospital setting with continued presence in the OPD environment and
   nosochomial spread. Hence the administration and management of the
   hospital must give top priority to support the hospital infection
   control program by establishing a committee to constantly monitor on
   hygienic conditions and apply the appropriate methods for preventing
   nosochomial infections.}},
Publisher = {{IEEE COMPUTER SOC}},
Address = {{10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Tharannum, S (Reprint Author), PES Inst Technol, Dept Biotechnol PG, Bangalore 560085, Karnataka, India.
   Tharannum, Seema; Nithya, J.; Manjula, T. S., PES Inst Technol, Dept Biotechnol PG, Bangalore 560085, Karnataka, India.}},
DOI = {{10.1109/ICECS.2009.76}},
ISBN = {{978-0-7695-3937-9}},
Keywords = {{Air sampler; Nosocomial infections; beta-lactamases; Enterobacteriaceae;
   plasmid; antibiotic resistance}},
Keywords-Plus = {{NOSOCOMIAL OUTBREAK; KLEBSIELLA; CEPHALOSPORINS; INFECTIONS}},
Research-Areas = {{Computer Science}},
Web-of-Science-Categories  = {{Computer Science, Theory \& Methods}},
Author-Email = {{seemakabir@gmail.com}},
Cited-References = {{BRUNBUISSON C, 1987, LANCET, V2, P302.
   BUTTNER MP, 1993, APPL ENVIRON MICROB, V59, P219.
   CESAR, 2008, EMERGENCE MANAGEMENT, V6, P637.
   JOHANN DD, 2008, EXPECT REV ANTIINFEC, V6, P5657.
   MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001.
   MONTGOMERIE JZ, 1979, REV INFECT DIS, V1, P736.
   {*}NAT COMM CLIN LAB, 1997, M2A6 NAT COMM CLIN L.
   Plowman R, 1999, SOCIO EC BURDEN HOSP.
   PONCEDELEON S, 1991, J HOSP INFECT, V18, P376, DOI 10.1016/0195-6701(91)90044-9.
   WENZEL RP, 1995, J HOSP INFECT, V31, P79, DOI 10.1016/0195-6701(95)90162-0.
   1990, P 3 DEC INT C NOS IN, P30.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BOP17}},
Unique-ID = {{ISI:000277196300085}},
DA = {{2018-08-13}},
}

@article{ ISI:000268436700012,
Author = {Thoen, Charles O. and LoBue, Philip A. and Enarson, Donald A. and
   Kaneene, John B. and de Kantor, Isabel N.},
Title = {{Tuberculosis: a re-emerging disease in animals and humans}},
Journal = {{VETERINARIA ITALIANA}},
Year = {{2009}},
Volume = {{45}},
Number = {{1}},
Pages = {{135-181}},
Month = {{JAN-MAR}},
Abstract = {{Tuberculosis continues to be an important disease both in humans and
   animals. It causes morbidity, mortality and economic loss worldwide. The
   occurrence of Mycobacterium bovis disease in human,.;, domesticated and
   wild animals confirms the relevance of this zoonosis. M. bovis in humans
   continues to be reported in industrialised countries and in immigrants
   from regions of the world where tuberculosis in cattle is endemic. The
   real incidence of M. bovis in humans in developing countries continues
   to be roughly underestimated due to the scarcity of appropriate
   laboratory facilities to isolate and to differentiate M. bovis strains.
   In Latin America, less than 1\% of tuberculosis cases are reported as
   being due to M. bovis. However, the economic relevance that meat and
   dairy industries play in these Countries stimulates the promotion of
   bovine tuberculosis eradication programmes. Human-to-human airborne
   transmission of M. bovis does occur and it may be important where human
   immunodeficiency virus (HIV) infection in humans is prevalent, M. bovis
   infection in cattle is enzootic and pasteurisation of dairy products is
   not routinely practised. Eradication of M. bovis in cattle and
   pasteurisation of dairy products are the cornerstones of prevention of
   human disease. Measures should be developed to identify and control M.
   bovis infection in wild animals as these may be important reservoirs of
   infection for domesticated food-producing animals. There is a need for
   medical and veterinary professionals to cooperate on disease Outbreaks.
   The information presented herein strongly Supports the `One World/One
   Health/one Medicine' concept.}},
Publisher = {{IST ZOOPROFILATTICO SPERIMENTALE ABRUZZO \& MOLISE G CAPORALE-IZS A\&M}},
Address = {{CAMPO BOARIO, TERAMO, 64100, ITALY}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Thoen, CO (Reprint Author), Iowa State Univ, Coll Vet Med, Dept Vet Microbiol \& Prevent Med, Ames, IA 50011 USA.
   Thoen, Charles O., Iowa State Univ, Coll Vet Med, Dept Vet Microbiol \& Prevent Med, Ames, IA 50011 USA.
   LoBue, Philip A., Ctr Dis Control \& Prevent, TB Eliminat Div, Med Consultat Team, Atlanta, GA 30333 USA.
   Enarson, Donald A., Int Union TB \& Lung Dis, F-75006 Paris, France.
   Kaneene, John B., Michigan State Univ, Coll Vet Med, Ctr Comparat Epidemiol, E Lansing, MI 48824 USA.
   de Kantor, Isabel N., WHO, RA-1429 Buenos Aires, DF, Argentina.}},
ISSN = {{0505-401X}},
EISSN = {{1828-1427}},
Keywords = {{Health; Mycobacterium; Mycobacterium bovis; Mycobacterium tuberculosis;
   One Health; Public health; Tuberculosis}},
Keywords-Plus = {{MYCOBACTERIUM-BOVIS INFECTION; KRUGER-NATIONAL-PARK; WHITE-TAILED DEER;
   MULTIDRUG-RESISTANT TUBERCULOSIS; IMMUNODEFICIENCY-VIRUS-INFECTION;
   FERRETS MUSTELA-FURO; SAN-DIEGO COUNTY; HEDGEHOGS ERINACEUS-EUROPAEUS;
   LENGTH-POLYMORPHISM ANALYSIS; POLYMERASE-CHAIN-REACTION}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{cthoen@iastate.edu}},
Cited-References = {{Allix C, 2006, J CLIN MICROBIOL, V44, P1951, DOI 10.1128/JCM.01775-05.
   {*}AM THOR SOC, 2000, MMWR RECOMM REP, V49, P1.
   {*}AM THOR SOC CDCP, 2003, AM J RESP CRIT CARE, V167, P603.
   Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Aranaz A, 2004, J CLIN MICROBIOL, V42, P2602, DOI 10.1128/JCM.42.6.2602-2608.2004.
   Aranaz A, 1999, INT J SYST BACTERIOL, V49, P1263, DOI 10.1099/00207713-49-3-1263.
   Ashford D. A., 2006, MYCOBACTERIUM BOVIS, P305.
   Baker MG, 2006, EPIDEMIOL INFECT, V134, P1068, DOI 10.1017/S0950268806005930.
   Barlow AM, 1999, VET REC, V145, P639, DOI 10.1136/vr.145.22.639.
   BARROW PA, 1981, J HYG-CAMBRIDGE, V86, P237, DOI 10.1017/S0022172400068984.
   Belli L B, 1962, Can Vet J, V3, P356.
   Bengis RG, 1996, ONDERSTEPOORT J VET, V63, P15.
   Besser RE, 2001, PEDIATRICS, V108, P305, DOI 10.1542/peds.108.2.305.
   Blazquez J, 1997, J CLIN MICROBIOL, V35, P1390.
   Blunden AS, 1996, VET REC, V138, P87, DOI 10.1136/vr.138.4.87.
   Bolske G, 2006, MYCOBACTERIUM BOVIS, P84.
   Briones V, 2000, EMERG INFECT DIS, V6, P189, DOI 10.3201/eid0602.000214.
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299.
   Bruning-Fann CS, 2001, J WILDLIFE DIS, V37, P58, DOI 10.7589/0090-3558-37.1.58.
   BUDDLE BM, 1995, VACCINE, V13, P1123, DOI 10.1016/0264-410X(94)00055-R.
   BUSH M, 1990, J ZOO WILDLIFE MED, V21, P171.
   CABRYN LN, 1982, WOLVES WORLD PERSPEC, P106.
   CALLE PP, 1989, J ZOO WILDLIFE MED, V20, P307.
   Catanzaro A, 2000, JAMA-J AM MED ASSOC, V283, P639, DOI 10.1001/jama.283.5.639.
   {*}CDCP, 2008, MMWR-MORBID MORTAL W, V57, P281.
   Cedeno I, 2005, REV SCI TECH OIE, V24, P1067, DOI 10.20506/rst.24.3.1633.
   {[}Centers for Disease Control and Prevention Department of Health and Human], 2007, REP TUB US 2006.
   Centers for Disease Control and Prevention, 2007, MAN DRUG INT TREATM.
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P605.
   CHARCON O, 2006, MYCOBACTERIUM BOVIS, P285.
   CLANCEY JK, 1977, TUBERCLE, V58, P151, DOI 10.1016/0041-3879(77)90017-4.
   Cleaveland S, 2005, J WILDLIFE DIS, V41, P446, DOI 10.7589/0090-3558-41.2.446.
   CliftonHadley RS, 1996, BRIT VET J, V152, P243, DOI 10.1016/S0007-1935(96)80097-2.
   CLIFTONHADLEY RS, 1995, EPIDEMIOL INFECT, V114, P179, DOI 10.1017/S0950268800052031.
   CLIFTONHADLEY RS, 1993, EPIDEMIOL INFECT, V111, P9, DOI 10.1017/S0950268800056624.
   CLIFTONHADLEY RS, 1991, VET REC, V129, P5, DOI 10.1136/vr.129.1.5.
   CLIFTONHADLEY RS, 1991, P 6 INT S VET EP EC, P434.
   Cobo J, 2001, INT J TUBERC LUNG D, V5, P413.
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159.
   Coleman JD, 1999, NEW ZEAL VET J, V47, P119, DOI 10.1080/00480169.1999.36127.
   Cooke M., 1998, Surveillance (Wellington), V25, P10.
   Corner LAL, 2006, VET MICROBIOL, V112, P303, DOI 10.1016/j.vetmic.2005.11.015.
   Cosivi O, 1998, EMERG INFECT DIS, V4, P59, DOI 10.3201/eid0401.980108.
   Costello E, 1999, J CLIN MICROBIOL, V37, P3217.
   Cousins D., 2006, MYCOBACTERIUM BOVIS, P258.
   COUSINS DV, 1993, AUST VET J, V70, P92, DOI 10.1111/j.1751-0813.1993.tb03284.x.
   Cross ML, 2007, VET J, V174, P472, DOI 10.1016/j.tvjl.2006.10.005.
   Curry FJ, 2008, DRUG RESISTANT TUBER.
   DALOVISIO JR, 1992, CLIN INFECT DIS, V15, P598, DOI 10.1093/clind/15.4.598.
   DANKNER WM, 1993, MEDICINE, V72, P11, DOI 10.1097/00005792-199301000-00002.
   de Kantor IN, 2006, VET MICROBIOL, V112, P111, DOI 10.1016/j.vetmic.2005.11.033.
   de Kantor IN, 2008, TUBERCULOSIS, V88, P358, DOI 10.1016/j.tube.2007.11.007.
   de Lisle GW, 2002, REV SCI TECH OIE, V21, P317, DOI 10.20506/rst.21.2.1339.
   de Lisle GW, 2001, REV SCI TECH OIE, V20, P86, DOI 10.20506/rst.20.1.1262.
   De Vos V, 2001, ONDERSTEPOORT J VET, V68, P119.
   Dean R, 2006, VET REC, V158, P419, DOI 10.1136/vr.158.12.419.
   DEKANTOR IN, 1994, VET MICROBIOL, V40, P5, DOI 10.1016/0378-1135(94)90042-6.
   DEKANTOR IN, 2008, TEMAS ZOONOSIS, V4, P309.
   Delahay RJ, 2002, VET J, V164, P90, DOI 10.1053/tvjl.2001.0667.
   DELISLE GW, 1990, NEW ZEAL VET J, V38, P10, DOI 10.1080/00480169.1990.35606.
   deLisle GW, 1995, NEW ZEAL VET J, V43, P266, DOI 10.1080/00480169./1995.35905.
   DELISLE GW, 1993, NZ VET J, V41, P144.
   DILONARDO M, 1995, TUBERCLE LUNG DIS, V76, P185, DOI 10.1016/S0962-8479(05)80002-4.
   DILONARDO M, 2003, EMERG INFECT DIS, V8, P965.
   DODD K, 1984, VET REC, V115, P592, DOI 10.1136/vr.115.23.592.
   DONDO A, 2006, MYCOBACTERIUM BOVIS, P117.
   ENARSON DA, 1989, AM J EPIDEMIOL, V129, P1268, DOI 10.1093/oxfordjournals.aje.a115246.
   Enarson DA, 1995, MYCOBACTERIUM BOVIS, pxix.
   Essey M. A., 1983, Proceedings of the United States Animal Health Association, V87, P589.
   ESSEY MA, 1981, P ANN M US ANIM HLTH, V87, P538.
   ETCHECHOURY I, 2009, ZOONOSES PU IN PRESS.
   Evans JT, 2007, LANCET, V369, P1270, DOI 10.1016/S0140-6736(07)60598-4.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   FANNING A, 1991, LANCET, V338, P1253, DOI 10.1016/0140-6736(91)92113-G.
   {*}FAO, 2008, GLOB LIV PROD HLTH A.
   FELDMAN W. H., 1934, Journal of the American Veterinary Medical Association, V85, P653.
   FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28.
   de Mera IGF, 2008, DEV COMP IMMUNOL, V32, P85, DOI 10.1016/j.dci.2007.05.001.
   FLAMAND JRB, 1994, VET REC, V134, P115, DOI 10.1136/vr.134.5.115.
   FLORES CF, 2005, REV INVESTIG VET PER, V16, P65.
   FOWLER ME, 1978, P S MYC INF ZOO AN, P185.
   FRANCIS J, 1971, AUST VET J, V47, P414, DOI 10.1111/j.1751-0813.1971.tb02165.x.
   Francis J., 1958, TUBERCULOSIS ANIMALS.
   FREMMING BD, 1957, AM REV TUBERC PULM, V76, P225.
   Friend M, 1963, NEW YORK FISH GAME J, V10, P118.
   FROST PA, 2006, MYCOBACTERIUM BOVIS, P271.
   GALLAGHER J, 1972, Tropical Animal Health and Production, V4, P204, DOI 10.1007/BF02360112.
   GALLAGHER J, 1980, BADGERS CATTLE TUBER, P203.
   Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100.
   Gay G, 2000, NEW ZEAL VET J, V48, P78, DOI 10.1080/00480169.2000.36164.
   GIBSON JP, 1971, LAB ANIM SCI, V21, P62.
   GILL JW, 1993, NEW ZEAL VET J, V41, P147, DOI 10.1080/00480169.1993.35756.
   Gilsdorf M., 2006, MYCOBACTERIUM BOVIS, P211.
   Goble Marian, 1994, P259.
   Goodchild T., 2006, MYCOBACTERIUM BOVIS, P100, DOI 10.1002/9780470344538.ch12.
   Gortazar C, 2005, VET RES, V36, P43, DOI 10.1051/vetres:2004051.
   Griffin JFT, 2004, TUBERCULOSIS, V84, P293, DOI 10.1016/j.tube.2003.11.001.
   Griffin JM, 2005, PREV VET MED, V67, P237, DOI 10.1016/j.prevetmed.2004.10.009.
   GunnMoore DA, 1996, VET REC, V138, P53, DOI 10.1136/vr.138.3.53.
   Haagsma J, 1995, MYCOBACTERIUM BOVIS, P73.
   Haberle A. J., 1970, Journal of Zoo Animal Medicine, V1, P10, DOI 10.2307/20094053.
   HADWEN SEYMOUR, 1942, JOUR AMER VET MED ASSOC, V100, P19.
   HARRIS NB, 2006, MYCOBACTERIUM BOVIS, P54.
   Havlir DV, 1999, NEW ENGL J MED, V340, P367, DOI 10.1056/NEJM199902043400507.
   HEIN WR, 1981, AUST VET J, V57, P543, DOI 10.1111/j.1751-0813.1981.tb00429.x.
   Helman RG, 1998, J VET DIAGN INVEST, V10, P89, DOI 10.1177/104063879801000118.
   Hewinson RG, 2006, VET MICROBIOL, V112, P127, DOI 10.1016/j.vetmic.2005.11.050.
   HIMES EM, 1980, J AM VET MED ASSOC, V177, P825.
   Hines N, 2006, J VET DIAGN INVEST, V18, P243, DOI 10.1177/104063870601800302.
   HLAVSA M, CLIN INFECT DIS, V47, P168.
   Hope JC, 2008, COMP IMMUNOL MICROB, V31, P77, DOI 10.1016/j.cimid.2007.07.003.
   {*}I MED, 2000, END NEGL EL TUB US, P27.
   ISAAC J, 1983, AUST VET J, V60, P243, DOI 10.1111/j.1751-0813.1983.tb05974.x.
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292.
   JORGENSEN J B, 1988, Dansk Veterinaertidsskrift, V71, P806.
   Kahn Laura H, 2007, Vet Ital, V43, P5.
   Kaneene JB, 2004, JAVMA-J AM VET MED A, V224, P685, DOI 10.2460/javma.2004.224.685.
   Kaneene JB, 2002, AM J VET RES, V63, P1507, DOI 10.2460/ajvr.2002.63.1507.
   Kaneene JB, 2002, J AM VET MED ASSOC, V220, P656, DOI 10.2460/javma.2002.220.656.
   KANEENE JB, 2006, MYCOBACTERIUM BOVIS, P44.
   KARLSON ALFRED G., 1962, ADVANCES VET SCI, V7, P147.
   Keating LA, 2005, MOL MICROBIOL, V56, P163, DOI 10.1111/j.1365-2958.2005.04524.x.
   Keet DF, 2000, ONDERSTEPOORT J VET, V67, P115.
   Keet DF, 1996, ONDERSTEPOORT J VET, V63, P239.
   Keet DF, 2001, ONDERSTEPOORT J VET, V68, P225.
   Kinde H, 2007, J FOOD PROTECT, V70, P47, DOI 10.4315/0362-028X-70.1.47.
   Koch R., 1882, BERL KLIN WOCHENSCHR, V19, P221.
   Koller M. A., 2006, MYCOBACTERIUM BOVIS, P226.
   KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991.
   Kriek NP, 2006, MYCOBACTERIUM BOVIS, P238.
   LEUNG AN, 1992, RADIOLOGY, V182, P87, DOI 10.1148/radiology.182.1.1727316.
   Levine P. P., 1934, CORNELL VET, V24, P264.
   Lisle G. W. de, 1993, Surveillance (Wellington), V20, P24.
   LITTLE TWA, 1982, J HYG-CAMBRIDGE, V89, P211, DOI 10.1017/S0022172400070741.
   LOBUE P, 2006, MYCOBACTERIUM BOVIS, P6.
   LoBue PA, 2003, AM J RESP CRIT CARE, V168, P443, DOI 10.1164/rccm.200303-390OC.
   LoBue PA, 2005, INT J TUBERC LUNG D, V9, P501.
   LoBue PA, 2003, INT J TUBERC LUNG D, V7, P180.
   LOBUE PA, 1994, INT J TUBERC LUNG D, V9, P333.
   LOMME JR, 1976, J AM VET MED ASSOC, V169, P912.
   LUGTON I, 1995, OTAGO C SERIES, V3, P239.
   Lugton IW, 1995, NEW ZEAL VET J, V43, P342, DOI 10.1080/00480169./1995.35917.
   LUMEIJ JT, 1987, VET REC, V120, P302, DOI 10.1136/vr.120.13.302.
   Lyashchenko KP, 2008, VET MICROBIOL, V132, P283, DOI 10.1016/j.vetmic.2008.05.029.
   Lyashchenko KP, 2007, CLIN VACCINE IMMUNOL, V14, P1158, DOI 10.1128/CVI.00230-07.
   Mancilla E Marcos, 2006, Rev. chil. infectol., V23, P220, DOI 10.4067/S0716-10182006000300004.
   Martinez Horacio Zendejas, 2007, Vet Ital, V43, P629.
   Martinez LR, 2008, J VET DIAGN INVEST, V20, P707, DOI 10.1177/104063870802000601.
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1.
   Mathews F, 2006, P ROY SOC B-BIOL SCI, V273, P357, DOI 10.1098/rspb.2005.3298.
   Maue AC, 2007, VACCINE, V25, P4735, DOI 10.1016/j.vaccine.2007.03.052.
   Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49.
   MCADAMS HP, 1995, RADIOL CLIN N AM, V33, P655.
   McInerney J, 1995, AUST VET J, V72, P448, DOI 10.1111/j.1751-0813.1995.tb03486.x.
   {*}MICH GOV, 2008, 23906 IC MICH GOV MI.
   Michalak K, 1998, EMERG INFECT DIS, V4, P283, DOI 10.3201/eid0402.980217.
   Michel AL, 2002, ANN NY ACAD SCI, V969, P251, DOI 10.1111/j.1749-6632.2002.tb04387.x.
   Michel AL, 1998, J S AFR VET ASSOC, V69, P64.
   Michishita Y, 2006, J HIGH ENERGY PHYS.
   Mikota SK, 2001, J ZOO WILDLIFE MED, V32, P1.
   Milian-Suazo F, 2000, AM J VET RES, V61, P86, DOI 10.2460/ajvr.2000.61.86.
   Miller J, 1997, J VET DIAGN INVEST, V9, P244, DOI 10.1177/104063879700900304.
   Miller R, 2003, J WILDLIFE DIS, V39, P84, DOI 10.7589/0090-3558-39.1.84.
   Miller RA, 2006, AM J VET RES, V67, P604, DOI 10.2460/ajvr.67.4.604.
   Miller R, 2007, PREV VET MED, V82, P111, DOI 10.1016/j.prevetmed.2007.05.011.
   {*}MINS AGR, 2008, PROGR NAC CONTR ERR.
   MIRSKY ML, 1992, J AM VET MED ASSOC, V200, P1540.
   Monies B, 2006, VET REC, V158, P245, DOI 10.1136/vr.158.7.245-a.
   Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC.
   Morris PJ, 1996, J ZOO WILDLIFE MED, V27, P392.
   MORRIS RS, 1994, VET MICROBIOL, V40, P153, DOI 10.1016/0378-1135(94)90053-1.
   Morris RS, 1995, NEW ZEAL VET J, V43, P256, DOI 10.1080/00480169./1995.35904.
   MUIRHEAD RH, 1974, VET REC, V95, P552.
   MYERS JA, 1969, BOVINE TUBERCULOSIS.
   Naranjo V, 2008, VET MICROBIOL, V127, P1, DOI 10.1016/j.vetmic.2007.10.002.
   Nishi JS, 2006, VET MICROBIOL, V112, P325, DOI 10.1016/j.vetmic.2005.11.013.
   Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014.
   NUGENT G, 1995, OTAGO C SERIES, V3, P273.
   O'Brien DJ, 2006, VET MICROBIOL, V112, P313, DOI 10.1016/j.vetmic.2005.11.014.
   O'Brien DJ, 2001, J WILDLIFE DIS, V37, P608, DOI 10.7589/0090-3558-37.3.608.
   O'Reilly L. M., 1988, Irish Veterinary News, V10, P11.
   Oh P, 2002, EMERG INFECT DIS, V8, P1290.
   OLSEN I, 2010, PATHOGENESI IN PRESS.
   OREILLY LM, 1995, TUBERCLE LUNG DIS, V76, P1, DOI 10.1016/0962-8479(95)90591-X.
   OREILLY LM, 1995, MYCOBACTERIUM BOVIS, P177.
   {*}PAHO WHO, 1992, PREV VET MED, V55, P255.
   {*}PAHO WHO, 2008, MAN BACT DIAGN TUB 2.
   Palmer MV, 2006, CLIN VACCINE IMMUNOL, V13, P387, DOI 10.1128/CVI.13.3.387-394.2006.
   Palmer MV, 2000, J AM VET MED ASSOC, V216, P1921, DOI 10.2460/javma.2000.216.1921.
   Parra A, 2005, VET MICROBIOL, V110, P293, DOI 10.1016/j.vetmic.2005.07.013.
   Parra A, 2003, VET MICROBIOL, V97, P123, DOI 10.1016/j.vetmic.2003.08.007.
   Pate M, 2006, J VET MED B, V53, P387, DOI 10.1111/j.1439-0450.2006.01000.x.
   Pattyn S. R., 1967, Acta Zoologica et Pathologica Antverpiensia, V43, P125.
   PAVLIK I, 1990, VET MED CZECK, V47, P122.
   PAVLIK I, 2006, MYCOBACTERIUM BOVIS, P173.
   Pavlik I., 2006, MYCOBACTERIUM BOVIS, P136.
   Payeur JB, 2002, ANN NY ACAD SCI, V969, P259, DOI 10.1111/j.1749-6632.2002.tb04389.x.
   Pollock JM, 1997, INFECT IMMUN, V65, P2587.
   POTKAY S, 1966, AM J VET RES, V27, P331.
   Proano-Perez F, 2006, AM J TROP MED HYG, V75, P318.
   Quigley FC, 1997, VET REC, V141, P516, DOI 10.1136/vr.141.20.516.
   QUINN JF, 1963, P 100 ANN M AM VET M, P262.
   QUINN PJ, 2006, MYCOBACTERIUM BOVIS, P124.
   Ragg JR, 2000, NEW ZEAL VET J, V48, P166, DOI 10.1080/00480169.2000.36188.
   Ragg JR, 1995, NEW ZEAL VET J, V43, P338, DOI 10.1080/00480169./1995.35916.
   Ragg JR, 1995, NEW ZEAL VET J, V43, P333, DOI 10.1080/00480169./1995.35915.
   Ramos A, 2004, CLIN INFECT DIS, V39, pE53, DOI 10.1086/423276.
   RETAMAL P, 1081, REV CHIL INFECTOL, V20, P166.
   RHYAN J, 1995, P VET EP EC S 31 MAY.
   RITACCO V, 2006, MYCOBACTERIUM BOVIS, P13.
   RITACCO V, 2006, MYCOBACTERIUM BOVIS, P149.
   Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538.
   RYAN TJ, 1998, P SOC VET EP PREV ME, P1.
   {*}SAGARPA, 2008, CAMP NAC TUB BOV BRU.
   Samper S, 1997, AIDS, V11, P1237, DOI 10.1097/00002030-199710000-00006.
   SAPOLSKY RM, 1987, J MED PRIMATOL, V16, P229.
   SAWA TR, 1974, J AM VET MED ASSOC, V165, P998.
   SCHLIESSER TA, 1978, P S MYC INF ZOO AN 6, P29.
   Schmitt SM, 1997, J WILDLIFE DIS, V33, P749, DOI 10.7589/0090-3558-33.4.749.
   Schmitt SM, 2002, ANN NY ACAD SCI, V969, P262, DOI 10.1111/j.1749-6632.2002.tb04390.x.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   Serraino A, 1999, J CLIN MICROBIOL, V37, P2766.
   Skuce RA, 2005, VET REC, V157, P501, DOI 10.1136/vr.157.17.501.
   SNIDER WR, 1971, AM REV RESPIR DIS, V104, P866.
   STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465.
   Stetter MD, 1995, J AM VET MED ASSOC, V207, P1618.
   Stumpff C. D., 1982, Proceedings of the American Animal Health Association, V86, P524.
   Stumpff C. D., 1984, Proceedings of the United States Animal Health Association, V88, P564.
   Suazo FM, 2002, PREV VET MED, V55, P255.
   SUNDER S, 2009, J CLIN MICROBIOL, V10, P1128.
   Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06.
   TARARA R, 1985, J WILDLIFE DIS, V21, P137, DOI 10.7589/0090-3558-21.2.137.
   TESSARO SV, 1986, CAN VET J, V27, P119.
   Thoen C, 2006, VET MICROBIOL, V112, P339, DOI 10.1016/j.vetmic.2005.11.047.
   Thoen C., 2006, MYCOBACTERIUM BOVIS, P49.
   Thoen C. O., 2008, ONE HLTH NEWSLETTER, V1, P5.
   THOEN CC, 2010, MERCK VET M IN PRESS.
   Thoen CO, 2007, LANCET, V369, P1236, DOI 10.1016/S0140-6736(07)60572-8.
   Thoen Charles O., 1994, P157.
   Thoen Charles O., 1993, P45.
   THOEN CO, 1980, AM J VET RES, V41, P833.
   THOEN CO, 1992, J VET DIAGN INVEST, V4, P423, DOI 10.1177/104063879200400410.
   THOEN CO, 1977, ARCH PATHOL LAB MED, V101, P291.
   THOEN CO, 1977, J AM VET MED ASSOC, V170, P987.
   THOEN CO, 1981, REV INFECT DIS, V3, P960.
   THOEN CO, 1988, AM J VET RES, V49, P1861.
   THOEN CO, 2006, DIS SWINE, P807.
   THOEN CO, 1995, MYCOBACTERIUM BOVIS, P3.
   THOEN CO, 1995, MYCOBACTERIUM BOVIS, P93.
   Thoen CO, 2006, MYCOBACTERIUM BOVIS, P18.
   THOMPSON PJ, 1993, AM REV RESPIR DIS, V147, P164, DOI 10.1164/ajrccm/147.1.164.
   Thorel MF, 1998, VET RES, V29, P207.
   THOREL MF, 1980, TUBERCLE, V61, P101, DOI 10.1016/0041-3879(80)90018-5.
   Tiruviluamala P, 2002, ANNU REV PUBL HEALTH, V23, P403, DOI 10.1146/annurev.publhealth.23.100901.140519.
   TORRES PM, 2004, TEMAS ZOONOSIS, V2, P235.
   TOWAR DR, 1965, AM J VET RES, V26, P339.
   Tryland Morten, 2000, Infectious Disease Review, V2, P55.
   Twomey DF, 2007, VET REC, V160, P170, DOI 10.1136/vr.160.5.170.
   Valpreda M., 1994, ALPE ADRIA MICROBIOL, V3, P296.
   VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578.
   VERMA R, MYCOBACTERIUM BOVIS, P161.
   Vicente J, 2006, VET RES, V37, P107, DOI 10.1051/vetres:2005044.
   Vincente J., 2007, VET RES, V38, P451.
   Vordermeier M, 2005, CATTLE PRACT, V13, P323.
   Wahlstrom H, 2000, PREV VET MED, V43, P103, DOI 10.1016/S0167-5877(99)00091-4.
   WEISS R, 2006, MYCOBACTERIUM BOVIS, P246.
   WELLS A, 1961, LANCET, V1, P1221.
   WEST G, 2006, MYCOBACTERIUM BOVIS, P248.
   Weyer K, 1999, INT J TUBERC LUNG D, V3, P1113.
   {*}WHO, 1959, TECHN REP SER WHO, V169.
   {*}WHO, 2008, EST BURD TB AM 1990, P214.
   {*}WHO, 2004, 3 WHO.
   WILKINS MJ, 2006, EMERG INFECT DIS, V14, P1.
   WILSON P, 1984, LAB ANIM, V18, P383, DOI 10.1258/002367784780865351.
   WOBESER G, 1995, OTAGO C SERIES, V3, P267.
   WOLF RH, 1988, LAB ANIM SCI, V38, P25.
   WOOD PR, 1991, AUST VET J, V68, P286, DOI 10.1111/j.1751-0813.1991.tb03254.x.
   WOODFORD MH, 1982, TROP ANIM HEALTH PRO, V14, P81, DOI 10.1007/BF02282586.
   WOODS R, 1995, J WILDLIFE DIS, V31, P83, DOI 10.7589/0090-3558-31.1.83.
   {*}WORLD ORG AN HLTH, 2008, DIS INF BOV TUB.
   Wyss D, 2000, VET REC, V147, P713.
   ZHAO D, MYCOBACTERIUM BOVIS, P244.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.
   ZINSSTAG J, 2006, MYCOBACTERIUM BOVIS, P199, DOI DOI 10.1002/9780470344538.CH19.
   Zinsstag J., 2006, MYCOBACTERIUM BOVIS, P68, DOI 10.1002/9780470344538.ch9.
   ZUMPE D, 1980, LAB ANIM SCI, V30, P237.
   2004, FED REG, V69, P9749.}},
Number-of-Cited-References = {{287}},
Times-Cited = {{47}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{24}},
Journal-ISO = {{Vet. Ital.}},
Doc-Delivery-Number = {{476JQ}},
Unique-ID = {{ISI:000268436700012}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000264902200002,
Author = {Chikere, C. B. and Chikere, B. O. and Omoni, V. T.},
Title = {{Antibiogram of clinical isolates from a hospital in Nigeria}},
Journal = {{AFRICAN JOURNAL OF BIOTECHNOLOGY}},
Year = {{2008}},
Volume = {{7}},
Number = {{24}},
Pages = {{4359-4363}},
Month = {{DEC 17}},
Abstract = {{Antibiogram of clinical isolates from four wards in a government
   hospital in Port Harcourt, Nigeria was investigated. Swab and air
   samples were obtained from patients, personnel, formites and air in
   orthopaedic, medical, surgical and paediatric wards. A total of 56
   isolates were obtained of which Staphylococcus epidermidis ( 22) was the
   highest. This was followed by Staphylococcus aureus ( 16), Streptococcus
   spp. ( 5), Escherichia coli ( 4) and Klebsiella pneumonia ( 3). Proteus
   spp., Enterobacter aerogenes and Bacillus cereus had 2 strains each
   isolated. The Gram positive bacteria were more resistant to norfloxacin,
   floxapen, and ciprofloxacin but very sensitive to gentamycin, lincocin,
   rifampicin and streptomycin. S. aureus accounted for the highest
   resistance to ampiclox followed by S. epidermidis to ciprofloxacin and
   norfloxacin. The Gram negative bacilli showed highest resistance to
   ampicillin followed by augumentin, ceporex, and nalidixic acid whereas
   they were more sensitive to tarivid, peflacin and streptomycin. It could
   be inferred from the results that patients in this hospital might be at
   the risk of being infected with antibiotic resistant strains during
   admission.}},
Publisher = {{ACADEMIC JOURNALS}},
Address = {{P O BOX 5170-00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chikere, CB (Reprint Author), Univ Port Harcourt, Dept Microbiol, PMB 5323, Port Harcourt, Rivers State, Nigeria.
   Chikere, C. B.; Omoni, V. T., Univ Port Harcourt, Dept Microbiol, Port Harcourt, Rivers State, Nigeria.
   Chikere, B. O., Fed Univ Technol Owerri, Dept Microbiol, Owerri, Imo, Nigeria.}},
ISSN = {{1684-5315}},
Keywords = {{Antibiogram; nosocomial; Port Harcourt; clinical isolates; gram positive
   bacteria; gram negative bacteria}},
Keywords-Plus = {{INTENSIVE-CARE-UNIT; BETA-LACTAMASES; ESCHERICHIA-COLI; RESISTANCE;
   INFECTIONS; EMERGENCE; COMMUNITY; BACTERIA; STATES; ICU}},
Research-Areas = {{Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology}},
Author-Email = {{ujuazed@yahoo.com}},
Cited-References = {{Buhlmann M, 2008, J CLIN MICROBIOL, V46, P2151, DOI 10.1128/JCM.01957-07.
   Cheesbrough M., 1992, MED LAB MANUAL TROPI, V2nd.
   Cloete TE, 2003, INT BIODETER BIODEGR, V51, P277, DOI 10.1016/S0964-8305(03)00042-8.
   Coyle MB, 2005, MANUAL ANTIMICROBIAL, P25.
   {*}DEP MICR, 2004, MANUAL LAB EXERCISES, P19.
   Depardieu F, 2007, CLIN MICROBIOL REV, V20, P79, DOI 10.1128/CMR.00015-06.
   EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428.
   Esposito S, 2007, INT J ANTIMICROB AG, V29, P494, DOI 10.1016/j.ijantimicag.2006.10.017.
   Leavitt A, 2007, ANTIMICROB AGENTS CH, V51, P3026, DOI 10.1128/AAC.00299-07.
   Lewis JS, 2007, ANTIMICROB AGENTS CH, V51, P4015, DOI 10.1128/AAC.00576-07.
   Lockhart SR, 2007, J CLIN MICROBIOL, V45, P3352, DOI 10.1128/JCM.01284-07.
   Mendonca N, 2007, ANTIMICROB AGENTS CH, V51, P1946, DOI 10.1128/AAC.01412-06.
   Moland ES, 2006, J CLIN MICROBIOL, V44, P3318, DOI 10.1128/JCM.00756-06.
   Mulvey MR, 2004, ANTIMICROB AGENTS CH, V48, P1204, DOI 10.1128/AAC.48.4.1204-1214.2004.
   Piddock LJV, 2006, CLIN MICROBIOL REV, V19, P382, DOI 10.1128/CMR.19.2.382-402.2006.
   Pitout JDD, 2005, J ANTIMICROB CHEMOTH, V56, P52, DOI 10.1093/jac/dki166.
   Prescott LM, 2005, MICROBIOLOGY, P833.
   Rhomberg PR, 2006, DIAGN MICR INFEC DIS, V56, P57, DOI 10.1016/j.diagmicrobio.2005.12.009.
   Singh A, 2006, CLIN MICROBIOL REV, V19, P512, DOI 10.1128/CMR.00025-05.
   Turnidge J, 2007, CLIN MICROBIOL REV, V20, P391, DOI 10.1128/CMR.00047-06.
   Villain-Guillot P, 2007, ANTIMICROB AGENTS CH, V51, P3117, DOI 10.1128/AAC.00343-07.
   Weber JT, 2005, EMERG INFECT DIS, V11, P791, DOI 10.3201/eid1106.050471.
   Zhanel GG, 2008, ANTIMICROB AGENTS CH, V52, P1430, DOI 10.1128/AAC.01538-07.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Afr. J. Biotechnol.}},
Doc-Delivery-Number = {{429DY}},
Unique-ID = {{ISI:000264902200002}},
DA = {{2018-08-13}},
}

@article{ ISI:000261553500001,
Author = {Basu, S. and Galvani, A. P.},
Title = {{The transmission and control of XDR TB in South Africa: an operations
   research and mathematical modelling approach}},
Journal = {{EPIDEMIOLOGY AND INFECTION}},
Year = {{2008}},
Volume = {{136}},
Number = {{12}},
Pages = {{1585-1598}},
Month = {{DEC}},
Abstract = {{Extensively drug-resistant tuberculosis (XDR TB) has emerged as a threat
   to TB control efforts in several high-burden areas, generating
   international concern. XDR TB is now found in every region of the world,
   but appears most worrisome in the context of HIV and in resource-limited
   settings with congregate hospital wards. Here, we examine the emergence
   and transmission dynamics of the disease, incorporating the mathematical
   modelling literature related to airborne infection and epidemiological
   studies related to the operations of TB control programmes in
   resource-limited settings. We find that while XDR TB may present many
   challenges in the setting, of resource constraints, the central problems
   highlighted by the emergence of XDR TB are those that have plagued TB
   programmes for years. These Include a slow rate of case detection that
   permits prolonged infectiousness, the threat of airborne infection in
   enclosed spaces. the problem of inadequate treatment delivery and
   treatment completion, and the need to develop health systems that can
   address the combination of TB and poverty. Mathematical models of TB
   transmission shed light on the idea that community-based therapy and
   rapid detection systems may be beneficial in resource-limited settings,
   while congregate hospital wards are sites for major structural reform.}},
Publisher = {{CAMBRIDGE UNIV PRESS}},
Address = {{32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Basu, S (Reprint Author), Yale Univ, Sch Med, Dept Epidemiol \& Publ Hlth, 60 Coll St, New Haven, CT 06510 USA.
   Basu, S.; Galvani, A. P., Yale Univ, Sch Med, Dept Epidemiol \& Publ Hlth, New Haven, CT 06510 USA.}},
DOI = {{10.1017/S0950268808000964}},
ISSN = {{0950-2688}},
EISSN = {{1469-4409}},
Keywords = {{HIV; infection control; mathematical modeling; quarantine; South Africa;
   tuberculosis - extensively drug resistant}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; HIV-INFECTED PATIENTS;
   IMMUNODEFICIENCY-VIRUS-INFECTION; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL
   OUTBREAK; DRUG-RESISTANCE; STRAIN; HOSPITALS; SPREAD; AIR}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{sanjay.basu@yale.edu}},
Cited-References = {{Anderson R. M., 1991, INFECT DIS HUMANS DY.
   ANDREWS J, 2007, INT J TUBERC LUNG D, V11, pS263.
   ASHANTI A, 2006, CASE STUDIES.
   Basu S, 2007, LANCET, V369, P272, DOI 10.1016/S0140-6736(07)60143-3.
   Basu S, 2007, LANCET INFECT DIS, V7, P442, DOI 10.1016/S1473-3099(07)70142-1.
   Basu S, 2007, LANCET, V370, P1500, DOI 10.1016/S0140-6736(07)61636-5.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Behr MA, 2004, AM J RESP CRIT CARE, V169, P554, DOI 10.1164/rccm.2401001.
   BLOWER SM, 1995, NAT MED, V1, P815, DOI 10.1038/nm0895-815.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   {*}CDC, 1996, MMWR-MORBID MORTAL W, V45, P330.
   Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P1176.
   Cohen T, 2004, NAT MED, V10, P1117, DOI 10.1038/nm1110.
   Cohen T, 2003, LANCET INFECT DIS, V3, P13, DOI 10.1016/S1473-3099(03)00483-3.
   Connolly LE, 2007, PLOS MED, V4, P435, DOI 10.1371/journal.pmed.0040120.
   Corbett EL, 2007, PLOS MED, V4, P164, DOI 10.1371/journal.pmed.0040022.
   CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052.
   Crush J., 2005, Development Southern Africa, V22, P293, DOI 10.1080/03768350500253153.
   DIPERRI G, 1989, LANCET, V2, P1502.
   Dugger C. W., 2008, NY TIMES.
   Dye C, 2000, P NATL ACAD SCI USA, V97, P8180, DOI 10.1073/pnas.140102797.
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7.
   Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814.
   Dye C, 2001, P ROY SOC B-BIOL SCI, V268, P45, DOI 10.1098/rspb.2000.1328.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   Espinal MA, 2003, INT J TUBERC LUNG D, V7, P607.
   Farmer P, 1998, INT J TUBERC LUNG D, V2, P869.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   Gagneux S, 2006, SCIENCE, V312, P1944, DOI 10.1126/science.1124410.
   Gagneux S, 2006, PLOS PATHOG, V2, P603, DOI 10.1371/journal.ppat.0020061.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   GANDHI N, 2006, 16 INT AIDS C TOR.
   GANDHI N, 2008, 15 C RETR OPP INF.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Gupta R, 2001, SCIENCE, V293, P1049, DOI 10.1126/science.1061861.
   {*}HARV MED SCH OP S, 1999, GLOB IMP MULT RES TU.
   Havlir DV, 1999, NEW ENGL J MED, V340, P367, DOI 10.1056/NEJM199902043400507.
   {*}HLTH SYST TRUST, 2007, INC TB ALL TYP PER 1.
   {*}HLTH SYST TRUST, 2007, INT DEF RAT NEW SMEA.
   {*}HLTH SYST TRUST, 2007, HIV PREV.
   ISEMAN MD, 2000, CLIN GUID TUBERCULOS.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Kaplan EH, 2002, P NATL ACAD SCI USA, V99, P10935, DOI 10.1073/pnas.162282799.
   Kawai V, 2006, AM J TROP MED HYG, V75, P1027.
   Kenyon TA, 1997, ANN INTERN MED, V127, P32, DOI 10.7326/0003-4819-127-1-199707010-00006.
   Kleinrock L, 1975, QUEUEING SYSTEMS.
   Lee K, 2004, J OCCUP ENVIRON HYG, V1, P22, DOI 10.1080/15459620490250026.
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x.
   Manabe YC, 2003, INFECT IMMUN, V71, P6004, DOI 10.1128/IAI.71.10.6004-6011.2003.
   Manca C, 2004, INFECT IMMUN, V72, P5511, DOI 10.1128/IAI.72.9.5511-5514.2004.
   Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   MOLL A, 2007, INT J TUBERC LUNG D, V11, pS240.
   MOODLEY P, 2007, INT J TUBERC LUNG S, V11, pS56.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Moro ML, 1998, AIDS, V12, P1095, DOI 10.1097/00002030-199809000-00018.
   Moro ML, 2000, INT J TUBERC LUNG D, V4, P61.
   Moss AR, 1997, INT J TUBERC LUNG D, V1, P115.
   NARDELL E, 2000, TUBERCULOSIS CURRENT, P50.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Narvskaya O, 2002, EUR J CLIN MICROBIOL, V21, P596, DOI 10.1007/s10096-002-0775-4.
   Noakes CJ, 2006, EPIDEMIOL INFECT, V134, P1082, DOI 10.1017/S0950268806005875.
   Nolan CM, 1997, J INFECT DIS, V176, P748, DOI 10.1086/514099.
   {*}OP SOC I MED SANS, 2007, UN WORLD C LUNG HLTH.
   Pillay M, 2007, CLIN INFECT DIS, V45, P1409, DOI 10.1086/522987.
   POSEL D, 2002, C LAB MARK POV S AFR.
   RICH ML, 2003, PIH GUIDE MED MANAGE.
   RILEY EC, 1978, AM J EPIDEMIOL, V107, P421, DOI 10.1093/oxfordjournals.aje.a112560.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   Ritacco V, 1997, J INFECT DIS, V176, P637, DOI 10.1086/514084.
   {*}S AFR DEP HLTH, 2007, TUB STRAT PLAN S AFR.
   {*}S AFR DEP HLTH, KZN OUTBR.
   {*}S AFR PRESS ASS, 2007, XDR TB FOUND ALL PRO.
   Sacks LV, 1999, CLIN INFECT DIS, V29, P96, DOI 10.1086/520189.
   SHAH NS, 2007, EMERGING INFECT DIS, V13.
   SHAH S, 2008, COMMUNICATION   0304.
   Sherman DR, 1996, SCIENCE, V272, P1641, DOI 10.1126/science.272.5268.1641.
   Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050.
   {*}SPEC PROGR TROP D, 2006, DIAGN TUB GLOB DEM M.
   STURM AW, 2007, MULTI EXTENSIVELY DR.
   Tokars JI, 2001, INFECT CONT HOSP EP, V22, P449, DOI 10.1086/501933.
   {*}UNFPA, 1999, DAY 6 BILL.
   VELLA V, 2007, SURVEILLANCE XDR MDR.
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665.
   Wells W.F., 1955, AIRBORNE CONTAGION A.
   WEYER K, 2001, NATL SURVEY TUBERCUL.
   {*}WHO, 2006, PROGR GLOB ACC HIV A.
   {*}WHO IUATLD, 2008, ANT DRUG RES WORLD.
   WILLIAMS B, 1998, OCCUPATIONAL LUNG DI.
   Williams BG, 2003, SCIENCE, V301, P1535, DOI 10.1126/science.1086845.
   World Health Organization, 2006, GUID PROGR MAN DRUG.
   2007, PATIENTS DRUG RESIST.}},
Number-of-Cited-References = {{96}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Epidemiol. Infect.}},
Doc-Delivery-Number = {{381RL}},
Unique-ID = {{ISI:000261553500001}},
DA = {{2018-08-13}},
}

@article{ ISI:000264352100007,
Author = {Van Wyk, J. A.},
Title = {{Production trials involving use of the FAMACHA (c) system for
   haemonchosis in sheep: preliminary results}},
Journal = {{ONDERSTEPOORT JOURNAL OF VETERINARY RESEARCH}},
Year = {{2008}},
Volume = {{75}},
Number = {{4}},
Pages = {{331-345}},
Month = {{DEC}},
Abstract = {{VAN WYK, J.A. 2008 Production trials involving use of the FAMACHA (c)
   system for haemonchosis in sheep: preliminary results. Onderstepoort
   Journal of Veterinaty Research, 75:331-345
   In three trials conducted on two separate farms the production of sheep
   treated for naturally acquired haemonchosis using the FAMACHA (c) system
   of targeted selective treatment (TST) (i.e. to treat only those animals
   unable to manage unaided in the face of heavy Haemonchus challenge) was
   compared to that of suppressively drenched sheep in the same flock. As
   expected by the research team who developed and evaluated the FAMACHA
   (c) system, TST did result in some loss in production. However, despite
   high levels of worm challenge in two of the trials and the fact that the
   comparison was with suppressive drenching which is not sustainable, the
   total effect was relatively small in relation to the important advantage
   of using the TST as regards reduced selection for anthelmintic
   resistance (AR).
   Concerning the sustainability of worm control, it is concluded that the
   development of drug resistance to anthelmintics leaves sheep and goat
   farmers in South Africa no choice but to use methods of TST such as
   FAMACHA (c). The FAMACHA (c) system can also be a useful clinical aid
   for early on-farm detection of AIR by farmers; the degree of improvement
   in the colour of the ocular mucous membrane from pale to red in
   individually drenched anaemic animals over a period of 7-14 days can
   give a good indication of the efficacy of the compound(s) used.}},
Publisher = {{AOSIS}},
Address = {{POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH
   AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Van Wyk, JA (Reprint Author), Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, Private Bag X04, ZA-0110 Onderstepoort, South Africa.
   Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, ZA-0110 Onderstepoort, South Africa.}},
ISSN = {{0030-2465}},
EISSN = {{2219-0635}},
Keywords = {{Animal production; body condition scoring; FAMACHA (c); haemonchosis;
   sheep; targeted selective treatment}},
Keywords-Plus = {{HAEMONCHUS-CONTORTUS; ANTHELMINTIC RESISTANCE; SOUTH-AFRICA; FIELD
   STRAINS; WILD ANIMALS; RAFOXANIDE; IVERMECTIN; CLOSANTEL; HELMINTHS;
   PARASITES}},
Research-Areas = {{Veterinary Sciences}},
Web-of-Science-Categories  = {{Veterinary Sciences}},
Author-Email = {{jan.vanwyk@up.ac.za}},
Funding-Acknowledgement = {{EU; National Wool Grower's Association and Cape Wools of South Africa}},
Funding-Text = {{These investigations were done with the support of the EU PARASOL
   project (EU FP6 call for applications), the National Wool Grower's
   Association and Cape Wools of South Africa. Without the enthusiastic
   cooperation of and disregard of potential losses by the two farmers
   involved, this work could not have materialised. Prof. H.T. Groeneveld
   did the statistical evaluations and Mrs Rachel Coetzee was responsible
   for the data capture.}},
Cited-References = {{BARGER IA, 1985, INT J PARASITOL, V15, P645, DOI 10.1016/0020-7519(85)90010-4.
   BATH GF, 1996, P S AFRICAN VET ASS, P264.
   BATH GF, 2001, P 5 INT SHEEP VET C.
   Bisset SA, 2001, P 5 INT SHEEP VET C.
   CARMICHAEL I, 1987, J S AFR VET ASSOC, V58, P93.
   COTTLE DJ, 1991, AUSTR SHEEP WOOL HDB.
   HORAK IG, 1978, ONDERSTEPOORT J VET, V45, P1.
   HORAK IG, 1977, ONDERSTEPOORT J VET, V44, P261.
   Kaplan RM, 2004, VET PARASITOL, V123, P105, DOI 10.1016/j.vetpar.2004.06.005.
   Leathwick DM, 2006, NEW ZEAL VET J, V54, P305, DOI 10.1080/00480169.2006.36715.
   Leathwick DM, 2006, NEW ZEAL VET J, V54, P297, DOI 10.1080/00480169.2006.36714.
   Malan F.S., 1992, P S AFR VET ASS BIEN, P139.
   Malan FS, 2001, ONDERSTEPOORT J VET, V68, P165.
   Michel J. F., 1969, Advances in Parasitology, V7, P211.
   Michel J.F., 1976, Advances Parasit, V14, P355, DOI 10.1016/S0065-308X(08)60517-5.
   Miller CM, 2006, NEW ZEAL VET J, V54, P323, DOI 10.1080/00480169.2006.36718.
   Molento Marcelo Beltrão, 2004, Cienc. Rural, V34, P1139, DOI 10.1590/S0103-84782004000400027.
   Molento MB, 2004, VET REC, V155, P95.
   REINECKE RK, 1973, 106 TECHN COMM DEP A.
   REYNECKE DP, 2007, THESIS U PRETORIA.
   Rhodes A. P., 2006, Proceedings of the New Zealand Society of Animal Production, V66, P14.
   SOTOMAIOR C, 2003, P 5 INT SEM AN PAR M, P61.
   Van Wyk J. A., 2006, Proceedings of the New Zealand Society of Animal Production, V66, P4.
   Wyk JA, 2006, VET PARASITOL, V139, P336, DOI 10.1016/j.vetpar.2006.04.023.
   Van Wyk JA, 1999, ONDERSTEPOORT J VET, V66, P273.
   van Wyk JA, 2002, VET RES, V33, P509, DOI 10.1051/vetres:2002036.
   Van Wyk JA, 2001, ONDERSTEPOORT J VET, V68, P55.
   VANWYK JA, 1987, ONDERSTEPOORT J VET, V54, P143.
   VANWYK JA, 1988, VET REC, V123, P226, DOI 10.1136/vr.123.9.226.
   VANWYK JA, 1982, ONDERSTEPOORT J VET, V49, P257.
   vanWyk JA, 1997, VET PARASITOL, V70, P111, DOI 10.1016/S0304-4017(96)01147-8.
   VANWYK JA, 1990, VET PARASITOL, V35, P61, DOI 10.1016/0304-4017(90)90116-S.
   VANWYK JA, 1997, P WORKSH HELD 16 INT, P51.
   VANWYK JA, 2001, P 5 INT SHEEP VET C.
   VANWYK JA, 2003, P 5 INT SEM AN PAR M, P39.
   Waller PJ, 1997, VET PARASITOL, V72, P391, DOI 10.1016/S0304-4017(97)00107-6.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{14}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Onderstepoort J. Vet. Res.}},
Doc-Delivery-Number = {{421IH}},
Unique-ID = {{ISI:000264352100007}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000260457800005,
Author = {Chikere, C. B. and Omoni, V. T. and Chikere, B. O.},
Title = {{Distribution of potential nosocomial pathogens in a hospital environment}},
Journal = {{AFRICAN JOURNAL OF BIOTECHNOLOGY}},
Year = {{2008}},
Volume = {{7}},
Number = {{20}},
Pages = {{3535-3539}},
Month = {{OCT 20}},
Abstract = {{The distribution of probable nosocomial pathogens in a government
   hospital in Nigeria was investigated. Thirty swab and air samples were
   collected from patients, hospital personnel, formites and air in four
   wards namely orthopaedic (OW), paediatric (PW), surgical (SW) and
   medical (MW). For the patients and personnel, skin and nasal samples
   were taken. A total of 56 Gram positive (45) and Gram negative (11)
   bacteria were isolated. Gram positive cocci were the highest number of
   isolates of which Staphylococcus epidermidis (22; 39.2\%) occurred the
   most especially from the skin in all the wards. This was followed by
   Staphylococcus aureus (16; 28.5\%) and the least being Streptococcus
   spp. (5; 8.9\%). Among the Gram negative bacilli, Escherichia coli was
   the highest (4; 7.1\%). Others were Klebsiella pneumonia (3; 5.3\%),
   Proteus spp. (2; 3.5\%) and Enterobacter aerogenes (2; 3.5\%). The only
   Gram positive bacilli isolated were Bacillus cereus. Orthopaedic ward
   (22) had the highest number of isolates followed by paediatric ward
   (15). Surgical and medical wards had 10 and 9 isolates, respectively.
   Statistical analysis of the questionnaire distributed to the patients
   and hospital personnel in the four wards revealed that duration of
   admission and length of service were significant determining factors for
   the carriage rate of the isolates in the individuals examined. The
   findings of the study showed that the hospital may be a potential
   reservoir of organisms likely to cause nosocomial infections.}},
Publisher = {{ACADEMIC JOURNALS}},
Address = {{P O BOX 5170-00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chikere, CB (Reprint Author), Univ Port Harcourt, Dept Microbiol, PMB 5323, Port Harcourt, Rivers State, Nigeria.
   Chikere, C. B.; Omoni, V. T., Univ Port Harcourt, Dept Microbiol, Port Harcourt, Rivers State, Nigeria.
   Chikere, B. O., Fed Univ Technol Owerri, Dept Microbiol, Owerri, Imo State, Nigeria.}},
ISSN = {{1684-5315}},
Keywords = {{Distribution; nosocomial pathogens; government hospital; Nigeria; gram
   positive bacteria; gram negative bacteria}},
Keywords-Plus = {{INTENSIVE-CARE-UNIT; RESISTANT STAPHYLOCOCCUS-AUREUS;
   METHICILLIN-RESISTANT; BETA-LACTAMASES; ANTIMICROBIAL RESISTANCE;
   ESCHERICHIA-COLI; INFECTIONS; EMERGENCE; COMMUNITY; STATES}},
Research-Areas = {{Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology}},
Author-Email = {{ujuazed@yahoo.com}},
Cited-References = {{BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148.
   Esposito S, 2007, INT J ANTIMICROB AG, V29, P494, DOI 10.1016/j.ijantimicag.2006.10.017.
   Fridkin SK, 2001, CLIN INFECT DIS, V33, P324, DOI 10.1086/321893.
   Kainer MA, 2007, EMERG INFECT DIS, V13, P1024, DOI 10.3201/eid1307.070019.
   Kuehnert MJ, 2005, EMERG INFECT DIS, V11, P868.
   Lewis JS, 2007, ANTIMICROB AGENTS CH, V51, P4015, DOI 10.1128/AAC.00576-07.
   Lockhart SR, 2007, J CLIN MICROBIOL, V45, P3352, DOI 10.1128/JCM.01284-07.
   McCraig LF, 2006, EMERG INFECT DIS, V12, P1715.
   Moland ES, 2006, J CLIN MICROBIOL, V44, P3318, DOI 10.1128/JCM.00756-06.
   Moran GJ, 2005, EMERG INFECT DIS, V11, P928.
   Mulvey MR, 2005, EMERG INFECT DIS, V11, P844, DOI 10.3201/eid1106.041146.
   Mulvey MR, 2004, ANTIMICROB AGENTS CH, V48, P1204, DOI 10.1128/AAC.48.4.1204-1214.2004.
   PELCZAR JR, 1993, MICROBIOLOGY CONCEPT, P591.
   Pitout JDD, 2005, J ANTIMICROB CHEMOTH, V56, P52, DOI 10.1093/jac/dki166.
   Pitout JDD, 2007, ANTIMICROB AGENTS CH, V51, P1281, DOI 10.1128/AAC.01377-06.
   Prescott LM, 2005, MICROBIOLOGY, P833.
   Rhomberg PR, 2006, DIAGN MICR INFEC DIS, V56, P57, DOI 10.1016/j.diagmicrobio.2005.12.009.
   SCHEIDERLINDER V, 2007, EMERG INFECT DIS, V13, P994.
   Weber JT, 2005, EMERG INFECT DIS, V11, P791, DOI 10.3201/eid1106.050471.
   Zhanel GG, 2008, ANTIMICROB AGENTS CH, V52, P1430, DOI 10.1128/AAC.01538-07.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Afr. J. Biotechnol.}},
Doc-Delivery-Number = {{366CI}},
Unique-ID = {{ISI:000260457800005}},
DA = {{2018-08-13}},
}

@article{ ISI:000258654500013,
Author = {Liaqat, Iram and Sabri, Anjum Nasim},
Title = {{Analysis of cell wall constituents of biocide-resistant isolates from
   dental-unit water line biofilms}},
Journal = {{CURRENT MICROBIOLOGY}},
Year = {{2008}},
Volume = {{57}},
Number = {{4}},
Pages = {{340-347}},
Month = {{OCT}},
Abstract = {{In past years, the significance of microbial resistance to biocides has
   increased. Twenty biocide-resistant bacterial strains were isolated from
   dental-unit water line biofilm. All strains resisted high biocide
   concentrations (up to 100 mu g ml(-)1): sodium dodecyl sulphate,
   hydrogen peroxide, sodium hypochlorite, phenol, Tween 20,
   ethylenediaminetetraacetic acid, chlorohexidine gluconate, and povidine
   iodine. Among bacteria, biocide sensitivity is based on permeability of
   biocides through the cell wall. Gram-positive bacteria are more
   permeable and susceptible to biocides, whereas Gram-negative bacteria
   have a more complex cell wall and are the least sensitive bacteria. The
   present study was designed to study the effect of biocides on the cell
   wall of biocide-resistant bacteria. Peptidoglycan (PG), diaminopimelic
   acid (DAP), and teichoic acid contents of the cell wall were determined
   in L-broth and L-broth supplemented with biocides at different
   temperatures (3 degrees C and 45 degrees C) and pH levels (7 and 9). In
   general and Gram staining-specific comparison, a significant increase (p
   < 0.05) in the DAP content of biocide-resistant bacteria was observed at
   pH 7 and at both temperatures. In tubing-specific comparison, a
   significant increase in the amount of teichoic acid in air water tubing
   (37 degrees C at pH 9) and DAP in patient tubing (pH 7 at both
   temperatures) was observed. In main water pipe, a significant decrease
   (p > 0.05) in PG content was noticed at 45 degrees C and pH 9. Overall,
   a significant increase in DAP content may be an important constituent in
   the manifestation of isolate resistance against various biocides.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Liaqat, I (Reprint Author), Univ Punjab, Dept Microbiol \& Mol Genet, Quaid e Azam Campus, Lahore 54590, Pakistan.
   Liaqat, Iram; Sabri, Anjum Nasim, Univ Punjab, Dept Microbiol \& Mol Genet, Lahore 54590, Pakistan.}},
DOI = {{10.1007/s00284-008-9200-2}},
ISSN = {{0343-8651}},
Keywords-Plus = {{PEPTIDOGLYCAN; CONTAMINATION; SYSTEMS; ACID}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{iramliaq@hotmail.com}},
Cited-References = {{AMES BN, 1966, METHOD ENZYMOL, V8, P116.
   Barbeau J, 1996, APPL ENVIRON MICROB, V62, P3954.
   Bhavsar AP, 2004, J BACTERIOL, V186, P7865, DOI 10.1128/JB.186.23.7865-7873.2004.
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945.
   CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033.
   Cui LZ, 2000, ANTIMICROB AGENTS CH, V44, P2276, DOI 10.1128/AAC.44.9.2276-2285.2000.
   Fraud S, 2003, J ANTIMICROB CHEMOTH, V51, P575, DOI 10.1093/jac/dkg099.
   Gerhardt P., 1994, METHODS GEN MOL BACT.
   HANCOCK IC, 1994, CHEM METHODS PROKARY, P63.
   KAULFERS PM, 1995, ZBL HYG UMWELTMED, V197, P252.
   LAMBERT PA, 2002, S SER SOC APPL MICRO, V31, pS46.
   LEDUC M, 1982, J BACTERIOL, V152, P26.
   Liaqat I, 2008, CURR MICROBIOL, V56, P619, DOI 10.1007/s00284-008-9136-6.
   Russell A. D., 2003, Science Progress, V86, P283, DOI 10.3184/003685003783238608.
   Russell A. D., 2002, S SER SOC APPL MICRO, V31, p1S.
   Russell AD, 2000, AM J INFECT CONTROL, V28, P204.
   Singh R, 2003, APPL ENVIRON MICROB, V69, P3412, DOI 10.1128/AEM.69.6.3412-3420.2003.
   Steel RGD, 1981, PRINCIPAL PROCEDURES.
   Walker JT, 2000, APPL ENVIRON MICROB, V66, P3363, DOI 10.1128/AEM.66.8.3363-3367.2000.
   Wolfert MA, 2007, INFECT IMMUN, V75, P706, DOI 10.1128/IAI.01597-06.
   Work E., 1957, BIOCHEM J, V67, P417.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Curr. Microbiol.}},
Doc-Delivery-Number = {{340OI}},
Unique-ID = {{ISI:000258654500013}},
DA = {{2018-08-13}},
}

@article{ ISI:000259525000001,
Author = {Sampathkumar, Priya},
Title = {{Drug resistant tuberculosis: a global public health issue}},
Journal = {{INTERNATIONAL JOURNAL OF DERMATOLOGY}},
Year = {{2008}},
Volume = {{47}},
Number = {{10}},
Pages = {{985-988}},
Month = {{OCT}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Sampathkumar, P (Reprint Author), Mayo Clin, Div Infect Dis, 200 1st St SW, Rochester, MN 55905 USA.
   Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA.}},
DOI = {{10.1111/j.1365-4632.2008.03822.x}},
ISSN = {{0011-9059}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; AIR-TRAVEL; TRANSMISSION}},
Research-Areas = {{Dermatology}},
Web-of-Science-Categories  = {{Dermatology}},
Author-Email = {{sampathkumar.priya@mayo.edu}},
Cited-References = {{{*}CDC, 2007, MORBIDITY MORTALITY, V56, P250.
   {*}CDC, 1992, EXP PASS FLIGHT CREW, P137.
   {*}CDC, 2006, MMWR-MORBID MORTAL W, V55, P301.
   {*}CDC, 1991, MMWR-MORBID MORTAL W, V40, P585.
   {*}CDC, 2007, INV TRAV MULT RES TU.
   {*}CDC, 2007, CDC INV TRAV EXT DRU.
   {*}CDC, 2007, MMWR-MORBID MORTAL W, V56, P245.
   Centers for Disease Control, 1990, MMWR-MORBID MORTAL W, V39, P718.
   Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P1176.
   DeHart RL, 2003, ANNU REV PUBL HEALTH, V24, P133, DOI 10.1146/annurev.publhealth.24.100901.140853.
   DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Garwood P, 2007, B WORLD HEALTH ORGAN, V85, P331.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9.
   MOSER MR, 1979, AM J EPIDEMIOL, V110, P1.
   Palomino JC, 2006, CURR OPIN PULM MED, V12, P172, DOI 10.1097/01.mcp.0000219265.50310.9b.
   Wise J, 2007, B WORLD HEALTH ORGAN, V85, P328.
   World Health Organization, 2004, ANT TUB DRUG RES WOR.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Dermatol.}},
Doc-Delivery-Number = {{352VH}},
Unique-ID = {{ISI:000259525000001}},
DA = {{2018-08-13}},
}

@article{ ISI:000259345800005,
Author = {Sexton, Keith and Balharry, Dominique and BeruBe, Kelly A.},
Title = {{Genomic biomarkers of pulmonary exposure to tobacco smoke components}},
Journal = {{PHARMACOGENETICS AND GENOMICS}},
Year = {{2008}},
Volume = {{18}},
Number = {{10}},
Pages = {{853-860}},
Month = {{OCT}},
Abstract = {{Background Associations between smoking and the development of
   tobacco-related diseases in humans have historically been assessed by
   epidemiological studies. These studies are further complicated by the
   number of chemicals used in tobacco and individual smoking habits. An
   alternative approach is required to assess the biological responses.
   Objective Toxicogenomics was carried out to identify early molecular
   markers for events in pulmonary injury resulting from tobacco smoke
   components (TSC) exposure.
   Materials and methods EpiAirway-100 cells were exposed at the air/liquid
   interface to representative particle (nicotine; cadmium) and vapour
   phase {[}formaldehyde (FA) and ethyl carbamate] components of cigarette
   smoke. Microarray technology was used to compare expression profiles of
   human genes associated with toxicity and drug resistance, from control
   and TSC-treated respiratory epithelium (n = 5/dose).
   Results Using the GEArray `toxicology and drug resistance' microarray
   followed by significance analysis of microarray analysis, 42 mRNA
   transcripts were found to be significantly altered by the TSC exposure.
   The vapour {[}ethyl carbamate, FA and particle (nicotine, cadmium)]
   phase TSC exhibited differential transcriptional responses that could
   not be attributed to their chemical phase. The transcriptional changes
   could be classified according to a functional family, where ethyl
   carbamate, FA and cadmium classified as carcinogens, demonstrated the
   highest gene homology when compared with the noncarcinogen, nicotine.
   Discussion Analysis of the microarray data and further confirmation
   (reverse transcriptase-PCR) identified three potential biomarkers for
   TSC-induced injury. These three genes (CYP7A1, HMOX1 and PTGS1) are
   highly upregulated and have been linked with mechanistic pathways of
   disease.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sexton, K (Reprint Author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.
   Sexton, Keith; Balharry, Dominique; BeruBe, Kelly A., Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales.}},
DOI = {{10.1097/FPC.0b013e328307bddf}},
ISSN = {{1744-6872}},
Keywords = {{human airway epithelium; in vitro; pulmonary toxicity; tobacco smoke;
   toxicogenomics}},
Keywords-Plus = {{EMBRYONIC STEM-CELLS; MAJOR VAULT PROTEIN; BREAST-CANCER CELLS;
   EPITHELIAL-CELLS; IN-VITRO; OXIDATIVE STRESS; LUNG CARCINOGENESIS;
   SIGNALING PATHWAYS; CIGARETTE-SMOKE; EXPRESSION}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity;
   Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Genetics \& Heredity;
   Pharmacology \& Pharmacy}},
Author-Email = {{Sextonk@cardiff.ac.uk}},
ORCID-Numbers = {{BeruBe, Kelly/0000-0002-7471-7229
   Balharry, Dominique/0000-0001-7439-2105}},
Funding-Acknowledgement = {{Institute for Science and Health, USA}},
Funding-Text = {{This study was funded by the Institute for Science and Health, USA.}},
Cited-References = {{Agu RU, 2006, J PHARM PHARMACOL, V58, P1459, DOI 10.1211/jpp.58.11.0006.
   Andreoli C, 2003, TOXICOL IN VITRO, V17, P587, DOI 10.1016/S0887-2333(03)00091-2.
   Asero R, 2007, CLIN EXP DERMATOL, V32, P661, DOI 10.1111/j.1365-2230.2007.02464.x.
   Balharry D, 2005, TOXICOL APPL PHARM, V204, P101, DOI 10.1016/j.taap.2004.08.022.
   Balharry D, 2008, TOXICOLOGY, V244, P66, DOI 10.1016/j.tox.2007.11.001.
   Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5.
   Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051.
   BERUBE KA, 2006, AIR POLLUTION HLTH, P69.
   Borgerding M, 2005, EXP TOXICOL PATHOL, V57, P43, DOI 10.1016/j.etp.2005.05.010.
   Brydun A, 2007, HYPERTENS RES, V30, P341, DOI 10.1291/hypres.30.341.
   Cai J, 2007, HEPATOLOGY, V45, P1229, DOI 10.1002/hep.21582.
   Chen SC, 2006, J PHARM SCI-US, V95, P1364, DOI 10.1002/jps.20510.
   Chilvers M A, 2000, Paediatr Respir Rev, V1, P27, DOI 10.1053/prrv.2000.0009.
   Coggins CRE, 2007, INT J TOXICOL, V26, P331, DOI 10.1080/1091581070140190.
   COHEN JC, 1992, GENOMICS, V14, P153, DOI 10.1016/S0888-7543(05)80298-8.
   Cox LA, 2006, RISK ANAL, V26, P135, DOI 10.1111/j.1539-6924.2006.00723.x.
   de Vos S, 2003, LAB INVEST, V83, P271, DOI 10.1097/01.LAB.0000053913.85892.E9.
   Ekwall B., 1990, SHORT TERM TOXICITY, P75.
   Erickson SK, 2003, J LIPID RES, V44, P1001, DOI 10.1194/jlr.M200489-JLR200.
   Fong PY, 2006, J CLIN PATHOL, V59, P179, DOI 10.1136/jcp.2005.028027.
   Godfrey RWA, 1997, MICROSC RES TECHNIQ, V38, P488, DOI 10.1002/(SICI)1097-0029(19970901)38:5<488::AID-JEMT5>3.0.CO;2-E.
   Griendling KK, 2003, CIRCULATION, V108, P1912, DOI 10.1161/01.CIR.0000093660.86242.BB.
   Hansen T, 2007, TOXICOL APPL PHARM, V221, P222, DOI 10.1016/j.taap.2007.03.003.
   Hawse JR, 2006, MOL VIS, V12, P342.
   Hernandez-Vargas H, 2007, BREAST CANCER RES TR, V102, P157, DOI 10.1007/s10549-006-9322-9.
   Hukkanen J, 2005, PHARMACOL REV, V57, P79, DOI 10.1124/pr.57.1.3.
   Imaoka S, 2001, CANCER LETT, V166, P119, DOI 10.1016/S0304-3835(00)00572-3.
   Jiang GJ, 2007, EUR J PHARMACOL, V562, P183, DOI 10.1016/j.ejphar.2007.01.066.
   Jin ZH, 2006, J BIOL CHEM, V281, P14446, DOI 10.1074/jbc.M511914200.
   KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001.
   Kakazu A, 2004, INVEST OPHTH VIS SCI, V45, P3485, DOI 10.1167/iovs.04-0372.
   Kowalski MP, 2007, SCIENCE, V317, P130, DOI 10.1126/science.1142311.
   Lieber CS, 1997, PHYSIOL REV, V77, P517.
   MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6.
   Minamoto K, 2005, J EXP MED, V202, P283, DOI 10.1084/jem.20050377.
   Nakamura Haruhiko, 2007, Ann Thorac Cardiovasc Surg, V13, P87.
   Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015.
   Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877.
   O'Connor R, 2007, ANTICANCER RES, V27, P1267.
   Overall evaluations of carcinogenicity, 1987, IARC MONOGR EVAL C S, V7, P1.
   Palmer K, 2001, GENE THER, V8, P282, DOI 10.1038/sj.gt.3301386.
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236.
   Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016.
   Parke D V, 1996, Int J Occup Med Environ Health, V9, P331.
   Pinot F, 2000, Rev Environ Health, V15, P299.
   Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132.
   Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387.
   Ritchie KJ, 2007, CANCER RES, V67, P9248, DOI 10.1158/0008-5472.CAN-07-1764.
   Roos WP, 2007, CELL DEATH DIFFER, V14, P1422, DOI 10.1038/sj.cdd.4402136.
   Russell W.M.S., 1959, PRINCIPLES HUMANE EX.
   SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578.
   Shia S, 2005, J MOL BIOL, V346, P1335, DOI 10.1016/j.jmb.2004.12.048.
   Shiu LY, 2007, FOOD CHEM TOXICOL, V45, P2155, DOI 10.1016/j.fct.2007.05.009.
   Siemiatycki J, 2004, ENVIRON HEALTH PERSP, V112, P1447, DOI 10.1289/ehp.7047.
   Smith CJ, 2006, INHAL TOXICOL, V18, P667, DOI 10.1080/08958370600742821.
   Speit G, 2007, MUTAGENESIS, V22, P387, DOI 10.1093/mutage/gem031.
   Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104.
   TREADWELL JA, 2004, NEUROCHEM RES, V29, P257.
   VAINIO H, 1993, SCAND J WORK ENV HEA, V19, P360.
   Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003.
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108.
   Xu LH, 2006, CANCER RES, V66, P11859, DOI 10.1158/0008-5472.CAN-06-1445.
   Yang CF, 1997, ENVIRON HEALTH PERSP, V105, P712, DOI 10.2307/3433726.
   Yee SB, 1997, CHEM-BIOL INTERACT, V104, P87, DOI 10.1016/S0009-2797(97)00019-7.
   Yildiz D, 2004, TOXICON, V43, P619, DOI 10.1016/j.toxicon.2004.01.017.
   Zhou JL, 2005, MOL CELL BIOL, V25, P9874, DOI 10.1128/MCB.25.22.9874-9885.2005.
   2006, IARC MONOGR EVAL CAR, V88, P1.}},
Number-of-Cited-References = {{67}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Pharmacogenet. Genomics}},
Doc-Delivery-Number = {{350IK}},
Unique-ID = {{ISI:000259345800005}},
DA = {{2018-08-13}},
}

@article{ ISI:000259576900003,
Author = {Loennroth, Knut and Raviglione, Mario},
Title = {{Global epidemiology of tuberculosis: Prospects for control}},
Journal = {{SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2008}},
Volume = {{29}},
Number = {{5}},
Pages = {{481-491}},
Month = {{OCT}},
Abstract = {{The burden of tuberculosis (TB) is now very slowly decreasing globally.
   However, the rate of decline is too slow to reach all the
   epidemiological impact targets set for 2015. The prospects for reaching
   the TB elimination target set for 2050 are even bleaker. Implementation
   of the World Health Organization's Stop TB Strategy is currently lagging
   behind the envisioned scale-up pace, particularly with regard to TB/HIV
   collaborative activities and management of drug resistant TB. To ensure
   long-term TB control there is, first, a need to ensure that all
   components of the Stop TB Strategy are scaled up according to plans,
   with special attention to improved access for the poor. However, this
   may not be enough. Recent analyses suggest that the impact of current
   efforts to reduce TB incidence is less than expected and that improved
   diagnostic and curative efforts need to be combined with additional
   preventive efforts. New and more effective vaccines and drugs for
   preventive treatment would revolutionize TB control. A stronger focus on
   prevention would also entail more concerted actions to limit the impact
   of TB risk factors, including HIV/AIDS, smoking, malnutrition,
   alcoholism, diabetes, crowded living conditions, and indoor air
   pollution, which may all contribute a considerable proportion of the
   global TB burden.}},
Publisher = {{THIEME MEDICAL PUBL INC}},
Address = {{333 SEVENTH AVE, NEW YORK, NY 10001 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Lonnroth, K (Reprint Author), WHO, Stop TB Dept, 20 Ave Appia, CH-1211 Geneva, Switzerland.
   Loennroth, Knut; Raviglione, Mario, WHO, Stop TB Dept, CH-1211 Geneva, Switzerland.}},
DOI = {{10.1055/s-0028-1085700}},
ISSN = {{1069-3424}},
EISSN = {{1098-9048}},
Keywords = {{tuberculosis; strategy; epidemiology; disease control; determinants}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; DOTS STRATEGY; SOUTH-INDIA; MORTALITY;
   HEALTH; PREVALENCE; DISEASE; ELIMINATION; INFECTION; INDONESIA}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{lonnrothk@who.int}},
ResearcherID-Numbers = {{Lonnroth, Knut/H-5470-2017
   Lonnroth, Knut/L-2339-2014
   }},
ORCID-Numbers = {{Lonnroth, Knut/0000-0001-6944-0256
   Lonnroth, Knut/0000-0001-5054-8240
   RAVIGLIONE, Mario/0000-0002-9331-2067}},
Cited-References = {{Al-Maniri A, 2007, INT J TUBERC LUNG D, V11, P175.
   Borgdorff MW, 2004, EMERG INFECT DIS, V10, P1523, DOI 10.3201/eid1009.040349.
   Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217.
   Cegielski JP, 2004, INT J TUBERC LUNG D, V8, P286.
   Chen XY, 2004, LANCET, V364, P417.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   Cox HS, 2008, BRIT MED J, V336, P484, DOI 10.1136/bmj.39463.640787.BE.
   DEMARCO JR, 2007, CONTROL TUBERCULOSIS.
   Dye C, 2007, INT J TUBERC LUNG D, V11, P1225.
   Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7.
   Dye C, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P289.
   Dye C, 2008, J R SOC INTERFACE, V5, P653, DOI 10.1098/rsif.2007.1138.
   Food and Agricultural Organization of the United Nations, 2006, STAT FOOD INS WORLD.
   Glynn JR, 2006, EMERG INFECT DIS, V12, P736.
   Gonzalez E, 2007, INT J TUBERC LUNG D, V11, P405.
   Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x.
   Hanekom M, 2007, J CLIN MICROBIOL, V45, P1483, DOI 10.1128/JCM.02191-06.
   HANSON C, 2006, COMPREHENSIVE INT AP, P1097.
   Harling G, 2008, SOC SCI MED, V66, P492, DOI 10.1016/j.socscimed.2007.08.026.
   HASSMILLER K, 2007, IMPACT SMOKING POPUL.
   Huong NT, 2006, INT J TUBERC LUNG D, V10, P963.
   {*}INT DIAB FED, 2006, DIAB ATL.
   Irawati SR, 2007, INT J TUBERC LUNG D, V11, P33.
   LAXMINARAYAN R, 2007, 4295 WORLD BANK.
   Leon DA, 1997, LANCET, V350, P383, DOI 10.1016/S0140-6736(97)03360-6.
   Lienhardt C, 2001, EPIDEMIOL REV, V23, P288, DOI 10.1093/oxfordjournals.epirev.a000807.
   Lin H., 2007, PLOS MED, V4, pe142.
   Lonnroth K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-289.
   Mackay J, 2006, TOBACCO ATLAS.
   Maher D, 2007, B WORLD HEALTH ORGAN, V85, P341, DOI 10.2471/BLT.06.037820.
   Matiru R, 2007, B WORLD HEALTH ORGAN, V85, P348, DOI 10.2471/BLT.06.035402.
   MCKEOWN T, 1962, POP STUD-J DEMOG, V16, P94, DOI 10.2307/2173119.
   Menzies D, 2007, INT J TUBERC LUNG D, V11, P593.
   Muniyandi M, 2007, INT J TUBERC LUNG D, V11, P1042.
   PORTER JDH, 1999, TUBERCULOSIS INTERDI.
   Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0.
   Raviglione MC, 2006, LANCET, V367, P952, DOI 10.1016/S0140-6736(06)68392-X.
   Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7.
   Rehfuess E., 2006, FUEL LIFE HOUSEHOLD.
   Rieder HL, 1999, EPIDEMIOLOGIC BASIS.
   Shilova MV, 2001, PHILOS T ROY SOC B, V356, P1069, DOI 10.1098/rstb.2001.0895.
   Slam K, 2007, INT J TUBERC LUNG D, V11, P1049.
   Soemantri S, 2007, INT J TUBERC LUNG D, V11, P398.
   Stevenson CR, 2007, CHRONIC ILLN, V3, P228, DOI 10.1177/1742395307081502.
   Stevenson CR, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-234.
   {*}STOP TB PARTN, 2006, WHOHTMSTB200635 STOP.
   Storla DG, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-15.
   Styblo K, 1991, TUBERCULOSIS CAN BE.
   Suarez PG, 2001, J INFECT DIS, V184, P473, DOI 10.1086/322777.
   Subramani R, 2007, INT J EPIDEMIOL, V36, P387, DOI 10.1093/ije/dyl216.
   {*}UNAIDS WHO, 2006, 2006 AIDS EP UPD SPE.
   Van Leth F, 2008, B WORLD HEALTH ORGAN, V86, P20, DOI 10.2471/BLT.06.037804.
   Vree M, 2007, EMERG INFECT DIS, V13, P796, DOI 10.3201/eid1305.060904.
   Walberg P, 1998, BRIT MED J, V317, P312, DOI 10.1136/bmj.317.7154.312.
   WATT C, TUBERCULOSI IN PRESS.
   {*}WHO, 2008, WHOHTMTB2008393.
   {*}WHO, 2004, WHOHTMTB2005352.
   {*}WHO, 2006, WHOEIPEQH012006.
   {*}WHO, 2005, WHOHTMTB2005349.
   {*}WHO IUATLD, 2007, WHOHTMTB2007390.
   Who. World Health Organization, 1994, WHOTB94179.
   World Bank, 1993, WORLD DEV REP 1993 I.
   World Health Organization, 2006, WHOHTMTB2006368.
   World Health Organization, 1991, WHA441991REC1 WHO.
   ZUÑIGA G. MANUEL, 2002, Rev. chil. enferm. respir., V18, P55, DOI 10.4067/S0717-73482002000100008.}},
Number-of-Cited-References = {{65}},
Times-Cited = {{149}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{22}},
Journal-ISO = {{Semin. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{353OI}},
Unique-ID = {{ISI:000259576900003}},
DA = {{2018-08-13}},
}

@article{ ISI:000259120500022,
Author = {Amado, Elkin and Kerth, Andreas and Blume, Alfred and Kressler, Joerg},
Title = {{Infrared reflection absorption spectroscopy coupled with Brewster angle
   microscopy for studying interactions of amphiphilic triblock copolymers
   with phospholipid monolayers}},
Journal = {{LANGMUIR}},
Year = {{2008}},
Volume = {{24}},
Number = {{18}},
Pages = {{10041-10053}},
Month = {{SEP 16}},
Abstract = {{Novel water-soluble amphiphilic triblock copolymers poly(glycerol
   monomethacrylate)-b-poly(propylene oxide)b-poly(glycerol
   monomethacrylate) (PGMA-b-PPO-b-PGMA) were synthesized because of their
   expected enhanced ability to interact with biological membranes compared
   to the well-known poly(ethylene oxide)-b-poly(propylene oxide)-b-poly
   (ethylene oxide) (PEO-b-PPO-b-PEO) block copolymers. Their bulkier
   hydrophilic PGMA blocks might induce a disturbance in the packing of
   liquid-crystalline lipid bilayers in addition to the effect caused by
   the hydrophobic PPO block alone. To gain a better insight into the
   polymer-membrane interactions at the molecular level, the adsorption
   kinetics and concomitant interactions of (PGMA(14))(2)-PPO34 with model
   membranes of dipalmitoylphosphatidylcholine (DPPC) and
   dimyristoylphosphatidylcholine (DMPQ were monitored using infrared
   reflection absorption spectroscopy (IRRAS) coupled with Brewster angle
   microscopy (BAM) and surface pressure (pi) measurements. The maximum
   penetration surface pressure of ca. 39 mN/m suggests that
   (PGMA(14))(2)-PPO34 is able to insert into lipid monolayers even above
   the so-called monolayer-bilayer equivalent pressure of 30-35 mN/m.
   Copolymer adsorption to a liquid-expanded DPPC-d(62) monolayer proceeds
   in a two-step mechanism: (i) initially only the more hydrophobic PPO
   middle block penetrates the lipid monolayer; (ii) following the
   liquid-expanded-liquid-condensed (LE-LC) phase transition, the bulky
   PGMA hydrophilic blocks are dragged into the headgroup region as the PPO
   block inserts further into the fatty acid region. The adsorption
   kinetics is considerably faster for DMPC-d(54) monolayers due to their
   higher fluidity. Copolymer adsorption to an LC-DPPC-d(62) monolayer
   leads to a change in the monolayer packing by forcing the lipid alkyl
   chains into a more vertical orientation, their tilt angle with respect
   to the surface normal being reduced from initially 30 degrees +/- 3
   degrees to 18 degrees +/- 3 degrees. BAM images rule out macroscopic
   phase separation and show that coalescence of DPPC-d(62) LC domains
   takes place at relatively low surface pressures of pi >= 23 mN/m,
   suggesting that (PGMA(14))(2)-PPO34 partitions into both LE as well as
   LC domains.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kressler, J (Reprint Author), Univ Halle Wittenberg, Dept Chem, D-06099 Halle, Saale, Germany.
   Amado, Elkin; Kerth, Andreas; Blume, Alfred; Kressler, Joerg, Univ Halle Wittenberg, Dept Chem, D-06099 Halle, Saale, Germany.}},
DOI = {{10.1021/la801768m}},
ISSN = {{0743-7463}},
Keywords-Plus = {{AIR-WATER-INTERFACE; PLURONIC BLOCK-COPOLYMERS; 2-HYDROXYETHYL
   METHACRYLATE HYDROGELS; TRANSFER RADICAL POLYMERIZATION; 1ST-ORDER
   PHASE-TRANSITIONS; INSOLUBLE LIPID MONOLAYERS; MULTIDRUG-RESISTANCE;
   AQUEOUS-SOLUTIONS; POLOXAMER 188; POLY(PERFLUOROHEXYLETHYL METHACRYLATE)}},
Research-Areas = {{Chemistry; Materials Science}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary}},
Author-Email = {{alfred.blume@chemie.uni-halle.de
   joerg.kressler@chemie.uni-halle.de}},
Funding-Acknowledgement = {{``Deutsche Forschungsgemeinschaft{''} (DFG) {[}GK-894, SFB-418]}},
Funding-Text = {{We thank the ``Deutsche Forschungsgemeinschaft{''} (DFG) for the
   financial support through the programs GK-894 and SFB-418.}},
Cited-References = {{ALEXANDRIDIS P, 1994, LANGMUIR, V10, P2604, DOI 10.1021/la00020a019.
   ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009.
   Amado E, 2006, MACROMOLECULES, V39, P9486, DOI 10.1021/ma060794n.
   ARMSTRONG JK, 1995, THROMB RES, V79, P437, DOI 10.1016/0049-3848(95)00134-D.
   Batrakova E, 1999, PHARM RES-DORDR, V16, P1373, DOI 10.1023/A:1018942823676.
   Bertie JE, 1996, APPL SPECTROSC, V50, P1047, DOI 10.1366/0003702963905385.
   BHAKOO M, 1982, BIOCHEMISTRY-US, V21, P6879, DOI 10.1021/bi00269a039.
   BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7.
   CASAL HL, 1984, BIOCHIM BIOPHYS ACTA, V779, P381, DOI 10.1016/0304-4157(84)90017-0.
   Chang LC, 2005, J COLLOID INTERF SCI, V285, P640, DOI 10.1016/j.jcis.2004.11.011.
   Charron JR, 1996, J PHYS CHEM-US, V100, P3179, DOI 10.1021/jp9521619.
   Charron JR, 1997, LANGMUIR, V13, P5524, DOI 10.1021/la9704765.
   Chiappetta DA, 2007, EUR J PHARM BIOPHARM, V66, P303, DOI 10.1016/j.ejpb.2007.03.022.
   Demina T, 2005, BIOCHEMISTRY-US, V44, P4042, DOI 10.1021/bi048373q.
   Discher BM, 1999, BIOPHYS J, V77, P2051, DOI 10.1016/S0006-3495(99)77046-3.
   Duncan SL, 2008, BIOPHYS J, V94, P2965, DOI 10.1529/biophysj.107.114215.
   Escobar-Chavez JJ, 2006, J PHARM PHARM SCI, V9, P339.
   EUROKAVA VY, 2000, BIOCHIM BIOPHYS ACTA, V1468, P73.
   Flach CR, 2001, APPL SPECTROSC, V55, P1060, DOI 10.1366/0003702011952965.
   Flach CR, 1999, BBA-BIOMEMBRANES, V1416, P11, DOI 10.1016/S0005-2736(98)00205-3.
   Flach CR, 1997, J PHYS CHEM B, V101, P58, DOI 10.1021/jp962288d.
   FLORSHEIMER M, 1989, CHEM PHYS LIPIDS, V49, P231, DOI 10.1016/0009-3084(89)90071-6.
   Frey SL, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2768947.
   Frey SL, 2007, LANGMUIR, V23, P2631, DOI 10.1021/la0626398.
   Gates G, 2003, POLYMER, V44, P215, DOI 10.1016/S0032-3861(02)00723-1.
   Gates G, 2003, POLYMER, V44, P207, DOI 10.1016/S0032-3861(02)00725-5.
   GERICKE A, 1993, VIB SPECTROSC, V4, P335, DOI 10.1016/0924-2031(93)80007-3.
   HENON S, 1991, REV SCI INSTRUM, V62, P936, DOI 10.1063/1.1142032.
   HIFEDA YF, 1992, LANGMUIR, V8, P197, DOI 10.1021/la00037a036.
   HONIG D, 1992, THIN SOLID FILMS, V210, P64, DOI 10.1016/0040-6090(92)90169-C.
   Hubner W, 1998, CHEM PHYS LIPIDS, V96, P99, DOI 10.1016/S0009-3084(98)00083-8.
   Hussain H, 2004, J PHYS CHEM B, V108, P9962, DOI 10.1021/jp0495702.
   Hussain H, 2002, MACROMOL CHEM PHYSIC, V203, P2103, DOI 10.1002/1521-3935(200210)203:14<2103::AID-MACP2103>3.0.CO;2-X.
   Kabanov AV, 2002, ADV DRUG DELIVER REV, V54, P759, DOI 10.1016/S0169-409X(02)00047-9.
   Kabanov AV, 2003, ADV DRUG DELIVER REV, V55, P151, DOI 10.1016/S0169-409X(02)00176-X.
   KAUSHIK N, 1991, BIOCHIM BIOPHYS ACTA, V1068, P157.
   Krylova OO, 2004, BIOCHEMISTRY-US, V43, P3696, DOI 10.1021/bi0357681.
   Kuzmin V. L., 1981, Optics and Spectroscopy, V51, P383.
   KUZMIN VL, 1992, OPT SPEKTROSK+, V73, P3.
   LEUNG BKO, 1993, J APPL POLYM SCI, V47, P1207, DOI 10.1002/app.1993.070470708.
   Lewis RNAH, 1998, CHEM PHYS LIPIDS, V96, P9, DOI 10.1016/S0009-3084(98)00077-2.
   Maeda Y, 2001, MACROMOLECULES, V34, P8246, DOI 10.1021/ma010222x.
   Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5.
   Maskarinec SA, 2003, LANGMUIR, V19, P1809, DOI 10.1021/la026175z.
   Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4.
   McConlogue CW, 1997, LANGMUIR, V13, P7158, DOI 10.1021/la970898e.
   MENDELSOHN R, 1995, ANNU REV PHYS CHEM, V46, P305, DOI 10.1146/annurev.pc.46.100195.001513.
   MILLER A, 1987, J CHEM PHYS, V86, P4258, DOI 10.1063/1.451886.
   Miller DW, 1999, PHARMACEUT RES, V16, P396, DOI 10.1023/A:1018873702411.
   MOHWALD H, 1988, THIN SOLID FILMS, V159, P1, DOI 10.1016/0040-6090(88)90612-8.
   Munshi N, 1997, CANCER LETT, V118, P13, DOI 10.1016/S0304-3835(97)00218-8.
   NAUMANN C, 1994, LANGMUIR, V10, P1919, DOI 10.1021/la00018a051.
   Nielsen LK, 2007, LANGMUIR, V23, P11684, DOI 10.1021/la7016352.
   PALLAS NR, 1985, LANGMUIR, V1, P509, DOI 10.1021/la00064a019.
   PastranaRios B, 1995, BIOPHYS J, V69, P2531, DOI 10.1016/S0006-3495(95)80124-4.
   Patten TE, 1998, ADV MATER, V10, P901, DOI 10.1002/(SICI)1521-4095(199808)10:12<901::AID-ADMA901>3.0.CO;2-B.
   Pavlov DN, 2006, J DRUG DELIV SCI TEC, V16, P259, DOI 10.1016/S1773-2247(06)50048-6.
   Seelig A, 2006, EXPERT OPIN DRUG MET, V2, P733, DOI 10.1517/17425255.2.5.733.
   Sharma V, 1996, BIOPHYS J, V71, P3229, DOI 10.1016/S0006-3495(96)79516-4.
   Sommer K, 2008, J MED CHEM, V51, P4253, DOI 10.1021/jm800177c.
   Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375.
   Thirumoorthy K, 2007, LANGMUIR, V23, P6991, DOI 10.1021/la070168z.
   VAKNIN D, 1991, BIOPHYS J, V59, P1325, DOI 10.1016/S0006-3495(91)82347-5.
   Wang C, 2008, BIOMACROMOLECULES, V9, P561, DOI 10.1021/bm701102y.
   WANKA G, 1994, MACROMOLECULES, V27, P4145, DOI 10.1021/ma00093a016.
   Wu GH, 2005, BIOPHYS J, V89, P3159, DOI 10.1529/biophysj.104.052290.}},
Number-of-Cited-References = {{66}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{35}},
Journal-ISO = {{Langmuir}},
Doc-Delivery-Number = {{347DJ}},
Unique-ID = {{ISI:000259120500022}},
DA = {{2018-08-13}},
}

@article{ ISI:000262709600008,
Author = {Mehrgan, Hadi and Mojab, Faraz and Pakdaman, Shima and Poursaeed,
   Mahshid},
Title = {{Antibacterial Activity of Thymus pubescens Methanolic Extract}},
Journal = {{IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH}},
Year = {{2008}},
Volume = {{7}},
Number = {{4}},
Pages = {{291-295}},
Month = {{FAL}},
Abstract = {{During the last two decades, various medicinal plants have been studied
   for their possible antimicrobial activity to discover new antimicrobial
   agents capable of resolving problems such as the development of drug
   resistance in pathogenic microorganisms as well as the side effects of
   some present antibiotics. In this study, the antibacterial activity of
   methanolic extract of T. pubescens (rich in flavonoids) was
   investigated.
   The aerial parts of the plant were collected from Alvand mountainside
   (Hamadan, Iran) in May 2005 and identified by Hamadan Natural Sources
   Organization. The air-dried plant materials were ground to fine powder
   and then extracted by soxhelet apparatus using methanol. The extract was
   tested at a concentration of 100 mg/ml against a panel of Gram-positive
   and Gram-negative bacteria using the disk diffusion technique. This
   methanolic extract demonstrated antibacterial activity against
   Gram-positive bacteria including Staphylococcus aureus,
   Methicillin-resistant S. aureus (MRSA), Streptococcus pyogenes,
   Enterococcus faecalis, Vancomycin-resistant E. faecalis (VRE) and
   Micrococcus luteus, and produced inhibition zones with 8-16 mm
   diameters. However, it showed no activity against Gram-negative
   bacteria, such as Escherichia coli, Pseudomonas aeruginosa and
   Salmonella spp. Minimum concentrations (MC) of the extract forming a
   clear zone were determined against susceptible bacteria. MC 90 of the
   extract against 10 MRSA strains tested was 1.56 mg/ml, indicating its
   good activity against this important nosocomial pathogen. T. pubescens
   seems to be a good candidate for further phythochemical studies in an
   attempt to find new chemical entities combating resistant bacteria.}},
Publisher = {{SHAHEED BEHESHTI UNIV, SCH PHARMACY}},
Address = {{NO 10 SHAMS ALLEY, VALI-E ASR ST, TEHRAN, 00000, IRAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mojab, F (Reprint Author), Shahid Beheshti Univ, Sch Pharm \& Pharmaceut Sci, Res Ctr, Tehran, Iran.
   Mehrgan, Hadi; Mojab, Faraz, Shahid Beheshti Univ, Sch Pharm \& Pharmaceut Sci, Res Ctr, Tehran, Iran.
   Pakdaman, Shima; Poursaeed, Mahshid, Islamic Azad Univ, Sch Pharm, Tehran, Iran.}},
ISSN = {{1735-0328}},
Keywords = {{Antibacterial activity; Thymus pubescens; Disk diffusion; MRSA}},
Keywords-Plus = {{STAPHYLOCOCCUS-AUREUS; METHICILLIN-RESISTANT; FLAVONOIDS; SUSCEPTIBILITY}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{sfmojab@yahoo.com}},
Funding-Acknowledgement = {{Pharmaceutical Sciences Research Center (PSRC); Shaheed Beheshti
   University, Tehran, Iran}},
Funding-Text = {{This work was supported by Pharmaceutical Sciences Research Center
   (PSRC), Shaheed Beheshti University (M. C.), Tehran, Iran.}},
Cited-References = {{BAUER AW, 1966, AM J CLIN PATHOL, V45, P493.
   Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564.
   Denyer S.P., 2004, HUGO RUSSELLS PHARM, P306.
   DIXON RA, 1983, ADV ENZYMOL RAMB, V55, P1.
   Essawi T, 2000, J ETHNOPHARMACOL, V70, P343, DOI 10.1016/S0378-8741(99)00187-7.
   Fazly Bazzaz BS, 2005, IRAN J PHARM RES, V4, P87.
   Friedman M, 2007, MOL NUTR FOOD RES, V51, P116, DOI 10.1002/mnfr.200600173.
   KANDIL O, 1994, J ETHNOPHARMACOL, V44, P19, DOI 10.1016/0378-8741(94)90094-9.
   Maheswara M, 2006, ASIAN J CHEM, V18, P2761.
   MARKHAM KR, 1982, TECHNIQUES FLAVONOID, P24.
   Morteza-Semnani K, 2006, J ESSENT OIL RES, V18, P272, DOI 10.1080/10412905.2006.9699085.
   Ozcelik B, 2006, Z NATURFORSCH C, V61, P632.
   Proestos C, 2005, J AGR FOOD CHEM, V53, P1190, DOI 10.1021/jf040083t.
   Rasooli I, 2002, FITOTERAPIA, V73, P244, DOI 10.1016/S0367-326X(02)00064-3.
   Sato Y, 2004, ANTIMICROB AGENTS CH, V48, P1357, DOI 10.1128/AAC.48.4.1357-1360.2004.
   Tsuchiya H, 1996, J ETHNOPHARMACOL, V50, P27, DOI 10.1016/0378-8741(96)85514-0.
   Vila R., 2002, THYME GENUS THYMUS, P144.
   Xu HX, 2001, PHYTOTHER RES, V15, P39, DOI 10.1002/1099-1573(200102)15:1<39::AID-PTR684>3.0.CO;2-R.
   Zaidi MA, 2005, J ETHNOPHARMACOL, V96, P331, DOI 10.1016/j.jep.2004.07.023.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Iran. J. Pharm. Res.}},
Doc-Delivery-Number = {{398CR}},
Unique-ID = {{ISI:000262709600008}},
DA = {{2018-08-13}},
}

@article{ ISI:000260442300014,
Author = {Escombe, A. Roderick and Moore, David A. J. and Gilman, Robert H. and
   Pan, William and Navincopa, Marcos and Ticona, Eduardo and Martinez,
   Carlos and Caviedes, Luz and Sheen, Patricia and Gonzalez, Armando and
   Noakes, Catherine J. and Friedland, Jon S. and Evans, Carlton A.},
Title = {{The Infectiousness of Tuberculosis Patients Coinfected with HIV}},
Journal = {{PLOS MEDICINE}},
Year = {{2008}},
Volume = {{5}},
Number = {{9}},
Pages = {{1387-1397}},
Month = {{SEP}},
Abstract = {{Background
   The current understanding of airborne tuberculosis (TB) transmission is
   based on classic 1950s studies in which guinea pigs were exposed to air
   from a tuberculosis ward. Recently we recreated this model in Lime,
   Peru, and in this paper we report the use of molecular fingerprinting to
   investigate patient infectiousness in the current era of HIV infection
   and multidrug-resistant (MDR) TB.
   Methods and Findings
   All air from a mechanically ventilated negative-pressure HIV-TB ward was
   exhausted over guinea pigs housed in an airborne transmission study
   facility on the roof. Animals had monthly tuberculin skin tests, and
   positive reactors were removed for autopsy and organ culture for M.
   tuberculosis. Temporal exposure patterns, drug susceptibility testing,
   and DNA fingerprinting of patient and animal TB strains defined
   infectious TB patients. Relative patient infectiousness was calculated
   using the Wells-Riley model of airborne infection. Over 505 study days
   there were 118 ward admissions of 97 HIV-positive pulmonary TB patients.
   Of 292 exposed guinea pigs, 144 had evidence of TB disease; a further 30
   were tuberculin skin test positive only. There was marked variability in
   patient infectiousness; only 85\% of 118 ward admissions by TB patients
   were shown by DNA fingerprinting to have caused 98\% of the 125
   characterised cases of secondary animal TB. 90\% of TB transmission
   occurred from inadequately treated MDR TB patients. Three highly
   infectious MDR TB patients produced 226, 52, and 40 airborne infectious
   units (quanta) per hour.
   Conclusions
   A small number of inadequately treated MDR TB patients coinfected with
   HIV were responsible for almost all TB transmission, and some patients
   were highly infectious. This result highlights the importance of rapid
   TB durg-susceptibility testing to allow prompt initiation of effective
   treatment, and environmental control measures to reduce ongoing TB
   transmission in crowded health care settings. TB infection control must
   be prioritized in order to prevent health care facilities from
   disseminating the drug-resistant TB that they are attempting to treat.}},
Publisher = {{PUBLIC LIBRARY SCIENCE}},
Address = {{1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Escombe, AR (Reprint Author), Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immunity, London, England.
   Escombe, A. Roderick; Moore, David A. J.; Friedland, Jon S.; Evans, Carlton A., Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis \& Immunity, London, England.
   Escombe, A. Roderick; Moore, David A. J.; Friedland, Jon S.; Evans, Carlton A., Univ London Imperial Coll Sci Technol \& Med, Wellcome Trust Ctr Clin Trop Med, London, England.
   Escombe, A. Roderick; Moore, David A. J.; Gilman, Robert H.; Evans, Carlton A., Asociac Benef PRISMA, Lima, Peru.
   Moore, David A. J.; Gilman, Robert H.; Caviedes, Luz; Sheen, Patricia; Evans, Carlton A., Univ Peruana Cayetano Heredia, Fac Ciencias, Lima, Peru.
   Gilman, Robert H.; Pan, William; Evans, Carlton A., Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   Navincopa, Marcos; Ticona, Eduardo, Hosp Mayo, Serv Enfermedades Trop \& Infecciosas, Lima, Peru.
   Navincopa, Marcos; Gonzalez, Armando, Univ Nacl Mayor San Marcos, Lima 14, Peru.
   Martinez, Carlos, Hosp Nacl Mayo, Serv Neumol, Lima, Peru.
   Noakes, Catherine J., Univ Leeds, Sch Civil Engn, Leeds, W Yorkshire, England.}},
DOI = {{10.1371/journal.pmed.0050188}},
Article-Number = {{e188}},
ISSN = {{1549-1676}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; AIRBORNE TRANSMISSION; MULTIDRUG-RESISTANT; CONTACTS;
   SPUTUM; CHEMOTHERAPY; BACILLI; AIR}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{rod.escombe@imperial.ac.uk}},
ORCID-Numbers = {{Ticona, Eduardo/0000-0002-6556-1082
   Evans, Carlton/0000-0002-6873-5447
   Navincopa, Marcos/0000-0002-9951-8234
   Gonzalez, Armando/0000-0003-1909-1873}},
Funding-Acknowledgement = {{Sir Halley Stewart Trust; Sir Samuel Scott of Yews Trust; Innovation for
   Health and Development (IFHAD); Welcomen Trust; Wellcome Trust Clinial
   Tropical Medicine Research Fellowships; USAID {[}HRN-5986-A-00-6006-00,
   GHS-A00-03-00019-00]; Global Research Activity Cooperative Agreement;
   NIH/NIAID {[}T35A107646]}},
Funding-Text = {{This research was funded by the Sir Halley Stewart Trust and the Sir
   Samuel Scott of Yews Trust, the charity Innovation for Health and
   Development (IFHAD), and the Welcomen Trust. ARE, DAJM, RHG, JSF, and
   CAE are funded by the Welcome Trust, UK; and ARE, DAJM, and CAE had
   Wellcome Trust Clinial Tropical Medicine Research Fellowships. RHG is
   supported by USAID award \#HRN-5986-A-00-6006-00, GHS-A00-03-00019-00
   and Global Research Activity Cooperative Agreement, NIH/NIAID
   (T35A107646). These funding agencies had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   BALASUBRAMANIAN V, 1992, INFECT IMMUN, V60, P4762.
   Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   Bonnet M, 2005, INT J TUBERC LUNG D, V9, P1147.
   Borgdorff MW, 2001, AM J EPIDEMIOL, V154, P934, DOI 10.1093/aje/154.10.934.
   Burgos M, 2003, J INFECT DIS, V188, P1878, DOI 10.1086/379895.
   Calder R A, 1991, Bull Int Union Tuberc Lung Dis, V66, P103.
   CAPEWELL S, 1984, BRIT J DIS CHEST, V78, P317.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   Caviedes L, 2000, J CLIN MICROBIOL, V38, P1203.
   Caviedes L, 2002, J CLIN MICROBIOL, V40, P1873, DOI 10.1128/JCM.40.5.1873-1874.2002.
   Cox H, 2006, PLOS MED, V3, P1836, DOI 10.1371/journal.pmed.0030384.
   Cruciani M, 2001, CLIN INFECT DIS, V33, P1922, DOI 10.1086/324352.
   Desjardin LE, 1999, AM J RESP CRIT CARE, V160, P203, DOI 10.1164/ajrccm.160.1.9811006.
   Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   ESCOMBE AR, 2006, THESIS U LONDON LOND.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   Fennelly KP, 2007, CLIN INFECT DIS, V44, P1358, DOI 10.1086/516617.
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630.
   Jindani A, 2003, AM J RESP CRIT CARE, V167, P1348, DOI 10.1164/rccm.200210-1125OC.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109.
   MALASKY C, 1990, AM REV RESPIR DIS, V142, P505, DOI 10.1164/ajrccm/142.3.505.
   {*}MIN SAL PER, 2001, ACT DOCTR NORM PROC.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Palmero D, 2002, MEDICINA-BUENOS AIRE, V62, P221.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069.
   ROSE CE, 1979, AM REV RESPIR DIS, V119, P603.
   ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2.
   Shamputa IC, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-99.
   SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125.
   {*}SPSS, 1999, SPSS US MAN VERS 10.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321.
   van Soolingen D, 1999, J INFECT DIS, V180, P726, DOI 10.1086/314930.
   {*}WHO, 1998, LAB SERV TB CONTR.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{82}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{PLos Med.}},
Doc-Delivery-Number = {{365XG}},
Unique-ID = {{ISI:000260442300014}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000260446200002,
Author = {Decraene, Valerie and Ready, Derren and Pratten, Jonathan and Wilson,
   Michael},
Title = {{Air-borne microbial contamination of surfaces in a UK dental clinic}},
Journal = {{JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY}},
Year = {{2008}},
Volume = {{54}},
Number = {{4}},
Pages = {{195-203}},
Month = {{AUG}},
Abstract = {{Little is known about the number, type, or antibiotic resistance
   profiles, of air-borne microbes present in hospital settings yet such
   information is important in designing effective measures to reduce
   cross-infection. In this study settle plates were used to identify and
   quantify the air-borne microbes present in a dental clinic. All isolates
   were identified to species level using partial 16S ribosomal RNA gene
   sequencing and their susceptibility to ampicillin, chloramphenicol,
   erythromycin, gentamicin, penicillin, tetracycline or vancomycin was
   performed. The mean numbers of viable bacteria detected for each
   sampling occasion during periods of clinical activity and in the absence
   of such activity were 21.9x10(2) cfu/m(2)/h and 2.3x10(2) cfu/m(2)/h
   respectively. One hundred ninety-three distinct colony morphotypes,
   comprising 73 species, were isolated during the study and 48\% of these
   were resistant to at least one antibiotic. The mean numbers of different
   morphotypes detected per sampling occasion were 14.3 and 5 during
   periods of clinical activity and inactivity respectively.
   Propionibacterium acnes, Micrococcus luteus and Staphylococcus
   epidermidis were frequently isolated regardless of whether any clinical
   activities were taking place. These findings highlight the importance of
   preventing surfaces from becoming reservoirs of antibiotic-resistant
   bacteria and thereby contributing to cross-infection in the dental
   clinic.}},
Publisher = {{MICROBIOL RES FOUNDATION}},
Address = {{JAPAN ACAD SOC CENTER BLDG 4-16 YAYOI 2-CHOME, TOKYO, 113-0032, JAPAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pratten, J (Reprint Author), UCL Eastman Dent Inst, Div Microbiol Dis, 256 Grays Inn Rd, London WC1X 8LD, England.
   Decraene, Valerie; Ready, Derren; Pratten, Jonathan; Wilson, Michael, UCL Eastman Dent Inst, Div Microbiol Dis, London WC1X 8LD, England.}},
DOI = {{10.2323/jgam.54.195}},
ISSN = {{0022-1260}},
EISSN = {{1349-8037}},
Keywords = {{air-borne microbes; antibiotic resistance; cross-infection; dental
   clinics; settle plates}},
Keywords-Plus = {{BACTERIAL AEROSOLS; ORAL CAVITY; AEROBIOLOGY; SPLATTER}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{j.pratten@eastman.ucl.ac.uk}},
ResearcherID-Numbers = {{Wilson, Michael/D-2085-2009
   Pratten, Jonathan/C-1784-2008}},
Funding-Acknowledgement = {{Charles Wolfson Charitable Trust; UCLH/UCL; Department of Health's NIHR
   Biomedical Research Centres}},
Funding-Text = {{This work was supported by a grant from the Charles Wolfson Charitable
   Trust and was undertaken at UCLH/UCL who received a proportion of
   funding from the Department of Health's NIHR Biomedical Research Centres
   funding scheme.}},
Cited-References = {{Anesti V, 2005, ENVIRON MICROBIOL, V7, P1227, DOI 10.1111/j.1462-2920.2005.00805.x.
   BENTLEY CD, 1994, J AM DENT ASSOC, V125, P579, DOI 10.14219/jada.archive.1994.0093.
   CASEWELL MW, 1984, J HOSP INFECT, V5, P76, DOI 10.1016/0195-6701(84)90104-X.
   Cellini L, 2001, PUBLIC HEALTH, V115, P301, DOI 10.1016/S0033-3506(01)00464-4.
   FISCHER G, 1972, Zeitschrift fuer die Gesamte Hygiene und ihre Grenzgebiete, V18, P729.
   Funke G, 1997, CLIN MICROBIOL REV, V10, P125.
   Harrel SK, 2004, J AM DENT ASSOC, V135, P429, DOI 10.14219/jada.archive.2004.0207.
   JENSEN PA, 1992, AM IND HYG ASSOC J, V53, P660, DOI 10.1202/0002-8894(1992)053<0660:EOEBSC>2.0.CO;2.
   Cono Joanne, 2003, MMWR Recomm Rep, V52, P1.
   LOGOTHETIS D D, 1988, General Dentistry, V36, P496.
   MICIK RE, 1969, J DENT RES, V48, P49, DOI 10.1177/00220345690480012401.
   Miller CH, 2001, DISINFECTION STERILI, P1049.
   MILLER RL, 1971, J DENT RES, V50, P621, DOI 10.1177/00220345710500031701.
   Noro A, 1998, Bull Tokyo Dent Coll, V39, P15.
   Osorio R, 1995, Int Dent J, V45, P352.
   Pasquarella C, 2000, J HOSP INFECT, V46, P241, DOI 10.1053/jhin.2000.0820.
   Rautemaa R, 2006, J HOSP INFECT, V64, P76, DOI 10.1016/j.jhin.2006.04.011.
   Smith AJ, 2001, J MED MICROBIOL, V50, P940, DOI 10.1099/0022-1317-50-11-940.
   Wilson M., 2005, MICROBIAL INHABITANT.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Gen. Appl. Microbiol.}},
Doc-Delivery-Number = {{365YP}},
Unique-ID = {{ISI:000260446200002}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000260531700002,
Author = {Ogunlana, O. E. and Ogunlana, O. O.},
Title = {{In vitro assessment of antioxidant activity of Newbouldia laevis}},
Journal = {{JOURNAL OF MEDICINAL PLANTS RESEARCH}},
Year = {{2008}},
Volume = {{2}},
Number = {{8}},
Pages = {{176-179}},
Month = {{AUG}},
Abstract = {{Poverty, drug resistance and other factors including increasing
   difficulty in the control of mosquitoes (the vector of the causative
   organism of malaria), have led to a growing interest in phytochemical
   research. The antioxidant activity of Newbouldia laevis stem bark was
   investigated. Air dried stem bark of N. laevis was powdered and
   extracted with 95 \% v/v methanol by maceration, and the extract
   concentrated at 40 degrees C using rotary evaporator. The total phenolic
   composition of methanolic extract of air dried stem bark was estimated
   using spectrophotometric method. Antioxidant activity of the extract was
   evaluated on the basis of its ability to prevent the oxidation of
   -carotene and the strength of its ferric reducing capacity also
   determined. Phenolic composition was calculated to be approximately
   35\%. Plant extract showed concentration - dependent antioxidant
   activity and ferric reducing power. Plant extract achieved a maximum
   antioxidant activity of 4\% within 40 min. The total phenolic content,
   antioxidant activity and reducing power of the extract had direct
   relationship.}},
Publisher = {{ACADEMIC JOURNALS}},
Address = {{P O BOX 5170-00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ogunlana, OE (Reprint Author), Covenant Univ, Dept Biol Sci, Coll Sci \& Technol, Kilometer 10,Idi Iroko Rd, Ota, Ogun state, Nigeria.
   Ogunlana, O. E.; Ogunlana, O. O., Covenant Univ, Dept Biol Sci, Coll Sci \& Technol, Ota, Ogun state, Nigeria.}},
ISSN = {{1996-0875}},
Keywords = {{Newbouldia laevis; -carotene; phenolic composition; antioxidant
   activity; reducing power}},
Keywords-Plus = {{GASTROINTESTINAL DISORDERS; PLANT-EXTRACTS; ENTEROBACTERIA; GUATEMALA;
   TOXICITY}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Chemistry, Medicinal}},
Author-Email = {{seyio2001@yahoo.com}},
ResearcherID-Numbers = {{Ogunlana, Olubanke/M-8157-2013}},
ORCID-Numbers = {{Ogunlana, Olubanke/0000-0001-5781-592X}},
Cited-References = {{AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915.
   Amos S, 2002, Boll Chim Farm, V141, P471.
   Bensasson R., 1993, EXCITED STATES FREE.
   Burkill H. M., 1997, USEFUL PLANTS W TROP, V4.
   Burkill HM, 1985, USEFUL PLANTS W TROP, V1.
   BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156.
   CACERES A, 1993, J ETHNOPHARMACOL, V38, P31, DOI 10.1016/0378-8741(93)90076-H.
   CACERES A, 1990, J ETHNOPHARMACOL, V30, P55, DOI 10.1016/0378-8741(90)90017-N.
   CHEESEMAN KH, 1993, BRIT MED BULL, V49, P481, DOI 10.1093/oxfordjournals.bmb.a072625.
   Davies K J, 1995, Biochem Soc Symp, V61, P1.
   Droge W, 2002, PHYSIOL REV, V82, P47.
   ETSUO N, 1991, AM J CLIN NUTR, V53, P2015.
   Eyong KO, 2006, PHYTOCHEMISTRY, V67, P605, DOI 10.1016/j.phytochem.2005.12.019.
   Farombi EO, 1999, FOOD CHEM, V64, P315, DOI 10.1016/S0308-8146(98)00108-3.
   Farombi EO, 2000, PHARMACOL RES, V42, P75.
   FRANKEL EN, 1995, J AGR FOOD CHEM, V43, P890, DOI 10.1021/jf00052a008.
   GBEASSOR M, 2006, PHYTOTHER RES, V4, P115.
   GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T.
   GOW CY, 1994, J AGR FOOD CHEM, V42, P629.
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x.
   HOUNZANGBEADOTE S, J HELMINTHOL, V79, P29.
   Iwu MM, 1993, HDB AFRICAN MED PLAN, P223.
   Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l.
   KASHIWADA Y, 1992, J NAT PROD, V55, P1033, DOI 10.1021/np50086a002.
   KOPPENOL WH, 1993, FREE RADICAL BIO MED, V15, P645, DOI 10.1016/0891-5849(93)90168-T.
   Kuete V, 2007, PHARMAZIE, V62, P552, DOI 10.1691/ph.2007.7.6757.
   LEE Y, 1995, J FOOD SCI, V60, P473, DOI 10.1111/j.1365-2621.1995.tb09806.x.
   Maged Y, 1999, TOXICOLOGY, P111.
   Mendel F., 1997, J AGR FOOD CHEM, V45, P1523.
   Ogunlana EO, 1975, PLANTA MED, V27, P534.
   Okezie IA, 1996, FREE RADICAL BIO MED, V20, P675.
   OLIVERBEVER B, 1986, MED PLANTS TROPICAL, P134.
   Owen PL, 2007, J BIOCHEM MOL TOXIC, V21, P231, DOI 10.1002/jbt.20186.
   OYAIZU M, 1986, JPN J NUTR, V44, P629.
   PAOLO DM, 1991, AM J CLIN NUTR, V53, pS194.
   Pin-Der Duh, 1998, Journal of the American Oil Chemists' Society, V75, P455, DOI 10.1007/s11746-998-0248-8.
   RUCH RJ, 1989, CARCINOGENESIS, V10, P1003, DOI 10.1093/carcin/10.6.1003.
   Sowemimo AA, 2007, J ETHNOPHARMACOL, V113, P427, DOI 10.1016/j.jep.2007.06.024.
   SU JD, 1988, PHYTOCHEMISTRY, V27, P1315, DOI 10.1016/0031-9422(88)80184-5.
   SWALLOW AJ, 1953, BIOCHEM J, V54, P253, DOI 10.1042/bj0540253.
   TAFA MS, 1984, J AM OIL CHEM SOC, V81, P928.
   Tor-anyiin T. A., 2003, Journal of Herbs, Spices \& Medicinal Plants, V10, P61, DOI 10.1300/J044v10n03\_07.
   Weiss J, 1944, NATURE, V153, P748, DOI 10.1038/153748a0.
   Weiss S J, 1986, Acta Physiol Scand Suppl, V548, P9.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Med. Plants Res.}},
Doc-Delivery-Number = {{367DC}},
Unique-ID = {{ISI:000260531700002}},
DA = {{2018-08-13}},
}

@article{ ISI:000256905000004,
Author = {Hlavsa, Michele C. and Moonan, Patrick K. and Cowan, Lauren S. and
   Navin, Thomas R. and Kammerer, J. Steve and Morlock, Glenn P. and
   Crawford, Jack T. and LoBue, Philip A.},
Title = {{Human tuberculosis due to Mycobacterium bovis in the United States,
   1995-2005}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2008}},
Volume = {{47}},
Number = {{2}},
Pages = {{168-175}},
Month = {{JUL 15}},
Abstract = {{Background. Understanding the epidemiology of human Mycobacterium bovis
   tuberculosis (TB) in the United States is imperative; this disease can
   be foodborne or airborne, and current US control strategies are focused
   on TB due to Mycobacterium tuberculosis and airborne transmission. The
   National TB Genotyping Service's work has allowed systematic
   identification of M. tuberculosis-complex isolates and enabled the first
   US-wide study of M. bovis TB.
   Methods. Results of spacer oligonucleotide and mycobacterial
   interspersed repetitive units typing were linked to corresponding
   national surveillance data for TB cases reported for the period
   2004-2005 and select cases for the period 1995-2003. We also used
   National TB Genotyping Service data to evaluate the traditional
   antituberculous drug resistance-based case definition of M. bovis TB.
   Results. Isolates from 165 (1.4\%) of 11,860 linked cases were
   identified as M. bovis. Patients who were not born in the United States,
   Hispanic patients, patients <15 years of age, patients reported to be
   HIV infected, and patients with extrapulmonary disease each had
   increased adjusted odds of having M. bovis versus M. tuberculosis TB.
   Most US-born, Hispanic patients with TB due to M. bovis (29 {[}90.6\%]
   of 32) had extrapulmonary disease, and their overall median age was 9.5
   years. The National TB Genotyping Service's data indicated that the
   pyrazinamide-based case definition's sensitivity was 82.5\% (95\%
   confidence interval; 75.3\%-87.9\%) and that data identified 14 errors
   in pyrazinamide-susceptibility testing or reporting.
   Conclusions. The prevalence of extrapulmonary disease in the young,
   US-born Hispanic population suggests recent transmission of M. bovis,
   possibly related to foodborne exposure. Because of its significantly
   different epidemiologic profile, compared with that of M. tuberculosis
   TB, we recommend routine surveillance of M. bovis TB. Routine
   surveillance and an improved understanding of M. bovis TB transmission
   dynamics would help direct the development of additional control
   measures.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hlavsa, MC (Reprint Author), Ctr Dis Control \& Prevent, Div Parasit Dis, Epidem Intelligence Serv, Off Workforce \& Career Dev, 4770 Buford Hwy,MS F-22, Atlanta, GA 30341 USA.
   Hlavsa, Michele C., Ctr Dis Control \& Prevent, Div Parasit Dis, Epidem Intelligence Serv, Off Workforce \& Career Dev, Atlanta, GA 30341 USA.
   Hlavsa, Michele C.; Moonan, Patrick K.; Cowan, Lauren S.; Navin, Thomas R.; Kammerer, J. Steve; Morlock, Glenn P.; Crawford, Jack T.; LoBue, Philip A., Ctr Dis Control \& Prevent, Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Div TB Eliminat, Atlanta, GA 30341 USA.
   Kammerer, J. Steve, Northrup Grumman, Atlanta, GA USA.}},
DOI = {{10.1086/589240}},
ISSN = {{1058-4838}},
Keywords-Plus = {{TRANSMISSION; EPIDEMIOLOGY; INFECTION; POPULATION; CALIFORNIA; COMPLEX;
   MEXICO}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{acz3@cdc.gov}},
ResearcherID-Numbers = {{Moonan, Patrick/F-4307-2014
   }},
ORCID-Numbers = {{Moonan, Patrick/0000-0002-3550-2065}},
Cited-References = {{{[}Anonymous], 2005, MMWR-MORBID MORTAL W, V54, P605.
   Baker MG, 2006, EPIDEMIOL INFECT, V134, P1068, DOI 10.1017/S0950268806005930.
   Besser RE, 2001, PEDIATRICS, V108, P305, DOI 10.1542/peds.108.2.305.
   Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299.
   Brudey K, 2006, BMC MICROBIOL, V6, DOI 10.1186/1471-2180-6-23.
   {*}CDCP, GUID APPL GEN TUB PR.
   Centers for Disease Control and Prevention, 2006, REP TUB US.
   Cousins DV, 1999, INT J TUBERC LUNG D, V3, P715.
   Cowan LS, 2005, J CLIN MICROBIOL, V43, P688, DOI 10.1128/JCM.43.2.688-695.2005.
   de Jong BC, 2005, J CLIN MICROBIOL, V43, P3530, DOI 10.1128/JCM.43.7.3530-3532.2005.
   Desmond E, 2004, EMERG INFECT DIS, V10, P921.
   ENARSON DA, 2006, MYCOBACTERIUM BOVIC, P1.
   Evans JT, 2007, LANCET, V369, P1270, DOI 10.1016/S0140-6736(07)60598-4.
   FORBES BA, 1998, BAILEY SCOTTS DIAGNO, P733.
   Gibson AL, 2004, J CLIN MICROBIOL, V42, P431, DOI 10.1128/JCM.42.1.431-434.2004.
   Gilsdorf M., 2006, MYCOBACTERIUM BOVIS, P89.
   Grange JM, 2001, TUBERCULOSIS, V81, P71, DOI 10.1054/tube.2000.0263.
   Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3.
   Hannan MM, 2001, J CLIN MICROBIOL, V39, P647, DOI 10.1128/JCM.39.2.647-650.2001.
   Harris NB, 2007, APPL ENVIRON MICROB, V73, P1025, DOI 10.1128/AEM.01956-06.
   Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907.
   LOBUE P, 2006, MYCOBACTERIUM BOVIS, P6.
   Milian-Suazo F, 2000, AM J VET RES, V61, P86, DOI 10.2460/ajvr.2000.61.86.
   Morlock GP, 2000, ANTIMICROB AGENTS CH, V44, P2291, DOI 10.1128/AAC.44.9.2291-2295.2000.
   O'Reilly LM, 1995, TUBERCLE LUNG DIS, V76, pS1.
   Rigaud NI, 2004, TUBERCULOSIS, P609.
   Robert J, 1999, INT J TUBERC LUNG D, V3, P711.
   Thoen C, 2006, VET MICROBIOL, V112, P339, DOI 10.1016/j.vetmic.2005.11.047.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{84}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{315UF}},
Unique-ID = {{ISI:000256905000004}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000257825200010,
Author = {Safatov, Alexandre S. and Andreeva, Irina S. and Belan, Boris D. and
   Buryak, Galina A. and Emelyanova, Elena K. and Jaenicke, Ruprecht and
   Panchenko, Mikhail V. and Pechurkina, Natalya I. and Puchkova, Larisa I.
   and Repin, Vladimir E. and Saranina, Irina V. and Sergeev, Alexander N.},
Title = {{To what extent can viable bacteria in atmospheric aerosols be dangerous
   for humans?}},
Journal = {{CLEAN-SOIL AIR WATER}},
Year = {{2008}},
Volume = {{36}},
Number = {{7}},
Pages = {{564-571}},
Month = {{JUL}},
Abstract = {{Multi-year monitoring of atmospheric bioaerosol in Southwestern Siberia
   revealed the presence of a large number of various culturable
   microorganisms. It is known that viable microorganisms can cause
   directly or provoke different human diseases. It's very difficult to
   evaluate the danger represented by each microorganism to man directly.
   Therefore, a relatively simple method is required for evaluation of
   potential danger represented to man by the whole assembly of culturable
   microorganisms in an atmospheric aerosol sample. For bacteria, the
   method can be based on a number of individual characteristics of each
   microorganism determined in the course of biochemical and other test
   required for identification of the detected bacterium, and a number of
   other tests. It is proposed to classify the measured individual
   characteristics of bacteria under four groups of indices responsible
   for: (i) potential pathogenicity for man; (ii) the numbers of bacteria
   in the sample; (iii) resistance to unfavorable environmental factors;
   (iv) drug resistance of bacteria. Each of four groups of indices is
   numerically evaluated by a certain integral index, which quantitatively
   reflects the contribution of experimentally determined characteristics
   of bacteria. Expert evaluation of the contribution of each
   characteristic of microorganisms to the corresponding group of indices
   is performed. The generalized index of potential danger of culturable
   bacteria in atmospheric aerosols for human health is presented as the
   product of four integral indices summarizing the normalized individual
   integral indices for all bacteria detected in the sample. The work
   presents the results of measuring the variations of all the above
   indices for atmospheric air samples collected during one year.}},
Publisher = {{WILEY-V C H VERLAG GMBH}},
Address = {{PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jaenicke, R (Reprint Author), Johannes Gutenberg Univ Mainz, Inst Atmospher Phys, D-55099 Mainz, Germany.
   Jaenicke, Ruprecht, Johannes Gutenberg Univ Mainz, Inst Atmospher Phys, D-55099 Mainz, Germany.
   Safatov, Alexandre S.; Andreeva, Irina S.; Buryak, Galina A.; Emelyanova, Elena K.; Pechurkina, Natalya I.; Puchkova, Larisa I.; Repin, Vladimir E.; Saranina, Irina V., Fed State Res Inst State Res Ctr Virol \& Biotechn, Koltsov, Russia.
   Belan, Boris D.; Panchenko, Mikhail V., RAS, SB, Inst Atmospher Opt, Tomsk, Russia.}},
DOI = {{10.1002/clen.200700194}},
ISSN = {{1863-0650}},
Keywords = {{bioaerosols; atmospheric aerosols; culturable bacteria; health effects}},
Keywords-Plus = {{AIR SAMPLES; MICROORGANISMS; TRANSPORT; ALTITUDE; DUST}},
Research-Areas = {{Science \& Technology - Other Topics; Environmental Sciences \& Ecology;
   Marine \& Freshwater Biology; Water Resources}},
Web-of-Science-Categories  = {{GREEN \& SUSTAINABLE SCIENCE \& TECHNOLOGY; Environmental Sciences;
   Marine \& Freshwater Biology; Water Resources}},
Author-Email = {{jaenicke@uni-mainz.de}},
ResearcherID-Numbers = {{Belan, Boris/A-6506-2014
   Sergeev, Alexandr/C-2434-2011
   Safatov, Alexander/A-3815-2014
   }},
ORCID-Numbers = {{Belan, Boris/0000-0003-1481-6847
   Safatov, Alexander/0000-0002-9161-6438
   Sergeev, Alexander/0000-0001-5984-8776}},
Cited-References = {{ALVAREZ AJ, 1995, APPL ENVIRON MICROB, V61, P3639.
   Andreeva I S, 2001, Dokl Biol Sci, V381, P530, DOI 10.1023/A:1013362001995.
   ANDREEVA IS, 2002, CHEM SUSTAINABLE DEV, V10, P523.
   ANISIMOV AP, 1999, THESIS SARATOV OBOLE.
   Ashmarin I.P., 1962, STAT METHODS MICROBI.
   BELAN BD, 1995, ATMOS OCEANIC OPTICS, V8, P66.
   BELAN BD, 1994, ATMOS OCEANIC OPT, V7, P585.
   BELAN BD, 1993, ATMOS OCEANIC OPT, V6, P124.
   Borodulin AI, 2005, DOKL EARTH SCI, V404, P1090.
   BOVALLIUS A, 1978, APPL ENVIRON MICROB, V35, P1231.
   BOVALLIUS A, 1978, APPL ENVIRON MICROB, V35, P847.
   CHERMASHENTSEV VM, 1993, VESTN ROS AKAD MED+, P3.
   Cox CS., 1995, BIOAEROSOLS HDB.
   FULTON JD, 1966, APPL MICROBIOL, V14, P237.
   GERHARDT F, 1984, METHODS GEN BACTERIO, V3.
   Gregory PH, 1961, MICROBIOLOGY ATMOSPH.
   Griffin Dale W., 2004, Aerobiologia, V20, P135, DOI 10.1023/B:AERO.0000032948.84077.12.
   GRIFFITHS WD, 1994, J AEROSOL SCI, V25, P1425, DOI 10.1016/0021-8502(94)90218-6.
   Harrison RM, 2005, INT J BIOMETEOROL, V49, P167, DOI 10.1007/s00484-004-0225-3.
   Holt J. G., 1986, BERGEYS MANUAL SYSTE, V1-2.
   Hryhorczuk D, 2001, ANN AGR ENV MED, V8, P177.
   IMSHENETSKY AA, 1978, APPL ENVIRON MICROB, V35, P1.
   Kellogg CA, 2006, TRENDS ECOL EVOL, V21, P638, DOI 10.1016/j.tree.2006.07.004.
   KELLY CD, 1954, CAN J BOT, V32, P591, DOI 10.1139/b54-057.
   KUSHNER DJ, 1978, MICROBIAL LIFE EXTRE.
   LEBEDEVA MN, 1973, GUIDE PRACTICAL STUD.
   Lighthart B, 1997, FEMS MICROBIOL ECOL, V23, P263, DOI 10.1016/S0168-6496(97)00036-6.
   MANNIATIS T, 1984, GENETIC ENG METHODS.
   MILLER G, 1976, EXPT MOL GENETICS.
   MULLER E, 1995, MYCOLOGY.
   NAZAROV LE, 1985, T I EXP METEOR, V9, P76.
   Oren A, 2004, PHILOS T R SOC B, V359, P623, DOI 10.1098/rstb.2003.1458.
   Peccia J, 2006, ATMOS ENVIRON, V40, P3941, DOI 10.1016/j.atmosenv.2006.02.029.
   PETO S, 1953, BIOMETRICS, V9, P320, DOI 10.2307/3001707.
   Proctor BE, 1935, J BACTERIOL, V30, P363.
   Prospero JM, 2005, AEROBIOLOGIA, V21, P1, DOI 10.1007/s10453-004-5872-7.
   Pyatkin K. D., 1980, MICROBIOLOGY.
   REPIN VE, 1998, BIOTECHNOL, V2, P18.
   Safatov A.S., 2006, CHEM ENG T, V10, P401.
   SAFATOV AS, 2007, 17 INT C NUCL ATM AE, P741.
   SAGGIE E, 1983, METHODS SOIL MICROBI.
   SMIRNOVA AM, 1975, PROBLEMS IMMUNOLOGY.
   SMIRNOVA AM, 1977, MICROBIOLOGY PROPHYL.
   Starr M. P., 1981, PROKARYOTES HDB HABI.
   SUPOTNITSKIY MV, 2000, MICROORGANISMS TOXIN.
   Tong YY, 2000, AEROSOL SCI TECH, V32, P393, DOI 10.1080/027868200303533.
   Wainwright M, 2003, FEMS MICROBIOL LETT, V218, P161, DOI 10.1111/j.1574-6968.2003.tb11513.x.
   WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/jb.173.2.697-703.1991.
   Zuev V. E., 1992, ATMOS OCEANIC OPT, V5, P658.
   1987, EQUIPMENT REMOTE PRO.}},
Number-of-Cited-References = {{50}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Clean-Soil Air Water}},
Doc-Delivery-Number = {{328VB}},
Unique-ID = {{ISI:000257825200010}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000258501600002,
Author = {Curtis, L. T.},
Title = {{Prevention of hospital-acquired infections: review of
   non-pharmacological interventions}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{2008}},
Volume = {{69}},
Number = {{3}},
Pages = {{204-219}},
Month = {{JUL}},
Abstract = {{Hospital-acquired (nosocomial) infections (HAls) increase morbidity,
   mortality and medical costs. In the USA alone, nosocomial infections
   cause about 1.7 million infections and 99000 deaths per year. HAls are
   spread by numerous routes including surfaces (especially hands), air,
   water, intravenous routes, oral routes and through surgery.
   Interventions such as proper hand and surface cleaning, better
   nutrition, sufficient numbers of nurses, better ventilator management,
   use of coated urinary and central venous catheters and use of
   high-efficiency particulate air (HEPA) filters have all been associated
   with significantly lower nosocomial infection rates. Multiple infection
   control techniques and strategies simultaneously ('bundling') may offer
   the best opportunity to reduce the morbidity and mortality toll. of
   HAls. Most of these infection control strategies will more than pay for
   themselves by saving the medical costs associated with nosocomial
   infections. Many non-pharmacological interventions to prevent many HAls
   will also reduce the need for tong or multiple-drug antibiotic courses
   for patients. Lower antibiotic drug usage with reduce risk of
   antibiotic-resistant organisms and should improve efficacy of
   antibiotics given to patients who do acquire infections. (C) 2008 The
   Hospital Infection Society. Published by Elsevier Ltd. All. rights
   reserved.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Curtis, LT (Reprint Author), 1328 Greenwood Ave, Wilmette, IL 60091 USA.
   Curtis, L. T., Norwegian Amer Hosp, Chicago, IL USA.}},
DOI = {{10.1016/j.jhin.2008.03.018}},
ISSN = {{0195-6701}},
EISSN = {{1532-2939}},
Keywords = {{nosocomial infection; hand washing; hospital cleaning; nutrition;
   urinary tract infections; ventitator-associated pneumonia; HEPA
   filtration}},
Keywords-Plus = {{RESISTANT STAPHYLOCOCCUS-AUREUS; INTENSIVE-CARE-UNIT;
   VENTILATOR-ASSOCIATED PNEUMONIA; BLOOD-STREAM INFECTIONS; CENTRAL VENOUS
   CATHETERS; RANDOMIZED CONTROLLED-TRIAL; PARTICULATE AIR FILTRATION;
   COATED URINARY CATHETERS; MAXIMAL STERILE BARRIERS; HAND HYGIENE}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{luketcurtis@aol.com}},
ResearcherID-Numbers = {{Wei, Jianjian/F-7788-2011}},
ORCID-Numbers = {{Wei, Jianjian/0000-0001-8859-8462}},
Cited-References = {{Aboelela SW, 2007, J HOSP INFECT, V66, P101, DOI 10.1016/j.jhin.2006.10.019.
   Adrie C, 2005, J CRIT CARE, V20, P46, DOI 10.1016/j.jcrc.2004.10.005.
   Akalin H, 2006, INFECT CONT HOSP EP, V27, P404, DOI 10.1086/503349.
   Anaissie EJ, 2002, CLIN INFECT DIS, V35, pE86, DOI 10.1086/342305.
   Anaissie EJ, 2002, ARCH INTERN MED, V162, P1483, DOI 10.1001/archinte.162.13.1483.
   {*}ASHRAE ANSI, 2001, 622001 ASHRAE ANSI.
   Aziz O, 2006, ANN SURG ONCOL, V13, P413, DOI 10.1245/ASO.2006.05.045.
   Aziz O, 2006, ANN SURG, V243, P17, DOI 10.1097/01.sla.0000193602.74417.14.
   Babcock HM, 2004, CHEST, V125, P2224, DOI 10.1378/chest.125.6.2224.
   BEARDPEGLER MA, 1988, J MED MICROBIOL, V26, P251, DOI 10.1099/00222615-26-4-251.
   Beggs CB, 2003, INDOOR BUILT ENVIRON, V12, P9, DOI 10.1177/142032603032201.
   Bernards AT, 1998, AM J INFECT CONTROL, V26, P544, DOI 10.1053/ic.1998.v26.a84555.
   Biscione FM, 2007, INFECT CONT HOSP EP, V28, P1103, DOI 10.1086/519931.
   Bjerke Nancy B, 2004, Crit Care Nurs Q, V27, P295.
   BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003.
   BOLISTER NJ, 1992, EPIDEMIOL INFECT, V109, P121.
   Bonten MJM, 1996, LANCET, V348, P1615, DOI 10.1016/S0140-6736(96)02331-8.
   Borschel DM, 2006, AM J INFECT CONTROL, V34, P388, DOI 10.1016/j.ajic.2005.08.004.
   BOSWELL T, 2006, 2006 FED INF SOC M C.
   Boswell TC, 2006, J HOSP INFECT, V63, P47, DOI 10.1016/j.jhin.2005.11.011.
   Boyce JM, 2002, AM J INFECT CONTROL, V30, pS1, DOI 10.1067/mic.2002.130391.
   BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148.
   Boyce JM, 2007, J HOSP INFECT, V65, P50, DOI 10.1016/S0195-6701(07)60015-2.
   Bracco D, 2007, INTENS CARE MED, V33, P836, DOI 10.1007/s00134-007-0559-5.
   Brown SM, 2003, INFECT CONT HOSP EP, V24, P172, DOI 10.1086/502186.
   BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108.
   Carling PC, 2008, INFECT CONT HOSP EP, V29, P1, DOI 10.1086/524329.
   Cepeda JA, 2005, LANCET, V365, P295, DOI 10.1016/S0140-6736(05)17783-6.
   Chaiyakunapruk N, 2002, ANN INTERN MED, V136, P792, DOI 10.7326/0003-4819-136-11-200206040-00007.
   Cheadle WG, 2006, SURG INFECT LARCH S1, V7, pS7, DOI DOI 10.1089/SUR.2006.7.S1-7.
   Chopra R, 2003, AM SURGEON, V69, P966.
   Cocanour CS, 2006, J TRAUMA, V61, P122, DOI 10.1097/01.ta.0000223971.25845.b3.
   Coopersmith CM, 2002, CRIT CARE MED, V30, P59, DOI 10.1097/00003246-200201000-00009.
   Daley AJ, 2005, J HOSP INFECT, V61, P264, DOI 10.1016/j.jhin.2005.02.001.
   Dancer SJ, 2006, AM J INFECT CONTROL, V34, P10, DOI 10.1016/j.ajic.2005.08.009.
   Dee SA, 2006, CAN J VET RES, V70, P168.
   Demirturk N, 2006, INFECT CONT HOSP EP, V27, P1410, DOI 10.1086/509859.
   Dettenkofer M, 2004, AM J INFECT CONTROL, V32, P84, DOI 10.1016/j.ajic.2003.07.006.
   DiGiovine B, 1999, AM J RESP CRIT CARE, V160, P976, DOI 10.1164/ajrccm.160.3.9808145.
   Dixon M, 2000, INTENS CARE MED, V26, P250, DOI 10.1007/s001340050056.
   Doyle B, 2001, Lippincotts Case Manag, V6, P127, DOI 10.1097/00129234-200105000-00007.
   Duquette-Petersen L, 1999, Oncol Nurs Forum, V26, P1319.
   Eckmanns T, 2006, J HOSP INFECT, V63, P406, DOI 10.1016/j.jhin.2006.03.015.
   Eckmanns T, 2006, J INFECT DIS, V193, P1408, DOI 10.1086/503435.
   Eckstein BC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-61.
   FARR BM, 1988, LANCET, V2, P669.
   French GL, 2004, J HOSP INFECT, V57, P31, DOI 10.1016/j.jhin.2004.03.006.
   Friberg B, 2001, J HOSP INFECT, V47, P110, DOI 10.1053/jhin.2000.0909.
   Gabbay J, 2006, J IND TEXT, V35, P323.
   Gallego E, 2006, NEPHRON CLIN PRACT, V104, pC1, DOI 10.1159/000093252.
   Garcia-Martin M, 2001, INFECT CONT HOSP EP, V22, P708, DOI 10.1086/501850.
   Garcia-Nunez M, 2008, FEMS IMMUNOL MED MIC, V52, P202, DOI 10.1111/j.1574-695X.2007.00362.x.
   Gastmeier P, 2007, J HOSP INFECT, V67, P1, DOI 10.1016/j.jhin.2007.06.011.
   GRAHAM J, 2008, CHICAGO TRIBUNE 0106, P1.
   Grant J, 2006, INFECT CONT HOSP EP, V27, P191, DOI 10.1086/500623.
   Hacek DM, 1999, AM J CLIN PATHOL, V111, P647.
   Hahn T, 2002, INFECT CONT HOSP EP, V23, P525, DOI 10.1086/502101.
   Hayden MK, 2006, CLIN INFECT DIS, V42, P1552, DOI 10.1086/503845.
   Heidelberg JF, 1997, APPL ENVIRON MICROB, V63, P3585.
   Hickson M, 2007, BMJ-BRIT MED J, V335, P80, DOI 10.1136/bmj.39231.599815.55.
   Hilburn J, 2003, AM J INFECT CONTROL, V31, P109, DOI 10.1067/mic.2003.15.
   Hu KK, 2004, CLIN INFECT DIS, V39, P1441, DOI 10.1086/425309.
   Hu KK, 2004, AM J INFECT CONTROL, V32, P142, DOI 10.1016/j.ajic.2003.10.006.
   Huang HI, 2008, WATER RES, V42, P73, DOI 10.1016/j.watres.2007.07.003.
   Humphreys H, 2007, J HOSP INFECT, V66, P1, DOI 10.1016/j.jhin.2007.01.007.
   {*}IICRC, 2003, S520 IICRC.
   Isakow W, 2006, SEMIN RESP CRIT CARE, V27, P5, DOI 10.1055/s-2006-933668.
   JENSEN P, 2005, MMWR RECOMM REP, V41, P1.
   Johnson JR, 2006, ANN INTERN MED, V144, P116, DOI 10.7326/0003-4819-144-2-200601170-00009.
   Johnson PDR, 2005, MED J AUSTRALIA, V183, P509.
   Jones Clare A, 2006, Br J Nurs, V15, P364.
   Kampf G, 2004, J HOSP INFECT, V56, pS3, DOI 10.1016/j.jhin.2003.12.023.
   Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004.
   Kilgore ML, 2008, MED CARE, V46, P101, DOI 10.1097/MLR.0b013e3181468991.
   Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763.
   Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205.
   Kubrak C, 2007, INT J NURS STUD, V44, P1036, DOI 10.1016/j.ijnurstu.2006.07.015.
   Larson E, 1999, CLIN INFECT DIS, V29, P1287, DOI 10.1086/313468.
   Larson EL, 2007, AM J INFECT CONTROL, V35, P666, DOI 10.1016/j.ajic.2006.10.006.
   Lau H, 2004, SURG ENDOSC, V18, P1013, DOI 10.1007/s00464-003-8266-y.
   Leung M, 2006, MED SCI MONITOR, V12, pSR17.
   LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10.
   Loo VG, 1996, INFECT CONT HOSP EP, V17, P360.
   MAKI DG, 1989, J CHEMOTHERAPY, V1, P3.
   Manian FA, 2007, INFECT CONT HOSP EP, V28, P337, DOI 10.1086/510811.
   Manley KJ, 2007, MED J AUSTRALIA, V186, P454.
   Marin MG, 2000, CRIT CARE MED, V28, P3332, DOI 10.1097/00003246-200009000-00035.
   Mayfield JL, 2000, CLIN INFECT DIS, V31, P995, DOI 10.1086/318149.
   McConkey SJ, 1999, INFECT CONT HOSP EP, V20, P533, DOI 10.1086/501665.
   McFarland LV, 2006, AM J GASTROENTEROL, V101, P812, DOI 10.1111/j.1572-0241.2006.00465.x.
   Melling AC, 2001, LANCET, V358, P876, DOI 10.1016/S0140-6736(01)06071-8.
   Merlani GM, 2003, CURR OPIN INFECT DIS, V16, P343, DOI 10.1097/01.qco.0000083565.72029.6e.
   Mermel LA, 2007, J HOSP INFECT, V65, P30, DOI 10.1016/S0195-6701(07)60011-5.
   Merrer J, 2001, JAMA-J AM MED ASSOC, V286, P700, DOI 10.1001/jama.286.6.700.
   Modol J, 2007, CLIN INFECT DIS, V44, P263, DOI 10.1086/510430.
   Montejo JC, 2003, CLIN NUTR, V22, P221, DOI 10.1016/S0261-5614(03)00007-4.
   Noskin GA, 2008, INFECT CONT HOSP EP, V29, P16, DOI 10.1086/524327.
   O'Neill E, 2005, J HOSP INFECT, V59, P273, DOI 10.1016/j.jhin.2004.09.031.
   OTTER J, 2006, 16 ANN SCI M SOC HEA.
   Page Leigh, 2005, Mater Manag Health Care, V14, P16.
   Paillaud E, 2005, AGE AGEING, V34, P619, DOI 10.1093/ageing/afi197.
   Panagea S, 2005, J HOSP INFECT, V59, P102, DOI 10.1016/j.jhin.2004.09.018.
   Paradisi F, 1998, CRIT CARE CLIN, V14, P165, DOI 10.1016/S0749-0704(05)70390-0.
   Pedro-Botet ML, 2007, CLIN INFECT DIS, V45, P84, DOI 10.1086/518584.
   Pierce RA, 2007, SURG ENDOSC, V21, P378, DOI 10.1007/s00464-006-9115-6.
   Pirson M, 2005, J HOSP INFECT, V59, P33, DOI 10.1016/j.jhin.2004.07.006.
   Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2.
   Poirot JL, 2007, AM J INFECT CONTROL, V35, P460, DOI 10.1016/j.ajic.2607.02.006.
   Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115.
   Puzniak LA, 2004, INFECT CONT HOSP EP, V25, P418, DOI 10.1086/502416.
   Puzniak LA, 2002, CLIN INFECT DIS, V35, P18, DOI 10.1086/340739.
   Raineri E, 2007, J HOSP INFECT, V67, P308, DOI 10.1016/j.jhin.2007.08.013.
   Roline CE, 2007, PREHOSP EMERG CARE, V11, P241, DOI 10.1080/10903120701205125.
   Rosenthal VD, 2005, AM J INFECT CONTROL, V33, P392, DOI 10.1016/j.ajic.2004.08.009.
   Rothan-Tondeur M, 2003, J AM GERIATR SOC, V51, P997, DOI 10.1046/j.1365-2389.2003.51314.x.
   Rupp ME, 2008, INFECT CONT HOSP EP, V29, P8, DOI 10.1086/524333.
   Rupp ME, 2004, AM J INFECT CONTROL, V32, P445, DOI 10.1016/j.ajic.2004.05.002.
   Rutala WA, 2004, CLIN INFECT DIS, V39, P702, DOI 10.1086/423182.
   RUTALA WA, 1995, INFECT CONT HOSP EP, V16, P391.
   Sabria M, 2001, INFECT CONT HOSP EP, V22, P673, DOI 10.1086/501843.
   Sabria M, 2002, LANCET INFECT DIS, V2, P368, DOI 10.1016/S1473-3099(02)00291-8.
   Sabria Miguel, 2003, Am J Respir Med, V2, P235.
   Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9.
   Saint S, 1998, AM J MED, V105, P236, DOI 10.1016/S0002-9343(98)00240-X.
   Saint S, 1999, ARCH INTERN MED, V159, P800, DOI 10.1001/archinte.159.8.800.
   Santos Alice Medeiros Lutz, 2005, Rev. Latino-Am. Enfermagem, V13, P86, DOI 10.1590/S0104-11692005000100014.
   SCHAAL KP, 1991, J HOSP INFECT, V18, P451, DOI 10.1016/0195-6701(91)90056-E.
   Schneider SM, 2004, BRIT J NUTR, V92, P105, DOI 10.1079/BJN20041152.
   Sengupta Sharmila, 2000, Indian Journal of Pediatrics, V67, P197, DOI 10.1007/BF02723663.
   SHERERTZ RJ, 1987, AM J MED, V83, P709, DOI 10.1016/0002-9343(87)90902-8.
   Simon AC, 2004, ACTA CLIN BELG, V59, P189, DOI 10.1179/acb.2004.028.
   Singh A, 2006, CLIN MICROBIOL REV, V19, P512, DOI 10.1128/CMR.00025-05.
   Srinivasan M, 2007, JPN J INFECT DIS, V60, P121.
   Stone PW, 2007, MED CARE, V45, P571, DOI 10.1097/MLR.0b013e3180383667.
   Stout JE, 2007, INFECT CONT HOSP EP, V28, P818, DOI 10.1086/518754.
   Sullivan R, 2007, AM J MED SCI, V334, P458, DOI 10.1097/MAJ.0b013e318068b24c.
   Tadiparthi S, 2007, ANN ROY COLL SURG, V89, P661, DOI 10.1308/003588407X209419.
   Tanner J, 2006, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004122.PUB3.
   Temple LKF, 1999, CAN J SURG, V42, P377.
   Toles Angela, 2002, J Pediatr Oncol Nurs, V19, P164, DOI 10.1016/S1043-4542(02)00009-7.
   Trick WE, 2003, CLIN INFECT DIS, V36, P1383, DOI 10.1086/374852.
   VandenbrouckeGrauls CMJE, 1996, INFECT CONT HOSP EP, V17, P512.
   Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554.
   Vonberg RP, 2007, J HOSP INFECT, V65, P15, DOI 10.1016/j.jhin.2006.09.018.
   WEBSTER J, 1994, J PAEDIATR CHILD H, V30, P59, DOI 10.1111/j.1440-1754.1994.tb00568.x.
   WEBSTER J, 2006, COCHRANE DB SYST REV, V19.
   WELLS WF, 1955, AIRBORNE CONTAGION A, pCH2.
   Wendt C, 1998, J CLIN MICROBIOL, V36, P3734.
   Wenzel RP, 2007, CLIN INFECT DIS, V45, P85, DOI 10.1086/518136.
   Wertheim HFL, 2004, J HOSP INFECT, V56, P321, DOI 10.1016/j.jhin.2004.01.026.
   Widmer AF, 2000, CLIN INFECT DIS, V31, P136, DOI 10.1086/313888.
   WIDMER AF, 1997, PREVENTION CONTROL N, P771.
   Wilson RD, 2004, ANAESTH INTENS CARE, V32, P202.
   Winslow ER, 2003, SURGERY, V134, P647, DOI 10.1016/S0039-6060(03)00312-X.
   Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673.
   Wu JA, 2003, ANTIMICROB AGENTS CH, V47, P3407, DOI 10.1128/AAC.47.11.3407-3414.2003.
   Xie X, 2007, INDOOR AIR, V17, P211, DOI 10.1111/j.1600-0668.2006.00469.x.
   Yang Ke-Ping, 2003, J Nurs Res, V11, P149.
   Yip Esah, 2004, J Infus Nurs, V27, P227, DOI 10.1097/00129804-200407000-00007.
   ZAFAR AB, 1995, AM J INFECT CONTROL, V23, P200, DOI 10.1016/0196-6553(95)90042-X.}},
Number-of-Cited-References = {{160}},
Times-Cited = {{58}},
Usage-Count-Last-180-days = {{6}},
Usage-Count-Since-2013 = {{47}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{338IT}},
Unique-ID = {{ISI:000258501600002}},
DA = {{2018-08-13}},
}

@article{ ISI:000260888300002,
Author = {Avila, Maria and Said, Najwane and Ojcius, David M.},
Title = {{The book reopened on infectious diseases}},
Journal = {{MICROBES AND INFECTION}},
Year = {{2008}},
Volume = {{10}},
Number = {{9, SI}},
Pages = {{942-947}},
Month = {{JUL}},
Abstract = {{Emerging infectious diseases represent a major challenge to human health
   worldwide. The risk of evolving new infectious pathogens has been
   intensifying due to urbanization. demographic changes. air travel,
   inappropriate use of antibiotics. and climate change. These pathogens
   call affect humans from urban centers to the remotest corners of the
   globe. Far from being a scourge C of the past, infectious diseases are
   relevant for the world today. (C) 2008 Elsevier Masson SAS. All rights
   reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ojcius, DM (Reprint Author), Univ Calif, Sch Nat Sci, POB 2039, Merced, CA 95344 USA.
   Avila, Maria; Said, Najwane; Ojcius, David M., Univ Calif, Sch Nat Sci, Merced, CA 95344 USA.}},
DOI = {{10.1016/j.micinf.2008.07.012}},
ISSN = {{1286-4579}},
Keywords = {{Infectious diseases; Pathogens; Worldwide; Pandemics; History}},
Keywords-Plus = {{GLOBAL CLIMATE-CHANGE; ANTIBIOTIC-RESISTANCE; CHLAMYDIA-PNEUMONIAE;
   PUBLIC-HEALTH; TUBERCULOSIS; EVOLUTION; ORIGINS; TRANSMISSION;
   CHIKUNGUNYA; CHALLENGE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{dojcius@ucmerced.edu}},
Cited-References = {{{[}Anonymous], 2007, 2007 AIDS EP UPD.
   Barnes David S., 2006, GREAT STINK PARIS 19.
   BERMINGHAM A, 2005, SARS CASE STUDY EMER.
   Binder S, 1999, SCIENCE, V284, P1311, DOI 10.1126/science.284.5418.1311.
   BROWN K, 2004, PENICILLIN MAN A FLE.
   Campbell LA, 2004, NAT REV MICROBIOL, V2, P23, DOI 10.1038/nrmicro796.
   Centers for Disease Control {[}CDC], 2008, CHRON DIS PREV.
   Charrel RN, 2008, LANCET INFECT DIS, V8, P5, DOI 10.1016/S1473-3099(07)70296-7.
   COHEN A, 2003, INT J ENV HLTH, V13, pS13.
   Cohen ML, 2000, NATURE, V406, P762, DOI 10.1038/35021206.
   CONFALONIERI U, 2007, HUMAN HLTH CLIMATE C, P391.
   Ewald P. W., 1994, EVOLUTION INFECT DIS.
   Ewald PW, 2004, INFECT DIS CLIN N AM, V18, P1, DOI 10.1016/S0891-5520(02)00099-0.
   FENNE F, 1988, SMALLPOX ITS ERADICA.
   Fonseca DM, 2004, SCIENCE, V303, P1535, DOI 10.1126/science.1094247.
   Fraser DW, 2005, LANCET INFECT DIS, V5, P237, DOI 10.1016/S1473-3099(05)70054-2.
   Haines A, 2004, JAMA-J AM MED ASSOC, V291, P99, DOI 10.1001/jama.291.1.99.
   Hawkey PM, 2008, BRIT J PHARMACOL, V153, pS406, DOI 10.1038/sj.bjp.0707632.
   Hawkey PM, 1998, BRIT MED J, V317, P657, DOI 10.1136/bmj.317.7159.657.
   Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507.
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870.
   Karl TR, 2003, SCIENCE, V302, P1719, DOI 10.1126/science.1090228.
   KRASNER RL, 2008, 20 CENTURY MICROBE H.
   Kuiken T, 2005, SCIENCE, V309, P1680, DOI 10.1126/science.1113310.
   Levy E., 2003, NEW KILLER DIS.
   Mahalingam S, 2004, TRENDS IMMUNOL, V25, P636, DOI 10.1016/j.it.2004.10.002.
   Marks DJB, 2006, CURR TOP MICROBIOL, V305, P105, DOI 10.1007/3-540-29714-6\_6.
   McMichael A., 2004, COMP QUANTIFICATION, P1543.
   MCMICHAEL AJ, 2005, SARS CASE STUDY EMER.
   Merrell DS, 2004, NATURE, V430, P250, DOI 10.1038/nature02760.
   Mohamadzadeh M, 2007, NAT REV IMMUNOL, V7, P556, DOI 10.1038/nri2098.
   Morens DM, 2004, NATURE, V430, P242, DOI 10.1038/nature02759.
   Mussa FF, 2006, J VASC SURG, V43, P1301, DOI 10.1016/j.jvs.2006.02.050.
   NABEL GJ, 2004, EBOLA MARBURG VIRUSE.
   {*}NAT CTR HLTH STAT, 1989, VIT HLTH STAT, V3.
   Onyebujoh P, 2004, NAT REV MICROBIOL, V2, P930, DOI 10.1038/nrmicro1050.
   PABLOSMENDEZ A, 2000, CLIN MISMANAGEMENT O.
   PAGLIUSI SR, 2007, PAPILLOMAVIRUS.
   PATTERSON KD, 1991, B HIST MED, V65, P4.
   Patz J, 2008, ANNU REV PUBL HEALTH, V29, P27, DOI 10.1146/annurev.publhealth.29.020907.090750.
   Pearce-Duvet JMC, 2006, BIOL REV, V81, P369, DOI 10.1017/S1464793106007020.
   Pepper DJ, 2007, DRUG DISCOV TODAY, V12, P980, DOI 10.1016/j.drudis.2007.08.001.
   Purse BV, 2005, NAT REV MICROBIOL, V3, P171, DOI 10.1038/nrmicro1090.
   REYBURN W, 1991, FLUSHED PRIDE STORY.
   Sencer David J., 2006, MMWR-MORBID MORTAL W, V55, p{[}745, 745].
   Shah NS, 2007, EMERG INFECT DIS, V13, P380, DOI 10.3201/eid1303.061400.
   SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227.
   STANEK G, 2002, LYME BORRELIOSIS BIO.
   Wang H, 2008, LANCET, V371, P1427, DOI 10.1016/S0140-6736(08)60493-6.
   Weiss RA, 2001, PHILOS T R SOC B, V356, P957, DOI 10.1098/rstb.2001.0838.
   Weissmann G, 2008, FASEB J, V22, P635, DOI 10.1096/fj.08-0301ufm.
   Whitcomb JM, 2002, AIDS, V16, pF41, DOI 10.1097/00002030-200210180-00002.
   {*}WHO, 2007, WHO REP GLOB SURV EP.
   WILLERSON JT, 2004, CIRCULATION S1, V109, P112.
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775.
   World Health Organization, 2007, INT SPREAD DIS THREA.
   World Health Organization, 2007, WORLD HLTH REP SAF F.
   Wu JH, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-300.
   Zhou DS, 2006, MICROBES INFECT, V8, P273, DOI 10.1016/j.micinf.2005.06.006.
   Zink AR, 2003, J CLIN MICROBIOL, V41, P359, DOI 10.1128/JCM.41.1.359-367.2003.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{55}},
Journal-ISO = {{Microbes Infect.}},
Doc-Delivery-Number = {{372FU}},
Unique-ID = {{ISI:000260888300002}},
DA = {{2018-08-13}},
}

@article{ ISI:000255383300006,
Author = {Gilbert, Brian E. and McLeay, Matthew T.},
Title = {{MegaRibavirin aerosol for the treatment of influenza A virus infections
   in mice}},
Journal = {{ANTIVIRAL RESEARCH}},
Year = {{2008}},
Volume = {{78}},
Number = {{3}},
Pages = {{223-229}},
Month = {{JUN}},
Abstract = {{While newer neuraminidase inhibitors have been used recently to treat
   influenza A and B virus infections, emergence of drug resistance poses
   potential problems. Previous ribavirin aerosol treatments of influenza
   were effective and drug resistance was not observed. To make ribavirin
   aerosol treatment a quicker process and limited to once or twice daily
   treatments, a MegaRibavirin formulation (100 mg of ribavirin/mL) was
   developed that when used with the Aerotech II nebulizer was effective in
   preventing death in a lethal influenza A virus mouse model. Aerosol
   generated using the Aerotech II nebulizer flowing at 10 L of air/min
   produced aerosol droplets that contained 2.3 mg of ribavirin/L with a
   mass median aerodynamic diameter of 1.8 mu m. Using this system for
   treatment, a single daily 30-min exposure on days 1-4 produced a
   survival rate of greater than 90\%. Delaying the start of aerosol
   treatment for 48 or 72 h and treating once daily for 30 min for two days
   (days 2-3 and 3-4, respectively) still significantly increased the
   number of survivors and mean time to death. For the treatment of
   influenza in general and for pandemic avian influenza, the
   MegaRibavirin-Aerotech II method of aerosol treatment allows for short
   treatment periods, minimizes environmental issues and costs less. (C)
   2008 Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gilbert, BE (Reprint Author), Baylor Coll Med, Dept Mol Virol \& Microbiol, 1 Baylor Pl,Mail Stop BCM-280, Houston, TX 77030 USA.
   Gilbert, Brian E., Baylor Coll Med, Dept Mol Virol \& Microbiol, Houston, TX 77030 USA.
   McLeay, Matthew T., LLC, MTM Res, Omaha, NE USA.}},
DOI = {{10.1016/j.antiviral.2008.01.005}},
ISSN = {{0166-3542}},
Keywords = {{aerosol; ribavirin; influenza; mice; treatment}},
Keywords-Plus = {{DURATION RIBAVIRIN AEROSOL; TRANSPLANT RECIPIENTS; COMBINATION THERAPY;
   COTTON RATS; NUDE-MICE; OSELTAMIVIR; PHARMACOKINETICS; CYCLOSPORINE;
   PROTECTION; CHILDREN}},
Research-Areas = {{Pharmacology \& Pharmacy; Virology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Virology}},
Author-Email = {{bgilbert@bcm.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}N01AI15437]; WHI NIH HHS {[}N01 AI015437]; PHS HHS
   {[}N01-AI-15437]}},
Cited-References = {{Boeckh M, 2007, CLIN INFECT DIS, V44, P245, DOI 10.1086/509930.
   Chevaliez S, 2007, J VIROL, V81, P7732, DOI 10.1128/JVI.00382-07.
   Chung DH, 2007, J VIROL, V81, P11722, DOI 10.1128/JVI.00874-07.
   Crotty S, 2000, NAT MED, V6, P1375.
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598.
   ENGLUND JA, 1990, J PEDIATR-US, V117, P313, DOI 10.1016/S0022-3476(05)80554-2.
   ENGLUND JA, 1994, J PEDIATR-US, V125, P635, DOI 10.1016/S0022-3476(94)70026-5.
   Galabov Angel S., 2006, Antiviral Chemistry \& Chemotherapy, V17, P251.
   GILBERT B E, 1990, Drugs of Today, V26, P195.
   GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201.
   GILBERT BE, 1992, ANTIVIR RES, V17, P33, DOI 10.1016/0166-3542(92)90088-M.
   GILBERT BE, 1988, ANTIMICROB AGENTS CH, V32, P117, DOI 10.1128/AAC.32.1.117.
   GILBERT BE, 1991, ANTIMICROB AGENTS CH, V35, P1448, DOI 10.1128/AAC.35.7.1448.
   GILBERT BE, 1985, ANTIMICROB AGENTS CH, V27, P309, DOI 10.1128/AAC.27.3.309.
   Iacono AT, 2006, NEW ENGL J MED, V354, P141, DOI 10.1056/NEJMoa043204.
   Ilyushina NA, 2007, ANTIVIR RES, V74, pA31, DOI 10.1016/j.antiviral.2007.01.020.
   Ilyushina NA, 2007, ANTIVIR THER, V12, P363.
   Knight V, 1999, CANCER CHEMOTH PHARM, V44, P177, DOI 10.1007/s002800050965.
   KNIGHT V, 1988, J INFECT DIS, V158, P443, DOI 10.1093/infdis/158.2.443.
   KNIGHT V, 1988, EUR J CLIN MICROBIOL, V7, P721, DOI 10.1007/BF01975037.
   KNIGHT V, 1981, LANCET, V2, P945.
   Knight V, 1987, Infect Dis Clin North Am, V1, P441.
   Koshkina NV, 2004, J AEROSOL MED, V17, P7, DOI 10.1089/089426804322994415.
   Krilov LR, 2002, PEDIATR INFECT DIS J, V21, P479, DOI {[}10.1097/00006454-200205000-00037, 10.1097/01.inf.0000014463.51019.d0].
   MCCLUNG HW, 1983, JAMA-J AM MED ASSOC, V249, P2671, DOI 10.1001/jama.249.19.2671.
   Phalen R. F., 1984, INHALATION STUDIES F.
   SCHLESINGER RB, 1985, J TOXICOL ENV HEALTH, V15, P197, DOI 10.1080/15287398509530647.
   Smee Donald F., 2006, Antiviral Chemistry \& Chemotherapy, V17, P185.
   Subbarao K, 2007, NAT REV IMMUNOL, V7, P267, DOI 10.1038/nri2054.
   TABER LH, 1983, PEDIATRICS, V72, P613.
   Verschraegen CF, 2004, CLIN CANCER RES, V10, P2319, DOI 10.1158/1078-0432.CCR-0929-3.
   WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393.
   WIGGINS NA, 1991, DRUG DEV IND PHARM, V17, P1971, DOI 10.3109/03639049109048062.
   WILSON SZ, 1984, ANTIMICROB AGENTS CH, V26, P200, DOI 10.1128/AAC.26.2.200.
   WYDE PR, 1987, ANTIVIR RES, V7, P211, DOI 10.1016/0166-3542(87)90029-5.
   WYDE PR, 1977, INFECT IMMUN, V15, P221.
   WYDE PR, 1986, ANTIMICROB AGENTS CH, V30, P942, DOI 10.1128/AAC.30.6.942.
   Yen HL, 2007, J VIROL, V81, P12418, DOI 10.1128/JVI.01067-07.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Antiviral Res.}},
Doc-Delivery-Number = {{294DC}},
Unique-ID = {{ISI:000255383300006}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000255850300005,
Author = {Torky, Abdelrahman and Raemisch, Anja and Glahn, Felix and Foth, Heidi},
Title = {{Arachidonic acid pathway activates multidrug resistance related protein
   in cultured human lung cells}},
Journal = {{ARCHIVES OF TOXICOLOGY}},
Year = {{2008}},
Volume = {{82}},
Number = {{5}},
Pages = {{323-332}},
Month = {{MAY}},
Abstract = {{Primary cultures of human lung cells can serve as a model system to
   study the mechanisms underlying the effects of irritants in air and to
   get a deeper insight into the (patho)physiological roles of the
   xenobiotic detoxification systems. For 99 human lung cancer cases the
   culture duration for bronchial epithelium and peripheral lung cells
   (PLC) are given in term of generations and weeks. Using this system, we
   investigated whether and how prostaglandins (PG) modify multidrug
   resistance related protein (MRP) function in normal human lung cells.
   PGF2 alpha had no effect on MRP function, whereas PGE2 induced MRP
   activity in cultured NHBECs. The transport activity study of MRP in
   NHBEC, PLC, and A549 under the effect of exogenously supplied PGF2 alpha
   (10 mu M, 1 day) using single cell fluorimetry revealed no alteration in
   transport activity of MRP. PG concentrations were within the
   physiological range. COX I and II inhibitors indomethacin (5, 10 mu M)
   and celecoxib (5, 10 mu M) could substantially decrease the transport
   activity of MRP in NHBEC, PLC, and A549 in 1- and 4-day trials.
   Prostaglandin E2 did not change cadmium-induced caspase 3/7 activation
   in NHBECs and had no own effect on caspase 3/7 activity. Cadmium
   chloride (5, 10 mu M) was an effective inducer of caspase 3/7 activation
   in NHBECs with a fivefold and ninefold rise of activity. In primary
   human lung cells arachidonic acid activates MRP transport function only
   in primary epithelial lung cells by prostaglandin E2 but not by F2 alpha
   mediated pathways and this effect needs some time to develop.}},
Publisher = {{SPRINGER HEIDELBERG}},
Address = {{TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Foth, H (Reprint Author), Univ Halle Wittenberg, Inst Environm Toxicol, D-06097 Halle, Germany.
   Torky, Abdelrahman; Raemisch, Anja; Glahn, Felix; Foth, Heidi, Univ Halle Wittenberg, Inst Environm Toxicol, D-06097 Halle, Germany.}},
DOI = {{10.1007/s00204-007-0251-0}},
ISSN = {{0340-5761}},
Keywords = {{human lung cells; MRPs; immunocytochemistry; transport; PGs; COX
   inhibitors}},
Keywords-Plus = {{CANCER-CELLS; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; TUMOR-CELLS;
   EXPRESSION; MRP1; TRANSPORTERS; CYCLOOXYGENASE-2; GENES; LINES}},
Research-Areas = {{Toxicology}},
Web-of-Science-Categories  = {{Toxicology}},
Author-Email = {{heidi.foth@medizin.uni-halle.de}},
Cited-References = {{{*}BUA, 2003, 244 BUA.
   Cherrington NJ, 2004, DRUG METAB DISPOS, V32, P734, DOI 10.1124/dmd.32.7.734.
   Cruz-Gervis Roberto, 2002, Respir Res, V3, P17, DOI 10.1186/rr166.
   Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020.
   Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005.
   Fernandez-Cobo M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-99.
   Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199.
   Ikegami Y, 2000, J CELL PHYSIOL, V185, P293, DOI 10.1002/1097-4652(200011)185:2<293::AID-JCP14>3.0.CO;2-C.
   Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355.
   Lag M, 2002, CELL BIOL TOXICOL, V18, P29, DOI 10.1023/A:1014467112463.
   Lee G, 2003, J PHARM SCI-US, V92, P2152, DOI 10.1002/jps.10493.
   Lehmann T, 2005, ARCH TOXICOL, V79, P600, DOI 10.1007/s00204-005-0669-1.
   Lehmann T, 2001, TOXICOLOGY, V167, P59, DOI 10.1016/S0300-483X(01)00458-9.
   Liao ZX, 2007, DRUGS, V67, P821, DOI 10.2165/00003495-200767060-00001.
   Qualtrough D, 2007, INT J CANCER, V121, P734, DOI 10.1002/ijc.22755.
   RAEMISCH A, 2005, TOXICOL LETT, V158, P237.
   Runge DM, 2001, ARCH TOXICOL, V75, P335, DOI 10.1007/s002040100248.
   Scotto KW, 2003, ONCOGENE, V22, P7496, DOI 10.1038/sj.onc.1206950.
   Shin YK, 2005, CANCER RES, V65, P9501, DOI 10.1158/0008-5472.CAN-05-0220.
   Shiota G, 1999, HEPATO-GASTROENTEROL, V46, P407.
   Stehfest E, 2006, ARCH TOXICOL, V80, P125, DOI 10.1007/s00204-005-0017-5.
   Stein U, 1997, J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807.
   Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290.
   Torky ARW, 2005, TOXICOLOGY, V207, P437, DOI 10.1016/j.tox.2004.10.014.
   You CS, 2005, J NUTR, V135, P227.
   Ziemann C, 2002, HEPATOLOGY, V35, P579, DOI 10.1053/jhep.2002.31778.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Arch. Toxicol.}},
Doc-Delivery-Number = {{300UI}},
Unique-ID = {{ISI:000255850300005}},
DA = {{2018-08-13}},
}

@article{ ISI:000255834000011,
Author = {Dueger, Erica L. and Asturias, Edwin J. and Matheu, Jorge and Gordillo,
   Remei and Torres, Olga and Halsey, Neal},
Title = {{Increasing penicillin and trimethoprim-sulfamethoxazole resistance in
   nasopharyngeal Streptococcus pneumoniae isolates from Guatemalan
   children, 2001-2006}},
Journal = {{INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2008}},
Volume = {{12}},
Number = {{3}},
Pages = {{289-297}},
Month = {{MAY}},
Abstract = {{Objectives: We aimed to determine nasopharyngeal colonization rates and
   antibiotic resistance patterns of Streptococcus pneumoniae isolated from
   Guatemalan children, and to determine risk factors for colonization and
   antibiotic nonsusceptibility.
   Methods: Isolates were obtained from children aged 5 to 60 months
   attending public and private outpatient clinics and daycare centers
   during August 2001-June 2002 and outpatient clinics during November
   2005-February 2006 in Guatemala City. Minimal inhibitory concentrations
   of penicillin, trimethoprim-sulfamethoxazole (TMS), cefotaxime, and
   erythromycin were determined using the E-test.
   Results: The overall nasopharyngeal colonization rate for S. pneumoniae
   was 59.1\%. From 2001/2 to 2005/6 TMS nonsusceptibility increased from
   42.4\% to 60.8\% (p < 0.05) in public clinics and from 51.4\% to 84.0\%
   (p = 0.009) in private clinics, and penicillin nonsusceptibility
   increased from 1.5\% to 33.3\% in public clinics (p < 0.001). Reported
   antibiotic use was not strictly associated with nonsusceptibility to
   that same antibiotic. Resistance to three or four antibiotics increased
   in public clinics from 2001/2 (0\%) to 2005/6 (10.7\%; p < 0.001). Risk
   factors for nasopharyngeal colonization with penicillin- or
   TMS-nonsusceptible S. pneumoniae were low family income, daycare center
   attendance, and recent penicillin use.
   Conclusions: Increasing antibiotic nonsusceptibility rates in
   nasopharyngeal S. pneumoniae isolates from Guatemalan children reflect
   worldwide trends. Policies encouraging more judicious use of TMS should
   be considered. (C) 2007 International Society for Infectious Diseases.
   Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dueger, EL (Reprint Author), Univ Guatemala, Dept Int Hlth, Johns Hopkins Bloomberg Sch Publ Hlth, 11 Calle 15-79 Zona 15 VH 3, Guatemala City, Guatemala.
   Dueger, Erica L.; Asturias, Edwin J.; Halsey, Neal, Univ Guatemala, Dept Int Hlth, Johns Hopkins Bloomberg Sch Publ Hlth, Guatemala City, Guatemala.
   Matheu, Jorge; Gordillo, Remei, Guatemala Minist Hlth, Guatemala City, Guatemala.
   Torres, Olga, Lab Diagnost Mol, Guatemala City, Guatemala.}},
DOI = {{10.1016/j.ijid.2007.09.001}},
ISSN = {{1201-9712}},
Keywords = {{antibiotic resistance; erythromycin; cefotaxime; macrolide;
   cephalosporin; risk factors}},
Keywords-Plus = {{DAY-CARE-CENTERS; ANTIMICROBIAL SURVEILLANCE PROGRAM; INDOOR
   AIR-POLLUTION; PNEUMOCOCCAL CONJUGATE VACCINE; RESPIRATORY-TRACT
   INFECTION; LATIN-AMERICAN COUNTRIES; ANTIBIOTIC-RESISTANCE;
   HEALTHY-CHILDREN; RISK-FACTORS; MOLECULAR EPIDEMIOLOGY}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{edueger@jhsph.edu}},
Funding-Acknowledgement = {{FIC NIH HHS {[}K01 TW006659-01, K01 TW06659, K01 TW006659, K01
   TW006659-04, K01 TW006659-03, K01 TW006659-02]}},
Cited-References = {{APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   Arason VA, 1996, BMJ-BRIT MED J, V313, P387.
   Arason VA, 2006, MICROB DRUG RESIST, V12, P169, DOI 10.1089/mdr.2006.12.169.
   Baquero F, 2002, J ANTIMICROB CHEMOTH, V50, P27, DOI 10.1093/jac/dkf504.
   Castaneda E, 1997, MICROB DRUG RESIST, V3, P147, DOI 10.1089/mdr.1997.3.147.
   Castanheira M, 2004, CLIN MICROBIOL INFEC, V10, P645, DOI 10.1046/j.1469-0691.2004.00872.x.
   CATALANO M, 1990, REV INFECT DIS, V12, pS998.
   Chiu SS, 2001, ANTIMICROB AGENTS CH, V45, P2765, DOI 10.1128/AAC.45.10.2765-2770.2001.
   Cohen R, 2006, PEDIATR INFECT DIS J, V25, P977, DOI 10.1097/01.inf.0000239271.10784.1e.
   DeNap JCB, 2005, ORG BIOMOL CHEM, V3, P959, DOI 10.1039/b500182j.
   Drusano GL, 2006, CLIN INFECT DIS, V42, P525, DOI 10.1086/499046.
   Farrell DJ, 2005, EMERG INFECT DIS, V11, P851, DOI 10.3201/eid1106.050222.
   Farrell DJ, 2004, J CLIN MICROBIOL, V42, P764, DOI 10.1128/JCM.42.2.764-768.2004.
   Fedler KA, 2006, DIAGN MICR INFEC DIS, V56, P427, DOI 10.1016/j.diagmicrobio.2006.07.003.
   Felmingham D, 2005, J ANTIMICROB CHEMOTH, V56, P3, DOI 10.1093/jac/dki297.
   Finkelstein JA, 2003, PEDIATRICS, V112, P862, DOI 10.1542/peds.112.4.862.
   Garcia S, 2006, REV PANAM SALUD PUBL, V19, P340, DOI 10.1590/S1020-49892006000500007.
   Ghaffar F, 1999, PEDIATR INFECT DIS J, V18, P638, DOI 10.1097/00006454-199907000-00016.
   Granizo JJ, 2000, J ANTIMICROB CHEMOTH, V46, P767, DOI 10.1093/jac/46.5.767.
   Greenwood B, 1999, PHILOS T ROY SOC B, V354, P777, DOI 10.1098/rstb.1999.0430.
   Hogberg L, 2006, MICROB DRUG RESIST, V12, P16, DOI 10.1089/mdr.2006.12.16.
   Hortal M, 2001, MICROB DRUG RESIST, V7, P391, DOI 10.1089/10766290152773400.
   Hortal M, 2000, Rev Panam Salud Publica, V8, P185, DOI 10.1590/S1020-49892000000800006.
   Inostroza J, 1998, CLIN DIAGN LAB IMMUN, V5, P176.
   Jenkins SG, 2005, J INFECTION, V51, P355, DOI 10.1016/j.jinf.2005.04.015.
   Johnson DM, 2006, DIAGN MICR INFEC DIS, V56, P69, DOI 10.1016/j.diagmicrobio.2005.12.008.
   Kellner JD, 1999, ARCH PEDIAT ADOL MED, V153, P495, DOI 10.1001/archpedi.153.5.495.
   Laval CB, 2006, CLIN MICROBIOL INFEC, V12, P50, DOI 10.1111/j.1469-0691.2005.01304.x.
   Livermore DM, 2003, CLIN INFECT DIS, V36, pS11, DOI 10.1086/344654.
   LloydEvans N, 1996, PEDIATR INFECT DIS J, V15, P866, DOI 10.1097/00006454-199610000-00007.
   Lynch JP, 2005, SEMIN RESP CRIT CARE, V26, P575, DOI 10.1055/s-2005-925524.
   Marchisio P, 2002, EMERG INFECT DIS, V8, P479.
   McDermott PF, 2003, INT J TOXICOL, V22, P135, DOI 10.1080/10915810390198410.
   Melander E, 2000, PEDIATR INFECT DIS J, V19, P1172, DOI 10.1097/00006454-200012000-00011.
   Mendes C., 2003, Braz J Infect Dis, V7, P44, DOI 10.1590/S1413-86702003000100006.
   Mishra V, 1997, Natl Fam Health Surv Bull, P1.
   Mishra V, 2003, INT J EPIDEMIOL, V32, P847, DOI 10.1093/ije/dyg240.
   Nasrin D, 1999, J PAEDIATR CHILD H, V35, P558, DOI 10.1046/j.1440-1754.1999.00416.x.
   Neto AS, 2003, MICROB DRUG RESIST, V9, P99, DOI 10.1089/107662903764736409.
   Nilsson P, 2005, SCAND J INFECT DIS, V37, P436, DOI 10.1080/00365540510037795.
   Ochoa TJ, 2005, DIAGN MICR INFEC DIS, V52, P59, DOI 10.1016/j.diagmicrobio.2004.12.014.
   Okeke IN, 2005, LANCET INFECT DIS, V5, P481, DOI 10.1016/S1473-3099(05)70189-4.
   PANDEY MR, 1989, LANCET, V1, P427.
   Petrosillo N, 2002, EUR J CLIN MICROBIOL, V21, P181, DOI 10.1007/s10096-001-0689-6.
   Quinones-Falconi F, 2004, DIAGN MICR INFEC DIS, V49, P53, DOI 10.1016/j.diagmicrobio.2004.02.001.
   Regev-Yochay G, 2003, SCAND J INFECT DIS, V35, P219, DOI 10.1080/00365540310000319.
   Rey LC, 2002, INT J ANTIMICROB AG, V20, P86, DOI 10.1016/S0924-8579(02)00128-0.
   Russell FM, 2006, ANN TROP PAEDIATR, V26, P187, DOI 10.1179/146532806X120273.
   Saldias F, 2005, REV MED CHILE, V133, P42, DOI 10.4067/S0034-98872005000100006.
   Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701.
   Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518.
   Solorzano-Santos F, 2005, SALUD PUBLICA MEXICO, V47, P276, DOI 10.1590/s0036-36342005000400004.
   Sombrero L, 1999, AM J TROP MED HYG, V60, P397, DOI 10.4269/ajtmh.1999.60.397.
   Tomasson G, 2005, SCAND J INFECT DIS, V37, P422, DOI 10.1080/00365540510035346.
   Volonakis K, 2006, INT J ANTIMICROB AG, V28, P297, DOI 10.1016/j.ijantimicag.2006.07.002.
   Zemlickova H, 2006, EPIDEMIOL INFECT, V134, P1179, DOI 10.1017/S0950268806006157.
   Zemlickova H, 2005, MICROB DRUG RESIST, V11, P195, DOI 10.1089/mdr.2005.11.195.
   Zhanel GG, 2003, ANTIMICROB AGENTS CH, V47, P1867, DOI 10.1128/AAC.47.6.1867-1874.2003.}},
Number-of-Cited-References = {{58}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Int. J. Infect. Dis.}},
Doc-Delivery-Number = {{300OK}},
Unique-ID = {{ISI:000255834000011}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000255289600024,
Author = {Berrang, M. E. and Meinersmann, R. J. and Smith, D. P. and Zhuang, H.},
Title = {{The effect of chilling in cold air or ice water on the microbiological
   quality of broiler carcasses and the population of Campylobacter}},
Journal = {{POULTRY SCIENCE}},
Year = {{2008}},
Volume = {{87}},
Number = {{5}},
Pages = {{992-998}},
Month = {{MAY}},
Abstract = {{Cold air or ice water can be used to chill poultry carcasses after
   slaughter. The objective of this study was to compare the effect of 2
   chill methods on broiler carcass bacteria. Broiler carcasses were cut in
   half along the dorsal-ventral midline; one half was subjected to an
   ice-water immersion chill in an agitated bath for 50 min, whereas the
   reciprocal half was subjected to an air chill in a 1 C cold room for 150
   min. Total aerobic bacteria, coliforms, Escherichia coli, and
   Campylobacter were enumerated from half-carcass rinses. Species of
   Campylobacter isolates was determined by a commercial PCR method, which
   was followed by molecular subtyping with pulsed-field gel
   electrophoresis and determination of antimicrobial susceptibility to 9
   drugs. Although significantly fewer of each bacterial type were detected
   per milliliter from immersion-chilled carcasses than from air-chilled
   car-casses, in each case the difference was less than 1 log(10) cfu/mL.
   Chilling method did not affect species; both Campylobacter jejuni and
   Campylobacter coli were recovered. Results of pulsed-field gel
   electrophoresis subtyping did not suggest that either chilling method
   selected for any specific subtypes; most subtypes were found on carcass
   halves used for both the air chill and water immersion chill. Resistance
   to 2 antimicrobial drugs was noted in 9 C. coli isolates, 6 from
   air-chilled carcass halves and 3 from immersion-chilled carcass halves.
   These data showed that immersion-chilled carcasses had lower numbers of
   bacteria; however, the difference was not large and may have been due to
   simple dilution. Both methods were effective for lowering carcass
   temperature, and neither chilling method seemed to select for specific
   species, subtypes, or antimicrobial-resistant Campylobacter.}},
Publisher = {{POULTRY SCIENCE ASSOC INC}},
Address = {{1111 N DUNLAP AVE, SAVOY, IL 61874-9604 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Berrang, ME (Reprint Author), USDA ARS, Russell Res Ctr, 950 Coll Stn Rd, Athens, GA 30604 USA.
   Berrang, M. E.; Meinersmann, R. J.; Smith, D. P.; Zhuang, H., USDA ARS, Russell Res Ctr, Athens, GA 30604 USA.}},
DOI = {{10.3382/ps.2007-00406}},
ISSN = {{0032-5791}},
Keywords = {{Campylobacter; broiler; air chill; immersion chill}},
Keywords-Plus = {{CROSS-CONTAMINATION; HYGIENE ASPECTS; POULTRY; NUMBERS; SPP.;
   ESTABLISHMENT; VARIABILITY; SALMONELLA; PROFILE; HALVES}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Agriculture, Dairy \& Animal Science}},
Author-Email = {{mark.berrang@ars.usda.gov}},
Cited-References = {{Allen VM, 2000, INT J FOOD MICROBIOL, V58, P39, DOI 10.1016/S0168-1605(00)00259-2.
   Allen VM, 2000, BRIT POULTRY SCI, V41, P575, DOI 10.1080/00071660020009108.
   Alter T, 2005, FOOD MICROBIOL, V22, P345, DOI 10.1016/j.fm.2004.08.008.
   Berrang ME, 2000, J APPL POULTRY RES, V9, P43, DOI 10.1093/japr/9.1.43.
   Bilgili SF, 2002, J APPL POULTRY RES, V11, P233, DOI 10.1093/japr/11.3.233.
   Blank G, 1995, J FOOD PROTECT, V58, P1386, DOI 10.4315/0362-028X-58.12.1386.
   Cason JA, 2002, POULTRY SCI, V81, P126, DOI 10.1093/ps/81.1.126.
   Clinical and Laboratory Standards Institute, 2006, METH ANT DIL DISK SU.
   Fluckey WM, 2003, J FOOD PROTECT, V66, P272, DOI 10.4315/0362-028X-66.2.272.
   Fries R, 1999, BRIT POULTRY SCI, V40, P52, DOI 10.1080/00071669987836.
   Hunter SB, 2005, J CLIN MICROBIOL, V43, P1045, DOI 10.1128/JCM.43.3.1045-1050.2005.
   IZAT AL, 1990, POULTRY SCI, V69, P864, DOI 10.3382/ps.0690864.
   Lindblad M, 2006, J FOOD PROTECT, V69, P495, DOI 10.4315/0362-028X-69.3.495.
   Mead GC, 2000, BRIT POULTRY SCI, V41, P158, DOI 10.1080/713654915.
   RENWICK SA, 1993, J FOOD PROTECT, V56, P694, DOI 10.4315/0362-028X-56.8.694.
   Sanchez MX, 2002, J FOOD PROTECT, V65, P948, DOI 10.4315/0362-028X-65.6.948.
   Smith DP, 2005, J FOOD PROTECT, V68, P1340, DOI 10.4315/0362-028X-68.7.1340.
   Stern NJ, 2003, J FOOD PROTECT, V66, P1557, DOI 10.4315/0362-028X-66.9.1557.
   STERN NJ, 1992, J FOOD PROTECT, V55, P514, DOI 10.4315/0362-028X-55.7.514.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Poult. Sci.}},
Doc-Delivery-Number = {{292TS}},
Unique-ID = {{ISI:000255289600024}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000254086300006,
Author = {Abdulla, Hesham and Morshedy, Hekmate and Dewedar, Ahmed},
Title = {{Characterization of actinomycetes isolated from the indoor air of the
   church of Saint Katherine Monastery, Egypt}},
Journal = {{AEROBIOLOGIA}},
Year = {{2008}},
Volume = {{24}},
Number = {{1}},
Pages = {{35-41}},
Month = {{MAR}},
Abstract = {{Actinomycetes were isolated from the indoor air of the church of Saint
   Katherin Monastery during different visiting hours. Fifty air samples
   collected over one year by using automated air sampler were plated on
   four different media. The low nutrient-content medium 1/10 SC was
   significantly effective in recovery of actinomycetes compared to the
   other formula of rich media. Average counts of bacteria, actinomycetes
   and fungi were 487, 65 and 90 cfu/m(3), respectively. Fifty-six
   morphologically different actinomycetes isolates were recovered during
   this study assigned into five different genera, in addition to three
   unidentified isolates. Tentative identification of the isolates
   indicated predominance of genus Streptomyces, representing 59\% of the
   isolates. Isolates were screened for resistance to 11 antibiotics,
   antimicrobial activities towards seven microbial strains, Growth on 12
   different carbon source, acid production and pigmentation. About 77\% of
   actinomycete isolates were resistant to the antibiotics with different
   resistance patterns. 12.5\% of the airborne actinomycetes exhibited
   antinmicrobial activities. The isolates showed wide variation in carbon
   source usage. Forty percent of the isolates were able to utilize all
   tested carbon sources while 80\% were acid producers. Melanin production
   was produced by 34\% of the isolates. While 45\% of the isolates were
   able to produce other diffusible pigments, the majority of the pigments
   were brown in color however; yellow, orange and green pigments were
   produced by a number of isolates. The impact of these activities on the
   historical objects of the church and the tourist's health is discussed.}},
Publisher = {{SPRINGER}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Abdulla, H (Reprint Author), Suez Canal Univ, Fac Sci, Dept Bot, Ismailia 41522, Egypt.
   Abdulla, Hesham; Morshedy, Hekmate; Dewedar, Ahmed, Suez Canal Univ, Fac Sci, Dept Bot, Ismailia 41522, Egypt.}},
DOI = {{10.1007/s10453-007-9080-0}},
ISSN = {{0393-5965}},
Keywords = {{actinomycetes; airborne microbes; Saint Katherine Monastery;
   biodeterioration}},
Keywords-Plus = {{SPORES; IDENTIFICATION; ENVIRONMENT; QUALITY; HEALTH}},
Research-Areas = {{Life Sciences \& Biomedicine - Other Topics; Environmental Sciences \&
   Ecology}},
Web-of-Science-Categories  = {{Biology; Environmental Sciences}},
Author-Email = {{hesham\_abdulla@hotmail.com}},
Cited-References = {{ABDULLA H, 2001, THESIS SUEZ CANAL U.
   Andersson MA, 1998, APPL ENVIRON MICROB, V64, P4767.
   Castillo UF, 2002, MICROBIOL-SGM, V148, P2675.
   Chang C, 2004, CLIN REV ALLERG IMMU, V27, P219, DOI 10.1385/CRIAI:27:3:219.
   DALES RE, 1991, AM J EPIDEMIOL, V134, P196, DOI 10.1093/oxfordjournals.aje.a116072.
   de Kok TMCM, 2004, EUR RESPIR J, V24, P1069, DOI 10.1183/09031936.04.00113404.
   Demain A.L., 1999, MANUAL IND MICROBIOL.
   Giacobini C, 1988, BIODETERIORATION, V7, P418.
   Grigorevski-Lima AL, 2006, BUILD ENVIRON, V41, P1540, DOI 10.1016/j.buildenv.2005.06.009.
   Harrison PTC, 2002, OCCUP ENVIRON MED, V59, P73, DOI 10.1136/oem.59.2.73.
   Hirvonen MR, 1997, ENVIRON TOXICOL PHAR, V3, P57, DOI 10.1016/S1382-6689(96)00140-8.
   Holt J. G., 1994, BERGEYS MANUAL DETER.
   Huttunen K, 2003, ENVIRON HEALTH PERSP, V111, P85, DOI 10.1289/ehp.5478.
   Jussila J, 2001, TOXICOL APPL PHARM, V171, P61, DOI 10.1006/taap.2000.9116.
   KARAPOVICHTATE N, 1990, INT BIODETERIOR, V27, P282.
   Kieser T, 2000, PRACTICAL STREPTOMYC.
   KRUMBEIN WE, 1991, P 2 INT S CONS MON M, P219.
   LACEY J, 1994, J AEROSOL SCI, V25, P1371, DOI 10.1016/0021-8502(94)90215-1.
   LACEY J, 1989, BERGEYS MANUAL SYSTE, V4, P2573.
   May E., 2003, ART BIOL CONSERVATIO, P452.
   MCCARTHY AJ, 1992, GENE, V115, P189, DOI 10.1016/0378-1119(92)90558-7.
   Nielsen EM, 1997, ANN OCCUP HYG, V41, P325, DOI 10.1016/S0003-4878(96)00045-2.
   Reponen TA, 1998, APPL ENVIRON MICROB, V64, P3807.
   SCHAAL KP, 1985, CHEM METHODS BACTERI, P359.
   SHIRLING E. B., 1966, INT J SYST BACTERIOL, V16, P313.
   STANECK JL, 1974, APPL MICROBIOL, V28, P226.
   Williams S., 1989, BERGEYS MANUAL SYSTE, V4, P2452.
   WILLIAMS ST, 1985, INT BIODETERIOR, V21, P201.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Aerobiologia}},
Doc-Delivery-Number = {{275QI}},
Unique-ID = {{ISI:000254086300006}},
DA = {{2018-08-13}},
}

@article{ ISI:000252712300011,
Author = {Nehme, Benjamin and Letourneau, Valerie and Forster, Robert J. and
   Veillette, Marc and Duchaine, Caroline},
Title = {{Culture-independent approach of the bacterial bioaerosol diversity in
   the standard swine confinement buildings, and assessment of the seasonal
   effect}},
Journal = {{ENVIRONMENTAL MICROBIOLOGY}},
Year = {{2008}},
Volume = {{10}},
Number = {{3}},
Pages = {{665-675}},
Month = {{MAR}},
Abstract = {{The bacterial bioaerosol community of eight swine confinement buildings
   (SCB) was monitored during two visits in the winter, and one during the
   summer. To our knowledge, culture-independent approaches and molecular
   biology tools such as biomass quantification and biodiversity analyses
   have never been applied to swine building bioaerosol analyses. Total DNA
   of each sample was extracted and analysed by quantitative real-time
   polymerase chain reaction, denaturing gradient gel electrophoresis
   (DGGE) and phylogenetic analysis using primers targeting the bacterial
   16S rRNA gene. Even though the total bacterial concentration was higher
   in winter than in summer, the total bacterial concentration for both
   seasons was 100 to1000 times higher than the total cultural bacteria.
   The concentration of bioaerosol was influenced by the temperature
   indoors, which was regulated with an electronic fan system driving warm
   air and particles outside of the SCB. Comparison of the DGGE profiles
   showed the same biodiversity in each SCB during both seasons. The
   phylogenetic analysis revealed a large number of sequences (93.8\%)
   related to Gram-positive anaerobic bacteria, such as Clostridia, and
   dominated by the Clostridia cluster I (C. disporicum) and the Clostridia
   cluster XI (C. glycolycum). The bioaerosol diversity also contained also
   a low proportion of Bacteroidetes and Lactobacillales-Streptococcales
   sequences. Analyses of the global community and phylotype diversity
   showed that the main source of bioaerosols could come from the pig
   manure slurry.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Duchaine, C (Reprint Author), Hop Laval, Ctr Rech, Inst Rech Cardiol \& Pneumol, Quebec City, PQ, Canada.
   Nehme, Benjamin; Letourneau, Valerie; Veillette, Marc; Duchaine, Caroline, Hop Laval, Ctr Rech, Inst Rech Cardiol \& Pneumol, Quebec City, PQ, Canada.
   Nehme, Benjamin; Letourneau, Valerie; Veillette, Marc; Duchaine, Caroline, Univ Laval, Dept Biochim \& Microbiol, Fac Sci \& Genie, Quebec City, PQ, Canada.
   Forster, Robert J., Lethbridge Res Ctr, Agr \& Agri Food Canada, Bioprod \& bioproc Program, Lethbridge, AB, Canada.}},
DOI = {{10.1111/j.1462-2920.2007.01489.x}},
ISSN = {{1462-2912}},
Keywords-Plus = {{16S RIBOSOMAL-RNA; SEQUENCE-ANALYSIS; RESPIRATORY SYMPTOMS;
   ANTIBIOTIC-RESISTANT; PCR COAMPLIFICATION; CHIMERIC MOLECULES; FEEDING
   OPERATION; FARM-WORKERS; GENES; PIG}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{caroline.duchaine@bcm.ulaval.ca}},
Cited-References = {{ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999.
   AMANN RI, 1995, MICROBIOL REV, V59, P143.
   Bach HJ, 2002, J MICROBIOL METH, V49, P235, DOI 10.1016/S0167-7012(01)00370-0.
   Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104.
   Chang CW, 2001, APPL ENVIRON MICROB, V67, P155, DOI 10.1128/AEM.67.1.155-161.2001.
   Chapin A, 2005, ENVIRON HEALTH PERSP, V113, P137, DOI 10.1289/ehp.7473.
   Charavaryamath C, 2006, J OCCUP MED TOXICOL, V1, DOI 10.1186/1745-6673-1-10.
   CHOUDAT D, 1994, SCAND J WORK ENV HEA, V20, P48, DOI 10.5271/sjweh.1429.
   Cole JR, 2003, NUCLEIC ACIDS RES, V31, P442, DOI 10.1093/nar/gkg039.
   COLLINS MD, 1994, INT J SYST BACTERIOL, V44, P812, DOI 10.1099/00207713-44-4-812.
   CORMIER Y, 1990, AM IND HYG ASSOC J, V51, P304, DOI 10.1202/0002-8894(1990)051<0304:AMCITT>2.0.CO;2.
   Cormier Y, 2000, EUR RESPIR J, V15, P560, DOI 10.1034/j.1399-3003.2000.15.22.x.
   CROOK B, 1991, AM IND HYG ASSOC J, V52, P271, DOI 10.1202/0002-8894(1991)052<0271:ADAMAA>2.0.CO;2.
   DONHAM K, 1989, BRIT J IND MED, V46, P31.
   DONHAM KJ, 1991, AM J VET RES, V52, P1723.
   DONHAM KJ, 1986, AM J IND MED, V10, P294, DOI 10.1002/ajim.4700100318.
   Dosman JA, 2004, EUR RESPIR J, V24, P698, DOI 10.1183/09031936.04.00112102.
   Duchaine C, 2000, AM IND HYG ASSOC J, V61, P56, DOI 10.1202/0002-8894(2000)061<0056:IOBMEF>2.0.CO;2.
   Dutil S, 2007, ENVIRON MICROBIOL, V9, P2836, DOI 10.1111/j.1462-2920.2007.01395.x.
   Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543.
   Gibbs SG, 2004, J OCCUP ENVIRON HYG, V1, P699, DOI 10.1080/15459620490515824.
   Gibbs SG, 2006, ENVIRON HEALTH PERSP, V114, P1032, DOI 10.1289/ehp.8910.
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234.
   Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002.
   HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114.
   Israel-Assayag E, 2002, EUR RESPIR J, V19, P833, DOI 10.1183/09031936.02.02182001.
   Klappenbach JA, 2001, NUCLEIC ACIDS RES, V29, P181, DOI 10.1093/nar/29.1.181.
   Leser TD, 2002, APPL ENVIRON MICROB, V68, P673, DOI 10.1128/AEM.68.2.673-690.2002.
   Leung K, 2001, FEMS MICROBIOL ECOL, V38, P169, DOI 10.1016/S0168-6496(01)00181-7.
   Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102.
   Mackiewicz B, 1998, ANN AGR ENV MED, V5, P169.
   Marchesi JR, 1998, APPL ENVIRON MICROB, V64, P795.
   MUYZER G, 1993, APPL ENVIRON MICROB, V59, P695.
   Predicala BZ, 2002, CURR MICROBIOL, V44, P136, DOI 10.1007/s00284-001-0064-y.
   Robbins C A, 2000, Appl Occup Environ Hyg, V15, P773.
   Schmalenberger A, 2001, APPL ENVIRON MICROB, V67, P3557, DOI 10.1128/AEM.67.8.3557-3563.2001.
   Snell-Castro R, 2005, FEMS MICROBIOL ECOL, V52, P229, DOI 10.1016/j.femsec.2004.11.016.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Wang GCY, 1996, MICROBIOL-UK, V142, P1107, DOI 10.1099/13500872-142-5-1107.
   Wang GCY, 1997, APPL ENVIRON MICROB, V63, P4645.
   Whitford MF, 1998, ANAEROBE, V4, P153, DOI 10.1006/anae.1998.0155.
   Wilson KH, 1996, APPL ENVIRON MICROB, V62, P2273.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{94}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{39}},
Journal-ISO = {{Environ. Microbiol.}},
Doc-Delivery-Number = {{256FE}},
Unique-ID = {{ISI:000252712300011}},
DA = {{2018-08-13}},
}

@article{ ISI:000253941600012,
Author = {Sreejith, P. and Vishad, V. and Pappachan, Joseph M. and Laly, D. C. and
   Jayaprakash, R. and Ranjith, V. T.},
Title = {{Pneumocephalus as a complication of multidrug-resistant Klebsiella
   pneumoniae meningitis}},
Journal = {{EUROPEAN JOURNAL OF INTERNAL MEDICINE}},
Year = {{2008}},
Volume = {{19}},
Number = {{2}},
Pages = {{140-142}},
Month = {{MAR}},
Abstract = {{Pneumocephalus implies air inside the cranial vault, which usually
   results from cranio-facial trauma. Occasionally, meningitis caused by
   gas-forming organisms can result in pneumocephalus. Klebsiella
   pneumoniae meningitis can, on rare occasions, cause pneumocephalus as a
   complication. The drug of choice for K. pneumoniae meningitis is a
   third-generation cephalosporin, and resistance to these drugs is
   unusual. We report a case of multidrug-resistant K. pneumoniae
   meningitis resulting from chronic suppurative otitis media, which was
   later complicated by pneumocephalus. The patient was successfully
   managed with meropenam and amikacin, the only antibiotics to which these
   bacilli showed no resistance. (c) 2007 European Federation of Internal
   Medicine. Published by Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pappachan, JM (Reprint Author), Kottayam Med Coll, Dept Med, S India 686008, India.
   Sreejith, P.; Vishad, V.; Pappachan, Joseph M.; Laly, D. C.; Jayaprakash, R., Kottayam Med Coll, Dept Med, S India 686008, India.
   Ranjith, V. T., Kottayam Med Coll, Dept Otolaryngol, S India 686008, India.}},
DOI = {{10.1016/j.ejim.2007.03.021}},
ISSN = {{0953-6205}},
EISSN = {{1879-0828}},
Keywords = {{chronic otitis media; Klebsiella pneumoniae; pneumocephalus}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{drpappachan@yahoo.co.in}},
ORCID-Numbers = {{M Pappachan, Joseph/0000-0003-0886-5255}},
Cited-References = {{Gorogh T, 2005, CLIN CHEM, V51, P1704, DOI 10.1373/clinchem.2005.054916.
   Jones Mark E, 2004, Ann Clin Microbiol Antimicrob, V3, P3, DOI 10.1186/1476-0711-3-3.
   Leskinen K, 2005, CLIN OTOLARYNGOL, V30, P511, DOI 10.1111/j.1749-4486.2005.01085.x.
   Markham J W, 1967, Acta Neurochir (Wien), V16, P1.
   Parmar M S, 2004, J Postgrad Med, V50, P272.
   SKILES MS, 1978, SURG GYNECOL OBSTET, V147, P65.}},
Number-of-Cited-References = {{6}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Intern. Med.}},
Doc-Delivery-Number = {{273OR}},
Unique-ID = {{ISI:000253941600012}},
DA = {{2018-08-13}},
}

@article{ ISI:000254164300004,
Author = {Murray, Clinton K.},
Title = {{Epidemiology of infections associated with combat-related injuries in
   Iraq and Afghanistan}},
Journal = {{JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE}},
Year = {{2008}},
Volume = {{64}},
Number = {{3, S}},
Pages = {{S232-S238}},
Month = {{MAR}},
Abstract = {{Enhanced medical training of front line medical personnel, personal
   protective equipment, and the presence of far forward surgical assets
   have improved the survival of casualties in the current wars in Iraq and
   Afghanistan. As such, casualties are at higher risk of infectious
   complications of their injuries including sepsis, which was a noted
   killer of casualties in previous wars. During the current conflicts,
   military personnel who develop combat-related injuries are at
   substantial risk of developing infections with multidrug resistant
   bacteria. Herein, we describe the bacteriology of combat-related
   injuries in Operation Iraqi Freedom and Operation Enduring Freedom that
   develop infections with particular attention to injuries of the
   extremities, central nervous system, abdomen and thorax, head and neck,
   and burns. In addition, the likely sources of combat-related injuries
   with multidrug resistant bacteria infections are explored.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Murray, CK (Reprint Author), Brooke Army Med Ctr, Infect Dis Serv, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
   Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA.}},
DOI = {{10.1097/TA.0b013e318163c3f5}},
ISSN = {{0022-5282}},
Keywords = {{Iraq; Afghanistan; infection; combat}},
Keywords-Plus = {{OPERATION-ENDURING-FREEDOM; EXTREMITY VASCULAR INJURY; TRAUMATIC
   BRAIN-INJURY; US ARMY SOLDIERS; BALAD AIR BASE; WAR WOUNDS;
   ACINETOBACTER-BAUMANNII; UNITED-STATES; COMPLETE MANAGEMENT; MILITARY
   PERSONNEL}},
Research-Areas = {{General \& Internal Medicine; Surgery}},
Web-of-Science-Categories  = {{Critical Care Medicine; Surgery}},
Author-Email = {{chnton.murray@amedd.army.mil}},
Cited-References = {{Al-Assaf DA, 2007, J CRANIOFAC SURG, V18, P606, DOI 10.1097/01.scs.0000248661.91522.c5.
   Albrecht MA, 2006, J AM COLL SURGEONS, V203, P546, DOI 10.1016/j.jamcollsurg.2006.06.013.
   ARNOLD K, 1978, MIL MED, V143, P161.
   Aronson NE, 2006, CLIN INFECT DIS, V43, P1045, DOI 10.1086/507539.
   Beitler AL, 2006, MIL MED, V171, P189, DOI 10.7205/MILMED.171.3.189.
   Bird SM, 2007, INT J EPIDEMIOL, V36, P841, DOI 10.1093/ije/dym103.
   Centers for Disease C and Prevention, 2004, MMWR-MORBID MORTAL W, V53, P1063.
   Chambers LW, 2006, J TRAUMA, V60, P1155, DOI 10.1097/01.ta.000220340.91356.7e.
   Chambers LW, 2006, J TRAUMA, V60, P1161.
   Cho JM, 2005, MIL MED, V170, P268, DOI 10.7205/MILMED.170.4.268.
   Davis KA, 2005, EMERG INFECT DIS, V11, P1218, DOI 10.3201/1108.050103.
   Ecker JA, 2006, J CLIN MICROBIOL, V44, P2921, DOI 10.1128/JCM.00619-06.
   Ellis MW, 2004, CLIN INFECT DIS, V39, P971, DOI 10.1086/423965.
   Fitzpatrick S., 2004, J CARIBBEAN ARCHAEOL, V5, P1.
   Fleming A, 1915, LANCET, V2, P638.
   Gagne PJ, 2007, J VASC SURG, V45, P1204.
   Gao Z, 2007, P NATL ACAD SCI USA, V104, P2927, DOI 10.1073/pnas.0607077104.
   Garzoni C, 2005, EMERG INFECT DIS, V11, P1591, DOI 10.3201/eid1110.050715.
   Gleeson T, 2005, J ANTIMICROB CHEMOTH, V56, P602, DOI 10.1093/jac/dki274.
   Griffith ME, 2007, INFECT CONT HOSP EP, V28, P720, DOI 10.1086/518966.
   Griffith ME, 2006, INFECT CONT HOSP EP, V27, P659, DOI 10.1086/506596.
   HARDAWAY RM, 1978, J TRAUMA, V18, P635, DOI 10.1097/00005373-197809000-00004.
   Hawley JS, 2007, ANTIMICROB AGENTS CH, V51, P376, DOI 10.1128/AAC.00858-06.
   HEGGERS JP, 1969, MIL MED, V134, P602.
   Hujer KM, 2006, ANTIMICROB AGENTS CH, V50, P4114, DOI 10.1128/AAC.00778-06.
   Ingari John V, 2007, Tech Hand Up Extrem Surg, V11, P130, DOI 10.1097/bth.0b013e3180312738.
   JACOB E, 1989, MIL MED, V154, P311.
   Jerassy Z, 2006, J HOSP INFECT, V62, P230, DOI 10.1016/j.jhin.2005.07.007.
   Johnson Brent A, 2005, J Foot Ankle Surg, V44, P177, DOI 10.1053/j.jfas.2005.02.007.
   Johnson EN, 2007, CLIN INFECT DIS, V45, P409, DOI 10.1086/520029.
   Kanafani ZA, 2003, INFECT CONT HOSP EP, V24, P864, DOI 10.1086/502151.
   Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008.
   KLEIN RS, 1975, ANN SURG, V182, P15, DOI 10.1097/00000658-197507000-00003.
   Kortepeter MG, 2005, CLIN INFECT DIS, V41, P1604.
   Kortepeter MG, 2005, CLIN INFECT DIS, V41, P1675.
   KOVARIC JJ, 1968, MIL MED, V133, P622.
   Leininger BE, 2006, J TRAUMA, V61, P1207, DOI 10.1097/01.ta.0000241150.15342.da.
   Lin DL, 2004, J ORTHOP TRAUMA, V18, P300.
   Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021.
   Mabry RL, 2000, J TRAUMA, V49, P528.
   Murray CK, 2006, CLIN INFECT DIS, V43, P383, DOI 10.1086/505601.
   Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516.
   Murray CK, 2005, MIL MED, V170, P501, DOI 10.7205/MILMED.170.6.501.
   Murray CK, 2006, MIL MED, V171, P821.
   Murray CK, 2006, MIL MED, V171, P826, DOI 10.7205/MILMED.171.9.826.
   Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102.
   Oncul O, 2002, J HOSP INFECT, V51, P47, DOI 10.1053/jhin.2002.1205.
   Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb.
   Peck MA, 2007, J VASC SURG, V45, P1197, DOI 10.1016/j.jvs.2007.02.003.
   Peoples GE, 2005, MIL MED, V170, P462, DOI 10.7205/MILMED.170.6.462.
   Petersen K, 2007, ANN SURG, V245, P803, DOI 10.1097/01.sla.0000251707.32332.c1.
   PETTIT RT, 1919, JAMA-J AM MED ASSOC, P73.
   RESSNER RA, IN PRESS J AM COLL S.
   Rotimi VO, 1998, DIAGN MICR INFEC DIS, V30, P53, DOI 10.1016/S0732-8893(97)00180-6.
   Scott P, 2007, CLIN INFECT DIS, V44, P1577, DOI 10.1086/518170.
   Steele SR, 2007, DIS COLON RECTUM, V50, P870, DOI 10.1007/s10350-007-0235-4.
   Stoddard JL, 1918, J AMER MED ASSOC, V71, P1400, DOI 10.1001/jama.1918.26020430022009g.
   THORESBY FP, 1967, BRIT J SURG, V54, P359, DOI 10.1002/bjs.1800540509.
   Tien HC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-95.
   TONG MJ, 1972, J AMER MED ASSOC, V219, P1044, DOI 10.1001/jama.219.8.1044.
   Turton JF, 2006, J CLIN MICROBIOL, V44, P2630, DOI 10.1128/JCM.00547-06.
   Wolf SE, 2006, ANN SURG, V243, P792.
   Wolf SE, 2006, ANN SURG, V243, P786, DOI 10.1097/01.sla.0000219645.88867.b7.
   Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246.}},
Number-of-Cited-References = {{64}},
Times-Cited = {{57}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Trauma-Injury Infect. Crit. Care}},
Doc-Delivery-Number = {{276SY}},
Unique-ID = {{ISI:000254164300004}},
DA = {{2018-08-13}},
}

@article{ ISI:000256444000021,
Author = {Arif Cheema, Mohammad and Taboada, Pablo and Barbosa, Silvia and Castro,
   Emilio and Siddiq, Mohammad and Mosquera, Victor},
Title = {{A comparative study of the thermodynamic properties at the air-water
   interface and in the bulk of structurally related phenothiazine drugs
   aqueous solutions}},
Journal = {{JOURNAL OF CHEMICAL THERMODYNAMICS}},
Year = {{2008}},
Volume = {{40}},
Number = {{2}},
Pages = {{298-308}},
Month = {{FEB}},
Abstract = {{Surface tension, conductivity, density, and ultrasound velocity
   measurements have been performed in order to determine in a systhematic
   manner some of the aggregation properties of the phenothiazine drugs
   promazine and triflupromazine hydrochlorides. Both drugs are
   structurally related, differing in an extra CF(3) group in the
   triflupromazine molecular structure. Surface tension data showed that
   the presence of an extra CF(3) in the molecular structure of
   triflupromazine involves a higher hydrophobicity of this drug and a
   restriction in the number of conformations molecules can adopt due to
   the presence of this bulkier atomic group. This involves a larger
   surface area in order to accommodate triflupromazine molecules at the
   interface. From conductivity measurements at different temperatures, the
   thermodynamic quantities of the micellization process of these drugs
   indicate that the aggregation is a spontaneous process, mainly
   enthalpic, where the London-dispersion forces play an active role. Using
   density and ultrasound velocity measurements, apparent molar volume and
   adiabatic compressibility of aqueous solutions of the amphiphilic
   cationic drugs have been determined. Positive deviations from the
   Debye-Huckel limiting law of the apparent molar volume were obtained
   from both drugs over the whole temperature range, which provides
   evidence of possible pre-association at concentrations below the
   critical concentration. Apparent molar adiabatic compressibility of the
   aggregates formed by these drugs was typical of those corresponding for
   an aggregate formed by a stacking process. (C) 2007 Elsevier Ltd. All
   rights reserved.}},
Publisher = {{ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Taboada, P (Reprint Author), Univ Santiago de Compostela, Fac Fis, Lab Fis Coloides \& Polimeros, Grp Sistemas Complejos,Dept Fis Mat Condensada, E-15782 Santiago De Compostela, Spain.
   Arif Cheema, Mohammad; Taboada, Pablo; Barbosa, Silvia; Castro, Emilio; Mosquera, Victor, Univ Santiago de Compostela, Fac Fis, Lab Fis Coloides \& Polimeros, Grp Sistemas Complejos,Dept Fis Mat Condensada, E-15782 Santiago De Compostela, Spain.
   Siddiq, Mohammad, Quaid I Azam Univ, Dept Chem, Islamabad 45320, Pakistan.}},
DOI = {{10.1016/j.jct.2007.06.008}},
ISSN = {{0021-9614}},
Keywords = {{phenothiazine; aggregation; thermodynamics; hydration}},
Keywords-Plus = {{AMPHIPHILIC ANTIDEPRESSANT DRUGS; MICELLAR PROPERTIES;
   MULTIDRUG-RESISTANCE; SURFACE-PROPERTIES; SELF-ASSOCIATION; MOLAL
   VOLUMES; ELECTRONIC ABSORPTION; HEAT-CAPACITIES; COMPRESSIBILITIES;
   SODIUM}},
Research-Areas = {{Thermodynamics; Chemistry}},
Web-of-Science-Categories  = {{Thermodynamics; Chemistry, Physical}},
Author-Email = {{fmpablo@usc.es}},
ResearcherID-Numbers = {{Taboada, Pablo/C-3000-2015
   Mosquera, Victor/F-3070-2016
   Siddiq, Mohammad/I-7280-2015
   Barbosa, Silvia/F-2336-2016}},
ORCID-Numbers = {{Taboada, Pablo/0000-0002-2903-7857
   Mosquera, Victor/0000-0002-2863-5652
   Barbosa, Silvia/0000-0003-1831-1686}},
Cited-References = {{Amaral L, 2001, INT J ANTIMICROB AG, V18, P411, DOI 10.1016/S0924-8579(01)00432-0.
   ATHERTON AD, 1985, J COLLOID INTERF SCI, V106, P479, DOI 10.1016/S0021-9797(85)80023-0.
   ATTWOOD D, 1995, J COLLOID INTERF SCI, V175, P201, DOI 10.1006/jcis.1995.1446.
   ATTWOOD D, 1995, ADV COLLOID INTERFAC, V55, P271, DOI 10.1016/0001-8686(94)00228-5.
   ATTWOOD D, 1994, COLLOID POLYM SCI, V272, P108, DOI 10.1007/BF00653315.
   ATTWOOD D, 1980, J CHEM SOC FARAD T 1, V76, P2187, DOI 10.1039/f19807602187.
   ATTWOOD D, 1994, MAGN RESON CHEM, V32, P468, DOI 10.1002/mrc.1260320807.
   ATTWOOD D, 1987, J PHYS CHEM-US, V91, P4203, DOI 10.1021/j100299a050.
   ATTWOOD D, 1990, J PHYS CHEM-US, V94, P6034, DOI 10.1021/j100378a075.
   ATTWOOD D, 1990, COLLOID SURFACE, V48, P35, DOI 10.1016/0166-6622(90)80216-Q.
   ATTWOOD D, 1993, J COLLOID INTERF SCI, V161, P19, DOI 10.1006/jcis.1993.1434.
   ATTWOOD D, 1974, J PHARM SCI, V63, P988, DOI 10.1002/jps.2600630649.
   ATTWOOD D, 1984, SURFACTANT SYSTEMS.
   Blanco E, 2005, J COLLOID INTERF SCI, V288, P247, DOI 10.1016/j.jcis.2005.02.085.
   BRADLEY DJ, 1979, J PHYS CHEM-US, V83, P1599, DOI 10.1021/j100475a009.
   BRUN TS, 1978, J COLLOID INTERF SCI, V63, P89, DOI 10.1016/0021-9797(78)90038-3.
   Caetano W, 2003, J COLLOID INTERF SCI, V260, P414, DOI 10.1016/S0021-9797(02)00248-5.
   Caetano W, 2000, J COLLOID INTERF SCI, V225, P69, DOI 10.1006/jcis.2000.6720.
   CHAMBERS JF, 1956, J PHYS CHEM-US, V60, P985, DOI 10.1021/j150541a040.
   Cheema MA, 2006, CHEM PHYS, V328, P243, DOI 10.1016/j.chemphys.2006.07.003.
   De Lisi R, 2001, LANGMUIR, V17, P8078, DOI 10.1021/la0111607.
   Dea P. K., 1986, MODERN BIOELECTROCHE, P481.
   del Castillo JL, 2000, COLLOID SURFACE A, V166, P161, DOI 10.1016/S0927-7757(99)00515-4.
   Desnoyers J.E., 1979, PERRONSOLUTION CHEM, V1.
   Desnoyers J. E., 1987, SURFACTANT SOLUTIONS.
   DJAVANBAKHT A, 1977, J PHYS CHEM-US, V81, P2620, DOI 10.1021/j100541a009.
   Eap CB, 1996, CLIN PHARMACOL THER, V59, P322, DOI 10.1016/S0009-9236(96)80010-5.
   FEINBERG AP, 1975, P NATL ACAD SCI USA, V72, P1899, DOI 10.1073/pnas.72.5.1899.
   FLORENCE AT, 1972, J PHYS CHEM B, V75, P3554.
   FORD JM, 1990, PHARMACOL REV, V42, P155.
   FOWLER GJS, 1990, PHOTOCHEM PHOTOBIOL, V52, P489, DOI 10.1111/j.1751-1097.1990.tb01790.x.
   Fukada K., 2002, J OLEO SCI, V51, P103.
   Funasaki N, 2000, LANGMUIR, V16, P5584, DOI 10.1021/la991639n.
   GARNSEY R, 1969, J CHEM PHYS, V50, P5222, DOI 10.1063/1.1671038.
   Gianni P, 1996, J SOLUTION CHEM, V25, P1, DOI 10.1007/BF00972756.
   Gutierrez-Pichel M, 2003, MOL PHYS, V101, P3455, DOI 10.1080/0026897032000174254.
   Gutierrez-Pichel M, 2003, COLLOID POLYM SCI, V281, P575, DOI 10.1007/s00396-002-0817-6.
   Hamed H.S., 1957, PHYSICAL CHEMISTRY E.
   Hoiland H., 1986, THERMODYNAMIC DATA B.
   Kissa E, 1994, FLUORINATED SURFACTA, pvii + 469.
   Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798.
   LALIBERTE LH, 1970, J PHYS CHEM-US, V74, P4116.
   Lide D R, 1995, HDB CHEM PHYS.
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0.
   MATIJEVIC E, 1958, T FARADAY SOC, V54, P1382, DOI 10.1039/tf9585401382.
   Mayer M, 2004, J AM CHEM SOC, V126, P4453, DOI 10.1021/ja0398870.
   Mazumder R, 2001, INT J ANTIMICROB AG, V18, P403, DOI 10.1016/S0924-8579(01)00324-7.
   Moulik SP, 1996, J PHYS CHEM-US, V100, P701, DOI 10.1021/jp9506494.
   MUKERJEE P, 1971, NATL STAND DATA SER, V36.
   MUSBALLY GM, 1974, J COLLOID INTERF SCI, V48, P494, DOI 10.1016/0021-9797(74)90194-5.
   NUSSELDER JJH, 1992, J COLLOID INTERF SCI, V148, P353, DOI 10.1016/0021-9797(92)90174-K.
   PARKANYI C, 1993, SPECTROCHIM ACTA A, V49, P1715, DOI 10.1016/0584-8539(93)80239-7.
   Perez-Rodriguez M, 1998, LANGMUIR, V14, P4422, DOI 10.1021/la980296a.
   Perrine D. M., 1996, CHEM MIND ALTERING D.
   PHILLIPS JN, 1955, T FARADAY SOC, V51, P561, DOI 10.1039/tf9555100561.
   PITZER KS, 1973, J PHYS CHEM-US, V77, P268, DOI 10.1021/j100621a026.
   RAMU A, 1992, CANCER CHEMOTH PHARM, V30, P165, DOI 10.1007/BF00686306.
   REDLICH O, 1964, CHEM REV, V64, P221, DOI 10.1021/cr60229a001.
   Ruso J.M., 2004, COLLOID SURFACE B, V11, P165.
   Shedlovsky T., 1932, Journal of the American Chemical Society, V54, P1411, DOI 10.1021/ja01343a020.
   Taboada P, 2003, PHYS CHEM CHEM PHYS, V5, P703, DOI 10.1039/b209720f.
   Taboada P, 2002, COLLOID SURFACE A, V197, P95, DOI 10.1016/S0927-7757(01)00867-6.
   Taboada P, 2001, COLLOID SURFACE A, V179, P125, DOI 10.1016/S0927-7757(00)00730-5.
   Taboada P, 2001, LANGMUIR, V17, P173, DOI 10.1021/la0007325.
   Tanford C., 1980, HYDROPHOBIC EFFECT F.
   Tsakovska IM, 2003, BIOORGAN MED CHEM, V11, P2889, DOI 10.1016/S0968-0896(03)00222-0.
   WANBAHDI W, 1992, J PHYS CHEM-US, V96, P918, DOI 10.1021/j100181a071.
   WOOLLEY EM, 1984, J PHYS CHEM-US, V88, P2155, DOI 10.1021/j150654a043.
   ZANA R, 1987, SURFACTANT SOLUTIONS, V2.
   ZIELINSKI R, 1988, J CHEM SOC FARAD T 1, V84, P151, DOI 10.1039/f19888400151.
   ZOGRAFI G, 1966, BIOCHEM PHARMACOL, V15, P591, DOI 10.1016/0006-2952(66)90026-8.}},
Number-of-Cited-References = {{71}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{J. Chem. Thermodyn.}},
Doc-Delivery-Number = {{309ER}},
Unique-ID = {{ISI:000256444000021}},
DA = {{2018-08-13}},
}

@article{ ISI:000253386200033,
Author = {Landrum, Michael L. and Murray, Clinton K.},
Title = {{Ventilator associated pneumonia in a military deployed selling: The
   impact of an aggressive infection control program}},
Journal = {{JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE}},
Year = {{2008}},
Volume = {{64}},
Number = {{2, S}},
Pages = {{S123-S127}},
Month = {{FEB}},
Abstract = {{Background: Since the onset of military operations in Iraq and
   Afghanistan, there has been a marked increased in multidrug resistant
   bacterial infections among combat casualties. We describe the rates of
   ventilator-associated pneumonia (VAP) before and after the
   implementation of aggressive infection control measures at the Air Force
   Theater Hospital in Iraq.
   Methods: All patients admitted to the intensive care unit (ICU) were
   followed prospectively for the development of VAP. Baseline VAP rate was
   determined in May 2006, and preventive measures were implemented by June
   2006. Interventions included hand hygiene, contact barrier precautions,
   patient and staff cohorting, chlorhexidine oral care, and reducing the
   duration and spectrum of surgical antimicrobial prophylaxis.
   Additionally, each ICU tent was closed periodically for cleaning and
   disinfection. Daily inspections provided ongoing staff education and
   enforcement of procedures. Monthly VAP rates were calculated and
   compared for trend.
   Results: There were 475 ICU admissions from May 2006 through August 2006
   for a mean admission rate of 119 per month. The rate of VAP per 1,000
   ventilator days was 60.6 in May, 31.6 in June, 21.3 in July, and 11.1 in
   August (p = 0.029). Targeted surveillance in November and December
   revealed VAP rates of 11.6 and 9.7, respectively. Notably, the most
   common bacteria, Acinetobacter, had improved antimicrobial
   susceptibilities after the interventions.
   Conclusions: Implementation of aggressive infection control procedures
   in a combat military hospital was associated with a significant decrease
   in the rate of VAP. Despite the numerous challenges in theater,
   infection control can have measurable and sustainable impact in a combat
   theater hospital.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Murray, CK (Reprint Author), Brooke Army Med Ctr, San Antonio Mil Med Ctr, Infect Dis Serv, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
   Murray, Clinton K., Brooke Army Med Ctr, San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA.
   Landrum, Michael L.; Murray, Clinton K., San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX USA.
   Landrum, Michael L., Infect Dis Clin Res Program, Bethesda, MD USA.}},
DOI = {{10.1097/TA.0b013e31816086dc}},
ISSN = {{0022-5282}},
Keywords = {{ventilator; pneumonia; infection control; Iraq}},
Keywords-Plus = {{RESISTANT ACINETOBACTER-BAUMANNII; US ARMY SOLDIERS; NOSOCOMIAL
   INFECTIONS; TRAUMA; IRAQ; ANTIBIOTICS; BACTERIA; OUTBREAK}},
Research-Areas = {{General \& Internal Medicine; Surgery}},
Web-of-Science-Categories  = {{Critical Care Medicine; Surgery}},
Author-Email = {{Clinton.Murray@amedd.army.mil}},
Cited-References = {{{[}Anonymous], 2005, AM J RESP CRIT CARE, V171, P388.
   ARNOLD K, 1978, MIL MED, V143, P161.
   Aronson NE, 2006, CLIN INFECT DIS, V43, P1045, DOI 10.1086/507539.
   BAMBERGER DM, 1992, ARCH INTERN MED, V152, P1132.
   Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001.
   Griffith ME, 2007, INFECT CONT HOSP EP, V28, P720, DOI 10.1086/518966.
   Griffith ME, 2006, INFECT CONT HOSP EP, V27, P659, DOI 10.1086/506596.
   Gruson D, 2000, AM J RESP CRIT CARE, V162, P837, DOI 10.1164/ajrccm.162.3.9905050.
   Hoth JJ, 2003, J TRAUMA, V55, P249, DOI 10.1097/01.T.A.0000083334.93868.65.
   Jawad A, 1996, J CLIN MICROBIOL, V34, P2881.
   Luchette FA, 2000, J TRAUMA, V48, P508, DOI 10.1097/00005373-200003000-00024.
   LUCHETTE FA, 1998, E PRACTICE MANAGEMEN.
   Maragakis LL, 2004, JAMA-J AM MED ASSOC, V292, P3006, DOI 10.1001/jama.292.24.3006.
   Murray CK, 2006, MIL MED, V171, P821.
   Navon-Venezia S, 2005, CURR OPIN INFECT DIS, V18, P306, DOI 10.1097/01.qco.0000171920.44809.f0.
   Scott P, 2007, CLIN INFECT DIS, V44, P1577, DOI 10.1086/518170.
   SIEGEL JD, 2006, HEALTHCARE INFECTION.
   Urban C, 2003, CLIN INFECT DIS, V36, P1268, DOI 10.1086/374847.
   Velmahos GC, 2002, ARCH SURG-CHICAGO, V137, P537, DOI 10.1001/archsurg.137.5.537.
   White AC, 1997, CLIN INFECT DIS, V25, P230.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Trauma-Injury Infect. Crit. Care}},
Doc-Delivery-Number = {{265UJ}},
Unique-ID = {{ISI:000253386200033}},
OA = {{green\_published}},
DA = {{2018-08-13}},
}

@article{ ISI:000253844200009,
Author = {Lelong-Rebel, Isabelle and Brisson, Christine and Fabre, Michel and
   Bergerat, Jean-Pierre and Rebel, Gerard},
Title = {{Effect of pO(2) on antitumor drug cytotoxicity on MDR and non-MDR
   variants selected from the LoVo metastatic colon carcinoma cell line}},
Journal = {{ANTICANCER RESEARCH}},
Year = {{2008}},
Volume = {{28}},
Number = {{1A}},
Pages = {{55-68}},
Month = {{JAN-FEB}},
Abstract = {{Two chemosensitive cell lines, LoVo-fusoid (LoVof) and LoVo-small cells
   (LoVo-sc) were derived from the original LoVo cell line. These two
   variants and the multidrug-resistant (MDR) cell line LoVo-Dox were
   screened for various properties. In non-permeabilized cells, only
   LoVo-sc showed mucin-2 staining whereas labelling was positive in all
   permeabilized cell lines. As shown by electron microscopy screening and
   by relative resistance to trypsin detachment, only LoVo-sc cells showed
   strong mucus secretion. All three cell lines displayed strong staining
   for P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP)
   and lung-resistance-related protein (LRP) in different locations
   according to the drug resistance state. The three cell lines showed
   intracellular labelling of LRP and MRP. The sensitive cells showed P-gp
   in a large perinuclear ring and in the cytoplasm, but little (LoVo-sc
   cells) or no staining (LoVo-f cells) was shown at the plasma membrane
   level. For the LovoDox cells, P-gp was located in the plasma membrane,
   in cellular anchorages and in the cytoplasm as well. Cell resistance
   against antineoplastic agents often results from mobilization of various
   factors, the modulation of which is linked to the culture conditions. As
   most of the protocols utilize cells growing in (air+5-10\% CO2)
   atmosphere e.g. 20\% O-2, balance of the respective participants in the
   MDR multi-modal mechanism may not be representative of the in vivo
   situation and may lead to erratic pharmacological response. Indeed,
   cells within solid tumours were exposed to low pO(2), most of them being
   under hypoxic condition (0.1-5\% O-2). In the absence of anticancer
   drugs, all LoVo cell lines grew notably faster at 20\% O-2 than at 5\%
   O-2. Moreover, respective sensitivities of both non-MDR variants to
   doxorubicin were altered according the pO(2). Whatever the pO(2) was,
   virtually none of the antioxidants tested affected the cytotoxic
   activity of doxorubicin for the three cell lines. By contrast, trolox
   showed a strong inhibitory effect on doxorubicin activity. These results
   underline the importance of evaluating the role of hypoxia on the
   cytotoxic effect of chemotherapeutic agents used either as single drugs
   or in combination therapy.}},
Publisher = {{INT INST ANTICANCER RESEARCH}},
Address = {{EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lelong-Rebel, I (Reprint Author), HUS IRCAD, Lab Cancerol Expt Radiobiol, EA ULP 3430, 1 Pl Hop,BP426, F-67091 Strasbourg, France.
   Lelong-Rebel, Isabelle; Bergerat, Jean-Pierre; Rebel, Gerard, HUS IRCAD, Lab Cancerol Expt Radiobiol, EA ULP 3430, F-67091 Strasbourg, France.
   Brisson, Christine, Fac Med Laennec, INSERM, U433, F-69372 Lyon 08, France.
   Fabre, Michel, Univ Strasbourg, Fac Med, Hist Inst, F-67000 Strasbourg, France.}},
ISSN = {{0250-7005}},
EISSN = {{1791-7530}},
Keywords = {{colon carcinoma; cell lines; multidrug resistance; P-glycoprotein;
   pO(2); antioxidants}},
Keywords-Plus = {{LOW-OXYGEN-TENSION; INTRACELLULAR P-GLYCOPROTEIN; MUCIN GENE-EXPRESSION;
   IN-VITRO; MULTIDRUG-RESISTANCE; TAURINE UPTAKE; LIPID-PEROXIDATION;
   CULTURE-CONDITIONS; CANCER METASTASIS; PARTIAL PRESSURES}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{Isabelle.Lelong@ircad.u-strasbg.fr}},
Cited-References = {{Abbaszadegan MR, 1996, CANCER RES, V56, P5435.
   Adam MF, 1999, INT J RADIAT ONCOL, V45, P171, DOI 10.1016/S0360-3016(99)00157-1.
   BALIN AK, 1984, J EXP MED, V160, P152, DOI 10.1084/jem.160.1.152.
   BENCHEKROUN MN, 1993, FEBS LETT, V326, P301.
   Bendayan R, 2006, J HISTOCHEM CYTOCHEM, V54, P1159, DOI 10.1369/jhc.5A6870.2006.
   BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063.
   BROXMEYER HE, 1990, BLOOD, V76, P323.
   BURTON GW, 1989, ANN NY ACAD SCI, V570, P7.
   CAPOLONGO L, 1993, BRIT J CANCER, V68, P916, DOI 10.1038/bjc.1993.454.
   CERVANTES A, 1988, CANCER LETT, V41, P169, DOI 10.1016/0304-3835(88)90113-9.
   D'Ippolito G, 2006, BONE, V39, P513, DOI 10.1016/j.bone.2006.02.061.
   DEGRAFF W, 1994, BIOCHEM PHARMACOL, V48, P1427, DOI 10.1016/0006-2952(94)90567-3.
   Deret S, 2004, AMINO ACIDS, V26, P183, DOI 10.1007/s00726-003-0035-7.
   DEVINE PL, 1992, TUMOR BIOL, V13, P268, DOI 10.1159/000217775.
   DOLFINI E, 1993, ANTICANCER RES, V13, P1123.
   Dominguez-Rodriguez JR, 2001, ANTICANCER RES, V21, P1869.
   DREWINKO B, 1976, CANCER RES, V36, P467.
   DUENSING TD, 1994, ANTICANCER RES, V14, P13.
   Ferrao P, 2001, LEUKEMIA RES, V25, P395, DOI 10.1016/S0145-2126(00)00156-9.
   Ferrao P, 2001, LEUKEMIA RES, V25, P827, DOI 10.1016/S0145-2126(01)00120-5.
   GRANDI M, 1986, BRIT J CANCER, V54, P515, DOI 10.1038/bjc.1986.206.
   Gulledge CJ, 1996, ANTICANCER RES, V16, P741.
   Hageman GJ, 2001, MUTAT RES-FUND MOL M, V475, P45, DOI 10.1016/S0027-5107(01)00078-1.
   HO SB, 1996, J HISTOCHEM CYTOCHEM, V44, P1161.
   Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266.
   HOLLENBERG M, 1971, CIRC RES, V28, P148.
   HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101.
   KAPLAN B, 1993, GEN PHARMACOL, V24, P1411, DOI 10.1016/0306-3623(93)90427-Y.
   KATAHIRA J, 1987, INT J CELL CLONING, V5, P412, DOI 10.1002/stem.5530050506.
   KEIZER HG, 1990, PHARMACOL THERAPEUT, V47, P219, DOI 10.1016/0163-7258(90)90088-J.
   Kelly G S, 1998, Altern Med Rev, V3, P114.
   Kilburn DG, 2000, BIOTECHNOL BIOENG, V67, P657.
   Kitamura H, 1996, EUR J CANCER, V32A, P1788, DOI 10.1016/0959-8049(96)00168-2.
   KNORR HLJ, 1993, OPHTHALMIC RES, V25, P226, DOI 10.1159/000267318.
   KUAN SF, 1987, CANCER RES, V47, P5715.
   KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0.
   Lawrence DA, 1996, FUND APPL TOXICOL, V29, P287, DOI 10.1006/faat.1996.0033.
   LELONG IH, 1991, MOL PHARMACOL, V40, P490.
   Lelong IH, 1998, J PHARMACOL TOXICOL, V39, P203, DOI 10.1016/S1056-8719(98)00019-7.
   LELONGREBEL IH, UNPUB MYCOBACTERIUM.
   LIN TP, 1991, IN VITRO CELL DEV B, V27, P191.
   Lojda Z, 1996, ACTA HISTOCHEM, V98, P285, DOI 10.1016/S0065-1281(96)80021-3.
   Malisza KL, 1996, FREE RADICAL RES, V24, P9, DOI 10.3109/10715769609087995.
   MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176.
   Meschini S, 2000, INT J CANCER, V87, P615, DOI 10.1002/1097-0215(20000901)87:5<615::AID-IJC1>3.3.CO;2-W.
   MIURA T, 1993, BIOCHEM MOL BIOL INT, V31, P125.
   Muller I, 1998, INT J MOL MED, V1, P491.
   OGASAWARA M, 1994, ADV EXP MED BIOL, V359, P71.
   OGATA S, 1992, CANCER RES, V52, P5971.
   OKAMOTO K, 1985, J NUTR SCI VITAMINOL, V31, P129.
   OLLINGER K, 1994, BIOCHEM PHARMACOL, V48, P1707, DOI 10.1016/0006-2952(94)90455-3.
   PETTERSEN EO, 1983, BRIT J CANCER, V48, P809, DOI 10.1038/bjc.1983.271.
   PROBST H, 1988, CANCER RES, V48, P2053.
   QUARONI A, 1986, JNCI-J NATL CANCER I, V76, P571, DOI 10.1093/jnci/76.4.571.
   REMY L, 1992, INT J CANCER, V51, P204, DOI 10.1002/ijc.2910510207.
   RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429.
   ROSAZZA JPN, 1986, ALKALOIDS, V27, P323.
   RUECKERT RR, 1960, CANCER RES, V20, P944.
   SCHWARTZ B, 1992, INT J CANCER, V52, P60, DOI 10.1002/ijc.2910520113.
   Shapiro AB, 1998, INT J CANCER, V76, P857, DOI 10.1002/(SICI)1097-0215(19980610)76:6<857::AID-IJC15>3.0.CO;2-\#.
   SHRIEVE DC, 1983, CANCER RES, V43, P3521.
   SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C.
   SLOVAK ML, 1988, CANCER RES, V48, P2793.
   SMITH E, 1980, BRIT J CANCER, V42, P568, DOI 10.1038/bjc.1980.281.
   Spahn-Langguth H, 1998, INT J CLIN PHARM TH, V36, P16.
   Steiber Alison, 2004, Molecular Aspects of Medicine, V25, P455, DOI 10.1016/j.mam.2004.06.006.
   SUTHERLAND R, 1986, INT J RADIAT ONCOL, V12, P611, DOI 10.1016/0360-3016(86)90070-2.
   Suzuki H, 2000, EUR J PHARM SCI, V12, P3, DOI 10.1016/S0928-0987(00)00178-0.
   TAKAHASHI S, 1985, J CELL PHYSIOL, V125, P107, DOI 10.1002/jcp.1041250114.
   TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L.
   Tian JQ, 1999, AM J PHYSIOL-GASTR L, V276, pG1094, DOI 10.1152/ajpgi.1999.276.5.G1094.
   VAUPEL P, 1990, ADV EXP MED BIOL, V277, P895.
   VILE GF, 1988, FEBS LETT, V238, P353, DOI 10.1016/0014-5793(88)80511-8.
   Walter E, 1996, J PHARM SCI, V85, P1070, DOI 10.1021/js960110x.
   Wersinger C, 2003, ADV EXP MED BIOL, V526, P411.
   Wersinger C, 2001, AMINO ACIDS, V21, P91, DOI 10.1007/s007260170018.
   Wersinger C, 2000, AMINO ACIDS, V19, P667, DOI 10.1007/s007260070015.
   WINTERBOURN CC, 1981, FEBS LETT, V136, P89, DOI 10.1016/0014-5793(81)81220-3.
   Wozniak Grazyna, 2002, Acta Pol Pharm, V59, P31.
   YANG LY, 1990, CANCER RES, V50, P3218.
   YANG LY, 1993, INT J CANCER, V53, P478, DOI 10.1002/ijc.2910530321.
   Zhou SY, 2001, TOXICOL LETT, V121, P151, DOI 10.1016/S0378-4274(01)00329-0.}},
Number-of-Cited-References = {{82}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Anticancer Res.}},
Doc-Delivery-Number = {{272FB}},
Unique-ID = {{ISI:000253844200009}},
DA = {{2018-08-13}},
}

@article{ ISI:000261671900030,
Author = {Edwards, Thea M. and Myers, John Peterson},
Title = {{Environmental exposures and gene regulation in disease etiology
   (Reprinted from Environmental Health Perpectives, vol 115, pg 1264-1270,
   2007)}},
Journal = {{CIENCIA \& SAUDE COLETIVA}},
Year = {{2008}},
Volume = {{13}},
Number = {{1}},
Pages = {{269-281}},
Month = {{JAN-FEB}},
Abstract = {{Health or disease is shaped for all individuals by interactions between
   their genes and environment. Exactly how the environment changes gene
   expression and how this can lead to disease are being explored in a
   fruitful new approach to environmental health research, representative
   studies of which are reviewed here. We searched Web of Science and
   references of relevant publications to understand the diversity of gene
   regulatory mechanisms affected by environmental exposures with disease
   implications. Pharmaceuticals, pesticides, air pollutants, industrial
   chemicals, heavy metals, hormones, nutrition, and behavior can change
   gene expression through a broad array of gene regulatory mechanisms.
   Furthermore, chemically induced changes in gene regulation are
   associated with serious and complex human diseases, including cancer,
   diabetes and obesity, infertility, respiratory diseases, allergies, and
   neurodegenerative disorders such as Parkinson and Alzheimer diseases.
   The reviewed studies indicate that genetic predisposition for disease is
   best predicted in the context of environmental exposures. And the
   genetic mechanisms investigated in these studies offer new avenues for
   risk assessment research. Finally, we are likely to witness dramatic
   improvements in human health, and reductions in medical costs, if
   environmental pollution is decreased.}},
Publisher = {{ABRASCO}},
Address = {{RUA HESPERIA, 16-PARTE MANGUINHOS, RIO DE JANEIRO, 21050-040, BRAZIL}},
Type = {{Reprint}},
Language = {{English}},
Affiliation = {{Edwards, TM (Reprint Author), Univ Florida, Dept Zool, 521A Bartram Hall,POB 118525, Gainesville, FL 32611 USA.
   Edwards, Thea M., Univ Florida, Dept Zool, Gainesville, FL 32611 USA.}},
DOI = {{10.1289/ehp.9951}},
ISSN = {{1413-8123}},
Keywords = {{DNA methylation; Drug resistance; Endocrine disruption; Gene expression;
   Gene regulation}},
Keywords-Plus = {{DIESEL EXHAUST PARTICLES; ACTIVATOR MESSENGER-RNA; AIRWAY
   EPITHELIAL-CELLS; PRIMORDIAL GERM-CELLS; SMOOTH-MUSCLE-CELLS; IGF-II
   GENES; PARKINSONS-DISEASE; PROSTATE-CANCER; ALPHA-SYNUCLEIN;
   2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{tedwards@zoo.ufl.edu}},
Cited-References = {{Akesson AA, 2005, ENVIRON HEALTH PERSP, V113, P1627, DOI 10.1289/ehp.8033.
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190.
   Baba M, 1998, AM J PATHOL, V152, P879.
   Baccarelli A, 2006, CARCINOGENESIS, V27, P2001, DOI 10.1093/carcin/bgl011.
   Bao BY, 2006, CARCINOGENESIS, V27, P32, DOI 10.1093/carcin/bgi170.
   BENJAMIN RC, 1980, J BIOL CHEM, V255, P502.
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395.
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834.
   Boland S, 2000, AM J PHYSIOL-LUNG C, V278, pL25.
   Bolognesi C, 2003, MUTAT RES-REV MUTAT, V543, P251, DOI 10.1016/S1383-5742(03)00015-2.
   BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185.
   BROWN AWA, 1986, J AM MOSQUITO CONTR, V2, P123.
   CAIRNS J, 1991, GENETICS, V128, P695.
   {*}CDCP, 2005, NAT CTR ENV HLTH PUB.
   CervantesLaurean D, 1996, J BIOL CHEM, V271, P10461, DOI 10.1074/jbc.271.18.10461.
   Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200.
   Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022.
   Cheng RYS, 2002, ENVIRON HEALTH PERSP, V110, P801, DOI 10.1289/ehp.02110801.
   COPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419, DOI 10.1016/0006-2952(95)00067-A.
   Day JK, 2002, J NUTR, V132, P2419.
   De Petro G, 1998, CANCER RES, V58, P2234.
   Diefenbach J, 2005, CELL MOL LIFE SCI, V62, P721, DOI 10.1007/s00018-004-4503-3.
   Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526.
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700.
   Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3.
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651.
   El-Sawy M, 2005, J MOL BIOL, V354, P246, DOI 10.1016/j.jmb.2005.09.050.
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2.
   FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119.
   FOSTER PL, 1994, GENETICS, V138, P253.
   GAIDO KW, 1995, TOXICOL APPL PHARM, V133, P34, DOI 10.1006/taap.1995.1124.
   Gao ZH, 2002, J CLIN ENDOCR METAB, V87, P1170, DOI 10.1210/jc.87.3.1170.
   Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002.
   Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598.
   Guerrero-Bosagna C, 2005, EVOL DEV, V7, P341, DOI 10.1111/j.1525-142X.2005.05033.x.
   GUGLIUCCI A, 1995, BIOCHEM BIOPH RES CO, V212, P56, DOI 10.1006/bbrc.1995.1935.
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8.
   Hastings PJ, 2004, PLOS BIOL, V2, P2220, DOI 10.1371/journal.pbio.0020399.
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491.
   HENRY WM, 1980, ENVIRON SCI TECHNOL, V14, P450, DOI 10.1021/es60164a010.
   Hersh MN, 2004, RES MICROBIOL, V155, P352, DOI 10.1016/j.resmic.2004.01.020.
   Jirajaroenrat K, 2001, INSECT BIOCHEM MOLEC, V31, P867, DOI 10.1016/S0965-1748(01)00032-7.
   Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9.
   Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H.
   Koivisto P, 1997, CANCER RES, V57, P314.
   Kraunz KS, 2006, INT J CANCER, V119, P1553, DOI 10.1002/ijc.22013.
   Kurata Y, 2003, JPN J VET RES, V50, P175.
   Lee MH, 2004, TOXICOL APPL PHARM, V197, P19, DOI 10.1016/j.taap.2004.02.003.
   Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x.
   Li SF, 1997, CANCER RES, V57, P4356.
   Li SF, 2003, ANN NY ACAD SCI, V983, P161, DOI 10.1111/j.1749-6632.2003.tb05971.x.
   Lilienthal H, 2000, TOXICOL SCI, V57, P292, DOI 10.1093/toxsci/57.2.292.
   Lu KP, 2000, MUTAT RES-FUND MOL M, V454, P35, DOI 10.1016/S0027-5107(00)00095-6.
   Lu KP, 1998, BIOCHEM BIOPH RES CO, V253, P828, DOI 10.1006/bbrc.1998.9866.
   Marano F, 2002, CELL BIOL TOXICOL, V18, P315, DOI 10.1023/A:1019548517877.
   Meredith GE, 2004, PARKINSONISM RELAT D, V10, P191, DOI 10.1016/j.parkreldis.2004.01.001.
   Minegishi T, 2003, MOL CELL ENDOCRINOL, V202, P123, DOI 10.1016/S0303-7207(03)00073-X.
   Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718.
   Morales JF, 2002, MUTAGENESIS, V17, P193, DOI 10.1093/mutage/17.3.193.
   Mytilineou C, 2004, J NEURAL TRANSM, V111, P1237, DOI 10.1007/s00702-004-0167-2.
   Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355.
   Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655.
   Palus J, 2003, MUTAT RES-GEN TOX EN, V540, P19, DOI 10.1016/S1383-5718(03)00167-0.
   PENTECOST BT, 1987, J BIOL CHEM, V262, P10134.
   Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014.
   PRODY CA, 1989, P NATL ACAD SCI USA, V86, P690, DOI 10.1073/pnas.86.2.690.
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443.
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554.
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2.
   Ritchie JM, 2005, ENVIRON RES, V98, P104, DOI 10.1016/j.envres.2004.05.013.
   Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b.
   Roling JA, 2004, MAR ENVIRON RES, V57, P377, DOI 10.1016/j.marenvres.2003.11.001.
   Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080.
   Roulland S, 2004, CANCER RES, V64, P2264, DOI 10.1158/0008-5472.CAN-03-3604.
   Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103.
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015.
   Samet JM, 2002, ENVIRON HEALTH PERSP, V110, P985, DOI 10.1289/ehp.02110985.
   SCHIFF R, 1991, GENE DEV, V5, P521, DOI 10.1101/gad.5.4.521.
   Schroeder JC, 2001, EPIDEMIOLOGY, V12, P701, DOI 10.1097/00001648-200111000-00020.
   Schwartz GG, 2003, DIABETES CARE, V26, P468, DOI 10.2337/diacare.26.2.468.
   Shiao YH, 2005, TOXICOL APPL PHARM, V205, P290, DOI 10.1016/j.taap.2004.10.017.
   Shimba S, 2000, BIOCHEM BIOPH RES CO, V272, P441, DOI 10.1006/bbrc.2000.2789.
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278.
   Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266.
   Smith FM, 2006, CYTOGENET GENOME RES, V113, P279, DOI 10.1159/000090843.
   Smith MT, 2005, TOXICOL APPL PHARM, V206, P237, DOI 10.1016/j.taap.2004.11.026.
   Stribinskis V, 2006, CANCER RES, V66, P2616, DOI 10.1158/0008-5472.CAN-05-3478.
   Sun F, 2005, J PHARMACOL EXP THER, V315, P69, DOI 10.1124/jpet.105.084632.
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186.
   TAM PPL, 1994, DEVELOPMENT, V120, P2925.
   TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170.
   TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159.
   TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520.
   TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382.
   Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324.
   TURUSOV VS, 1992, INT J CANCER, V50, P131, DOI 10.1002/ijc.2910500126.
   VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070.
   Verschure PJ, 2004, BIOL CELL, V96, P569, DOI 10.1016/j.biolcel.2004.07.001.
   Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375.
   Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275.
   Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791.
   Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005.
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276.
   WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163.
   Wu GY, 2004, J NUTR, V134, P2169.
   Wu Q, 2004, BIOL REPROD, V70, P1790, DOI 10.1095/biolreprod.103.025387.
   Xu Q, 2005, PEST MANAG SCI, V61, P1096, DOI 10.1002/ps.1090.
   Yang JM, 2003, REPROD TOXICOL, V17, P553, DOI 10.1016/S0890-6238(03)00100-X.
   Yu W, 1999, TOXICOL APPL PHARM, V158, P161, DOI 10.1006/taap.1999.8692.
   2007, ENVIRONMENTAL HLTH P, V115, P1264.}},
Number-of-Cited-References = {{110}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{17}},
Journal-ISO = {{Cienc. Saude Coletiva}},
Doc-Delivery-Number = {{383KG}},
Unique-ID = {{ISI:000261671900030}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000252126000016,
Author = {Wang, Ge and Maier, Robert J.},
Title = {{Critical role of RecN in recombinational DNA repair and survival of
   Helicobacter pylori}},
Journal = {{INFECTION AND IMMUNITY}},
Year = {{2008}},
Volume = {{76}},
Number = {{1}},
Pages = {{153-160}},
Month = {{JAN}},
Abstract = {{Homologous recombination is one of the key mechanisms responsible for
   the repair of DNA double-strand breaks. Recombinational repair normally
   requires a battery of proteins, each with specific DNA recognition,
   strand transfer, resolution, or other functions. Helicobacter pylori
   lacks many of the proteins normally involved in the early stage
   (presynapsis) of recombinational repair, but it has a RecN homologue
   with an unclear function. A recN mutant strain of H. pylori was shown to
   be much more sensitive than its parent to mitomycin C, an agent
   predominantly causing DNA double-strand breaks. The recN strain was
   unable to survive exposure to either air or acid as well as the parent
   strain, and air exposure resulted in no viable recN cells recovered
   after 8 h. In oxidative stress conditions (i.e., air exposure), a recN
   strain accumulated significantly more damaged (multiply fragmented) DNA
   than the parent strain. To assess the DNA recombination abilities of
   strains, their transformation abilities were compared by separately
   monitoring transformation using H. pylori DNA fragments containing
   either a site-specific mutation (conferring rifampin resistance) or a
   large insertion (kanamycin resistance cassette). The transformation
   frequencies using the two types of DNA donor were 10- and 50-fold lower,
   respectively, for the recN strain than for the wild type, indicating
   that RecN plays an important role in facilitating DNA recombination. In
   two separate mouse colonization experiments, the recN strain colonized
   most of the stomachs, but the average number of recovered cells was
   10-fold less for the mutant than for the parent strain (a statistically
   significant difference). Complementation of the recN strain by
   chromosomal insertion of a functional recN gene restored both the
   recombination frequency and mouse colonization ability to the wild-type
   levels. Thus, H. pylori RecN, as a component of DNA recombinational
   repair, plays a significant role in H. pylori survival in vivo.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Maier, RJ (Reprint Author), Univ Georgia, Dept Microbiol, 815 Biol Sci Bldg, Athens, GA 30602 USA.
   Univ Georgia, Dept Microbiol, Athens, GA 30602 USA.}},
DOI = {{10.1128/IAI.00791-07}},
ISSN = {{0019-9567}},
Keywords-Plus = {{DOUBLE-STRAND BREAKS; BACILLUS-SUBTILIS RECN; OXIDATIVE DAMAGE;
   HOMOLOGOUS RECOMBINATION; NEISSERIA-GONORRHOEAE; ESCHERICHIA-COLI;
   ANTIBIOTIC-RESISTANCE; HOST COLONIZATION; HYDROGEN-PEROXIDE; DEFICIENT
   MUTANTS}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{rmaier@uga.edu}},
Funding-Acknowledgement = {{NIDDK NIH HHS {[}R01DK06285201]}},
Cited-References = {{Bjorkholm B, 2001, P NATL ACAD SCI USA, V98, P14607, DOI 10.1073/pnas.241517298.
   Brown EW, 2001, ENVIRON MOL MUTAGEN, V38, P248, DOI 10.1002/em.1079.
   BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x.
   Cox MM, 2000, NATURE, V404, P37.
   Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1.
   DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.bi.63.070194.004411.
   Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720.
   Eutsey R, 2007, DNA REPAIR, V6, P19, DOI 10.1016/j.dnarep.2006.08.006.
   Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857.
   Falush D, 2001, P NATL ACAD SCI USA, V98, P15056, DOI 10.1073/pnas.251396098.
   Fernandez S, 2000, RES MICROBIOL, V151, P481, DOI 10.1016/S0923-2508(00)00165-0.
   FINCH PW, 1985, J BACTERIOL, V164, P653.
   Fischer W, 2004, J BACTERIOL, V186, P777, DOI 10.1128/JB.186.3.777-784.2004.
   Hacker J, 2003, SCIENCE, V301, P790, DOI 10.1126/science.1086802.
   Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4.
   Hirano T, 2006, NAT REV MOL CELL BIO, V7, P311, DOI 10.1038/nrm1909.
   Hofreuter D, 2001, MOL MICROBIOL, V41, P379, DOI 10.1046/j.1365-2958.2001.02502.x.
   Huang S, 2006, J BACTERIOL, V188, P6224, DOI 10.1128/JB.00477-06.
   Kang J, 2006, J BACTERIOL, V188, P5450, DOI 10.1128/JB.00275-06.
   Kansau I, 1996, RES MICROBIOL, V147, P661, DOI 10.1016/0923-2508(96)84023-X.
   Kidane D, 2004, MOL MICROBIOL, V52, P1627, DOI 10.1111/j.1365-2958.2004.04102.x.
   Kidane D, 2005, J CELL BIOL, V170, P357, DOI 10.1083/jcb.200412090.
   Kraft C, 2005, INT J MED MICROBIOL, V295, P299, DOI 10.1016/j.ijmm.2005.06.002.
   Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751.
   Loughlin MF, 2003, INFECT IMMUN, V71, P2022, DOI 10.1128/IAI.71.4.2022-2031.2003.
   Mathieu A, 2006, J BACTERIOL, V188, P7464, DOI 10.1128/JB.00851-06.
   Meddows TR, 2005, MOL MICROBIOL, V57, P97, DOI 10.1111/j.1365-2958.2005.04677.x.
   Merino D, 2002, MOL MICROBIOL, V44, P877, DOI 10.1046/j.1365-2958.2002.02929.x.
   MICHAELS ML, 1992, J BACTERIOL, V174, P6321.
   MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122.
   O'Rourke EJ, 2003, P NATL ACAD SCI USA, V100, P2789, DOI 10.1073/pnas.0337641100.
   PICKSLEY SM, 1984, MOL GEN GENET, V195, P267, DOI 10.1007/BF00332758.
   Pinto AV, 2005, MOL CELL, V17, P113, DOI 10.1016/j.molcel.2004.11.035.
   Robinson K, 2005, J INFECT DIS, V191, P579, DOI 10.1086/427657.
   SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120.
   Sanchez H, 2005, NUCLEIC ACIDS RES, V33, P2343, DOI 10.1093/nar/gki533.
   Sanchez H, 2006, J BACTERIOL, V188, P353, DOI 10.1128/JB.188.2.353-360.2006.
   Saunders NJ, 1999, MICROBIOL-UK, V145, P3523, DOI 10.1099/00221287-145-12-3523.
   Scott DR, 2007, P NATL ACAD SCI USA, V104, P7235, DOI 10.1073/pnas.0702300104.
   Seyler RW, 2001, INFECT IMMUN, V69, P4034, DOI 10.1128/IAI.69.6.4034-4040.2001.
   Skaar EP, 2002, J BACTERIOL, V184, P919, DOI 10.1128/jb.184.4.919-927.2002.
   Stohl EA, 2005, MOL MICROBIOL, V58, P520, DOI 10.1111/j.1365-2958.2005.04839.x.
   Stohl EA, 2006, J BACTERIOL, V188, P7645, DOI 10.1128/JB.00801-06.
   Storz G, 2000, BACTERIAL STRESS RESPONSES, P47.
   Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619.
   Suerbaum S, 2000, INT J MED MICROBIOL, V290, P175.
   THOMPSON SA, 1995, INFECT IMMUN, V63, P2185.
   Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483.
   Wang G, 2005, MOL MICROBIOL, V58, P166, DOI 10.1111/j.1365-2958.2005.04833.x.
   Wang G, 2004, INFECT IMMUN, V72, P1391, DOI 10.1128/IAI.72.3.1391-1396.2004.
   Wang G, 2006, MOL MICROBIOL, V61, P847, DOI 10.1111/j.1365-2958.2006.05302.x.
   Wang GE, 2001, ANTIMICROB AGENTS CH, V45, P727, DOI 10.1128/AAC.45.3.727-733.2001.
   Zirkle RE, 1996, J APPL BACTERIOL, V81, P133, DOI 10.1111/j.1365-2672.1996.tb04490.x.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Infect. Immun.}},
Doc-Delivery-Number = {{248BJ}},
Unique-ID = {{ISI:000252126000016}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000252803800001,
Author = {Uckay, I. and Sax, H. and Harbarth, S. and Bernard, L. and Pittet, D.},
Title = {{Multi-resistant infections in repatriated patients after natural
   disasters: lessons learned from the 2004 tsunami for hospital infection
   control}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{2008}},
Volume = {{68}},
Number = {{1}},
Pages = {{1-8}},
Month = {{JAN}},
Note = {{46th Interscience Conference on Antimicrobial Agents and Chemotherapy,
   San Francisco, CA, SEP 27-30, 2006}},
Abstract = {{Infections are a frequent consequence of natural disasters. Repatriated
   victims may require hospital care due to multiple fractures, pneumonia
   or wound infections caused by multi-resistant pathogens that require
   specific infection control measures. To address potential pitfalls of
   infection control and clinical care in repatriated patients, we sought
   to provide microbiological insight into the possible origins of
   multi-drug antibiotic resistance in survivors of natural disasters. A
   review of the medical literature was performed from 1986 to 2006 with an
   emphasis on the 2004 tsunami disaster in the Indian Ocean. After natural
   disasters, polymicrobial infections may occur following heavy
   inoculation during trauma. Multi-resistant Gram-negative pathogens are
   more prevalent than Gram-positive bacteria. A high incidence of extended
   spectrum beta-lactamase-producing bacteria and difficult-to-treat fungal
   infections in otherwise immunocompetent hosts may challenge routine
   hospital, care. We recommend that survivors of natural disasters should
   be kept in pre-emptive contact isolation during air transport and
   hospitalisation until the results of all microbiological cultures become
   available. A meticulous diagnostic work-up is necessary upon admission
   and empiric antibiotic treatment should be avoided. Infections may also
   become manifest after several weeks of hospitalisation. In case of
   life-threatening infection, antibiotic therapy should cover
   non-fermenting pathogens. (c) 2007 The Hospital Infection Society.
   Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Pittet, D (Reprint Author), Univ Geneva Hosp, Infect Control Programme, 224 Rue Micheli Crest, CH-1211 Geneva 14, Switzerland.
   Uckay, I.; Sax, H.; Harbarth, S.; Pittet, D., Univ Geneva Hosp, Infect Control Programme, CH-1211 Geneva 14, Switzerland.
   Bernard, L., Raymond Poincare Univ Hosp, Div Infect Dis, Garches, France.
   Bernard, L., Hop Paris, Garches, France.}},
DOI = {{10.1016/j.jhin.2007.10.018}},
ISSN = {{0195-6701}},
Keywords = {{tsunami; natural disaster; multi-drug resistance; multi-resistant
   isolation; pre-emptive; air transport; air evacuation; infection control}},
Keywords-Plus = {{PREVENTING NOSOCOMIAL TRANSMISSION; RESISTANT STAPHYLOCOCCUS-AUREUS;
   GRAM-NEGATIVE BACTERIA; ACINETOBACTER-BAUMANNII; SOUTHERN THAILAND;
   METHICILLIN-RESISTANT; ANTIBIOTIC-RESISTANCE; WOUND INFECTIONS;
   ESCHERICHIA-COLI; CARE}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{Didier.pittet@hcuge.ch}},
ResearcherID-Numbers = {{Sax, Hugo/A-9377-2016}},
ORCID-Numbers = {{Sax, Hugo/0000-0002-1532-2198}},
Cited-References = {{Abramson MA, 1999, INFECT CONT HOSP EP, V20, P408, DOI 10.1086/501641.
   AGHABABIAN RV, 1992, ANN EMERG MED, V21, P362, DOI 10.1016/S0196-0644(05)82651-4.
   Andresen D, 2005, LANCET, V365, P876, DOI 10.1016/S0140-6736(05)71046-1.
   Apisarnthanarak A, 2006, CLIN INFECT DIS, V42, P768, DOI 10.1086/500325.
   Arya SC, 2006, LANCET INFECT DIS, V6, P388, DOI 10.1016/S1473-3099(06)70500-X.
   Bogaerts P, 2006, J CLIN MICROBIOL, V44, P4189, DOI 10.1128/JCM.00796-06.
   Brandt Mary, 2006, Morbidity and Mortality Weekly Report, V55, P1.
   Burgos JM, 2005, J DAIRY SCI, V88, P1391, DOI 10.3168/jds.S0022-0302(05)72806-X.
   {*}CDCP, 2005, GUID AIR MED TRANSP.
   Chierakul W, 2005, CLIN INFECT DIS, V41, P982, DOI 10.1086/432942.
   Ciervo A, 2006, J CHEMOTHERAPY, V18, P443, DOI 10.1179/joc.2006.18.4.443.
   DANCHAIVIJITR S, 2005, J MED ASS THAI, V88, P14.
   Dhawan B, 2005, INDIAN J MED RES, V121, P784.
   Dries D, 2005, CRIT CARE MED, V33, P1178, DOI 10.1097/01.CCM.0000163220.55649.F0.
   Fischer D, 2004, J TRAVEL MED, V11, P44, DOI 10.2310/7060.2004.13647.
   Floret N, 2006, EMERG INFECT DIS, V12, P543, DOI 10.3201/eid1204.051569.
   Fournier PE, 2006, CLIN INFECT DIS, V42, P692, DOI 10.1086/500202.
   Garzoni C, 2005, EMERG INFECT DIS, V11, P1591, DOI 10.3201/eid1110.050715.
   Grissom TE, 2005, CRIT CARE MED S, V33, pS13.
   Harris L F, 1992, Ala Med, V61, P16.
   Hiransuthikul N, 2006, CLIN INFECT DIS, V42, P890, DOI 10.1086/500461.
   HIRANSUTHIKUL N, 2005, CLIN INFECT DIS, V41, P93.
   Hota B, 2004, CLIN INFECT DIS, V39, P1182, DOI 10.1086/424667.
   Ivers LC, 2006, CURR OPIN INFECT DIS, V19, P408, DOI 10.1097/01.qco.0000244044.85393.9e.
   Jitsurong Siroj, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P131.
   Kaiser AM, 2004, CLIN MICROBIOL INFEC, V10, P972, DOI 10.1111/j.1469-0691.2004.01000.x.
   Kallman O, 2006, SCAND J INFECT DIS, V38, P448, DOI 10.1080/00365540500452499.
   Kartowisastro Hermansyur, 2005, World Hosp Health Serv, V41, P19.
   Kateruttanakul Pairaj, 2005, Journal of the Medical Association of Thailand, V88, P754.
   Kazancioglu R, 2002, CLIN MICROBIOL INFEC, V8, P202, DOI 10.1046/j.1469-0691.2002.00371.x.
   Keven K, 2003, SCAND J INFECT DIS, V35, P110, DOI 10.1080/0036554021000027013.
   KHALAKDINA A, 2005, EUROSURVEILL, V10, P50623.
   Kim SH, 2005, J FOOD PROTECT, V68, P2022, DOI 10.4315/0362-028X-68.10.2022.
   Kluytmans-VandenBergh MFQ, 2005, INFECTION, V33, P309, DOI 10.1007/s15010-005-5079-z.
   Kuntaman K, 2005, EMERG INFECT DIS, V11, P1363.
   Lee SH, 2006, J EUR ACAD DERMATOL, V20, P860, DOI 10.1111/j.1468-3083.2006.01666.x.
   Lee VJ, 2005, ANN ACAD MED SINGAP, V34, P586.
   Leelarasamee Amorn, 1992, Journal of the Medical Association of Thailand, V75, P680.
   Leppaniemi A, 2005, SCAND J SURG, V94, P5, DOI 10.1177/145749690509400103.
   Ligon B Lee, 2006, Semin Pediatr Infect Dis, V17, P36, DOI 10.1053/j.spid.2006.01.002.
   M'Zali FH, 1997, J ANTIMICROB CHEMOTH, V40, P823, DOI 10.1093/jac/40.6.823.
   Mader JT, 1999, CLIN ORTHOP RELAT R, P14.
   Maegele M, 2005, CRIT CARE MED, V33, P1136, DOI 10.1097/01.CCM.0000163269.42524.50.
   Maegele M, 2006, CRIT CARE, V10, DOI 10.1186/cc4868.
   Masur H, 2005, CRIT CARE MED, V33, P1179, DOI 10.1097/01.CCM.0000163271.78189.0F.
   Millie M, 2000, AM SURGEON, V66, P223.
   Mohan A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-143.
   Morgan O, 2005, PLOS MED, V2, P491, DOI 10.1371/journal.pmed.0020184.
   Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213.
   NECHAEV EA, 1990, ANTIBIOT KHIMIOTERAP, V35, P21.
   Nieminen T, 2005, EUROSURVEILLANCE, V10.
   Noguchi N, 2005, J MED MICROBIOL, V54, P557, DOI 10.1099/jmm.0.45902-0.
   Noji E. K., 2005, CRITICAL CARE MED, V33, P29.
   Okeke IN, 1999, EMERG INFECT DIS, V5, P18, DOI 10.3201/eid0501.990103.
   PARKER MM, 2006, CRIT CARE, V34, P52.
   Petrini B, 2006, MED MYCOL, V44, P189, DOI 10.1080/136980500294949.
   Rhoads J, 2006, J AM ACAD NURSE PRAC, V18, P318, DOI 10.1111/j.1745-7599.2006.00139.x.
   Roy N, 2005, INJURY, V36, P927, DOI 10.1016/j.injury.2005.02.017.
   Schulte B, 2005, J HOSP INFECT, V61, P356, DOI 10.1016/j.jhin.2005.05.009.
   Shultz JM, 2005, EPIDEMIOL REV, V27, P21, DOI 10.1093/epirev/mxi011.
   Siegel JD, 2006, MANAGEMENT MULTIDRUG.
   Stosor V, 1998, ARCH INTERN MED, V158, P522, DOI 10.1001/archinte.158.5.522.
   Straif-Bourgeois Susanne, 2006, J La State Med Soc, V158, P136.
   Svensson E, 2006, SCAND J INFECT DIS, V38, P71, DOI 10.1080/00365540500264738.
   Tansuphasiri Unchalee, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P162.
   Teichman PG, 2007, NEW ENGL J MED, V356, P262, DOI 10.1056/NEJMra063651.
   Thamlikitkul V, 2003, AM J INFECT CONTROL, V31, P80, DOI 10.1067/mic.2003.64.
   Todd B, 2006, AM J NURS, V106, P29.
   Towner KJ, 2002, J ANTIMICROB CHEMOTH, V50, P1092, DOI 10.1093/jac/dkg012.
   van Griensven F, 2006, JAMA-J AM MED ASSOC, V296, P537, DOI 10.1001/jama.296.5.537.
   Waring Stephen C, 2005, Disaster Manag Response, V3, P41, DOI 10.1016/j.dmr.2005.02.003.
   Watson J, 2006, EMERG INFECT DIS, V12, P1468, DOI 10.3201/eid1209.060500.
   Wattanawaitunechai C, 2005, NEW ENGL J MED, V352, P962, DOI 10.1056/NEJMp058040.
   Wilder-Smith A, 2005, ANN ACAD MED SINGAP, V34, P625.
   WILLIAMS JD, 1989, EUR J EPIDEMIOL, V5, P207, DOI 10.1007/BF00156832.
   World Health Organization, 2006, WHO GUID HAND HYG HL.
   Wuthiekanun V, 2006, J CLIN MICROBIOL, V44, P239, DOI 10.1128/JCM.44.1.239-240.2006.
   Yorsaengrat Weerawat, 2006, Journal of the Medical Association of Thailand, V89, P518.
   Zanetti G, 2007, INFECT CONT HOSP EP, V28, P723, DOI 10.1086/517956.}},
Number-of-Cited-References = {{79}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{257MS}},
Unique-ID = {{ISI:000252803800001}},
DA = {{2018-08-13}},
}

@article{ ISI:000255450800017,
Author = {Borkow, Gadi and Gabbay, Jeffrey},
Title = {{Biocidal textiles can help fight nosocomial infections}},
Journal = {{MEDICAL HYPOTHESES}},
Year = {{2008}},
Volume = {{70}},
Number = {{5}},
Pages = {{990-994}},
Abstract = {{The rates of nosocomial infections, especially by those caused by
   antibiotic resistant bacteria, are increasing alarmingly over the globe.
   Although more rigorous infection control measures are being implemented,
   it is clear that the current modalities to reduce nosocomial infections
   are not sufficient.
   Textiles are an excellent substrate for bacterial growth under
   appropriate moisture and temperature conditions. Patients shed bacteria
   and contaminate their pyjamas and sheets. The temperature and humidity
   between the patients and the bed are appropriate conditions allowing for
   effective bacterial. proliferation. Several studies have found that
   personnel in contact with contaminated textiles were the source of
   transmission of the micro-organisms to susceptible patients.
   Furthermore, it has been reported that bed making in hospitals releases
   large quantities of micro-organisms into the air, which contaminate the
   immediate and non-immediate surroundings. Contaminated textiles in
   hospitals can thus be an important source of microbes contributing to
   endogenous, indirect-contact, and aerosol transmission of nosocomial
   related pathogens.
   We hypothesize that the use of antimicrobial textiles, especially in
   those textiles that are in close contact with the patients, may
   significantly reduce bioburden in clinical settings and consequently
   reduce the risk of nosocomial infections. These textiles should possess
   broad spectrum biocidal properties. They should be safe for use and
   highly effective against antibiotic resistant micro-organisms, including
   those that are commonly involved in hospital-acquired infections, and
   they should not permit the development of resistant micro-organisms to
   the active compound. (C) 2007 Elsevier Ltd. All rights reserved.}},
Publisher = {{CHURCHILL LIVINGSTONE}},
Address = {{JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Borkow, G (Reprint Author), Hameyasdim 44, IL-76910 Kfar Gibton, Israel.
   Borkow, Gadi; Gabbay, Jeffrey, Cupron Inc, Greensboro, NC 27404 USA.}},
DOI = {{10.1016/j.mehy.2007.08.025}},
ISSN = {{0306-9877}},
Keywords-Plus = {{RESISTANT STAPHYLOCOCCUS-AUREUS; AIRBORNE TRANSMISSION; HAND HYGIENE;
   HOSPITALS; CONTAMINATION; OUTBREAK; AGENTS; WARD}},
Research-Areas = {{Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental}},
Author-Email = {{gadi@cupron.com}},
Cited-References = {{ALLEN KD, 1987, J HOSP INFECT, V9, P110, DOI 10.1016/0195-6701(87)90048-X.
   AYLIFFE GAJ, 1988, J HOSP INFECT, V11, P226, DOI 10.1016/0195-6701(88)90101-6.
   Beggs CB, 2003, INDOOR BUILT ENVIRON, V12, P9, DOI 10.1177/142032603032201.
   Bernards AT, 1998, AM J INFECT CONTROL, V26, P544, DOI 10.1053/ic.1998.v26.a84555.
   Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622.
   BRACHMAN P S, 1974, Preventive Medicine, V3, P500, DOI 10.1016/0091-7435(74)90014-0.
   {*}CDC, 2007, FACT SHEET.
   Coello R, 2005, J HOSP INFECT, V60, P93, DOI 10.1016/j.jhin.2004.10.019.
   CORONEL D, 2001, REANIMATION S, V10, P43.
   COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4.
   FARRINGTON M, 1990, EPIDEMIOL INFECT, V105, P215, DOI 10.1017/S0950268800047828.
   Gabbay J, 2006, J IND TEXT, V35, P323.
   Gastmeier P, 2006, AM J INFECT CONTROL, V34, P603, DOI 10.1016/j.ajic.2006.01.014.
   GREENE V W, 1960, Mod Hosp, V95, P136.
   GUSTAFSON TL, 1983, J HOSP INFECT, V4, P367, DOI 10.1016/0195-6701(83)90007-5.
   Hughes AJ, 2005, INFECT CONT HOSP EP, V26, P100, DOI 10.1086/502494.
   Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494.
   JOZSEF E, 2007, ITALIE SCANDALIS HOP.
   Kampf G, 2004, CLIN MICROBIOL REV, V17, P863, DOI 10.1128/CMR.17.4.863-893.2004.
   Kelsen S G, 1980, Ann N Y Acad Sci, V353, P218, DOI 10.1111/j.1749-6632.1980.tb18925.x.
   Klevens RM, 2007, PUBLIC HEALTH REP, V122, P160, DOI 10.1177/003335490712200205.
   Kramer A, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-130.
   KROPEC A, 1993, INTENS CARE MED, V19, P161, DOI 10.1007/BF01720533.
   LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10.
   Lowy FD, 2003, J CLIN INVEST, V111, P1265, DOI 10.1172/JC1200318535.
   McGuckin M, 1999, AM J INFECT CONTROL, V27, P309, DOI 10.1016/S0196-6553(99)70049-0.
   MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319.
   Nguyen QV, 2006, HOSP ACQUIRED INFECT.
   NOBLE WA, 1981, MICROBIOLOGY HUMAN S, P77.
   NOBLE WC, 1965, J CLIN PATHOL, V18, P16, DOI 10.1136/jcp.18.1.16.
   Olesevich M, 2007, J PEDIATR SURG, V42, P765, DOI 10.1016/j.jpedsurg.2006.12.027.
   PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582.
   Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2.
   Pratt RJ, 2007, J HOSP INFECT, V65, pS1, DOI 10.1016/S0195-6701(07)60002-4.
   RUTULA WA, 1983, J CLIN MICROBIOL, V18, P683.
   Scheckler WE, 1998, INFECT CONT HOSP EP, V19, P114.
   Shiomori T, 2002, J HOSP INFECT, V50, P30, DOI 10.1053/jhin.2001.1136.
   Solberg C O, 1965, Acta Med Scand Suppl, V436, P1.
   Takahashi A, 1998, J HOSP INFECT, V40, P135, DOI 10.1016/S0195-6701(98)90092-5.
   VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127.
   WALTER CW, 1963, JAMA-J AM MED ASSOC, V186, P908.
   WALTER EA, 1995, INFECT DIS CLIN N AM, V9, P823.
   Weinstein RA, 1998, EMERG INFECT DIS, V4, P416, DOI 10.3201/eid0403.980320.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{77}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Med. Hypotheses}},
Doc-Delivery-Number = {{295BU}},
Unique-ID = {{ISI:000255450800017}},
DA = {{2018-08-13}},
}

@article{ ISI:000251398100007,
Author = {Andrews, Jason R. and Shah, N. Sarita and Gandhi, Neel and Moll, Tony
   and Friedland, Gerald and Tugela Ferry Care \& Res},
Title = {{Multidrug-resistant and extensively drug-resistant tuberculosis:
   Implications for the HIV epidemic and antiretroviral therapy rollout in
   South Africa}},
Journal = {{JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{196}},
Number = {{3}},
Pages = {{S482-S490}},
Month = {{DEC 1}},
Abstract = {{Drug-resistant tuberculosis (TB) is emerging as a major clinical and
   public health challenge in areas of sub-Saharan Africa where there is a
   high prevalence of human immunodeficiency virus (HIV) infection. TB
   drug-resistance surveillance in this region has been limited by
   laboratory capacity and the public health infrastructure; however, with
   the maturation of the HIV epidemic, the burden of drug-resistant TB is
   increasing rapidly. The recent discovery of large numbers of cases of
   multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB in
   South Africa likely represents an unrecognized and evolving epidemic
   rather than sporadic, localized outbreaks. The combination of a large
   population of HIV-infected susceptible hosts with poor TB treatment
   success rates, a lack of airborne infection control, limited
   drug-resistance testing, and an overburdened MDR-TB treatment program
   provides ideal conditions for an MDR-TB and XDR-TB epidemic of
   unparalleled magnitude. In the present article, we review the history of
   drug-resistant TB in South Africa, describe its interaction with the HIV
   epidemic and the resultant consequences, and suggest measures necessary
   for controlling MDR-TB and XDR-TB in this context. A successful response
   to the emergence of MDR-TB and XDR-TB will necessitate increased
   resources for and collaboration between TB and HIV programs.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Andrews, JR (Reprint Author), Yale Univ, Sch Med, AIDS Program, 135 Coll St,Ste 323, New Haven, CT 06510 USA.
   Yale Univ, Sch Med, AIDS Program, New Haven, CT 06510 USA.
   Albert Einstein Coll Med, Bronx, NY 10467 USA.
   Philanjalo \& Church Scotland Hosp, Tugela Ferry, KwaZulu Natal, South Africa.}},
DOI = {{10.1086/521121}},
ISSN = {{0022-1899}},
EISSN = {{1537-6613}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; RESOURCE-LIMITED SETTINGS;
   MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RISK-FACTORS;
   RIFAMPICIN RESISTANCE; TREATMENT PROGRAM; INFECTED PATIENTS; RAPID
   DETECTION; WESTERN-CAPE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{Jasonandr@gmail.com}},
ResearcherID-Numbers = {{Trajman, Anete/C-7679-2016}},
ORCID-Numbers = {{Trajman, Anete/0000-0002-4000-4984}},
Cited-References = {{ANDREWS J, 2007, CLIN PREDICTORS DRUG, V79.
   Aziz MA, 2006, LANCET, V368, P2142, DOI 10.1016/S0140-6736(06)69863-2.
   BASU S, 2007, IN PRESS LANCET.
   Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   Campos PE, 2003, EMERG INFECT DIS, V9, P1571, DOI 10.3201/eid0912.020731.
   {*}CDCP, 1996, MMWR-MORBID MORTAL W, V45, P330.
   Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034, DOI 10.1164/ajrccm.154.4.8887603.
   Churchyard GJ, 2000, INT J TUBERC LUNG D, V4, P433.
   Davies GR, 1999, INT J TUBERC LUNG D, V3, P799.
   Dean GL, 2002, AIDS, V16, P75, DOI 10.1097/00002030-200201040-00010.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229.
   Friedland G, 2004, CLIN INFECT DIS, V38, pS421, DOI 10.1086/421407.
   Friedland G, 2007, J INFECT DIS, V196, pS1, DOI 10.1086/1518667.
   GANDHI N, 2006, 16 INT AIDS C TOR.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   {*}GLOB XDR TB TASK, 2006, M GLOB XDR TB TASK F.
   Gordin FM, 1996, AM J RESP CRIT CARE, V154, P1478, DOI 10.1164/ajrccm.154.5.8912768.
   GREENTHOMPSON R, 2006, M GLOB XDRTB TASK FO.
   Holtz TH, 2006, INT J TUBERC LUNG D, V10, P649.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Johnson JL, 1998, INT J TUBERC LUNG D, V2, P397.
   Joint United Nations Programme on HIV/AIDS, 2006, 2006 REP GLOB AIDS E.
   Kawai V, 2006, AM J TROP MED HYG, V75, P1027.
   Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4.
   Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd.
   LONG R, 1991, AM J PUBLIC HEALTH, V81, P1326, DOI 10.2105/AJPH.81.10.1326.
   Louw GE, 2006, INT J TUBERC LUNG D, V10, P802.
   Manosuthi W, 2006, JAIDS-J ACQ IMM DEF, V43, P42, DOI 10.1097/01.qai.0000230521.86964.86.
   Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928.
   MOLL A, 2007, 38 UN WORLD C LUNG H.
   MOODLEY P, 2007, 47 INT C ANT AG CHEM.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   Morgan M, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-62.
   Moro ML, 1998, AIDS, V12, P1095, DOI 10.1097/00002030-199809000-00018.
   Munsiff SS, 2006, INT J TUBERC LUNG D, V10, P639.
   Murray J, 1999, AM J RESP CRIT CARE, V159, P733, DOI 10.1164/ajrccm.159.3.9804147.
   Nathanson E, 2006, EMERG INFECT DIS, V12, P1389, DOI 10.3201/eid1209.051618.
   Pai M, 2005, J INFECTION, V51, P175, DOI 10.1016/j.jint.2005.05.017.
   PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518.
   Perlman DC, 1997, CLIN INFECT DIS, V25, P242, DOI 10.1086/514546.
   Punnotok J, 2000, INT J TUBERC LUNG D, V4, P537.
   Rajbhandary SS, 2004, INT J TUBERC LUNG D, V8, P1012.
   Ridzon R, 1998, AM J RESP CRIT CARE, V157, P1881, DOI 10.1164/ajrccm.157.6.9712009.
   Shah NS, 2007, EMERG INFECT DIS, V13, P380, DOI 10.3201/eid1303.061400.
   South African Department of Health, 2000, S AFR TUB CONTR PROG.
   Tappero JW, 2005, CLIN INFECT DIS, V41, P461, DOI 10.1086/431984.
   VANDERWAL M, 2006, STANDARDIZED APPROAC.
   Victor TC, 2007, INT J TUBERC LUNG D, V11, P195.
   Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665.
   WEYER K, 1995, S AFR MED J, V85, P499.
   WEYER K, 1992, TUBERCLE LUNG DIS, V73, P106, DOI 10.1016/0962-8479(92)90064-Q.
   Weyer K, 2004, SURVEY TUBERCULOSIS.
   WEYER K, 1998, INT J TUBERC LUNG D, V2, pS165.
   {*}WHO, 2007, UNIVERSAL ACCESS SCA.
   WHO, 2004, INT POL COLL TB HIV.
   Wilkinson D, 1996, T ROY SOC TROP MED H, V90, P692, DOI 10.1016/S0035-9203(96)90440-X.
   World Health Organization, 1999, GUID PREV TUB HLTH C.
   World Health Organization, 2004, WHOHTMTB2004343.
   World Health Organization, 2007, WHOHTMTB2007376.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.}},
Number-of-Cited-References = {{62}},
Times-Cited = {{70}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Infect. Dis.}},
Doc-Delivery-Number = {{237TA}},
Unique-ID = {{ISI:000251398100007}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000250222800008,
Author = {Beduneau, Arnaud and Saulnier, Patrick and Hindre, Francois and
   Clavreul, Anne and Leroux, Jean-Christophe and Benoit, Jean-Pierre},
Title = {{Design of targeted lipid nanocapsules by conjugation of whole antibodies
   and antibody Fab' fragments}},
Journal = {{BIOMATERIALS}},
Year = {{2007}},
Volume = {{28}},
Number = {{33}},
Pages = {{4978-4990}},
Month = {{NOV}},
Abstract = {{Immunonanocapsules were synthesized by conjugation to lipid nanocapsules
   (LNC) of whole OX26 monoclonal antibodies (OX26 MAb) directed against
   the transferrin receptor (TfR). The TfR is overexpressed on the cerebral
   endothelium and mediates the transcytosis mechanism. Fab' fragments,
   known for their reduced interaction with the reticuloendothelial system,
   were also conjugated to LNC. This coupling was facilitated by the
   incorporation of lipid PEG(2000) functionalized. with
   reactive-sulfbydryl maleimide groups (DSPE-PEG(2000)-maleimide) into LNC
   shells by a post-insertion procedure, developed initially for liposome
   pegylation. An interfacial model using the dynamic rising drop technique
   helped determine the parameters influencing the DSPE-PEG(2000)-maleimide
   insertion and the quality of the anchorage. Heat was essential to
   promote both an important and stable adsorption of
   DSPE-PEG(2000)-maleimide onto LNC. OX26 MAb were thiolated to react with
   maleimide functions whereas thiol residues on Fab' fragments were used
   directly. The number of ligands per nanocapsule was adjusted according
   to their initial quantity in the coupling reaction mixture, with
   densities from 16 tol83 whole antibodies and between 42 and 173 Fab'
   fragments per LNC. The specific association of immunonanocapsules to
   cells overexpressing TfR was thus demonstrated, suggesting their ability
   to deliver drugs to the brain. (c) 2007 Published by Elsevier Ltd.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Benoit, JP (Reprint Author), Univ Angers, INSERM, U646, F-49100 Angers, France.
   Univ Angers, INSERM, U646, F-49100 Angers, France.
   CHU Angers, Dept Neurochirurg, F-49033 Angers, France.
   Fac Pharm, Canada Res Chair Drug Delivery, Montreal, PQ H3C 3J7, Canada.}},
DOI = {{10.1016/j.biomaterials.2007.05.014}},
ISSN = {{0142-9612}},
Keywords = {{immunonanocapsules; ox26 monoclonal antibody; Fab' fragment; transferrin
   receptor; brain targeting; interfacial rheology}},
Keywords-Plus = {{REVERSES MULTIDRUG-RESISTANCE; AIR-WATER-INTERFACE; DRUG-DELIVERY;
   IMMUNOLIPOSOMES; LIPOSOMES; RECEPTOR; ACID; PHARMACOKINETICS;
   IMMUNOGENICITY; NANOPARTICLES}},
Research-Areas = {{Engineering; Materials Science}},
Web-of-Science-Categories  = {{Engineering, Biomedical; Materials Science, Biomaterials}},
Author-Email = {{jean-pierre.benoit@univ-angers.fr}},
ResearcherID-Numbers = {{hindre, francois/K-5613-2015
   Benoit, Jean-Pierre/K-4387-2015
   Leroux, Jean-Christophe/N-4202-2015
   SAULNIER, Patrick/K-4271-2015
   Clavreul, Anne/K-4725-2015}},
ORCID-Numbers = {{Leroux, Jean-Christophe/0000-0001-5601-1292
   }},
Cited-References = {{Aktas Y, 2005, BIOCONJUGATE CHEM, V16, P1503, DOI 10.1021/bc050217o.
   Ansell SM, 1996, BIOCONJUGATE CHEM, V7, P490, DOI 10.1021/bc960036+.
   BALLOT S, 2006, EUR J NUCL MED MOL I, P1.
   BOURY F, 1995, LANGMUIR, V11, P2131, DOI 10.1021/la00006a047.
   BUCKINGHAM LE, 1995, INT J CANCER, V62, P436, DOI 10.1002/ijc.2910620413.
   CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723.
   COON JS, 1991, CANCER RES, V51, P897.
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6.
   Escobar NI, 1996, NUCL MED BIOL, V23, P641, DOI 10.1016/0969-8051(96)00028-5.
   FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771.
   Garcion E, 2006, MOL CANCER THER, V5, P1710, DOI 10.1158/1535-7163.MCT-06-0289.
   Harasym TO, 1998, ADV DRUG DELIVER REV, V32, P99, DOI 10.1016/S0169-409X(97)00134-8.
   Heurtault B, 2002, INT J PHARM, V242, P167, DOI 10.1016/S0378-5173(02)00144-8.
   Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668.
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164.
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0.
   Koning GA, 2003, PHARMACEUT RES, V20, P1249, DOI 10.1023/A:1025009300562.
   KUNIEDA H, 1985, J COLLOID INTERF SCI, V107, P1.
   Lamprecht A, 2006, J CONTROL RELEASE, V112, P208, DOI 10.1016/j.jconrel.2006.02.014.
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5.
   Malzert A, 2000, LANGMUIR, V16, P1861, DOI 10.1021/la990492x.
   MATZKU S, 1990, CANCER IMMUNOL IMMUN, V31, P285, DOI 10.1007/BF01740936.
   Minkov I, 2005, COLLOID SURFACE B, V45, P14, DOI 10.1016/j.colsurfb.2005.03.009.
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X.
   MOREHEAD HW, 1991, J CHROMATOGR, V587, P171, DOI 10.1016/0021-9673(91)85153-7.
   NEZLIN RS, 1977, STRUCTURE BIOSYNTHES.
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814.
   Passirani C, 2005, BIOMATERIALS FOR DELIVERY AND TARGETING OF PROTEINS AND NUCLEIC ACIDS, P187.
   PHILLIPS NC, 1991, IMMUNOL LETT, V30, P291, DOI 10.1016/0165-2478(91)90040-H.
   PHILLIPS NC, 1995, IMMUNOL LETT, V45, P149, DOI 10.1016/0165-2478(94)00251-L.
   Saulnier P, 2001, LANGMUIR, V17, P8104, DOI 10.1021/la001634m.
   Schnyder A, 2005, J DRUG TARGET, V13, P325, DOI 10.1080/10611860500206674.
   SCHNYDER A, 2005, NEURORX, V2, P99, DOI DOI 10.1602/NEURORX.2.1.99.
   SHAHINIAN S, 1995, BBA-BIOMEMBRANES, V1239, P157, DOI 10.1016/0005-2736(95)00145-S.
   SIMS GEC, 1980, ANAL BIOCHEM, V107, P60, DOI 10.1016/0003-2697(80)90492-3.
   Uster PS, 1996, FEBS LETT, V386, P243, DOI 10.1016/0014-5793(96)00452-8.
   Van Hecke E, 2003, POLYM INT, V52, P559, DOI 10.1002/pi.1054.
   Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820.
   Xu L, 2002, MOL CANCER THER, V1, P337.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{85}},
Usage-Count-Last-180-days = {{5}},
Usage-Count-Since-2013 = {{66}},
Journal-ISO = {{Biomaterials}},
Doc-Delivery-Number = {{221JI}},
Unique-ID = {{ISI:000250222800008}},
DA = {{2018-08-13}},
}

@article{ ISI:000251118500016,
Author = {Polashock, James J. and Saftner, Robert A. and Kramer, Matthew},
Title = {{Postharvest Highbush blueberry fruit antimicrobial volatile profiles in
   relation to anthracnose fruit rot resistance}},
Journal = {{JOURNAL OF THE AMERICAN SOCIETY FOR HORTICULTURAL SCIENCE}},
Year = {{2007}},
Volume = {{132}},
Number = {{6}},
Pages = {{859-868}},
Month = {{NOV}},
Abstract = {{Fruit of highbush blueberry (Vaccinium corymbosum L.) produce
   antimicrobial volatiles, including trans-2-hexenal, that may confer
   resistance to anthracnose fruit rot, an important postharvest disease
   caused by Colletotrichum acutatum J.H. Simmonds. To investigate whether
   aromatic volatiles in highbush blueberry fruit are associated with
   postharvest fruit rot resistance, we compared volatiles emitted from
   whole fruit and extracts from fruit kept in air at 20 degrees C for 0 to
   6 days postharvest from cultivars having a wide range of resistance to
   anthracnose. Antimicrobial volatiles detected included the aldehydes,
   trans-2-hexenal and hexanal; the monoterpenes, limonene, linalool,
   8-hydroxylinalool, alpha-terpineol, and terpinyl acetate; and the
   sesquiterpenes, cadinene, caryophyllene, and alpha-farnesene. There were
   significant correlations between some detected volatiles and these
   differed in whole fruit and extracts. Hexanal (in fruit extracts),
   trans-2-hexenal, terpinyl acetate, and cadinene emissions increased in
   most cultivars when fruit were kept in air at 20 degrees C for various
   times postharvest. Volatile emissions from whole fruit and extracts
   varied widely among the cultivars with early ripening cultivars
   generally showing higher volatile emissions than later ripening
   cultivars. Although the cultivars tested differed in quantities, and in
   some cases, the types of volatiles produced, these differences were not
   related to pedigree (i.e., species composition) nor to known anthracnose
   resistance ratings. Except for the confounded emissions of terpinyl
   acetate and cadinene, more than 80\% of the variation observed for each
   volatile was attributable to the cultivar (genetic), year
   (environmental), and cultivar-by-year interaction. The results suggest
   that, although antimicrobial aldehydes and terpenes emitted from fully
   ripe highbush blueberry fruit and extracts might be important flavor and
   aroma components, they do not significantly contribute to disease
   resistance against anthracnose fruit rot.}},
Publisher = {{AMER SOC HORTICULTURAL SCIENCE}},
Address = {{113 S WEST ST, STE 200, ALEXANDRIA, VA 22314-2851 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Polashock, JJ (Reprint Author), USDA, ARS, Fruit Lab, 125A Lake Oswego Rd, Chatsworth, NJ 08019 USA.
   USDA, ARS, Fruit Lab, Chatsworth, NJ 08019 USA.
   USDA ARS, Henry A Wallace Agr Res Ctr, Produce Qual \& Safety Lab, Beltsville, MD 20705 USA.
   USDA ARS, Henry A Wallace Agr Res Ctr, Biometr Consulting Serv, Beltsville, MD 20705 USA.}},
ISSN = {{0003-1062}},
Keywords-Plus = {{ESSENTIAL OILS; ANTIFUNGAL ACTIVITY; BOTRYTIS-CINEREA;
   CHEMICAL-COMPOSITION; ASPERGILLUS-FLAVUS; PLANT VOLATILES; SHELF-LIFE;
   STORAGE; CONSTITUENTS; BIOCHEMISTRY}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Horticulture}},
Author-Email = {{james.polashock@ars.usda.gov}},
Cited-References = {{Al-Howiriny T. A., 2003, PAK J BIOL SCI, V6, P133.
   ANDERSON RJ, 1994, HUM-COMPUT INTERACT, V9, P42.
   Archbold DD, 1997, J AGR FOOD CHEM, V45, P4032, DOI 10.1021/jf970332w.
   Azaz D, 2002, Z NATURFORSCH C, V57, P817.
   BALOGA DW, 1995, ACS SYM SER, V596, P235.
   Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x.
   Burnham K.P., 1998, MODEL SELECTION INFE.
   BUTTERY RG, 1993, ACS SYM SER, V525, P23.
   Caccioni D. R. L., 1994, Journal of Essential Oil Research, V6, P173.
   CARSON CF, 1995, J APPL BACTERIOL, V78, P264, DOI 10.1111/j.1365-2672.1995.tb05025.x.
   Cavaleiro C, 2006, J APPL MICROBIOL, V100, P1333, DOI 10.1111/j.1365-2672.2006.02862.x.
   CHAPPELL J, 1995, PLANT PHYSIOL, V107, P1.
   Corbo MR, 2000, J AGR FOOD CHEM, V48, P2401, DOI 10.1021/jf991223f.
   Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564.
   DAYKIN ME, 1984, PLANT DIS, V68, P948, DOI 10.1094/PD-69-948.
   Delaquis PJ, 2002, INT J FOOD MICROBIOL, V74, P101, DOI 10.1016/S0168-1605(01)00734-6.
   DEMARSAY A, 2005, THESIS STATE U NEW J.
   Demirci B, 2006, J AGR FOOD CHEM, V54, P3146, DOI 10.1021/JF053222V.
   Ding CK, 2002, PLANTA, V214, P895, DOI 10.1007/s00425-001-0698-9.
   Dorman HJD, 2000, J APPL MICROBIOL, V88, P308, DOI 10.1046/j.1365-2672.2000.00969.x.
   DRAPER A, 1987, HORTSCIENCE, V22, P320.
   Dudareva N, 2004, PLANT PHYSIOL, V135, P1893, DOI 10.1104/pp.104.049981.
   Forney CF, 2001, HORTTECHNOLOGY, V11, P529.
   Fraternale D, 2004, J ESSENT OIL RES, V16, P617, DOI 10.1080/10412905.2004.9698810.
   FRENCH RC, 1992, MYCOLOGIA, V84, P277, DOI 10.2307/3760180.
   Gardini F, 2001, LETT APPL MICROBIOL, V33, P50, DOI 10.1046/j.1472-765X.2001.00956.x.
   Govinden-Soulange J, 2004, BIOL PHARM BULL, V27, P1814, DOI 10.1248/bpb.27.1814.
   HAMILTONKEMP TR, 1992, J CHEM ECOL, V18, P1083, DOI 10.1007/BF00980064.
   HATANAKA A, 1993, PHYTOCHEMISTRY, V34, P1201, DOI 10.1016/0031-9422(91)80003-J.
   HIMEJIMA M, 1992, J CHEM ECOL, V18, P1809, DOI 10.1007/BF02751105.
   Knobloch K., 1989, Journal of Essential Oil Research, V1, P119.
   Kramer K, 2004, BAS SCI CARDIOLOGIST, V16, P127.
   Kramer Matthew, 2005, P C APPL STAT AGR, V17, P148.
   Lambert RJW, 2001, J APPL MICROBIOL, V91, P453, DOI 10.1046/j.1365-2672.2001.01428.x.
   Lanciotti R, 1999, J AGR FOOD CHEM, V47, P4769, DOI 10.1021/jf990611e.
   Latrasse A, 1991, VOLATILE COMPOUNDS F, P329.
   Mari M, 1998, PHYTOPARASITICA, V26, P59, DOI 10.1007/BF02981267.
   MILHOLLAND RD, 1995, COMPENDIUM BLUEBERRY, P17.
   Overton S., 1999, VOLATILE ORGANIC COM.
   Pawliszyn J., 1997, SOLID PHASE MICROEXT.
   Peana AT, 1999, PLANTA MED, V65, P752, DOI 10.1055/s-2006-960857.
   Plotto A., 2003, ACTA HORTIC, V628, P737.
   Polashock JJ, 2005, PLANT DIS, V89, P33, DOI 10.1094/PD-89-0033.
   {*}RAINTR NUTR INC, 2004, BIOL ACT COMP JAT HY.
   Saftner RA, 1999, J AM SOC HORTIC SCI, V124, P682.
   Saftner RA, 2002, J AM SOC HORTIC SCI, V127, P1006.
   SIPAILIENE A, 2006, J ESSENT OIL RES, V18, P1.
   Song L, 2007, AM J CHINESE MED, V35, P353, DOI 10.1142/S0192415X07004874.
   Tabanca N, 2007, J CHROMATOGR B, V850, P221, DOI 10.1016/j.jchromb.2006.11.041.
   Tabanca N, 2006, J AGR FOOD CHEM, V54, P6593, DOI 10.1021/jf0608773.
   Tepe B, 2004, J AGR FOOD CHEM, V52, P1132, DOI 10.1021/jf035094l.
   Utama IMS, 2002, J AGR FOOD CHEM, V50, P6371, DOI 10.1021/jf020484d.
   Wilson CL, 1997, PLANT DIS, V81, P204, DOI 10.1094/PDIS.1997.81.2.204.
   Zeringue HJ, 1996, J AGR FOOD CHEM, V44, P403, DOI 10.1021/jf950313r.}},
Number-of-Cited-References = {{54}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Am. Soc. Hortic. Sci.}},
Doc-Delivery-Number = {{233VN}},
Unique-ID = {{ISI:000251118500016}},
DA = {{2018-08-13}},
}

@article{ ISI:000251828800010,
Author = {Forder, A. A.},
Title = {{A brief history of infection control - past and present}},
Journal = {{SAMJ SOUTH AFRICAN MEDICAL JOURNAL}},
Year = {{2007}},
Volume = {{97}},
Number = {{11, 3}},
Pages = {{1161-1164}},
Month = {{NOV}},
Abstract = {{The scientific study of hospital or nosocomial cross-infection began
   during the first half of the 18th century, and from that time until the
   start of the `Bacteriological Era' many of the most notable
   contributions originated in Scotland. However it was only 100 years
   later in 1858 that Florence Nightingale promoted the case for hospital
   reform.
   The real understanding of hospital infection followed upon the
   discoveries of Pasteur, Koch and Lister and the beginning of the
   `Bacteriological Era'.
   The close of the 19th century saw the triumphs of hospital reform and
   asepsis and seemed to herald the final victory over hospital
   cross-infection.
   However, the victory was short-lived. It was soon realised that
   infections occurred not only in obstetric and surgical patients, but in
   medical patients as well, and that air could also be a source of
   infection.
   Streptococcal, staphylococcal and then Gram-negative bacilli as a cause
   of hospital infection became a focus of attention, as did
   antibiotic-resistant organisms.
   This paper looks briefly at the establishment of the control of
   infection doctor, infection control committee and infection control
   nurse as well as summarising the changes, problems and advances in
   infection control up to the present time.}},
Publisher = {{SA MEDICAL ASSOC}},
Address = {{BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Forder, AA (Reprint Author), Univ Cape Town, Dept Med Microbiol, Cape Town, South Africa.
   Forder, A. A., Univ Cape Town, Dept Med Microbiol, Cape Town, South Africa.}},
ISSN = {{0256-9574}},
Keywords-Plus = {{HOSPITAL INFECTION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{ndp@sun.ac.za}},
Cited-References = {{{*}CDC, 1971, P INT C NOS INF AUG, P318.
   {*}CDC, 1971, P INT C NOS INF AUG.
   DIXON RE, 1981, NOSOCOMIAL INFECTION, pR9.
   ECKHOFF T, 1981, NOSOCOMIAL INFECTION, P1.
   {*}EPIC, 2007, J HOSP INFECT S, V65, pS1.
   GARDNER AMN, 1962, LANCET, V2, P710.
   Gunn W, 1928, J HYG-CAMBRIDGE, V28, P250, DOI 10.1017/S0022172400009608.
   {*}HOSP INF SOC, 1995, J HOSP INFECT SA, V18.
   {*}HOSP INF SOC, 2006, J HOSP INFECT, V64, pS1.
   {*}HOSP INF SOC, 1995, J HOSP INFECT S, V30.
   {*}HOSP INF SOC, 1999, J HOSP INFECT S, V43.
   {*}HOSP INF SOC, 1988, J HOSP INFECT SA, V11.
   Medical Research Council, 1941, 6 MRC.
   {*}NAT GLYC RES ENT, 2006, J HOSP INFECT, V62, pS1.
   PHILLIPS I, 1988, J HOSP INFECT, V11, P3, DOI 10.1016/0195-6701(88)90158-2.
   SELWYN S, 1991, J HOSP INFECT, V18, P5, DOI 10.1016/0195-6701(91)90004-R.
   SELWYN S. A. F. MACCABE, 1964, SCOT MED J, V9, P409.
   SHANSON DC, 1986, BRIT J HOSP MED, V35, P312.
   TAYLOR DM, 1999, J HOSP INFECT S, V43, P569.
   Weightman NC, 2004, J HOSP INFECT, V56, P1, DOI 10.1016/j.jhin.2003.09.006.
   2003, J HOSP INFECT, V55, pS2.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{SAMJ S. Afr. Med. J.}},
Doc-Delivery-Number = {{243WU}},
Unique-ID = {{ISI:000251828800010}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000250487000027,
Author = {Basu, Sanjay and Andrews, Jason R. and Poolman, Eric M. and Gandhi, Neel
   R. and Shah, N. Sarita and Moll, Anthony and Moodley, Prashini and
   Galvani, Alison P. and Friedland, Gerald H.},
Title = {{Prevention of nosocomial transmission of extensively drug-resistant
   tuberculosis in rural South African district hospitals: an
   epidemiological modelling study}},
Journal = {{LANCET}},
Year = {{2007}},
Volume = {{370}},
Number = {{9597}},
Pages = {{1500-1507}},
Month = {{OCT-NOV}},
Abstract = {{Background Extensively drug-resistant (XDR) tuberculosis has spread
   among hospitalised patients in South Africa, but the epidemic-level
   effect of hospital-based infection control strategies remains unknown.
   We modelled the plausible effect of rapidly available infection control
   strategies on the overall course of the XDR tuberculosis epidemic in a
   rural area of South Africa.
   Methods We investigated the effect of administrative, environmental, and
   personal infection control measures on the epidemic trajectory of XDR
   tuberculosis in the rural community of Tugela Ferry. Assessments were
   done with a mathematical model incorporating over 2 years of
   longitudinal inpatient and community-based data. The model simulated
   inpatient airborne tuberculosis transmission, community tuberculosis
   transmission, and the effect of HIV and antiretroviral therapy.
   Findings If no new interventions are introduced, about 1300 cases of XDR
   tuberculosis are predicted to occur in the area of Tugela Ferry by the
   end of 2012, more than half of which are likely to be nosocomially
   transmitted. Mask use alone would avert fewer than 10\% of cases in the
   overall epidemic, but could prevent a large proportion of cases of XDR
   tuberculosis in hospital staff. The combination of mask use with reduced
   hospitalisation time and a shift to outpatient therapy could prevent
   nearly a third of XDR tuberculosis cases. Supplementing this approach
   with improved ventilation, rapid drug resistance testing, HIV treatment,
   and tuberculosis isolation facilities could avert 48\% of XDR
   tuberculosis cases (range 34-50\%) by the end of 2012. However,
   involuntary detention could result in an unexpected rise in incidence
   due to restricted isolation capacity.
   Interpretation A synergistic combination of available nosocomial
   infection control strategies could prevent nearly half of XDR
   tuberculosis cases, even in a resource-limited setting. XDR tuberculosis
   transmission will probably continue in the community, indicating the
   need to develop and implement parallel community-based programmes.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Basu, S (Reprint Author), Yale Univ, Sch Med, Dept Epidemiol \& Publ Hlth, 333 Cedar St, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Epidemiol \& Publ Hlth, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, AIDS Program, New Haven, CT 06520 USA.
   Albany Med Coll, Div Gen Internal Med, Bronx, NY USA.
   Albany Med Coll, Div Infect Dis, Bronx, NY USA.
   Albany Med Coll, Div Epidemiol, Bronx, NY USA.
   Univ KwaZulu Natal, Nelson R Mandela Sch Med, Durban, South Africa.
   Church Scotland Hosp \& Philanjalo, Kwa Zulu, South Africa.}},
DOI = {{10.1016/S0140-6736(07)61636-5}},
ISSN = {{0140-6736}},
EISSN = {{1474-547X}},
Keywords-Plus = {{NEW-YORK-CITY; PERSONAL RESPIRATORY PROTECTION;
   MYCOBACTERIUM-TUBERCULOSIS; INFECTION-CONTROL; OUTBREAK; ASSAY; TB;
   VENTILATION; DISEASE; COMPLEX}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{sanjay.basu@yale.edu}},
ORCID-Numbers = {{Andrews, Jason/0000-0002-5967-251X}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI072706-01, R01 AI068932, R01 AI072706]; NIGMS NIH
   HHS {[}T32 GM007205, 5 T32 GM07205-32]}},
Cited-References = {{ANDREWS J, 2007, THESIS YALE U.
   Beggs CB, 2003, INT J TUBERC LUNG D, V7, P1015.
   Biscotto CR, 2005, INT J TUBERC LUNG D, V9, P545.
   BLOWER SM, 1994, INT STAT REV, V62, P229, DOI 10.2307/1403510.
   Bock NN, 2007, J INFECT DIS, V196, pS108, DOI 10.1086/518661.
   {*}CDCP, 2006, MMWR-MORBID MORTAL W, V55, P301.
   Cooksey RC, 1997, J CLIN MICROBIOL, V35, P1281.
   da Silva PA, 2006, CLIN MICROBIOL INFEC, V12, P293, DOI 10.1111/j.1469-0691.2005.01355.x.
   de Luna FFA, 2006, J CLIN MICROBIOL, V44, P3025, DOI 10.1128/JCM.00068-06.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   ESCOMBE AR, 2007, PLOS MED, V4, pE38.
   Espinal MA, 2001, INT J TUBERC LUNG D, V5, P887.
   Fennelly KP, 2005, INT J TUBERC LUNG D, V9, P476.
   Fennelly KP, 1997, CLIN CHEST MED, V18, P1, DOI 10.1016/S0272-5231(05)70352-X.
   FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   GANDHI N, 2006, 16 INT C AIDS.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Iseman MD, 2000, CLIN GUIDE TUBERCULO.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Lawn SD, 2007, AIDS, V21, P335, DOI 10.1097/QAD.0b013e328011efac.
   Li Y, 2007, INDOOR AIR, V17, P2, DOI 10.1111/j.1600-0668.2006.00445.x.
   MAKHAYE C, DEADLY TB UPWARD SPI.
   MOLL A, 2006, 16 INT AIDS C TOR.
   Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Narvskaya O, 2002, EUR J CLIN MICROBIOL, V21, P596, DOI 10.1007/s10096-002-0775-4.
   Noakes CJ, 2006, EPIDEMIOL INFECT, V134, P1082, DOI 10.1017/S0950268806005875.
   RICH ML, 2003, PIH GUIDE MED MANAGE.
   RILEY RL, 1957, AM REV TUBERC PULM, V75, P420.
   {*}S AFR DEP HLTH, KZN OUTBR.
   {*}S AFR PRESS ASS, 2007, XDR TB FOUND ALL PRO.
   Sacks LV, 1999, CLIN INFECT DIS, V29, P96, DOI 10.1086/520189.
   SHAH NS, WORLDWIDE EMERGENCE.
   Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   VELLA V, 2007, KWAZULU NATAL EPIDEM, V15, P8.
   WEYER K, 2007, C RETR OPP INF LOS A.
   WEYER K, 2001, NATL SURVEY TUBERCUL.
   WHO, 2006, M WHO GLOB TASK FORC.
   World Health Organization, 1999, GUID PREV TUB HLTH C.
   World Health Organization, 2007, GLOB MAP INF XDR TB.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.
   2006, MMWR, V55, P11176.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{123}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{224ZN}},
Unique-ID = {{ISI:000250487000027}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000249200600020,
Author = {Edwards, Thea M. and Myers, John Peterson},
Title = {{Environmental exposures and gene regulation in disease etiology}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{2007}},
Volume = {{115}},
Number = {{9}},
Pages = {{1264-1270}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: Health or disease is shaped for all individuals by
   interactions between their genes and environment. Exactly how the
   environment changes gene expression and how this can lead to disease are
   being explored in a fruitful new approach to environmental health
   research, representative studies of which are reviewed here.
   DATA SOURCES: We searched Web of Science and references of relevant
   publications to understand the diversity of gene regulatory mechanisms
   affected by environmental exposures with disease implications.
   DATA SYNTHESIS: Pharmaceuticals, pesticides, air pollutants, industrial
   chemicals, heavy metals, hormones, nutrition, and behavior can change
   gene expression through a broad array of gene regulatory mechanisms.
   Mechanisms include regulation of gene translocation, histone
   modifications, DNA methylation, DNA repair, transcription, RNA
   stability, alternative RNA splicing, protein degradation, gene copy
   number, and transposon activation. Furthermore, chemically induced
   changes in gene regulation are associated with serious and complex human
   diseases, including cancer, diabetes and obesity, infertility,
   respiratory diseases, allergies, and neurodegenerative disorders such as
   Parkinson and Alzheimer diseases. One of the best-studied areas of gene
   regulation is epigenetics, especially DNA methylation. Our examples of
   environmentally induced changes in DNA methylation are presented in the
   context of early development, when methylation patterns are initially
   laid down. This approach highlights the potential role for altered DNA
   methylation in fetal origins of adult disease and inheritance of
   acquired genetic change.
   CONCLUSIONS: The reviewed studies indicate that genetic predisposition
   for disease is best predicted in the context of environmental exposures.
   Second, the genetic mechanisms investigated in these studies offer new
   avenues for risk assessment research. Finally, we are likely to witness
   dramatic improvements in human health, and reductions in medical costs,
   if environmental pollution is decreased.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Edwards, TM (Reprint Author), Univ Florida, Dept Zool, Gainesville, FL 32611 USA.
   Univ Florida, Dept Zool, Gainesville, FL 32611 USA.
   Environm Hlth Sci, Charlottesville, VA USA.}},
DOI = {{10.1289/ehp.9951}},
ISSN = {{0091-6765}},
Keywords = {{chemicals; disease risk; DNA methylation; drug resistance; endocrine
   disruption; environment; fetal origins of adult disease; gene
   expression; gene regulation; susceptibility}},
Keywords-Plus = {{DIESEL EXHAUST PARTICLES; ACTIVATOR MESSENGER-RNA; AIRWAY
   EPITHELIAL-CELLS; PRIMORDIAL GERM-CELLS; SMOOTH-MUSCLE-CELLS;
   PARKINSONS-DISEASE; PROSTATE-CANCER; ALPHA-SYNUCLEIN;
   2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ESCHERICHIA-COLI}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Author-Email = {{tedwards@zoo.ufl.edu}},
ORCID-Numbers = {{Edwards, Thea/0000-0002-6176-2872}},
Cited-References = {{Akesson AA, 2005, ENVIRON HEALTH PERSP, V113, P1627, DOI 10.1289/ehp.8033.
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190.
   Baba M, 1998, AM J PATHOL, V152, P879.
   Baccarelli A, 2006, CARCINOGENESIS, V27, P2001, DOI 10.1093/carcin/bgl011.
   Bao BY, 2006, CARCINOGENESIS, V27, P32, DOI 10.1093/carcin/bgi170.
   BENJAMIN RC, 1980, J BIOL CHEM, V255, P502.
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395.
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834.
   Boland S, 2000, AM J PHYSIOL-LUNG C, V278, pL25.
   Bolognesi C, 2003, MUTAT RES-REV MUTAT, V543, P251, DOI 10.1016/S1383-5742(03)00015-2.
   BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185.
   BROWN AWA, 1986, J AM MOSQUITO CONTR, V2, P123.
   CAIRNS J, 1991, GENETICS, V128, P695.
   {*}CDCP, 2005, 050570 NAT CTR ENV H.
   CervantesLaurean D, 1996, J BIOL CHEM, V271, P10461, DOI 10.1074/jbc.271.18.10461.
   Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200.
   Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022.
   Cheng RYS, 2002, ENVIRON HEALTH PERSP, V110, P801, DOI 10.1289/ehp.02110801.
   COPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419, DOI 10.1016/0006-2952(95)00067-A.
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S.
   De Petro G, 1998, CANCER RES, V58, P2234.
   Diefenbach J, 2005, CELL MOL LIFE SCI, V62, P721, DOI 10.1007/s00018-004-4503-3.
   Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526.
   Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700.
   Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3.
   Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951.
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651.
   El-Sawy M, 2005, J MOL BIOL, V354, P246, DOI 10.1016/j.jmb.2005.09.050.
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2.
   FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119.
   FOSTER PL, 1994, GENETICS, V138, P253.
   GAIDO KW, 1995, TOXICOL APPL PHARM, V133, P34, DOI 10.1006/taap.1995.1124.
   Gao Z, 2003, J DRUG TARGET, V11, P87, DOI 10.1080/1061186031000138623.
   Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002.
   Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598.
   Guerrero-Bosagna C, 2005, EVOL DEV, V7, P341, DOI 10.1111/j.1525-142X.2005.05033.x.
   GUGLIUCCI A, 1995, BIOCHEM BIOPH RES CO, V212, P56, DOI 10.1006/bbrc.1995.1935.
   Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8.
   Hastings PJ, 2004, PLOS BIOL, V2, P2220, DOI 10.1371/journal.pbio.0020399.
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491.
   HENRY WM, 1980, ENVIRON SCI TECHNOL, V14, P450, DOI 10.1021/es60164a010.
   Hersh MN, 2004, RES MICROBIOL, V155, P352, DOI 10.1016/j.resmic.2004.01.020.
   Jirajaroenrat K, 2001, INSECT BIOCHEM MOLEC, V31, P867, DOI 10.1016/S0965-1748(01)00032-7.
   Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9.
   Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H.
   Koivisto P, 1997, CANCER RES, V57, P314.
   Kraunz KS, 2006, INT J CANCER, V119, P1553, DOI 10.1002/ijc.22013.
   Kurata Y, 2003, JPN J VET RES, V50, P175.
   Lee MH, 2004, TOXICOL APPL PHARM, V197, P19, DOI 10.1016/j.taap.2004.02.003.
   Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x.
   Li SF, 1997, CANCER RES, V57, P4356.
   LI SF, 2003, EPIGENETICS CANC PRE, P191.
   Lilienthal H, 2000, TOXICOL SCI, V57, P292, DOI 10.1093/toxsci/57.2.292.
   Lu KP, 2000, MUTAT RES-FUND MOL M, V454, P35, DOI 10.1016/S0027-5107(00)00095-6.
   Lu KP, 1998, BIOCHEM BIOPH RES CO, V253, P828, DOI 10.1006/bbrc.1998.9866.
   Marano F, 2002, CELL BIOL TOXICOL, V18, P315, DOI 10.1023/A:1019548517877.
   Meredith GE, 2004, PARKINSONISM RELAT D, V10, P191, DOI 10.1016/j.parkreldis.2004.01.001.
   Minegishi T, 2003, MOL CELL ENDOCRINOL, V202, P123, DOI 10.1016/S0303-7207(03)00073-X.
   Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718.
   Morales JF, 2002, MUTAGENESIS, V17, P193, DOI 10.1093/mutage/17.3.193.
   Mytilineou C, 2004, J NEURAL TRANSM, V111, P1237, DOI 10.1007/s00702-004-0167-2.
   Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355.
   Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655.
   Palus J, 2003, MUTAT RES-GEN TOX EN, V540, P19, DOI 10.1016/S1383-5718(03)00167-0.
   PENTECOST BT, 1987, J BIOL CHEM, V262, P10134.
   Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014.
   PRODY CA, 1989, P NATL ACAD SCI USA, V86, P690, DOI 10.1073/pnas.86.2.690.
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443.
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554.
   Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2.
   Ritchie JM, 2005, ENVIRON RES, V98, P104, DOI 10.1016/j.envres.2004.05.013.
   Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b.
   Roling JA, 2004, MAR ENVIRON RES, V57, P377, DOI 10.1016/j.marenvres.2003.11.001.
   Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080.
   Roulland S, 2004, CANCER RES, V64, P2264, DOI 10.1158/0008-5472.CAN-03-3604.
   Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103.
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015.
   Samet JM, 2002, ENVIRON HEALTH PERSP, V110, P985, DOI 10.1289/ehp.02110985.
   SCHIFF R, 1991, GENE DEV, V5, P521, DOI 10.1101/gad.5.4.521.
   Schroeder JC, 2001, EPIDEMIOLOGY, V12, P701, DOI 10.1097/00001648-200111000-00020.
   Schwartz GG, 2003, DIABETES CARE, V26, P468, DOI 10.2337/diacare.26.2.468.
   Shiao YH, 2005, TOXICOL APPL PHARM, V205, P290, DOI 10.1016/j.taap.2004.10.017.
   Shimba S, 2000, BIOCHEM BIOPH RES CO, V272, P441, DOI 10.1006/bbrc.2000.2789.
   Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278.
   Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266.
   Smith FM, 2006, CYTOGENET GENOME RES, V113, P279, DOI 10.1159/000090843.
   Smith MT, 2005, TOXICOL APPL PHARM, V206, P237, DOI 10.1016/j.taap.2004.11.026.
   Stribinskis V, 2006, CANCER RES, V66, P2616, DOI 10.1158/0008-5472.CAN-05-3478.
   Sun F, 2005, J PHARMACOL EXP THER, V315, P69, DOI 10.1124/jpet.105.084632.
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186.
   TAM PPL, 1994, DEVELOPMENT, V120, P2925.
   TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170.
   TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159.
   TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520.
   TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382.
   Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324.
   TURUSOV VS, 1992, INT J CANCER, V50, P131, DOI 10.1002/ijc.2910500126.
   VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070.
   Verschure PJ, 2004, BIOL CELL, V96, P569, DOI 10.1016/j.biolcel.2004.07.001.
   Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375.
   Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275.
   Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791.
   Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005.
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276.
   WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163.
   Wu GY, 2004, J NUTR, V134, P2169.
   Wu Q, 2004, BIOL REPROD, V70, P1790, DOI 10.1095/biolreprod.103.025387.
   Xu Q, 2005, PEST MANAG SCI, V61, P1096, DOI 10.1002/ps.1090.
   Yang JM, 2003, REPROD TOXICOL, V17, P553, DOI 10.1016/S0890-6238(03)00100-X.
   Yu W, 1999, TOXICOL APPL PHARM, V158, P161, DOI 10.1006/taap.1999.8692.}},
Number-of-Cited-References = {{110}},
Times-Cited = {{138}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{64}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{206RM}},
Unique-ID = {{ISI:000249200600020}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000249636700012,
Author = {Al-Zenki, Sameer and Al-Nasser, Affaf and Al-Safar, AbdulAmir and
   Alomirah, Husam and Al-Haddad, Abdulla and Hendriksen, Rene S. and
   Aarestrup, Frank M.},
Title = {{Prevalence and antibiotic resistance of Salmonella isolated from a
   poultry farm and processing plant environment in the state of Kuwait}},
Journal = {{FOODBORNE PATHOGENS AND DISEASE}},
Year = {{2007}},
Volume = {{4}},
Number = {{3}},
Pages = {{367-373}},
Month = {{FAL}},
Abstract = {{The prevalence of Salmonella isolated from a poultry farm and from the
   poultry processing plant environment were evaluated from August 2004 to
   July 2005 along with microbial antibiotic resistance. In total, 3242
   samples were collected from the farm and processing plant. Samples
   collected from the farm included hatching eggs, paper liners, litter,
   feed, water, drinkers, air, bird rinse, and ceca. While samples
   collected from the processing plant included carcass rinse and ceca. Out
   of 2882 samples collected from the farm, the overall percentage
   prevalence of Salmonella was 5.4\% with prevalence rates of 10\%, 1.5\%,
   0.7\%, 0.2\%, 13.5\%, and 12.6\% for hatching eggs, litter, feed,
   drinkers, bird rinse and ceca, respectively. No Salmonella were detected
   in any of the paper liner, water, or air samples. Out of 360 samples
   collected from the processing plant, the overall percentage prevalence
   of Salmonella was 4.7\% with prevalence rates of 6.1\% and 3.3\% for
   carcass rinse and ceca samples, respectively. Salmonella Enteritidis was
   the most prevalent serotype. All of the isolates were resistant to at
   least one antibiotic and 10 different resistance profiles were found
   among 173 isolates of Salmonella Enteritidis. Resistance to ampicillin,
   nalidixic acid, and tetracycline were the most common. The widespread
   occurrence of multiple resistant Salmonella Enteritidis is a cause for
   concern, and local regulatory enforcement agencies should ensure prudent
   use of antibiotics.}},
Publisher = {{MARY ANN LIEBERT INC}},
Address = {{140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Al-Zenki, S (Reprint Author), Kuwait Inst Sci Res, Dept Biotechnol, Div Food Resources \& Marine Sci, POB 24885, Safat 13109, Kuwait.
   Kuwait Inst Sci Res, Dept Biotechnol, Food Resource \& Marine Sci Div, Safat, Kuwait.
   Kuwait Inst Sci Res, Dept Aridland Agriculture \& Greenery, Food Resource \& Marine Sci Div, Safat, Kuwait.
   Natl Food Inst, WHO Collaborat Ctr, Antimicrobial Resistance Foodborne Pathogens, Commun Ref Lab Antimicrobial Resistance, Copenhagen, Denmark.}},
DOI = {{10.1089/fpd.2007.0017}},
ISSN = {{1535-3141}},
Keywords-Plus = {{ENTERITIDIS PHAGE TYPE-4; QUINOLONE RESISTANCE; EGG; SPAIN; HENS;
   TYPHIMURIUM; INFECTION; PRODUCTS; CHICKEN}},
Research-Areas = {{Food Science \& Technology}},
Web-of-Science-Categories  = {{Food Science \& Technology}},
Author-Email = {{szenki@safat.kisr.edu.kw}},
ResearcherID-Numbers = {{Tast Lahti, Elina/R-8664-2016
   }},
ORCID-Numbers = {{Hendriksen, Rene S./0000-0003-2934-8214}},
Cited-References = {{ABURUWAIDA AS, 1994, J FOOD PROTECT, V57, P887, DOI 10.4315/0362-028X-57.10.887.
   Antunes P, 2003, INT J FOOD MICROBIOL, V82, P97, DOI 10.1016/S0168-1605(02)00251-9.
   Bailey JS, 1998, POULTRY SCI, V77, P394, DOI 10.1093/ps/77.3.394.
   BARNHART HM, 1991, J FOOD PROTECT, V54, P488, DOI 10.4315/0362-028X-54.7.488.
   Betancor L, 2004, J CLIN MICROBIOL, V42, P1155, DOI 10.1128/JCM.42.3.1155-1162.2004.
   Brisabois A, 1997, EUROSURVEILLANCE, V2, P19.
   Capita R, 2003, INT J FOOD MICROBIOL, V81, P169, DOI 10.1016/S0168-1605(02)00195-2.
   {*}CLSI, 2003, M07 A6 METH DIL AN S.
   Cox NA, 2000, POULTRY SCI, V79, P1571, DOI 10.1093/ps/79.11.1571.
   {*}FDA, 1995, BACT AN MAN ONL, pCH5.
   Gast RK, 1998, POULTRY SCI, V77, P1759, DOI 10.1093/ps/77.12.1759.
   Helms M, 2004, J INFECT DIS, V190, P1652, DOI 10.1086/424570.
   Helms M, 2002, EMERG INFECT DIS, V8, P490, DOI 10.3201/eid0805.010267.
   Humphrey T., 2000, Salmonella in domestic animals., P245, DOI 10.1079/9780851992617.0245.
   HUMPHREY TJ, 1990, WORLD POULTRY SCI J, V46, P5, DOI 10.1079/WPS19900002.
   HUMPHREY TJ, 1989, EPIDEMIOL INFECT, V103, P415, DOI 10.1017/S0950268800030818.
   Icgen B, 2002, FOOD MICROBIOL, V19, P375, DOI 10.1006/yfmic.479.
   Marimon JM, 2004, ANTIMICROB AGENTS CH, V48, P3789, DOI 10.1128/ACC.48.10.3789-3793.2004.
   Popoff M., 2001, ANTIGENIC FORMULAS S.
   SAWAYA WN, 1992, 4239 KUW I SCI RES.
   Suresh T, 2006, FOOD MICROBIOL, V23, P294, DOI 10.1016/j.fm.2005.04.001.
   Usera MA, 2002, J FOOD PROTECT, V65, P768, DOI 10.4315/0362-028X-65.5.768.
   1994, ANN REPORT NOTIFIED.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Foodborne Pathog. Dis.}},
Doc-Delivery-Number = {{212ZW}},
Unique-ID = {{ISI:000249636700012}},
DA = {{2018-08-13}},
}

@article{ ISI:000249267400013,
Author = {Kamgang, J. O. and Briandet, R. and Herry, J. M. and Brisset, J. L. and
   Naitali, M.},
Title = {{Destruction of planktonic, adherent and biofilm cells of Staphylococcus
   epidermidis using a gliding discharge in humid air}},
Journal = {{JOURNAL OF APPLIED MICROBIOLOGY}},
Year = {{2007}},
Volume = {{103}},
Number = {{3}},
Pages = {{621-628}},
Month = {{SEP}},
Abstract = {{Aims:To determine the efficiency of an electric discharge of the gliding
   arc type for the destruction of Staphylococcus epidermidis planktonic,
   adherent and biofilm cells.
   Methods and Results: Bacterial cells were treated in humid air and at
   atmospheric pressure by a nonthermal quenched plasma of the glidarc
   type. The kinetics of destruction (followed by plating) were modelled by
   an Add-inn for Microsoft (R) Excel, GInaFiT. For planktonic cells,
   log-linear destruction was obtained, whereas biphasic kinetics were
   observed for sessile cells. An increased resistance of biofilm cells was
   observed: the reduction of 6 logarithm units of the population was
   obtained in 15, 30 and 70 min for planktonic, adherent and biofilm
   cells, respectively. The experiments also show that the cells
   destruction did not depend on the adhesion surface but was governed by
   the gap between the target and the plasma source.
   Conclusion:The complete destruction of planktonic, adherent and more
   resistant biofilm cells of Staph. epidermidis is achieved by a glidarc
   air plasma at atmospheric pressure.
   Significance and Impact of the Study:The glidarc plasma technology is a
   promising candidate among the emerging nonthermal techniques for
   decontamination, as it can destroy even biofilms that are known as
   particularly resistant to various antimicrobials.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Naitali, M (Reprint Author), ENSIA INRA, UMR BHM, 25 Ave Republ, F-91744 Massy, France.
   ENSIA INRA, UMR BHM, F-91744 Massy, France.
   Univ Rouen, Lab Electrochim Interfaciale \& Chim Anayt, Rouen, France.}},
DOI = {{10.1111/j.1365-2672.2007.03286.x}},
ISSN = {{1364-5072}},
Keywords = {{adherent and biofilm cell resistance; destruction kinetics; gliding
   electric discharge; humid air arc plasma; nonthermal bacterial
   destruction}},
Keywords-Plus = {{PLASMA TREATMENT; LOW-PRESSURE; BACILLUS-SUBTILIS; STERILIZATION;
   RESISTANCE; INACTIVATION; TEMPERATURE; MECHANISMS; SPORES; ARC}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{naitali@ensia.fr}},
ORCID-Numbers = {{briandet, romain/0000-0002-8123-3492}},
Cited-References = {{Baxter HC, 2005, J GEN VIROL, V86, P2393, DOI 10.1099/vir.0.81016-0.
   Baxter HC, 2006, IEEE T PLASMA SCI, V34, P1337, DOI 10.1109/TPS.2006.878387.
   Benstaali B, 1998, EUR PHYS J-APPL PHYS, V4, P171, DOI 10.1051/epjap:1998258.
   Chavant P, 2004, FEMS MICROBIOL LETT, V236, P241, DOI 10.1016/j.femsle.2004.05.040.
   Choi JH, 2006, J ELECTROSTAT, V64, P17, DOI 10.1016/j.elstat.2005.04.001.
   Chu PK, 2002, MAT SCI ENG R, V36, P143, DOI 10.1016/S0927-796X(02)00004-9.
   FRANK JF, 1990, J FOOD PROTECT, V53, P235.
   Geeraerd AH, 2005, INT J FOOD MICROBIOL, V102, P95, DOI 10.1016/j.ijfoodmicro.2004.11.038.
   Hoyle B D, 1991, Prog Drug Res, V37, P91.
   Hury S, 1998, LETT APPL MICROBIOL, V26, P417.
   KUZMICHEV AI, 2000, HIGH PRESSURE LOW TE, V2, P402.
   Laroussi M, 2005, PLASMA PROCESS POLYM, V2, P391, DOI 10.1002/ppap.200400078.
   Laroussi M, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/341.
   Laroussi M, 2004, INT J MASS SPECTROM, V233, P81, DOI 10.1016/j.ijms.2003.11.016.
   Laroussi M., 1999, IEEE T PLASMA SCI, V27, P69.
   Lerouge S, 2000, J BIOMED MATER RES, V51, P128, DOI 10.1002/(SICI)1097-4636(200007)51:1<128::AID-JBM17>3.0.CO;2-\#.
   Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2.
   Moisan M, 2001, INT J PHARMACEUT, V226, P1, DOI 10.1016/S0378-5173(01)00752-9.
   Moisan M, 2002, PURE APPL CHEM, V74, P349, DOI 10.1351/pac200274030349.
   Montie TC, 2000, IEEE T PLASMA SCI, V28, P41, DOI 10.1109/27.842860.
   Moreau M, 2005, J APPL MICROBIOL, V98, P1039, DOI 10.1111/j.1365-2672.2004.02535.x.
   MOREAU M, 2006, THESIS FRANCE U ROUS.
   Moreau S, 2000, J APPL PHYS, V88, P1166, DOI 10.1063/1.373792.
   Moussa D, 2005, EUR PHYS J-APPL PHYS, V29, P189, DOI {[}10.1051/epjap:2004211, 10.1051/epjap.2004211].
   NEIMIRA BA, 2005, APPL ENVIRON MICROB, V71, P2732.
   NOUBISSI JOK, 2005, THESIS FRANCE U ROUE.
   Patel R, 2005, CLIN ORTHOP RELAT R, P41, DOI 10.1097/01.blo.0000175714.68624.74.
   Ratkowsky D. A., 2003, MODELING MICROBIAL R, P151.
   Setlow P, 2006, J APPL MICROBIOL, V101, P514, DOI 10.1111/j.1365-2672.2005.02736.x.
   Sladek REJ, 2004, IEEE T PLASMA SCI, V32, P1540, DOI 10.1109/TPS.2004.832636.
   Stewart PS, 2002, INT J MED MICROBIOL, V292, P107, DOI 10.1078/1438-4221-00196.
   Villeger S, 2004, EUR PHYS J-APPL PHYS, V26, P203, DOI 10.1051/epjap:2004034.
   VITRAC H, 2000, HIGH PRESSURE LOW TE, V2, P393.
   Yu H, 2006, J APPL MICROBIOL, V101, P1323, DOI 10.1111/j.1365-2672.2006.03033.x.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{J. Appl. Microbiol.}},
Doc-Delivery-Number = {{207QY}},
Unique-ID = {{ISI:000249267400013}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000249704900002,
Author = {Tien, Homer C. and Battad, Anthony and Bryce, Elizabeth A. and Fuller,
   Jeffrey and Mulvey, Michael and Bernard, Kathy and Brisebois, Ronald and
   Doucet, Jay J. and Rizoli, Sandro B. and Fowler, Robert and Simor,
   Andrew},
Title = {{Multi-drug resistant Acinetobacter infections in critically injured
   Canadian forces soldiers}},
Journal = {{BMC INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{7}},
Month = {{AUG 14}},
Abstract = {{Background: Military members, injured in Afghanistan or Iraq, have
   returned home with multidrug resistant Acinetobacter baumannii
   infections. The source of these infections is unknown.
   Methods: Retrospective study of all Canadian soldiers who were injured
   in Afghanistan and who required mechanical ventilation from January 1
   2006 to September 1 2006. Patients who developed A. baumannii ventilator
   associated pneumonia ( VAP) were identified. All A. baumannii isolates
   were retrieved for study patients and compared with A. baumannii
   isolates from environmental sources from the Kandahar military hospital
   using pulsed-field gel electrophoresis ( PFGE).
   Results: During the study period, six Canadian Forces ( CF) soldiers
   were injured in Afghanistan, required mechanical ventilation and were
   repatriated to Canadian hospitals. Four of these patients developed A.
   baumannii VAP. A. baumannii was also isolated from one environmental
   source in Kandahar - a ventilator air intake filter. Patient isolates
   were genetically indistinguishable from each other and from the isolates
   cultured from the ventilator filter. These isolates were resistant to
   numerous classes of antimicrobials including the carbapenems. C
   onclusion: These results suggest that the source of A. baumannii
   infection for these four patients was an environmental source in the
   military field hospital in Kandahar. A causal linkage, however, was not
   established with the ventilator. This study suggests that infection
   control efforts and further research should be focused on the military
   field hospital environment to prevent further multi-drug resistant A.
   baumannii infections in injured soldiers.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tien, HC (Reprint Author), SUNY Hlth Sci Ctr, Dept Surg, Trauma Program, H186-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
   SUNY Hlth Sci Ctr, Dept Surg, Trauma Program, Toronto, ON M4N 3M5, Canada.
   1st Canadian Field Hosp, CFB Petawawa, Petawawa, ON, Canada.
   Vancouver Gen Hosp, Dept Pathol \& Lab Med, Vancouver, BC, Canada.
   Univ Alberta Hosp, Dept Lab Med \& Pathol, Edmonton, AB T6G 2R7, Canada.
   Nosocomial Infect \& Antimicrobial Resistance Lab, Natl Microbiol Lab, Winnipeg, MB, Canada.
   Univ Alberta Hosp, Dept Surg \& Crit Care Med, Edmonton, AB T6G 2B7, Canada.
   Vancouver Gen Hosp, Dept Surg, Vancouver, BC, Canada.
   SUNY Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada.
   SUNY Hlth Sci Ctr, Dept Microbiol, Toronto, ON, Canada.}},
DOI = {{10.1186/1471-2334-7-95}},
Article-Number = {{95}},
ISSN = {{1471-2334}},
Keywords-Plus = {{FIELD GEL-ELECTROPHORESIS; INTENSIVE-CARE-UNIT; BAUMANNII; OUTBREAK;
   CASUALTIES; IRAQ; WAR}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Author-Email = {{homer.tien@sunnybrook.ca
   a.battad@shaw.ca
   elizabeth.bryce@vch.ca
   jeffrey.fuller@provlab.ab
   michael\_mulvey@phac-aspc.gc.ca
   kathy\_bernard@phac-aspc.gc.ca
   ronald.brisebois@shaw.ca
   Jay.doucet@yahoo.com
   sandro.rizoli@sunnybrook.ca
   rob.fowler@sunnybrook.ca
   andrew.simor@sunnybrook.ca}},
ResearcherID-Numbers = {{Doucet, Jay/O-3005-2018}},
ORCID-Numbers = {{Doucet, Jay/0000-0001-9617-001X}},
Cited-References = {{CEFAI C, 1993, J HOSP INFECT, V25, P15.
   Centers for Disease C and Prevention, 2004, MMWR-MORBID MORTAL W, V53, P1063.
   Cox TR, 1998, MIL MED, V163, P389.
   Dealler S, 1998, J HOSP INFECT, V38, P147, DOI 10.1016/S0195-6701(98)90068-8.
   Fournier PE, 2006, CLIN INFECT DIS, V42, P692, DOI 10.1086/500202.
   Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317.
   Heath C.H., 2003, AUST INFECT CONTROL, V2, P43.
   HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659.
   Jones A, 2006, LANCET INFECT DIS, V6, P317, DOI 10.1016/S1473-3099(06)70471-6.
   SEIFERT H, 1995, J CLIN MICROBIOL, V33, P1402.
   Simor AE, 2002, INFECT CONT HOSP EP, V23, P261, DOI 10.1086/502046.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   TONG MJ, 1972, J AMER MED ASSOC, V219, P1044, DOI 10.1001/jama.219.8.1044.
   Urban C, 2003, CLIN INFECT DIS, V36, P1268, DOI 10.1086/374847.
   Zapor MJ, 2005, CURR OPIN INFECT DIS, V18, P395, DOI 10.1097/01.qco.0000182102.50430.2c.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{51}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{BMC Infect. Dis.}},
Doc-Delivery-Number = {{213ZD}},
Unique-ID = {{ISI:000249704900002}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000249682900009,
Author = {Sisniega, J. Lopez and Profant, Milan and Kostrica, Rom and Waskin,
   Hetty},
Title = {{Oral garenoxacin in the treatment of acute bacterial maxillary
   sinusitis: A phase II, multicenter, noncomparative, open-label study in
   adult patients undergoing sinus aspiration}},
Journal = {{CLINICAL THERAPEUTICS}},
Year = {{2007}},
Volume = {{29}},
Number = {{8}},
Pages = {{1632-1644}},
Month = {{AUG}},
Abstract = {{Background: Garenoxacin is a des-F(6)-quinolone with in vitro activity
   against key respiratory pathogens, including Streptococcus pneumoniae,
   Hemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis.
   Limited data are available regarding the effect of garenoxacin in the
   treatment of acute bacterial sinusitis.
   Objective: The aim of this study was to assess the efficacy and
   tolerability of garenoxacin in adults with acute bacterial maxillary
   sinusitis undergoing a pretreatment diagnostic sinus aspirate.
   Methods: This Phase II, multicenter, noncomparative, open-label study
   was conducted at 30 centers in the United States, Mexico, Argentina, and
   Europe. Male and female patients aged 18 to 80 years with clinical signs
   and symptoms lasting >= 5 but : 28 days and radiologic signs (air-fluid
   level, opacification, mucosal thickening) of acute maxillary sinusitis
   were eligible. The entry criteria for the 5-day treatment regimen did
   not include mucosal thickening of >= 5 mm because it was believed that
   improvement in mucosal thickening might not be reliably measurable at
   the 5-day time point. All patients received garenoxacin 400 mg QD for 5
   or 10 days. Maxillary sinus needle aspiration for Gram stain, routine
   culture, and susceptibility testing were performed before treatment,
   and, if clinically indicated, during and after treatment. Bacteriologic
   eradication (negative culture on repeat sinus aspiration) and cure rates
   (complete resolution of all signs and symptoms) were assessed at a
   test-of-cure visit 5 to 18 days after the end of treatment. The
   occurrence of adverse events was recorded by the investigators up to 30
   days after the last administration of garenoxacin by questioning
   patients.
   Results: A total of 546 patients were enrolled and 543 were randomized
   (5-day cohort: mean age, 40 years; mean weight, 76 kg; 56\% women;
   10-day cohort: mean age, 41 years; mean weight, 77 kg; 5 8 \% women).
   Clinically evaluable patients included 253 in the 5-day cohort and 266
   in the 10-day cohort. Cure rates were 93\% (236/253; 95\% CI, 89\%-96\%)
   and 91\% (243/266; 95\% CI, 87\%-94\%) for evaluable patients in the 5-
   and 10-day cohorts, respectively. Bacteriologic eradication rates in
   microbiologically evaluable patients were 94\% in both cohorts (5 days,
   204/217; 10 days, 182/193). Eradication rates in the 5- and 10-day
   cohorts were as follows: S pneumoniae, 94\% (62166) and 93\% (39/42); H
   influenzae, 100\% (30/30) and 93\% (26/28); S aureus, 96\% (23/24) and
   91\% (31/34); and M catarrhalis, 89\% (8/9) and 86\% (12/14). Of the 9
   patients with acute bacterial sinusitis due to multidrug-resistant S
   pneumoniae, 8 achieved clinical cure with garenoxacin treatment. Adverse
   events (AEs) most frequently reported were diarrhea (<= 2\%), nausea
   (2\%-6\%), headache (2\%-6\%), and dizziness (52\%). Two percent of
   patients withdrew because of an AE (allergic reaction, adverse
   gastrointestinal effects, dyspnea, dizziness, headache, or elevation in
   liver enzymes).
   Conclusion: In this population of patients with signs and symptoms of
   acute maxillary sinusitis, oral garenoxacin 400 mg QD for 5 or 10 days
   eradicated 94\% of bacterial pathogens associated with acute bacterial
   sinusitis in this population and appeared to be well tolerated in
   adults. (Clin Tber. 2007;29:16321644) Copyright (c) 2007 Excerpta
   Medica, Inc.}},
Publisher = {{ELSEVIER}},
Address = {{685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Waskin, H (Reprint Author), Schering Plough Res Inst, 2015 Galloping Hall Rd, Kenilworth, NJ 07033 USA.
   Schering Plough Res Inst, Kenilworth, NJ 07033 USA.
   Hosp Clin Parque, Chihuahua, Mexico.
   Fac Hosp, Bratislava, Slovakia.
   St Anne Fac Hosp, Brno, Czech Republic.}},
DOI = {{10.1016/j.clinthera.2007.08.002}},
ISSN = {{0149-2918}},
Keywords = {{des-F(6)-quinolone; garenoxacin; Hemophilus influenzae; Moraxella
   catarrhalis; sinusitis; Streptococcus pneumoniae}},
Keywords-Plus = {{RESISTANT STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY-TRACT INFECTIONS;
   MORAXELLA-CATARRHALIS; IN-VITRO; PNEUMOCOCCAL PNEUMONIA;
   HAEMOPHILUS-INFLUENZAE; UNITED-STATES; ANTIMICROBIAL RESISTANCE;
   DOUBLE-BLIND; LEVOFLOXACIN}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{hetty.waskin@spcorp.com}},
Cited-References = {{Andrews J, 2003, J ANTIMICROB CHEMOTH, V51, P727, DOI 10.1093/jac/dkg110.
   {[}Anonymous], 2000, OTOLARYNGOL HEAD NEC, V123, P5.
   Ariza H, 2006, BMC EAR NOSE THROAT, V6, DOI 10.1186/1472-6815-6-8.
   Azoulay-Dupuis E, 2004, ANTIMICROB AGENTS CH, V48, P765, DOI 10.1128/AAC.48.3.765-773.2004.
   Bassetti M, 2002, ANTIMICROB AGENTS CH, V46, P234, DOI 10.1128/AAC.46.1.234-238.2002.
   BELLO A, 2002, 37 ANN AM SOC HLTH S.
   Biedenbach DJ, 2001, DIAGN MICR INFEC DIS, V39, P245, DOI 10.1016/S0732-8893(01)00224-3.
   Boswell FJ, 2001, J ANTIMICROB CHEMOTH, V48, P446, DOI 10.1093/jac/48.3.446.
   Brook I, 1999, ANN OTO RHINOL LARYN, V108, P645, DOI 10.1177/000348949910800704.
   Brooks I, 2000, Ann Otol Rhinol Laryngol Suppl, V182, P2.
   Clifford K, 1999, ANN OTO RHINOL LARYN, V108, P360, DOI 10.1177/000348949910800408.
   {*}COSTART, 1995, COD SYST THES ADV RE.
   Davidson R, 2002, NEW ENGL J MED, V346, P747, DOI 10.1056/NEJMoa012122.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P2884.
   Edmiston CE, 2005, J ANTIMICROB CHEMOTH, V56, P872, DOI 10.1093/jac/dki348.
   Elies Wolfgang, 2004, Treat Respir Med, V3, P269, DOI 10.2165/00151829-200403050-00001.
   Empey PE, 2001, ANN PHARMACOTHER, V35, P687.
   {*}EUR AG EV MED PRO, 2002, GUIDL GOOD CLIN PRAC.
   Furuno JP, 2006, PHARMACOEPIDEM DR S, V15, P1, DOI 10.1002/pds.1135.
   Gajjar DA, 2003, ANTIMICROB AGENTS CH, V47, P2256, DOI 10.1128/AAC.47.7.2256-2263.2003.
   Gales A, 2001, ANTIMICROB AGENTS CH, V45, P1463, DOI 10.1128/AAC.45.5.1463-1466.2001.
   Garrison N, 2000, ANN ALLERG ASTHMA IM, V84, P63, DOI 10.1016/S1081-1206(10)62742-1.
   Gehanno P, 2003, J INT MED RES, V31, P434, DOI 10.1177/147323000303100513.
   Jacobs MR, 2003, J ANTIMICROB CHEMOTH, V52, P229, DOI 10.1093/jac/dkg321.
   Jones RN, 2003, DIAGN MICR INFEC DIS, V45, P273, DOI 10.1016/S0732-8893(03)00002-6.
   Jones RN, 2001, DIAGN MICR INFEC DIS, V39, P133, DOI 10.1016/S0732-8893(00)00233-9.
   Lasko B, 1998, J INT MED RES, V26, P281, DOI 10.1177/030006059802600602.
   Lawrence LE, 2002, ANTIMICROB AGENTS CH, V46, P191, DOI 10.1128/AAC.46.1.191-195.2002.
   Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029.
   National Committee for Clinical Laboratory Standards, 2000, METH DIL ANT SUSC TE.
   Pfaller MA, 2006, J CLIN MICROBIOL, V44, P819, DOI 10.1128/JCM.44.3.819-826.2006.
   Piccirillo JF, 2004, NEW ENGL J MED, V351, P902, DOI 10.1056/NEJMcp035553.
   Poole M, 2006, OTOLARYNG HEAD NECK, V134, P10, DOI 10.1016/j.otohns.2005.11.026.
   POOLE MD, 1999, AM J MED, V106, pS48.
   Poole Michael D., 1999, American Journal of Medicine, V106, p38S.
   Ross JJ, 2002, NEW ENGL J MED, V347, P65.
   Sher LD, 2002, CLIN THER, V24, P269, DOI 10.1016/S0149-2918(02)85023-8.
   Siegert R, 2000, RESP MED, V94, P337, DOI 10.1053/rmed.1999.0769.
   STEWART C, 2001, 41 INT C ANT AG CHEM.
   Takahata M, 1999, ANTIMICROB AGENTS CH, V43, P1077.
   TAM V, 2001, 39 ANN M INF DIS SOC.
   Thornsberry C, 1997, DIAGN MICR INFEC DIS, V29, P249, DOI 10.1016/S0732-8893(97)00195-8.
   Weckx L.L.M., 2005, Braz J Infect Dis, V9, P162, DOI 10.1590/S1413-86702005000200007.
   {*}WORLD MED ASS DEC, ETH PRINC MED RES IN.
   Zhanel GG, 2006, J ANTIMICROB CHEMOTH, V58, P112, DOI 10.1093/jac/dkl159.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Clin. Ther.}},
Doc-Delivery-Number = {{213QT}},
Unique-ID = {{ISI:000249682900009}},
DA = {{2018-08-13}},
}

@article{ ISI:000248229500006,
Author = {Hata, Yoshinobu and Takagi, Keigo and Sasamoto, Shuichi and Kato,
   Nobuhide and Satoh, Fumitomo and Otsuka, Hajime and Fukumori, Kazuhiko},
Title = {{Infected giant bulla treated by percutaneous drainage followed later by
   resection: Report of a case}},
Journal = {{SURGERY TODAY}},
Year = {{2007}},
Volume = {{37}},
Number = {{8}},
Pages = {{656-659}},
Month = {{AUG}},
Abstract = {{A 55-year-old man was hospitalized for treatment of a giant,
   fluid-filled bulla in the upper lobe of the right lung. The infection
   was resistant to antibiotics, and the resulting drug-induced liver
   dysfunction prohibited us from performing emergency lobectomy.
   Percutaneous drainage of the bulla was done initially, using a 28-Fr
   chest tube, after which the symptoms of infection improved rapidly.
   Despite a small air leakage, which became evident on day 4 of drainage,
   shrinkage of the bulla was achieved, and elective bullectomy was
   performed after continuous drainage for 21 days. Thus, percutaneous
   drainage was effective in controlling the infection and minimizing the
   invasiveness of surgery.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hata, Y (Reprint Author), Toho Univ, Omori Med Ctr, Dept Chest Surg, Ota Ku, 6-11-1 Omori Nichi, Tokyo 1438541, Japan.
   Toho Univ, Omori Med Ctr, Dept Chest Surg, Ota Ku, Tokyo 1438541, Japan.}},
DOI = {{10.1007/s00595-007-3474-z}},
ISSN = {{0941-1291}},
Keywords = {{infected bulla; giant bulla; percutaneous drainage}},
Keywords-Plus = {{LUNG ABSCESS; MANAGEMENT}},
Research-Areas = {{Surgery}},
Web-of-Science-Categories  = {{Surgery}},
Cited-References = {{DEAN NC, 1987, CHEST, V91, P928, DOI 10.1378/chest.91.6.928.
   GINSBERG RJ, 1988, CHEST, V94, P1125, DOI 10.1378/chest.94.6.1125b.
   Goto Rie, 2002, Nihon Kokyuki Gakkai Zasshi, V40, P26.
   HOSHINO H, 2000, NIHON KYOBU RINSYO, V59, P536.
   Kambayashi Takatoyo, 2004, Nihon Kokyuki Gakkai Zasshi, V42, P533.
   KANEKI T, 1997, KYOBU SHIKKAN GAKKAI, V35, P801.
   Kirschner LA, 1997, CHEST, V111, P1772, DOI 10.1378/chest.111.6.1772.
   Matsuno O, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P479.
   OZAKI S, 2002, HIROSHIMA IGAKU, V55, P660.
   SHIM C, 1990, LUNG, V168, P201, DOI 10.1007/BF02719693.
   Takizawa S, 2000, CEREBROVASC DIS, V10, P409, DOI 10.1159/000016098.
   Tanaka K, 1989, Nihon Kyobu Geka Gakkai Zasshi, V37, P1511.
   Wali SO, 2002, SCAND J INFECT DIS, V34, P673, DOI 10.1080/0036540210147660.
   Yanase K, 1998, Nihon Kokyuki Gakkai Zasshi, V36, P81.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Surg. Today}},
Doc-Delivery-Number = {{192US}},
Unique-ID = {{ISI:000248229500006}},
DA = {{2018-08-13}},
}

@article{ ISI:000249027600001,
Author = {van der Deen, Margaretha and Timens, Wim and Timmer-Bosscha, Hetty and
   van der Strate, Barry W. and Scheper, Rik J. and Postma, Dirkje S. and
   de Vries, Elisabeth G. and Kerstjens, Huib A.},
Title = {{Reduced inflammatory response in cigarette smoke exposed MrpI/MdrIa/Ib
   deficient mice}},
Journal = {{RESPIRATORY RESEARCH}},
Year = {{2007}},
Volume = {{8}},
Month = {{JUL 7}},
Abstract = {{Background: Tobacco smoke is the principal risk factor for chronic
   obstructive pulmonary disease (COPD), though the mechanisms of its
   toxicity are still unclear. The ABC transporters multidrug
   resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp/MDR1)
   extrude a wide variety of toxic substances across cellular membranes and
   are highly expressed in bronchial epithelium. Their impaired function
   may contribute to COPD development by diminished detoxification of
   noxious compounds in cigarette smoke.
   Methods: We examined whether triple knock-out (TKO) mice lacking the
   genes for Mrp1 and Mdr1a/1b are more susceptible to develop COPD
   features than their wild-type (WT) littermates. TKO and WT mice (six per
   group) were exposed to 2 cigarettes twice daily by nose-only exposure or
   room air for 6 months. Inflammatory infiltrates were analyzed in lung
   sections, cytokines and chemokines in whole lung homogenates, emphysema
   by mean linear intercept. Multiple linear regression analysis with an
   interaction term was used to establish the statistical significances of
   differences.
   Results: TKO mice had lower levels of interleukin (IL)-7, KC (mouse
   IL-8), IL-12p70, IL-17, TNF-alpha, G-CSF, GM-CSF and MIP-1-alpha than WT
   mice independent of smoke exposure (P < 0.05). IL-1-alpha, IL-6, IL-8,
   IL-13, IL-17, TNF-alpha, G-CSF, GM-CSF and MCP-1 increased after smoke
   exposure in both groups, but the increase in IL-8 was lower in TKO than
   WT mice (P < 0.05) with a same trend for G-CSF (P < 0.10). Smoke-induced
   increase in pulmonary inflammatory cells in WT mice was almost absent in
   TKO mice. The mean linear intercept was not different between groups.
   Conclusion: Mrp1/Mdr1a/1b knock-out mice have a reduced inflammatory
   response to cigarette smoke. In addition, the expression levels of
   several cytokines and chemokines were also lower in lungs of Mrp1/
   Mdr1a/1b knock-out mice independent of smoke exposure. Further studies
   are required to determine whether dysfunction of MRP1 and/or P-gp
   contribute to the pathogenesis of COPD.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kerstjens, HA (Reprint Author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulm, Groningen, Netherlands.
   Univ Groningen, Med Ctr, Dept Med Oncol, NL-9700 AB Groningen, Netherlands.
   Univ Groningen, Med Ctr, Dept Pathol, NL-9700 AB Groningen, Netherlands.
   Free Univ Amsterdam Hosp, Dept Pathol, Amsterdam, Netherlands.}},
DOI = {{10.1186/1465-9921-8-49}},
Article-Number = {{49}},
ISSN = {{1465-9921}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE PROTEIN-1; INDUCED PULMONARY-EMPHYSEMA; INCREASED
   SENSITIVITY; BRONCHIAL EPITHELIUM; DENDRITIC CELLS; LUNG; LACKING; COPD;
   GENE; MRP1}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{margaretha.vanderdeen@umassmed.edu
   w.timens@path.umcg.nl
   h.timmer-bosscha@int.umcg.nl
   B.W.A.van.der.Strate@med.umcg.nl
   RJ.Scheper@vumc.nl
   d.s.postma@int.umcg.nl
   e.g.e.de.vries@int.umcg.nl
   h.a.m.kerstjens@int.umcg.nl}},
ResearcherID-Numbers = {{Timens, Wim/K-5570-2013}},
ORCID-Numbers = {{Timens, Wim/0000-0002-4146-6363}},
Cited-References = {{Balayssac D, 2005, TOXICOL LETT, V156, P319, DOI 10.1016/j.toxlet.2004.12.008.
   Brechot JM, 1998, J HISTOCHEM CYTOCHEM, V46, P513, DOI 10.1177/002215549804600411.
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704.
   D'hulst AI, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-147.
   de Boer WI, 2002, CHEST, V121, p209S, DOI 10.1378/chest.121.5\_suppl.209S.
   GRIFFITH RB, 1985, TOXICOLOGY, V34, P123, DOI 10.1016/0300-483X(85)90162-3.
   Guerassimov A, 2004, AM J RESP CRIT CARE, V170, P974, DOI 10.1164/rccm.200309-1270oc.
   Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086.
   Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158.
   Ishizawa K, 2004, FEBS LETT, V556, P249, DOI 10.1016/S0014-5793(03)01399-1.
   Johnson DR, 2001, CANCER RES, V61, P1469.
   LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x.
   Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200.
   Lorico A, 1997, CANCER RES, V57, P5238.
   Pease James E, 2002, Am J Respir Med, V1, P19.
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146.
   Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3.
   Scheffer GL, 2002, J CLIN PATHOL, V55, P332, DOI 10.1136/jcp.55.5.332.
   Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028.
   Schultz MJ, 2001, J IMMUNOL, V166, P4059, DOI 10.4049/jimmunol.166.6.4059.
   THURLBEC.WM, 1967, AM REV RESPIR DIS, V95, P752.
   van de Ven R, 2006, J IMMUNOL, V176, P5191, DOI 10.4049/jimmunol.176.9.5191.
   van der Deen M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-59.
   van der Deen M, 2006, VIRCHOWS ARCH, V449, P682, DOI 10.1007/s00428-006-0240-3.
   van der Strate BWA, 2006, AM J RESP CRIT CARE, V173, P751, DOI 10.1164/rccm.200504-594OC.
   Verbon A, 2002, CLIN EXP IMMUNOL, V130, P32, DOI 10.1046/j.1365-2249.2002.01952.x.
   Vlahos R, 2006, AM J PHYSIOL-LUNG C, V290, pL931, DOI 10.1152/ajplung.00201.2005.
   Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267.
   Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275.
   Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904.
   Xu DM, 2004, IMMUNOL CELL BIOL, V82, P462, DOI 10.1111/j.1440-1711.2004.01274.x.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{36}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Respir. Res.}},
Doc-Delivery-Number = {{204EX}},
Unique-ID = {{ISI:000249027600001}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000247379200011,
Author = {Vache, Christel and Camares, Olivier and Cardoso-Ferreira, Marie-Celeste
   and Dastugue, Bernard and Creveaux, Isabelle and Vaury, Chantal and
   Bamdad, Mahchid},
Title = {{A potential genomic biomarker for the detection of polycyclic aromatic
   hydrocarbon pollutants: Multidrug resistance gene 49 in Drosophila
   melanogaster}},
Journal = {{ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY}},
Year = {{2007}},
Volume = {{26}},
Number = {{7}},
Pages = {{1418-1424}},
Month = {{JUL}},
Abstract = {{Polycyclic aromatic hydrocarbons (PAHs) are a major source of air,
   water, and soil pollution. The multidrug resistance (mdr)/permeability
   glycoprotein (P-gp) complex is implicated in the multidrug resistance
   pattern developed against various drugs and xenobiotics, including
   polycyclic aromatic hydrocarbons. In order to develop a genomic
   biomarker, we investigated the response of the mdr49 gene (mdr49) of
   Drosophila melanogaster to PAHs. Structural analysis of mdr49-PA, which
   is the putative protein expressed from Drosophila mdr49gene,
   demonstrated that this transmembrane protein indeed belongs to the
   adenosine triphosphatebinding cassette transporter superfamily.
   Polymerase chain reaction (PCR) and real-time PCR analysis revealed that
   the mdr49 gene is expressed continuously at all the stages of fly
   development, including embryos, pupae, larvae, and adults, as well as in
   embryonic Drosophila S12 cells. In the adult fly, the mdr49 gene was
   expressed in all the analyzed segments (head, thorax, and abdomen) and
   organs (olfactory and sexual organs). The quantification of mdr49
   transcripts by real-time PCR in adult flies exposed to benzo{[}a]pyrene
   over time or in presence of increasing concentrations of this pollutant
   showed a clear dose-dependent response. Similarly, mdr49 gene expression
   increased after adult flies were exposed to structurally varied PAHs.
   The detection of tested PAHs by Drosophila P-gp efflux pump was checked
   by flow cytometry.}},
Publisher = {{SOCIETY ENVIRONMENTAL TOXICOLOGY \& CHEMISTRY-SETAC}},
Address = {{1010 NORTH 12TH AVE, PENSACOLA, FL 32501-3367 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bamdad, M (Reprint Author), Univ Auvergne, Fac Med, Lab Biochim Med, INSERM,UMR 384, 28 Pl Henri Dunant, F-63001 Clermont Ferrand, France.
   Univ Auvergne, Fac Med, Lab Biochim Med, INSERM,UMR 384, F-63001 Clermont Ferrand, France.
   Ensemble Univ Cezeaux, Dept Genie Biol, Inst Univ Technol, F-63172 Aubiere, France.}},
DOI = {{10.1897/06-552R.1}},
ISSN = {{0730-7268}},
Keywords = {{multidrug resistance; mdr49 gene; Drosophila; polycyclic aromatic
   hydrocarbons; biomarker}},
Keywords-Plus = {{P-GLYCOPROTEIN; TETRAHYMENA-PYRIFORMIS; ABC TRANSPORTERS; EFFLUX PUMP;
   MECHANISM; SEQUENCE; HOMOLOG; TISSUES; SYSTEM; CELLS}},
Research-Areas = {{Environmental Sciences \& Ecology; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Toxicology}},
Author-Email = {{mahchid.bamdad@inserm.u-clermont1.fr}},
ResearcherID-Numbers = {{Vaury, Chantal/I-4658-2015
   Marion-Poll, Frederic/D-8882-2011}},
ORCID-Numbers = {{Vaury, Chantal/0000-0002-7725-5760
   Marion-Poll, Frederic/0000-0001-6824-0180}},
Cited-References = {{Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185.
   Ambudkar SV, 2006, EUR J PHARM SCI, V27, P392, DOI 10.1016/j.ejps.2005.10.010.
   Ambudkar SV, 2006, FEBS LETT, V580, P1049, DOI 10.1016/j.febslet.2005.12.051.
   Bamdad M, 1997, CYTOMETRY, V28, P170, DOI 10.1002/(SICI)1097-0320(19970601)28:2<170::AID-CYTO11>3.0.CO;2-N.
   Bamdad M, 1999, FEBS LETT, V456, P389, DOI 10.1016/S0014-5793(99)00978-3.
   Brighigna L, 2002, REV BIOL TROP, V50, P577.
   Chang G, 2003, FEBS LETT, V555, P102, DOI 10.1016/S0014-5793(03)01085-8.
   CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346.
   DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2.
   GERRARD B, 1993, GENOMICS, V17, P83, DOI 10.1006/geno.1993.1286.
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5.
   Ismert M, 2002, CHEMOSPHERE, V46, P273, DOI 10.1016/S0045-6535(01)00124-2.
   Klumpp A, 2002, ENVIRON SCI POLLUT R, V9, P199, DOI 10.1007/BF02987489.
   Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305.
   Suneela Motati, 2004, J Environ Sci Eng, V46, P245.
   Tapadia MG, 2005, CELL STRESS CHAPERON, V10, P7, DOI 10.1379/CSC-67R.1.
   Vache C, 2006, ENVIRON TOXICOL CHEM, V25, P572, DOI 10.1897/04-425.1.
   Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240.
   WU CT, 1991, MOL CELL BIOL, V11, P3940, DOI 10.1128/MCB.11.8.3940.
   YEH GC, 1992, CANCER RES, V52, P6692.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Environ. Toxicol. Chem.}},
Doc-Delivery-Number = {{180PY}},
Unique-ID = {{ISI:000247379200011}},
DA = {{2018-08-13}},
}

@article{ ISI:000248003100003,
Author = {{[}Anonymous]},
Title = {{Extensively drug-resistant tuberculosis (XDR TB): Air travel exposure}},
Journal = {{INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{11}},
Number = {{4}},
Pages = {{288}},
Month = {{JUL}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{News Item}},
Language = {{English}},
ISSN = {{1201-9712}},
EISSN = {{1878-3511}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Infect. Dis.}},
Doc-Delivery-Number = {{189QH}},
Unique-ID = {{ISI:000248003100003}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000247595300028,
Author = {Mohsen, Tarek and Abou Zeid, Amany and Haj-Yahia, Saleem},
Title = {{Lobectomy or pneumonectomy for multidrug-resistant pulmonary
   tuberculosis can be performed with acceptable morbidity and mortality: A
   seven-year review of a single institution's experience}},
Journal = {{JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY}},
Year = {{2007}},
Volume = {{134}},
Number = {{1}},
Pages = {{194-198}},
Month = {{JUL}},
Abstract = {{Objective: Combination chemotherapy is considered the first-line
   treatment for pulmonary tuberculosis. Despite related morbidity, the
   need for surgical resections coincides with the emergence of
   multidrug-resistant tuberculosis. This study presents a
   single-institution retrospective audit of the surgical management of 23
   patients with multidrug-resistant tuberculosis.
   Methods: We analyzed 23 consecutive patients undergoing anatomic
   pulmonary resections for human immunodeficiency virus-negative
   multidrug-resistant tuberculosis. Twenty were male (87\%) and 3 were
   female (13\%); their mean age was 24.4 years. We defined resistance in
   this cohort as failure to respond to combination chemotherapy, including
   isoniazid and rifampicin, with a mean duration of administration being
   90 days. Fifteen of 23 (65.3\%) patients, although sputum negative, were
   considered at risk for relapse owing to extensive parenchymal disease.
   Eight (34.7\%) of 23 patients were sputum positive at the time of
   operation. We performed pneumonectomy on 11 (47.8\%) and lobectomy on 12
   (52\%) patients. All had adjuvant chemotherapy for 18 to 24 months, with
   follow-ups ranging from 14 to 27 months.
   Results: Stay in the intensive treatment unit was 2.9 days (range 1-17
   days) and hospital stay, 8.6 days (range 5-45 days). Four (17\%)
   patients had prolonged air leak, 3 (13\%) required further treatment for
   empyema, with re-exploration for bleeding in 1 (4\%). Hospital mortality
   was 4.3\%. All patients attained sputum-negative status postoperatively
   (range 1-5 months). One (4\%) patient had a relapse after 12 months.
   Conclusion: Surgery should be considered as an adjunct to medical
   therapy when eradicating multidrug-resistant tuberculosis in affected
   patients. Anatomic lung resections can be performed with acceptable
   morbidity and mortality. Early referral of such patients for surgical
   consideration is warranted.}},
Publisher = {{MOSBY-ELSEVIER}},
Address = {{360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Haj-Yahia, S (Reprint Author), Royal Brompton \& Harefield Hosp, Natl Heart \& Lung Inst, Imperial Coll London, Dept Cardiothorac Surg, London, England.
   Royal Brompton \& Harefield Hosp, Natl Heart \& Lung Inst, Imperial Coll London, Dept Cardiothorac Surg, London, England.
   Cairo Univ, Kasar El Aini Hosp, Dept Cardiothorac Surg, Cairo, Egypt.
   Cairo Univ, Kasar El Aini Hosp, Dept Chest Med, Cairo, Egypt.}},
DOI = {{10.1016/j.jtcvs.2007.03.022}},
ISSN = {{0022-5223}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; SURGERY; FLUOROQUINOLONES; COMPLICATIONS;
   RESECTION; RIFAMPIN}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
Author-Email = {{s.haj-yahia@imperial.ac.uk}},
Cited-References = {{Connery CP, 2003, ANN THORAC SURG, V75, P1613, DOI 10.1016/S0003-4975(02)04901-9.
   Freixinet J, 1997, WORLD J SURG, V21, P475, DOI 10.1007/PL00012272.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   Hu YM, 2003, ANTIMICROB AGENTS CH, V47, P653, DOI 10.1128/AAC.47.2.653-657.2003.
   HUBERT B, 1995, MED THER, V1, P7.
   ISEMAN MD, 1990, AM REV RESPIR DIS, V328, P527.
   Kir A, 1997, EUR J CARDIO-THORAC, V12, P531, DOI 10.1016/S1010-7940(97)00230-3.
   LANGSTON HT, 1966, ANN SURG, V164, P567.
   Nahid Payam, 2006, Proc Am Thorac Soc, V3, P103, DOI 10.1513/pats.200511-119JH.
   Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339.
   Pomerantz M, 1995, Semin Thorac Cardiovasc Surg, V7, P108.
   REED CE, 1989, ANN THORAC SURG, V48, P165, DOI 10.1016/0003-4975(89)90062-3.
   RIZZI A, 1995, ANN THORAC SURG, V59, P896, DOI 10.1016/0003-4975(95)00011-9.
   Shiraishi Y, 2004, J THORAC CARDIOV SUR, V128, P523, DOI 10.1016/j.jtcvs.2004.06.012.
   Sulochana S, 2005, J CHEMOTHERAPY, V17, P169, DOI 10.1179/joc.2005.17.2.169.
   Sung SW, 1999, EUR J CARDIO-THORAC, V16, P187, DOI 10.1016/S1010-7940(99)00158-X.
   TREASURE RL, 1991, ANN THORAC SURG, V52, P1108.
   {*}WHO, 1999, WHO IUATLD GLOB PROJ.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{35}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Thorac. Cardiovasc. Surg.}},
Doc-Delivery-Number = {{183TO}},
Unique-ID = {{ISI:000247595300028}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000247639700003,
Author = {Sampathkumar, Priya},
Title = {{Dealing with threat of drug-resistant tuberculosis: Background
   information for interpreting the Andrew Speaker and related cases}},
Journal = {{MAYO CLINIC PROCEEDINGS}},
Year = {{2007}},
Volume = {{82}},
Number = {{7}},
Pages = {{799-802}},
Month = {{JUL}},
Publisher = {{MAYO CLINIC PROCEEDINGS}},
Address = {{660 SIEBENS BLDG MAYO CLINIC, ROCHESTER, MN 55905 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Sampathkumar, P (Reprint Author), Mayo Clin, Div Infect Dis, 200 1st St SW, Rochester, MN 55905 USA.
   Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA.}},
DOI = {{10.4065/82.7.799}},
ISSN = {{0025-6196}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; AIR-TRAVEL; TRANSMISSION; AIRLINER}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{sampathkumar.priya@mayo.edu}},
Cited-References = {{American Thoracic Society; CDC; Infectious Diseases Society of America, 2003, MMWR RECOMM REP, V52, P1.
   American Thoracic Society; CDC; Infectious Diseases Society of America, 2005, MMWR RECOMM REP, V53, P1203.
   {*}CDCP, 1991, MMWR-MORBID MORTAL W, V40, P585.
   {*}CDCP, CDC INV TRAV EXT DRU.
   {*}CDCP, 2007, MMWR-MORBID MORTAL W, V56, P245.
   {*}CDCP, 2005, MMWR-MORBID MORTAL W, V55, P1176.
   Centers for Disease Control and Prevention, 1990, MMWR-MORBID MORTAL W, V39, P718.
   Centers for Disease Control and Prevention (CDC), 1995, MMWR-MORBID MORTAL W, V44, P137.
   Centers for Disease Control and Prevention (CDC), 1995, MMWR-MORBID MORTAL W, V44, P175.
   DeHart RL, 2003, ANNU REV PUBL HEALTH, V24, P133, DOI 10.1146/annurev.publhealth.24.100901.140853.
   DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031.
   ENGEL EL, 2007, HOUSTON CHRONIC 0608.
   Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1.
   Garwood P, 2007, B WORLD HEALTH ORGAN, V85, P331.
   KAHN C, 2007, US TODAY        0402.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   MCFARLAND JW, 1993, LANCET, V342, P112, DOI 10.1016/0140-6736(93)91311-9.
   MOSER MR, 1979, AM J EPIDEMIOL, V110, P1.
   Palomino JC, 2006, CURR OPIN PULM MED, V12, P172, DOI 10.1097/01.mcp.0000219265.50310.9b.
   Shah N. S., 2007, Morbidity and Mortality Weekly Report, V56, P250.
   {*}US DEP HHS CDCP, REC CAS EXT DRUG RES.
   {*}US DEP HHS CDCP, 2006, FACT SHEET LEG AUTH.
   WHO (World Health Organization), 2007, XDR TB EXT DRUG RES.
   WICK RL, 1995, AVIAT SPACE ENVIR MD, V66, P220.
   Wise J, 2007, B WORLD HEALTH ORGAN, V85, P328.
   World Health Organisation, 2006, TUB AIR TRAV GUID PR.
   Zignol M, 2006, J INFECT DIS, V194, P479, DOI 10.1086/505877.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Mayo Clin. Proc.}},
Doc-Delivery-Number = {{184KJ}},
Unique-ID = {{ISI:000247639700003}},
DA = {{2018-08-13}},
}

@article{ ISI:000246577400019,
Author = {Beauvais, Anne and Schmidt, Christine and Guadagnini, Stephanie and
   Roux, Pascal and Perret, Emmanuelle and Henry, Christine and Paris,
   Sophie and Mallet, Adeline and Prevost, Marie-Christine and Latge, Jean
   Paul},
Title = {{An extracellular matrix glues together the aerial-grown hyphae of
   Aspergillus fumigatus}},
Journal = {{CELLULAR MICROBIOLOGY}},
Year = {{2007}},
Volume = {{9}},
Number = {{6}},
Pages = {{1588-1600}},
Month = {{JUN}},
Abstract = {{Pulmonary infections due to Aspergillus fumigatus result from the
   development of a colony of tightly associated hyphae in contact with the
   air, either in the alveoli (invasive aspergillosis) or in an existing
   cavity (aspergilloma). The fungal ball observed in vivo resembles an
   aerial colony obtained in agar medium in vitro more than a mycelial mass
   obtained in liquid shaken conditions that have been classically used to
   date to study A. fumigatus physiology. For this reason, we embarked on
   an analysis of the characteristics of A. fumigatus colonies grown in
   aerial static conditions. (i) Under static aerial conditions, mycelial
   growth is greater than in shaken, submerged conditions. (ii) The colony
   surface of A. fumigatus revealed the presence of an extracellular
   hydrophobic matrix that acts as a cohesive linkage bonding hyphae into a
   contiguous sheath. (iii) The extracellular matrix is composed of
   galactomannan, alpha 1,3 glucans, monosaccharides and polyols, melanin
   and proteins including major antigens and hydrophobins. (iv) A.
   fumigatus colonies were more resistant to polyenes than shake, submerged
   mycelium. This is the first analysis of the three dimensional structure
   of a mycelial colony. Knowledge of this multicellular organization will
   impact our future understanding of the pathobiology of aerial mold
   pathogens.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Beauvais, A (Reprint Author), Inst Pasteur, Aspergilus Unit, Paris, France.
   Inst Pasteur, Aspergilus Unit, Paris, France.
   Inst Pasteur, Electron Microscopy Platform, Paris, France.
   Inst Pasteur, Dynam Imagery Platform, Paris, France.}},
DOI = {{10.1111/j.1462-5822.2007.00895.x}},
ISSN = {{1462-5814}},
EISSN = {{1462-5822}},
Keywords-Plus = {{CANDIDA-ALBICANS BIOFILMS; CRYPTOCOCCUS-NEOFORMANS; SURFACE
   HYDROPHOBICITY; ANTIBIOTIC-RESISTANCE; ANTIFUNGAL AGENTS; IN-VITRO;
   GENE; SUSCEPTIBILITY; PATHOGEN; MELANIN}},
Research-Areas = {{Cell Biology; Microbiology}},
Web-of-Science-Categories  = {{Cell Biology; Microbiology}},
Author-Email = {{abeauvai@pasteur.fr}},
ResearcherID-Numbers = {{Beauvais, Anne/A-6358-2012
   Latge, Jean Paul/C-9846-2014}},
Cited-References = {{ANWAR H, 1992, ANTIMICROB AGENTS CH, V36, P1347, DOI 10.1128/AAC.36.7.1347.
   Baillie GS, 2000, J ANTIMICROB CHEMOTH, V46, P397, DOI 10.1093/jac/46.3.397.
   Beauvais A, 2005, APPL ENVIRON MICROB, V71, P1531, DOI 10.1128/AEM.71.3.1531-1538.2005.
   Beauvais A, 1997, J BIOL CHEM, V272, P6238, DOI 10.1074/jbc.272.10.6238.
   Brooun A, 2000, ANTIMICROB AGENTS CH, V44, P640, DOI 10.1128/AAC.44.3.640-646.2000.
   Calera JA, 1997, INFECT IMMUN, V65, P4718.
   Chandra J, 2001, J BACTERIOL, V183, P5385, DOI 10.1128/JB.183.18.5385-5394.2001.
   DAWES EA, 1971, METHODS MICROBIOLO A, V6, P53.
   Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002.
   Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966-842X(02)00002-1.
   Garcia-Sanchez S, 2004, EUKARYOT CELL, V3, P536, DOI 10.1128/EC.3.2.536-545.2004.
   GERBER LD, 1992, J BIOL CHEM, V267, P12168.
   HAZEN KC, 1987, J MICROBIOL METH, V6, P289, DOI 10.1016/0167-7012(87)90066-2.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Latge Jean-Paul, 2003, Mycologist, V17, P56, DOI 10.1017/S0269915X0300209X.
   Lewis K, 2001, ANTIMICROB AGENTS CH, V45, P999, DOI 10.1128/AAC.45.4.999-1007.2001.
   Linder MB, 2005, FEMS MICROBIOL REV, V29, P877, DOI 10.1016/j.femsre.2005.01.004.
   Mack D, 1996, J BACTERIOL, V178, P175, DOI 10.1128/jb.178.1.175-183.1996.
   Maira-Litran T, 2000, J ANTIMICROB CHEMOTH, V45, P789, DOI 10.1093/jac/45.6.789.
   Martinez LR, 2006, ANTIMICROB AGENTS CH, V50, P1021, DOI 10.1128/AAC.50.3.1021-1033.2006.
   Paris S, 2003, APPL ENVIRON MICROB, V69, P1581, DOI 10.1128/AEM.69.3.1581-1588.2003.
   PARIS S, 1993, FEMS MICROBIOL LETT, V111, P31.
   PHILLIPS DM, 1992, AIDS RES HUM RETROV, V8, P1863, DOI 10.1089/aid.1992.8.1863.
   Ramage G, 2005, METH MOLEC MED, V118, P71.
   Ramage G, 2002, J ANTIMICROB CHEMOTH, V49, P973, DOI {[}10.1093/jac/dkf049, 10.1093/jac.dkf049].
   Richter M, 1998, FEMS MICROBIOL LETT, V163, P165, DOI 10.1111/j.1574-6968.1998.tb13041.x.
   Rosas AL, 2000, INFECT IMMUN, V68, P2845, DOI 10.1128/IAI.68.5.2845-2853.2000.
   Samaranayake YH, 2005, J CLIN MICROBIOL, V43, P818, DOI 10.1128/JCM.43.2.818-825.2005.
   Sarfati J, 2006, DIAGN MICR INFEC DIS, V55, P279, DOI 10.1016/j.diagmicrobio.2006.02.002.
   STYNEN D, 1992, INFECT IMMUN, V60, P2237.
   Sugareva V, 2006, ARCH MICROBIOL, V186, P345, DOI 10.1007/s00203-006-0144-2.
   Sugawara T, 2003, J ELECTRON MICROSC, V52, P237, DOI 10.1093/jmicro/52.2.237.
   Tekaia F, 2005, CURR OPIN MICROBIOL, V8, P385, DOI 10.1016/j.mib.2005.06.017.
   Tillotson RD, 1998, MOL MICROBIOL, V30, P595, DOI 10.1046/j.1365-2958.1998.01093.x.
   Wosten HAB, 2000, BBA-REV BIOMEMBRANES, V1469, P79, DOI 10.1016/S0304-4157(00)00002-2.
   Wosten HAB, 1996, EMBO J, V15, P4274.
   Wosten HAB, 1999, CURR BIOL, V9, P85, DOI 10.1016/S0960-9822(99)80019-0.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{125}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{20}},
Journal-ISO = {{Cell Microbiol.}},
Doc-Delivery-Number = {{169FF}},
Unique-ID = {{ISI:000246577400019}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000248602100011,
Author = {Walker, J. T. and Hoffman, P. and Bennett, A. M. and Vos, M. C. and
   Thomas, M. and Tomlinson, N.},
Title = {{Hospital and community acquired infection and the built environment -
   design and testing of infection control rooms}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{2007}},
Volume = {{65}},
Number = {{2}},
Pages = {{43-49}},
Month = {{JUN}},
Note = {{6th International Conference of the Hospital-Infection-Society,
   Amsterdam, NETHERLANDS, OCT 15-18, 2006}},
Organization = {{Hosp Infect Soc}},
Abstract = {{Negative-pressure isolation rooms are required to house patients
   infected with agents transmissible by the aerosol route in order to
   minimise exposure of healthcare workers and other patients. Housing
   patients in a separate room provides a barrier which minimises any
   physical contact with other patients. An isolation room held at negative
   pressure to reduce aerosol escape and a high air-change rate to allow
   rapid removal of aerosols can eliminate transmission of infectious
   aerosols to those outside the room. However, badly designed and/or
   incorrectly operating isolation rooms have been shown to place
   healthcare workers and other patients at risk from airborne diseases
   such as tuberculosis. Few standards are available for the design of
   isolation rooms and no pressure differential or air-change rates are
   specified. Techniques such as aerosol particle tracer sampling and
   computational fluid dynamics can be applied to study the performance of
   negative-pressure rooms and to assess how design variables can affect
   their performance. This should allow cost-effective designs for
   isolation rooms to be developed. Healthcare staff should be trained to
   understand how these rooms operate and there should be systems in place
   to ensure they are functioning correctly. (C) 2007 The Hospital
   Infection Society. Published by Elsevier Ltd. All rights reserved.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Walker, JT (Reprint Author), Ctr Emergency Response \& Preparedness, Hlth Protect Agcy, Salisbury SP4 0JG, Wilts, England.
   Ctr Emergency Response \& Preparedness, Hlth Protect Agcy, Salisbury SP4 0JG, Wilts, England.
   Ctr Infect, HPA, London, England.
   Univ Rotterdam, Erasmus Med Ctr, Dept Med Microbiol \& Infect Dis, Rotterdam, Netherlands.
   Dept Hlth, Estates \& Facil Directorate, London SE1 6TE, England.}},
DOI = {{10.1016/S0195-6701(07)60014-0}},
ISSN = {{0195-6701}},
Keywords = {{isolation rooms; HCAI; infection control; airborne infection; built
   environment; multi-drug resistant tuberculosis; tracer gas test;
   potassium iodide}},
Keywords-Plus = {{HEALTH-CARE WORKERS; PARTICULATE AIR FILTRATION; AIRBORNE INFECTION;
   IMMUNOCOMPROMISED PATIENTS; INVASIVE ASPERGILLOSIS; RESPIRATORY
   ISOLATION; AEROSOL TRANSMISSION; PROTECTIVE ISOLATION; PRESSURE
   ISOLATION; VENTILATION}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{jimmy.walker@hpa.org.uk}},
Cited-References = {{Bartley JM, 2000, AM J INFECT CONTROL, V28, P156.
   Bennett Allan, 2005, APPL BIOSAFETY, V10, P139.
   Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3.
   Cheong KWD, 2006, BUILD ENVIRON, V41, P1161, DOI 10.1016/j.buildenv.2005.05.007.
   Chow TT, 2005, J HOSP INFECT, V59, P138, DOI 10.1016/j.jhin.2004.09.006.
   Dull PM, 2002, EMERG INFECT DIS, V8, P1044, DOI 10.3201/eid0810.020356.
   Eckmanns T, 2006, J INFECT DIS, V193, P1408, DOI 10.1086/503435.
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC.
   FICA CA, 2006, REV CHILENA INFECT, V23, P290.
   FOORD N, 1975, J HYG-CAMBRIDGE, V75, P15, DOI 10.1017/S0022172400047033.
   FOORD N, 1975, J HYG-CAMBRIDGE, V75, P31, DOI 10.1017/S0022172400047045.
   FOORD N, 1972, J HYG-CAMB, V70, P279, DOI 10.1017/S0022172400022336.
   FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623.
   Fung CP, 2004, INFECT CONT HOSP EP, V25, P1026, DOI 10.1086/502339.
   Gould D, 1996, INT J NURS STUD, V33, P143, DOI 10.1016/0020-7489(95)00048-8.
   Hahn T, 2002, INFECT CONT HOSP EP, V23, P525, DOI 10.1086/502101.
   HITCHINGS DT, 1994, ASHRAE J, V36, P336.
   Hoffman PN, 2004, J HOSP INFECT, V57, P345, DOI 10.1016/j.jhin.2004.04.013.
   Humphreys H, 2004, J HOSP INFECT, V56, P93, DOI 10.1016/j.jhin.2003.10.011.
   IWEN PC, 1994, INFECT CONT HOSP EP, V15, P303.
   Kao PH, 2006, J HOSP INFECT, V62, P338, DOI 10.1016/j.jhin.2005.07.019.
   Kuzu N, 2005, INFECT CONT HOSP EP, V26, P312, DOI 10.1086/502545.
   Maertens J, 2005, J ANTIMICROB CHEMOTH, V56, P33, DOI 10.1093/jac.dki222.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   Menzies D, 2000, ANN INTERN MED, V133, P779, DOI 10.7326/0003-4819-133-10-200011210-00010.
   Menzies D, 1998, INT J TUBERC LUNG D, V2, pS98.
   MOLLER J, 1984, SCAND J INFECT DIS, V16, P43.
   NAGAO T, 1986, Tokai Journal of Experimental and Clinical Medicine, V11, P23.
   Pavelchak N, 2000, INFECT CONT HOSP EP, V21, P191, DOI 10.1086/501742.
   Pavelchak N, 2001, INFECT CONT HOSP EP, V22, P518, DOI 10.1086/501943.
   PHILLIPS DA, 2004, ISOLATION ROAM VENTI, P1.
   RUSSELL JA, 1992, LANCET, V339, P38, DOI 10.1016/0140-6736(92)90153-T.
   Rydock James P, 2002, Appl Occup Environ Hyg, V17, P486, DOI 10.1080/10473220290035688.
   Rydock JP, 2004, J HOSP INFECT, V57, P228, DOI 10.1016/j.jhin.2004.01.032.
   Schwartzman K, 1996, AM J RESP CRIT CARE, V154, P1006, DOI 10.1164/ajrccm.154.4.8887599.
   Skladny H, 1999, J CLIN MICROBIOL, V37, P3865.
   STREIFEL AJ, 1983, APPL ENVIRON MICROB, V46, P375.
   Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022.
   Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426.
   1996, VENTILATION AIR COND.
   1994, NRR, V43, P41.
   1996, GUIDELINES DESIGN CO, P1.
   2001, CAN COMMUNICABLE DIS, V2752, P1.
   1998, DRUG RESISTANT INCLU, P1.
   2000, MORB MORTAL WKLY REP, V49, P491.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{198BN}},
Unique-ID = {{ISI:000248602100011}},
DA = {{2018-08-13}},
}

@article{ ISI:000245781500015,
Author = {Escombe, A. Roderick and Oeser, Clarissa and Gilman, Robert H. and
   Navincopa, Marcos and Ticona, Eduardo and Martinez, Carlos and Caviedes,
   Luz and Sheen, Patricia and Gonzalez, Armando and Noakes, Catherine and
   Moore, David A. J. and Friedland, Jon S. and Evans, Carlton A.},
Title = {{The detection of airborne transmission of tuberculosis from HIV-infected
   patients, using an in vivo air sampling model}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2007}},
Volume = {{44}},
Number = {{10}},
Pages = {{1349-1357}},
Month = {{MAY 15}},
Abstract = {{Background. Nosocomial transmission of tuberculosis remains an important
   public health problem. We created an in vivo air sampling model to study
   airborne transmission of tuberculosis from patients coinfected with
   human immunodeficiency virus (HIV) and to evaluate environmental control
   measures.
   Methods. An animal facility was built above a mechanically ventilated
   HIV-tuberculosis ward in Lima, Peru. A mean of 92 guinea pigs were
   continuously exposed to all ward exhaust air for 16 months. Animals had
   tuberculin skin tests performed at monthly intervals, and those with
   positive reactions were removed for autopsy and culture for
   tuberculosis.
   Results. Over 505 consecutive days, there were 118 ward admissions by 97
   patients with pulmonary tuberculosis, with a median duration of
   hospitalization of 11 days. All patients were infected with HIV and
   constituted a heterogeneous group with both new and existing diagnoses
   of tuberculosis. There was a wide variation in monthly rates of guinea
   pigs developing positive tuberculin test results (0\%-53\%). Of 292
   animals exposed to ward air, 159 developed positive tuberculin skin test
   results, of which 129 had laboratory confirmation of tuberculosis. The
   HIV-positive patients with pulmonary tuberculosis produced a mean of 8.2
   infectious quanta per hour, compared with 1.25 for HIV-negative patients
   with tuberculosis in similar studies from the 1950s. The mean monthly
   patient infectiousness varied greatly, from production of 0-44
   infectious quanta per hour, as did the theoretical risk for a health
   care worker to acquire tuberculosis by breathing ward air.
   Conclusions. HIV-positive patients with tuberculosis varied greatly in
   their infectiousness, and some were highly infectious. Use of
   environmental control strategies for nosocomial tuberculosis is
   therefore a priority, especially in areas with a high prevalence of both
   tuberculosis and HIV infection.}},
Publisher = {{OXFORD UNIV PRESS INC}},
Address = {{JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Escombe, AR (Reprint Author), Hammersmith Hosp, Dept Infect Dis \& Immun, Imperial Coll London, Campus Commonwealth Bldg,Du Cane Rd, London W12 0NN, England.
   Hammersmith Hosp, Dept Infect Dis \& Immun, Imperial Coll London, London W12 0NN, England.
   Imperial Coll London, Wellcome Trust Ctr Clin Trop Med, London, England.
   Univ Leeds, Sch Civil Engn, Leeds, W Yorkshire, England.
   Hosp Nacl Dos de Mayo, Asociac Benefica PRISMA, Lima, Peru.
   Univ Nacl Mayor San Marcos, Lima 14, Peru.
   Univ Peruana Cayetano Heredia, Lima, Peru.
   Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.}},
DOI = {{10.1086/515397}},
ISSN = {{1058-4838}},
EISSN = {{1537-6591}},
Keywords-Plus = {{ULTRAVIOLET GERMICIDAL IRRADIATION; MULTIDRUG-RESISTANT TUBERCULOSIS;
   IMMUNODEFICIENCY-VIRUS TYPE-1; SOUTH INDIAN PATIENTS; UPPER-ROOM AIR;
   MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; TUBERCLE-BACILLI;
   GUINEA-PIGS; AEROGENIC INFECTION}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{rod.escombe@imperial.ac.uk}},
ORCID-Numbers = {{Gonzalez, Armando/0000-0003-1909-1873
   Evans, Carlton/0000-0002-6873-5447
   Ticona, Eduardo/0000-0002-6556-1082
   Navincopa, Marcos/0000-0002-9951-8234}},
Funding-Acknowledgement = {{Wellcome Trust {[}057434]; NIAID NIH HHS {[}T35AI-07646, T35 AI007646]}},
Cited-References = {{{[}Anonymous], 1998, LAB SERV TB CONTR 1.
   BALASUBRAMANIAN V, 1992, INFECT IMMUN, V60, P4762.
   Beggs CB, 2003, INT J TUBERC LUNG D, V7, P1015.
   BHATIA AL, 1961, B WORLD HEALTH ORGAN, V25, P313.
   Caviedes L, 2000, J CLIN MICROBIOL, V38, P1203.
   COHN ML, 1970, AM REV RESPIR DIS, V102, P97.
   Cruciani M, 2001, CLIN INFECT DIS, V33, P1922, DOI 10.1086/324352.
   Curtis AB, 2000, INT J TUBERC LUNG D, V4, P308.
   DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   ELLIOTT AM, 1993, AIDS, V7, P981.
   Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068.
   ESCOMBE AR, 2006, THESIS LONDON IMPERI.
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC.
   FOK JS, 1976, J INFECT DIS, V133, P137, DOI 10.1093/infdis/133.2.137.
   GANGADHARAM PRJ, 1963, AM REV RESPIR DIS, V87, P200.
   IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152.
   Jenssen HK, 2005, INDIANA U MATH J, V54, P1, DOI 10.1512/iumj.2005.54.2685.
   Luna-Herrera J, 2003, EUR J CLIN MICROBIOL, V22, P21, DOI 10.1007/s10096-002-0855-5.
   LURIE MAX B., 1930, JOUR EXP MED, V51, P753, DOI 10.1084/jem.51.5.753.
   LURIE MAX B., 1930, JOUR EXP MED, V51, P769, DOI 10.1084/jem.51.5.769.
   Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005.
   Mastorides SM, 1999, CHEST, V115, P19, DOI 10.1378/chest.115.1.19.
   MILLS CC, 1960, B JOHNS HOPKINS HOSP, V106, P36.
   MITCHISON D, 1961, B WORLD HEALTH ORGAN, V25, P285.
   MITCHISON D A, 1960, Tubercle, V41, P1, DOI 10.1016/S0041-3879(60)80019-0.
   Mohle-Boetani JC, 2002, CLIN INFECT DIS, V34, P668, DOI 10.1086/338815.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Nardell EA, 1999, CHEST, V116, P1143, DOI 10.1378/chest.116.4.1143.
   {*}NAT VET SERV LAB, 1998, S ASS 636 EV BATCH P.
   NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1.
   PRABHAKAR R, 1987, TUBERCLE, V68, P3, DOI 10.1016/0041-3879(87)90003-1.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1995, AM J EPIDEMIOL, V142, P3, DOI 10.1093/oxfordjournals.aje.a117542.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   Schafer MP, 1998, AM IND HYG ASSOC J, V59, P540, DOI 10.1202/0002-8894(1998)059<0540:SAAMDF>2.0.CO;2.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8.
   VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151.
   {*}WHO, 1999, WHO GUID PREV TUB HE.
   Xu P, 2005, ENVIRON SCI TECHNOL, V39, P9656, DOI 10.1021/es0504892.
   Xu P, 2003, ATMOS ENVIRON, V37, P405, DOI 10.1016/S1352-2310(02)00825-7.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{53}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{158HD}},
Unique-ID = {{ISI:000245781500015}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000245852100010,
Author = {Fradette, Caroline and Batonga, Joelle and Teng, Shirley and
   Piquette-Miller, Micheline and du Souich, Patrick},
Title = {{Animal models of acute moderate hypoxia are associated with a
   down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of
   CYP3A6 and P-glycoprotein in liver}},
Journal = {{DRUG METABOLISM AND DISPOSITION}},
Year = {{2007}},
Volume = {{35}},
Number = {{5}},
Pages = {{765-771}},
Month = {{MAY}},
Abstract = {{In humans, indirect evidence suggests that hypoxia reduces the rate of
   biotransformation of drugs cleared by cytochrome P450 (P450) subfamilies
   CYP1A, 2B, and 2C. The aim of this study was to assess whether acute
   moderate hypoxia modulates the expression of CYP2B4, 2C5, and 2C16 in
   vivo, and to determine whether the changes in hepatic P450 are conveyed
   by serum mediators. Moreover, because hypoxia increases the expression
   of P-glycoprotein in vitro, we examined whether in vivo acute moderate
   hypoxia modulates the expression of several membrane transporters in the
   liver. Rabbits and rats were exposed to a fractional concentration of
   oxygen of 8\% for 48 h to generate a stable arterial partial pressure of
   O-2 of 34 +/- 1 mm Hg. Compared with rabbits breathing room air, hypoxia
   in rabbits reduced the amount of CYP1A1, 1A2, 2B4, 2C5, and 2C16
   proteins and increased the expression of CYP3A6. Sera of rabbits with
   hypoxia were fractionated by size exclusion chromatography, the
   fractions were tested for their ability to modify the expression of P450
   isoforms, and serum mediators were identified through neutralization
   experiments. The serum mediators responsible for the down-regulation of
   P450 isoforms were interferon-gamma, interleukin-1 beta (IL-1 beta), and
   IL-2. In vivo, in rats, hypoxia increased the mRNA and protein
   expression of P-glycoprotein but did not affect the mRNA of breast
   cancer resistance protein and organic anion-transporting polypeptide 2.
   It is concluded that in vivo, hypoxia down-regulates rabbit hepatic
   CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulates CYP3A6. CYP3A11 and
   P-glycoprotein were up-regulated in the livers of hypoxic rats.}},
Publisher = {{AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{du Souich, P (Reprint Author), Univ Montreal, Fac Med, Dept Pharmacol, Local R-412,CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.
   Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.
   Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.}},
DOI = {{10.1124/dmd.106.013508}},
ISSN = {{0090-9556}},
EISSN = {{1521-009X}},
Keywords-Plus = {{NF-KAPPA-B; PREGNANE-X-RECEPTOR; HEPATIC CYTOCHROME-P450;
   MULTIDRUG-RESISTANCE; METABOLIZING-ENZYMES; SIGNALING PATHWAYS;
   IN-VITRO; EXPRESSION; INFLAMMATION; GENE}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Author-Email = {{patrick.du.souich@umontreal.ca}},
Cited-References = {{ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100.
   Anapolsky A, 2006, DRUG METAB DISPOS, V34, P405, DOI 10.1124/dmd.105.006197.
   Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200.
   Bleau AM, 2003, EUR J PHARMACOL, V473, P197, DOI 10.1016/S0014-2999(03)01968-X.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3.
   Burk O, 2005, BIOL CHEM, V386, P503, DOI 10.1515/BC.2005.060.
   Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115.
   Chung IJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P220, DOI 10.1006/abbi.1996.9815.
   Comerford KM, 2004, CANCER RES, V64, P9057, DOI 10.1158/0008-5472.CAN-04-1919.
   Cumming J F, 1976, Clin Pharmacol Ther, V19, P498.
   Dixit SG, 2005, CURR DRUG METAB, V6, P385, DOI 10.2174/1389200054633907.
   ElKadi AOS, 1997, BRIT J PHARMACOL, V121, P1164, DOI 10.1038/sj.bjp.0701232.
   Ellery JM, 2002, CYTOKINE GROWTH F R, V13, P27, DOI 10.1016/S1359-6101(01)00023-5.
   Engel G, 1996, CLIN PHARMACOL THER, V59, P613, DOI 10.1016/S0009-9236(96)90001-6.
   Fradette C, 2004, CURR DRUG METAB, V5, P257, DOI 10.2174/1389200043335577.
   Fradette C, 2003, BRIT J PHARMACOL, V140, P1146, DOI 10.1038/sj.bjp.0705543.
   Fradette C, 2002, BRIT J PHARMACOL, V137, P881, DOI 10.1038/sj.bjp.0704933.
   GEISTERFER M, 1993, CYTOKINE, V5, P1, DOI 10.1016/1043-4666(93)90017-Y.
   Giancarlo GM, 2001, EUR J CLIN PHARMACOL, V57, P31, DOI 10.1007/s002280100268.
   HA HR, 1995, BRIT J CLIN PHARMACO, V39, P321, DOI 10.1111/j.1365-2125.1995.tb04455.x.
   Ho EA, 2006, CURR CANCER DRUG TAR, V6, P295, DOI 10.2174/156800906777441753.
   Iber H, 2000, ARCH BIOCHEM BIOPHYS, V377, P187, DOI 10.1006/abbi.2000.1772.
   Kalitsky-Szirtes J, 2004, DRUG METAB DISPOS, V32, P20, DOI 10.1124/dmd.32.1.20.
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200.
   Kurdi J, 1999, BRIT J PHARMACOL, V128, P365, DOI 10.1038/sj.bjp.0702795.
   LOWRY OH, 1951, J BIOL CHEM, V193, P265.
   Michiels C, 2000, BBA-MOL CELL RES, V1497, P1, DOI 10.1016/S0167-4889(00)00041-0.
   Murakami T, 2002, PHARMAZIE, V57, P102.
   Naldini A, 1997, J CELL PHYSIOL, V173, P335, DOI 10.1002/(SICI)1097-4652(199712)173:3<335::AID-JCP5>3.3.CO;2-T.
   PIAFSKY KM, 1977, CLIN PHARMACOL THER, V21, P310.
   SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405.
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474.
   Sharer JE, 1996, DRUG METAB DISPOS, V24, P487.
   Song XR, 2006, CANCER CHEMOTH PHARM, V58, P776, DOI 10.1007/s00280-006-0224-7.
   Teng S, 2005, J PHARMACOL EXP THER, V312, P841, DOI 10.1124/jpet.104.076141.
   Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510.
   Tinel M, 2003, J HEPATOL, V39, P171, DOI 10.1016/S0168-8278(03)00238-1.
   VOZEH S, 1978, JAMA-J AM MED ASSOC, V240, P1882, DOI 10.1001/jama.240.17.1882.
   Wartenberg M, 2003, FASEB J, V17, P503, DOI 10.1096/fj.02-0358fje.
   Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{46}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Drug Metab. Dispos.}},
Doc-Delivery-Number = {{159FZ}},
Unique-ID = {{ISI:000245852100010}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000246098100008,
Author = {Franchi, Alberto and Richeldi, Luca and Parrinello, Giovanni and Franco,
   Giuliano},
Title = {{Room size is the major determinant for tuberculin conversion in health
   care workers exposed to a multidrug-resistant tuberculosis patient}},
Journal = {{INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH}},
Year = {{2007}},
Volume = {{80}},
Number = {{6}},
Pages = {{533-538}},
Month = {{MAY}},
Abstract = {{Objective Transmission of Mycobacterium tuberculosis (MTB) to health
   care workers (HCWs) still represents a public health concern. A total of
   71 obstetric workers underwent contact tracing after recent workplace
   exposure to a highly infectious multidrug-resistant tuberculosis patient
   {[}i.e., index case (IC)]. Aim of the study was to identify the main
   exposure predictors for the risk of conversion through evaluation of
   tuberculin screening results.
   Methods HCWs were investigated by a questionnaire (community,
   occupational, IC exposure risk factors) and tuberculin skin test
   screening.
   Results Conversion was detected in 5 (8\%) of the 63 exposed workers and
   was not associated with either community or previous work-related risk
   factors. According to risk assessment, tuberculin conversion was related
   to neither amount time of exposure, workshifts, nor number of contacts.
   Conversely, an exposure to the IC in different hospital rooms was found
   significantly different among converters compared to non-converters
   (chi(2), P = 0.004). In particular, conversion was associated with
   exposure in two (obstetric emergency room, ambulatory discharge) out of
   the nine contact environments. Tuberculin conversion rates were
   associated with the room cubations of the exposure environments (chi(2)
   stop for trend, P < 0.01) and with worker age. In a logistic regression
   model adjusted for age, the lower room cubation was found the strongest
   predictor for tuberculin conversion (OR = 2.46, P = 0.02).
   Conclusions The study shows that the factors affecting airborne
   mycobacterial dose (patient infectiousness, low sized confined rooms)
   were the major determinants for MTB transmission after a brief exposure
   to a highly infectious TB case.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING STREET, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Franchi, A (Reprint Author), Policlin Hosp, Occupat Hlth Unit, 8th Floor,Room 8-056,Via Largo Pozzo 71, I-41100 Modena, Italy.
   Policlin Hosp, Occupat Hlth Unit, I-41100 Modena, Italy.
   Univ Modena, Dept Med \& Med Specialties, I-41100 Modena, Italy.
   Univ Brescia, Sect Med Stat, I-25121 Brescia, Italy.}},
DOI = {{10.1007/s00420-006-0160-1}},
ISSN = {{0340-0131}},
Keywords = {{tuberculosis; latent tuberculosis infection; health care workers; casual
   contacts; hospital transmission; occupational risk}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; CONTACT INVESTIGATIONS; TRANSMISSION; RISK;
   EPIDEMIOLOGY; INFECTION; PREGNANCY; MODEL}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{franchi.alberto@policlinico.mo.it}},
Cited-References = {{Bailey WC, 2002, JAMA-J AM MED ASSOC, V287, P996, DOI 10.1001/jama.287.8.996.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   {*}CDCP AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221.
   Cronin WA, 2002, EMERG INFECT DIS, V8, P1271.
   Diel R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-35.
   Dye C, 2002, J INFECT DIS, V185, P1197, DOI 10.1086/339818.
   Espinal MA, 1996, J INFECT DIS, V173, P488, DOI 10.1093/infdis/173.2.488.
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   Golub JE, 2001, ARCH INTERN MED, V161, P2254, DOI 10.1001/archinte.161.18.2254.
   HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204.
   HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011.
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286.
   Kammerer JS, 2005, AM J PREV MED, V28, P201, DOI 10.1016/j.amepre.2004.10.011.
   Lessnau KDKL, 2003, CHEST, V123, P953, DOI 10.1378/chest.123.3.953.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   Menzies D, 2000, ANN INTERN MED, V133, P779, DOI 10.7326/0003-4819-133-10-200011210-00010.
   Nicas M, 2000, AM IND HYG ASSOC J, V61, P334, DOI 10.1080/15298660008984541.
   Reichler MR, 2002, JAMA-J AM MED ASSOC, V287, P991, DOI 10.1001/jama.287.8.991.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   {*}US DEP LAB OCC SA, 1997, FED REGISTER, V62, P54161.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Int. Arch. Occup. Environ. Health}},
Doc-Delivery-Number = {{162OU}},
Unique-ID = {{ISI:000246098100008}},
DA = {{2018-08-13}},
}

@article{ ISI:000243946800042,
Author = {Thorne, Peter S.},
Title = {{Environmental health impacts of concentrated animal feeding operations:
   Anticipating hazards - Searching for solutions}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{2007}},
Volume = {{115}},
Number = {{2}},
Pages = {{296-297}},
Month = {{FEB}},
Abstract = {{A scientific conference and workshop was held March 2004 in Iowa City,
   Iowa, that brought together environmental scientists from North America
   and Europe to address major environmental health issues associated with
   concentrated animal feeding operations (CAFOs) in large, industrialized
   livestock production facilities. After one and a half days of plenary
   sessions, five expert workgroups convened to consider the most relevant
   research areas, including respiratory health effects, modeling and
   monitoring of air toxics, water quality issues, influenza pandemics and
   antibiotic resistance, and community health and socioeconomic issues.
   The workgroup reports that follow outline the state of the science and
   public health concerns relating to livestock production as they apply to
   each workgroup topic. The reports also identify areas in which further
   research is needed and suggest opportunities to translate science to
   policy initiatives that would effect improvements in public and
   environmental health. Viable solutions to some of the current
   environmental health problems associated with CAFOs are outlined. In
   addition, these reports bring to lot several major concerns, including
   air and water contamination, the rise of antibiotic-resistant bacteria
   in livestock, and the specter of influenza outbreaks arising from siting
   industrialized poultry and swine production in proximity to each other
   and to humans.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Thorne, PS (Reprint Author), Univ Iowa, Coll Publ Hlth, 100 Oakdale Campus,176 IREH, Iowa City, IA 52242 USA.
   Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA.}},
DOI = {{10.1289/ehp.8831}},
ISSN = {{0091-6765}},
Keywords = {{air quality; animal confinements; antibiotic resistance; antimicrobial
   growth promotants; avian influenza; bioaerosols; livestock; poultry;
   swine; water quality}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Author-Email = {{peter-thorne@uiowa.edu}},
Funding-Acknowledgement = {{NIEHS NIH HHS {[}P30 ES05605-14S, P30 ES005605]}},
Cited-References = {{Bunton B, 2007, ENVIRON HEALTH PERSP, V115, P303, DOI 10.1289/ehp.8838.
   BURKHOLDER J, 2004, ENV HLTH PERSPECT, V115, P308.
   DONHAM KJ, 2004, ENV HLTH PERSPECT, V115, P317.
   Gilchrist MJ, 2007, ENVIRON HEALTH PERSP, V115, P313, DOI 10.1289/ehp.8837.
   Heederik D, 2007, ENVIRON HEALTH PERSP, V115, P298, DOI 10.1289/ehp.8835.
   {*}IOW STAT U U IOW, 2002, IOW CONC AN FEED OP.
   OTTO D, 2000, IOWA PORT IND 2000 T.}},
Number-of-Cited-References = {{7}},
Times-Cited = {{43}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{42}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{132ML}},
Unique-ID = {{ISI:000243946800042}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000247111200014,
Author = {Bertagnolio, Silvia and Soto-Ramirez, Luis and Pilon, Richard and
   Rodriguez, Roberto and Viveros, Monica and Fuentes, Luis and Harrigan,
   P. Richard and Mo, Theresa and Sutherland, Don and Sandstrom, Paul},
Title = {{HIV-1 drug resistance surveillance using dried whole blood spots}},
Journal = {{ANTIVIRAL THERAPY}},
Year = {{2007}},
Volume = {{12}},
Number = {{1}},
Pages = {{107-113}},
Abstract = {{Background: Field-friendly methods for HIV drug resistance (HIVDR)
   surveillance in resource-limited regions are urgently needed. Despite
   evidence that dried blood spots (DIBS) are suitable for HIV serology,
   viral load and CD4(+) T-cell enumeration, no study has evaluated DBS for
   HIVDR genotyping. We assessed the feasibility of genotyping HIV-1 from
   field-collected DBS stored under challenging environmental conditions.
   Methods: We prospectively collected specimens from newly diagnosed,
   treatment-naive HIV-positive subjects in Mexico. Whole blood was spotted
   onto filter cards, air dried at ambient temperature and stored with
   desiccant at 37 degrees C and 85\% humidity for 3 months. Genotypes
   obtained from DBS-extracted nucleic acids using an in-house nested
   reverse transcription-PCR method were compared to genotypes derived from
   matched plasma.
   Results: Genotypes from 103 phylogenetically matched plasma and DBS were
   compared. In total, 90.1\% of all DBS specimens could be amplified in
   either the region of HIV protease or the region of reverse
   transcriptase. Failure to amplify from DBS did not correlate with low
   plasma viral loads. Between paired specimens, the median nucleotide
   similarity was 99.95\%. In the nine specimens with drug resistance
   mutations, all differences between pairs were partial discordances.
   Mutations identified in plasma were found in the majority of replicate
   DBS amplifications.
   Conclusion: The results suggest that genotypes obtained from DBS are
   equivalent to those from plasma. DBS are a promising public health tool
   for HIVDR surveillance of treatment-naive subjects, especially in
   regions where specimens might be exposed to severe environmental
   conditions and where logistical difficulties could prevent timely
   specimen processing. More studies are needed to validate DBS for patient
   monitoring.}},
Publisher = {{INT MEDICAL PRESS LTD}},
Address = {{2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bertagnolio, S (Reprint Author), WHO, HIV Dept, Geneva, Switzerland.
   WHO, HIV Dept, Geneva, Switzerland.
   Inst Nacl Ciencias Med \& Nutr Salvador Zubiran, Dept Infect Dis, Mol Virol Lab, Mexico City, DF, Mexico.
   Ctr Infect Dis Prevent \& Control, Publ Hlth Agcy Canada, Ottawa, ON, Canada.
   BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada.}},
ISSN = {{1359-6535}},
Keywords-Plus = {{PLASMA SPOTS; RNA; QUANTIFICATION}},
Research-Areas = {{Infectious Diseases; Pharmacology \& Pharmacy; Virology}},
Web-of-Science-Categories  = {{Infectious Diseases; Pharmacology \& Pharmacy; Virology}},
Author-Email = {{bertagnolios@who.int}},
Cited-References = {{Alexander CS, 1999, AIDS, V13, P981, DOI 10.1097/00002030-199905280-00015.
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495.
   Brambilla D, 2003, J CLIN MICROBIOL, V41, P1888, DOI 10.1128/JCM.41.5.1888-1893.2003.
   Cassol S, 1996, AIDS RES HUM RETROV, V12, P1435, DOI 10.1089/aid.1996.12.1435.
   Cassol S, 1997, J CLIN MICROBIOL, V35, P2795.
   Galli RA, 2003, J CLIN MICROBIOL, V41, P2900, DOI 10.1128/JCM.41.7.2900-2907.2003.
   Ghosn J, 2004, AIDS, V18, P447, DOI 10.1097/01.aids.0000111383.02002.9a.
   JOHNSON AV, 2005, TOP HIV MED, V13, P51.
   Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150.
   Mwaba P, 2003, LANCET, V362, P1459, DOI 10.1016/S0140-6736(03)14693-4.
   Mwaba P, 2003, LANCET, V362, P2067, DOI 10.1016/S0140-6736(03)15103-3.
   O'Shea S, 1999, AIDS, V13, P630, DOI 10.1097/00002030-199904010-00019.
   Plantier JC, 2005, AIDS, V19, P391, DOI 10.1097/01.aids.0000161768.98534.e7.
   Shafer RW, 2001, J CLIN MICROBIOL, V39, P1522, DOI 10.1128/JCM.39.4.1522-1529.2001.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{53}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Antivir. Ther.}},
Doc-Delivery-Number = {{176UU}},
Unique-ID = {{ISI:000247111200014}},
DA = {{2018-08-13}},
}

@article{ ISI:000249120400011,
Author = {Panagopoulou, Paraskevi and Filioti, Joanna and Farmaki, Evangelia and
   Maloukou, Avgi and Roilides, Emmanuel},
Title = {{Filamentous fungi in a tertiary care hospital: Environmental
   surveillance and susceptibility to antifungal drugs}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{2007}},
Volume = {{28}},
Number = {{1}},
Pages = {{60-67}},
Month = {{JAN}},
Abstract = {{Objective. To evaluate filamentous fungi with respect to environmental
   load and potential drug resistance in a tertiary care teaching hospital.
   Design. Monthly survey in 2 buildings of the hospital during a 12-month
   period.
   Setting. Hippokration Hospital in Thessaloniki, Greece.
   Methods. Air, surface, and tap water sampling was performed in 4
   departments with high-risk patients. As sampling sites, the solid-organ
   transplantation department and the hematology department ( in the older
   building) and the pediatric oncology department and the pediatric
   intensive care unit ( in the newer building) were selected.
   Results. From January to May of 2000, the fungal load in air ( FLA) was
   low, ranging from 0 to 12 colony-forming units (cfu) per m(3) in both
   buildings. During the summer months, when high temperature and humidity
   predominate, the FLA increased to 4-56 cfu/m(3). The fungi commonly
   recovered from culture of air specimens were Aspergillus niger (
   25.9\%), Aspergillus flavus ( 17.7\%), and Aspergillus fumigatus (
   12.4\%). Non-Aspergillus filamentous fungi, such as Zygomycetes and
   Dematiaceous species, were also recovered. The pediatric intensive care
   unit had the lowest mean FLA ( 7.7 cfu/m(3)), compared with the
   pediatric oncology department ( 8.7 cfu/m(3)), the solid-organ
   transplantation department (16.1 cfu/m(3)), and the hematology
   department ( 22.6 cfu/m(3)). Environmental surfaces were swabbed, and
   62.7\% of the swab samples cultured yielded filamentous fungi similar to
   the fungi recovered from air but with low numbers of colony-forming
   units. Despite vigorous sampling, culture of tap water yielded no fungi.
   The increase in FLA observed during the summer coincided with renovation
   in the building that housed the solid-organ transplantation and
   hematology departments. All 54 Aspergillus air isolates randomly
   selected exhibited relatively low minimum inhibitory or effective
   concentrations for amphotericin B, itraconazole, voriconazole,
   posaconazole, micafungin, and anidulafungin.
   Conclusion. Air and surface fungal loads may vary in different
   departments of the same hospital, especially during months when the
   temperature and humidity are high. Environmental Aspergillus isolates
   are characterized by lack of resistance to clinically important
   antifungal agents.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Roilides, E (Reprint Author), Hippokrateion Hosp, Dept Pediat 3, Konstantinoupoleos 49, GR-54642 Thessaloniki, Greece.
   Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Pediat 3, Thessaloniki, Greece.}},
DOI = {{10.1086/508832}},
ISSN = {{0899-823X}},
Keywords-Plus = {{INVASIVE PULMONARY ASPERGILLOSIS; MOLD INFECTIONS; WATER-SYSTEM;
   FUMIGATUS; AIR; EPIDEMIOLOGY; RESISTANCE; PREVENTION; FUSARIUM;
   ITRACONAZOLE}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{roilides@med.auth.gr}},
ORCID-Numbers = {{Panagopoulou, Paraskevi/0000-0002-1585-1372}},
Cited-References = {{Anaissie EJ, 2001, CLIN INFECT DIS, V33, P1871, DOI 10.1086/324501.
   Anaissie EJ, 2002, CLIN INFECT DIS, V34, P780, DOI 10.1086/338958.
   Arikan S, 2001, ANTIMICROB AGENTS CH, V45, P327, DOI 10.1128/AAC.45.1.327-330.2001.
   Arvanitidou M, 2000, J HOSP INFECT, V45, P225, DOI 10.1053/jhin.2000.0763.
   Arvanitidou M, 1999, LETT APPL MICROBIOL, V29, P81, DOI 10.1046/j.1365-2672.1999.00583.x.
   Ascioglu S, 2002, CLIN INFECT DIS, V34, P7, DOI 10.1086/323335.
   BENBOUGH JE, 1993, J APPL BACTERIOL, V74, P170, DOI 10.1111/j.1365-2672.1993.tb03011.x.
   Boucher HW, 2004, DRUGS, V64, P1997, DOI 10.2165/00003495-200464180-00001.
   Bouza E, 2002, J HOSP INFECT, V52, P234, DOI 10.1053/jhin.2002.1316.
   {*}CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1.
   Clark TA, 2002, CURR OPIN INFECT DIS, V15, P569, DOI 10.1097/01.qco.0000044774.05458.c6.
   Curtis L, 2005, J HOSP INFECT, V59, P188, DOI 10.1016/j.jhin.2004.05.017.
   Dannaoui E, 2001, J ANTIMICROB CHEMOTH, V47, P333, DOI 10.1093/jac/47.3.333.
   De Rosa FG, 2003, INFECT CONT HOSP EP, V24, P477, DOI 10.1086/502250.
   Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943.
   Espinel-Ingroff Ana, 2003, Revista Iberoamericana de Micologia, V20, P121.
   Gangneux JP, 2002, CLIN INFECT DIS, V35, P343, DOI 10.1086/341318.
   GOODLEY JM, 1994, J HOSP INFECT, V26, P27, DOI 10.1016/0195-6701(94)90076-0.
   Guinea J, 2005, ANTIMICROB AGENTS CH, V49, P3495, DOI 10.1128/AAC.49.8.3495-3497.2005.
   Hospenthal DR, 1998, MED MYCOL, V36, P165, DOI 10.1080/02681219880000241.
   Ibrahim-Granet O, 2003, INFECT IMMUN, V71, P891, DOI 10.1128/IAI.71.2.891-903.2003.
   Kennedy HF, 1995, J HOSP INFECT, V31, P322, DOI 10.1016/0195-6701(95)90213-9.
   Kontoyiannis DP, 2002, LANCET, V359, P1135, DOI 10.1016/S0140-6736(02)08162-X.
   Latge JP, 1999, CLIN MICROBIOL REV, V12, P310.
   Leenders ACAP, 1999, J CLIN MICROBIOL, V37, P1752.
   Manavathu EK, 2000, J ANTIMICROB CHEMOTH, V46, P229, DOI 10.1093/jac/46.2.229.
   Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202.
   Martino R, 2002, ANN HEMATOL, V81, P233, DOI 10.1007/s00277-002-0466-3.
   Menotti J, 2005, J HOSP INFECT, V60, P61, DOI 10.1016/j.jhin.2004.10.009.
   Moore CB, 2000, J INFECTION, V41, P203, DOI 10.1053/jinf.2000.0747.
   Morris G, 2000, J HOSP INFECT, V44, P81, DOI 10.1053/jhin.1999.0688.
   Munoz P, 2001, CLIN MICROBIOL INFEC, V7, P38, DOI 10.1111/j.1469-0691.2001.tb00008.x.
   NCCLS, 2002, REF METH BROTH DIL.
   Panagopoulou P, 2002, J HOSP INFECT, V52, P185, DOI 10.1053/jhin.2002.1298.
   Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P251, DOI 10.1016/S0732-8893(97)00246-0.
   Rath PM, 1997, J HOSP INFECT, V37, P47, DOI 10.1016/S0195-6701(97)90072-4.
   RHAME FS, 1991, J HOSP INFECT, V18, P466, DOI 10.1016/0195-6701(91)90058-G.
   Roilides E, 2003, REV MED MICROBIOL, V14, P63.
   Sanglard D, 2002, LANCET INFECT DIS, V2, P73, DOI 10.1016/S1473-3099(02)00181-0.
   SMID T, 1989, AM IND HYG ASSOC J, V50, P235, DOI 10.1202/0002-8894(1989)050<0235:EOVFIO>2.0.CO;2.
   VERHOEFF AP, 1990, ALLERGY, V45, P275, DOI 10.1111/j.1398-9995.1990.tb00496.x.
   Warris A, 2002, CLIN INFECT DIS, V34, P1159, DOI 10.1086/339754.
   Warris A, 2001, J HOSP INFECT, V47, P143, DOI 10.1053/jhin.2000.0876.
   Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{205NI}},
Unique-ID = {{ISI:000249120400011}},
DA = {{2018-08-13}},
}

@article{ ISI:000249866100005,
Author = {Atoyan, Janet A. and Patenaude, Erika L. and Potts, David A. and Amador,
   Jose A.},
Title = {{Effects of tetracycline on antibiotic resistance and removal of fecal
   indicator bacteria in aerated and unaerated leachfield mesocosms}},
Journal = {{JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART A-TOXIC/HAZARDOUS
   SUBSTANCES \& ENVIRONMENTAL ENGINEERING}},
Year = {{2007}},
Volume = {{42}},
Number = {{11}},
Pages = {{1571-1578}},
Abstract = {{Antibiotics can be present in low concentrations in domestic wastewater,
   but little is known about their effect on bacteria in onsite wastewater
   treatment systems. Mesocosms, consisting of soil-filled lysimeters
   representing the leachfield of a septic system under aerated (AIR) and
   unaerated (LEACH) conditions, were used to study the effects of
   tetracycline addition (5 mg L-1) to septic tank effluent on tetracycline
   resistance in the fecal indicator bacteria Escherichia coli and fecal
   streptococci, and on their removal. The mesocosms were dosed with
   antibiotic for 10 days, and effects monitored for 52 days. The fraction
   of resistant bacteria in mesocosm drainage water relative to that in
   septic tank effluent, Gamma(Res), for E. coli ranged from 0 to 0.66 in
   the AIR treatment and from 0 to 3.32 in the LEACH treatment. For fecal
   streptococci, Gamma(Res) ranged from 0 to 0.41 and from 0.63 to 1.06 in
   the AIR and LEACH treatments, respectively. No significant differences
   in antibiotic resistance of fecal indicator bacteria were observed among
   sampling dates in soil or water from either treatment. Tetracycline had
   no significant effect on removal of fecal indicator bacteria, which
   ranged from 99.9 to 100\% for E. coli and from 95.9 to 100\% for fecal
   streptococci. Our results suggest that short-term addition of
   tetracycline at environmentally-relevant concentrations is likely to
   have minimal consequences on pathogen removal from wastewater and
   development of antibiotic resistance among pathogenic bacteria in leach
   field soil.}},
Publisher = {{TAYLOR \& FRANCIS INC}},
Address = {{325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Amador, JA (Reprint Author), Univ Rhode Isl, Coastal Inst 024, 1 Greenhouse Rd, Kingston, RI 02881 USA.
   Univ Rhode Isl, Lab Soil Ecol \& Microbiol, Kingston, RI 02881 USA.
   Geomatrix LLC, Killingworth, CT 06419 USA.}},
DOI = {{10.1080/10934520701513498}},
ISSN = {{1093-4529}},
Keywords = {{tetracycline; leachfield; antibiotic resistance; fecal indicator
   bacteria}},
Keywords-Plus = {{ESCHERICHIA-COLI; ENVIRONMENT; OXYTETRACYCLINE; METRONIDAZOLE;
   OLAQUINDOX; EFFLUENT; PATTERNS; TYLOSIN; SEWAGE; SLUDGE}},
Research-Areas = {{Engineering; Environmental Sciences \& Ecology}},
Web-of-Science-Categories  = {{Engineering, Environmental; Environmental Sciences}},
Author-Email = {{jamador@uri.edu}},
Cited-References = {{American Public Health Association, 1998, STAND METH EX WAT WA.
   BAQUERO F, 1997, ANTIBIOTIC RESISTANC, P93.
   Chander Y, 2005, J ENVIRON QUAL, V34, P1952, DOI 10.2134/jeq2005.0017.
   Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001.
   Costanzo SD, 2005, MAR POLLUT BULL, V51, P218, DOI 10.1016/j.marpolbul.2004.10.038.
   Harwood VJ, 2000, APPL ENVIRON MICROB, V66, P3698, DOI 10.1128/AEM.66.9.3698-3704.2000.
   Henze M., 1997, WASTEWATER TREATMENT.
   KRISTIANSEN R, 1981, J ENVIRON QUAL, V10, P361, DOI 10.2134/jeq1981.00472425001000030022x.
   Kumar K, 2005, ADV AGRON, V87, P1, DOI 10.1016/S0065-2113(05)87001-4.
   Kummerer K, 2003, J ANTIMICROB CHEMOTH, V52, P5, DOI 10.1093/jac/dkg293.
   Levy SB, 2001, CLIN INFECT DIS S3, V33, P124.
   LEVY SB, 1997, ANTIBIOTIC RESISTANC, P1.
   Loke ML, 2002, CHEMOSPHERE, V48, P351, DOI 10.1016/S0045-6535(02)00078-4.
   MEZRIOUI N, 1994, WATER RES, V28, P2399, DOI 10.1016/0043-1354(94)90056-6.
   {*}NCCLS, 1997, M2A6 NCCLS, P19087.
   PATENAUDE EL, 2006, THESIS U RHODE ISLAN.
   Potts D.A., 2000, U.S. Patent, Patent No. 6485647.
   Potts DA, 2004, J ENVIRON QUAL, V33, P1828, DOI 10.2134/jeq2004.1828.
   Rabolle M, 2000, CHEMOSPHERE, V40, P715, DOI 10.1016/S0045-6535(99)00442-7.
   Reinthaler FF, 2003, WATER RES, V37, P1685, DOI 10.1016/S0043-1354(02)00569-9.
   TURCO RF, 1994, METHODS SOIL ANAL 2, P145.
   {*}US CENS BUR, 2003, AM HOUS SURV US 2003.
   US EPA, 2002, EPA625R00008.
   Yang SW, 2005, J CHROMATOGR A, V1097, P40, DOI 10.1016/j.chroma.2005.08.027.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{J. Environ. Sci. Health Part A-Toxic/Hazard. Subst. Environ. Eng.}},
Doc-Delivery-Number = {{216GI}},
Unique-ID = {{ISI:000249866100005}},
DA = {{2018-08-13}},
}

@article{ ISI:000242500200032,
Author = {Gandara, Angelina and Mota, Linda C. and Flores, Carissa and Perez,
   Hernando R. and Green, Christopher F. and Gibbs, Shawn G.},
Title = {{Isolation of Staphylococcus aureus and antibiotic-resistant
   Staphylococcus aureus from residential indoor bioaerosols}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{2006}},
Volume = {{114}},
Number = {{12}},
Pages = {{1859-1864}},
Month = {{DEC}},
Abstract = {{OBJECTIVE: In this study we evaluated the levels of Staphylococcus
   aureus and antibiotic-resistant S. aureus in colony-forming units (CFU)
   per cubic meter of air.
   DESIGN: We used Andersen two-stage samplers to collect bioaerosol
   samples from 24 houses in El Paso, Texas, using tryptic soy agar as the
   collection media, followed by the replicate plate method on Chapman
   Stone selective medium to isolate S. aureus. The Kirby-Bauer disk
   diffusion method was used to determine antibiotic resistance to
   ampicillin, penicillin, and cefaclor, which represent two distinct
   classes of antibiotics.
   RESULTS: The average recovered concentration of respirable heterotrophic
   organisms found outside each home was 345.38 CFU/m(3), with an average
   of 12.63 CFU/m(3) for S. aureus. The average recovered concentration of
   respirable heterotrophic organisms found inside each home was 460.23
   CFU/m(3), with an average of 15.39 CFU/m3 for S. aureus. The respirable
   S. aureus recovered from inside each home had an average resistance of
   54.59\% to ampicillin and 60.46\%. to penicillin. Presence of
   cefaclor-resistant and of multidrug-resistant S. aureus was the same,
   averaging 13.20\% per house. The respirable S. aureus recovered from
   outside each home had an average resistance of 34.42\% to ampicillin and
   41.81\% to penicillin. Presence of cefaclor-resistant and of
   multidrug-resistant S. aureus was the same, averaging 13.96\% per house.
   CONCLUSIONS: This study indicates that antibiotic-resistant bioaerosols
   are commonly found within residential homes. Our results also suggest
   that resistant strains of airborne culturable S. aureus are present in
   higher concentrations inside the study homes than outside the homes.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gibbs, SG (Reprint Author), Univ Texas, Ctr Hlth Sci, Sch Publ Hlth, 1100 N Stanton,Suite 110, El Paso, TX 79902 USA.
   Univ Texas, Ctr Hlth Sci, Sch Publ Hlth, El Paso, TX 79902 USA.
   Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA.
   Univ Cincinnati, Dept Civil \& Environm Engn, Cincinnati, OH 45221 USA.}},
DOI = {{10.1289/ehp.9585}},
ISSN = {{0091-6765}},
Keywords = {{antibiotic resistant; bioaerosols; residential indoor air;
   Staphylococcus aureus}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; RISK-FACTORS; AIRBORNE TRANSMISSION; BACTERIA;
   EPIDEMIOLOGY; CHILDREN; SUSCEPTIBILITY; BUILDINGS; INFECTION; OUTBREAK}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Author-Email = {{shawn.g.gibbs@uth.tmc.edu}},
ResearcherID-Numbers = {{Mota, Linda/E-4878-2014}},
Funding-Acknowledgement = {{NIMHD NIH HHS {[}P20 MD000548-01, P20 MD000548]}},
Cited-References = {{{*}AND SAMPL INC, 1976, OP MAN AND SAMP INC.
   Barker KF, 1999, BRIT J CLIN PHARMACO, V48, P109, DOI 10.1046/j.1365-2125.1999.00997.x.
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493.
   Beggs CB, 2003, INDOOR BUILT ENVIRON, V12, P9, DOI 10.1177/142032603032201.
   {*}CDC, 1999, MMWR-MORBID MORTAL W, V48, P707.
   CDC, 2006, MMWR-MORBID MORTAL W, V55, P329.
   Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204.
   COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050.
   Conly J, 2002, CAN MED ASSOC J, V167, P885.
   Cooper BS, 2004, BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533.
   Cotterill S, 1996, J HOSP INFECT, V32, P207, DOI 10.1016/S0195-6701(96)90147-4.
   Dacarro C, 2003, J APPL MICROBIOL, V95, P904, DOI 10.1046/j.1365-2672.2003.02044.x.
   Das I, 2002, J HOSP INFECT, V50, P110, DOI 10.1053/jhin.2001.1127.
   Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184.
   Garcia-Lara J, 2005, DRUG DISCOV TODAY, V10, P643, DOI 10.1016/S1359-6446(05)03432-X.
   Gibbs SG, 2004, J OCCUP ENVIRON HYG, V1, P699, DOI 10.1080/15459620490515824.
   Gibbs SG, 2006, ENVIRON HEALTH PERSP, V114, P1032, DOI 10.1289/ehp.8910.
   Gorak EJ, 1999, CLIN INFECT DIS, V29, P797, DOI 10.1086/520437.
   Green Christopher F., 2003, Aerobiologia, V19, P159, DOI 10.1023/B:AERO.0000006531.35387.bd.
   Groom AV, 2001, JAMA-J AM MED ASSOC, V286, P1201, DOI 10.1001/jama.286.10.1201.
   Heidelberg JF, 1997, APPL ENVIRON MICROB, V63, P3585.
   Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593.
   Hussain FM, 2000, PEDIATR INFECT DIS J, V19, P1163, DOI 10.1097/00006454-200012000-00009.
   Hyvarinen A, 2001, AEROSOL SCI TECH, V35, P688, DOI 10.1080/027868201316900016.
   {*}IOM, 2004, COMM DAMP IND SPAC H.
   LEDERBERG J, 1952, J BACTERIOL, V63, P399.
   Maranan MC, 1997, INFECT DIS CLIN N AM, V11, P813, DOI 10.1016/S0891-5520(05)70392-5.
   Marcinak JF, 2003, CURR OPIN INFECT DIS, V16, P265, DOI 10.1097/01.qco.0000073778.11390.16.
   Meklin T, 2002, ATMOS ENVIRON, V36, P6031, DOI 10.1016/S1352-2310(02)00769-0.
   National Committee for Clinical Laboratory Standards (NCCLS), 2000, M7A5 NCCLS.
   {*}NCCLS, 2001, PERF STAND ANT SUSCT.
   NCCLS (National Committee for Clinical Laboratory Standards), 1997, M2A6 NCCLS.
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064.
   Pastuszka JS, 2000, ATMOS ENVIRON, V34, P3833, DOI 10.1016/S1352-2310(99)00527-0.
   Peacock SJ, 2001, TRENDS MICROBIOL, V9, P605, DOI 10.1016/S0966-842X(01)02254-5.
   Rao GG, 1998, DRUGS, V55, P323, DOI 10.2165/00003495-199855030-00001.
   Roberts K, 2006, INDOOR BUILT ENVIRON, V15, P135.
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051.
   Salgado CD, 2003, CLIN INFECT DIS, V36, P131, DOI 10.1086/345436.
   Smith RD, 2002, B WORLD HEALTH ORGAN, V80, P126.
   Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279, DOI 10.1016/S1081-1206(10)62971-7.
   Virk A, 2000, MAYO CLIN PROC, V75, P200.
   WAGENVOORT JHT, 1993, LANCET, V341, P8404.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{43}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{23}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{112BN}},
Unique-ID = {{ISI:000242500200032}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000242610700005,
Author = {Narasipura, Srinivas D. and Ren, Ping and Dyavaiah, Madhu and Auger,
   Ivan and Chaturvedi, Vishnu and Chaturvedi, Sudha},
Title = {{An efficient method for homologous gene reconstitution in Cryptococcus
   gattii using URA5 auxotrophic marker}},
Journal = {{MYCOPATHOLOGIA}},
Year = {{2006}},
Volume = {{162}},
Number = {{6}},
Pages = {{401-409}},
Month = {{DEC}},
Abstract = {{Cryptococcus gattii (Cg) is an emerging pathogen of both healthy and
   immunocompromised patients worldwide. Understanding the molecular
   genetic basis of virulence and physiology of this pathogen will be
   critical for defining its pathogenic mechanisms. The purine biosynthetic
   gene, URA5 encoding orate phosphorybosyltransferase (OPRTase), has been
   successfully used as a selectable marker for gene disruption by
   transformation and homologous recombination in Cg. Here, we report the
   characterization of ura5 auxotrophy and URA5 reversion phenomenon at the
   molecular, genetic, and structural levels, and use of ura5 -> URA5
   reversion as a tool for reconstitution of gene of interest and
   auxotrophic marker to their native loci. We identified a single mutation
   of GG(128)T -> GAT with substitution of glycine to aspartic acid at
   amino acid position 43 resulting in ura5 auxotrophy. The ura5 -> URA5
   reversion on CSM lacking uracil (CSM-U) was found to be a rare
   phenomenon with a reversion frequency of 0.000002\%, and sequence
   analysis of URA5 from all the reverted strains revealed mutation of
   GA(128)T -> GGT back to its ancestral state. The URA5 allele in the
   reverted strains was fully functional, as demonstrated by the excellent
   growth of these strains on medium lacking uracil, as well as by the
   ability of this allele to efficiently transform ura5 mutant to restore
   prototrophy. The deduced Cg URA5 protein modeled on the known crystal
   structures of OPRTase from Salmonella typhimurium (1LH0\_A, 1STO) and
   from Escherichia coli (1ORO\_A) indicated that the glycine 43 of Cg URA5
   was situated on a conserved loop, and it's substitution to more globose
   aspartic acid may have resulted in URA5 inactivation in auxotrophic
   strain. The advantages of this approach for the generation of a
   reconstituted strain are (1) that it restores the functionality of the
   native URA5, (2) that it eliminates an additional biolistic delivery of
   exogenous URA5, and (3) that it allows easy selection of reconstituted
   strains with homologous integration. This strategy was successfully used
   for the generation of Cg can2+CAN2/URA5 homologous reconstituted
   strains, which grew in ambient air to the wild-type level while can2
   mutant exhibited severe growth defect under similar conditions.}},
Publisher = {{SPRINGER}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Narasipura, SD (Reprint Author), New York State Dept Hlth, Wadsworth Ctr, Mycol Lab, 120 New Scotland Ave, Albany, NY 12208 USA.
   New York State Dept Hlth, Wadsworth Ctr, Mycol Lab, Albany, NY 12208 USA.
   New York State Dept Hlth, Wadsworth Ctr, Bioinformat Lab, Albany, NY 12208 USA.
   SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12222 USA.}},
DOI = {{10.1007/s11046-006-0076-z}},
ISSN = {{0301-486X}},
Keywords = {{efficient method; homologous gene reconstitution; auxotrophic marker;
   Cryptococcus gattii}},
Keywords-Plus = {{OROTATE PHOSPHORIBOSYLTRANSFERASE; SALMONELLA-TYPHIMURIUM;
   ANTIBIOTIC-RESISTANCE; DISTINCT ROLES; NEOFORMANS; VIRULENCE; SELECTION;
   DATABASE; BIOLOGY}},
Research-Areas = {{Mycology}},
Web-of-Science-Categories  = {{Mycology}},
Author-Email = {{schaturv@wadsworth.org}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R03-AI05887701]; PHS HHS {[}R01-A48462]}},
Cited-References = {{Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389.
   Bahn YS, 2005, CURR BIOL, V15, P2013, DOI 10.1016/j.cub.2005.09.047.
   Bauer A. M., 2005, NUCLEIC ACIDS RES, V33, P192, DOI {[}10.1093/nar/gki06915608175, DOI 10.1093/NAR/KG2].
   Casadevall A, 1998, CRYPTOCOCCUS NEOFORM.
   Chaturvedi S, 2005, MYCOPATHOLOGIA, V160, P207, DOI 10.1007/s11046-005-0162-7.
   DENISDUPHIL M, 1989, BIOCHEM CELL BIOL, V67, P612, DOI 10.1139/o89-094.
   Drivinya A., 2004, Japanese Journal of Medical Mycology, V45, P1.
   Henriksen A, 1996, BIOCHEMISTRY-US, V35, P3803, DOI 10.1021/bi952226y.
   Hua J, 2000, CLIN DIAGN LAB IMMUN, V7, P125, DOI 10.1128/CDLI.7.1.125-128.2000.
   Hull CM, 2002, ANNU REV GENET, V36, P557, DOI 10.1146/annurev.genet.36.052402.152652.
   Idnurm A, 2004, EUKARYOT CELL, V3, P420, DOI 10.1128/EC.3.2.420-429.2004.
   Kwon-Chung K. J., 1992, MED MYCOLOGY.
   Kwon-Chung KJ, 1998, CURR OPIN MICROBIOL, V1, P381, DOI 10.1016/S1369-5274(98)80053-2.
   KWONCHUNG KJ, 1992, J MED VET MYCOL, V30, P61.
   Levin BR, 2000, GENETICS, V154, P985.
   LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L.
   Maisnier-Patin S, 2002, MOL MICROBIOL, V46, P355, DOI 10.1046/j.1365-2958.2002.03173.x.
   McDade HC, 2001, MED MYCOL, V39, P151, DOI 10.1080/714030997.
   Narasipura SD, 2005, MOL MICROBIOL, V55, P1782, DOI 10.1111/j.1365-2958.2005.04503.x.
   Narasipura SD, 2003, MOL MICROBIOL, V47, P1681, DOI 10.1046/j.1365-2958.2003.03393.x.
   OZTURK DH, 1995, BIOCHEMISTRY-US, V34, P10755, DOI 10.1021/bi00034a007.
   Ren P, 2006, EUKARYOT CELL, V5, P1065, DOI 10.1128/EC.00009-06.
   SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001.
   Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Wang P, 2002, EUKARYOT CELL, V1, P257, DOI 10.1128/EC.1.2.257-272.2002.
   Wills EA, 2001, MOL MICROBIOL, V40, P610, DOI 10.1046/j.1365-2958.2001.02401.x.
   Yu JH, 2004, FUNGAL GENET BIOL, V41, P973, DOI 10.1016/j.fgb.2004.08.001.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Mycopathologia}},
Doc-Delivery-Number = {{113PV}},
Unique-ID = {{ISI:000242610700005}},
DA = {{2018-08-13}},
}

@article{ ISI:000241158100011,
Author = {Sapkota, A. R. and Ojo, K. K. and Roberts, M. C. and Schwab, K. J.},
Title = {{Antibiotic resistance genes in multidrug-resistant Enterococcus spp. and
   Streptococcus spp. recovered from the indoor air of a large-scale
   swine-feeding operation}},
Journal = {{LETTERS IN APPLIED MICROBIOLOGY}},
Year = {{2006}},
Volume = {{43}},
Number = {{5}},
Pages = {{534-540}},
Month = {{NOV}},
Abstract = {{Aims: In this study, multidrug-resistant bacteria previously recovered
   from the indoor air of a large-scale swine-feeding operation were tested
   for the presence of five macrolide, lincosamide and streptogramin (MLS)
   resistance genes and five tetracycline (tet) resistance genes.
   Methods and Results: Enterococcus spp. (n = 16) and Streptococcus spp.
   (n =16) were analysed using DNA-DNA hybridization, polymerase chain
   reaction (PCR) and oligoprobing of PCR products. All isolates carried
   multiple MLS resistance genes, while 50\% of the Enterococcus spp. and
   44\% of the Streptococcus spp. also carried multiple tet resistance
   genes. All Enterococcus spp. carried erm(A) and erm(B), 69\% carried
   erm(F), 44\% carried mef(A), 75\% carried tet(M), 69\% carried tet(L)
   and 19\% carried tet(K). All Streptococcus spp. carried erm(B), 94\%
   carried erm(F), 75\% carried erm(A), 38\% carried mef(A), 50\% carried
   tet(M), 81\% carried tet(L) and 13\% carried tet(K).
   Conclusions: Multidrug resistance among airborne bacteria recovered from
   a swine operation is encoded by multiple MLS and tet resistance genes.
   These are the first data regarding resistance gene carriage among
   airborne bacteria from swine-feeding operations.
   Significance: The high prevalence of multiple resistance genes reported
   here suggests that airborne Gram-positive bacteria from swine operations
   may be important contributors to environmental reservoirs of resistance
   genes.}},
Publisher = {{BLACKWELL PUBLISHING}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schwab, KJ (Reprint Author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room E6620, Baltimore, MD 21205 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.
   Univ Washington, Sch Publ Hlth \& Community Med, Dept Pathobiol, Seattle, WA 98195 USA.}},
DOI = {{10.1111/j.1472-765X.2006.01996.x}},
ISSN = {{0266-8254}},
Keywords = {{airborne bacteria; antibiotic resistance genes; Enterococcus; multidrug
   resistance; Streptococcus; swine}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; BACTERIA; FAECIUM; POULTRY; DENMARK; PIGS;
   DIVERSITY; BROILERS; ANIMALS; HUMANS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{kschwab@jhsph.edu}},
ResearcherID-Numbers = {{Sapkota, Amy/A-6046-2011}},
Cited-References = {{Aarestrup FM, 2000, MICROB DRUG RESIST, V6, P63, DOI 10.1089/mdr.2000.6.63.
   Aarestrup FM, 2000, DIAGN MICR INFEC DIS, V37, P127, DOI 10.1016/S0732-8893(00)00130-9.
   Bager F, 1997, PREV VET MED, V31, P95, DOI 10.1016/S0167-5877(96)01119-1.
   Chapin A, 2005, ENVIRON HEALTH PERSP, V113, P137, DOI 10.1289/ehp.7473.
   Chee-Sanford JC, 2001, APPL ENVIRON MICROB, V67, P1494, DOI 10.1128/AEM.67.4.1494-1502.2001.
   Chung WSO, 1999, J ANTIMICROB CHEMOTH, V43, P5, DOI 10.1093/jac/43.1.5.
   Donabedian SM, 2003, J CLIN MICROBIOL, V41, P1109, DOI 10.1128/JCM.41.3.1109-1113.2003.
   Gambarotto K, 2001, J CLIN MICROBIOL, V39, P2354, DOI 10.1128/JCM.39.6.2354-2355.2001.
   Gibbs SG, 2004, J OCCUP ENVIRON HYG, V1, P699, DOI 10.1080/15459620490515824.
   Gibbs SG, 2006, ENVIRON HEALTH PERSP, V114, P1032, DOI 10.1289/ehp.8910.
   Hayes JR, 2003, APPL ENVIRON MICROB, V69, P7153, DOI 10.1128/AEM.69.12.7153-7160.2003.
   Jackson CR, 2004, APPL ENVIRON MICROB, V70, P4205, DOI 10.1128/AEM.70.7.4205-4210.2004.
   Jensen LB, 2002, MICROB DRUG RESIST, V8, P369, DOI 10.1089/10766290260469642.
   Jensen LB, 2002, ENVIRON INT, V28, P487, DOI 10.1016/S0160-4120(02)00076-4.
   Luna VA, 1998, J ANTIMICROB CHEMOTH, V42, P613, DOI 10.1093/jac/42.5.613.
   Luna VA, 2000, ANTIMICROB AGENTS CH, V44, P2503, DOI 10.1128/AAC.44.9.2503-2506.2000.
   Martel A, 2003, INT J FOOD MICROBIOL, V84, P27, DOI 10.1016/S0168-1605(02)00390-2.
   Miranda CD, 2003, ANTIMICROB AGENTS CH, V47, P883, DOI 10.1128/AAC.47.3.883-888.2003.
   Murray PRE, 2003, MANUAL CLIN MICROBIO.
   Nandi S, 2004, P NATL ACAD SCI USA, V101, P7118, DOI 10.1073/pnas.0306466101.
   {*}NAT RES COUNC, 1999, US DRUGS FOOD AN BEN.
   Ojo KK, 2004, ANTIMICROB AGENTS CH, V48, P3451, DOI 10.1128/AAC.48.9.3451-3456.2004.
   PANG Y, 1994, MOL CELL PROBE, V8, P417, DOI 10.1006/mcpr.1994.1059.
   SCARPINO PV, 1998, J AEROSOL SCI, V29, pS553.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{7}},
Usage-Count-Since-2013 = {{33}},
Journal-ISO = {{Lett. Appl. Microbiol.}},
Doc-Delivery-Number = {{093HE}},
Unique-ID = {{ISI:000241158100011}},
DA = {{2018-08-13}},
}

@article{ ISI:000240825900083,
Author = {Hidalgo, A. A. and Pimentel, A. S. and Tabak, M. and Oliveira, Jr., O.
   N.},
Title = {{Thermodynamic and infrared analyses of the interaction of chlorpromazine
   with phospholipid monolayers}},
Journal = {{JOURNAL OF PHYSICAL CHEMISTRY B}},
Year = {{2006}},
Volume = {{110}},
Number = {{39}},
Pages = {{19637-19646}},
Month = {{OCT 5}},
Abstract = {{An investigation has been made of the interaction between chlorpromazine
   (CPZ) and monolayers of 1,2-dipalmitoyl- sn-3-glycerophosphatidylcholine
   ( DPPC) and 1,2-dipalmitoyl-sn-3-glycero{[}phospho-rac-(1-glycerol)] (
   DPPG), both at the air/water interface and in transferred
   Langmuir-Blodgett films. The Gibbs free energy, Delta G, and the
   compressibility modulus (C-S(-1)), obtained from the surface pressure
   isotherms, indicated changes in the in-plane interactions of CPZ/DPPG
   mixed monolayers, with positive values of Delta G. The arrangement of
   CPZ in the zwitterionic DPPC monolayers causes a weaker interaction in
   CPZ/ DPPC mixed monolayers, with the Delta G fluctuating around zero. IR
   measurements in transferred monolayers showed that CPZ did not affect
   the conformational order of the acyl chains, its effects being limited
   to the bands corresponding to the headgroups. Furthermore, since no
   shift was observed for the acyl chain bands, the phase transition
   induced by CPZ is not a liquid expanded (LE) to liquid condensed (LC)
   transition, as the latter is associated with chain ordering. Taken
   together, the IR and compressibility results demonstrate that the effect
   from CPZ cannot be correlated with temperature changes in the subphase
   for pure monolayers, in contrast to models proposed by other authors.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hidalgo, AA (Reprint Author), Inst Quim, Dept Quim \& Fis Mol, Sao Carlos, Brazil.
   Inst Quim, Dept Quim \& Fis Mol, Sao Carlos, Brazil.
   Univ Sao Paulo, Inst Fis Sao Carlos, BR-13560970 Sao Carlos, SP, Brazil.}},
DOI = {{10.1021/jp0633143}},
ISSN = {{1520-6106}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE; AIR/WATER INTERFACE; BILAYER-MEMBRANES;
   ACYL-CHAIN; STATE; PHOSPHATIDYLCHOLINE; VESICLES; LIPIDS; FILMS; AREA}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Physical}},
Author-Email = {{angel.ufu@gmail.com}},
ResearcherID-Numbers = {{Sao Carlos Institute of Physics, IFSC/USP/M-2664-2016
   Pimentel, Andre/B-1278-2010
   Tabak, Marcel/I-3173-2014
   Oliveira, Osvaldo/A-1714-2008}},
ORCID-Numbers = {{Pimentel, Andre/0000-0002-1301-0561
   Oliveira, Osvaldo/0000-0002-5399-5860}},
Cited-References = {{Agasosler AV, 2001, BIOCHEM PHARMACOL, V61, P817, DOI 10.1016/S0006-2952(01)00542-1.
   Agasoster AV, 2001, BIOPHYS CHEM, V91, P37.
   BEURER G, 1987, EUR BIOPHYS J BIOPHY, V14, P403.
   BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7.
   BROCKMAN H, 1999, CURR OPIN STRUC BIOL, V9, P425.
   CAETANO W, 2001, BIOPHYS CHEM, V97, P21.
   Diociaiuti M, 2002, BIOPHYS J, V82, P3198, DOI 10.1016/S0006-3495(02)75662-2.
   Feng SS, 1999, LANGMUIR, V15, P998, DOI 10.1021/la980144f.
   FLACH CR, 1994, BIOPHYS J, V67, P402, DOI 10.1016/S0006-3495(94)80495-3.
   FLACH CR, 1993, BIOPHYS J, V65, P1994, DOI 10.1016/S0006-3495(93)81276-1.
   Flach CR, 1997, J PHYS CHEM B, V101, P58, DOI 10.1021/jp962288d.
   GAINES GL, 1966, J COLLOID INTERF SCI, V21, P315, DOI 10.1016/0095-8522(66)90015-8.
   Gjerde AU, 2004, BBA-MOL CELL BIOL L, V1682, P28.
   Hac-Wydro K, 2005, BIOPHYS CHEM, V116, P77, DOI 10.1016/j.bpc.2005.03.001.
   Harrick N. J., 1987, INTERNAL REFLECTION.
   Hendrich AB, 2003, BIOCHEM BIOPH RES CO, V304, P260, DOI 10.1016/S0006-291X(03)00580-1.
   Hendrich AB, 2003, CURR DRUG TARGETS, V4, P23, DOI 10.2174/1389450033347172.
   Hendrich AB, 2001, BBA-BIOMEMBRANES, V1510, P414, DOI 10.1016/S0005-2736(00)00373-4.
   Hidalgo AA, 2005, CHEM PHYS LIPIDS, V134, P97, DOI 10.1016/j.chemphyslip.2004.12.006.
   Hidalgo AA, 2004, BIOPHYS CHEM, V109, P85, DOI 10.1016/j.bpc.2003.10.020.
   Holopainen JM, 2001, BIOPHYS J, V80, P765, DOI 10.1016/S0006-3495(01)76056-0.
   Jutila A, 2001, CHEM PHYS LIPIDS, V112, P151, DOI 10.1016/S0009-3084(01)00175-X.
   Lewis R. N. A. H., 1996, INFRARED SPECTROSCOP.
   Li XM, 2000, BIOPHYS J, V78, P1921, DOI 10.1016/S0006-3495(00)76740-3.
   Lieber M.R., 1984, J BIOL CHEM, V259, P9925.
   LUXNAT M, 1984, BIOCHEM J, V224, P1023, DOI 10.1042/bj2241023.
   LUXNAT M, 1986, BIOCHIM BIOPHYS ACTA, V856, P274, DOI 10.1016/0005-2736(86)90037-4.
   Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5.
   Mohwald H, 1995, STRUCTURE DYNAMICS M.
   Molnar J, 1997, ANTICANCER RES, V17, P481.
   Nassar PM, 1997, BBA-BIOMEMBRANES, V1328, P140, DOI 10.1016/S0005-2736(97)00081-3.
   NEAL MJ, 1976, MOL PHARMACOL, V12, P144.
   Nerdal W, 2000, BBA-BIOMEMBRANES, V1464, P165, DOI 10.1016/S0005-2736(00)00125-5.
   Perez-Rodriguez M, 2000, COLLOID POLYM SCI, V278, P706, DOI 10.1007/s003960000331.
   ROMER J, 1979, BIOCHEM PHARMACOL, V28, P799, DOI 10.1016/0006-2952(79)90361-7.
   Song C, 2006, BIOPHYS CHEM, V120, P178, DOI 10.1016/j.bpc.2005.11.007.
   Takegami S, 2005, CHEM PHARM BULL, V53, P147, DOI 10.1248/cpb.53.147.
   Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375.
   Vollhardt D, 2000, J PHYS CHEM B, V104, P4115, DOI 10.1021/jp992529s.
   Yeagle P.L, 2004, STRUCTURE BIOL MEMBR.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{J. Phys. Chem. B}},
Doc-Delivery-Number = {{088QJ}},
Unique-ID = {{ISI:000240825900083}},
DA = {{2018-08-13}},
}

@article{ ISI:000239278600057,
Author = {Sambhy, Varun and MacBride, Megan M. and Peterson, Blake R. and Sen,
   Ayusman},
Title = {{Silver bromide nanoparticle/polymer composites: Dual action tunable
   antimicrobial materials}},
Journal = {{JOURNAL OF THE AMERICAN CHEMICAL SOCIETY}},
Year = {{2006}},
Volume = {{128}},
Number = {{30}},
Pages = {{9798-9808}},
Month = {{AUG 2}},
Abstract = {{We present a simple method of fabricating highly potent dual action
   antibacterial composites consisting of a cationic polymer matrix and
   embedded silver bromide nanoparticles. A simple and novel technique of
   on-site precipitation of AgBr was used to synthesize the
   polymer/nanoparticle composites. The synthesized composites have potent
   antibacterial activity toward both gram-positive and gram-negative
   bacteria. The materials form good coatings on surfaces and kill both
   airborne and waterborne bacteria. Surfaces coated with these composites
   resist biofilm formation. These composites are different from other
   silver-containing antibacterial materials both in the ease of synthesis
   and in the use of a silver salt nanoparticle instead of elemental silver
   or complex silver compounds. We also demonstrate the ability to tune the
   release of biocidal Ag(+) ions from these composites by controlling the
   size of the embedded AgBr nanoparticles. These composites are
   potentially useful as antimicrobial coatings in a wide variety of
   biomedical and general use applications.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Sen, A (Reprint Author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.
   Penn State Univ, Dept Chem, University Pk, PA 16802 USA.}},
DOI = {{10.1021/ja061442z}},
Article-Number = {{JA061442Z}},
ISSN = {{0002-7863}},
Keywords-Plus = {{TRANSFER RADICAL POLYMERIZATION; STAPHYLOCOCCUS-AUREUS ADHESION; CENTRAL
   VENOUS CATHETER; DE-NOVO DESIGN; ANTIBIOTIC-RESISTANCE; BIOFILM
   FORMATION; ESCHERICHIA-COLI; ANTIBACTERIAL ACTIVITIES; METHACRYLATE
   POLYMERS; BACTERIAL BIOFILMS}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary}},
Author-Email = {{asen@psu.edu}},
ResearcherID-Numbers = {{Sen, Ayusman/A-9406-2009
   Peterson, Blake/O-2497-2016}},
ORCID-Numbers = {{Sen, Ayusman/0000-0002-0556-9509
   Peterson, Blake/0000-0001-8251-3579}},
Cited-References = {{Affinito J, 1995, THIN SOLID FILMS, V270, P43, DOI 10.1016/0040-6090(95)06853-8.
   Alasino RV, 2005, MACROMOL BIOSCI, V5, P207, DOI 10.1002/mabi.200400168.
   Andes D, 2004, INFECT IMMUN, V72, P6023, DOI 10.1128/IAI.72.10.6023-6031.2004.
   Arciola CR, 2005, BIOMATERIALS, V26, P6530, DOI 10.1016/j.biomaterials.2005.04.031.
   Aymonier C, 2002, CHEM COMMUN, P3018, DOI 10.1039/b208575e.
   BARTH E, 1989, BIOMATERIALS, V10, P325, DOI 10.1016/0142-9612(89)90073-2.
   Beech IB, 2000, BIOFOULING, V16, P93, DOI 10.1080/08927010009378435.
   Brady MJ, 2003, AM J INFECT CONTROL, V31, P208, DOI 10.1067/mic.2003.23.
   Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a.
   Changez M, 2005, BIOMATERIALS, V26, P2095, DOI 10.1016/j.biomaterials.2004.06.008.
   Chauhan BPS, 2005, J AM CHEM SOC, V127, P5790, DOI 10.1021/ja042824c.
   Chauhan BPS, 2004, MACROMOLECULES, V37, P5136, DOI 10.1021/ma0496798.
   Chauhan BPS, 2004, J AM CHEM SOC, V126, P8493, DOI 10.1021/ja049604j.
   Chen YJ, 2003, IND ENG CHEM RES, V42, P280, DOI 10.1021/ie020266+.
   Cioffi N, 2005, CHEM MATER, V17, P5255, DOI 10.1021/cm0505244.
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318.
   Cushing BL, 2004, CHEM REV, V104, P3893, DOI 10.1021/cr030027b.
   Davenas J, 2002, BIOMOL ENG, V19, P263, DOI 10.1016/S1389-0344(02)00037-0.
   DESAI NP, 1992, BIOMATERIALS, V13, P417, DOI 10.1016/0142-9612(92)90160-P.
   Dizman B, 2005, BIOMACROMOLECULES, V6, P514, DOI 10.1021/bm049383+.
   Dizman B, 2004, J APPL POLYM SCI, V94, P635, DOI 10.1002/app.20872.
   Dowling DP, 2003, SURF COAT TECH, V163, P637, DOI 10.1016/S0257-8972(02)00689-8.
   Dowling DP, 2001, THIN SOLID FILMS, V398, P602, DOI 10.1016/S0040-6090(01)01326-8.
   Favia P., 2000, PLASMAS POLYM, DOI {[}10.1023/A:1009517408368, DOI 10.1023/A:1009517408368].
   Feng QL, 2000, J BIOMED MATER RES, V52, P662, DOI 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3.
   Gerrard JJ, 2005, SURF COAT INT PT B-C, V88, P83, DOI 10.1007/BF02699538.
   Gosheger G, 2004, BIOMATERIALS, V25, P5547, DOI 10.1016/j.biomaterials.2004.01.008.
   Greenberg CB, 2005, THIN SOLID FILMS, V484, P324, DOI 10.1016/j.tsf.2005.03.008.
   GUISEPPIELIE A, 1995, LANGMUIR, V11, P1768, DOI 10.1021/la00005a055.
   Hachem RY, 2003, BIOMATERIALS, V24, P3619, DOI 10.1016/S0142-9612(03)00185-6.
   Harris LG, 2004, J MATER SCI-MATER M, V15, P311, DOI 10.1023/B:JMSM.0000021093.84680.bb.
   Heilmann A, 2002, POLYM FILMS EMBEDDED.
   Herigstad B, 2001, J MICROBIOL METH, V44, P121, DOI 10.1016/S0167-7012(00)00241-4.
   Ho CH, 2004, ADV MATER, V16, P957, DOI 10.1002/adma.200306253.
   Hoffman LR, 2005, NATURE, V436, P1171, DOI 10.1038/nature03912.
   Hollinger MA, 1996, CRIT REV TOXICOL, V26, P255, DOI 10.3109/10408449609012524.
   Holt KB, 2005, BIOCHEMISTRY-US, V44, P13214, DOI 10.1021/bi0508542.
   Hudson MC, 1999, FEMS MICROBIOL LETT, V173, P279, DOI 10.1016/S0378-1097(99)00079-8.
   Iconomopoulou SM, 2005, J CONTROL RELEASE, V103, P451, DOI 10.1016/j.jconrel.2004.12.014.
   Ignatova M, 2006, LANGMUIR, V22, P255, DOI 10.1021/la051954b.
   Ilker MF, 2004, J AM CHEM SOC, V126, P15870, DOI 10.1021/ja045664d.
   Ilker MF, 2004, MACROMOLECULES, V37, P694, DOI 10.1021/ma035407d.
   Jiang HQ, 2004, J APPL POLYM SCI, V93, P1411, DOI 10.1002/app.20561.
   Joly S, 2000, LANGMUIR, V16, P1354, DOI 10.1021/la991089t.
   Jones GL, 2006, J ANTIMICROB CHEMOTH, V57, P266, DOI 10.1093/jac/dki447.
   Kasuga N. C., 2004, J CHEM SOC DA, V21, P3732.
   Kim HJ, 2000, BIOMATERIALS, V21, P131, DOI 10.1016/S0142-9612(99)00140-4.
   Kiriukhin MY, 2001, J BACTERIOL, V183, P3506, DOI 10.1128/JB.183.11.3506-3514.2001.
   Kohnen W, 2003, BIOMATERIALS, V24, P4865, DOI 10.1016/S0142-9612(03)00379-X.
   Kuroda K, 2005, J AM CHEM SOC, V127, P4128, DOI 10.1021/ja044205+.
   LAMOTTA EJ, 1982, J ENV ENG DIV-ASCE, V108, P1326.
   Landry RM, 2006, MOL MICROBIOL, V59, P142, DOI 10.1111/j.1365-2958.2005.04941.x.
   Lee SB, 2004, BIOMACROMOLECULES, V5, P877, DOI 10.1021/bm034352k.
   Li GJ, 1998, J APPL POLYM SCI, V67, P1761, DOI 10.1002/(SICI)1097-4628(19980307)67:10<1761::AID-APP9>3.0.CO;2-H.
   Lide D. R., 2002, CRC HDB CHEM PHYS.
   Lin J, 2003, BIOTECHNOL LETT, V25, P1661, DOI 10.1023/A:1025613814588.
   Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475.
   Lu Y, 2005, NANO LETT, V5, P5, DOI 10.1021/nl048965u.
   Mah TF, 2003, NATURE, V426, P306, DOI 10.1038/nature02122.
   Masse A, 2000, J BIOMED MATER RES, V53, P600, DOI 10.1002/1097-4636(200009)53:5<600::AID-JBM21>3.0.CO;2-D.
   McDonnell AMP, 2005, ADV FUNCT MATER, V15, P336, DOI 10.1002/adfm.200400183.
   Meaume S, 2005, J Wound Care, V14, P411.
   Melaiye A, 2005, J AM CHEM SOC, V127, P2285, DOI 10.1021/ja040226s.
   Millsap KW, 1997, BIOMATERIALS, V18, P87, DOI 10.1016/S0142-9612(96)00105-6.
   Morrier JJ, 1998, DENT MATER, V14, P150, DOI 10.1016/S0109-5641(98)00022-0.
   Moskowitz SM, 2005, J ANTIMICROB CHEMOTH, V56, P879, DOI 10.1093/jac/dki338.
   Multanen M, 2000, UROL RES, V28, P327, DOI 10.1007/s002400000133.
   Multanen M, 2001, UROL RES, V29, P113, DOI 10.1007/s002400000166.
   Nablo BJ, 2005, BIOMATERIALS, V26, P917, DOI 10.1016/j.biomaterials.2004.03.031.
   Nablo BJ, 2001, J AM CHEM SOC, V123, P9712, DOI 10.1021/ja0165077.
   Nuzzo RG, 2003, NAT MATER, V2, P207, DOI 10.1038/nmat872.
   O'Toole GA, 2005, NAT BIOTECHNOL, V23, P1378, DOI 10.1038/ndt1105-1378.
   OLOFFS A, 1994, BIOMATERIALS, V15, P753, DOI 10.1016/0142-9612(94)90028-0.
   Parikh DV, 2005, TEXT RES J, V75, P134, DOI 10.1177/004051750507500208.
   Percival SL, 2005, J HOSP INFECT, V60, P1, DOI 10.1016/j.jhin.2004.11.014.
   Podsiadlo P, 2005, LANGMUIR, V21, P11915, DOI 10.1021/la051284+.
   Porel S, 2005, CHEM MATER, V17, P9, DOI 10.1021/cm0485963.
   PRICE WR, 1966, AM J SURG, V112, P674, DOI 10.1016/0002-9610(66)90103-6.
   Raad II, 2005, ANTIMICROB AGENTS CH, V49, P5046, DOI 10.1128/AAC.49.12.5046-5050.2005.
   Ramage G, 2001, J CLIN MICROBIOL, V39, P3234, DOI 10.1128/JCM.39.9.3234-3240.2001.
   Rathore R, 2003, J AM CHEM SOC, V125, P8712, DOI 10.1021/ja035518s.
   Robbins ME, 2004, LANGMUIR, V20, P10296, DOI 10.1021/la048368n.
   Rosato AE, 2004, AM J INFECT CONTROL, V32, P486, DOI 10.1016/j.ajic.2004.06.002.
   Rupp ME, 2004, AM J INFECT CONTROL, V32, P445, DOI 10.1016/j.ajic.2004.05.002.
   Rupp ME, 2005, ANN INTERN MED, V143, P570, DOI 10.7326/0003-4819-143-8-200510180-00007.
   Russell AD, 1994, PROGR MED CHEM, V31, P351, DOI DOI 10.1016/S0079-6468(08)70024-9.
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012.
   Sun YY, 2004, IND ENG CHEM RES, V43, P5015, DOI 10.1021/ie030846m.
   TAKAHASHI H, 1987, J PHYS SOC JPN, V56, P3593, DOI 10.1143/JPSJ.56.3593.
   Tang HZ, 2005, CHEM COMMUN, P1537, DOI 10.1039/b413679a.
   Tashiro T, 2001, MACROMOL MATER ENG, V286, P63.
   Tew GN, 2002, P NATL ACAD SCI USA, V99, P5110, DOI 10.1073/pnas.082046199.
   Tiller JC, 2002, BIOTECHNOL BIOENG, V79, P465, DOI 10.1002/bit.10299.
   Tiller JC, 2001, P NATL ACAD SCI USA, V98, P5981, DOI 10.1073/pnas.111143098.
   Tolker-Nielsen T, 2004, PSEUDOMONAS, VOL 1: GENOMICS, LIFE STYLE AND MOLECULAR ARCHITECTURE, P547.
   Tsukada M, 2003, J APPL POLYM SCI, V89, P638, DOI 10.1002/app.11911.
   Ueshige M, 1999, J DENT, V27, P517, DOI 10.1016/S0300-5712(99)00009-3.
   Wang XS, 2005, J AM CHEM SOC, V127, P8924, DOI 10.1021/ja0511365a.
   Weickmann H, 2005, MACROMOL MATER ENG, V290, P875, DOI 10.1002/mame.200500153.
   Yoshida K, 1999, J BIOMED MATER RES, V47, P516, DOI 10.1002/(SICI)1097-4636(19991215)47:4<516::AID-JBM7>3.0.CO;2-E.
   Zachariadis CP, 2004, EUR J INORG CHEM, V7, P1420.
   2003, NCCLS APPROVED STAND.}},
Number-of-Cited-References = {{102}},
Times-Cited = {{438}},
Usage-Count-Last-180-days = {{13}},
Usage-Count-Since-2013 = {{333}},
Journal-ISO = {{J. Am. Chem. Soc.}},
Doc-Delivery-Number = {{067CH}},
Unique-ID = {{ISI:000239278600057}},
DA = {{2018-08-13}},
}

@article{ ISI:000239035100033,
Author = {Gibbs, Shawn G. and Green, Christopher F. and Tarwater, Patrick M. and
   Mota, Linda C. and Mena, Kristina D. and Scarpino, Pasquale V.},
Title = {{Isolation of antibiotic-resistant bacteria from the air plume downwind
   of a swine confined or concentrated animal feeding operation}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{2006}},
Volume = {{114}},
Number = {{7}},
Pages = {{1032-1037}},
Month = {{JUL}},
Abstract = {{OBJECTIVE: In this study we evaluated the levels of antibiotic- and
   multidrug-resistant bacteria in bioaerosols upwind, within, and downwind
   at locations 25 in, 50 in, 100 in, and 150 in from a swine confined
   animal feeding operation.
   DESIGN: We used Andersen two-stage samplers to collect bacterial
   samples, the replicate plate method to isolate organisms, and the
   Kirby-Bauer disk diffusion method to determine antibiotic resistance.
   RESULTS: The percentage of organisms resistant to at least two
   antibiotic classes and all four classes evaluated were, respectively,
   2.1 and 3.0 times higher inside (n = 69) than upwind (n = 59) of the
   facility. Staphylococcus aureus was the most prevalent organism
   recovered. Concentrations of antibiotic-resistant S. aureus decreased
   with increasing distance from the facility. Using Fisher's exact
   methods, the change in distribution of antibiotic resistance profiles
   for each antibiotic was statistically significant (oxytetracycline, p =
   0.010; tetracycline, p = 0.014; ampicillin, p = 0.007; erythromycin, p =
   0.035); however, this relationship was not seen with lincomycin and
   penicillin (p > 0.05). In addition, the levels of antibiotic-resistant
   S. aureas 25 in downwind were significantly greater than the levels from
   samples taken upwind from the facility for the same four antibiotics (p
   < 0.05). The percentage of resistant group A streptococci and fecal
   coliform increased within the facility compared with upwind values for
   all antibiotics evaluated, except for lincomycin. The percentage of
   resistant total coliform organisms increased within the facility
   compared with upwind values for oxytetracycline and tetracycline.
   CONCLUSIONS: Bacterial concentrations with multiple antibiotic
   resistances or multidrug resistance were recovered inside and outside to
   (at least) 150 in downwind of this facility at higher percentages than
   upwind. Bacterial concentrations with multiple antibiotic resistances
   were found within and downwind of the facility even after subtherapeutic
   antibiotics were discontinued. This could pose a potential human health
   effect for those who work within or live in close proximity to these
   facilities.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gibbs, SG (Reprint Author), Univ Texas, Ctr Hlth Sci, Sch Publ Hlth, El Paso Reg Campus,1100 N Stanton,Suite 110, El Paso, TX 79902 USA.
   Univ Texas, Ctr Hlth Sci, Sch Publ Hlth, El Paso, TX 79902 USA.
   Univ Cincinnati, Dept Civil \& Environm Engn, Cincinnati, OH 45221 USA.}},
DOI = {{10.1289/ehp.8910}},
ISSN = {{0091-6765}},
Keywords = {{antibiotic resistant; bioacrosols; CAFO; confined/concentrated animal
   feeding operation; microorganisms}},
Keywords-Plus = {{ANTIMICROBIAL AGENTS; DRUG-RESISTANCE; PUBLIC-HEALTH; ENTEROCOCCI;
   SUSCEPTIBILITY; PERSISTENCE; AVOPARCIN}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Author-Email = {{shawn.g.gibbs@uth.tmc.edu}},
ResearcherID-Numbers = {{Mota, Linda/E-4878-2014}},
Cited-References = {{BAUER AW, 1966, AM J CLIN PATHOL, V45, P493.
   Burriel AR, 1997, RES VET SCI, V63, P189, DOI 10.1016/S0034-5288(97)90016-3.
   Chapin A, 2005, ENVIRON HEALTH PERSP, V113, P137, DOI 10.1289/ehp.7473.
   Davies R, 1999, LETT APPL MICROBIOL, V29, P327, DOI 10.1046/j.1472-765X.1999.00634.x.
   DUPONT HL, 1987, REV INFECT DIS, V9, P447.
   Gibbs SG, 2004, J OCCUP ENVIRON HYG, V1, P699, DOI 10.1080/15459620490515824.
   Green CF, 2006, J OCCUP ENVIRON HYG, V3, P9, DOI 10.1080/15459620500430615.
   HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904.
   JENSEN PA, 1992, AM IND HYG ASSOC J, V53, P660, DOI 10.1202/0002-8894(1992)053<0660:EOEBSC>2.0.CO;2.
   Johnsen PJ, 2005, APPL ENVIRON MICROB, V71, P159, DOI 10.1128/AEM.71.1.159-168.2005.
   LEDERBERG J, 1952, J BACTERIOL, V63, P399.
   LENHART SW, 1982, J TOXICOL ENV HEALTH, V10, P613, DOI 10.1080/15287398209530280.
   Manson JM, 2004, APPL ENVIRON MICROB, V70, P5764, DOI 10.1128/AEM.70.10.5764-5768.2004.
   McGeer AJ, 1998, CAN MED ASSOC J, V159, P1119.
   National Committee for Clinical Laboratory Standards (NCCLS), 2000, M7A5 NCCLS.
   NCCLS, 2001, M100S11 NCCLS.
   NCCLS (National Committee for Clinical Laboratory Standards), 1997, M2A6 NCCLS.
   Nijsten R, 1996, J ANTIMICROB CHEMOTH, V37, P1131, DOI 10.1093/jac/37.6.1131.
   PEREZTRALLERO E, 1995, INT J ANTIMICROB AG, V6, P59, DOI 10.1016/0924-8579(95)00022-7.
   Predicala BZ, 2002, CURR MICROBIOL, V44, P136, DOI 10.1007/s00284-001-0064-y.
   SCARPINO PV, 1998, J AEROSOL SCI, V29, pS553.
   TAKAFUJI ET, 1977, PREV MED, V6, P312, DOI 10.1016/0091-7435(77)90057-3.
   THRELFALL EJ, 1993, EPIDEMIOL INFECT, V111, P189, DOI 10.1017/S0950268800056892.
   Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{81}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{48}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{063QR}},
Unique-ID = {{ISI:000239035100033}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000236749400037,
Author = {Uhlich, GA and Cooke, PH and Solomon, EB},
Title = {{Analyses of the red-dry-rough phenotype of an Escherichia coli O157 : H7
   strain and its role in biofilm formation and resistance to antibacterial
   agents}},
Journal = {{APPLIED AND ENVIRONMENTAL MICROBIOLOGY}},
Year = {{2006}},
Volume = {{72}},
Number = {{4}},
Pages = {{2564-2572}},
Month = {{APR}},
Abstract = {{In a previous study, we identified Congo red-binding and -nonbinding
   phase variants of Escherichia coli serotype O157:H7 strain ATCC 43895.
   The Congo red-binding variant, strain 438950R, produced a dry,
   aggregative colony that was similar to the red, dry, and rough (rdar)
   phenotype characteristic of certain strains of Salmonella. In contrast,
   variant 43895OW produced a smooth and white colony morphology. In this
   study, we show that, similar to rdar strains of Salmonella enterica
   serovar Typhimurium, strain 438950R forms large aggregates in broth
   cultures, firm pellicles at the air-medium interface on glass, and dense
   biofilms on glass and polystyrene. However, unlike S. enterica serovar
   Typhimurium, strain 43895OR does not stain positive for cellulose
   production. When strain 43895OR was fixed on agar, scanning electron
   microscopy showed cells expressing extracellular matrix (ECM) containing
   curli fibers. Strain 43895OW was devoid of any ECM or curli fibers on
   agar but showed expression of curli fibers during attachment to glass.
   Strain 438950R produced > 4-fold-larger amounts of biofilm than strain
   43895OW on polystyrene, glass, stainless steel, and Teflon; formation
   was > 3-fold higher in rich medium than in nutrient-limited medium.
   Biofilm-associated cells of both strains showed statistically greater
   resistance (P < 0.05) to hydrogen peroxide and quaternary ammonium
   sanitizer than their respective planktonic cells. This study shows that
   the rdar phenotype of E. coli O157:H7 strain 43895OR is important in
   multicellular growth, biofilm formation, and resistance to sanitizers.
   However, the lack of cellulose production by strain 43895OR indicates
   important differences in the ECM composition compared to that of
   Salmonella.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Uhlich, GA (Reprint Author), USDA ARS, Microbial Food Safety Res Unit, Eastern Reg Res Ctr, 600 E Mermaid Ln, Wyndmoor, PA 19038 USA.
   USDA ARS, Microbial Food Safety Res Unit, Eastern Reg Res Ctr, Wyndmoor, PA 19038 USA.
   USDA ARS, Microbial Biophys \& Residue Chem \& Core Technol, Eastern Reg Res Ctr, Wyndmoor, PA 19038 USA.
   DuPont Chem Solut Enterprise, Expt Stn Lab, Wilmington, DE USA.}},
DOI = {{10.1128/AEM.72.4.2564-2572.2006}},
ISSN = {{0099-2240}},
EISSN = {{1098-5336}},
Keywords-Plus = {{SALMONELLA-TYPHIMURIUM; LISTERIA-MONOCYTOGENES; AGGREGATIVE BEHAVIOR;
   FIBRONECTIN-BINDING; CURLI EXPRESSION; STAINLESS-STEEL; CSGD PROMOTER;
   FOOD-INDUSTRY; CELLS; ENTERITIDIS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{guhlich@errc.ars.usda.gov}},
Cited-References = {{Austin JW, 1998, FEMS MICROBIOL LETT, V162, P295, DOI 10.1016/S0378-1097(98)00137-2.
   CARPENTIER B, 1993, J APPL BACTERIOL, V75, P499, DOI 10.1111/j.1365-2672.1993.tb01587.x.
   COLLINSON SK, 1991, J BACTERIOL, V173, P4773, DOI 10.1128/jb.173.15.4773-4781.1991.
   Danese PN, 2000, J BACTERIOL, V182, P3593, DOI 10.1128/JB.182.12.3593-3596.2000.
   DEWANTI R, 1995, INT J FOOD MICROBIOL, V26, P147, DOI 10.1016/0168-1605(94)00103-D.
   Hammar M, 1995, MOL MICROBIOL, V18, P661, DOI 10.1111/j.1365-2958.1995.mmi\_18040661.x.
   Hammar M, 1996, P NATL ACAD SCI USA, V93, P6562, DOI 10.1073/pnas.93.13.6562.
   Kumar CG, 1998, INT J FOOD MICROBIOL, V42, P9, DOI 10.1016/S0168-1605(98)00060-9.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Lund BM, 2000, MICROBIOLOGICAL SAFE.
   Mireles JR, 2001, J BACTERIOL, V183, P5848, DOI 10.1128/JB.183.20.5848-5854.2001.
   Nasr Abdelhakim Ben, 1996, Molecular Microbiology, V20, P927, DOI 10.1111/j.1365-2958.1996.tb02534.x.
   OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0.
   Olsen A, 1998, INFECT IMMUN, V66, P944.
   Pawar DM, 2005, J APPL MICROBIOL, V99, P418, DOI 10.1111/j.1365-2672.2004.02499.x.
   Prouty AM, 2002, INFECT IMMUN, V70, P2640, DOI 10.1128/IAI.70.5.2640-2649.2002.
   Robbins JB, 2005, J FOOD PROTECT, V68, P494, DOI 10.4315/0362-028X-68.3.494.
   Romling U, 1998, MOL MICROBIOL, V28, P249, DOI 10.1046/j.1365-2958.1998.00791.x.
   Romling U, 1998, J BACTERIOL, V180, P722.
   Romling U, 2000, MOL MICROBIOL, V36, P10, DOI 10.1046/j.1365-2958.2000.01822.x.
   Romling U, 1999, FEMS MICROBIOL LETT, V180, P91.
   Ryu JH, 2005, APPL ENVIRON MICROB, V71, P247, DOI 10.1128/AEM.71.1.247-254.2005.
   Ryu JH, 2004, LETT APPL MICROBIOL, V39, P359, DOI 10.1111/j.1472-765X.2004.01591.x.
   Scher K, 2005, APPL ENVIRON MICROB, V71, P1163, DOI 10.1128/AEM.71.3.1163-1168.2005.
   Sivapalasingam S, 2004, J FOOD PROTECT, V67, P2342, DOI 10.4315/0362-028X-67.10.2342.
   SJOHRING U, 1994, MOL MICROBIOL, V14, P443.
   Solano C, 2002, MOL MICROBIOL, V43, P793, DOI 10.1046/j.1365-2958.2002.02802.x.
   Solomon EB, 2005, J FOOD PROTECT, V68, P906, DOI 10.4315/0362-028X-68.5.906.
   SOMERS EB, 1994, INT J FOOD MICROBIOL, V22, P269, DOI 10.1016/0168-1605(94)90178-3.
   Stopforth JD, 2002, J FOOD PROTECT, V65, P1717, DOI 10.4315/0362-028X-65.11.1717.
   Uhlich GA, 2001, APPL ENVIRON MICROB, V67, P2367, DOI 10.1128/AEM.67.5.2367-2370.2001.
   Uhlich GA, 2002, INFECT IMMUN, V70, P395, DOI 10.1128/IAI.70.1.395-399.2002.
   Vidal O, 1998, J BACTERIOL, V180, P2442.
   Zogaj X, 2001, MOL MICROBIOL, V39, P1452, DOI 10.1046/j.1365-2958.2001.02337.x.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{127}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{Appl. Environ. Microbiol.}},
Doc-Delivery-Number = {{032BR}},
Unique-ID = {{ISI:000236749400037}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000236484300005,
Author = {Huff, GR and Huff, WE and Rath, NC and Tellez, G},
Title = {{Limited treatment with beta-1,3/1,6-glucan improves production values of
   broiler chickens challenged with Escherichia coli}},
Journal = {{POULTRY SCIENCE}},
Year = {{2006}},
Volume = {{85}},
Number = {{4}},
Pages = {{613-618}},
Month = {{APR}},
Abstract = {{The development of antibiotic-resistant bacteria has led to a need for
   alternatives to antibiotics for growth promotion and disease prevention
   in poultry production. The helical polysaccharide beta-1,3/1,6-glucan is
   derived from the cell wall of Saccharomyces cervisiae and has
   immunomodulating activities. The objective of this study was to
   determine the ability of 2 supplementation programs with a commercial
   beta-1,3/1,6-glucan product to protect broiler chicks from experimental
   respiratory challenge with Escherichia coli. Chicks were housed in
   battery-brooders from 1 d of age and fed a standard starter diet or the
   same diet containing 20 g/ton (22 ppm) of purified beta-1,3/1,6-glucan
   either continuously (BG25d) or for only the first 7 d prior to challenge
   (BG7d). At d 7 one-half of the birds were inoculated in the thoracic air
   sac with 800 cfu of a serotype O2, nonmotile strain of E. coli. All
   surviving birds were necropsied at d 25. Body weight of survivors and
   feed conversion efficiency were protected from the adverse effects of E.
   coli challenge by BG7d but not by BG25d. Mortality was nominally
   decreased from 63\% (control) to 53\% in BG25d and 47\% in BG7d, but
   these decreases were not significant. The relative weights of the liver
   and heart were increased, and the bursa of Fabricius relative weights
   were decreased by E. coli challenge, and these effects were modulated by
   beta-glucan treatment. Despite positive effects of BG7d in E.
   coli-challenged birds, the BW of nonchallenged birds was decreased by
   BG7d and BG25d. These results suggest that supplementation of broiler
   diets with beta-1,3/1,6-glucan may be valuable for decreasing production
   losses due to E. coli respiratory disease, but that the immune
   stimulation provided may also result in decreased production values
   under experimental battery conditions or for birds raised in an
   environment with minimal disease challenges.}},
Publisher = {{POULTRY SCIENCE ASSOC INC}},
Address = {{1111 NORTH DUNLAP AVE, SAVOY, IL 61874-9604 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Huff, GR (Reprint Author), Univ Arkansas, USDA, Agr Res Serv, Fayetteville, AR 72701 USA.
   Univ Arkansas, USDA, Agr Res Serv, Fayetteville, AR 72701 USA.
   Univ Arkansas, Dept Poultry Sci, Fayetteville, AR 72701 USA.}},
DOI = {{10.1093/ps/85.4.613}},
ISSN = {{0032-5791}},
Keywords = {{yeast cell wall; beta-glucan; antibiotic alternative; colibacillosis;
   immune modulation}},
Keywords-Plus = {{BETA-GLUCAN; GROWTH-PERFORMANCE; IMMUNE-RESPONSE; RESISTANCE; FEED;
   ENHANCEMENT; INFECTION; PIGS}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Agriculture, Dairy \& Animal Science}},
Author-Email = {{grhuff@uark.edu}},
Cited-References = {{BARNES HJ, 2003, DIS POULTRY, P631.
   BAYHL AK, 2002, POULT SCI S1, V80, P116.
   Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3.
   Chang CF, 2000, FISH SHELLFISH IMMUN, V10, P505, DOI 10.1006/fsim.2000.0266.
   Cleary JA, 1999, IMMUNOL CELL BIOL, V77, P395, DOI 10.1046/j.1440-1711.1999.00848.x.
   Dibner JJ, 2005, POULTRY SCI, V84, P634, DOI 10.1093/ps/84.4.634.
   DRITZ SS, 1995, J ANIM SCI, V73, P3341.
   GERSEMA LM, 1986, DRUG INTEL CLIN PHAR, V20, P214, DOI 10.1177/106002808602000308.
   Hiss S, 2003, J ANIM PHYSIOL AN N, V87, P2, DOI 10.1046/j.1439-0396.2003.00376.x.
   Huff G.R., 2002, POULT SCI S1, V80, P18.
   KLASING KC, 1987, J NUTR, V117, P1629.
   Lowry VK, 2005, INT J FOOD MICROBIOL, V98, P309, DOI {[}10.1016/j.ijfoodmicro.2004.06.008, 10.1016/j.ijfoodchem.2004.06.008].
   MANSELL PWA, 1978, IMMUNE MODULATION CO.
   National Research Council, 1994, NUTR REQ POULTR.
   PIERCY DWT, 1976, J COMP PATHOL, V86, P203, DOI 10.1016/0021-9975(76)90044-X.
   Plat J, 2005, CURR OPIN LIPIDOL, V16, P31, DOI 10.1097/00041433-200502000-00007.
   REYNOLDS JA, 1980, INFECT IMMUN, V30, P51.
   Roura E., 1992, J NUTR, V122, P2283.
   Russell SM, 2003, POULTRY SCI, V82, P1326, DOI 10.1093/ps/82.8.1326.
   SAKURAI T, 1992, INT J IMMUNOPHARMACO, V14, P821, DOI 10.1016/0192-0561(92)90080-5.
   SAS Institute Inc, 1988, SAS STAT US GUID.
   Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2.
   SONG YL, 1997, FISH VACCINOLOGY DEV, V90, P413.
   Tzianabos AO, 2000, CLIN MICROBIOL REV, V13, P523, DOI 10.1128/CMR.13.4.523-533.2000.
   VETVICKA V, 2001, JANA, P31.
   Williams D L, 1979, Adv Exp Med Biol, V121, P291.
   Young SH, 2001, J BIOL CHEM, V276, P20781, DOI 10.1074/jbc.M101111200.
   Yun CH, 2003, FEMS IMMUNOL MED MIC, V35, P67, DOI 10.1016/S0928-8244(02)00460-1.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{57}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Poult. Sci.}},
Doc-Delivery-Number = {{028JU}},
Unique-ID = {{ISI:000236484300005}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000236324800001,
Author = {Kobae, Y and Sekino, T and Yoshioka, H and Nakagawa, T and Martinoia, E
   and Maeshima, M},
Title = {{Loss of AtPDR8, a plasma membrane ABC transporter of Arabidopsis
   thaliana, causes hypersensitive cell death upon pathogen infection}},
Journal = {{PLANT AND CELL PHYSIOLOGY}},
Year = {{2006}},
Volume = {{47}},
Number = {{3}},
Pages = {{309-318}},
Month = {{MAR}},
Abstract = {{Plants contain a large number of ATP-binding cassette (ABC) transporters
   belonging to different subclasses. AtPDR8 is the only member of the
   pleiotropic drug resistance (PDR) ABC transporter subclass in
   Arabidopsis that is constitutively highly expressed. In transgenic
   Arabidopsis plants harboring the AtPDR8 promoter fused to
   beta-glucuronidase (GUS), reporter expression was shown to he strong in
   the stomata and hydathode. In the stomata, transcripts of AtPDR8 were
   particularly frequent in the cells surrounding air spaces. Subcellular
   fractionation and immunochemical analysis showed that AtPDR8 was
   localized in the plasma membrane. When a knockout mutant of AtPDR8
   (atpdr8) was infected with bacterial and oomycete pathogens, the plants
   exhibited chlorotic lesions and a hypersensitive response (HR)-like cell
   death. Cell death was detected in the atpdr8 mutants within 10 h of
   infection with the virulent bacterial pathogen, Pseudomonas syringae. As
   a result, the growth of P syringae in the leaves of the atpdr8 mutant
   was reduced to 1\% of that in the wild type. The defense response genes,
   PR-1, PR-2, PR-5, VPE gamma, AtrbohD and AtrbohF were highly expressed
   when the mutant plants were grown under non-sterile conditions. The
   expression of the AtPDR8 gene was enhanced by infection of virulent and
   avirulent bacterial pathogens. Our results indicate that AtPDR8 is a key
   factor controlling the extent of cell death in the defense response and
   suggest that AtPDR8 transports some substance(s) which is closely
   related to the response of plants to pathogens.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Maeshima, M (Reprint Author), Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan.
   Nagoya Univ, Grad Sch Bioagr Sci, Lab Cell Dynam, Nagoya, Aichi 4648601, Japan.
   Nagoya Univ, Grad Sch Bioagr Sci, Lab Def PlantPathogen Interact, Nagoya, Aichi 4648601, Japan.
   Shimane Univ, Dept Mol \& Funct Genom, Matsue, Shimane 6908504, Japan.
   Univ Zurich, Inst Plant Biol, Zurich Basel Plant Sci Ctr, CH-8008 Zurich, Switzerland.}},
DOI = {{10.1093/pcp/pcj001}},
ISSN = {{0032-0781}},
Keywords = {{ABC transporter; Arabidopsis; non-host resistance; PDR}},
Keywords-Plus = {{PSEUDOMONAS-SYRINGAE STRAINS; AVIRULENCE GENE AVRRPT2; DISEASE
   RESISTANCE; NONHOST RESISTANCE; PHYTOPHTHORA-INFESTANS; DEFENSE
   RESPONSES; COMPLETE INVENTORY; CDNA CLONING; PLANT; EXPRESSION}},
Research-Areas = {{Plant Sciences; Cell Biology}},
Web-of-Science-Categories  = {{Plant Sciences; Cell Biology}},
Author-Email = {{maeshima@agr.nagoya-u.ac.jp}},
ResearcherID-Numbers = {{Maeshima, Masayoshi/D-3073-2013
   }},
ORCID-Numbers = {{Maeshima, Masayoshi/0000-0002-1611-5481
   Kobae, Yoshihiro/0000-0002-9997-490X}},
Cited-References = {{ABEL S, 1998, ARABIDOPSIS PROTOCOL, P209.
   Alexandersson E, 2004, PLANT CELL PHYSIOL, V45, P1543, DOI 10.1093/pcp/pch209.
   Campbell E. J., 2003, PLANT PHYSIOL, V133, P1.
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x.
   Collins NC, 2003, NATURE, V425, P973, DOI 10.1038/nature02076.
   Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137.
   DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61.
   Froehlich JE, 2003, J PROTEOME RES, V2, P413, DOI 10.1021/pr034025j.
   Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1.
   Glazebrook J, 1996, GENETICS, V143, P973.
   Glombitza S, 2004, PLANT MOL BIOL, V54, P817, DOI 10.1007/s11103-004-0274-3.
   Hatsugai N, 2004, SCIENCE, V305, P855, DOI 10.1126/science.1099859.
   Holland I. B., 2003, ABC PROTEINS BACTERI.
   Hugouvieux V, 1998, MOL PLANT MICROBE IN, V11, P537, DOI 10.1094/MPMI.1998.11.6.537.
   Huitema E, 2003, MOL PLANT PATHOL, V4, P487, DOI {[}10.1046/j.1364-3703.2003.00195.x, 10.1046/J.1364-3703.2003.00195.X].
   Jasinski M, 2003, PLANT PHYSIOL, V131, P1169, DOI 10.1104/pp.102.014720.
   Jasinski M, 2001, PLANT CELL, V13, P1095, DOI 10.1105/tpc.13.5.1095.
   Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039.
   Kobae Y, 2004, PLANT CELL PHYSIOL, V45, P1749, DOI 10.1093/pcp/pci015.
   KUNKEL BN, 1993, PLANT CELL, V5, P865.
   Lee M, 2005, PLANT PHYSIOL, V138, P827, DOI 10.1109/pp.104.058107.
   Lipka V, 2005, SCIENCE, V310, P1180, DOI 10.1126/science.1119409.
   Martinoia E, 2002, PLANTA, V214, P345, DOI 10.1007/s004250100661.
   Millard Ann V., 2004, ARABIDOPSIS BOOK, P1, DOI DOI 10.1199/TAB.0009.
   Mysore KS, 2004, TRENDS PLANT SCI, V9, P97, DOI 10.1016/j.tplants.2003.12.005.
   Niinemets U, 2004, TRENDS PLANT SCI, V9, P180, DOI 10.1016/j.tplants.2004.02.006.
   Obayashi T, 2004, DNA RES, V11, P11, DOI 10.1093/dnares/11.1.11.
   Piper P, 1998, EMBO J, V17, P4257, DOI 10.1093/emboj/17.15.4257.
   Quirino BF, 2000, TRENDS PLANT SCI, V5, P278, DOI 10.1016/S1360-1385(00)01655-1.
   Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200.
   Sasabe M, 2002, FEBS LETT, V518, P164, DOI 10.1016/S0014-5793(02)02697-2.
   Sazuka T, 2004, DNA RES, V11, P101, DOI 10.1093/dnares/11.2.101.
   Seo S, 2003, PLANT CELL, V15, P863, DOI 10.1105/tpc.010231.
   Shirasu K, 1999, CELL, V99, P355, DOI 10.1016/S0092-8674(00)81522-6.
   Smart CC, 1996, J BIOL CHEM, V271, P19351, DOI 10.1074/jbc.271.32.19351.
   Srivastava S, 2004, PLANT CELL PHYSIOL, V45, P1320, DOI 10.1093/pcp/pch137.
   Stukkens Y, 2005, PLANT PHYSIOL, V139, P341, DOI 10.1104/pp.105.062372.
   Tholl D, 2005, PLANT J, V42, P757, DOI 10.1111/j.1365-313X.2005.02417.x.
   Thordal-Christensen H, 2003, CURR OPIN PLANT BIOL, V6, P351, DOI 10.1016/S1369-5266(03)00063-3.
   Torres MA, 2002, P NATL ACAD SCI USA, V99, P517, DOI 10.1073/pnas.012452499.
   van den Brule S, 2002, PLANT J, V30, P649, DOI 10.1046/j.1365-313X.2002.01321.x.
   von Roepenack-Lahaye E, 2004, PLANT PHYSIOL, V134, P548, DOI 10.1104/pp.103.032714.
   Yoshioka H, 1999, PLANT CELL PHYSIOL, V40, P993, DOI 10.1093/oxfordjournals.pcp.a029633.
   Yoshioka H, 2003, PLANT CELL, V15, P706, DOI 10.1105/tpc.008680.
   YU GL, 1993, MOL PLANT MICROBE IN, V6, P434, DOI 10.1094/MPMI-6-434.
   Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367.
   Zipfel C, 2004, NATURE, V428, P764, DOI 10.1038/nature02485.}},
Number-of-Cited-References = {{47}},
Times-Cited = {{106}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{33}},
Journal-ISO = {{Plant Cell Physiol.}},
Doc-Delivery-Number = {{026FM}},
Unique-ID = {{ISI:000236324800001}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000235397400027,
Author = {Thoen, C and LoBue, P and de Kantor, I},
Title = {{The importance of Mycobacterium bovis as a zoonosis}},
Journal = {{VETERINARY MICROBIOLOGY}},
Year = {{2006}},
Volume = {{112}},
Number = {{2-4, SI}},
Pages = {{339-345}},
Month = {{FEB 25}},
Note = {{4th International Conference on Mycobacterium Bovis, Dublin, IRELAND,
   AUG 22-26, 2005}},
Organization = {{CVERA}},
Abstract = {{Mycobacterium bovis and closely associated acid-fast bacilli cause
   disease in humans. Epidermologic investigations reveal that the organism
   may be ingested or inhaled. Extra pulmonary lesions may occur associated
   to the consumption of infected milk, even though with the practice of
   boiling milk, and the growth of milk pasteurization plants all over the
   world, the digestive route of infection became less important. On the
   other hand, airborne infection continues to occur among meat industry
   and slaughterhouse workers, in regions where the infection is still
   prevalent in cattle. Evidence of person to person transmission is rare.
   Main causes of concern related to M. bovis in industrialized countries
   are: epizootics in domesticated and wild mammals and latent infection in
   immigrants. Although multidrug-resistant (MDR) strains of M. bovis have
   been identified, case reports reveal that anti-tuberculosis drugs
   routinely used to treat Mycobacterium tuberculosis-infected patients are
   effective when properly administered. (c) 2005 Elsevier B.V. All rights
   reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Thoen, C (Reprint Author), Iowa State Univ, Dept Vet Microbiol \& Prevent Med, Coll Vet Med, Ames, IA 50011 USA.
   Iowa State Univ, Dept Vet Microbiol \& Prevent Med, Coll Vet Med, Ames, IA 50011 USA.
   Ctr Dis Control \& Prevent, Div TB Eliminat, Atlanta, GA USA.
   WHO, RA-1429 Buenos Aires, DF, Argentina.}},
DOI = {{10.1016/j.vetmic.2005.11.047}},
ISSN = {{0378-1135}},
Keywords = {{zoonotic tuberculosis; Mycobacterium bovis; bovine tuberculosis}},
Keywords-Plus = {{SOUTHEAST ENGLAND; SAN-DIEGO; PULMONARY TUBERCULOSIS; INFECTION;
   STRAINS; OUTBREAK; TRANSMISSION; PREVALENCE; CALIFORNIA; DIAGNOSIS}},
Research-Areas = {{Microbiology; Veterinary Sciences}},
Web-of-Science-Categories  = {{Microbiology; Veterinary Sciences}},
Author-Email = {{cthoen@iastate.edu}},
Cited-References = {{Aranaz A, 1999, INT J SYST BACTERIOL, V49, P1263, DOI 10.1099/00207713-49-3-1263.
   BARRERA L, 1987, TROP GEOGR MED, V39, P222.
   Besser RE, 2001, PEDIATRICS, V108, P305, DOI 10.1542/peds.108.2.305.
   Blazquez J, 1997, J CLIN MICROBIOL, V35, P1390.
   Boisvert H, 1973, Ann Soc Belg Med Trop, V53, P233.
   CANETTI G, 1969, TECHNIQUES INDICATIO.
   CHRISTIE JD, 1995, CLIN LAB MED, V15, P279, DOI 10.1016/S0272-2712(18)30333-0.
   COLLINS CH, 1981, TUBERCLE, V62, P113, DOI 10.1016/0041-3879(81)90018-0.
   COLLINS CH, 1983, J APPL BACTERIOL, V55, P13, DOI 10.1111/j.1365-2672.1983.tb02643.x.
   CORREA CN, 1974, BRAZIL ARQ I BIOL SA, V41, P131.
   Cosivi O, 1998, EMERG INFECT DIS, V4, P59, DOI 10.3201/eid0401.980108.
   Cotter TP, 1996, TUBERCLE LUNG DIS, V77, P545, DOI 10.1016/S0962-8479(96)90053-2.
   Cousins DV, 1999, INT J TUBERC LUNG D, V3, P715.
   Cousins DV, 2003, INT J SYST EVOL MICR, V53, P1305, DOI 10.1099/ijs.0.02401-0.
   DANKNER WM, 1993, MEDICINE, V72, P11, DOI 10.1097/00005792-199301000-00002.
   Dankner WM, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e79.
   de Beco O, 1970, Arch Inst Pasteur Alger, V48, P93.
   DREESEN DW, 1970, AM REV RESPIR DIS, V101, P289.
   Drobniewski F, 2003, EPIDEMIOL INFECT, V130, P235, DOI 10.1017/S0950268802008105.
   ENARSON D, 2005, MYCOBACTERIUM BOVIS.
   FANNING A, 1991, LANCET, V338, P1253, DOI 10.1016/0140-6736(91)92113-G.
   GRANGE J, 1982, J EPIDEMIOL COMMUN H, V36, P157, DOI 10.1136/jech.36.3.157.
   GRANGE JM, 1994, VET MICROBIOL, V40, P137, DOI 10.1016/0378-1135(94)90052-3.
   GRANGE JM, 1995, MYCOBACTERIUM BOVIS.
   Gutierrez M, 1997, J CLIN MICROBIOL, V35, P3328.
   Gutierrez MC, 1999, J CLIN MICROBIOL, V37, P971.
   HOUDE C, 1988, PEDIATR INFECT DIS J, V7, P810.
   HUBLART M, 1969, Bulletin de l'Academie Veterinaire de France, V42, P69.
   Hughes VM, 2003, INT J TUBERC LUNG D, V7, P1191.
   IDIGBE EO, 1986, J TROP MED HYG, V89, P143.
   KANTOR IN, 1974, MEDICINA BUENO AIRES, V34, P244.
   Kappler W, 1986, Z Erkr Atmungsorgane, V167, P42.
   KARLSON AG, 1970, ANN INTERN MED, V73, P979, DOI 10.7326/0003-4819-73-6-979.
   Kataria Y P, 1969, Tubercle, V50, P14, DOI 10.1016/0041-3879(69)90004-X.
   Kazwala RR, 2001, INT J TUBERC LUNG D, V5, P87.
   Kubica T, 2003, J CLIN MICROBIOL, V41, P3070, DOI 10.1128/JCM.41.7.3070-3077.2003.
   LAMBIN S, 1961, PRECIS MICROBIOLOGIE, P53.
   Lesslie I W, 1968, Bull Int Union Tuberc, V41, P285.
   LISS GM, 1994, CAN J PUBLIC HEALTH, V85, P326.
   LoBue PA, 2004, INT J TUBERC LUNG D, V8, P1142.
   LoBue PA, 2003, INT J TUBERC LUNG D, V7, P180.
   LoBue RA, 2004, INT J TUBERC LUNG D, V8, P868.
   MEISSNER G, 1969, ZENTBL BAKTERIOLOG P, V211, P69.
   Milian F, 2000, Rev Latinoam Microbiol, V42, P13.
   OIE, 2005, BOV TUB.
   PATTYN S R, 1970, Annales des Societes Belges de Medecine Tropicale de Parasitologie et de Mycologie, V50, P211.
   Peluffo G, 1982, Rev Argent Microbiol, V14, P91.
   POLETAEV S D, 1970, Problemy Tuberkuleza, V48, P38.
   Rasolofo-Razanamparany V, 1999, INT J TUBERC LUNG D, V3, P632.
   Rivero A, 2001, CLIN INFECT DIS, V32, P159, DOI 10.1086/317547.
   Robert J, 1999, INT J TUBERC LUNG D, V3, P711.
   ROBINSON P, 1989, AUST N Z J MED, V19, P409.
   Samper S, 1997, AIDS, V11, P1237, DOI 10.1097/00002030-199710000-00006.
   Sequeira M. D., 2005, MYCOBACTERIUM BOVIS.
   SJOGREN I, 1978, SCAND J RESPIR DIS, V59, P167.
   SPINA G, 1972, ARCH MONALDI, V27, P343.
   Tesink J, 1970, Tijdschr Ziekenverpl, V23, P824.
   THOEN CO, 1984, MYCOBACTERIA SOURC B, P1209.
   THOEN CO, 2005, MYCOBACTERIUM BOVIS.
   THOMPSON PJ, 1993, AM REV RESPIR DIS, V147, P164, DOI 10.1164/ajrccm/147.1.164.
   {*}WHO, 2004, WHOHTMTB2004331, P145.
   WIGLE WD, 1972, AM REV RESPIR DIS, V106, P258.
   WILKINS EGL, 1986, THORAX, V41, P685, DOI 10.1136/thx.41.9.685.
   WILKINS EGL, 1986, Q J MED, V59, P627.
   Winters A., 2005, Morbidity and Mortality Weekly Report, V54, P605.
   YATES MD, 1988, EPIDEMIOL INFECT, V101, P225, DOI 10.1017/S0950268800054133.
   ZINSTAAG J, 2005, MYCOBACTERIUM BOVIS.}},
Number-of-Cited-References = {{67}},
Times-Cited = {{124}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{23}},
Journal-ISO = {{Vet. Microbiol.}},
Doc-Delivery-Number = {{013GI}},
Unique-ID = {{ISI:000235397400027}},
DA = {{2018-08-13}},
}

@article{ ISI:000234792000033,
Author = {Vache, C and Camares, O and De Graeve, F and Dastugue, B and Meiniel, A
   and Vaury, C and Pellier, S and Leoz-Garziandia, E and Bamdad, M},
Title = {{Drosophila melanogaster P-glycoprotein: A membrane detoxification system
   toward polycyclic aromatic hydrocarbon pollutants}},
Journal = {{ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY}},
Year = {{2006}},
Volume = {{25}},
Number = {{2}},
Pages = {{572-580}},
Month = {{FEB}},
Abstract = {{Polycyclic aromatic hydrocarbons (PAHs) are well-known ubiquitous
   environmental contaminants. Permeability glycoprotein (P-gp) is a
   transmembrane detoxification efflux pump transporting various lipophilic
   xenobiotics, such as PAHs, out of the cells. The existence of a P-gp
   detoxification system inducible by PAHs was investigated in Drosophila
   melanogaster. Western blot experiments showed that D. melanogaster
   expressed a 140-kDa P-gp in S12 cells, embryos, and adult flies.
   Permeability glycoprotein was expressed in adult flies in the head,
   abdomen, and thorax and sublocalized in the sexual and olfactory organs.
   Flow cytometry experiments using Drosophila S12 cells in the presence of
   PAHs and target P-gp drug compounds revealed that Drosophila P-gp acted
   as an efflux detoxification pump. In Drosophila exposed to
   benzo{[}a]pyrene or to ambient air polluted by higher or lower PAH
   concentrations, P-gp expression was clearly showed a dose-dependent
   increase response. The P-gp induction was detected both in adult flies
   and in different fly parts, such as the head, thorax, and antennae.
   Drosophila P-gp acts as a membrane barrier against PAH pollutants.}},
Publisher = {{SETAC}},
Address = {{1010 NORTH 12TH AVE, PENSACOLA, FL 32501-3367 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bamdad, M (Reprint Author), Univ Auvergne, Fac Med, Lab Biochim Med, INSERM,UMR 384, F-63001 Clermont Ferrand, France.
   IUT, Dept Genie Biol, F-15013 Aurillac, France.
   Univ Nice, INSERM, Lab Neurobiol Vasc, U615, F-06108 Nice 2, France.
   ATMO Auvergne, F-63000 Clermont Ferrand, France.
   INERIS, Direct Risques Chron, F-60550 Verneuil En Halatte, France.}},
DOI = {{10.1897/04-425.1}},
ISSN = {{0730-7268}},
Keywords = {{permeability; glycoprotein; polycyclic; aromatic; hydrocarbons; air
   pollution; Drosophila detoxification}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE GENE; TETRAHYMENA-PYRIFORMIS; NORMAL-TISSUES;
   EFFLUX PUMP; RAT-LIVER; TRANSPORT; CELLS; EXPRESSION;
   3-METHYLCHOLANTHRENE; IDENTIFICATION}},
Research-Areas = {{Environmental Sciences \& Ecology; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Toxicology}},
Author-Email = {{mahchid.bamdad@inserm.u-clermont1.fr}},
ResearcherID-Numbers = {{Vaury, Chantal/I-4658-2015
   INERIS, Ineris/B-5682-2009}},
ORCID-Numbers = {{Vaury, Chantal/0000-0002-7725-5760
   }},
Cited-References = {{ABRAHAM SK, 1979, MUTAT RES, V66, P195, DOI 10.1016/0165-1218(79)90067-3.
   Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185.
   Bamdad M, 1997, CYTOMETRY, V28, P170, DOI 10.1002/(SICI)1097-0320(19970601)28:2<170::AID-CYTO11>3.0.CO;2-N.
   Bamdad M, 1999, FEBS LETT, V456, P389, DOI 10.1016/S0014-5793(99)00978-3.
   Barnes DM, 2001, COMP BIOCHEM PHYS A, V130, P301, DOI 10.1016/S1095-6433(01)00389-0.
   Bosch I, 1996, AM J PHYSIOL-CELL PH, V271, pC1527.
   CHANG G, 2003, FEBS LETT, V27, P102.
   Delgado-Rodriguez A, 1999, CHEMOSPHERE, V39, P33, DOI 10.1016/S0045-6535(98)00586-4.
   Doi AM, 2001, AQUAT TOXICOL, V55, P157, DOI 10.1016/S0166-445X(01)00180-1.
   DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2.
   Fardel O, 1996, BIOCHEM PHARMACOL, V51, P1427, DOI 10.1016/0006-2952(96)00081-0.
   Fiala Z, 1999, Acta Medica (Hradec Kralove) Suppl, V42, P77.
   GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614.
   GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152.
   GERDES RA, 1971, ATMOS ENVIRON, V5, P113, DOI 10.1016/0004-6981(71)90073-4.
   GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0.
   GERRARD B, 1993, GENOMICS, V17, P83, DOI 10.1006/geno.1993.1286.
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5.
   HENDERSON DM, 1992, MOL CELL BIOL, V12, P2855, DOI 10.1128/MCB.12.6.2855.
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7.
   KAWAI K, 1994, BIOCHEM BIOPH RES CO, V198, P804, DOI 10.1006/bbrc.1994.1115.
   KURELEC B, 1992, CRIT REV TOXICOL, V22, P23, DOI 10.3109/10408449209145320.
   Lanning CL, 1996, BBA-GEN SUBJECTS, V1291, P155, DOI 10.1016/0304-4165(96)00060-8.
   Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912.
   LUM BL, 1995, HEMATOL ONCOL CLIN N, V9, P319.
   Mathieu MC, 2001, J BIOL CHEM, V276, P4819, DOI 10.1074/jbc.M008495200.
   NG WF, 1989, MOL CELL BIOL, V9, P1224, DOI 10.1128/MCB.9.3.1224.
   Nuti SL, 2002, J BIOL CHEM, V277, P29417, DOI 10.1074/jbc.M204054200.
   PENNY JI, 1994, BBA-MOL BASIS DIS, V1226, P232, DOI 10.1016/0925-4439(94)90034-5.
   SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353.
   Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305.
   Skupinska Katarzyna, 2004, Acta Pol Pharm, V61, P233.
   THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300.
   TOMATIS L, 1976, ANN NY ACAD SCI, V271, P396, DOI 10.1111/j.1749-6632.1976.tb23139.x.
   UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X.
   Veau C, 2002, J PHARMACOL EXP THER, V302, P742, DOI 10.1124/jpet.302.2.742.
   Wang Q, 1999, J BIOL CHEM, V274, P10309, DOI 10.1074/jbc.274.15.10309.
   Wang W, 1996, PLANT MOL BIOL, V31, P683, DOI 10.1007/BF00042240.
   WU CT, 1991, MOL CELL BIOL, V11, P3940, DOI 10.1128/MCB.11.8.3940.
   YEH GC, 1992, CANCER RES, V52, P6692.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Environ. Toxicol. Chem.}},
Doc-Delivery-Number = {{004ZS}},
Unique-ID = {{ISI:000234792000033}},
DA = {{2018-08-13}},
}

@article{ ISI:000235483300003,
Author = {Beggs, CB and Kerr, KG and Snelling, AM and Sleigh, PA},
Title = {{Acinetobacter spp. and the clinical environment}},
Journal = {{INDOOR AND BUILT ENVIRONMENT}},
Year = {{2006}},
Volume = {{15}},
Number = {{1}},
Pages = {{19-24}},
Month = {{FEB}},
Note = {{2nd International Conference on the Quality of the Indoor Environment in
   Hospitals, Prague, CZECH REPUBLIC, OCT 06-07, 2005}},
Organization = {{Charles Univ; Inst Clin \& Expt Med}},
Abstract = {{Infections associated with Acinetobacter spp. are an increasing problem
   in hospitals around the world, with many infections being multiply
   resistant to antibiotics. Acinetobacter spp. are particularly hardy and
   can survive on dry surfaces for long periods of time. They have also
   been cultured from the air on hospital wards. While it is known that
   environmental factors can contribute to the spread of infections caused
   by Acinetobacter spp., the precise role of the clinical environment in
   this process remains unclear. This review paper investigates this issue
   and seeks to identify environmental factors which may influence the
   spread of infections associated with Acinetobacter spp.}},
Publisher = {{SAGE PUBLICATIONS LTD}},
Address = {{1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Beggs, CB (Reprint Author), Univ Bradford, Sch Engn Design \& Technol, Bradford BD7 1DP, W Yorkshire, England.
   Univ Bradford, Sch Engn Design \& Technol, Bradford BD7 1DP, W Yorkshire, England.
   Univ Bradford, Dept Biomed Sci, Bradford BD7 1DP, W Yorkshire, England.
   Univ Leeds, Sch Civil Engn, Leeds LS2 9JT, W Yorkshire, England.}},
DOI = {{10.1177/1420326X06062501}},
ISSN = {{1420-326X}},
Keywords = {{Acinetobacter spp.; Acinetobacter baumannii; transmissibility; airborne
   transmission; humidity clinical environment}},
Keywords-Plus = {{INTENSIVE-CARE-UNIT; CARBAPENEM-RESISTANT ACINETOBACTER; DRY SURFACES;
   HONG-KONG; NOSOCOMIAL INFECTION; VENTILATOR CIRCUITS; BAUMANNII
   OUTBREAK; HOSPITAL OUTBREAK; SURVIVAL; CALCOACETICUS}},
Research-Areas = {{Construction \& Building Technology; Engineering; Public, Environmental
   \& Occupational Health}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Engineering, Environmental; Public,
   Environmental \& Occupational Health}},
Author-Email = {{C.B.Beggs@Bradford.ac.uk}},
ResearcherID-Numbers = {{Sleigh, Andrew/E-6675-2010
   }},
ORCID-Numbers = {{Sleigh, Andrew/0000-0001-9218-5660}},
Funding-Acknowledgement = {{Engineering and Physical Sciences Research Council {[}GR/S48462/01]}},
Cited-References = {{ALLEN KD, 1987, J HOSP INFECT, V9, P110, DOI 10.1016/0195-6701(87)90048-X.
   Aygun G, 2002, J HOSP INFECT, V52, P259, DOI 10.1053/jhin.2002.1300.
   BECKSAGUE CM, 1990, AM J EPIDEMIOL, V132, P723, DOI 10.1093/oxfordjournals.aje.a115714.
   BEGGS CB, 2002, USE SMALL NEGATIVE A.
   Bernards AT, 1998, AM J INFECT CONTROL, V26, P544, DOI 10.1053/ic.1998.v26.a84555.
   Borer A, 2005, EMERG INFECT DIS, V11, P1160.
   Catalano M, 1999, J HOSP INFECT, V42, P27, DOI 10.1053/jhin.1998.0535.
   CEFAI C, 1990, J HOSP INFECT, V15, P177, DOI 10.1016/0195-6701(90)90128-B.
   Chu YW, 1999, J CLIN MICROBIOL, V37, P2962.
   Corbella X, 2000, J CLIN MICROBIOL, V38, P4086.
   CRAVEN DE, 1984, AM J MED, V77, P834, DOI 10.1016/0002-9343(84)90520-5.
   Das I, 2002, J HOSP INFECT, V50, P110, DOI 10.1053/jhin.2001.1127.
   Forster DH, 1998, EUR J CLIN MICROBIOL, V17, P73, DOI 10.1007/BF01682159.
   GERNERSMIDT P, 1994, APMIS, V102, P5.
   GERNERSMIDT P, 1987, J HOSP INFECT, V10, P265, DOI 10.1016/0195-6701(87)90008-9.
   HARTSTEIN AI, 1988, AM J MED, V85, P624, DOI 10.1016/S0002-9343(88)80233-X.
   HIRAI Y, 1991, J HOSP INFECT, V19, P191, DOI 10.1016/0195-6701(91)90223-U.
   Houang ETS, 2001, J CLIN MICROBIOL, V39, P228, DOI 10.1128/JCM.39.1.228-234.2001.
   Irwin R S, 1980, Respir Care, V25, P232.
   Jawad A, 1996, J CLIN MICROBIOL, V34, P2881.
   Jawad A, 1998, J HOSP INFECT, V39, P235, DOI 10.1016/S0195-6701(98)90263-8.
   Jawad A, 1998, J CLIN MICROBIOL, V36, P1938.
   JAWAD A, 1994, J CLIN MICROBIOL, V32, P2353.
   Koeleman JGM, 1998, J CLIN MICROBIOL, V36, P2522.
   McDonald LC, 1998, PEDIATR INFECT DIS J, V17, P716, DOI 10.1097/00006454-199808000-00011.
   Melamed R, 2003, J HOSP INFECT, V53, P31, DOI 10.1053/jhin.2002.1324.
   Mulin B, 1997, INFECT CONT HOSP EP, V18, P499.
   MUSA EK, 1990, J HOSP INFECT, V15, P219, DOI 10.1016/0195-6701(90)90029-N.
   Obbard JP, 2003, WATER AIR SOIL POLL, V144, P333, DOI 10.1023/A:1022973402453.
   Paul M, 2005, J HOSP INFECT, V60, P256, DOI 10.1016/j.jhin.2005.01.007.
   Rello J, 1999, CHEST, V115, P1226, DOI 10.1378/chest.115.5.1226.
   Roberts SA, 2001, J HOSP INFECT, V48, P228, DOI 10.1053/jhin.2001.0985.
   Seifert H, 1997, J CLIN MICROBIOL, V35, P2819.
   SHELLY MP, 1986, CRIT CARE MED, V12, P328.
   SHERERTZ RJ, 1985, J INFECT DIS, V151, P252, DOI 10.1093/infdis/151.2.252.
   Siau H, 1996, J MED MICROBIOL, V44, P340, DOI 10.1099/00222615-44-5-340.
   SMITH PW, 1977, JAMA-J AM MED ASSOC, V237, P795, DOI 10.1001/jama.237.8.795.
   STONE JW, 1985, J HOSP INFECT, V6, P42.
   THORNTON T, 2004, ASHRAE IAQ C TAMP FL.
   VANDENBROUCKEGRAULS CMJE, 1988, EUR J CLIN MICROBIOL, V7, P485, DOI 10.1007/BF01962597.
   VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639.
   Wagenvoort JHT, 2002, J HOSP INFECT, V52, P226, DOI 10.1053/jhin.2001.1294.
   Webster CA, 1998, EUR J CLIN MICROBIOL, V17, P171, DOI 10.1007/BF01691113.
   WEERNINK A, 1995, J HOSP INFECT, V29, P189, DOI 10.1016/0195-6701(95)90328-3.
   Wendt C, 1997, J CLIN MICROBIOL, V35, P1394.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Indoor Built Environ.}},
Doc-Delivery-Number = {{014MC}},
Unique-ID = {{ISI:000235483300003}},
DA = {{2018-08-13}},
}

@article{ ISI:000235483300007,
Author = {Noakes, CJ and Sleigh, PA and Escombe, AR and Beggs, CB},
Title = {{Use of CFD analysis in modifying a TB ward in Lima, Peru}},
Journal = {{INDOOR AND BUILT ENVIRONMENT}},
Year = {{2006}},
Volume = {{15}},
Number = {{1}},
Pages = {{41-47}},
Month = {{FEB}},
Note = {{2nd International Conference on the Quality of the Indoor Environment in
   Hospitals, Prague, CZECH REPUBLIC, OCT 06-07, 2005}},
Organization = {{Charles Univ; Inst Clin \& Expt Med}},
Abstract = {{The high world-wide prevalence of tuberculosis (TB) and the increase in
   multi-drug resistant strains (MDRTB) have prompted increased interest in
   engineering control solutions such as ventilation system design and the
   use of ultraviolet germicidal irradiation (UVGI). This study considers
   the contribution of the ventilation airflow to the transmission of TB,
   and uses computational fluid dynamics (CFD) simulations to examine how
   changes in the design of a ward, in Hospital Nacional Dos de Mayo, Lima,
   Peru may reduce the transmission of TB from patients to health-care
   workers, visitors and other patients. The results of this study were
   used to advise the architects and engineers in the remodelling of the
   ward.}},
Publisher = {{SAGE PUBLICATIONS LTD}},
Address = {{1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Sleigh, PA (Reprint Author), Univ Leeds, Sch Civil Engn, Aerobiol Res Grp, Leeds LS2 9JT, W Yorkshire, England.
   Univ Leeds, Sch Civil Engn, Aerobiol Res Grp, Leeds LS2 9JT, W Yorkshire, England.
   Univ London Imperial Coll Sci Technol \& Med, Dept Infect Dis, Wellcome Ctr Clin Trop Med, London, England.
   Univ Bradford, Sch Engn Design \& Technol, Med Engn Grp, Bradford BD7 1DP, W Yorkshire, England.}},
DOI = {{10.1177/1420326X06062364}},
ISSN = {{1420-326X}},
Keywords = {{CFD; ventilation; tuberculosis; airborne infection; ultraviolet}},
Keywords-Plus = {{TUBERCULOSIS}},
Research-Areas = {{Construction \& Building Technology; Engineering; Public, Environmental
   \& Occupational Health}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Engineering, Environmental; Public,
   Environmental \& Occupational Health}},
Author-Email = {{P.A.Sleigh@leeds.ac.uk}},
ResearcherID-Numbers = {{Sleigh, Andrew/E-6675-2010
   }},
ORCID-Numbers = {{Sleigh, Andrew/0000-0001-9218-5660}},
Cited-References = {{Beggs CB, 2000, T ROY SOC TROP MED H, V94, P141, DOI 10.1016/S0035-9203(00)90250-5.
   Brouns C., 1991, GUIDE CONTAMINANT RE.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Noakes C. J., 2004, ASHRAE IAQ C TAMP FL.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   TANCOCK N, DEVELOPMENTS 1998, P30.
   Wells W. F., 1955, AIRBORNE CONTAGION.
   1994, CDC MMRW        1028, P1.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Indoor Built Environ.}},
Doc-Delivery-Number = {{014MC}},
Unique-ID = {{ISI:000235483300007}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000238645500072,
Author = {McNeice, G. M. and Tyler, O. Z. and Blackhurst, D. W.},
Editor = {{Pandey, M and Xie, WC and Xu, L}},
Title = {{Antimicrobial treated construction materials and air filters reduce
   facility bioburden and improve air quality in a healthcare environment}},
Booktitle = {{ADVANCES IN ENGINEERING STRUCTURES, MECHANICS \& CONSTRUCTION,
   PROCEEDINGS}},
Series = {{Solid Mechanics and its Applications}},
Year = {{2006}},
Volume = {{140}},
Pages = {{841+}},
Note = {{International Conference on Advances in Engineering Structures,
   Mechanics and Construction, Univ Waterloo, Waterloo, CANADA, MAY 14-17,
   2006}},
Publisher = {{SPRINGER}},
Address = {{PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{McNeice, GM (Reprint Author), Clemson Univ, Clemson, SC 29631 USA.
   McNeice, G. M., Clemson Univ, Clemson, SC 29631 USA.
   Tyler, O. Z., OZ Enterprises, Richmond, VA 23224 USA.
   Blackhurst, D. W., Greenville Hosp Syst, Greenville, NC USA.}},
ISSN = {{0925-0042}},
ISBN = {{1-4020-4890-4}},
Keywords-Plus = {{ANTIBIOTIC-RESISTANCE; TRICLOSAN}},
Research-Areas = {{Construction \& Building Technology; Engineering}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Engineering, Mechanical}},
Cited-References = {{{*}APIC, 2000, 27 ANN ED C INT M MI.
   BURKE R, 2000, AM J INFECT CONTROL, V28.
   {*}CDC, 2000, 4 DEC INT C NOS INF.
   Diekema DJ, 2004, CLIN INFECT DIS, V38, P78, DOI 10.1086/380457.
   DONELAN S, 2000, AM J INFECT CONTROL, V28.
   DRUSIN LM, 2000, AM J INFECT CONTROL, V28.
   {*}FDA, 1997, JOINT M NONPR DRUGS.
   Fraise AP, 2002, J APPL MICROBIOL, V92, p158S, DOI 10.1046/j.1365-2672.92.5s1.2.x.
   GOLDMAN CR, 2000, AM J INFECT CONTROL, V28.
   GOULD MA, 2000, AM J INFECT CONTROL, V28.
   GREENE LA, 2000, AM J INFECT CONTROL, V28.
   HARRIS AD, 2000, AM J INFECT CONTROL, V28.
   HOFMANN K, 2000, AM J INFECT CONTROL, V28.
   Jones RD, 2000, AM J INFECT CONTROL, V28, P184, DOI 10.1016/S0196-6553(00)90027-0.
   Jones RD, 1999, AM J INFECT CONTROL, V27, P351, DOI 10.1016/S0196-6553(99)70056-8.
   KASSIS I, 2000, AM J INFECT CONTROL, V28.
   LAI KK, 2000, AM J INFECT CONTROL, V28.
   LISAY CM, 2000, AM J INFECT CONTROL, V28.
   MANAGAN LP, 2000, AM J INFECT CONTROL, V28.
   McBain AJ, 2002, J IND MICROBIOL BIOT, V29, P326, DOI 10.1038/sj.jim.7000324.
   McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970.
   Medlin J, 1997, ENVIRON HEALTH PERSP, V105, P290, DOI 10.2307/3433265.
   MERMEL LA, 2000, AM J INFECT CONTROL, V28.
   MYLOTTE JM, 2000, AM J INFECT CONTROL, V28.
   Noskin GA, 2000, AM J INFECT CONTROL, V28, P311, DOI 10.1067/mic.2000.108129.
   OBER JF, 2000, AM J INFECT CONTROL, V28.
   {*}OMH, 2004, DIS SEV AC RESP SYND.
   PENTELLA MA, 2000, AM J INFECT CONTROL, V28.
   {*}PHTS, 2000, CONTR BIOL CHEM EXP.
   RAAD II, 2000, AM J INFECT CONTROL, V28.
   REBMANN T, 2000, AM J INFECT CONTROL, V28.
   RISA KJ, 2000, AM J INFECT CONTROL, V28.
   Russell AD, 2002, AM J INFECT CONTROL, V30, P495, DOI 10.1067/mic.2002.124676.
   RUTALA WA, 2000, AM J INFECT CONTROL, V28.
   RUTULA WA, 2000, AM J INFECT CONTROL, V28.
   TEMPLE RS, 2000, AM J INFECT CONTROL, V28.
   TESSARIN M, 2000, AM J INFECT CONTROL, V28.
   VALENA FD, 2000, AM J INFECT CONTROL, V28.
   VANENK RA, 2000, AM J INFECT CONTROL, V28.
   VOLAVKA M, 2005, REPORT PENNSYLVANIA.
   WEISTEIN RA, 1998, J EMERGING INFECT DI, V4, P1.
   Young JM, 2005, AM J INFECT CONTROL, V33, P170, DOI 10.1016/j.ajic.2004.11.005.
   Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868.
   ZOUTMAN RE, 2003, AM J INFECT CONTROL, V31.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BEP64}},
Unique-ID = {{ISI:000238645500072}},
DA = {{2018-08-13}},
}

@incollection{ ISI:000242453600009,
Author = {Tatem, A. J. and Rogers, D. J. and Hay, S. I.},
Editor = {{Hay, SI and Graham, A and Rogers, DJ}},
Title = {{Global transport networks and infectious disease spread}},
Booktitle = {{ADVANCES IN PARASITOLOGY, VOL 62: GLOBAL MAPPING OF INFECTIOUS DISEASES:
   METHODS, EXAMPLES AND EMERGING APPLICATIONS}},
Series = {{Advances in Parasitology}},
Year = {{2006}},
Volume = {{62}},
Pages = {{293-343}},
Abstract = {{Air, sea and land transport networks continue to expand in,reach, speed
   of travel and volume of passengers and goods carried. :Pathogens and
   their vectors can now move further, faster and in greater numbers than
   ever before. Three important consequences of global transport network
   expansion are infectious disease pandemics, vector invasion events and
   vector-borne pathogen importation. This review briefly examines some of
   the important historical examples of these disease and vector movements,
   such as the global influenza pandemics, the devastating Anopheles
   gambiae invasion of Brazil and the recent increases in imported
   Plasmodium falciparum malaria cases. We then outline potential
   approaches for future studies of disease movement, focussing on vector
   invasion and vector-borne disease importation. Such approaches allow us
   to explore the potential implications of international air travel,
   shipping routes and other methods of transport on global pathogen and
   vector traffic.}},
Publisher = {{ELSEVIER ACADEMIC PRESS INC}},
Address = {{525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Review; Book Chapter}},
Language = {{English}},
Affiliation = {{Tatem, AJ (Reprint Author), Univ Oxford, Dept Zool, TALA Res Grp, S Parks Rd,Tinbergen Bldg, Oxford OX1 3PS, England.
   Univ Oxford, Dept Zool, TALA Res Grp, Oxford OX1 3PS, England.
   KEMRI, Ctr Geog Med, Malaria Publ Hlth \& Epidemiol Grp, Nairobi 00100, Kenya.}},
DOI = {{10.1016/S0065-308X(05)62009-X}},
ISSN = {{0065-308X}},
ISBN = {{0-12-031762-1}},
Keywords-Plus = {{WEST-NILE-VIRUS; JAPONICUS-JAPONICUS THEOBALD; DRUG-RESISTANT MALARIA;
   NEW-YORK-CITY; AEDES-ALBOPICTUS; UNITED-STATES; BIOLOGICAL INVASIONS;
   PANDEMIC INFLUENZA; ANOPHELES-GAMBIAE; GEOGRAPHIC SPREAD}},
Research-Areas = {{Parasitology}},
Web-of-Science-Categories  = {{Parasitology}},
ResearcherID-Numbers = {{Hay, Simon/F-8967-2015}},
ORCID-Numbers = {{Hay, Simon/0000-0002-0611-7272}},
Funding-Acknowledgement = {{Wellcome Trust {[}069045]}},
Cited-References = {{Alibek K, 2004, INT J INFECT DIS, V8, pS3, DOI 10.1016/j.ijid.2004.09.004.
   Anderson R. M., 1991, INFECT DIS HUMANS DY.
   Anderson TJC, 2005, ACTA TROP, V94, P269, DOI 10.1016/j.actatropica.2005.04.010.
   Bailey N. T. J., 1967, MATH APPROACH BIOL M.
   BARRETTO A, 1994, LANCET, V345, P983.
   Bozzette SA, 2003, NEW ENGL J MED, V348, P416, DOI 10.1056/NEJMsa025075.
   Bronfman MN, 2002, AIDS, V16, pS42, DOI 10.1097/00002030-200212003-00007.
   Cash RA, 2000, B WORLD HEALTH ORGAN, V78, P1358.
   {*}CDC, 1986, EPIDEIOLOGIC NOTES R, V35, P649.
   Chevallier E, 2004, EUR J PUBLIC HEALTH, V14, P274, DOI 10.1093/eurpub/14.3.274.
   Cieslak TJ, 1999, EMERG INFECT DIS, V5, P552, DOI 10.3201/eid0504.990418.
   Cox NJ, 2000, ANNU REV MED, V51, P407, DOI 10.1146/annurev.med.51.1.407.
   CROCKETT GS, 1953, BRIT MED J, V21, P1141.
   Curtin Philip, 1995, DEATH MIGRATION EURO.
   Danis M, 1996, MED MALADIES INFECT, V26, P393, DOI 10.1016/S0399-077X(96)80181-8.
   Dauphin G, 2004, COMP IMMUNOL MICROB, V27, P343, DOI 10.1016/j.cimid.2004.03.009.
   Dewan PK, 2002, EMERG INFECT DIS, V8, P1066, DOI 10.3201/eid0810.020330.
   Diamond Jared, 1998, GUNS GERMS STEEL SHO.
   Drake JM, 2004, P ROY SOC B-BIOL SCI, V271, P575, DOI 10.1098/rspb.2003.2629.
   DUPLAIX N, 1988, NATL GEOGR, V173, P114.
   Dye C, 2003, SCIENCE, V300, P1884, DOI 10.1126/science.1086925.
   Eckert EA, 2000, B HIST MED, V74, P1.
   Effler PV, 2005, EMERG INFECT DIS, V11, P742.
   Enserink M, 2004, SCIENCE, V306, P392, DOI 10.1126/science.306.5695.392.
   ERDAS, 2003, ERDAS FIELD GUID.
   Faruque SM, 2003, EMERG INFECT DIS, V9, P1116.
   Ferguson NM, 2003, NATURE, V425, P681, DOI 10.1038/nature02007.
   Ferguson NM, 2003, NATURE, V422, P428, DOI 10.1038/nature01509.
   FERGUSON NM, 2001, SCIENCE, V292, P1150.
   Fouchier R, 2005, NATURE, V435, P419, DOI 10.1038/435419a.
   Frank C, 2004, EMERG INFECT DIS, V10, P903, DOI 10.3201/eid1005.030495.
   Gage KL, 2005, ANNU REV ENTOMOL, V50, P505, DOI 10.1146/annurev.ento.50.071803.130337.
   Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004.
   Giacomini T, 1998, Rev Prat, V48, P264.
   GIACOMINI T, 1989, REV HIST PHARM, V36, P164.
   GOULD P, 1999, BECOMING GEOGRAPHER.
   GOULD PR, 1995, RECHERCHE, V280, P36.
   Grais RF, 2003, EPIDEMIOL INFECT, V131, P849, DOI 10.1017/S0950268803008811.
   Grais RF, 2003, EUR J EPIDEMIOL, V18, P1065, DOI 10.1023/A:1026140019146.
   Granwehr BP, 2004, LANCET INFECT DIS, V4, P547, DOI 10.1016/S1473-3099(04)01128-4.
   Gratz NG, 2000, B WORLD HEALTH ORGAN, V78, P995.
   Gratz NG, 2004, MED VET ENTOMOL, V18, P215, DOI 10.1111/j.0269-283X.2004.00513.x.
   Greene CM, 2002, EMERG INFECT DIS, V8, P1048, DOI 10.3201/eid0810.020329.
   Gubler DJ, 2004, NAT MED, V10, P129, DOI 10.1038/nm0204-129.
   GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55.
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013.
   Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8.
   Gubler DJ, 2003, LANCET INFECT DIS, V3, P751, DOI 10.1016/S1473-3099(03)00826-0.
   Guimera R, 2005, P NATL ACAD SCI USA, V102, P7794, DOI 10.1073/pnas.0407994102.
   Haggett P., 2000, GEOGRAPHICAL STRUCTU.
   Halloran ME, 2002, SCIENCE, V298, P1428, DOI 10.1126/science.1074674.
   Hartl DL, 2004, NAT REV MICROBIOL, V2, P15, DOI 10.1038/nrmicro795.
   Hastings IM, 2005, ACTA TROP, V94, P218, DOI 10.1016/j.actatropica.2005.04.003.
   Hastings IM, 1998, PARASITOLOGY, V117, P411, DOI 10.1017/S0031182098003291.
   HAWLEY WA, 1987, SCIENCE, V236, P1114, DOI 10.1126/science.3576225.
   Hay SI, 2000, ADV PARASIT, V47, P173, DOI 10.1016/S0065-308X(00)47009-0.
   Hay SI, 2005, NAT REV MICROBIOL, V3, P81, DOI 10.1038/nrmicro1069.
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6.
   Hayes CG, 2001, ANN NY ACAD SCI, V951, P25.
   Henderson DA, 1999, EMERG INFECT DIS, V5, P537, DOI 10.3201/eid0504.990415.
   Heymann DL, 2004, PHILOS T ROY SOC B, V359, P1127, DOI 10.1098/rstb.2004.1484.
   Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101.
   ISAACSON M, 1989, B WORLD HEALTH ORGAN, V67, P737.
   Jelinek T, 2000, CLIN INFECT DIS, V31, P144, DOI 10.1086/313889.
   Jonassen TO, 1997, VIROLOGY, V231, P43, DOI 10.1006/viro.1997.8510.
   KAPLAN EH, 2002, P NATL ACAD SCI USA, V99, P4346.
   KARLEN A, 1995, PLAGUES PROGR.
   KAY BH, 1990, MED J AUSTRALIA, V153, P368.
   Keeling MJ, 2003, NATURE, V421, P136, DOI 10.1038/nature01343.
   Keeling MJ, 2000, NATURE, V407, P903, DOI 10.1038/35038073.
   Killeen GF, 2003, LANCET INFECT DIS, V3, P663, DOI 10.1016/S1473-3099(03)00776-X.
   Killeen GF, 2002, LANCET INFECT DIS, V2, P618, DOI 10.1016/S1473-3099(02)00397-3.
   Kilpatrick AM, 2005, EMERG INFECT DIS, V11, P425, DOI 10.3201/eid1103.040364.
   Kortepeter MG, 1999, EMERG INFECT DIS, V5, P523, DOI 10.3201/eid0504.990411.
   Kuhn KG, 2003, P NATL ACAD SCI USA, V100, P9997, DOI 10.1073/pnas.1233687100.
   KUMAR S, 1995, LANCET, V345, P714, DOI 10.1016/S0140-6736(95)90876-5.
   Lagarde E, 2003, INT J EPIDEMIOL, V32, P744, DOI 10.1093/ije/dyg111.
   LAIRD M, 1990, J AM MOSQUITO CONTR, V6, P287.
   LAIRD M, 1994, J AM MOSQUITO CONTR, V10, P14.
   Lane HC, 2001, NAT MED, V7, P1271, DOI 10.1038/nm1201-1271.
   LAYTON M, 1995, LANCET, V346, P729, DOI 10.1016/S0140-6736(95)91503-6.
   Lemey P, 2003, P NATL ACAD SCI USA, V100, P6588, DOI 10.1073/pnas.0936469100.
   Levine JM, 2003, CONSERV BIOL, V17, P322, DOI 10.1046/j.1523-1739.2003.02038.x.
   Lockwood JL, 2005, TRENDS ECOL EVOL, V20, P223, DOI 10.1016/j.tree.2005.02.004.
   LONGINI IM, 1986, AM J EPIDEMIOL, V123, P383, DOI 10.1093/oxfordjournals.aje.a114253.
   Lounibos LP, 2002, ANNU REV ENTOMOL, V47, P233, DOI 10.1146/annurev.ento.47.091201.145206.
   Mackenzie J.S., 2004, NAT MED S12, V10, P98.
   Madjid M, 2003, J ROY SOC MED, V96, P345, DOI 10.1258/jrsm.96.7.345.
   {*}MAL REF LAB, 2004, CDR WEEKLY, V14, P18.
   MANN JM, 1989, CURRENT TOPICS AIDS.
   Markel Howard, 2005, GERMS TRAVEL 6 MAJOR.
   Marsden AG, 2003, MED J AUSTRALIA, V179, P172.
   Massey A., 1933, EPIDEMIOLOGY RELATIO.
   MCNEILL William H, 1976, PLAGUES AND PEOPLE.
   Medlock JM, 2005, MED VET ENTOMOL, V19, P2, DOI 10.1111/j.0269-283X.2005.00547.x.
   Meltzer MI, 2001, EMERG INFECT DIS, V7, P959, DOI 10.3201/eid0706.010607.
   Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063.
   Misao T., 1945, RINSHO TO KENKYU, V22, P44.
   MITCHELL CJ, 1995, J VECTOR ECOL, V20, P44.
   Moore CG, 1997, EMERG INFECT DIS, V3, P329, DOI 10.3201/eid0303.970309.
   Moore CG, 1999, J AM MOSQUITO CONTR, V15, P221.
   Muentener P, 1999, B WORLD HEALTH ORGAN, V77, P560.
   MUSTERMANN LE, 1999, VECTOR ECOLOPGY NEWS, V30, P7.
   Mutebi JP, 2002, MICROBES INFECT, V4, P1459, DOI 10.1016/S1286-4579(02)00028-X.
   Naidoo A, 2002, J R SOC PROMO HEALTH, V122, P89, DOI 10.1177/146642400212200209.
   New M, 2002, CLIMATE RES, V21, P1, DOI 10.3354/cr021001.
   Nicholson KG, 2003, LANCET, V362, P1733, DOI 10.1016/S0140-6736(03)14854-4.
   Normile D, 2004, SCIENCE, V306, P968, DOI 10.1126/science.306.5698.968.
   Osterholm MT, 2005, NEW ENGL J MED, V352, P1839, DOI 10.1056/NEJMp058068.
   Osterholm MT, 2005, NATURE, V435, P417, DOI 10.1038/435417a.
   Oxford J, 2004, NATURE, V429, P345, DOI 10.1038/429345a.
   Oxford JS, 2005, LANCET INFECT DIS, V5, P129.
   PALESE P, 2004, NAT MED S, V10, P582.
   Peiris J, 2004, NAT MED, V10, P88.
   PERLMAN DC, 2003, CDC MORBIDITY MORTAL, V52, P725.
   Perrin L, 2003, LANCET INFECT DIS, V3, P22, DOI 10.1016/S1473-3099(03)00484-5.
   Perrings C, 2005, TRENDS ECOL EVOL, V20, P212, DOI 10.1016/j.tree.2005.02.011.
   Petersen LR, 2004, NEW ENGL J MED, V351, P2257, DOI 10.1056/NEJMp048261.
   Peyton EL, 1999, J AM MOSQUITO CONTR, V15, P238.
   Phukan AC, 2004, T ROY SOC TROP MED H, V98, P563, DOI 10.1016/j.trstmh.2004.01.002.
   Reidl J, 2002, FEMS MICROBIOL REV, V26, P125, DOI 10.1016/S0168-6445(02)00091-8.
   Reiter P, 1998, J AM MOSQUITO CONTR, V14, P83.
   REITER P, 1987, J AM MOSQUITO CONTR, V3, P494.
   Rogers D. J., 2004, TRYPANOSOMIASES.
   ROGERS L, 1919, FEVERS TROPICS.
   Romi R, 1999, J AM MOSQUITO CONTR, V15, P425.
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876.
   Russell KL, 2000, AIDS, V14, P1785, DOI 10.1097/00002030-200008180-00014.
   Russell R. C., 1989, TRAVEL MED INT, V7, P26.
   RUSSELL RC, 1987, B WORLD HEALTH ORGAN, V65, P659.
   RVACHEV LA, 1985, MATH BIOSCI, V75, P3.
   Ryan ET, 2002, NEW ENGL J MED, V347, P505, DOI 10.1056/NEJMra020118.
   Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7.
   Salit IE, 2005, CAN MED ASSOC J, V172, P884, DOI 10.1503/cmaj.1040877.
   Schaffner F, 2003, J AM MOSQUITO CONTR, V19, P1.
   Scott S., 2004, RETURN BLACK DEATH W.
   Seas C, 2000, AM J TROP MED HYG, V62, P513, DOI 10.4269/ajtmh.2000.62.513.
   Shu PY, 2005, EMERG INFECT DIS, V11, P460, DOI 10.3201/eid1103.040420.
   Skowronski DA, 2005, ANNU REV MED, V56, P357, DOI 10.1146/annurev.med.56.091103.134135.
   Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102.
   SOPER FL, 1943, ANOPHELES GAMBIAE BR.
   Spira AM, 2003, LANCET, V361, P1459, DOI 10.1016/S0140-6736(03)13141-8.
   Sugihara G, 2003, P NATL ACAD SCI USA, V100, P5246, DOI 10.1073/pnas.0831096100.
   Tanser FC, 2003, LANCET, V362, P1792, DOI 10.1016/S0140-6736(03)14898-2.
   Tatem AJ, 2004, J URBAN HEALTH, V81, P363, DOI 10.1093/jurban/jth124.
   TATEM AJ, 2006, UNPUB EMERGING INFEC.
   TATEM AJ, 2006, IN PRESS P NATL ACAD.
   Thomas RW, 1992, GEOMEDICAL SYSTEMS I.
   TOOVEY R, 2003, TRAVEL MED INFECT DI, V1, P167.
   Turell MJ, 2001, J MED ENTOMOL, V38, P130, DOI 10.1603/0022-2585-38.2.130.
   TWIGG G, 2003, LOCAL POPULATION STU, V71, P40.
   Twigg G., 1984, BLACK DEATH BIOL APP.
   UNAIDS, 2004, REP GLOB AIDS EP.
   Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021.
   Upham P, 2003, J AIR TRANSP MANAG, V9, P145, DOI 10.1016/S0969-6997(02)00078-9.
   Viboud C, 2004, EMERG INFECT DIS, V10, P32, DOI 10.3201/eid1001.020705.
   Vila M, 2001, BIOL CONSERV, V100, P397, DOI 10.1016/S0006-3207(01)00047-7.
   Vogel G, 2003, SCIENCE, V300, P558, DOI 10.1126/science.300.5619.558.
   Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350.
   Webster R, 2005, NATURE, V435, P415, DOI 10.1038/435415a.
   Weir E, 2004, CAN MED ASSOC J, V170, P1092, DOI 10.1503/cmaj.1040287.
   WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/eid0102.950201.
   Wilson ME, 2003, J APPL MICROBIOL, V94, p1S.
   Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6.
   World Health Organization, 2003, WEEKLY EPIDEMIOLOGIC, V78, P129.
   ZACHCIAL M, 2003, ISL SHIPPING STAT YB.
   Zinsser H., 1943, RATS LICE HIST.}},
Number-of-Cited-References = {{167}},
Times-Cited = {{144}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{49}},
Journal-ISO = {{Adv.Parasitol.}},
Doc-Delivery-Number = {{BFK10}},
Unique-ID = {{ISI:000242453600009}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000236669400002,
Author = {Estrela, JM and Ortega, A and Obrador, E},
Title = {{Glutathione in cancer biology and therapy}},
Journal = {{CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES}},
Year = {{2006}},
Volume = {{43}},
Number = {{2}},
Pages = {{143-181}},
Abstract = {{The glulathione (GSH) content of cancer cells is particularly relevant
   in regulating mutagenic mechanisms, DNA synthesis, growth, and multidrug
   and radiation resistance. In malignant tumors, as compared with normal
   tissues, that resistance associates in most cases with higher GSH levels
   within these cancer cells. Thus, approaches to cancer treatment based on
   modulation of GSH should control possible growth-associated changes in
   GSH content and synthesis in these cells. Despite the potential benefits
   for cancer therapy of a selective GSH-depleting strategy, such a
   methodology has remained elusive up to now.
   Metastatic spread, not primary tumor burden, is the leading cause of
   cancer death. For patient prognosis to improve, new systemic therapies
   capable of effectively inhibiting the outgrowth of seeded tumor cells
   air needed. Interaction of metastatic cells with the vascular
   endothelium, activates local release of proinflammatory cytokines, which
   act as signals promoting cancer cell adhesion, extravasation, and
   proliferation. Recent work shows that a high percentage of metastatic
   cells with high GSH Levels survive the combined nitrosative and
   oxidative stresses elicited by the vascular endothelium. and possibly by
   macrophages and granulotyles. gamma-Glutamyl transpeptidase
   overexpression and an inter-organ flow of GSH (where the liverplays a
   central role), by increasing cysteine availability for tumor GSH
   synthesis, function in combination as a metastatic-growth promoting
   mechanism. The present review focuses on an analysis of links among GSH,
   adaptive responses to stress, molecular mechanisms of invasive cancer
   cell survival and death, and sensitization of metastatic cells to
   therapy. Experimental evidence shows that acceleration of GSH efflux
   facilitates selective GSH depletion in metastatic cells.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Estrela, JM (Reprint Author), Univ Valencia, Dept Physiol, Fac Med \& Dent, 17 Av Blasco Ibanez, Valencia 46010, Spain.
   Univ Valencia, Dept Physiol, Fac Med \& Dent, Valencia 46010, Spain.}},
DOI = {{10.1080/10408360500523878}},
ISSN = {{1040-8363}},
EISSN = {{1549-781X}},
Keywords = {{Bcl-2; cancer; cell adhesion; cell death; endothelium; glutathione;
   invasion; metastases; mitochondria; multidrug resistance proteins;
   therapy}},
Keywords-Plus = {{B16 MELANOMA-CELLS; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE;
   RESISTANCE-ASSOCIATED PROTEIN; HEPATIC SINUSOIDAL ENDOTHELIUM; BCL-2
   ANTISENSE OLIGONUCLEOTIDES; YEAST SACCHAROMYCES-CEREVISIAE; INDUCED
   OXIDATIVE STRESS; ACUTE MYELOID-LEUKEMIA; NECROSIS-FACTOR-ALPHA;
   OF-CELLULAR-FUNCTIONS}},
Research-Areas = {{Medical Laboratory Technology}},
Web-of-Science-Categories  = {{Medical Laboratory Technology}},
Author-Email = {{jose.m.estrela@uv.es}},
ResearcherID-Numbers = {{Estrela, Jose/H-4449-2015
   Ortega, Angel/A-4113-2014
   OBRADOR, ELENA/H-4069-2015}},
ORCID-Numbers = {{Estrela, Jose/0000-0002-2540-9190
   Ortega, Angel/0000-0002-9901-3383
   OBRADOR, ELENA/0000-0002-5934-5543}},
Cited-References = {{AKERBOOM TPM, 1989, METHOD ENZYMOL, V173, P523.
   Aliya S, 2003, MOL CELL BIOCHEM, V253, P319, DOI 10.1023/A:1026036521852.
   AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258.
   ANANTHASWAMY HN, 1988, CANCER RES, V48, P3341.
   Anasagasti MJ, 1996, J CELL PHYSIOL, V167, P314, DOI 10.1002/(SICI)1097-4652(199605)167:2<314::AID-JCP16>3.3.CO;2-K.
   Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510.
   ANASAGASTI MJ, 1997, HEPATHOLOGY, V25, P810.
   ANDERSON ME, 1980, J BIOL CHEM, V255, P9530.
   Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924.
   Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje.
   Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x.
   ARRICK BA, 1984, CANCER RES, V44, P4224.
   Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6.
   Aw TY, 2005, TOXICOL APPL PHARM, V204, P320, DOI 10.1016/j.taap.2004.11.016.
   Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149.
   Baliga BC, 2002, HEMATOL ONCOL, V20, P63, DOI 10.1002/hon.685.
   Ballatori N, 1998, SEMIN LIVER DIS, V18, P377, DOI 10.1055/s-2007-1007171.
   Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213.
   BARRON ESG, 1953, TEX REP BIOL MED, V11, P653.
   Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200.
   Bayon LG, 1996, HEPATOLOGY, V23, P1224, DOI 10.1002/hep.510230542.
   Benlloch M, 2005, J BIOL CHEM, V280, P6950, DOI 10.1074/jbc.M408531200.
   BENLLOCH M, 2005, J BIOL CHEM     1101.
   BERGER SJ, 1994, CANCER RES, V54, P4077.
   Borst P, 2000, J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295.
   BRIVIBA K, 1993, BIOCHEM J, V294, P631, DOI 10.1042/bj2940631.
   BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7.
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S.
   Calvert Paula, 1998, Chemico-Biological Interactions, V111-112, P213, DOI 10.1016/S0009-2797(98)00008-8.
   Carretero J, 2000, FREE RADICAL BIO MED, V29, P913, DOI 10.1016/S0891-5849(00)00392-0.
   Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200.
   Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078.
   Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599.
   CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167.
   Chiang KT, 2000, TOXICOL APPL PHARM, V167, P30, DOI 10.1006/taap.2000.8970.
   CONWAY JG, 1987, CARCINOGENESIS, V8, P999, DOI 10.1093/carcin/8.7.999.
   Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042.
   CROOK TR, 1986, CANCER RES, V46, P5035.
   Csala M, 2003, BIOFACTORS, V17, P27, DOI 10.1002/biof.5520170104.
   Cullen KV, 2001, BIOCHEM PHARMACOL, V62, P417, DOI 10.1016/S0006-2952(01)00681-5.
   D'Alessio M, 2004, FASEB J, V18, P1609, DOI 10.1096/fj.04-1813fje.
   DALTON WS, 1993, CANC PRINCIPLES PRAC, P2655.
   DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025.
   Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404.
   de Menezes DEL, 2000, CLIN CANCER RES, V6, P2891.
   DEGRAFF WG, 1985, J BIOL CHEM, V260, P8312.
   Deneke S.M., 1989, AM J PHYSIOL, V257, P163.
   Depeille P, 2005, BRIT J CANCER, V93, P216, DOI 10.1038/sj.bjc.6602681.
   DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492.
   Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7.
   Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x.
   DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4.
   ESKENAZI AE, 1993, J NATL CANCER I, V85, P711, DOI 10.1093/jnci/85.9.711.
   ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84.
   ESTRELA JM, 1992, BIOCHEM J, V286, P257, DOI 10.1042/bj2860257.
   Estrela JM, 2004, HEPATOLOGY, V39, P570, DOI 10.1002/hep.20041.
   Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4.
   FariasEisner R, 1996, J BIOL CHEM, V271, P6144, DOI 10.1074/jbc.271.11.6144.
   FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7.
   FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148.
   FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773.
   FIDLER IJ, 1990, CANCER RES, V50, P6130.
   FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199.
   FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363.
   Filomeni G, 2005, FREE RADICAL BIO MED, V39, P345, DOI 10.1016/j.freeradbiomed.2005.03.022.
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951.
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299.
   GADSBY DC, 1999, PHYSIOL REV, V79, P77.
   GAROFALO A, 1995, CANCER RES, V55, P414.
   Gatti L, 2005, METH MOLEC MED, V111, P127.
   Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7.
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706.
   Grant CM, 1997, MOL BIOL CELL, V8, P1699.
   Griffith O W, 1999, Free Radic Biol Med, V27, P922.
   Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7.
   GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668.
   Gupta MP, 1997, AM J PHYSIOL-LUNG C, V272, pL1133.
   Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547.
   GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628.
   Hall AG, 1999, EUR J CLIN INVEST, V29, P238.
   Hall AG, 1999, ADV EXP MED BIOL, V457, P199.
   HAN J, 1995, BIOL NITRIC OXIDE, P84.
   HANIGAN MH, 1995, CARCINOGENESIS, V16, P181, DOI 10.1093/carcin/16.2.181.
   Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851.
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857.
   Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0.
   Hidalgo M, 1998, CLIN CANCER RES, V4, P2763.
   Higashi K, 2004, CANCER LETT, V209, P155, DOI 10.1016/j.canlet.2004.01.003.
   Higuchi Y, 2004, J CELL MOL MED, V8, P455, DOI 10.1111/j.1582-4934.2004.tb00470.x.
   HIRONO I, 1961, GANN, V52, P39.
   Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633.
   Hochwald SN, 1996, J NATL CANCER I, V88, P193, DOI 10.1093/jnci/88.3-4.193.
   Hofseth LJ, 2003, FREE RADICAL BIO MED, V34, P955, DOI 10.1016/S0891-5849(02)01363-1.
   HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149.
   Homolya L, 2003, BIOFACTORS, V17, P103, DOI 10.1002/biof.5520170111.
   Honda T, 2004, CANCER GENE THER, V11, P249, DOI 10.1038/sj.cgt.7700684.
   Hopkins FG, 1938, BIOCHEM J, V32, P611, DOI 10.1042/bj0320611.
   Hopkins FG, 1936, BIOCHEM J, V30, P1446, DOI 10.1042/bj0301446.
   HUANG CS, 1993, J BIOL CHEM, V268, P19675.
   Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje.
   HWANG C, 1995, METHOD ENZYMOL, V251, P212, DOI 10.1016/0076-6879(95)51123-7.
   HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409.
   IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341.
   Jakobisiak M, 2003, IMMUNOL LETT, V90, P103, DOI 10.1016/j.imlet.2003.08.005.
   Jessup JM, 1999, CANCER RES, V59, P1825.
   Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj.onc.1205018.
   KANG YJ, 1990, EXP CELL RES, V187, P177, DOI 10.1016/0014-4827(90)90134-V.
   KETTERER B, 1988, MUTAT RES, V202, P343, DOI 10.1016/0027-5107(88)90197-2.
   Klasa RJ, 2000, CLIN CANCER RES, V6, P2492.
   Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x.
   Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851.
   Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7.
   Kretz-Remy C, 2002, METHOD ENZYMOL, V348, P200, DOI 10.1016/S0076-6879(02)48639-9.
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994.
   Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619.
   Kwon YW, 2003, BIOL CHEM, V384, P991, DOI 10.1515/BC.2003.111.
   LAFRENIE R, 1992, CANCER METAST REV, V11, P377, DOI 10.1007/BF01307188.
   LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937.
   Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102.
   Lei XG, 2002, METHOD ENZYMOL, V347, P213.
   LI L, 1991, CANCER RES, V51, P245.
   LIEBERMANN DA, 1995, ONCOGENE, V11, P199.
   LINSDELL P, 1998, AM J PHYSIOL, V275, P323.
   Liu HL, 2004, ANN NY ACAD SCI, V1019, P346, DOI 10.1196/annals.1297.059.
   Loe DW, 2000, J PHARMACOL EXP THER, V293, P530.
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485.
   LU SC, 1991, J CLIN INVEST, V88, P260, DOI 10.1172/JCI115286.
   Lu SC, 1999, FASEB J, V13, P1169.
   LU SC, 1992, AM J PHYSIOL, V263, pC1181.
   Lu SC, 2000, CURR TOP CELL REGUL, V36, P95.
   Lu SC, 1998, SEMIN LIVER DIS, V18, P331, DOI 10.1055/s-2007-1007168.
   MARAHATTA SB, 2005, CANC LETT.
   Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142.
   Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev.
   MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185.
   MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778.
   MATSUBARA T, 1986, J IMMUNOL, V137, P3295.
   MCCLOSKEY TW, 1992, HEPATOLOGY, V16, P191, DOI 10.1002/hep.1840160130.
   MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560.
   MEISTER A, 1988, J BIOL CHEM, V263, P17205.
   MEISTER A, 1986, J AM COLL NUTR, V5, P137.
   MEISTER A, 1985, METHOD ENZYMOL, V113, P571.
   MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290.
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431.
   MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X.
   Meister A, 1984, Nutr Rev, V42, P397.
   Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237.
   Mendoza L, 1998, J CELL PHYSIOL, V174, P322.
   MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747.
   Meurette O, 2005, CLIN CANCER RES, V11, P3075, DOI 10.1158/1078-0432.CCR-04-1764.
   Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310.
   MISTRY P, 1991, PHARMACOL THERAPEUT, V49, P125, DOI 10.1016/0163-7258(91)90026-I.
   Mitchell J B, 1987, Br J Cancer Suppl, V8, P96.
   Miyake H, 1999, CANCER RES, V59, P4030.
   Moellering D, 1998, ARCH BIOCHEM BIOPHYS, V358, P74, DOI 10.1006/abbi.1998.0854.
   MORAES EC, 1989, NUCLEIC ACIDS RES, V17, P8301, DOI 10.1093/nar/17.20.8301.
   MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283.
   Moran LK, 2001, CURR MED CHEM, V8, P763, DOI 10.2174/0929867013372904.
   Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481.
   Navarro J, 1999, FREE RADICAL BIO MED, V26, P410, DOI 10.1016/S0891-5849(98)00213-5.
   Navarro J, 1997, FREE RADICAL BIO MED, V22, P1203, DOI 10.1016/S0891-5849(96)00554-0.
   Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930.
   Nishikawa M, 1998, HEPATOLOGY, V28, P1474, DOI 10.1002/hep.510280605.
   NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0.
   Nkabyo YS, 2002, AM J PHYSIOL-GASTR L, V283, pG1352, DOI 10.1152/ajpgi.00183.2002.
   Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277.
   Obrador E., 2001, Current Pharmaceutical Biotechnology, V2, P119, DOI 10.2174/1389201013378743.
   Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0.
   OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2.
   OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2.
   Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y.
   Ohshima H, 2003, TOXICOL LETT, V140, P99, DOI 10.1016/S0378-4274(02)00506-4.
   Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2.
   OOKHTENS M, 1994, AM J PHYSIOL, V266, pR979.
   Ookhtens M, 1998, SEMIN LIVER DIS, V18, P313, DOI 10.1055/s-2007-1007167.
   OPPENHEIMER L, 1979, J BIOL CHEM, V254, P5184.
   ORLOWSKI M, 1970, P NATL ACAD SCI USA, V67, P1248, DOI 10.1073/pnas.67.3.1248.
   Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P.
   Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200.
   Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200.
   Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717.
   PACELLI R, 1995, J EXP MED, V182, P1469, DOI 10.1084/jem.182.5.1469.
   Palomares T, 1997, CLIN EXP METASTAS, V15, P329, DOI 10.1023/A:1018433701345.
   Paolicchi A, 2002, BIOCHEM PHARMACOL, V64, P1027, DOI 10.1016/S0006-2952(02)01173-5.
   Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6.
   Pendyala L, 1997, CLIN CANCER RES, V3, P793.
   PERRY RR, 1993, CANCER, V72, P783, DOI 10.1002/1097-0142(19930801)72:3<783::AID-CNCR2820720325>3.0.CO;2-U.
   Petrovic AS, 1998, BLOOD, V91, P3952.
   Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422.
   PITOT HC, 1981, J SUPRAMOL STR CELL, V17, P133, DOI 10.1002/jsscb.380170204.
   RADERER M, 1993, CANCER, V72, P3553, DOI 10.1002/1097-0142(19931215)72:12<3553::AID-CNCR2820721203>3.0.CO;2-B.
   RAINWATER R, 1995, MOL CELL BIOL, V15, P3892.
   Rappa G, 1997, CANCER RES, V57, P5232.
   Ray G, 2000, BREAST CANCER RES TR, V59, P163, DOI 10.1023/A:1006357330486.
   RELIENE R, 2005, CARCINOGENSIS.
   REVESZ L, 1994, INT J RADIAT ONCOL, V29, P403, DOI 10.1016/0360-3016(94)90298-4.
   Ricci G, 2005, J BIOL CHEM, V280, P26397, DOI 10.1074/jbc.M503295200.
   Rudin CM, 2003, CANCER RES, V63, P312.
   Sadani GR, 1996, CANCER LETT, V109, P231, DOI 10.1016/S0304-3835(96)04484-9.
   Salinas AE, 1999, CURR MED CHEM, V6, P279.
   Sander CS, 2004, INT J DERMATOL, V43, P326, DOI 10.1111/j.1365-4632.2004.02222.x.
   Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096.
   SCHADENDORF D, 1995, J INVEST DERMATOL, V105, P109, DOI 10.1111/1523-1747.ep12313403.
   Schiavone N, 2000, FASEB J, V14, P174.
   SCHULTEHERMANN R, 1994, INT ARCH ALLERGY IMM, V105, P363, DOI 10.1159/000236784.
   SELLAK H, 1994, BLOOD, V83, P2669.
   Sen CK, 1996, FASEB J, V10, P709.
   Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0.
   Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X.
   SIES H, 1985, BIOCHEM J, V226, P545, DOI 10.1042/bj2260545.
   SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401.
   STANBRIDGE EJ, 1990, SCIENCE, V247, P12, DOI 10.1126/science.2403692.
   Stavrovskaya AA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P95.
   STOLE E, 1994, J BIOL CHEM, V269, P21435.
   SUAREZ HG, 1989, CANCER RES, V49, P1223.
   SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111.
   Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321.
   Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8.
   SUTHANTHIRAN M, 1990, P NATL ACAD SCI USA, V87, P3343, DOI 10.1073/pnas.87.9.3343.
   Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147.
   TERRADEZ P, 1993, BIOCHEM J, V292, P477, DOI 10.1042/bj2920477.
   THRALL BD, 1991, CARCINOGENESIS, V12, P1319, DOI 10.1093/carcin/12.7.1319.
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940.
   Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI {[}10.1016/S0753-3322(03)00043-X, 10.1016/S0753-3322(03)00013-X].
   Tsuchiya K, 1995, GENOMICS, V30, P630, DOI 10.1006/geno.1995.1293.
   TSURUO T, 1981, CANCER RES, V41, P1967.
   Turella P, 2005, CANCER RES, V65, P3751, DOI 10.1158/0008-5472.CAN-04-3903.
   Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0.
   van der Kolk DM, 1999, ADV EXP MED BIOL, V457, P187.
   VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281.
   Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680.
   Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956.
   VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047.
   Wang HM, 2000, CANCER RES, V60, P5862.
   Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8.
   Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711.
   WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813.
   Wong CW, 2001, CANCER RES, V61, P333.
   Wu GY, 2004, J NUTR, V134, P489.
   Wu HH, 1998, J BIOL CHEM, V273, P18898, DOI 10.1074/jbc.273.30.18898.
   YAN N, 1990, J BIOL CHEM, V265, P1588.
   Ye Z, 2005, EUR J CANCER, V41, P980, DOI 10.1016/j.ejca.2005.01.014.
   YUAN ZM, 1991, DRUG METAB DISPOS, V19, P625.
   ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690.
   Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624.
   Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718.
   ZHOU DC, 1995, LEUKEMIA, V9, P1661.
   Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0.}},
Number-of-Cited-References = {{248}},
Times-Cited = {{452}},
Usage-Count-Last-180-days = {{20}},
Usage-Count-Since-2013 = {{109}},
Journal-ISO = {{Crit. Rev. Clin. Lab. Sci.}},
Doc-Delivery-Number = {{030XT}},
Unique-ID = {{ISI:000236669400002}},
DA = {{2018-08-13}},
}

@article{ ISI:000205613200043,
Author = {Olgac, Guven and Aydogmus, Umit and Mulazimoglu, Lutfiye and Kutlu,
   Cemal Asim},
Title = {{Antibiotics are not needed during tube thoracostomy for spontaneous
   pneumothorax: an observational case study}},
Journal = {{JOURNAL OF CARDIOTHORACIC SURGERY}},
Year = {{2006}},
Volume = {{1}},
Abstract = {{Background: Usefulness of prophylactic antibiotics following tube
   thoracostomy remains controversial in the literature. In this study, we
   aimed to investigate the consequences of closed tube thoracostomy for
   primary spontaneous pneumothorax without the use of antibiotics.
   Methods: One-hundred and nineteen patients underwent tube thoracostomy
   for primary spontaneous pneumothorax. None of them received prophylactic
   antibiotic treatment. Eight patients with prolonged air leak undergoing
   either video assisted thoracoscopic surgery or thoracotomy were
   excluded.
   Results: Of the remaining 111 ( 104 male and 7 female), 28 (25\%)
   patients developed some induration around the entry site of chest tube
   that settled without further treatment. White blood cell count was high
   without any other evidence of infection in 12 (11\%) patients and
   returned to its normal levels before discharge home in all. There was
   also some degree of fever not lasting for more than 48 hours in 8 (7\%)
   patients. Bacterial cultures from suspected sites did not reveal any
   significant growth in these patients.
   Conclusion: Prophylactic antibiotic treatment seems avoidable during
   closed tube thoracostomy for primary spontaneous pneumothorax. This
   policy was not only cost-effective but also prevented our patients from
   detrimental properties of unnecessary antibiotic use, such as
   development of drug resistance and undesirable side effects.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Olgac, G (Reprint Author), Sureyyapasa Chest \& Cardiovasc Dis Teaching \& Res, Dept Thorac Surg, Istanbul, Turkey.
   Olgac, Guven; Kutlu, Cemal Asim, Sureyyapasa Chest \& Cardiovasc Dis Teaching \& Res, Dept Thorac Surg, Istanbul, Turkey.
   Aydogmus, Umit, Yedikule Teaching \& Res Hosp Chest Dis \& Thorac S, Dept Thorac Surg, Istanbul, Turkey.
   Mulazimoglu, Lutfiye, Marmara Univ, Sch Med, Dept Infect Dis \& Clin Microbiol, Istanbul, Turkey.}},
DOI = {{10.1186/1749-8090-1-43}},
Article-Number = {{43}},
ISSN = {{1749-8090}},
Research-Areas = {{Cardiovascular System \& Cardiology}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems}},
Author-Email = {{guvenolgac@gmail.com
   umitbile@yahoo.com
   lmulazimoglu@yahoo.com
   cakutlu@tnn.net}},
Cited-References = {{BRUNNER RG, 1990, J TRAUMA, V30, P1148, DOI 10.1097/00005373-199009000-00011.
   Dellinger P., 1998, HOSP INFECT, P571.
   GROVER FL, 1977, J THORAC CARDIOV SUR, V74, P528.
   Hatz RA, 2000, ANN THORAC SURG, V70, P253, DOI 10.1016/S0003-4975(00)01411-9.
   Henry M, 2003, THORAX S2, V58, pii39.
   KERNODLE DS, 1988, ANTIMICROB AGENTS CH, V32, P202, DOI 10.1128/AAC.32.2.202.
   Lang-Lazdunski L, 2003, ANN THORAC SURG, V75, P960, DOI 10.1016/S0003-4975(02)04544-7.
   Mangram AJ, 1999, AM J INFECT CONTROL, V27, P97, DOI 10.1016/S0196-6553(99)70088-X.
   MILLER KS, 1987, CHEST, V91, P258, DOI 10.1378/chest.91.2.258.
   NEUGEBAUER MK, 1971, J THORAC CARDIOV SUR, V61, P882.
   NICHOLS RL, 1994, CHEST, V106, P1493, DOI 10.1378/chest.106.5.1493.
   Turna A, 2003, THORAC CARDIOV SURG, V51, P84, DOI 10.1055/s-2003-38991.
   Weissberg D, 2000, CHEST, V117, P1279, DOI 10.1378/chest.117.5.1279.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Cardiothorac. Surg.}},
Doc-Delivery-Number = {{V83AY}},
Unique-ID = {{ISI:000205613200043}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000234420700039,
Author = {Becker, K and Koutsospyros, A and Yin, SM and Christodoulatos, C and
   Abramzon, N and Joaquin, JC and Brelles-Marino, G},
Title = {{Environmental and biological applications of microplasmas}},
Journal = {{PLASMA PHYSICS AND CONTROLLED FUSION}},
Year = {{2005}},
Volume = {{47}},
Number = {{12B, SI}},
Pages = {{B513-B523}},
Month = {{DEC}},
Note = {{32nd European-Physical-Society Conference on Plasma Physics, Tarragona,
   SPAIN, JUN 27-JUL 01, 2005}},
Organization = {{European Physical Soc}},
Abstract = {{Stable glow-type discharge plasmas at elevated pressures can be
   generated and maintained easily when the plasma is spatially confined to
   cavities with critical dimensions below 1 mm ('microplasmas'). We
   studied the properties of several atmospheric-pressure microplasmas and
   their use in the remediation of volatile organic compounds (VOCs) and
   biological decontamination. The VOCs studied include individual
   prototypcal aliphatic and aromatic compounds as well as mixtures such as
   BTEX (benzene, toluene, ethylbenzene and xylene). The biological systems
   under study included individual bacteria as well as bacterial biofilms,
   which are highly structured communities of bacteria that are very
   resistant to antibiotics, germicides, and other conventional forms of
   destruction.}},
Publisher = {{IOP PUBLISHING LTD}},
Address = {{DIRAC HOUSE, TEMPLE BACK, BRISTOL BS1 6BE, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Becker, K (Reprint Author), Stevens Inst Technol, Dept Phys \& Engn Phys, Hoboken, NJ 07030 USA.
   Stevens Inst Technol, Dept Phys \& Engn Phys, Hoboken, NJ 07030 USA.
   Stevens Inst Technol, Ctr Environm Syst, Hoboken, NJ 07030 USA.
   Univ New Haven, Dept Civil \& Environm Engn, New Haven, CT 06516 USA.
   PlasmaSol Corp, Hoboken, NJ 07030 USA.
   Stevens Inst Technol, Dept Civil Environm \& Ocean Engn, Hoboken, NJ 07030 USA.
   Calif State Polytech Univ Pomona, Dept Phys, Pomona, CA 91768 USA.
   Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA.}},
DOI = {{10.1088/0741-3335/47-12B/S37}},
ISSN = {{0741-3335}},
Keywords-Plus = {{ATMOSPHERIC-PRESSURE; GLOW-DISCHARGE; AMBIENT-PRESSURE; PLASMA; AIR;
   STERILIZATION; DECONTAMINATION; INACTIVATION; DESTRUCTION; OXYGEN}},
Research-Areas = {{Physics}},
Web-of-Science-Categories  = {{Physics, Fluids \& Plasmas}},
Author-Email = {{kbecker@stevens.edu}},
Cited-References = {{AMORER LE, 1999, THESIS STEVENS I TEC.
   Becker KH, 2002, PHYS PLASMAS, V9, P2399, DOI 10.1063/1.1449464.
   BECKER KH, 2005, IN PRESS J PHYS D.
   BECKER KH, 2004, NONEQUILIBRUM AIR PL, pCH6.
   BECKER KH, 2004, NONEQUILIBRIUM AIR P, pCH9.
   BERINGER JE, 1974, J GEN MICROBIOL, V84, P188.
   Birmingham JG, 2000, IEEE T PLASMA SCI, V28, P51, DOI 10.1109/27.842862.
   Efremov NM, 2000, IEEE T PLASMA SCI, V28, P238, DOI 10.1109/27.842912.
   FUTURAMA S, 1998, IEEE T IND APPL, V34, P967.
   Hermann H.W., 1999, PHYS PLASMAS, V6, P2284.
   JOAQUIN JC, 2005, UNPUB APPL ENV MICRO.
   Koutsospyros A, 2004, INT J MASS SPECTROM, V233, P305, DOI 10.1016/j.ijms.2003.12.033.
   Koutsospyros AD, 2005, IEEE T PLASMA SCI, V33, P42, DOI 10.1109/TPS.2004.841925.
   Kunhardt E.E., 1997, P 12 INT C GAS DISCH, P1.
   Kunhardt E. E., 1999, US Patents, Patent No. {[}5872426, 6005349, 6147452].
   Kunhardt E.E., 2000, IEEE T PLASMA SCI, V28, P1.
   KUNHARDT EE, 1998, P 4 INT C PROT REST.
   KUNHARDT EE, 2000, Patent No. 6005349.
   KUNHARDT EE, 2005, Patent No. 6879103.
   KUNHARDT EE, 1997, B AM PHYS SOC, V42, P1716.
   KUNHARDT EE, 2004, Patent No. 6147452.
   Kushner MJ, 2005, J PHYS D APPL PHYS, V38, P1633, DOI 10.1088/0022-3727/38/11/001.
   Laroussi M, 2003, NEW J PHYS, V5, DOI 10.1088/1367-2630/5/1/341.
   Laroussi M, 2004, INT J MASS SPECTROM, V233, P81, DOI 10.1016/j.ijms.2003.11.016.
   Laroussi M, 1996, IEEE T PLASMA SCI, V24, P1188, DOI 10.1109/27.533129.
   Laroussi M, 2000, IEEE T PLASMA SCI, V28, P184, DOI 10.1109/27.842899.
   Laroussi M, 2002, IEEE T PLASMA SCI, V30, P1409, DOI 10.1109/TPS.2002.804220.
   LAROUSSI M, 2004, NON EQUILIBRIUM AIR.
   LAROUSSI M, 2002, APPL PHYS LETT, V81, P722.
   Lerouge S, 2000, J BIOMED MATER RES, V51, P128, DOI 10.1002/(SICI)1097-4636(200007)51:1<128::AID-JBM17>3.0.CO;2-\#.
   Masoud N, 2005, J PHYS D APPL PHYS, V38, P1674, DOI 10.1088/0022-3727/38/11/006.
   McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703.
   Mendis DA, 2000, IEEE T PLASMA SCI, V28, P1304, DOI 10.1109/27.893321.
   Moisan M, 2001, INT J PHARMACEUT, V226, P1, DOI 10.1016/S0378-5173(01)00752-9.
   Montie TC, 2000, IEEE T PLASMA SCI, V28, P41, DOI 10.1109/27.842860.
   Moreau S, 2000, J APPL PHYS, V88, P1166, DOI 10.1063/1.373792.
   Moskwinski L., 2003, P 14 S APPL PLASM PR, P17.
   NELSON CL, 1989, CURR MICROBIOL, V18, P275, DOI 10.1007/BF01570305.
   NUNEZ CM, 1993, J AIR WASTE MANAGE, V43, P242.
   OKAZAKI S, 1993, J PHYS D APPL PHYS, V26, P889, DOI 10.1088/0022-3727/26/5/025.
   Panikov NS, 2002, IEEE T PLASMA SCI, V30, P1424, DOI 10.1109/TPS.2002.804195.
   Penetrante BM, 1997, PLASMA SOURCES SCI T, V6, P251, DOI 10.1088/0963-0252/6/3/002.
   PENETRANTE BM, 1993, P NATO ASI A, V34.
   YIN SM, 2003, P INT C ENV SYST ICE.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{110}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{24}},
Journal-ISO = {{Plasma Phys. Control. Fusion}},
Doc-Delivery-Number = {{999WD}},
Unique-ID = {{ISI:000234420700039}},
DA = {{2018-08-13}},
}

@article{ ISI:000233219200001,
Author = {Joshi, G and Sultana, R and Tangpong, J and Cole, MP and St Clair, DK
   and Vore, M and Estus, S and Butterfield, DA},
Title = {{Free radical mediated oxidative stress and toxic side effects in brain
   induced by the anti cancer drug adriamycin: Insight into chemobrain}},
Journal = {{FREE RADICAL RESEARCH}},
Year = {{2005}},
Volume = {{39}},
Number = {{11}},
Pages = {{1147-1154}},
Month = {{NOV}},
Abstract = {{Adriamycin (ADR) is a chemotherapeutic agent useful in treating various
   cancers. ADR is a quinone-containing anthracycline chemotherapeutic and
   is known to produce reactive oxygen species (ROS) in heart. Application
   of this drug can have serious side effects in various tissues, including
   brain, apart from the known cardiotoxic side effects, which limit the
   successful use of this drug in treatment of cancer. Neurons treated with
   ADR demonstrate significant protein oxidation and lipid peroxidation.
   Patients under treatment with this drug often complain of forgetfulness,
   lack of concentration, dizziness (collectively called somnolence or
   sometimes called chemobrain). In this study, we tested the hypothesis
   that ADR induces oxidative stress in brain. Accordingly, we examined the
   in vivo levels of brain protein oxidation and lipid peroxidation induced
   by i.p. injection of ADR. We also measured levels of the multidrug
   resistance-associated protein (AIR) in brain isolated from ADRP1 or
   saline-injected mice. MRP1 mediates ATP-dependent export of cytotoxic
   organic anions, glutathione S-conjugates and sulphates. The current
   results demonstrated a significant increase in levels of protein
   oxidation and lipid peroxidation and increased expression of MRP1 in
   brain isolated from mice, 72 h post i.p injection of ADR. These results
   are discussed with reference to potential use of this redox cycling
   chemotheraputic agent in the treatement of cancer and its chemobrain
   side effect in brain.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Butterfield, DA (Reprint Author), Univ Kentucky, Dept Chem, Ctr Membrane Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Chem, Ctr Membrane Sci, Lexington, KY 40506 USA.
   Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40506 USA.
   Univ Kentucky, Dept Physiol, Lexington, KY 40506 USA.
   Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA.}},
DOI = {{10.1080/10715760500143478}},
ISSN = {{1071-5762}},
Keywords-Plus = {{ALZHEIMERS-DISEASE BRAIN; RESISTANCE-ASSOCIATED PROTEIN; AMYLOID
   BETA-PEPTIDE; SYNAPTOSOMAL MEMBRANE-PROTEINS; CENTRAL-NERVOUS-SYSTEM;
   LIPID-PEROXIDATION; REACTIVE OXYGEN; NADH DEHYDROGENASE; NITRIC-OXIDE;
   PROTEOMIC IDENTIFICATION}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Author-Email = {{dabcns@uky.edu}},
ResearcherID-Numbers = {{Joshi, Gururaj/G-3819-2012
   Vore, Mary/E-2177-2012}},
Funding-Acknowledgement = {{NIA NIH HHS {[}AG-05119, AG-10836]; NCI NIH HHS {[}CA-80152, CA-94853]}},
Cited-References = {{Abali H, 2002, AM J CLIN ONCOL-CANC, V25, P632, DOI 10.1097/00000421-200212000-00023.
   Abd El-Gawad H, 2004, J BIOCHEM MOL TOXIC, V18, P69, DOI 10.1002/jbt.20013.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3.
   Butterfield DA, 2001, MECH AGEING DEV, V122, P945, DOI 10.1016/S0047-6374(01)00249-4.
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6.
   Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3.
   Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x.
   Castegna A, 2002, FREE RADICAL BIO MED, V33, P562, DOI 10.1016/S0891-5849(02)00914-0.
   CHENG KC, 1992, J BIOL CHEM, V267, P166.
   CHUANG RY, 1979, BIOCHEMISTRY-US, V18, P2069, DOI 10.1021/bi00577a035.
   COOPER AJL, 1997, GLUTATHIONE BRAIN DI, P1195.
   CUMMINGS J, 1991, EUR J CANCER, V27, P532, DOI 10.1016/0277-5379(91)90209-V.
   DAVIES KJA, 1986, J BIOL CHEM, V261, P3060.
   DAVIES KJA, 1983, FEBS LETT, V153, P227, DOI 10.1016/0014-5793(83)80153-7.
   DeAtley SM, 1999, CANCER LETT, V136, P41, DOI 10.1016/S0304-3835(98)00306-1.
   DeAtley SM, 1998, PHARMACOL TOXICOL, V83, P62, DOI 10.1111/j.1600-0773.1998.tb01445.x.
   Decleves X, 2000, J NEUROSCI RES, V60, P594, DOI 10.1002/(SICI)1097-4547(20000601)60:5<594::AID-JNR4>3.0.CO;2-6.
   DOROSHOW JH, 1983, CANCER RES, V43, P4543.
   Dorr RT, 1996, SEMIN ONCOL, V23, P23.
   Eisenhauer EA, 1998, DRUGS, V55, P5, DOI 10.2165/00003495-199855010-00002.
   Gutierrez PL, 2000, FREE RADICAL BIO MED, V29, P263, DOI 10.1016/S0891-5849(00)00314-2.
   GUTTERIDGE JMC, 1984, BIOCHEM PHARMACOL, V33, P1725, DOI 10.1016/0006-2952(84)90340-X.
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x.
   HANDA K, 1975, GANN, V66, P43.
   HENSLEY K, 1995, J NEUROCHEM, V65, P2146.
   Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6.
   Hirrlinger J, 2001, J NEUROCHEM, V76, P627, DOI 10.1046/j.1471-4159.2001.00101.x.
   Huai-Yun Han, 1998, Biochemical and Biophysical Research Communications, V243, P816, DOI 10.1006/bbrc.1997.8132.
   JEDLITSCHKY G, 1994, CANCER RES, V54, P4833.
   KALYANARAMAN B, 1991, ARCH BIOCHEM BIOPHYS, V286, P164, DOI 10.1016/0003-9861(91)90023-C.
   KAPPUS H, 1987, ARCH TOXICOL, V60, P144, DOI 10.1007/BF00296968.
   Kienzl E, 1999, LIFE SCI, V65, P1973, DOI 10.1016/S0024-3205(99)00458-0.
   Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337.
   Koppal T, 1999, J NEUROCHEM, V72, P310, DOI 10.1046/j.1471-4159.1999.0720310.x.
   Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200.
   Kwok JC, 2003, MOL PHARMACOL, V63, P849, DOI 10.1124/mol.63.4.849.
   Lauderback CM, 2003, FREE RADICAL RES, V37, P355, DOI 10.1080/1071576021000040664.
   Lauderback CM, 2001, J NEUROCHEM, V78, P413, DOI 10.1046/j.1471-4159.2001.00451.x.
   Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675.
   Mark RJ, 1997, J NEUROCHEM, V68, P255.
   Markesbery WR, 1998, NEUROBIOL AGING, V19, P33, DOI 10.1016/S0197-4580(98)00009-8.
   Nies AT, 2004, NEUROSCIENCE, V129, P349, DOI 10.1016/j.neuroscience.2004.07.051.
   Priebe W, 1998, BIOCHEM BIOPH RES CO, V247, P859, DOI 10.1006/bbrc.1998.8887.
   Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900.
   Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079.
   Sayre LM, 1997, J NEUROCHEM, V68, P2092.
   Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r.
   Steiner D, 2004, VISUAL COMPUT, V20, P266, DOI 10.1007/s00371-003-0232-0.
   Subramaniam R, 1997, J NEUROCHEM, V69, P1161.
   Sultana R, 2004, FREE RADICAL RES, V38, P449, DOI 10.1080/1071576042000206478.
   Sultana R, 2004, NEUROCHEM RES, V29, P2215, DOI 10.1007/s11064-004-7028-0.
   vanderVliet A, 1996, METHOD ENZYMOL, V269, P175.
   Vasquez-Vivar J, 1999, FREE RADICAL RES, V31, P607, DOI 10.1080/10715769900301181.
   VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e.
   WEISS RB, 1986, CANCER CHEMOTH PHARM, V18, P185.
   Xie CS, 1998, FREE RADICAL BIO MED, V25, P979, DOI 10.1016/S0891-5849(98)00186-5.
   Yen HC, 1999, ARCH BIOCHEM BIOPHYS, V362, P59, DOI 10.1006/abbi.1998.1011.}},
Number-of-Cited-References = {{57}},
Times-Cited = {{100}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Free Radic. Res.}},
Doc-Delivery-Number = {{983GK}},
Unique-ID = {{ISI:000233219200001}},
DA = {{2018-08-13}},
}

@article{ ISI:000233814800011,
Author = {Verran, J and Whitehead, K},
Title = {{Factors affecting microbial adhesion to stainless steel and other
   materials used in medical devices}},
Journal = {{INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS}},
Year = {{2005}},
Volume = {{28}},
Number = {{11}},
Pages = {{1138-1145}},
Month = {{NOV}},
Abstract = {{The role of biofilm in medical device associated infections is well
   documented. Biofilms are more resistant to antibiotics than planktonic
   cells, these are extremely difficult to treat. Prevention strategies
   include efforts to insert implants under stringent aseptic conditions,
   and also encompass the development of novel materials which interfere
   with the initial attachment of microorganisms to the surface of the
   device.
   Microbial cells also attach onto hygienic surfaces in the hospital
   setting, and thereby pose a crossinfection problem. In this case,
   vigorous cleaning and sanitizing regimes may be employed in addition to
   any surface modifications.
   Many factors affect the initial attachment of organisms to inert
   substrata, and their subsequent retention or removal/detachment,
   including the physical and chemical nature and location of the
   substratum, the type of organic material and microorganisms potentially
   fouling the surface, and the nature of the interface (solid-liquid in
   the body; solid-air on environmental surfaces). Focusing on one factor,
   surface topography, it is apparent that many further variables need to
   be defined in order to fully understand the interactions occurring
   between the cell and surface. It is therefore important when modifying
   one substratum surface property in order to reduce adhesion, to also
   consider other potentially confounding factors.}},
Publisher = {{WICHTIG EDITORE}},
Address = {{72/74 VIA FRIULI, 20135 MILAN, ITALY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Verran, J (Reprint Author), Manchester Metropolitan Univ, Dept Biol Sci, Chester St, Manchester M15 6BH, Lancs, England.
   Manchester Metropolitan Univ, Dept Biol Sci, Manchester M15 6BH, Lancs, England.}},
ISSN = {{0391-3988}},
Keywords = {{biofilm; microbial adhesion; stainless steel; medical devices}},
Keywords-Plus = {{BACTERIAL ADHESION; SURFACE-ROUGHNESS; BIOFILMS; INFECTIONS; CANDIDA;
   COMMUNITIES; TOPOGRAPHY; PATHOGENESIS; MANAGEMENT; RETENTION}},
Research-Areas = {{Engineering; Transplantation}},
Web-of-Science-Categories  = {{Engineering, Biomedical; Transplantation}},
Author-Email = {{j.verran@mmu.ac.uk}},
ORCID-Numbers = {{Whitehead, Kathryn A./0000-0001-6001-6686}},
Cited-References = {{Banning Maggi, 2005, Br J Nurs, V14, P548.
   Boyd RD, 2002, LANGMUIR, V18, P2343, DOI 10.1021/la011142p.
   Boyd RD, 2000, J ADHES SCI TECHNOL, V14, P1195, DOI 10.1163/156856100743176.
   Bruinsma GM, 2001, BIOMATERIALS, V22, P3217, DOI 10.1016/S0142-9612(01)00159-4.
   Busscher H. J., 2000, SGM S 59 COMM STRUCT, P25.
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318.
   Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295.
   Deligianni DD, 2001, BIOMATERIALS, V22, P1241, DOI 10.1016/S0142-9612(00)00274-X.
   Donlan RM, 2002, EMERG INFECT DIS, V8, P881, DOI 10.3201/eid0809.020063.
   Douglas LJ, 2003, TRENDS MICROBIOL, V11, P30, DOI 10.1016/S0966-842X(02)00002-1.
   EDGERTON M, 1992, J PROSTHET DENT, V68, P683, DOI 10.1016/0022-3913(92)90387-P.
   Ehrlich GD, 2004, ASM NEWS, V70, P127.
   Fux CA, 2005, TRENDS MICROBIOL, V13, P34, DOI 10.1016/j.tim.2004.11.010.
   Gilbert P, 2002, ADV MICROB PHYSIOL, V46, P203, DOI 10.1016/S0065-2911(02)46005-5.
   Kojic EM, 2004, CLIN MICROBIOL REV, V17, P255, DOI 10.1128/CMR.17.2.255-267.2004.
   Kolenbrander PE, 2000, ANNU REV MICROBIOL, V54, P413, DOI 10.1146/annurev.micro.54.1.413.
   KONONEN M, 1992, J BIOMED MATER RES, V26, P1325.
   Kumon H, 2001, INT J ANTIMICROB AG, V17, P311, DOI 10.1016/S0924-8579(00)00360-5.
   Lamfon H, 2003, EUR J ORAL SCI, V111, P465, DOI 10.1111/j.0909-8836.2003.00084.x.
   Poortinga A. T., 2002, SURF SCI REP, P1, DOI {[}10.1016/S0167-5729(02)00032-8, DOI 10.1016/S0167-5729(02)00032-8].
   Price CL, 2005, J BIOMED MATER RES B, V74B, P481, DOI 10.1002/jbm.b.30226.
   Rupp CJ, 2005, APPL ENVIRON MICROB, V71, P2175, DOI 10.1128/AEM.71.4.2175-2178.2005.
   Sauer K, 2002, J BACTERIOL, V184, P1140, DOI 10.1128/jb.184.4.1140-1154.2002.
   STICKLER D, 2005, MICROBIOLOGY TODAY, P22.
   Stoodley P, 2002, ANNU REV MICROBIOL, V56, P187, DOI 10.1146/annurev.micro.56.012302.160705.
   Taylor RL, 1998, J MATER SCI-MATER M, V9, P17, DOI 10.1023/A:1008874326324.
   Verran J, 2005, Oral Dis, V11 Suppl 1, P24, DOI 10.1111/j.1601-0825.2005.01083.x.
   Verran J, 2002, FOOD BIOPROD PROCESS, V80, P292, DOI 10.1205/096030802321154808.
   Verran J, 2001, BIOFOULING, V17, P59, DOI 10.1080/08927010109378465.
   Verran J, 2002, BIOFOULING, V18, P167, DOI 10.1080/08927010290006736.
   Verran J, 1999, ROY SOC CH, P25.
   Verran J., 1999, ORAL BIOFILMS PLAQUE, P175.
   VERRAN J, 2000, BIOFILMS BIOFOULING, V1, P145.
   von Eiff C, 2005, DRUGS, V65, P179, DOI 10.2165/00003495-200565020-00003.
   von Eiff C, 2002, LANCET INFECT DIS, V2, P677, DOI 10.1016/S1473-3099(02)00438-3.
   Whitehead KA, 2005, COLLOID SURFACE B, V41, P129, DOI 10.1016/j.colsurfb.2004.10.010.
   Whitehead KA, 2004, INT BIODETER BIODEGR, V54, P143, DOI 10.1016/j.ibiod.2004.03.010.
   WHITEHEAD KA, 2005, BIOFILMS PERSISTENCE, P211.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Int. J. Artif. Organs}},
Doc-Delivery-Number = {{991LF}},
Unique-ID = {{ISI:000233814800011}},
DA = {{2018-08-13}},
}

@article{ ISI:000233146800005,
Author = {Pokorny, R and Olejnikova, P and Balog, M and Zifcak, P and Holker, U
   and Janssen, M and Bend, J and Hofer, M and Holiencin, R and Hudecova, D
   and Varecka, L},
Title = {{Characterization of microorganisms isolated from lignite excavated from
   the Zahorie coal mine (southwestern Slovakia)}},
Journal = {{RESEARCH IN MICROBIOLOGY}},
Year = {{2005}},
Volume = {{156}},
Number = {{9}},
Pages = {{932-943}},
Month = {{NOV}},
Abstract = {{Microorganisms were isolated from lignite freshly excavated in the
   Zahorie coal mine (southwestern Slovakia) under conditions excluding
   contamination with either soil or air-borne microorganisms. The isolates
   represented both Prokarya and Eukarya (fungi). All were able to grow on
   standard media, although some microorganisms were unstable and became
   extinct during storage of coal samples. Bacteria belonged to the genera
   Bacillus, Staphylococcus, and Rhodococcus, according to both
   morphological criteria and ITS sequences. Several bacterial isolates
   were resistant to antibiotics. The presence of anaerobic bacteria was
   also documented, although they have not yet been identified. Fungal
   isolates were typified by using their ITS sequences. They belonged to
   the genera Trichoderma (Hypocrea), Penicillium, Epicoccum, Metarhizium
   (Cordyceps), and Cladosporium. Several fungi produced compounds with
   antibiotic action against standard bacterial strains. The evidence for
   the presence of microorganisms in native lignite was obtained by means
   of fluorescence microscopy, scanning electron microscopy, and electron
   microprobe analysis. Results demonstrated that microorganisms were able
   to survive in the low-rank coal over a long time period. (c) 2005
   Elsevier SAS. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Varecka, L (Reprint Author), Slovak Univ Technol Bratislava, Dept Biochem \& Microbiol, Radlinskeho 9, Bratislava 81237, Slovakia.
   Slovak Univ Technol Bratislava, Dept Biochem \& Microbiol, Bratislava 81237, Slovakia.
   Univ Bonn, Inst Cellular \& Mol Bot, D-53115 Bonn, Germany.
   Bioreact Gmbh, D-53115 Bonn, Germany.
   Slovak Acad Sci, Inst Inorgan Chem, Bratislava, Slovakia.
   Inst Welding, Bratislava, Slovakia.
   Bana Zahorie, Cary, Slovakia.}},
DOI = {{10.1016/j.resmic.2005.04.010}},
ISSN = {{0923-2508}},
Keywords = {{ancient microorganisms; cryptobiosis; low-rank coal; antibiotic
   resistance; molecular typing}},
Keywords-Plus = {{TRICHODERMA-ATROVIRIDE; FUSARIUM-OXYSPORUM; ANTARCTIC ICE; LAKE VOSTOK;
   IDENTIFICATION; SOLUBILIZATION; EXPRESSION; BACTERIA; LACCASE; FUNGI}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{ludovit.varecka@stuba.sk}},
Cited-References = {{Abyzov S S, 1979, Life Sci Space Res, V17, P99.
   Abyzov SS, 2001, ADV SPACE RES, V28, P701, DOI 10.1016/S0273-1177(01)00318-0.
   AKSENOV S I, 1982, Mikrobiologiya, V51, P877.
   Ausubel F. M., 1992, SHORT PROTOCOLS MOL.
   CANO RJ, 1995, SCIENCE, V268, P1060, DOI 10.1126/science.7538699.
   Clegg JS, 2001, COMP BIOCHEM PHYS B, V128, P613, DOI 10.1016/S1096-4959(01)00300-1.
   Gallmetzer M, 2002, FEMS MICROBIOL LETT, V210, P221, DOI 10.1016/S0378-1097(02)00605-5.
   Greenblatt CL, 1999, MICROBIAL ECOL, V38, P58, DOI 10.1007/s002489900153.
   Gurtler V, 1996, MICROBIOL-SGM, V142, P3, DOI 10.1099/13500872-142-1-3.
   Holker U, 2002, J IND MICROBIOL BIOT, V28, P207, DOI 10.1038/sj/jim/7000232.
   Holker U, 1999, APPL MICROBIOL BIOT, V52, P57, DOI 10.1007/s002530051486.
   Karl DM, 1999, SCIENCE, V286, P2144, DOI 10.1126/science.286.5447.2144.
   Kobayashi M, 1996, J BIOL CHEM, V271, P16263, DOI 10.1074/jbc.271.27.16263.
   Kovac M, 1998, GEOL CARPATH, V49, P445.
   Kuhls K, 1996, P NATL ACAD SCI USA, V93, P7755, DOI 10.1073/pnas.93.15.7755.
   Poglazova M N, 2001, Mikrobiologiia, V70, P838.
   Price PB, 2000, P NATL ACAD SCI USA, V97, P1247, DOI 10.1073/pnas.97.3.1247.
   Priscu JC, 1999, SCIENCE, V286, P2141, DOI 10.1126/science.286.5447.2141.
   Scheel T, 1999, APPL MICROBIOL BIOT, V52, P66, DOI 10.1007/s002530051488.
   Scheel T, 2000, APPL MICROBIOL BIOT, V54, P686, DOI 10.1007/s002530000427.
   Siegert M J, 2000, Sci Prog, V83 ( Pt 3), P223.
   Toritsuka N, 1997, BBA-PROTEIN STRUCT M, V1338, P93, DOI 10.1016/S0167-4838(96)00193-8.
   Vreeland RH, 2000, NATURE, V407, P897, DOI 10.1038/35038060.
   Vreeland RH, 2002, EXTREMOPHILES, V6, P445, DOI 10.1007/s00792-002-0278-3.
   Vreeland RH, 2002, J IND MICROBIOL BIOT, V28, P32, DOI 10.1038/sj/jim/7000174.
   White T. J., 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Res. Microbiol.}},
Doc-Delivery-Number = {{982GT}},
Unique-ID = {{ISI:000233146800005}},
DA = {{2018-08-13}},
}

@article{ ISI:000232410400002,
Author = {Sun, YY and Chen, ZB and Braun, M},
Title = {{Preparation and physical and antimicrobial properties of a
   cellulose-supported chloromelamine derivative}},
Journal = {{INDUSTRIAL \& ENGINEERING CHEMISTRY RESEARCH}},
Year = {{2005}},
Volume = {{44}},
Number = {{21}},
Pages = {{7916-7920}},
Month = {{OCT 12}},
Abstract = {{A reactive melamine derivative, 2-amino-4-chloro-6-hydroxy-s-triazine
   (ACHT), was covalently bound onto cotton cellulose through nucleophilic
   substitutions. Four treatment methods, including cold-pad-batch,
   pad-dry-cure, pad-steaming, and exhaustion, were employed in the
   reactions. The pad-dry-cure method provided the highest reaction
   efficiency. The mechanical properties of the treated fabrics were
   characterized, and the reaction mechanism was further discussed. Upon
   chlorine bleaching treatment, the covalently bound ACHT moieties could
   be transformed into chloromelamine derivatives, providing potent,
   durable, and rechargeable antimicrobial functions against 10(6)-10(7)
   CFU/mL of drug-resistant gram-negative and gram-positive bacteria under
   both waterborne and airborne conditions.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sun, YY (Reprint Author), Univ Texas, Dept Human Ecol, Austin, TX 78712 USA.
   Univ Texas, Dept Human Ecol, Austin, TX 78712 USA.}},
DOI = {{10.1021/ie0504452}},
ISSN = {{0888-5885}},
Keywords-Plus = {{HALAMINE POLYMERIC BIOCIDES; STYRENE-DIVINYLBENZENE COPOLYMERS;
   HYDANTOIN-CONTAINING MONOMERS; ACTIVE CHLORINE; WATER; DISINFECTION;
   REAGENTS; BEADS}},
Research-Areas = {{Engineering}},
Web-of-Science-Categories  = {{Engineering, Chemical}},
Author-Email = {{yysun@mail.utexas.edu}},
Cited-References = {{Binder S, 1999, SCIENCE, V284, P1311, DOI 10.1126/science.284.5418.1311.
   Braun M, 2004, J POLYM SCI POL CHEM, V42, P3818, DOI 10.1002/pola.20270.
   Carr C M, 1995, CHEM TEXTILES IND.
   Chen YJ, 2003, IND ENG CHEM RES, V42, P280, DOI 10.1021/ie020266+.
   Chen YJ, 2003, IND ENG CHEM RES, V42, P5715, DOI 10.1021/ie0303303.
   EMERSON DW, 1993, IND ENG CHEM RES, V32, P1228, DOI 10.1021/ie00018a031.
   EMERSON DW, 1991, IND ENG CHEM RES, V30, P2426, DOI 10.1021/ie00059a010.
   EMERSON DW, 1990, IND ENG CHEM RES, V29, P448, DOI 10.1021/ie00099a022.
   Estevao LRM, 2003, IND ENG CHEM RES, V42, P5950, DOI 10.1021/ie0206960.
   Jayaraman A, 2002, IND ENG CHEM RES, V41, P441, DOI 10.1021/ie0102549.
   Larson E, 2001, AM J INFECT CONTROL, V29, P69, DOI 10.1067/mic.2001.114194.
   O'Connor R. T., 1972, INSTRUMENTAL ANAL CO.
   PADGETT WM, 1958, J AM CHEM SOC, V80, P803, DOI 10.1021/ja01537a014.
   Pernak J, 2004, IND ENG CHEM RES, V43, P1966, DOI 10.1021/ie030118z.
   RICHMOND JY, BIOSAFETY MICROBIOLO.
   Sun YY, 2004, IND ENG CHEM RES, V43, P5015, DOI 10.1021/ie030846m.
   Sun YY, 2003, J APPL POLYM SCI, V88, P1032, DOI 10.1002/app.11772.
   Sun YY, 2001, J APPL POLYM SCI, V81, P617, DOI 10.1002/app.1477.
   Tiller JC, 2001, P NATL ACAD SCI USA, V98, P5981, DOI 10.1073/pnas.111143098.
   WORLEY SD, 1988, CRIT REV ENV CONTR, V18, P133, DOI 10.1080/10643388809388345.
   Worley SD, 1996, TRENDS POLYM SCI, V4, P364.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Ind. Eng. Chem. Res.}},
Doc-Delivery-Number = {{971UN}},
Unique-ID = {{ISI:000232410400002}},
DA = {{2018-08-13}},
}

@article{ ISI:000232425300004,
Author = {Barnett, ED and Chen, LH},
Title = {{Prevention of travel-related infectious diseases in families of
   internationally adopted children}},
Journal = {{PEDIATRIC CLINICS OF NORTH AMERICA}},
Year = {{2005}},
Volume = {{52}},
Number = {{5}},
Pages = {{1271+}},
Month = {{OCT}},
Abstract = {{Prevention of travel-related infectious diseases for adoptive families
   starts before and extends beyond the travel period. Many families
   adopting internationally travel to their child's birth country at least
   once before bringing their new family member home. Most commonly,
   families are traveling to the republics of the former Soviet Union,
   China, Guatemala, or other developing countries in Asia, Central or
   South America, or Africa. Family members who travel and family and close
   contacts of the child who remain at home all need information about
   protecting themselves during travel and preventing acquisition of
   diseases that could be transmitted by the internationally adopted child
   after arrival in the United States.
   Travel for adoption presents risks that are different from those
   encountered by the tourist or business traveler or those travelers who
   travel to visit friends and relatives (VFR travelers). Although the
   application to adopt internationally usually requires at least I or 2
   years of preparation, families may be notified about travel within 2 to
   3 weeks of departure. Adoptive families may not have a choice in their
   travel destination or itinerary, the time of travel, or accommodations
   during the trip. They may not speak the local language or have regular
   access to interpreters and may be apprehensive about accommodations,
   visa requirements, and overseas procedures. They may be inexperienced
   first-time parents or may be traveling with other children who require
   attention to their own needs.
   Travel for adoption may lead to prolonged and unexpected stays in the
   country, possibly with accommodation in nontourist facilities, such as
   local apartments, hostels, or their child's orphanage. Because of a
   desire to please the many individuals with power over the adoption
   process (eg, facilitators, interpreters, court and government officials,
   agency and orphanage personnel), families may accept risks they would
   ordinarily avoid, such as eating local foods or drinking potentially
   unsafe water, drinking more or different types of alcohol, seeking
   medical care in rural health facilities, or using local means of
   transport without seat belts or car seats. Families may be exposed to
   extreme air pollution, farm animals, second-hand cigarette smoke, or
   infectious agents, such as tuberculosis, that they might otherwise avoid
   were it not for the adoption process.
   As the field of travel medicine evolves, distinct groups of travelers
   with specific risks have been identified, such as VFR travelers. It is
   possible that the families and close contacts of internationally adopted
   children comprise such a group. Better description of these risks
   through systematic study may lead to improved interventions in this
   population in the future. This article addresses the current body of
   knowledge and recommendations for preventing travel-related illness in
   this group (see Appendix).}},
Publisher = {{W B SAUNDERS CO}},
Address = {{INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Barnett, ED (Reprint Author), Boston City Hosp, Maxwell Finland Lab Infect Dis, Boston Med Ctr, Room 503,774 Albany St, Boston, MA 02118 USA.
   Boston City Hosp, Maxwell Finland Lab Infect Dis, Boston Med Ctr, Boston, MA 02118 USA.
   Boston Univ, Sch Med, Dept Pediat, Boston, MA 02118 USA.
   Mt Auburn Hosp, Travel Med Ctr, Div Infect Dis, Cambridge, MA 02238 USA.
   Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.}},
DOI = {{10.1016/j.pcl.2005.06.002}},
ISSN = {{0031-3955}},
Keywords-Plus = {{YOUNG-CHILDREN; HEPATITIS-A; MALARIA CHEMOPROPHYLAXIS; DRUG-RESISTANCE;
   TRANSMISSION; HEALTH; DIARRHEA; INFANTS; VACCINE; CIPROFLOXACIN}},
Research-Areas = {{Pediatrics}},
Web-of-Science-Categories  = {{Pediatrics}},
Author-Email = {{ebarnett@bu.edu}},
ORCID-Numbers = {{Barnett, Elizabeth/0000-0003-4822-5949}},
Cited-References = {{Adachi JA, 2003, CLIN INFECT DIS, V37, P1165, DOI 10.1086/378746.
   ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7.
   Albers LH, 1997, JAMA-J AM MED ASSOC, V278, P922, DOI 10.1001/jama.278.11.922.
   BEZRUCHKA SA, 2003, TRAVEL TROPICAL MED, P112.
   CDCMMWR, 1993, MMWR-MORBID MORTAL W, V42, P1.
   {*}CDCP, 1982, MMWR-MORBID MORTAL W, V31, P285.
   {*}CDCP, 2005, HLTH INF INT TRAV 20.
   {*}CDCP, 2002, MMWR-MORBID MORTAL W, V51, P1115.
   {*}CDCP, 2004, MMWR-MORBID MORTAL W, V53, P309.
   {*}CDCP, 2004, MMWR-MORBID MORTAL W, V53, pQ1.
   {*}CDCP, 2002, MMWR-MORBID MORTAL W, V51, P394.
   Centers for Disease Control and Prevention, 2005, MMWR-MORBID MORTAL W, V53, pQ1.
   Centers for Disease Control and Prevention, 2005, REC CHILDH AD IMM SC.
   Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P1.
   Centers for Disease Control and Prevention and Healthcare Infection Control Advisory Committee (HICPAC), 2003, MMWR-MORBID MORTAL W, V52, P1.
   Chen LH, 2003, ANN INTERN MED, V139, P371, DOI 10.7326/0003-4819-139-5\_Part\_1-200309020-00013.
   CONNOR BA, 2005, HLTH INFORM INT TRAV, P278.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   DuPont HL, 2001, CLIN INFECT DIS, V33, P1807, DOI 10.1086/323814.
   Ericsson CD, 1998, INFECT DIS CLIN N AM, V12, P285, DOI 10.1016/S0891-5520(05)70006-4.
   FISHER PR, 1998, INFECT DIS CLIN N AM, V12, P355.
   FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26.
   HENDLEY JO, 1975, J INFECT DIS, V132, P55.
   HERSHOW RC, 1987, PEDIATR INFECT DIS J, V6, P431, DOI 10.1097/00006454-198705000-00002.
   HOSTETTER MK, 1991, NEW ENGL J MED, V325, P479, DOI 10.1056/NEJM199108153250706.
   HOSTETTER MK, 1989, PEDIATRICS, V84, P937.
   JOHNSON DE, 1992, JAMA-J AM MED ASSOC, V268, P3446, DOI 10.1001/jama.268.24.3446.
   Kain KC, 2001, CLIN INFECT DIS, V33, P226, DOI 10.1086/321817.
   MACKELL S, 2003, TRAVEL TROPICAL MED, P167.
   Mackell SM, 2003, CLIN INFECT DIS, V37, P1508, DOI 10.1086/379515.
   McMullen Russell, 2003, TRAVEL TROPICAL MED.
   Miller LC, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e76.
   MILLER LC, 2005, HDB INT ADOPTION MED, P135.
   PARISE M, 2005, HLTH INFORM INT TRAV, P189.
   PASS RF, 1987, NEW ENGL J MED, V316, P1366, DOI 10.1056/NEJM198705283162203.
   Pickering LK, 2003, RED BOOK 2003 REPORT, P472.
   QUICK R, 2005, HLTH INFORM INT TRAV, P29.
   Ryan ET, 2000, NEW ENGL J MED, V342, P1716, DOI 10.1056/NEJM200006083422306.
   Saiman L, 2001, PEDIATRICS, V108, P608, DOI 10.1542/peds.108.3.608.
   Shanks GD, 1999, CLIN INFECT DIS, V29, P942, DOI 10.1086/520469.
   Shanks GD, 2001, CLIN INFECT DIS, V33, P381, DOI 10.1086/321866.
   SOKAL EM, 1995, ARCH DIS CHILD, V72, P191, DOI 10.1136/adc.72.2.191-a.
   Spira AM, 2003, LANCET, V361, P1368, DOI 10.1016/S0140-6736(03)13075-9.
   Stauffer WM, 2003, J TRAVEL MED, V10, P225.
   Stauffer WM, 2002, J TRAVEL MED, V9, P82.
   Stauffer WM, 2002, J TRAVEL MED, V9, P141.
   Stauffer WM, 2001, J TRAVEL MED, V8, P254.
   Thoelen S, 1999, VACCINE, V17, P1657, DOI 10.1016/S0264-410X(98)00421-6.
   WEINBERG N, 2005, HLTH INFORM INT TRAV, P434.
   WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702.
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823.
   Wilson ME, 2001, CLIN INFECT DIS, V33, P1083, DOI 10.1086/323200.
   2001, MED LETT DRUGS THER, V43, P67.}},
Number-of-Cited-References = {{53}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Pediatr. Clin. N. Am.}},
Doc-Delivery-Number = {{972AD}},
Unique-ID = {{ISI:000232425300004}},
DA = {{2018-08-13}},
}

@article{ ISI:000233260600006,
Author = {Edmiston, CE and Seabrook, GR and Cambria, RA and Brown, KR and Lewis,
   BD and Sommers, JR and Krepel, CJ and Wilson, PJ and Sinski, S and
   Towne, JB},
Title = {{Molecular epidemiology of microbial contamination in the operating room
   environment: Is there a risk for infection?}},
Journal = {{SURGERY}},
Year = {{2005}},
Volume = {{138}},
Number = {{4}},
Pages = {{573-579}},
Month = {{OCT}},
Note = {{62nd Annual Meeting of the Central-Surgical-Association, Tucson, AZ, MAR
   10-12, 2005}},
Organization = {{Cent Surg Assoc}},
Abstract = {{Background. Modern operating rooms are considered to be aseptic
   environments. The use of surgical mask, frequent air exchanges, and
   architectural barriers are used to reduce airborne microbial
   populations. Breaks in surgical technique, host contamination, or
   hematogenous seeding are suggested as causal factors in these
   infections. This study implicates contamination of the operating room
   air as an additional etiology of infection.
   Methods. To investigate the potential sources of perioperative
   contamination, an innovative in situ air-sampling analysis was conducted
   during an 18-month period involving 70 separate vascular surgical
   procedures. Air-sample cultures were obtained from multiple points
   within the operating room, ranging from 0.5 to 4 m from the surgical
   wound. Selected microbial clonality was determined by pulse-field gel
   electrophoresis. In a separate series of studies microbial
   nasopharyngeal shedding was evaluated under controlled environmental
   conditions in the presence and absence of a surgical mask.
   Results. Coagulase-negative staphylococci were recovered from 86\% of
   air samples, 51\% from within 0.5 m of the surgical wound, whereas
   Staphylococcus aureus was recovered from 64\% of air samples, 39\%
   within 0.5 in from the wound. Anterior nares swabs were obtained from 11
   members of the vascular team, clonality was observed between 8 strains
   of S epidermidis, and 2 strains of S aureus were recovered from selected
   team members and air-samples collected throughout the operating room
   environment. Miscellaneous Gram-negative isolates were recovered less
   frequently (<33\%); however, 7 isolates expressed multiple patterns of
   antimicrobial resistance. The traditional surgical mask demonstrated
   limited effectiveness at curtailing microbial shedding, especially
   during symptomatic periods of rhinorrhea.
   Conclusions. Gram-positive staphylococcal isolates were frequently
   isolated from air samples obtained throughout the operating room,
   including areas adjacent to the operative field. Nasopharyngeal shedding
   from Person participating in the operation was identified as the source
   of many of these airborne contaminants. Failure of the traditional
   surgical mask to prevent microbial shedding is likely associated with an
   increased risk of perioperative contamination of biomedical implants,
   especially in procedures lasting longer than 90 minutes.}},
Publisher = {{MOSBY, INC}},
Address = {{11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Edmiston, CE (Reprint Author), Med Coll Wisconsin, Dept Surg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Infect Control Dept, Milwaukee, WI 53226 USA.
   Kimberly Clark Inc, Roswell, GA USA.}},
DOI = {{10.1016/j.surg.2005.06.045}},
ISSN = {{0039-6060}},
Keywords-Plus = {{COAGULASE-NEGATIVE STAPHYLOCOCCI; SURGICAL-SITE INFECTIONS; WOUND
   CONTAMINATION; RHINOVIRUS INFECTION; RELATIVE IMPORTANCE;
   GENERAL-SURGERY; AUREUS; AIRBORNE; ROUTES; AIR}},
Research-Areas = {{Surgery}},
Web-of-Science-Categories  = {{Surgery}},
Author-Email = {{edmiston@mcw.edu}},
Cited-References = {{Bassetti S, 2005, INFECT CONT HOSP EP, V26, P196, DOI 10.1086/502526.
   Bischoff WE, 2004, INFECT CONT HOSP EP, V25, P504, DOI 10.1086/502430.
   Bitkover CY, 2000, ANN THORAC SURG, V69, P1110, DOI 10.1016/S0003-4975(99)01432-0.
   CHARNLEY J, 1969, BRIT J SURG, V56, P641, DOI 10.1002/bjs.1800560902.
   Clarke MT, 2004, ACTA ORTHOP SCAND, V75, P544, DOI 10.1080/00016470410001394.
   Dharan S, 2002, J HOSP INFECT, V51, P79, DOI 10.1053/jhin.2002.1217.
   Edmiston C E Jr, 1999, AORN J, V69, P1169, DOI 10.1016/S0001-2092(06)61884-X.
   Edmiston CE, 1993, UPDATE SURG SEPSIS, P444.
   Faibis F, 2005, INFECT CONT HOSP EP, V26, P213, DOI 10.1086/502529.
   FITZGERALD RH, 1979, ARCH SURG-CHICAGO, V114, P772.
   Friedrich MG, 2002, EUR HEART J, V23, P183.
   Geiger A M, 2001, Contrib Microbiol, V8, P20.
   Gosden PE, 1998, J HOSP INFECT, V39, P173, DOI 10.1016/S0195-6701(98)90255-9.
   LEVY MF, 1990, J CLIN MICROBIOL, V28, P664.
   Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620.
   Martone WJ, 2001, CLIN INFECT DIS, V33, P67.
   Martorell C, 2004, AM J INFECT CONTROL, V32, P63, DOI 10.1016/j.ajic.2003.09.005.
   Murray P. R., 1999, MANUAL CLIN MICROBIO.
   Seabrook GR, 2001, CRITICAL CARE INFECT, P873.
   Sherertz RJ, 1996, ANN INTERN MED, V124, P539, DOI 10.7326/0003-4819-124-6-199603150-00001.
   SMITH CL, 1987, METHOD ENZYMOL, V155, P449.
   Tammelin A, 2001, INFECT CONT HOSP EP, V22, P338, DOI 10.1086/501910.
   Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426.
   WHYTE W, 1992, J HOSP INFECT, V22, P41, DOI 10.1016/0195-6701(92)90129-A.
   WHYTE W, 1991, J HOSP INFECT, V18, P93, DOI 10.1016/0195-6701(91)90154-Z.
   WHYTE W, 1982, J HOSP INFECT, V3, P122.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{47}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Surgery}},
Doc-Delivery-Number = {{983VP}},
Unique-ID = {{ISI:000233260600006}},
DA = {{2018-08-13}},
}

@article{ ISI:000231783200399,
Author = {Weyer, K and Parsons, S and Jensen, P and Nardell, E and Roberts, L and
   First, M and Wells, C},
Title = {{Airborne Infection Research (AIR) Facility: Transmission dynamics of
   multidrug-resistant tuberculosis and evidence-based policies for
   environmental control}},
Journal = {{EPIDEMIOLOGY}},
Year = {{2005}},
Volume = {{16}},
Number = {{5}},
Pages = {{S156}},
Month = {{SEP}},
Note = {{17th Annual Conference of the
   International-Society-for-Environmental-Epidemiology, Johannesburg,
   SOUTH AFRICA, SEP 13-16, 2005}},
Organization = {{Int Soc Environm Epidemiol}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{MRC, Pretoria, South Africa.
   CSIR, Pretoria, South Africa.
   Ctr Dis Control \& Prevent, Atlanta, GA USA.
   Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.}},
DOI = {{10.1097/00001648-200509000-00400}},
ISSN = {{1044-3983}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Epidemiology}},
Doc-Delivery-Number = {{963DJ}},
Unique-ID = {{ISI:000231783200399}},
DA = {{2018-08-13}},
}

@article{ ISI:000234476200022,
Author = {Powers, WJ and Angel, CR and Applegate, TJ},
Title = {{Air emissions in poultry production: Current challenges and future
   directions}},
Journal = {{JOURNAL OF APPLIED POULTRY RESEARCH}},
Year = {{2005}},
Volume = {{14}},
Number = {{3}},
Pages = {{613-621}},
Month = {{FAL}},
Abstract = {{In the last few years, regulatory focus has been on nutrient management
   from animal feeding operations with recent emphasis on air emissions.
   The main challenge is establishing current emission levels and
   determining best methodologies for measuring these accurately.
   Methodologies to measure air emissions under field and research
   conditions are currently available and are being further developed, but
   extensive challenges exist as to accuracy and precision of the different
   methods. Current best estimates are based on a mass balance modeling
   approach {[}1], but due to lack of current biologically generated data
   to use in the models, nutrient excretion and emission levels appear to
   be overestimated by these models. Extensive work is being conducted
   using dietary strategies to reduce nitrogenous excretions from poultry,
   but the impact of these on air emissions is not always defined. Litter
   management strategies that reduce volatilization of nitrogenous and
   other compounds have shown promise and are being further developed.
   Flock, house, and whole farm management strategies are also being
   successfully implemented and further developed. The magnitude of the
   potential impact on air emissions of each of these strategies is still
   in question. There is no question, however, as to the need for the use
   of whole farm systems that implement different strategies at all
   management levels if large decreases in air emissions from animal
   feeding operations are to be achieved.}},
Publisher = {{POULTRY SCIENCE ASSOC INC}},
Address = {{1111 NORTH DUNLAP AVE, SAVOY, IL 61874-9604 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Angel, CR (Reprint Author), Univ Maryland, Dept Anim \& Avian Sci, Anim Sci Ctr 4131, College Pk, MD 20742 USA.
   Univ Maryland, Dept Anim \& Avian Sci, Anim Sci Ctr 4131, College Pk, MD 20742 USA.
   Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.
   Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA.}},
DOI = {{10.1093/japr/14.3.613}},
ISSN = {{1056-6171}},
Keywords = {{air emissions; ammonia; poultry; mass balance; particulate}},
Keywords-Plus = {{BROILER PRODUCTION FACILITIES; ANTIMICROBIAL RESISTANCE;
   DIETARY-PROTEIN; AMMONIA; LITTER; CATTLE; ODORS; DUST}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Agriculture, Dairy \& Animal Science}},
Author-Email = {{rangel@umd.edu}},
ORCID-Numbers = {{Applegate, Todd/0000-0002-2406-5058}},
Cited-References = {{Arvanitidou M, 1998, INT J FOOD MICROBIOL, V40, P197, DOI 10.1016/S0168-1605(98)00020-8.
   BURNS RT, 2004, P S GAS OD EM AN PRO, P88.
   Carey JB, 2004, J APPL POULTRY RES, V13, P509, DOI 10.1093/japr/13.3.509.
   CASEY KD, 2003, P S GAS OD EM AN PRO, P213.
   DAOUST JY, 1992, J FOOD PROTECT, V55, P428, DOI 10.4315/0362-028X-55.6.428.
   DEFOER N, 2003, P S GAS OD EM AN PRO, P152.
   Elwinger K, 1996, J AGR ENG RES, V64, P197, DOI 10.1006/jaer.1996.0061.
   Ferguson NS, 1998, POULTRY SCI, V77, P1085, DOI 10.1093/ps/77.8.1085.
   Gallmann E., 2003, P INT S GAS OD EM AN, P122.
   Guarino M., 2003, P INT S GAS OD EM AN, P140.
   Harper LA, 2000, J ENVIRON QUAL, V29, P1356, DOI 10.2134/jeq2000.00472425002900040045x.
   HEBER AJ, 2003, P S GAS OD EM AN PRO, P167.
   JACOB JP, 1994, P 29 PAC NW AN NUTR, P137.
   Jacobson L.D., 2003, P INT S GAS OD EM AN, P194.
   JOHNSON KA, 1995, J ANIM SCI, V73, P2483.
   LIANG Y, 2003, P S GAS OD EM AN PRO, P203.
   Lim TT, 2001, T ASAE, V44, P1275.
   LOUHELAINEN K, 2003, P S GAS OD EM AN PRO, P180.
   Manie T, 1999, J FOOD PROTECT, V62, P615, DOI 10.4315/0362-028X-62.6.615.
   Mukhtar S, 2004, J APPL POULTRY RES, V13, P514, DOI 10.1093/japr/13.3.514.
   Muller H. - J., 2003, P INT S GAS OD EM AN, P172.
   NEY RA, 1996, IOWAR GREENHOUSE GAS.
   {*}NRC, 2003, AIR EM AN FEED OP CU.
   Powers WJ, 1999, J ANIM SCI, V77, P1412.
   POWERS WJ, 2003, P S GAS OD EM AN PRO, P346.
   STOUT V., 2003, P INT S GAS OD EM AN, P96.
   {*}US EPA, 2004, NAT AMB AIR QUAL STA.
   Zahn JA, 2001, J ANIM SCI S1, V79, P783.
   2004, FED REG, V69, P23857.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Appl. Poult. Res.}},
Doc-Delivery-Number = {{000QD}},
Unique-ID = {{ISI:000234476200022}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000230837900023,
Author = {Huss, WJ and Gray, DR and Greenberg, NM and Mohler, JL and Smith, GJ},
Title = {{Breast cancer resistance protein-mediated efflux of androgen in putative
   benign and malignant prostate stem cells}},
Journal = {{CANCER RESEARCH}},
Year = {{2005}},
Volume = {{65}},
Number = {{15}},
Pages = {{6640-6650}},
Month = {{AUG 1}},
Abstract = {{Malignantly transformed stem cells represent a potential common nidus
   for the primary cancer and the recurrent cancer that arises after
   treatment failure. Putative prostate stem cells and prostate tumor stem
   cells in benign and malignant human prostate tissue, in primary human
   prostate xenografts, and in the transgenic adenocarcinoma of the mouse
   prostate (TRAMP) mouse model of prostate cancer, are defined by
   expression of breast cancer resistance protein (BCRP), a marker of
   pluripotent hematopoietic, muscle, and neural stem cells, and by an
   absence of androgen receptor (AR) protein. Inhibition of BCRP-mediated
   efflux of dihydrotestosterone by novobiocin or furnitremorgin C in a rat
   prostate progenitor cell line that expresses BCRP and AR mRNAs, but
   minimal AR protein, results in stabilization and nuclear translocation
   of AR protein, providing a mechanism for lack of AIR protein in
   BCRP-expressing stem cells. In both benign and malignant human prostate
   tissue, the rare epithelial cells that express BCRP and lack AR protein
   are localized in the basal cell compartment, survive androgen
   deprivation, and maintain proliferative potential in the hypoxic,
   androgen-deprived prostate. Putative prostate tumor stem cells that
   express BCRP but not AR protein in TRAMP are the source of a
   BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit
   amplifying compartment that progresses to the poorly differentiated
   carcinomas that arise rapidly after castration. Therefore, BCRP
   expression isolates prostate stem/tumor stem cells from the prostate
   tissue microenvironment through constitutive efflux of androgen,
   protecting the putative tumor stem cells from androgen deprivation,
   hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent
   prostate cancer.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Smith, GJ (Reprint Author), Univ N Carolina, Dept Pathol \& Lab Med, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Dept Pathol \& Lab Med, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Div Urol, Dept Surg, Chapel Hill, NC 27599 USA.
   Baylor Coll Med, Dept Mol \& Cellular Biol, Houston, TX 77030 USA.
   Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA.
   SUNY Buffalo, Dept Urol, Buffalo, NY 14260 USA.
   Roswell Pk Canc Inst, Dept Urol Oncol, Buffalo, NY 14263 USA.}},
DOI = {{10.1158/0008-5472.CAN-04-2548}},
ISSN = {{0008-5472}},
Keywords-Plus = {{VENTRAL PROSTATE; DIFFERENTIAL EXPRESSION; TRANSGENIC ADENOCARCINOMA;
   DRUG-RESISTANCE; TRAMP MODEL; BLOOD-FLOW; CASTRATION; RAT; PROGRESSION;
   GROWTH}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{gary.smith@pathology.unc.edu}},
Funding-Acknowledgement = {{NCI NIH HHS {[}CA64865, CA64851, CA84296, P01 CA077739, CA77739]; NIEHS
   NIH HHS {[}ES07017]}},
Cited-References = {{Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007.
   Allen JD, 2003, CANCER RES, V63, P1339.
   Bonkhoff H, 1996, PROSTATE, V28, P98.
   Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011.
   Buttyan R, 1999, TRENDS ENDOCRIN MET, V10, P47, DOI 10.1016/S1043-2760(98)00104-0.
   Chen ZS, 2003, CANCER RES, V63, P4048.
   Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417.
   Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938.
   Feldser D, 1999, CANCER RES, V59, P3915.
   Guo YL, 2003, STEM CELLS, V21, P15, DOI 10.1634/stemcells.21-1-15.
   Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032.
   Huss WJ, 2004, PROSTATE, V60, P77, DOI 10.1002/pros.20041.
   Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163.
   Huss WJ, 2001, CANCER RES, V61, P2736.
   Imai Y, 2002, MOL CANCER THER, V1, P611.
   Imai Y, 2003, MOL PHARMACOL, V64, P610, DOI 10.1124/mol.64.3.610.
   ISAACS JT, 1989, PROSTATE S, V2, P33.
   Johnson MA, 2005, PROSTATE, V62, P322, DOI 10.1002/pros.20148.
   Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599.
   Kaplan PJ, 1999, CANCER RES, V59, P2203.
   Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215.
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200.
   Kurita T, 2001, CELL DEATH DIFFER, V8, P192, DOI 10.1038/sj.cdd.4400797.
   Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384.
   Lekas E, 1997, UROL RES, V25, P309, DOI 10.1007/BF01294656.
   Lockhart AC, 2003, MOL CANCER THER, V2, P685.
   Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341.
   Mirosevich J, 2005, PROSTATE, V62, P339, DOI 10.1002/pros.20131.
   MIROSEVICH J, 2005, IN PRESS PROSTATE.
   Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03.
   MONAGHAN AP, 1993, DEVELOPMENT, V119, P567.
   O'Neill R R, 1989, Appl Theor Electrophor, V1, P163.
   PIERCE GB, 1974, AM J PATHOL, V77, P103.
   Presnell SC, 1999, PROSTATE CANCER P D, V2, P257, DOI 10.1038/sj.pcan.4500363.
   Presnell SC, 2001, AM J PATHOL, V159, P855, DOI 10.1016/S0002-9440(10)61761-0.
   RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23.
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167.
   Schalken JA, 2003, UROLOGY, V62, P11, DOI 10.1016/S0090-4295(03)00758-1.
   Scheffer GL, 2002, J CLIN PATHOL, V55, P332, DOI 10.1136/jcp.55.5.332.
   Shabisgh A, 1999, ENDOCRINOLOGY, V140, P1920, DOI 10.1210/en.140.4.1920.
   Shabsigh A, 2001, J CELL BIOCHEM, V81, P437, DOI 10.1002/1097-4644(20010601)81:3<437::AID-JCB1057>3.0.CO;2-6.
   Shabsigh A, 1998, PROSTATE, V36, P201, DOI 10.1002/(SICI)1097-0045(19980801)36:3<201::AID-PROS9>3.0.CO;2-J.
   Shiozawa K, 2004, INT J CANCER, V108, P146, DOI 10.1002/ijc.11528.
   Slack JMW, 2000, SCIENCE, V287, P1431, DOI 10.1126/science.287.5457.1431.
   Summer R, 2003, AM J PHYSIOL-LUNG C, V285, pL97, DOI 10.1152/ajplung.00009.2003.
   Uzgare AR, 2003, PROSTATE, V55, P128, DOI 10.1002/pros.10212.
   van Weerden WM, 2000, PROSTATE, V43, P263.
   Wikstrom P, 2005, PROSTATE, V62, P148, DOI 10.1002/pros.20123.
   Woodham C, 2003, ENDOCRINOLOGY, V144, P4841, DOI 10.1210/en.2003-0035.
   Zamber CP, 2003, PHARMACOGENETICS, V13, P19, DOI 10.1097/00008571-200301000-00004.
   Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/192276999.
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028.}},
Number-of-Cited-References = {{52}},
Times-Cited = {{89}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Cancer Res.}},
Doc-Delivery-Number = {{950DN}},
Unique-ID = {{ISI:000230837900023}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000230683200005,
Author = {Lewis, K and Klibanov, AM},
Title = {{Surpassing nature: rational design of sterile-surface materials}},
Journal = {{TRENDS IN BIOTECHNOLOGY}},
Year = {{2005}},
Volume = {{23}},
Number = {{7}},
Pages = {{343-348}},
Month = {{JUL}},
Abstract = {{The rise of multidrug-resistant pathogens and recalcitrance of biofilm
   infections present a formidable challenge to combating infectious
   diseases. There are numerous disinfectants and antiseptics for treating
   materials in hospitals and community settings, and devices such as
   catheters impregnated with anti-infectives have been introduced into
   practice. However, there are many limitations of materials impregnated
   with a leaching antibacterial agent. Recently, non-leaching, permanent,
   sterile-surface materials have been developed in which one end of a
   long-chained hydrophobic polycation containing antimicrobial monomers is
   attached covalently to the surface of a material, for example, cotton or
   plastic. The polymeric chain allows the antimicrobial moieties to
   permeate into, and kill, the cells of the pathogen. These
   sterile-surface materials kill both air- and waterborne pathogens and
   are not susceptible to existing resistance mechanisms.}},
Publisher = {{ELSEVIER SCIENCE LONDON}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{Lewis, K (Reprint Author), Northeastern Univ, Dept Biol, 360 Huntington Ave, Boston, MA 02115 USA.
   Northeastern Univ, Dept Biol, Boston, MA 02115 USA.
   MIT, Dept Chem, Cambridge, MA 02139 USA.
   MIT, Div Biol Engn, Cambridge, MA 02139 USA.}},
DOI = {{10.1016/j.tibtech.2005.05.004}},
ISSN = {{0167-7799}},
Keywords-Plus = {{PSEUDOMONAS-AERUGINOSA; BACTERIAL BIOFILMS; DRUG DISCOVERY; MULTIDRUG
   PUMP; RESISTANCE; BERBERINE; MECHANISM; CELLS}},
Research-Areas = {{Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology}},
Author-Email = {{k.lewis@neu.edu}},
Funding-Acknowledgement = {{NIGMS NIH HHS {[}GM59903, GM061162]}},
Cited-References = {{Cen L, 2003, LANGMUIR, V19, P10295, DOI 10.1021/la035104c.
   Chopra Ian, 2003, Expert Rev Anti Infect Ther, V1, P45, DOI 10.1586/14787210.1.1.45.
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318.
   Danese PN, 2002, CHEM BIOL, V9, P873, DOI 10.1016/S1074-5521(02)00192-8.
   Denyer S.P., 1991, MECH ACTION CHEM BIO.
   Hsieh PC, 1998, P NATL ACAD SCI USA, V95, P6602, DOI 10.1073/pnas.95.12.6602.
   ISQUITH AJ, 1972, APPL MICROBIOL, V24, P859.
   JENNINGS BR, 1983, BIOPHYS STRUCT MECH, V10, P71, DOI 10.1007/BF00535543.
   Jesaitis AJ, 2003, J IMMUNOL, V171, P4329, DOI 10.4049/jimmunol.171.8.4329.
   Kaeberlein T, 2002, SCIENCE, V296, P1127, DOI 10.1126/science.1070633.
   Keren I, 2004, J BACTERIOL, V186, P8172, DOI 10.1128/JB.18624.8172-8180.2004.
   Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287.
   Lee SB, 2004, BIOMACROMOLECULES, V5, P877, DOI 10.1021/bm034352k.
   Leid JG, 2002, INFECT IMMUN, V70, P6339, DOI 10.1128/IAI.70.11.6339-6345.2002.
   Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145.
   Lewis K, 2001, ANTIMICROB AGENTS CH, V45, P999, DOI 10.1128/AAC.45.4.999-1007.2001.
   LEWIS K, 2002, BACTERIAL RESISTANCE, P61.
   Lewis K, 2002, BACTERIAL RESISTANCE.
   Li XZ, 2004, DRUGS, V64, P159, DOI 10.2165/00003495-200464020-00004.
   Lin J, 2003, BIOTECHNOL BIOENG, V83, P168, DOI 10.1002/bit.10651.
   Lin J, 2003, BIOTECHNOL LETT, V25, P1661, DOI 10.1023/A:1025613814588.
   Lin J, 2002, BIOTECHNOL PROGR, V18, P1082, DOI 10.1021/bp025597w.
   Lin J, 2002, BIOTECHNOL LETT, V24, P801, DOI 10.1023/A:1015584423358.
   MILOVIC NM, IN PRESS BIOTECHNOL.
   MORGAN HC, 2000, Patent No. 6146688.
   Osburne MS, 2000, ASM NEWS, V66, P411.
   Parsek MR, 2003, ANNU REV MICROBIOL, V57, P677, DOI 10.1146/annurev.micro.57.030502.090720.
   Severina II, 2001, IUBMB LIFE, V52, P321, DOI 10.1080/152165401317291183.
   Sidhu MS, 2002, ANTIMICROB AGENTS CH, V46, P2797, DOI 10.1128/AAC.46.9.2797-2803.2002.
   Smith SM, 1996, J MED, V27, P293.
   Spoering AL, 2001, J BACTERIOL, V183, P6746, DOI 10.1128/JB.183.23.6746-6751.2001.
   Stermitz FR, 2000, P NATL ACAD SCI USA, V97, P1433, DOI 10.1073/pnas.030540597.
   Tiller JC, 2002, BIOTECHNOL BIOENG, V79, P465, DOI 10.1002/bit.10299.
   Tiller JC, 2001, P NATL ACAD SCI USA, V98, P5981, DOI 10.1073/pnas.111143098.
   Vuong C, 2004, CELL MICROBIOL, V6, P269, DOI 10.1111/j.1462-5822.2004.00367.x.
   Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727.
   WASCHINSKI C, 2004, POLYM PREP AM CHEM S, V45, P471.
   Weinstein RA, 1998, EMERG INFECT DIS, V4, P416, DOI 10.3201/eid0403.980320.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{187}},
Usage-Count-Last-180-days = {{2}},
Usage-Count-Since-2013 = {{54}},
Journal-ISO = {{Trends Biotechnol.}},
Doc-Delivery-Number = {{947YM}},
Unique-ID = {{ISI:000230683200005}},
DA = {{2018-08-13}},
}

@article{ ISI:000231563600001,
Author = {van der Deen, M and de Vries, EGE and Timens, W and Scheper, RJ and
   Timmer-Bosscha, H and Postma, DS},
Title = {{ATP-binding cassette (ABC) transporters in normal and pathological lung}},
Journal = {{RESPIRATORY RESEARCH}},
Year = {{2005}},
Volume = {{6}},
Month = {{JUN 20}},
Abstract = {{ATP-binding cassette ( ABC) transporters are a family of transmembrane
   proteins that can transport a wide variety of substrates across
   biological membranes in an energy-dependent manner. Many ABC
   transporters such as P-glycoprotein ( P-gp), multidrug
   resistance-associated protein 1 ( MRP1) and breast cancer resistance
   protein ( BCRP) are highly expressed in bronchial epithelium. This
   review aims to give new insights in the possible functions of ABC
   molecules in the lung in view of their expression in different cell
   types. Furthermore, their role in protection against noxious compounds,
   e. g. air pollutants and cigarette smoke components, will be discussed
   as well as the ( mal) function in normal and pathological lung. Several
   pulmonary drugs are substrates for ABC transporters and therefore, the
   delivery of these drugs to the site of action may be highly dependent on
   the presence and activity of many ABC transporters in several cell
   types. Three ABC transporters are known to play an important role in
   lung functioning. Mutations in the cystic fibrosis transmembrane
   conductance regulator ( CFTR) gene can cause cystic fibrosis, and
   mutations in ABCA1 and ABCA3 are responsible for respectively Tangier
   disease and fatal surfactant deficiency. The role of altered function of
   ABC transporters in highly prevalent pulmonary diseases such as asthma
   or chronic obstructive pulmonary disease ( COPD) have hardly been
   investigated so far. We especially focused on polymorphisms, knock-out
   mice models and in vitro results of pulmonary research. Insight in the
   function of ABC transporters in the lung may open new ways to facilitate
   treatment of lung diseases.}},
Publisher = {{BIOMED CENTRAL LTD}},
Address = {{236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Postma, DS (Reprint Author), Dept Pulm Med, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
   Dept Pulm Med, NL-9713 GZ Groningen, Netherlands.
   Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9713 GZ Groningen, Netherlands.
   Dept Pathol \& Lab Med, NL-9713 GZ Groningen, Netherlands.
   Free Univ Amsterdam, Dept Pathol, NL-1081 HV Amsterdam, Netherlands.}},
DOI = {{10.1186/1465-9921-6-59}},
Article-Number = {{59}},
ISSN = {{1465-993X}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;
   P-GLYCOPROTEIN EXPRESSION; DENSITY-LIPOPROTEIN DEFICIENCY; BRONCHIAL
   EPITHELIAL-CELLS; ORGANIC ANION TRANSPORTER; CYSTIC-FIBROSIS PATIENTS;
   DEPENDENT EXPORT PUMP; NITRIC-OXIDE SYNTHASE; BLOOD-BRAIN-BARRIER}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Author-Email = {{m.van.der.deen@int.umcg.nl
   e.g.e.de.vries@int.umcg.nl
   w.timens@path.umcg.nl
   rj.scheper@vumc.nl
   h.timmer-bosscha@int.umcg.nl
   d.s.postma@int.umcg.nl}},
ResearcherID-Numbers = {{Timens, Wim/K-5570-2013}},
ORCID-Numbers = {{Timens, Wim/0000-0002-4146-6363}},
Cited-References = {{Agassandian M, 2004, AM J RESP CELL MOL, V31, P227, DOI 10.1165/rcmb.2004-0038OC.
   Bain LJ, 2003, XENOBIOTICA, V33, P1173, DOI 10.1080/00498250310001609138.
   Bandi N, 2002, EUR J PHARMACOL, V437, P9, DOI 10.1016/S0014-2999(02)01267-0.
   Baudouin-Legros M, 2003, AM J PHYSIOL-CELL PH, V284, pC620, DOI 10.1152/ajpcell.00457.2002.
   Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200.
   Beck K, 2003, J HISTOCHEM CYTOCHEM, V51, P887, DOI 10.1177/002215540305100704.
   Beer TW, 1996, THORAX, V51, P526, DOI 10.1136/thx.51.5.526.
   Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294.
   Booth CL, 1998, CANCER RES, V58, P3641.
   Borst P, 2000, J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295.
   Brady JM, 2002, DRUG METAB DISPOS, V30, P838, DOI 10.1124/dmd.30.7.838.
   Brechot JM, 1998, J HISTOCHEM CYTOCHEM, V46, P513, DOI 10.1177/002215549804600411.
   Brezillon S, 1997, HUM PATHOL, V28, P944, DOI 10.1016/S0046-8177(97)90010-1.
   BREZILLON S, 1995, LAB INVEST, V72, P191.
   Brooks-Wilson A, 1999, NAT GENET, V22, P336.
   Buchler M, 1996, J BIOL CHEM, V271, P15091.
   Campbell L, 2003, J PHARMACOL EXP THER, V304, P441, DOI 10.1124/jpet.102.042994.
   Chen ZS, 2005, MOL PHARMACOL, V67, P545, DOI 10.1124/mol.104.007138.
   Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200.
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704.
   Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008.
   CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900.
   COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342.
   Crapo J D, 1982, Am Rev Respir Dis, V125, P740.
   Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x.
   Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6.
   Cui YH, 1999, MOL PHARMACOL, V55, P929.
   Dean M, 2001, J LIPID RES, V42, P1007.
   DEGREEF C, 1995, BIOCHEM J, V307, P713, DOI 10.1042/bj3070713.
   DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551.
   Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203.
   Doubre Helene, 2005, International Journal of Cancer, V113, P568, DOI 10.1002/ijc.20617.
   DOYAL LA, 1998, P NATL ACAD SCI USA, V95, P15665.
   Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250.
   Ehrhardt C, 2003, PHARMACEUT RES, V20, P545, DOI 10.1023/A:1023230328687.
   Eichelbaum M, 2004, THER DRUG MONIT, V26, P180, DOI 10.1097/00007691-200404000-00017.
   Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923.
   ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028.
   Flens MJ, 1996, AM J PATHOL, V148, P1237.
   Forbes Ben, 2000, Pharmaceutical Science and Technology Today, V3, P18, DOI 10.1016/S1461-5347(99)00231-X.
   GIANGRECO A, 2003, AM J PHYSL LUNG CELL.
   GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C.
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706.
   Grauer MT, 2004, J PSYCHOPHARMACOL, V18, P66, DOI 10.1177/0269881104042831.
   Hamilton KO, 2002, CURR DRUG METAB, V3, P1, DOI 10.2174/1389200023338170.
   Hamilton KO, 2001, INT J PHARM, V228, P171, DOI 10.1016/S0378-5173(01)00836-5.
   Hamilton KO, 2001, J PHARMACOL EXP THER, V298, P1199.
   Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086.
   Hendrikse NH, 1999, CANCER RES, V59, P2411.
   Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953.
   Hickman-Davis JM, 2002, AM J PHYSIOL-LUNG C, V282, pL944, DOI 10.1152/ajplung.00216.2001.
   HIGGINS CF, 1995, J BIOENERG BIOMEMBR, V27, P63, DOI 10.1007/BF02110332.
   Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6.
   Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397.
   HOLLAND IB, 2003, ABC PROTEINS BACTERI, P427.
   Hollande E, 1998, EUR J CELL BIOL, V76, P220, DOI 10.1016/S0171-9335(98)80037-X.
   Hooijberg JH, 1999, CANCER RES, V59, P2532.
   Hopper-Borge E, 2004, CANCER RES, V64, P4927, DOI 10.1158/0008-5472.CAN-03-3111.
   HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27.
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5.
   Hurbain I, 2003, PEDIATR RES, V54, P627, DOI 10.1203/01.PDR.0000090926.16166.3F.
   Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319.
   Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200.
   Ito S, 2001, PHARMACOGENETICS, V11, P175, DOI 10.1097/00008571-200103000-00008.
   JACKSON A, 1980, HISTOPATHOLOGY, V4, P607, DOI 10.1111/j.1365-2559.1980.tb02956.x.
   Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200.
   Johannesson M, 1997, BIOCHEM BIOPH RES CO, V239, P606, DOI 10.1006/bbrc.1997.7519.
   Johnson DR, 2001, CANCER RES, V61, P1469.
   Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599.
   Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731.
   Kamisako T, 1999, HEPATOLOGY, V30, P485, DOI 10.1002/hep.510300220.
   Kerb R, 2001, PHARMACOGENOMICS, V2, P51, DOI 10.1517/14622416.2.1.51.
   Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0.
   Kogan I, 2003, EMBO J, V22, P1981, DOI 10.1093/emboj/cdg194.
   KOMATANI H, CANC RES, V61, P2827.
   Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914.
   Kool M, 1997, CANCER RES, V57, P3537.
   KUNZELMANN K, 1994, J CELL PHYSIOL, V161, P393, DOI 10.1002/jcp.1041610302.
   Kuroda M, 2004, J GASTROEN HEPATOL, V19, P146, DOI 10.1111/j.1440-1746.2004.03275.x.
   Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230.
   LechaptZalcman E, 1997, EUR RESPIR J, V10, P1837, DOI 10.1183/09031936.97.10081837.
   Lehmann T, 2001, TOXICOLOGY, V167, P59, DOI 10.1016/S0300-483X(01)00458-9.
   LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x.
   LEIER I, 1994, J BIOL CHEM, V269, P27807.
   Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200.
   Linsdell P, 1999, BRIT J PHARMACOL, V126, P1471, DOI 10.1038/sj.bjp.0702458.
   Loe DW, 1997, MOL PHARMACOL, V51, P1034.
   Loe DW, 1998, CANCER RES, V58, P5130.
   Lorico A, 2002, TOXICOLOGY, V171, P201, DOI 10.1016/S0300-483X(01)00584-4.
   Lorico A, 1997, CANCER RES, V57, P5238.
   McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245.
   Meng QH, 2000, J PATHOL, V190, P126, DOI 10.1002/(SICI)1096-9896(200002)190:2<126::AID-PATH500>3.0.CO;2-\#.
   MORRIS AP, 1992, J BIOL CHEM, V267, P5575.
   MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033.
   MULLER M, HUMAN ABC TRANSPORTE.
   Muramatsu T, 2004, ONCOL RES, V14, P331.
   Nagayoshi Keiko, 2004, Drug Metab Pharmacokinet, V19, P407, DOI 10.2133/dmpk.19.407.
   Neuringer IP, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-6.
   Oguri T, 2001, INT J CANCER, V93, P584, DOI 10.1002/ijc.1369.
   Oselin K, 2003, EUR J CLIN PHARMACOL, V59, P347, DOI 10.1007/s00228-003-0625-z.
   Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126.
   Penque D, 2000, LAB INVEST, V80, P857, DOI 10.1038/labinvest.3780090.
   Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215.
   Prehm P, 2004, BIOCHEM PHARMACOL, V68, P1401, DOI 10.1016/j.bcp.2004.06.017.
   PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485, DOI 10.1165/ajrcmb/7.5.485.
   Puddu P, 1999, LAB INVEST, V79, P1299.
   PUNJABI CJ, 1994, AM J RESP CELL MOL, V11, P165, DOI 10.1165/ajrcmb.11.2.7519435.
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146.
   RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35.
   REID G, 2003, P NATL ACAD SCI US.
   Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360.
   RIORDAN JR, 1989, SCIENCE, V245, P1066.
   Roerig DL, 2004, DRUG METAB DISPOS, V32, P953, DOI 10.1124/dmd.104.000042.
   Saito S, 2002, J HUM GENET, V47, P147, DOI 10.1007/s100380200018.
   Savaraj N, 2003, INT J ONCOL, V23, P173.
   Scheffer GL, 2002, J CLIN PATHOL, V55, P332, DOI 10.1136/jcp.55.5.332.
   Scheffer GL, 2002, LAB INVEST, V82, P515, DOI 10.1038/labinvest.3780444.
   Scheffer GL, 2002, LAB INVEST, V82, P193, DOI 10.1038/labinvest.3780411.
   Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028.
   Schultz MJ, 2001, J IMMUNOL, V166, P4059, DOI 10.4049/jimmunol.166.6.4059.
   Seree E, 1998, BIOCHEM BIOPH RES CO, V252, P392, DOI 10.1006/bbrc.1998.9662.
   Shen B.-Q., 1994, American Journal of Physiology, V266, pL493.
   Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178.
   Sinues B, 2003, ONCOLOGY-BASEL, V64, P183, DOI 10.1159/000067770.
   Summer R, 2003, AM J PHYSIOL-LUNG C, V285, pL97, DOI 10.1152/ajplung.00009.2003.
   Suzuki T, 2001, CURR DRUG METAB, V2, P367, DOI 10.2174/1389200013338289.
   Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026.
   THOMAS GA, 1994, EUR J CANCER, V30A, P1705, DOI 10.1016/0959-8049(94)00290-L.
   Torky ARW, 2005, TOXICOLOGY, V207, P437, DOI 10.1016/j.tox.2004.10.014.
   Trezise AEO, 1997, HUM MOL GENET, V6, P527, DOI 10.1093/hmg/6.4.527.
   Trompier D, 2004, CANCER RES, V64, P4950, DOI 10.1158/0008-5472.CAN-04-0143.
   VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0.
   Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13.
   van den Berge M, 2004, J ALLERGY CLIN IMMUN, V114, P737, DOI 10.1016/j.jaci.2004.05.071.
   VANDERDEEN M, 2003, AM J RESP CRIT CARE, V167, pA397.
   VANDERDEEN M, 2004, P AM ASSOC CANC RES, V45, pA508.
   VANDERVALK P, 1990, ANN ONCOL, V1, P56.
   Verbon A, 2002, CLIN EXP IMMUNOL, V130, P32, DOI 10.1046/j.1365-2249.2002.01952.x.
   VOLM M, 1992, CANCER, V70, P764, DOI 10.1002/1097-0142(19920815)70:4<764::AID-CNCR2820700408>3.0.CO;2-M.
   VOLM M, 1991, BRIT J CANCER, V64, P700, DOI 10.1038/bjc.1991.384.
   Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200.
   Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033.
   Weinberger B, 1999, PHARMACOL THERAPEUT, V84, P401, DOI 10.1016/S0163-7258(99)00044-3.
   Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200.
   Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267.
   Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275.
   Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797.
   Wioland MA, 2000, J HISTOCHEM CYTOCHEM, V48, P1215, DOI 10.1177/002215540004800905.
   Wood L, 1998, BRIT J CANCER, V77, P627, DOI 10.1038/bjc.1998.100.
   Yamamoto T, 2004, BIOCHEM BIOPH RES CO, V321, P72, DOI 10.1016/j.bbrc.2004.06.112.
   Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3.
   Yoh K, 2004, CLIN CANCER RES, V10, P1691, DOI 10.1158/1078-0432.CCR-0937-3.
   Young LC, 1999, CLIN CANCER RES, V5, P673.
   Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886.
   Zheng HX, 2004, J CLIN PHARMACOL, V44, P135, DOI 10.1177/0091270003262108.}},
Number-of-Cited-References = {{155}},
Times-Cited = {{103}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Respir. Res.}},
Doc-Delivery-Number = {{960AW}},
Unique-ID = {{ISI:000231563600001}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000229643700021,
Author = {Granich, RM and Oh, P and Lewis, B and Porco, TC and Flood, J},
Title = {{Multidrug resistance among persons with tuberculosis in California,
   1994-2003}},
Journal = {{JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION}},
Year = {{2005}},
Volume = {{293}},
Number = {{22}},
Pages = {{2732-2739}},
Month = {{JUN 8}},
Abstract = {{Context Between 1994 and 2003, tuberculosis (TB) cases in California
   declined 33\% (4834 to 3224). However, in 2003 California reported the
   largest number of cases in the nation, and over the past decade the
   proportion of cases with multidrug-resistant tuberculosis (MDR-TB) has
   not decreased.
   Objective To describe the magnitude, trends, geographic distribution,
   clinical characteristics, risk factors, and outcomes of MDR-TB cases
   reported to the California registry of Reports of Verified Cases of TB.
   Design, Setting, and Cases Analysis of 38 291 TB cases reported from all
   61 local health jurisdictions in California during 1994-2003.
   Multidrug-resistant TB was defined as resistance to at least isoniazid
   and rifampin.
   Main Outcome Measures Results of univariate and multivariable analyses
   of MDR-TB magnitude, trends, geographic distribution, clinical
   characteristics, associated factors, and outcomes.
   Results Of 38 291 reported TB cases, 28 712 (75\%) were tested for
   resistance to at least isoniazid and rifampin; of these, 407 MDR-TB
   cases (1.4\%) were reported from 38 of 61 California health
   jurisdictions (62\%); the proportion of MDR-TB cases did not
   significantly change over the study period (P=.87). Cases of MDR-TB were
   twice as likely to have cavitary lesions compared with non-MDR-TB cases
   (P<.001) and were 7 times more likely to have reported previous
   treatment for TB (P<.001). Of MDR-TB cases with outcomes, 231 (67\%)
   completed therapy, and those with MDR-TB were significantly less likely
   to complete therapy than those without MDR-TB (P<.001). Multivariate
   analysis identified previous TB diagnosis, positive acid-fast bacilli
   sputum smear results, Asian/Pacific Islander ethnicity, time in the
   United States less than 5 years at the time of diagnosis, and outcomes
   of ``died{''} and ``moved{''} as factors associated with MDR-TB.
   Conclusions Multidrug-resistant TB, an airborne disease with limited,
   costly treatment options, persists in 1\% to 2 \% of all cases despite
   California's control efforts. Local and global TB control efforts are
   needed to prevent the further development and spread of MDR-TB.}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60654-0946 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Granich, RM (Reprint Author), Off US Global AIDS Coordinator, 2100 Penn Ave NW, Washington, DC 20522 USA.
   Ctr Dis Control \& Prevent, Div TB Eliminat, Natl Ctr HIV STD \& TB Prevent, Atlanta, GA USA.
   Calif Dept Hlth Serv, TB Control Branch, Sacramento, CA USA.}},
DOI = {{10.1001/jama.293.22.2732}},
ISSN = {{0098-7484}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; PULMONARY TUBERCULOSIS;
   TRANSMISSION; OUTBREAK; INFECTIONS; OUTCOMES}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{granichrm@state.gov}},
Cited-References = {{Agerton T, 1997, JAMA-J AM MED ASSOC, V278, P1073, DOI 10.1001/jama.278.13.1073.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665.
   {*}CA DEP HLTH SERV, 2001, REP TUB CAL 2000.
   CAMPBELL R, 1993, JAMA-J AM MED ASSOC, V269, P978.
   {*}CDCP, 1990, JAMA-J AM MED ASSOC, V264, P173.
   Centers for Disease Control and Prevention, 1998, MMWR-MORBID MORTAL W, V47, P1.
   Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-11590C.
   CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052.
   Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537.
   FRIEDMAN CR, 1995, AM J RESP CRIT CARE, V152, P355, DOI 10.1164/ajrccm.152.1.7599845.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   Granich RM, 2001, INT J TUBERC LUNG D, V5, P53.
   KOO D, 1995, WESTERN J MED, V163, P441.
   Lobato MN, 1998, PEDIATR INFECT DIS J, V17, P407, DOI 10.1097/00006454-199805000-00012.
   Lockman S, 2001, CLIN INFECT DIS, V32, P373, DOI 10.1086/318489.
   MILLER A, 2003, SUBSET SELECTION REG.
   Moore M, 1997, JAMA-J AM MED ASSOC, V278, P833, DOI 10.1001/jama.278.10.833.
   NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45.
   Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301.
   Peter CR, 1998, WESTERN J MED, V169, P208.
   Rajbhandary SS, 2004, INT J TUBERC LUNG D, V8, P1012.
   Raviglione MC, 2001, ANN NY ACAD SCI, V953, P88, DOI 10.1111/j.1749-6632.2001.tb11364.x.
   Ridzon R, 1997, J PEDIATR-US, V131, P863, DOI 10.1016/S0022-3476(97)70034-9.
   RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282.
   {*}STAT CA DEP FIN, 2003, CAL CURR POP SURV RE.
   {*}STAT CA DEP FIN, 2002, REV HIST CIT COUNT S.
   Viallefont V, 2001, STAT MED, V20, P3215, DOI 10.1002/sim.976.abs.
   BAYESIAN MODEL AVERI.
   1991, MMWR MORB MORTAL WKL, V40, P649.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{55}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{JAMA-J. Am. Med. Assoc.}},
Doc-Delivery-Number = {{933OV}},
Unique-ID = {{ISI:000229643700021}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000229057500016,
Author = {Louis, M and Rosato, RR and Battaglia, E and Neguesque, A and Lapotre, A
   and Grant, S and Bagrel, D},
Title = {{Modulation of sensitivity to doxorubicin by the histone deacetylase
   inhibitor sodium butyrate in breast cancer cells}},
Journal = {{INTERNATIONAL JOURNAL OF ONCOLOGY}},
Year = {{2005}},
Volume = {{26}},
Number = {{6}},
Pages = {{1569-1574}},
Month = {{JUN}},
Abstract = {{The hi!;tone deacetylase inhibitor sodium butyrate induces several gene
   products that modify cellular metabolism. Here, we investiiated its
   ability to modulate glutathionerelated detoxification enzymes in the
   breast cancer cell line MCF-7 and a derivative resistant to vincristine
   (VCREMS). We found that,odium butyrate induced glutathione S-transferase
   and glutathione-dependent peroxidase activities and triggered gluathione
   depletion. Expression of MRP1 air ATP-dependent GS-X pump, was
   unmodified. Moreover, isobologram analysis showed that sodium butyrate
   sensitized VCREMS to doxorubicin-mediated toxicity. Verapamil, an
   inhibitor of MRP1, did not significantly affect this chemosensitizing
   effect, suggesting that the observed toxicity sterns from multifactorial
   mechanisms. Interestingly, synergism between sodium butyrate and
   doxorubicin was more pronounced in resistant VCREMS cells than in
   parental sensitive MCF-7 cells.}},
Publisher = {{PROFESSOR D A SPANDIDOS}},
Address = {{1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bagrel, D (Reprint Author), Univ Metz, Lab Ingn Mol \& Biochim Pharmacol, EA 3472 UFR SciFA, Campus Bridoux,Rue Gen Delestraint, F-57070 Metz, France.
   Univ Metz, Lab Ingn Mol \& Biochim Pharmacol, EA 3472 UFR SciFA, F-57070 Metz, France.
   Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Div Hematol Oncol, Richmond, VA 23298 USA.}},
ISSN = {{1019-6439}},
Keywords = {{sodium butyrate; histone deacetylase; doxorubicin; breast cancer;
   glutathione; drug combinations}},
Keywords-Plus = {{COLON-CANCER; OXIDATIVE STRESS; TOPOISOMERASE-II; DRUG-RESISTANCE;
   P-GLYCOPROTEIN; GLUTATHIONE; APOPTOSIS; ANTHRACYCLINES; DNA;
   TRANSFECTION}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Author-Email = {{bagrel@sc.ences.univ-metz.fr}},
Cited-References = {{Avivi-Green C, 2000, ONCOL RES, V12, P83.
   Ban N, 1996, CANCER RES, V56, P3577.
   BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002.
   Biffi A, 1998, ANTICANCER RES, V18, P4109.
   CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553.
   CARMAGNOL F, 1983, BIOCHIM BIOPHYS ACTA, V759, P49, DOI 10.1016/0304-4165(83)90188-5.
   Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994.
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4.
   Doroshow JH, 1995, TOXICOL LETT, V82-3, P395, DOI 10.1016/0378-4274(95)03570-2.
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951.
   FRASER DJ, 1995, MOL PHARMACOL, V47, P696.
   Guano F, 1999, MOL PHARMACOL, V56, P77.
   HABIG WH, 1974, P NATL ACAD SCI USA, V71, P3879, DOI 10.1073/pnas.71.10.3879.
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491.
   Henderson Colin J., 1998, Chemico-Biological Interactions, V111-112, P69.
   Johnson SA, 1998, BLOOD REV, V12, P52, DOI 10.1016/S0268-960X(98)90030-3.
   Kim MS, 2003, CANCER RES, V63, P7291.
   Kirlin WG, 1999, J NUTR, V129, P1827.
   Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844.
   LEROY P, 1993, BIOMED CHROMATOGR, V7, P86, DOI 10.1002/bmc.1130070208.
   Louis M, 2004, INT J ONCOL, V25, P1701.
   LOWRY OH, 1951, J BIOL CHEM, V193, P265.
   Medina V, 1998, JPEN-PARENTER ENTER, V22, P14, DOI 10.1177/014860719802200114.
   Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6.
   MOSCOW JA, 1989, MOL PHARMACOL, V36, P22.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Rosato RR, 2004, EXPERT OPIN INV DRUG, V13, P21, DOI 10.1517/eoid.13.1.21.25283.
   WHELAN RDH, 1992, INT J CANCER, V52, P241, DOI 10.1002/ijc.2910520215.
   Wolf CR, 2001, P NATL ACAD SCI USA, V98, P2941, DOI 10.1073/pnas.071042698.
   Yu CR, 2003, BLOOD, V102, P3765, DOI 10.1182/blood-2003-03-0737.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Int. J. Oncol.}},
Doc-Delivery-Number = {{925MP}},
Unique-ID = {{ISI:000229057500016}},
DA = {{2018-08-13}},
}

@article{ ISI:000228099400019,
Author = {Kuczkowski, J and Narozny, W and Stankiewicz, C and Mikaszewski, B and
   Izycka-Swieszewska, E},
Title = {{Zygomatic abscess with temporal myositis - a rare extracranial
   complication of acute otitis media}},
Journal = {{INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY}},
Year = {{2005}},
Volume = {{69}},
Number = {{4}},
Pages = {{555-559}},
Month = {{APR}},
Abstract = {{Acute mastoiditis is the most common complication of acute otitis media
   (AOM) and its early recognition and management still poses a challenge
   due to potentially serious consequences. The incidences of extracranial
   and intracranial. suppurative complications of AOM in children have
   decreased significantly, yet they remain a serious clinical problem,
   especially when caused by bacteria resistant to antibiotics. The authors
   presented a case of rare AOM complication - zygomatic abscess with
   temporal myositis. A 6-year-old boy was admitted to the ENT Department
   with 4 weeks of ear pain, treated for AOM with cefuroxime axetyl and
   amoxicilline, with acute mastoiditis and subsequent abscess formation in
   zygomatic and preauricular region. The inflammatory process spread
   through anterior air cells to the zygomatic cells leading to a fistula
   formation in the zygomatic bone and breakthrough into the temporal
   muscle. The surgical procedures applied were: myringotomy with drainage,
   cortical mastoidectomy and revision of zygomatic area and treatment with
   antibiotics (ceftriaxon). Enterococcus faecalis and Streptococcus
   viridans were found in the culture of middle ear and mastoid effusion.
   After half a year of follow-up the child had a normal hearing. Severe
   complications of AOM are rare today. An early diagnosis in order to
   promote adequate management and prevent inherently suppurative
   complications is essential. (c) 2004 Elsevier Ireland Ltd. All rights
   reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kuczkowski, J (Reprint Author), Med Univ Gdansk, Dept Otolaryngol, Poland Ul Debinki 7,Bldg 16, PL-80211 Gdansk, Poland.
   Med Univ Gdansk, Dept Otolaryngol, PL-80211 Gdansk, Poland.
   Med Univ Gdansk, Dept Pathol, PL-80211 Gdansk, Poland.}},
DOI = {{10.1016/j.ijporl.2004.10.018}},
ISSN = {{0165-5876}},
Keywords = {{acute otitis media; children mastoiditis; complications}},
Keywords-Plus = {{ACUTE MASTOIDITIS; INTRACRANIAL COMPLICATIONS; CHILDREN; THERAPY}},
Research-Areas = {{Otorhinolaryngology; Pediatrics}},
Web-of-Science-Categories  = {{Otorhinolaryngology; Pediatrics}},
Author-Email = {{jerzyk@amg.gda.pl}},
Cited-References = {{Aronovitz GH, 2000, CLIN THER, V22, P29, DOI 10.1016/S0149-2918(00)87975-8.
   Babin E, 2003, J LARYNGOL OTOL, V117, P173.
   Butbul-Aviel Y, 2003, INT J PEDIATR OTORHI, V67, P277, DOI 10.1016/S0165-5876(02)00388-9.
   Casselbrant M., 1999, EVIDENCE BASED OTITI, P117.
   Cohen-Kerem R, 1999, J LARYNGOL OTOL, V113, P1081.
   Dagan R, 2002, LANCET INFECT DIS, V2, P593, DOI 10.1016/S1473-3099(02)00394-8.
   De S, 2002, J LARYNGOL OTOL, V116, P440.
   DeRosa J, 2002, PEDIATR ANN, V31, P814, DOI 10.3928/0090-4481-20021201-10.
   Go C, 2000, INT J PEDIATR OTORHI, V52, P143, DOI 10.1016/S0165-5876(00)00283-4.
   Kuczkowski J, 2001, INT J PEDIATR OTORHI, V60, P227, DOI 10.1016/S0165-5876(01)00524-9.
   Leskinen K, 2004, INT J PEDIATR OTORHI, V68, P317, DOI 10.1016/j.ijporl.2003.10.018.
   MAGLIULO G, 1995, INT J PEDIATR OTORHI, V31, P147, DOI 10.1016/0165-5876(94)01079-D.
   PALVA T, 1959, J Laryngol Otol, V73, P573, DOI 10.1017/S0022215100055742.
   PALVA T, 1985, J LARYNGOL OTOL, V99, P127, DOI 10.1017/S0022215100096407.
   Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0.
   Siegel RM, 2003, PEDIATRICS, V112, P527, DOI 10.1542/peds.112.3.527.
   Spratley J, 2000, INT J PEDIATR OTORHI, V56, P33, DOI 10.1016/S0165-5876(00)00406-7.
   Taylor MF, 2004, ANN OTO RHINOL LARYN, V113, P69, DOI 10.1177/000348940411300115.
   Vassbotn FS, 2002, INT J PEDIATR OTORHI, V62, P237, DOI 10.1016/S0165-5876(01)00626-7.
   Zapalac JS, 2002, ARCH OTOLARYNGOL, V128, P660, DOI 10.1001/archotol.128.6.660.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Pediatr. Otorhinolaryngol.}},
Doc-Delivery-Number = {{912SI}},
Unique-ID = {{ISI:000228099400019}},
DA = {{2018-08-13}},
}

@article{ ISI:000228102700002,
Author = {Sieber, F and Daziano, JP and Gunther, WHH and Krieg, M and Miyagi, K
   and Sampson, RW and Ostrowski, MD and Anderson, GS and Tsujino, L and
   Bula, RJ},
Title = {{Elemental selenium generated by the photobleaching of seleno-merocyanine
   Photosensitizers forms conjugates with serum macro-molecules that are
   toxic to tumor cells}},
Journal = {{PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS}},
Year = {{2005}},
Volume = {{180}},
Number = {{3-4}},
Pages = {{647-657}},
Month = {{MAR-APR}},
Note = {{9th International Conference on the Chemistry of Selenium and Tellurium,
   Inst Technol Bombay, Bombay, INDIA, FEB 23-27, 2004}},
Abstract = {{Elemental selenium generated by the pholobleaching of selenomerocyanine
   dyes forms conjugates with serum albumin. and serum lipoproteins that
   are toxic to leukemia and selected solid tumor cells but well tolerated
   by normal CD34-positive hematopoietic stem and progenitor cells. Serum.
   albumin and lipoproteins act as Trojan horses that deliver the cytotoxic
   entity (elemental selenium) to tumor cells as part of a physiological
   process. They exploit the fact that many tumors have an increased demand
   for albumin and/or low-density lipoprotein. Se(0)-protein conjugates are
   more toxic than selenium dioxide, sodium selenite, selenomethionine, or
   selenocystine. They are only minimally affected by a drug resistance
   mechanism, and they potentiate the cytotaxic effect of ionizing
   radiation and several standard chemotherapeutic agents. The cytotoxic
   mechanism of Se(0)-protein conjugates is not yet fully understood.
   Currently available data are consistent with the notion that
   Se(0)-protein conjugates act as air oxidation catalysts that cause a
   rapid depletion of intracellular glutathione and induce apoptosis. Drugs
   modeled after our Se(0)-protein conjugates may prove useful for the
   local and/or systemic therapy of cancer.}},
Publisher = {{TAYLOR \& FRANCIS LTD}},
Address = {{4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Sieber, F (Reprint Author), Med Coll Wisconsin, Dept Pediat, 8701 Watertown Pk Rd, Milwaukee, WI 53226 USA.
   Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA.
   WHHG Consulting, W Chester, PA USA.
   GPT Glendale, Attleboro Falls, MA USA.
   AgSpace Technol Int, Cross Plains, WI USA.}},
DOI = {{10.1080/10426500590907200}},
ISSN = {{1042-6507}},
Keywords-Plus = {{LEUKEMIC-CELLS; DYES; INVIVO}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Inorganic \& Nuclear; Chemistry, Organic}},
Author-Email = {{fsieber@mail.mcw.edu}},
Funding-Acknowledgement = {{NCI NIH HHS {[}R01 CA077387, R01 CA077387-03, R01 CA077387-04S1, R01
   CA077387-02, R01 CA077387-04, R01 CA077387-01A1]}},
Cited-References = {{Anderson GS, 2002, J PHOTOCH PHOTOBIO B, V68, P101, DOI 10.1016/S1011-1344(02)00377-9.
   COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438.
   GUNTHER WHH, 1992, SEMIN HEMATOL, V29, P88.
   GUNTHER WHH, 1992, PHOSPHORUS SULFUR, V67, P417, DOI 10.1080/10426509208045864.
   KRIEG M, 1995, CANCER RES THER CONT, V4, P163.
   PONTY E, 1993, INT J CANCER, V54, P411, DOI 10.1002/ijc.2910540311.
   RICE GC, 1986, CANCER RES, V46, P6105.
   SIEBER F, 1984, P NATL ACAD SCI-BIOL, V81, P7584, DOI 10.1073/pnas.81.23.7584.
   Stehle G, 1997, CRIT REV ONCOL HEMAT, V26, P77, DOI 10.1016/S1040-8428(97)00015-2.
   Stehle G, 1999, ANTI-CANCER DRUG, V10, P785, DOI 10.1097/00001813-199909000-00012.
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I.
   VITOLS S, 1990, P NATL ACAD SCI USA, V87, P2598, DOI 10.1073/pnas.87.7.2598.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Phosphorus Sulfur Silicon Relat. Elem.}},
Doc-Delivery-Number = {{912TL}},
Unique-ID = {{ISI:000228102700002}},
OA = {{green\_accepted}},
DA = {{2018-08-13}},
}

@article{ ISI:000227053000010,
Author = {Torky, ARW and Stehfest, E and Viehweger, K and Taege, C and Foth, H},
Title = {{Immuno-histochemical detection of MRPs in human lung cells in culture}},
Journal = {{TOXICOLOGY}},
Year = {{2005}},
Volume = {{207}},
Number = {{3}},
Pages = {{437-450}},
Month = {{FEB 28}},
Abstract = {{The transport of molecules across membranes is an essential function of
   all living organisms and a large number of specific transporters have
   evolved to carry out this function. The largest transporter gene family
   is the ATP-binding cassette (ABC) transporter superfamily. The multidrug
   resistance-associated protein (MRP) family is comprised of nine related
   ABC transporters. The intra-cellular distribution of the different MRP
   isoforms in relation to their physiological and non physiological
   function is still a point of discussion. For this purpose we used normal
   human lung cells (bronchial epithelial cells, NHBEC, and peripheral lung
   cells, PLC) as well as tumor cell cultures as test tools to investigate
   the intracelluar localization of these proteins under classical culture
   conditions and under air-liquid interface by means of indirect
   fluorescence microscopy. Characterization of the cultured cells as lung
   epithelial cells was performed by means of immuno-histochemical
   analysis.
   MRP1 and MRP3 were localised to the cellular membrane in all tested lung
   cell types. In contrast to that MRP2, MRP4 and MRP5 could be described
   as intracellular proteins in NHBEC and PLC. All MRP1-MRP5 isoforms could
   be characterized in A549 tumor cell line as membrane proteins.
   In order to imitate the physiological in vivo circumstances in the lung,
   we have established a dry/wet method (air-liquid interface) for cell
   cultivation so that cultured cells have the option to polarize between
   air and basal membrane and this might influence the distribution pattern
   of MRP1 and MRP2 in NHBEC. Using confocal laser scanning techniques we
   could show that in cells kept under dry/wet conditions MRP1 was found to
   be localised to baso-lateral cell regions while MRP2 was localised to
   all cell regions. Under classical culture conditions MRP1 was not
   localized to particular membrane regions and MRP2 was found to be an
   intracellular protein. (C) 2004 Elsevier Ireland Ltd. All rights
   reserved.}},
Publisher = {{ELSEVIER SCI IRELAND LTD}},
Address = {{CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE,
   IRELAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Foth, H (Reprint Author), Univ Halle Wittenberg, Inst Environm Toxicol, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Inst Environm Toxicol, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Inst Pharmaceut Biol \& Pharmacol, D-06097 Halle Saale, Germany.
   Univ Halle Wittenberg, Inst Pathol, D-06097 Halle Saale, Germany.}},
DOI = {{10.1016/j.tox.2004.10.014}},
ISSN = {{0300-483X}},
Keywords = {{human lung cells; bronchial cells; peripheral cells; MRPs;
   immunhistochernistry; confocal LASER scan microscopy}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; CONJUGATE
   EXPORT PUMP; BINDING CASSETTE TRANSPORTER; KIDNEY PROXIMAL TUBULES;
   STRUCTURAL REQUIREMENTS; SUBSTRATE-SPECIFICITY; TISSUE DISTRIBUTION;
   EPITHELIAL-CELLS; DRUG-RESISTANCE}},
Research-Areas = {{Pharmacology \& Pharmacy; Toxicology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Toxicology}},
Author-Email = {{heidi.foth@medizin.uni-halle.de}},
ORCID-Numbers = {{Viehweger, Katrin/0000-0002-4594-9039}},
Cited-References = {{Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322.
   Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735.
   Bodo A, 2003, J BIOL CHEM, V278, P23529, DOI 10.1074/jbc.M303515200.
   Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4.
   Brechot JM, 1998, J HISTOCHEM CYTOCHEM, V46, P513, DOI 10.1177/002215549804600411.
   CHILDS JM, 1994, IMPORTANT ADV ONCOL, P21.
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704.
   Cui YH, 1999, MOL PHARMACOL, V55, P929.
   Dean M, 2001, J LIPID RES, V42, P1007.
   DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S.
   Dobbs LG, 1997, AM J PHYSIOL-LUNG C, V273, pL347.
   Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535.
   FERNANDES DJ, 1990, BIOCHEMISTRY-US, V29, P4235, DOI 10.1021/bi00469a028.
   Flens MJ, 1996, AM J PATHOL, V148, P1237.
   Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199.
   HIPFNER DR, 1999, BIOCHIM BIOPHYS ACTA, V1461, P276.
   Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181.
   Hirrlinger J, 2002, J NEUROCHEM, V82, P716, DOI 10.1046/j.1471-4159.2002.01082.x.
   Homolya L, 2003, BIOFACTORS, V17, P103, DOI 10.1002/biof.5520170111.
   ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V.
   Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646.
   JENNER P, 1986, J NEURAL TRANSM, P11.
   Jiang X, 2001, J MEMBRANE BIOL, V181, P195, DOI 10.1007/s00232-001-0022-4.
   JOHNSON LG, 1993, AM J PHYSIOL, V264, pL560.
   Kartenbeck J, 1996, HEPATOLOGY, V23, P1061.
   Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0.
   Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3.
   Kohsa K, 1996, CELL STRUCT FUNCT, V21, P81, DOI 10.1247/csf.21.81.
   Konno T, 2003, J BIOL CHEM, V278, P22908, DOI 10.1074/jbc.M302868200.
   Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914.
   Kool M, 1997, CANCER RES, V57, P3537.
   Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953.
   Lee K, 2000, J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934.
   Lee K, 1998, CANCER RES, V58, P2741.
   Lehmann T, 2001, TOXICOLOGY, V167, P59, DOI 10.1016/S0300-483X(01)00458-9.
   McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541.
   Miller DS, 2000, MOL PHARMACOL, V58, P1357.
   Mitani A, 2003, EUR J PHARMACOL, V466, P223, DOI 10.1016/S0014-2999(03)01552-8.
   MOLLER JV, 1983, PHARMACOL REV, V34, P315.
   Mottino AD, 2000, J PHARMACOL EXP THER, V293, P717.
   Nies AT, 2002, J UROLOGY, V167, P2271, DOI 10.1016/S0022-5347(05)65141-5.
   Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x.
   Pei QL, 2002, HEPATOL RES, V22, P58, DOI 10.1016/S1386-6346(01)00110-3.
   PRIMECHAPMAN HM, 2004, J PHARM EXP THER.
   PRITCHARD JB, 1993, PHYSIOL REV, V73, P765.
   Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200.
   Rost D, 2002, AM J PHYSIOL-GASTR L, V282, pG720, DOI 10.1152/ajpgi.00318.2001.
   Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213.
   Scheffer GL, 2000, CANCER RES, V60, P5269.
   Scheffer GL, 2002, J CLIN PATHOL, V55, P332, DOI 10.1136/jcp.55.5.332.
   Scheffer GL, 2002, LAB INVEST, V82, P193, DOI 10.1038/labinvest.3780411.
   SCHEUTZ JD, 1999, NAT MED, V5, P1048.
   Sekine T, 2000, PFLUG ARCH EUR J PHY, V440, P337, DOI 10.1007/s004240000297.
   Sharma R, 2003, CURR CANCER DRUG TAR, V3, P89, DOI 10.2174/1568009033482047.
   St-Pierre MV, 2000, AM J PHYSIOL-REG I, V279, pR1495.
   Stride BD, 1996, MOL PHARMACOL, V49, P962.
   Suzuki T, 2000, GENE, V242, P167, DOI 10.1016/S0378-1119(99)00529-6.
   Takeda M, 1999, KIDNEY INT, V56, P2128, DOI 10.1046/j.1523-1755.1999.00789.x.
   Uchiumi T, 1998, BIOCHEM BIOPH RES CO, V252, P103, DOI 10.1006/bbrc.1998.9546.
   Ullrich KJ, 1997, J MEMBRANE BIOL, V158, P95, DOI 10.1007/s002329900247.
   Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF216.
   Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13.
   Van Luyn MJA, 1998, INT J CANCER, V76, P55, DOI 10.1002/(SICI)1097-0215(19980330)76:1<55::AID-IJC10>3.3.CO;2-O.
   Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267.
   Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797.
   WIJNHOLDS J, 2000, P NATL ACAD SCI USA, V97, P7479.
   Wright SR, 1998, CLIN CANCER RES, V4, P2279.}},
Number-of-Cited-References = {{67}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Toxicology}},
Doc-Delivery-Number = {{898CH}},
Unique-ID = {{ISI:000227053000010}},
DA = {{2018-08-13}},
}

@article{ ISI:000226104200004,
Author = {Saha, M and Ghosh, D and Ghosh, D and Garai, D and Jaisankar, P and
   Sarkar, KK and Dutta, PK and Das, S and Jha, T and Mukherjee, J},
Title = {{Studies on the production and purification of an antimicrobial compound
   and taxonomy of the producer isolated from the marine environment of the
   Sundarbans}},
Journal = {{APPLIED MICROBIOLOGY AND BIOTECHNOLOGY}},
Year = {{2005}},
Volume = {{66}},
Number = {{5}},
Pages = {{497-505}},
Month = {{FEB}},
Abstract = {{A microorganism isolated from the Sundarbans region of the Bay of
   Bengal, India, showed potent antimicrobial activity against
   gram-positive and gram-negative bacteria, molds, yeast and several
   multiple-drug-resistant (MDR) bacteria, including methicillin-resistant
   Staphylococcus aureus (MRSA). The isolate grew in the presence of 20\%
   (w/v) NaCl, antibiotic production being maximum with 5\% (w/v) NaCl in
   the production medium. Natural seawater stimulated antibiotic
   biosynthesis. The absence of catabolite repression during the synthesis
   of the antimicrobial substance was demonstrated by the utilization of
   glucose by this isolate. The 16S rRNA gene of this aerobic,
   gram-positive, mycelium- and spore-forming microorganism was amplified,
   and molecular phylogenetic analysis of the DNA sequence showed less than
   93\% similarity with its closest relative, indicating differentiation at
   the genus level. The highly stable, active principle was purified by
   butyl acetate extraction and silica-gel chromatography and a single
   compound was found to posses the broad-spectrum activity. Molecular
   characterization showed that the active compound is a lipid. Bioreactor
   studies demonstrated that antibiotic production is strongly dependent on
   the scale of operation and there is a definite relation between the
   dissolved oxygen concentration, medium pH, glucose utilization, cell
   differentiation and antibiotic production. Maximum production in 30 h
   could be obtained by regulation of the medium pH in the alkaline range
   by a combination of controlled addition of NaOH, regulation of the air
   supply and changes in the reactor configuration. Considering all of the
   above evidences and based on comparison with the current literature, a
   novel antimicrobial appears to have been isolated.}},
Publisher = {{SPRINGER}},
Address = {{233 SPRING ST, NEW YORK, NY 10013 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mukherjee, J (Reprint Author), Jadavpur Univ, Environm Sci Programme, Kolkata 700032, India.
   Jadavpur Univ, Environm Sci Programme, Kolkata 700032, India.
   Jadavpur Univ, Dept Life Sci, Kolkata 700032, India.
   Jadavpur Univ, Dept Biotechnol, Kolkata 700032, India.
   Indian Inst Chem Biol, LCMS Div, Kolkata 700032, India.
   Peerless Hosp, Dept Microbiol \& Immunol, Kolkata 700094, India.
   BK Roy Res Ctr, Dept Microbiol \& Immunol, Kolkata 700094, India.
   Jadavpur Univ, Dept Pharmaceut Technol, Kolkata 700032, India.}},
DOI = {{10.1007/s00253-004-1706-3}},
ISSN = {{0175-7598}},
EISSN = {{1432-0614}},
Keywords-Plus = {{STRUCTURE ELUCIDATION; ANTIBIOTICS; CULTIVATION; ANTIFUNGAL; EXPRESSION;
   BACTERIUM; ALIGNMENT; PROTEIN; CLONING}},
Research-Areas = {{Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology}},
Author-Email = {{joymukherjee@vsnl.net}},
ResearcherID-Numbers = {{Ghosh, Dhritiman/C-3032-2011
   }},
ORCID-Numbers = {{Jha, Tarun/0000-0002-9996-738X}},
Cited-References = {{AKEDA Y, 1995, J ANTIBIOT, V48, P363, DOI 10.7164/antibiotics.48.363.
   Alm EW, 1996, APPL ENVIRON MICROB, V62, P3557.
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999.
   Bordoloi GN, 2001, BIOSCI BIOTECH BIOCH, V65, P1856, DOI 10.1271/bbb.65.1856.
   de Swaaf ME, 2003, APPL MICROBIOL BIOT, V61, P40, DOI 10.1007/s00253-002-1118-1.
   DEVEREUX R, 1990, J BACTERIOL, V172, P3609, DOI 10.1128/jb.172.7.3609-3619.1990.
   DOBSON SJ, 1993, INT J SYST BACTERIOL, V43, P665, DOI 10.1099/00207713-43-4-665.
   Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115.
   FIEDLER HP, 1996, J ANTIBIOT TOKYO, V8, P758.
   Heuer H, 1997, APPL ENVIRON MICROB, V63, P3233.
   Hsu FF, 2004, J AM SOC MASS SPECTR, V15, P1, DOI 10.1016/j.jasms.2003.08.006.
   {*}IMTECH, 1998, LAB MAN ACT IS SCREE, P64.
   Kwon HJ, 2001, J AM CHEM SOC, V123, P3385, DOI 10.1021/ja0100827.
   Marwick JD, 1999, MAR BIOTECHNOL, V1, P495, DOI 10.1007/PL00011806.
   Mincer TJ, 2002, APPL ENVIRON MICROB, V68, P5005, DOI 10.1128/AEM.68.10.5005-5011.2002.
   MULKS MH, 1990, ANTIMICROB AGENTS CH, V34, P1762, DOI 10.1128/AAC.34.9.1762.
   Proksch P, 2002, APPL MICROBIOL BIOT, V59, P125, DOI 10.1007/s00253-002-1006-8.
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406.
   Stach JEM, 2003, ENVIRON MICROBIOL, V5, P828, DOI 10.1046/j.1462-2920.2003.00483.x.
   Tateno H, 2003, J BIOL CHEM, V278, P40455, DOI 10.1074/jbc.M306836200.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Woo JH, 2003, APPL MICROBIOL BIOT, V62, P407, DOI 10.1007/s00253-003-1235-5.
   Yan LM, 2003, APPL ENVIRON MICROB, V69, P3719, DOI 10.1128/AEM.69.7.3719-3727.2003.
   Yan LM, 2002, MAR BIOTECHNOL, V4, P356, DOI 10.1007/s10126-002-0041-x.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Appl. Microbiol. Biotechnol.}},
Doc-Delivery-Number = {{884RR}},
Unique-ID = {{ISI:000226104200004}},
DA = {{2018-08-13}},
}

@article{ ISI:000227169400029,
Author = {Chapin, A and Rule, A and Gibson, K and Buckley, T and Schwab, K},
Title = {{Airborne multidrug-resistant bacteria isolated from a concentrated swine
   feeding operation}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{2005}},
Volume = {{113}},
Number = {{2}},
Pages = {{137-142}},
Month = {{FEB}},
Abstract = {{The use of nontherapeutic levels of antibiotics in swine production can
   select for antibiotic resistance in commensal and pathogenic bacteria in
   swine. As a result, retail pork products, as well as surface and
   groundwaters contaminated with swine waste, have been shown to be
   sources of human exposure to antibiotic-resistant bacteria. However, it
   is unclear whether the air within swine operations also serves as a
   source of exposure to antibiotic-resistant bacterial pathogens. To
   investigate this issue, we sampled the air within a concentrated swine
   feeding operation with an all-glass impinger. Samples were analyzed
   using a method for the isolation of Enterococcus. A total of 137
   presumptive Enterococcus isolates were identified to species level using
   standard biochemical tests and analyzed for resistance to erythromycin,
   clindamycin, virginiamycin, tetracycline, and vancomycin using the agar
   dilution method. Thirty-four percent of the isolates were confirmed as
   Enterococcus, 32\% were identified as coagulase-negative staphylococci,
   and 33\% were identified as viridans group streptococci. Regardless of
   bacterial species, 98\% of the isolates expressed high-level resistance
   to at least two antibiotics commonly used in swine production. None of
   the isolates were resistant to vancomycin, an antibiotic that has never
   been approved for use in livestock in the United States. In conclusion,
   high-level multidrug-resistant Enterococcus, coagulase-negative
   staphylococci, and viridans group streptococci were detected in the air
   of a concentrated swine feeding operation. These findings suggest that
   the inhalation of air from these facilities may serve as an exposure
   pathway for the transfer of multidrug-resistant bacterial pathogens from
   swine to humans.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Schwab, K (Reprint Author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room E6620, Baltimore, MD 21205 USA.
   Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA.}},
DOI = {{10.1289/ehp.7473}},
ISSN = {{0091-6765}},
Keywords = {{air sampling; airborne bacteria; antibiotic resistance; CAFO;
   concentrated swine feeding operation; multidrug-resistant bacteria.}},
Keywords-Plus = {{ENTEROCOCCUS-FAECIUM; ANTIMICROBIAL RESISTANCE; CONFINEMENT BUILDINGS;
   UNITED-STATES; ANIMAL FEED; POULTRY; HEALTH; DENMARK; GENES; DUST}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Author-Email = {{kschwab@jhsph.edu}},
ResearcherID-Numbers = {{Sapkota, Amy/A-6046-2011}},
Funding-Acknowledgement = {{ODCDC CDC HHS {[}T42/CCT31049-09]}},
Cited-References = {{Aarestrup FM, 2000, MICROB DRUG RESIST, V6, P63, DOI 10.1089/mdr.2000.6.63.
   Aarestrup FM, 2000, DIAGN MICR INFEC DIS, V37, P127, DOI 10.1016/S0732-8893(00)00130-9.
   Aubry-Damon H, 2004, EMERG INFECT DIS, V10, P873, DOI 10.3201/eid1005.030735.
   Bager F, 1997, PREV VET MED, V31, P95, DOI 10.1016/S0167-5877(96)01119-1.
   Bryskier A, 2002, CLIN MICROBIOL INFEC, V8, P65, DOI 10.1046/j.1198-743x.2001.00398.x.
   Campagnolo ER, 2002, SCI TOTAL ENVIRON, V299, P89, DOI 10.1016/S0048-9697(02)00233-4.
   Chee-Sanford JC, 2001, APPL ENVIRON MICROB, V67, P1494, DOI 10.1128/AEM.67.4.1494-1502.2001.
   CLARK S, 1983, AM IND HYG ASSOC J, V44, P537, DOI 10.1080/15298668391405265.
   COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069.
   CORMIER Y, 1990, AM IND HYG ASSOC J, V51, P304, DOI 10.1202/0002-8894(1990)051<0304:AMCITT>2.0.CO;2.
   CROOK B, 1991, AM IND HYG ASSOC J, V52, P271, DOI 10.1202/0002-8894(1991)052<0271:ADAMAA>2.0.CO;2.
   Donabedian SM, 2003, J CLIN MICROBIOL, V41, P1109, DOI 10.1128/JCM.41.3.1109-1113.2003.
   {*}ENV DEF, 1997, AN WAST SUMM.
   {*}FOOD DRUG ADM, 2004, FDA APPR AN DRUG PRO.
   Gambarotto K, 2001, J CLIN MICROBIOL, V39, P2354, DOI 10.1128/JCM.39.6.2354-2355.2001.
   Gorbach SL, 2001, NEW ENGL J MED, V345, P1202, DOI 10.1056/NEJM200110183451610.
   Hamscher G, 2003, ENVIRON HEALTH PERSP, V111, P1590, DOI 10.1289/ehp.6288.
   Hayes JR, 2003, APPL ENVIRON MICROB, V69, P7153, DOI 10.1128/AEM.69.12.7153-7160.2003.
   Institute of Medicine, 1998, ANT RES ISS OPT.
   Jensen LB, 2002, MICROB DRUG RESIST, V8, P369, DOI 10.1089/10766290260469642.
   Jensen LB, 1998, ANTIMICROB AGENTS CH, V42, P3330.
   Johnson AP, 1999, LANCET, V354, P2012, DOI 10.1016/S0140-6736(99)00344-X.
   Lewis DL, 2002, ENVIRON SCI TECHNOL, V36, p286A, DOI 10.1021/es0223426.
   Lin XJ, 1997, AM IND HYG ASSOC J, V58, P480, DOI 10.1080/15428119791012577.
   Mackiewicz B, 1998, ANN AGR ENV MED, V5, P169.
   Marcinak JF, 2003, CURR OPIN INFECT DIS, V16, P265, DOI 10.1097/01.qco.0000073778.11390.16.
   Mascini EM, 2001, INT J ANTIMICROB AG, V18, P395, DOI 10.1016/S0924-8579(01)00413-7.
   Mellon M., 2001, HOGGING IT ESTIMATES.
   Murray PRE, 2003, MANUAL CLIN MICROBIO.
   Nandi S, 2004, P NATL ACAD SCI USA, V101, P7118, DOI 10.1073/pnas.0306466101.
   {*}NAT RES COUNC, 1999, US DRUGS FOOD AN BEN.
   NCCLS, 2002, M31A2 NCCLS.
   {*}NNIS, 2001, AM J INFECT CONTROL, V29, P404.
   Predicala BZ, 2002, CURR MICROBIOL, V44, P136, DOI 10.1007/s00284-001-0064-y.
   Sorensen TL, 2001, NEW ENGL J MED, V345, P1161, DOI 10.1056/NEJMoa010692.
   {*}US EPA, 2000, EPA821R97004.
   van den Bogaard AE, 1999, DRUGS, V58, P589, DOI 10.2165/00003495-199958040-00002.
   WEBER D, 1989, S MED J, V92, P1204.
   Wegener HC, 1999, EMERG INFECT DIS, V5, P329, DOI 10.3201/eid0503.990303.
   Wegener HC, 2003, CURR OPIN MICROBIOL, V6, P439, DOI 10.1016/j.mib.2003.09.009.
   White DG, 2001, NEW ENGL J MED, V345, P1147, DOI 10.1056/NEJMoa010315.
   Wing S, 2000, ENVIRON HEALTH PERSP, V108, P233, DOI 10.2307/3454439.
   ZAHN JA, 2001, J ANIM SCI, V79, P189.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{74}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{57}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{899TY}},
Unique-ID = {{ISI:000227169400029}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000227112500030,
Author = {Mishra, M and Parise, G and Jackson, KD and Wozniak, DJ and Deora, R},
Title = {{The BvgAS signal transduction system regulates biofilm development in
   Bordetella}},
Journal = {{JOURNAL OF BACTERIOLOGY}},
Year = {{2005}},
Volume = {{187}},
Number = {{4}},
Pages = {{1474-1484}},
Month = {{FEB}},
Abstract = {{The majority of Bordetella sp. virulence determinants are regulated by
   the BvgAS signal transduction system. BvgAS mediates the control of
   multiple phenotypic phases and a spectrum of gene expression profiles
   specific to each phase in response to incremental changes in the
   concentrations of environmental signals. Studies highlighting the
   critical role of this signaling circuitry in the Bordetella infectious
   cycle have focused on planktonically growing bacterial cells. It is
   becoming increasingly clear that the major mode of bacterial existence
   in the environment and within the body is a surface-attached state known
   as a biofilm. Biofilms are defined as consortia of sessile
   microorganisms that are embedded in a matrix. During routine growth of
   Bordetella under agitating conditions, we noticed the formation of a
   bacterial ring at the air-liquid interface of the culture tubes. We show
   here that this surface adherence property reflects the ability of these
   organisms to form biofilms. Our data demonstrate that the BvgAS locus
   regulates biofilm development in Bordetella. The results reported in
   this study suggest that the Bvg-mediated control in biofilm development
   is exerted at later time points after the initial attachment of bacteria
   to the different surfaces. Additionally, we show that these biofilms are
   highly tolerant of a number of antimicrobials, including the ones that
   are currently recommended for treatment of veterinary and human
   infections caused by Bordetella spp. Finally, we discuss the
   significance of the biofilm lifestyle mode as a potential contributor to
   persistent infections.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Deora, R (Reprint Author), Wake Forest Univ Hlth Sci, Dept Microbiol \& Immunol, Med Ctr Blvd,Gray 5086, Winston Salem, NC 27157 USA.
   Wake Forest Univ Hlth Sci, Dept Microbiol \& Immunol, Winston Salem, NC 27157 USA.
   Wake Forest Univ Hlth Sci, Program Mol Genet, Winston Salem, NC 27157 USA.}},
DOI = {{10.1128/JB.187.4.1474-1484.2005}},
ISSN = {{0021-9193}},
Keywords-Plus = {{PSEUDOMONAS-AERUGINOSA BIOFILMS; VIRULENCE GENE-EXPRESSION;
   VIBRIO-CHOLERAE; ANTIBIOTIC-RESISTANCE; ERYTHROMYCIN RESISTANCE;
   PERTUSSIS INFECTION; MICROBIAL BIOFILMS; BACTERIAL BIOFILMS;
   ESCHERICHIA-COLI; CYSTIC-FIBROSIS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{rdeora@wfubmc.edu}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI-35177]; NHLBI NIH HHS {[}R01 HL058334, HL-58334]}},
Cited-References = {{AKERLEY BJ, 1993, J BACTERIOL, V175, P3468, DOI 10.1128/jb.175.11.3468-3479.1993.
   AKERLEY BJ, 1995, CELL, V80, P611, DOI 10.1016/0092-8674(95)90515-4.
   Anderson GG, 2003, SCIENCE, V301, P105, DOI 10.1126/science.1084550.
   Bartkus JM, 2003, J CLIN MICROBIOL, V41, P1167, DOI 10.1128/JCM.41.3.1167-1172.2003.
   Birkebaek NH, 1999, CLIN INFECT DIS, V29, P1239, DOI 10.1086/313448.
   Bourgeois N, 2003, J ANTIMICROB CHEMOTH, V51, P742, DOI 10.1093/jac/dkg145.
   Carbone M, 1999, INT J ANTIMICROB AG, V12, P355, DOI 10.1016/S0924-8579(99)00077-1.
   Cherry JD, 1999, CLIN INFECT DIS, V28, pS112, DOI 10.1086/515058.
   Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318.
   COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431.
   Cotter PA, 1997, MOL MICROBIOL, V24, P671, DOI 10.1046/j.1365-2958.1997.3821741.x.
   Cotter PA, 2003, TRENDS MICROBIOL, V11, P367, DOI 10.1016/S0966-842X(03)00156-2.
   COTTER PA, 1994, INFECT IMMUN, V62, P3381.
   Danese PN, 2001, METHOD ENZYMOL, V336, P19, DOI 10.1016/S0076-6879(01)36574-6.
   Davey ME, 2000, MICROBIOL MOL BIOL R, V64, P847, DOI 10.1128/MMBR.64.4.847-867.2000.
   Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295.
   de Tejada GM, 1998, INFECT IMMUN, V66, P2762.
   Deora R, 2004, TRENDS MICROBIOL, V12, P63, DOI 10.1016/j.tim.2003.12.004.
   Deora R, 2002, J BACTERIOL, V184, P6942, DOI 10.1128/JB.184.24.6942-6951.2002.
   Deora R, 2001, MOL MICROBIOL, V40, P669, DOI 10.1046/j.1365-2958.2001.02415.x.
   deTejada GM, 1996, MOL MICROBIOL, V22, P895.
   Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a.
   Friedman L, 2004, MOL MICROBIOL, V51, P675, DOI 10.1046/j.1365-2958.2003.03877.x.
   Gilberg S, 2002, J INFECT DIS, V186, P415, DOI 10.1086/341511.
   GOODNOW RA, 1980, MICROBIOL REV, V44, P722.
   Hammer BK, 2003, MOL MICROBIOL, V50, P101, DOI 10.1046/j.1365-2958.2003.03688.x.
   Hamon MA, 2001, MOL MICROBIOL, V42, P1199, DOI 10.1046/j.1365-2958.2001.02709.x.
   Heininger U, 2002, INFECT IMMUN, V70, P3777, DOI 10.1128/IAI.70.7.3777-3784.2002.
   Irie Y, 2004, J BACTERIOL, V186, P5692, DOI 10.1128/JB.186.17.5692-5698.2004.
   Kinnear SM, 1999, J BACTERIOL, V181, P5234.
   KNAPP S, 1988, J BACTERIOL, V170, P5059, DOI 10.1128/jb.170.11.5059-5066.1988.
   LAM J, 1980, INFECT IMMUN, V28, P546.
   LEWIS K, 1995, PEDIATR INFECT DIS J, V14, P388, DOI 10.1097/00006454-199505000-00010.
   Mah TF, 2003, NATURE, V426, P306, DOI 10.1038/nature02122.
   Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2.
   Mattoo S, 2000, INFECT IMMUN, V68, P2024, DOI 10.1128/IAI.68.4.2024-2033.2000.
   Mattoo S, 2001, FRONT BIOSCI, V6, pE168, DOI 10.2741/Mattoo.
   MILLER JF, 1989, J BACTERIOL, V171, P6345, DOI 10.1128/jb.171.11.6345-6348.1989.
   MILLER JF, 1992, J BACTERIOL, V174, P970, DOI 10.1128/jb.174.3.970-979.1992.
   Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2.
   O'Toole GA, 1999, METHOD ENZYMOL, V310, P91.
   Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227.
   Parsek MR, 2000, P NATL ACAD SCI USA, V97, P8789, DOI 10.1073/pnas.97.16.8789.
   Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x.
   Purevdorj B, 2002, APPL ENVIRON MICROB, V68, P4457, DOI 10.1128/AEM.68.9.4457-4464.2002.
   RELMAN D, 1990, CELL, V61, P1375, DOI 10.1016/0092-8674(90)90701-F.
   SCARLATO V, 1991, J BACTERIOL, V173, P7401, DOI 10.1128/jb.173.22.7401-7404.1991.
   Schaefer AL, 2001, METHOD ENZYMOL, V336, P41, DOI 10.1016/S0076-6879(01)36576-X.
   Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627.
   Solano C, 2002, MOL MICROBIOL, V43, P793, DOI 10.1046/j.1365-2958.2002.02802.x.
   STAINER DW, 1970, J GEN MICROBIOL, V63, P211, DOI 10.1099/00221287-63-2-211.
   Stanley NR, 2004, MOL MICROBIOL, V52, P917, DOI 10.1111/j.1365-2958.2004.04036.x.
   Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1.
   Stockbauer KE, 2001, MOL MICROBIOL, V39, P65, DOI 10.1046/j.1365-2958.2001.02191.x.
   Stoodley P, 2002, ANNU REV MICROBIOL, V56, P187, DOI 10.1146/annurev.micro.56.012302.160705.
   Stoodley P, 1999, J APPL MICROBIOL, V85, p19S, DOI 10.1111/j.1365-2672.1998.tb05279.x.
   Sutherland IW, 2001, TRENDS MICROBIOL, V9, P222, DOI 10.1016/S0966-842X(01)02012-1.
   Swords WE, 2004, INFECT IMMUN, V72, P106, DOI 10.1128/IAI.72.1.106-113.2004.
   VanderZee A, 1997, J BACTERIOL, V179, P6609, DOI 10.1128/jb.179.21.6609-6617.1997.
   Watnick P, 2000, J BACTERIOL, V182, P2675, DOI 10.1128/JB.182.10.2675-2679.2000.
   Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x.
   Wilson KE, 2002, J CLIN MICROBIOL, V40, P2942, DOI 10.1128/JCM.40.8.2942-2944.2002.
   Wozniak DJ, 2003, P NATL ACAD SCI USA, V100, P7907, DOI 10.1073/pnas.1231792100.
   Wright SW, 1998, SOUTHERN MED J, V91, P702.
   Yeh Sylvia H, 2003, Expert Rev Vaccines, V2, P113, DOI 10.1586/14760584.2.1.113.
   Yuk MH, 2000, MOL MICROBIOL, V35, P991, DOI 10.1046/j.1365-2958.2000.01785.x.
   Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299.}},
Number-of-Cited-References = {{67}},
Times-Cited = {{45}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Bacteriol.}},
Doc-Delivery-Number = {{898YQ}},
Unique-ID = {{ISI:000227112500030}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@incollection{ ISI:000234108500001,
Author = {Kumar, K and Gupta, SC and Chander, Y and Singh, AK},
Editor = {{Sparks, DL}},
Title = {{Antibiotic use in agriculture and its impact on the terrestrial
   environment}},
Booktitle = {{ADVANCES IN AGRONOMY, VOL 87}},
Series = {{Advances in Agronomy}},
Year = {{2005}},
Volume = {{87}},
Pages = {{1-54}},
Abstract = {{Since their discovery, antibiotics have been instrumental in treating
   infectious diseases that were previously known to kill humans and
   animals. However, their widespread use as an additive in animal feeds
   has raised concerns about the development of antibiotic-resistant
   microorganisms. Increasingly, more microorganisms are becoming resistant
   to multiple antibiotics. A high proportion of the antibiotics added to
   animal feed is excreted in urine or manure. In some cases, as much as
   90\% of the antibiotic administered orally may pass through the animal
   unchanged. Once excreted in urine and manure, these antibiotics can
   enter surface and/or groundwater through nonpoint source pollution from
   manure-applied lands. The literature shows that most of the antibiotics
   are strongly adsorbed in soils and are not readily degraded. An
   important environmental concern is the presence of antibiotics in
   sources of potable water. Except erythromycin and some sulfa drugs, most
   of the antibiotics found in surface waters have been only in minute
   quantities. In all cases, the amounts observed are in parts per billion
   ranges; 100- to 1000-fold below minimum inhibitory concentration.
   Tetracyclines and penicillins, two of the most commonly used antibiotics
   in animal agriculture, have seldom been found in sources of potable
   water. There has been some reported presence of resistant bacteria in
   surface waters. This may have been from transport of resistant bacteria
   via animal or insect vectors, in airborne dusts, or simply water flow
   from some antibiotic-rich setting such as manure lagoons. Direct toxic
   effects of antibiotics on plants and soil micro-flora and -fauna are
   unlikely because of the low concentrations at which antibiotics in
   manure are land-applied. The indirect effects of antibiotics on the food
   web, however, cannot be discounted at this stage. Decrease in some
   components of the soil microbial populations due to manure-applied
   antibiotics could cause loss of food sources for other soil organisms,
   which, in turn, could affect important soil microbial processes such as
   decomposition and mineralization. Also, repeated application of
   antibiotic-laden manure can provide an environment in which selection of
   anti biotic-resistant bacteria can occur. Prudent use of antibiotics to
   a bare minimum along with alternative methods that minimize development
   and proliferation of resistant bacteria need investigation. (c) 2005,
   Elsevier Inc.}},
Publisher = {{ELSEVIER ACADEMIC PRESS INC}},
Address = {{525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Review; Book Chapter}},
Language = {{English}},
Affiliation = {{Kumar, K (Reprint Author), Univ Minnesota, Dept Soil Water \& Climate, St Paul, MN 55108 USA.
   Univ Minnesota, Dept Soil Water \& Climate, St Paul, MN 55108 USA.
   Univ Minnesota, Dept Vet Diagnost Med, St Paul, MN 55108 USA.}},
DOI = {{10.1016/S0065-2113(05)87001-4}},
ISSN = {{0065-2113}},
ISBN = {{0-12-000785-1}},
Keywords-Plus = {{TETRACYCLINE RESISTANCE GENES; TANDEM MASS-SPECTROMETRY; FLUOROQUINOLONE
   ANTIBACTERIAL AGENTS; PERFORMANCE LIQUID-CHROMATOGRAPHY; WASTE-WATER
   CONTAMINANTS; SOLID-PHASE EXTRACTION; ESCHERICHIA-COLI; AQUATIC
   ENVIRONMENT; VETERINARY ANTIBIOTICS; ENTEROCOCCUS-FAECIUM}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Agronomy}},
ResearcherID-Numbers = {{chander, yogesh/C-7166-2011}},
ORCID-Numbers = {{chander, yogesh/0000-0002-5047-8331}},
Cited-References = {{Aga DS, 2003, ANALYST, V128, P658, DOI 10.1039/b301630g.
   Aiello S. E., 1998, MERCK VET MANUAL.
   Al-Ahmad A, 1999, ARCH ENVIRON CON TOX, V37, P158, DOI 10.1007/s002449900501.
   ALDER CA, 2001, S SERIES AM CHEM SOC, V791.
   Aminov RI, 2001, APPL ENVIRON MICROB, V67, P22, DOI 10.1128/AEM.67.1.22-32.2001.
   Andreozzi R, 2003, CHEMOSPHERE, V50, P1319, DOI 10.1016/S0045-6535(02)00769-5.
   Arnold CG, 1998, ENVIRON SCI TECHNOL, V32, P2976, DOI 10.1021/es980114z.
   Arvanitidou M, 1997, WATER RES, V31, P1112, DOI 10.1016/S0043-1354(96)00340-5.
   Ash RJ, 2002, EMERG INFECT DIS, V8, P713, DOI 10.3201/eid0807.010264.
   Avery AM, 2004, ANTIMICROB AGENTS CH, V48, P1892, DOI 10.1128/AAC.48.5.1892-1894.2004.
   Bager F, 1997, PREV VET MED, V31, P95, DOI 10.1016/S0167-5877(96)01119-1.
   Baguer AJ, 2000, CHEMOSPHERE, V40, P751, DOI 10.1016/S0045-6535(99)00449-X.
   BATCHELDER AR, 1982, J ENVIRON QUAL, V11, P675, DOI 10.2134/jeq1982.00472425001100040023x.
   BENET CZ, 1990, PHARM BASIS THERAPEU.
   BESTER K, 2003, ABSTRACTS PAPERS AM, V223.
   Boehm R., 1996, DTW (Deutsche Tieraerztliche Wochenschrift), V103, P264.
   Boothe DH, 2003, J FOOD PROTECT, V66, P94, DOI 10.4315/0362-028X-66.1.94.
   Boreen AL, 2003, AQUAT SCI, V65, P320, DOI 10.1007/s00027-003-0672-7.
   Bower CK, 1999, INT J FOOD MICROBIOL, V50, P33, DOI 10.1016/S0168-1605(99)00075-6.
   Boxall A., 2003, ENVIRON SCI TECHNOL, V37, p287A.
   Boxall ABA, 2004, REV ENVIRON CONTAM T, V180, P1, DOI 10.1007/0-387-21729-0\_1.
   Boxall ABA, 2002, TOXICOL LETT, V131, P19, DOI 10.1016/S0378-4274(02)00063-2.
   Bryan A, 2004, APPL ENVIRON MICROB, V70, P2503, DOI 10.1128/AEM.70.4.2503-2507.2004.
   Calamari D, 2003, ENVIRON SCI TECHNOL, V37, P1241, DOI 10.1021/es020158e.
   Campagnolo ER, 2002, SCI TOTAL ENVIRON, V299, P89, DOI 10.1016/S0048-9697(02)00233-4.
   Carballa M, 2004, WATER RES, V38, P2918, DOI 10.1016/j.watres.2004.03.029.
   CHANDER Y, 2003, ASA CSSA SSSA M NOV.
   Chee-Sanford JC, 2001, APPL ENVIRON MICROB, V67, P1494, DOI 10.1128/AEM.67.4.1494-1502.2001.
   CHURCH DC, 1982, BASIC ANIMAL NUTR FE, P238.
   Corpet DE, 1996, REV MED VET-TOULOUSE, V147, P851.
   DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624.
   De Liguoro M, 1998, ANALYST, V123, P1279.
   De Liguoro M, 2003, CHEMOSPHERE, V52, P203, DOI 10.1016/S0045-6535(03)00284-4.
   Dewey CE, 1997, PREV VET MED, V31, P133, DOI 10.1016/S0167-5877(96)01077-X.
   Doll TE, 2003, CHEMOSPHERE, V52, P1757, DOI 10.1016/S0045-6535(03)00446-6.
   DONOHO AL, 1984, J ANIM SCI, V58, P1528.
   Doughton C.G., 1999, ENV HLTH PERSPECT, V107, P907.
   ELMUND GK, 1971, B ENVIRON CONTAM TOX, V6, P129, DOI 10.1007/BF01540093.
   {*}FDA, 1998, FDA APPR AN DRUG LIS.
   {*}FDA CTR VET MED, 2001, HUM HLTH IMP FLUOR R.
   FEINMAN SE, 1978, DRAFT ENV IMPACT STA, P372.
   GASKINS HR, 2002, PORK QUALITY SAFETY, P213.
   GAST RK, 1988, POULTRY SCI, V67, P699, DOI 10.3382/ps.0670699.
   GAVALCHIN J, 1994, J AOAC INT, V77, P481.
   GILBERTSON TJ, 1990, J AGR FOOD CHEM, V38, P890, DOI 10.1021/jf00093a064.
   GODSMITH RS, 1992, BASIC CLIN PHARM, P723.
   GOLDBURG D, 1999, ENV DEFENSE NEWS LET.
   Golet EM, 2003, ENVIRON SCI TECHNOL, V37, P3243, DOI 10.1021/es0264448.
   Golet EM, 2002, ENVIRON SCI TECHNOL, V36, P3645, DOI 10.1021/es0256212.
   GOYAL SM, 1979, REV MICROBIOL, V10, P50.
   GuerrierTakada C, 1997, P NATL ACAD SCI USA, V94, P8468, DOI 10.1073/pnas.94.16.8468.
   GUPTA SC, 2003, ASA CSSA SSSA M NOV.
   Haller MY, 2002, J CHROMATOGR A, V952, P111, DOI 10.1016/S0021-9673(02)00083-3.
   Halling-Sorensen B, 2003, CHEMOSPHERE, V50, P1331, DOI 10.1016/S0045-6535(02)00766-X.
   Halling-Sorensen B, 2003, ARCH ENVIRON CON TOX, V44, P7, DOI 10.1007/s00244-002-1234-z.
   Halling-Sorensen B, 2001, ARCH ENVIRON CON TOX, V40, P451, DOI 10.1007/s002440010197.
   Halling-Sorensen B, 1998, CHEMOSPHERE, V36, P357, DOI 10.1016/S0045-6535(97)00354-8.
   Halling-Sorensen B, 2002, ARCH ENVIRON CON TOX, V42, P263, DOI 10.1007/s00244-001-0017-2.
   Hamscher G, 2002, ANAL CHEM, V74, P1509, DOI 10.1021/ac015588m.
   Heinemann JA, 1999, DRUG DISCOV TODAY, V4, P72, DOI 10.1016/S1359-6446(98)01294-X.
   HEKTOEN H, 1995, AQUACULTURE, V133, P175, DOI 10.1016/0044-8486(94)00310-K.
   HERRMAN T, 2001, MED FEED ADDITIVES B.
   HERRMAN T, 2001, MED FEED ADDITIVES S.
   HERRON PR, 1997, SOIL BIOL BIOCHEM, V30, P673.
   Hirsch R, 1999, SCI TOTAL ENVIRON, V225, P109, DOI 10.1016/S0048-9697(98)00337-4.
   HIRSH DC, 1977, AM J VET RES, V38, P1137.
   HOEVERSTADT T, 1986, SCAND J GASTROENTERO, V21, P997.
   Hofacre CL, 2000, AVIAN DIS, V44, P963, DOI 10.2307/1593073.
   HOGUE DE, 1956, J ANIM SCI, V14, P788.
   Houglum JE, 1997, J AOAC INT, V80, P961.
   Hudson CR, 2000, J CLIN MICROBIOL, V38, P1860.
   HUMMEL R, 1986, J BASIC MICROB, V26, P461, DOI 10.1002/jobm.3620260806.
   HUNTER JEB, 1992, EPIDEMIOL INFECT, V108, P271, DOI 10.1017/S0950268800049748.
   HUNTER JEB, 1994, EPIDEMIOL INFECT, V112, P473, DOI 10.1017/S0950268800051177.
   Ingerslev F, 2001, ECOTOX ENVIRON SAFE, V48, P311, DOI 10.1006/eesa.2000.2026.
   Ingerslev F, 2000, ENVIRON TOXICOL CHEM, V19, P2467, DOI 10.1897/1551-5028(2000)019<2467:BPOSIA>2.3.CO;2.
   Ingerslev F, 2001, CHEMOSPHERE, V44, P865, DOI 10.1016/S0045-6535(00)00479-3.
   INGHAM ER, 1984, MICROBIAL ECOL, V10, P345, DOI 10.1007/BF02015559.
   INGHAM ER, 1991, PEDOBIOLOGIA, V35, P297.
   Jensen J, 2003, CHEMOSPHERE, V50, P437, DOI 10.1016/S0045-6535(02)00336-3.
   Jjemba PK, 2002, CHEMOSPHERE, V46, P1019, DOI 10.1016/S0045-6535(01)00139-4.
   Jorgensen SE, 2000, CHEMOSPHERE, V40, P691, DOI 10.1016/S0045-6535(99)00438-5.
   Kay P, 2004, ENVIRON TOXICOL CHEM, V23, P1136, DOI 10.1897/03-374.
   KELLY TR, 1997, POULTRY SCI, V77, P243.
   Khachatourians GG, 1998, CAN MED ASSOC J, V159, P1129.
   Klare I, 1995, MICROB DRUG RESIST, V1, P265, DOI 10.1089/mdr.1995.1.265.
   KLOPFENSTEIN TJ, 1964, J ANIM SCI, V23, P490.
   KOBE A, 1995, BERL MUNCH TIERARZTL, V108, P412.
   Koenraad PMFJ, 1995, EPIDEMIOL INFECT, V115, P475, DOI 10.1017/S0950268800058635.
   Kolpin DW, 2004, SCI TOTAL ENVIRON, V328, P119, DOI 10.1016/j.scitotenv.2004.01.015.
   Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j.
   KROKER R, 1983, WISSENSCHAFT UMWELT, V4, P305.
   KULDA J, 1995, PARASIT PROTOZ, V10, P225.
   Kumar K, 2004, J ENVIRON QUAL, V33, P250, DOI 10.2134/jeq2004.0250.
   KUMAR K, 2002, ASA CSSA SSSA M NOV, P188.
   Kummerer K, 2001, CHEMOSPHERE, V45, P957, DOI 10.1016/S0045-6535(01)00144-8.
   Kummerer K, 2000, CHEMOSPHERE, V40, P701, DOI 10.1016/S0045-6535(99)00439-7.
   LAI HT, 1995, J ENVIRON SCI HEAL A, V30, P1897, DOI 10.1080/10934529509376311.
   LANZKY PF, 1997, CHEMOSPHERE, V35, P253.
   Levy S. B., 1992, ANTIBIOTIC PARADOX M.
   LEVY SB, 1976, NATURE, V260, P40, DOI 10.1038/260040a0.
   Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46.
   Lindsey ME, 2001, ANAL CHEM, V73, P4640, DOI 10.1021/ac010514w.
   Lipsitcht M, 2002, P NATL ACAD SCI USA, V99, P5752, DOI 10.1073/pnas.09214299.
   LUNESTAD BT, 1990, DIS AQUAT ORGAN, V9, P67, DOI 10.3354/dao009067.
   Malik YS, 2003, AVIAN DIS, V47, P588, DOI 10.1637/6086.
   MARCI A, 1988, ECOTOX ENVIRON SAFE, V16, P90.
   Marengo JR, 1997, ENVIRON TOXICOL CHEM, V16, P462, DOI 10.1897/1551-5028(1997)016<0462:ABOCSH>2.3.CO;2.
   Mazel D, 1999, CELL MOL LIFE SCI, V56, P742, DOI 10.1007/s000180050021.
   McEwen SA, 2002, CLIN INFECT DIS, V34, pS93, DOI 10.1086/340246.
   McManus PS, 2002, ANNU REV PHYTOPATHOL, V40, P443, DOI 10.1146/annurev.phyto.40.120301.093927.
   Mellon M., 2001, HOGGING IT ESTIMATES.
   Migliore L, 1997, WATER RES, V31, P1801, DOI 10.1016/S0043-1354(96)00412-5.
   Morrison S. M., 1969, AN WAST MAN CORN U C, P336.
   NANDI S, 2004, P NAT ACAD SCI, P1.
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064.
   NIKOLICH MP, 1994, APPL ENVIRON MICROB, V60, P3255.
   NORDENBERG T, 1998, FDA CONSUM, V32, P6.
   Nowara A, 1997, J AGR FOOD CHEM, V45, P1459, DOI 10.1021/jf960215l.
   NYSTEN R, 1996, J ANTIMICROB CHEMOTH, V37, P1131.
   NYSTEN R, 1996, J ANTIMICROB CHEMOTH, V37, P1141.
   O'Brien TF, 2002, CLIN INFECT DIS, V34, pS78, DOI 10.1086/340244.
   OKA H, 1989, J AGR FOOD CHEM, V37, P226, DOI 10.1021/jf00085a052.
   Oka H, 2000, J CHROMATOGR A, V882, P109, DOI 10.1016/S0021-9673(99)01316-3.
   Park JC, 2003, WATER SCI TECHNOL, V47, P249.
   PATTEN DK, 1980, J ENVIRON QUAL, V9, P167, DOI 10.2134/jeq1980.00472425000900010035x.
   PINCK L. A., 1961, SOIL SCI, V91, P94, DOI 10.1097/00010694-196102000-00003.
   PINCK L. A., 1962, SOIL SCI, V94, P129, DOI 10.1097/00010694-196208000-00011.
   PINCK LOUIS A., 1961, SOIL SCI, V91, P22, DOI 10.1097/00010694-196101000-00006.
   Pursell L, 1995, AQUACULTURE, V135, P245, DOI 10.1016/0044-8486(95)01028-9.
   Rabolle M, 2000, CHEMOSPHERE, V40, P715, DOI 10.1016/S0045-6535(99)00442-7.
   RAUN AP, 1990, RUMENSIN 1990S, pA1.
   Richter A, 1996, PRAKT TIERARZT, V77, P603.
   Rooklidge SJ, 2004, SCI TOTAL ENVIRON, V325, P1, DOI 10.1016/j.scitotenv.2003.11.007.
   ROTH FX, 1993, J ANIM PHYSIOL AN N, V69, P175, DOI 10.1111/j.1439-0396.1993.tb00803.x.
   Sacher F, 2001, J CHROMATOGR A, V938, P199, DOI 10.1016/S0021-9673(01)01266-3.
   SAMUELSEN OB, 1989, AQUACULTURE, V83, P7, DOI 10.1016/0044-8486(89)90056-2.
   Schlusener MP, 2003, ANAL BIOANAL CHEM, V375, P942, DOI {[}10.1007/s00216-003-2009-8, 10.1007/s00216-003-1838-9].
   Schroeder CM, 2002, APPL ENVIRON MICROB, V68, P576, DOI 10.1128/AEM.68.2.576-581.2002.
   Sengelov G, 2003, ENVIRON INT, V28, P587, DOI 10.1016/S0160-4120(02)00084-3.
   Shea KM, 2003, PEDIATRICS, V112, P253.
   SINGH AK, 2004, UNPUB GEODERMA.
   Smith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001.
   SOLOMONS IA, 1978, J ANIM SCI, V46, P1360.
   Sommer C, 2002, EUR J SOIL BIOL, V38, P155, DOI 10.1016/S1164-5563(02)01138-X.
   SOULIDES DA, 1962, SOIL SCI, V91, P90.
   Stobberingh E, 1999, ANTIMICROB AGENTS CH, V43, P2215.
   Summers AO, 2002, CLIN INFECT DIS, V34, pS85, DOI 10.1086/340245.
   SUNDIN GW, 1995, CAN J MICROBIOL, V41, P792, DOI 10.1139/m95-109.
   Swartz MN, 2002, CLIN INFECT DIS, V34, pS111, DOI 10.1086/340248.
   Tedeschi LO, 2003, J ENVIRON QUAL, V32, P1591, DOI 10.2134/jeq2003.1591.
   Ternes T, 2001, J CHROMATOGR A, V938, P175, DOI 10.1016/S0021-9673(01)01205-5.
   Terpstra S, 1999, J HOSP INFECT, V43, P195, DOI 10.1053/jhin.1999.0636.
   Thiele-Bruhn S, 2003, J PLANT NUTR SOIL SC, V166, P145, DOI 10.1002/jpln.200390023.
   TIETJEN C, 1975, MANAGING LIVESTOCK W, P328.
   Tolls J, 2001, ENVIRON SCI TECHNOL, V35, P3397, DOI 10.1021/es0003021.
   {*}US EPA, 1993, RED FACTS HYDR MON O.
   {*}US EPA, 1992, RED FACTS STREPT STR.
   {*}US OFF TECHN ASS, 1995, IMP ANT RES BACT, pCH1.
   {*}USDA, 1997, DAT MAN PROD US.
   van den Bogaard AE, 2002, J ANTIMICROB CHEMOTH, V49, P497, DOI 10.1093/jac/49.3.497.
   van den Bogaard AE, 2001, J ANTIMICROB CHEMOTH, V47, P763, DOI 10.1093/jac/47.6.763.
   Van Dijk J., 2000, RESIDUES VET DRUGS F.
   VANGOOL S, 1993, TIJDSCHR DIERGENEESK, P8.
   VELAGALETI RR, 1993, ABSTR PAP AM CHEM S, V205, P92.
   Vidaver AK, 2002, CLIN INFECT DIS, V34, pS107, DOI 10.1086/340247.
   Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219.
   WARMAN PR, 1977, SOIL BIOL BIOCHEM, V9, P267, DOI 10.1016/0038-0717(77)90033-5.
   WARMAN PR, 1981, CAN J SOIL SCI, V61, P161, DOI 10.4141/cjss81-017.
   WARMAN PR, 1980, J SOIL SCI SOC AM, V44, P1333.
   WEBB KE, 1975, J ANIM SCI, V41, P1212.
   Weerasinghe CA, 1997, ENVIRON TOXICOL CHEM, V16, P1873, DOI 10.1897/1551-5028(1997)016<1873:ABOVIS>2.3.CO;2.
   Wegener HC, 1999, EMERG INFECT DIS, V5, P329, DOI 10.3201/eid0503.990303.
   Weldon W C., 1997, P WORLD PORK EXP SWI.
   Westergaard K, 2001, SOIL BIOL BIOCHEM, V33, P2061, DOI 10.1016/S0038-0717(01)00134-1.
   Winckler C., 2001, Journal of Soils and Sediments, V1, P66, DOI 10.1007/BF02987711.
   Witte W., 2000, INT J ANTIMICROB S1, V16, P19, DOI DOI 10.1016/S0924-8579(00)00301-0.
   Yang SW, 2003, WATER RES, V37, P4645, DOI 10.1016/S0043-1354(03)00399-3.
   YEAGER RL, 1990, J AGR FOOD CHEM, V38, P883, DOI 10.1021/jf00093a062.
   ZEPP RG, 1977, ENVIRON SCI TECHNOL, V11, P359, DOI 10.1021/es60127a013.
   Zhu J, 2001, J CHROMATOGR A, V928, P177, DOI 10.1016/S0021-9673(01)01139-6.
   1999, FDA SHOULD BAN USE C.}},
Number-of-Cited-References = {{182}},
Times-Cited = {{224}},
Usage-Count-Last-180-days = {{24}},
Usage-Count-Since-2013 = {{243}},
Journal-ISO = {{Adv. Agron.}},
Doc-Delivery-Number = {{BDL16}},
Unique-ID = {{ISI:000234108500001}},
DA = {{2018-08-13}},
}

@article{ ISI:000227476800014,
Author = {Donderski, W and Walczak, M and Pietrzak, M},
Title = {{Microbiological contamination of air within the City of Torun}},
Journal = {{POLISH JOURNAL OF ENVIRONMENTAL STUDIES}},
Year = {{2005}},
Volume = {{14}},
Number = {{2}},
Pages = {{223-230}},
Abstract = {{Research was conducted for the present paper on microbiological
   contamination of the air within the City of Torun. It follows from the
   studies conducted that microorganisms occurred in greater numbers in the
   air within the area of the Old Town than in the Rubinkowo residential
   district. The number of microorganisms in the air was subject to
   seasonal changes. The highest numbers of heterotrophic mesophylic
   bacteria (CFU 37degreesC) were found in the summer season and the lowest
   in the winter season. The majority of isolated bacteria belonged to Gram
   positive forms - bacilli or cocci. A significant proportion of the
   isolated bacteria displayed antibiotic resistance to commonly used
   antibiotics.}},
Publisher = {{HARD}},
Address = {{POST-OFFICE BOX, 10-718 OLSZTYN 5, POLAND}},
Type = {{Letter}},
Language = {{English}},
Affiliation = {{Walczak, M (Reprint Author), Nicholas Copernicus Univ, Dept Environm Microbiol \& Biotechnol, Ul Gagarina 9, PL-87100 Torun, Poland.
   Nicholas Copernicus Univ, Dept Environm Microbiol \& Biotechnol, PL-87100 Torun, Poland.}},
ISSN = {{1230-1485}},
Keywords = {{microflora of the air; antibiotic resistance}},
Research-Areas = {{Environmental Sciences \& Ecology}},
Web-of-Science-Categories  = {{Environmental Sciences}},
Author-Email = {{walczak@biol.uni.torun.pl}},
ORCID-Numbers = {{Walczak, Maciej/0000-0002-1039-9516}},
Cited-References = {{ALKIEWICZ J, 1966, MED MICROBIOLOGY.
   ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   BLANCHARD DC, 1970, SCIENCE, V170, P626, DOI 10.1126/science.170.3958.626.
   BOURDILLON RB, 1948, STUDIES AIR HYGIENE.
   CAMANN D, 1980, EPA600980028169.
   Cox CS, 1987, AEROBIOLOGICAL PATHW, P1403.
   CRONHOLM LS, 1980, APPL ENVIRON MICROB, V39, P6.
   DROGOSZ K, 1980, OCHRONA POWIETRZA, V3, P60.
   DUTKIEWICZ J, 1989, BIOL HASARDS WORK.
   Filipkowska Z, 2000, POL J ENVIRON STUD, V9, P273.
   FILIPKOWSKA Z, 1999, POLITECHNIKA CZESTOC, V48.
   FILIPKOWSKA Z, 1999, INZYNIERIA OCHRONA S, V2, P333.
   GADZIKIEWICZ W, 1949, METHOD HYGIENIC EXAM.
   JUDA J, 1974, CONSERVATION ATMOSPH.
   Kajak Z, 1998, HYDROBIOLOGY LIMNOLO.
   KALUZEWSKI S, 1976, PRINCIPLES METHODS D.
   KEDZIA W., 1990, MICROBIOLOGICAL DIAG.
   KOSINSKA I, 1994, MICROORGANISMS ATMOS.
   KRZYSZTOFIK B, 1968, K NAUK TECHN NOT PZI.
   KULIG A, 1986, METHODS EVALUATION C.
   KUNICKIGOLDFING.W, 1998, LIFE BACTERIA.
   MARSZEWSKAZIEMI.J, 1969, MICROBIOLOGY SOIL OR.
   MILLER G, 1983, OUTLINE MICROBIOLOGY.
   OSSOWSKACYPRYK K, 1987, MAT 11 K NAUK TECH N, V82.
   PIETRZAK M, 2002, 8 OG SEM STUD BIOT S.
   {*}POL NORM, AIR PUR PROT MICR TE.
   PRZYLECKI S, 1952, MED PRACY, V2, P177.
   ROMANSKA B, 1963, POLSKI TYGODNIK LEKA, V18, P625.
   SLACHCIAK W, 2002, BIBLIO MONITORINGU S.
   SLACHCIAK W, 2001, BIBLIO MONITORINGU S.
   SMITH J, 1960, INTRO IND MYCOLOGY.
   ZDZIENICKI S, 1969, BIOL AEROSOLS.}},
Number-of-Cited-References = {{32}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Pol. J. Environ. Stud.}},
Doc-Delivery-Number = {{904DR}},
Unique-ID = {{ISI:000227476800014}},
DA = {{2018-08-13}},
}

@article{ ISI:000225556600004,
Author = {Clausell, A and Busquets, MA and Pujol, M and Alsina, A and Cajal, Y},
Title = {{Polymyxin B-lipid interactions in Langmuir-Blodgett monolayers of
   Escherichia coli lipids: A thermodynamic and atomic force microscopy
   study}},
Journal = {{BIOPOLYMERS}},
Year = {{2004}},
Volume = {{75}},
Number = {{6}},
Pages = {{480-490}},
Month = {{DEC 15}},
Abstract = {{The dramatically increased frequency of antibiotic resistance has led to
   intensive efforts towards developing new families of antibiotics.
   Membrane-active antibiotic peptides such as polymyxin B (PxB) hold
   promise as the next generation of antibiotics, since they rarely spur
   the evolution of resistance. At low concentrations in the membrane, PxB
   forms vesicle-vesicle contacts and induces lipid exchange without
   leakage or fusion, a phenomenon that can explain its specificity towards
   Gram-negative bacteria by contact formation between the two
   phospholipids interfaces in the periplasmatic space. In this work, the
   interaction of PxB and the nonantibiotic derivative polymyxin B
   nonapeptide (PxB-NP) with monolayers of Escherichia coli membrane lipids
   (ECL) has been studied by thermodynamic and structural methods. PxB
   inserts itself into ECL monolayers as a conformation that forms
   intermembrane contacts with vesicles injected underneath, and induces
   lipid exchange when the monolayer surface pressure is set at 32 mN/m
   (membrane equivalence pressure) or net transfer vesicle-to-monolayer at
   lower surface pressures. Thermodynamic analysis of the compression
   isotherms of mixed monolayers indicates that PxB inserts into the
   monolayer with an expansion of the mean molecular area, implying that
   peptide and lipids form nonideal mixtures. At low concentrations,
   corresponding to the membrane-membrane contact form of PxB, the mixed
   monolayers present positive excess energy values (DeltaG(m)(Ex)), and
   atomic force microscopy (AFM) imaging reveals structures of similar
   to120-nm diameter that protrude from the lipid surface similar to0.7 nm.
   At concentrations of PxB above 4 mol \%, thermodynamic analysis gives a
   very high DeltaG(m)(Ex), corresponding to nonfavorable interactions, and
   AFM images show round structures of 20-30nm diameter. PxB-NP behaves in
   a totally different way, in agreement with its inability to form.
   vesicle-vesicle contacts and its lack of antibiotic effect. These
   results are discussed in the light of the mechanism of action of PxB on
   the membrane of Gram-negative bacteria. (C) 2004 Wiley Periodicals, Inc.}},
Publisher = {{JOHN WILEY \& SONS INC}},
Address = {{111 RIVER ST, HOBOKEN, NJ 07030 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cajal, Y (Reprint Author), Univ Barcelona, Fac Pharm, Dept Chem Phys, Avn Joan 23 S-N, E-08028 Barcelona, Spain.
   Univ Barcelona, Fac Pharm, Dept Chem Phys, E-08028 Barcelona, Spain.}},
DOI = {{10.1002/bip.20165}},
ISSN = {{0006-3525}},
Keywords = {{antibiotic peptides; lipid exchange; polymyxins; Langmuir-Blodgett
   monolayers; lipid-peptide interaction}},
Keywords-Plus = {{INTERMEMBRANE MOLECULAR CONTACTS; CATIONIC ANTIMICROBIAL PEPTIDES;
   ANTIBIOTIC-RESISTANCE; AIR/WATER INTERFACE; PHOSPHOLIPIDS; MEMBRANES;
   EXCHANGE; STRESS; INDUCE; FILMS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biophysics}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biophysics}},
Author-Email = {{ycajal@ub.edu}},
ResearcherID-Numbers = {{Busquets, M. Antonia/H-6555-2015
   PUJOL, Montserrat/G-1315-2016
   Cajal, Yolanda/G-4144-2016}},
ORCID-Numbers = {{Busquets, M. Antonia/0000-0002-6232-9886
   PUJOL, Montserrat/0000-0001-9675-1789
   Cajal, Yolanda/0000-0003-1603-8313}},
Cited-References = {{Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D.
   Birdi K. S., 1989, LIPID BIOPOLYMER MON, P57.
   Bruch MD, 1999, J AM CHEM SOC, V121, P11993, DOI 10.1021/ja992376m.
   Cajal Y, 1996, BIOCHEMISTRY-US, V35, P299, DOI 10.1021/bi9512408.
   Cajal Y, 1996, BIOCHEMISTRY-US, V35, P5684, DOI 10.1021/bi952703c.
   CAJAL Y, 1995, BIOCHEM BIOPH RES CO, V210, P746, DOI 10.1006/bbrc.1995.1722.
   Cassell GH, 2001, JAMA-J AM MED ASSOC, V285, P601, DOI 10.1001/jama.285.5.601.
   Clausell A, 2001, J PHYS IV, V11, P227, DOI 10.1051/jp4:20011036.
   Coates A, 2002, NAT REV DRUG DISCOV, V1, P895, DOI 10.1038/nrd940.
   Davies J., 1963, INTERFACIAL PHENOMEN.
   Denton M, 1998, CLIN MICROBIOL REV, V11, P57.
   Diociaiuti M, 2002, BIOPHYS J, V82, P3198, DOI 10.1016/S0006-3495(02)75662-2.
   Dufrene YF, 2000, BBA-BIOMEMBRANES, V1509, P14, DOI 10.1016/S0005-2736(00)00346-1.
   Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4.
   Feng SS, 2002, LANGMUIR, V18, P4061, DOI 10.1021/la011545p.
   Gaines G., 1966, INSOLUBLE MONOLAYERS.
   Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856.
   Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317.
   Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7.
   Jin Y, 2003, BIOCHEMISTRY-US, V42, P9395, DOI 10.1021/bi034338s.
   JOOS R, 1969, BIOCHIM BIOPHYS ACTA, V183, P447.
   Kim K, 2000, J BIOMED MATER RES, V52, P836, DOI 10.1002/1097-4636(20001215)52:4<836::AID-JBM30>3.0.CO;2-4.
   Krol S, 2000, BIOPHYS J, V79, P904, DOI 10.1016/S0006-3495(00)76346-6.
   KUBESCH P, 1987, BIOCHEMISTRY-US, V26, P2139, DOI 10.1021/bi00382a012.
   Liechty A, 2000, BBA-BIOMEMBRANES, V1463, P55, DOI 10.1016/S0005-2736(99)00178-9.
   Lucentini J, 2003, SCIENTIST, V17, P29.
   Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5.
   Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3.
   MCCLARE CWF, 1971, ANAL BIOCHEM, V39, P527, DOI 10.1016/0003-2697(71)90443-X.
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064.
   Oh JT, 2000, BBA-BIOMEMBRANES, V1463, P43, DOI 10.1016/S0005-2736(99)00177-7.
   Oh JT, 1998, BBA-BIOMEMBRANES, V1415, P235, DOI 10.1016/S0005-2736(98)00195-3.
   Oh JT, 1998, BIOCHEM BIOPH RES CO, V246, P619, DOI 10.1006/bbrc.1998.8682.
   RODRIGUEZ JM, 2001, J COLLOID INTERF SCI, V240, P113.
   SABERWAL G, 1994, BBA-REV BIOMEMBRANES, V1197, P109, DOI 10.1016/0304-4157(94)90002-7.
   STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451.
   Taylor SE, 1997, BBA-BIOMEMBRANES, V1326, P257, DOI 10.1016/S0005-2736(97)00029-1.
   Trommeshauser D, 1998, CHEM PHYS LIPIDS, V94, P81, DOI 10.1016/S0009-3084(98)00047-4.
   World Health Organization, 2001, WHO GLOB STRAT CONT.
   Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299.
   Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a.
   Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000.
   Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Biopolymers}},
Doc-Delivery-Number = {{877GT}},
Unique-ID = {{ISI:000225556600004}},
DA = {{2018-08-13}},
}

@article{ ISI:000226174000011,
Author = {Pultz, NJ and Hoyen, CK and Donskey, CJ},
Title = {{Inhibition of methicillin-resistant Staphylococcus aureus by an in vitro
   continuous-flow culture containing human stool microflora}},
Journal = {{FEMS MICROBIOLOGY LETTERS}},
Year = {{2004}},
Volume = {{241}},
Number = {{2}},
Pages = {{201-205}},
Month = {{DEC 15}},
Abstract = {{We used an in vitro continuous-flow culture model of human stool
   microflora to examine the ability of human stool microflora to inhibit
   growth of two methicillin-resistant S. aureus (MRSA) strains.
   Continuous-flow cultures consistently eliminated MRSA inocula of 10(6)
   cfu/mL within 4 days, and addition of continuous-flow culture resulted
   in elimination of a pre-established MRSA culture (similar to10(8)
   cfu/mL) within 6-8 days. Anaerobic or ``aerobic{''} (i.e., continuous
   bubbling of room air to eliminate obligate anaerobes) cultures
   eliminated MRSA at similar rates. The MRSA strains were unable to
   replicate under anaerobic conditions in sterile filtrates produced from
   the continuous-flow culture, but rapid growth occurred when glucose was
   added. These data demonstrate that indigenous stool microflora
   efficiently eliminate MRSA colonization and obligate anaerobes are not
   essential for inhibition. Our findings also suggest that inhibition of
   MRSA in continuous-flow cultures is due to depletion of nutrients rather
   than production of inhibitory conditions. (C) 2004 Federation of
   European Microbiological Societies. Published by Elsevier B.V. All
   rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Donskey, CJ (Reprint Author), Case Western Reserve Univ, Res Sect, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Res Sect, Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA.
   Rainbow Babies \& Childrens Hosp, Cleveland, OH 44106 USA.}},
DOI = {{10.1016/j.femsle.2004.10.021}},
ISSN = {{0378-1097}},
Keywords = {{Staphylococcus aureus; colonization; intestinal; continuous-flow}},
Keywords-Plus = {{ANTIBIOTIC-RESISTANT; COLONIZED PATIENTS; ENTEROCOCCI; CARRIAGE;
   INFECTIONS; NUTRIENTS; THERAPY}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Author-Email = {{curtisd123@yahoo.com}},
Cited-References = {{Bhalla A, 2003, INFECT CONT HOSP EP, V24, P644, DOI 10.1086/502267.
   CUMMINGS JH, 1987, AM J CLIN NUTR, V45, P1243, DOI 10.1093/ajcn/45.5.1243.
   Donskey CJ, 2001, J INFECT DIS, V184, P1624, DOI 10.1086/324533.
   Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604.
   FRETER R, 1983, INFECT IMMUN, V39, P676.
   FRETER R, 1983, INFECT IMMUN, V39, P686.
   HUME ME, 2004, CURR MICROBIOL, V189, P1113.
   KatoMatsunaga N, 1996, INFECT IMMUN, V64, P4231.
   Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806.
   Masalha M, 2001, J BACTERIOL, V183, P7260, DOI 10.1128/JB.183.24.7260-7272.2001.
   Ray AJ, 2003, CLIN INFECT DIS, V37, P875, DOI 10.1086/377451.
   RIMLAND D, 1986, J CLIN MICROBIOL, V24, P137.
   Sorensen TL, 2001, NEW ENGL J MED, V345, P1161, DOI 10.1056/NEJMoa010692.
   Squier C, 2002, INFECT CONT HOSP EP, V23, P495.
   USHIJIMA T, 1991, J MED MICROBIOL, V35, P111, DOI 10.1099/00222615-35-2-111.
   WILSON KH, 1988, INFECT IMMUN, V56, P2610.
   Yoshida Y, 1999, SURG TODAY, V29, P327.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{FEMS Microbiol. Lett.}},
Doc-Delivery-Number = {{885RG}},
Unique-ID = {{ISI:000226174000011}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000225628000013,
Author = {Jarvis, WR},
Title = {{The State of the Science of health care epidemiology, infection control,
   and patient safety, 2004}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{2004}},
Volume = {{32}},
Number = {{8}},
Pages = {{496-503}},
Month = {{DEC}},
Abstract = {{Being aware and implementing the latest and best scientific evidence in
   infection control and health care epidemiology is critical to enhancing
   patient outcomes. In this review, the latest published scientific data
   in health care epidemiology and patient safety were reviewed for the
   period May 2003-May 2004. Medline reviews and reviews of infection
   control and infectious diseases journals were used for this period. The
   latest guidelines and publications on antimicrobial resistance, nursing
   or infection control professional staffing, West Nile virus, and Severe
   Acute Respiratory Syndrome (SARS) are included. Awareness of these and
   other important infection control publications is essential if the
   latest measures are to be implemented to prevent and control health
   care-associated infections.}},
Publisher = {{MOSBY, INC}},
Address = {{11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA}},
Type = {{Article}},
Language = {{English}},
DOI = {{10.1016/j.ajic.2004.09.001}},
ISSN = {{0196-6553}},
Keywords-Plus = {{VANCOMYCIN-RESISTANT ENTEROCOCCI; ACUTE RESPIRATORY SYNDROME;
   WEST-NILE-VIRUS; STAPHYLOCOCCUS-AUREUS; UNITED-STATES;
   METHICILLIN-RESISTANT; SARS TRANSMISSION; AIRBORNE TRANSMISSION; CONTROL
   PROGRAMS; INTENSIVE-CARE}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{{[}Anonymous], 2004, MMWR, V53, P1.
   Bhalla A, 2004, INFECT CONT HOSP EP, V25, P164, DOI 10.1086/502369.
   {*}CDC, 2004, MMWR-MORBID MORTAL W, V53, P100.
   Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025.
   Charlebois ED, 2004, CLIN INFECT DIS, V39, P47, DOI 10.1086/421090.
   Chen YC, 2004, EMERG INFECT DIS, V10, P895, DOI 10.3201/eid1005.030777.
   HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990.
   Hein T.T., 2004, NEW ENGL J MED, V350, P1179.
   Isakbaeva ET, 2004, EMERG INFECT DIS, V10, P225, DOI 10.3201/eid1002.030734.
   Iwamoto M, 2003, NEW ENGL J MED, V348, P2196, DOI 10.1056/NEJMoa022987.
   Kohn WG, 2004, J AM DENT ASSOC, V135, P33, DOI 10.14219/jada.archive.2004.0019.
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781.
   Lally RT, 2004, AM J INFECT CONTROL, V32, P44, DOI 10.1016/S0196-6553(03)00088-9.
   Lepelletier D, 2004, INFECT CONT HOSP EP, V25, P162, DOI 10.1086/502368.
   Mayer RA, 2003, AM J INFECT CONTROL, V31, P221, DOI 10.1067/mic.2003.45.
   Montecalvo MA, 1997, CLIN INFECT DIS, V25, P929, DOI 10.1086/597643.
   Muto CA, 2003, INFECT CONT HOSP EP, V24, P362, DOI 10.1086/502213.
   MUTSCH M, 2004, NEW ENGL J MED, V35, P896.
   Nelson DB, 2003, INFECT CONT HOSP EP, V24, P532, DOI 10.1086/502237.
   O'Boyle C, 2002, AM J INFECT CONTROL, V30, P321, DOI 10.1067/mic.2002.127930.
   Park BJ, 2004, EMERG INFECT DIS, V10, P244.
   Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969.
   Peck AJ, 2004, EMERG INFECT DIS, V10, P217, DOI 10.3201/eid1002.030746.
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498.
   Perencevich EN, 2004, CLIN INFECT DIS, V38, P1108, DOI 10.1086/382886.
   Rosenberg J, 2004, INFECT CONT HOSP EP, V25, P408, DOI 10.1086/502414.
   Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051.
   Sa-Leao R, 2001, MICROB DRUG RESIST, V7, P237, DOI 10.1089/10766290152652783.
   Saint S, 2003, AM J INFECT CONTROL, V31, P354, DOI 10.1067/mic.2003.50.
   Sehulster Lynne, 2003, MMWR Recomm Rep, V52, P1.
   SETO WH, 2003, NEW ENGL J MED, V361, P1519.
   Shopsin B, 2000, J INFECT DIS, V182, P359, DOI 10.1086/315695.
   Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899.
   Whitener CJ, 2004, CLIN INFECT DIS, V38, P1049, DOI 10.1086/382357.
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867.
   Zoutman DE, 2003, AM J INFECT CONTROL, V31, P266, DOI 10.1067/mic.2003.88.}},
Number-of-Cited-References = {{36}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{878DZ}},
Unique-ID = {{ISI:000225628000013}},
DA = {{2018-08-13}},
}

@article{ ISI:000225725100016,
Author = {Thrupp, L and Bradley, S and Smith, P and Simor, A and Gantz, N and
   Crossley, K and Loeb, M and Strausbaugh, L and Nicolle, L and Bradley, S
   and Crossley, K and Gainer, RB and Gantz, N and Loeb, M and Nicolle, L
   and Quiros, R and Simor, A and Smith, P and Steele, L and Stevenson, K
   and Strausbaugh, L and Thrupp, L and SHEA Long-Term-Care Comm},
Title = {{Tuberculosis prevention and control in long-term-care facilities for
   older adults}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{2004}},
Volume = {{25}},
Number = {{12}},
Pages = {{1097-1108}},
Month = {{DEC}},
Abstract = {{In the United States, older adults comprise 22\% of cases of tuberculous
   disease but only 12\% of the population. Most cases of tuberculosis (TB)
   occur in community dwellers, but attack rates are highest among frail
   residents of long-term-care facilities. The detection and treatment of
   latent TB infection and TB disease can pose special challenges in older
   adults. Rapid recognition of possible disease, diagnosis, and
   implementation of airborne precautions are essential to prevent spread.
   It is the intent of this evidence-based guideline to assist healthcare
   providers in the prevention and control of TB, specifically in skilled
   nursing facilities for the elderly.}},
Publisher = {{CAMBRIDGE UNIV PRESS}},
Address = {{32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Thrupp, L (Reprint Author), Univ Calif Irvine, Ctr Med, Infect Control Dept, Bldg 53,Rm 220,101 City Dr, Orange, CA 92868 USA.
   Univ Calif Irvine, Ctr Med, Infect Control Dept, Orange, CA 92868 USA.
   Univ Michigan, Dept Internal Med, Med Sch, Ann Arbor, MI 48109 USA.
   Univ Michigan, Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA.
   Univ Nebraska, Med Ctr, Dept Internal Med Infect Dis, Omaha, NE USA.
   Sunnybrook \& Womens Coll, Hlth Sci Ctr, Dept Microbiol, Toronto, ON, Canada.
   Boulder Community Hosp, Dept Infect Dis, Boulder, CO USA.
   Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
   Minneapolis VA Med Ctr, Dept Educ, Minneapolis, MN USA.
   Minneapolis VA Med Ctr, Dept Internal Med, Minneapolis, MN USA.
   McMaster Univ, Dept Clin Epidemiol \& Biostat, Hamilton, ON, Canada.
   Hamilton Reg Lab Program, Hamilton, ON, Canada.
   Oregon Hlth \& Sci Univ, Sch Med, Portland, OR 97201 USA.
   Portland VA Med Ctr, Portland, OR USA.
   Hlth Sci Ctr, Dept Med, Winnipeg, MB, Canada.}},
DOI = {{10.1086/502350}},
ISSN = {{0899-823X}},
EISSN = {{1559-6834}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; BACTEC MGIT 960; PULMONARY
   TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; SKIN-TEST; ISONIAZID
   CHEMOPROPHYLAXIS; MILIARY TUBERCULOSIS; CLINICAL SPECIMENS;
   DRUG-RESISTANCE; ELDERLY PERSONS}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{Alcaide F, 2000, J CLIN MICROBIOL, V38, P398.
   ALEXANDER WJ, 1979, J AM GERIATR SOC, V27, P123, DOI 10.1111/j.1532-5415.1979.tb04140.x.
   ALVAREZ S, 1987, AM J MED, V82, P602, DOI 10.1016/0002-9343(87)90106-9.
   American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P1376, DOI DOI 10.1164/AJRCCM.161.4.16141.
   American Thoracic Society, 1997, AM J RESP CRIT CARE, V155, P1804.
   American Thoracic Society; CDC; Infectious Diseases Society of America, 2003, MMWR RECOMM REP, V52, P1.
   BANYAI AL, 1930, AM REV TUBERC, V21, P568.
   Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159.
   Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964.
   BARRY MA, 1987, J AM GERIATR SOC, V35, P147, DOI 10.1111/j.1532-5415.1987.tb01344.x.
   Bennedsen J, 1996, J CLIN MICROBIOL, V34, P1407.
   BENTLEY DW, 1990, INFECT CONT HOSP EP, V11, P42.
   BERESFORD OD, 1958, AM REV TUBERC PULM, V77, P323.
   Blumberg HM, 2000, JAMA-J AM MED ASSOC, V283, P2793, DOI 10.1001/jama.283.21.2793.
   Brunello F, 1999, J CLIN MICROBIOL, V37, P1206.
   CAPLIN M, 1958, Tubercle, V39, P84, DOI 10.1016/S0041-3879(58)80023-9.
   CARPENTIER E, 1995, J CLIN MICROBIOL, V33, P3106.
   {*}CDCP, 2003, MMWR-MORBID MORTAL W, V52, P735.
   {*}CDCP, 1990, MMWR-MORBID MORTAL W, V39, P7.
   {*}CDCP, 1998, MMWR-MORBID MORTAL W, V47, P911.
   {*}CDCP, 2001, SURV REP 2001.
   {*}CDCP, 1995, MMWR-MORBID MORTAL W, V44, P19.
   {*}CDCP, 2003, MMWR-MORBID MORTAL W, V52, P15.
   Centers for Disease Control and Prevention, 2003, MMWR-MORBID MORTAL W, V52, P101.
   Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P1.
   Centers for Disease Control and Prevention and Healthcare Infection Control Advisory Committee (HICPAC), 2003, MMWR-MORBID MORTAL W, V52, P1.
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P950.
   CHESROW EJ, 1967, DIS CHEST, V51, P635.
   CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362.
   CUCIN RL, 1973, J CHRON DIS, V26, P355, DOI 10.1016/0021-9681(73)90038-6.
   DAMATO RF, 1995, J CLIN MICROBIOL, V33, P1832.
   Frost WH, 1939, AM J HYG, V30, P91, DOI 10.1093/oxfordjournals.aje.a118570.
   Fukushima T, 1999, J AM GERIATR SOC, V47, P259, DOI 10.1111/j.1532-5415.1999.tb04591.x.
   GIANNINI D, 1957, LANCET, V1, P525.
   GILBERT D, 2002, SANFORD GUIDE ANTIMI.
   GONZALEZ R, 1987, DIAGN MICR INFEC DIS, V8, P69, DOI 10.1016/0732-8893(87)90152-0.
   GORDIN F, 1990, ARCH PATHOL LAB MED, V114, P1025.
   GRIEP W A, 1957, Tubercle, V38, P259.
   GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421.
   Hanna BA, 1999, J CLIN MICROBIOL, V37, P748.
   HAVLIR DV, 1991, CHEST, V99, P1172, DOI 10.1378/chest.99.5.1172.
   HEAF F R, 1955, J R Inst Public Health, V18, P324.
   Hoft DF, 1999, ANN INTERN MED, V131, P32, DOI 10.7326/0003-4819-131-1-199907060-00007.
   Horsburgh CR, 2000, CLIN INFECT DIS, V31, P633, DOI 10.1086/314007.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968.
   Ijaz K, 2002, J AM GERIATR SOC, V50, P1213, DOI 10.1046/j.1532-5415.2002.50307.x.
   {*}INT UN TUB COMM P, 1982, B WORLD HEALTH ORGAN, V60, P555.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Jasmer RM, 2002, ANN INTERN MED, V137, P640, DOI 10.7326/0003-4819-137-8-200210150-00007.
   JOHNSTON RN, 1963, BMJ-BRIT MED J, P720, DOI 10.1136/bmj.2.5359.720.
   KATZ PR, 1987, J AM GERIATR SOC, V35, P512, DOI 10.1111/j.1532-5415.1987.tb01396.x.
   KENNEDY DJ, 1992, CHEST, V102, P1040, DOI 10.1378/chest.102.4.1040.
   KHAN MA, 1977, AM J MED, V62, P31, DOI 10.1016/0002-9343(77)90346-1.
   KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991.
   KOX LFF, 1995, RESP MED, V89, P399, DOI 10.1016/0954-6111(95)90207-4.
   Leung CC, 2002, J AM GERIATR SOC, V50, P1219, DOI 10.1046/j.1532-5415.2002.50308.x.
   MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65.
   MCDONALD RJ, 1992, ARCH GERONTOL GERIAT, V15, P29, DOI 10.1016/0167-4943(92)90037-5.
   MILLER SD, 1973, AM REV RESPIR DIS, V107, P530, DOI 10.1164/arrd.1973.107.4.530.
   MORRIS CDW, 1988, S AFR MED J, V74, P117.
   MORRIS CDW, 1990, THORAX, V45, P912, DOI 10.1136/thx.45.12.912.
   MUDER RR, 1993, INFECT CONT HOSP EP, V14, P523.
   MUSIAL CE, 1988, J CLIN MICROBIOL, V26, P2120.
   MYERS JA, 1976, AM J PUBLIC HEALTH, V66, P1101, DOI 10.2105/AJPH.66.11.1101.
   MYERS JA, 1930, AM REV TUBERC, V21, P541.
   NAGAMI PH, 1983, J AM GERIATR SOC, V31, P356, DOI 10.1111/j.1532-5415.1983.tb05747.x.
   Nelson SM, 1998, J CLIN MICROBIOL, V36, P467.
   Nolan CM, 1999, JAMA-J AM MED ASSOC, V281, P1014, DOI 10.1001/jama.281.11.1014.
   Ormerod P, 1998, THORAX, V53, P536.
   Perez-Guzman C, 1999, CHEST, V116, P961, DOI 10.1378/chest.116.4.961.
   Piersimoni C, 1997, J CLIN MICROBIOL, V35, P193.
   POWELL KE, 1980, J INFECT DIS, V142, P946, DOI 10.1093/infdis/142.6.946.
   PRICE LE, 1987, INFECT CONT HOSP EP, V8, P353, DOI 10.1017/S0195941700067400.
   Rajagopalan S, 2001, CLIN INFECT DIS, V33, P1034, DOI 10.1086/322671.
   Robertson JM, 1996, ANN INTERN MED, V124, P779, DOI 10.7326/0003-4819-124-9-199605010-00001.
   ROBINS AB, 1954, AM REV TUBERC PULM, V69, P1057.
   ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709.
   RUDD A, 1985, J AM GERIATR SOC, V33, P566, DOI 10.1111/j.1532-5415.1985.tb04623.x.
   SAHN SA, 1974, AM J MED, V56, P495, DOI 10.1016/0002-9343(74)90482-3.
   Salpeter SR, 1997, ANN INTERN MED, V127, P1051, DOI 10.7326/0003-4819-127-12-199712150-00001.
   SHINNICK TM, 1995, CLIN INFECT DIS, V21, P291, DOI 10.1093/clinids/21.2.291.
   SIMON JA, 1983, SOUTHERN MED J, V76, P866, DOI 10.1097/00007611-198307000-00012.
   Slovis BS, 2000, JAMA-J AM MED ASSOC, V283, P2003, DOI 10.1001/jama.283.15.2003.
   SMIEJA MJ, 2001, COCHRANE LIBR.
   SORRESSO DJ, 1995, CHEST, V108, P706, DOI 10.1378/chest.108.3.706.
   STEAD WW, 1981, ANN INTERN MED, V94, P606, DOI 10.7326/0003-4819-94-5-606.
   STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837.
   STEAD WW, 1983, J INFECT DIS, V147, P951, DOI 10.1093/infdis/147.5.951.
   STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304.
   STEAD WW, 1968, ANN INTERN MED, V68, P731, DOI 10.7326/0003-4819-68-4-731.
   STEAD WW, 1965, AM REV RESPIR DIS, V91, P811.
   STERN JK, 1991, GERIATRIC FOCUS INFE, V1, P6.
   STRUMPF IJ, 1979, AM REV RESPIR DIS, V119, P599.
   TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404.
   TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767.
   THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587.
   TROISIER J., 1929, PRESSE MED, V37, P137.
   VANDENBRANDE P, 1995, AM J RESP CRIT CARE, V152, P1705, DOI 10.1164/ajrccm.152.5.7582317.
   VUORINEN P, 1995, J CLIN MICROBIOL, V33, P1856.
   WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702.
   YOSHIKAWA TT, 1994, INFECT DIS CLIN PRAC, V3, P62, DOI 10.1097/00019048-199401000-00020.
   YOSHIKAWA TT, 1992, J AM GERIATR SOC, V40, P178, DOI 10.1111/j.1532-5415.1992.tb01941.x.
   YOSHIKAWA TT, 1982, GERIATRICS, V37, P61.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{104}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{879NS}},
Unique-ID = {{ISI:000225725100016}},
DA = {{2018-08-13}},
}

@article{ ISI:000225214700041,
Author = {Munson, EL and Heard, SO and Doern, GV},
Title = {{In vitro exposure of bacteria to antimicrobial impregnated-central
   venous catheters does not directly lead to the emergence of
   antimicrobial resistance}},
Journal = {{CHEST}},
Year = {{2004}},
Volume = {{126}},
Number = {{5}},
Pages = {{1628-1635}},
Month = {{NOV}},
Abstract = {{Objective: Use of central venous catheters (CVCs) impregnated with
   minocycline and rifampin reduces the density of bacterial growth on
   catheters and decreases the incidence of catheter-related bloodstream
   infections. Questions have been raised over the possibility that the use
   of these catheters will lead to the emergence of antibiotic-resistant
   organisms. In this study, we sought to determine if in vitro exposure of
   four test organisms to catheter segments impregnated with minocycline
   and rifampin would lead to the development of antibiotic resistance.
   Methods: Catheter segments (1.0 cm) were placed on the surface of agar
   plates previously inoculated with bacterial suspensions, such that a
   subconfluent lawn of colony growth would be apparent after 24 h
   incubation at 35degreesC in air. Test organisms included American Type
   Culture Collection strains of Staphylococcus aureus, Staphylococcus
   epidermidis, Enterococcus faecalis, Escherichia coli, and Pseudomonas
   aeruginosa. Zones of inhibition of colony growth surrounding catheters
   were measured at 24-h intervals up to 7 days (two catheter segments per
   test). Colonies on agar surfaces located at varying distances from
   catheter segments were examined for minocycline and rifampin resistance
   following various periods of exposure (six catheter segments per test).
   In addition, selected colonies were subsequently exposed to minocycline
   and rifampin in broth and examined for selection of minocycline and
   rifampin resistance (> 28 colonies per selection test).
   Results: Inhibitory zones of 14 to 47 mm were observed with S aureus, S
   epidermidis, E faecalis, and E coli. Growth of P aeruginosa was not
   inhibited by CVC segments. Testing of colonies of the first four
   organisms at various distances from CVC segments after varying periods
   of exposure revealed only a single instance of the emergence of
   resistance (eg, S aureus vs rifampin). Recovery of resistant clones was
   enhanced with minocycline and rifampin broth selection; however, a
   direct link between CVC exposure and the emergence of resistance was not
   established.
   Conclusions: Our in vitro data suggest that the exposure of
   Gram-positive cocci to either rifampin or minocycline can lead to the
   development of resistance. However, exposure of bacteria to these
   antibiotics in combination does not directly lead to resistance.
   Clinical investigations will be required to determine the true risk and
   implications of the development of resistance.}},
Publisher = {{AMER COLL CHEST PHYSICIANS}},
Address = {{3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Heard, SO (Reprint Author), Univ Massachusetts, Sch Med, Dept Anesthesiol, 55 Lake Ave N, Worcester, MA 01655 USA.
   Univ Massachusetts, Sch Med, Dept Anesthesiol, Worcester, MA 01655 USA.
   Med Sci Labs, Wauwatosa, WI USA.
   Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA.}},
DOI = {{10.1378/chest.126.5.1628}},
ISSN = {{0012-3692}},
Keywords = {{antibiotic-impregnated catheters; antimicrobrial resistance;
   catheter-related infection; minocycline; rifampin}},
Keywords-Plus = {{BLOOD-STREAM INFECTIONS; PREVENTION; COLONIZATION; SUSCEPTIBILITY;
   ANTIBIOTICS; EFFICACY; TRIAL; MINOCYCLINE; ANTISEPTICS; RIFAMPIN}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{stephen.heard@umassmed.edu}},
ORCID-Numbers = {{Munson, Erik/0000-0001-5359-6643}},
Cited-References = {{Bach A, 1996, J ANTIMICROB CHEMOTH, V37, P315, DOI 10.1093/jac/37.2.315.
   Chatzinikolaou Ioannis, 2003, American Journal of Medicine, V115, P352, DOI 10.1016/S0002-9343(03)00367-X.
   Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101.
   DiGiovine B, 1999, AM J RESP CRIT CARE, V160, P976, DOI 10.1164/ajrccm.160.3.9808145.
   Fluit AC, 2000, CLIN INFECT DIS, V30, P454, DOI 10.1086/313710.
   Fluit AC, 2001, J CLIN MICROBIOL, V39, P3727, DOI 10.1128/JCM.39.10.3727-3732.2001.
   Hanna HA, 2003, CHEST, V124, P1030, DOI 10.1378/chest.124.3.1030.
   Jones RN, 1999, CLIN INFECT DIS, V29, P495, DOI 10.1086/598621.
   MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9.
   Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001.
   MAKI DG, 2000, 40 INT SCI C ANT AG.
   Mandell GL, 1983, REV INFECT DIS S3, V5, P463.
   Marik PE, 1999, CRIT CARE MED, V27, P1128, DOI 10.1097/00003246-199906000-00034.
   Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009.
   Raad I, 1996, J INFECT DIS, V173, P418, DOI 10.1093/infdis/173.2.418.
   RAAD I, 1995, ANTIMICROB AGENTS CH, V39, P2397, DOI 10.1128/AAC.39.11.2397.
   Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002.
   RAAD II, 1994, INFECT CONT HOSP EP, V15, P231.
   Sampath LA, 2001, INFECT CONT HOSP EP, V22, P640, DOI 10.1086/501836.
   SANDE MA, 1983, REV INFECT DIS S3, V5, P399.
   SHERERTZ RJ, 1989, ANTIMICROB AGENTS CH, V33, P1174, DOI 10.1128/AAC.33.8.1174.
   Tambe SM, 2001, J ANTIMICROB CHEMOTH, V47, P589, DOI 10.1093/jac/47.5.589.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Chest}},
Doc-Delivery-Number = {{872NU}},
Unique-ID = {{ISI:000225214700041}},
DA = {{2018-08-13}},
}

@article{ ISI:000224781700005,
Author = {Gibbs, SG and Green, CF and Tarwater, PM and Scarpino, PV},
Title = {{Airborne antibiotic resistant and nonresistant bacteria and fungi
   recovered from two swine herd confined animal feeding operations}},
Journal = {{JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE}},
Year = {{2004}},
Volume = {{1}},
Number = {{11}},
Pages = {{699-706}},
Month = {{NOV}},
Abstract = {{Inhalation of microorganisms could be a health concern for workers
   inside and downwind of animal confinement units. Using the Andersen
   two-stage viable microbial particle sizing sampler, air samples were
   collected from locations upwind, inside, and downwind during two visits
   to two swine herd confined animal feeding operations. Six samples were
   taken at each location on each site. Bacteria isolated from each site
   were then tested for antibiotic resistance using the Kirby-Bauer disc
   diffusion method. Resistant bacterial forms were found inside and
   downwind of the swine confinement facilities, indicating that resistant
   organisms were being produced in and released from these facilities.
   Resistance to a battery of antibiotics including ampicillin,
   erythromycin, oxytetracycline, penicillin, tetracycline, and tylosin was
   found in the following bioaerosols: Staphylococcus aureus, Salmonella
   spp., and fecal coliforms. The major conclusion reached by this study
   was that bacteria were recovered inside and downwind of these facilities
   in levels that previous studies had stated could cause a potential human
   health hazard.}},
Publisher = {{TAYLOR \& FRANCIS INC}},
Address = {{325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Gibbs, SG (Reprint Author), Univ Texas, Sch Publ Hlth, Hlth Sci Ctr, El Paso Reg Campus, El Paso, TX 79968 USA.
   Univ Texas, Sch Publ Hlth, Hlth Sci Ctr, El Paso, TX 79968 USA.
   Univ Cincinnati, Dept Civil \& Environm Engn, Cincinnati, OH 45221 USA.}},
DOI = {{10.1080/15459620490515824}},
ISSN = {{1545-9624}},
Keywords = {{antibiotic resistant; bioaerosols; confined animal feeding operation;
   microorganisms}},
Keywords-Plus = {{ANTIMICROBIAL AGENTS; DRUG-RESISTANCE; BUILDINGS; WORKERS; HEALTH;
   SUSCEPTIBILITY; EXPOSURE}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
Funding-Acknowledgement = {{ODCDC CDC HHS {[}T42/CCT510420]}},
Cited-References = {{BAUER AW, 1966, AM J CLIN PATHOL, V45, P493.
   Burriel AR, 1997, RES VET SCI, V63, P189, DOI 10.1016/S0034-5288(97)90016-3.
   Chang CW, 2001, APPL ENVIRON MICROB, V67, P155, DOI 10.1128/AEM.67.1.155-161.2001.
   CLARK S, 1983, AM IND HYG ASSOC J, V44, P537, DOI 10.1080/15298668391405265.
   COHEN BS, 1995, AIR SAMPLING INSTRUM, P279.
   Davies R, 1999, LETT APPL MICROBIOL, V29, P327, DOI 10.1046/j.1472-765X.1999.00634.x.
   DONHAM K, 1989, BRIT J IND MED, V46, P31.
   DUNLOP RH, 1998, PREV VET MED, V34, P547.
   DUPONT HL, 1987, REV INFECT DIS, V9, P447.
   Ferrando R, 1975, World Rev Nutr Diet, V22, P183.
   HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904.
   LEDERBERG J, 1952, J BACTERIOL, V63, P399.
   MALLOCH D, 1981, MOULDS THEIR ISOLATI.
   Mathew AG, 1998, J ANIM SCI, V76, P429.
   McGeer AJ, 1998, CAN MED ASSOC J, V159, P1119.
   NCCLS, 1997, PERF STAND ANT DISK.
   Nijsten R, 1996, J ANTIMICROB CHEMOTH, V37, P1131, DOI 10.1093/jac/37.6.1131.
   PEREIRA MSV, 1995, LETT APPL MICROBIOL, V20, P391, DOI 10.1111/j.1472-765X.1995.tb01328.x.
   PEREZTRALLERO E, 1995, INT J ANTIMICROB AG, V6, P59, DOI 10.1016/0924-8579(95)00022-7.
   SCARPINO PV, 1998, J AEROSOL SCI, V29, pS553.
   TAKEFUJI ET, 1977, PREV MED, V6, P312.
   THRELFALL EJ, 1993, EPIDEMIOL INFECT, V111, P189, DOI 10.1017/S0950268800056892.
   Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{45}},
Usage-Count-Last-180-days = {{5}},
Usage-Count-Since-2013 = {{26}},
Journal-ISO = {{J. Occup. Environ. Hyg.}},
Doc-Delivery-Number = {{866OB}},
Unique-ID = {{ISI:000224781700005}},
DA = {{2018-08-13}},
}

@article{ ISI:000222910600020,
Author = {Richeldi, L and Ewer, K and Losi, M and Bergamini, BM and Roversi, P and
   Deeks, J and Fabbri, LM and Lalvani, A},
Title = {{T cell-based tracking of multidrug resistant tuberculosis infection
   after brief exposure}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2004}},
Volume = {{170}},
Number = {{3}},
Pages = {{288-295}},
Month = {{AUG 1}},
Abstract = {{Molecular epidemiology indicates significant transmission of
   Mycobacterium tuberculosis after casual contact with infectious
   tuberculosis cases. We investigated M. tuberculosis transmission after
   brief exposure using a T cell-based assay, the enzyme-linked-immunospot
   (ELISPOT) for IFN-gamma. After childbirth, a mother was diagnosed with
   sputum smear-positive multidrug-resistant tuberculosis. Forty-one
   neonates and 47 adults were present during her admission on the
   maternity unit; 11 weeks later, all underwent tuberculin skin testing
   (TST) and ELISPOT. We correlated test results with markers of exposure
   to the index case. The participants, who were asymptomatic and
   predominantly had no prior tuberculosis exposure, had 6.05 hours mean
   exposure (range: 0-65 hours) to the index case. Seventeen individuals,
   including two newborns, were ELISPOT-positive, and ELISPOT results
   correlated significantly with three of four predefined measures of
   tuberculosis exposure. For each hour sharing room air with the index
   case, the odds of a positive ELISPOT result increased by 1.05 (95\% Cl:
   1.02-1.09, p = 0.003). Only four adults were TST-positive and TST
   results did not correlate with exposure. Thus, ELISPOT, but not TST,
   suggested quite extensive nosocomial transmission of multidrug-resistant
   M. tuberculosis after brief exposure. These results help to explain the
   apparent importance of casual contact for tuberculosis transmission, and
   may have implications for prevention.}},
Publisher = {{AMER THORACIC SOC}},
Address = {{25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lalvani, A (Reprint Author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Level 7, Oxford OX3 9DU, England.
   Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.
   Inst Hlth Sci, Ctr Stat Med, Oxford, England.
   Univ Modena, Resp Dis \& Pediat Clin, Modena, Italy.
   Azienda Osped Policlin Modena, Modena, Italy.}},
DOI = {{10.1164/rccm.200403-307OC}},
ISSN = {{1073-449X}},
EISSN = {{1535-4970}},
Keywords = {{contact tracing; nosocomial; T cell; tuberculin skin test; tuberculosis}},
Keywords-Plus = {{LATENT MYCOBACTERIUM-TUBERCULOSIS; INTENSIVE-CARE-UNIT; CONGENITAL
   TUBERCULOSIS; NURSERY EXPOSURE; RAPID DETECTION; DRUG-RESISTANT; CASUAL
   CONTACT; SKIN-TEST; TRANSMISSION; ENUMERATION}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{ajit.lalvani@ndm.ox.ac.uk}},
ResearcherID-Numbers = {{Losi, Monica/A-7028-2010
   Bergamini, Barbara Maria/F-4182-2017
   Ewer, Katie/B-4328-2011
   Fabbri, Leonardo/I-4055-2012
   }},
ORCID-Numbers = {{Bergamini, Barbara Maria/0000-0003-3681-0921
   Ewer, Katie/0000-0001-9827-9836
   Fabbri, Leonardo/0000-0001-8894-1689
   Deeks, Jonathan/0000-0002-8850-1971}},
Cited-References = {{Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2.
   Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000.
   ATS/CDC, 2000, AM J RESP CRIT CARE, V161, pS221.
   Barnes PF, 2001, AM J RESP CRIT CARE, V163, P807, DOI 10.1164/ajrccm.163.4.ed0201c.
   Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159.
   Barnes PF, 2003, NEW ENGL J MED, V349, P1149, DOI 10.1056/NEJMra021964.
   Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520.
   Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042.
   Brandt L, 1996, J IMMUNOL, V157, P3527.
   BURK JR, 1978, SOUTHERN MED J, V71, P7, DOI 10.1097/00007611-197801000-00004.
   Chapman ALN, 2002, AIDS, V16, P2285, DOI 10.1097/00002030-200211220-00008.
   Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9.
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9.
   Golub JE, 2001, ARCH INTERN MED, V161, P2254, DOI 10.1001/archinte.161.18.2254.
   Greenaway C, 2003, INT J TUBERC LUNG D, V7, pS479.
   HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   Laartz BW, 2002, INFECT CONT HOSP EP, V23, P573, DOI 10.1086/501973.
   Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859.
   Lalvani A, 2003, THORAX, V58, P916, DOI 10.1136/thorax.58.11.916.
   Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100.
   Lalvani A, 2001, J INFECT DIS, V183, P469, DOI 10.1086/318081.
   Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1.
   Lee LH, 1998, CLIN INFECT DIS, V27, P474, DOI 10.1086/514690.
   Manabe YC, 2000, NAT MED, V6, P1327, DOI 10.1038/82139.
   Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120.
   Ormerod P, 2000, THORAX, V55, P887.
   Raffalli J, 1996, ARCH INTERN MED, V156, P1053, DOI 10.1001/archinte.156.10.1053.
   Richeldi L, 2004, ANN INTERN MED, V140, P709, DOI 10.7326/0003-4819-140-9-200405040-00010.
   RICHELDI L, 2003, TRACKING NOSOCOMIAL.
   RICHELDI L, 2003, EUR RESPIR J, V22, pS167.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125.
   STEINER P, 1976, AM REV RESPIR DIS, V113, P267.
   Teixeira L, 2001, INT J TUBERC LUNG D, V5, P321.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   van Deutekom H, 2004, AM J RESP CRIT CARE, V169, P806, DOI 10.1164/rccm.200306-856OC.
   VILLARINO ME, 1992, MMWR-MORBID MORTAL W, V41, P61.
   Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002.
   Weis SE, 2002, AM J RESP CRIT CARE, V166, P36, DOI 10.1164/rccm.2109089.
   Whelan AO, 2003, INFECT IMMUN, V71, P6420, DOI 10.1128/IAI.71.11.6420-6425.2003.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{110}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{841DX}},
Unique-ID = {{ISI:000222910600020}},
DA = {{2018-08-13}},
}

@article{ ISI:000223290100009,
Author = {Johnson, LK and Brown, MB and Carruthers, EA and Ferguson, JA and
   Dombek, PE and Sadowsky, MJ},
Title = {{Sample size, library composition, and genotypic diversity among natural
   populations of Escherichia coli from different animals influence
   accuracy of determining sources of fecal pollution}},
Journal = {{APPLIED AND ENVIRONMENTAL MICROBIOLOGY}},
Year = {{2004}},
Volume = {{70}},
Number = {{8}},
Pages = {{4478-4485}},
Month = {{AUG}},
Abstract = {{A horizontal, fluorophore-enhanced, repetitive extragenic
   palindromic-PCR (rep-PCR) DNA fingerprinting technique (HFERP) was
   developed and evaluated as a means to differentiate human from animal
   sources of Escherichia coli. Box AIR primers and PCR were used to
   generate 2,466 rep-PCR and 1,531 HFERP DNA fingerprints from E. coli
   strains isolated from fecal material from known human and 12 animal
   sources: dogs, cats, horses, deer, geese, ducks, chickens, turkeys,
   cows, pigs, goats, and sheep. HFERP DNA fingerprinting reduced
   within-gel grouping of DNA fingerprints and improved alignment of DNA
   fingerprints between gels, relative to that achieved using rep-PCR DNA
   fingerprinting. Jackknife analysis of the complete rep-PCR DNA
   fingerprint library, done using Pearson's product-moment correlation
   coefficient, indicated that animal and human isolates were assigned to
   the correct source groups with an 82.2\% average rate of correct
   classification. However, when only unique isolates were examined,
   isolates from a single animal having a unique DNA fingerprint, Jackknife
   analysis showed that isolates were assigned to the correct source groups
   with a 60.5\% average rate of correct classification. The percentages of
   correctly classified isolates were about 15 and 17\% greater for rep-PCR
   and HFERP, respectively, when analyses were done using the curve-based
   Pearson's product-moment correlation coefficient, rather than the
   band-based Jaccard algorithm. Rarefaction analysis indicated that,
   despite the relatively large size of the known-source database, genetic
   diversity in E. coli was very great and is most likely accounting for
   our inability to correctly classify many environmental E. coli isolates.
   Our data indicate that removal of duplicate genotypes within DNA
   fingerprint libraries, increased database size, proper methods of
   statistical analysis, and correct alignment of band data within and
   between gels improve the accuracy of microbial source tracking methods.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sadowsky, MJ (Reprint Author), Univ Minnesota, Dept Soil Water \& Climate, 439 Borlaug Hall,1991 Upper Buford Cir, St Paul, MN 55108 USA.
   Univ Minnesota, Dept Soil Water \& Climate, St Paul, MN 55108 USA.}},
DOI = {{10.1128/AEM.70.8.4478-4485.2004}},
ISSN = {{0099-2240}},
Keywords-Plus = {{ANTIBIOTIC-RESISTANCE ANALYSIS; POLYMERASE CHAIN-REACTION; EXTRAGENIC
   PALINDROMIC-PCR; BACTERIAL SOURCE TRACKING; MICROBIAL SOURCE TRACKING;
   REPETITIVE DNA-SEQUENCES; DISCRIMINANT-ANALYSIS; NONPOINT SOURCES;
   IDENTIFICATION; PATTERNS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{Sadowsky@soils.umn.edu}},
ResearcherID-Numbers = {{Sadowsky, Michael/J-2507-2016}},
ORCID-Numbers = {{Sadowsky, Michael/0000-0001-8779-2781}},
Cited-References = {{Albert JM, 2003, ENVIRON SCI TECHNOL, V37, P4554, DOI 10.1021/es034211q.
   Burnes BS, 2003, ENVIRON MONIT ASSESS, V85, P87, DOI 10.1023/A:1023357200980.
   Carson CA, 2003, APPL ENVIRON MICROB, V69, P1836, DOI 10.1128/AEM.69.3.1836-1839.2003.
   Carson CA, 2001, APPL ENVIRON MICROB, V67, P1503, DOI 10.1128/AEM.67.4.1503-1507.2001.
   DEBRUIJN FJ, 1992, APPL ENVIRON MICROB, V58, P2180.
   Dombek PE, 2000, APPL ENVIRON MICROB, V66, P2572, DOI 10.1128/AEM.66.6.2572-2577.2000.
   Gordon DM, 2001, MICROBIOL-SGM, V147, P1079, DOI 10.1099/00221287-147-5-1079.
   Graves AK, 2002, J ENVIRON QUAL, V31, P1300, DOI 10.2134/jeq2002.1300.
   Guan Shukui, 2002, Applied and Environmental Microbiology, V68, P2690, DOI 10.1128/AEM.68.6.2690-2698.2002.
   Hagedorn C, 1999, APPL ENVIRON MICROB, V65, P5522.
   HANE BG, 1993, ELECTROPHORESIS, V14, P967, DOI 10.1002/elps.11501401154.
   Hartel PG, 2003, WATER RES, V37, P3263, DOI 10.1016/S0043-1354(03)00170-2.
   Hartel PG, 2002, J ENVIRON QUAL, V31, P1273, DOI 10.2134/jeq2002.1273.
   HARTL DL, 1984, ANNU REV GENET, V18, P31, DOI 10.1146/annurev.ge.18.120184.000335.
   Harwood VJ, 2000, APPL ENVIRON MICROB, V66, P3698, DOI 10.1128/AEM.66.9.3698-3704.2000.
   Jenkins MB, 2003, J ENVIRON QUAL, V32, P305.
   JUDD AK, 1993, APPL ENVIRON MICROB, V59, P1702.
   Krebs C. J., 1999, ECOLOGICAL METHODOLO.
   Legendre P., 1998, NUMERICAL ECOLOGY.
   LIPMAN LJA, 1995, VET MICROBIOL, V43, P13, DOI 10.1016/0378-1135(94)00070-D.
   Louws FJ, 1999, ANNU REV PHYTOPATHOL, V37, P81, DOI 10.1146/annurev.phyto.37.1.81.
   MARTIN B, 1992, NUCLEIC ACIDS RES, V20, P3479, DOI 10.1093/nar/20.13.3479.
   McLellan SL, 2003, APPL ENVIRON MICROB, V69, P2587, DOI 10.1128/AEM.69.5.2587-2594.2003.
   Nebra Y, 2003, APPL ENVIRON MICROB, V69, P2651, DOI 10.1128/AEM.69.5.2651-2656.2003.
   Parveen S, 1997, APPL ENVIRON MICROB, V63, P2607.
   Parveen S, 2001, WATER RES, V35, P379, DOI 10.1016/S0043-1354(00)00269-4.
   RADEMAKER JLW, 1999, MOL MICROBIAL ECOL S, V4, P1.
   RADEMAKER JLW, 1998, MOL MICROBIOL ECOL S, V3, P1.
   Sadowsky MJ, 1998, BACTERIAL GENOMES, P399.
   Sadowsky MJ, 1996, APPL ENVIRON MICROB, V62, P3489.
   Scott TM, 2003, APPL ENVIRON MICROB, V69, P1089, DOI 10.1128/AEM.69.2.1089-1092.2003.
   Scott TM, 2002, APPL ENVIRON MICROB, V68, P5796, DOI 10.1128/AEM.68.12.5796-5803.2002.
   Seurinck S, 2003, APPL ENVIRON MICROB, V69, P4942, DOI 10.1128/AEM.69.8.4942-4950.2003.
   SIMPSON JM, 2003, ENVIRON SCI TECHNOL, V36, P5780.
   Souza V, 1999, APPL ENVIRON MICROB, V65, P3373.
   Tyler KD, 1997, J CLIN MICROBIOL, V35, P339.
   US EPA, 2000, EPA841R00001 OFF WAT.
   {*}US EPA, 2001, S41R00002 EPA OFF WA.
   VERSALOVIC J, 1995, ARCH PATHOL LAB MED, V119, P23.
   VERSALOVIC J, 1991, NUCLEIC ACIDS RES, V19, P6823, DOI 10.1093/nar/19.24.6823.
   Versalovic James, 1994, Methods in Molecular and Cellular Biology, V5, P25.
   Wheeler AL, 2002, J ENVIRON QUAL, V31, P1286, DOI 10.2134/jeq2002.1286.
   Whitlock JE, 2002, WATER RES, V36, P4273, DOI 10.1016/S0043-1354(02)00139-2.
   Wiggins BA, 1999, APPL ENVIRON MICROB, V65, P3483.
   Wiggins BA, 1996, APPL ENVIRON MICROB, V62, P3997.
   Wiggins BA, 2003, APPL ENVIRON MICROB, V69, P3399, DOI 10.1128/AEM.69.6.3399-3405.2003.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{142}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{27}},
Journal-ISO = {{Appl. Environ. Microbiol.}},
Doc-Delivery-Number = {{846BQ}},
Unique-ID = {{ISI:000223290100009}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000221652000043,
Author = {MacLean, RC and Bell, G and Rainey, PB},
Title = {{The evolution of a pleiotropic fitness tradeoff in Pseudomonas
   fluorescens}},
Journal = {{PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA}},
Year = {{2004}},
Volume = {{101}},
Number = {{21}},
Pages = {{8072-8077}},
Month = {{MAY 25}},
Abstract = {{The evolution of ecological specialization is expected to carry a cost,
   due to either antagonistic pleiotropy or mutation accumulation. In
   general, it has been difficult to distinguish between these two
   possibilities. Here, we demonstrate that the experimental evolution of
   niche-specialist genotypes of the bacterium Pseudomonas fluorescens that
   colonize the air-broth interface of spatially structured microcosms is
   accompanied by pleiotropic fitness costs in terms of reduced carbon
   catabolism. Prolonged selection in spatially structured microcosms
   caused the cost of specialization to decline without loss of the
   benefits associated with specialization. The decline in the cost of
   specialization can be explained by either compensatory adaptation within
   specialist lineages or clonal competition among specialist lineages.
   These results provide a possible explanation of conflicting accounts for
   the cost of specialization.}},
Publisher = {{NATL ACAD SCIENCES}},
Address = {{2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MacLean, RC (Reprint Author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.
   McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada.
   Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand.
   Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England.}},
DOI = {{10.1073/pnas.0307195101}},
ISSN = {{0027-8424}},
Keywords-Plus = {{ESCHERICHIA-COLI POPULATIONS; ECOLOGICAL SPECIALIZATION; ADAPTIVE
   RADIATION; ANTIBIOTIC-RESISTANCE; ADAPTATION; GENERALISTS; MAINTENANCE;
   ENVIRONMENT; SPECIALISTS; MECHANISMS}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Author-Email = {{rmacle2@po-box.mcgill.ca}},
ResearcherID-Numbers = {{Rainey, Paul/A-3207-2008
   }},
ORCID-Numbers = {{Rainey, Paul/0000-0003-0879-5795
   MacLean, Craig/0000-0002-7941-813X}},
Cited-References = {{Andersson DI, 1999, CURR OPIN MICROBIOL, V2, P489, DOI 10.1016/S1369-5274(99)00005-3.
   Bochner BR, 2003, NAT REV GENET, V4, P309, DOI 10.1038/nrg1046.
   Bull JJ, 2000, MOL BIOL EVOL, V17, P942, DOI 10.1093/oxfordjournals.molbev.a026375.
   Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343.
   COHAN FM, 1994, EVOLUTION, V48, P81, DOI 10.1111/j.1558-5646.1994.tb01296.x.
   Cooper VS, 2000, NATURE, V407, P736, DOI 10.1038/35037572.
   Cooper VS, 2001, J BACTERIOL, V183, P2834, DOI 10.1128/JB.183.9.2834-2841.2001.
   Cooper VS, 2001, EVOLUTION, V55, P889, DOI 10.1554/0014-3820(2001)055{[}0889:EOTDOG]2.0.CO;2.
   Crill WD, 2000, GENETICS, V154, P27.
   Ebert D, 1998, SCIENCE, V282, P1432, DOI 10.1126/science.282.5393.1432.
   Elena SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/nrg1088.
   Fry JD, 1996, AM NAT, V148, pS84, DOI 10.1086/285904.
   FUTUYMA DJ, 1988, ANNU REV ECOL SYST, V19, P207, DOI 10.1146/annurev.es.19.110188.001231.
   GERRISH PJ, 1998, GENETICA, V103, P127.
   Giraud A, 2001, SCIENCE, V291, P2606, DOI 10.1126/science.1056421.
   Hartl DL, 1997, PRINCIPLES POPULATIO.
   Kassen R, 2002, J EVOLUTION BIOL, V15, P173, DOI 10.1046/j.1420-9101.2002.00377.x.
   Kawecki TJ, 1997, J EVOLUTION BIOL, V10, P407, DOI 10.1007/s000360050032.
   KAWECKI TJ, 1994, AM NAT, V144, P833, DOI 10.1086/285709.
   LEVENE H, 1953, AM NAT, V88, P690.
   Levins R., 1968, EVOLUTION CHANGING E.
   LYNCH M, 1987, AM NAT, V129, P282.
   MacLean RC, 2002, AM NAT, V160, P569, DOI 10.1086/342816.
   Maisnier-Patin S, 2002, MOL MICROBIOL, V46, P355, DOI 10.1046/j.1365-2958.2002.03173.x.
   Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900.
   Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906.
   Reboud X, 1997, HEREDITY, V78, P507, DOI 10.1038/hdy.1997.79.
   ROUGHGARDEN J, 1972, AM NAT, V106, P683, DOI 10.1086/282807.
   SHRAG SJ, 1997, P R SOC LOND B, V264, P1287.
   Spiers AJ, 2002, GENETICS, V161, P33.
   Spiers AJ, 2003, MOL MICROBIOL, V50, P15, DOI 10.1046/j.1365-2958.2003.03670.x.
   Travisano M, 2000, AM NAT, V156, pS35, DOI 10.1086/303414.
   WHITLOCK MC, 1996, AM NAT             S, V148, P65.
   WILSON DS, 1994, AM NAT, V144, P692, DOI 10.1086/285702.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{105}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{38}},
Journal-ISO = {{Proc. Natl. Acad. Sci. U. S. A.}},
Doc-Delivery-Number = {{823ZC}},
Unique-ID = {{ISI:000221652000043}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000221546300008,
Author = {Brooks, WA and Yunus, M and Santosham, M and Wahed, MA and Nahar, K and
   Yeasmin, S and Black, RE},
Title = {{Zinc for severe pneumonia in very young children: double-blind
   placebo-controlled trial}},
Journal = {{LANCET}},
Year = {{2004}},
Volume = {{363}},
Number = {{9422}},
Pages = {{1683-1688}},
Month = {{MAY 22}},
Abstract = {{Background Pneumonia is a leading cause of morbidity and mortality in
   young children. Early reversal of severity signs-chest indrawing,
   hypoxia, and tachypnoea-improves outcome. We postulated that zinc, an
   acute phase reactant, would shorten duration of severe pneumonia and
   time in hospital.
   Methods In a double-blind placebo-controlled clinical trial in Matlab
   Hospital, Bangladesh, 270 children aged 2-23 months were randomised to
   receive elemental zinc (20 mg per day) or placebo, plus the hospital's
   standard antimicrobial management, until discharge. The outcomes were
   time to cessation of severe pneumonia (no chest indrawing, respiratory
   rate 50 per min or less, oxygen saturation at least 95\% on room air)
   and discharge from hospital. Discharge was allowed when respiratory rate
   was 40 per minute or less for 24 consecutive hours while patients were
   maintained only on oral antibiotics.
   Findings The group receiving zinc had reduced duration of severe
   pneumonia (relative hazard {[}RH]=0.70, 95\% CI 0.51-0.98), including
   duration of chest indrawing (0.80, 0.61-1.05), respiratory rate more
   than 50 per min (0.74, 0.57-0.98), and hypoxia (0.79, 0.61-1.04), and
   overall hospital duration (0.75, 0.57-0.99). The mean reduction is
   equivalent to 1 hospital day for both severe pneumonia and time in
   hospital. All effects were greater when children with wheezing were
   omitted from the analysis.
   Interpretation Adjuvant treatment with 20 mg zinc per day accelerates
   recovery from severe pneumonia in children, and could help reduce
   antimicrobial resistance by decreasing multiple antibiotic exposures,
   and lessen complications and deaths where second line drugs are
   unavailable.}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Brooks, WA (Reprint Author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth \& Populat Res, Hlth Syst Infect Dis Div, Programme Infect Dis \& Vaccine Sci, GPO Box 128, Dhaka 1000, Bangladesh.
   Int Ctr Diarrhoeal Dis Res, Ctr Hlth \& Populat Res, Hlth Syst Infect Dis Div, Programme Infect Dis \& Vaccine Sci, Dhaka 1000, Bangladesh.
   Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.}},
DOI = {{10.1016/S0140-6736(04)16252-1}},
ISSN = {{0140-6736}},
Keywords-Plus = {{ACUTE-PHASE RESPONSE; RANDOMIZED CONTROLLED-TRIALS; HEPATIC
   PROTEIN-SYNTHESIS; ACUTE DIARRHEA; RECOMBINANT INTERLEUKIN-1;
   RESPIRATORY-INFECTIONS; BANGLADESHI CHILDREN; DEVELOPING-COUNTRIES;
   POOLED ANALYSIS; IMMUNE FUNCTION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Author-Email = {{abrooks@icddrb.org}},
ORCID-Numbers = {{Black, Robert/0000-0001-9926-7984}},
Cited-References = {{Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059.
   Bhandari N, 2002, BRIT MED J, V324, P1358, DOI 10.1136/bmj.324.7350.1358.
   Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7.
   Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516.
   Braunschweig CL, 1997, J NUTR, V127, P70.
   Casal J, 2002, J ANTIMICROB CHEMOTH, V50, P83, DOI 10.1093/jac/dkf502.
   Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2.
   COUSINS RJ, 1985, PHYSIOL REV, V65, P238.
   Duff M, 2002, CELLS TISSUES ORGANS, V172, P21, DOI 10.1159/000064383.
   Fontaine O, 2001, J HEALTH POPUL NUTR, V19, P339.
   FOSMIRE GJ, 1990, AM J CLIN NUTR, V51, P225.
   Gaetke LM, 1997, AM J PHYSIOL-ENDOC M, V272, pE952.
   GOLDBLUM SE, 1987, AM J PHYSIOL, V252, P27.
   Groeneveld ABJ, 2001, CLIN DIAGN LAB IMMUN, V8, P1189, DOI 10.1128/CDLI.8.6.1189-1195.2001.
   HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607.
   Iwata M, 1999, HISTOCHEM CELL BIOL, V112, P283, DOI 10.1007/s004180050449.
   JIANG SL, 1992, FOLIA HISTOCHEM CYTO, V30, P133.
   Ling PR, 1996, AM J PHYSIOL-ENDOC M, V270, pE305.
   Luk HH, 2002, EUR J PHARMACOL, V443, P197, DOI 10.1016/S0014-2999(02)01592-3.
   Ninh NX, 1996, AM J CLIN NUTR, V63, P514.
   Noursadeghi M, 2002, J IMMUNOL, V169, P913, DOI 10.4049/jimmunol.169.2.913.
   Osendarp SJM, 2002, AM J CLIN NUTR, V76, P1401.
   Osendarp SJM, 2001, LANCET, V357, P1080, DOI 10.1016/S0140-6736(00)04260-4.
   Peters M, 1996, HEPATOLOGY, V23, P909, DOI 10.1053/jhep.1996.v23.ajhep0230909.
   Rahman MM, 2002, AM J CLIN NUTR, V75, P92.
   RAMADORI G, 1985, J EXP MED, V162, P930, DOI 10.1084/jem.162.3.930.
   Ramadori G, 1999, SEMIN LIVER DIS, V19, P141, DOI 10.1055/s-2007-1007106.
   RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817.
   Roberts RM, 1995, CRIT REV EUKAR GENE, V5, P385, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.80.
   Roy SK, 1997, ARCH DIS CHILD, V77, P196, DOI 10.1136/adc.77.3.196.
   Sazawal S, 1997, Indian Pediatr, V34, P589.
   Sazawal S, 1998, PEDIATRICS, V102, P1, DOI 10.1542/peds.102.1.1.
   SAZAWAL S, 1995, NEW ENGL J MED, V333, P839, DOI 10.1056/NEJM199509283331304.
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S.
   SIMMER K, 1988, AM J CLIN NUTR, V47, P1036.
   STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9.
   Szalai AJ, 2000, J IMMUNOL, V165, P1030, DOI 10.4049/jimmunol.165.2.1030.
   Thurnham DI, 1997, J CLIN PATHOL, V50, P887, DOI 10.1136/jcp.50.11.887.
   Truong-Tran AQ, 2002, AM J RESP CELL MOL, V27, P286, DOI 10.1165/rcmb.2001-0014OC.
   Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{127}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{822NG}},
Unique-ID = {{ISI:000221546300008}},
DA = {{2018-08-13}},
}

@article{ ISI:000221227900011,
Author = {Bucki, R and Pastore, JJ and Randhawa, P and Vegners, R and Weiner, DJ
   and Janmey, PA},
Title = {{Antibacterial activities of rhodamine B-conjugated gelsolin-derived
   peptides compared to those of the antimicrobial peptides cathelicidin
   LL37, magainin II, and melittin}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{2004}},
Volume = {{48}},
Number = {{5}},
Pages = {{1526-1533}},
Month = {{MAY}},
Abstract = {{The growing number of antibiotic-resistant bacteria necessitates the
   search for new antimicrobial agents and the principles by which they
   work. We report that cell membrane-permeant rhodamine B (RhB)-conjugated
   peptides based on the phosphatidylinositol-4,5-bisphosphate binding site
   of gelsolin can kill the gram-negative organisms Escherichia coli and
   Pseudomonas aeruginosa and the gram-positive organism Streptococcus
   pneumoniae. RhB linkage to the QRLFQVKGRR sequence in gelsolin was
   essential for the antibacterial function, since the unconjugated peptide
   had no effect on the bacteria tested. Because RhB-QRLFQVKGRR (also
   termed PBP10), its scrambled sequence (RhB-FRVKLKQGQR), and PBP10
   synthesized from D-isomer amino acids show similar antibacterial
   properties, the physical and chemical properties of these derivatives
   appear to be more important than specific peptide folding for their
   antibacterial functions. The similar activities of PBP10 and
   all-D-amino-acid PBP10 also indicate that a specific interaction between
   RhB derivatives and bacterial proteins is unlikely to be involved in the
   bacterial killing function of PBP10. By using a phospholipid monolayer
   system, we found a positive correlation between the antibacterial
   function of PBP10, as well as some naturally occurring antibacterial
   peptides, and the intrinsic surface pressure activity at the
   hydrophobic-hydrophilic interface. Surprisingly, we observed little or
   no dependence of the insertion of these peptides into lipid monolayers
   on the phospholipid composition. These studies show that an effective
   antimicrobial agent can be produced from a peptide sequence with
   specificity to a phospholipid not found in bacteria, and comparisons
   with other antimicrobial agents suggest that the surface activities of
   these peptides are more important than specific binding to bacterial
   proteins or lipids for their antimicrobial functions.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Bucki, R (Reprint Author), Univ Penn, Dept Physiol, IME, 3340 Smith Walk, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Physiol, IME, Philadelphia, PA 19104 USA.
   Univ Penn, Inst Med \& Engn, Vagelos Res Labs, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA.
   Med Acad Bialystok, Dept Physiol, PL-15230 Bialystok, Poland.
   Organuskas Sintezes Inst, Peptide Synth Lab, LV-1006 Riga, Latvia.}},
DOI = {{10.1128/AAC.48.5.1526-1533.2004}},
ISSN = {{0066-4804}},
Keywords-Plus = {{PHOSPHOINOSITIDE-BINDING PEPTIDE; POTENT ANTIBIOTIC-ACTIVITY; SURFACTANT
   PROTEIN-D; AIR-WATER-INTERFACE; ESCHERICHIA-COLI; TUMOR-CELLS; MEMBRANE;
   CECROPIN; PHOSPHATIDYLINOSITOL; CONFORMATION}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{buckirob@mail.med.upenn.edu}},
ORCID-Numbers = {{Weiner, Daniel/0000-0001-8245-1961}},
Funding-Acknowledgement = {{NHLBI NIH HHS {[}R01 HL67286, R01 HL067286]; NIAMS NIH HHS {[}R01
   AR038910, AR38910]}},
Cited-References = {{Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t.
   Bland JM, 2001, MOL CELL BIOCHEM, V218, P105, DOI 10.1023/A:1007293816634.
   BOMAN HG, 1993, INFECT IMMUN, V61, P2978.
   Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X.
   Bucki R, 2001, BIOCHEMISTRY-US, V40, P15752, DOI 10.1021/bi010899c.
   Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200.
   De Yang, 2000, J Exp Med, V192, P1069, DOI 10.1084/jem.192.7.1069.
   DEMEL RA, 1973, BIOCHIM BIOPHYS ACTA, V311, P507, DOI 10.1016/0005-2736(73)90126-0.
   Foster WJ, 2001, BIOPHYS CHEM, V91, P211, DOI 10.1016/S0301-4622(01)00171-5.
   Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542.
   GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035.
   Guttman JA, 2002, J CELL SCI, V115, P499.
   Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718.
   Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063.
   LARRAMENDY ML, 1995, REV BRAS GENET, V18, P63.
   LARRICK JW, 1994, J IMMUNOL, V152, P231.
   Lee DG, 2002, BBA-PROTEINS PROTEOM, V1598, P185, DOI 10.1016/S0167-4838(02)00373-4.
   Lee KH, 2000, BIOORGAN MED CHEM, V8, P833, DOI 10.1016/S0968-0896(00)00019-5.
   Lee RE, 2001, CONTEMP FAM THER, V23, P231, DOI 10.1023/A:1011154404188.
   Medina OP, 2001, CANCER RES, V61, P3978.
   OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244.
   Oh D, 2000, BIOCHEMISTRY-US, V39, P11855, DOI 10.1021/bi000453g.
   ROZGONYI F, 1980, ACTA MICROBIOL HUNG, V27, P23.
   Sai Y, 1999, J CELL SCI, V112, P4535.
   Shin SY, 2000, BIOCHEM BIOPH RES CO, V275, P904, DOI 10.1006/bbrc.2000.3269.
   Silvestro L, 2000, ANTIMICROB AGENTS CH, V44, P602, DOI 10.1128/AAC.44.3.602-607.2000.
   SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724.
   Taneva S, 1997, BIOCHEMISTRY-US, V36, P8173, DOI 10.1021/bi963040h.
   Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000.
   Xian WJ, 1995, BIOPHYS J, V69, P2695, DOI 10.1016/S0006-3495(95)80140-2.
   Yang D, 2001, CELL MOL LIFE SCI, V58, P978, DOI 10.1007/PL00000914.
   Zanetti M, 1997, ANN NY ACAD SCI, V832, P147, DOI 10.1111/j.1749-6632.1997.tb46244.x.
   ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O.
   Zanetti M, 2000, ADV EXP MED BIOL, V479, P203.
   Zendzian-Piotrowska M, 2000, HORM METAB RES, V32, P386, DOI 10.1055/s-2007-978659.
   Zhao HX, 2003, ANTIMICROB AGENTS CH, V47, P965, DOI 10.1128/AAC.47.3.965-971.2003.
   Zhao HX, 2001, BIOPHYS J, V81, P2979, DOI 10.1016/S0006-3495(01)75938-3.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{55}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{16}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{818EH}},
Unique-ID = {{ISI:000221227900011}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000221338700010,
Author = {Berger, P and Pascal, L and Sartor, C and Delorme, J and Monge, P and
   Ragon, CP and Charbit, M and Sambuc, R and Drancourt, M},
Title = {{Generalized Additive Model demonstrates. uoroquinolone use/resistance
   relationships for Staphylococcus aureus}},
Journal = {{EUROPEAN JOURNAL OF EPIDEMIOLOGY}},
Year = {{2004}},
Volume = {{19}},
Number = {{5}},
Pages = {{453-460}},
Month = {{MAY}},
Abstract = {{Mathematical models currently used to study the relationship between the
   prevalence of the resistance to an antibiotic and the amount of drug may
   not be adequate because they do not integrate temporal and area analyses
   simultaneously. Furthermore, the forms of such relationship are unknown.
   We applied the Generalized Additive Model (GAM) to study fluoroquinolone
   use and the incidence of fluoroquinolone-resistance in Staphylococcus
   aureus in our institution over a 3-year period. Overall institution and
   individual hospital unit-restricted analyses were performed. Relative
   risk (RR) observed for increasing fluoroquinolone use with a 4-month lag
   from the 25th percentile to the 75th percentile was 1.27 (95\% CI:
   1.13-1.42). In the surgery units, RR was 1.23 ( 95\% CI: 1.01-1.50) for
   fluoroquinolone use with a 2-months lag. GAM enabled us to observe for
   the first time a significant temporal relationship between
   fluoroquinolone use and the incidence of fluoroquinolone-resistant
   nosocomial S. aureus isolates.}},
Publisher = {{KLUWER ACADEMIC PUBL}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Drancourt, M (Reprint Author), Fac Med Marseille, Unite Rickettsies, 24 Blvd Jean Moulin, F-13385 Marseille 05, France.
   Fac Med Marseille, Unite Rickettsies, F-13385 Marseille 05, France.
   Hop Hotel Dieu, Comite Lutte Infect Nosocomiales, Marseille, France.
   Hosp Concept, Dept Informat Med, Marseille, France.
   Pharm Hosp Timone, Marseille, France.
   Pharm Hosp Concept, Marseille, France.
   Pharm Hosp St Marguerite, Marseille, France.
   Pharm Hop Nord, Marseille, France.
   Hop Hotel Dieu, Lab Evolut Hosp Mesare Sante, Fac Med, Marseille, France.
   Hop Hotel Dieu, Lab Evolut Hosp, Fac Med, Marseille, France.}},
ISSN = {{0393-2990}},
Keywords = {{anti-infective agents; fluoroquinolone/drug resistance;
   Microbial/Generalized additive Model/Staphylococcus aureus}},
Keywords-Plus = {{ANTIMICROBIAL SURVEILLANCE PROGRAM; BLOOD-STREAM INFECTIONS;
   ANTIBIOTIC-RESISTANCE; AIR-POLLUTION; MICROBIAL RESISTANCE;
   BACTERIAL-RESISTANCE; ESCHERICHIA-COLI; UNITED-STATES; TIME-SERIES;
   SUSCEPTIBILITY}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Author-Email = {{Michel.Drancourt@medecine.univ-mrs.fr}},
Cited-References = {{Acar JF, 1997, CLIN INFECT DIS, V24, pS67, DOI 10.1093/clinids/24.Supplement\_1.S67.
   Akaike H, 1973, INT S INF THEOR, P267, DOI DOI 10.2307/2334537.
   Arason VA, 1996, BMJ-BRIT MED J, V313, P387.
   Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152.
   BALLOW CH, 1992, DIAGN MICR INFEC DIS, V15, pS37.
   Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P12106, DOI 10.1073/pnas.94.22.12106.
   BURMAN LG, 1992, ANTIMICROB AGENTS CH, V36, P989, DOI 10.1128/AAC.36.5.989.
   {*}CDCP, 1997, MMWR-MORBID MORTAL W, V46, P626.
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407.
   Cohen ML, 2000, NATURE, V406, P762, DOI 10.1038/35021206.
   COURCOL RJ, 1989, J ANTIMICROB CHEMOTH, V23, P441, DOI 10.1093/jac/23.3.441.
   Crowcroft NS, 1999, INFECT CONT HOSP EP, V20, P31, DOI 10.1086/501555.
   Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184.
   Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192.
   Fluit AC, 2000, CLIN INFECT DIS, V30, P454, DOI 10.1086/313710.
   GERDING DN, 1991, ANTIMICROB AGENTS CH, V35, P1284, DOI 10.1128/AAC.35.7.1284.
   GREENWOOD D, 1995, LANCET, V345, P1371, DOI 10.1016/S0140-6736(95)92572-4.
   Grundmann H, 2002, J INFECT DIS, V185, P481, DOI 10.1086/338568.
   Hanberger H, 2001, J HOSP INFECT, V48, P161, DOI 10.1053/jhin.2001.0987.
   Hastier T. J., 1990, GEN ADDITIVE MODELS.
   LEVINE JF, 1985, J INFECT DIS, V151, P295, DOI 10.1093/infdis/151.2.295.
   Lopez-Lozano JM, 2000, INT J ANTIMICROB AG, V14, P21, DOI 10.1016/S0924-8579(99)00135-1.
   Magee JT, 1999, BMJ-BRIT MED J, V319, P1239, DOI 10.1136/bmj.319.7219.1239.
   McCullagh P, 1989, GEN LINEAR MODELS.
   MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033.
   MOLLER JK, 1989, J ANTIMICROB CHEMOTH, V24, P983, DOI 10.1093/jac/24.6.983.
   Monnet DL, 1998, INFECT CONT HOSP EP, V19, P388.
   MOUTON R P, 1976, Journal of Antimicrobial Chemotherapy, V2, P9, DOI 10.1093/jac/2.1.9.
   MOUTON RP, 1990, J ANTIMICROB CHEMOTH, V26, P573, DOI 10.1093/jac/26.4.573.
   MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710.
   {*}NAT COMM CLIN STA, 1998, MIN INH CONC INT STA.
   Natsch S, 1998, INFECT CONT HOSP EP, V19, P653.
   Norris G, 2000, THORAX, V55, P466, DOI 10.1136/thorax.55.6.466.
   PENA C, 1995, ANTIMICROB AGENTS CH, V39, P520, DOI 10.1128/AAC.39.2.520.
   Public Health Laboratory Service, 1997, COMMUN DIS REP CDR W, V7, P191.
   RICHARD P, 1994, J INFECT DIS, V170, P377, DOI 10.1093/infdis/170.2.377.
   Saez M, 2001, J EPIDEMIOL COMMUN H, V55, P423, DOI 10.1136/jech.55.6.423.
   SCHWARTZ J, 1994, CAN J STAT, V22, P471, DOI 10.2307/3315405.
   Schwartz J, 1996, J EPIDEMIOL COMMUN H, V50, pS3, DOI 10.1136/jech.50.Suppl\_1.S3.
   SCHWARTZ J, 1993, AM J EPIDEMIOL, V137, P1136, DOI 10.1093/oxfordjournals.aje.a116617.
   Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701.
   TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615.
   Vincent JL, 2000, INTENS CARE MED, V26, pS3, DOI 10.1007/s001340051111.
   Wadman M, 2001, NATURE, V409, P273, DOI 10.1038/35053297.
   {*}WHO COLL CTR DRUG, 2000, AN THER CHEM CLASS I.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Eur. J. Epidemiol.}},
Doc-Delivery-Number = {{819TO}},
Unique-ID = {{ISI:000221338700010}},
DA = {{2018-08-13}},
}

@article{ ISI:000220838400001,
Author = {Bradley, PM and Angeles-Boza, AM and Dunbar, KR and Turro, C},
Title = {{Direct DNA photocleavage by a new intercalating dirhodium(II/II)
   complex: Comparison to Rh-2(mu-O2CCH3)(4)}},
Journal = {{INORGANIC CHEMISTRY}},
Year = {{2004}},
Volume = {{43}},
Number = {{8}},
Pages = {{2450-2452}},
Month = {{APR 19}},
Abstract = {{Transition metal complexes possessing the intercalating dppz ligand
   (dppz = dipyrido{[}3,2-a:2',3'-c]phenazine) typically bind ds-DNA
   through intercalation (K-b similar to 10(5)-10(6) M-1), and DNA
   photocleavage by these complexes with visible light proceeds through the
   generation of a reactive oxygen species. The DNA binding and
   photocleavage by {[}Rh-2(mu-O2CCH3)(2)(eta(1)-O2CCH3)(CH3OH)(dppz)](+)
   (2) is reported and compared to that of Rh-2(mu-O2CCH3)(4) (1). Spectral
   changes and an increase in viscosity provide evidence for the
   intercalation of 2 to double stranded DNA with K-b = 1.8 x 101 M-1. DNA
   photocleavage by 2 is observed upon irradiation with lambda(irr) > 395
   nm both in air and deoxygenated solution. DNA photocleavage is not
   observed for 1 or free dppz ligand under these irradiation conditions.
   The coupling of a single dppz ligand to a dirhodium(II/II) bimetallic
   core in 2 provides a means to access oxygen-independent DNA
   photocleavage with visible light.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Dunbar, KR (Reprint Author), Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.
   Ohio State Univ, Dept Chem, Columbus, OH 43210 USA.
   Texas A\&M Univ, College Stn, TX 77842 USA.}},
DOI = {{10.1021/ic035424j}},
ISSN = {{0020-1669}},
Keywords-Plus = {{DIPYRIDOPHENAZINE COMPLEXES; DRUG-RESISTANCE; IN-VITRO; RHODIUM(II)
   CARBOXYLATES; PHOTODYNAMIC THERAPY; ANTITUMOR-ACTIVITY;
   ETHIDIUM-BROMIDE; CHARGE-TRANSFER; SINGLET OXYGEN; BINDING}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Inorganic \& Nuclear}},
Author-Email = {{dunbar@mail.chem.tamu.edu
   turro.1@osu.edu}},
ResearcherID-Numbers = {{Angeles-Boza, Alfredo/C-6563-2008
   Turro, Claudia/H-5335-2015
   Dunbar, Kim/B-6488-2015}},
ORCID-Numbers = {{Angeles-Boza, Alfredo/0000-0002-5560-4405
   Turro, Claudia/0000-0003-3202-5870
   Dunbar, Kim/0000-0001-5728-7805}},
Funding-Acknowledgement = {{NIGMS NIH HHS {[}R01 GM64040-01]}},
Cited-References = {{Allen CM, 2002, TUMOR TARGETING CANC, P329.
   Aoki K, 2001, INORG CHIM ACTA, V316, P50, DOI 10.1016/S0020-1693(01)00376-0.
   Arounaguiri S, 1996, INORG CHEM, V35, P4267, DOI 10.1021/ic9508684.
   BEAR JL, 1978, CURR CHEMOTHER, P1321.
   Benites PJ, 2003, J AM CHEM SOC, V125, P6434, DOI 10.1021/ja020939f.
   BOYAR EB, 1983, COORDIN CHEM REV, V50, P109, DOI 10.1016/0010-8545(83)85028-0.
   Broxterman HJ, 2001, DRUG RESIST UPDATE, V4, P197, DOI 10.1054/drup.2001.0216.
   CARTER MT, 1989, J AM CHEM SOC, V111, P8901, DOI 10.1021/ja00206a020.
   Chifotides HT, 2004, INORG CHEM, V43, P1175, DOI 10.1021/ic034438m.
   Chifotides HT, 2003, J AM CHEM SOC, V125, P10703, DOI 10.1021/ja027779s.
   Chifotides HT, 2003, J AM CHEM SOC, V125, P10714, DOI 10.1021/ja0291585.
   Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0.
   CRAWFORD CA, 1993, INORG CHEM, V32, P3125, DOI 10.1021/ic00066a026.
   Crawford CA, 1997, INORG CHEM, V36, P2361, DOI 10.1021/ic9610288.
   Da Ros T, 2001, CURR PHARM DESIGN, V7, P1781, DOI 10.2174/1381612013397140.
   DALE LD, 1989, ANTI-CANCER DRUG DES, V4, P295.
   Dalla Via Lisa, 2001, Current Medicinal Chemistry, V8, P1405.
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6.
   Dhar S, 2003, J AM CHEM SOC, V125, P12118, DOI 10.1021/ja036681q.
   Erkkila KE, 1999, CHEM REV, V99, P2777, DOI 10.1021/cr9804341.
   Esposito BP, 2002, COORDIN CHEM REV, V232, P137, DOI 10.1016/S0010-8545(02)00049-8.
   Evstigneeva Rima P., 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P383, DOI 10.2174/1568011033482260.
   FELTHOUSE TR, 1982, PROG INORG CHEM, V29, P73, DOI 10.1002/9780470166307.ch2.
   Fleisher M.B., 1986, INORG CHEM, V25, P3549.
   Fu PKL, 2002, INORG CHEM, V41, P3808, DOI 10.1021/ic020136t.
   Fu PKL, 2001, INORG CHEM, V40, P2476, DOI 10.1021/ic010118w.
   Fuertes M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P539, DOI 10.2174/1568011023353958.
   Fuertes MA, 2003, CHEM REV, V103, P645, DOI 10.1021/cr020010d.
   Goldie JH, 2001, CANCER METAST REV, V20, P63, DOI 10.1023/A:1013164609041.
   Guppy M, 2002, BIOCHEM BIOPH RES CO, V299, P676, DOI 10.1016/S0006-291X(02)02710-9.
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704.
   Hergueta-Bravo A, 2002, J PHYS CHEM B, V106, P4010, DOI 10.1021/jp013542r.
   Holmlin RE, 1999, INORG CHEM, V38, P174, DOI 10.1021/ic9808955.
   HOWARD RA, 1977, J MED CHEM, V20, P943, DOI 10.1021/jm00217a016.
   HOWARD RA, 1979, CANCER RES, V39, P2568.
   Hsi RA, 1999, DRUGS, V57, P725, DOI 10.2165/00003495-199957050-00005.
   Jin L, 1998, MICROCHEM J, V58, P144, DOI 10.1006/mchj.1997.1535.
   Jones B U, 2001, Clin Lung Cancer, V3, P37, DOI 10.3816/CLC.2001.n.016.
   Kanzaki A, 2002, MOL CANCER THER, V1, P1327.
   KHAN AU, 1976, J PHYS CHEM-US, V80, P2219, DOI 10.1021/j100561a018.
   Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314.
   McCaughan JS, 1999, DRUG AGING, V15, P49, DOI 10.2165/00002512-199915010-00005.
   Nair RB, 1998, INORG CHEM, V37, P139, DOI 10.1021/ic970432j.
   Oroskar AA, 1996, FREE RADICAL BIO MED, V20, P751, DOI 10.1016/0891-5849(95)02158-2.
   Ortmans I, 1998, COORDIN CHEM REV, V168, P233, DOI 10.1016/S0010-8545(97)00070-2.
   PAOLETTI C, 1971, J MOL BIOL, V55, P75, DOI 10.1016/0022-2836(71)90282-8.
   Pruchnik FP, 2002, APPL ORGANOMET CHEM, V16, P587, DOI 10.1002/aoc.347.
   RAO PN, 1980, J NATL CANCER I, V64, P905.
   Rempel G. A., 2007, INORG SYNTH, V13, P90.
   RUBIN JR, 1991, ACTA CRYSTALLOGR C, V47, P1712, DOI 10.1107/S010827019100032X.
   Sastri CV, 2003, J INORG BIOCHEM, V94, P138, DOI 10.1016/S0162-0134(02)00622-0.
   Schondorf Thomas, 2003, Recent Results Cancer Res, V161, P111.
   SENTAGNE C, 1994, J PHOTOCH PHOTOBIO B, V26, P165, DOI 10.1016/1011-1344(94)07031-8.
   Siddik Zahid H, 2002, Cancer Treat Res, V112, P263.
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933.
   SMITH SR, 1994, NEW J CHEM, V18, P397.
   SODET O, 2003, CURR MED CHEM ANTI C, V3, P271.
   Sorasaenee K, 2003, INORG CHEM, V42, P1267, DOI 10.1021/ic020591p.
   Suh D, 2001, PROCESS BIOCHEM, V37, P521, DOI 10.1016/S0032-9592(01)00229-1.
   Swavey S, 2002, INORG CHEM, V41, P6196, DOI 10.1021/ic0257726.
   Tang TC, 1999, ELECTROANAL, V11, P1185, DOI 10.1002/(SICI)1521-4109(199911)11:16<1185::AID-ELAN1185>3.0.CO;2-\#.
   Thomas AM, 2003, J INORG BIOCHEM, V94, P171, DOI 10.1016/S0162-0134(02)00613-X.
   Tolomeo M., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P387, DOI 10.2174/1568011024606361.
   TURRO C, 1995, UNPUB.
   Welch TW, 1997, INORG CHEM, V36, P4812, DOI 10.1021/ic9703944.
   Yam VWW, 1997, J CHEM SOC DALTON, P2067.}},
Number-of-Cited-References = {{66}},
Times-Cited = {{65}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{19}},
Journal-ISO = {{Inorg. Chem.}},
Doc-Delivery-Number = {{812KM}},
Unique-ID = {{ISI:000220838400001}},
DA = {{2018-08-13}},
}

@article{ ISI:000189249300014,
Author = {Fennelly, KP and Martyny, JW and Fulton, KE and Orme, IM and Cave, DM
   and Heifets, LB},
Title = {{Cough-generated aerosols of Mycobacterium tuberculosis - A new method to
   study infectiousness}},
Journal = {{AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE}},
Year = {{2004}},
Volume = {{169}},
Number = {{5}},
Pages = {{604-609}},
Month = {{MAR 1}},
Abstract = {{The concentration and size distribution of infectious aerosols produced
   by patients with pulmonary tuberculosis (TB) has never been directly
   measured. We aimed to assess the feasibility of a method that we
   developed to collect and quantify culturable cough-generated aerosols of
   Mycobacterium tuberculosis. Subjects were recruited from a referral
   hospital and most had multidrug-resistant TB. They coughed into a
   chamber containing microbial air samplers while cough frequency was
   measured during two 5-minute sessions. Cough-generated aerosol cultures
   were positive in 4 of 16 subjects (25\%) with smear-positive pulmonary
   TB. There was a rapid decrease in the cough-generated aerosol cultures
   within the first 3 weeks of effective treatment. Culture-positive cough
   aerosols were associated with lack of treatment during the previous week
   (p = 0.007), and there was a trend in the association with cough
   frequency (p = 0.08). The size distributions of these aerosols were
   variable, but most particle sizes were in the respirable range.
   Quantification of viable cough-generated aerosols is feasible and offers
   a new approach to study infectiousness and transmission of M.
   tuberculosis and other airborne pathogens.}},
Publisher = {{AMER THORACIC SOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019-4374 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Fennelly, KP (Reprint Author), Univ Med \& Dent New Jersey, New Jersey Med Sch, Ctr Study Emerging \& Reemerging Pathogens, Dept Med, 185 S Orange Ave,MSB A-901, Newark, NJ 07103 USA.
   Univ Med \& Dent New Jersey, New Jersey Med Sch, Ctr Study Emerging \& Reemerging Pathogens, Dept Med, Newark, NJ 07103 USA.
   Natl Jewish Med \& Res Ctr, Dept Med, Denver, CO USA.
   Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.
   Univ Arkansas Med Sci, Dept Microbiol, Little Rock, AR 72205 USA.}},
DOI = {{10.1164/rccm.200308-1101OC}},
ISSN = {{1073-449X}},
Keywords = {{disease transmission; communicable disease control; air microbiology;
   infectivity; contact tracing}},
Keywords-Plus = {{POLYMERASE-CHAIN-REACTION; PULMONARY TUBERCULOSIS; TUBERCLE-BACILLI;
   TRANSMISSION; AIR; CHEMOTHERAPY; EPIDEMIOLOGY; INFECTIVITY; WARD}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Author-Email = {{fennelkp@umdnj.edu}},
Funding-Acknowledgement = {{ODCDC CDC HHS {[}U50/CCU810073]; NIAID NIH HHS {[}1K23 AI01676]}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   ANDERSEN AA, 1958, J BACTERIOL, V76, P471.
   Bauer J, 2000, INT J TUBERC LUNG D, V4, P295.
   Borgdorff MW, 2001, AM J EPIDEMIOL, V154, P934, DOI 10.1093/aje/154.10.934.
   BROOKS SM, 1973, AM REV RESPIR DIS, V108, P799.
   Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009.
   DUGUID J P, 1945, Edinb Med J, V52, P385.
   Dunlap NE, 2000, AM J RESP CRIT CARE, V161, P1376.
   FENNELLY KP, 1998, AM J RESP CRIT CARE, V157, pA706.
   FENNELLY KP, 1998, INT J TUBERC LUNG D, V2, pS313.
   Golub JE, 2001, ARCH INTERN MED, V161, P2254, DOI 10.1001/archinte.161.18.2254.
   HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410.
   Heifets L, 1997, CLIN CHEST MED, V18, P35, DOI 10.1016/S0272-5231(05)70354-3.
   KENT PT, 1985, PULBIC HLTH MYCOBACT.
   LINCOLN E, 1965, ADV TUBERC RES, V12, P157.
   LOUDON RG, 1967, AM REV RESPIR DIS, V95, P435.
   LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109.
   Mastorides SM, 1997, CLIN INFECT DIS, V25, P756, DOI 10.1086/516953.
   Mastorides SM, 1999, CHEST, V115, P19, DOI 10.1378/chest.115.1.19.
   Orme Ian M., 1994, P113.
   Raffalli J, 1996, ARCH INTERN MED, V156, P1053, DOI 10.1001/archinte.156.10.1053.
   Rich A.R., 1951, PATHOGENESIS TUBERCU.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069.
   ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2.
   Schafer MP, 1998, AM IND HYG ASSOC J, V59, P540, DOI 10.1202/0002-8894(1998)059<0540:SAAMDF>2.0.CO;2.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   {*}US DEP HHS, 1993, P WORKSH ENG CONTR P.
   van Geuns H A, 1975, Bull Int Union Tuberc, V50, P107.
   Wells WF, 1941, AM J HYG, V34, P21, DOI 10.1093/oxfordjournals.aje.a118732.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   WELLS WF, 1948, AM J HYG, V47, P11, DOI 10.1093/oxfordjournals.aje.a119179.
   Wells WF, 1955, AIRBORNE CONTAGION H.
   WENDT SL, 1980, AM REV RESPIR DIS, V122, P259.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{140}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{17}},
Journal-ISO = {{Am. J. Respir. Crit. Care Med.}},
Doc-Delivery-Number = {{778PE}},
Unique-ID = {{ISI:000189249300014}},
DA = {{2018-08-13}},
}

@article{ ISI:000220962500006,
Author = {Kinuya, S and Li, XF and Yokoyama, K and Mori, H and Shiba, K and
   Watanabe, N and Shuke, N and Bunko, H and Michigishi, T and Tonami, N},
Title = {{Hypoxia as a factor for Ga-67 accumulation in tumour cells}},
Journal = {{NUCLEAR MEDICINE COMMUNICATIONS}},
Year = {{2004}},
Volume = {{25}},
Number = {{1}},
Pages = {{49-53}},
Month = {{JAN}},
Abstract = {{Recent reports have demonstrated that hypoxia induces the up-regulation
   of transferrin receptor expression in tumour cells. Tumour cells take up
   Ga-67 in the form of a Ga-67-transferrin complex via transferrin
   receptors. As a result, we attempted to determine the influence of
   hypoxic conditions on Ga-67 uptake in tumour cells. B16 melanoma cells
   and LS180 colon cancer cells were incubated in 95\% air/5\% CO2 or 95\%
   N-2/5\% CO2 for 1 h at 37 degreesC. Cellular uptake of Ga-67 citrate was
   subsequently determined at 20, 40, 60 and 90 min. Uptake of the
   Ga-67-transferrin complex pre-chelated in vitro was similarly assessed.
   The effect of hypoxia on Ga-67 binding to serum proteins was also
   investigated. Both B16 and LS180 cells displayed increased cellular
   uptake of Ga-67 citrate in N-2 gas in comparison to that in air (P <
   0.0001). Hypoxia more prominently influenced cellular uptake of
   Ga-67-transferrin relative to that of Ga-67 citrate (P < 0.0001).
   Hypoxia did not affect the percentages of Ga-67 radioactivity bound to
   protein in medium supplemented with fetal calf serum, indicating that
   the results were not caused by the alteration of Ga-67-transferrin
   formation. These findings suggest the role of tissue hypoxia with
   respect to accumulation of Ga-67 in tumours, which is likely mediated by
   transferrin receptors. ((C) 2004 Lippincott Williams Wilkins).}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kinuya, S (Reprint Author), Kanazawa Univ, Grad Sch Med Sci, Dept Biotracer Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.
   Kanazawa Univ, Grad Sch Med Sci, Dept Biotracer Med, Kanazawa, Ishikawa 9208640, Japan.
   Kanazawa Univ, Radioisotope Ctr, Kanazawa, Ishikawa 920, Japan.
   Toyama Med \& Pharmaceut Univ, Dept Radiol, Toyama, Japan.
   Asahikawa Med Coll, Dept Radiol, Asahikawa, Hokkaido 078, Japan.
   Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan.}},
DOI = {{10.1097/01.mnm.0000109360.12233.7e}},
ISSN = {{0143-3636}},
Keywords = {{Ga-67 scintigraphy; hypoxia; transferrin}},
Keywords-Plus = {{POSITRON-EMISSION-TOMOGRAPHY; NON-HODGKIN-LYMPHOMA; TRANSFERRIN
   RECEPTOR; GA-67-CITRATE SCINTIGRAPHY; MULTIDRUG-RESISTANCE;
   DRUG-RESISTANCE; CANCER-CELLS; PREDICTION; DISEASE; TC-99M-HL91}},
Research-Areas = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Author-Email = {{kinuya@med.kanazawa-u.ac.jp}},
Cited-References = {{Ballinger JR, 2001, CANCER BIOTHER RADIO, V16, P1, DOI 10.1089/108497801750095907.
   Bar-Shalom R, 2001, SEMIN NUCL MED, V31, P177, DOI 10.1053/snuc.2001.23519.
   BARABAS K, 1993, BIOCHEM BIOPH RES CO, V197, P702, DOI 10.1006/bbrc.1993.2536.
   Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223.
   Brenot-Rossi I, 2001, EUR J NUCL MED, V28, P1482.
   Chajari M, 2002, EUR J NUCL MED MOL I, V29, P380, DOI 10.1007/s00259-001-0704-2.
   CHITAMBAR CR, 1987, CANCER RES, V47, P3929.
   CLAVO AC, 1995, J NUCL MED, V36, P1625.
   Coiffier B, 2001, Curr Oncol Rep, V3, P266, DOI 10.1007/s11912-001-0060-1.
   Cook GJR, 1998, J NUCL MED, V39, P99.
   Del Vecchio S, 2000, CANCER BIOTHER RADIO, V15, P327, DOI 10.1089/cbr.2000.15.327.
   Delcambre C, 2000, EUR J NUCL MED, V27, P176, DOI 10.1007/s002590050024.
   Fritzer M, 1996, BIOCHEM PHARMACOL, V51, P489, DOI 10.1016/0006-2952(95)02225-2.
   Front D, 2000, RADIOLOGY, V214, P253, DOI 10.1148/radiology.214.1.r00ja03253.
   Front D, 1999, RADIOLOGY, V210, P487, DOI 10.1148/radiology.210.2.r99fe07487.
   HARRIS AW, 1977, CANCER RES, V37, P3634.
   Israel O, 2002, CANCER, V94, P873.
   Israel O, 2002, J NUCL MED, V43, P1295.
   Iyer RV, 2001, J NUCL MED, V42, P337.
   Kalff V, 2002, EUR J NUCL MED MOL I, V29, P506, DOI 10.1007/s00259-001-0735-8.
   Kinuya S, 2002, EUR J NUCL MED MOL I, V29, P1006, DOI 10.1007/s00259-002-0846-x.
   Kostakoglu L, 2002, CANCER, V94, P879, DOI 10.1002/cncr.10336.
   Kostakoglu L, 2000, Clin Lymphoma, V1, P67, DOI 10.3816/CLM.2000.n.007.
   LARSON SM, 1979, J NUCL MED, V20, P837.
   Luttropp CA, 1998, J NUCL MED, V39, P1405.
   Ojha B, 2002, CLIN NUCL MED, V27, P638, DOI 10.1097/01.RLU.0000023893.61105.C9.
   OSTROY F, 1979, CANCER RES, V39, P4971.
   Rini JN, 2002, CLIN NUCL MED, V27, P572, DOI 10.1097/01.RLU.0000020591.68403.03.
   Sadava D, 2002, CANCER LETT, V179, P151, DOI 10.1016/S0304-3835(02)00005-8.
   Shen YY, 2002, ONCOL REP, V9, P321.
   Tacchini L, 2002, HEPATOLOGY, V36, P103, DOI 10.1053/jhep.2002.33997.
   Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142.
   Tatsumi M, 1999, EUR J NUCL MED, V26, P91, DOI 10.1007/s002590050364.
   Toth I, 1999, J BIOL CHEM, V274, P4467, DOI 10.1074/jbc.274.7.4467.
   TSAN MF, 1980, INT J NUCL MED BIOL, V7, P270, DOI 10.1016/0047-0740(80)90107-2.
   Van den Bossche B, 2002, NUCL MED COMMUN, V23, P1079, DOI 10.1097/01.mnm.0000040969.72730.00.
   WONG H, 1980, INT J NUCL MED BIOL, V7, P9, DOI 10.1016/0047-0740(80)90003-0.
   Yutani K, 1999, J NUCL MED, V40, P854.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Nucl. Med. Commun.}},
Doc-Delivery-Number = {{814GF}},
Unique-ID = {{ISI:000220962500006}},
DA = {{2018-08-13}},
}

@article{ ISI:000186508300017,
Author = {Herren, CD and Rocha, ER and Smith, CJ},
Title = {{Genetic analysis of an important oxidative stress locus in the anaerobe
   Bacteroides fragilis}},
Journal = {{GENE}},
Year = {{2003}},
Volume = {{316}},
Pages = {{167-175}},
Month = {{OCT 16}},
Abstract = {{The obligate anaerobe, Bacteroides fragilis, is a highly aerotolerant
   intestinal tract organism that has evolved a complex oxidative stress
   response (OSR). The redox regulator OxyR controls several OSR genes
   (katB, dps, and ahpC), but there is little else known about other genes
   it regulates. To identify additional genes in the OxyR regulon,
   two-dimensional gel electrophoresis was used to isolate proteins from a
   mutant that constitutively expresses genes in the regulon. The 28,500 Da
   protein thioredoxin peroxidase (Tpx) was identified. Two additional
   genes induced during oxidative stress were identified adjacent to tpx, a
   putative RNA-binding protein (rbpA) and a cytochrome-c peroxidase (ccp).
   Transcriptional analyses showed that tpx and rbpA were transcribed as
   monocistronic mRNA species or as a bicistronic operon. Transcription of
   tpx was induced by exposure to air or H2O2 from an OxyR-dependent
   promoter and to a lesser extent from a second OxyR-independent promoter.
   Expression of the rbpA gene during oxidative stress was regulated by the
   OxyR-dependent tpx promoter resulting in the bicistronic tpx/rbp mRNA.
   The ccp gene was expressed only as a monocistronic message and induction
   was only observed after exposure to H2O2 in an OxyR-in dependent manner.
   Disruption of the tpx operon or ccp resulted in sensitivity to the
   organic peroxides cumene hydroperoxide (CHP) and t-butyl hydroperoxide
   (TBHP) but not to H2O2. This work brings the total of oxyR-controlled
   genes in B. fragilis to five and suggests the existence of a second
   peroxide response regulator that controls ccp expression. (C) 2003
   Elsevier B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Smith, CJ (Reprint Author), E Carolina Univ, Brody Sch Med, Dept Microbiol \& Immunol, 600 Moye Blvd, Greenville, NC 27858 USA.
   E Carolina Univ, Brody Sch Med, Dept Microbiol \& Immunol, Greenville, NC 27858 USA.}},
DOI = {{10.1016/S0378-1119(03)00759-5}},
ISSN = {{0378-1119}},
Keywords = {{thioredoxin peroxidase; cytochrome-c peroxidase; OxyR}},
Keywords-Plus = {{ALKYL HYDROPEROXIDE REDUCTASE; ESCHERICHIA-COLI; ANTIBIOTIC-RESISTANCE;
   SUPEROXIDE-DISMUTASE; ANTIOXIDANT; PEROXIDE; PROTEINS; CATALASE;
   DEFENSE; REGULON}},
Research-Areas = {{Genetics \& Heredity}},
Web-of-Science-Categories  = {{Genetics \& Heredity}},
ORCID-Numbers = {{Rocha, Edson R./0000-0002-3472-8951}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI40588]}},
Cited-References = {{Bayley DP, 2000, FEMS MICROBIOL LETT, V193, P149, DOI 10.1016/S0378-1097(00)00472-9.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3.
   CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635.
   CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017.
   FINEGOLD SM, 1986, ANAEROBIC INFECT HUM.
   Gonchar MV, 1997, APPL MICROBIOL BIOT, V48, P454, DOI 10.1007/s002530051079.
   GOODHEW CF, 1990, BIOCHEM J, V271, P707, DOI 10.1042/bj2710707.
   GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181.
   GREGORY EM, 1985, ARCH BIOCHEM BIOPHYS, V238, P83, DOI 10.1016/0003-9861(85)90143-2.
   GREGORY EM, 1977, J BACTERIOL, V129, P1298.
   GUINEY DG, 1984, P NATL ACAD SCI-BIOL, V81, P7203, DOI 10.1073/pnas.81.22.7203.
   HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Minard KL, 2001, FREE RADICAL BIO MED, V31, P832, DOI 10.1016/S0891-5849(01)00666-9.
   PRIVITERA G, 1979, J INFECT DIS, V139, P97, DOI 10.1093/infdis/139.1.97.
   RENVALL S, 1975, AM J SURG, V130, P286, DOI 10.1016/0002-9610(75)90387-6.
   Rocha ER, 1999, J BACTERIOL, V181, P5701.
   Rocha ER, 2000, J BACTERIOL, V182, P5059, DOI 10.1128/JB.182.18.5059-5069.2000.
   Rocha ER, 1996, J BACTERIOL, V178, P6895, DOI 10.1128/jb.178.23.6895-6903.1996.
   Rocha ER, 1998, J BACTERIOL, V180, P5906.
   Rocha ER, 1997, J BACTERIOL, V179, P7033, DOI 10.1128/jb.179.22.7033-7039.1997.
   ROLFE RD, 1977, AM J CLIN NUTR, V30, P1762.
   SALYERS AA, 1984, ANNU REV MICROBIOL, V38, P293, DOI 10.1146/annurev.mi.38.100184.001453.
   Sambrook J, 1989, MOL CLONING LAB MANU.
   Smalley D, 2002, J BACTERIOL, V184, P895, DOI 10.1128/jb.184.4.895-903.2002.
   SMITH BA, 1995, AVIAT WEEK SPACE TEC, V143, P34.
   SMITH CJ, 1992, J CLIN MICROBIOL, V30, P806.
   SMITH CJ, 2002, PROKARYOTES EVOLVING.
   Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2.
   TERPENNING MS, 1989, GERONTOLOGY, V35, P130.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Gene}},
Doc-Delivery-Number = {{742GD}},
Unique-ID = {{ISI:000186508300017}},
DA = {{2018-08-13}},
}

@article{ ISI:000185215500003,
Author = {Bielke, LR and Elwood, AL and Donoghue, DJ and Donoghue, AM and
   Newberry, LA and Neighbor, NK and Hargis, BM},
Title = {{Approach for selection of individual enteric bacteria for competitive
   exclusion in turkey poults}},
Journal = {{POULTRY SCIENCE}},
Year = {{2003}},
Volume = {{82}},
Number = {{9}},
Pages = {{1378-1382}},
Month = {{SEP}},
Abstract = {{The intentional early colonization of the intestinal tract with
   beneficial microflora, known as competitive exclusion, has been shown to
   successfully protect poultry from selected enteric pathogens. Although
   effective cultures have been produced and are available, an inexpensive,
   air-tolerant, and completely defined culture is needed. Presently, we
   developed an in vitro competition assay to select for individual
   facultative anaerobes of poultry enteric origin that could exclude
   Salmonella. Using this assay, 24 isolates were selected and stored
   individually. These 24 isolates were amplified in batch culture (tryptic
   soy broth, 4 h at 40degreesC) and administered at final dilutions of 10,
   100, or 1,000 cfu to day-of-hatch poults. Forty-eight hours later,
   poults were challenged with 100 to 1,000 cfu
   antibiotic-resistance-marked Salmonella enteritidis PT 13A by oral
   gavage. Five days later, all poults were killed, and cecal tonsils were
   aseptically removed for tetrathionate enrichment (24 h at 37degreesC)
   followed by selective plating with marker antibiotics. Selected
   lactose-negative, antibiotic-resistant colonies typical of Salmonella
   were further confirmed by serogrouping. Treatment-related protection
   ranged from 0 to 100\% in three experiments. Greatest protection was
   related to the lowest concentrations of the protective microflora in
   each experiment. These data suggest that effective combinations of
   competitive enteric microflora can be identified by appropriate in vitro
   selection methods.}},
Publisher = {{POULTRY SCIENCE ASSOC INC}},
Address = {{1111 NORTH DUNLAP AVE, SAVOY, IL 61874-9604 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hargis, BM (Reprint Author), Univ Arkansas, Dept Poultry Sci, Fayetteville, AR 72701 USA.
   Univ Arkansas, Dept Poultry Sci, Fayetteville, AR 72701 USA.
   USDA, ARS, PP\&PSRU, Fayetteville, AR 72701 USA.}},
DOI = {{10.1093/ps/82.9.1378}},
ISSN = {{0032-5791}},
Keywords = {{competitive exclusion; Salmonella; turkey poult; cecal microflora;
   poultry}},
Keywords-Plus = {{SALMONELLA COLONIZATION; BROILER CHICKS; INFECTION; CULTURE; FEED}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Agriculture, Dairy \& Animal Science}},
Cited-References = {{BAILEY JS, 1988, AVIAN DIS, V32, P324, DOI 10.2307/1590821.
   CORRIER DE, 1995, POULTRY SCI, V74, P916, DOI 10.3382/ps.0740916.
   COX NA, 1992, POULTRY SCI, V71, P1781, DOI 10.3382/ps.0711781.
   {*}DIFCO LAB, 1984, DIFCO MAN DEHYDR CUL.
   Gast R. K., 1997, DIS POULTRY, P81.
   IMPEY CS, 1987, J APPL BACTERIOL, V63, P139, DOI 10.1111/j.1365-2672.1987.tb02696.x.
   Mead GC, 2000, VET J, V159, P111, DOI 10.1053/tvjl.1999.0423.
   National Research Council, 1994, NUTR REQ POULTR.
   NISBET DJ, 1996, J FOOD PROTECT, V59, P1278.
   NURMI E, 1973, NATURE, V241, P210, DOI 10.1038/241210a0.
   NURMI EV, 1921, Patent No. 4689226.
   SCHNEITZ C, 1992, BRIT POULTRY SCI, V33, P207, DOI 10.1080/00071669208417459.
   SNOEYENBOS GH, 1979, AVIAN DIS, V24, P904.
   STAVRIC S, 1987, J FOOD PROTECT, V50, P928, DOI 10.4315/0362-028X-50.11.928.
   TELLEZ GI, 1993, AVIAN DIS, V37, P143, DOI 10.2307/1591467.
   {*}USDA, 1995, FED REGISTER, V60, P6774.
   Zar J. H., 1984, BIOSTATISTICAL ANAL.
   ZIPRIN RL, 1993, AVIAN DIS, V37, P183, DOI 10.2307/1591472.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Poult. Sci.}},
Doc-Delivery-Number = {{719QM}},
Unique-ID = {{ISI:000185215500003}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000184460300011,
Author = {Bozdogan, B and Appelbaum, PC and Kelly, LM and Hoellman, DB and
   Tambic-Andrasevic, A and Drukalska, L and Hryniewicz, W and Hupkova, H
   and Jacobs, MR and Kolman, J and Konkoly-Thege, M and Miciuleviciene, J
   and Pana, M and Setchanova, L and Trupl, J and Urbaskova, P},
Title = {{Activity of telithromycin and seven other agents against 1034 pediatric
   Streptococcus pneumoniae isolates from ten central and eastern European
   centers}},
Journal = {{CLINICAL MICROBIOLOGY AND INFECTION}},
Year = {{2003}},
Volume = {{9}},
Number = {{7}},
Pages = {{653-661}},
Month = {{JUL}},
Abstract = {{Objective To test the activity of telithromycin against 1034
   Streptococcus pneumoniae isolates from pediatric patients in ten centers
   from ten central and eastern European countries during 2000-2001, and to
   compare it with the activities of erythromycin A, azithromycin,
   clarithromycin, clindamycin, and quinupristin-dalfopristin.
   Methods The minimum inhibitory concentrations (MICs) of telithromycin,
   erythromycin A, azithromycin, clarithromycin, clindamycin, levofloxacin,
   quinupristin-dalfopristin and penicillin G were tested by the agar
   dilution method with incubation in air, and mechanisms of resistance to
   macrolides and quinolones were investigated.
   Results Strains were isolated from sputum, tracheal aspirates, ear, eye,
   blood, and cerebrospinal fluid. Among S. pneumoniae strains tested, 36\%
   had raised penicillin G MICs (greater than or equal to 0.12 mg/L).
   Susceptibilities were as follows: telithromycin,
   quinupristin-dalfopristin and levofloxacin, greater than or equal to
   99\%; clindamycin, 83\%; and erythromycin A, azithromycin and
   clarithromycin, 78\%. Of 230 (22.3\%) erythromycin A-resistant S.
   pneumoniae strains, 176 (79.6\%) had erm(B) , 38 (16.1\%) had mef(A) ,
   and 10 (4.3\%) had mutations in 23S ribosomal RNA or in ribosomal
   protein L4. The rates of drug-resistant S. pneumoniae are high in all
   centers except Kaunas, Riga, and Prague.
   Conclusion Telithromycin had low MICs against all strains, irrespective
   of macrolide, azalide or clindamycin resistance. Ribosomal methylation
   was the most prevalent resistance mechanism among all resistant strains,
   except in Sofia, where the prevalence of the efflux mechanism was
   higher.}},
Publisher = {{WILEY-BLACKWELL}},
Address = {{COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Appelbaum, PC (Reprint Author), Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, 500 Univ Dr, Hershey, PA 17033 USA.
   Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA.
   Univ Zagreb, Univ Hosp Infect Dis, Zagreb, Croatia.
   Med Acad Latvia, Childrens Hosp, Riga, Latvia.
   Sera \& Vaccine Lab, Warsaw, Poland.
   St Cyril \& Method Hosp, Bratislava, Slovakia.
   Case Western Reserve Univ, Cleveland, OH 44106 USA.
   Univ Ljubljana, Ljubljana, Slovenia.
   Natl Ctr Epidemiol, Budapest, Hungary.
   Kaunas Med Univ Hosp, Kaunas, Lithuania.
   Inst Cantacuzino, Bucharest, Romania.
   Med Acad, Hosp Infect Dis, Sofia, Bulgaria.
   Natl Canc Inst, Bratislava, Slovakia.
   Natl Antibiot Reference Lab, Prague, Czech Republic.}},
DOI = {{10.1046/j.1469-0691.2003.00597.x}},
ISSN = {{1198-743X}},
Keywords = {{Central Europe; Eastern Europe; Streptococcus pneumoniae; telithromycin;
   drug resistance}},
Keywords-Plus = {{MACROLIDE RESISTANCE MECHANISMS; ANTIBIOTIC-RESISTANCE; BACTERIAL
   PATHOGENS; SUSCEPTIBILITIES; ERYTHROMYCIN; SURVEILLANCE; PNEUMOCOCCI;
   PREVALENCE; MUTATION; KETOLIDE}},
Research-Areas = {{Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology}},
Author-Email = {{pappelbaum@psu.edu}},
ResearcherID-Numbers = {{Hryniewicz, Waleria/J-3168-2012
   Bozdogan, Bulent/C-9137-2018}},
ORCID-Numbers = {{Bozdogan, Bulent/0000-0001-8846-7649}},
Cited-References = {{Angot P, 2000, EUR J CLIN MICROBIOL, V19, P755, DOI 10.1007/s100960000358.
   APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   Bergan T, 1998, INT J ANTIMICROB AG, V10, P77, DOI 10.1016/S0924-8579(98)00018-1.
   Depardieu F, 2001, ANTIMICROB AGENTS CH, V45, P319, DOI 10.1128/AAC.45.1.319-323.2001.
   Felmingham D, 2000, J ANTIMICROB CHEMOTH, V45, P191, DOI 10.1093/jac/45.2.191.
   Felmingham D, 1998, J ANTIMICROB CHEMOTH, V41, P411, DOI 10.1093/jac/41.3.411.
   Hoban DJ, 2001, ANTIMICROB AGENTS CH, V45, P2147, DOI 10.1128/AAC.45.7.2147-2150.2001.
   Jacobs MR, 1999, ANTIMICROB AGENTS CH, V43, P1901.
   Kozlov RS, 2002, ANTIMICROB AGENTS CH, V46, P2963, DOI 10.1128/AAC.46.9.2963-2968.2002.
   LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1267, DOI 10.1128/AAC.35.7.1267.
   MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302.
   Nagai K, 2002, ANTIMICROB AGENTS CH, V46, P371, DOI 10.1128/AAC.46.2.371-377.2002.
   Nagai K, 2000, ANTIMICROB AGENTS CH, V44, P2740, DOI 10.1128/AAC.44.10.2740-2746.2000.
   National Committee for Clinical Laboratory Standards NCCLS, 2000, M7A5 NCCLS.
   Pankuch GA, 1998, ANTIMICROB AGENTS CH, V42, P624.
   Perez-Trallero E, 2001, ANTIMICROB AGENTS CH, V45, P3334, DOI 10.1128/AAC.45.12.3334-3340.2001.
   Rosato A, 1998, ANTIMICROB AGENTS CH, V42, P1392.
   Shortridge VD, 1999, CLIN INFECT DIS, V29, P1186, DOI 10.1086/313452.
   SOUSSY CJ, 2000, 40 INT C ANT AG CHEM, P136.
   Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P2562.
   Tait-Kamradt A, 2000, ANTIMICROB AGENTS CH, V44, P3395, DOI 10.1128/AAC.44.12.3395-3401.2000.
   TaitKamradt A, 1997, ANTIMICROB AGENTS CH, V41, P2251.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Microbiol. Infect.}},
Doc-Delivery-Number = {{706NT}},
Unique-ID = {{ISI:000184460300011}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000183666700019,
Author = {Liu, J and Lei, DW and Waalkes, MP and Beliles, RP and Morgan, DL},
Title = {{Genomic analysis of the rat lung following elemental mercury vapor
   exposure}},
Journal = {{TOXICOLOGICAL SCIENCES}},
Year = {{2003}},
Volume = {{74}},
Number = {{1}},
Pages = {{174-181}},
Month = {{JUL}},
Abstract = {{Elemental mercury (Hg-0) is a highly toxic chemical with increasing
   public health concern. Although the lung receives the highest exposure
   to Hg-0 vapor, it is resistant to Hg-0 toxicity relative to the kidney
   and brain. In an earlier study, exposure of rats to 4 mg Hg-0
   vapor/m(3), 2 h per day for 10 days, did not produce pathological
   alterations in the lung but increased metallothionein and glutathione
   S-transferase in the kidney. This study was undertaken to examine
   pulmonary gene expression associated with Hg-0 vapor inhalation. Total
   RNA was extracted from lung tissues of rats, previously exposed to air
   or Hg-0 vapor, and subjected to microarray analysis. Hg-0 vapor exposure
   increased the expression of genes encoding inflammatory responses, such
   as chemokines, tumor necrosis factor-alpha (TNFalpha), TNF-receptor-1,
   interleukin-2 (IL-2), IL-7, prostaglandin E2 receptor, and heat-shock
   proteins. As adaptive responses, glutathione S-transferases (GST-pi,
   mGST1), metallothionein, and thioredoxin peroxidase were all increased
   in response to Hg exposure. Some transporters, such as multidrug
   resistance-associated protein (MRP), P-glycoprotein, and zinc
   transporter ZnT1, were also increased in an attempt to reduce pulmonary
   Hg load. The expression of transcription factor c-jun/AP-1 and
   PI3-kinases was suppressed, while the expression of protein kinase-C was
   increased. Expression of epidermal fatty acid-binding protein was also
   enhanced. Real-time RT-PCR and Western blot analyses confirmed the
   microarray results. In summary, genomic analysis revealed an array of
   gene alterations in response to Hg-0 vapor exposure, which could be
   important for the development of pulmonary adaptation to Hg during Hg-0
   vapor inhalation.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Morgan, DL (Reprint Author), NIEHS, Mol Toxicol Lab, MD IF-00, Res Triangle Pk, NC 27709 USA.
   NIEHS, Mol Toxicol Lab, Res Triangle Pk, NC 27709 USA.
   NIEHS, Inorgan Carcinogenesis Sect, NCI, Res Triangle Pk, NC 27709 USA.
   US EPA, ORD, NCEA, Oakton, VA USA.
   Guiyang Med Coll, Guizhou 550004, Peoples R China.}},
DOI = {{10.1093/toxsci/kfg091}},
ISSN = {{1096-6080}},
Keywords = {{mercury vapor inhalation; lung; microarray; gene expression; adaptation}},
Keywords-Plus = {{METALLOTHIONEIN-NULL MICE; GENE-EXPRESSION; INORGANIC MERCURY;
   SUPEROXIDE-DISMUTASE; REAL-TIME; TOXICITY; INHALATION; TOXICOLOGY;
   PROTEIN; KIDNEY}},
Research-Areas = {{Toxicology}},
Web-of-Science-Categories  = {{Toxicology}},
Cited-References = {{Agency for Toxic Substances and Disease Registry (ATSDR), 1997, TOX PROF NICK, P1.
   Asano S, 2000, PATHOL INT, V50, P169, DOI 10.1046/j.1440-1827.2000.01032.x.
   Badou A, 1997, J BIOL CHEM, V272, P32411, DOI 10.1074/jbc.272.51.32411.
   Ballatori N, 2002, ENVIRON HEALTH PERSP, V110, P689, DOI 10.1289/ehp.02110s5689.
   Bennaars-Eiden A, 2002, J BIOL CHEM, V277, P50693, DOI 10.1074/jbc.M209493200.
   Brambila E, 2002, J TOXICOL ENV HEAL A, V65, P1273, DOI 10.1080/00984100290071405.
   Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098.
   Goering PL, 2002, J APPL TOXICOL, V22, P167, DOI 10.1002/jat.844.
   GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I.
   HURSH JB, 1976, ARCH ENVIRON HEALTH, V31, P302, DOI 10.1080/00039896.1976.10667240.
   IPCS, 1991, ENV HLTH CRIT, P118.
   KIM CY, 1995, TOXICOLOGY, V98, P67, DOI 10.1016/0300-483X(94)02960-3.
   Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267.
   Liu J, 2002, TOXICOLOGY, V170, P55, DOI 10.1016/S0300-483X(01)00532-7.
   Liu J, 2001, TOXICOL SCI, V61, P314, DOI 10.1093/toxsci/61.2.314.
   Liu WH, 2002, ANAL BIOCHEM, V302, P52, DOI 10.1006/abio.2001.5530.
   LIVARDJANI F, 1991, TOXICOLOGY, V66, P289, DOI 10.1016/0300-483X(91)90200-K.
   Mackert JR, 1997, CRIT REV ORAL BIOL M, V8, P410, DOI 10.1177/10454411970080040401.
   Marcusson JA, 2000, ENVIRON RES, V83, P123, DOI 10.1006/enrs.1999.4030.
   MCFARLAND RB, 1978, J OCCUP ENVIRON MED, V20, P532, DOI 10.1097/00043764-197808000-00003.
   Morgan DL, 2002, TOXICOL SCI, V66, P261, DOI 10.1093/toxsci/66.2.261.
   Nadarajah V, 1996, J TOXICOL ENV HEALTH, V49, P113.
   Rahman Q, 1999, CRIT REV TOXICOL, V29, P543, DOI 10.1080/10408449991349276.
   Satoh H, 2000, IND HEALTH, V38, P153, DOI 10.2486/indhealth.38.153.
   Solis MT, 2000, AM J EMERG MED, V18, P599, DOI 10.1053/ajem.2000.4006.
   Sugawara N, 1998, TOXICOLOGY, V126, P23, DOI 10.1016/S0300-483X(97)00170-4.
   Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0.
   Turney KD, 1999, TOXICOL APPL PHARM, V160, P262, DOI 10.1006/taap.1999.8772.
   Vernhet L, 2000, TOXICOLOGY, V142, P127.
   Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8.
   Woods JS, 2002, ENVIRON HEALTH PERSP, V110, P819, DOI 10.1289/ehp.02110s5819.
   Yoshida M, 2002, TOXICOLOGY, V175, P215, DOI 10.1016/S0300-483X(02)00084-7.
   Yoshida M, 1999, TOXICOLOGY, V139, P129, DOI 10.1016/S0300-483X(99)00117-1.
   Yoshida M, 1999, LIFE SCI, V64, P1861, DOI 10.1016/S0024-3205(99)00129-0.
   Zalups RK, 2002, J TOXICOL ENV HEAL A, V65, P1471, DOI 10.1080/00984100290071612.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Toxicol. Sci.}},
Doc-Delivery-Number = {{692NG}},
Unique-ID = {{ISI:000183666700019}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000181761700009,
Author = {Strausbaugh, LJ and Sukumar, SR and Joseph, CL},
Title = {{Infectious disease outbreaks in nursing homes: An unappreciated hazard
   for frail elderly persons}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{2003}},
Volume = {{36}},
Number = {{7}},
Pages = {{870-876}},
Month = {{APR 1}},
Abstract = {{The common occurrence and dire consequences of infectious disease
   outbreaks in nursing homes often go unrecognized and unappreciated.
   Nevertheless, these facilities provide an ideal environment for
   acquisition and spread of infection: susceptible residents who share
   sources of air, food, water, and health care in a crowded institutional
   setting. Moreover, visitors, staff, and residents constantly come and
   go, bringing in pathogens from both the hospital and the community.
   Outbreaks of respiratory and gastrointestinal infection predominate in
   this setting, but outbreaks of skin and soft-tissue infection and
   infections caused by antimicrobial-resistant bacteria also occur with
   some frequency.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{1427 E 60TH ST, CHICAGO, IL 60637-2954 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Strausbaugh, LJ (Reprint Author), Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Div Hosp \& Specialty Med P31D, POB 1034, Portland, OR 97239 USA.
   Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Div Hosp \& Specialty Med, Infect Dis Sect, Portland, OR 97201 USA.
   Oregon Hlth Sci Univ, Vet Affairs Med Ctr, Div Hosp \& Specialty Med, Geriatr Sect, Portland, OR 97201 USA.
   Oregon Hlth \& Sci Univ, Sch Med, Dept Med, Div Infect Dis, Portland, OR USA.
   Oregon Hlth \& Sci Univ, Sch Med, Dept Med, Div Gen Internal Med, Portland, OR USA.}},
DOI = {{10.1086/368197}},
ISSN = {{1058-4838}},
Keywords-Plus = {{LONG-TERM-CARE; RESISTANT STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI
   O157-H7; CLOSTRIDIUM-DIFFICILE; ENTEROCOCCUS-FAECIUM; UNITED-STATES;
   FACILITIES; INFLUENZA; RESIDENTS; DIARRHEA}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Author-Email = {{strausba@ohsu.edu}},
Cited-References = {{ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704.
   Andersen BM, 2000, J HOSP INFECT, V45, P160, DOI 10.1053/jhin.1999.0716.
   ARDEN N, 1995, AM J PUBLIC HEALTH, V85, P399, DOI 10.2105/AJPH.85.3.399.
   Armstrong-Evans M, 1999, INFECT CONT HOSP EP, V20, P312, DOI 10.1086/501623.
   AUERBACH SB, 1992, ARCH INTERN MED, V152, P1017, DOI 10.1001/archinte.152.5.1017.
   BENDER BS, 1986, LANCET, V2, P11.
   BENNETT RG, 1993, INFECT CONT HOSP EP, V14, P397.
   BLOOM HG, 1990, J AM GERIATR SOC, V38, P804, DOI 10.1111/j.1532-5415.1990.tb01473.x.
   Bonilla HF, 1997, INFECT CONT HOSP EP, V18, P333.
   Bradley SF, 1999, INFECT CONT HOSP EP, V20, P362, DOI 10.1086/501637.
   Bradley SF, 1999, INFECT CONT HOSP EP, V20, P629, DOI 10.1086/501687.
   BROOKS SE, 1992, INFECT CONT HOSP EP, V13, P98.
   Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9.
   CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403.
   Castle NG, 1996, MED CARE RES REV, V53, P123, DOI 10.1177/107755879605300201.
   {*}CDCP, 1990, MMWR-MORBID MORTAL W, V39, P7.
   DEGELAU J, 1992, INFECT CONT HOSP EP, V13, P421.
   FALSEY AR, 1991, INFECT CONT HOSP EP, V12, P602.
   Faulks JT, 2000, J AM GERIATR SOC, V48, P1216, DOI 10.1111/j.1532-5415.2000.tb02593.x.
   Gleich S, 2000, INFECT CONT HOSP EP, V21, P711, DOI 10.1086/501717.
   Green KY, 2002, J INFECT DIS, V185, P133, DOI 10.1086/338365.
   HARKNESS GA, 1992, AM J INFECT CONTROL, V20, P142, DOI 10.1016/S0196-6553(05)80181-6.
   JACKSON MM, 1985, AM J INFECT CONTROL, V13, P63, DOI 10.1016/0196-6553(85)90084-7.
   JACOBSON C, 1990, AM J INFECT CONTROL, V18, P151, DOI 10.1016/0196-6553(90)90180-Z.
   KASHEF I, 2002, J AM GERIATR SOC, V50, P1213.
   KROGSTAD DJ, 1978, ANN INTERN MED, V88, P89, DOI 10.7326/0003-4819-88-1-89.
   Layton MC, 1997, INFECT CONT HOSP EP, V18, P115.
   LEVINE WC, 1991, JAMA-J AM MED ASSOC, V266, P2105, DOI 10.1001/jama.266.15.2105.
   LEW JF, 1991, JAMA-J AM MED ASSOC, V265, P3280, DOI 10.1001/jama.265.24.3280.
   Li JH, 1996, AM J EPIDEMIOL, V143, P1042.
   Loeb M, 2000, CAN MED ASSOC J, V162, P1133.
   McCall B, 2000, Commun Dis Intell, V24, P272.
   MORENS DM, 1995, INFECT CONT HOSP EP, V16, P275.
   Nuorti JP, 1998, NEW ENGL J MED, V338, P1861, DOI 10.1056/NEJM199806253382601.
   Olsen S J, 2000, MMWR CDC Surveill Summ, V49, P1.
   PATRIARCA PA, 1986, AM J EPIDEMIOL, V124, P114, DOI 10.1093/oxfordjournals.aje.a114355.
   Rajagopalan S, 2000, INFECT CONT HOSP EP, V21, P611, DOI 10.1086/501816.
   RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193.
   Richards CL, 2002, INFECTION MANAGEMENT FOR GERIATRICS IN LONG-TERM CARE FACILITIES, P133.
   RUBEN FL, 1984, ANN INTERN MED, V101, P494, DOI 10.7326/0003-4819-101-4-494.
   RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631.
   Ryan MJ, 1997, J INFECTION, V34, P49, DOI 10.1016/S0163-4453(97)80009-6.
   SCHWARTZ B, 1992, INFECT CONT HOSP EP, V13, P742.
   Simor AE, 2002, INFECT CONT HOSP EP, V23, P696, DOI 10.1086/501997.
   Smith JL, 1998, J FOOD PROTECT, V61, P1229, DOI 10.4315/0362-028X-61.9.1229.
   SMITH PF, 1988, JAMA-J AM MED ASSOC, V260, P1446, DOI 10.1001/jama.260.10.1446.
   Smith Philip W., 1994, P131.
   SPINDEL SJ, 1995, INFECT CONT HOSP EP, V16, P217.
   STANDAERT SM, 1994, INFECT CONT HOSP EP, V15, P22.
   STORCH GA, 1987, INFECT CONT HOSP EP, V8, P24, DOI 10.1017/S0195941700066947.
   Stout JE, 2000, J AM GERIATR SOC, V48, P1589, DOI 10.1111/j.1532-5415.2000.tb03868.x.
   Strausbaugh Larry J., 1999, P1461.
   Strausbaugh LJ, 1996, INFECT CONT HOSP EP, V17, P129.
   STRAUSBAUGH LJ, 1991, INFECT CONT HOSP EP, V12, P36.
   Tallis G, 1999, AUST NZ J PUBL HEAL, V23, P421, DOI 10.1111/j.1467-842X.1999.tb01287.x.
   Troy CJ, 1997, JAMA-J AM MED ASSOC, V277, P1214, DOI 10.1001/jama.277.15.1214.
   WALD TG, 1995, ANN INTERN MED, V123, P588, DOI 10.7326/0003-4819-123-8-199510150-00004.
   WHITE KE, 1989, J INFECT DIS, V160, P298, DOI 10.1093/infdis/160.2.298.
   Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517.
   1998, EPIDEMIOL B, V98, P1.}},
Number-of-Cited-References = {{60}},
Times-Cited = {{87}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{659DF}},
Unique-ID = {{ISI:000181761700009}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000182305600002,
Author = {Gilbert, P and McBain, AJ},
Title = {{Potential impact of increased use of biocides in consumer products on
   prevalence of antibiotic resistance}},
Journal = {{CLINICAL MICROBIOLOGY REVIEWS}},
Year = {{2003}},
Volume = {{16}},
Number = {{2}},
Pages = {{189+}},
Month = {{APR}},
Abstract = {{There has recently been much controversy surrounding the increased use
   of antibacterial substances in a wide range of consumer products and the
   possibility that, as with antibiotics, indiscriminate use of biocides
   might contribute to the overall pattern of susceptibility in the general
   environment and in the clinic. Such speculation, based on the isolation
   of resistant mutants from in vitro monoculture experiments, is not
   reflected by air emergence of biocide-resistant strains in vivo. This
   review provides a broad coverage of the biocide and resistance
   literature and evaluates the potential risks, perceived from such
   laboratory monoculture experiments, against evidence gathered over 50
   years of field studies. An explanation for the continued effectiveness
   of broad-spectrum biocidal agents against the decline in efficacy of
   therapeutic agents is provided based on the fitness costs of resistance
   and the ubiquity of naturally occurring substances that possess
   antibacterial effect. While we conclude from this review of the
   literature that the incorporation of antibacterial agents into a
   widening sphere of personal products has had little or no impact on the
   patterns of microbial susceptibility observed in the environment, the
   associated risks remain finite. The use of such products should
   therefore be associated with a clear demonstration of added value either
   to consumer health or to the product life. Hygienic products should
   therefore be targeted to applications for which the risks have been
   established.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Gilbert, P (Reprint Author), Univ Manchester, Sch Pharm \& Pharmaceut Sci, Oxford Rd, Manchester M13 9PL, Lancs, England.
   Univ Manchester, Sch Pharm \& Pharmaceut Sci, Manchester M13 9PL, Lancs, England.}},
DOI = {{10.1128/CMR.16.2.189-208.2003}},
ISSN = {{0893-8512}},
Keywords-Plus = {{GRAM-NEGATIVE BACTERIA; QUATERNARY AMMONIUM-COMPOUNDS; MULTIDRUG EFFLUX
   PUMP; STAPHYLOCOCCUS-AUREUS STRAINS; PSEUDOMONAS-AERUGINOSA PAO; CARRIER
   PROTEIN REDUCTASE; FATTY-ACID COMPOSITION; ESCHERICHIA-COLI BIOFILMS;
   BETA-LACTAM ANTIBIOTICS; URINARY-TRACT INFECTION}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
ORCID-Numbers = {{McBain, Andrew/0000-0002-5255-5425}},
Cited-References = {{ADAIR FW, 1969, APPL MICROBIOL, V18, P299.
   ADAIR FW, 1971, APPL MICROBIOL, V21, P1058.
   Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067.
   Alekshun MN, 1999, TRENDS MICROBIOL, V7, P410, DOI 10.1016/S0966-842X(99)01589-9.
   Allen KD, 1997, J HOSP INFECT, V35, P307, DOI 10.1016/S0195-6701(97)90225-5.
   ALMASAUDI SB, 1988, LETT APPL MICROBIOL, V7, P45, DOI 10.1111/j.1472-765X.1988.tb01249.x.
   ALMASAUDI SB, 1991, J APPL BACTERIOL, V70, P279, DOI 10.1111/j.1365-2672.1991.tb02937.x.
   ALMASAUDI SB, 1988, J APPL BACTERIOL, V65, P329, DOI 10.1111/j.1365-2672.1988.tb01899.x.
   ALMASAUDI SB, 1991, J APPL BACTERIOL, V71, P331, DOI 10.1111/j.1365-2672.1991.tb03796.x.
   ALMASAUDI SB, 1991, J APPL BACTERIOL, V71, P239, DOI 10.1111/j.1365-2672.1991.tb04454.x.
   Alqurashi AM, 1996, J ANTIMICROB CHEMOTH, V38, P745, DOI 10.1093/jac/38.4.745.
   Anderson RL, 1997, INFECT CONT HOSP EP, V18, P195.
   BACQUERO F, 1991, J HOSP INFECT SB, V18, P5.
   Bagley DM, 2000, AM J DENT, V13, P148.
   BAILLIE LWJ, 1993, J ANTIMICROB CHEMOTH, V31, P219, DOI 10.1093/jac/31.2.219.
   BAILLIE LWJ, 1992, J HOSP INFECT, V20, P127, DOI 10.1016/0195-6701(92)90118-6.
   Bamber AI, 1999, J HOSP INFECT, V41, P107, DOI 10.1016/S0195-6701(99)90047-6.
   BARKER J, 1995, ANTIMICROB AGENTS CH, V39, P2684, DOI 10.1128/AAC.39.12.2684.
   BARKER J, 1992, APPL ENVIRON MICROB, V58, P2420.
   Bass L, 1999, ANTIMICROB AGENTS CH, V43, P2925.
   BEHR H, 1994, PATHOL BIOL, V42, P438.
   BENITO H, 1994, PATHOL BIOL, V42, P438.
   BERKELMAN RL, 1984, APPL ENVIRON MICROB, V47, P752.
   Bert F, 1996, J ANTIMICROB CHEMOTH, V37, P809, DOI 10.1093/jac/37.4.809.
   Beumer R, 1999, Ann Ig, V11, P11.
   Block C, 2002, J HOSP INFECT, V51, P201, DOI 10.1053/jhin.2002.1246.
   Bloomfield SF, 1998, MICROBIOL-UK, V144, P1, DOI 10.1099/00221287-144-1-1.
   BLOOMFIELD SF, 1974, J APPL BACTERIOL, V37, P117, DOI 10.1111/j.1365-2672.1974.tb00422.x.
   Bloomfield SF, 2002, J APPL MICROBIOL, V92, p144S, DOI 10.1046/j.1365-2672.92.5s1.15.x.
   BOLHUIS H, 1994, J BACTERIOL, V176, P6957.
   BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092.
   BOLTON KJ, 1988, LETT APPL MICROBIOL, V6, P31, DOI 10.1111/j.1472-765X.1988.tb01208.x.
   Bordas AC, 1997, J FOOD PROTECT, V60, P531, DOI 10.4315/0362-028X-60.5.531.
   Boyce JM, 1997, INFECT CONT HOSP EP, V18, P622.
   Bradley CR, 1996, J HOSP INFECT, V34, P191, DOI 10.1016/S0195-6701(96)90065-1.
   Braid JJ, 2002, J ANTIMICROB CHEMOTH, V49, P87, DOI 10.1093/jac/49.1.87.
   Brown M R, 1969, J Gen Microbiol, V55, P17.
   BROWN MRW, 1979, J PHARM SCI, V68, P146, DOI 10.1002/jps.2600680207.
   BROWN MRW, 1993, J APPL BACTERIOL, V74, pS87, DOI 10.1111/j.1365-2672.1993.tb04345.x.
   BROWN MRW, 1985, ANNU REV MICROBIOL, V39, P527, DOI 10.1146/annurev.mi.39.100185.002523.
   BROWN MRW, 1990, ANTIMICROB AGENTS CH, V34, P1623, DOI 10.1128/AAC.34.9.1623.
   Brown MRW, 1999, TRENDS MICROBIOL, V7, P45.
   BRUMFITT W, 1985, LANCET, V1, P1442.
   CEFAI C, 1994, LANCET, V344, P539, DOI 10.1016/S0140-6736(94)91926-7.
   CHAZAL PM, 1995, EUR J EPIDEMIOL, V11, P1, DOI 10.1007/BF01719939.
   CHOPRA I, 1991, MECH ACTION CHEM BIO, P45.
   Christensen BB, 1998, APPL ENVIRON MICROB, V64, P2247.
   Chuanchuen R, 2002, J BACTERIOL, V184, P5036, DOI 10.1128/JB.184.18.5036-5044.2002.
   Chuanchuen R, 2001, ANTIMICROB AGENTS CH, V45, P428, DOI 10.1128/AAC.45.2.428-432.2001.
   COHEN SP, 1993, J BACTERIOL, V175, P7856.
   COHEN SP, 1989, ANTIMICROB AGENTS CH, V33, P1318, DOI 10.1128/AAC.33.8.1318.
   COLLIER PJ, 1991, INT J PHARM, V74, P195, DOI 10.1016/0378-5173(91)90237-I.
   COLLIER PJ, 1990, J APPL BACTERIOL, V69, P578, DOI 10.1111/j.1365-2672.1990.tb01551.x.
   COLLIER PJ, 1990, INT J PHARM, V66, P201, DOI 10.1016/0378-5173(90)90400-X.
   COOKSEY DA, 1987, APPL ENVIRON MICROB, V53, P454.
   COOKSEY RC, 1987, MANUAL CLIN MICROBIO, P1099.
   COOKSON BD, 1991, LANCET, V337, P1548, DOI 10.1016/0140-6736(91)93242-2.
   COOKSON BD, 1991, ANTIMICROB AGENTS CH, V35, P1997, DOI 10.1128/AAC.35.10.1997.
   CREMIEUX A, 1986, DRUG EXP CLIN RES, V12, P899.
   Cristino JM, 1999, INT J ANTIMICROB AG, V12, P199, DOI 10.1016/S0924-8579(99)00052-7.
   DANCE DAB, 1987, J HOSP INFECT, V10, P10, DOI 10.1016/0195-6701(87)90027-2.
   Dancer SJ, 1999, J HOSP INFECT, V43, pS19, DOI 10.1016/S0195-6701(99)90062-2.
   Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573.
   DENHAM J, 2000, UK ANTIMICROBIAL STR.
   Denyer SP, 1998, INT BIODETER BIODEGR, V41, P261, DOI 10.1016/S0964-8305(98)00023-7.
   Desai B., 1989, INDIAN J MED MICROBI, V7, P170.
   Dixon B, 2000, ASM NEWS, V66, P264.
   DODD CER, 1998, BIOCHEMIST      0412.
   Earnshaw AM, 1998, J APPL MICROBIOL, V84, P642, DOI 10.1046/j.1365-2672.1998.00395.x.
   ELMOUG T, 1985, J ANTIMICROB CHEMOTH, V16, P685.
   EMSLIE KR, 1986, J MED MICROBIOL, V22, P9, DOI 10.1099/00222615-22-1-9.
   EVANS DJ, 1991, J ANTIMICROB CHEMOTH, V27, P177, DOI 10.1093/jac/27.2.177.
   Fan F, 2002, ANTIMICROB AGENTS CH, V46, P3343, DOI 10.1128/AAC.46.11.1143-3347.2002.
   Fang CT, 2002, ANTIMICROB AGENTS CH, V46, P2024, DOI 10.1128/AAC.46.6.2024-2028.2002.
   Feinman SE, 1998, ASM NEWS, V64, P24.
   FERNANDEZASTORGA A, 1995, LETT APPL MICROBIOL, V20, P308, DOI 10.1111/j.1472-765X.1995.tb00452.x.
   Foley I, 1999, J ANTIMICROB CHEMOTH, V43, P164, DOI 10.1093/jac/43.1.164.
   FRENEY J, 1988, ANTIMICROB AGENTS CH, V32, P873, DOI 10.1128/AAC.32.6.873.
   Fujii M, 1996, NEUROL SURG TOKYO, V24, P241.
   Georgala DL, 1999, REPORT MICROBIAL ANT.
   George AM, 1996, FEMS MICROBIOL LETT, V139, P1, DOI 10.1016/0378-1097(96)00127-9.
   GEORGE AM, 1983, J BACTERIOL, V155, P531.
   GILBERT P, 1977, MICROBIOS, V20, P29.
   GILBERT P, 1977, MICROBIOS, V19, P125.
   Gilbert P, 2002, J APPL MICROBIOL, V92, p98S, DOI 10.1046/j.1365-2672.92.5s1.5.x.
   Gilbert P, 2002, ADV MICROB PHYSIOL, V46, P203, DOI 10.1016/S0065-2911(02)46005-5.
   GILBERT P, 1990, ANTIMICROB AGENTS CH, V34, P1865, DOI 10.1128/AAC.34.10.1865.
   GILBERT P, 1980, MICROBIOS, V28, P7.
   GILBERT P, 1978, MICROBIOS, V22, P203.
   Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901.
   GORDON J, 1987, ROYAL SOC MED SERVIC, V129, P133.
   Greenway DLA, 1999, LETT APPL MICROBIOL, V29, P298, DOI 10.1046/j.1365-2672.1999.00615.x.
   Greenway DLA, 1999, LETT APPL MICROBIOL, V29, P323, DOI 10.1046/j.1472-765X.1999.00642.x.
   Grkovic S, 1998, J BIOL CHEM, V273, P18665, DOI 10.1074/jbc.273.29.18665.
   Guerin-Mechin L, 2000, INT J FOOD MICROBIOL, V55, P157, DOI 10.1016/S0168-1605(00)00189-6.
   Guerin-Mechin L, 1999, J APPL MICROBIOL, V87, P735, DOI 10.1046/j.1365-2672.1999.00919.x.
   Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545.
   Gupta A, 1998, NAT BIOTECHNOL, V16, P888, DOI 10.1038/nbt1098-888.
   GUTMANN L, 1985, J INFECT DIS, V151, P501, DOI 10.1093/infdis/151.3.501.
   HAMILTON WA, 1968, J GEN MICROBIOL, V50, P441, DOI 10.1099/00221287-50-3-441.
   HAMMOND SA, 1987, J HOSP INFECT, V9, P255, DOI 10.1016/0195-6701(87)90122-8.
   Hampton S, 1997, Nurs Times, V93, P74.
   Hancock REW, 1998, CLIN INFECT DIS, V27, pS93, DOI 10.1086/514909.
   HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P428.
   Hart CA, 1998, BRIT MED J, V316, P1255, DOI 10.1136/bmj.316.7140.1255.
   Hay AG, 2001, FEMS MICROBIOL ECOL, V36, P105, DOI 10.1111/j.1574-6941.2001.tb00830.x.
   Heath RJ, 2002, APPL MICROBIOL BIOT, V58, P695, DOI 10.1007/s00253-001-0918-z.
   Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316.
   Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110.
   Heinzel M, 1998, INT BIODETER BIODEGR, V41, P225, DOI 10.1016/S0964-8305(98)00028-6.
   HEIR E, 1995, J APPL BACTERIOL, V79, P149, DOI 10.1111/j.1365-2672.1995.tb00928.x.
   Heir E, 1999, INT J FOOD MICROBIOL, V48, P211, DOI 10.1016/S0168-1605(99)00044-6.
   Heir E, 1998, FEMS MICROBIOL LETT, V163, P49, DOI 10.1111/j.1574-6968.1998.tb13025.x.
   Heir E, 1999, J APPL MICROBIOL, V86, P378, DOI 10.1046/j.1365-2672.1999.00672.x.
   Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593.
   HIGGINBOTTOM C, 1964, J APPL BACTERIOL, V27, P385.
   Hoang TT, 1999, J BACTERIOL, V181, P5489.
   HOBSON DW, 1999, INFECT CONT TODA MAY, P22.
   HOUANG ET, 1976, J CLIN PATHOL, V29, P752, DOI 10.1136/jcp.29.8.752.
   Hovander L, 2002, ARCH ENVIRON CON TOX, V42, P105.
   Irizarry L, 1996, CHEMOTHERAPY, V42, P248, DOI 10.1159/000239451.
   ISMAEEL N, 1986, Microbios Letters, V33, P59.
   JARVINEN H, 1993, ANTIMICROB AGENTS CH, V37, P1158, DOI 10.1128/AAC.37.5.1158.
   JONES KH, 1999, OPINION SCI STEERING.
   Jones RD, 1999, AM J INFECT CONTROL, V27, P351, DOI 10.1016/S0196-6553(99)70056-8.
   Joynson JA, 2002, J APPL MICROBIOL, V93, P96, DOI 10.1046/j.1365-2672.2002.01667.x.
   KAATZ GW, 1993, ANTIMICROB AGENTS CH, V37, P1086, DOI 10.1128/AAC.37.5.1086.
   KAULFERS PM, 1987, ZENTRALBLATT BAKTE A, V226, P239.
   Kazama H, 1999, FEMS MICROBIOL LETT, V174, P379, DOI 10.1016/S0378-1097(99)00167-6.
   Kazama H, 1998, FEMS MICROBIOL LETT, V165, P295, DOI 10.1111/j.1574-6968.1998.tb13160.x.
   KHOR S Y, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P199.
   KLEMPERER RMM, 1980, J APPL BACTERIOL, V48, P349, DOI 10.1111/j.1365-2672.1980.tb01022.x.
   Klossner BL, 1997, DERMATOLOGY, V195, P10.
   Kohler T, 1997, ANTIMICROB AGENTS CH, V41, P2540.
   KRAMER VC, 1984, CAN J MICROBIOL, V30, P699, DOI 10.1139/m84-104.
   Kucken D, 2000, FEMS MICROBIOL LETT, V183, P95.
   LAKSHMI VV, 1989, FEMS MICROBIOL LETT, V48, P275.
   Lambert RJW, 2001, J APPL MICROBIOL, V91, P972, DOI 10.1046/j.1365-2672.2001.01460.x.
   Langsrud S, 1997, J APPL MICROBIOL, V82, P705, DOI 10.1046/j.1365-2672.1997.00186.x.
   Lawrence JG, 2000, ASM NEWS, V66, P281.
   Lear JC, 2002, J IND MICROBIOL BIOT, V29, P238, DOI 10.1038/sj.jim.7000320.
   LECHEVALLIER MW, 1988, APPL ENVIRON MICROB, V54, P649.
   LEELAPORN A, 1994, J MED MICROBIOL, V40, P214, DOI 10.1099/00222615-40-3-214.
   Levy SB, 2002, J APPL MICROBIOL, V92, p65S, DOI 10.1046/j.1365-2672.92.5s1.4.x.
   Levy SB, 1998, BRIT MED J, V317, P612, DOI 10.1136/bmj.317.7159.612.
   LEVY SB, 1998, SCI AM           MAR, P322.
   Lewis K, 1997, ASM NEWS, V63, P605.
   LEWIS R, 1988, J HOSP INFECT, V11, P150, DOI 10.1016/0195-6701(88)90057-6.
   Leyer GJ, 1997, APPL ENVIRON MICROB, V63, P461.
   LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948.
   LI XZ, 1994, ANTIMICROB AGENTS CH, V38, P1732, DOI 10.1128/AAC.38.8.1732.
   LI XZ, 1994, ANTIMICROB AGENTS CH, V38, P1742, DOI 10.1128/AAC.38.8.1742.
   Li XZ, 1997, J BACTERIOL, V179, P6127, DOI 10.1128/jb.179.19.6127-6132.1997.
   LINTON KB, 1972, J HYG-CAMB, V70, P99, DOI 10.1017/S0022172400022130.
   Lisle JT, 1998, APPL ENVIRON MICROB, V64, P4658.
   LITTLEJOHN TG, 1991, GENE, V101, P59, DOI 10.1016/0378-1119(91)90224-Y.
   LITTLEJOHN TG, 1992, FEMS MICROBIOL LETT, V95, P259.
   LITTLEJOHN TG, 1991, MOL BIOL STAPHYLOCOC, P175.
   LYON BR, 1987, MICROBIOL REV, V51, P88.
   MA D, 1993, J BACTERIOL, V175, P6299.
   MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x.
   Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8.
   Magee JT, 1999, BMJ-BRIT MED J, V319, P1239, DOI 10.1136/bmj.319.7219.1239.
   MAILLARD JY, 1995, LETT APPL MICROBIOL, V21, P215, DOI 10.1111/j.1472-765X.1995.tb01044.x.
   Maira-Litran T, 2000, J ANTIMICROB CHEMOTH, V45, P789, DOI 10.1093/jac/45.6.789.
   Maira-Litran T, 2000, J APPL MICROBIOL, V88, P243, DOI 10.1046/j.1365-2672.2000.00963.x.
   MANNEEWANNAKUL K, 1996, ANTIMICROB AGENTS CH, V40, P1695.
   MARRIE TJ, 1981, APPL ENVIRON MICROB, V42, P1093.
   MASTERTON RG, 1995, J HOSP INFECT, V29, P318, DOI 10.1016/0195-6701(95)90284-8.
   McDonnell G, 1998, ASM NEWS, V64, P670.
   McDonnell G, 1999, CLIN MICROBIOL REV, V12, P147.
   MCMURRAY BE, 1992, PHARMACOTHERAPY, V12, pS86.
   McMurry LM, 1999, ANTIMICROB AGENTS CH, V43, P711.
   McMurry LM, 1998, FEMS MICROBIOL LETT, V166, P305, DOI 10.1111/j.1574-6968.1998.tb13905.x.
   MCMURRY LM, 1998, NATURE, V394, P621.
   MEAD GC, 1986, LETT APPL MICROBIOL, V3, P131, DOI 10.1111/j.1472-765X.1986.tb01566.x.
   Meade MJ, 2001, FEMS MICROBIOL LETT, V204, P45, DOI 10.1016/S0378-1097(01)00377-9.
   Mechin L, 1999, J APPL MICROBIOL, V86, P859, DOI 10.1046/j.1365-2672.1999.00770.x.
   Miller PF, 1996, MOL MICROBIOL, V21, P441, DOI 10.1111/j.1365-2958.1996.tb02553.x.
   Mitchell BA, 1998, ANTIMICROB AGENTS CH, V42, P475.
   Moken MC, 1997, ANTIMICROB AGENTS CH, V41, P2770.
   MURRAY GE, 1984, APPL ENVIRON MICROB, V48, P73.
   Murtough S, 2000, PHARM J, V264, P446.
   MYCOCK G, 1985, LANCET, V2, P949.
   NAGAI I, 1990, J HOSP INFECT, V15, P149, DOI 10.1016/0195-6701(90)90124-7.
   Nagai K, 1996, BIOL PHARM BULL, V19, P873.
   NAKAHARA H, 1981, ZBL BAKT-INT J MED M, V251, P177.
   NAKAMURA H, 1968, J BACTERIOL, V96, P987.
   NAMBA Y, 1985, Nagoya Journal of Medical Science, V47, P101.
   NEWMAN KA, 1984, INFECT CONT HOSP EP, V5, P219, DOI 10.1017/S0195941700060148.
   NG EYW, 1994, ANTIMICROB AGENTS CH, V38, P1345, DOI 10.1128/AAC.38.6.1345.
   NICOLETTI G, 1993, J HOSP INFECT, V23, P87, DOI 10.1016/0195-6701(93)90014-Q.
   Nikaido H, 1998, J BACTERIOL, V180, P4686.
   Nikaido H, 1998, CLIN INFECT DIS, V27, pS32, DOI 10.1086/514920.
   Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0.
   Nishihara T, 2000, J APPL MICROBIOL, V88, P641, DOI 10.1046/j.1365-2672.2000.01007.x.
   Noguchi N, 1999, FEMS MICROBIOL LETT, V172, P247, DOI 10.1016/S0378-1097(99)00041-5.
   NOSKIN GA, 1995, INFECT CONT HOSP EP, V16, P577.
   Noskin GA, 2000, AM J INFECT CONTROL, V28, P311, DOI 10.1067/mic.2000.108129.
   Oblak E, 1996, FOLIA MICROBIOL, V41, P116, DOI 10.1007/BF02816365.
   OBLAK E, 1988, ACTA MICROBIOL POL, V37, P261.
   Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/jb.178.1.306-308.1996.
   Paulsen IT, 1998, J BACTERIOL, V180, P3477.
   PAULSEN IT, 1993, ANTIMICROB AGENTS CH, V37, P761, DOI 10.1128/AAC.37.4.761.
   Paulsen IT, 1996, MICROBIOL REV, V60, P575.
   Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630.
   PAULSEN IT, 1993, GENE, V24, P1.
   Payne DN, 1998, J ROY SOC HEALTH, V118, P18, DOI 10.1177/146642409811800105.
   Payne DN, 1999, LETT APPL MICROBIOL, V28, P7, DOI 10.1046/j.1365-2672.1999.00482.x.
   Pearce H, 1999, J HOSP INFECT, V43, P101, DOI 10.1053/jhin.1999.0250.
   Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200.
   PLATT JH, 1988, J HOSP INFECT, V11, P396, DOI 10.1016/0195-6701(88)90095-3.
   POOLE K, 1993, J BACTERIOL, V175, P7363.
   Price CTD, 2002, APPL ENVIRON MICROB, V68, P5417, DOI 10.1128/AEM.68.11.5417-5421.2002.
   PRINCE HN, 1978, J PHARM SCI, V67, P1629, DOI 10.1002/jps.2600671134.
   Rao GG, 1998, DRUGS, V55, P323, DOI 10.2165/00003495-199855030-00001.
   RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242.
   REVERDY ME, 1993, PATHOL BIOL, V41, P897.
   REVERDY ME, 1992, MED MICROBIOL LETT, V1, P56.
   ROSSOUW FT, 1984, J APPL BACTERIOL, V56, P63, DOI 10.1111/j.1365-2672.1984.tb04697.x.
   ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x.
   Rubino JR, 2000, PEDIATR INFECT DIS J, V19, pS123, DOI 10.1097/00006454-200010001-00009.
   Rupp ME, 2001, INFECT CONT HOSP EP, V22, P301, DOI 10.1086/501905.
   Russell A. D., 1998, PROG MED CHEM, V35, P134.
   Russell A.D, 1996, UNDERSTANDING ANTIBA.
   Russell AD, 1996, J APPL BACTERIOL, V81, pS87, DOI 10.1111/j.1365-2672.1996.tb04602.x.
   Russell AD, 1999, J HOSP INFECT, V43, pS57, DOI 10.1016/S0195-6701(99)90066-X.
   Russell AD, 2000, J PHARM PHARMACOL, V52, P227, DOI 10.1211/0022357001773742.
   Russell AD, 2000, AM J INFECT CONTROL, V28, P204.
   RUSSELL AD, 1986, J HOSP INFECT, V7, P213, DOI 10.1016/0195-6701(86)90071-X.
   RUSSELL AD, 1986, J HOSP INFECT, V8, P47, DOI 10.1016/0195-6701(86)90104-0.
   Russell AD, 2002, J APPL MICROBIOL, V92, p121S, DOI 10.1046/j.1365-2672.92.5s1.12.x.
   Russell AD, 1999, J MED MICROBIOL, V48, P613, DOI 10.1099/00222615-48-7-613.
   Russell AD, 2000, J HOSP INFECT, V44, P1, DOI 10.1053/jhin.1999.0654.
   Russell AD, 1998, ANTIMICROB AGENTS CH, V42, P2151.
   RUSSELL AD, 1985, J HOSP INFECT, V6, P9, DOI 10.1016/S0195-6701(85)80013-X.
   RUSSELL AD, 1990, CLIN MICROBIOL REV, V3, P99.
   RUSSELL AD, 1997, J APPL MICROBIOL, V82, P155.
   RUSSELL AD, 1995, 50 YEARS ANTIMICROBI, P329.
   Russell AD, 1999, PRINCIPLES PRACTICE.
   Rutala WA, 2000, INFECT CONT HOSP EP, V21, P33, DOI 10.1086/501694.
   Rutala WA, 1997, INFECT CONT HOSP EP, V18, P417.
   Sagripanti JL, 1997, AM J INFECT CONTROL, V25, P335, DOI 10.1016/S0196-6553(97)90026-2.
   Saier MH, 1998, FASEB J, V12, P265.
   SANDERSON PJ, 1987, J HOSP INFECT, V10, P173, DOI 10.1016/0195-6701(87)90144-7.
   Sasatsu M, 1995, MICROBIOS, V84, P161.
   SASATSU M, 1993, LANCET, V341, P756, DOI 10.1016/0140-6736(93)90526-M.
   SASATSU M, 1992, FEMS MICROBIOL LETT, V93, P109.
   Schmitz FJ, 1998, J HOSP INFECT, V38, P237, DOI 10.1016/S0195-6701(98)90282-1.
   Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944.
   Schweizer HP, 1998, ANTIMICROB AGENTS CH, V42, P394.
   Scully FE, 1999, WATER ENVIRON RES, V71, P277, DOI 10.2175/106143098X121905.
   SEAL DV, 1983, BRIT J CLIN PRACT S, V23, P46.
   Shlaes DM, 1997, CLIN INFECT DIS, V25, P584, DOI 10.1086/513766.
   SICHU MS, 2001, MICROB DRUG RESIST, V7, P363.
   SILVER S, 1967, J BACTERIOL, V93, P560.
   SIMS CH, 1998, THESIS KINGS COLL LO.
   SKURRAY R A, 1988, Journal of Antimicrobial Chemotherapy, V21, P19.
   Skurray RA, 1997, CIBA F SYMP, V207, P167.
   Smith TL, 1998, INFECT CONT HOSP EP, V19, P515.
   Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701.
   SONDOSSI M, 1986, J IND MICROBIOL, V1, P97, DOI 10.1007/BF01569317.
   STECCHINI ML, 1992, INT J FOOD MICROBIOL, V16, P79, DOI 10.1016/0168-1605(92)90128-P.
   Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907.
   STICKLER D, 1991, EUR J CLIN MICROBIOL, V10, P157, DOI 10.1007/BF01964448.
   STICKLER D, 1989, EUR J CLIN MICROBIOL, V8, P974, DOI 10.1007/BF01967568.
   Stickler D J, 1971, Paraplegia, V8, P243.
   STICKLER DJ, 1976, J CLIN PATHOL, V29, P815, DOI 10.1136/jcp.29.9.815.
   STICKLER DJ, 1981, PARAPLEGIA, V19, P50, DOI 10.1038/sc.1981.13.
   Stickler DJ, 2002, J APPL MICROBIOL, V92, p163S, DOI 10.1046/j.1365-2672.92.5s1.6.x.
   STICKLER DJ, 1980, J CLIN PATHOL, V33, P288, DOI 10.1136/jcp.33.3.288.
   Stickler DJ, 1999, PRINCIPLES AND PRACTICE OF DISINFECTION, PRESERVATION AND STERILIZATION, 3RD EDITION, P284.
   Stickler DJ, 1983, BRIT J CLIN PRACT, V25, P23.
   SUKUPOLVI S, 1984, J BACTERIOL, V159, P704.
   SULAVIK MC, 1995, MOL MED, V1, P436.
   Suller MTE, 2000, J ANTIMICROB CHEMOTH, V46, P11, DOI 10.1093/jac/46.1.11.
   Suller MTE, 1999, J HOSP INFECT, V43, P281, DOI 10.1016/S0195-6701(99)90424-3.
   Sundheim G, 1995, INT BIODETER BIODEGR, V36, P441, DOI 10.1016/0964-8305(95)00108-5.
   Sundheim G, 1998, INT BIODETER BIODEGR, V41, P235, DOI 10.1016/S0964-8305(98)00027-4.
   TABER HW, 1987, MICROBIOL REV, V51, P439.
   Tattawasart U, 1999, J HOSP INFECT, V42, P219, DOI 10.1053/jhin.1999.0591.
   Tattawasart U, 2000, J ANTIMICROB CHEMOTH, V45, P145, DOI 10.1093/jac/45.2.145.
   TATTAWASART U, 2000, INT J ANTIMICROB AGE.
   TENNENT JM, 1989, J GEN MICROBIOL, V135, P1.
   TENNENT JM, 1985, ANTIMICROB AGENTS CH, V27, P79, DOI 10.1128/AAC.27.1.79.
   Thanassi DG, 1997, J BACTERIOL, V179, P2512, DOI 10.1128/jb.179.8.2512-2518.1997.
   Tierno PM, 1999, AM J INFECT CONTROL, V27, P71, DOI 10.1016/S0196-6553(99)70079-9.
   TOWNSEND DE, 1983, MED J AUSTRALIA, V2, P310.
   Turner NA, 2000, J ANTIMICROB CHEMOTH, V46, P27, DOI 10.1093/jac/46.1.27.
   VANKLINGEREN B, 1993, J HOSP INFECT, V25, P147, DOI 10.1016/0195-6701(93)90107-B.
   Viljanen P, 1991, FEMS Microbiol Rev, V8, P43.
   Waldvogel FA, 1999, NEW ENGL J MED, V340, P556, DOI 10.1056/NEJM199902183400709.
   Wall PG, 1996, LANCET, V348, P471, DOI 10.1016/S0140-6736(96)24033-4.
   Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779.
   Weber DJ, 2001, INFECT CONT HOSP EP, V22, P306, DOI 10.1053/ajot.2001.26499.
   WIDMER AF, 1991, ANTIMICROB AGENTS CH, V35, P714.
   WILKINSON DE, 1987, J APPL BACTERIOL, V63, P25.
   WILLIAMS RJ, 1984, J MED MICROBIOL, V17, P283, DOI 10.1099/00222615-17-3-283.
   Willinghan EM, 1996, AVIAN DIS, V40, P510, DOI 10.2307/1592258.
   Winder CL, 2000, J APPL MICROBIOL, V89, P289, DOI 10.1046/j.1365-2672.2000.01119.x.
   Wise R, 1998, BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609.
   YAMAMOTO T, 1988, ANTIMICROB AGENTS CH, V32, P932, DOI 10.1128/AAC.32.6.932.
   YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990.}},
Number-of-Cited-References = {{303}},
Times-Cited = {{154}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{37}},
Journal-ISO = {{Clin. Microbiol. Rev.}},
Doc-Delivery-Number = {{668QX}},
Unique-ID = {{ISI:000182305600002}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000182512300001,
Author = {Powers, WJ},
Title = {{Keeping science in environmental regulations: The role of the animal
   scientist}},
Journal = {{JOURNAL OF DAIRY SCIENCE}},
Year = {{2003}},
Volume = {{86}},
Number = {{4}},
Pages = {{1045-1051}},
Month = {{APR}},
Abstract = {{Environmental issues continue to be one of the biggest challenges faced
   by livestock producers. Whereas issues of the past have focused on
   manure nutrient impacts on water quality with some regulatory activity
   addressing odors, emerging issues are more diverse. To address emerging
   air quality issues, such as ammonia emissions, antibiotic transfer,
   human health impacts of emissions from animal agriculture, and estrogens
   in the environment, scientists with expertise in physiology, genetics,
   animal management, and nutrition will need to be enlisted. The
   objectives of this review are to highlight some of the prominent
   environmental regulatory activity that has occurred nationally in the
   past few years, to outline some of the emerging environmental issues,
   and to move members of the animal science profession toward thinking
   about what they can contribute toward addressing these issues. Animal
   scientists are uniquely qualified to engage in environmental research,
   education, and policymaking because of our comprehensive understanding
   of the complexity of whole-farm management and the interactions between
   animal management and manure management. Animal science departments have
   the opportunity to train students to be leaders in addressing
   environmental issues related to animal production, provided departments
   incorporate environmental education into curricula. Animal scientists
   can contribute greatly to the many areas of research that address
   emerging and current environmental issues, helping to ensure that policy
   is science-based and mitigation strategies are feasible.}},
Publisher = {{AMER DAIRY SCIENCE ASSOC}},
Address = {{1111 N DUNLAP AVE, SAVOY, IL 61874 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Powers, WJ (Reprint Author), Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.
   Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.}},
DOI = {{10.3168/jds.S0022-0302(03)73688-1}},
ISSN = {{0022-0302}},
Keywords = {{environment; regulation; air quality; animal science curricula}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; EMISSIONS; NITROGEN; AMMONIA}},
Research-Areas = {{Agriculture; Food Science \& Technology}},
Web-of-Science-Categories  = {{Agriculture, Dairy \& Animal Science; Food Science \& Technology}},
Cited-References = {{Arvanitidou M, 1998, INT J FOOD MICROBIOL, V40, P197, DOI 10.1016/S0168-1605(98)00020-8.
   DAOUST JY, 1992, J FOOD PROTECT, V55, P428, DOI 10.4315/0362-028X-55.6.428.
   EPA, 1998, NAT AIR POLL EM TREN.
   Finlay-Moore O, 2000, J ENVIRON QUAL, V29, P1604, DOI 10.2134/jeq2000.00472425002900050030x.
   Harper LA, 2000, J ENVIRON QUAL, V29, P1356, DOI 10.2134/jeq2000.00472425002900040045x.
   JOHNSON KA, 1995, J ANIM SCI, V73, P2483.
   Lenis NP, 1999, ASIAN AUSTRAL J ANIM, V12, P305, DOI 10.5713/ajas.1999.305.
   Manie T, 1999, J FOOD PROTECT, V62, P615, DOI 10.4315/0362-028X-62.6.615.
   Miller TL, 2001, J DAIRY SCI, V84, P1445, DOI 10.3168/jds.S0022-0302(01)70177-4.
   NEY RA, 1996, IOWA GREENHOUSE GAS.
   Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493.
   Zahn JA, 2001, J ANIM SCI S1, V79, P783.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{J. Dairy Sci.}},
Doc-Delivery-Number = {{672GF}},
Unique-ID = {{ISI:000182512300001}},
DA = {{2018-08-13}},
}

@article{ ISI:000183034800007,
Author = {Kalliokoski, P},
Title = {{Risks caused by airborne microbes in hospitals - Source control is
   important}},
Journal = {{INDOOR AND BUILT ENVIRONMENT}},
Year = {{2003}},
Volume = {{12}},
Number = {{1-2}},
Pages = {{41-46}},
Month = {{FEB-APR}},
Note = {{International Conference on Indoor Environment Quality in Hospitals,
   PRAGUE, CZECH REPUBLIC, OCT 10-11, 2002}},
Abstract = {{Effective source control is the key issue in all matters concerning
   hygiene and hospitals are by no means an exception. Besides taking steps
   to provide good isolation, this means that local ventilation exhausts
   and isolating enclosures should be used if there are obvious or even
   probable sources. Quick repair of moisture damage from whatever source
   is important. The control of microbes. dispersed by the personnel in a
   hospital is also controlled most effectively by wearing special
   protective clothing and restricting it to the environment where it is
   needed. Even though it is generally admitted by the medical
   professionals that prevention is highly cost-effective, this is,
   nevertheless, commonly forgotten in hospitals.}},
Publisher = {{SAGE PUBLICATIONS LTD}},
Address = {{1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Kalliokoski, P (Reprint Author), Univ Kuopio, Dept Environm Sci, POB 1627, SF-70211 Kuopio, Finland.
   Univ Kuopio, Dept Environm Sci, SF-70211 Kuopio, Finland.}},
DOI = {{10.1177/142032603032676}},
ISSN = {{1420-326X}},
Keywords = {{airborne infection; nosocomial infection; tuberculosis; multi-drug
   resistance; ventilation; water damage}},
Keywords-Plus = {{TUBERCULOSIS; INFECTION}},
Research-Areas = {{Construction \& Building Technology; Engineering; Public, Environmental
   \& Occupational Health}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Engineering, Environmental; Public,
   Environmental \& Occupational Health}},
Author-Email = {{Pentti.Kalliokoski@uku.fi}},
ResearcherID-Numbers = {{Bencko, Vladimir/H-8598-2017}},
ORCID-Numbers = {{Bencko, Vladimir/0000-0003-1935-2228}},
Cited-References = {{ALCINI D, 1995, HLTH BUILDINGS 93, V2, P1061.
   Bex V., 2000, HLTH BUILDINGS 2000, V1, P359.
   CASEWELL MW, 1998, J HOSP INFECT, V40, P3.
   EDELSTEIN PH, 1988, J HOSP INFECT, V11, P182, DOI 10.1016/0195-6701(88)90185-5.
   EMMERSON AM, 1995, J HOSP INFECT, V30, P421, DOI 10.1016/0195-6701(95)90047-0.
   Ensor E, 1996, J HOSP INFECT, V32, P9, DOI 10.1016/S0195-6701(96)90160-7.
   INTAG CE, 1975, ASHRAE J, V17, P27.
   JOSEPH C, 1996, P 11 M EUR WORKSH GR, P111.
   KATILA ML, 1989, EUR J CLIN INFECT DI, V8, P889.
   Kohler JR, 1999, J HOSP INFECT, V41, P301, DOI 10.1053/jhin.1998.0517.
   Kolmos HJ, 1997, J HOSP INFECT, V35, P207, DOI 10.1016/S0195-6701(97)90208-5.
   Kruuner A, 2001, INT J TUBERC LUNG D, V5, P170.
   Kumari DNP, 1998, J HOSP INFECT, V39, P127, DOI 10.1016/S0195-6701(98)90326-7.
   LUSCUERE PG, 1995, HLTH BUILDINGS 95, V1, P135.
   MAKELA P, 1979, J HYG-CAMBRIDGE, V83, P199.
   Manuel RJ, 1998, J HOSP INFECT, V39, P95, DOI 10.1016/S0195-6701(98)90323-1.
   Mathys W, 1999, J HOSP INFECT, V43, P242, DOI 10.1053/jhin.1999.0628.
   NJEMI H, 2000, HLTH BUILDINGS 2000, V3, P191.
   RILEY RL, 1988, ARCHIT DESIGN, P174.
   RUTALA WA, 1995, INFECT CONT HOSP EP, V16, P391.
   SCHAAL KP, 1991, J HOSP INFECT, V18, P451, DOI 10.1016/0195-6701(91)90056-E.
   Simmons RB, 1997, AM IND HYG ASSOC J, V58, P900.
   STREIFEL AJ, 1996, HOSP EPIDEMIOLOGY IN, P955.
   STREIFEL AJ, 1995, INFECT CONTROL STERI, V5, P18.
   STREIFEL AJ, 1994, AIR CULTURES FUNGI C.
   Tammelin A, 2000, J HOSP INFECT, V44, P119, DOI 10.1053/jhin.1999.0665.
   TARVAINEN K, 1994, HLTH BUILDINGS 94, V2, P217.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Indoor Built Environ.}},
Doc-Delivery-Number = {{681KF}},
Unique-ID = {{ISI:000183034800007}},
DA = {{2018-08-13}},
}

@article{ ISI:000181091200003,
Author = {Wang, SH and Sheng, WH and Chang, YY and Wang, LH and Lin, HC and Chen,
   ML and Pan, HJ and Ko, WJ and Chang, SC and Lin, FY},
Title = {{Healthcare-associated outbreak due to pan-drug resistant Acinetobacter
   baumannii in a surgical intensive care unit}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{2003}},
Volume = {{53}},
Number = {{2}},
Pages = {{97-102}},
Month = {{FEB}},
Abstract = {{Acinetobacter baumannii is ubiquitous and has recently become one of the
   most important healthcare-associated (HA) pathogens in hospitals.
   Infection caused by this organism often leads to significant morbidity
   and mortality. Outbreaks of pan-drug resistant Acinetobacter baumannii
   (PDRAB) have rarely been reported. During a two-month period, an
   outbreak of PDRAB colonization and infection affecting 7 patients
   occurred in our surgical intensive care unit (SICU). The colonized sites
   were respiratory tract (N = 7) and central venous catheter (N = 2). One
   of the patients had a surgical wound infection. Extensive environmental
   contamination was identified, including sites such as bed rails, bedside
   tables, surface of ventilators and infusion pump, water for nasogastric
   feeding and ventilator rinsing and sinks. All of the isolates were
   analysed by pulsed-field gel electrophoresis (PFGE) and showed an
   identical pattern. After use of strict cohort nursing, hand hygiene
   environmental cleaning, and replacement of a dysfunctional
   high-efficiency particulate air filter (HEPA), the outbreak was
   controlled. (C) 2003 The Hospital Infection Society.}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Chang, SC (Reprint Author), Natl Taiwan Univ Hosp, Dept Internal Med, Infect Dis Sect, 7 Chung Shan S Rd, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Internal Med, Infect Dis Sect, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Nursing, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.
   Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan.}},
DOI = {{10.1053/jhin.2002.1348}},
ISSN = {{0195-6701}},
Keywords = {{pan-drug resistant Acinetobacter baumannii (PDRAB); intensive care unit;
   outbreak}},
Keywords-Plus = {{RISK-FACTORS; NOSOCOMIAL OUTBREAK; HOSPITAL OUTBREAK; INFECTIONS;
   CALCOACETICUS; EPIDEMIOLOGY; ANITRATUS; STRAIN; COLONIZATION;
   ACQUISITION}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
ORCID-Numbers = {{CHANG, SHAN-CHWEN/0000-0001-6505-4139
   SHENG, WANG-HUEI/0000-0002-5605-7853}},
Cited-References = {{ALLEN KD, 1987, J HOSP INFECT, V9, P110, DOI 10.1016/0195-6701(87)90048-X.
   BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148.
   Berlau J, 1999, EUR J CLIN MICROBIOL, V18, P179.
   CEFAI C, 1990, J HOSP INFECT, V15, P177, DOI 10.1016/0195-6701(90)90128-B.
   Chang SC, 2000, DIAGN MICR INFEC DIS, V37, P279, DOI 10.1016/S0732-8893(00)00157-7.
   Corbella X, 1996, CLIN INFECT DIS, V23, P329, DOI 10.1093/clinids/23.2.329.
   Corbella X, 2000, J CLIN MICROBIOL, V38, P4086.
   Dy ME, 1999, INFECT CONT HOSP EP, V20, P565, DOI 10.1086/501673.
   Fierobe L, 2001, INFECT CONT HOSP EP, V22, P35, DOI 10.1086/501822.
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3.
   Garner Julia S., 1996, Infection Control and Hospital Epidemiology, V17, P53.
   GRAEVENITZ A, 1995, MANUAL CLIN MICROBIO, P520.
   Hsueh PR, 2002, EMERG INFECT DIS, V8, P827.
   Husni RN, 1999, CHEST, V115, P1378, DOI 10.1378/chest.115.5.1378.
   Jawad A, 1998, J CLIN MICROBIOL, V36, P1938.
   Koeleman JGM, 1997, J HOSP INFECT, V37, P113, DOI 10.1016/S0195-6701(97)90181-X.
   Ling ML, 2001, INFECT CONT HOSP EP, V22, P48, DOI 10.1086/501827.
   LORTHOLARY O, 1995, CLIN INFECT DIS, V20, P790, DOI 10.1093/clinids/20.4.790.
   MULIN B, 1995, EUR J CLIN MICROBIOL, V14, P569, DOI 10.1007/BF01690727.
   {*}NAT COMM CLIN LAB, 2000, M7A4 NCCLS.
   PATTERSON JE, 1991, AM J MED, V91, P479, DOI 10.1016/0002-9343(91)90183-X.
   SHERERTZ RJ, 1985, J INFECT DIS, V151, P252, DOI 10.1093/infdis/151.2.252.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   TILLEY PAG, 1994, CLIN INFECT DIS, V18, P896, DOI 10.1093/clinids/18.6.896.
   Traub WH, 1999, CHEMOTHERAPY, V45, P349, DOI 10.1159/000007226.
   URBAN C, 1993, J INFECT DIS, V167, P448, DOI 10.1093/infdis/167.2.448.
   Villers D, 1998, ANN INTERN MED, V129, P182, DOI 10.7326/0003-4819-129-3-199808010-00003.
   Webster CA, 1998, EUR J CLIN MICROBIOL, V17, P171, DOI 10.1007/BF01691113.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{81}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{647KD}},
Unique-ID = {{ISI:000181091200003}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000189200200016,
Author = {Beggs, CB and Sleigh, PA and Fletcher, LA and Noakes, CJ and Kerr, KG},
Book-Group-Author = {{IMECHE}},
Title = {{A simple model for predicting the performance of upper-room UV air
   disinfection systems}},
Booktitle = {{HEALTHCARE ENGINEERING - LATEST DEVELOPMENTS AND APPLICATIONS}},
Series = {{IMECHE CONFERENCE TRANSACTIONS}},
Year = {{2003}},
Volume = {{2003}},
Number = {{5}},
Pages = {{169-178}},
Note = {{International Conference on Healthcare Engineering, IMECHE HEADQUARTERS,
   LONDON, ENGLAND, NOV 25-26, 2003}},
Organization = {{IEE; Assoc Bldg Engineers Assoc; NHS Estate; IHEEM; ASHRAE; IPEM;
   IMechE, Construct \& Bldg Serv Div}},
Abstract = {{With the global rise in tuberculosis cases, coupled with the emergence
   of strains of Mycobacterium tuberculosis which are multiply-antibiotic
   resistant, interest has been renewed in the use of upper-room UV systems
   to control the spread of airborne infection. Whilst a number of
   researchers have demonstrated that tipper-room UV fields might be
   effective, few guidelines exist for the design of such systems. In
   addition, it is technically difficult to optimise the performance of
   upper-room UV installations, because the biological and physical
   processes involved can be complex. This paper presents a simple model
   for predicting the performance of upper-room systems, a model that can
   also be used as a tool to assist in their design.}},
Publisher = {{PROFESSIONAL ENGINEERING PUBLISHING LTD}},
Address = {{1 BIRDCAGE WALK, WESTMINISTER SW1H 9JJ, ENGLAND}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Beggs, CB (Reprint Author), Univ Leeds, Aerobiol Res Grp, Leeds LS2 9JT, W Yorkshire, England.
   Univ Leeds, Aerobiol Res Grp, Leeds LS2 9JT, W Yorkshire, England.}},
ISSN = {{1356-1448}},
ISBN = {{1-86058-429-2}},
Keywords-Plus = {{TUBERCULOSIS; TRANSMISSION; OUTBREAK; BACILLI}},
Research-Areas = {{Construction \& Building Technology; Health Care Sciences \& Services;
   Engineering}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Health Care Sciences \& Services;
   Engineering, Industrial}},
ResearcherID-Numbers = {{Sleigh, Andrew/E-6675-2010}},
Cited-References = {{ALLEN KD, 1987, J HOSP INFECT, V9, P110, DOI 10.1016/0195-6701(87)90048-X.
   Beggs CB, 2002, PHOTOCH PHOTOBIO SCI, V1, P431, DOI 10.1039/b202801h.
   BEGGS CB, 2002, J AEROSOL SCI, V23, P1681.
   Bernards AT, 1998, AM J INFECT CONTROL, V26, P544, DOI 10.1053/ic.1998.v26.a84555.
   Brachman P. S., 1970, P INT C NOS INF AM H, P189.
   Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3.
   FARRINGTON M, 1990, EPIDEMIOL INFECT, V105, P215, DOI 10.1017/S0950268800047828.
   GREENE VW, 1960, MODERN HOSP      AUG.
   GRIEBLE HG, 1974, J INFECT DIS, V130, P602, DOI 10.1093/infdis/130.6.602.
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286.
   JENSEN MM, 1964, APPL MICROBIOLOGY, V52, P418.
   LIDWELL OM, 1994, J HOSP INFECT, V28, P245, DOI 10.1016/0195-6701(94)90088-4.
   Luckiesh M., 1946, APPL GERMICIDAL ERYT.
   Mertens R, 1996, BAILLIERE CLIN INF D, V3, P159.
   Miller MA, 1996, TUBERCLE LUNG DIS, V77, P414, DOI 10.1016/S0962-8479(96)90113-6.
   MILLER SL, 1999, P 8 INT C IND AIR QU, V2, P665.
   Nicas M, 1999, Appl Occup Environ Hyg, V14, P317.
   RENTSCHLER HC, 1941, J BACTERIOL, V42, P745.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RUTULA WA, 1983, J CLIN MICROBIOL, V18, P683.
   Sharp DG, 1938, J BACTERIOL, V35, P589.
   SHARP DG, 1940, J BACTERIOL, V38, P535.
   Stead WW, 1996, INFECT CONT HOSP EP, V17, P11.
   TANCOCK N, 1998, DEVELOPMENTS, P30.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BY41T}},
Unique-ID = {{ISI:000189200200016}},
DA = {{2018-08-13}},
}

@article{ ISI:000179668900020,
Author = {Hamilton-Miller, JMT and Shah, S},
Title = {{Activity of ketolide ABT-773 (cethromycin) against
   erythromycin-resistant Streptococcus pneumoniae: correlation with
   extended MLSK phenotypes}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{2002}},
Volume = {{50}},
Number = {{6}},
Pages = {{907-913}},
Month = {{DEC}},
Abstract = {{Objectives: (i) To determine the inhibitory and bactericidal activities
   of ABT-773, a novel ketolide, against sensitive and
   erythromycin-resistant pneumococci; (ii) to subdivide
   erythromycin-resistant pneumococci into resistance phenotypes, more
   extensive than the conventional M and MLS(B) groups, by assessing
   susceptibilities to, and interactions between, erythromycin (14-membered
   macrolide), clindamycin (lincosamide), rokitamycin (16-membered
   macrolide), ABT-773 (ketolide), quinupristin (streptogramin B) and
   dalfopristin (streptogramin A).
   Methods: MICs and MBCs of ABT-773 were determined for 165 strains of
   pneumococci (113 resistant to erythromycin). Extended phenotypes for the
   erythromycin-resistant strains were described in terms of intrinsic
   susceptibility to, and induction of resistance by, the antibiotics
   listed above.
   Results: Erythromycin-resistant strains could be divided into 10
   extended phenotypes (designated II-XI), two of which (II and IX)
   predominated. ABT-773 at 0.12 mg/L inhibited 109 strains (median 0.03
   mg/L). MICs for the other four strains (of phenotypes X and XI) were
   0.25-1 mg/L. MICs were only slighter higher when measured on agar in
   CO(2) than by the NCCLS method (in broth in air). MBCs were usually less
   than or equal to2 x MIC, but for 10 strains (eight of phenotype X, one
   each of types IX and XI) MBCs were >1 mg/L, and three of the latter (all
   type X) were tolerant. Clones of reduced susceptibility (MICs 1-8 mg/L,
   increased by up to 32-fold) could be isolated from some strains of
   phenotypes VII, IX and X, but not from those of type II (efflux
   mechanism) or from erythromycin-sensitive strains.
   Conclusions: ABT-773 was active against all 113 erythromycin-resistant
   pneumococci tested, which belonged to 10 phenotypes. Extended
   phenotyping of pneumococci revealed interesting and potentially useful
   subdivisions of the classical phenotypes.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hamilton-Miller, JMT (Reprint Author), UCL Royal Free \& Univ Coll Med Sch, Dept Med Microbiol, London NW3 2PF, England.
   UCL Royal Free \& Univ Coll Med Sch, Dept Med Microbiol, London NW3 2PF, England.}},
DOI = {{10.1093/jac/dkf237}},
ISSN = {{0305-7453}},
Keywords-Plus = {{IN-VITRO ACTIVITIES; ANTIMICROBIAL RESISTANCE; MACROLIDE RESISTANCE;
   SUSCEPTIBILITY; STAPHYLOCOCCI; TELITHROMYCIN; SURVEILLANCE; AGENTS}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Author-Email = {{j.hamilton-miller@rfc.ucl.ac.uk}},
Cited-References = {{Angot P, 2000, EUR J CLIN MICROBIOL, V19, P755, DOI 10.1007/s100960000358.
   Barry AL, 2001, ANTIMICROB AGENTS CH, V45, P2922, DOI 10.1128/AAC.45.10.2922-2924.2001.
   BARRY AL, 1999, 39 INT C ANT AG CHEM, P348.
   Bonnefoy A, 1997, J ANTIMICROB CHEMOTH, V40, P85, DOI 10.1093/jac/40.1.85.
   Bryskier A, 2000, CLIN MICROBIOL INFEC, V6, P661, DOI 10.1046/j.1469-0691.2000.00185.x.
   Davies TA, 2000, ANTIMICROB AGENTS CH, V44, P1894, DOI 10.1128/AAC.44.7.1894-1899.2000.
   FELMINGHAM D, 2001, 41 INT C ANT AG CHEM, P128.
   Hamilton-Miller JMT, 2000, J ANTIMICROB CHEMOTH, V46, P941, DOI 10.1093/jac/46.6.941.
   Hamilton-Miller JMT, 1999, EUR J CLIN MICROBIOL, V18, P225, DOI 10.1007/s100960050265.
   Hoban DJ, 2001, ANTIMICROB AGENTS CH, V45, P2147, DOI 10.1128/AAC.45.7.2147-2150.2001.
   Hsueh PR, 2001, ANTIMICROB AGENTS CH, V45, P3205, DOI 10.1128/AAC.45.11.3205-3208.2001.
   Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857.
   Leclercq R, 2002, CLIN INFECT DIS, V34, P482, DOI 10.1086/324626.
   Naaber P, 2000, CLIN MICROBIOL INFEC, V6, P675, DOI 10.1046/j.1469-0691.2000.00184.x.
   National Committee for Clinical Laboratory Standards, 2000, M2A7 NCCLS.
   National Committee for Clinical Laboratory Standards NCCLS, 2000, M7A5 NCCLS.
   Nilius AM, 2001, ANTIMICROB AGENTS CH, V45, P2163, DOI 10.1128/AAC.45.7.2163-2168.2001.
   Oteo J, 2001, J ANTIMICROB CHEMOTH, V47, P215, DOI 10.1093/jac/47.2.215.
   Pantosti A, 2000, CLIN INFECT DIS, V31, P1373, DOI 10.1086/317502.
   Reinert RR, 2001, J CLIN MICROBIOL, V39, P1187, DOI 10.1128/JCM.39.3.1187-1189.2001.
   REINERT RR, 2001, 41 INT C ANT AG CHEM, P130.
   Shortridge VD, 2002, ANTIMICROB AGENTS CH, V46, P783, DOI 10.1128/AAC.46.3.783-786.2002.
   Singh KV, 2001, ANTIMICROB AGENTS CH, V45, P3640, DOI 10.1128/AAC.45.12.3640-3643.2001.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{622VY}},
Unique-ID = {{ISI:000179668900020}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000179428400011,
Author = {Grancelli, A and Morros, A and Cabanas, ME and Domenech, O and Merino, S
   and Vazquez, JL and Montero, MT and Vinas, M and Hernandez-Borrell, J},
Title = {{Interaction of 6-fluoroquinolones with dipalmitoylphosphatidylcholine
   monolayers and liposomes}},
Journal = {{LANGMUIR}},
Year = {{2002}},
Volume = {{18}},
Number = {{24}},
Pages = {{9177-9182}},
Month = {{NOV 26}},
Abstract = {{The interaction of 6-fluoroquinolones at the lipid-water interface is
   the primary step for the activity of membrane transporters involved in
   the generation of drug resistance, In this work the interaction of the
   antibiotic ciprofloxacin (CPX) and its N-4-butylpiperazinyl derivative
   (BCPX) with dipalmitoylphosphatidylcholine (DPPC) as a model membrane is
   described. BCPX forms a stable film at the air-water interface and
   induces a condensing effect of the DPPC monolayer. A basic thermodynamic
   analysis was performed which suggests a possible segregation of the drug
   at the lowest proportion studied. The temperature dependence of
   3-(4-(6-phenyl)-1,3,5-hexatrienyl)phenylpropionic acid fluorescence
   anisotropy measurements shows that the incorporation of CPX or BCPX into
   bilayers does not greatly modify the DPPC lamellar gel state. In the
   liquid-crystalline phase, BCPX lowered the anisotropy values and both
   drugs lowered the main transition temperature (T-m) of pure DPPC by
   approximately 1 degreesC. On the other hand, significant changes in the
   cooperativity of the phospholipid transition were found only in the
   presence of BCPX. In P-31-NMR experiments the presence of BCPX induced,
   both below and above the main transition, a strong line shape narrowing
   of the DPPC spectra that suggests an increase in the local mobility of
   the phosphate groups; that is, the interactions between DPPC headgroups
   are altered by the presence of BCPX. Although the incorporation of CPX
   also promotes a remarkable line shape narrowing in the fluid phase, it
   only slightly modifies the spectral parameters of DPPC in the gel phase.
   This suggests that CPX could be ``squeezed out{''} or segregated from
   the lipid-water interface when the phospholipids are in this tight
   packed phase. The segregation is likely to occur to defects on the gel
   phase. Values of 1-anilino-8-\textbackslash{}naphthalenes sulfonate
   binding to the liposome surface were fitted to a Freundlich-like
   isotherm. The binding constant (K) and maximum concentration bound to
   liposomes (C-m) both are dependent on the structure of the drugs, which
   indicates a definite effect due to the drug hydrophobicity. K values in
   the presence and absence of drug were used to calculate the variation in
   the surface potential (AT) of the liposomes, All the results are
   consistent with an electrostatic interaction of 6-fluoroquinolones at
   the lipid-water interface. This interaction is favored by the presence
   of the N-4-butyl chain and could have important implications in the
   efflux of this drug from bacteria.}},
Publisher = {{AMER CHEMICAL SOC}},
Address = {{1155 16TH ST, NW, WASHINGTON, DC 20036 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Hernandez-Borrell, J (Reprint Author), Univ Barcelona, Lab Fisicoquim 5, Fac Farm, E-08028 Barcelona, Spain.
   Univ Barcelona, Lab Fisicoquim 5, Fac Farm, E-08028 Barcelona, Spain.
   UAB, Unitat Biofis, Dept Bioquim \& Biol Mol, Fac Med, Bellaterra 08193, Spain.
   Univ Barcelona, Microbiol Lab, Lhospitalet De Llobregat 08907, Spain.}},
DOI = {{10.1021/la025837h}},
ISSN = {{0743-7463}},
Keywords-Plus = {{PHOSPHATIDYLCHOLINE BILAYERS; MEMBRANE SYSTEMS; LIPID MIXTURES;
   P-31-NMR; H-2-NMR; ORDER; NMR; PHOSPHATIDYLETHANOLAMINE; CIPROFLOXACIN;
   FLUORESCENCE}},
Research-Areas = {{Chemistry; Materials Science}},
Web-of-Science-Categories  = {{Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary}},
ResearcherID-Numbers = {{Cabanas Egana, Miquel/A-1430-2011
   Borrell, Jordi/M-1390-2014
   Domenech, Oscar/I-2373-2014
   }},
ORCID-Numbers = {{Cabanas Egana, Miquel/0000-0003-0104-0197
   Borrell, Jordi/0000-0002-8022-7891
   Domenech, Oscar/0000-0002-7281-8915
   Vinas, Miguel/0000-0003-2073-3386
   Montero Barrientos, M Teresa/0000-0002-1149-040X}},
Cited-References = {{BEYER K, 1986, BIOCHIM BIOPHYS ACTA, V855, P365, DOI 10.1016/0005-2736(86)90082-9.
   BROWNING JL, 1980, BIOCHEMISTRY-US, V19, P1262, DOI 10.1021/bi00547a034.
   CHARVALOS E, 1995, ANTIMICROB AGENTS CH, V39, P2019, DOI 10.1128/AAC.39.9.2019.
   CHEN SC, 1980, P NATL ACAD SCI-BIOL, V77, P5060, DOI 10.1073/pnas.77.9.5060.
   CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V507, P207, DOI 10.1016/0005-2736(78)90417-0.
   DAVIS JH, 1983, BIOCHIM BIOPHYS ACTA, V737, P117, DOI 10.1016/0304-4157(83)90015-1.
   DEBOECK H, 1988, BIOCHIM BIOPHYS ACTA, V507, P244.
   GAILLARD S, 1991, EUR BIOPHYS J, V19, P265.
   Girault L, 1996, EUR BIOPHYS J BIOPHY, V24, P413, DOI 10.1007/BF00576713.
   Gomez-Fernandez JC, 1999, EUR J BIOCHEM, V259, P739, DOI 10.1046/j.1432-1327.1999.00109.x.
   Herreros B, 2000, SOLID STATE NUCL MAG, V16, P141, DOI 10.1016/S0926-2040(00)00063-1.
   HIRAI K, 1986, ANTIMICROB AGENTS CH, V30, P248, DOI 10.1128/AAC.30.2.248.
   Hooper D. C., 1995, QUINOLONE ANTIMICROB.
   KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1105, P253, DOI 10.1016/0005-2736(92)90202-W.
   LEONARD A, 1991, BIOCHIMIE, V73, P1295, DOI 10.1016/0300-9084(91)90092-F.
   LEWIS RN, 1998, BIOCHEMISTRY-US, V27, P880.
   Marsh D, 1990, HDB LIPID BILAYERS, P135.
   Merino S, 2002, LANGMUIR, V18, P3288, DOI 10.1021/la015627p.
   MILL I, 1988, QUANTITIES UNITS SYM, P46.
   Minones J, 2002, COLLOID SURFACE A, V203, P273, DOI 10.1016/S0927-7757(01)01107-4.
   Montenez JP, 1996, EUR J PHARMACOL, V314, P215, DOI 10.1016/S0014-2999(96)00553-5.
   Montero MT, 1997, INT J PHARM, V149, P161, DOI 10.1016/S0378-5173(97)04866-7.
   Montero MT, 1998, LANGMUIR, V14, P2451, DOI 10.1021/la9706882.
   Nag K., 1996, Journal of Liposome Research, V6, P713, DOI 10.3109/08982109609039923.
   NOTTER RH, 1980, J LIPID RES, V21, P10.
   PAGANO RE, 1972, J PHYS CHEM-US, V76, P1238, DOI 10.1021/j100653a002.
   Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000.
   RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7.
   Serra R, 2000, ELECTROANAL, V12, P60, DOI 10.1002/(SICI)1521-4109(20000101)12:1<60::AID-ELAN60>3.0.CO;2-O.
   Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4.
   VANBLITTERSWIJK WJ, 1981, BIOCHIM BIOPHYS ACTA, V644, P323, DOI 10.1016/0005-2736(81)90390-4.
   Vazquez JL, 2001, PHOTOCHEM PHOTOBIOL, V73, P14.
   Vazquez JL, 2001, LANGMUIR, V17, P1009, DOI 10.1021/la0008582.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{40}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{Langmuir}},
Doc-Delivery-Number = {{618QH}},
Unique-ID = {{ISI:000179428400011}},
DA = {{2018-08-13}},
}

@article{ ISI:000178605200004,
Author = {Munoz, FM and Ong, LT and Seavy, D and Medina, D and Correa, A and
   Starke, JR},
Title = {{Tuberculosis among adult visitors of children with suspected
   tuberculosis and employees at a children's hospital}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{2002}},
Volume = {{23}},
Number = {{10}},
Pages = {{568-572}},
Month = {{OCT}},
Abstract = {{OBJECTIVE: Few children with tuberculosis (TB) have communicable
   disease, and most do not require isolation within the hospital. However,
   parents or adult visitors with unrecognized pulmonary TB may be a threat
   to hospital staff and other patients. We prospectively evaluated adults
   accompanying children hospitalized for suspected TB at a children's
   hospital to determine the frequency of undiagnosed, potentially
   contagious disease.
   METHODS: From 1992 to 1998, chest radiographs were obtained from adult
   caretakers accompanying 59 consecutive children admitted to Texas
   Children's Hospital with suspected TB. A child and his or her family
   were placed under Airborne Precautions only if the child or the
   accompanying adult exhibited characteristics of potentially contagious
   disease. Annual rates of tuberculin skin test conversion in hospital
   employees were obtained for the same period.
   RESULTS: Of the 105 screened adults, 16 (15916) had previously
   undetected pulmonary TB. These adults were associated with 14 (24\%) of
   the 59 children. In all instances in which the adult was the patients
   parent, he or she was the source of infection to the child. Only 8
   (13.5\%.) of the 59 children required isolation. Tuberculin skin test
   conversion from a negative to a positive reaction occurred in 127
   employees (8 per 1,000 employee-years at risk). Only 4 of these 127
   employees performed activities involving direct patient contact. None
   was in contact with families with a known potentially contagious adult
   or pediatric patient.
   CONCLUSIONS:The risk of infection of healthcare workers from pediatric
   patients with primary TB appeared to be minimal, and most children with
   TB did not need isolation. Infection control efforts should be focused
   on accompanying adults and adult visitors.}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Munoz, FM (Reprint Author), Baylor Coll Med, Dept Mol Virol \& Microbiol, MC-BCM-280, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Mol Virol \& Microbiol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Sect Infect Dis, Houston, TX 77030 USA.
   Texas Childrens Hosp, Houston, TX 77030 USA.}},
DOI = {{10.1086/501972}},
ISSN = {{0899-823X}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL
   TRANSMISSION; CDC SURVEY; INFECTION; CARE; MANAGEMENT; OUTBREAK;
   POLICIES}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{AZNAR J, 1995, PEDIATR INFECT DIS J, V14, P44, DOI 10.1097/00006454-199501000-00009.
   Burroughs M, 1999, PEDIATR INFECT DIS J, V18, P440, DOI 10.1097/00006454-199905000-00008.
   Cardona M, 1999, J PAEDIATR CHILD H, V35, P375, DOI 10.1046/j.1440-1754.1999.00385.x.
   {*}CDCP, 1998, TUB US 1997.
   {*}CDCP, 1999, TUB US 1998.
   Christie CDC, 1998, INFECT CONT HOSP EP, V19, P168.
   Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002.
   GEORGE RH, 1986, J HOSP INFECT, V8, P129, DOI 10.1016/0195-6701(86)90039-3.
   Kellerman S, 1998, AM J INFECT CONTROL, V26, P478, DOI 10.1016/S0196-6553(98)70019-7.
   Kellerman SE, 1998, AM J INFECT CONTROL, V26, P483, DOI 10.1016/S0196-6553(98)70020-3.
   Kellerman SE, 2001, PEDIATR INFECT DIS J, V20, P566, DOI 10.1097/00006454-200106000-00004.
   Lane NE, 1997, INFECT CONT HOSP EP, V18, P400.
   Lee LH, 1998, CLIN INFECT DIS, V27, P474, DOI 10.1086/514690.
   Lindquist SW, 1997, PEDIATR INFECT DIS J, V16, P333, DOI 10.1097/00006454-199703000-00020.
   MACHIN GA, 1992, PEDIATR PATHOL, V12, P707, DOI 10.3109/15513819209024224.
   Matlow AG, 2000, INFECT CONT HOSP EP, V21, P222, DOI 10.1086/501749.
   Moore M, 1998, J PEDIATR-US, V133, P108, DOI 10.1016/S0022-3476(98)70188-X.
   Nivin B, 1998, CLIN INFECT DIS, V26, P303, DOI 10.1086/516296.
   Pope AS, 1942, J PEDIATR-US, V20, P297, DOI 10.1016/S0022-3476(42)80184-5.
   Rabalais G, 1991, Lancet, V338, P826, DOI 10.1016/0140-6736(91)90719-6.
   SCHUTZE GE, 1993, PEDIATR INFECT DIS J, V12, P29, DOI 10.1097/00006454-199301000-00008.
   STARKE JR, 1995, PEDIATR INFECT DIS J, V14, P455, DOI 10.1097/00006454-199506000-00001.
   STARKE JR, 2001, SEMIN PEDIAT INFECT, V12, P115.
   STARKE JR, 1998, TXB PEDIAT INFECT DI, P1196.
   VARTERESIANKARANFIL L, 1988, NEW ENGL J MED, V319, P1018.
   WEINSTEIN JW, 1995, PEDIATR INFECT DIS J, V14, P232, DOI 10.1097/00006454-199503000-00011.
   WRIGHT HP, 1938, ACTA PAEDIATR SCAND, V22, P18.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{604FE}},
Unique-ID = {{ISI:000178605200004}},
DA = {{2018-08-13}},
}

@article{ ISI:000178038900003,
Author = {Tegnell, A and Saeedi, B and Isaksson, B and Granfeldt, H and Ohman, L},
Title = {{A clone of coagulase-negative staphylococci among patients with
   post-cardiac surgery infections}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{2002}},
Volume = {{52}},
Number = {{1}},
Pages = {{37-42}},
Month = {{SEP}},
Abstract = {{Coagulase-negative staphylococci (CoNS) are important causes of
   hospital-acquired infections such as infections after cardiac surgery.
   Efforts to reduce these infections are hampered by the lack of knowledge
   concerning the epidemiology of CoNS in this setting. Forty strains of
   CoNS collected during the surgical revision of 27 patients operated on
   between 1997 and 2000 were analysed. Strains were also collected from
   the ambient air in the operating suite. Their pulsed-field gel
   electrophoresis (PFGE) characteristics and antibiotic resistance were
   analysed. Using PFGE 19 of 40 strains from 15 of 27 patients were shown
   to belong to one clone, and strains from this clone were also isolated
   from the ambient air. This clone had caused infections throughout the
   period. Antibiotic resistance did not correlate with PFGE patterns.
   Using PFGE one clone could be identified that caused 56\% of the CoNS
   infections during this period. A strain from this clone was also found
   in the air of the operating suite suggesting the origin of the CoNS
   causing infections was the hospital environment. (C) 2002 The Hospital
   Infection Society}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tegnell, A (Reprint Author), Linkoping Univ, Fac Hlth Sci, Dept Hlth \& Environm, Div Infect Dis, S-58185 Linkoping, Sweden.
   Linkoping Univ, Fac Hlth Sci, Dept Hlth \& Environm, Div Infect Dis, S-58185 Linkoping, Sweden.
   Linkoping Univ, Fac Hlth Sci, Dept Hlth \& Environm, Div Clin Microbiol, S-58185 Linkoping, Sweden.
   Linkoping Univ, Fac Hlth Sci, Dept Med \& Care, Div Cardiothorac Surg, S-58185 Linkoping, Sweden.}},
DOI = {{10.1053/jhin.2002.1267}},
ISSN = {{0195-6701}},
Keywords = {{CoNS; pulsed-field gel electrophoresis; cardiac surgery; infection}},
Keywords-Plus = {{FIELD GEL-ELECTROPHORESIS; INTENSIVE-CARE-UNIT; EPIDERMIDIS;
   MEDIASTINITIS; PERIOD; AUREUS}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BROOK I, 1989, J CLIN MICROBIOL, V27, P806.
   EHRENKRANZ NJ, 1991, REV INFECT DIS, V13, P803.
   HORAN TC, 1992, AM J INFECT CONTROL, V20, P271, DOI 10.1016/S0196-6553(05)80201-9.
   Hubner J, 1995, ZBL BAKT-INT J MED M, V283, P169.
   Lang S, 1999, J HOSP INFECT, V43, P187, DOI 10.1053/jhin.1999.0245.
   LYYTIKAINEN O, 1995, CLIN INFECT DIS, V20, P24, DOI 10.1093/clinids/20.1.24.
   Robicsek F, 2000, AM SURGEON, V66, P184.
   RUPP ME, 1994, CLIN INFECT DIS, V19, P231, DOI 10.1093/clinids/19.2.231.
   Sloos JH, 1998, J CLIN PATHOL, V51, P62, DOI 10.1136/jcp.51.1.62.
   SONG MD, 1987, FEBS LETT, V221, P167, DOI 10.1016/0014-5793(87)80373-3.
   Tammelin A, 2000, J HOSP INFECT, V44, P119, DOI 10.1053/jhin.1999.0665.
   Tammelin A, 2001, J HOSP INFECT, V47, P266, DOI 10.1053/jhin.2000.0914.
   TENOVER FC, 1994, J CLIN MICROBIOL, V32, P407.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   Van Eldere J, 2000, CLIN INFECT DIS, V31, P24, DOI 10.1086/313915.
   vanBelkum A, 1995, J HOSP INFECT, V31, P285, DOI 10.1016/0195-6701(95)90207-4.
   Villari P, 2000, J CLIN MICROBIOL, V38, P1740.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{594FR}},
Unique-ID = {{ISI:000178038900003}},
DA = {{2018-08-13}},
}

@article{ ISI:000178150200006,
Author = {Kinuya, S and Yokoyama, K and Li, XF and Bai, JM and Watanabe, N and
   Shuke, N and Takayama, T and Bunko, H and Michigishi, T and Tonami, N},
Title = {{Hypoxia-induced alteration of tracer accumulation in cultured cancer
   cells and xenografts in mice: Implications for pre-therapeutic
   prediction of treatment outcomes with Tc-99m-sestamibi, Tl-201 chloride
   and Tc-99m-HL91}},
Journal = {{EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING}},
Year = {{2002}},
Volume = {{29}},
Number = {{8}},
Pages = {{1006-1011}},
Month = {{AUG}},
Abstract = {{Weak visualization of tumours in pre-therapeutic scintigrams with
   technetium-99m sestamibi (MIBI) is likely a predictive sign of
   unfavourable tumour response to radiotherapy and chemotherapy. However,
   factors relating to this scintigraphic finding are not well understood.
   The presence of hypoxic tumour cells is one of the major reasons for
   therapeutic failure; consequently, we attempted to determine whether
   oxygenation status affects Tc-99m-MIBI accumulation in tumour cells.
   LS180 human colon cancer and T24 human bladder cancer cells were
   incubated in air or N-2 gas at 37degreesC. Cellular uptake of
   Tc-99m-MIBI was subsequently determined at 15, 60 and 120 min. Uptake of
   thallium-201 chloride was also assessed. Uptake of Tc-99m-HL91 was
   assessed as a hypoxic marker. Accumulation of the tracers in LS180
   xenografts was observed in mice treated with 5 mg/kg hydralazine and
   compared with that in untreated mice. pO(2) in the medium and tumours
   was measured with O-2 microelectrodes. N-2 gas flow gradually reduced
   pO(2) in the cell suspension to 1-2 mmHg in 60 min. Cellular uptake of
   Tc-99m-MIBI in LS180 cells decreased by approximately 30\% in N-2 gas in
   comparison to that in air throughout the study. Hypoxia had a more
   prominent influence on Tl-201 uptake, which displayed a reduction of
   approximately 60\% in N-2 gas at 120 min, than on Tc-99m-MIBI uptake. On
   the other hand, N-2 gas induced an increase of 170\% in Tc-99m-HL91
   uptake at 120 min, indicating the hypoxic condition of cells. The
   results of in vitro assays employing the T24 cell line were similar to
   those obtained with the LS180 cell line. Hydralazine treatment markedly
   reduced Tc-99m-MIBI and Tl-201 accumulation in LS180 xenografts;
   moreover, intratumoural pO(2) decreased from 14.5 +/- 6.6 mmHg to 7.6
   +/- 6.2 mmHg Tc-99m-HL91 accurnulation in xenografts was markedly
   increased by hydralazine. In conclusion, hypoxia reduced accumulation of
   Tc-99m-MIBI and Tl-201 in tumour cells. Accordingly, hypoxia may be an
   important factor in terms of the interpretation of scintigraphic
   findings obtained with those tracers for pre-therapeutic prediction of
   tumour response to treatment. Furthermore, the enhanced Tc-99m-HL91
   accumulation in hypoxic tumour cells indicates the usefulness of this
   tracer in this regard.}},
Publisher = {{SPRINGER-VERLAG}},
Address = {{175 FIFTH AVE, NEW YORK, NY 10010 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kinuya, S (Reprint Author), Kanazawa Univ, Grad Sch Med Sci, Dept Biotracer Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.
   Kanazawa Univ, Grad Sch Med Sci, Dept Biotracer Med, Kanazawa, Ishikawa 9208640, Japan.
   Toyama Med \& Pharmaceut Univ, Dept Radiol, Toyama, Japan.
   Asahikawa Med Coll, Dept Radiol, Asahikawa, Hokkaido 078, Japan.
   Kanazawa Univ, Sch Hlth Sci, Dept Radiol Technol, Kanazawa, Ishikawa 920, Japan.
   Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan.}},
DOI = {{10.1007/s00259-002-0846-x}},
ISSN = {{1619-7070}},
Keywords = {{tumour uptake; hypoxia; pre-therapeutic prediction; Tc-99m-sestamibi;
   Tc-99m-HL91}},
Keywords-Plus = {{LUNG-CANCER; P-GLYCOPROTEIN; TUMOR HYPOXIA; CHEMOTHERAPEUTIC RESPONSE;
   MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BLOOD-FLOW; TECHNETIUM-99M-MIBI;
   CARCINOMA; SPECT}},
Research-Areas = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Web-of-Science-Categories  = {{Radiology, Nuclear Medicine \& Medical Imaging}},
Cited-References = {{Arbab AS, 1998, J NUCL MED, V39, P266.
   Arbab AS, 1997, NUCL MED COMMUN, V18, P235, DOI 10.1097/00006231-199703000-00007.
   Arbab AS, 1996, J NUCL MED, V37, P1551.
   Ballinger JR, 2001, CANCER BIOTHER RADIO, V16, P1, DOI 10.1089/108497801750095907.
   Bom HS, 1998, J NUCL MED, V39, P91.
   Ceriani L, 1997, NUCL MED COMMUN, V18, P1087, DOI 10.1097/00006231-199711000-00013.
   CHAPLIN DJ, 1989, J NATL CANCER I, V81, P618, DOI 10.1093/jnci/81.8.618.
   Cook GJR, 1998, J NUCL MED, V39, P99.
   Cowan D S, 1996, Br J Cancer Suppl, V27, pS264.
   Del Vecchio S, 2000, CANCER BIOTHER RADIO, V15, P327, DOI 10.1089/cbr.2000.15.327.
   Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266.
   Honess DJ, 1998, INT J RADIAT ONCOL, V42, P731, DOI 10.1016/S0360-3016(98)00300-9.
   Iyer RV, 2001, J NUCL MED, V42, P337.
   KALRA R, 1993, INT J CANCER, V54, P650, DOI 10.1002/ijc.2910540421.
   Kao CH, 1998, CANCER, V83, P64, DOI 10.1002/(SICI)1097-0142(19980701)83:1<64::AID-CNCR9>3.0.CO;2-E.
   Kao CH, 2000, CLIN CANCER RES, V6, P820.
   Kinuya S, 2001, EUR J NUCL MED, V28, P750, DOI 10.1007/s002590100531.
   Kostakoglu L, 1997, J NUCL MED, V38, P1009.
   Lewis JS, 2001, J NUCL MED, V42, P655.
   Maini CL, 1997, J NUCL MED, V38, P1546.
   Moretti JL, 1996, EUR J NUCL MED, V23, P980, DOI 10.1007/BF01084375.
   Nagamachi S, 1996, NUCL MED COMMUN, V17, P935, DOI 10.1097/00006231-199611000-00003.
   NAITO S, 1995, JPN J CANCER RES, V86, P1112, DOI 10.1111/j.1349-7006.1995.tb03028.x.
   Nishiyama Y, 2000, EUR J NUCL MED, V27, P536, DOI 10.1007/s002590050540.
   Nishiyama Y, 2000, CLIN NUCL MED, V25, P364, DOI 10.1097/00003072-200005000-00010.
   Nishiyama Y, 1997, J NUCL MED, V38, P1358.
   NISHIZAWA K, 1991, INT J RADIAT ONCOL, V20, P593, DOI 10.1016/0360-3016(91)90075-F.
   Ohira H, 2000, J NUCL MED, V41, P1561.
   Omar WS, 1997, ANTICANCER RES, V17, P1639.
   SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405.
   Schuetz EG, 1996, MOL PHARMACOL, V49, P311.
   Shih WJ, 1998, CLIN NUCL MED, V23, P505, DOI 10.1097/00003072-199808000-00002.
   Tatsumi M, 1999, EUR J NUCL MED, V26, P91, DOI 10.1007/s002590050364.
   Yamamoto Y, 1998, J NUCL MED, V39, P1626.
   Yutani K, 1999, J NUCL MED, V40, P854.}},
Number-of-Cited-References = {{35}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Eur. J. Nucl. Med. Mol. Imaging}},
Doc-Delivery-Number = {{596EB}},
Unique-ID = {{ISI:000178150200006}},
DA = {{2018-08-13}},
}

@article{ ISI:000178352200035,
Author = {Padma, PN and Rao, AB and Yadav, JS and Reddy, G},
Title = {{Optimization of fermentation conditions for production of glycopeptide
   antibiotic vancomycin by Amycolatopsis orientalis}},
Journal = {{APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY}},
Year = {{2002}},
Volume = {{102}},
Pages = {{395-405}},
Month = {{JUL-DEC}},
Abstract = {{Glycopeptides produced by Streptomyces species are the drugs used
   against beta-lactam drug-resistant staphylococcal infections, and
   vancomycin is important among them. Increased prevalence of resistant
   strains increased the usage of vancomycin worldwide and also promoted
   attempts for indigenous production. The optimum process conditions pH,
   temperature, inoculum size, agitation, and aeration for vancomycin
   production by Amycolatopsis orientalis were evaluated, statistically
   analyzed, and the response surface curves were constructed. The optimum
   process conditions were a pH of 7.6, a temperature of 29degreesC, an
   inoculum size of 4.5\%, an agitation of 255 rpm, and an aeration of less
   than 1:10 medium-to-air ratio.}},
Publisher = {{HUMANA PRESS INC}},
Address = {{999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Reddy, G (Reprint Author), Osmania Univ, Dept Microbiol, Hyderabad 500007, Andhra Pradesh, India.
   Osmania Univ, Dept Microbiol, Hyderabad 500007, Andhra Pradesh, India.
   Indian Inst Chem Technol, Hyderabad 500007, Andhra Pradesh, India.}},
DOI = {{10.1385/ABAB:102-103:1-6:395}},
ISSN = {{0273-2289}},
Keywords = {{fermentation; antibiotic; glycopeptide; vancomycin; optimization}},
Keywords-Plus = {{INVITRO}},
Research-Areas = {{Biochemistry \& Molecular Biology; Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Biotechnology \& Applied Microbiology}},
ResearcherID-Numbers = {{Yadav, J/D-9452-2011}},
Cited-References = {{GOLDSTEIN FW, 1994, EUR J CLIN MICROBIOL, V13, P33, DOI 10.1007/BF02026121.
   GRUER LD, 1984, J ANTIMICROB CHEMOTH, V13, P577, DOI 10.1093/jac/13.6.577.
   JADEJA L, 1983, ANTIMICROB AGENTS CH, V24, P145, DOI 10.1128/AAC.24.2.145.
   NAGARAJAN R, 1991, ANTIMICROB AGENTS CH, V35, P605, DOI 10.1128/AAC.35.4.605.
   Nagl M, 1999, ANTIMICROB AGENTS CH, V43, P1932.
   SARADA I, 1995, THESIS OSMANIA U HYD.
   Sen R, 1997, APPL MICROBIOL BIOT, V47, P358, DOI 10.1007/s002530050940.
   SORRELL TC, 1982, ANN INTERN MED, V97, P334.
   SZTARICSKAI F, 1983, J ANTIBIOT, V36, P1691, DOI 10.7164/antibiotics.36.1691.
   TUNAC JB, 1989, J FERMENT BIOENG, V68, P157, DOI 10.1016/0922-338X(89)90068-8.
   WATANAKUNAKORN C, 1984, J ANTIMICROB CHEMOTH, V14, P7, DOI 10.1093/jac/14.suppl\_D.7.
   Watier D, 1996, APPL ENVIRON MICROB, V62, P1233.
   WEBER DJ, 1988, ANTIMICROB AGENTS CH, V32, P642, DOI 10.1128/AAC.32.5.642.
   WILLIAMS DH, 1988, BIOCHEM PHARMACOL, V37, P133, DOI 10.1016/0006-2952(88)90765-4.
   1999, BRIT PHARMACOPOEIA, pA352.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Appl. Biochem. Biotechnol.}},
Doc-Delivery-Number = {{599TX}},
Unique-ID = {{ISI:000178352200035}},
DA = {{2018-08-13}},
}

@article{ ISI:000180359800016,
Author = {Leistevuo, J and Leistevuo, T and Helenius, H and Pyy, L and Huovinen, P
   and Tenovuo, J},
Title = {{Mercury in saliva and the risk of exceeding limits for sewage in
   relation to exposure to amalgam fillings}},
Journal = {{ARCHIVES OF ENVIRONMENTAL HEALTH}},
Year = {{2002}},
Volume = {{57}},
Number = {{4}},
Pages = {{366-370}},
Month = {{JUL-AUG}},
Abstract = {{The concentration of total mercury in stimulated saliva was studied in
   humans with dental amalgam fillings and in 2 nonamalgam groups. The
   probability of exceeding the limits of mercury permitted in wastewater
   increased proportionally as the number of amalgam-filled surfaces
   increased. The mercury limit for sewage is 0.05 mg/l (= 250 nmol/l)
   effluent, according to the Council of European Communities directive
   84/156/EEC. In neither of the nonamalgam groups was this limit exceeded,
   but 20.5\% in the amalgam group exceeded the limit (p < .001). The risk
   of exceeding the limit increased 2-fold for every 10 additional
   amalgam-filled surfaces (odds ratio = 2.0; 95\% confidence interval =
   1.3, 3.3). These results demonstrate that humans, especially in
   populated areas, can be a significant source of mercury pollutants. As a
   consequence of mercury release, bacteria may acquire mercury resistance,
   as well as resistance to other antimicrobial agents, thus resulting in
   failure of antibiotic treatment.}},
Publisher = {{HELDREF PUBLICATIONS}},
Address = {{1319 EIGHTEENTH ST NW, WASHINGTON, DC 20036-1802 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Leistevuo, J (Reprint Author), Natl Publ Hlth Inst, Antimicrobial Res Lab, POB 57, FIN-20521 Turku, Finland.
   Natl Publ Hlth Inst, Antimicrobial Res Lab, FIN-20521 Turku, Finland.
   Turku Univ, Inst Dent, Turku, Finland.
   Turku Univ Hosp, Dept Phys Med \& Rehabil, FIN-20520 Turku, Finland.
   Univ Turku, Dept Biostat, Turku, Finland.
   Oulu Reg Inst Occupat Hlth, Oulu, Finland.}},
DOI = {{10.1080/00039890209601423}},
ISSN = {{0003-9896}},
Keywords = {{amalgam fillings; environmental; mercury; saliva; sewage}},
Keywords-Plus = {{GRAM-NEGATIVE BACILLI; ORAL AIR MERCURY; DENTAL AMALGAM; ANTIMICROBIAL
   RESISTANCE; ANTIBIOTIC-RESISTANCE; BACTERIA; PRIMATES}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health}},
ResearcherID-Numbers = {{Huovinen, Pentti/C-1917-2009}},
Cited-References = {{Agresti A, 1990, CATEGORICAL DATA ANA.
   {[}Anonymous], 1993, GUID DRINK WAT QUAL, V1, P174.
   BERGLUND A, 1990, J DENT RES, V69, P1646, DOI 10.1177/00220345900690100401.
   Bjorkman L, 1997, TOXICOL APPL PHARM, V144, P156, DOI 10.1006/taap.1997.8128.
   BOYD ND, 1991, AM J PHYSIOL, V261, pR1010.
   Edlund C, 1996, CLIN INFECT DIS, V22, P944, DOI 10.1093/clinids/22.6.944.
   HAHN LJ, 1990, FASEB J, V4, P3256.
   JOKSTAD A, 1992, PHARMACOL TOXICOL, V70, P308, DOI 10.1111/j.1600-0773.1992.tb00478.x.
   KRUMPERMAN PH, 1983, APPL ENVIRON MICROB, V46, P165.
   LAJUNEN LHJ, 1985, ATOM SPECTROSC, V6, P49.
   Leistevuo T, 1996, ANTIMICROB AGENTS CH, V40, P1931.
   Levy SB, 1998, BRIT MED J, V317, P612, DOI 10.1136/bmj.317.7159.612.
   MAGOS L, 1969, BRIT J IND MED, V26, P144.
   NAKAHARA H, 1977, APPL ENVIRON MICROB, V33, P975.
   OSTERBLAD M, 1995, ANTIMICROB AGENTS CH, V39, P2499, DOI 10.1128/AAC.39.11.2499.
   OSTERBLAD M, 2000, THESIS ABO AKAD U AB, P4.
   OTT KHR, 1984, DEUT ZAHNAERZTL Z, V39, P199.
   PATTERSON JE, 1985, B ENVIRON CONTAM TOX, V34, P459, DOI 10.1007/BF01609761.
   SKINNER EW, 1969, SCI DENT MAT, P303.
   SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825.
   {*}TURK STAND I, 1994, AUT FUELS LEAD PETR, P1.
   VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111.
   VIMY MJ, 1985, J DENT RES, V64, P1069, DOI 10.1177/00220345850640080901.
   VIMY MJ, 1985, J DENT RES, V64, P1072, DOI 10.1177/00220345850640081001.
   VIMY MJ, 1990, AM J PHYSIOL, V258, pR939.
   {*}WHO, 1991, ENV HLTH CRIT 118 IN, P35.
   {*}WHO, 1996, GUID DRINK WAT QUAL, V2, P942.
   Wireman J, 1997, APPL ENVIRON MICROB, V63, P4494.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Arch. Environ. Health}},
Doc-Delivery-Number = {{634UM}},
Unique-ID = {{ISI:000180359800016}},
DA = {{2018-08-13}},
}

@article{ ISI:000176363900015,
Author = {Kato, S and Post, GC and Bierbaum, VM and Koch, TH},
Title = {{Chemical ionization mass spectrometric determination of acrolein in
   human breast cancer cells}},
Journal = {{ANALYTICAL BIOCHEMISTRY}},
Year = {{2002}},
Volume = {{305}},
Number = {{2}},
Pages = {{251-259}},
Month = {{JUN 15}},
Abstract = {{A selected ion flow tube-chemical ionization mass spectrometric method
   is presented for the first determination of acrolein metabolically
   produced in biological tissues. Acrolein in aqueous samples (2.5 ml) is
   preconcentrated by distillation and directly analyzed using gas-phase
   proton transfer from H3O+. This method provides sensitive detection of
   acrolein with the method detection limit of 15 nM at the 99\% confidence
   level. Detection is linear up to the highest concentration studied (13.5
   muM, R-2 = 0.998). Acrolein levels are determined in
   doxorubicin-sensitive (MCF-7) and doxorubicin-resistant (MCF-7/Adr)
   human breast cancer cells in vitro. The intracellular acrolein
   concentrations differ insignificantly: 0.61 muM for sensitive cells and
   0.54 muM for resistant cells. Treatment with a physiological
   concentration of doxorubicin (0.5 muM) for 24 h at 37degreesC increased
   acrolein levels by factors of 2.6 and 1.9 for MCF-7 and MCF-7/Adr cells,
   respectively. The differential enhancement observed is consistent with
   the lower levels of enzymes that neutralize oxidative stress in
   sensitive MCF-7 cells and overexpression of an active drug efflux pump
   P-170 glycoprotein in resistant MCF-7/Adr cells. (C) 2002 Elsevier
   Science (USA).}},
Publisher = {{ACADEMIC PRESS INC ELSEVIER SCIENCE}},
Address = {{525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kato, S (Reprint Author), Univ Colorado, Dept Chem \& Biochem, 215 UCB, Boulder, CO 80309 USA.
   Univ Colorado, Dept Chem \& Biochem, Boulder, CO 80309 USA.
   Univ Colorado, Ctr Canc, Denver, CO 80262 USA.}},
DOI = {{10.1006/abio.2002.5682}},
ISSN = {{0003-2697}},
Keywords = {{chemical ionization mass spectrometry; acrolein; breast cancer cells;
   doxorubicin; drug resistance}},
Keywords-Plus = {{CARBONYL-COMPOUNDS; CYTOTOXIC ALDEHYDES; LIPID-PEROXIDATION;
   GAS-CHROMATOGRAPHY; TRANSGENIC MICE; ANTITUMOR DRUGS; EXPIRED AIR; DNA
   ADDUCTS; FORMALDEHYDE; ADRIAMYCIN}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Biochemistry \& Molecular Biology;
   Chemistry, Analytical}},
Cited-References = {{ARENS JF, 1960, ADV ORG CHEM, V2, P117.
   BAGCHI D, 1995, TOXICOLOGY, V95, P1, DOI 10.1016/0300-483X(94)02867-T.
   Bao ML, 1998, J CHROMATOGR A, V809, P75, DOI 10.1016/S0021-9673(98)00188-5.
   BEAUCHAMP RO, 1985, CRC CR REV TOXICOL, V14, P309, DOI 10.3109/10408448509037461.
   CHUNG FL, 1984, CANCER RES, V44, P990.
   CROOK TR, 1986, CANCER RES, V46, P5029.
   CULLINANE C, 1994, BIOCHEMISTRY-US, V33, P4632, DOI 10.1021/bi00181a025.
   EBELER SE, 1994, J CHROMATOGR B, V654, P9, DOI 10.1016/0378-4347(93)E0436-T.
   Ebeler SE, 1997, J CHROMATOGR B, V702, P211, DOI 10.1016/S0378-4347(97)00369-1.
   EBELER SE, 1992, ANAL BIOCHEM, V205, P183, DOI 10.1016/0003-2697(92)90597-Z.
   EBELER SE, 1994, LIPID CHROMATOGRAPHI, P223.
   ESTERBAUER H, 1975, Z NATURFORSCH C, V30, P466.
   Fenick DJ, 1997, J MED CHEM, V40, P2452, DOI 10.1021/jm970237e.
   Gaudiano G, 2000, BIOCHEM PHARMACOL, V60, P1915, DOI 10.1016/S0006-2952(00)00521-9.
   GLASER JA, 1981, ENVIRON SCI TECHNOL, V15, P1426, DOI 10.1021/es00094a002.
   GLAZE WH, 1989, ENVIRON SCI TECHNOL, V23, P838, DOI 10.1021/es00065a013.
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125.
   Jacobs TL, 1942, J AM CHEM SOC, V64, P223, DOI 10.1021/ja01254a008.
   Kato S, 2000, CHEM RES TOXICOL, V13, P509, DOI 10.1021/tx000008m.
   Kato S, 2001, ANAL CHEM, V73, P2992, DOI 10.1021/ac001498q.
   LIDE DR, 1994, CRC HDB CHEM PHYSICS.
   Luce RA, 1999, BIOCHEMISTRY-US, V38, P8682, DOI 10.1021/bi990553q.
   LUO XP, 1995, ANAL BIOCHEM, V228, P294, DOI 10.1006/abio.1995.1353.
   Luo XP, 1997, BBA-MOL BASIS DIS, V1360, P45.
   LYASHCHUK SN, 1994, RUSS J ORG CHEM+, V30, P10.
   Miyake T, 1996, FOOD CHEM TOXICOL, V34, P1009, DOI 10.1016/S0278-6915(96)00063-4.
   {*}NIST, 2001, CHEM WEBB.
   Schauenstein E., 1977, ALDEHYDES BIOL SYSTE.
   SHALLEY CA, 1998, EUR J ORG CHEM, P987.
   SHARA MA, 1992, J CHROMATOGR-BIOMED, V576, P221, DOI 10.1016/0378-4347(92)80196-W.
   SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C.
   SNIDER JR, 1985, J GEOPHYS RES-ATMOS, V90, P3797, DOI 10.1029/JD090iD02p03797.
   Spanel P, 1999, RAPID COMMUN MASS SP, V13, P1354, DOI 10.1002/(SICI)1097-0231(19990730)13:14<1354::AID-RCM641>3.0.CO;2-J.
   Taatjes DJ, 1999, CHEM RES TOXICOL, V12, P588, DOI 10.1021/tx990008q.
   Taatjes DJ, 1997, J MED CHEM, V40, P1276, DOI 10.1021/jm960835d.
   TAMURA H, 1991, J AGR FOOD CHEM, V39, P439, DOI 10.1021/jf00003a002.
   WILSON VL, 1991, CARCINOGENESIS, V12, P1483, DOI 10.1093/carcin/12.8.1483.
   WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8.
   YASUHARA A, 1989, J ASSOC OFF ANA CHEM, V72, P749.
   Yazdanpanah M, 1997, FREE RADICAL BIO MED, V23, P870, DOI 10.1016/S0891-5849(97)00070-1.
   Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561.
   ZHOU XL, 1990, ENVIRON SCI TECHNOL, V24, P1864, DOI 10.1021/es00082a013.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{24}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Anal. Biochem.}},
Doc-Delivery-Number = {{565HM}},
Unique-ID = {{ISI:000176363900015}},
DA = {{2018-08-13}},
}

@article{ ISI:000176077500006,
Author = {Sanchez, MX and Fluckey, WM and Brashears, MM and McKee, SR},
Title = {{Microbial profile and antibiotic susceptibility of Campylobacter spp.
   and Salmonella spp. in broilers processed in air-chilled and
   immersion-chilled environments}},
Journal = {{JOURNAL OF FOOD PROTECTION}},
Year = {{2002}},
Volume = {{65}},
Number = {{6}},
Pages = {{948-956}},
Month = {{JUN}},
Abstract = {{Carcass chilling is considered a critical step for inhibiting bacterial
   growth during poultry processing. The objective of this study was to
   compare microbiological loads and the incidence of Salmonella spp. and
   Campylobacter spp. on broiler carcasses subjected to immersion chilling
   and air chilling. Additionally, the antibiotic resistance patterns of
   pathogen isolates were determined. The results of this study indicated
   that the incidence of Salmonella spp. and Campylobacter spp. tends to be
   significantly lower in air-chilled broilers, suggesting that
   cross-contamination may be more prevalent for immersion-chilled
   broilers. No significant differences were detected between chilling
   treatments for total aerobic populations or for generic E. coli or
   coliform counts. Psychrotrophic populations were significantly larger (P
   < 0.05) in immersion-chilled broilers than in their air-chilled
   counterparts. Campylobacter isolates from immersion-chilled broilers had
   a higher incidence of resistance to nalidixic acid (NAL) and related
   fluoroquinolones than isolates from air-chilled broilers did.
   Additionally, Campylobacter isolates from air-chilled broilers had a
   higher frequency of resistance to tetracycline than isolates from
   immersion-chilled broilers did. With regard to Salmonella, isolates from
   immersion-chilled broilers had a higher incidence of resistance to NAL
   than isolates from air-chilled samples did, No Salmonella isolates from
   immersion-or air-chilled broilers were resistant to the fluoroquinolones
   tested. The chilling method used during processing may influence the
   microbial profile of postchilled broilers.}},
Publisher = {{INT ASSOC FOOD PROTECTION}},
Address = {{6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{McKee, SR (Reprint Author), Univ Nebraska, Dept Food Sci \& Technol, Lincoln, NE 68583 USA.
   Univ Nebraska, Dept Food Sci \& Technol, Lincoln, NE 68583 USA.
   Texas Tech Univ, Dept Anim Sci \& Food Technol, Lubbock, TX 79409 USA.}},
DOI = {{10.4315/0362-028X-65.6.948}},
ISSN = {{0362-028X}},
EISSN = {{1944-9097}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; POULTRY; JEJUNI; STRAINS; PREVALENCE;
   CARCASSES; CHICKEN; COLI; MECHANISMS; QUINOLONE}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Author-Email = {{smekeehensarling2@unl.edu}},
Cited-References = {{ACUFF GR, 1986, J FOOD PROTECT, V49, P712, DOI 10.4315/0362-028X-49.9.712.
   Alekshun MN, 1997, ANTIMICROB AGENTS CH, V41, P2067.
   Archer DL, 1996, TRENDS FOOD SCI TECH, V7, P91, DOI 10.1016/0924-2244(96)81303-3.
   Atabay HI, 1998, INT J FOOD MICROBIOL, V41, P53, DOI 10.1016/S0168-1605(98)00034-8.
   Bailey J. S., 1987, MICROBIOLOGY POULTRY, P193.
   BAILEY JS, 1993, POULTRY SCI, V72, P1169, DOI 10.3382/ps.0721169.
   {*}CDC, 1990, MMWR-MORBID MORTAL W, V38, P877.
   {*}CDC, 1999, 1999 NARMS ANN REP N.
   CHANG YH, 1989, POULTRY SCI, V68, P656, DOI 10.3382/ps.0680656.
   COATES D, 1987, EPIDEMIOL INFECT, V99, P265, DOI 10.1017/S095026880006773X.
   DEMING MS, 1987, AM J EPIDEMIOL, V126, P526, DOI 10.1093/oxfordjournals.aje.a114685.
   DICKENS JA, 1992, POULTRY SCI, V71, P560, DOI 10.3382/ps.0710560.
   DICKENS JA, 1995, POULTRY SCI, V74, P1044, DOI 10.3382/ps.0741044.
   Engberg J, 2001, EMERG INFECT DIS, V7, P24, DOI 10.3201/eid0701.010104.
   {*}FOOD DRUG ADMN, 1995, FDA APPR FLUOR ANT P.
   {*}FOOD SAF INSP SER, 1998, NEW WAT RET RUL MEAT.
   Gaudreau C, 1998, ANTIMICROB AGENTS CH, V42, P2106.
   HARRIS NV, 1986, AM J PUBLIC HEALTH, V76, P401, DOI 10.2105/AJPH.76.4.401.
   HICKS CR, 1993, FUNDAMENTAL CONCEPTS, P25.
   HOLLINGER K, 2000, 2 INT C EM INF DIS A.
   HOUSTON DL, 1985, POULTRY SCI, V64, P481, DOI 10.3382/ps.0640481.
   HUNT JM, 1995, FOOD DRUG ADM BACTER.
   IZAT AL, 1988, POULTRY SCI, V67, P1568, DOI 10.3382/ps.0671568.
   JAMES WO, 1992, J AM VET MED ASSOC, V200, P57.
   JONES DM, 1984, CURR MICROBIOL, V10, P105, DOI 10.1007/BF01575768.
   JUVEN BJ, 1986, J FOOD PROTECT, V49, P290, DOI 10.4315/0362-028X-49.4.290.
   Kelley TR, 1998, POULTRY SCI, V77, P243, DOI 10.1093/ps/77.2.243.
   KNOOP GN, 1971, POULTRY SCI, V50, P530, DOI 10.3382/ps.0500530.
   LEE CY, 1994, INT J FOOD MICROBIOL, V24, P161, DOI 10.1016/0168-1605(94)90115-5.
   LILLARD HS, 1989, J FOOD PROTECT, V52, P829, DOI 10.4315/0362-028X-52.11.829.
   LILLARD HS, 1971, J FOOD SCI, V36, P1008.
   Lucey B, 2000, J APPL MICROBIOL, V89, P727, DOI 10.1046/j.1365-2672.2000.01153.x.
   MALLINSON ET, 1995, B MARYLAND COOPERATI, V348.
   MAY KN, 1974, POULTRY SCI, V53, P1282, DOI 10.3382/ps.0531282.
   MEAD PS, 1999, FOOD RELATED ILLNESS, V5.
   OOSTEROM J, 1983, J FOOD PROTECT, V46, P339, DOI 10.4315/0362-028X-46.4.339.
   OPARA OO, 1992, AVIAN DIS, V36, P664, DOI 10.2307/1591762.
   Prats G, 2000, ANTIMICROB AGENTS CH, V44, P1140, DOI 10.1128/AAC.44.5.1140-1145.2000.
   REINA J, 1992, EUR J CLIN MICROBIOL, V11, P1163, DOI 10.1007/BF01961137.
   Rice BE, 1996, CLIN DIAGN LAB IMMUN, V3, P669.
   ROBERTS TA, 1996, MICROORGANISMS FOODS, P45.
   ROSSITER S, 2000, 137 AM VET MED ASS A.
   ROSSITER S, 2000, AM SOC MICR ANN M AT.
   ROSSITER S, 2000, 2 INT C EM INF DIS A.
   Saenz Y, 2000, ANTIMICROB AGENTS CH, V44, P267, DOI 10.1128/AAC.44.2.267-271.2000.
   SAMS AR, 1994, ENCY AGR SCI, V3, P433.
   SKIRROW MB, 1982, TECHNICAL SERIES SOC, V17, P313.
   Smith KE, 1999, NEW ENGL J MED, V340, P1525, DOI 10.1056/NEJM199905203402001.
   Tauxe R V, 1988, MMWR CDC Surveill Summ, V37, P1.
   TAYLOR DE, 1988, ANTIMICROB AGENTS CH, V32, P1107, DOI 10.1128/AAC.32.8.1107.
   THOMSON JE, 1975, POULTRY SCI, V54, P1452, DOI 10.3382/ps.0541452.
   Threlfall EJ, 2000, INT J FOOD MICROBIOL, V62, P1, DOI 10.1016/S0168-1605(00)00351-2.
   Tollefson L, 1998, VET CLIN N AM-FOOD A, V14, P141, DOI 10.1016/S0749-0720(15)30285-1.
   {*}USDA, 1995, NAT BROIL CHICK MICR.
   {*}USDA, 1996, FED REG FIN RUL PATH.
   {*}USDA FOOD SAF INS, 1998, MICR LAB GUID.
   Veerkamp C. H., 1972, Fleischwirtschaft, V52, P612.
   WALTMAN D, 2000, WORKSHOP MANUAL, P70.}},
Number-of-Cited-References = {{58}},
Times-Cited = {{50}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{J. Food Prot.}},
Doc-Delivery-Number = {{560HW}},
Unique-ID = {{ISI:000176077500006}},
DA = {{2018-08-13}},
}

@article{ ISI:000175634500010,
Author = {Lin, J and Tiller, JC and Lee, SB and Lewis, K and Klibanov, AM},
Title = {{Insights into bactericidal action of surface-attached
   poly(vinyl-N-hexylpyridinium) chains}},
Journal = {{BIOTECHNOLOGY LETTERS}},
Year = {{2002}},
Volume = {{24}},
Number = {{10}},
Pages = {{801-805}},
Month = {{MAY}},
Abstract = {{The surface of polyethylene slides nanocoated with silica and
   derivatized with long-chain poly(vinyl-N-hexylpyridinium) becomes
   permanently bactericidal: it kills 90-99\% of (both airborne and
   waterborne) wild-type and antibiotic-resistant strains of the human
   pathogen Staphylococcus aureus. The material created was similarly
   lethal to strains expressing multidrug resistance pumps, the only known
   mechanism of resistance to cationic antiseptics.}},
Publisher = {{KLUWER ACADEMIC PUBL}},
Address = {{VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Klibanov, AM (Reprint Author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   MIT, Dept Chem, Cambridge, MA 02139 USA.
   Northeastern Univ, Dept Biol, Boston, MA 02115 USA.}},
DOI = {{10.1023/A:1015584423358}},
ISSN = {{0141-5492}},
Keywords = {{antibacterial; immobilized; polycation; polymer; surfaces}},
Keywords-Plus = {{STAPHYLOCOCCUS-AUREUS; RESISTANCE; CHROMOSOME; STRAINS; PUMPS; NORA}},
Research-Areas = {{Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology}},
ResearcherID-Numbers = {{Tiller, Joerg/S-2010-2016}},
Cited-References = {{Cunliffe D, 1999, APPL ENVIRON MICROB, V65, P4995.
   De Lencastre H, 2000, MICROB DRUG RESIST, V6, P1, DOI 10.1089/mdr.2000.6.1.
   de Lencastre H, 1997, CLIN MICROBIOL INFEC, V3, P289.
   Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8.
   Hsieh PC, 1998, P NATL ACAD SCI USA, V95, P6602, DOI 10.1073/pnas.95.12.6602.
   INGRAHAM JL, 1983, GROWTH BACTERIAL CEL, pCH5.
   Kaatz GW, 1999, ANTIMICROB AGENTS CH, V43, P2222.
   Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505.
   Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46.
   LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6.
   Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247.
   LEWIS K, 2001, BACTERIAL RESISTANCE.
   NG EYW, 1994, ANTIMICROB AGENTS CH, V38, P1345, DOI 10.1128/AAC.38.6.1345.
   ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x.
   SEVERINA II, 2002, IN PRESS BIOCH INT.
   Tiller JC, 2001, P NATL ACAD SCI USA, V98, P5981, DOI 10.1073/pnas.111143098.
   TILLER JC, 2002, IN PRESS BIOTECHNOL, V79.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{114}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{20}},
Journal-ISO = {{Biotechnol. Lett.}},
Doc-Delivery-Number = {{552RU}},
Unique-ID = {{ISI:000175634500010}},
DA = {{2018-08-13}},
}

@article{ ISI:000174996500006,
Author = {Oku, N and Asai, T and Watanabe, K and Kuromi, K and Nagatsuka, M and
   Kurohane, K and Kikkawa, H and Ogino, K and Tanaka, M and Ishikawa, D
   and Tsukada, H and Momose, M and Nakayama, J and Taki, T},
Title = {{Anti-neovascular therapy using novel peptides homing to angiogenic
   vessels}},
Journal = {{ONCOGENE}},
Year = {{2002}},
Volume = {{21}},
Number = {{17}},
Pages = {{2662-2669}},
Month = {{APR 18}},
Abstract = {{Cancer chemotherapy targeted to angiogenic vessels is expected to cause
   indirect tumor regression through the damage of the neovasculature
   without the induction of drug resistance. To develop a tool for
   neovasculature-specific drug delivery, we isolated novel peptides homing
   to angiogenic vessels formed by a dorsal air sac method from a
   phage-displayed peptide library. Three distinct phage clones that
   markedly accumulated in murine tumor xenografts presented
   PRPGAPLAGSWPGTS-, DRWRPALPVVLFPLH- or ASSSYPLIHWRPWAR-peptide
   respectively. After the determination of the epitope sequences of these
   peptides, we modified liposomes with epitope penta-peptides. Liposome
   modified with APRPG-peptide showed high accumulation in murine tumor
   xenografts, and APRPG-modified liposome encapsulating adriamycin
   effectively suppressed experimental tumor growth. Finally, specific
   binding of APRPG-modified liposome to human umbilical endothelial cells,
   and that of PRP-containing peptide to angiogenic vessels in human
   tumors, i.e., islet cell tumor and glioblastoma, were demonstrated. The
   present study indicates the usefulness of APRPG-peptide as a tool for
   anti-neovascular therapy, a novel modality of cancer treatment.}},
Publisher = {{NATURE PUBLISHING GROUP}},
Address = {{MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Oku, N (Reprint Author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, 52-1 Yada, Shizuoka 4228526, Japan.
   Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem Med, Shizuoka 4228526, Japan.
   Otsuka Pharmaceut Co Ltd, Inst Mol Sci Med, Tokushima 7710192, Japan.
   Hamamatsu Photon KK, Shizuoka 4340041, Japan.
   Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano 3908621, Japan.
   Shinshu Univ Hosp, Cent Clin Labs, Matsumoto, Nagano 3908621, Japan.}},
DOI = {{10.1038/sj/onc/1205347}},
ISSN = {{0950-9232}},
EISSN = {{1476-5594}},
Keywords = {{anti-neovascular therapy; phage-displayed peptide library; liposome; PRP}},
Keywords-Plus = {{ENDOTHELIAL PROGENITOR CELLS; LONG-CIRCULATING LIPOSOMES; ALPHA-V
   INTEGRINS; DRUG-DELIVERY; IN-VIVO; LIBRARY; CANCER; LIGANDS; BINDING;
   ANGIOSTATIN}},
Research-Areas = {{Biochemistry \& Molecular Biology; Oncology; Cell Biology; Genetics \&
   Heredity}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Oncology; Cell Biology; Genetics \&
   Heredity}},
Author-Email = {{oku@u-shizuoka-ken.ac.jp}},
Cited-References = {{Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377.
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964.
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964.
   Asai T, 1998, BIOL PHARM BULL, V21, P766.
   Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126.
   Browder T, 2000, CANCER RES, V60, P1878.
   Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654.
   Brown JM, 1998, CANCER RES, V58, P1408.
   Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389.
   Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869.
   Gho YS, 1997, CANCER RES, V57, P3733.
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48.
   HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012.
   Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547.
   Ishikawa D, 1998, FEBS LETT, V441, P20, DOI 10.1016/S0014-5793(98)01511-7.
   Ito H, 1999, CANCER RES, V59, P5875.
   KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205.
   Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X.
   Langer R, 1998, NATURE, V392, P5.
   MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129.
   Nishi T, 1996, FEBS LETT, V399, P237, DOI 10.1016/S0014-5793(96)01329-4.
   Oku N, 1999, ADV DRUG DELIVER REV, V37, P53, DOI 10.1016/S0169-409X(98)00110-0.
   Oku N, 1999, ADV DRUG DELIVER REV, V40, P63, DOI 10.1016/S0169-409X(99)00040-X.
   OKU N, 1994, INT J CANCER, V58, P415, DOI 10.1002/ijc.2910580318.
   OKU N, 1992, BIOCHIM BIOPHYS ACTA, V1126, P255, DOI 10.1016/0005-2760(92)90238-Q.
   OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689.
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542.
   Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0.
   SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028.
   Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222.
   St Croix B, 2000, SCIENCE, V289, P1197.
   Takikawa M, 2000, FEBS LETT, V466, P381, DOI 10.1016/S0014-5793(00)01110-8.
   Viti F, 1999, CANCER RES, V59, P347.
   Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{85}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Oncogene}},
Doc-Delivery-Number = {{541RA}},
Unique-ID = {{ISI:000174996500006}},
DA = {{2018-08-13}},
}

@article{ ISI:000174776200008,
Author = {Park, SK and Lee, CM and Heu, JP and Song, SD},
Title = {{A retrospective study for the outcome of pulmonary resection in 49
   patients with multidrug-resistant tuberculosis}},
Journal = {{INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE}},
Year = {{2002}},
Volume = {{6}},
Number = {{2}},
Pages = {{143-149}},
Month = {{FEB}},
Abstract = {{BACKGROUND: Outcome of treatment using only chemotherapy for multi
   drug-resistant tuberculosis is usually considered not to be
   satisfactory. The combination of chemotherapy with surgical treatment
   has been producing higher acid-fast bacilli (AFB) negative sputum
   conversion and longer survival rates. This treatment strategy may be the
   solution for patients with multidrug-resistant tuberculosis.
   MATERIALS AND METHODS: A retrospective review was performed of the
   medical records and laboratory findings of 49 patients with
   multidrug-resistant tuberculosis among 130 patients who underwent
   pulmonary resection for pulmonary tuberculosis between January 1995 and
   December 1999 at National Masan Tuberculosis Hospital, Korea.
   RESULTS: The mean number of drugs to which the patients were resistant
   was 4.5. Patients had a mean age of 35 years. Cavitary lesions on plain
   chest X-ray were shown in 43/49 patients (87.8\%); 31 had positive
   sputum cultures preoperatively (63.3\%). The surgical techniques used
   were as follows: 12 pneumonectomies, 28 lobectomies, seven lobectomies
   with segmentectomies or wedge resections, one wedge resection and one
   cavernoplasty. The AFB negative sputum conversion rate was 93.5\% with
   continuous postoperative chemotherapy. There were no deaths after
   surgery. Postoperative complications that developed were six cases of
   air leakage over a week, one of postoperative bleeding and one of wound
   infection.
   CONCLUSIONS: This study demonstrated the effectiveness of pulmonary
   resection with postoperative chemotherapy in cases of
   multidrug-resistant tuberculosis. Although there are different ideas
   about indications for surgery and the length and content of
   postoperative drug regimens, pulmonary resection should be considered an
   effective measure in combination with chemotherapy for treatment of
   multidrug-resistant pulmonary tuberculosis.}},
Publisher = {{INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)}},
Address = {{68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Park, SK (Reprint Author), Natl Masan TB Hosp, Dept Chest Surg, 486 Gapo Dong, Seoul 631710, South Korea.
   Natl Masan TB Hosp, Dept Chest Surg, Seoul 631710, South Korea.}},
ISSN = {{1027-3719}},
Keywords = {{MDR-TB; cavitary lesions; pulmonary resection}},
Keywords-Plus = {{NEW-YORK-CITY; DRUG-RESISTANT; MYCOBACTERIUM-TUBERCULOSIS;
   SURGICAL-MANAGEMENT; TRANSMISSION; EMERGENCE; RIFAMPIN; DISEASE; SURGERY}},
Research-Areas = {{Infectious Diseases; Respiratory System}},
Web-of-Science-Categories  = {{Infectious Diseases; Respiratory System}},
Cited-References = {{Alexander J., 1937, COLLAPSE THERAPY TUB.
   ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745.
   CANETTI G, 1963, B WORLD HEALTH ORGAN, V29, P565.
   CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21.
   FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   ISEMAN MD, 1994, P NATL ACAD SCI USA, V91, P2428, DOI 10.1073/pnas.91.7.2428.
   ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623, DOI 10.1164/ajrccm/141.3.623.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302.
   LANGSTON HT, 1966, ANN SURG, V164, P567.
   Leuvan M V, 1997, ANN THORAC SURG, V63, P1368.
   O'Brien R J, 1994, Semin Respir Infect, V9, P104.
   Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339.
   POMERANTZ M, 1991, ANN THORAC SURG, V52, P1108, DOI 10.1016/0003-4975(91)91289-8.
   Pomerantz M, 1995, Semin Thorac Cardiovasc Surg, V7, P108.
   Pomerantz M, 1997, CLIN CHEST MED, V18, P123, DOI 10.1016/S0272-5231(05)70361-0.
   REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110.
   RIZZI A, 1995, ANN THORAC SURG, V59, P896, DOI 10.1016/0003-4975(95)00011-9.
   SHAFER RW, 1995, J INFECT DIS, V171, P170, DOI 10.1093/infdis/171.1.170.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125.
   STEINER P, 1986, AM REV RESPIR DIS, V134, P446.
   STEINHARDT PJ, 1980, ANN PHYS-NEW YORK, V128, P425, DOI 10.1016/0003-4916(80)90327-9.
   TREASURE RL, 1995, ANN THORAC SURG, V59, P1405, DOI 10.1016/0003-4975(95)00145-B.
   1990, MMWR, V39, P718.
   1990, MMWR, V39, P369.}},
Number-of-Cited-References = {{28}},
Times-Cited = {{56}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Tuberc. Lung Dis.}},
Doc-Delivery-Number = {{537TT}},
Unique-ID = {{ISI:000174776200008}},
DA = {{2018-08-13}},
}

@article{ ISI:000173688300004,
Author = {Smalley, D and Rocha, ER and Smith, CJ},
Title = {{Aerobic-type ribonucleotide reductase in the anaerobe Bacteroides
   fragilis}},
Journal = {{JOURNAL OF BACTERIOLOGY}},
Year = {{2002}},
Volume = {{184}},
Number = {{4}},
Pages = {{895-903}},
Month = {{FEB}},
Abstract = {{Bacteroides fragilis, a component of the normal intestinal flora, is an
   obligate anaerobe capable of long-term survival in the presence of air.
   Survival is attributed to an elaborate oxidative stress response that
   controls the induction of more than 28 peptides, but there is limited
   knowledge concerning the identities of these peptides. In this report,
   RNA fingerprinting by arbitrarily primed PCR identified five new genes
   whose expression increased following exposure to O-2. Nucleotide
   sequence analysis of the cloned genes indicated that they encoded an
   outer membrane protein, an aspartate decarboxylase, an efflux pump, heat
   shock protein HtpG, and an NrdA ortholog constituting the large subunit
   of a class Ia ribonucleotide reductase (RRase). Attention was focused on
   the nrdA gene since class I RRases are obligate aerobic enzymes
   catalyzing the reduction of ribonucleoside 5'-diphosphates by a
   mechanism that requires molecular oxygen for activity. Sequence analysis
   of the nrd locus showed that two genes, nrdA and nrdB, are located in
   the same orientation in a 4.5-kb region. Northern hybridization and
   primer extension experiments confirmed induction of the genes by O-2 and
   suggested they are an operon. The B. fragilis nrdA and nrdB genes were
   overexpressed in Escherichia coli, and CDP reductase assays confirmed
   that they encoded an active enzyme. The enzyme activity was inhibited by
   hydroxyurea, and ATP was shown to be a positive effector of CDP
   reductase activity, while dATP was an inhibitor, indicating that the
   enzyme was a class Ia RRase. A nrdA mutant was viable under anaerobic
   conditions but had decreased survival following exposure to O-2, and it
   could not rapidly resume growth after O-2 treatment. The results
   presented indicate that during aerobic conditions B. fragilis NrdAB may
   have a role in maintaining deoxyribonucleotide pools for DNA repair and
   growth recovery.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1752 N ST NW, WASHINGTON, DC 20036-2904 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Smith, CJ (Reprint Author), E Carolina Univ, Dept Microbiol \& Immunol, Brody Sch Med, 600 Moye Blvd, Greenville, NC 27858 USA.
   E Carolina Univ, Dept Microbiol \& Immunol, Brody Sch Med, Greenville, NC 27858 USA.}},
DOI = {{10.1128/jb.184.4.895-903.2002}},
ISSN = {{0021-9193}},
Keywords-Plus = {{OXIDATIVE STRESS; PORPHYROMONAS-GINGIVALIS; ANTIBIOTIC-RESISTANCE;
   SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; POSITIVE CONTROL; MODEL SYSTEMS;
   HEAT-SHOCK; IN-VIVO; PEROXIDE}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}R01 AI040588, AI40588, R56 AI040588]}},
Cited-References = {{Bayley DP, 2000, FEMS MICROBIOL LETT, V193, P149, DOI 10.1016/S0378-1097(00)00472-9.
   Bonass WA, 2000, INFECT IMMUN, V68, P4012, DOI 10.1128/IAI.68.7.4012-4017.2000.
   Chen CC, 2000, J IND MICROBIOL BIOT, V25, P132, DOI 10.1038/sj.jim.7000043.
   CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8.
   Coyne MJ, 2000, INFECT IMMUN, V68, P6176, DOI 10.1128/IAI.68.11.6176-6181.2000.
   DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387.
   EHRENBERG A, 1972, J BIOL CHEM, V247, P3485.
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X.
   Finegold SM, 1989, ANAEROBIC INFECT HUM.
   GODOY VG, 1993, INFECT IMMUN, V61, P4415.
   GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181.
   GREGORY EM, 1985, ARCH BIOCHEM BIOPHYS, V238, P83, DOI 10.1016/0003-9861(85)90143-2.
   GREGORY EM, 1977, J BACTERIOL, V129, P1298.
   GUINEY DG, 1984, P NATL ACAD SCI-BIOL, V81, P7203, DOI 10.1073/pnas.81.22.7203.
   Hecker M, 1996, MOL MICROBIOL, V19, P417, DOI 10.1046/j.1365-2958.1996.396932.x.
   Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306.
   Jordan A, 1999, J BACTERIOL, V181, P3974.
   Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71.
   Lopatin DE, 2000, INFECT IMMUN, V68, P1980, DOI 10.1128/IAI.68.4.1980-1987.2000.
   Lumppio HL, 2001, J BACTERIOL, V183, P101, DOI 10.1128/JB.183.1.101-108.2001.
   Lumppio HL, 2001, J BACTERIOL, V183, P2970.
   Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200.
   NIES DH, 1992, J BACTERIOL, V174, P8102.
   Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829.
   PRIVITERA G, 1979, J INFECT DIS, V139, P97, DOI 10.1093/infdis/139.1.97.
   Reeves AR, 1997, J BACTERIOL, V179, P643, DOI 10.1128/jb.179.3.643-649.1997.
   Rocha ER, 1999, J BACTERIOL, V181, P5701.
   Rocha ER, 2000, J BACTERIOL, V182, P5059, DOI 10.1128/JB.182.18.5059-5069.2000.
   Rocha ER, 1996, J BACTERIOL, V178, P6895, DOI 10.1128/jb.178.23.6895-6903.1996.
   Rocha ER, 1998, J BACTERIOL, V180, P5906.
   Rocha ER, 1997, J BACTERIOL, V179, P7033, DOI 10.1128/jb.179.22.7033-7039.1997.
   ROCHA ER, 1995, J BACTERIOL, V177, P3111, DOI 10.1128/jb.177.11.3111-3119.1995.
   ROLFE RD, 1977, AM J CLIN NUTR, V30, P1762.
   Sambrook J, 1989, MOL CLONING LAB MANU.
   SMITH BA, 1995, AVIAT WEEK SPACE TEC, V143, P34.
   SMITH CJ, 1992, J CLIN MICROBIOL, V30, P806.
   SOKOLOV BP, 1994, NUCLEIC ACIDS RES, V22, P4009, DOI 10.1093/nar/22.19.4009.
   STEEPER JR, 1970, ANAL BIOCHEM, V34, P123, DOI 10.1016/0003-2697(70)90092-8.
   Storz G, 2000, BACTERIAL STRESS RESPONSES, P47.
   Tang YXP, 1999, MOL MICROBIOL, V32, P139, DOI 10.1046/j.1365-2958.1999.01337.x.
   TZIANABOS AO, 1993, SCIENCE, V262, P416, DOI 10.1126/science.8211161.
   Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001.}},
Number-of-Cited-References = {{42}},
Times-Cited = {{26}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Bacteriol.}},
Doc-Delivery-Number = {{518VJ}},
Unique-ID = {{ISI:000173688300004}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000174854200002,
Author = {Carter, JE and Langridge, WHR},
Title = {{Plant-based vaccines for protection against infectious and autoimmune
   diseases}},
Journal = {{CRITICAL REVIEWS IN PLANT SCIENCES}},
Year = {{2002}},
Volume = {{21}},
Number = {{2}},
Pages = {{93-109}},
Abstract = {{Over the last 2 decades, the number of emergent infectious diseases has
   increased at an alarming rate. Also disheartening is the rise of known
   infectious pathogens that have acquired extensive drug resistance and
   reemerged with greater virulence. More recently, the threat of
   bioweapons has rekindled an urgency for the development of mass
   immunization programs. In response to this increased infectious disease
   threat, efforts have been intensified to identify more effective,
   inexpensive, and more easily deliverable mucosal vaccination methods.
   One area of research currently under development is the genetic
   modification of plants for production of immunoprotective proteins. The
   ability of plants to synthesize complex proteins using the elements of
   sunlight, soil, air, and water makes them ideal organisms for harvesting
   large quantities of therapeutic proteins. The introduction of antigen or
   antibody encoding genes into the genome of a plant through stable
   transformation enables them to manufacture vaccine proteins that are
   directly applicable for use in disease treatment, unlike yeast,
   bacterial, insect or other expression systems that require purification
   steps before delivery. As an alternative to stable transformation,
   plants can be used to generate large quantities of vaccines by acting as
   hosts for genetically altered plant viruses in which antigen proteins
   can be expressed and later purified from infected plant tissues. In this
   review, we survey current experimental strategies for using edible
   plants to achieve passive and active immunization against infectious
   disease organisms. In addition, methods are described for the
   construction of transformed plants that can provide protection against
   autoimmune diseases. Concerns and present obstacles to effective
   immunization with plant-based vaccines for animals and humans are
   presented.}},
Publisher = {{CRC PRESS LLC}},
Address = {{2000 CORPORATE BLVD NW, JOURNALS CUSTOMER SERVICE, BOCA RATON, FL 33431
   USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Carter, JE (Reprint Author), Loma Linda Univ, Dept Biochem, Ctr Mol Biol \& Gene Therapy, Loma Linda, CA 92350 USA.
   Loma Linda Univ, Dept Biochem, Ctr Mol Biol \& Gene Therapy, Loma Linda, CA 92350 USA.}},
DOI = {{10.1080/0735-260291044197}},
ISSN = {{0735-2689}},
Keywords = {{multicomponent; mucosal; immunity; oral; tolerance; transformation;
   plants; virus}},
Keywords-Plus = {{TOXIN-B-SUBUNIT; TOBACCO MOSAIC-VIRUS; TRANSMISSIBLE GASTROENTERITIS
   CORONAVIRUS; STRUCTURAL PROTEIN VP1; MYELIN BASIC-PROTEIN; TRANSGENIC
   PLANTS; ORAL IMMUNIZATION; SURFACE-ANTIGEN; MONOCLONAL-ANTIBODY; MUCOSAL
   SURFACES}},
Research-Areas = {{Plant Sciences}},
Web-of-Science-Categories  = {{Plant Sciences}},
Cited-References = {{Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810.
   Arakawa T, 1999, TRANSGENICS, V3, P51.
   Arakawa T, 1998, NAT BIOTECHNOL, V16, P934, DOI 10.1038/nbt1098-934.
   Belanger H, 2000, FASEB J, V14, P2323, DOI 10.1096/fj.00-0144com.
   Bellmann K, 1998, DIABETOLOGIA, V41, P844, DOI 10.1007/s001250050997.
   Bergerot I, 1997, P NATL ACAD SCI USA, V94, P4610, DOI 10.1073/pnas.94.9.4610.
   BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X.
   Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707.
   BORGESON NS, 2000, TRANSGENIC PLANTS 2.
   Brennan FR, 1999, VACCINE, V17, P1846, DOI 10.1016/S0264-410X(98)00485-X.
   Brennan FR, 1999, MICROBIOL-SGM, V145, P2061, DOI 10.1099/13500872-145-8-2061.
   Carrillo C, 1998, J VIROL, V72, P1688.
   Castanon S, 1999, J VIROL, V73, P4452.
   {*}CDCP, 2000, MMWR-MORBID MORTAL W, V49, P585.
   Centers for Disease Control and Prevention, 2001, INV HUM HLTH EFF ASS.
   CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O.
   Conrad U, 1998, PLANT MOL BIOL, V38, P101, DOI 10.1023/A:1006029617949.
   CZERKINSKY C, 1995, ADV EXP MED BIOL, V371, P1409.
   Czerkinsky C, 1996, ANN NY ACAD SCI, V778, P185, DOI 10.1111/j.1749-6632.1996.tb21127.x.
   Dalsgaard K, 1997, NAT BIOTECHNOL, V15, P248, DOI 10.1038/nbt0397-248.
   Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921.
   De Cosa B, 2001, NAT BIOTECHNOL, V19, P71, DOI 10.1038/83559.
   De Jaeger G, 2000, PLANT MOL BIOL, V43, P419, DOI 10.1023/A:1006471528756.
   Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5.
   Fernandez-Fernandez MR, 2001, VIROLOGY, V280, P283, DOI 10.1006/viro.2000.0762.
   Fernandez-Fernandez MR, 1998, FEBS LETT, V427, P229, DOI 10.1016/S0014-5793(98)00429-3.
   FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688.
   FRY AM, 1989, SCIENCE, V246, P1044, DOI 10.1126/science.2511630.
   Gavilondo JV, 2000, BIOTECHNIQUES, V29, P128.
   Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054.
   GIANESSI LP, 1999, AGR BIOTECHNOLOGY IN.
   Gil F, 2001, FEBS LETT, V488, P13, DOI 10.1016/S0014-5793(00)02405-4.
   Goldsby RA, 2000, KUBY IMMUNOLOGY.
   Gomez N, 2000, ARCH VIROL, V145, P1725, DOI 10.1007/s007050070087.
   Gomez N, 1998, VIROLOGY, V249, P352, DOI 10.1006/viro.1998.9315.
   HAJISHENGALLIS G, 1995, J IMMUNOL, V154, P4322.
   HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379.
   HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0.
   HIGGINS PJ, 1988, J IMMUNOL, V140, P440.
   HOLMGREN J, 1994, AM J TROP MED HYG, V50, P42.
   Huang Z, 2001, VACCINE, V19, P2163, DOI 10.1016/S0264-410X(00)00390-X.
   Janeway C. A., 1999, IMMUNOBIOLOGY IMMUNE.
   JEANFRANCOIS B, 2001, ANNU REV IMMUNOL, V19, P131.
   Joelson T, 1997, J GEN VIROL, V78, P1213, DOI 10.1099/0022-1317-78-6-1213.
   Kapusta J, 1999, FASEB J, V13, P1796.
   Koo M, 1999, P NATL ACAD SCI USA, V96, P7774, DOI 10.1073/pnas.96.14.7774.
   KUMAGAI MH, 1993, P NATL ACAD SCI USA, V90, P427, DOI 10.1073/pnas.90.2.427.
   Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598.
   Lauterslager TGM, 2001, VACCINE, V19, P2749, DOI 10.1016/S0264-410X(00)00513-2.
   Lee RWH, 2001, INFECT IMMUN, V69, P5786, DOI 10.1128/IAI.69.9.5786-5793.2001.
   Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338.
   LUPPI P, 1995, J MOL MED, V73, P381.
   Lycke N, 2001, CURR OPIN MOL THER, V3, P37.
   MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380.
   MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120.
   Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601.
   Ma SW, 1997, NAT MED, V3, P793, DOI 10.1038/nm0797-793.
   Mason HS, 1998, VACCINE, V16, P1336, DOI 10.1016/S0264-410X(98)80020-0.
   MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745.
   Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335.
   McCormick AA, 1999, P NATL ACAD SCI USA, V96, P703, DOI 10.1073/pnas.96.2.703.
   MCGARVEY PB, 1995, BIO-TECHNOL, V13, P1484, DOI 10.1038/nbt1295-1484.
   McLain L, 1996, VACCINE, V14, P799, DOI 10.1016/0264-410X(95)00229-T.
   MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606.
   Modelska A, 1998, P NATL ACAD SCI USA, V95, P2481, DOI 10.1073/pnas.95.5.2481.
   Nemchinov LG, 2000, ARCH VIROL, V145, P2557, DOI 10.1007/s007050070008.
   Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001.
   Ploix C, 1999, DIABETES, V48, P2150, DOI 10.2337/diabetes.48.11.2150.
   PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417.
   Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9.
   Richter L, 1999, CURR TOP MICROBIOL, V240, P159.
   Richter LJ, 2000, NAT BIOTECHNOL, V18, P1167, DOI 10.1038/81153.
   Romagnani S, 1998, AUTOIMMUNE DISEASES, THIRD EDITION, P163.
   Sanchez J, 1997, FEBS LETT, V401, P95, DOI 10.1016/S0014-5793(96)01445-7.
   Sandhu JS, 1999, PLANT CELL REP, V18, P394, DOI 10.1007/s002990050592.
   Sandhu JS, 2000, TRANSGENIC RES, V9, P127, DOI 10.1023/A:1008979525909.
   SCHEIBNER V, 1993, VACCINATIONS 100 YEA.
   Schouten A, 1996, PLANT MOL BIOL, V30, P781, DOI 10.1007/BF00019011.
   Stewart CN, 2000, BIOTECHNIQUES, V29, P832.
   Stoger E, 2000, PLANT MOL BIOL, V42, P583, DOI 10.1023/A:1006301519427.
   Streatfield SJ, 2001, VACCINE, V19, P2742, DOI 10.1016/S0264-410X(00)00512-0.
   SUGIYAMA Y, 1995, FEBS LETT, V359, P247, DOI 10.1016/0014-5793(95)00054-D.
   Sutton Dennis W., 1992, Transgenic Research, V1, P228, DOI 10.1007/BF02524753.
   Tackaberry ES, 1999, VACCINE, V17, P3020, DOI 10.1016/S0264-410X(99)00150-4.
   Tacket CO, 2000, J INFECT DIS, V182, P302, DOI 10.1086/315653.
   Tacket CO, 1998, NAT MED, V4, P607, DOI 10.1038/nm0598-607.
   THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358.
   Torrey EF, 1999, BEHAV HEALTHC TOM, V8, P6.
   Tuboly T, 2000, VACCINE, V18, P2023, DOI 10.1016/S0264-410X(99)00525-3.
   TURPEN TH, 1995, BIO-TECHNOL, V13, P53, DOI 10.1038/nbt0195-53.
   {*}USDA AGR RES SERV, 2001, STRAT CONTR INF NON.
   USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598.
   Vaquero C, 1999, P NATL ACAD SCI USA, V96, P11128, DOI 10.1073/pnas.96.20.11128.
   Verch T, 1998, J IMMUNOL METHODS, V220, P69, DOI 10.1016/S0022-1759(98)00149-5.
   Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0.
   Weiner HL, 2000, J CLIN INVEST, V106, P935, DOI 10.1172/JCI11348.
   WHITACRE CC, 1996, CLIN IMMUNOL IMMUNOP, V80, P31.
   Wigdorovitz A, 1999, VIROLOGY, V264, P85, DOI 10.1006/viro.1999.9923.
   Wigdorovitz A, 1999, VIROLOGY, V255, P347, DOI 10.1006/viro.1998.9590.
   Yu J, 2001, NAT BIOTECHNOL, V19, P548, DOI 10.1038/89297.
   YU J, 2000, TRANSGENICS, V40, P1.
   Yusibov V, 1997, P NATL ACAD SCI USA, V94, P5784, DOI 10.1073/pnas.94.11.5784.
   Zeitlin L, 1998, NAT BIOTECHNOL, V16, P1361.
   ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252.}},
Number-of-Cited-References = {{104}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{Crit. Rev. Plant Sci.}},
Doc-Delivery-Number = {{539DH}},
Unique-ID = {{ISI:000174854200002}},
DA = {{2018-08-13}},
}

@article{ ISI:000175677200013,
Author = {Heal, RD and Parsons, AT},
Title = {{Novel intercellular communication system in Escherichia coli that
   confers antibiotic resistance between physically separated populations}},
Journal = {{JOURNAL OF APPLIED MICROBIOLOGY}},
Year = {{2002}},
Volume = {{92}},
Number = {{6}},
Pages = {{1116-1122}},
Abstract = {{Aims: To determine whether intercellular signalling can occur between
   physically separated populations of Escherichia coli .
   Methods and Results: Intercellular signalling between physically
   discrete populations of E. coli BL21 was analysed in bi-partite Petri
   dishes. Transfer of a growth-promoting signal resulted in induction of
   resistance to the antibiotic ampicillin. Optimal expression of the
   signal occurred when the signalling population was established as a
   bacterial lawn for 24 h. This represented an entry into the stationary
   phase of growth, as indicated by the expression profile of the RNA
   polymerase subunit sigma(38) (sigma(S) ; sigma S). The growth-promoting
   effect was also observed when E. coli DH5alpha (luxS(-)) was used as the
   signalling population. Preventing passage of air between the two
   populations resulted in a complete cessation of the growth-promoting
   effect.
   Conclusions: A growth-promoting signal occurs between physically
   separated cultures of E. coli . The exact nature of the signal remains
   to be determined but does not involve the production of autoinducer-2
   from the luxS gene. Signal transmission is likely to involve airborne
   transfer of a signal species.
   Significance and Impact of the Study: Intercellular signalling systems
   exist in bacteria that enable antibiotic resistance to be conferred
   between physically separated populations.}},
Publisher = {{BLACKWELL PUBLISHING LTD}},
Address = {{9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Heal, RD (Reprint Author), QinetiQ Ltd, Winfrith Technol Ctr, BioPhys Res Grp, Dorchester DT2 8XJ, Dorset, England.
   QinetiQ Ltd, Winfrith Technol Ctr, BioPhys Res Grp, Dorchester DT2 8XJ, Dorset, England.}},
DOI = {{10.1046/j.1365-2672.2002.01647.x}},
ISSN = {{1364-5072}},
Keywords-Plus = {{VIBRIO-HARVEYI; SALMONELLA-TYPHIMURIUM; BACTERIA; SIGNALS; LUMINESCENCE;
   EXPRESSION; CELLS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Cited-References = {{Baca-DeLancey RR, 1999, P NATL ACAD SCI USA, V96, P4610, DOI 10.1073/pnas.96.8.4610.
   BASSLER BL, 1993, MOL MICROBIOL, V9, P773, DOI 10.1111/j.1365-2958.1993.tb01737.x.
   Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3.
   BUDRENE EO, 1995, NATURE, V376, P49, DOI 10.1038/376049a0.
   Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X.
   HORINOUCHI S, 1992, ANNU REV MICROBIOL, V46, P377, DOI 10.1146/annurev.micro.46.1.377.
   Ishihama A, 1997, CURR OPIN GENET DEV, V7, P582, DOI 10.1016/S0959-437X(97)80003-2.
   Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996.
   Kaplan HB, 1996, FEMS MICROBIOL LETT, V139, P89, DOI 10.1016/0378-1097(96)00102-4.
   Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x.
   LOWEN PC, 1994, ANNU REV MICROBIOL, V48, P53.
   Matsuhashi M, 1996, J GEN APPL MICROBIOL, V42, P315, DOI 10.2323/jgam.42.315.
   MATSUHASHI M, 1995, J BACTERIOL, V177, P688, DOI 10.1128/jb.177.3.688-693.1995.
   Matsuhashi M, 1998, J GEN APPL MICROBIOL, V44, P49, DOI 10.2323/jgam.44.49.
   Matsuhashi M, 1996, MICROB DRUG RESIST, V2, P91, DOI 10.1089/mdr.1996.2.91.
   Msadek T, 1999, TRENDS MICROBIOL, V7, P201, DOI 10.1016/S0966-842X(99)01479-1.
   Sambrook J, 1989, MOL CLONING LAB MANU.
   Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627.
   Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639.
   Surette MG, 1998, P NATL ACAD SCI USA, V95, P7046, DOI 10.1073/pnas.95.12.7046.
   Wang DD, 2001, J BACTERIOL, V183, P4210, DOI 10.1128/JB.183.14.4210-4216.2001.
   Withers HL, 1998, P NATL ACAD SCI USA, V95, P15694, DOI 10.1073/pnas.95.26.15694.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{16}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{J. Appl. Microbiol.}},
Doc-Delivery-Number = {{553LT}},
Unique-ID = {{ISI:000175677200013}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000173513200004,
Author = {De Luca, G and Zanetti, F and Perari, AC and Stampi, S},
Title = {{Airborne coagulase negative staphylococci produced by a sewage treatment
   plant}},
Journal = {{INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH}},
Year = {{2001}},
Volume = {{204}},
Number = {{4}},
Pages = {{231-238}},
Month = {{DEC}},
Note = {{9th Conference of the Society-of-Hygiene-and-Environmental-Medicine,
   BAVARIA, GERMANY, SEP 06-07, 2001}},
Organization = {{Soc Hygiene Environm Med}},
Abstract = {{Since some coagulase-negative staphylococci species are involved in
   clinical and environmental situations, the authors carried out a study
   on the spread of these bacteria in the air of a sewage treatment plant.
   For these purposes a total of 196 samples were taken from 16 sampling
   stations, 11 during the day and 5 at night (only at 4 points), using the
   settle plate technique. Altogether 13 species of coagulase negative
   staphylococci were isolated: S. haemolyticus, S. xylosus and S. cohnii
   were particularly common. Station no. 2 (an area almost always kept
   closed containing the fine screens) was found to be the most
   contaminated. The presence of coagulase negative staphylococci was
   favoured by high temperatures and low humidity. No differences were
   found due to variations in wind speed and direction or between day and
   night.}},
Publisher = {{URBAN \& FISCHER VERLAG}},
Address = {{BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Stampi, S (Reprint Author), Univ Bologna, Dipartimento Med \& Sanita Pubbl, Sez Igiene, Div Hyg, Via S Giacomo 12, I-40126 Bologna, Italy.
   Univ Bologna, Dipartimento Med \& Sanita Pubbl, Sez Igiene, Div Hyg, I-40126 Bologna, Italy.}},
DOI = {{10.1078/1438-4639-00098}},
ISSN = {{1438-4639}},
Keywords = {{treatment plant; airborne contamination; staphylococci}},
Keywords-Plus = {{ANTIBIOTIC-RESISTANCE; INFECTIONS; AEROSOLS; WATER; MILK;
   IDENTIFICATION; CONTAMINATION; BACTERIA; MASTITIS; SYSTEM}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{ADAMS AP, 1970, SCIENCE, V169, P1218, DOI 10.1126/science.169.3951.1218.
   Angelillo I F, 1990, Arch Stomatol (Napoli), V31, P511.
   BAUTISTA L, 1988, APPL ENVIRON MICROB, V54, P566.
   BECKSAGUE CM, 1992, INFECT CONT HOSP EP, V13, P526.
   Bernagozzi M, 1992, Ann Ig, V4, P35.
   BERNAGOZZI M, 1984, IG SAN PUBBL, V40, P193.
   BIANUCCI F, 1988, RIV ITALIANA IGIENE, V48, P352.
   BLENKHARN JI, 1989, J HOSP INFECT, V14, P73, DOI 10.1016/0195-6701(89)90137-0.
   Bohn WW, 1996, INFECT CONT HOSP EP, V17, P419.
   Bonadonna L., 1997, Igiene Moderna, V107, P217.
   Brandi G, 2000, J APPL MICROBIOL, V88, P845, DOI 10.1046/j.1365-2672.2000.01024.x.
   BRANDI G, 1993, INGENERIA AMBIENTALE, V22, P621.
   CARDUCCI A, 1998, BIOL ITALIANI, V5, P42.
   CRASS BA, 1986, J CLIN MICROBIOL, V23, P43.
   DANDALIDES PC, 1986, J HOSP INFECT, V8, P233, DOI 10.1016/0195-6701(86)90118-0.
   DeLuca G, 1997, INT J FOOD MICROBIOL, V35, P267, DOI 10.1016/S0168-1605(96)01229-9.
   FANNIN KF, 1985, APPL ENVIRON MICROB, V49, P1191.
   FANNIN KF, 1977, WATER RES, V11, P181, DOI 10.1016/0043-1354(77)90124-5.
   HOOVER DG, 1983, APPL ENVIRON MICROB, V46, P649.
   HORIBA N, 1995, J ENDODONT, V21, P21, DOI 10.1016/S0099-2399(06)80552-2.
   Kessie G, 1998, J APPL MICROBIOL, V84, P417, DOI 10.1046/j.1365-2672.1998.00358.x.
   Kiss L, 1996, Acta Microbiol Immunol Hung, V43, P39.
   Laverdiere M, 1998, MICROB DRUG RESIST, V4, P119, DOI 10.1089/mdr.1998.4.119.
   LEMBKE LL, 1985, CAN J MICROBIOL, V31, P198, DOI 10.1139/m85-038.
   Maniatis AN, 1997, CHEMOTHERAPY, V43, P69, DOI 10.1159/000239538.
   Marinella MA, 1997, ARCH INTERN MED, V157, P786, DOI 10.1001/archinte.157.7.786.
   MARSIK FJ, 1982, J CLIN MICROBIOL, V15, P640.
   MYLLYS V, 1994, ACTA VET SCAND, V35, P363.
   MYLLYS V, 1995, J DAIRY RES, V62, P51, DOI 10.1017/S0022029900033665.
   NAYAK N, 1993, INDIAN J MED RES-A, V97, P72.
   Pitzurra M, 1996, Ann Ig, V8, P441.
   Rozand CV, 1996, INT J FOOD MICROBIOL, V30, P373, DOI 10.1016/0168-1605(96)00953-1.
   SADKOWSKA EZ, 1995, ACTA POL PHARM, V52, P173.
   SORBER CA, 1979, WATER SEWAGE WORKS, V126, P56.
   SPENDLOVE JC, 1981, JAPCA J AIR WASTE MA, V31, P1279, DOI 10.1080/00022470.1981.10465359.
   SUZUKI A, 1984, J HYG-CAMBRIDGE, V93, P567, DOI 10.1017/S0022172400065141.
   VALLE J, 1990, APPL ENVIRON MICROB, V56, P1323.
   VARALDO PE, 1987, GLI STAFILOCOCCHI AS, P25.
   WILSON IG, 1991, APPL ENVIRON MICROB, V57, P1793.}},
Number-of-Cited-References = {{39}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Hyg. Environ. Health.}},
Doc-Delivery-Number = {{515TR}},
Unique-ID = {{ISI:000173513200004}},
DA = {{2018-08-13}},
}

@article{ ISI:000172013500012,
Author = {Baumann, RP and Hodnick, WF and Seow, HA and Belcourt, MF and Rockwell,
   S and Sherman, DH and Sartorelli, AC},
Title = {{Reversal of mitomycin C resistance by overexpression of bioreductive
   enzymes in Chinese hamster ovary cells}},
Journal = {{CANCER RESEARCH}},
Year = {{2001}},
Volume = {{61}},
Number = {{21}},
Pages = {{7770-7776}},
Month = {{NOV 1}},
Abstract = {{The clinical utility of antineoplastic agents is limited by the
   development of drug resistance by tumors. Mitomycin C (MC) is a
   bacterial product that must be enzymatically reduced to exert anticancer
   activity. We have demonstrated that expression of the bacterial MC
   resistance-associated (MCRA) protein in Chinese hamster ovary (CHO)
   cells confers profound resistance to this antibiotic under aerobic
   conditions, but not under hypoxia. MCRA produces resistance to MC by
   redox cycling of the activated hydroquinone intermediate back to the
   prodrug form. A CHO cell line developed by stepwise exposure to
   increasing concentrations of MC likewise expressed high level resistance
   to MC in air, but not under hypoxia. The overexpression of DT-diaphorase
   and NADPH:cytochrome c (P-450) reductase, two enzymes known to activate
   MC, restored sensitivity to MC in both MCRA-transfected and
   drug-selected cell lines. The level of sensitization was proportional to
   the quantity of enzyme activity expressed, supporting the concept that
   the levels of these two activating enzymes are important for sensitivity
   to MC. The findings of resistance to MC in air but not under hypoxic
   conditions and of restoration of sensitivity to MC by increasing levels
   of DT-diaphorase activity, properties not adequately explained by other
   resistance mechanisms (i.e., decreases in MC activation, repair of DNA
   lesions, and/or drug efflux), support the hypothesis that a functional
   mammalian homologue of MCRA may be involved in producing resistance to
   MC.}},
Publisher = {{AMER ASSOC CANCER RESEARCH}},
Address = {{PO BOX 11806, BIRMINGHAM, AL 35202 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sartorelli, AC (Reprint Author), Yale Univ, Sch Med, Dept Pharmacol, Canc Ctr, 333 Cedar St, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Pharmacol, Canc Ctr, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dept Therapeut Radiol, Canc Ctr, New Haven, CT 06520 USA.
   Yale Univ, Sch Med, Dev Therapeut Program, Canc Ctr, New Haven, CT 06520 USA.
   Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA.
   Univ Minnesota, Biol Proc Technol Inst, Minneapolis, MN 55455 USA.}},
ISSN = {{0008-5472}},
Keywords-Plus = {{COLON-CARCINOMA CELLS; DT-DIAPHORASE; HYPOXIC CONDITIONS; REDUCTIVE
   ACTIVATION; CANCER-CELLS; STREPTOMYCES-LAVENDULAE; DEFICIENT ACTIVATION;
   METABOLIC-ACTIVATION; P-450 REDUCTASE; CHO CELLS}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
ResearcherID-Numbers = {{Rockwell, Sara/B-8458-2009}},
Funding-Acknowledgement = {{NCI NIH HHS {[}CA-71961, CA-80845]}},
Cited-References = {{AUGUST PR, 1994, J BACTERIOL, V176, P4448, DOI 10.1128/jb.176.14.4448-4454.1994.
   August PR, 1996, GENE, V175, P261, DOI 10.1016/0378-1119(96)00172-2.
   BEALL HD, 1994, CANCER RES, V54, P3196.
   BEGLEITER A, 1989, CANCER LETT, V45, P173, DOI 10.1016/0304-3835(89)90073-6.
   BEGLEITER A, 1988, CANCER RES, V48, P1727.
   Belcourt MF, 1996, BIOCHEM PHARMACOL, V51, P1669, DOI 10.1016/0006-2952(96)00143-8.
   Belcourt MF, 1996, P NATL ACAD SCI USA, V93, P456, DOI 10.1073/pnas.93.1.456.
   Belcourt MF, 1998, ADV ENZYME REGUL, V38, P111, DOI 10.1016/S0065-2571(97)00009-5.
   BELCOURT MF, 1999, P NATL ACAD SCI USA, V96, P10488.
   BUCHWALD M, 1991, J CELL PHYSIOL, V148, P472, DOI 10.1002/jcp.1041480320.
   CHAKRABARTY S, 1986, CANCER RES, V46, P3456.
   DULHANTY AM, 1991, CANCER RES, V51, P1860.
   DULHANTY AM, 1989, CANCER RES, V49, P117.
   Ernster L, 1967, METHOD ENZYMOL, P309, DOI DOI 10.1016/0076-6879(67)10059-1.
   Fisher J., 1982, DEV BIOCHEM, V21, P240.
   GUSTAFSON DL, 1992, J NATL CANCER I, V84, P1180, DOI 10.1093/jnci/84.15.1180.
   Gustafson DL, 1996, MOL PHARMACOL, V50, P728.
   HATA T, 1956, J ANTIBIOT, V9, P141.
   HOBAN PR, 1990, CANCER RES, V50, P4692.
   Hodnick WF, 1997, ANAL BIOCHEM, V252, P165, DOI 10.1006/abio.1997.2313.
   HODNICK WF, 1993, CANCER RES, V53, P4907.
   HUGHES CS, 1991, CANCER COMMUN, V3, P29.
   IYER VN, 1964, SCIENCE, V145, P55, DOI 10.1126/science.145.3627.55.
   Johnson DA, 1997, J AM CHEM SOC, V119, P2576, DOI 10.1021/ja963880j.
   Joseph P, 2000, BRIT J CANCER, V82, P1305.
   KENNEDY KA, 1982, BIOCHEM PHARMACOL, V31, P2011, DOI 10.1016/0006-2952(82)90414-2.
   KEYES SR, 1991, CANCER COMMUN, V3, P351.
   Kumar GS, 1997, BIOCHEMISTRY-US, V36, P14128.
   LING V, 1979, CELL, V18, P423, DOI 10.1016/0092-8674(79)90061-8.
   MARSHALL RS, 1989, BRIT J CANCER, V59, P341, DOI 10.1038/bjc.1989.67.
   Mikami K, 1996, CANCER RES, V56, P2823.
   Morrow C S, 1988, Oncology (Williston Park), V2, P55.
   PAN SS, 1984, J BIOL CHEM, V259, P959.
   PAN SS, 1992, CANCER CHEMOTH PHARM, V31, P23, DOI 10.1007/BF00695990.
   PENKETH PG, 1996, DRUG RESISTANCE, P65.
   POWIS G, 1995, ANTICANCER RES, V15, P1141.
   PRITSOS CA, 1986, CANCER RES, V46, P3528.
   Rauth AM, 1997, ONCOL RES, V9, P339.
   SCHWARTZ HS, 1962, J PHARMACOL EXP THER, V136, P250.
   SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019.
   SIEGEL D, 1990, CANCER RES, V50, P7483.
   TRAVER RD, 1992, CANCER RES, V52, P797.
   VERWEIJ J, 1990, CANC CHEMOTHERAPY PR, P382.
   WILLSON JKV, 1985, CANCER RES, V45, P5281.
   XU BH, 1994, INT J CANCER, V58, P686, DOI 10.1002/ijc.2910580512.
   XU BH, 1994, BRIT J CANCER, V69, P242, DOI 10.1038/bjc.1994.46.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Cancer Res.}},
Doc-Delivery-Number = {{489VQ}},
Unique-ID = {{ISI:000172013500012}},
DA = {{2018-08-13}},
}

@article{ ISI:000172039700004,
Author = {Wahl, MJ},
Title = {{Amalgam - Resurrection and redemption. Part 2: The medical mythology of
   anti-amalgam}},
Journal = {{QUINTESSENCE INTERNATIONAL}},
Year = {{2001}},
Volume = {{32}},
Number = {{9}},
Pages = {{696-710}},
Month = {{OCT}},
Abstract = {{Mercury-containing amalgam restorative material has come under attack
   for its alleged harmful effects on systemic health. A literature search
   revealed that amalgam restorations release small quantities of mercury
   but apparently not enough to cause systemic health problems. Mercury
   from dental amalgam restorations cannot be linked to kidney damage,
   Alzheimer's disease, multiple sclerosis, other central nervous system
   diseases, ``amalgam disease,{''} mental disorders, damage to the immune
   system, increases in antibiotic resistance, or harmful reproductive
   effects. Dentists occupationally exposed to mercury have not been shown
   to suffer harmful reproductive or other systemic health effects,
   provided proper mercury hygiene is used. There are legitimate health
   concerns about alternative restorative materials, including resin
   composite. According to the latest scientific information available,
   dental amalgam remains a safe and effective restorative material.}},
Publisher = {{QUINTESSENCE PUBL CO INC}},
Address = {{551 NORTH KIMBERLY DR, CAROL STREAM, IL 60188-1881 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Wahl, MJ (Reprint Author), 1601 Concord Pike, Wilmington, DE 19803 USA.}},
ISSN = {{0033-6572}},
Keywords = {{amalgam; biocompatibility; mercury; resin composite; safety; toxicity}},
Keywords-Plus = {{DENTIN BONDING AGENTS; SILVER TOOTH FILLINGS; INTRAORAL MERCURY-VAPOR;
   LOW-DOSE EXPOSURE; ORAL AIR MERCURY; IN-VITRO; COMPOSITE RESTORATIONS;
   OCCUPATIONAL EXPOSURE; MULTIPLE-SCLEROSIS; BENZOYL PEROXIDE}},
Research-Areas = {{Dentistry, Oral Surgery \& Medicine}},
Web-of-Science-Categories  = {{Dentistry, Oral Surgery \& Medicine}},
Cited-References = {{ABRAHAM JE, 1984, J DENT RES, V63, P71, DOI 10.1177/00220345840630011801.
   AHLQWIST M, 1988, COMMUNITY DENT ORAL, V16, P227, DOI 10.1111/j.1600-0528.1988.tb01760.x.
   AHLQWIST M, 1993, COMMUNITY DENT ORAL, V21, P40, DOI 10.1111/j.1600-0528.1993.tb00717.x.
   ALNAZHAN S, 1988, J ENDODONT, V14, P236, DOI 10.1016/S0099-2399(88)80176-6.
   Arenholt-Bindslev D, 1998, EUR J ORAL SCI, V106, P713, DOI 10.1046/j.0909-8836.1998.eos10602ii06.x.
   ARENHOLTBINDSLE.D, 1994, DENT RES, V73, P952.
   Bangsi D, 1998, INT J EPIDEMIOL, V27, P667, DOI 10.1093/ije/27.4.667.
   BERDOUSES E, 1995, J DENT RES, V74, P1185, DOI 10.1177/00220345950740050701.
   BERGLUND A, 1988, J DENT RES, V67, P1235, DOI 10.1177/00220345880670091701.
   BERGLUND A, 1990, J DENT RES, V69, P1646, DOI 10.1177/00220345900690100401.
   Berry TG, 1998, J AM DENT ASSOC, V129, P1547, DOI 10.14219/jada.archive.1998.0101.
   Bjorkman L, 1996, COMMUNITY DENT ORAL, V24, P260, DOI 10.1111/j.1600-0528.1996.tb00856.x.
   Blomgren J, 1996, J ORAL PATHOL MED, V25, P311, DOI 10.1111/j.1600-0714.1996.tb00268.x.
   BONFIL RD, 1989, INT J CANCER, V44, P165, DOI 10.1002/ijc.2910440129.
   Bouillaguet S, 1996, J ENDODONT, V22, P244, DOI 10.1016/S0099-2399(06)80141-X.
   BOYD ND, 1991, AM J PHYSIOL, V261, pR1010.
   Bratel J, 1997, EUR J ORAL SCI, V105, P234, DOI 10.1111/j.1600-0722.1997.tb00206.x.
   Bratel J, 1997, EUR J ORAL SCI, V105, P244, DOI 10.1111/j.1600-0722.1997.tb00207.x.
   BRODSKY JB, 1985, J AM DENT ASSOC, V111, P779, DOI 10.14219/jada.archive.1985.0182.
   Carmichael AJ, 1997, BRIT DENT J, V183, P297, DOI 10.1038/sj.bdj.4809499.
   CAUGHMAN WF, 1990, J PROSTHET DENT, V63, P513, DOI 10.1016/0022-3913(90)90067-M.
   CHRISTENSEN GJ, 1999, DENT EC, V89, P34.
   CLAUSEN J, 1993, ACTA NEUROL SCAND, V87, P461.
   Costa CAD, 1999, DENT MATER, V15, P434.
   Costa CAD, 2000, J ENDODONT, V26, P512.
   Dahl JE, 1999, SCAND J WORK ENV HEA, V25, P285, DOI 10.5271/sjweh.436.
   Dickerson W G, 1997, Dent Econ, V87, P30.
   Dickerson W G, 1998, Dent Econ, V88, P42.
   DICKERSON WG, 1998, DENT EC, V88, P105.
   DING GS, 1991, J APPL TOXICOL, V11, P7, DOI 10.1002/jat.2550110103.
   Dodes JE, 2001, J AM DENT ASSOC, V132, P348, DOI 10.14219/jada.archive.2001.0178.
   DOMB B, 1999, DENT EC, V89, P17.
   DOUGLASS C, 1999, ORAL CARE REP, V9, P1.
   DOWDEN WE, 1983, J PROSTHET DENT, V50, P497, DOI 10.1016/0022-3913(83)90568-1.
   Echeverria D, 1998, FASEB J, V12, P971.
   ECHEVERRIA D, 1995, NEUROTOXICOL TERATOL, V17, P161, DOI 10.1016/0892-0362(94)00049-J.
   Edlund C, 1996, CLIN INFECT DIS, V22, P944, DOI 10.1093/clinids/22.6.944.
   EGGLESTON DW, 1984, J PROSTHET DENT, V51, P617, DOI 10.1016/0022-3913(84)90404-9.
   EGGLESTON DW, 1987, J PROSTHET DENT, V58, P704, DOI 10.1016/0022-3913(87)90424-0.
   Eley BM, 1997, BRIT DENT J, V182, P455, DOI 10.1038/sj.bdj.4809412.
   Eley BM, 1997, BRIT DENT J, V182, P413, DOI 10.1038/sj.bdj.4809401.
   Eley BM, 1997, BRIT DENT J, V182, P293, DOI 10.1038/sj.bdj.4809370.
   ENESTROM S, 1995, INT ARCH ALLERGY IMM, V106, P180, DOI 10.1159/000236843.
   ERICSON A, 1989, INT ARCH OCC ENV HEA, V61, P329, DOI 10.1007/BF00409388.
   ETI S, 1995, PHARMACOL TOXICOL, V76, P47, DOI 10.1111/j.1600-0773.1995.tb00101.x.
   FUNG YK, 1992, J TOXICOL-CLIN TOXIC, V30, P49, DOI 10.3109/15563659208994445.
   GAY DD, 1979, LANCET, V1, P985.
   Geurtsen W, 1998, EUR J ORAL SCI, V106, P687, DOI 10.1046/j.0909-8836.1998.eos10602ii04.x.
   Geurtsen W, 1998, J BIOMED MATER RES, V41, P474, DOI 10.1002/(SICI)1097-4636(19980905)41:3<474::AID-JBM18>3.0.CO;2-I.
   Geurtsen W, 2000, CRIT REV ORAL BIOL M, V11, P333, DOI 10.1177/10454411000110030401.
   Grandjean P, 1997, J OCCUP ENVIRON MED, V39, P707, DOI 10.1097/00043764-199708000-00004.
   HAHN LJ, 1990, FASEB J, V4, P3256.
   HAHN LJ, 1989, FASEB J, V3, P2641.
   HALBACH S, 1995, J DENT RES, V74, P1103, DOI 10.1177/00220345950740041101.
   HALBACH S, 1995, INT ARCH OCC ENV HEA, V67, P295, DOI 10.1007/BF00385643.
   HALBACH S, 1994, HUM EXP TOXICOL, V13, P496, DOI 10.1177/096032719401300708.
   HANKS CT, 1991, J DENT RES, V70, P1450, DOI 10.1177/00220345910700111201.
   HANSASUTA C, 1993, J PROSTHET DENT, V69, P611, DOI 10.1016/0022-3913(93)90291-U.
   Hansel C, 1998, J DENT RES, V77, P60, DOI 10.1177/00220345980770010601.
   HANSON M, 1991, EXPERIENTIA, V47, P9, DOI 10.1007/BF02041243.
   HEIDAM LZ, 1984, J EPIDEMIOL COMMUN H, V38, P149, DOI 10.1136/jech.38.2.149.
   HENSTENPETTERSE.A, 1987, QUALITY EVALUATION D, P357.
   HERRSTROM P, 1993, SCAND J DENT RES, V101, P232.
   HERRSTROM P, 1995, ARCH ENVIRON HEALTH, V50, P103, DOI 10.1080/00039896.1995.9940886.
   HERRSTROM P, 1994, ARCH ENVIRON HEALTH, V49, P160, DOI 10.1080/00039896.1994.9940376.
   Herrstrom Per, 1994, Scandinavian Journal of Primary Health Care, V12, P3, DOI 10.3109/02813439408997049.
   Hikage S, 1999, Dent Mater J, V18, P76.
   Huggins H A, 1983, Oral Health, V73, P42.
   Huggins H A, 1985, Dent Assist, V54, P10.
   Imazato S, 2000, J DENT, V28, P61, DOI 10.1016/S0300-5712(99)00039-1.
   Isacsson G, 1997, EUR J ORAL SCI, V105, P251, DOI 10.1111/j.1600-0722.1997.tb00208.x.
   Itota T, 1999, Dent Mater J, V18, P271.
   JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186.
   JONTELL M, 1995, J DENT RES, V74, P1162, DOI 10.1177/00220345950740050401.
   Kidd RF, 2000, ALTERN THER HEALTH M, V6, P49.
   Kingman A, 1998, J DENT RES, V77, P461, DOI 10.1177/00220345980770030501.
   KOCH MJ, 1994, J DENT RES, V73, P293.
   KURTZ KS, 1994, J DENT RES, V73, P1130, DOI 10.1177/00220345940730060101.
   Laine J, 1999, J ORAL PATHOL MED, V28, P117.
   LANGWORTH S, 1993, SCAND J WORK ENV HEA, V19, P405, DOI 10.5271/sjweh.1454.
   Langworth S, 1997, J DENT RES, V76, P1397, DOI 10.1177/00220345970760071001.
   LANGWORTH S, 1988, SWED DENT J, V12, P71.
   Larsson K S, 1991, Int Dent J, V41, P206.
   Larsson K S, 1992, Adv Dent Res, V6, P114.
   Leistevuo J, 2000, ANTIMICROB AGENTS CH, V44, P456, DOI 10.1128/AAC.44.2.456-457.2000.
   Leong CCW, 2001, NEUROREPORT, V12, P733, DOI 10.1097/00001756-200103260-00024.
   LEYHAUSEN G, 1997, J DENT RES, V76, P382.
   Li YM, 1998, J AM DENT ASSOC, V129, P494.
   Lichtenberg H, 1993, J ORTHOMOL MED, V8, P145.
   LIND PO, 1988, ACTA ODONTOL SCAND, V46, P63, DOI 10.3109/00016358809004748.
   LINDBERG NE, 1994, ACTA ODONTOL SCAND, V52, P219, DOI 10.3109/00016359409029050.
   Loftenius A, 1998, J TOXICOL ENV HEAL A, V54, P547.
   LORSCHEIDER FL, 1995, FASEB J, V9, P504.
   Lutz F U, 1996, Pract Periodontics Aesthet Dent, V8, P385.
   Lygre H, 1999, EUR J ORAL SCI, V107, P378, DOI 10.1046/j.0909-8836.1999.eos107509.x.
   Mackert J R Jr, 1992, Adv Dent Res, V6, P90.
   Mackert JR, 1997, CRIT REV ORAL BIOL M, V8, P410, DOI 10.1177/10454411970080040401.
   MACKERT JR, 1991, J AM DENT ASSOC, V122, P49, DOI 10.14219/jada.archive.1991.0095.
   MACKERT JR, 1987, J DENT RES, V66, P1775, DOI 10.1177/00220345870660121501.
   MACKERT JR, 1991, J AM DENT ASSOC, V122, P54.
   MALVIN RL, 1992, AM J PHYSIOL, V262, pR716.
   MAROON M, 1998, DENT LEADER      MAR, P2.
   MARTIN MD, 1995, J AM DENT ASSOC, V126, P1502, DOI 10.14219/jada.archive.1995.0079.
   McGrother CW, 1999, BRIT DENT J, V187, P261, DOI 10.1038/sj.bdj.4800255a.
   Melchart D, 1998, EUR J ORAL SCI, V106, P770, DOI 10.1046/j.0909-8836.1998.eos106303.x.
   MICHEL I, 1989, SWED DENT J, V13, P33.
   Mjor IA, 1999, J ROY COLL SURG EDIN, V44, P146.
   MOLIN M, 1987, SCAND J DENT RES, V95, P328.
   MOLIN M, 1990, ACTA ODONTOL SCAND, V48, P189, DOI 10.3109/00016359009005875.
   MUNKSGAARD EC, 1992, SCAND J DENT RES, V100, P189.
   NALEWAY C, 1991, J PUBLIC HEALTH DENT, V51, P12, DOI 10.1111/j.1752-7325.1991.tb02169.x.
   NATHANSON D, 1979, ORAL SURG ORAL MED O, V47, P329, DOI 10.1016/0030-4220(79)90255-X.
   NGIM CH, 1992, BRIT J IND MED, V49, P782.
   NYLANDER M, 1987, SWED DENT J, V11, P179.
   NYLANDER M, 1986, LANCET, V1, P442.
   NYLANDER M, 1989, SWED DENT J, V13, P235.
   OCONNELL JF, 1986, CANCER RES, V46, P2863.
   OLSSON S, 1992, J DENT RES, V71, P414, DOI 10.1177/00220345920710021201.
   Olsson S, 1987, J Dent Res, V66, P1288, DOI 10.1177/00220345870660071401.
   Ortengren U, 1999, EUR J ORAL SCI, V107, P496, DOI 10.1046/j.0909-8836.1999.eos107612.x.
   Osborne J W, 1992, Adv Dent Res, V6, P135.
   OSTERBLAD M, 1995, ANTIMICROB AGENTS CH, V39, P2499, DOI 10.1128/AAC.39.11.2499.
   OYSAED H, 1988, J DENT RES, V67, P1289, DOI 10.1177/00220345880670100901.
   PACKER M, 1990, AM HEART J, V120, P1579, DOI 10.1016/0002-8703(90)90062-3.
   PATTERSON JE, 1985, B ENVIRON CONTAM TOX, V34, P459, DOI 10.1007/BF01609761.
   Pendergrass AC, 1997, NEUROTOXICOLOGY, V18, P315.
   PETROS H, 1973, BRIT J DERMATOL, V88, P505, DOI 10.1111/j.1365-2133.1973.tb15459.x.
   Pleva Jaro, 1994, Reviews on Environmental Health, V10, P1.
   Rakich DR, 1998, J ENDODONT, V24, P528, DOI 10.1016/S0099-2399(98)80071-X.
   Rodvall Y, 1998, ORAL ONCOL, V34, P265, DOI 10.1016/S1368-8375(97)00096-1.
   ROWLAND AS, 1994, OCCUP ENVIRON MED, V51, P28, DOI 10.1136/oem.51.1.28.
   RUYTER IE, 1994, J DENT RES, V73, P293.
   Ruyter IE, 1995, ADV DENT RES, V9, P344.
   Sandborgh Englund G., 1994, Journal of Dental Research, V73, P620.
   SandborghEnglund G, 1996, AM J PHYSIOL-REG I, V271, pR941.
   SAXE SR, 1995, J AM DENT ASSOC, V126, P1495, DOI 10.14219/jada.archive.1995.0078.
   Saxe SR, 1999, J AM DENT ASSOC, V130, P191, DOI 10.14219/jada.archive.1999.0168.
   Schmalz G, 1998, EUR J ORAL SCI, V106, P696, DOI 10.1046/j.0909-8836.1998.eos10602ii05.x.
   Schutte JW, 1996, SOC BEHAV PERSONAL, V24, P9, DOI 10.2224/sbp.1996.24.1.9.
   Schuurs AHB, 1999, J DENT, V27, P249, DOI 10.1016/S0300-5712(97)00039-0.
   Schweikl H, 1997, J BIOMED MATER RES, V36, P284, DOI 10.1002/(SICI)1097-4636(19970905)36:3<284::AID-JBM2>3.0.CO;2-A.
   Schweikl H, 1996, BIOMATERIALS, V17, P1451, DOI 10.1016/0142-9612(96)87289-9.
   SCHWEIKL H, 1994, J BIOMED MATER RES, V28, P1061, DOI 10.1002/jbm.820280911.
   SCHWEIKL H, 1997, J DENT RES, V76, P382.
   SHAPIRO IM, 1982, LANCET, V1, P1147.
   SHEARER BG, 1993, ANTIMICROB AGENTS CH, V37, P1730, DOI 10.1128/AAC.37.8.1730.
   Siblerud RL, 1990, J ORTHOMOL MED, V5, P95.
   SIKORSKI R, 1987, INT ARCH OCC ENV HEA, V59, P551, DOI 10.1007/BF00377918.
   Simonsen R J, 1995, Quintessence Int, V26, P157.
   SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284.
   Sletten GBG, 1999, ACTA ODONTOL SCAND, V57, P316, DOI 10.1080/000163599428544.
   Soderholm KJ, 1999, J AM DENT ASSOC, V130, P201.
   Stanley H R, 1992, Adv Dent Res, V6, P55.
   Stromberg Rolf, 1999, European Journal of Oral Sciences, V107, P208, DOI 10.1046/j.0909-8836.1999.eos1070308.x.
   SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825.
   SUNBY J, 1994, J WOMENS HEALTH, V3, P65.
   Tan EK, 2000, J AM DENT ASSOC, V131, P211, DOI 10.14219/jada.archive.2000.0149.
   THORP JM, 1992, OBSTET GYNECOL, V79, P874.
   VIMY MJ, 1985, J DENT RES, V64, P1069, DOI 10.1177/00220345850640080901.
   VIMY MJ, 1985, J DENT RES, V64, P1072, DOI 10.1177/00220345850640081001.
   Wahl MJ, 2001, QUINTESSENCE INT, V32, P525.
   Wahl MJ, 1996, J AM DENT ASSOC, V127, P422, DOI 10.14219/jada.archive.1996.0215.
   WARFVINGE K, 1995, BRIT DENT J, V178, P149, DOI 10.1038/sj.bdj.4808684.
   Wataha J C, 1999, Clin Oral Investig, V3, P144, DOI 10.1007/s007840050093.
   WATAHA JC, 1994, J ORAL REHABIL, V21, P453, DOI 10.1111/j.1365-2842.1994.tb01159.x.
   WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P.
   {*}WHO, 1991, EV HUM HLTH RISKS, P108.
   {*}WHO, 1991, PREV EV INT BOD, P116.
   Zamm AV, 1990, J ORTHOMOL MED, V5, P138.}},
Number-of-Cited-References = {{169}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{15}},
Journal-ISO = {{Quintessence Int.}},
Doc-Delivery-Number = {{490FL}},
Unique-ID = {{ISI:000172039700004}},
DA = {{2018-08-13}},
}

@article{ ISI:000172060000008,
Author = {Ko, GP and Burge, HA and Nardell, EA and Thompson, KM},
Title = {{Estimation of tuberculosis risk and incidence under upper room
   ultraviolet germicidal irradiation in a waiting room in a hypothetical
   scenario}},
Journal = {{RISK ANALYSIS}},
Year = {{2001}},
Volume = {{21}},
Number = {{4}},
Pages = {{657-673}},
Month = {{AUG}},
Abstract = {{Environmental control measures (ventilation, high-efficiency particulate
   air filtration, and upper room ultraviolet germicidal irradiation
   {[}UVGI]) are recommended to effectively control tuberculosis (TB)
   transmission from unsuspected TB patients in high-risk settings, but the
   effectiveness of their use is not often clear. This study presents a
   simulation model for a hypothetical hospital waiting room, in which the
   number of susceptible immunocompetent people in the waiting room follows
   a Poisson distribution (M = 5) in either low (annual number of TB
   patients = 5) or high TB risk settings (annual number of TB patients =
   50), and used the model to evaluate the reduction of TB transmission
   risk by upper room UVGI. An exponential dose-response model was used for
   TB transmission and a two-zone model was used for evaluating the effect
   of tipper room UVGI. Upper room UVGI reduced TB risk by 1.6-fold at 3
   muW/cm(2) UV irradiance in the upper room in the low TB risk setting and
   by 4.1-fold at 15 muW/cm(2) UV irradiance in the upper room in the high
   TB risk setting. Use of upper room UVGI also reduced the mean annual new
   infection rate from 2.2 to 1.3 infections per year at 3 muW/cm(2) and to
   0.6 infections per year at 15 muW/cm(2) in our hypothetical high-risk
   settings. The effect of upper room UVGI was sensitive to both vertical
   air velocity (air mixing) and UV irradiance level. Results from
   partitioning variability indicate that most variability of TB
   transmission risk came from waiting time in our hypothetical hospital.}},
Publisher = {{WILEY}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ko, GP (Reprint Author), Univ N Carolina, Dept Environm Sci \& Engn, Rosenau Hall,CB 7400, Chapel Hill, NC 27599 USA.
   Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   Cambridge Hosp, Cambridge, MA 02139 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
   Massachusetts Dept Publ Hlth, TB Control Program, Boston, MA USA.
   Harvard Univ, Sch Publ Hlth, Dept Hlth Policy \& Management, Boston, MA 02115 USA.
   Harvard Univ, Ctr Risk Anal, Boston, MA 02115 USA.}},
DOI = {{10.1111/0272-4332.214142}},
ISSN = {{0272-4332}},
EISSN = {{1539-6924}},
Keywords = {{tuberculosis; risk; upper room UVGI; environmental control measures;
   simulation}},
Keywords-Plus = {{MULTIDRUG-RESISTANT TUBERCULOSIS; NEW-YORK-CITY;
   MYCOBACTERIUM-TUBERCULOSIS; AIR DISINFECTION; TRANSMISSION; INFECTION;
   SUSCEPTIBILITY; PROTECTION; VOLUNTEERS; OUTBREAK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Mathematics; Mathematical
   Methods In Social Sciences}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Mathematics,
   Interdisciplinary Applications; Social Sciences, Mathematical Methods}},
Author-Email = {{gko@email.unc.edu}},
Cited-References = {{ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   ALLEN BW, 1981, J CLIN PATHOL, V34, P719, DOI 10.1136/jcp.34.7.719.
   {*}AM C GOV IND HYG, 1999, THRESH LIM VAL CHEM.
   {*}AM SOC HEAT REFR, 1992, 551992 ASHRAE.
   Barnes PF, 1997, JAMA-J AM MED ASSOC, V278, P1159, DOI 10.1001/jama.278.14.1159.
   Barnhart S, 1997, J OCCUP ENVIRON MED, V39, P849, DOI 10.1097/00043764-199709000-00008.
   BASS JB, 1990, AM REV RESPIR DIS, V142, P725.
   Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002.
   Bloom BR, 1998, NEW ENGL J MED, V338, P677, DOI 10.1056/NEJM199803053381008.
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   Brubacher J, 1996, CHEST, V109, P582, DOI 10.1378/chest.109.2.582-a.
   {*}CDC, 1995, MMWR-MORBID MORTAL W, V44, P137.
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1, DOI DOI 10.HTTP://WWW.CDC.G0V/MMWR/PREVIEW/MMWRHTML/00032890.HTM.
   COLE JN, 1995, BYTE, V20, P20.
   DAVID HL, 1973, AM REV RESPIR DIS, V108, P1175.
   Dumyahn T, 1999, AM IND HYG ASSOC J, V60, P219, DOI 10.1202/0002-8894(1999)060<0219:COUURA>2.0.CO;2.
   DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304.
   Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677.
   FAGAN MJ, 1994, ANN INTERN MED, V120, P930, DOI 10.7326/0003-4819-120-11-199406010-00005.
   FIRST MW, 1999, GUIDELINES APPL UP 2.
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310.
   Garrett Denise O., 1999, P477.
   Goldfeld AE, 1998, JAMA-J AM MED ASSOC, V279, P226, DOI 10.1001/jama.279.3.226.
   Hass C. N., 1999, QUANTITATIVE MICROBI.
   Heymann SJ, 1999, JAMA-J AM MED ASSOC, V281, P2138, DOI 10.1001/jama.281.22.2138.
   HIRAI Y, 1991, J HOSP INFECT, V19, P191, DOI 10.1016/0195-6701(91)90223-U.
   HORNICK RB, 1971, B NEW YORK ACAD MED, V47, P1181.
   IMSHENETSKY AA, 1978, APPL ENVIRON MICROB, V35, P1.
   {*}INT AG RES CANC, 1992, SOL ULTR RAD.
   Jones TF, 1999, ANN INTERN MED, V131, P557, DOI 10.7326/0003-4819-131-8-199910190-00002.
   Kenyon TA, 1997, ANN INTERN MED, V127, P32, DOI 10.7326/0003-4819-127-1-199707010-00006.
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501.
   Ko G, 2000, TUBERCLE LUNG DIS, V80, P217, DOI 10.1054/tuld.2000.0249.
   KO G, 1998, J AM BIOL SAFETY ASS, V3, P65.
   LOUDON RG, 1969, AM REV RESPIR DIS, V100, P165.
   Lurie M. B, 1964, RESISTANCE TUBERCULO.
   Macher JM, 1992, APPL OCCUP ENV HYG, V7, P505.
   MACHER JM, 1992, APPL OCCUPATIONAL EN, V9, P1.
   MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306.
   MATTHEWS TG, 1989, ENVIRON INT, V15, P545, DOI 10.1016/0160-4120(89)90074-3.
   {*}MED RES COUNC, 1954, AIR DIS ULTR IRR ITS.
   MOSSMAN MJ, 1994, MEANS MECH COST DATA.
   Murray CJL, 1996, GLOBAL BURDEN DIS CO.
   NARDELL EA, 1995, AM J INFECT CONTROL, V23, P156, DOI 10.1016/0196-6553(95)90261-9.
   Nardell EA, 1998, INT J TUBERC LUNG D, V2, pS110.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   Nardell EA, 1996, JAMA-J AM MED ASSOC, V276, P1259, DOI 10.1001/jama.276.15.1259.
   NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1.
   Nardell Edward A., 1994, P53.
   NELSON C, 1998, VITAL HLTH STAT, V13, P136.
   Nicas M, 1999, Appl Occup Environ Hyg, V14, P317.
   Nicas M, 1996, RISK ANAL, V16, P527, DOI 10.1111/j.1539-6924.1996.tb01098.x.
   Nicas M, 1997, RISK ANAL, V17, P609, DOI 10.1111/j.1539-6924.1997.tb00901.x.
   NICAS M, AM IND HYGIENE ASS J, V57, P16.
   NOLAN CM, 1994, ANN INTERN MED, V120, P964, DOI 10.7326/0003-4819-120-11-199406010-00009.
   PERKINS JE, 1947, AM J PUBLIC HEALTH, V37, P529.
   PLANT JE, 1982, NATURE, V297, P510, DOI 10.1038/297510a0.
   Porter J D, 1991, CDR (Lond Engl Rev), V1, pR136.
   PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303.
   Rich A, 1944, PATHOGENESIS TUBERCU.
   Ridzon R, 1997, INFECT CONT HOSP EP, V18, P422.
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046.
   RILEY EC, 1978, AM J EPIDEMIOL, V107, P421, DOI 10.1093/oxfordjournals.aje.a112560.
   RILEY RL, 1972, APPL MICROBIOL, V23, P1113.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P208, DOI 10.1080/00039896.1971.10665834.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V23, P35, DOI 10.1080/00039896.1971.10665951.
   RILEY RL, 1988, ARCHIT DESIGN, P174.
   RUBIN LG, 1987, REV INFECT DIS, V9, P488.
   SCHURR E, 1991, IMMUNOL TODAY, V12, P42.
   SCOTT B, 1994, ARCH INTERN MED, V154, P326, DOI 10.1001/archinte.154.3.326.
   SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0.
   STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937.
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702.
   STERENBORG HJCM, 1988, PHOTOCHEM PHOTOBIOL, V47, P245, DOI 10.1111/j.1751-1097.1988.tb02722.x.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   TEUNIS PFM, 1996, 284550002 BILTH.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   Vander A, 1994, HUMAN PHYSL.
   Volk WA, 1991, ESSENTIALS MED MICRO.
   WELLS MW, 1950, JAMA-J AM MED ASSOC, V142, P1337, DOI 10.1001/jama.1950.02910350007004.
   Wells W F, 1935, Science, V82, P280, DOI 10.1126/science.82.2125.280-a.
   Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   WHO (World Health Organisation), 1994, ULTR RAD.
   World Health Organization, 1997, ANT TUB DRUG RES WOR.
   1992, J AM MED ASS, V267, P483.
   1999, MMWR MORBIDITY MORTA, V48, P79.}},
Number-of-Cited-References = {{89}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Risk Anal.}},
Doc-Delivery-Number = {{490PJ}},
Unique-ID = {{ISI:000172060000008}},
DA = {{2018-08-13}},
}

@article{ ISI:000171176200010,
Author = {Tokars, JI and McKinley, GF and Otten, J and Woodley, C and Sordillo, EM
   and Caldwell, J and Liss, CM and Gilligan, ME and Diem, L and Onorato,
   IM and Jarvis, WR},
Title = {{Use and efficacy of tuberculosis infection control practices at
   hospitals with previous outbreaks of multidrug-resistant tuberculosis}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{2001}},
Volume = {{22}},
Number = {{7}},
Pages = {{449-455}},
Month = {{JUL}},
Abstract = {{OBJECTIVE: To evaluate the implementation and efficacy of selected
   Centers for Disease Control and Prevention guidelines for preventing
   spread of Mycobacterium tuberculosis.
   DESIGN: Analysis of prospective observational data.
   SETTING: Two medical centers where outbreaks of multidrug-resistant
   tuberculosis (TB) had occurred.
   PARTICIPANTS: All hospital inpatients who had active TB or who were
   placed in TB isolation and healthcare workers who were assigned to
   selected wards on which TB patients were treated.
   METHODS: During 1995 to 1997, study personnel prospectively recorded
   information on patients who had TB or were in TB isolation, performed
   observations of TB isolation rooms, and recorded tuberculin skin-test
   results of healthcare workers. Genetic typing of M tuberculosis isolates
   was performed by restriction fragment-length polymorphism analysis.
   RESULTS: We found that only 8.6\% of patients placed in TB isolation
   proved to have TB; yet, 19\% of patients with pulmonary TB were not
   isolated on the first day of hospital admission. Specimens were ordered
   for acid-fast bacillus smear and results received promptly, and most TB
   isolation rooms were tinder negative pressure. Among persons entering TB
   isolation rooms, 44.2\% to 97.1\% used an appropriate (particulate,
   high-efficiency particulate air or N95) respirator, depending on the
   hospital and year; others entering the rooms used a surgical mask or
   nothing. We did not find evidence of transmission of TB among healthcare
   workers (based on tuberculin skin-test results) or patients (based on
   epidemiological investigation and genetic typing).
   CONCLUSIONS: We found problems in implementation of some TB infection
   control measures, but no evidence of healthcare-associated transmission,
   possibly in part because of limitations in the number of patients and
   workers studied. Similar evaluations should be performed at hospitals
   treating TB patients to find inadequacies and guide improvements in
   infection control (Inject Control Hosp Epidemiol 2001;22:449-455).}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Tokars, JI (Reprint Author), Ctr Dis Control \& Prevent, Hosp Infect Program, 1600 Clifton Rd,MS E-55, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Div Healthcare Qual Promot, Atlanta, GA USA.
   Ctr Dis Control \& Prevent, Natl Ctr Infect Dis, Div TB Eliminat, Atlanta, GA USA.
   Ctr Dis Control \& Prevent, Natl Ctr HIV STD \& TB Prevent, Atlanta, GA USA.
   St Lukes Roosevelt Hosp, New York, NY USA.
   Jackson Mem Hosp, Miami, FL 33136 USA.}},
DOI = {{10.1086/501933}},
ISSN = {{0899-823X}},
Keywords-Plus = {{HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL
   TRANSMISSION; IDENTIFICATION; STAFF; TB}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Bifani PJ, 1999, JAMA-J AM MED ASSOC, V282, P2321, DOI 10.1001/jama.282.24.2321.
   BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003.
   Blumberg HM, 1998, CLIN INFECT DIS, V27, P826, DOI 10.1086/514963.
   Burman WJ, 1997, AM J RESP CRIT CARE, V155, P1140, DOI 10.1164/ajrccm.155.3.9117000.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   French AL, 1998, ANN INTERN MED, V129, P856, DOI 10.7326/0003-4819-129-11\_Part\_1-199812010-00003.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135.
   JARVIS WR, 1995, AM J INFECT CONTROL, V23, P146, DOI 10.1016/0196-6553(95)90259-7.
   Knirsch CA, 1998, INFECT CONT HOSP EP, V19, P94.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   MENZIES D, 1995, NEW ENGL J MED, V332, P93.
   Michele TM, 1997, JAMA-J AM MED ASSOC, V278, P1093, DOI 10.1001/jama.278.13.1093.
   Pegues CF, 1996, INFECT CONT HOSP EP, V17, P412.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   Wurtz R, 1996, INFECT CONT HOSP EP, V17, P409.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{34}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{475QU}},
Unique-ID = {{ISI:000171176200010}},
DA = {{2018-08-13}},
}

@article{ ISI:000170414400008,
Author = {Ruspantini, I and Diociaiuti, M and Ippoliti, R and Lendaro, E and
   Gaudiano, MC and Cianfriglia, M and Chistolini, P and Arancia, G and
   Molinari, A},
Title = {{Immunogold localisation of P-glycoprotein in supported lipid bilayers by
   transmission electron microscopy and atomic force microscopy}},
Journal = {{HISTOCHEMICAL JOURNAL}},
Year = {{2001}},
Volume = {{33}},
Number = {{5}},
Pages = {{305-309}},
Month = {{MAY}},
Abstract = {{In this study, purified P-glycoprotein molecules, a membrane drug pump
   responsible for the multidrug resistance phenomenon, were incorporated
   in model membranes deposited onto solid supports, according to the
   method described by Puu and Gustafson (1997). The insertion of proteins
   into planar supported model membranes is of interest, as the films are
   fundamental in biosensor applications and for the investigation of how
   proteins conform and aggregate in a lipid environment. In our
   investigation, two model membranes were prepared by transferring
   liposomes containing P-glycoprotein to different hydrophobic supports:
   (a) thin amorphous carbon films; (b) Langmuir-Blodgett lipid monolayers
   on mica. After the labelling of P-glycoprotein with two
   well-characterised monoclonal antibodies, MM4.17 and MRK-16, samples (a)
   were observed by transmission electron microscopy (TEM) and samples (b)
   by atomic force microscopy (AFM).
   The comparative analysis performed by TEM and AFM allowed us to
   demonstrate the successful insertion of P-glycoprotein in the model
   membranes and their stability under different environmental conditions
   (vacuum, air and water). P-glycoprotein appeared to maintain, after
   purification and insertion in lipid bilayers, a good part of its
   conformational features as shown by the P-glycoprotein segments bearing
   the specific monoclonal antibody epitopes.}},
Publisher = {{KLUWER ACADEMIC PUBL}},
Address = {{SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Molinari, A (Reprint Author), Ist Super Sanita, Ultrastrutture Lab, Viale Regina Elena 299, I-00161 Rome, Italy.
   Ist Super Sanita, Ultrastrutture Lab, I-00161 Rome, Italy.
   Ist Super Sanita, Lab Ingn Biomed, I-00161 Rome, Italy.
   Ist Super Sanita, Lab Chim Farmaco, I-00161 Rome, Italy.
   Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy.
   Univ Roma La Sapienza, Dipartimento Sci Biochim, I-00185 Rome, Italy.}},
DOI = {{10.1023/A:1017933225226}},
ISSN = {{0018-2214}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE; MONOCLONAL-ANTIBODY; EPITOPE; RECONSTITUTION;
   EXPRESSION; LIPOSOMES; PROTEINS; CELLS}},
Research-Areas = {{Cell Biology}},
Web-of-Science-Categories  = {{Cell Biology}},
ResearcherID-Numbers = {{Molinari, Agnese/E-7588-2015
   RUSPANTINI, IRENE/E-6670-2015
   }},
ORCID-Numbers = {{Molinari, Agnese/0000-0002-9592-5465
   RUSPANTINI, IRENE/0000-0002-9780-0682
   DIOCIAIUTI, MARCO/0000-0002-0749-2824
   IPPOLITI, RODOLFO/0000-0003-0652-3470}},
Cited-References = {{CIANFRIGLIA M, 1994, INT J CANCER, V56, P153.
   Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875.
   EPPELL SJ, 1995, BIOPHYS J, V68, P671, DOI 10.1016/S0006-3495(95)80228-6.
   GEORGES E, 1993, J BIOL CHEM, V268, P1792.
   GOLDSTEIN LJ, 1992, CRIT REV ONCOL HEMAT, V12, P243, DOI 10.1016/1040-8428(92)90057-W.
   Higgins CF, 1997, SEMIN CANCER BIOL, V8, P135, DOI 10.1006/scbi.1997.0067.
   JACHEZ B, 1994, ANTI-CANCER DRUG, V5, P655, DOI 10.1097/00001813-199412000-00008.
   Jones PM, 2000, EUR J BIOCHEM, V267, P5298, DOI 10.1046/j.1432-1327.2000.01628.x.
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7.
   Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482.
   Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908.
   MOLINARI A, 1994, INT J CANCER, V59, P789, DOI 10.1002/ijc.2910590614.
   Puu G, 1997, BBA-BIOMEMBRANES, V1327, P149, DOI 10.1016/S0005-2736(97)00052-7.
   RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V.
   Roberts G, 1990, LANGMUIR BLODGETT FI.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Histochem.J.}},
Doc-Delivery-Number = {{462HJ}},
Unique-ID = {{ISI:000170414400008}},
DA = {{2018-08-13}},
}

@article{ ISI:000168323300018,
Author = {Guerrero, A and Torres, P and Duran, MT and Ruiz-Diez, B and Rosales, M
   and Rodriguez-Tudela, JL},
Title = {{Airborne outbreak of nosocomial Scedosporium prolificans infection}},
Journal = {{LANCET}},
Year = {{2001}},
Volume = {{357}},
Number = {{9264}},
Pages = {{1267-1268}},
Month = {{APR 21}},
Abstract = {{We describe six inpatients with acute non-lymphocytic leukaemia who
   developed invasive infection with Scedosporium prolificans resistant to
   amphotericin B, flucytosine, ketoconazole, fluconazole, and
   itraconazole, All six patients died. Phenotypic and genotypic assessment
   of samples from clinical material and ambient air from the isolation
   rooms where the patients were being treated showed that the epidemic was
   caused by a single strain. After implementation of aerial control
   measures, there were no further infections with this organism. We
   conclude that fatal multidrug-resistant S prolificans epidemics can be
   aerially transmitted and can be prevented with implementation of
   appropriate infection-control measures.}},
Publisher = {{LANCET LTD}},
Address = {{84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Guerrero, A (Reprint Author), Complexo Hosp Juan Canalejo, Microbiol Serv, Dept Microbiol, Xubias de Arriba S-N, A Coruna 15006, Spain.
   Complexo Hosp Juan Canalejo, Microbiol Serv, Dept Microbiol, A Coruna 15006, Spain.
   Complexo Hosp Juan Canalejo, Dept Haematol, A Coruna 15006, Spain.
   Complexo Hosp Juan Canalejo, Dept Prevent Med, A Coruna 15006, Spain.
   Inst Salud Carlos III, Dept Mycol, Madrid, Spain.}},
DOI = {{10.1016/S0140-6736(00)04423-8}},
ISSN = {{0140-6736}},
Keywords-Plus = {{DNA}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
ResearcherID-Numbers = {{Duran-Valle, MTeresa/B-7957-2016}},
ORCID-Numbers = {{Duran-Valle, MTeresa/0000-0002-4432-9313}},
Cited-References = {{Berenguer J, 1997, MEDICINE, V76, P256, DOI 10.1097/00005792-199707000-00004.
   Bowman Barbara H., 1993, P423.
   RuizDiez B, 1997, CURR MICROBIOL, V35, P186, DOI 10.1007/s002849900236.
   SanMillan R, 1997, J CLIN MICROBIOL, V35, P2270.
   VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Lancet}},
Doc-Delivery-Number = {{425YY}},
Unique-ID = {{ISI:000168323300018}},
DA = {{2018-08-13}},
}

@article{ ISI:000166720400018,
Author = {Lee, MH and Lee, HJ and Ryu, PD},
Title = {{Public health risks: Chemical and antibiotic residues - Review}},
Journal = {{ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES}},
Year = {{2001}},
Volume = {{14}},
Number = {{3}},
Pages = {{402-413}},
Month = {{MAR}},
Note = {{APEC China Seminar on Public Health Issues in Animal Production/Animal
   Products, BEIJING, PEOPLES R CHINA, OCT 15-19, 2000}},
Abstract = {{Food safety is a term broadly applied to food quality that may adversely
   affect human health. These include zoonotic diseases and acute and
   chronic effects of ingesting natural and human-made xenobiotics. There
   are two major areas of concern over the presence of residues of
   antibiotics in animal-derived foodstuffs with regard to human health.
   The first is allergic reactions. Some antibiotics, such as penicillins
   can evoke allergic reactions even though small amounts of them are
   ingested or exposed by parenteral routes. The second is development of
   antibiotic resistance in gut bacteria of human. Recently multi-resistant
   pneumococcal, glycopeptide-resistant enterococci and gram negative
   bacteria with extended-spectrum p-lactamases have spread all over the
   world, and are now a serious therapeutic problem in human. Although it
   is evident that drugs are required in the efficient production of meat,
   milk and eggs, their indiscriminate use should never be substituted for
   hygienic management of farm. Drug should be used only when they are
   required. In addition to veterinary drugs, environmental contaminants
   that were contaminated in feed, water and air can make residues in
   animal products. Mycotoxins, heavy metals, pesticides, herbicides and
   other chemicals derived from industries can be harmful both to animal
   and human health. Most of organic contaminants, such as dioxin, PCBs and
   DDT, and metals are persistent in environment and biological organisms
   and can be accumulated in far and hard tissues. Some of them are
   suspected to have endocrine disrupting, carcinogenic, teratogenic,
   immunodepressive and nervous effects. The governmental agencies
   concerned make efforts to prevent residue problems; approval of drugs
   including withdrawal times of each preparation of drugs, establishment
   of tolerances, guidelines regarding drug use and sanitation enforcement
   of livestock products. National residue program is conducted to audit
   the status of the chemical residues in foods. Recently HACCP has been
   introduced to promote food safety from farm to table by reducing
   hazardous biological, chemical and physical factors. Animal Production
   Food Safety Program, Quality Assurance Programs, Food Animal Residue
   Avoidance Databank are para- or non-governmental activities ensuring
   food safety. This topic will cover classification and usage or sources
   of chemical residues, their adverse effects, and chemical residue status
   of some countries. Issues are expanded to residue detection
   methodologies, toxicological and pharmacokinetic backgrounds of MRL and
   withdrawal time establishments, and the importance of non-governmental
   activities with regard to reducing chemical residues in food.}},
Publisher = {{ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOCIETIES}},
Address = {{COLLEGE AGRICULTURE LIFE SCIENCES, DEPT ANIMAL SCIENCE TECHNOLOGY, SUWON
   441-744, SOUTH KOREA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Ryu, PD (Reprint Author), Seoul Natl Univ, Coll Vet Med, Pharmacol Lab, 103 Seodundong, Suwon 441744, South Korea.
   Seoul Natl Univ, Coll Vet Med, Pharmacol Lab, Suwon 441744, South Korea.
   Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea.}},
DOI = {{10.5713/ajas.2001.402}},
ISSN = {{1011-2367}},
Keywords = {{tissue residue; MRLs; withdrawal times; risk assessment}},
Keywords-Plus = {{DRUG RESIDUES; FOOD ANIMALS}},
Research-Areas = {{Agriculture}},
Web-of-Science-Categories  = {{Agriculture, Dairy \& Animal Science}},
Cited-References = {{{*}AM HOSP FORM SERV, 1998, AHFS DRUG INF.
   APPELBAUM PC, 1999, 2 INT S ANT RES ANSO.
   BATES J, 1993, LANCET, V342, P490, DOI 10.1016/0140-6736(93)91613-Q.
   BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507.
   BEVILL RF, 1989, JAVMA, V202, P1723.
   Craigmill A.L., 1994, HDB COMP PHARMACOKIN.
   CRAIGMILL AL, 1996, P INT S FOOD HYG SAF.
   CRISP TM, 1998, ENV HLTH PERSPECT S1, V106.
   CROSS HR, 1996, P INT S EST FOOD SAF.
   {*}DEP LIV MAN MIN A, 1997, COD VET DRUG REG.
   {*}DEP LIV MAN MIN A, 1997, COD AN FEED REG.
   KINDRED TP, 1993, J AM VET MED ASSOC, V202, P46.
   {*}KOR FOOD DRUG ADM, 1997, COD FOOD STAND.
   Lee HJ, 2000, ASIAN AUSTRAL J ANIM, V13, P1604, DOI 10.5713/ajas.2000.1604.
   Lee HJ, 2000, ASIAN AUSTRAL J ANIM, V13, P1775, DOI 10.5713/ajas.2000.1775.
   Lee HJ, 2001, ASIAN AUSTRAL J ANIM, V14, P378, DOI 10.5713/ajas.2001.378.
   LEEMPUT LV, 1994, P POST C WORKSH 6 IN.
   MERCER HD, 1990, COMP CONT EDUC PRACT, V12, P124.
   RIVIERE JE, 1991, J AM VET MED ASSOC, V198, P809.
   RIVIERE JE, 1992, AGRI-PRACTICE, V13, P11.
   Riviere JE, 1995, VET PHARM THERAPEUTI.
   SUNDLOF SF, 1992, FOOD ANIMAL RESIDUE.
   SUNDLOF SF, 1989, VET CLIN N AM-FOOD A, V5, P441.
   VANDRESSER WR, 1989, J AM VET MED ASSOC, V194, P1700.
   WILLIAMSON R, 1989, MED MICRBIOL LETT, V1, P11.
   1988, CTR VET MED GUIDELIN.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{41}},
Usage-Count-Last-180-days = {{3}},
Usage-Count-Since-2013 = {{59}},
Journal-ISO = {{Asian Australas. J. Anim. Sci.}},
Doc-Delivery-Number = {{397WG}},
Unique-ID = {{ISI:000166720400018}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000167087600011,
Author = {Jimenez-Arribas, G and Leautaud, V and Amabile-Cuevas, CF},
Title = {{Regulatory locus soxRS partially protects Escherichia coli against ozone}},
Journal = {{FEMS MICROBIOLOGY LETTERS}},
Year = {{2001}},
Volume = {{195}},
Number = {{2}},
Pages = {{175-177}},
Month = {{FEB 20}},
Abstract = {{Ozone is one of the major city air pollutants. Since it is known to
   induce the overexpression of superoxide-dismutase in various models, and
   is also a powerful oxidant, we tested if ozone can induce the expression
   of the soxRS regulon of Escherichia coli, which is activated by
   superoxide and nitric oxide. A sub-lethal exposure to ozone was unable
   to activate the expression of soxS' :: lacZ transcriptional fusions.
   However, cells lacking the soxRS locus were more susceptible than
   wild-type to ozone-mediated killing. Constitutive expression of the
   soxRS did not increase the resistance to ozone. Ozone might be exerting
   a selective pressure upon oxidative-stress defense mechanisms in
   airborne bacteria. (C) 2001 Federation of European Microbiological
   Societies. Published by Elsevier Science B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Amabile-Cuevas, CF (Reprint Author), Fdn LUSARA, POB 102-006, Mexico City 08930, DF, Mexico.
   Fdn LUSARA, Mexico City 08930, DF, Mexico.}},
DOI = {{10.1016/S0378-1097(01)00007-6}},
ISSN = {{0378-1097}},
Keywords = {{Escherichia coli; ozone; soxRS locus}},
Keywords-Plus = {{MULTIPLE ANTIBIOTIC-RESISTANCE; OXIDATIVE STRESS REGULON;
   SUPEROXIDE-DISMUTASE; GENES; INACTIVATION; ACTIVATION; INDUCTION;
   CATALASE; CENTERS}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Cited-References = {{AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479.
   BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8.
   DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531.
   DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3.
   EZCURRA E, 1991, CIENCIAS, V22, P41.
   Fisher CW, 2000, APPL ENVIRON MICROB, V66, P1405, DOI 10.1128/AEM.66.4.1405-1409.2000.
   Fuentes AM, 1997, FEMS MICROBIOL LETT, V154, P385, DOI 10.1111/j.1574-6968.1997.tb12671.x.
   Fuentes AM, 1998, MICROBIOL-SGM, V144, P1731, DOI 10.1099/00221287-144-7-1731.
   Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082.
   GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181.
   Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4.
   Jair KW, 1996, MOL MICROBIOL, V19, P307, DOI 10.1046/j.1365-2958.1996.368893.x.
   Miller J. H., 1992, SHORT COURSE BACTERI.
   MILLER PF, 1994, ANTIMICROB AGENTS CH, V38, P1773, DOI 10.1128/AAC.38.8.1773.
   NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054.
   NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794.
   NUNOSHIBA T, 1993, CANCER RES, V53, P3250.
   PRYOR WA, 1993, J LAB CLIN MED, V122, P483.
   SEINFELD JH, 1989, SCIENCE, V243, P745, DOI 10.1126/science.243.4892.745.
   VICTORIN K, 1992, MUTAT RES, V277, P221, DOI 10.1016/0165-1110(92)90045-B.
   WHITESIDE C, 1987, ARCH BIOCHEM BIOPHYS, V257, P464, DOI 10.1016/0003-9861(87)90591-1.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{FEMS Microbiol. Lett.}},
Doc-Delivery-Number = {{404FW}},
Unique-ID = {{ISI:000167087600011}},
DA = {{2018-08-13}},
}

@article{ ISI:000166992500011,
Author = {Souilamas, R and Riquet, M and Barthes, FL and Chehab, A and Capuani, A
   and Faure, E},
Title = {{Surgical treatment of active and sequelar forms of pulmonary
   tuberculosis}},
Journal = {{ANNALS OF THORACIC SURGERY}},
Year = {{2001}},
Volume = {{71}},
Number = {{2}},
Pages = {{443-447}},
Month = {{FEB}},
Abstract = {{Background. The incidence of tuberculosis has risen since 1990, and in
   some countries, the resistant forms are becoming more and more frequent.
   Surgical treatment is once again needed to manage these problems. The
   purpose of this study was to analyze the indications and results of
   resection, which we performed for pulmonary tuberculosis.
   Methods. From 1980 to 1997, 477 patients were operated on for thoracic
   or intrathoracic tuberculosis in Laennec Hospital, Paris (259 suffered
   lung diseases). There were 165 women and 94 men, aged 25 to 86 years
   (mean 46 years), from Europe (n = 148), North Africa (n = 65),
   Subsaharian Africa (n = 34), Asia (n = 7), and the West Indies (n = 5).
   This population was reviewed concerning the lung tuberculosis (sequelae
   or active lesions), the indications of lung resection, the type of
   resections performed, and the results at 1, 6, and 12 months.
   Results. Active lesions were present in 97 eases and sequelae in 162.
   Surgery was performed for a therapeutic purpose in 104 patients with
   sequelae, and in 10 patients with active tuberculosis (pneumonectomy, n
   = 19; pleuropneumonectomy, n = 19; lobectomy, n = 54; and segmentectomy,
   n = 22), Surgery was performed for a diagnostic purpose in 54 patients
   with sequelae, and in 87 patients with active lesions (lobectomy, n =
   32; segmentectomy, n = 19; wedge resection, n = 94, of which 11
   performed by video-assisted thoracoscopy since 1991). One patient died
   after pleuropneumonectomy. We observed 25 complications: empyema, n =
   7;hemothorax, n = 2; prolonged air leaks, n = 14; and pneumopathy, n 2.
   All patients with active lesions subsequently were given antitubercular
   drugs. Follow-up was 100\% at 1 month, 57\% (n = 92) and 77\% (n = 75)
   at 6 months for patients with sequelae and for patients with active
   lesions, respectively. All were asymptomatic with a normal chest
   roentgenogram. The number of operations for active lesions is increasing
   over the years, while it is decreasing for sequelar lesions.
   Conclusions. In our department, surgery is being performed more
   frequently to make a diagnosis in cases of active tuberculosis, and to
   treat complicated lesions in case of sequelae. Lung resection for active
   tuberculosis evolving under treatment or for drug resistance was rare.
   However, our study confirms the good results commonly obtained by
   surgery and supports the idea that surgery may help eradicate
   tuberculosis when social and economic circumstances render its medical
   management difficult or hazardous. (C) 2001 by The Society of Thoracic
   Surgeons.}},
Publisher = {{ELSEVIER SCIENCE INC}},
Address = {{655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Riquet, M (Reprint Author), Hop Laennec, Dept Chirurg Thorac, 42 Rue Sevres, F-75007 Paris, France.
   Hop Laennec, Dept Thorac Surg, F-75007 Paris, France.}},
DOI = {{10.1016/S0003-4975(00)02377-8}},
ISSN = {{0003-4975}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS; SURGERY; EXPERIENCE; RESECTION}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
ORCID-Numbers = {{Le Pimpec-Barthes, Francoise/0000-0001-6364-4813}},
Cited-References = {{Ashour M, 1997, EUR J CARDIO-THORAC, V12, P209, DOI 10.1016/S1010-7940(97)00155-3.
   BRECHOT JM, 1995, PRESSE MED, V24, P931.
   Debrosse D, 1995, REV MAL RESPIR, V12, P459.
   Haas C, 1995, PRESSE MED, V24, P1911.
   HRUBAN RH, 1994, PULMONARY PATHOLOGY, P331.
   HUBERT B, 1995, MED THER, V1, P7.
   ISHIDA T, 1992, RESP MED, V86, P431, DOI 10.1016/S0954-6111(06)80011-9.
   Kir A, 1997, EUR J CARDIO-THORAC, V12, P531, DOI 10.1016/S1010-7940(97)00230-3.
   MCLAUGHLIN JS, 1974, ANN THORAC SURG, V17, P513, DOI 10.1016/S0003-4975(10)65689-5.
   MOUROUX J, 1995, J THORAC CARDIOVASC, V110, P1.
   Perelman MI, 1997, WORLD J SURG, V21, P457, DOI 10.1007/PL00012270.
   Pomerantz M, 1995, Semin Thorac Cardiovasc Surg, V7, P108.
   REED CE, 1989, ANN THORAC SURG, V48, P165, DOI 10.1016/0003-4975(89)90062-3.
   RIBET M, 1994, REV MAL RESPIR, V11, P437.
   Riquet M, 1998, ANN THORAC SURG, V66, P1824, DOI 10.1016/S0003-4975(98)00963-1.
   RIZZI A, 1995, ANN THORAC SURG, V59, P896, DOI 10.1016/0003-4975(95)00011-9.
   TCHAKAMIAN S, 1995, BEH, V52, P225.
   TREASURE RL, 1995, ANN THORAC SURG, V59, P1405, DOI 10.1016/0003-4975(95)00145-B.
   VanLeuven M, 1997, ANN THORAC SURG, V63, P1368.
   WHYTE RI, 1989, RESP MED, V83, P357, DOI 10.1016/S0954-6111(89)80213-6.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Thorac. Surg.}},
Doc-Delivery-Number = {{402MQ}},
Unique-ID = {{ISI:000166992500011}},
DA = {{2018-08-13}},
}

@article{ ISI:000168097700005,
Author = {Carlisle, JB and Gratten, M and Leach, AJ},
Title = {{Molecular epidemiology of multiple drug resistant type 6B Streptococcus
   pneumoniae in the Northern Territory and Queensland, Australia}},
Journal = {{EPIDEMIOLOGY AND INFECTION}},
Year = {{2001}},
Volume = {{126}},
Number = {{1}},
Pages = {{25-29}},
Month = {{FEB}},
Abstract = {{The emergence of type 6B Streptococcus pneumoniae resistant to five
   antibiotics (penicillin, chloramphenicol,
   trimethoprim-sulphamethoxazole, erythromycin and tetracycline) in both
   the Northern Territory and Queensland prompted an investigation of the
   genetic relatedness and patterns of migration of the isolates. Pulsed
   field gel electrophoresis of genomic DNA of 74 multiple drug-resistant
   (MDR) isolates cultured in both regions between August 1988 and June
   1997 showed that 100 \% of MDR isolates from the Northern Territory and
   96 \% of MDR strains from Queensland were genetically indistinguishable
   or closely related to the index strain. None of a further 65 type 6B
   isolates that were resistant to one or two, or susceptible to all of the
   above antibiotics, were clonally related to the MDR pneumococci. The
   geographical distribution of the MDR type 6B clone increased over time.
   The index strain, first isolated in Darwin in August 1988, was
   identified in Brisbane, 2900 km distant, less than 4 years later and
   subsequently in other Queensland centres. Surveillance programmes are
   important to monitor the emergence and spread of potentially invasive
   MDR pneumococcal clones in countries that are well serviced by air and
   road transport.}},
Publisher = {{CAMBRIDGE UNIV PRESS}},
Address = {{32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Carlisle, JB (Reprint Author), Queensland Hlth Sci Serv, PO 594, Archerfield, Qld 4108, Australia.
   Queensland Hlth Sci Serv, Brisbane, Qld, Australia.
   Menzies Sch Hlth Res, Casuarina, NT, Australia.}},
ISSN = {{0950-2688}},
EISSN = {{1469-4409}},
Keywords-Plus = {{FIELD GEL-ELECTROPHORESIS; MULTIRESISTANT CLONE; DNA; SUSCEPTIBILITY;
   ACQUISITION; PENICILLIN; CARRIAGE; STRAINS}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   Eskola J, 1999, PEDIATR INFECT DIS J, V18, P543, DOI 10.1097/00006454-199906000-00015.
   Gratten M, 1996, J CLIN MICROBIOL, V34, P338.
   GRATTEN M, 1986, BIOL NEONATE, V50, P114.
   Gratten M, 1997, Commun Dis Intell, V21, P133.
   GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923.
   JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402.
   KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171.
   LEACH AJ, 1995, COMMUN DIS INTELL, V19, P134.
   LEFEVRE JC, 1993, J CLIN MICROBIOL, V31, P2724.
   Lund E., 1978, METHOD MICROBIOL, V12, P241.
   Matushek MG, 1996, J CLIN MICROBIOL, V34, P2598.
   Moissenet D, 1997, J CLIN MICROBIOL, V35, P298.
   MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302.
   {*}NAT COMM CLIN LAB, 1995, M100S6 NAT COMM CLIN.
   NESIN M, 1997, INT J INFECT DIS, V2, P91.
   RADETSKY MS, 1981, LANCET, V2, P771.
   SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158.
   Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   Yoshida R, 1997, EPIDEMIOL INFECT, V118, P105, DOI 10.1017/S0950268896007273.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{5}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Epidemiol. Infect.}},
Doc-Delivery-Number = {{422BH}},
Unique-ID = {{ISI:000168097700005}},
OA = {{green\_published}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000176065600098,
Author = {Ruspantini, I and Diociaiuti, M and Molinari, A and Chistolini, P},
Editor = {{Magjarevic, R and Tonkovic, S and Bilas, V and Lackovic, I}},
Title = {{Characterization of a supported model lipid membrane incorporating
   transmembrane proteins: An aim study}},
Booktitle = {{MEDICON 2001: PROCEEDINGS OF THE INTERNATIONAL FEDERATION FOR MEDICAL \&
   BIOLOGICAL ENGINEERING, PTS 1 AND 2}},
Year = {{2001}},
Pages = {{332-335}},
Note = {{9th Mediterranean Conference on Medical and Biological Engineering and
   Computing, PULA, CROATIA, JUN 12-15, 2001}},
Organization = {{Croatian Med \& Biol Engn Soc; Int Federat Med \& Biol Engn; Minist Sci
   \& Technol Republ Croatia; Univ Zagreb; Croatian Med Assoc; Assoc
   Italiana Ingegner Med \& Biol; Cyprus Assoc Med Phys \& Biomed Engn;
   Greek Soc Biomed Engn; Israel Soc Med \& Biol Engn; Slovenian Soc Med \&
   Biol Engn; Soc Electriciens \& Electroniciens Francais; Spanish Soc
   Biomed Engn}},
Abstract = {{Supported lipid bilayers have found an interesting application in
   biosensors technology as they act as a suitable lipid environment for
   sensing biomolecules, such as proteins. The stability and uniformity of
   the supported lipid membranes, and the persistence of the incorporated
   biomolecules are key features in biosensors engineering. In this study
   Atomic Force Microscopy was employed to characterize, in air and liquid,
   a model membrane obtained by transferring liposomes to a micasupported
   lipid monolayer. The liposomes contained or not a multidrug resistant
   transmembrane protein, the P-glycoprotein. Our results show a higher
   uniformity and stability in protein-containing model membranes.}},
Publisher = {{UNIV ZAGREB}},
Address = {{P O BOX 327, 41001 ZAGREB, CROATIA}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Ruspantini, I (Reprint Author), Ist Super Sanita, Biomed Engn Lab, Rome, Italy.
   Ist Super Sanita, Biomed Engn Lab, Rome, Italy.}},
ISBN = {{953-184-023-7}},
Keywords-Plus = {{ATOMIC-FORCE MICROSCOPY; P-GLYCOPROTEIN; SOLID SUPPORTS; BILAYERS;
   RECONSTITUTION; STABILITY; LIPOSOMES}},
Research-Areas = {{Engineering; Medical Informatics}},
Web-of-Science-Categories  = {{Engineering, Biomedical; Medical Informatics}},
Cited-References = {{CIANFRIGLIA M, 1994, INT J CANCER, V56, P153.
   Dong MQ, 1996, J BIOL CHEM, V271, P28875, DOI 10.1074/jbc.271.46.28875.
   EPPELL SJ, 1995, BIOPHYS J, V68, P671, DOI 10.1016/S0006-3495(95)80228-6.
   Hollars CW, 1998, BIOPHYS J, V75, P342, DOI 10.1016/S0006-3495(98)77518-6.
   JAP BK, 1992, ULTRAMICROSCOPY, V46, P45, DOI 10.1016/0304-3991(92)90007-7.
   KELLER CA, 1999, PHYS REV LETT, V84, P5433.
   Puu G, 1997, BBA-BIOMEMBRANES, V1327, P149, DOI 10.1016/S0005-2736(97)00052-7.
   Puu G, 2000, BIOSENS BIOELECTRON, V15, P31, DOI 10.1016/S0956-5663(00)00050-6.
   Reviakine I, 2000, LANGMUIR, V16, P1806, DOI 10.1021/la9903043.
   RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V.
   Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43.
   VESENKA J, 1995, BIOTECHNIQUES, V19, P240.
   VIKHOLM I, 1995, BBA-BIOMEMBRANES, V1233, P111, DOI 10.1016/0005-2736(94)00221-A.}},
Number-of-Cited-References = {{13}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BU46P}},
Unique-ID = {{ISI:000176065600098}},
DA = {{2018-08-13}},
}

@article{ ISI:000166029700004,
Author = {Seelig, A and Landwojtowicz, E},
Title = {{Structure-activity relationship of P-glycoprotein substrates and
   modifiers}},
Journal = {{EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES}},
Year = {{2000}},
Volume = {{12}},
Number = {{1}},
Pages = {{31-40}},
Month = {{NOV}},
Abstract = {{The air-water partition coefficients, K-aw, highly correlated with the
   corresponding lipid-water partition coefficients, K-iw, and the critical
   micelle concentrations. CMC, were measured for 11 compounds for which
   the kinetic parameters of P-glycoprotein ATPase activation
   (Michaelis-Menten constant, K-m, and maximal velocity, V-max) had been
   determined previously in inside-out vesicles of CR1R12 Chinese hamster
   ovary cells. In addition, the hydrogen bond donor patterns (type I and
   type II) relevant for substrate recognition by P-glycoprotein were
   determined from the energy-minimized three-dimensional structure of
   these compounds. A linear relation between the air-water partition
   coefficient, K-aw, and the inverse of the Michaelis-Menten constant,
   K-m, was observed such that K-m-K(aw)similar to1. The maximal velocity,
   V-max, was shown to decrease with the number and strength of electron
   donor (hydrogen bond acceptor) groups in recognition patterns. If two
   substrates are applied simultaneously to P-glycoprotein the compound
   with the higher potential to form hydrogen bonds generally acts as an
   inhibitor. We conclude that partitioning into the lipid membrane is the
   rate-limiting step for the interaction of a substrate with
   P-glycoprotein and that dissociation of the P-glycoprotein-substrate
   complex is determined by the number and strength of the hydrogen bonds
   formed between the substrate and the transporter. (C) 2000 Elsevier
   Science BN. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Seelig, A (Reprint Author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.
   Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland.}},
DOI = {{10.1016/S0928-0987(00)00177-9}},
ISSN = {{0928-0987}},
Keywords = {{P-glycoprotein; multidrug resistance; Michaelis-Menten constant, K-m;
   maximal velocity, V-max; drug transport; P-gp ATPase activation;
   competitive binding; hydrogen bond formation}},
Keywords-Plus = {{BLOOD-BRAIN-BARRIER; MODULATE MULTIDRUG RESISTANCE; ATPASE ACTIVITY;
   CELL-LINES; PHARMACOLOGICAL ACTIVITY; HYDROPHOBIC PEPTIDES; DRUG
   TRANSPORT; REVERSAL; ANALOGS; VINBLASTINE}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{AKIYAMA SI, 1988, MOL PHARMACOL, V33, P144.
   Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361.
   Benet LZ, 1999, J CONTROL RELEASE, V62, P25, DOI 10.1016/S0168-3659(99)00034-6.
   BESCHIASCHVILI G, 1992, BIOCHEMISTRY-US, V31, P10044, DOI 10.1021/bi00156a026.
   Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4.
   Budworth J, 1996, BRIT J CANCER, V73, P1063, DOI 10.1038/bjc.1996.205.
   BURKERT U, 1982, ACS MONOGRAPH, V177.
   Chiba P, 1997, ARCH PHARM, V330, P343, DOI 10.1002/ardp.19973301105.
   DESCOTEAUX S, 1992, MOL BIOCHEM PARASIT, V54, P201, DOI 10.1016/0166-6851(92)90112-W.
   ECKER G, 1995, WIEN KLIN WOCHENSCHR, V107, P681.
   Ecker G, 1999, MOL PHARMACOL, V56, P791.
   Fischer H, 1998, J MEMBRANE BIOL, V165, P201, DOI 10.1007/s002329900434.
   FORD JM, 1990, CANCER RES, V50, P1748.
   FORD JM, 1989, MOL PHARMACOL, V35, P105.
   Gordeliy VI, 1998, BIOPHYS J, V75, P2343, DOI 10.1016/S0006-3495(98)77678-7.
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125.
   JACOB SW, 1986, CRYOBIOLOGY, V23, P14, DOI 10.1016/0011-2240(86)90014-3.
   Letrent SP, 1999, BIOCHEM PHARMACOL, V58, P951, DOI 10.1016/S0006-2952(99)00180-X.
   Litman T, 1997, BBA-MOL BASIS DIS, V1361, P147, DOI 10.1016/S0925-4439(97)00025-2.
   Litman T, 1997, BBA-MOL BASIS DIS, V1361, P169, DOI 10.1016/S0925-4439(97)00027-6.
   Litman T, 1997, BBA-MOL BASIS DIS, V1361, P159, DOI 10.1016/S0925-4439(97)00026-4.
   Meijer DKF, 1999, NEPHROL DIAL TRANSPL, V14, P1.
   MIYAUCHI S, 1992, BIOCHIM BIOPHYS ACTA, V1110, P144, DOI 10.1016/0005-2736(92)90351-L.
   Orlowski S, 1998, Cancer Biochem Biophys, V16, P85.
   PEARCE HL, 1989, P NATL ACAD SCI USA, V86, P5128, DOI 10.1073/pnas.86.13.5128.
   Putman M, 1999, BIOCHEMISTRY-US, V38, P13900, DOI 10.1021/bi991262k.
   Rosen M. J., 1989, SURFACTANTS INTERFAC.
   SARKADI B, 1994, FASEB J, V8, P766.
   Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699.
   Seelig A, 2000, INT J CLIN PHARM TH, V38, P111.
   Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x.
   SEELIG A, 1994, P NATL ACAD SCI USA, V91, P68, DOI 10.1073/pnas.91.1.68.
   Seelig A, 1998, INT J CLIN PHARM TH, V36, P50.
   SHARMA RC, 1992, J BIOL CHEM, V267, P5731.
   Sharom FJ, 1996, BIOCHEM J, V320, P421, DOI 10.1042/bj3200421.
   Stein WD, 1997, PHYSIOL REV, V77, P545.
   TANFORD C, 1987, Biochemical Society Transactions, V15, p1S.
   TANGWAI DF, 1993, BIOCHEMISTRY-US, V32, P6470, DOI 10.1021/bi00076a022.
   THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300.
   THIMMAIAH KN, 1990, CANCER COMMUN, V2, P249.
   TOFFOLI G, 1995, BIOCHEM PHARMACOL, V50, P1245, DOI 10.1016/0006-2952(95)02003-U.
   UEDA K, 1992, J BIOL CHEM, V267, P24248.
   Vinogradov S, 1971, HYDROGEN BONDING.
   ZAMORA JM, 1988, MOL PHARMACOL, V33, P454.
   ZHANG L, 1994, J BIOL CHEM, V269, P15973.
   ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{218}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{Eur. J. Pharm. Sci.}},
Doc-Delivery-Number = {{385XD}},
Unique-ID = {{ISI:000166029700004}},
DA = {{2018-08-13}},
}

@article{ ISI:000165279900006,
Author = {Niemeyer, DM and Jaffe, RI and Wiggins, LB},
Title = {{Feasibility determination for use of polymerase chain reaction in the US
   Air Force air-transportable hospital field environment: Lessons learned}},
Journal = {{MILITARY MEDICINE}},
Year = {{2000}},
Volume = {{165}},
Number = {{11}},
Pages = {{816-820}},
Month = {{NOV}},
Abstract = {{At present, the use of molecular probes and polymerase chain reaction
   (PCR) for the identification of microorganisms in body fluids or tissues
   is becoming more commonplace. There is an added advantage when
   serological or culture methods are difficult, expensive, or unavailable.
   Slow-growing or fastidious microorganisms, including Mycobacterium
   tuberculosis, spirochetes, viruses, and the dimorphic fungi, can be
   detected rapidly using these techniques. The presence of different
   chromosomal or plasmid-mediated antibiotic-resistant markers can also be
   determined. PCR is an extremely powerful tool that has been applied to
   research, and more recently it has been used to augment standard
   clinical applications. It is a very simple process that can amplify
   nucleic acid sequences, both DNA and RNA, a million times over. The
   sensitivity, rapidity, broad applicability, and compactness of this
   technology make it an ideal candidate for use in the military arena. we
   recently established a molecular biology laboratory at a Deployable
   Medical System at the Camp Parks Army Reserve Training Facility in
   Dublin, California. This article will briefly summarize the use of PCR
   and its applicability in the air-transportable hospital field
   environment. Proper handling, processing, and testing as well as the
   requirements for setting up a molecular biology laboratory Will be
   discussed. Finally, the benefits and disadvantages of using PCR-based
   techniques in the deployed field environment will be considered.}},
Publisher = {{ASSN MILITARY SURG US}},
Address = {{9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Niemeyer, DM (Reprint Author), USAF, Force Protect Battlelab, Lackland AFB, TX 78236 USA.
   USAF, Force Protect Battlelab, Lackland AFB, TX 78236 USA.}},
ISSN = {{0026-4075}},
Keywords-Plus = {{AMPLIFICATION; DNA}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{{*}AIR FORC OP TEST, 1999, FR99095 AIR FORC OP, P1.
   Belgrader P, 1998, CLIN CHEM, V44, P2191.
   {*}BETH RES LAB, 1984, FOCUS, V6, P7.
   Christel LA, 1999, J BIOMECH ENG-T ASME, V121, P22, DOI 10.1115/1.2798037.
   DEMPSEY M, 1999, VIP OP HOUS NELL AIR.
   HILYARD E, 1997, ANN M SAFMLS P, V21, P32.
   IBRAHIM S, 1995, MCMRUIDR701Z US ARM.
   {*}ID TECHN, 1999, RUGG ADV PATH ID DEV.
   JONES E, 1999, ANN M SAFMLS P, V23, P37.
   Koch WM, 1996, JNCI-J NATL CANCER I, V88, P1580, DOI 10.1093/jnci/88.21.1580.
   KULESH D, 1999, ANN M SAFMLS P, V23, P35.
   Lin Z, 1995, FORENSIC SCI INT, V75, P197, DOI 10.1016/0379-0738(95)01789-5.
   {*}MJ RES NOT, 1997, BIOM PROD B, V22, P1.
   NIEMEYER D, 1998, MIL MED, V168, P226.
   PODZORSKI R, 1995, MANUAL CLIN MICROBIO.
   {*}QIAG, 1995, QIAAMP BLOOD KIT QIA.
   RAMALINGASWAMI V, 1995, NAT MED, V1, P1237, DOI 10.1038/nm1295-1237.
   ROY R, 1995, J FORENSIC SCI, V40, P266.
   SINGH N, J ENV MOL MUTAGENESI.
   {*}TECHN, 1994, PROG THERM MAN.
   Wittwer CT, 1997, BIOTECHNIQUES, V22, P130.
   WOO T, 1997, J CLIN MICROBIOL, V335, P3140.
   WOODWARD SR, 1994, PCR METH APPL, V3, P244.
   WOOLLEN N, 1999, CONCEPT OPERATIONS T.
   YAMISCHPERRON C, 1985, GENE, V33, P103.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Milit. Med.}},
Doc-Delivery-Number = {{373GF}},
Unique-ID = {{ISI:000165279900006}},
DA = {{2018-08-13}},
}

@article{ ISI:000089838400006,
Author = {Osato, MS},
Title = {{Antimicrobial susceptibility testing for Helicobacter pylori:
   Sensitivity test results and their clinical relevance}},
Journal = {{CURRENT PHARMACEUTICAL DESIGN}},
Year = {{2000}},
Volume = {{6}},
Number = {{15}},
Pages = {{1545-1555}},
Month = {{OCT}},
Abstract = {{There are multiple test methodologies to determine the antibiogram of an
   organism. Standardized susceptibility test methods are based upon
   rapidly growing, aerobic microorganisms in which overnight incubation
   results in definitive endpoints. In vitro susceptibility testing for
   fastidious organisms that require complex media for growth, require
   incubation in atmospheres other than ambient air, or are slow-growing
   (anaerobes, mycobacteria, filamentous fungi) are problematic and in
   general are not standardized. H. pylori falls into this category of
   troublesome organisms. For the microaerobic organism H. pylori, testing
   is challenging because the organism grows slowly even under optimal
   culture conditions. Recently the National Committee for Clinical
   Laboratory Standards (NCCLS) approved the agar dilution method as the
   test of choice for testing H. pylori. While not entirely reliable in
   predicting the outcome of treatment for metronidazole resistant
   organisms, the resistance determined for clarithromycin by this method
   generally predicts treatment failure. Quality control breakpoints for H.
   pylori ATCC 43504 were established and breakpoints for clarithromycin
   were approved by the NCCLS in 1999. Breakpoints are minimum inhibitory
   concentrations (MIC) of a drug at which an organism is deemed either
   susceptible or resistant to the antibiotic using standard dosing
   regimens containing that drug. Significant progress has been made with
   respect to development of tests to detect antimicrobial resistance, but
   there still. remains no consensus as to the breakpoints for agents used
   in the treatment of H. pylori infection other than clarithromycin. This
   article will address the controversies associated with the reporting of
   antibiotic resistance data and the interpretation of these data.}},
Publisher = {{BENTHAM SCIENCE PUBL LTD}},
Address = {{PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Osato, MS (Reprint Author), Vet Affairs Med Ctr, Gastroenterol Microbiol Lab, 2002 Holcombe Blvd,Rm 3A-320, Houston, TX 77030 USA.
   Vet Affairs Med Ctr, Gastroenterol Microbiol Lab, Houston, TX 77030 USA.
   Baylor Coll Med, Houston, TX 77030 USA.}},
DOI = {{10.2174/1381612003399059}},
ISSN = {{1381-6128}},
Keywords-Plus = {{23S RIBOSOMAL-RNA; METRONIDAZOLE RESISTANCE; CLARITHROMYCIN RESISTANCE;
   ANTIBIOTIC-RESISTANCE; BROTH MICRODILUTION; AMOXICILLIN; STRAINS;
   ERADICATION; INFECTION; MUTATIONS}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{Adamek RJ, 1998, AM J GASTROENTEROL, V93, P386.
   AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137.
   Alarcon T, 1999, INT J ANTIMICROB AG, V12, P19, DOI 10.1016/S0924-8579(99)00051-5.
   Boyanova L, 1999, DIAGN MICR INFEC DIS, V35, P33, DOI 10.1016/S0732-8893(99)00039-5.
   Breuer T, 1999, AM J GASTROENTEROL, V94, P725.
   Covacci A, 1997, TRENDS MICROBIOL, V5, P205, DOI 10.1016/S0966-842X(97)01035-4.
   Debets-Ossenkopp YJ, 1999, J ANTIMICROB CHEMOTH, V43, P511, DOI 10.1093/jac/43.4.511.
   Donelli G, 1998, FEMS MICROBIOL LETT, V168, P9, DOI 10.1016/S0378-1097(98)00405-4.
   Dore MP, 1998, GASTROENTEROLOGY, V114, pA108.
   Dore MP, 1999, J ANTIMICROB CHEMOTH, V43, P47, DOI 10.1093/jac/43.1.47.
   Dore MP, 2000, DIGEST DIS SCI, V45, P68, DOI 10.1023/A:1005457226341.
   Dore MP, 1998, ALIMENT PHARM THERAP, V12, P635.
   EDWARDS DI, 1973, J GEN MICROBIOL, V76, P135, DOI 10.1099/00221287-76-1-135.
   Ellenrieder V, 1999, SCAND J GASTROENTERO, V34, P750.
   Glupczynski Y, 1998, ACTA GASTRO-ENT BELG, V61, P357.
   Goodwin A, 1998, MOL MICROBIOL, V28, P383, DOI 10.1046/j.1365-2958.1998.00806.x.
   HAAS R, 1993, MOL MICROBIOL, V8, P753, DOI 10.1111/j.1365-2958.1993.tb01618.x.
   Hachem CY, 1996, DIAGN MICR INFEC DIS, V24, P37, DOI 10.1016/0732-8893(95)00252-9.
   Houben MHMG, 1999, ALIMENT PHARM THERAP, V13, P883.
   Houben MHMG, 1999, ALIMENT PHARM THERAP, V13, P1047.
   KWON HY, 2000, UNPUB INT J ANTIMICR.
   LINDMARK DG, 1976, ANTIMICROB AGENTS CH, V10, P476, DOI 10.1128/AAC.10.3.476.
   Megraud F, 1999, ANTIMICROB AGENTS CH, V43, P2747.
   Megraud F, 1997, GASTROENTEROLOGY, V112, pA216.
   Megraud F, 1998, GUT, V43, pS61, DOI 10.1136/gut.43.2008.S61.
   Megraud F, 1998, BRIT MED BULL, V54, P207.
   Midolo PD, 1996, LANCET, V347, P1194, DOI 10.1016/S0140-6736(96)90657-1.
   {*}NAT COMM CLIN LAB, 1997, M27A NAT COMM CLIN L, P17.
   National Committee for Clinical Laboratory Standards, 1999, M100S9 NAT COMM CLIN.
   NOACH LA, 1994, SCAND J INFECT DIS, V26, P321, DOI 10.3109/00365549409011802.
   Osato MS, 1997, GASTROENTEROLOGY, V112, pA1057.
   Piccolomini R, 1997, J CLIN MICROBIOL, V35, P1842.
   Vakil N, 1998, AM J GASTROENTEROL, V93, P1432, DOI 10.1111/j.1572-0241.1998.455\_t.x.
   van der Hulst RWM, 1998, GUT, V42, P166, DOI 10.1136/gut.42.2.166.
   Versalovic J, 1997, J ANTIMICROB CHEMOTH, V40, P283, DOI 10.1093/jac/40.2.283.
   Versalovic J, 1996, ANTIMICROB AGENTS CH, V40, P477.
   VONRECKLINGHAUSEN G, 1995, ZBL BAKT-INT J MED M, V282, P83, DOI 10.1016/S0934-8840(11)80799-1.
   WANG Y, 1993, J GEN MICROBIOL, V139, P2485, DOI 10.1099/00221287-139-10-2485.
   Weiss K, 1998, CAN J GASTROENTEROL, V12, P181, DOI 10.1155/1998/765795.
   Williams SL, 1999, J CLIN MICROBIOL, V37, P304.
   Yamaguchi H, 1999, FEMS MICROBIOL LETT, V175, P107, DOI 10.1016/S0378-1097(99)00180-9.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Curr. Pharm. Design}},
Doc-Delivery-Number = {{363MA}},
Unique-ID = {{ISI:000089838400006}},
DA = {{2018-08-13}},
}

@article{ ISI:000167877500003,
Author = {Salzedo, E and Duca, S and Gianelli, M and Mutani, R},
Title = {{Quantitative MR (volumetry and relaxometry) in the study of temporal
   epilepsy}},
Journal = {{RIVISTA DI NEURORADIOLOGIA}},
Year = {{2000}},
Volume = {{13}},
Number = {{5}},
Pages = {{683-692}},
Month = {{OCT}},
Abstract = {{The most common neuropathologic lesion in patients with temporal
   epilepsy is hippocampal sclerosis, present in 50-70\% of patients with
   drug-resistant epilepsy. Diagnosis of hippocampal sclerosis is made by
   MR investigation. but despite the use of appropriate sequences for study
   of the temporal region, around 40\% of MR scans are negative for this
   disease. The ``quantitative MR{''} technique was introduced to enhance
   to sensitivity of MR by relaxometry and computerised volumetry
   techniques.
   We examined 14 healthy subjects and 32 patients with temporal epilepsy
   assessing seizure type, age at onset of epilepsy; duration, history of
   febrile convulsions, seizure frequency. drug resistance, secondary
   generalisation and EEG patterns. MR investigation was performed using a
   high field system (1.5 T) for target assessment of the temporal regional
   as well as sequences for relaxometry and volumetry of the hippocampus
   For relaxometry studies Ive performed monoslice multiecho T2-weighted
   sequences mapping hippocampal T2 relaxation times measured in
   milliseconds with coronal sections perpendicular to the largest axis of
   the hippocampus. Images for volumetric assessment of the hippocampus Ir
   ere obtained from T1 3D FFE coronal sequences 3 mm thick. The
   hippocampal surface was drawn manually and the total volume calculated
   by multiplying the surfaces obtained by the number and thickness of the
   sections in which the hippocampus was present. Statistical analysis of
   tire results was done using Pearson's correlation coefficient, Student's
   t test and the C2 test.
   Results showed that both hippocampuses were reduced in volume in the
   patients with temporal lobe epilepsy compared with the control group,
   whereas relaxometric analysis showed a significant change in T2
   relaxation times of the hippocampus in temporal epilepsy patients only
   if the findings correlated with the EEG focus. Volumetric measurements
   allow accurate assessment of the size of the hippocampus, but tile
   firming of volumetric reduction of a hippocampus is based on comparison
   with tile controlateral hippocampus: volumetry alone is insufficient in
   assessing bilateral hippocampus sclerosis. Study of T2 relaxation times
   has the advantage of supplying absolute numerical values expressed in
   milliseconds which be compared with normal or pathological values
   described in die literature.
   In addition, this measurement does not require corrections or
   interpretation which could make investigation less objective. Instead,
   the disadvantage of this technique is that increased T2 relaxation time
   is air aspecific index, not necessarily linked to hippocampus sclerosis.
   Another limitation is that this measurement is made on a single 5mm
   thick sequence so that hippocampus signal changes not included in the
   section may be missed. As quantitative MR requires considerable
   technical and human resources and significantly longer MR examination
   times, this method should riot be applied in all patients with suspect
   hippocampus sclerosis, but confirmed to cases with negative qualitative
   e MR, those with suspect bilateral involvement of hippocampus structures
   and surgical candidates}},
Publisher = {{EDIZIONI CENTAURO}},
Address = {{VIA DEL PRATELLO, 8, 40122 BOLOGNA, ITALY}},
Type = {{Article}},
Language = {{Italian}},
Affiliation = {{Osped Gradenigo, Dipartimento Neurosci, I-10100 Turin, Italy.
   Osped Koelliker, Turin, Italy.
   Neurol Univ, Osped San Luigi, Orbassano, Italy.}},
DOI = {{10.1177/197140090001300503}},
ISSN = {{1120-9976}},
Keywords = {{temporal epilepsy; hippocampal sclerosis; volumetry; relaxometry; MR}},
Keywords-Plus = {{T2 RELAXATION-TIME; LOBE EPILEPSY; HIPPOCAMPUS; SENSITIVITY}},
Research-Areas = {{Neurosciences \& Neurology; Radiology, Nuclear Medicine \& Medical
   Imaging}},
Web-of-Science-Categories  = {{Neurosciences; Neuroimaging; Radiology, Nuclear Medicine \& Medical
   Imaging}},
Cited-References = {{ADAM C, 1994, ARCH NEUROL-CHICAGO, V51, P130, DOI 10.1001/archneur.1994.00540140036012.
   BERKOVIC SF, 1995, NEUROLOGY, V45, P1358, DOI 10.1212/WNL.45.7.1358.
   Bernasconi N, 1999, NEUROLOGY, V52, P1870, DOI 10.1212/WNL.52.9.1870.
   CENDES F, 1993, NEUROLOGY, V43, P719, DOI 10.1212/WNL.43.4.719.
   COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001.
   Duncan JS, 1996, AM J NEURORADIOL, V17, P1805.
   DUNCAN JS, 1987, NEUROLOGY, V37, P405, DOI 10.1212/WNL.37.3.405.
   Engel Jerome Jr., 1993, P609.
   GRUNEWALD RA, 1994, AM J NEURORADIOL, V15, P1149.
   JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282.
   JACKSON GD, 1993, NEUROLOGY, V43, P1793, DOI 10.1212/WNL.43.9.1793.
   Kuzniecky RI, 1995, MAGNETIC RESONANCE E, P107.
   Lehericy S, 1996, J RADIOL, V77, P1095.
   MARK LP, 1993, AM J NEURORADIOL, V14, P709.
   Serrano-Castro PJ, 1998, REV NEUROLOGIA, V26, P592.
   SPENCER SS, 1993, NEUROLOGY, V43, P2117, DOI 10.1212/WNL.43.10.2117.
   STEVENS JM, 1999, RIV NEURORADIOLOG S3, V12, P57.
   VanPaesschen W, 1995, NEUROLOGY, V45, P2233.
   VanPaesschen W, 1997, ANN NEUROL, V41, P41, DOI 10.1002/ana.410410109.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Riv. Neuroradiol.}},
Doc-Delivery-Number = {{418EG}},
Unique-ID = {{ISI:000167877500003}},
DA = {{2018-08-13}},
}

@article{ ISI:000089099900006,
Author = {Miller, SL and Macher, JM},
Title = {{Evaluation of a methodology for quantifying the effect of room air
   ultraviolet germicidal irradiation on airborne bacteria}},
Journal = {{AEROSOL SCIENCE AND TECHNOLOGY}},
Year = {{2000}},
Volume = {{33}},
Number = {{3}},
Pages = {{274-295}},
Month = {{SEP}},
Abstract = {{As a result of the recent resurgence in tuberculosis (TB) and the
   increasing incidence of multidrug-resistant TB, there has been renewed
   interest in engineering controls to reduce the spread of TB and other
   airborne infectious diseases in high-risk settings. Techniques such as
   the use of tamps that produce ultraviolet germicidal radiation may
   reduce exposure to infectious agents by inactivating or killing
   microorganisms while they are airborne. We designed and evaluated a test
   method to quantitatively estimate the efficacy of germicidal lamps, in
   conjunction with dilution ventilation, for reducing the concentration of
   viable airborne bacteria, Bacterial particles were generated in a 36
   m(3) room and collected with midget impingers at 5-7 locations. The
   effectiveness of the control technique was determined by comparing
   concentrations of culturable airborne bacteria with and without the
   control in operation, Results for a single, 15 W germicidal lamp showed
   reductions of 50\% for Bacillus subtilis (B, subtilis) and Micrococcus
   luteus (M. luteus); tests with Escherichia coli (E. coli) showed nearly
   100\% reduction (E, coli were isolated only from the sampler nearest the
   aerosol source when the lamp was operating). The addition of louvers to
   a lamp greatly reduced its efficacy. Decay experiments showed that
   roughly 4-6 equivalent air changes per hour were achieved for B,
   subtilis with one or two lamps operating. These preliminary experiments
   demonstrated that this methodology was well suited for these evaluations
   and identified factors that could be modified to refine the study design
   for future work.}},
Publisher = {{TAYLOR \& FRANCIS INC}},
Address = {{325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Miller, SL (Reprint Author), Univ Colorado, Dept Mech Engn, Boulder, CO 80309 USA.
   Univ Colorado, Dept Mech Engn, Boulder, CO 80309 USA.
   Calif Dept Hlth Serv, Environm Hlth Lab Branch, Berkeley, CA 94704 USA.}},
DOI = {{10.1080/027868200416259}},
ISSN = {{0278-6826}},
Keywords-Plus = {{TUBERCULOSIS-CONTROL; MYCOBACTERIUM-TUBERCULOSIS; ENVIRONMENTAL-CONTROL;
   DISINFECTION; TRANSMISSION; HOSPITALS; RADIATION; PARTICLES; EXPOSURE}},
Research-Areas = {{Engineering; Environmental Sciences \& Ecology; Meteorology \&
   Atmospheric Sciences}},
Web-of-Science-Categories  = {{Engineering, Chemical; Engineering, Mechanical; Environmental Sciences;
   Meteorology \& Atmospheric Sciences}},
Cited-References = {{{*}ACGIH, 2000, AM C GOV IND HYG CIN, P164.
   {*}ACOEM, 1998, J OCCUP ENVIRON MED, V40, P765.
   {*}AIHA, 1991, NON RAD GUID SER.
   Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305.
   Behrman AJ, 1998, ANN EMERG MED, V31, P370, DOI 10.1016/S0196-0644(98)70349-X.
   Brubacher J, 1996, CHEST, V109, P582, DOI 10.1378/chest.109.2.582-a.
   BURK JR, 1978, SOUTHERN MED J, V71, P7, DOI 10.1097/00007611-197801000-00004.
   {*}CDC, 1989, MMWR-MORBID MORTAL W, V38, P313.
   {*}CDC, 1992, MMWR-MORBID MORTAL W, V41, P13.
   {*}CDC, 1989, MMWR-MORBID MORTAL W, V38, P325.
   {*}CDHS, 1990, US ULTR RAD VENT CON.
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1, DOI DOI 10.HTTP://WWW.CDC.G0V/MMWR/PREVIEW/MMWRHTML/00032890.HTM.
   Cheng YS, 1999, AEROSOL SCI TECH, V30, P186, DOI 10.1080/027868299304778.
   COLLINS FM, 1971, APPL MICROBIOL, V21, P411.
   CONROY LM, 1994, ESSENTIALS MODERN HO, P106.
   CRUMP JG, 1981, J AEROSOL SCI, V12, P405, DOI 10.1016/0021-8502(81)90036-7.
   DAVID HL, 1973, AM REV RESPIR DIS, V108, P1175.
   DRESCHER AC, 1995, INDOOR AIR, V5, P204, DOI 10.1111/j.1600-0668.1995.t01-1-00007.x.
   Dumyahn T, 1999, AM IND HYG ASSOC J, V60, P219, DOI 10.1202/0002-8894(1999)060<0219:COUURA>2.0.CO;2.
   EHRLICH R, 1974, DEV IND MICROBIOL, V15, P28.
   GIBSON T, 1974, BERGEYS MANUAL DETER, P531.
   Goldner J. L., 1980, AIRBORNE CONTAGION, P271.
   Grinshpun SA, 1997, AEROSOL SCI TECH, V26, P326, DOI 10.1080/02786829708965434.
   {*}HEALTHC HAZ MAT M, 1994, HEALTHCARE HAZARDOUS, V7, P5.
   HENNINGSON E, 1986, 4005344 FOA A.
   Hernandez M, 1999, AEROSOL SCI TECH, V30, P145, DOI 10.1080/027868299304741.
   Hinds W. C., 1999, AEROSOL TECHNOLOGY P, P182.
   HOLLANDER A, 1942, PUBL AM ASS ADV SCI, V17.
   Hopewell PC., 1986, RESP INFECT, P191.
   {*}IARC, 1992, IARC MON EV CARC RIS, P227.
   JONES TR, 1992, AM J EMERG MED, V10, P508.
   Kellerman S, 1997, INFECT CONT HOSP EP, V18, P542.
   KOCUR M, 1986, BERGEYS MANUAL SYSTE, V2, P1004.
   LIDWELL OM, 1994, J HOSP INFECT, V28, P245, DOI 10.1016/0195-6701(94)90088-4.
   LUCKIESH M, 1946, APPL GERMICIDAL ERYT, P107.
   MACHER JM, 1993, INFECT CONT HOSP EP, V14, P723.
   MACHER JM, 1994, APPL OCCUP ENV HYG, V9, P462.
   Macher JM, 1992, APPL OCCUP ENV HYG, V7, P505.
   MAGE DT, 1996, ASTM STP, V1287, P263.
   MAY KR, 1968, J GEN MICROBIOL, V51, P353, DOI 10.1099/00221287-51-3-353.
   MCLEAN RL, 1961, AM REV RESPIR DIS, V83, P36.
   MillerLeiden S, 1996, J AIR WASTE MANAGE, V46, P869, DOI 10.1080/10473289.1996.10467523.
   MULLER W, 1981, ZBL BAKT MIK HYG B, V173, P180.
   MURRAY WE, 1990, HEALTH PHYS, V58, P507.
   NAGIN D, 1994, OCCUP MED, V9, P609.
   NARDELL EA, 1995, AM J INFECT CONTROL, V23, P156, DOI 10.1016/0196-6553(95)90261-9.
   NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1.
   Nazaroff WW, 1998, INDOOR AIR, V8, P205, DOI 10.1111/j.1600-0668.1998.00002.x.
   Nicas M, 1999, Appl Occup Environ Hyg, V14, P317.
   Nicas M, 1996, AM IND HYG ASSOC J, V57, P542, DOI 10.1080/15428119691014756.
   {*}NIOSH, 1972, DHEW PUBL.
   {*}NIOSH, 1992, HAZ EL TECHN ASS REP.
   {*}NIOSH, 1992, HAZ EV TECHN ASS REP.
   NOLL ML, 1995, APPL OCCUP ENV HYG, V10, P969.
   OFFERMANN FJ, 1985, ATMOS ENVIRON, V19, P1761, DOI 10.1016/0004-6981(85)90003-4.
   ORSKOV F, 1984, BERGEYS MANUAL SYSTE, V1, P420.
   PERKINS JE, 1947, AJPH, V37, P529.
   Rahn RO, 1999, PHOTOCHEM PHOTOBIOL, V70, P314, DOI 10.1562/0031-8655(1999)070<0314:DORAGN>2.3.CO;2.
   RAJHANS GS, 1983, AIR SAMPLING INSTRUM, pQ1.
   RILEY RL, 1972, APPL MICROBIOL, V23, P1113.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P208, DOI 10.1080/00039896.1971.10665834.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1957, AM REV TUBERC PULM, V75, P420.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1991, PRINCIPLES UV AIR DI.
   RILEY RL, 1961, AIRBORNE INFECT TRAN, P81.
   SALIE F, 1995, AM IND HYG ASSOC J, V56, P987, DOI 10.1202/0002-8894(1995)056<0987:LEOAMR>2.0.CO;2.
   Schafer MP, 1999, AEROSOL SCI TECH, V30, P161, DOI 10.1080/027868299304750.
   SEGALMAURER S, 1994, CLIN INFECT DIS, V19, P299, DOI 10.1093/clinids/19.2.299.
   Stead WW, 1996, INFECT CONT HOSP EP, V17, P11.
   Stricof RL, 1998, AM J INFECT CONTROL, V26, P270, DOI 10.1016/S0196-6553(98)80012-6.
   SUMMER W, 1962, ULTRAVIOLET INFRARED, P197.
   Sutton PM, 1998, INFECT CONT HOSP EP, V19, P487.
   Wayne L. G., 1986, BERGEYS MANUAL SYSTE, P1436.
   WEBB SJ, 1959, CAN J MICROBIOL, V5, P649, DOI 10.1139/m59-079.
   Wells W. F., 1942, ARCH PHYS THER, V23, P143.
   Wells W. F., 1950, JAMA-J AM MED ASSOC, V142, P1337.
   Wells W. F., 1955, AIRBORNE CONTAGION.
   Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789.
   Wells WF, 1938, AM J PUBLIC HEALTH N, V28, P343, DOI 10.2105/AJPH.28.3.343.
   WILLMON TL, 1948, AM J HYG, V48, P227, DOI 10.1093/oxfordjournals.aje.a119237.
   1997, FED REG, V62, P54299.
   1997, FED REG, V62, P54253.
   1997, FED REG, V62, P54160.}},
Number-of-Cited-References = {{84}},
Times-Cited = {{39}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{Aerosol Sci. Technol.}},
Doc-Delivery-Number = {{350KM}},
Unique-ID = {{ISI:000089099900006}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000089223800015,
Author = {Matte, C and Marquis, JF and Blanchette, J and Gros, P and Faure, R and
   Posner, BI and Olivier, M},
Title = {{Peroxovanadium-mediated protection against murine leishmaniasis: role of
   the modulation of nitric oxide}},
Journal = {{EUROPEAN JOURNAL OF IMMUNOLOGY}},
Year = {{2000}},
Volume = {{30}},
Number = {{9}},
Pages = {{2555-2564}},
Month = {{SEP}},
Abstract = {{The phosphotyrosine phosphatase inhibitor bpV(phen) has the ability to
   markedly decrease the progression of leishmaniasis in vivo. Here, we
   have identified the mechanisms that are responsible for this protective
   effect. We report that two potent peroxovanadium (pV) compounds,
   bpV(phen) and bpV(pic), control progression of leishmaniasis in a
   similar manner by modulating NO-dependent microbicidal action. We
   observed that their injection can rapidly and transiently induce the
   expression of inducible NO synthase (iNOS) in livers of mice and enhance
   circulating nitrate levels. Treatment of mice with bpV(phen) or bpV(pic)
   completely controlled progression of leishmaniasis in an NO-dependent
   manner,since inhibition of iNOS with aminoguanidine completely reversed
   this pV-mediated protection. This NO-dependent pV-mediated protection
   was further demonstrated by the incapacity of bpV(phen)-treated
   Nramp(-/-), iNOS(-/-) mutant mice to control Leishmania major infection.
   Using an air pouch model, we showed that bpV(phen) can strongly modulate
   secretion of L. major-induced pro-inflammatory molecules and neutrophil
   recruitment. In addition, we observed that bpV(phen) per se can strongly
   induce the expression of Th1 type cytokines over Th2 in spleens of
   animals. Overall, this study has allowed us to establish the in vivo
   functional and immunological events involved in pV-mediated protective
   mechanism against leishmaniasis and that NO plays a pivotal role in this
   process.}},
Publisher = {{WILEY-V C H VERLAG GMBH}},
Address = {{MUHLENSTRASSE 33-34, D-13187 BERLIN, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Olivier, M (Reprint Author), Univ Laval, Fac Med, CHU Quebec, Ctr Rech Infectiol, RC-709,Pavillon CHUL,2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.
   Univ Laval, Fac Med, CHU Quebec, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada.
   Univ Laval, Fac Med, CHU Quebec, Dept Med Biol, St Foy, PQ G1V 4G2, Canada.
   McGill Univ, Dept Biochem, Montreal, PQ, Canada.
   Univ Laval, Fac Med, CHU Quebec, Unite Rech Pediat, St Foy, PQ G1V 4G2, Canada.
   Univ Laval, Fac Med, CHU Quebec, Dept Med, St Foy, PQ G1V 4G2, Canada.
   McGill Univ, Dept Med, Montreal, PQ, Canada.}},
DOI = {{10.1002/1521-4141(200009)30:9<2555::AID-IMMU2555>3.0.CO;2-X}},
ISSN = {{0014-2980}},
Keywords = {{Leishmania; protein tyrosine phosphatase; macrophage activation; SHP-1;
   JAK2}},
Keywords-Plus = {{TYROSINE KINASE INHIBITORS; NEUTROPHIL MIGRATION; DRUG-RESISTANCE;
   IN-VIVO; MACROPHAGE; SYNTHASE; INFECTION; EXPRESSION; DONOVANI; MICE}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
ResearcherID-Numbers = {{Posner, Barry/B-6733-2008}},
Cited-References = {{Ajuebor MN, 1998, IMMUNOLOGY, V95, P625.
   ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2.
   BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933.
   Bergeron Y, 1998, INFECT IMMUN, V66, P912.
   BEVAN AP, 1995, AM J PHYSIOL-ENDOC M, V268, pE60.
   Blanchette J, 1999, EUR J IMMUNOL, V29, P3737, DOI 10.1002/(SICI)1521-4141(199911)29:11<3737::AID-IMMU3737>3.0.CO;2-S.
   BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187.
   BUCHMULLERROUILLER Y, 1987, INFECT IMMUN, V55, P587.
   DONG ZY, 1993, J IMMUNOL, V151, P2717.
   Duong M, 1998, J INFECT DIS, V178, P1472, DOI 10.1086/314425.
   EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205.
   EVANS TG, 1993, J IMMUNOL, V151, P907.
   GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O.
   GREEN SP, 1992, BIOCHEM J, V288, P427, DOI 10.1042/bj2880427.
   GREENBERG S, 1994, J BIOL CHEM, V269, P3897.
   Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191.
   JACOBS P, 1995, J IMMUNOL, V155, P5306.
   Lima GMAC, 1998, IMMUNOL LETT, V64, P145, DOI 10.1016/S0165-2478(98)00099-6.
   Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580.
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741.
   NANDAN D, 1995, INFECT IMMUN, V63, P4495.
   Olivier M, 1996, PARASITOL TODAY, V12, P145, DOI 10.1016/0169-4758(96)10006-5.
   OLIVIER M, 1987, INFECT IMMUN, V55, P467.
   Olivier M, 1998, J BIOL CHEM, V273, P13944, DOI 10.1074/jbc.273.22.13944.
   OLIVIER M, 1992, P NATL ACAD SCI USA, V89, P7481, DOI 10.1073/pnas.89.16.7481.
   OLIVIER M, 1992, J IMMUNOL, V148, P1188.
   OUELLETTE M, 1993, PARASITOL TODAY, V9, P150, DOI 10.1016/0169-4758(93)90135-3.
   PINCHING AJ, 1990, IMMUNOL TODAY, V11, P256, DOI 10.1016/0167-5699(90)90100-N.
   POSNER BI, 1994, J BIOL CHEM, V269, P4596.
   Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984.
   REINER NE, 1988, P NATL ACAD SCI USA, V85, P4330, DOI 10.1073/pnas.85.12.4330.
   STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783.
   Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501.
   Tam FWK, 1996, KIDNEY INT, V49, P715, DOI 10.1038/ki.1996.100.
   Tsiani E, 1997, TRENDS ENDOCRIN MET, V8, P51, DOI 10.1016/S1043-2760(96)00262-7.
   TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433.
   VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655.
   WATING D, 1993, NATURE, V366, P166.
   WHITE TC, 1988, J BIOL CHEM, V263, P16977.
   Yan XT, 1998, INVEST OPHTH VIS SCI, V39, P1854.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{54}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Eur. J. Immunol.}},
Doc-Delivery-Number = {{352NB}},
Unique-ID = {{ISI:000089223800015}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000089296800016,
Author = {Cole, D and Todd, L and Wing, S},
Title = {{Concentrated swine feeding operations and public health: A review of
   occupational and community health effects}},
Journal = {{ENVIRONMENTAL HEALTH PERSPECTIVES}},
Year = {{2000}},
Volume = {{108}},
Number = {{8}},
Pages = {{685-699}},
Month = {{AUG}},
Abstract = {{Recent industry changes in swine-management practices have resulted in a
   growing controversy surrounding the environmental and public health
   effects of modern swine production. The numerous wastes produced by
   intensive swine production not only pose a significant challenge to
   effective environmental management but also are associated with
   decreased air quality in confinement houses, potentially transferable
   antimicrobial resistance patterns, and several infectious agents that
   can be pathogenic to humans. Published studies have documented a variety
   of contaminants, microbial agents, and health effects in those
   occupationally exposed to swine, and these have provided the groundwork
   for an increasing body of research to evaluate possible community health
   effects. Nonetheless, several factors limit our ability to define and
   quantify the potential role of intensive swine-rearing facilities in
   occupational and community health. Our incomplete understanding and
   ability to detect specific exposures; the complicated nature of disease
   etiology, pathogenesis, and surveillance; and the inherent difficulties
   associated with study design all contribute to the inadequate level of
   knowledge that currently prevails. However, an evaluation of the
   published literature, and a recognition of the elements that may be
   compromising these studies, provides the foundation from which future
   studies may develop.}},
Publisher = {{US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE}},
Address = {{NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Cole, D (Reprint Author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7400 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   Univ N Carolina, Sch Publ Hlth, Dept Environm Sci \& Engn, Chapel Hill, NC 27599 USA.}},
DOI = {{10.2307/3434721}},
ISSN = {{0091-6765}},
Keywords = {{air quality; air sampling; CAFOs; community health; occupational health;
   hygiene; industrial wastes; swine production}},
Keywords-Plus = {{HEPATITIS-E VIRUS; ANTIBIOTIC-RESISTANCE PATTERNS;
   SALMONELLA-TYPHIMURIUM DT104; ENDOTOXIN EXPOSURE-RESPONSE; THRESHOLD
   LIMIT VALUES; CONFINEMENT BUILDINGS; ESCHERICHIA-COLI; RESPIRATORY
   SYMPTOMS; UNITED-STATES; LUNG-FUNCTION}},
Research-Areas = {{Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health; Toxicology}},
Web-of-Science-Categories  = {{Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
Funding-Acknowledgement = {{NIEHS NIH HHS {[}ES08206-04]}},
Cited-References = {{AALBAEK B, 1991, APMIS, V99, P1103, DOI 10.1111/j.1699-0463.1991.tb01307.x.
   ABRAMSON O, 1991, PEDIATR INFECT DIS J, V10, P434, DOI 10.1097/00006454-199106000-00003.
   {*}ACGIH, 1999, AM C GOV IND HYG 199.
   ADDISS DG, 1995, MMWR-MORBID MORTAL W, V44, P1.
   Amass S, 1999, VET MED-US, V94, P480.
   ANDERSEN JK, 1991, INT J FOOD MICROBIOL, V13, P231, DOI 10.1016/0168-1605(91)90007-C.
   ARMSTRONG GL, 1998, INT C EM INF DIS 8 1, P110.
   ARRIGHI HM, 1994, EPIDEMIOLOGY, V5, P189, DOI 10.1097/00001648-199403000-00009.
   ASHFORD DA, 1998, INT C EM INF DIS 8 1, P135.
   ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1202/0002-8894(1987)048<0745:ASOTRB>2.0.CO;2.
   BANWART WL, 1975, J ENVIRON QUAL, V4, P363, DOI 10.2134/jeq1975.00472425000400030017x.
   Barker J.C., 1996, LAGOON DESIGN MANAGE.
   Bartelink AKM, 1995, LANCET, V346, P1707, DOI 10.1016/S0140-6736(95)92874-X.
   BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507.
   BAXTERPOTTER WR, 1988, J ENVIRON QUAL, V17, P27, DOI 10.2134/jeq1988.00472425001700010004x.
   BENDER JB, 1998, INT C EM INF DIS 8 1, P116.
   Besser TE, 1997, VET REC, V140, P75.
   BONGERS P, 1987, BRIT J IND MED, V44, P819.
   BRENNER KP, 1988, APPL ENVIRON MICROB, V54, P409.
   Brown I. H., 1996, Pig Journal, V36, P150.
   BUCHANAN TM, 1974, MEDICINE, V53, P427, DOI 10.1097/00005792-197411000-00003.
   CAMANN DE, 1988, J WATER POLLUT CON F, V60, P1960.
   CAMPAGNOLO ER, UNPUB.
   CARVALHEIRO MF, 1995, AM J IND MED, V27, P65, DOI 10.1002/ajim.4700270107.
   CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005.
   {*}CDC NAT CTR ENV H, 1998, CONF AN FEED OP WORK.
   Chappell CL, 1996, J INFECT DIS, V173, P232, DOI 10.1093/infdis/173.1.232.
   Checkoway H, 1989, RES METHODS OCCUPATI.
   CHOUDAT D, 1994, SCAND J WORK ENV HEA, V20, P48, DOI 10.5271/sjweh.1429.
   CIRAVOLO TG, 1979, J ENVIRON QUAL, V8, P126, DOI 10.2134/jeq1979.00472425000800010027x.
   CLARK S, 1983, AM IND HYG ASSOC J, V44, P537, DOI 10.1080/15298668391405265.
   COHEN ML, 1986, SCIENCE, V234, P964, DOI 10.1126/science.3535069.
   COMLY HH, 1945, JAMA-J AM MED ASSOC, V129, P112, DOI 10.1001/jama.1945.02860360014004.
   Cormier Y, 1997, EUR RESPIR J, V10, P1516, DOI 10.1183/09031936.97.10071516.
   CORMIER Y, 1990, AM IND HYG ASSOC J, V51, P304, DOI 10.1202/0002-8894(1990)051<0304:AMCITT>2.0.CO;2.
   Cox C. S., 1995, P77.
   COX CS, 1989, SCI PROG, V73, P469.
   CRANE SR, 1983, T ASAE, V26, P858.
   CRAWFORD RP, 1969, J AM VET MED ASSOC, V155, P2084.
   CROOK B, 1991, AM IND HYG ASSOC J, V52, P271, DOI 10.1202/0002-8894(1991)052<0271:ADAMAA>2.0.CO;2.
   Davies PR, 1997, EPIDEMIOL INFECT, V119, P237, DOI 10.1017/S095026889700784X.
   Davies PR, 1998, J AM VET MED ASSOC, V212, P1925.
   Davies PR, 1997, J AM VET MED ASSOC, V210, P386.
   DEBOER E, 1991, INT J FOOD MICROBIOL, V12, P375, DOI 10.1016/0168-1605(91)90151-E.
   DONHAM K, 1989, BRIT J IND MED, V46, P31.
   DONHAM K, 1993, ORGANIC DUST HDB, P219.
   DONHAM KJ, 1985, INT J ZOONOSES, V12, P163.
   DONHAM KJ, 1985, AM IND HYG ASSOC J, V46, P658, DOI 10.1202/0002-8894(1985)046<0658:ALOSGI>2.3.CO;2.
   DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309.
   DONHAM KJ, 1990, AM J IND MED, V17, P17.
   DONHAM KJ, 1977, J OCCUP ENVIRON MED, V19, P383, DOI 10.1097/00043764-197706000-00004.
   DOSMAN JA, 1988, J OCCUP ENVIRON MED, V30, P715.
   DOTY RL, 1988, ARCH OTOLARYNGOL, V114, P1422.
   DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763.
   DOUWES J, 1997, INT J OCCUP ENV HEAL, V3, pS26.
   Dowdle Walter R., 1997, Journal of Infectious Diseases, V176, pS69, DOI 10.1086/514180.
   DUPAS D, 1992, J OCCUP ENVIRON MED, V34, P1102, DOI 10.1097/00043764-199211000-00013.
   DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304.
   EDWARDS B, 2000, SOCIOL SPECTRUM, V20, P1.
   Ekperigin HE, 1998, VET CLIN N AM-FOOD A, V14, P17, DOI 10.1016/S0749-0720(15)30276-0.
   Evans S, 1996, VET REC, V139, P557.
   EVERARD COR, 1989, J TROP MED HYG, V92, P253.
   Fan AM, 1996, REGUL TOXICOL PHARM, V23, P35, DOI 10.1006/rtph.1996.0006.
   FORSHELL LP, 1993, J VET MED B, V40, P654, DOI 10.1111/j.1439-0450.1993.tb00188.x.
   FRIEDMAN CR, 1998, INT C EM INF DIS 8 1, P68.
   Garber L. P., 1994, Journal of the American Veterinary Medical Association, V205, P86.
   GELLIN G, 1989, APPL ENVIRON MICROB, V55, P2287.
   Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901.
   GROEN P, 1997, MAYO CLIN P, V72, P1197.
   Gustafson RH, 1997, J APPL MICROBIOL, V83, P531, DOI 10.1046/j.1365-2672.1997.00280.x.
   HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904.
   HAGLIND P, 1984, BRIT J IND MED, V41, P340.
   Hammond E. G., 1981, Iowa State Journal of Research, V55, P393.
   Hammond E. G., 1974, P INT S LIV ENV ASAE, P364.
   HAMMOND EG, 1981, AGR ENVIRON, V6, P395, DOI 10.1016/0304-1131(81)90041-2.
   HAMMOND EG, 1979, T ASAE, V22, P1186.
   HAMMOND EG, 1989, AGR ECOSYST ENVIRON, V25, P103, DOI 10.1016/0167-8809(89)90043-1.
   HARIHARAN H, 1995, CAN J VET RES, V59, P161.
   Hartung J., 1988, Volatile emissions from livestock farming and sewage operations. Proceedings of a workshop, Uppsala, Sweden 10-12 June 1987, P54.
   HARTUNG J, 1985, ENVIRON TECHNOL LETT, V6, P21, DOI 10.1080/09593338509384315.
   Hawkey PM, 1998, BRIT MED J, V317, P657, DOI 10.1136/bmj.317.7159.657.
   HEATH SE, 1994, J AM VET MED ASSOC, V205, P1518.
   HEEDERIK D, 1990, AM J IND MED, V17, P57.
   HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114.
   Hill DC, 1997, SOUTHERN MED J, V90, P1147, DOI 10.1097/00007611-199711000-00019.
   Hill VR, 1998, WATER SCI TECHNOL, V38, P119, DOI 10.1016/S0273-1223(98)00811-7.
   Hogue A., 1997, SITUATION ASSESSMENT.
   HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001.
   Holness D.L., 1989, PRINCIPLES HLTH SAFE, P69.
   HOLNESS DL, 1987, AM J IND MED, V11, P571, DOI 10.1002/ajim.4700110509.
   Homes M.J., 1996, P INT C AIR POLL AGR, P127.
   Horesh A J, 1966, J Asthma Res, V4, P125.
   House JK, 1998, VET MED-US, V93, P756.
   HUFFMAN RL, 1991, C P M AM SOC AGR ENG.
   HUFFMAN RL, 1994, 1994 INT SUMM M AM S.
   HUNTER L, 1994, JAMA-J AM MED ASSOC, V271, P1734.
   ISAACSON RE, 1995, DETECTION EPIDEMIOLO.
   Ito T, 1998, J VIROL, V72, P7367.
   Jacobs R.R., 1997, INT J OCCUP ENV HEAL, V3, pS42.
   Jacobs R.R., 1997, INT J OCCUP ENV HEAL, V3, P537.
   JANSSON C, 1992, ANTIMICROB AGENTS CH, V36, P2704, DOI 10.1128/AAC.36.12.2704.
   JOHNSON CJ, 1990, AM J IND MED, V18, P449, DOI 10.1002/ajim.4700180416.
   Jolie R, 1998, CAN J VET RES, V62, P44.
   KATSUDA K, 1995, J VET MED SCI, V57, P773, DOI 10.1292/jvms.57.773.
   KAY R, 1995, QJM-INT J MED, V88, P39.
   KEARNEY TE, 1993, J APPL BACTERIOL, V75, P215, DOI 10.1111/j.1365-2672.1993.tb02768.x.
   KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194.
   KHAKHRIA R, 1998, INT C EM INF DIS 8 1, P141.
   Kimura K, 1998, MAYO CLIN PROC, V73, P243, DOI 10.4065/73.3.243.
   Konkle DM, 1997, J VET INTERN MED, V11, P340, DOI 10.1111/j.1939-1676.1997.tb00477.x.
   Kramer M H, 1996, MMWR CDC Surveill Summ, V45, P1.
   KRIDER J, 1987, RURAL GROUNDWATER CO, P115.
   Kwo PY, 1997, MAYO CLIN PROC, V72, P1133, DOI 10.4065/72.12.1133.
   LADD A, IN PRESS RACE GENDER.
   LANGLOIS BE, 1978, J ANIM SCI, V46, P1383.
   Larsson BM, 1997, THORAX, V52, P638, DOI 10.1136/thx.52.7.638.
   LARSSON K, 1992, CHEST, V101, P767, DOI 10.1378/chest.101.3.767.
   LARSSON KA, 1994, AM J RESP CRIT CARE, V150, P973, DOI 10.1164/ajrccm.150.4.7921472.
   LEVIN AS, 1987, STATE ART REV OCCUP, V2, P669.
   LEVY SB, 1978, J INFECT DIS, V137, P688, DOI 10.1093/infdis/137.5.688.
   LOUHELAINEN K, 1987, EUR J RESPIR DIS, V71, P80.
   Mackiewicz B, 1998, ANN AGR ENV MED, V5, P169.
   MARSHALL B, 1990, P NATL ACAD SCI USA, V87, P6609, DOI 10.1073/pnas.87.17.6609.
   MARSHALL JS, 1994, CURR OPIN IMMUNOL, V6, P853, DOI 10.1016/0952-7915(94)90004-3.
   Mathew AG, 1999, APPL ENVIRON MICROB, V65, P2770.
   Mathew AG, 1998, J ANIM SCI, V76, P429.
   Meadows R, 1995, ENVIRON HEALTH PERSP, V103, P1096, DOI 10.2307/3432603.
   MEE BJ, 1983, J APPL BACTERIOL, V54, P225, DOI 10.1111/j.1365-2672.1983.tb02611.x.
   Meinhardt PL, 1996, EPIDEMIOL REV, V18, P118, DOI 10.1093/oxfordjournals.epirev.a017920.
   Meng XJ, 1998, J VIROL, V72, P9714.
   Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860.
   MERILAHTIPALO R, 1991, SCAND J INFECT DIS, V23, P55, DOI 10.3109/00365549109023375.
   Merkel J.A., 1969, T AM SOC AGR ENG, V12, P310.
   Michaud S, 1996, Can J Infect Dis, V7, P329.
   MICHEL D, 1997, INT J OCCUP ENV HL S, V3, pS18.
   MICHEL O, 1995, CLIN EXP ALLERGY, V25, P73, DOI 10.1111/j.1365-2222.1995.tb01005.x.
   Miller MA, 1998, VET CLIN N AM-FOOD A, V14, P71, DOI 10.1016/S0749-0720(15)30280-2.
   Milton DK, 1997, AM IND HYG ASSOC J, V58, P861.
   Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.3.CO;2-\#.
   MINER JR, 1975, 3 INT S LIV WAST 21, P351.
   Miner R.J, 1983, LIVESTOCK WASTE MANA.
   MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004.
   MOLIN G, 1989, J APPL BACTERIOL, V67, P347, DOI 10.1111/j.1365-2672.1989.tb02504.x.
   Moore JE, 1996, VET REC, V138, P306, DOI 10.1136/vr.138.13.306.
   MullerSuur C, 1997, EUR RESPIR J, V10, P376, DOI 10.1183/09031936.97.10020376.
   NESBAKKEN T, 1988, INT J FOOD MICROBIOL, V6, P287, DOI 10.1016/0168-1605(88)90022-0.
   Nijsten R, 1996, J ANTIMICROB CHEMOTH, V37, P1141, DOI 10.1093/jac/37.6.1141.
   NIJSTEN R, 1994, EPIDEMIOL INFECT, V113, P45, DOI 10.1017/S0950268800051451.
   NIOSH, 1997, NIOSH POCK GUID CHEM.
   Nowotny N, 1997, J INFECT DIS, V176, P1414, DOI 10.1086/517337.
   {*}OCC SAF HLTH STAN, 1999, 29 CFR OCC SAF HLTH.
   ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V.
   OJENIYI AA, 1989, EPIDEMIOL INFECT, V103, P513, DOI 10.1017/S0950268800030910.
   Olson D K, 1996, AAOHN J, V44, P198.
   Olson ME, 1997, VET PARASITOL, V68, P375, DOI 10.1016/S0304-4017(96)01072-2.
   ONEILL DH, 1992, J AGR ENG RES, V53, P23, DOI 10.1016/0021-8634(92)80072-Z.
   Orriss GD, 1997, EMERG INFECT DIS, V3, P497, DOI 10.3201/eid0304.970413.
   ORTEGAMORA LM, 1994, INFECT IMMUN, V62, P5003.
   OSTROFF S, 1994, YERSINIOSIS PRESENT, P5.
   OZANNE G, 1987, CAN J PUBLIC HEALTH, V78, P340.
   PAYMENT P, 1989, WATER SCI TECHNOL, V21, P283.
   Penny R. H. C., 1994, Pig Journal, V33, P30.
   PEREA A, 1994, J VET MED B, V41, P512, DOI 10.1111/j.1439-0450.1994.tb00257.x.
   PETERSEN K, 1998, SITUATION REPORT SAL.
   PICKRELL J, 1991, VET HUM TOXICOL, V33, P32.
   PICKRELL JA, 1995, VET HUM TOXICOL, V37, P430.
   Popendorf W., 1995, APPL OCCUP ENV HYG, V10, P595.
   PRELLER L, 1995, ANN OCCUP HYG, V39, P545, DOI 10.1093/annhyg/39.5.545.
   PRELLER L, 1995, OCCUP ENVIRON MED, V52, P654, DOI 10.1136/oem.52.10.654.
   PREUSCHEN G, 1974, P INT LIV ENV S U NE, P195.
   Purdy B. M., 1997, Journal of Agricultural and Applied Economics, V29, P149.
   Quilez J, 1996, PARASITOL RES, V82, P529, DOI 10.1007/s004360050157.
   Rao GG, 1998, DRUGS, V55, P323, DOI 10.2165/00003495-199855030-00001.
   RAPPAPORT SM, 1993, AM J IND MED, V23, P683, DOI 10.1002/ajim.4700230502.
   RAY S, 1998, INT C EM INF DIS 8 1, P82.
   REBOLI AC, 1989, CLIN MICROBIOL REV, V2, P354.
   REIF JS, 1989, AM J PUBLIC HEALTH, V79, P1528, DOI 10.2105/AJPH.79.11.1528.
   Reynolds S. J., 1997, Journal of Agromedicine, V4, P37, DOI 10.1300/J096v04n01\_06.
   Reynolds SJ, 1996, AM J IND MED, V29, P33, DOI 10.1002/(SICI)1097-0274(199601)29:1<33::AID-AJIM5>3.0.CO;2-\#.
   RITTER WF, 1989, J AGR ENG RES, V42, P51, DOI 10.1016/0021-8634(89)90039-5.
   ROACH SA, 1990, AM J IND MED, V17, P727, DOI 10.1002/ajim.4700170607.
   Robertson J. F., 1994, Pig Journal, V33, P113.
   ROOF MB, 1993, COMPENDIUM COLLECTIO, P191.
   RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209.
   RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981.
   SAIDA K, 1981, ANTIMICROB AGENTS CH, V19, P1032, DOI 10.1128/AAC.19.6.1032.
   SCHAEFER J, 1977, AGR ENVIRON, V3, P121, DOI 10.1016/0304-1131(77)90003-0.
   SCHAEFER J, 1973, 4265 CENTR I VOED.
   Schiffman SS, 1998, J ANIM SCI, V76, P1343.
   SCHIFFMAN SS, 1995, BRAIN RES BULL, V37, P369, DOI 10.1016/0361-9230(95)00015-1.
   SCHIFFMAN SS, 1974, SCIENCE, V185, P112, DOI 10.1126/science.185.4146.112.
   Schlauder GG, 1998, J GEN VIROL, V79, P447, DOI 10.1099/0022-1317-79-3-447.
   Scholtissek C, 1995, VIRUS GENES, V11, P209, DOI 10.1007/BF01728660.
   SCHUSTERMAN D, 1999, ENV HLTH PERSPECT, V94, P25.
   SCHUSTERMAN DJ, 1992, ARCH ENVIRON HEALTH, V47, P76.
   SCHWARTZ DA, 1992, ANN INTERN MED, V116, P630, DOI 10.7326/0003-4819-116-8-630.
   SCHWARTZ KJ, 1993, COMPENDIUM COLLECTIO, P202.
   SCLAR ED, 1980, INT J HEALTH SERV, V10, P563, DOI 10.2190/1K7N-N25A-BMJ7-PWAX.
   SCOTT CA, 1995, VET PARASITOL, V57, P277, DOI 10.1016/0304-4017(94)00694-8.
   Senthilselvan A, 1997, AM J RESP CRIT CARE, V156, P410, DOI 10.1164/ajrccm.156.2.9612069.
   SEURI M, 1992, SCAND J WORK ENV HEA, V18, P128, DOI 10.5271/sjweh.1600.
   Sjogren B, 1999, SCAND J WORK ENV HEA, V25, P39.
   SKILBECK NW, 1986, MED J AUSTRALIA, V144, P565.
   SMALLBECK DR, 1975, 3 INT S LIV WAST 21, P318.
   SMID T, 1992, AM REV RESPIR DIS, V146, P1474, DOI 10.1164/ajrccm/146.6.1474.
   SMID T, 1993, THESIS AGR U WAGENIN.
   SMITH HW, 1980, J HYG-CAMBRIDGE, V84, P467, DOI 10.1017/S0022172400027005.
   SPOELSTRA SF, 1980, AGR ENVIRON, V5, P241, DOI 10.1016/0304-1131(80)90004-1.
   STANFORD CF, 1990, EPIDEMIOL INFECT, V105, P565, DOI 10.1017/S0950268800048196.
   {*}SWIN OD TASK FORC, 1998, OPT MAN OD.
   Swinker M, 1998, N C Med J, V59, P16.
   TAKAHASHI T, 1987, J CLIN MICROBIOL, V25, P536.
   Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793.
   TAUXE RV, 1987, LANCET, V1, P1129.
   TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339.
   Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003.
   THOMAS DR, 1994, J EPIDEMIOL COMMUN H, V48, P151, DOI 10.1136/jech.48.2.151.
   Thorn J, 1998, THORAX, V53, P1047, DOI 10.1136/thx.53.12.1047.
   Thu K., 1997, Journal of Agricultural Safety and Health, V3, P13.
   Thu Kendall M., 1998, PIGS PROFITS RURAL C.
   TOWNER KJ, 1986, J APPL BACTERIOL, V61, P535, DOI 10.1111/j.1365-2672.1986.tb01726.x.
   TROUT D, 1995, J OCCUP ENVIRON MED, V37, P697, DOI 10.1097/00043764-199506000-00011.
   {*}USDA AN PLANT INS, 1999, INF SHEET SHEDD SALM.
   VINZENTS P, 1992, AM IND HYG ASSOC J, V53, P237, DOI 10.1202/0002-8894(1992)053<0237:VIETDA>2.0.CO;2.
   Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226.
   Vogelzang PFJ, 1998, J OCCUP ENVIRON MED, V40, P1048.
   Von Essen SG, 1998, J TOXICOL-CLIN TOXIC, V36, P557, DOI 10.3109/15563659809028049.
   VUGIA DJ, 1998, INT C EM INF DIS 8 1, P83.
   Wang Z, 1998, RESP MED, V92, P1022, DOI 10.1016/S0954-6111(98)90349-3.
   Wang Z, 1997, EUR RESPIR J, V10, P381, DOI 10.1183/09031936.97.10020381.
   Wang ZP, 1996, AM J RESP CRIT CARE, V153, P147, DOI 10.1164/ajrccm.153.1.8542108.
   Wang ZP, 1996, AM J RESP CRIT CARE, V154, P1261.
   WARE J, 1993, AM J EPIDEMIOL, V137, P1298.
   WARREN DW, 1992, PHYSIOL BEHAV, V51, P425, DOI 10.1016/0031-9384(92)90161-T.
   Webster RG, 1997, FEMS IMMUNOL MED MIC, V18, P275, DOI 10.1016/S0928-8244(97)00058-8.
   Webster RG, 1998, EMERG INFECT DIS, V4, P436, DOI 10.3201/eid0403.980325.
   WELLS DL, 1991, JAMA-J AM MED ASSOC, V265, P478, DOI 10.1001/jama.265.4.478.
   Wentworth DE, 1997, J INFECT DIS, V175, P7, DOI 10.1093/infdis/175.1.7.
   Westerman PW, 1995, T ASAE, V38, P1749.
   Wiggins BA, 1996, APPL ENVIRON MICROB, V62, P3997.
   WILHELMSSON J, 1989, AM J IND MED, V15, P311, DOI 10.1002/ajim.4700150306.
   Wing S, 2000, ENVIRON HEALTH PERSP, V108, P225, DOI 10.2307/3454438.
   Wing S, 2000, ENVIRON HEALTH PERSP, V108, P233, DOI 10.2307/3454439.
   WISE PJ, 1985, J APPL BACTERIOL, V58, P555, DOI 10.1111/j.1365-2672.1985.tb01711.x.
   XIAO LH, 1994, VET PARASITOL, V52, P331, DOI 10.1016/0304-4017(94)90124-4.
   ZANEN HC, 1975, LANCET, V1, P1286.
   ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49.
   ZEJDA JE, 1993, CHEST, V103, P702, DOI 10.1378/chest.103.3.702.
   ZEJDA JE, 1993, AM J IND MED, V23, P743, DOI 10.1002/ajim.4700230508.
   ZUSKIN E, 1991, ENVIRON RES, V56, P120, DOI 10.1016/S0013-9351(05)80002-7.
   ZUSKIN E, 1992, BRIT J IND MED, V49, P435.}},
Number-of-Cited-References = {{251}},
Times-Cited = {{110}},
Usage-Count-Last-180-days = {{4}},
Usage-Count-Since-2013 = {{48}},
Journal-ISO = {{Environ. Health Perspect.}},
Doc-Delivery-Number = {{353VU}},
Unique-ID = {{ISI:000089296800016}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000088824900007,
Author = {Patel, D and Madan, I},
Title = {{Methicillin-resistant Staphylococcus aureus and multidrug resistant
   tuberculosis: part 2}},
Journal = {{OCCUPATIONAL MEDICINE-OXFORD}},
Year = {{2000}},
Volume = {{50}},
Number = {{6}},
Pages = {{395-397}},
Month = {{AUG}},
Abstract = {{Drug resistant tuberculosis has been recognized since chemotherapy first
   became available. However, drug resistance has increased in many
   countries, and recently strains resistant to both rifampicin and
   isoniazid (multidrug resistant tuberculosis) have emerged. This review
   discusses the epidemiology of multidrug resistant tuberculosis (MDRTB),
   and the control of MDRTB in healthcare facilities. Relevant papers for
   this review were identified by a systematic literature search on
   Medline. MDRTB is already established world-wide, and although the
   overall problem of resistance remains low in the UK, it is of
   significant clinical importance due to its high case-fatality, higher
   transmission risk. and complex treatment. The key elements of MDRTB
   control are prompt recognition, confirmation and treatment of cases, and
   the institution of strict infection control procedures to reduce the
   airborne spread of infection from infectious patients to others. This
   review emphasizes the importance of a multidisciplinary approach to
   management, with liaison between tuberculosis physicians, the
   microbiology department, infection control team, consultant in
   communicable disease, and occupational health.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Patel, D (Reprint Author), St Thomas Hosp, Dept Occupat Hlth, Guys Kings \& St Thomas Sch Med, Lambeth Palace Rd, London SE1 7EH, England.
   St Thomas Hosp, Dept Occupat Hlth, Guys Kings \& St Thomas Sch Med, London SE1 7EH, England.}},
DOI = {{10.1093/occmed/50.6.395}},
ISSN = {{0962-7480}},
Keywords = {{contact tracing; healthcare workers; infection control; multidrug
   resistant tuberculosis; negative pressure ventilation; occupational
   health}},
Keywords-Plus = {{HEALTH-CARE WORKERS; NOSOCOMIAL TRANSMISSION; OUTBREAK; RISK}},
Research-Areas = {{Public, Environmental \& Occupational Health}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health}},
Cited-References = {{Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3.
   {*}CDC, 1991, MMWR-MORBID MORTAL W, V40, P585.
   Centers for Disease Control, 1990, MMWR-MORBID MORTAL W, V39, P718.
   {*}DEP HLTH STAND ME, 1998, PATH LEAST RES MAIN.
   {*}DEP HLTH WELSH OF, 1996, IMM INF DIS BIC ED.
   Drobniewski FA, 1998, BRIT MED J, V317, P1263, DOI 10.1136/bmj.317.7168.1263.
   {*}INT WORK GROUP TU, 1998, PREV CONTR TUB UK, V2.
   {*}INT WORK GROUP TU, 1998, PREV CONTR TUB UK, V1.
   Kenyon TA, 1997, ANN INTERN MED, V127, P32, DOI 10.7326/0003-4819-127-1-199707010-00006.
   Meredith S, 1996, BRIT MED J, V313, P522.
   Ormerod P, 1998, THORAX, V53, P536.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   Ridzon R, 1997, INFECT CONT HOSP EP, V18, P422.
   SKINNER C, 1994, THORAX, V49, P1193.
   Would Health Organization, 1997, ANT DRUG RES WORLD W.
   1994, CONTROL SUBSTANCES H.
   1995, REPORTING INJURIES D.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Occup. Med.-Oxf.}},
Doc-Delivery-Number = {{345PT}},
Unique-ID = {{ISI:000088824900007}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000088427900012,
Author = {Kami, M and Tanaka, Y and Kanda, Y and Ogawa, S and Masumoto, T and
   Ohtomo, K and Matsumura, T and Saito, T and Machida, U and Kashima, T
   and Hirai, H},
Title = {{Computed tomographic scan of the chest, latex agglutination test and
   plasma (1 -> 3)-beta-D-glucan assay in early diagnosis of invasive
   pulmonary aspergillosis: A prospective study of 215 patients}},
Journal = {{HAEMATOLOGICA}},
Year = {{2000}},
Volume = {{85}},
Number = {{7}},
Pages = {{745-752}},
Month = {{JUL}},
Abstract = {{Background and Objectives. Blood and radiologic tests are frequently
   used for diagnosis of invasive pulmonary aspergillosis, but it remains
   unknown which is more useful for its early diagnosis. The aim of the
   study was to compare usefulness of computed tomographic (CT) scan of
   chest, latex agglutination (LA) test and determination of plasma
   (1-->3)-beta-D-glucan (BDG) levels for early diagnosis of invasive
   pulmonary aspergillosis (IPA).
   Design and Methods. We treated 215 consecutive patients who underwent
   cytotoxic chemotherapy. From initiation of chemotherapy until death or
   discharge, blood samples were taken weekly and subjected to LA and BDG
   tests. We performed chest CT scans when patients had any signs of
   pulmonary infection or an antibiotic-resistant fever.
   Results. Of the 215 patients, 30 (14.0\%) were diagnosed as having IPA.
   In sixteen cases the diagnosis was definite and in 14 it was suspected.
   In patient-based analysis, sensitivities of LA and BDG were 44\% and
   63\%, respectively. Sensitivity tended to be lower in patients with IPA
   localized to the lung than those with disseminated invasive
   aspergillosis. Specificities were 93\% and 74\%, respectively. Either a
   halo or an air-crescent was observed in 7 of the 16 patients with IPA,
   and all of the IPA patients showed some abnormal signs on chest CT
   scans. On average, CT scan signs preceded a positive LA test by days and
   a positive BDG assay by 11.5 days. In of the 11 patients who became
   positive for either or BDG assay, CT scan signs preceded the positive
   results by more than seven days.
   Interpretations and conclusions. Chest CT scan is more beneficial than
   the blood tests and X-ray for early diagnosis of IPA. (C) 2000, Ferrata
   Storti Foundation.}},
Publisher = {{FERRATA STORTI FOUNDATION}},
Address = {{STRADA NUOVA 134, 27100 PAVIA, ITALY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kami, M (Reprint Author), Toranomon Hosp, Dept Hematol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.
   Univ Tokyo, Fac Med, Dept Hematol \& Oncol, Tokyo 113, Japan.
   Univ Tokyo, Fac Med, Dept Cell Therapy \& Transplantat Med, Tokyo 113, Japan.
   Univ Tokyo, Fac Med, Dept Radiol, Tokyo 113, Japan.
   Univ Tokyo, Fac Med, Dept Pathol, Tokyo 113, Japan.}},
ISSN = {{0390-6078}},
Keywords = {{invasive pulmonary aspergillosis; computed tomography; latex
   agglutination test; (1 -> 3)-beta-D-glucan; X-ray; hematologic
   malignancy; early diagnosis}},
Keywords-Plus = {{LINKED-IMMUNOSORBENT-ASSAY; CT HALO SIGN; BONE-MARROW; TRANSPLANT
   RECIPIENTS; NEUTROPENIC PATIENTS; ENZYME-IMMUNOASSAY; DEEP MYCOSIS;
   GALACTOMANNAN; MANAGEMENT; INFECTIONS}},
Research-Areas = {{Hematology}},
Web-of-Science-Categories  = {{Hematology}},
Cited-References = {{BENNETT JE, 1987, J INFECT DIS, V155, P1005, DOI 10.1093/infdis/155.5.1005.
   Caillot D, 1997, J CLIN ONCOL, V15, P139, DOI 10.1200/JCO.1997.15.1.139.
   Denning DW, 1997, EUR J CLIN MICROBIOL, V16, P424, DOI 10.1007/BF02471906.
   DENNING DW, 1990, REV INFECT DIS, V12, P1147.
   DUTHIE R, 1995, CLIN INFECT DIS, V20, P598, DOI 10.1093/clinids/20.3.598.
   Heussel CP, 1999, J CLIN ONCOL, V17, P796, DOI 10.1200/JCO.1999.17.3.796.
   HOPWOOD V, 1995, J CLIN PATHOL, V48, P210, DOI 10.1136/jcp.48.3.210.
   HRUBAN RH, 1987, J COMPUT ASSIST TOMO, V11, P534, DOI 10.1097/00004728-198705000-00033.
   KLEIN DL, 1980, AM J ROENTGENOL, V134, P543, DOI 10.2214/ajr.134.3.543.
   KUHLMAN JE, 1985, RADIOLOGY, V157, P611, DOI 10.1148/radiology.157.3.3864189.
   LIBSHITZ HI, 1981, RADIOLOGY, V140, P301, DOI 10.1148/radiology.140.2.7019958.
   Machetti M, 1998, BONE MARROW TRANSPL, V21, P917, DOI 10.1038/sj.bmt.1701206.
   MORI M, 1991, RADIOLOGY, V178, P721, DOI 10.1148/radiology.178.3.1994408.
   OBAYASHI T, 1992, J MED VET MYCOL, V30, P275.
   OBAYASHI T, 1995, LANCET, V345, P17, DOI 10.1016/S0140-6736(95)91152-9.
   PIZZO PA, 1993, NEW ENGL J MED, V328, P1323.
   STYNEN D, 1995, J CLIN MICROBIOL, V33, P497.
   Sulahian A, 1996, EUR J CLIN MICROBIOL, V15, P139, DOI 10.1007/BF01591487.
   VERWEIJ PE, 1995, J CLIN MICROBIOL, V33, P1912.}},
Number-of-Cited-References = {{19}},
Times-Cited = {{70}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Haematologica}},
Doc-Delivery-Number = {{338PF}},
Unique-ID = {{ISI:000088427900012}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000088267200015,
Author = {Trevino, S},
Title = {{Antibiotic resistance monitoring: A laboratory perspective}},
Journal = {{MILITARY MEDICINE}},
Year = {{2000}},
Volume = {{165}},
Number = {{7, S}},
Pages = {{40-42}},
Month = {{JUL}},
Note = {{Annual Military Public Health Laboratory Symposium and Workshop,
   WASHINGTON, D.C., SEP 21-23, 1999}},
Organization = {{Dept Defense Global Emerging Infect Surveillance \& Response Syst; Armed
   Forces Inst Pathol}},
Abstract = {{Efficient monitoring of antimicrobial resistance (AR) can produce timely
   and important data and information that will benefit patients and could
   assist in the detection of a bioterrorist event. The microbiology
   laboratory staff of the largest U.S. Air Force medical facility
   attempted to improve AR monitoring at their hospital by reviewing their
   current capabilities and the capabilities of other available monitoring
   systems. The systems reviewed included the DataTrac System (Vitek
   bioMerieux, Hazelwood, Missouri) and the military Composite Health Care
   System, which were already in use, and the WHONET 5 (World Heath
   Organization, Geneva, Switzerland) and The Surveillance Network (MRL
   Pharmaceutical Services, Herndon, Virginia), The Surveillance Network
   was selected for incorporation into the hospital AR monitoring program
   with modifications to comply with military command requirements.
   Information gathered during the review and selection process are
   presented and may be helpful to others who are looking to improve their
   hospital AR monitoring programs.}},
Publisher = {{ASSN MILITARY SURG US}},
Address = {{9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Trevino, S (Reprint Author), Wilford Hall USAF Med Ctr, 59 MDW,MTLLM,2200 Bergquist Dr,Suit 1, Lackland AFB, TX 78236 USA.
   Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA.}},
ISSN = {{0026-4075}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   Centers for Disease Control and Prevention (CDC), 2002, MMWR-MORBID MORTAL W, V48, P1165.
   HIERHOLZER WJ, 1995, AM J INFECT CONTROL, V23, P87.
   {*}MRL PHARM SERV, TECHN INF BROCH.
   Pavlin JA, 2000, MIL MED, V165, P25.
   Stelling JM, 1997, CLIN INFECT DIS, V24, pS157, DOI 10.1093/clinids/24.Supplement\_1.S157.
   {*}VIT BIOM, 1994, BIOLIAISON REF MAN.
   {*}WHO, COMM DIS SURV RESP W.
   World Health Organization (WHO), 1999, WHO WORKSH DEV GLOB.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Milit. Med.}},
Doc-Delivery-Number = {{335WF}},
Unique-ID = {{ISI:000088267200015}},
DA = {{2018-08-13}},
}

@article{ ISI:000088701900003,
Author = {Kwon, YM and Woodward, CL and Pillai, SD and Pena, J and Corrier, DE and
   Byrd, JA and Ricke, SC},
Title = {{Litter and aerosol sampling of chicken houses for rapid detection of
   Salmonella typhimurium contamination using gene amplification}},
Journal = {{JOURNAL OF INDUSTRIAL MICROBIOLOGY \& BIOTECHNOLOGY}},
Year = {{2000}},
Volume = {{24}},
Number = {{6}},
Pages = {{379-382}},
Month = {{JUN}},
Abstract = {{Rapid screening of poultry houses for contamination is critical for
   Salmonella control. Use of air filter sampling has great potential for
   efficient and reliable monitoring of Salmonella spp., as it could
   represent an entire poultry house and solve sample-size problems. Two
   sampling methods (litter and air filter) were compared for detection in
   four chicken pens inoculated with a S. typhimurium antibiotic resistant
   strain. Salmonella levels in both litter and air filter samples were
   determined by PCR amplification and by conventional enrichment. Although
   amplified DNA was not directly detected, amplified DNA could be detected
   using a dual probe hybridization sensor. The ratio of the positive
   samples to total samples determined by gene amplification was much lower
   than that obtained by conventional enrichments (29/128 versus 102/728
   samples). However, the ratio obtained by gene amplification with air
   filter samples was greater than that with litter samples (26/64 versus
   3/64). These results demonstrate that the air filter sampling method is
   an alternative method of Salmonella detection in poultry house using PCR
   gene amplification protocol.}},
Publisher = {{NATURE AMERICA INC}},
Address = {{345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Ricke, SC (Reprint Author), Texas A\&M Univ, Kleberg Ctr, Dept Poultry Sci, Room 101, College Stn, TX 77843 USA.
   Texas A\&M Univ, Kleberg Ctr, Dept Poultry Sci, College Stn, TX 77843 USA.
   Texas A\&M Univ, Environm Sci Program, El Paso, TX 79927 USA.
   USDA ARS, Food Anim Protect Res Lab, College Stn, TX 77845 USA.}},
DOI = {{10.1038/sj.jim.7000008}},
ISSN = {{1367-5435}},
Keywords = {{Salmonella; aerosol sampling; PCR; poultry house}},
Keywords-Plus = {{POLYMERASE-CHAIN-REACTION; HYBRIDIZATION SENSOR; BROILER; FOOD}},
Research-Areas = {{Biotechnology \& Applied Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology}},
Cited-References = {{Berrang M. E., 1995, Journal of Applied Poultry Research, V4, P83.
   Bottcher R. W., 1994, Journal of Applied Poultry Research, V3, P289.
   CANDRIAN U, 1995, J MICROBIOL METH, V23, P89, DOI 10.1016/0167-7012(95)00019-H.
   CASON JA, 1994, AVIAN DIS, V38, P583, DOI 10.2307/1592082.
   Corrier DE, 1998, J APPL POULTRY RES, V7, P132, DOI 10.1093/japr/7.2.132.
   DAVIES RH, 1994, INT J FOOD MICROBIOL, V24, P147, DOI 10.1016/0168-1605(94)90114-7.
   JONES FT, 1991, J FOOD PROTECT, V54, P502, DOI 10.4315/0362-028X-54.7.502.
   Kwon YM, 1999, J RAPID METH AUT MIC, V7, P103.
   Maciorowski KG, 1998, J RAPID METH AUT MIC, V6, P225, DOI 10.1111/j.1745-4581.1998.tb00202.x.
   MARSH M, 1990, NUCLEIC ACIDS RES, V18, P3397, DOI 10.1093/nar/18.11.3397.
   NIEDERHAUSER C, 1992, APPL ENVIRON MICROB, V58, P1564.
   OPENGART KN, 1991, AVIAN DIS, V35, P228, DOI 10.2307/1591320.
   Pena J, 1999, J ENVIRON SCI HEAL A, V34, P529, DOI 10.1080/10934529909376851.
   PILLAI SD, 1994, AVIAN DIS, V38, P598, DOI 10.2307/1592084.
   PILLAI SD, 1995, CRIT REV MICROBIOL, V21, P239, DOI 10.3109/10408419509113542.
   Poppe C, 1999, SALMONELLA ENTERICA SEROVAR ENTERITIDIS IN HUMANS AND ANIMALS: EPIDEMIOLOGY, PATHOGENESIS AND CONTROL, P3.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{22}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{J. Ind. Microbiol. Biotechnol.}},
Doc-Delivery-Number = {{343KQ}},
Unique-ID = {{ISI:000088701900003}},
DA = {{2018-08-13}},
}

@article{ ISI:000086537500017,
Author = {Ednie, LM and Jacobs, MR and Appelbaum, PC},
Title = {{Activity of gemifloxacin, a new broad-spectrum quinolone, against 200
   pneumococci by four different susceptibility testing methods}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{2000}},
Volume = {{45}},
Number = {{4}},
Pages = {{525-528}},
Month = {{APR}},
Abstract = {{Agar and microdilution tin air), Etest tin air and CO2) and disc
   diffusion tin air and CO2 susceptibility testing methods were used to
   investigate the activity of gemifloxacin against 200 pneumococci.
   MIC(50)s were 0.016-0.03 mg/L and MIC(90)s 0.125-0.25 mg/L for all
   methods. With agar dilution as reference, 187/200 strains gave essential
   agreement with microdilution and 196 with Etest (air and CO2). Disc
   zones were a few millimetres narrower in CO2 than in air, With discs in
   CO2, all ciprofloxacin-susceptible strains yielded zone diameters
   greater than or equal to 26 mm; values in air were greater than or equal
   to 28 mm. Zones for ciprofloxacin-resistant strains in CO2 were mostly
   21-26 mm; zones in air were a few millimetres wider, but mostly <31 mm.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Appelbaum, PC (Reprint Author), Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol Clin Microbiol, POB 850, Hershey, PA 17033 USA.
   Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol Clin Microbiol, Hershey, PA 17033 USA.
   Case Western Reserve Univ, Cleveland, OH 44106 USA.}},
DOI = {{10.1093/jac/45.4.525}},
ISSN = {{0305-7453}},
Keywords-Plus = {{RESISTANT STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE;
   FLUORONAPHTHYRIDONE; LB20304}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Cited-References = {{APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   Clark CL, 1998, J CLIN MICROBIOL, V36, P3579.
   Cormican MG, 1997, ANTIMICROB AGENTS CH, V41, P204.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208.
   FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377.
   JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119.
   KELLY LM, 1998, 38 INT C ANT AG CHEM, P254.
   National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE, pM7.
   National Committee for Clinical Laboratory Standards, 1997, PERF STAND ANT DISK.
   Oh JI, 1996, ANTIMICROB AGENTS CH, V40, P1564.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{305JZ}},
Unique-ID = {{ISI:000086537500017}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000086302500024,
Author = {Davies, TA and Kelly, LM and Jacobs, MR and Appelbaum, PC},
Title = {{Antipneumococcal activity of telithromycin by agar dilution,
   microdilution, E test, and disk diffusion methodologies}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{2000}},
Volume = {{38}},
Number = {{4}},
Pages = {{1444-1448}},
Month = {{APR}},
Abstract = {{Agar dilution and microdilution (both in air) and E test and disk
   diffusion (both in air and CO2) were used to test the activity of
   telithromycin against 110 erythromycin-susceptible and 106
   erythromycin-resistant pneumococci. The MICs at which 50 and 90\% of
   strains are inhibited (MIC(50)s and MIC(50)s, respectively) for
   erythromycin-susceptible strains varied between 0.008 and 0.016 mu g/ml
   and 0.016 and 0.03 mu g/ml when the samples were incubated in air. By
   comparison, telithromycin MIC(50)s and MIC(50)s for
   erythromycin-resistant strains were in air 0.03 to 0.125 and 0.125 to
   0.5 mu g/ml, respectively. When agar dilution was used as the reference
   method, essential agreement was found for 112 of 216 strains (51.9\%)
   for microdilution, 168 of 216 (77.8\%) for E test in air, and 132 of 216
   (61.1\%) for E test in CO2. With the exception of four strains tested by
   E test in CO2, all organisms were susceptible to a proposed
   telithromycin susceptibility breakpoint of less than or equal to 1 mu
   g/ml. By disk diffusion with 15-mu g telithromycin disks, all strains
   but one had zones of inhibition greater than or equal to 19 mm in
   diameter when incubated in CO2, while all strains had zone diameters of
   greater than or equal to 22 mm when incubated in air. Zone diameters in
   air were generally 4 to 5 mm larger than in CO2. By all methods, MICs
   and zones of all erythromycin-resistant strains occurred in clusters
   separated from those seen with erythromycin-susceptible strains. The
   results for macrolide-resistant strains with erm and mef resistance
   determinants were similar. The results show that (i) telithromycin is
   very active against erythromgrcin-susceptible and -resistant strains
   irrespective of macrolide resistance mechanism; (ii) susceptibility to
   telithromycin can be reliably tested by the agar, microdilution, E test,
   and disk diffusion methods; and (iii) incubation in CO, led to smaller
   zones by disk diffusion and higher MICs by E test, but at a susceptible
   MIC breakpoint of less than or equal to 1 mu g/ml and a susceptible zone
   diameter cutoff of greater than or equal to 19 mm in CO2, 215 of 216
   strains were found to be susceptible to telithromycin.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Appelbaum, PC (Reprint Author), Hershey Med Ctr, Dept Pathol, 500 Univ Dr, Hershey, PA 17033 USA.
   Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA.
   Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.}},
ISSN = {{0095-1137}},
Keywords-Plus = {{RESISTANT STREPTOCOCCUS-PNEUMONIAE; PENICILLIN-RESISTANT; UNITED-STATES;
   ANTIMICROBIAL RESISTANCE; PNEUMOCOCCAL INFECTIONS; ERYTHROMYCIN;
   SUSCEPTIBILITIES; CLARITHROMYCIN; AZITHROMYCIN; MANAGEMENT}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Cited-References = {{Agouridas C, 1997, ANTIMICROB AGENTS CH, V41, P2149.
   APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   ARTHUR M, 1990, ANTIMICROB AGENTS CH, V34, P2024, DOI 10.1128/AAC.34.10.2024.
   Block SL, 1997, PEDIATR INFECT DIS J, V16, P449, DOI 10.1097/00006454-199704000-00029.
   BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831.
   BRYSKIER A, 1996, EXPANDING INDICATION, P39.
   Clark CL, 1998, J CLIN MICROBIOL, V36, P3579.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208.
   Fasola EI, 1997, ANTIMICROB AGENTS CH, V41, P129.
   FRIEDLAND IR, 1992, PEDIATR INFECT DIS J, V11, P433, DOI 10.1097/00006454-199206000-00002.
   FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377.
   JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119.
   Jacobs MR, 1999, ANTIMICROB AGENTS CH, V43, P1901.
   Jones RN, 1996, J ANTIMICROB CHEMOTH, V38, P21, DOI 10.1093/jac/38.1.21.
   Jones RN, 1997, DIAGN MICR INFEC DIS, V27, P7, DOI 10.1016/S0732-8893(96)00181-2.
   MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176.
   MUNOZ R, 1992, CLIN INFECT DIS, V15, P112, DOI 10.1093/clinids/15.1.112.
   {*}NAT COMM CLIN LAB, 1997, M2A6 NCCLS.
   National Commitee for Clinical Laboratory Standards, 1997, M7A4 NCCLS.
   Pankuch GA, 1998, ANTIMICROB AGENTS CH, V42, P2914.
   Pankuch GA, 1998, ANTIMICROB AGENTS CH, V42, P624.
   SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273.
   Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P2562.
   Visalli MA, 1997, ANTIMICROB AGENTS CH, V41, P1867.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{301GN}},
Unique-ID = {{ISI:000086302500024}},
DA = {{2018-08-13}},
}

@article{ ISI:000085930600004,
Author = {Pavelchak, N and DePersis, RP and London, M and Stricof, R and Oxtoby, M
   and DiFerdinando, G and Marshall, E},
Title = {{Identification of factors that disrupt negative air pressurization of
   respiratory isolation rooms}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{2000}},
Volume = {{21}},
Number = {{3}},
Pages = {{191-195}},
Month = {{MAR}},
Abstract = {{OBJECTIVES: To investigate the airflow characteristics of respiratory
   isolation rooms (IRs) and to evaluate the use of visible smoke as a
   monitoring tool.
   METHODS: Industrial hygienists from the New York State Department of
   Health evaluated 140 designated IRs in 38 facilities within New York
   State during 1992 to 1998. The rooms were located in the following
   settings: hospitals (59\%), correctional facilities (40\%), and nursing
   homes (1\%). Each room was tested with visible smoke for directional
   airflow into the patient room (ie, negative air pressure relative to
   adjacent areas). Information was obtained on each facility's policies
   and procedures for maintaining and monitoring the operation of the IRs.
   RESULTS: Inappropriate outward airflow was observed in 38\% of the IRs
   tested. Multiple factors were associated with outward airflow direction,
   including ventilation systems not balanced (54\% of failed rooms),
   shared anterooms (14\%), turbulent airflow patterns (11\%), and
   automated control system inaccuracies (10\%). Of the 140 tested rooms,
   38 (27\%) had either electrical or mechanical devices to monitor air
   pressurization continuously. The direction of airflow at the door to
   50\% (19/38) of these rooms was the opposite of that indicated by the
   continuous monitors at the time of our evaluations. The inability of
   continuous monitors to indicate the direction of airflow was associated
   with instrument limitations (74\%) and malfunction of the devices
   (26\%). In one facility, daily smoke testing by infection control staff
   was responsible for identifying the malfunction of a state-of-the-art
   computerized ventilation monitoring and control system in a room housing
   a patient infectious with drug-resistant tuberculosis.
   CONCLUSION: A substantial percentage of IRs did not meet the negative
   air pressure criterion. These failures were associated with a variety of
   characteristics in the design and operation of the IRs. Our findings
   indicate that a balanced ventilation system does not guarantee inward
   airflow direction. Devices that continuously monitor and, in some cases,
   control the pressurization of IRs had poor reliability. This study
   demonstrates the utility of using visible smoke for testing directional
   airflow of IRs, whether or not continuous monitors are used.
   Institutional tuberculosis control programs should include provisions
   for appropriate monitoring and maintenance of IR systems on a frequent
   basis, including the use of visible smoke.}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Pavelchak, N (Reprint Author), New York State Dept Hlth, Div Occupat Hlth \& Environm Epidemiol, Ctr Environm Hlth, Flanigan Sq,547 River St,Room 230, Troy, NY 12180 USA.
   New York State Dept Hlth, Div Occupat Hlth \& Environm Epidemiol, Ctr Environm Hlth, Troy, NY 12180 USA.
   New York State Dept Hlth, Ctr Community Hlth, Troy, NY 12180 USA.}},
DOI = {{10.1086/501742}},
ISSN = {{0899-823X}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Funding-Acknowledgement = {{PHS HHS {[}U52/CCU200503]}},
Cited-References = {{{*}AC ARCH HLTH AM I, 1996, GUID DES CONSTR HOSP.
   {*}AM C GOV IND HYG, 1998, IND VENT MAN REC PRA.
   {*}AM HOSP ASS AM SO, 1993, HEALTHC FAC MAN SER.
   {*}AM SOC HEAT REFR, 1995, 1995 ASHRAE APPL HDB.
   BURTON DJ, 1989, IND VENTILATION WORK.
   Centers for Disease Control Yellow fever vaccine: recommendations of the Immunization Practices Advisory Committee (ACIP), 1990, MMWR-MORBID MORTAL W, V39, P1.
   {*}US DEP LAB OCC SA, 1993, ENF POL PROC OCC EXP.
   {*}US DEP LAB OCC SA, 1996, 2106 CPL OSHA US DEP.
   1997, FED REG         1017, V62, P54159.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{10}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{294VG}},
Unique-ID = {{ISI:000085930600004}},
DA = {{2018-08-13}},
}

@article{ ISI:000089418900003,
Author = {Beggs, CB and Donnelly, JK and Kerr, KG and Sleigh, PA and Mara, DD and
   Cairns, G},
Title = {{The use of engineering controls to disinfect Mycobacterium tuberculosis
   and airborne pathogens in hospital buildings}},
Journal = {{INDOOR AND BUILT ENVIRONMENT}},
Year = {{2000}},
Volume = {{9}},
Number = {{1}},
Pages = {{17-27}},
Month = {{JAN-FEB}},
Abstract = {{Nosocomial infections are a major problem in many hospital buildings,
   with approximately 10\% of patients acquiring such an infection during a
   hospital stay. Airborne transmission is one of the important routes for
   a number of nosocomial pathogens. To combat this problem there are a
   number of engineering control strategies, such as the use of ultraviotet
   germicidal irradiation and advanced ventilation techniques, which can be
   used. This paper outlines the `state of the art' in air disinfection,
   and reviews recent research work in this field. Copyright (C) 2000 S.
   Karger AG, Basel.}},
Publisher = {{SAGE PUBLICATIONS LTD}},
Address = {{1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Beggs, CB (Reprint Author), Univ Leeds, Sch Civil Engn, Leeds LS2 9JT, W Yorkshire, England.
   Univ Leeds, Sch Civil Engn, Leeds LS2 9JT, W Yorkshire, England.
   Univ Leeds, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England.
   Univ Leeds, Trin \& All Saints Coll, Leeds LS2 9JT, W Yorkshire, England.}},
DOI = {{10.1177/1420326X0000900106}},
ISSN = {{1420-326X}},
Keywords = {{tuberculosis; ultraviolet; air disinfection; infection control;
   ventilation; hospital buildings}},
Keywords-Plus = {{ULTRAVIOLET AIR DISINFECTION; DRUG-RESISTANT TUBERCULOSIS; TRANSMISSION;
   OUTBREAK; ROOM; SURVEILLANCE; PREVENTION; INFECTIONS}},
Research-Areas = {{Construction \& Building Technology; Engineering; Public, Environmental
   \& Occupational Health}},
Web-of-Science-Categories  = {{Construction \& Building Technology; Engineering, Environmental; Public,
   Environmental \& Occupational Health}},
Author-Email = {{c.b.beggs@leeds.ac.uk}},
ResearcherID-Numbers = {{Sleigh, Andrew/E-6675-2010
   }},
ORCID-Numbers = {{Sleigh, Andrew/0000-0001-9218-5660}},
Cited-References = {{Allegra L, 1997, J CLIN MICROBIOL, V35, P1918.
   ALLEN KD, 1987, J HOSP INFECT, V9, P110, DOI 10.1016/0195-6701(87)90048-X.
   Beggs CB, 2000, T ROY SOC TROP MED H, V94, P141, DOI 10.1016/S0035-9203(00)90250-5.
   BENENSON AS, 1990, CONTROL COMMUNICABLE, P408.
   BOURASSA GF, 1995, CONSULTING SPECI FEB, P30.
   Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3.
   CAUL EO, 1995, J HOSP INFECT, V30, P498, DOI 10.1016/0195-6701(95)90054-3.
   {*}CDC, 1993, TOOLS TECHN CDC OFF.
   {*}CDC, 1996, 250133 CDC.
   {*}COMM DIS SURV CTR, 1996, COMMUNICAB DIS REP, V6, P205.
   Cookson ST, 1997, INFECT DIS CLIN N AM, V11, P385, DOI 10.1016/S0891-5520(05)70362-7.
   COX RA, 1995, J HOSP INFECT, V29, P87, DOI 10.1016/0195-6701(95)90191-4.
   {*}DEP HHS, 1988, HOSP INF CONTR GUID.
   DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031.
   DUMYAHN T, 1997, CHARACTERIZATION ULT.
   {*}EL POW RES I, 1997, TUB PRESCR TECHN.
   Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229.
   GALSON EL, 1995, ASHRAE J         MAY, P48.
   GELLERT GA, 1994, LANCET, V343, P609.
   GEURRERO A, 1997, LANCET, V350, P1738.
   GREENE C, 1998, TECHNICAL BRIEF EFFE.
   HALEY RW, 1985, AM J INFECT CONTROL, V13, P78, DOI 10.1016/0196-6553(85)90085-9.
   Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8.
   HITCHINGS DT, 1998, 055156 AM SOC HEALTH.
   KENNEDY MJ, 1995, MANUAL CLIN MICROBIO, P786.
   LIDWELL OM, 1994, J HOSP INFECT, V28, P245, DOI 10.1016/0195-6701(94)90088-4.
   {*}LUM COMM LIGHT DE, ULTR SUPPL AIR DIS M.
   Mertens R, 1996, BAILLIERE CLIN INF D, V3, P159.
   Miller MA, 1996, TUBERCLE LUNG DIS, V77, P414, DOI 10.1016/S0962-8479(96)90113-6.
   MillerLeiden S, 1996, J AIR WASTE MANAGE, V46, P869, DOI 10.1080/10473289.1996.10467523.
   NARDELL EA, 1995, AM J INFECT CONTROL, V23, P156, DOI 10.1016/0196-6553(95)90261-9.
   NARDELL EA, 1993, C AM COLL CHEST PHYS, P873.
   NARDELL EA, 1997, P HLTH BUILD 97 WASH, V1, P301.
   {*}NHS EST, 1994, 2025 NHS HTM.
   {*}PHIL LIGHT, 1993, DIS UV RAD GERM LAMP.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1957, AM REV TUBERC PULM, V75, P420.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   Stead WW, 1996, INFECT CONT HOSP EP, V17, P11.
   STREIFEL AJ, 1997, P HLTH BUILD IAQ C W, V1, P433.
   TANCOCK N, 1998, DEVELOPMENTS, P30.
   Valway SE, 1998, NEW ENGL J MED, V338, P633, DOI 10.1056/NEJM199803053381001.
   WALTER EA, 1995, INFECT DIS CLIN N AM, V9, P823.
   WHO, 1994, TB GLOB EM WHO REP T.
   World health Organization, 1996, GROUPS RISK WHO REP.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Indoor Built Environ.}},
Doc-Delivery-Number = {{355ZR}},
Unique-ID = {{ISI:000089418900003}},
DA = {{2018-08-13}},
}

@article{ ISI:000166340400001,
Author = {Solberg, CO},
Title = {{Spread of Staphylococcus aureus in hospitals: Causes and prevention}},
Journal = {{SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES}},
Year = {{2000}},
Volume = {{32}},
Number = {{6}},
Pages = {{587-595}},
Abstract = {{Methicillin-resistant Staphylococcus aureus (MRSA) has become a major
   nosocomial pathogen in many hospitals worldwide. Even more alarming,
   MRSA strains that are vancomycin intermediate-susceptible are isolated
   with increasing frequency, making therapy for staphylococcal infections
   even more difficult and prevention more important than er er. Spread of
   S. aureus in hospitals and infection control measures are reviewed. The
   major sources of S. aureus in hospitals are septic lesions and carriage
   sites of patients and personnel. Carriage often precedes infection. The
   anterior nares are the most consistent carriage site, followed by the
   perineal area. Skin contamination and aerial dissemination vary markedly
   between carriers and are most pronounced for combined nasal and perineal
   carriers. The principal mode of transmission is via transiently
   contaminated hands of hospital personnel. Airborne transmission seems
   important in the acquisition of nasal carriage. Infection control
   strategies include screening and isolation of newly admitted patients
   suspected of carrying MRSA or S. aureus with intermediate resistance to
   vancomycin, implementation of an infection control program to prevent
   transmission of resistant strains between patients and hospital
   personnel, and institution of a proper antibiotic policy to minimize
   antibiotic resistance development. MRSA carriers should be treated with
   intranasal antibiotics, e.g. mupirocin, and skin disinfectants to
   eliminate carriage. Education of hospital personnel is essential.
   Improved knowledge about the best ways to ensure favourable infection
   control practices is needed. Active intervention against the spread of
   MRSA is important.}},
Publisher = {{TAYLOR \& FRANCIS AS}},
Address = {{CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Solberg, CO (Reprint Author), Haukeland Hosp, Dept Med, NO-5021 Bergen, Norway.
   Haukeland Hosp, Dept Med, NO-5021 Bergen, Norway.
   Univ Bergen, Bergen, Norway.}},
DOI = {{10.1080/003655400459478}},
ISSN = {{0036-5548}},
Keywords-Plus = {{MUPIROCIN CALCIUM OINTMENT; NASAL CARRIAGE; INFECTION-CONTROL;
   DOUBLE-BLIND; RESISTANT; COLONIZATION; EPIDEMIOLOGY; PREVALENCE;
   VANCOMYCIN; EFFICACY}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Cited-References = {{ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404.
   ARMSTRONGESTHER CA, 1976, ANN HUM BIOL, V3, P221, DOI 10.1080/03014467600001381.
   Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253.
   Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement\_1.S74.
   BARBER M, 1958, LANCET, V2, P64.
   BARBER M, 1955, LANCET, V2, P578.
   BATTAN R, 1991, AM J INFECT CONTROL, V19, P98, DOI 10.1016/0196-6553(91)90046-F.
   BERMAN DS, 1987, J INFECT DIS, V155, P829, DOI 10.1093/infdis/155.4.829-a.
   BLOWERS R, 1965, LANCET, V2, P681.
   BLUMBERG LH, 1994, EUR J CLIN MICROBIOL, V13, P82, DOI 10.1007/BF02026131.
   BOE J, 1964, BRIT MED J, V2, P280, DOI 10.1136/bmj.2.5404.280.
   BOELAERT JR, 1993, NEPHROL DIAL TRANSPL, V8, P235.
   BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639.
   BOYCE JM, 1994, EUR J CLIN MICROBIOL, V13, P45, DOI 10.1007/BF02026126.
   BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806.
   BRUUN JN, 1968, ACTA MED SCAND, V184, P417.
   BRUUN JN, 1970, ACTA MED SCAND S514, V188, P1.
   BRUUN JN, 1972, PREVENT, V1, P33.
   CASEWELL MW, 1995, J HOSP INFECT, V30, P465, DOI 10.1016/0195-6701(95)90050-0.
   CASEWELL MW, 1986, J ANTIMICROB CHEMOTH, V17, P365, DOI 10.1093/jac/17.3.365.
   CASEWELL MW, 1995, METHICILLIN RESISTAN, P141.
   Coello R, 1997, J HOSP INFECT, V37, P39, DOI 10.1016/S0195-6701(97)90071-2.
   COELLO R, 1994, EUR J CLIN MICROBIOL, V13, P74, DOI 10.1007/BF02026130.
   Cookson BD, 1998, J ANTIMICROB CHEMOTH, V41, P11, DOI 10.1093/jac/41.1.11.
   Cox RA, 1997, J HOSP INFECT, V35, P117, DOI 10.1016/S0195-6701(97)90100-6.
   DAVIES J, 1977, J ANTIMICROB CHEMOTH, V3, P473, DOI 10.1093/jac/3.5.473.
   DAVIES RR, 1962, LANCET, V2, P1295.
   DAVIES SJ, 1989, PERITON DIALYSIS INT, V9, P61.
   DAWSON SJ, 1994, J HOSP INFECT, V28, P75, DOI 10.1016/0195-6701(94)90157-0.
   DUGUID J P, 1948, Lancet, V2, P845.
   EHRENKRANTZ NJ, 1964, NEW ENGL J MED, V271, P225, DOI 10.1056/NEJM196407302710503.
   EICHENWALD HF, 1960, AM J DIS CHILD, V100, P161, DOI 10.1001/archpedi.1960.04020040163003.
   FERNANDEZ C, 1995, J ANTIMICROB CHEMOTH, V35, P399, DOI 10.1093/jac/35.3.399.
   GILLESPIE WA, 1958, LANCET, V2, P1075.
   Girou E, 1998, CLIN INFECT DIS, V27, P543, DOI 10.1086/514695.
   Harbarth S, 1999, ANTIMICROB AGENTS CH, V43, P1412.
   HARE R, 1961, BRIT MED J, V2, P333, DOI 10.1136/bmj.2.5248.333.
   HARE R, 1956, BMJ-BRIT MED J, V2, P840, DOI 10.1136/bmj.2.4997.840.
   HARE R, 1958, BRIT MED J, V1, P69, DOI 10.1136/bmj.1.5062.69.
   HEDSTROM SA, 1981, SCAND J INFECT DIS, V13, P115, DOI 10.3109/inf.1981.13.issue-2.07.
   HENDERSON RJ, 1963, J CLIN PATHOL, V16, P452, DOI 10.1136/jcp.16.5.452.
   Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8.
   Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505.
   LAURELL G, 1953, ACTA PATHOL MIC SC, V32, P424.
   LIDWELL OM, 1966, J HYG-CAMB, V64, P321, DOI 10.1017/S0022172400040602.
   LIDWELL OM, 1981, STAPHYLOCOCCI, P175.
   MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319.
   MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U.
   NOBLE WC, 1964, J CLIN PATHOL, V17, P79, DOI 10.1136/jcp.17.1.79.
   NOBLE WC, 1965, J CLIN PATHOL, V18, P16, DOI 10.1136/jcp.18.1.16.
   NOBLE WC, 1962, J CLIN PATHOL, V15, P552, DOI 10.1136/jcp.15.6.552.
   PARKER MT, 1965, BMJ-BRIT MED J, V1, P1101, DOI 10.1136/bmj.1.5442.1101.
   REAGAN DR, 1991, ANN INTERN MED, V114, P101, DOI 10.7326/0003-4819-114-2-101.
   RIDLEY M, 1959, BRIT MED J, V1, P270, DOI 10.1136/bmj.1.5117.270.
   RomeroVivas J, 1995, CLIN INFECT DIS, V21, P1417, DOI 10.1093/clinids/21.6.1417.
   ROSDAHL VT, 1994, ZBL BAKT S, V26, P3.
   Rubin RJ, 1999, EMERG INFECT DIS, V5, P9, DOI 10.3201/eid0501.990102.
   SANFORD MD, 1994, CLIN INFECT DIS, V19, P1123, DOI 10.1093/clinids/19.6.1123.
   Selkon J B, 1980, J Hosp Infect, V1, P41, DOI 10.1016/0195-6701(80)90030-4.
   Sherertz RJ, 1996, ANN INTERN MED, V124, P539, DOI 10.7326/0003-4819-124-6-199603150-00001.
   SIBONI KE, 1960, THESIS COPENHAGEN.
   SIMPSON K, 1960, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5169.315.
   Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701.
   SNYDMAN DR, 1990, ANN INTERN MED, V112, P102, DOI 10.7326/0003-4819-112-2-102.
   SOLBERG CO, 1965, ACTA MED SCAND S436, V178, P1.
   Solberg CO, 1972, PREVENT, V1, P43.
   SOLBERG CO, 1974, R3 S NORD ASS CONT C, V7, P1.
   SPICER WJ, 1984, J HOSP INFECT, V5, P45, DOI 10.1016/0195-6701(84)90029-X.
   STRUELENS MJ, 1994, EUR J CLIN MICROBIOL, V13, P56, DOI 10.1007/BF02026128.
   TULLOCH LG, 1960, BMJ-BRIT MED J, V2, P354, DOI 10.1136/bmj.2.5195.354.
   VandenbrouckeGrauls CMJE, 1996, INFECT CONT HOSP EP, V17, P512.
   VARGA DT, 1961, J CLIN INVEST, V40, P2209, DOI 10.1172/JCI104447.
   VERHOEF J, 1999, EUR J CLIN MICROBIOL, V18, P61.
   VOSS A, 1995, INT J ANTIMICROB AG, V5, P101, DOI 10.1016/0924-8579(94)00036-T.
   VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127.
   WEINKE T, 1992, EUR J CLIN MICROBIOL, V11, P985, DOI 10.1007/BF01967787.
   Wenzel RP, 1998, CLIN INFECT DIS, V27, P245, DOI 10.1086/514646.
   WHITE A, 1963, Antimicrob Agents Chemother (Bethesda), V161, P667.
   WHITE A, 1961, J LAB CLIN MED, V58, P273.
   WILLIAMS RE, 1963, BACTERIOL REV, V27, P56.
   WILLIAMS RE, 1966, BACTERIOL REV, V30, P660.
   WILLIAMS REO, 1966, HOSP INFECT CAUSES P.
   {*}WORK PART INF PRE, 1995, MAN POL METH RES STA, pA35.
   YU VL, 1986, NEW ENGL J MED, V315, P91, DOI 10.1056/NEJM198607103150204.}},
Number-of-Cited-References = {{84}},
Times-Cited = {{89}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{Scand. J. Infect. Dis.}},
Doc-Delivery-Number = {{391ED}},
Unique-ID = {{ISI:000166340400001}},
DA = {{2018-08-13}},
}

@article{ ISI:000084315500007,
Author = {Groning, R and Kuhland, U},
Title = {{Pulsed release of nitroglycerin from transdermal drug delivery systems}},
Journal = {{INTERNATIONAL JOURNAL OF PHARMACEUTICS}},
Year = {{1999}},
Volume = {{193}},
Number = {{1}},
Pages = {{57-61}},
Month = {{DEC 20}},
Abstract = {{To achieve a discontinuous drug delivery to the skin a new actively
   controlled transdermal system has been developed. The system consists of
   a tube shaped drug reservoir in combination: with an electronic circuit
   and a gas producing cell. A magnetic switch was used to control the
   onset of the production of hydrogen gas. The gas was generated with a
   constant rate. The tube reservoir was filled with a Solution of
   nitroglycerin in propylene glycol. A discontinuous distribution of
   nitroglycerin in the reservoir is responsible for the pulsed release. 2,
   3, 4, or 6 fractions of nitroglycerin solution, which were separated
   from each other by sections with air, were filled into the tube
   reservoir.:The release studies show that the release patterns directly
   reflect the number of doses, which were filled into the tube. A lag:time
   of about 60 min was obtained, if the gas production is regulated by a
   2.7 k Omega resistor. The drug is released during the pre-programmed
   time intervals within 6-7 h. Between the time intervals no drug release
   occurs. (C) 1999 Elsevier Science B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Groning, R (Reprint Author), Univ Munster, Inst Pharmaceut Technol, Corrensstr 1, D-48149 Munster, Germany.
   Univ Munster, Inst Pharmaceut Technol, D-48149 Munster, Germany.}},
DOI = {{10.1016/S0378-5173(99)00308-7}},
ISSN = {{0378-5173}},
Keywords = {{transdermal system; pulsed release; nitroglycerin; tube reservoir; gas
   producing cell}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{Baker R., 1987, CONTROLLED RELEASE B.
   BONN R, 1985, DTSCH APOTH ZTG, V125, P2073.
   HARDGRAFT J, 1990, INT J PHARM, V64, P187.
   LESCURE F, 1989, PHARM ACTA HELV, V64, P210.
   Muller R.H., 1997, PHARMAZEUTISCHE TECH.
   WEYEL S, 1995, THESIS WESTFALISCHE.
   WINSEL A, 1989, Patent No. 3711714.
   WINSEL A, 1989, DECHEMA MONOGR, V117, P265.
   1993, PRODUKTINFORMATION G.}},
Number-of-Cited-References = {{9}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Int. J. Pharm.}},
Doc-Delivery-Number = {{266TD}},
Unique-ID = {{ISI:000084315500007}},
DA = {{2018-08-13}},
}

@article{ ISI:000082341600022,
Author = {Sung, SW and Kang, CH and Kim, YT and Han, SK and Shim, YS and Kim, JH},
Title = {{Surgery increased the chance of cure in multi-drug resistant pulmonary
   tuberculosis}},
Journal = {{EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY}},
Year = {{1999}},
Volume = {{16}},
Number = {{2}},
Pages = {{187-193}},
Month = {{AUG}},
Abstract = {{Background: Medical treatment of multiple drug resistant (MDR) pulmonary
   tuberculosis is generally quite unsuccessful. Recently, surgical
   management is increasing and shows promise. We analyzed our experience
   to identify the benefits and complications of pulmonary resection in MDR
   pulmonary tuberculosis. Methods: A retrospective review was performed in
   27 patients undergoing pulmonary resection for MDR pulmonary
   tuberculosis between January 1994 and March 1998. Their average ages
   were 40 years and were diagnosed a median of 15 months before surgery.
   All patients had resistance to an average of 4.3 drugs including
   isoniazid and rifampin, and had received second line drugs selected
   according to drug sensitivity test preoperatively. Most patients
   (92.6\%) had cavitary lesions. Bilateral lesions were also identified in
   19 patients (70.4\%), but the main focus was recognized in one side of
   the lung. Most patients were indicated to operation for those who could
   not achieve negative sputum despite adequate medical treatment (n = 16,
   59.3\%); or for negative patients who had significant pulmonary
   parenchymal lesion (n = 11, 40.7\%) which would have had a high
   probability of recurrence. Pneumonectomy was done in nine patients,
   lobectomy in 16 and segmentectomy in two. Results: Then was no operative
   mortality. Morbidity occurred in seven patients (25.9\%): prolonged air
   leakage in three patients, reoperation due to bleeding in two,
   bronchopleural fistula in one, and reversible blindness in one. The
   median follow up period was 15 months (range 3-45). Sputum negative
   conversion was achieved in 22 patients (81.5\%) initially. However,
   continued postoperative chemotherapy could convert to negative in
   another four patients (14.8\%). Only one pneumonectomy patient (3.7\%)
   failed because of considerable contralateral cavity. Conclusion: For
   patients with MDR pulmonary tuberculosis which is localized, and with
   adequate pulmonary reserve function, surgical pulmonary resection
   combined with appropriate pre and postoperative anti-tuberculosis
   chemotherapy can achieve high success rate with acceptable morbidity.
   (C) 1999 Elsevier Science B.V. All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Sung, SW (Reprint Author), Seoul Natl Univ Hosp, Dept Thorac \& Cardiovasc Surg, 28 Yongon, Seoul 110744, South Korea.
   Seoul Natl Univ Hosp, Dept Thorac \& Cardiovasc Surg, Seoul 110744, South Korea.}},
DOI = {{10.1016/S1010-7940(99)00158-X}},
ISSN = {{1010-7940}},
Keywords = {{multi-drug resistant; tuberculosis; lung; surgery}},
Keywords-Plus = {{MYCOBACTERIUM-TUBERCULOSIS}},
Research-Areas = {{Cardiovascular System \& Cardiology; Respiratory System; Surgery}},
Web-of-Science-Categories  = {{Cardiac \& Cardiovascular Systems; Respiratory System; Surgery}},
ResearcherID-Numbers = {{Kim, Young/J-2744-2012
   Kang, Chang-Hyun/J-5364-2012
   Han, Sung Koo/J-5706-2012
   Library, JinyoungPark/F-3767-2011}},
ORCID-Numbers = {{Library, JinyoungPark/0000-0003-0952-1374}},
Cited-References = {{GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   Hong YP, 1997, TUBERC RESP DIS, V44, P1.
   ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623, DOI 10.1164/ajrccm/141.3.623.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   Jun HJ, 1997, KOR J THORAC CARDIOV, V30, P786.
   KOH WJ, 1997, TUBERC RESP DIS, V44, P975.
   Lee MS, 1996, GASTROINTEST ENDOSC, V43, P14.
   Leuvan M V, 1997, ANN THORAC SURG, V63, P1368.
   MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423.
   Moran JF., 1995, SURG CHEST, P752.
   POMERANTZ M, 1991, ANN THORAC SURG, V52, P1108, DOI 10.1016/0003-4975(91)91289-8.
   Pomerantz M, 1995, Semin Thorac Cardiovasc Surg, V7, P108.
   Pomerantz M, 1997, CLIN CHEST MED, V18, P123, DOI 10.1016/S0272-5231(05)70361-0.
   RIZZI A, 1995, ANN THORAC SURG, V59, P896, DOI 10.1016/0003-4975(95)00011-9.
   TREASURE RL, 1995, ANN THORAC SURG, V59, P1405, DOI 10.1016/0003-4975(95)00145-B.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{55}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Eur. J. Cardio-Thorac. Surg.}},
Doc-Delivery-Number = {{231ZQ}},
Unique-ID = {{ISI:000082341600022}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000082382400010,
Author = {Madinier, IM and Fosse, TB and Hitzig, C and Charbit, Y and Hannoun, LR},
Title = {{Resistance profile survey of 50 periodontal strains of Actinobacillus
   actinomycetemcomitans}},
Journal = {{JOURNAL OF PERIODONTOLOGY}},
Year = {{1999}},
Volume = {{70}},
Number = {{8}},
Pages = {{888-892}},
Month = {{AUG}},
Abstract = {{Background: Antibiotic resistance has been increasingly described among
   bacterial species colonizing periodontal pockets, particularly in
   Prevotella and Porphyromonas spp. strains producing beta-lactamases, and
   frequently associated with resistance to tetracycline and erythromycin.
   These resistance genes may be carried on motile genetic elements, or
   transposons, capable of interspecies and intergeneric transmission among
   bacterial strains colonizing a same ecological niche. The aim of this
   prospective study was to determine the resistance profile of
   Actinobacillus actinomycetemcomitans and the prevalence of A.
   actinomycetemcomitans strains producing beta-lactamases in periodontal
   pockets.
   Methods: Fifty strains of A. actinomycetemcomitans were isolated from 42
   patients with adult periodontitis. No patient had periodontal or
   antibiotic therapy in the previous 6 months. Bacterial samples were
   collected from periodontal pockets greater than or equal to 5 mm,
   appropriately diluted, inoculated onto selective medium (chocolate blood
   agar with bacitracin 75 mu g/ml and vancomycin 5 mu m/ml) and incubated
   for 5 days at 37 degrees C in air with 5\% CO2. After conventional
   identification, susceptibility testing to 11 antibiotics was performed
   by the broth dilution method, in trypticase soy broth supplemented with
   yeast extract, hemin, and 0.1\% NaHCO3 to maintain microaerophilic
   conditions in the microtitration plate wells by CO2 formation.
   Results: No strain demonstrated resistance to amoxicillin,
   amoxicillin-clavulanic acid combination, pristinamycin, or ciprofloxacin
   at the breakpoint, but 40\% of the strains were slightly resistant to
   penicillin G, and 4\% were resistant to erythromycin, 90\% to
   spiramycin, 18\% to clarythromycin, 4\% to tetracycline, 72\% to
   metronidazole, and 12\% to ornidazole. Amoxicillin, followed by
   tetracycline and erythromycin, was the most effective antibiotic on A.
   actinomycetemcomitans. The phenotypic research of a beta-lactamase was
   negative for all the strains tested.
   Conclusions: In this work, most A. actinomycetemcomitans strains were
   resistant to metronidazole, but the amoxicillin-metronidazole
   association may be of interest against subgingival anaerobic and
   capnophilic mixed flora. Pristinamycin and ciprofloxacin appeared as
   effective alternative monotherapies against A. actinomycetemcomitans.
   The threat of beta-lactam antibiotic resistance related to B-lactamase
   production is currently not a problem with A. actinomycetemcomitans as
   it has been reported in oral anaerobes.}},
Publisher = {{AMER ACAD PERIODONTOLOGY}},
Address = {{737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Fosse, TB (Reprint Author), CHU Nice, Hop Archet 2, Bacteriol Lab, BP 79, F-06202 Nice 3, France.
   CHU Nice, Bacteriol Lab, F-06202 Nice 3, France.
   Univ Nice Sophia Antipolis, Fac Chirurg Dent, Dept Parodontol, Nice, France.}},
DOI = {{10.1902/jop.1999.70.8.888}},
ISSN = {{0022-3492}},
Keywords = {{Actinobacillus actinomycetemcomitans; amoxicillin/therapeutic use;
   periodontitis/microbiology; periodontal pockets/microbiology;
   beta-lactamases; drug resistance, microbial; tetracycline/therapeutic
   use; erythromycin/therapeutic use; clavulanic acids/therapeutic use;
   ciprofloxacin/therapeutic use; pristinamycin/therapeutic use; penicillin
   G/therapeutic use; spiramycin/therapeutic use;
   clarythromycin/therapeutic use; metronidazole/therapeutic use;
   ornidazole/therapeutic use}},
Keywords-Plus = {{BETA-LACTAMASE; ADULT PERIODONTITIS; TETRACYCLINE RESISTANCE; PIGMENTED
   BACTEROIDES; CONJUGAL TRANSFER; ESCHERICHIA-COLI; BACTERIA;
   SUSCEPTIBILITY; SUPPRESSION; PREVALENCE}},
Research-Areas = {{Dentistry, Oral Surgery \& Medicine}},
Web-of-Science-Categories  = {{Dentistry, Oral Surgery \& Medicine}},
Cited-References = {{Bernal LA, 1998, ORAL MICROBIOL IMMUN, V13, P36, DOI 10.1111/j.1399-302X.1998.tb00748.x.
   Bollen CML, 1996, J PERIODONTOL, V67, P1143, DOI 10.1902/jop.1996.67.11.1143.
   Brogan JM, 1996, GENE, V169, P141, DOI 10.1016/0378-1119(95)00792-X.
   Bush K, 1997, CIBA F SYMP, V207, P152.
   CHRISTERSSON LA, 1993, J CLIN PERIODONTOL, V20, P395, DOI 10.1111/j.1600-051X.1993.tb00379.x.
   FOSSE T, 1999, IN PRESS ORAL MICROB.
   FOWERAKER JE, 1990, ANTIMICROB AGENTS CH, V34, P1501, DOI 10.1128/AAC.34.8.1501.
   GONCHAROFF P, 1993, INFECT IMMUN, V61, P3544.
   GUINEY DG, 1990, J BACTERIOL, V172, P495.
   Hedberg M, 1996, J CHEMOTHERAPY, V8, P3, DOI 10.1179/joc.1996.8.1.3.
   HEDBERG M, 1995, ANTIMICROB AGENTS CH, V39, P1458, DOI 10.1128/AAC.39.7.1458.
   JOHNSON CC, 1990, ANTIMICROB AGENTS CH, V34, P1597, DOI 10.1128/AAC.34.8.1597.
   KAPLAN AH, 1989, REV INFECT DIS, V11, P46.
   KINDER SA, 1986, J CLIN MICROBIOL, V23, P1127.
   KONONEN E, 1995, CLIN INFECT DIS, V20, pS364, DOI 10.1093/clinids/20.Supplement\_2.S364.
   Kononen E, 1997, CLIN INFECT DIS, V25, pS272.
   Lacroix JM, 1996, ORAL MICROBIOL IMMUN, V11, P282, DOI 10.1111/j.1399-302X.1996.tb00182.x.
   LACROIX JM, 1991, ANTIMICROB AGENTS CH, V35, P886, DOI 10.1128/AAC.35.5.886.
   LEWIS MAO, 1995, J ANTIMICROB CHEMOTH, V35, P785, DOI 10.1093/jac/35.6.785.
   LISTGARTEN MA, 1993, J PERIODONTOL, V64, P155, DOI 10.1902/jop.1993.64.3.155.
   MASHIMO PA, 1983, J PERIODONTOL, V54, P420, DOI 10.1902/jop.1983.54.7.420.
   Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement\_1.S19.
   MEYER DH, 1991, INFECT IMMUN, V59, P2719.
   Muller HP, 1998, J PERIODONTAL RES, V33, P49.
   NOWAK KF, 1998, ORAL MICROBIOL IMMUN, V13, P124.
   OCONNOR BC, 1990, J PERIODONTOL, V61, P228, DOI 10.1902/jop.1990.61.4.228.
   OLVISK B, 1993, CLIN INFECT DIS S4, V16, pS310.
   PAJUKANTA R, 1993, FEMS IMMUNOL MED MIC, V6, P241.
   Roe DE, 1996, J ANTIMICROB CHEMOTH, V37, P457, DOI 10.1093/jac/37.3.457.
   ROE DE, 1995, ORAL MICROBIOL IMMUN, V10, P227, DOI 10.1111/j.1399-302X.1995.tb00147.x.
   ROSCOE DL, 1992, ANTIMICROB AGENTS CH, V36, P2197, DOI 10.1128/AAC.36.10.2197.
   SLOTS J, 1980, INFECT IMMUN, V29, P1013.
   SLOTS J, 1983, J PERIODONTOL, V54, P193, DOI 10.1902/jop.1983.54.4.193.
   SLOTS J, 1980, ANTIMICROB AGENTS CH, V18, P9, DOI 10.1128/AAC.18.1.9.
   SLOTS J, 1982, ARCH MICROBIOL, V131, P60, DOI 10.1007/BF00451500.
   SREENIVASAN PK, 1991, INFECT IMMUN, V59, P4621.
   Tinoco EMB, 1998, J PERIODONTOL, V69, P1355, DOI 10.1902/jop.1998.69.12.1355.
   VANWINKELHOFF AJ, 1992, J PERIODONTOL, V63, P52, DOI 10.1902/jop.1992.63.1.52.
   vanWinkelhoff AJ, 1997, J CLIN PERIODONTOL, V24, P538.
   WAKER CB, 1985, J PERIODONTOL S, pS67.
   ZAMBON JJ, 1985, J CLIN PERIODONTOL, V12, P1, DOI 10.1111/j.1600-051X.1985.tb01348.x.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Periodont.}},
Doc-Delivery-Number = {{232QX}},
Unique-ID = {{ISI:000082382400010}},
DA = {{2018-08-13}},
}

@article{ ISI:000081936200016,
Author = {Mulholland, K},
Title = {{Strategies for the control of pneumococcal diseases}},
Journal = {{VACCINE}},
Year = {{1999}},
Volume = {{17}},
Number = {{1}},
Pages = {{S79-S84}},
Month = {{JUL 30}},
Note = {{1st International Symposium on Adult Immunization in Asia - Prevention
   of Influenza and Pneumococcal Infections, HANOI, VIETNAM, APR 20-22,
   1998}},
Organization = {{Marcel Merieux Fdn; WHO}},
Abstract = {{Streptococcus pneumoniae (pneumococcus) is a Gram-positive, encapsulated
   bacteria that is a major cause of human disease in people of all ages.
   It is the most important cause of bacterial pneumonia in infancy,
   childhood and adult life, and the most important cause of meningitis in
   all age groups except children of 3 months to 2 years in whom
   Haemophilus influenzae type b (Hib) predominates (in the absence of Hib
   vaccination). Antibodies to the pneumococcal polysaccharide capsule are
   protective, and at present 90 capsular serotypes are recognized.
   The global burden of pneumococcal disease is poorly understood. II is
   believed to be responsible for 1-2 million deaths among children under 5
   years of age every year and probably a similar number among adults.
   Thus, the global burden of pneumonia in adults is probably significantly
   underestimated at present. Strategies for the control of pneumococcal
   disease include control of risk factors, treatment of established cases
   and vaccination. In children, improved nutrition, better housing and
   reduced indoor air pollution are difficult to address, but should
   eventually reduce pneumonia rates. In adults, the risk factors are even
   more difficult to address, although control of alcohol and tobacco
   consumption and reduced transmission of HIV should all affect
   pneumococcal disease rates. Penicillin-resistant pneumococci are now
   widespread throughout the world. Where penicillin resistance occurs,
   penicillin should not be used to treat pneumococcal meningitis; however,
   penicillin, at higher doses if necessary, remains the drug of choice for
   the treatment of pneumococcal pneumonia, even where penicillin
   resistance is prevalent. There are three approaches to pneumococcal
   vaccination: polysaccharide vaccines (covering 23 serotypes),
   polysaccharide-protein conjugate vaccines (covering 9-11 serotypes) and
   common protein vaccines (which are not serotype-specific). Only
   polysaccharide vaccines are available now, but conjugate vaccines will
   be available soon. Polysaccharide vaccines probably have a role in
   protecting the elderly from pneumococcal disease, especially those at
   high risk. The potential role of conjugate vaccines in infants is
   unclear. (C) 1999 Elsevier Science Ltd. All rights reserved.}},
Publisher = {{ELSEVIER SCI LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Mulholland, K (Reprint Author), WHO, Global Programme Vaccines \& Immunizat, Vaccine Res \& Dev, CH-1211 Geneva 27, Switzerland.
   WHO, Global Programme Vaccines \& Immunizat, Vaccine Res \& Dev, CH-1211 Geneva 27, Switzerland.}},
DOI = {{10.1016/S0264-410X(99)00112-7}},
ISSN = {{0264-410X}},
Keywords = {{pneumonia; Streptococcus pneumoniae; disease burden; developing
   countries; vaccines; antimicrobial resistance}},
Keywords-Plus = {{RESPIRATORY-TRACT INFECTIONS; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE
   VACCINE; ANTIMICROBIAL RESISTANCE; POLYSACCHARIDE VACCINE; GAMBIAN
   CHILDREN; GUINEAN CHILDREN; B HIB; EPIDEMIOLOGY; CARRIAGE}},
Research-Areas = {{Immunology; Research \& Experimental Medicine}},
Web-of-Science-Categories  = {{Immunology; Medicine, Research \& Experimental}},
Cited-References = {{ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221.
   ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008.
   APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl\_C.31.
   BLOCK SL, 1997, 37 INT C ANT AG CHEM.
   BOGAERTS J, 1993, J INFECTION, V27, P157, DOI 10.1016/0163-4453(93)94728-T.
   Brandileone MCD, 1997, MICROB DRUG RESIST, V3, P141.
   Briles DE, 1996, VACCINE, V14, P858, DOI 10.1016/0264-410X(96)82948-3.
   BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826.
   CASADEVALL A, 1994, ANTIMICROB AGENTS CH, V38, P1695, DOI 10.1128/AAC.38.8.1695.
   Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271.
   DAVIDSON M, 1994, J INFECT DIS, V170, P368, DOI 10.1093/infdis/170.2.368.
   Falade AG, 1997, ANN TROP PAEDIATR, V17, P315, DOI 10.1080/02724936.1997.11747904.
   FEDSON DS, 1998, VACCINES.
   Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7.
   HENDRICHSEN J, 1995, J CLIN MICROBIOL, V33, P2759.
   JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119.
   JOHNSTON RB, 1991, REV INFECT DIS, V13, pS509.
   KRISTINSSON KG, 1997, 37 INT C ANT AG CHEM.
   LEHMANN D, 1991, ANN TROP PAEDIATR, V11, P247, DOI 10.1080/02724936.1991.11747510.
   Leowski J, 1986, World Health Stat Q, V39, P138.
   MBELLE N, 1997, 37 INT C ANT AG CHEM.
   MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2.
   Murray CJ, 1996, GLOBAL HLTH STAT.
   NAHM MH, 1997, 37 INT C ANT AG CHEM.
   NUTTALL N, 1997, 20 INT C CHEM SYDN.
   Obaro SK, 1996, BMJ-BRIT MED J, V312, P1521, DOI 10.1136/bmj.312.7045.1521.
   Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7.
   OBrien KL, 1996, PEDIATR INFECT DIS J, V15, P425, DOI 10.1097/00006454-199605000-00009.
   ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010.
   Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3.
   Ostroff SM, 1996, CLIN INFECT DIS, V23, P1069, DOI 10.1093/clinids/23.5.1069.
   PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802.
   RILEY ID, 1986, LANCET, V2, P877.
   TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982.
   TORZILLO PJ, 1995, MED J AUSTRALIA, V162, P182.
   Usen S, 1998, PEDIATR INFECT DIS J, V17, P23, DOI 10.1097/00006454-199801000-00006.
   {*}WHO YOUNG INF STU, IN PRESS PEDIAT INFE.
   {*}WORLD BANK, 1993, WORL DDEV REP 1993.
   Yamamoto M, 1997, INFECT IMMUN, V65, P640.
   Zangwill KM, 1996, J INFECT DIS, V174, P752, DOI 10.1093/infdis/174.4.752.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{60}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Vaccine}},
Doc-Delivery-Number = {{225BM}},
Unique-ID = {{ISI:000081936200016}},
DA = {{2018-08-13}},
}

@article{ ISI:000081364900006,
Author = {Caya, F and Fairbrother, JM and Lessard, L and Quessy, S},
Title = {{Characterization of the risk to human health of pathogenic Escherichia
   coli isolates from chicken carcasses}},
Journal = {{JOURNAL OF FOOD PROTECTION}},
Year = {{1999}},
Volume = {{62}},
Number = {{7}},
Pages = {{741-746}},
Month = {{JUL}},
Abstract = {{The purpose of this study was to evaluate the risk for human health
   associated with pathogenic Escherichia coli isolated from airsacculitis
   and cellulitis in chickens, by comparing the genotypic and phenotypic
   profiles of avian E. coli isolates and E. coli strains isolated from
   sick humans during the same period and in the same geographical area as
   the avian isolates. A total of 96 isolates and 46 isolates from lesions
   of cellulitis and airsacculitis, respectively, were obtained. Isolates
   from the backs of some of the affected and healthy birds and 91
   intestinal and extraintestinal isolates from humans with diarrhea,
   urinary tract infections, or septicemia were examined. The frequency of
   antimicrobial resistance was in general higher in the avian than in the
   human isolates. VT1-VT2-Eae and VT2-Eae, pathotypes associated with
   hemolytic and uremic syndrome and bloody diarrhea in humans, were the
   most frequently encountered pathotypes in human intestinal isolates but
   were not recovered from the avian isolates. Aero-Pap-TSH and Aero-TSH
   were the most frequently encountered pathotypes in avian isolates but
   were rarely observed in human isolates. No avian isolate was of
   serogroup O157, whereas many human isolates belonged to this O group.
   O78 and O2 were the most frequently observed O groups in avian isolates
   but were rarely found in human isolates. Only two avian isolates
   demonstrated possible relatedness to human isolates based on
   pulsed-field gel electrophoresis profiles, but they belonged to
   different pathotypes. Our results suggest that avian isolates recovered
   from cellulitis and air sacullitis possess very few of the attributes
   required to cause diseases in humans. It is also concluded that isolates
   from cellulitis and airsacculitis do not represent a greater hazard than
   isolates from the back of healthy birds.}},
Publisher = {{INT ASSOC MILK FOOD ENVIRONMENTAL SANITARIANS, INC}},
Address = {{6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Quessy, S (Reprint Author), Sante Canada, Lab Hyg Vet \& Alimentaire, 3400 Casavant Ouest, St Hyacinthe, PQ J2S 8E3, Canada.
   Sante Canada, Lab Hyg Vet \& Alimentaire, St Hyacinthe, PQ J2S 8E3, Canada.
   Univ Montreal, Fac Med Vet, Dept Pathol \& Microbiol, St Hyacinthe, PQ J2S 7C6, Canada.}},
DOI = {{10.4315/0362-028X-62.7.741}},
ISSN = {{0362-028X}},
Keywords-Plus = {{FIELD GEL-ELECTROPHORESIS; CLONAL RELATIONSHIPS; EPIDEMIOLOGIC ANALYSIS;
   RESTRICTION PATTERNS; ANIMAL INFECTIONS; O157-H7; STRAINS; CELLULITIS;
   LESIONS; PIGLETS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Cited-References = {{ACHTMAN M, 1986, INFECT IMMUN, V51, P268.
   BARRETT TJ, 1994, J CLIN MICROBIOL, V32, P3013.
   Beaudry M, 1996, J CLIN MICROBIOL, V34, P144.
   BOHM H, 1992, J CLIN MICROBIOL, V30, P2169.
   BROES A, 1988, J CLIN MICROBIOL, V26, P2402.
   Calnek BW, 1997, DIS POULTRY.
   CHERIFI A, 1994, J CLIN MICROBIOL, V32, P1197.
   CHERIFI A, 1991, FEMS MICROBIOL LETT, V80, P225, DOI 10.1111/j.1574-6968.1991.tb04666.x.
   CLOUD SS, 1985, AVIAN DIS, V29, P1084, DOI 10.2307/1590463.
   DAIGLE F, 1994, CAN J MICROBIOL, V40, P286, DOI 10.1139/m94-046.
   DOZOIS CM, 1992, INFECT IMMUN, V60, P2648.
   EDWARDS PR, 1962, IDENTIFICATION ENTER.
   Elfadil AA, 1996, AVIAN DIS, V40, P690, DOI 10.2307/1592282.
   GIBSON JR, 1995, EPIDEMIOL INFECT, V115, P215, DOI 10.1017/S0950268800058349.
   GROSS WB, 1994, ESCHERICHIA COLI DOM.
   HERENDA DC, 1996, POULTRY DIS MEAT HYG.
   JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80.
   KAUFMANN ME, 1994, METHODS PRACTICAL LA, pCH8.
   Krause U, 1996, J CLIN MICROBIOL, V34, P959.
   Laconcha I, 1998, INT J FOOD MICROBIOL, V40, P27, DOI 10.1016/S0168-1605(98)00007-5.
   LENNETTE EH, 1985, MANUAL CLIN MICROBIO.
   Maurer JJ, 1998, AVIAN DIS, V42, P106, DOI 10.2307/1592582.
   MESSIER S, 1993, AVIAN DIS, V37, P839, DOI 10.2307/1592039.
   MORRIS MP, 1991, BROILER IND      SEP, P32.
   {*}NAT COMM CLIN LAB, 1991, PERF STAND ANT DISKS.
   OJENIYI AA, 1989, EPIDEMIOL INFECT, V103, P513, DOI 10.1017/S0950268800030910.
   ORSKOV F, 1990, J INFECT DIS, V162, P76, DOI 10.1093/infdis/162.1.76.
   OSWALD E, 1994, J MED MICROBIOL, V40, P428, DOI 10.1099/00222615-40-6-428.
   PROVENCE DL, 1994, INFECT IMMUN, V62, P1369.
   SALYERS AA, 1994, BACTERIAL PATHOGENES, pCH16.
   SHAH PM, 1993, VET MICROBIOL, V35, P269, DOI 10.1016/0378-1135(93)90151-V.
   Shimizu A, 1997, AM J VET RES, V58, P1412.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   TZIPORI S, 1987, INFECT IMMUN, V55, P3117.
   VANDENBOSCH JF, 1981, A VAN LEEUW J MICROB, V47, P97, DOI 10.1007/BF02342193.
   WHATLING CA, 1993, ANAL BIOCHEM, V210, P98, DOI 10.1006/abio.1993.1156.
   WHITLEY T, 1993, IEEE PHOTONIC TECH L, V4, P399.
   WHITTAM TS, 1988, J INFECT DIS, V157, P1124, DOI 10.1093/infdis/157.6.1124.
   YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x.
   ZHU C, 1994, INFECT IMMUN, V62, P4153.
   1998, UNPUB AGR AGRIFOOD C.}},
Number-of-Cited-References = {{41}},
Times-Cited = {{21}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Food Prot.}},
Doc-Delivery-Number = {{215CT}},
Unique-ID = {{ISI:000081364900006}},
DA = {{2018-08-13}},
}

@article{ ISI:000081218500031,
Author = {Delaquis, PJ and Ward, SM and Holley, RA and Cliff, MC and Mazza, G},
Title = {{Microbiological, chemical and sensory properties of pre-cooked roast
   beef preserved with horseradish essential oil}},
Journal = {{JOURNAL OF FOOD SCIENCE}},
Year = {{1999}},
Volume = {{64}},
Number = {{3}},
Pages = {{519-524}},
Month = {{MAY-JUN}},
Abstract = {{Pre-cooked roast beef slices were stored 28 days at 4+/-2 degrees C in
   air or 100\% N-2 with and without vaporized horseradish essential oil
   (HEO). Addition of 20 mu L HEO/L restricted growth of most spoilage
   bacteria. Pseudomonas spp. and Enterobacteriaceae were strongly
   inhibited by HEO. Lactic acid bacteria were more resistant to the
   antimicrobial effect and dominated spoilage flora. Sensory evaluation
   and headspace analysis by gas chromatography/mass spectrometry revealed
   that development of off-flavors and odors derived from fat oxidation
   products was delayed by HEO. Cooked meat color was also preserved in
   samples stored under HEO.}},
Publisher = {{INST FOOD TECHNOLOGISTS}},
Address = {{SUITE 300 221 N LASALLE ST, CHICAGO, IL 60601-1291 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Delaquis, PJ (Reprint Author), Agr \& Agri Food Canada, Pacific Agr Food Res Ctr, Highway 97 S, Summerland, BC V0H 1Z0, Canada.
   Agr \& Agri Food Canada, Pacific Agr Food Res Ctr, Summerland, BC V0H 1Z0, Canada.
   Univ Manitoba, Dept Food Sci, Winnipeg, MB R3T 2N2, Canada.}},
DOI = {{10.1111/j.1365-2621.1999.tb15075.x}},
ISSN = {{0022-1147}},
Keywords = {{roast beef; spoilage; horseradish; isothiocyanates}},
Keywords-Plus = {{WARMED-OVER FLAVOR; MODIFIED ATMOSPHERE; FOOD PRESERVATION; MEAT;
   VACUUM; GROWTH}},
Research-Areas = {{Food Science \& Technology}},
Web-of-Science-Categories  = {{Food Science \& Technology}},
ResearcherID-Numbers = {{Mazza, Giuseppe/A-2833-2013}},
Cited-References = {{ANDERSON ML, 1989, MEAT SCI, V25, P69, DOI 10.1016/0309-1740(89)90067-3.
   {*}AOAC, 1990, OFF METH AN.
   DELAQUIS PJ, 1995, FOOD TECHNOL-CHICAGO, V49, P73.
   DELAQUIS PJ, 1997, J FOOD PROTECT, V60, P1.
   Dillon V., 1994, NATURAL ANTIMICROBIA.
   DYMICKY M, 1975, J FOOD SCI, V40, P306, DOI 10.1111/j.1365-2621.1975.tb02189.x.
   GREER GG, 1994, FOOD RES INT, V27, P371, DOI 10.1016/0963-9969(94)90193-7.
   HINTLIAN CB, 1987, J FOOD PROCESS PRES, V11, P171, DOI 10.1111/j.1745-4549.1987.tb00044.x.
   HINTLIAN CB, 1987, J FOOD PROTECT, V50, P218, DOI 10.4315/0362-028X-50.3.218.
   HUDSON JA, 1994, J FOOD PROTECT, V57, P204, DOI 10.4315/0362-028X-57.3.204.
   ISSHIKI K, 1992, BIOSCI BIOTECH BIOCH, V56, P1476, DOI 10.1271/bbb.56.1476.
   Kerler J, 1996, J FOOD SCI, V61, P1271, DOI 10.1111/j.1365-2621.1996.tb10977.x.
   KONIECKO ES, 1985, HDB MEAT ANAL.
   Kramlich W. E., 1973, PROCESSED MEATS.
   Kyung KH, 1997, J FOOD PROTECT, V60, P67, DOI 10.4315/0362-028X-60.1.67.
   MAZZA G, 1984, CAN I FOOD SC TECH J, V17, P18, DOI 10.1016/S0315-5463(84)72310-8.
   MICHEL ME, 1991, J FOOD PROTECT, V54, P767, DOI 10.4315/0362-028X-54.10.767.
   MOYLS L, 1992, T ASAE, V35, P1259.
   PALOP ML, 1995, INT J FOOD MICROBIOL, V26, P219, DOI 10.1016/0168-1605(95)00123-2.
   RAMARATHNAM N, 1991, J AGR FOOD CHEM, V39, P1839, DOI 10.1021/jf00010a031.
   {*}SAS, 1990, STAT US GUID VERS 6, V1.
   STANGELO AJ, 1987, J FOOD SCI, V52, P1163, DOI 10.1111/j.1365-2621.1987.tb14034.x.
   VELIOGLU YS, 1998, IN PRESS J AGR FOOD.
   Ward SM, 1998, FOOD RES INT, V31, P19, DOI 10.1016/S0963-9969(98)00054-4.
   YAMASAKI H, 1984, THEOR COMPUT SCI, V31, P1, DOI 10.1016/0304-3975(84)90121-X.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{30}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{12}},
Journal-ISO = {{J. Food Sci.}},
Doc-Delivery-Number = {{212LQ}},
Unique-ID = {{ISI:000081218500031}},
DA = {{2018-08-13}},
}

@article{ ISI:000080853700011,
Author = {Duchaine, C and Meriaux, A and Brochu, G and Bernard, K and Cormier, Y},
Title = {{Saccharopolyspora rectivirgula from Quebec dairy barns: application of
   simplified criteria for the identification of an agent responsible for
   farmer's lung disease}},
Journal = {{JOURNAL OF MEDICAL MICROBIOLOGY}},
Year = {{1999}},
Volume = {{48}},
Number = {{2}},
Pages = {{173-180}},
Month = {{FEB}},
Abstract = {{Saccharopolyspora rectivirgula (Micropolyspora faeni) is one of the
   major agents responsible for farmer's lung disease, a form of
   hypersensitivity pneumonitis. It is frequently isolated from the air of
   contaminated barns. The identification of this actinomycete is difficult
   because most of its phenotypic characteristics are variable and
   classical tests are not easy to perform on actinomycetes, Fatty acid
   analysis is very useful for the identification of these strains, but is
   not available except in some research or reference laboratories.
   Morphological (microscopic and macroscopic observations), physiological
   and biochemical tests (growth properties; macromolecules degraded;
   citrate utilisation and acid production from carbohydrates; resistance
   to antibiotics, lysozyme and heat), cell wall and fatty acid analyses
   and IgG analyses with serum from patients with farmer's lung were
   performed on 12 environmental isolates presumed to be S. rectivirgula
   and two control strains of S, rectivirgula. From this, a simple and
   rapid scheme for the identification of this actinomycete is proposed:
   optimal growth temperature (55 degrees C); colony appearance based on
   morphology (filamentous) and colour (beige to orange-brown); microscopic
   morphology (chains of spores on both aerial and substrate mycelium);
   growth on NaCl 10\%; cell-wall analysis (type IV); and the verification
   of antibody response with serum from a patient with farmer's lung. This
   last criterion is important to confirm the immunogenicity of the strains
   identified as S, rectivirgula, This scheme provides an accurate and
   efficient way of identifying S, rectivirgula strains and evaluating
   exposure to this bacterium, The study shows the limited value and the
   lack of reproducibility of some classical biochemical tests.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cormier, Y (Reprint Author), Hop Laval, Ctr Pneumol, Unite Rech, Ottawa, ON, Canada.
   Hop Laval, Ctr Pneumol, Unite Rech, Ottawa, ON, Canada.
   Univ Laval, Dept Microbiol, Laval, PQ, Canada.
   Lab Ctr Dis Control, Natl Bacteriol Lab, Ottawa, ON K1A 0L2, Canada.}},
DOI = {{10.1099/00222615-48-2-173}},
ISSN = {{0022-2615}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Cited-References = {{Bauer A W, 1966, Tech Bull Regist Med Technol, V36, P49.
   BERNARD KA, 1991, J CLIN MICROBIOL, V29, P83.
   CORMIER Y, 1990, AM IND HYG ASSOC J, V51, P304, DOI 10.1202/0002-8894(1990)051<0304:AMCITT>2.0.CO;2.
   CORMIER Y, 1985, THORAX, V40, P138, DOI 10.1136/thx.40.2.138.
   DERKSEN FJ, 1985, J APPL PHYSIOL, V58, P598.
   Goodfellow M, 1983, BIOL ACTINOMYCETES, P1.
   GORDON RE, 1966, J GEN MICROBIOL, V45, P355, DOI 10.1099/00221287-45-2-355.
   GORDON RE, 1957, J BACTERIOL, V73, P15.
   GORDON RE, 1974, INT J SYST BACTERIOL, V24, P54, DOI 10.1099/00207713-24-1-54.
   GORDON RUTH E., 1955, JOUR BACT, V69, P147.
   KHAN ZU, 1995, ANTON LEEUW INT J G, V67, P339, DOI 10.1007/BF00872932.
   KORNWENDISCH F, 1989, INT J SYST BACTERIOL, V39, P430, DOI 10.1099/00207713-39-4-430.
   KURUP VP, 1975, J CLIN MICROBIOL, V2, P55.
   MOORE WEC, 1980, APPL ENVIRON MICROB, V39, P900.
   PEPYS J, 1963, LANCET, V2, P607.
   Simmons JS, 1926, J INFECT DIS, V39, P209, DOI 10.1093/infdis/39.3.209.
   STANECK JL, 1974, APPL MICROBIOL, V28, P226.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{J. Med. Microbiol.}},
Doc-Delivery-Number = {{206AK}},
Unique-ID = {{ISI:000080853700011}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000077069400025,
Author = {Clark, CL and Jacobs, MR and Appelbaum, PC},
Title = {{Antipneumococcal activities of levofloxacin and clarithromycin as
   determined by agar dilution, microdilution, E-test, and disk diffusion
   methodologies}},
Journal = {{JOURNAL OF CLINICAL MICROBIOLOGY}},
Year = {{1998}},
Volume = {{36}},
Number = {{12}},
Pages = {{3579-3584}},
Month = {{DEC}},
Abstract = {{The activities of levofloxacin and clarithromycin against 199
   penicillin- and macrolide-susceptible and -resistant pneumococci were
   tested by agar and microdilution methods in air and by disk diffusion
   and E-test methods in air and CO2. For levofloxacin, greater than or
   equal to 99.0\% of strains were susceptible at less than or equal to 2.0
   mu g/ml with zone diameters of greater than or equal to 17 mm,
   regardless of incubation in air or CO2. Although zone sizes were smaller
   and E-test MICs were higher for clarithromycin in CO2 than those in air,
   category differences were minor, and susceptibility rates for
   clarithromycin were similar to those obtained by agar and microdilution
   in air (range, 76.9 to 80.9\% by all methods). For clarithromycin,
   adjustment of breakpoints based upon distribution of results resulted in
   susceptibility rates which were similar by all methods (75.8 to 76.9\%
   susceptible, 0 to 1.5\% intermediate, 22.6 to 23.1\% resistant). Minor
   discrepancies were obtained with levofloxacin for one strain (0.5\%) by
   microdilution and two strains (1.0\%) by disk diffusion in CO2. For
   clarithromycin, minor discrepancies were found in three strains (1.5\%)
   by microdilution, seven strains (3.5\%) by agar dilution, four strains
   (2.0\%) by E-test in air, six strains (3.0\%) by disk diffusion in air,
   and five strains (2.5\%) by disk diffusion in CO2. Major discrepancies
   occurred with levofloxacin in one strain (0.5\%) by microdilution but
   were not found with clarithromycin. Very major discrepancies were not
   seen with levofloxacin, but occurred with clarithromycin in five strains
   (2.5\%) by microdilution, three strains (1.5\%) by agar dilution, two
   strains (1.0\%) by E-test in air, eight strains (4.0\%) by disk
   diffusion in air, and one strain (0.5\%) by disk diffusion in CO2.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Appelbaum, PC (Reprint Author), Milton S Hershey Med Ctr, Dept Pathol, 500 Univ Dr, Hershey, PA 17033 USA.
   Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA.
   Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.}},
ISSN = {{0095-1137}},
Keywords-Plus = {{PENICILLIN-RESISTANT PNEUMOCOCCI; STREPTOCOCCUS-PNEUMONIAE;
   UNITED-STATES; ANTIMICROBIAL RESISTANCE; TIME-KILL; INFECTIONS;
   CIPROFLOXACIN; ERYTHROMYCIN; SUSCEPTIBILITIES; SPARFLOXACIN}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Cited-References = {{APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   BLOCK S, 1994, MMWR-MORBID MORTAL W, V43, P23.
   BOLMSTROM A, 1997, 3M INT C ANT AG CHEM, P89.
   BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208.
   Fasola EI, 1997, ANTIMICROB AGENTS CH, V41, P129.
   FRIEDLAND IR, 1992, PEDIATR INFECT DIS J, V11, P433, DOI 10.1097/00006454-199206000-00002.
   FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377.
   JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119.
   Jones RN, 1996, J ANTIMICROB CHEMOTH, V38, P21, DOI 10.1093/jac/38.1.21.
   MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176.
   MUNOZ R, 1992, CLIN INFECT DIS, V15, P112, DOI 10.1093/clinids/15.1.112.
   National Committee for Clinical Laboratory Standards, 1997, NCCLS PUBL, V11-A4.
   PANKUCH GA, 1995, J ANTIMICROB CHEMOTH, V35, P230, DOI 10.1093/jac/35.1.230.
   SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273.
   Visalli MA, 1997, ANTIMICROB AGENTS CH, V41, P1867.
   Visalli MA, 1996, ANTIMICROB AGENTS CH, V40, P362.
   Visalli MA, 1997, DIAGN MICR INFEC DIS, V28, P131, DOI 10.1016/S0732-8893(97)00017-5.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Clin. Microbiol.}},
Doc-Delivery-Number = {{140CP}},
Unique-ID = {{ISI:000077069400025}},
DA = {{2018-08-13}},
}

@article{ ISI:000076998200007,
Author = {Morihira, K and Nishimori, T and Kusama, H and Horiguchi, Y and
   Kuwajima, I and Tsuruo, T},
Title = {{Synthesis of C-ring aromatic taxoids and evaluation of their multi-drug
   resistance reversing activity}},
Journal = {{BIOORGANIC \& MEDICINAL CHEMISTRY LETTERS}},
Year = {{1998}},
Volume = {{8}},
Number = {{21}},
Pages = {{2973-2976}},
Month = {{NOV 3}},
Abstract = {{The C-aromatic taxoids were synthesized to develop effective inhibitors
   against drug efflux mediated by p-glycoproteins. Among those tested
   using multi-drug resistant tumor cells (278OAD). the benzoate II
   exhibited significant activity as potent as verapamil, a
   well-established MDR reversing agent. (C) 1998 Elsevier Science Ltd. Air
   rights reserved.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kuwajima, I (Reprint Author), Kitasato Inst, Minato Ku, 5-9-1 Shirokane, Tokyo 1088642, Japan.
   Tokyo Inst Technol, Dept Chem, Meguro Ku, Tokyo 1528551, Japan.
   Univ Tokyo, Inst Mol \& Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.}},
DOI = {{10.1016/S0960-894X(98)00539-3}},
ISSN = {{0960-894X}},
Keywords = {{antineoplastics; antitumor compounds; terpenes and terpenoids}},
Keywords-Plus = {{TAXUS-CUSPIDATA; P-GLYCOPROTEIN; DERIVATIVES; CANCER; CELLS}},
Research-Areas = {{Pharmacology \& Pharmacy; Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Medicinal; Chemistry, Organic}},
Cited-References = {{Bosch I, 1996, BBA-REV CANCER, V1288, pF37, DOI 10.1016/0304-419X(96)00022-4.
   FORD JM, 1993, CYTOTECHNOLOGY, V12, P171, DOI 10.1007/BF00744664.
   Georg G. I., 1995, ACS S SERIES, V583.
   Kobayashi J, 1997, BIOORG MED CHEM LETT, V7, P393, DOI 10.1016/S0960-894X(97)00029-2.
   KOBAYASHI J, 1994, TETRAHEDRON, V50, P7401, DOI 10.1016/S0040-4020(01)90470-3.
   NAKAMURA T, 1994, TETRAHEDRON LETT, V35, P7813, DOI 10.1016/0040-4039(94)80125-8.
   NAKAMURA T, 1994, SYNLETT, P584.
   NICOLAOU KC, 1994, J AM CHEM SOC, V116, P1591, DOI 10.1021/ja00083a063.
   Ojima I, 1998, BIOORG MED CHEM LETT, V8, P189, DOI 10.1016/S0960-894X(97)10218-9.
   Ojima I, 1998, CHEMTECH, V28, P31.
   PATEL NH, 1994, INVEST NEW DRUG, V12, P1, DOI 10.1007/BF00873229.
   SETO M, 1994, J ORG CHEM, V59, P3165, DOI 10.1021/jo00090a039.
   Suffness M., 1995, TAXOL SCI APPL.
   YOUNG WB, 1995, J AM CHEM SOC, V117, P5228, DOI 10.1021/ja00124a006.}},
Number-of-Cited-References = {{14}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Bioorg. Med. Chem. Lett.}},
Doc-Delivery-Number = {{138XH}},
Unique-ID = {{ISI:000076998200007}},
DA = {{2018-08-13}},
}

@article{ ISI:000076694200029,
Author = {Hernandez, A and Mellado, RP and Martinez, JL},
Title = {{Metal accumulation and vanadium-induced multidrug resistance by
   environmental isolates of Escherichia hermannii and Enterobacter cloacae}},
Journal = {{APPLIED AND ENVIRONMENTAL MICROBIOLOGY}},
Year = {{1998}},
Volume = {{64}},
Number = {{11}},
Pages = {{4317-4320}},
Month = {{NOV}},
Abstract = {{Contaminated soils from an oil refinery were screened for the presence
   of microorganisms capable of accumulating either nickel, vanadium, or
   both metals. Three strains of bacteria that belonged to the family
   Enterobacteriaceae were selected. Two of them were Escherichia hermannii
   strains, and outer membrane profile (OMP) analysis showed that they were
   similar to a strain of clinical origin; the other one was an
   Enterobacter cloacae strain that differed from clinical isolates. The
   selected bacteria accumulated both nickel and vanadium. Growth in the
   presence of vanadium induced multidrug resistance phenotypes in E.
   hermannii and E. cloacae. Incubation with this metal changed the OMP
   profile of E. hermannii but did not produce variations in the expression
   of the major OMPs of E. cloacae.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mellado, RP (Reprint Author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, Campus Univ, E-28049 Madrid, Spain.
   Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, E-28049 Madrid, Spain.}},
ISSN = {{0099-2240}},
Keywords-Plus = {{OUTER-MEMBRANE PROTEIN; HEAVY-METALS; BRADYRHIZOBIUM-JAPONICUM;
   QUANTITATIVE ASSESSMENT; PSEUDOMONAS-AERUGINOSA; NICKEL; COLI;
   CONTAMINATION; BIOSORPTION; AIR}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Author-Email = {{rpmellado@cnb.uam.es}},
ResearcherID-Numbers = {{Martinez, Jose/A-4725-2013
   Mellado, Rafael/D-2680-2009
   Martinez, Jose/C-4100-2008}},
ORCID-Numbers = {{Martinez, Jose/0000-0001-8813-7607
   }},
Cited-References = {{Atlas R. M., 1993, HDB MICROBIOLOGICAL.
   AYRES RU, 1992, P NATL ACAD SCI USA, V89, P815, DOI 10.1073/pnas.89.3.815.
   BAQUERO F, 1992, DIAGN MICR INFEC DIS, V15, P483, DOI 10.1016/0732-8893(92)90095-B.
   BRAVO MG, COMMUNICATION.
   BRENNER DJ, 1982, J CLIN MICROBIOL, V15, P703.
   CAMPBELL PM, 1986, ARCH BIOCHEM BIOPHYS, V244, P470, DOI 10.1016/0003-9861(86)90615-6.
   CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987.
   COHEN SP, 1993, J BACTERIOL, V175, P7856.
   CORDER SL, 1994, APPL BIOCHEM BIOTECH, V45-6, P847, DOI 10.1007/BF02941854.
   Davies RL, 1996, INT J SYST BACTERIOL, V46, P736, DOI 10.1099/00207713-46-3-736.
   Erb RW, 1997, NAT BIOTECHNOL, V15, P378, DOI 10.1038/nbt0497-378.
   FALAHIARDAKANI A, 1984, ECOTOX ENVIRON SAFE, V8, P152, DOI 10.1016/0147-6513(84)90057-5.
   Foght JM, 1996, MICROBIOL-UK, V142, P2333, DOI 10.1099/00221287-142-9-2333.
   FOUREST E, 1994, FEMS MICROBIOL REV, V14, P325.
   FUKUOKA T, 1993, ANTIMICROB AGENTS CH, V37, P322, DOI 10.1128/AAC.37.2.322.
   GADD GM, 1992, FEMS MICROBIOL LETT, V100, P197, DOI 10.1016/0378-1097(92)90209-7.
   GADD GM, 1993, TRENDS BIOTECHNOL, V11, P353, DOI 10.1016/0167-7799(93)90158-6.
   Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r.
   KASAN HC, 1987, MICROBIOS, V51, P89.
   KASPRZAK KS, 1995, CANCER INVEST, V13, P411, DOI 10.3109/07357909509031921.
   LAMPE AS, 1984, EUR J CLIN MICROBIOL, V3, P301, DOI 10.1007/BF01977477.
   Losi ME, 1997, APPL ENVIRON MICROB, V63, P3079.
   Lovley DR, 1997, CURR OPIN BIOTECH, V8, P285, DOI 10.1016/S0958-1669(97)80005-5.
   MADANY IM, 1992, SCI TOTAL ENVIRON, V116, P281, DOI 10.1016/0048-9697(92)90456-3.
   MAIER RJ, 1990, APPL ENVIRON MICROB, V56, P1905.
   MALLEA M, 1995, FEMS MICROBIOL LETT, V129, P273, DOI 10.1111/j.1574-6968.1995.tb07592.x.
   MIGLIORE L, 1993, MUTAT RES, V319, P205, DOI 10.1016/0165-1218(93)90080-W.
   MONTUELLE B, 1994, B ENVIRON CONTAM TOX, V53, P753.
   Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996.
   Nishimura LS, 1996, FEMS MICROBIOL LETT, V143, P253, DOI 10.1016/0378-1097(96)00322-9.
   NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0.
   OWUSUYAW J, 1990, TOXICOL LETT, V50, P327, DOI 10.1016/0378-4274(90)90026-I.
   Paulsen IT, 1996, MICROBIOL REV, V60, P575.
   PEDERSEN JC, 1993, APPL ENVIRON MICROB, V59, P1560.
   PUMPEL T, 1995, J IND MICROBIOL, V14, P213, DOI 10.1007/BF01569930.
   RATTRAY EAS, 1995, APPL ENVIRON MICROB, V61, P2950.
   RHODEN DL, 1987, J CLIN MICROBIOL, V25, P2363.
   Roane TM, 1996, CAN J MICROBIOL, V42, P593, DOI 10.1139/m96-080.
   SAID WA, 1991, APPL ENVIRON MICROB, V57, P1498.
   Saier MH, 1998, FASEB J, V12, P265.
   Sambrook J, 1989, MOL CLONING LAB MANU.
   Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X.
   Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753.
   SOKOLOV S M, 1986, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V30, P249.
   STULTS LW, 1987, J BACTERIOL, V169, P1398, DOI 10.1128/jb.169.4.1398-1402.1987.
   Unz RF, 1996, CURR OPIN BIOTECH, V7, P307, DOI 10.1016/S0958-1669(96)80035-8.
   VOLESKY B, 1995, BIOTECHNOL PROGR, V11, P235, DOI 10.1021/bp00033a001.
   VOLESKY B, 1994, FEMS MICROBIOL REV, V14, P291, DOI 10.1111/j.1574-6976.1994.tb00102.x.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{68}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{18}},
Journal-ISO = {{Appl. Environ. Microbiol.}},
Doc-Delivery-Number = {{133PD}},
Unique-ID = {{ISI:000076694200029}},
DA = {{2018-08-13}},
}

@article{ ISI:000076553600003,
Author = {Kellerman, SE and Tokars, JI and Jarvis, WR},
Title = {{The costs of healthcare worker respiratory protection and fit-testing
   programs}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{1998}},
Volume = {{19}},
Number = {{9}},
Pages = {{629-634}},
Month = {{SEP}},
Abstract = {{OBJECTIVE: We studied hospital costs associated with healthcare worker
   (HCW) respiratory protection and respirator fit-testing programs
   recommended by the Centers for Disease Control and Prevention (CDC) and
   mandated by the Occupational Safety and Health Administration to
   decrease nosocomial or occupational Mycobacterium tuberculosis (TB).
   DESIGN: The number and cost of high-efficiency particulate air
   (HEPA)-filter and dust-mist (DM) respirators for 1989 to 1994 were
   obtained from study hospital purchasing departments, and the costs of
   HCW fit-testing and education programs for 1994 were estimated from
   information provided by infection control practitioners. Costs of
   N-class respirator programs were estimated for study hospitals using
   retrospective cost analysis and an observational study.
   SETTING: Four urban hospitals with, and one rural community hospital
   without, documented nosocomial or occupational transmission of
   multidrug-resistant TB.
   RESULTS: During the study period, four of five hospitals introduced HEPA
   and DM respirators and respirator education and fit-testing programs.
   Median costs in 1994 were \$83,900 (range, \$2,000-\$223,000) for
   respirators and \$17,187 (range, \$8,736-\$26,175) for respiratory
   fit-testing programs. The projected median annual cost of N95
   respirators was \$62,023 (range, \$270-\$422,526).
   CONCLUSIONS: Compliance with CDC TB guidelines may require a substantial
   investment. However, outlays for respirators and education and
   fit-testing programs are more reasonable than would be suggested by
   analyses that estimated the costs of preventing one case of nosocomial
   TB (Infect Control Hosp Epidemiol 1998;19:629-634).}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kellerman, SE (Reprint Author), Ctr Dis Control \& Prevent, Hosp Infect Program, 1600 Clifton Rd,Mailstop E69, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Hosp Infect Program, Atlanta, GA 30333 USA.}},
ISSN = {{0899-823X}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTED PATIENTS;
   NEW-YORK-CITY; CARE WORKERS; NOSOCOMIAL TRANSMISSION; HOSPITAL WORKERS;
   OUTBREAK; RISK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Author-Email = {{sek0@cdc.gov}},
Cited-References = {{ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306.
   {[}Anonymous], 1993, Fed Regist, V58, P52810.
   Barnhart S, 1997, J OCCUP ENVIRON MED, V39, P849, DOI 10.1097/00043764-199709000-00008.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   CHEN SK, 1994, AM J INFECT CONTROL, V22, P65, DOI 10.1016/0196-6553(94)90116-3.
   {*}DEP HHS DEP LAB, 1995, FED REGISTER, V60, P30336.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Fella P, 1995, AM J INFECT CONTROL, V23, P352, DOI 10.1016/0196-6553(95)90265-1.
   {*}GUID PREV TRANSM, 1994, MMWR, V43.
   JARVIS WR, 1995, ANN INTERN MED, V122, P142, DOI 10.7326/0003-4819-122-2-199501150-00011.
   JEREB JA, 1995, ARCH INTERN MED, V155, P854, DOI 10.1001/archinte.155.8.854.
   Kenyon TA, 1997, ANN INTERN MED, V127, P32, DOI 10.7326/0003-4819-127-1-199707010-00006.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007.
   NICAS M, 1995, AM J IND MED, V27, P317, DOI 10.1002/ajim.4700270302.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   SOBEL E, 1994, NEW ENGL J MED, V331, P1658.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   1994, FED REG, V59, P26850.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{131AM}},
Unique-ID = {{ISI:000076553600003}},
DA = {{2018-08-13}},
}

@article{ ISI:000076337500017,
Author = {Cole, EC and Cook, CE},
Title = {{Characterization of infectious aerosols in health care facilities: An
   aid to effective engineering controls and preventive strategies}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{1998}},
Volume = {{26}},
Number = {{4}},
Pages = {{453-464}},
Month = {{AUG}},
Abstract = {{Assessment of strategies for engineering controls for the prevention of
   airborne infectious disease transmission to patients and to health care
   and related workers requires consideration of the factors relevant to
   aerosol characterization. These factors include aerosol generation,
   particle sizes and concentrations, organism viability, infectivity and
   virulence, airflow and climate, and environmental sampling and analysis.
   The major focus on attention to engineering controls comes from recent
   increases in tuberculosis, particularly the multidrug-resistant
   varieties in the general hospital population, the severely
   immunocompromised, and those in at-risk and confined environments such
   as prisons, long-term care facilities, and shelters For the homeless.
   Many workers are in close contact with persons who have active,
   undiagnosed, or insufficiently treated tuberculosis. Additionally,
   patients and health care workers may be exposed to a variety of
   pathogenic human viruses, opportunistic fungi, and bacteria. This report
   therefore focuses on the nature of infectious aerosol transmission in an
   attempt to determine which factors can be systematically addressed to
   result in proven, applied engineering approaches to the control of
   infectious aerosols in hospital and health care facility environments.
   The infectious aerosols of consideration are those that are generated as
   particles of respirable size by both human and environmental sources and
   that have the capability of remaining viable and airborne for extended
   periods in the indoor environment. This definition precludes skin and
   mucous membrane exposures occurring from splashes (rather than true
   aerosols) of blood or body fluids containing infectious disease agents.
   There are no epidemiologic or laboratory studies documenting the
   transmission of bloodborne virus by way of aerosols.}},
Publisher = {{MOSBY-ELSEVIER}},
Address = {{360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cole, EC (Reprint Author), DynCorp Hlth Res Serv, 4815 Emperor Rd,Suite 300, Durham, NC 27703 USA.
   DynCorp Hlth Res Serv, Durham, NC 27703 USA.}},
DOI = {{10.1016/S0196-6553(98)70046-X}},
ISSN = {{0196-6553}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL LEGIONNAIRES-DISEASE;
   INDOOR AIR; RELATIVE-HUMIDITY; LEGIONELLA-PNEUMOPHILA; INVASIVE
   ASPERGILLOSIS; HOSPITAL CONSTRUCTION; LIGHT-SCATTERING; OUTBREAK;
   TRANSMISSION}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{ARNOW PM, 1982, J INFECT DIS, V146, P460, DOI 10.1093/infdis/146.4.460.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Benenson AS, 1990, CONTROL COMMUNICABLE.
   BENNET J, 1978, HUMAN CHLAMYDIAL INF.
   BLASER MJ, 1986, REV INFECT DIS, V8, P21.
   BLOCH AB, 1985, PEDIATRICS, V75, P676.
   BOLLIN GE, 1985, APPL ENVIRON MICROB, V50, P1128.
   Brenner DJ, 1984, BERGEYS MANUAL SYSTE, V1, P279.
   CAGE AA, 1970, ARCH SURG-CHICAGO, V1001, P384.
   Carter CD, 1997, INFECT CONT HOSP EP, V18, P587.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   {*}CDC, 1990, MMWR MORB MORTAL WKL, V39.
   {*}CDC, 1991, MMWR-MORBID MORTAL W, V40, P585.
   {*}CDCP, 1994, MMWR MORB MORAL WKLY, V43.
   {*}CDCP, 1992, MMWR-MORBID MORTAL W, V41, P507.
   {*}CDCP, 1992, MMWR-MORBID MORTAL W, V41, P35.
   {*}CDCP, 1996, MMWR MORB MORTAL WKL.
   {*}CDCP, 1994, MMWR-MORBID MORTAL W, V43, P69.
   Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P33.
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P365.
   CHATIGNY M, 1983, AIR SAMPLING INSTRUM, pE2.
   COLE EC, 1990, AM SOC TEST MATER, V1071, P99, DOI 10.1520/STP25327S.
   COLE EC, 1996, ASTM STP, V1287, P153.
   Cotterill S, 1996, J HOSP INFECT, V32, P207, DOI 10.1016/S0195-6701(96)90147-4.
   COUCH RB, 1981, B NEW YORK ACAD MED, V57, P907.
   Cox CS, 1987, AEROBIOLOGICAL PATHW, P1403.
   DAVIS EJ, 1982, AEROSOL SCI TECH, V1, P337, DOI 10.1080/02786828208958599.
   DAVIS EJ, 1985, LANGMUIR, V1, P373, DOI 10.1021/la00063a020.
   DAVIS GW, 1971, APPL MICROBIOL, V21, P676.
   DESPREZ RM, 1990, PRINCIPLES PRACTICE, P1877.
   DONDERO TJ, 1980, NEW ENGL J MED, V302, P365, DOI 10.1056/NEJM198002143020703.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   EICKHOFF TC, 1994, INFECT CONT HOSP EP, V15, P663.
   FAIRCHILD GA, 1972, ARCH ENVIRON HEALTH, V25, P51, DOI 10.1080/00039896.1972.10666135.
   FALKINHAM JO, 1990, AM SOC TEST MATER, V1071, P71, DOI 10.1520/STP25325S.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   FLANNIGAN B, 1993, WORKSHOP SUMMARIES I.
   FRADKIN A, 1987, ASTM STP, V957, P66.
   Franke DL, 1997, INDOOR AIR, V7, P41, DOI 10.1111/j.1600-0668.1997.t01-3-00006.x.
   GERONE PJ, 1966, BACTERIOL REV, V30, P576.
   GURWITH MJ, 1971, ARCH INTERN MED, V128, P541, DOI 10.1001/archinte.128.4.541.
   HAMILTON WA, 1967, BIOCHIM BIOPHYS ACTA, V148, P801.
   HARPER GJ, 1961, J HYG-CAMBRIDGE, V59, P479, DOI 10.1017/S0022172400039176.
   HAYAMIZU M, 1989, J I ELECTROSTATICS J, V13, P322.
   HOFFLIN JM, 1987, ANN INTERN MED, V106, P209, DOI 10.7326/0003-4819-106-2-209.
   HUNT DL, 1988, P 31 BIOL SAF C BETH.
   IJAZ MK, 1985, J GEN VIROL, V66, P2743, DOI 10.1099/0022-1317-66-12-2743.
   IWEN PC, 1994, INFECT CONT HOSP EP, V15, P303.
   JENSEN PA, 1992, AM IND HYG ASSOC J, V53, P660, DOI 10.1202/0002-8894(1992)053<0660:EOEBSC>2.0.CO;2.
   Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207.
   JOSEPH CA, 1994, EPIDEMIOL INFECT, V112, P329, DOI 10.1017/S0950268800057745.
   KNIGHT V, 1993, VIRAL MYCOPLASMAL IN, P1.
   LUNDHOLM M, 1982, APPL ENVIRON MICROB, V44, P179.
   MARIER RL, 1993, INFECT CONT HOSP EP, V14, P700.
   MILLER S, 1967, P SOC EXP BIOL MED, V125, P222.
   MillerLeiden S, 1996, J AIR WASTE MANAGE, V46, P869, DOI 10.1080/10473289.1996.10467523.
   MIZUNO A, 1988, IEEE T IND APPL, V24, P387, DOI 10.1109/28.2886.
   Mohr A.J., 1991, MODELING ENV FATE MI, P160.
   MOREY PR, 1990, BIOL CONTAMINANTS IN.
   MURPHY F A, 1991, P9.
   Nardell E. A., 1988, ARCHIT DESIGN, P296.
   NEVALAINEN A, 1993, AEROSOL MEASUREMENT, P471.
   OWEN MK, 1992, ATMOS ENVIRON A-GEN, V26, P2149, DOI 10.1016/0960-1686(92)90403-8.
   PANNUTI CS, 1991, J CLIN ONCOL, V9, P77, DOI 10.1200/JCO.1991.9.1.77.
   PASANEN AL, 1992, ATMOS ENVIRON B-URB, V26, P117, DOI 10.1016/0957-1272(92)90043-R.
   PASANEN AL, 1992, INT BIODETER BIODEGR, V30, P273, DOI 10.1016/0964-8305(92)90033-K.
   Patterson JE, 1997, INFECT CONT HOSP EP, V18, P104.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RADER DJ, 1993, AEROSOL MEASUREMENT, P345.
   RHAME FS, 1991, J HOSP INFECT, V18, P466, DOI 10.1016/0195-6701(91)90058-G.
   Riley E C, 1980, Ann N Y Acad Sci, V353, P25, DOI 10.1111/j.1749-6632.1980.tb18902.x.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069.
   RILEY RL, 1988, ARCHIT DESIGN, P174.
   Rullan JV, 1996, EMERG INFECT DIS, V2, P125, DOI 10.3201/eid0202.960208.
   SAMSON RA, 1988, INTRO FOOD BORNE FUN, P64.
   SARUBBI FA, 1982, AM REV RESPIR DIS, V125, P33.
   SATTAR SA, 1984, APPL ENVIRON MICROB, V47, P879.
   SAWYER MH, 1994, J INFECT DIS, V169, P91, DOI 10.1093/infdis/169.1.91.
   SCHAFFER FL, 1976, ARCH VIROL, V51, P263, DOI 10.1007/BF01317930.
   SCHLOSSBERG D, 1988, TUBERCULOSIS, P9.
   Sepkowitz KA, 1996, CLIN INFECT DIS, V23, P954, DOI 10.1093/clinids/23.5.954.
   SNIDER D, 1992, OCCUP SAFETY HLTH RE, P1125.
   SORBER CA, 1987, METHODS RECOVERING V, P54.
   SORENSON WG, 1987, APPL ENVIRON MICROB, V53, P1370.
   Streifel A. J., 1988, ARCHIT DESIGN, P198.
   TANNER EI, 1980, J HYG-CAMBRIDGE, V85, P219, DOI 10.1017/S0022172400063257.
   THEUNISSEN HJH, 1993, APPL ENVIRON MICROB, V59, P2589.
   WADOWSKY RM, 1987, INFECT CONT HOSP EP, V8, P516, DOI 10.1017/S019594170006759X.
   Wayne L. G., 1986, BERGEYS MANUAL SYSTE, P1436.
   Wells WF, 1934, AM J HYG, V20, P619, DOI 10.1093/oxfordjournals.aje.a118098.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   WILLEKE K, 1993, P 6 INT C IND AIR QU, P131.
   WOO AH, 1986, AM J MED, V80, P567, DOI 10.1016/0002-9343(86)90809-0.
   Woods JE, 1988, ARCHIT DESIGN, P123.}},
Number-of-Cited-References = {{96}},
Times-Cited = {{97}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{23}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{127EK}},
Unique-ID = {{ISI:000076337500017}},
DA = {{2018-08-13}},
}

@article{ ISI:000075482500011,
Author = {McDonald, LC and Walker, M and Carson, L and Arduino, M and Aguero, SM
   and Gomez, P and McNeil, P and Jarvis, WR},
Title = {{Outbreak of Acinetobacter spp. bloodstream infections in a nursery
   associated with contaminated aerosols and air conditioners}},
Journal = {{PEDIATRIC INFECTIOUS DISEASE JOURNAL}},
Year = {{1998}},
Volume = {{17}},
Number = {{8}},
Pages = {{716-722}},
Month = {{AUG}},
Abstract = {{Background. Acinetobacter spp. are multidrug-resistant bacteria that
   grow well in water and cause infections with unexplained, increased
   summer prevalence. In August, 1996, eight infants acquired Acinetobacter
   spp. bloodstream infection (A-BSI) while in a nursery in the Bahamas;
   three infants died and an investigation was initiated.
   Methods. A case patient was defined as any newborn in the nursery during
   August 6 to 13, 1996, with A-BSI. To identify risk factors for A-BSI we
   conducted a retrospective cohort study and performed environmental
   cultures and air sampling using settle plates. The genetic relatedness
   of environmental isolates was assessed by pulsed field gel
   electrophoresis.
   Results. Of 33 patients in the nursery 8 (24\%) met the case definition.
   Patients with peripheral iv catheters were more likely to develop A-BSI
   (8 of 21 vs. 0 of 10, P < 0.05). Multivariate analysis among patients
   with iv catheters indicated that only exposure to one nurse was an
   independent risk factor for developing A-BSI (P < 0.005). Nursery settle
   plates were more likely to grow Acinetobacter spp. than were settle
   plates from other hospital areas (8 of 9 vs. 0 of 5, P < 0.005);
   cultures from nursery air conditioners also grew Acinetobacter spp.
   Environmental isolates were genetically diverse. After installation of a
   new air conditioner in May, 1995, A-BSIs occurred more frequently during
   months of increased absolute humidity or environmental dew point.
   Conclusions. Acinetobacter spp. may cause nosocomial BSI and death among
   infants during periods of polyclonal airborne dissemination; breaks in
   aseptic technique during: iv medication.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jarvis, WR (Reprint Author), Ctr Dis Control \& Prevent, Hosp Infect Program, 1600 Clifton Rd,MS E69, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Hosp Infect Program, Atlanta, GA 30333 USA.
   Princess Margaret Hosp, Nassau, Bahamas.}},
DOI = {{10.1097/00006454-199808000-00011}},
ISSN = {{0891-3668}},
Keywords = {{Acinetobacter spp.; bacteremia; nursery; airborne}},
Keywords-Plus = {{INTENSIVE-CARE UNIT; CALCOACETICUS BIOVAR ANITRATUS; RESISTANT
   ACINETOBACTER; EPIDEMIOLOGY; SEPTICEMIA}},
Research-Areas = {{Immunology; Infectious Diseases; Pediatrics}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Pediatrics}},
Author-Email = {{wrj1@cdc.gov}},
ResearcherID-Numbers = {{Arduino, Matthew/C-1461-2012}},
ORCID-Numbers = {{Arduino, Matthew/0000-0001-7072-538X}},
Cited-References = {{ALLEN KD, 1987, J HOSP INFECT, V9, P110, DOI 10.1016/0195-6701(87)90048-X.
   BAUMANN P, 1968, J BACTERIOL, V96, P39.
   Bernards AT, 1997, J HOSP INFECT, V35, P129, DOI 10.1016/S0195-6701(97)90101-8.
   CASTLE M, 1978, HEART LUNG, V7, P641.
   CHRISTIE C, 1995, INFECT CONT HOSP EP, V16, P590.
   Dean AG, 1996, EPI INFO WORD PROCES.
   Dobberkau H J, 1993, Gesundheitswesen, V55, P206.
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3.
   GERNERSMIDT P, 1987, J HOSP INFECT, V10, P265, DOI 10.1016/0195-6701(87)90008-9.
   GERVICH DH, 1985, AM J INFECT CONTROL, V13, P210, DOI 10.1016/0196-6553(85)90059-8.
   GO ES, 1994, LANCET, V344, P1329, DOI 10.1016/S0140-6736(94)90694-7.
   GRAEVENITZ A, 1995, MANUAL CLIN MICROBIO, P520.
   HORREVORTS A, 1995, J CLIN MICROBIOL, V33, P1567.
   KONEMAN EW, 1997, COLOR ATLAS TXB DIAG, P253.
   NG PC, 1989, J HOSP INFECT, V14, P363, DOI 10.1016/0195-6701(89)90077-7.
   REGEV R, 1993, INFECTION, V21, P394, DOI 10.1007/BF01728921.
   RETAILLIAU HF, 1979, J INFECT DIS, V140, P275, DOI 10.1093/infdis/140.2.275a.
   RETAILLIAU HF, 1979, J INFECT DIS, V139, P371, DOI 10.1093/infdis/139.3.371.
   RICHARDSON DK, 1993, PEDIATRICS, V91, P617.
   RITTER E, 1993, ZBL HYG UMWELTMED, V193, P461.
   SAKATA H, 1989, J HOSP INFECT, V14, P15, DOI 10.1016/0195-6701(89)90129-1.
   SAS, 1990, SAS PROC GUID.
   SCHLOESSER RL, 1990, INFECTION, V18, P230, DOI 10.1007/BF01643394.
   Siau H, 1996, J MED MICROBIOL, V44, P340, DOI 10.1099/00222615-44-5-340.
   SMITH CL, 1987, METHOD ENZYMOL, V155, P449.
   SMITH PW, 1977, JAMA-J AM MED ASSOC, V237, P795, DOI 10.1001/jama.237.8.795.
   SNYDMAN DR, 1977, AM J EPIDEMIOL, V106, P154, DOI 10.1093/oxfordjournals.aje.a112445.
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233.
   Towner KJ, 1997, J MED MICROBIOL, V46, P721, DOI 10.1099/00222615-46-9-721.
   Weyant R. S., 1995, IDENTIFICATION UNUSU.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{63}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Pediatr. Infect. Dis. J.}},
Doc-Delivery-Number = {{112FB}},
Unique-ID = {{ISI:000075482500011}},
DA = {{2018-08-13}},
}

@article{ ISI:000075546400002,
Author = {Cappelletty, D},
Title = {{Microbiology of bacterial respiratory infections}},
Journal = {{PEDIATRIC INFECTIOUS DISEASE JOURNAL}},
Year = {{1998}},
Volume = {{17}},
Number = {{8, S}},
Pages = {{S55-S61}},
Month = {{AUG}},
Abstract = {{The upper respiratory tract may become susceptible to bacterial
   infection as a result of health conditions such as allergies and viral
   infections, as well as the effects of smoking and airborne environmental
   pollutants, Streptococcus pneumoniae, Haemophilus influenzae and
   Moraxella catarrhalis are the most common bacterial pathogens in upper
   and lower respiratory tract infections. Streptococcus pyogenes is the
   predominant bacterial pathogen in pharyngitis and tonsillitis. Bacterial
   pathogens adhere to mucous membranes and colonization ensues, In an
   otherwise healthy individual the host immune system responds to the
   invading bacteria resulting in edema and swelling. If antimicrobial
   treatment does not eradicate the invading organisms and successfully
   interrupt the progress of the infection, the patient may develop
   recurrent or chronic disease.
   S. pneumoniae and other pathogens once susceptible to penicillin and
   other antibiotics are now becoming resistant. Bacterial resistance has
   developed and disseminated because of the widespread use of antibiotics.
   Major mechanisms of bacterial resistance to antimicrobials in upper
   respiratory tract infections include enzymatic inhibition, membrane
   impermeability, alteration of target enzymes, active pumping out of
   antibiotic and alteration of the ribosomal target.}},
Publisher = {{LIPPINCOTT WILLIAMS \& WILKINS}},
Address = {{TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Cappelletty, D (Reprint Author), Wayne State Univ, Div Infect Dis, Dept Pharm Practice, 3990 John R,4YC, Detroit, MI 48201 USA.
   Wayne State Univ, Div Infect Dis, Dept Pharm Practice, Detroit, MI 48201 USA.}},
DOI = {{10.1097/00006454-199808001-00002}},
ISSN = {{0891-3668}},
EISSN = {{1532-0987}},
Keywords = {{antimicrobial resistance; otitis media; sinusitis; bronchitis;
   pharyngitis; Streptococcus pneumoniae; Haemophilus influenzae; Moraxella
   catarrhalis}},
Keywords-Plus = {{ACUTE OTITIS-MEDIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; 30-CENTER
   NATIONAL SURVEILLANCE; OROPHARYNGEAL EPITHELIAL-CELLS; GROUP-A
   STREPTOCOCCI; HEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE;
   UNITED-STATES; HAEMOPHILUS-INFLUENZAE; ANTIBIOTIC-RESISTANCE}},
Research-Areas = {{Immunology; Infectious Diseases; Pediatrics}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Pediatrics}},
Cited-References = {{ANDERSSON B, 1988, MICROB PATHOGENESIS, V4, P267, DOI 10.1016/0882-4010(88)90087-3.
   APICELLA MA, 1984, J INFECT DIS, V150, P40, DOI 10.1093/infdis/150.1.40.
   APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   BAKALETZ LO, 1988, INFECT IMMUN, V56, P331.
   BARTLETT G, 1997, MANAGEMENT RESP TREA.
   BASS JW, 1994, ARCH PEDIAT ADOL MED, V148, P67, DOI 10.1001/archpedi.1994.02170010069016.
   BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307.
   BETRIU C, 1997, 37 INT C ANT AG CHEM.
   Bisno AL, 1997, CLIN INFECT DIS, V25, P574, DOI 10.1086/513768.
   Block SL, 1997, PEDIATR INFECT DIS J, V16, P449, DOI 10.1097/00006454-199704000-00029.
   BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002.
   CHERRY JD, 1992, PEDIAT INFECT DIS, P159.
   COLE P, 1989, CHEST, V95, pS217, DOI 10.1378/chest.95.3\_Supplement.217S.
   DENNY FW, 1974, J INFECT DIS, V129, P93, DOI 10.1093/infdis/129.2.93.
   Doern GV, 1997, ANTIMICROB AGENTS CH, V41, P292.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P2884.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208.
   FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004.
   FEKETE T, 1995, PERSPECT BIOL MED, V38, P363.
   GERBER MA, 1995, PEDIATR CLIN N AM, V42, P539.
   GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3.
   GWALTNEY JM, 1995, PRINCIPLES PRACTICE, pCH47.
   Jacobs MR, 1996, PEDIATR INFECT DIS J, V15, P940, DOI 10.1097/00006454-199610000-00031.
   JOHNSON AP, 1986, J MED MICROBIOL, V22, P265, DOI 10.1099/00222615-22-3-265.
   JOHNSON JA, 1995, BRIT J BIOMED SCI, V52, P157.
   KARMA P, 1987, ANN OTO RHINOL LARYN, V96, P1.
   MALE CJ, 1979, INFECT IMMUN, V26, P254.
   MANTERO E, 1997, 3M INT C ANT AG CHEM.
   MASON E, 1997, 37 INT C ANT AG CHEM.
   MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703.
   MAYER KH, 1995, PRINCIPLES PRACTICE, pCH13.
   MEDEIROS AA, 1989, MICROBIAL RESISTANCE, P101.
   Middleton DB, 1996, PRIMARY CARE, V23, P719, DOI 10.1016/S0095-4543(05)70359-6.
   MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067.
   {*}NAT COMM CLIN LAB, 1995, METH DIL ANT SUSC TE.
   NEEDHAM C A, 1988, Clinical Microbiology Reviews, V1, P218.
   Newton DA, 1996, PRIMARY CARE, V23, P701, DOI 10.1016/S0095-4543(05)70358-4.
   Niederman M S, 1990, Semin Respir Infect, V5, P173.
   NIEDERMAN MS, 1994, EUR RESPIR J, V7, P1737, DOI 10.1183/09031936.94.07101737.
   NORD CE, 1995, CLIN INFECT DIS, V20, P1512, DOI 10.1093/clinids/20.6.1512.
   PATON JC, 1984, INFECT IMMUN, V43, P1085.
   PICHICHERO ME, 1992, PEDIATR ASTHMA ALLER, V6, P167, DOI 10.1089/pai.1992.6.167.
   PIKIS A, 1995, ARCH PEDIAT ADOL MED, V149, P30, DOI 10.1001/archpedi.1995.02170130032007.
   READ RC, 1991, J INFECT DIS, V163, P549, DOI 10.1093/infdis/163.3.549.
   REYNOLDSH Y, 1995, PRINCIPLES PRACTICE, pCH48.
   RODRIQUEZ WJ, 1995, LARYNGOSCOPE, V105, P300, DOI 10.1288/00005537-199503000-00014.
   RUBINS JB, 1992, INFECT IMMUN, V60, P1740.
   SANDERS CC, 1992, CLIN INFECT DIS, V15, P824, DOI 10.1093/clind/15.5.824.
   Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701.
   SIEGEL JD, 1987, PEDIATR INFECT DIS J, V6, P95, DOI 10.1097/00006454-198701000-00048.
   SPIKA JS, 1991, J INFECT DIS, V163, P1273, DOI 10.1093/infdis/163.6.1273.
   STEELE RW, 1997, INFECT MED SA, V14, P9.
   Thornsberry C, 1996, ADV THER, V13, P301.
   THORNSBERRY C, 1988, CLIN THER, V11, P20.
   THORNSBERRY C, 1997, INFECT MED S, V14, P13.
   THORNSBERRY C, 1993, INFECTIONS MED SD, V10, P15.
   TSANG KWT, 1994, EUR RESPIR J, V7, P1746, DOI 10.1183/09031936.94.07101746.
   TUOMANEN E, 1985, J INFECT DIS, V151, P859, DOI 10.1093/infdis/151.5.859.
   Urwin G, 1996, CLIN INFECT DIS, V22, P1069, DOI 10.1093/clinids/22.6.1069.
   VANALPHEN L, 1988, INFECT IMMUN, V56, P1800.
   WALD ER, 1994, IMMUNOL ALLERGY CLIN, V14, P31.
   WANNER A, 1977, AM REV RESPIR DIS, V116, P73.
   WATSON DA, 1995, EUR J CLIN MICROBIOL, V14, P479, DOI 10.1007/BF02113425.
   WILSON R, 1987, J CLIN INVEST, V79, P221, DOI 10.1172/JCI112787.
   Wilson R., 1992, REV CONTEMP PHARMACO, V3, P103.
   YOUNG HK, 1989, T ROY SOC TROP MED H, V83, P38, DOI 10.1016/0035-9203(89)90699-8.}},
Number-of-Cited-References = {{66}},
Times-Cited = {{24}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Pediatr. Infect. Dis. J.}},
Doc-Delivery-Number = {{113JB}},
Unique-ID = {{ISI:000075546400002}},
DA = {{2018-08-13}},
}

@article{ ISI:000075095500008,
Author = {Manangan, LP and Simonds, DN and Pugliese, G and Kroc, K and Banerjee,
   SN and Rudnick, JR and Steingraber, K and Jarvis, WR},
Title = {{Are US hospitals making progress in implementing guidelines for
   prevention of Mycobacterium tuberculosis transmission?}},
Journal = {{ARCHIVES OF INTERNAL MEDICINE}},
Year = {{1998}},
Volume = {{158}},
Number = {{13}},
Pages = {{1440-1444}},
Month = {{JUL 13}},
Abstract = {{Background: Outbreaks of tuberculosis (TB) in hospitals have occurred
   when the Centers for Disease Control and Prevention (CDC) guideline
   recommendations for preventing the transmission of Mycobacterium
   tuberculosis were not fully implemented.
   Objective: To determine whether US hospitals are making progress in
   implementing the CDC guidelines for preventing TB.
   Methods: In 1992, we surveyed all public (city, county, Veterans
   Affairs, and primary medical school-affiliated) US hospitals (n = 632)
   and 444 (20\%) random samples of all private hospitals with 100 beds or
   more. In 1996, we resurveyed 136 random samples (50\%) of all 1992
   respondent hospitals with 6 or more TB admissions in 1991.
   Results: Of the 1076 hospitals surveyed in 1992, 763 (71\%) respondents
   returned a completed questionnaire. Among these, 536 (71\%) of 755
   reported having rooms chat met CDC criteria for acid-fast bacilli
   isolation, ie, negative air pressure, 6 or more air exchanges per hour,
   and air directly vented to the outside. The predominant respiratory
   protective device for health care workers was nonfitted surgical mask
   and attending physicians were infrequently (50\%) included in tuberculin
   skin-testing programs. In the 1996 resurvey, 103 (76\%) of 136
   respondents returned a completed questionnaire. Of these, 99 (96\%)
   reported having rooms that met CDC criteria for acid-fast bacilli
   isolation. The N95 respiratory protective devices were predominantly
   used by health care workers, and attending physicians were increasingly
   (69\%) included in the hospitals' tuberculin skin-testing programs.
   Conclusions: Most US hospitals are making progress in the implementation
   of CDC guidelines for preventing the transmission of M tuberculosis.}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60610 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Manangan, LP (Reprint Author), Ctr Dis Control \& Prevent, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.
   Ctr Dis Control \& Prevent, Hosp Infect Program, Atlanta, GA 30333 USA.
   Ctr Dis Control, Hosp Infect Program, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
   Amer Hosp Assoc, Chicago, IL USA.}},
DOI = {{10.1001/archinte.158.13.1440}},
ISSN = {{0003-9926}},
Keywords-Plus = {{INFECTION-CONTROL PROGRAMS; HEALTH-CARE WORKERS; MULTIDRUG-RESISTANT
   TUBERCULOSIS; CDC TB SURVEY; NOSOCOMIAL TRANSMISSION; MEMBER HOSPITALS;
   OUTBREAK; EFFICACY}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{{[}Anonymous], 1995, EP INF COMP PROGR VE.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   {*}CDCP, 1990, MMWR-MORBID MORTAL W, V39, P1.
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P365.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129.
   JEREB JA, 1993, J INFECT DIS, V168, P1219, DOI 10.1093/infdis/168.5.1219.
   KELLERMAN SE, 1996, AM J INFECT CONTROL, V24, P93.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   SAS Institute, 1990, SAS PROC GUID VERS 6.
   Sinkowitz RL, 1996, AM J INFECT CONTROL, V24, P226, DOI 10.1016/S0196-6553(96)90054-1.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   Tokars JI, 1996, J CLIN MICROBIOL, V34, P680.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Arch. Intern. Med.}},
Doc-Delivery-Number = {{105WA}},
Unique-ID = {{ISI:000075095500008}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:000075175700011,
Author = {Iwahana, M and Utoguchi, N and Mayumi, T and Goryo, M and Okada, K},
Title = {{Drug resistance and P-glycoprotein expression in endothelial cells of
   newly formed capillaries induced by tumors}},
Journal = {{ANTICANCER RESEARCH}},
Year = {{1998}},
Volume = {{18}},
Number = {{4C}},
Pages = {{2977-2980}},
Month = {{JUL-AUG}},
Abstract = {{The inhibitory effects of vincristine (VCR) with or without verapamil
   (T/ER) on angiogenesis in mouse subcutaneous fascia induced by mouse
   sarcoma 180 cells were assessed using the dorsal air sac method. VCR
   combined with VER had inhibitory effects on tumor-induced angiogenesis,
   but VCR alone did not inhibit capillarization. The chemosensitivity of
   human umbilical vein endothelial cells (HUVEC) and tumor-derived
   endothelial cells from rat KMT-17 fibrosarcoma (TEC) was examined using
   the microculture tetrazolium assay. VCR and taxol had strong
   anti-proliferative activity against HUVEC, but only weakly inhibited the
   proliferation of TEC. In combination with VER, VCR and Taxol inhibited
   the proliferation of TEC. Cisplatin, mitomycin C, and 5-fluorouracil had
   weakly anti-proliferative activity against both HUVEC and TEC.
   Expression of P-glycoprotein (P-gp) was found in TEC, but not in HUVEC
   using western blot analysis. These findings indicate that drug
   resistance and P-gp expression appeared on newly formed capillaries
   induced by rodents tumors.}},
Publisher = {{INT INST ANTICANCER RESEARCH}},
Address = {{EDITORIAL OFFICE 1ST KM KAPANDNTIOU-KALAMOU RD KAPANDRITI, POB 22,
   ATHENS 19014, GREECE}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Iwahana, M (Reprint Author), Daiichi Pharmaceut Co Ltd, New Prod Res Labs 4, Edogawa Ku, Kitakasai 1-16-13, Tokyo 1348630, Japan.
   Iwate Univ, Fac Agr, Dept Vet Pathol, Morioka, Iwate 0200066, Japan.
   Showa Coll Pharmaceut Sci, Tokyo 1940042, Japan.
   Osaka Univ, Fac Pharmaceut Sci, Osaka 5650871, Japan.}},
ISSN = {{0250-7005}},
Keywords = {{tumor angiogenesis; P-glycoprotein; drug resistance; endothelial cell;
   chemotherapy; KMT-17}},
Keywords-Plus = {{ANGIOGENESIS; CARCINOMA; LINES}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{ALLEY MC, 1988, CANCER RES, V48, P589.
   CORREIA JJ, 1991, PHARMACOL THERAPEUT, V52, P127, DOI 10.1016/0163-7258(91)90004-6.
   FOJO A, 1985, CANCER RES, V45, P3002.
   Folkman J, 1992, Semin Cancer Biol, V3, P89.
   FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X.
   Folkman J, 1976, Int Rev Exp Pathol, V16, P207.
   Iwahana M, 1996, INT J EXP PATHOL, V77, P109, DOI 10.1046/j.1365-2613.1996.00970.x.
   MITSUI I, 1995, JPN J CANCER RES, V86, P776, DOI 10.1111/j.1349-7006.1995.tb02468.x.
   OHTA S, 1994, JPN J CANCER RES, V85, P290, DOI 10.1111/j.1349-7006.1994.tb02096.x.
   PAVELIC ZP, 1993, ARCH OTOLARYNGOL, V119, P753.
   PETRYLAK DP, 1994, ANN ONCOL, V5, P835, DOI 10.1093/oxfordjournals.annonc.a059013.
   SHIFF PB, 1979, NATURE, V277, P665.
   SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629.
   SIPOS EP, 1994, ANN NY ACAD SCI, V732, P263, DOI 10.1111/j.1749-6632.1994.tb24741.x.
   Steiner R., 1992, ANGIOGENESIS KEY PRI, P449.
   Toth K, 1996, AM J PATHOL, V149, P853.
   UTOGUCHI N, 1995, JPN J CANCER RES, V86, P193, DOI 10.1111/j.1349-7006.1995.tb03039.x.}},
Number-of-Cited-References = {{17}},
Times-Cited = {{33}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Anticancer Res.}},
Doc-Delivery-Number = {{106XC}},
Unique-ID = {{ISI:000075175700011}},
DA = {{2018-08-13}},
}

@article{ ISI:000075433800020,
Author = {Weinstein, RA},
Title = {{Nosocomial infection update}},
Journal = {{EMERGING INFECTIOUS DISEASES}},
Year = {{1998}},
Volume = {{4}},
Number = {{3}},
Pages = {{416-420}},
Month = {{JUL-SEP}},
Note = {{International Conference on Emerging Infectious Diseases, ATLANTA,
   GEORGIA, MAR 08-11, 1998}},
Organization = {{Ctr Dis Control \& Prevent; Council State \& Terr Epidemiologists; Amer
   Soc Microbiol; Natl Fdn CDC; Alliance Prudent Use Antibiot; Amer Acad
   Pediat; Amer Assoc Blood Banks; Amer Assoc Hlth Plans; Amer Canc Soc;
   Amer Coll Prevent Med; Amer Hosp Assoc; Amer Med Assoc; Amer Mosquito
   Control Assoc; Amer Publ Hlth Assoc; Amer Sexually Transmitted Dis
   Assoc; Amer Soc Clin Pathologists; Amer Soc Trop Med \& Hyg; Amer Vet
   Med Assoc; Assoc Amer Vet Med Coll; Assoc Sch Publ Hlth; Assoc State \&
   Terr Directors Hlth Promot \& Publ Hlth Educ; Assoc State \& Terr Hlth
   Officials; Assoc State \& Terr Publ Hlth Lab Directors; Assoc Teachers
   Prevent Med; Burroughs Wellcome Fund; Emory Univ, Sch Med; Fogarty Int
   Ctr; US FDA; Indian Hlth Serv; Infect Dis Soc Amer; Int Life Sci Inst;
   Int Soc Infect Dis; Int Soc Travel Med; Int Union Hlth Promot \& Educ;
   Int Union Microbiol Soc; Minor Hlth Profess Fdn; Morehouse Sch Med;
   NASA; Natl Assoc City \& County Hlth Officials; Natl Assoc State Publ
   Hlth Vetinarians; Natl Council Int Hlth; Natl Fdn Infect Dis; Natl
   Hispan Med Assoc; NIAID; Natl Med Assoc; NOAA; Off Sci \& Technol
   Policy; Pan Amer Hlth Org; Emory Univ, Rollins Sch Publ Hlth; Soc
   Healthcare Epidemiol Amer; Soc Occupat \& Environm Hlth; Soc Publ Hlth
   Educ; Carter Ctr; Henry J Kaiser Family Fdn; HMO Grp; Robert Wood
   Johnson Fdn; Rockefeller Fdn; World Bank; Us Agcy Int Dev; USDA; US Dept
   Def; US Dept State; US Dept Justice; US Dept Vet Affairs; US EPA; WHO}},
Abstract = {{Historically, staphylococci, pseudomonads, nosocomial infection troika;
   nosocomial pneumonia, surgical wound infections, and vascular
   access-related bacteremia have caused the most illness and death in
   hospitalized patients; and intensive care units have been the epicenters
   of antibiotic resistance. Acquired antimicrobial resistance is the major
   problem, and vancomycin-resistant Staphylococcus aureus is the pathogen
   of greatest concern. The shift to outpatient care is leaving the most
   vulnerable patients in hospitals. Aging of our population and
   increasingly aggressive medical and surgical interventions, including
   implanted foreign bodies, organ transplantations, and
   xenotransplantation, create a cohort of particularly susceptible
   persons. Renovation of aging hospitals increases risk of airborne fungal
   and other infections, To prevent and control these emerging nosocomial
   infections, we need to increase national surveillance, ``risk adjust{''}
   infection rates so that interhospital comparisons are valid, develop
   more noninvasive infection-resistant devices, and work with health-care
   workers on better implementation of existing control measures such as
   hand washing.}},
Publisher = {{CENTER DISEASE CONTROL}},
Address = {{ATLANTA, GA 30333 USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Weinstein, RA (Reprint Author), Cook Cty Hosp, Chicago, IL 60612 USA.
   Cook Cty Hosp, Chicago, IL 60612 USA.
   Rush Med Coll, Chicago, IL 60612 USA.}},
DOI = {{10.3201/eid0403.980320}},
ISSN = {{1080-6040}},
Keywords-Plus = {{VANCOMYCIN-RESISTANT ENTEROCOCCI; INTENSIVE-CARE UNIT; HOSPITALS}},
Research-Areas = {{Immunology; Infectious Diseases}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases}},
Author-Email = {{rweinste@rush.edu}},
ResearcherID-Numbers = {{Hori, Katsutoshi/K-5289-2012}},
ORCID-Numbers = {{Hori, Katsutoshi/0000-0003-1994-3124}},
Cited-References = {{ACHIBALD L, 1997, CLIN INFECT DIS, V24, P211.
   Bonten MJM, 1996, LANCET, V348, P1615, DOI 10.1016/S0140-6736(96)02331-8.
   Favero MS, 1996, AM J INFECT CONTROL, V24, P380.
   Fridkin SK, 1997, INFECT DIS CLIN N AM, V11, P479, DOI 10.1016/S0891-5520(05)70366-4.
   Goldmann DA, 1996, JAMA-J AM MED ASSOC, V275, P234, DOI 10.1001/jama.275.3.234.
   HALEY RW, 1985, AM J EPIDEMIOL, V121, P159, DOI 10.1093/oxfordjournals.aje.a113988.
   HALEY RW, 1985, AM J EPIDEMIOL, V121, P182, DOI 10.1093/oxfordjournals.aje.a113990.
   Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8.
   Scheckler WE, 1998, INFECT CONT HOSP EP, V19, P114.
   Slaughter S, 1996, ANN INTERN MED, V125, P448, DOI 10.7326/0003-4819-125-6-199609150-00004.
   Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426.
   WEBSTER RG, 1998, EMERG INFECT DIS, V4.
   Weinstein RA, 1998, INFECT CONT HOSP EP, V19, P91.
   WEINSTEIN RA, 1991, AM J MED S3B, V91, P179.
   1998, NY TIMES        0312, pA12.}},
Number-of-Cited-References = {{15}},
Times-Cited = {{189}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Emerg. Infect. Dis}},
Doc-Delivery-Number = {{111JP}},
Unique-ID = {{ISI:000075433800020}},
OA = {{gold}},
DA = {{2018-08-13}},
}

@article{ ISI:000074129100004,
Author = {Grant, PS},
Title = {{Evaluation of infection control parameters according to the 1994 Centers
   for Disease Control and Prevention tuberculosis guidelines: A 2-year
   experience}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{1998}},
Volume = {{26}},
Number = {{3}},
Pages = {{224-231}},
Month = {{JUN}},
Abstract = {{Background: Because of classification as a high-risk institution for
   potential Mycobacterium tuberculosis exposure and an employee purified
   protein derivative conversion rate of 2.7\%, a large
   university-affiliated county hospital enhanced administrative and
   engineering controls, as recommended by its tuberculosis task force in
   early 1994.
   Methods: For 1994 and 1995 the medical records of all patients with
   culture-confirmed M. tuberculosis were reviewed according to the 1994
   Centers for Disease Control and Prevention guidelines for case
   surveillance and risk assessment (infection control parameters). The
   chi(2)-test was used to compare 1994 and 1995 infection control
   parameters for statistical significance (p less than or equal to 0.05).
   Results: In 1994 and 1995 there were 253 patients with tuberculosis,
   85\% of whom (214/253) had pulmonary-site tuberculosis. The
   ``representative{''} patient with pulmonary tuberculosis was profiled,
   along with institution-specific surveillance data on diagnostics,
   medication regimens, and airborne isolation practices. Between 1994 and
   1995 there was a trend toward increased numbers of homeless patients
   with tuberculosis, from 8.2\% to 17\% (p = 0.07). Decreases in the
   numbers of HIV seropositive patients with tuberculosis from 35\% in 1994
   to 24\% in 1995 (p = 0.2) and of jailed patients with tuberculosis from
   9.8\% to 5\% (p = 0.5) were not significant. Drug-resistance patterns
   increased from 13\% to 24\%, with borderline significance (p = 0.06).
   The employee purified protein derivative testing compliance rate
   increased from 49\% in 1994 to 74\% in 1995, with the purified protein
   derivative conversion rate also increasing from 2.7\% to 3.5\%.
   Conclusion: The infection control parameter data were beneficial in
   identification of institution-specific risk factors for our population
   with tuberculosis. Although labor-intensive, the annual tuberculosis
   reports supported requests for administrative and engineering controls;
   however, efficacy of the 1994 tuberculosis control plan was difficult to
   assess from purified protein derivative conversion rates alone, because
   the testing compliance rate also increased.}},
Publisher = {{MOSBY-YEAR BOOK INC}},
Address = {{11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Grant, PS (Reprint Author), RHD \& Trinity Med Ctrs Tenet HealthSyst, 7 Med Pkwy, Dallas, TX 75234 USA.
   Parkland Mem Hosp, Dallas, TX 75235 USA.}},
DOI = {{10.1016/S0196-6553(98)80005-9}},
ISSN = {{0196-6553}},
Keywords-Plus = {{HEALTH-CARE WORKERS; CONTINUOUS QUALITY IMPROVEMENT; CDC TB SURVEY;
   CONTROL PROGRAMS; HOSPITAL PERSONNEL; MEMBER HOSPITALS; UNITED-STATES;
   TRANSMISSION; PATIENT; OUTBREAK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{{[}Anonymous], 1994, FED REGISTER, V59, P54242.
   AVERBACH C, 1994, AJIC AM J INFECT CON, V22, P121.
   Barnes PF, 1996, JAMA-J AM MED ASSOC, V275, P305, DOI 10.1001/jama.275.4.305.
   BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   {*}CDCP, 1994, COR CURR TUB CLIN SH, P1.
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1, DOI DOI 10.HTTP://WWW.CDC.G0V/MMWR/PREVIEW/MMWRHTML/00032890.HTM.
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P365.
   Centers for Disease Control and Prevention (CDC), 1996, MMWR-MORBID MORTAL W, V45, P950.
   COOK JD, 1995, AM J INFECT CONTROL, V23, P323, DOI 10.1016/0196-6553(95)90064-0.
   Dahl KM, 1996, INFECT CONT HOSP EP, V17, P816.
   EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377.
   ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537.
   FAZAL BA, 1995, INFECT CONT HOSP EP, V16, P340.
   FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129.
   GERBERDING JL, 1993, INFECT CONT HOSP EP, V14, P686.
   GLATT AE, 1996, AJIC AM J INFECT CON, V24, P119.
   Goldrick BA, 1996, AM J INFECT CONTROL, V24, P223, DOI 10.1016/S0196-6553(96)90053-X.
   GORDIN F, 1992, JAMA-J AM MED ASSOC, V267, P2649, DOI 10.1001/jama.267.19.2649.
   HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204.
   HARMON JC, 1995, AM J INFECT CONTROL, V23, P329.
   JACOBSEN E, 1995, J HOSP INFECT, V30, P75, DOI 10.1016/0195-6701(95)90253-8.
   KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5.
   LUNDGREN R, 1987, TUBERCLE, V68, P147, DOI 10.1016/0041-3879(87)90032-8.
   McDiarmid M, 1996, INFECT CONT HOSP EP, V17, P159.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   MOODY B, 1995, AJIC AM J INFECT CON, V23, P95.
   PIERCE JR, 1992, CHEST, V101, P581, DOI 10.1378/chest.101.2.581.
   PUGES CF, 1996, INFECT CONT HOSP EP, V17, P412.
   Pugliese G, 1996, INFECT CONT HOSP EP, V17, P819.
   Rattner SL, 1996, INFECT CONT HOSP EP, V17, P369.
   Sepkowitz KA, 1996, ANN INTERN MED, V125, P826, DOI 10.7326/0003-4819-125-10-199611150-00007.
   Sinkowitz RL, 1996, AM J INFECT CONTROL, V24, P226, DOI 10.1016/S0196-6553(96)90054-1.
   SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011.
   VanDrunen N, 1996, AM J INFECT CONTROL, V24, P235, DOI 10.1016/S0196-6553(96)90055-3.
   Wurtz R, 1996, INFECT CONT HOSP EP, V17, P409.}},
Number-of-Cited-References = {{38}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{ZT802}},
Unique-ID = {{ISI:000074129100004}},
DA = {{2018-08-13}},
}

@article{ ISI:000074493000016,
Author = {Lamy, T and Bernard, M and Courtois, A and Jacquelinet, C and Chevrier,
   S and Dauriac, C and Grulois, I and Guiguen, C and Le Prise, P},
Title = {{Prophylactic use of itraconazole for the prevention of invasive
   pulmonary aspergillosis in high risk neutropenic patients}},
Journal = {{LEUKEMIA \& LYMPHOMA}},
Year = {{1998}},
Volume = {{30}},
Number = {{1-2}},
Pages = {{163-174}},
Month = {{JUN}},
Abstract = {{Invasive pulmonary aspergillosis (IPA) is an increasing cause of
   morbidity and mortality in patients with hematologic malignancies. A
   major program of construction work close to our unit prompted us to
   evaluate thee efficacy of itraconazole prophylaxis in preventing IPA in
   these patients. During September 1994 to December 1995, 77 patients
   undergoing 96 neutropenic episodes (mean duration, 19.3 days +/- 9.1)
   received itraconazole as antifungal prophylaxis. All patients were
   treated in laminar air flow rooms. Itraconazole was administered at a
   loading dose of 600mg/d, (day1 to day3) and 400mg/d on the following
   days, in 87 instances. In the remaining episodes, the daily dose was 200
   or 400mg. Oral doses were adjusted to reach a plasma itraconazole level
   (PIL) above 1000ng/l. In cases of inadequate Pa or poor oral intake, IV
   AmphoB was started at a 20 mg daily dose. Five cases of IPA (proven n =
   2, probable n = 3) were observed. This represents an incidence of 5.2\%
   of the total number of episodes. One out of 67 (2\%) treatment episodes
   with adequate PIL, were associated with IPA as compared to 4 of 29
   (14\%) episodes with inadequate PIL, (p < 0.02). AmphoB was added in 28
   cases because of low PIL (n = 25), and/or antibiotic-resistant fever
   persistent pulmonary infiltrate (n = 8). These results need to be
   interpreted with caution, because of the absence of randomization or a
   control group. The efficacy of Itraconazole in neutropenic patients with
   high risk IPA has to be confirmed on larger and prospective studies.}},
Publisher = {{HARWOOD ACAD PUBL GMBH}},
Address = {{C/O STBS LTD, PO BOX 90, READING, BERKS, ENGLAND RG1 8JL}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Lamy, T (Reprint Author), Hop Pontchaillou, Serv Hematol Clin, Rennes, France.
   Hop Pontchaillou, Serv Hematol Clin, Rennes, France.}},
DOI = {{10.3109/10428199809050939}},
ISSN = {{1042-8194}},
Keywords = {{itraconazole; neutropenia; aspergillosis; prophylaxis}},
Keywords-Plus = {{BONE-MARROW TRANSPLANTATION; DOSE AMPHOTERICIN-B; FUNGAL-INFECTIONS;
   HEMATOLOGIC MALIGNANCIES; ANTIFUNGAL PROPHYLAXIS; MULTICENTER TRIAL;
   ACUTE-LEUKEMIA; DOUBLE-BLIND; EFFICACY; THERAPY}},
Research-Areas = {{Oncology; Hematology}},
Web-of-Science-Categories  = {{Oncology; Hematology}},
Cited-References = {{BEYER J, 1994, ANTIMICROB AGENTS CH, V38, P911, DOI 10.1128/AAC.38.5.911.
   BOOGAERTS MA, 1989, MYCOSES, V32, P103, DOI 10.1111/j.1439-0507.1989.tb02299.x.
   DEBEULE K, 1988, MYCOSES, V31, P476.
   DEGREGORIO MW, 1982, AM J MED, V73, P543, DOI 10.1016/0002-9343(82)90334-5.
   DENNING DW, 1989, AM J MED, V86, P791, DOI 10.1016/0002-9343(89)90475-0.
   DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X.
   GOODMAN JL, 1992, NEW ENGL J MED, V326, P315.
   GOODRICH JM, 1991, J INFECT DIS, V164, P731, DOI 10.1093/infdis/164.4.731.
   GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003.
   GUIOT HFL, 1994, CLIN INFECT DIS, V18, P525, DOI 10.1093/clinids/18.4.525.
   HOELZER D, 1992, LEUKEMIA, V6, P175.
   JEFFERY GM, 1991, AM J MED, V90, P685.
   MEUNIERCARPENTIER F, 1984, NEW ENGL J MED, V311, P1056.
   MORRISON VA, 1994, AM J MED, V96, P497, DOI 10.1016/0002-9343(94)90088-4.
   ODONNELL MR, 1994, J CLIN ONCOL, V12, P827, DOI 10.1200/JCO.1994.12.4.827.
   PRENTICE AG, 1989, MYCOSES, V32, P96, DOI 10.1111/j.1439-0507.1989.tb02298.x.
   RILEY DK, 1994, AM J MED, V97, P509, DOI 10.1016/0002-9343(94)90345-X.
   ROUSEY SR, 1991, AM J MED, V91, P484, DOI 10.1016/0002-9343(91)90184-Y.
   SAUGIERVEBER P, 1993, BONE MARROW TRANSPL, V12, P121.
   THUNNISSEN PLM, 1991, NETH J MED, V39, P84.
   TRICOT G, 1987, REV INFECTIOUS DI S1, V9, P94.
   UZUN O, 1995, BLOOD, V86, P2063.
   VANTWOUT JW, 1991, J INFECTION, V22, P45, DOI 10.1016/0163-4453(91)90954-Q.
   VREUGDENHIL G, 1993, LEUKEMIA LYMPHOMA, V11, P353, DOI 10.3109/10428199309067926.
   WARREN RE, 1989, J ANTIMICROB CHEMOTH, V32, P5.
   WEEMS JJ, 1987, INFECT CONTROL, V8, P171.
   WEINBERGER M, 1992, MEDICINE, V71, P24, DOI 10.1097/00005792-199201000-00003.
   WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803.
   WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{19}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Leuk. Lymphoma}},
Doc-Delivery-Number = {{ZX229}},
Unique-ID = {{ISI:000074493000016}},
DA = {{2018-08-13}},
}

@article{ ISI:000073798600025,
Author = {Hanic-Joyce, PJ and Joyce, PBM},
Title = {{A high-copy-number ADE2-bearing plasmid for transformation of Candida
   glabrata}},
Journal = {{GENE}},
Year = {{1998}},
Volume = {{211}},
Number = {{2}},
Pages = {{395-400}},
Month = {{MAY 12}},
Abstract = {{The Candida glabrata ADE2 gene encoding aminoimidazole ribonucleotide
   (AIR) carboxylase (EC 4.1.1.21) was isolated by complementation of the
   ade2-1 mutation in Saccharomyces cerevisiae. The predicted amino acid
   (aa) sequence is 75\% identical to that of S. cerevisiae. Integrative
   transformation was used to produce a C. glabrata strain bearing a
   deletion of ADE2 coding sequences. A high-copy-number shuttle vector
   bearing the ADE2 gene was constructed and contains a fragment of S.
   cerevisiae mitochondrial (mt) DNA that confers the ability to replicate
   autonomously in C. glabrata. (C) 1998 Published by Elsevier Science B.V.
   All rights reserved.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Joyce, PBM (Reprint Author), Concordia Univ, Dept Chem \& Biochem, 1455 Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.
   Concordia Univ, Dept Chem \& Biochem, Montreal, PQ H3G 1M8, Canada.}},
DOI = {{10.1016/S0378-1119(98)00157-7}},
ISSN = {{0378-1119}},
EISSN = {{1879-0038}},
Keywords = {{yeast; AIR carboxylase; vector; purine biosynthesis}},
Keywords-Plus = {{5-AMINOIMIDAZOLE RIBONUCLEOTIDE-CARBOXYLASE; SACCHAROMYCES-CEREVISIAE;
   SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; PHOSPHORIBOSYLAMINOIMIDAZOLE
   CARBOXYLASE; ANTIFUNGAL RESISTANCE; PURINE BIOSYNTHESIS; SHUTTLE
   VECTORS; HOST STRAINS; ADE2 GENE}},
Research-Areas = {{Genetics \& Heredity}},
Web-of-Science-Categories  = {{Genetics \& Heredity}},
Author-Email = {{joycep@vax2.concordia.ca}},
ResearcherID-Numbers = {{Joyce, Paul/K-3989-2013}},
Cited-References = {{ANZIANO PQ, 1991, P NATL ACAD SCI USA, V88, P5592, DOI 10.1073/pnas.88.13.5592.
   BENNETT JE, 1977, ANN INTERN MED, V86, P319, DOI 10.7326/0003-4819-86-3-319.
   BEWSEY KE, 1991, BIOTECHNIQUES, V10, P724.
   CHAPMAN KA, 1994, PLANT MOL BIOL, V24, P389, DOI 10.1007/BF00020176.
   CHEN ZD, 1990, P NATL ACAD SCI USA, V87, P3097, DOI 10.1073/pnas.87.8.3097.
   CLARKWALKER GD, 1983, EMBO J, V2, P1465.
   CORUZZI G, 1979, J BIOL CHEM, V18, P9324.
   Denning DW, 1997, EUR J CLIN MICROBIOL, V16, P261, DOI 10.1007/BF01695630.
   DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0.
   EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274.
   GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382.
   GOURDON P, 1995, YEAST, V11, P1289, DOI 10.1002/yea.320111309.
   HIEP TT, 1993, YEAST, V9, P1251, DOI 10.1002/yea.320091112.
   HOROWITZ BJ, 1992, J CLIN PHARMACOL, V32, P248, DOI 10.1002/j.1552-4604.1992.tb03833.x.
   HYMAN BC, 1982, P NATL ACAD SCI-BIOL, V79, P1578, DOI 10.1073/pnas.79.5.1578.
   KIRSCH DR, 1991, INFECT IMMUN, V59, P3297.
   Kitada K, 1996, GENE, V175, P105, DOI 10.1016/0378-1119(96)00132-1.
   KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H.
   LAW D, 1994, J ANTIMICROB CHEMOTH, V34, P659, DOI 10.1093/jac/34.5.659.
   MACREADIE IG, 1994, BIOTECHNOL APPL BIOC, V19, P265.
   MEHRA RK, 1992, GENE, V113, P119, DOI 10.1016/0378-1119(92)90678-I.
   MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209.
   MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11.
   NEWLON CS, 1988, MICROBIOL REV, V52, P568.
   Nguyen MH, 1996, AM J MED, V100, P617.
   PERFECT JR, 1993, INFECT IMMUN, V61, P4446.
   PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169.
   ROMAN H, 1956, COLD SPRING HARB SYM, V21, P175, DOI 10.1101/SQB.1956.021.01.015.
   ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0.
   Sambrook J., 1989, MOL CLONING LAB MANU.
   SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712.
   Schmuke JJ, 1997, YEAST, V13, P769, DOI 10.1002/(SICI)1097-0061(19970630)13:8<769::AID-YEA133>3.3.CO;2-G.
   SHERMAN F, 1991, METHOD ENZYMOL, V194, P3.
   SIKORSKI RS, 1989, GENETICS, V122, P19.
   STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q.
   SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4.
   TIEDEMAN AA, 1989, J BACTERIOL, V171, P205, DOI 10.1128/jb.171.1.205-212.1989.
   WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319.
   WATANABE W, 1989, J BACTERIOL, V171, P198, DOI 10.1128/jb.171.1.198-204.1989.
   Weng YS, 1997, BIOTECHNIQUES, V23, P237.
   WHELAN WL, 1987, CRIT REV MICROBIOL, V14, P99, DOI 10.3109/10408418709104437.
   YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9.
   ZHOU PB, 1994, GENE, V142, P135, DOI 10.1016/0378-1119(94)90368-9.
   ZWEIFEL SG, 1990, YEAST, V6, P179, DOI 10.1002/yea.320060302.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{11}},
Usage-Count-Last-180-days = {{7}},
Usage-Count-Since-2013 = {{7}},
Journal-ISO = {{Gene}},
Doc-Delivery-Number = {{ZP887}},
Unique-ID = {{ISI:000073798600025}},
DA = {{2018-08-13}},
}

@article{ ISI:000073296300002,
Author = {Ekstrand, J and Bjorkman, L and Edlund, C and Sandborgh-Englund, G},
Title = {{Toxicological aspects on the release and systemic uptake of mercury from
   dental amalgam}},
Journal = {{EUROPEAN JOURNAL OF ORAL SCIENCES}},
Year = {{1998}},
Volume = {{106}},
Number = {{2, 2}},
Pages = {{678-686}},
Month = {{APR}},
Note = {{3rd Joint Annual Meeting of the
   International-Association-for-Dental-Research-Continental-European-Divis
   ion/Scandinavian-Division on Dental Filling Materials, BERLIN, GERMANY,
   SEP, 1996}},
Organization = {{Intl Assoc Dental Res, Continental European Div; Intl Assoc Dental Res,
   Scandinavian Div; Degussa; DeTrey Dentply; Espe Dental Med; GC Intl
   Corp; Heraeus Kulzer; Vivadent Dental}},
Abstract = {{This paper summarizes some recent reports on mercury release from
   amalgam fillings and resulting concentrations in biological fluids,
   development of antibiotic resistance, and kidney function. In a series
   of studies of subjects with amalgam fillings, mercury (Hg) levels were
   followed in saliva, feces, blood, plasma, and urine before and until 60
   d after removal of all of the fillings. The Hg concentrations in saliva
   remained elevated for at least 1 wk, suggesting that dissolved l-Hg
   vapor is not the major source of mercury in mixed saliva. An absorption
   phase of Hg was seen in plasma during 24 h after amalgam removal. After
   60 d the plasma Hg concentration was reduced to 40\% of the baseline
   level. The decrease per amalgam surface was 0.11 nmol/l (range
   0.02-0.40). The Hg level in feces increased two orders of magnitude two
   days after amalgam removal. At day 60, the median Hg concentration was
   still slightly higher than the median value of the amalgam free control
   group. The resistance patterns of the oral and intestinal microflora in
   these subjects were also studied. In the intestinal microflora, the
   relative amount of intestinal microorganisms resistant to 50 muM HgCl2
   peaked 7 d after removal of the amalgam fillings, with a median value
   per sample of 6.1\% compared to 1.3\% in samples collected prior to the
   Hg exposure. However, no statistical differences in the resistance
   pattern of the oral microflora were detected between the control and the
   experimental groups. A number of sensitive kidney function parameters
   were measured 1 wk before and 1, 2, and 60 after amalgam removal. No
   effects on the various kidney parameters studied were recorded.
   According to the conclusions of independent evaluations from different
   state health agencies, the release of mercury from dental amalgam does
   not present any non-acceptable risk to the general population.}},
Publisher = {{WILEY}},
Address = {{111 RIVER ST, HOBOKEN 07030-5774, NJ USA}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{Ekstrand, J (Reprint Author), Karolinska Inst, Fac Dent, Dept Basic Oral Sci, Div Dent Toxicol, Box 4064, S-14104 Huddinge, Sweden.
   Karolinska Inst, Fac Dent, Dept Basic Oral Sci, Div Dent Toxicol, S-14104 Huddinge, Sweden.
   Karolinska Inst, Dept Microbiol, S-14104 Huddinge, Sweden.}},
DOI = {{10.1046/j.0909-8836.1998.eos10602ii03.x}},
ISSN = {{0909-8836}},
EISSN = {{1600-0722}},
Keywords = {{human; blood; feces; microbiology; renal function}},
Keywords-Plus = {{ORAL AIR MERCURY; ANTIMICROBIAL RESISTANCE; GLUTATHIONE-PEROXIDASE;
   FECAL FLORA; FILLINGS; EXPOSURE; VAPOR; SELENIUM; ERYTHROCYTES; BLOOD}},
Research-Areas = {{Dentistry, Oral Surgery \& Medicine}},
Web-of-Science-Categories  = {{Dentistry, Oral Surgery \& Medicine}},
Author-Email = {{Jan.A.Ekstrand@ofa.ki.se}},
Cited-References = {{{*}ACGIH, 1994, AM C GOV IND HYG CIN.
   AKESSON I, 1991, ARCH ENVIRON HEALTH, V46, P102, DOI 10.1080/00039896.1991.9937436.
   Aronsson A M, 1989, Biol Met, V2, P25, DOI 10.1007/BF01116197.
   BEGEROW J, 1994, INT ARCH OCC ENV HEA, V66, P209, DOI 10.1007/BF00380782.
   Berglund A, 1996, EUR J ORAL SCI, V104, P56, DOI 10.1111/j.1600-0722.1996.tb00046.x.
   BERGLUND A, 1990, J DENT RES, V69, P1646, DOI 10.1177/00220345900690100401.
   Bjorkman L, 1997, TOXICOL APPL PHARM, V144, P156, DOI 10.1006/taap.1997.8128.
   BJORKMAN L, 1992, SCAND J DENT RES, V100, P354.
   BJORKMAN L, 1993, J TRACE ELEM ELECT H, V7, P157.
   BOYD ND, 1991, AM J PHYSIOL, V261, pR1010.
   BRUNE D, 1991, SCI TOTAL ENVIRON, V100, P235, DOI 10.1016/0048-9697(91)90380-W.
   BRUNE D, 1985, SCI TOTAL ENVIRON, V44, P51, DOI 10.1016/0048-9697(85)90050-6.
   CHERIAN MG, 1978, ARCH ENVIRON HEALTH, V33, P109, DOI 10.1080/00039896.1978.10667318.
   CLARKSON TW, 1988, BIOL MONITORING TOXI, P199.
   CLARKSON TW, 1988, BIOL MONITORING TOXI, P247.
   CLARKSON TW, 1992, POTENTIAL BIOL CONSE, P59.
   Edlund C, 1996, CLIN INFECT DIS, V22, P944, DOI 10.1093/clinids/22.6.944.
   Elinder C. G., 1988, BIOL MONITORING TOXI, P1.
   ETI S, 1995, PHARMACOL TOXICOL, V76, P47, DOI 10.1111/j.1600-0773.1995.tb00101.x.
   GAY DD, 1979, LANCET, V1, P985.
   GILBERT MP, 1988, PLASMID, V20, P127, DOI 10.1016/0147-619X(88)90015-7.
   HALBACH S, 1995, J DENT RES, V74, P1103, DOI 10.1177/00220345950740041101.
   HALBACH S, 1978, BIOCHIM BIOPHYS ACTA, V523, P522, DOI 10.1016/0005-2744(78)90055-4.
   HEIKKILA E, 1993, ANTIMICROB AGENTS CH, V37, P1297, DOI 10.1128/AAC.37.6.1297.
   HERRSTROM P, 1995, ARCH ENVIRON HEALTH, V50, P103, DOI 10.1080/00039896.1995.9940886.
   Isacsson G, 1997, EUR J ORAL SCI, V105, P251, DOI 10.1111/j.1600-0722.1997.tb00208.x.
   JOKSTAD A, 1992, PHARMACOL TOXICOL, V70, P308, DOI 10.1111/j.1600-0773.1992.tb00478.x.
   JOSELOW MM, 1968, ARCH ENVIRON HEALTH, V17, P39, DOI 10.1080/00039896.1968.10665185.
   LANGWORTH S, 1988, SWED DENT J, V12, P69.
   LANGWORTH S, 1988, SWED DENT J, V12, P71.
   LEVY SB, 1988, ANTIMICROB AGENTS CH, V32, P1801, DOI 10.1128/AAC.32.12.1801.
   LONDON N, 1994, J ANTIMICROB CHEMOTH, V34, P239, DOI 10.1093/jac/34.2.239.
   MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033.
   MISRA TK, 1992, PLASMID, V27, P4, DOI 10.1016/0147-619X(92)90002-R.
   MOLIN M, 1987, SCAND J DENT RES, V95, P328.
   MOLIN M, 1990, ACTA ODONTOL SCAND, V48, P189, DOI 10.3109/00016359009005875.
   {*}NIH, 1992, ADV DENT RES, V6, P3.
   OLSSON S, 1992, J DENT RES, V71, P414, DOI 10.1177/00220345920710021201.
   OLSTAD ML, 1987, J DENT RES, V66, P1179, DOI 10.1177/00220345870660061701.
   OSTERBLAD M, 1995, ANTIMICROB AGENTS CH, V39, P2499, DOI 10.1128/AAC.39.11.2499.
   OTT KHR, 1986, DEUT ZAHNAERZTL Z, V41, P968.
   OTT KHR, 1984, DEUT ZAHNAERZTL Z, V39, P199.
   PORTER FD, 1982, ANTIMICROB AGENTS CH, V22, P852, DOI 10.1128/AAC.22.5.852.
   Sallsten G, 1996, J DENT RES, V75, P594, DOI 10.1177/00220345960750011301.
   Sandborgh Englund G., 1994, Journal of Dental Research, V73, P620.
   SANDBORGHENGLUN.G, 1996, AM J PHYSIOL, V40, pR941.
   SandborghEnglund G, 1997, J DENT RES, V76, P1142.
   SCHWEINSBERG F, 1994, TOXICOL LETT, V72, P345, DOI 10.1016/0378-4274(94)90047-7.
   SKARE I, 1990, SCAND J WORK ENV HEA, V16, P340, DOI 10.5271/sjweh.1774.
   SNAPP KR, 1989, J DENT RES, V68, P780, DOI 10.1177/00220345890680050501.
   STARK CA, 1993, ANTIMICROB AGENTS CH, V37, P1665, DOI 10.1128/AAC.37.8.1665.
   SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825.
   SVARE CW, 1981, J DENT RES, V60, P1668, DOI 10.1177/00220345810600090601.
   {*}SWED MED RES COUN, 1992, POT BIOL CONS MERC R.
   {*}SWED NAT BOARD HL, 1994, BLIR MAN SJUK AV AM, P21.
   {*}US PHS DEP HHS, 1993, DENT AM SCI REV REC.
   VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111.
   VIMY MJ, 1985, J DENT RES, V64, P1069, DOI 10.1177/00220345850640080901.
   VIMY MJ, 1985, J DENT RES, V64, P1072, DOI 10.1177/00220345850640081001.
   WHO, 1991, ENV HLTH CRIT, V118.
   WHO, 1990, ENV HLTH CRIT.
   WILLERSHAUSENZONNCHEN B, 1992, DEUT MED WOCHENSCHR, V117, P1743, DOI 10.1055/s-2008-1062504.}},
Number-of-Cited-References = {{62}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Eur. J. Oral Sci.}},
Doc-Delivery-Number = {{ZK209}},
Unique-ID = {{ISI:000073296300002}},
DA = {{2018-08-13}},
}

@article{ ISI:000072505900001,
Author = {Rao, GG},
Title = {{Risk factors for the spread of antibiotic-resistant bacteria}},
Journal = {{DRUGS}},
Year = {{1998}},
Volume = {{55}},
Number = {{3}},
Pages = {{323-330}},
Month = {{MAR}},
Abstract = {{The emergence of antibiotic resistance is primarily due to excessive and
   often unnecessary use of antibiotics in humans and animals. Risk factors
   for the spread of resistant bacteria in hospitals and the community can
   be summarised as overcrowding, lapses in hygiene or poor infection
   control practices. Increasing antibiotic resistance in bacteria has been
   exacerbated by the slow pace in developing newer antibiotics.
   Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant
   enterococci (VRE) and multiresistant Gram-negative bacteria are spread
   primarily by direct or indirect person-to-person contact. Independent
   risk factors for MRSA include the use of broad spectrum antibiotics, the
   presence of decubitus ulcers and prosthetic devices while those for VRE
   include prolonged hospitalisation and treatment with glycopeptides or
   broad spectrum antibiotics. For the spread of resistant Gram-negative
   bacteria risk factors include urinary catheterisation, excessive use of
   antibiotics and contamination of humidifiers and nebulisers.
   The spread of penicillin-resistant pneumococci (PRP) and drug-resistant
   and multidrug-resistant tuberculosis (MDRTb) is due to airborne
   transmission. Risk factors for the spread of PRP include overcrowding,
   tracheostomies and excessive use of penicillins for viral respiratory
   infections; for MDRTb they include poor compliance, convergence of
   immunosuppressed patients, delayed diagnosis or treatment, and poor or
   inadequate ventilation and isolation facilities.
   Recent developments in the genomic mapping of many bacteria and advances
   in combinatorial chemistry promise to usher in a new era of antibiotic
   development. While this may result in our regaining some of the ground
   lost to resistant bacteria, there will still be a continuing need to
   minimise the spread of antibiotic resistance through the rational use of
   antibiotic agents and stringent infection control practice.}},
Publisher = {{ADIS INTERNATIONAL LTD}},
Address = {{41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW
   ZEALAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rao, GG (Reprint Author), Univ Hosp Lewisham, Dept Microbiol, Lewisham High St, London SE13 6LH, England.
   Univ Hosp Lewisham, Dept Microbiol, London SE13 6LH, England.}},
DOI = {{10.2165/00003495-199855030-00001}},
ISSN = {{0012-6667}},
Keywords-Plus = {{HIV-INFECTED PATIENTS; ENTEROCOCCUS-FAECIUM; HOSPITAL OUTBREAK;
   MYCOBACTERIUM-TUBERCULOSIS; STREPTOCOCCUS-PNEUMONIAE; GLYCOPEPTIDE
   RESISTANCE; TRANSMISSION; PNEUMOCOCCI; ANIMALS}},
Research-Areas = {{Pharmacology \& Pharmacy; Toxicology}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy; Toxicology}},
Cited-References = {{Abraham EP, 1941, LANCET, V2, P177.
   Appelbaum PC, 1996, DRUGS, V51, P1, DOI 10.2165/00003495-199600511-00003.
   AUSTRIAN R, 1994, ANN INTERN MED, V121, P807, DOI 10.7326/0003-4819-121-10-199411150-00013.
   BATES J, 1994, J ANTIMICROB CHEMOTH, V34, P507, DOI 10.1093/jac/34.4.507.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   CARTMILL TDI, 1992, J HOSP INFECT, V20, P130, DOI 10.1016/0195-6701(92)90121-2.
   Centers for Disease Control, 1990, MMWR-MORBID MORTAL W, V39, P718.
   {*}COMM DIS REP, 1995, COMMUN DIS REP WKLY, V5, P161.
   CRAWFORD LM, 1982, CONTROL ANTIBIOTIC R.
   {*}DAN INT ANT RES M, 1997, CONS ANT AG OCC ANT.
   DANCER SJ, 1997, PHLS MICROBIOL DIG, V14, P11.
   FULLER R, 1991, GUT, V32, P439, DOI 10.1136/gut.32.4.439.
   GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3.
   HALEY WH, 1986, HOSP INFECT.
   HANSMAN D, 1967, LANCET, V2, P264.
   ISENIAN MD, 1993, NEW ENGL J MED, V329, P784.
   {*}JOINT COMM US ANT, 1969, SWANN REP JOINT COMM.
   KLARE I, 1995, FEMS MICROBIOL LETT, V125, P165, DOI 10.1111/j.1574-6968.1995.tb07353.x.
   KNOWLES D, 1997, 20 INT C CHEM 1 JUL.
   LINTON AH, 1986, J ANTIMICROB CHEMOTH, V18, P189, DOI 10.1093/jac/18.Supplement\_C.189.
   LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112.
   MAGTAMI P, 1995, BRIT MED J, V310, P963.
   MURRAY BE, 1991, J INFECT DIS, V163, P780, DOI 10.1093/infdis/163.4.780.
   Nicolle LE, 1996, CLIN MICROBIOL REV, V9, P1.
   OBRIEN TF, 1986, J ANTIMICROB CHEMOTH, V18, P243, DOI 10.1093/jac/18.Supplement\_C.243.
   ORENSTEIN WA, 1995, PRINCIPLES PRACTICE.
   Rao GG, 1997, J HOSP INFECT, V35, P63, DOI 10.1016/S0195-6701(97)90169-9.
   SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563.
   TEALE C, 1991, J INFECTION, V23, P327, DOI 10.1016/0163-4453(91)93224-Z.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   WOODFORD N, 1995, CLIN MICROBIOL REV, V8, P585.}},
Number-of-Cited-References = {{31}},
Times-Cited = {{88}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{25}},
Journal-ISO = {{Drugs}},
Doc-Delivery-Number = {{ZB767}},
Unique-ID = {{ISI:000072505900001}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:000079335300011,
Author = {Phillips, JE and Johnson, WJ},
Editor = {{Chang, TY and Freeman, DA}},
Title = {{Efflux and plasma transport of biosynthetic sterols}},
Booktitle = {{INTRACELLULAR CHOLESTEROL TRAFFICKING}},
Year = {{1998}},
Pages = {{147-168}},
Note = {{Meeting on Intracellular Cholesterol Trafficking, ST LOUIS, MO, APR,
   1997}},
Organization = {{Bristol Myers Squibb; Merck \& Co; Parke Davis}},
Abstract = {{The pathway of cholesterol biosynthesis has many steps, producing
   several intermediates. Some of the intermediates, such as lanosterol,
   zymosterol and desmosterol, are delivered to the plasma membrane, and
   are available for efflux and entry into the pathway of reverse sterol
   transport. Our studies with CHO and other extrahepatic cells suggest
   that these intermediates constitute the majority of biosynthetic sterol
   released to HDL; however, we see very little release from liver-derived
   cell lines, which make mainly cholesterol. Interestingly, we find that
   one of the intermediates, desmosterol, is released from cells three
   times more efficiently than cholesterol to extracellular sterol
   accepters. This release may be an important mechanism in extrahepatic
   cells to prevent the pathology that is associated with the build-up of
   intermediates in cells and in tissues. In this chapter, we review what
   is known about biosynthetic sterols and their transport within cells,
   and summarize our data on their release to extracellular acceptors.}},
Publisher = {{KLUWER ACADEMIC PUBLISHERS}},
Address = {{101 PHILIP DRIVE, ASSINIPPI PARK, NORWELL, MA 02061 USA}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Phillips, JE (Reprint Author), Allegheny Univ Hlth Sci, Dept Biochem, 2900 Queen Lane, Philadelphia, PA 19129 USA.
   Allegheny Univ Hlth Sci, Dept Biochem, Philadelphia, PA 19129 USA.}},
ISBN = {{0-7923-8365-6}},
Keywords = {{caveolae; desmosterol; lipid-rich vesicle fraction; multidrug resistance
   proteins; Sonic Hedgehog protein; 7-dehydrocholesterol;
   Smith-Lemli-Opitz syndrome; sterol carrier protein; triparanol;
   unilamellar vesicles}},
Keywords-Plus = {{LEMLI-OPITZ-SYNDROME; INTRACELLULAR CHOLESTEROL TRANSPORT; NEWLY
   SYNTHESIZED CHOLESTEROL; LOW-DENSITY-LIPOPROTEIN; EXTRA-HEPATIC TISSUES;
   AIR-WATER-INTERFACE; ENDOPLASMIC-RETICULUM; CARRIER PROTEIN-2; HUMAN
   FIBROBLASTS; CULTURED-CELLS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Cell Biology; Endocrinology \&
   Metabolism}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Cell Biology; Endocrinology \&
   Metabolism}},
Cited-References = {{ANDERSEN JM, 1979, J LIPID RES, V20, P740.
   ANDERSEN JM, 1982, BIOCHIM BIOPHYS ACTA, V711, P421, DOI 10.1016/0005-2760(82)90056-X.
   AVIRAM M, 1989, J LIPID RES, V30, P65.
   AXELSON M, 1991, J LIPID RES, V32, P1441.
   Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490.
   BJORKHEM I, 1987, J LIPID RES, V28, P1137.
   BLOCH K, 1965, SCIENCE, V150, P19, DOI 10.1126/science.150.3692.19.
   BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790.
   BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7.
   BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645.
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311.
   BURKI E, 1987, J LIPID RES, V28, P1199.
   Clayton P, 1996, LANCET, V348, P404, DOI 10.1016/S0140-6736(05)65020-9.
   DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256.
   DEMEL R A, 1976, Biochimica et Biophysica Acta, V457, P109, DOI 10.1016/0304-4157(76)90008-3.
   DEMEL RA, 1972, BIOCHIM BIOPHYS ACTA, V255, P311, DOI 10.1016/0005-2736(72)90030-2.
   DIETSCHY JM, 1984, J LIPID RES, V25, P1469.
   DIETSCHY JM, 1968, J CLIN INVEST, V47, P166, DOI 10.1172/JCI105706.
   DIETSCHY JM, 1974, J BIOL CHEM, V249, P52.
   DIETSCHY JM, 1993, J LIPID RES, V34, P1637.
   DIETSCHY JM, 1968, J CLIN INVEST, V47, P286, DOI 10.1172/JCI105725.
   ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484.
   ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31.
   Evans RW, 1995, CHEM PHYS LIPIDS, V78, P163, DOI 10.1016/0009-3084(95)02495-5.
   EVANS RW, 1987, BIOCHEM J, V245, P455, DOI 10.1042/bj2450455.
   FIELD EJ, 1998, J LIPID RES, V39, P333.
   FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004.
   FRUCHART JC, 1994, ATHEROSCLEROSIS SUPP, V110, P535.
   FUJIWARA T, 1965, J EXP MED, V87, P155.
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0.
   HELLERSTEIN MK, 1995, CURR OPIN LIPIDOL, V6, P172, DOI 10.1097/00041433-199506000-00010.
   HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8.
   HOKLAND BM, 1993, J BIOL CHEM, V268, P25343.
   HOTTA S, 1954, ARCH BIOCHEM BIOPHYS, V56, P28.
   Ikonen E, 1997, CURR OPIN LIPIDOL, V8, P60, DOI 10.1097/00041433-199704000-00002.
   Jackson S M, 1997, Subcell Biochem, V28, P1.
   Johnson W J, 1997, Subcell Biochem, V28, P235.
   JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037.
   KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446.
   Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q.
   KOLVISTO PVI, 1988, LIPIDS, V23, P993.
   LANGE Y, 1984, J BIOL CHEM, V259, P4624.
   LANGE Y, 1991, J BIOL CHEM, V266, P21439.
   LAUGHLIN RC, 1962, JAMA-J AM MED ASSOC, V181, P129.
   LISCUM L, 1992, J LIPID RES, V33, P1239.
   LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044.
   Martins IJ, 1998, J LIPID RES, V39, P302.
   MAZZONE T, 1995, J LIPID RES, V36, P544.
   MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891.
   Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627.
   Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634.
   MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339.
   OPITZ JM, 1994, AM J MED GENET, V50, P326, DOI 10.1002/ajmg.1320500406.
   PANINI SR, 1987, J BIOL CHEM, V262, P14435.
   Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255.
   Puglielli L, 1996, BIOCHEM J, V317, P681, DOI 10.1042/bj3170681.
   PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723.
   ROTHBLAT GH, 1992, J LIPID RES, V33, P1091.
   SCHROEPFER GJ, 1972, PROC R SOC SER B-BIO, V180, P125, DOI 10.1098/rspb.1972.0010.
   Simoni R D, 1988, Prog Clin Biol Res, V282, P29.
   SIMONI RD, 1995, BIOCH BIOPHYSICAL RE, V206, P186.
   SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1237, P127, DOI 10.1016/0005-2736(95)00096-L.
   SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237.
   SLOTTE JP, 1994, BBA-BIOMEMBRANES, V1190, P435, DOI 10.1016/0005-2736(94)90105-8.
   SMABY JM, 1994, BIOCHEMISTRY-US, V33, P9135, DOI 10.1021/bi00197a016.
   SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185.
   Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427.
   SPADY DK, 1983, J LIPID RES, V24, P303.
   Strandberg TE, 1996, DIABETES, V45, P755, DOI 10.2337/diabetes.45.6.755.
   TABAS I, 1987, J CLIN INVEST, V84, P1713.
   TINT GS, 1995, J LIPID RES, V36, P89.
   TINT GS, 1995, J PEDIATR-US, V127, P82, DOI 10.1016/S0022-3476(95)70261-X.
   TURLEY SD, 1995, J LIPID RES, V36, P67.
   Turley SD, 1997, J LIPID RES, V38, P1598.
   URBANI L, 1990, J BIOL CHEM, V265, P1919.
   WILSON JD, 1968, J CLIN INVEST, V47, P175, DOI 10.1172/JCI105707.
   WONG H. Y. C., 1966, LIFE SCI, V5, P629, DOI 10.1016/0024-3205(66)90294-3.
   Woollett LA, 1996, J LIPID RES, V37, P1246.
   Zhang F, 1996, LAB INVEST, V75, P413.}},
Number-of-Cited-References = {{79}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BM64Z}},
Unique-ID = {{ISI:000079335300011}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XY72300057,
Author = {Rosas, I and Salinas, E and Yela, A and Calva, E and Eslava, C and
   Cravioto, A},
Title = {{Escherichia coli in settled-dust and air samples collected in
   residential environments in Mexico City}},
Journal = {{APPLIED AND ENVIRONMENTAL MICROBIOLOGY}},
Year = {{1997}},
Volume = {{63}},
Number = {{10}},
Pages = {{4093-4095}},
Month = {{OCT}},
Abstract = {{Escherichia coli, an important indicator of the presence of fecal
   material, was isolated from indoor and outdoor environments in Mexico
   City, The heterogeneity of E. coli was represented by 89 serotypes, most
   of them coming from settled-dust indoor samples; 21\% of them presented
   antibiotic multiresistance. The numbers of plasmids were higher among
   the antibiotic-resistant strains. The results of this study suggest that
   intestinal infections produced by environmental strains could be of more
   epidemiological impact than previously thought.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Rosas, I (Reprint Author), NATL AUTONOMOUS UNIV MEXICO,CTR CIENCIAS ATMOSFERA,MEXICO CITY 04510,DF,MEXICO.
   NATL AUTONOMOUS UNIV MEXICO,INST BIOTECHNOL,MEXICO CITY 04510,DF,MEXICO.
   NATL AUTONOMOUS UNIV MEXICO,FAC MED,MEXICO CITY 04510,DF,MEXICO.}},
ISSN = {{0099-2240}},
Keywords-Plus = {{RESISTANCE GENE; BACTERIA; DNA; COLONIZATION}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
ORCID-Numbers = {{Rosas Perez, Irma Aurora/0000-0003-0149-8931}},
Cited-References = {{BETLEY MJ, 1986, ANNU REV MICROBIOL, V40, P577, DOI 10.1146/annurev.mi.40.100186.003045.
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513.
   COX CS, 1987, AEROBIOLOGICAL PATHW, P172.
   CRAVIOTO A, 1988, MOL CELL PROBE, V2, P125, DOI 10.1016/0890-8508(88)90034-5.
   CRAVIOTO A, 1990, AM J EPIDEMIOL, V131, P886, DOI 10.1093/oxfordjournals.aje.a115579.
   CROOK B, 1987, ADV AEROBIOLOGY, P371.
   Ezcurra E, 1996, ENVIRONMENT, V38, P6, DOI 10.1080/00139157.1996.9930972.
   FERNANDEZASTORGA A, 1992, APPL ENVIRON MICROB, V58, P392.
   GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004.
   HABERBERGER RL, 1991, LANCET, V337, P235, DOI 10.1016/0140-6736(91)92197-A.
   JOBLING MG, 1988, FEMS MICROBIOL LETT, V49, P31, DOI 10.1016/0378-1097(88)90097-3.
   LAW D, 1994, CLIN MICROBIOL REV, V7, P152.
   MARTHI B, 1991, APPL ENVIRON MICROB, V57, P2775.
   MURRAY R, 1984, BERGEYS MANUAL SYSTE, V2.
   Murray RGE, 1984, BERGEYS MANUAL SYSTE, V1.
   NIEMI M, 1983, APPL ENVIRON MICROB, V45, P79.
   ORSKOV F, 1975, ACTA PATH MICRO IM B, V83, P595.
   Rosas I, 1996, AEROBIOLOGY, P89.
   SCHOENI JL, 1994, APPL ENVIRON MICROB, V60, P2958.
   SHOEMAKER NB, 1992, APPL ENVIRON MICROB, V58, P1313.
   SINGH KV, 1992, ANTIMICROB AGENTS CH, V36, P1720, DOI 10.1128/AAC.36.8.1720.
   Torres J, 1995, Arch Med Res, V26, P23.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{28}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Appl. Environ. Microbiol.}},
Doc-Delivery-Number = {{XY723}},
Unique-ID = {{ISI:A1997XY72300057}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XV70100004,
Author = {Visalli, MA and Jacobs, MR and Appelbaum, PC},
Title = {{Susceptibility of penicillin-susceptible and -resistant pneumococci to
   dirithromycin compared with susceptibilities to erythromycin,
   azithromycin, clarithromycin, roxithromycin, and clindamycin}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{1997}},
Volume = {{41}},
Number = {{9}},
Pages = {{1867-1870}},
Month = {{SEP}},
Abstract = {{Agar dilution with incubation in air and CO2 was used td determine the
   MICs of erythromycin, dirithromycin; azithromycin, clarithromycin,
   roxithromycin, and clindamycin for 79 penicillin-susceptible, 72
   penicillin-intermediate, and 74 penicillin-resistant pneumococci (158
   erythromycin-susceptible and 67 erythromycin-resistant pneumococci).
   MICs obtained in air were usually 1 to 3 dilutions lower than those
   obtained in CO2. In air, the respective MICs at which 50\% (MIC(50)s)
   and 90\% (MIC(50)s) of penicillin-susceptible, -intermediate, and
   -resistant strains are inhibited were as follows:erythromycin, 0.016 and
   0.5, 0.03 and >64, and 2 and >64 mu g/ml; dirithromycin, 0.03 and 0.5,
   0.06 and >64, and 8 and >64 mu g/ml; azithromycin, 0.03 and 0.5, 0.06
   and >64, and 2 and >64 mu g/ml; clarithromycin, 0.016 and 0.06, 0.03 and
   >64, and 2 and >64 mu g/ml; roxithromycin, 0.06 and 2, 0.06 and >64, and
   2 and >64 mu g/ml; and clindamycin, 0.03 and 0.06, 0.06 and >64, and
   0.06 and >64 mu g/ml. The MICs of erythromycin, azithromycin, and
   dirithromycin were very similar; however, clarithromycin MICs were;
   generally 1 to 2 dilutions lower and roxithromycin MICs were 1 to 2
   dilutions higher than those of the other compounds tested, Strains
   resistant to one macrolide were resistant to all macrolides; however,
   not all macrolide-resistant strains were resistant to clindamycin, and
   32 macrolide-resistant (MICs, greater than or equal to 128 mu g/ml),
   clindamycin-susceptible (MICs, less than or equal to 0.25 mu g/ml)
   strains were encountered, Time-kill testing of six strains showed
   similar killing kinetics for all compounds, with 99.9\% killing of all
   strains observed with the compounds only at or above the MIC after 24 h.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT PATHOL,HERSHEY,PA 17033.
   CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106.}},
ISSN = {{0066-4804}},
Keywords-Plus = {{STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL RESISTANCE; UNITED-STATES;
   INFECTIONS; ANTIBIOTICS; MANAGEMENT}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Cited-References = {{APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   BARRY AL, 1994, ANTIMICROB AGENTS CH, V38, P2419, DOI 10.1128/AAC.38.10.2419.
   BARRY AL, 1993, J ANTIMICROB CHEMOTH, V31, P27, DOI 10.1093/jac/31.suppl\_C.27.
   BAUERNFEIND A, 1993, J ANTIMICROB CHEMOTH, V31, P39, DOI 10.1093/jac/31.suppl\_C.39.
   BERGOGNEBEREZIN E, 1993, J ANTIMICROB CHEMOTH, V31, P77, DOI 10.1093/jac/31.suppl\_C.77.
   BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005.
   BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831.
   COUNTER FT, 1991, ANTIMICROB AGENTS CH, V35, P1116, DOI 10.1128/AAC.35.6.1116.
   Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208.
   Ednie LM, 1996, ANTIMICROB AGENTS CH, V40, P1950.
   Fasola EI, 1997, ANTIMICROB AGENTS CH, V41, P129.
   FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377.
   GESLIN P, 1994, MED MALADIES INFECT, V24, P948, DOI 10.1016/S0399-077X(05)80772-3.
   JACOBS MR, 1992, CLIN INFECT DIS, V15, P119, DOI 10.1093/clinids/15.1.119.
   LINARES J, 1991, 31 INT C ANT AG CHEM.
   MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703.
   MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302.
   National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE, pM7.
   NELSON CT, 1994, PEDIATR INFECT DIS J, V13, P585, DOI 10.1097/00006454-199407000-00001.
   PANKUCH GA, 1994, ANTIMICROB AGENTS CH, V38, P2065, DOI 10.1128/AAC.38.9.2065.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{27}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{XV701}},
Unique-ID = {{ISI:A1997XV70100004}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XR53400005,
Author = {Kellerman, S and Tokars, JI and Jarvis, WR},
Title = {{The cost of selected tuberculosis control measures at hospitals with a
   history of Mycobacterium tuberculosis outbreaks}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{1997}},
Volume = {{18}},
Number = {{8}},
Pages = {{542-547}},
Month = {{AUG}},
Abstract = {{OBJECTIVE: To determine the cost of nonrespirator-related tuberculosis
   (TB) control measures at several hospitals, following publication of the
   Centers for Disease Control and Prevention (CDC)'s revised TB infection
   control guidelines.
   DESIGN: Infection control (IC) and TB coordinators obtained cost
   information on tuberculin skin-test (TST) programs, addition of IC and
   employee health service (EHS) personnel, and the retrofit or new
   construction of environmental controls.
   SETTING: Four hospitals with, and one community hospital without, prior
   nosocomial multidrug-resistant TB transmission.
   RESULTS: During the study period, the TST program costs remained
   constant at four of five hospitals and increased at one hospital (median
   1994 TST program cost: \$5,568; range, \$2,393-\$44,902). Additional IC
   or EHS personnel were hired at four of five hospitals (median cost
   increase, \$125,500; range, \$63,000-\$228,000). The median cost of new
   construction or new equipment purchases (ie, sputum induction booths,
   ultraviolet lights, or portable high-efficiency particulate air filters)
   at study hospitals was \$163,000 (range, \$45,000-\$524,000) and
   \$70,000 (range, \$31,000-\$93,000), respectively.
   CONCLUSIONS: Costs associated with implementing control measures similar
   to those recommended in the CDC TB IC guidelines varied widely by
   hospital. Engineering controls involved the largest capital outlay, but
   increases in personnel were the largest continuing cost. These costs
   represent improvements made to upgrade selected aspects of hospital TB
   control programs, not the cost of an optimal TB control program (Infect
   Control Hosp Epidemiol 1997;18:542-547).}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Kellerman, S (Reprint Author), CTR DIS CONTROL \& PREVENT,HOSP INFECT PROGRAM,INVEST \& PREVENT BRANCH,MAIL STOP E-69,ATLANTA,GA 30333, USA.}},
ISSN = {{0899-823X}},
Keywords-Plus = {{HEALTH-CARE WORKERS; MULTIDRUG-RESISTANT TUBERCULOSIS; INFECTION-CONTROL
   PROGRAMS; CDC TB SURVEY; NOSOCOMIAL TRANSMISSION; MEMBER HOSPITALS;
   UNITED-STATES; EFFICACY; ADULTS}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x.
   {*}BATT MED TECHN AS, 1993, BROW.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595.
   Center for Disease Control, 1994, MMWR, V43.
   CHINH TL, 1984, INFECT CONTROL, V5, P570.
   DUNLAP NE, 1994, INFECT AGENT DIS, V3, P245.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129.
   JEREB JA, 1995, ARCH INTERN MED, V155, P854, DOI 10.1001/archinte.155.8.854.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RAAD I, 1989, INFECT CONT HOSP EP, V10, P465.
   ROSENBLUM LS, 1994, ANN INTERN MED, V121, P786, DOI 10.7326/0003-4819-121-10-199411150-00009.
   SHULKIN DJ, 1995, AM J INFECT CONTROL, V23, P1, DOI 10.1016/0196-6553(95)90001-2.
   SILBER P, 1987, PUBLIC HEALTH, V101, P297, DOI 10.1016/S0033-3506(87)80081-1.
   SNIDER DE, 1986, JAMA-J AM MED ASSOC, V255, P1579, DOI 10.1001/jama.255.12.1579.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.}},
Number-of-Cited-References = {{20}},
Times-Cited = {{18}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{XR534}},
Unique-ID = {{ISI:A1997XR53400005}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XG91400005,
Author = {Kenyon, TA and Ridzon, R and LuskinHawk, R and Schultz, C and Paul, WS
   and Valway, SE and Onorato, IM and Castro, K},
Title = {{A nosocomial outbreak of multidrug-resistant tuberculosis}},
Journal = {{ANNALS OF INTERNAL MEDICINE}},
Year = {{1997}},
Volume = {{127}},
Number = {{1}},
Pages = {{32-36}},
Month = {{JUL 1}},
Abstract = {{Background: An outbreak of seven cases (in six patients and one health
   care worker, all of whom had AIDS) of multidrug-resistant tuberculosis
   occurred in a hospital in Chicago. The hospital had a respirator-fit
   testing program but no acid-fast bacilli isolation rooms.
   Objective: To identify risk factors for transmission of Mycobacterium
   tuberculosis.
   Design: Retrospective cohort study.
   Setting: Private hospital.
   Participants: Patients and health care workers exposed to M.
   tuberculosis.
   Measurements: Analysis of M. tuberculosis isolates, tuberculin skin
   testing, assessment of exposure, and assessment of participant
   characteristics.
   Results: All seven M. tuberculosis isolates had matching DNA
   fingerprints. Of patients exposed to M. tuberculosis, those who
   developed tuberculosis had lower CD4(+) T-lymphocyte counts (P = 0.02)
   and were more likely to be ambulatory (P = 0.03) than those who did not.
   Of 74 exposed health care workers, the 11 (15\%)who had conversion on
   tuberculin skin testing were no more likely than those who did not have
   conversion to report that they always wore a respirator with a
   high-efficiency particulate air filter.
   Conclusions: Transmission of M. tuberculosis occurred in a hospital that
   did not have recommended isolation rooms. A respirator-fit testing
   program did not protect health care workers in this setting.}},
Publisher = {{AMER COLL PHYSICIANS}},
Address = {{INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{CTR DIS CONTROL \& PREVENT, DIV TB ELIMINAT, ATLANTA, GA 30333 USA.
   ST JOSEPH HOSP, CHICAGO, IL USA.
   CHICAGO DEPT PUBL HLTH, CHICAGO, IL USA.}},
DOI = {{10.7326/0003-4819-127-1-199707010-00006}},
ISSN = {{0003-4819}},
EISSN = {{1539-3704}},
Keywords-Plus = {{HIV-INFECTED PATIENTS; LENGTH-POLYMORPHISM ANALYSIS; HEALTH-CARE
   WORKERS; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; UNIT}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003.
   CAIAFFA WT, 1995, ARCH INTERN MED, V155, P2111, DOI 10.1001/archinte.155.19.2111.
   Center for Diseases Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1.
   Chaves F, 1996, J CLIN MICROBIOL, V34, P1118.
   CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052.
   DEAN AG, 1994, EPI INFO VERSION 6 W.
   Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129.
   IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152.
   JEREB JA, 1993, J INFECT DIS, V168, P1219, DOI 10.1093/infdis/168.5.1219.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{62}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Intern. Med.}},
Doc-Delivery-Number = {{XG914}},
Unique-ID = {{ISI:A1997XG91400005}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XG01100008,
Author = {Managan, LP and Perrotta, DM and Banerjee, SN and Hack, D and Simonds, D
   and Jarvis, WR},
Title = {{Status of tuberculosis infection control programs at Texas hospitals,
   1989 through 1991}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{1997}},
Volume = {{25}},
Number = {{3}},
Pages = {{229-235}},
Month = {{JUN}},
Abstract = {{Background: Paralleling the resurgence of tuberculosis (TB) in the
   United States, the reported number of persons with TB in Texas increased
   by 33\% during 1985 through 1992, the third largest rise among all the
   states. This increase prompted us to survey hospitals in Texas to
   determine their degree of compliance with recommendations in the Centers
   for Disease Control and Prevention TB guidelines.
   Methods: In April 1992, we mailed a voluntary questionnaire about TB
   infection control practices, health care worker tuberculin skin testing
   procedures, and Mycobacterium tuberculosis laboratory methods to a
   convenience sample of hospitals in Texas.
   Results: Of 180 hospitals surveyed, 151 (83\%) returned completed
   questionnaires. Of these, 90 (60\%) were nonteaching community
   hospitals; 28 (19\%) were teaching community hospitals; 13 (9\%) were
   university-affiliate hospitals; and 20 (13\%) were other hospitals. The
   number of hospitals to which patients with TB were admitted increased
   from 98 (65\%) in 1989 to 122 (81\%) in 1991. Respondent hospitals had a
   mean of 183 acute care beds (median 100, range 5 to 999), 6 acid-fast
   bacillus isolation rooms (median 2, range 0 to 57) and 7.5
   admissions/year of patients with TB (median 2, range 0 to 202). Of
   hospitals responding to specific questions, 20\% (27/137) admitted
   patients with multidrug-resistant TB, 18\% (25/140) reported not having
   any acid-fast bacillus isolation rooms, and 28\% (35/125) had no rooms
   meeting all of the Centers for Disease Control and Prevention criteria
   for acid-fast bacillus isolation (negative air pressure, greater than or
   equal to 6 air changes per hour, and air directly vented to the
   outside). The tuberculin skin test conversions among health care workers
   rose from 246 (0.6\%) in 1989 to 547 (0.9\%) in 1991.
   Conclusion: Although the number of Texas hospitals admitting patients
   with TB increased during 1989 through 1991, many facilities still did
   not have infection control practices consistent with the 1992 Centers
   for Disease Control and Prevention TB guidelines.}},
Publisher = {{MOSBY-YEAR BOOK INC}},
Address = {{11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Managan, LP (Reprint Author), CTR DIS CONTROL \& PREVENT,HOSP INFECT PROGRAM,NATL CTR INFECT DIS,MAILSTOP E-69,1600 CLIFTON RD,ATLANTA,GA 30333, USA.}},
DOI = {{10.1016/S0196-6553(97)90009-2}},
ISSN = {{0196-6553}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; CDC TB SURVEY; NOSOCOMIAL
   TRANSMISSION; MEMBER HOSPITALS; OUTBREAK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535.
   {*}CDCP, 1993, MMWR-MORBID MORTAL W, V42, P696.
   {*}CDCP, 1992, MMWR-MORBID MORTAL W, V41, P49.
   Centers for Disease Control Yellow fever vaccine: recommendations of the Immunization Practices Advisory Committee (ACIP), 1990, MMWR-MORBID MORTAL W, V39, P1.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129.
   JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RUDNICK JR, 1992, 1 WORLD C TUB ROCKV.
   Sinkowitz RL, 1996, AM J INFECT CONTROL, V24, P226, DOI 10.1016/S0196-6553(96)90054-1.
   STAGER CE, 1991, J CLIN MICROBIOL, V29, P154.
   TENOVER FC, 1993, J CLIN MICROBIOL, V31, P771.
   Tokars JI, 1996, J CLIN MICROBIOL, V34, P680.
   1994, MMWR RECOMM REP, V43, P1.}},
Number-of-Cited-References = {{18}},
Times-Cited = {{3}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{XG011}},
Unique-ID = {{ISI:A1997XG01100008}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XB19400006,
Author = {Rizzi, A and Rocco, G and Robustellini, M and Rossi, G and DellaPona, C
   and Vertemati, G},
Title = {{Modern morbidity following pulmonary resection for postprimary
   tuberculosis}},
Journal = {{WORLD JOURNAL OF SURGERY}},
Year = {{1997}},
Volume = {{21}},
Number = {{5}},
Pages = {{488-491}},
Month = {{JUN}},
Abstract = {{Between January 1991 and March 1996, a total of 28 patients with
   postprimary tuberculosis underwent resection for disease progression (n
   = 8), multidrug resistance or noncompliance to the medical treatment (n
   = 11), parenchymal sequelae (n = 3), suspected cancer (n = 5), and for
   the correction of postpneumonectomy bronchopleural fistula and empyema
   (n = 1). On admission, eight patients presented with sputum positivity
   (28.6\%). Similar to previous series, tubercular predilection for upper
   lobes was confirmed (21/28, 75\%); accordingly, upper lobectomy through
   an extrapleural approach was the most common procedure (16/28, 57.1\%).
   Atypical segmental resections or segmentectomies were performed in seven
   patients (25\%), whereas a bilobectomy was necessary in another three
   patients (10.7\%) and a completion pneumonectomy in one (3.6\%).
   Additional procedures were an open-window thoracostomy with
   transpericardial closure of the main bronchus and a tailored
   thoracoplasty. No operative mortality was reported. Healing was achieved
   in 26 patients (93\%). Bleeding, either from the chest wall or hilar
   dissection, was the only reported intraoperative complication. Median
   blood loss, inclusive of early postoperative collections from chest
   tubes, reached 1330 ml (range 100-3700 ml). Major postoperative
   complications included recurrent disease (2/28, 7\%) in sputum-positive
   patients and segmental pulmonary embolism (3.5\%). Causes of minor
   morbidity were air Leaks resulting in residual space undergoing
   spontaneous resolution (18\%), wound breakdown (14\%), and, fever
   (11\%). This limited series confirms the therapeutic value of the
   surgical treatment of postprimary tuberculosis, provided that correct
   indications, adequate pre- and post-operative medical coverage, and
   meticulous technique are applied.}},
Publisher = {{SPRINGER VERLAG}},
Address = {{175 FIFTH AVE, NEW YORK, NY 10010}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{E MORELLI REG HOSP,DIV THORAC SURG,SONDALO,SONDRIO,ITALY.}},
DOI = {{10.1007/PL00012274}},
ISSN = {{0364-2313}},
Keywords-Plus = {{SURGICAL-MANAGEMENT}},
Research-Areas = {{Surgery}},
Web-of-Science-Categories  = {{Surgery}},
ResearcherID-Numbers = {{Rocco, Gaetano/K-4801-2016}},
ORCID-Numbers = {{Rocco, Gaetano/0000-0003-4150-8604}},
Cited-References = {{Brown J, 1995, Chest Surg Clin N Am, V5, P289.
   POMERANTZ M, 1991, ANN THORAC SURG, V52, P1108, DOI 10.1016/0003-4975(91)91289-8.
   REED CE, 1989, ANN THORAC SURG, V48, P165, DOI 10.1016/0003-4975(89)90062-3.
   RIZZI A, 1995, ANN THORAC SURG, V59, P896, DOI 10.1016/0003-4975(95)00011-9.
   ROCCO G, 1994, ANN THORAC SURG, V57, P260, DOI 10.1016/0003-4975(94)90425-1.
   SHIELDS TW, 1989, GENERAL THORACIC SUR, P785.
   TREASURE RL, 1995, ANN THORAC SURG, V59, P1405, DOI 10.1016/0003-4975(95)00145-B.
   UTLEY JR, 1993, ANN THORAC SURG, V55, P672, DOI 10.1016/0003-4975(93)90274-L.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{World J.Surg.}},
Doc-Delivery-Number = {{XB194}},
Unique-ID = {{ISI:A1997XB19400006}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997XP03600014,
Author = {Jorgensen, JH and McElmeel, ML},
Title = {{Activity of quinupristin/dalfopristin and its components against
   Haemophilus influenzae}},
Journal = {{JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY}},
Year = {{1997}},
Volume = {{39}},
Number = {{A}},
Pages = {{69-73}},
Month = {{MAY}},
Abstract = {{Quinupristin/dalfopristin is an injectable streptogramin antibiotic that
   is constituted in a 30:70 (w/w) ratio of the two components.
   Quinupristin and dalfopristin are thought to act synergically by binding
   to two separate sites on the bacterial 50S ribosomal subunit. The
   in-vitro activities of the two components separately and together in
   different ratios were determined for a collection of 100 Haemophilus
   influenzae strains representing various antimicrobial resistance
   phenotypes. The NCCLS microdilution susceptibility testing procedure
   incorporating Haemophilus test medium (HTM) broth was used to determine
   MICs of quinupristin, dalfopristin and seven other antimicrobial agents.
   The MIC50 and MIC90 values were 4 and 8, 4 and 16, and 64 and 128 mg/L
   for quinupristin/dalfopristin (30:70), dalfopristin and quinupristin,
   respectively. MICs of quinupristin and dalfopristin were also determined
   in Mueller-Hinton lysed horse blood broth and by HTM agar dilution
   testing. Compared with HTM broth-derived results, the MICs of
   quinupristin/dalfopristin and its components were the same or one
   dilution higher in lysed horse blood and HTM agar incubated in air, and
   were equivalent or one dilution lower in HTM agar incubated in a CO2
   atmosphere. The MICs of quinupristin and dalfopristin separately or
   together were directly proportional to erythromycin MICs, but were
   otherwise unaffected by any of the resistance mechanisms represented in
   these strains. MICs of quinupristin and dalfopristin combined in ratios
   of 10:90, 70:30 and 90:10 did not differ significantly from those of the
   30:70 ratio. Thus, unlike the synergic activity noted against
   Gram-positive bacteria, the activity of quinupristin/dalfopristin
   against H. influenzae appears to be due almost entirely to the
   dalfopristin component of the combination.}},
Publisher = {{OXFORD UNIV PRESS}},
Address = {{GREAT CLARENDON ST, OXFORD, ENGLAND OX2 6DP}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Jorgensen, JH (Reprint Author), UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.}},
DOI = {{10.1093/jac/39.suppl\_1.69}},
ISSN = {{0305-7453}},
Keywords-Plus = {{RP 59500; SEMISYNTHETIC STREPTOGRAMIN; INVITRO ACTIVITY; STAPHYLOCOCCI;
   RP59500}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Cited-References = {{ARCHER GL, 1993, DIAGN MICR INFEC DIS, V16, P223, DOI 10.1016/0732-8893(93)90113-L.
   AUMERCIER M, 1992, ANTIMICROBIAL AGE SA, V39, P9.
   BARRY AL, 1995, ANTIMICROB AGENTS CH, V39, P238, DOI 10.1128/AAC.39.1.238.
   BOUANCHAUD DH, 1992, J ANTIMICROB CHEMOTH, V30, P95, DOI 10.1093/jac/30.suppl\_A.95.
   COLLINS LA, 1993, ANTIMICROB AGENTS CH, V37, P598, DOI 10.1128/AAC.37.3.598.
   DABERNAT H, 1993, PATHOL BIOL, V41, P641.
   JORGENSEN JH, 1987, J CLIN MICROBIOL, V25, P2105.
   LECLERCQ R, 1992, J ANTIMICROB CHEMOTH, V30, P67, DOI 10.1093/jac/30.suppl\_A.67.
   {*}NAT COMM CLIN LAB, 1995, M7A NCCLS.
   {*}NAT COMM CLIN LAB, 1994, M7A3 NCCLS.
   {*}NAT COMM CLIN LAB, 1993, M7A3 NCCLS.
   NEU HC, 1992, J ANTIMICROB CHEMOTH, V30, P83, DOI 10.1093/jac/30.suppl\_A.83.}},
Number-of-Cited-References = {{12}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{J. Antimicrob. Chemother.}},
Doc-Delivery-Number = {{XP036}},
Unique-ID = {{ISI:A1997XP03600014}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:A1997BJ48C00350,
Author = {Sidiskis, J and Sestakauskas, K and Skauminas, K and Klumbys, L and
   Gvazdaitis, R and Vilcinis, R},
Book-Group-Author = {{MONDUZZI EDITORE, INT PROC DIV}},
Title = {{Ventroposterolateral pallidotomy for relief of the main Parkinsonian
   symptoms}},
Booktitle = {{11TH INTERNATIONAL CONGRESS OF NEUROLOGICAL SURGERY, VOLS 1 AND 2}},
Year = {{1997}},
Pages = {{2043-2046}},
Note = {{11th International Congress of Neurological Surgery, AMSTERDAM,
   NETHERLANDS, JUL 06-11, 1997}},
Abstract = {{Best surgical methods in drug resistant parkinsonism are still
   discussed. We evaluated the effects of ventroposterolateral pallidotomy
   (VPT) on main parkinsonian symptoms. We present our data of 48
   VPT:unilateral - on 30 pts., (4 had contralateral thalamotomy (of n.
   Vim), - bilateral thalamotomies performed previously); bilateral VPT -
   on 9 pts. Good effect on tremor was achieved in 18/24 pts., satisfactory
   - in 5/24 patients. Relief of rigidity dose to normal - in 24/34 pt.,
   marked reduction - in 8/34 pts. Hypokinesia was markedly reduced in
   13/23 pts. with good effect on gait also, minor improvement, slight
   effect on gait 7/23 pts., no effect on gait - 1 pt., gait deteriorated -
   1 pt. Follow-up of 19 pts. (1.5-36 mths) suggests that most of them
   improve their daily living activities. We find pallidotomy to be
   effective for air main symptoms of parkinsonism with the best effect on
   rigidity, marked effect on tremor and hypokinesia.}},
Publisher = {{MONDUZZI EDITORE}},
Address = {{VIA FERRARESE 119/2, 40128 BOLOGNA, ITALY}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Sidiskis, J (Reprint Author), KAUNAS MED ACAD HOSP,CLIN NEUROSURG,KAUNAS,LITHUANIA.}},
ISBN = {{88-323-0706-5}},
Research-Areas = {{Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Clinical Neurology}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BJ48C}},
Unique-ID = {{ISI:A1997BJ48C00350}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997WA65600024,
Author = {Fasola, EI and Bajaksouzian, S and Appelbaum, PC and Jacobs, MR},
Title = {{Variation in erythromycin and clindamycin susceptibilities of
   Streptococcus pneumoniae by four test methods}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{1997}},
Volume = {{41}},
Number = {{1}},
Pages = {{129-134}},
Month = {{JAN}},
Abstract = {{Susceptibilities of 124 strains of Streptococcus pneumoniae to
   erythromycin and clindamycin were determined by the National Committee
   for Clinical Laboratory Standards (NCCLS) broth microdilution method,
   with incubation for 20 to 24 h in ambient air and with modifications of
   this method by incubation for up to 48 h in air and CO2. Strains were
   also tested by agar dilution, E-test, and disk diffusion; good
   correlation was obtained with these methods, with clear separation into
   bimodal populations of susceptible and resistant strains, The broth
   microdilution method, however, using incubation in air for 24 h (NCCLS
   method), misclassified 4 of 92 erythromycin-resistant strains (1 as
   susceptible and 3 as intermediate) and 25 of 58 clindamycin-resistant
   strains (all as susceptible), With the exception of one strain with
   clindamycin, susceptible and resistant strains were correctly classified
   by the microdilution method with incubation in CO2 for 24 h or in
   ambient air for 48 h, Disk diffusion, agar dilution, and E-test methods
   with incubation in 5\% CO2 are therefore reliable methods for
   susceptibility testing of pneumococci against these agents, However, the
   NCCLS microdilution method, which specifies incubation for 20 to 24 h in
   ambient air, produced significant very major errors (43\%) with
   clindamycin, Modification of the microdilution method by incubation in
   5\% CO2 or by extension of incubation time in ambient air to 48 h
   corrected these errors. Disk diffusion, however, was shown to be a
   simple, convenient, and reliable method for susceptibility testing of
   pneumococci to erythromycin and clindamycin and is suggested as the
   method of choice for these agents.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV HOSP CLEVELAND,DEPT PATHOL,CLEVELAND,OH 44106.
   CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106.
   MILTON S HERSHEY MED CTR,HERSHEY,PA.}},
ISSN = {{0066-4804}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; PATTERNS; PYOGENES}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Cited-References = {{APPELBAUM PC, 1992, CLIN INFECT DIS, V15, P77, DOI 10.1093/clinids/15.1.77.
   BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl\_C.31.
   BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005.
   GESLIN P, 1992, CLIN INFECT DIS, V15, P95, DOI 10.1093/clinids/15.1.95.
   HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803.
   HSUEH PR, 1995, ANTIMICROB AGENTS CH, V39, P2239, DOI 10.1128/AAC.39.10.2239.
   Jacobs M. R., 1995, REV MED MICROBIOL, V6, P77.
   KAM KM, 1995, ANTIMICROB AGENTS CH, V39, P2667, DOI 10.1128/AAC.39.12.2667.
   KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171.
   LONKS JR, 1993, ANTIMICROB AGENTS CH, V37, P1742, DOI 10.1128/AAC.37.9.1742.
   LONKS JR, 1994, INFECT MED, V11, P415.
   LONS JR, 1994, INFECT MED, V11, P423.
   MARTON A, 1991, J INFECT DIS, V163, P542, DOI 10.1093/infdis/163.3.542.
   {*}NAT COMM CLIN LAB, 1993, METH DIL ANT DISK SU.
   {*}NAT COMM CLIN LAB, 1995, M100S6 NAT COMM CLIN.
   NELSON CT, 1994, PEDIATR INFECT DIS J, V13, P585, DOI 10.1097/00006454-199407000-00001.
   POMILLA PV, 1994, ARCH INTERN MED, V154, P1793, DOI 10.1001/archinte.154.16.1793.
   SEPPALA H, 1993, J ANTIMICROB CHEMOTH, V32, P885, DOI 10.1093/jac/32.6.885.
   Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P1817.
   WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P797, DOI 10.1128/AAC.39.4.797.
   Woods Gail L., 1995, P1327.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{52}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{WA656}},
Unique-ID = {{ISI:A1997WA65600024}},
DA = {{2018-08-13}},
}

@inproceedings{ ISI:A1997BJ53U00002,
Author = {Emmerson, AM},
Editor = {{Emmerson, AM}},
Title = {{Infection control in the hospital and community settings}},
Booktitle = {{DEVELOPMENT OF CONSENSUS IN GLOBAL INFECTION CONTROL}},
Series = {{RESEARCH AND CLINICAL FORUMS}},
Year = {{1997}},
Volume = {{19}},
Number = {{6}},
Pages = {{19-25}},
Note = {{International Expert Meeting on Development of Consensus in Global
   Infection Control, TUNBRIDGE WELLS, ENGLAND, APR   11, 1997}},
Organization = {{Reckitt \& Colman Prod Ltd}},
Abstract = {{Surveillance of infection both within the community and the hospital is
   important in understanding the way that infections can be spread.
   Various methods of surveillance are used; a whole hospital survey may be
   considered, or a particular department targeted. Rates of infection vary
   between departments since some patients are more at risk from infection
   than others. Older, immunocompromised or catheterised patients are at
   higher risk of infection than immunocompetent patients without
   indwelling devices and, when comparing infection rates, patients should
   be stratified to compare like with like. Hospital-acquired infections
   are generally present in 8-10\% of patients at any one time and to limit
   the spread of infection, strict admission and isolation policies should
   be enforced when considering a potentially infectious patient. The mode
   of transfer of their particular disease should also be considered (ie.
   airborne, contact etc.). In this way, outbreaks can be monitored and
   restricted, resulting in lower morbidity and mortality. The emergence of
   antibiotic resistant bacterial strains should be controlled by
   implementing a policy to kerb the unnecessary prescribing of
   antibiotics. When combined with effective hygiene (particularly
   disinfection and handwashing) and isolation policies, surveillance
   should be continually repeated to ensure staff compliance with, and the
   effectiveness of, these measures.}},
Publisher = {{WELLS MEDICAL LTD}},
Address = {{CHAPEL PLACE, ROYAL TUNBRIDGE WELLS, KENT, ENGLAND TN1 1BP}},
Type = {{Proceedings Paper}},
Language = {{English}},
Affiliation = {{Emmerson, AM (Reprint Author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.}},
ISSN = {{0143-3083}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{BJ53U}},
Unique-ID = {{ISI:A1997BJ53U00002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1997WF17200002,
Author = {Yu, MC and Suo, J and Lin, TP and Luh, KT},
Title = {{In vitro activity of ofloxacin against Mycobacterium tuberculosis}},
Journal = {{JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION}},
Year = {{1997}},
Volume = {{96}},
Number = {{1}},
Pages = {{13-16}},
Month = {{JAN}},
Abstract = {{For the past 3 years, ofloxacin has been widely used in treating
   patients with drug-resistant tuberculosis in Taiwan. To study its
   usefulness in treating these patients, 139 isolates of Mycobacterium
   tuberculosis from patients treated at the Taiwan Provincial Chronic
   Disease Control Bureau from September 1994 to September 1995 were tested
   to determine the in vitro antituberculosis activity of ofloxacin. Of
   these, 131 had not been previously exposed to ofloxacin, and 130
   (99.2\%) were susceptible to ofloxacin. Sixty-four isolates were found
   to be susceptible to air conventional antituberculosis drugs, and all of
   these were also susceptible to ofloxacin. Of the remaining 67 isolates
   that were resistant to one or more conventional antituberculosis drugs,
   66 (98.5\%) were susceptible to ofloxacin. There was no association
   between susceptibility to ofloxacin and susceptibility to conventional
   antituberculosis drugs among the isolates tested. Of the eight isolates
   of M. tuberculosis previously exposed to ofloxacin, seven (87.5\%) were
   resistant. Our results indicate that patients with multidrug-resistant
   strains of M. tuberculosis who have not received prior ofloxacin
   treatment may be safely treated with ofloxacin, even without knowing the
   result of pretreatment ofloxacin susceptibility tests. We also found
   that ofloxacin resistance emerges frequently. Therefore, an adequate
   combination of antituberculosis drugs, along with ofloxacin, should be
   prescribed to prevent the development of resistance to ofloxacin.}},
Publisher = {{EXCERPTA MEDICA ASIA LTD}},
Address = {{3/F 13 DUDDELL STREET, CENTRAL, HONG KONG}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Yu, MC (Reprint Author), TAIWAN PROV CHRON DIS CONTROL BUR,10 CHINGTAO W RD,TAIPEI,TAIWAN.
   NATL TAIWAN UNIV HOSP,DEPT LAB MED,TAIPEI,TAIWAN.}},
ISSN = {{0929-6646}},
Keywords = {{Mycobacterium tuberculosis; ofloxacin; multidrug resistance; Taiwan}},
Keywords-Plus = {{PULMONARY TUBERCULOSIS; INVITRO ACTIVITY; CIPROFLOXACIN; RESISTANT;
   QUINOLONES; INFECTIONS; DL8280}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{{*}AM THOR SOC, 1994, AM REV RESPIR DIS, V49, P1359.
   BATES JH, 1995, AM J RESP CRIT CARE, V151, P942.
   BERNING SE, 1995, AM J RESP CRIT CARE, V151, P2006, DOI 10.1164/ajrccm.151.6.7767552.
   {*}BRIT THOR SOC JOI, 1990, THORAX, V45, P403.
   CANETTI G, 1963, B WORLD HEALTH ORGAN, V29, P565.
   CHEN CH, 1989, AM REV RESPIR DIS, V140, P987, DOI 10.1164/ajrccm/140.4.987.
   CREWEL AJ, 1988, AM REV RESPIR DIS, V137, P1141.
   {*}DEP HLTH EX YUAN, 1995, HLTH VIT STAT, V1, P476.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   HEIFETS LB, 1987, TUBERCLE, V68, P267, DOI 10.1016/0041-3879(87)90067-5.
   HEIFETS LB, 1991, DRUG SUSCEPTIBILITY, P27.
   {*}HONG KONG CHEST S, 1992, TUBERCLE LUNG DIS, V73, P59.
   International Union Against Tuberculosis and Lung Disease, 1988, B INT UNION TUBERC L, V63, P60.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   KOHNO S, 1992, CHEST, V102, P1815, DOI 10.1378/chest.102.6.1815.
   LEYSEN DC, 1989, ANTIMICROB AGENTS CH, V33, P1.
   Nakae I, 1991, Kekkaku, V66, P299.
   PEREA EJ, 1990, J ANTIMICROB CHEMOTH, V26, P55, DOI 10.1093/jac/26.suppl\_D.55.
   SUO J, 1994, THORAC MED S, V9, P39.
   TEXIERMAUGEIN J, 1987, EUR J CLIN MICROBIOL, V6, P584, DOI 10.1007/BF02014255.
   TODD PA, 1991, DRUGS, V42, P825, DOI 10.2165/00003495-199142050-00008.
   TSUKAMURA M, 1985, AM REV RESPIR DIS, V131, P352.
   TSUKAMURA M, 1985, AM REV RESPIR DIS, V131, P348.
   YEW WW, 1990, J ANTIMICROB CHEMOTH, V26, P227, DOI 10.1093/jac/26.2.227.
   YOUNG LS, 1987, AM J MED, V82, P23.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Formos. Med. Assoc.}},
Doc-Delivery-Number = {{WF172}},
Unique-ID = {{ISI:A1997WF17200002}},
DA = {{2018-08-13}},
}

@incollection{ ISI:A1997BH23E00015,
Author = {Liebert, CA and Wireman, J and Smith, T and Summers, AO},
Editor = {{Sigel, A and Sigel, H}},
Title = {{The impact of mercury released from dental `'silver'' fillings on
   antibiotic resistances in the primate oral and intestinal bacterial
   flora}},
Booktitle = {{METAL IONS IN BIOLOGICAL SYSTEMS, VOL 34: MERCURY AND ITS EFFECTS ON
   ENVIRONMENT AND BIOLOGY}},
Series = {{METAL IONS IN BIOLOGICAL SYSTEMS}},
Year = {{1997}},
Volume = {{34}},
Pages = {{441-460}},
Publisher = {{MARCEL DEKKER}},
Address = {{270 MADISON AVE, NEW YORK, NY 10016 USA}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{Liebert, CA (Reprint Author), UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA.}},
ISSN = {{0161-5149}},
ISBN = {{0-8247-9828-7}},
Keywords-Plus = {{HEAVY-METAL; MOLECULAR CHARACTERIZATION; ORGANOMERCURIAL LYASE;
   INORGANIC MERCURY; AMALGAM FILLINGS; FECAL FLORA; AIR MERCURY; PLASMIDS;
   EXPOSURE; INTEGRONS}},
Research-Areas = {{Biochemistry \& Molecular Biology; Chemistry; Environmental Sciences \&
   Ecology; Public, Environmental \& Occupational Health; Toxicology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary;
   Environmental Sciences; Public, Environmental \& Occupational Health;
   Toxicology}},
ORCID-Numbers = {{Summers, Anne/0000-0003-4258-9696}},
Cited-References = {{{*}AG TOX SUBST DIS, 1994, TOX PROF MERC.
   ANDERSON JD, 1973, J MED MICROBIOL, V6, P475, DOI 10.1099/00222615-6-4-475.
   ANDERSON JD, 1973, J MED MICROBIOL, V6, P461, DOI 10.1099/00222615-6-4-461.
   APOSHIAN HV, 1992, FASEB J, V6, P2472.
   AUSTEN RA, 1981, CAN J MICROBIOL, V27, P343, DOI 10.1139/m81-052.
   BARKAY T, 1986, APPL ENVIRON MICROB, V52, P403.
   Bauer J G, 1982, CDA J, V10, P47.
   BEGLEY TP, 1986, BIOCHEMISTRY-US, V25, P7186, DOI 10.1021/bi00370a063.
   BEGLEY TP, 1986, BIOCHEMISTRY-US, V25, P7192, DOI 10.1021/bi00370a064.
   BISSONNETTE L, 1992, J BACTERIOL, V174, P1248, DOI 10.1128/jb.174.4.1248-1257.1992.
   CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585.
   DANSCHER G, 1990, EXP MOL PATHOL, V52, P291, DOI 10.1016/0014-4800(90)90070-T.
   DELACRUZ F, 1982, J BACTERIOL, V151, P222.
   DRASCH G, 1994, EUR J PEDIATR, V153, P607, DOI 10.1007/s004310050200.
   DRASCH G, 1992, DTSCH ZAHNARZTL, V47, P490.
   EGGLESTON DW, 1984, J PROSTHET DENT, V51, P617, DOI 10.1016/0022-3913(84)90404-9.
   FOX J, 1992, ASM NEWS, V58, P124.
   GILBERT MP, 1988, PLASMID, V20, P127, DOI 10.1016/0147-619X(88)90015-7.
   GILLESPIE MT, 1985, J MED MICROBIOL, V19, P137, DOI 10.1099/00222615-19-2-137.
   GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I.
   GRIFFIN HG, 1987, P NATL ACAD SCI USA, V84, P3112, DOI 10.1073/pnas.84.10.3112.
   HAHN LJ, 1990, FASEB J, V4, P3256.
   HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x.
   HENRIETTE C, 1991, J APPL BACTERIOL, V71, P439, DOI 10.1111/j.1365-2672.1991.tb03814.x.
   HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0.
   HULTMAN P, 1994, FASEB J, V8, P1183.
   JOKSTAD A, 1992, PHARMACOL TOXICOL, V70, P308, DOI 10.1111/j.1600-0773.1992.tb00478.x.
   KHESIN RB, 1984, MOL GEN GENET, V197, P280, DOI 10.1007/BF00330974.
   KHOLODII GY, 1993, PLASMID, V30, P303, DOI 10.1006/plas.1993.1064.
   LAUBKUPERSZTEJN R, 1996, ANN MICROBIOL B, V125, P501.
   LEVY SB, 1988, ANTIMICROB AGENTS CH, V32, P1801, DOI 10.1128/AAC.32.12.1801.
   LIEBERT CA, 1996, UNPUB APPL ENV MICRO.
   LINTON KB, 1974, J MED MICROBIOL, V7, P91, DOI 10.1099/00222615-7-1-91.
   LORSCHEIDER FL, 1995, FASEB J, V9, P504.
   MCGOWAN JE, 1991, REV MED MICROBIOL, V2, P161.
   MILLER MA, 1967, NATURE, V215, P531, DOI 10.1038/215531a0.
   MISRA TK, 1992, PLASMID, V27, P4, DOI 10.1016/0147-619X(92)90002-R.
   NAKAHARA H, 1977, NATURE, V266, P165, DOI 10.1038/266165a0.
   NAKAHARA H, 1985, J GEN MICROBIOL, V131, P1053.
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064.
   OBRIEN TF, 1985, SCIENCE, V230, P87, DOI 10.1126/science.2994226.
   OLSON BH, 1979, APPL ENVIRON MICROB, V38, P478.
   OSBORN AM, 1993, APPL ENVIRON MICROB, V59, P4024.
   OSBORN AM, 1995, SYST APPL MICROBIOL, V18, P1.
   OSTERBLAD M, 1995, ANTIMICROB AGENTS CH, V39, P2499, DOI 10.1128/AAC.39.11.2499.
   PALKIEWICZ P, 1994, J NEUROCHEM, V62, P2049.
   PATTERSON JE, 1985, B ENVIRON CONTAM TOX, V34, P459, DOI 10.1007/BF01609761.
   PORTER FD, 1982, ANTIMICROB AGENTS CH, V22, P852, DOI 10.1128/AAC.22.5.852.
   REINHARDT JW, 1988, J PUBLIC HEALTH DENT, V48, P172, DOI 10.1111/j.1752-7325.1988.tb03188.x.
   RICHMOND MH, 1964, NATURE, V202, P1360, DOI 10.1038/2021360a0.
   ROCHELLE PA, 1989, J GEN MICROBIOL, V135, P409.
   SAYLER GS, 1975, APPL MICROBIOL, V30, P91.
   SKARE I, 1994, ARCH ENVIRON HEALTH, V49, P384, DOI 10.1080/00039896.1994.9954991.
   Stejskal VDM, 1996, J CLIN IMMUNOL, V16, P31, DOI 10.1007/BF01540970.
   STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x.
   SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.micro.40.1.607.
   SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825.
   SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992.
   SUMMERS AO, 1978, MICROBIOLOGY, V4, P128.
   SVARE CW, 1981, J DENT RES, V60, P1668, DOI 10.1177/00220345810600090601.
   TANNOCK GW, 1995, NORMAL MICROFLORA.
   TIBBLING L, 1995, INT J OCCUP MED TOX, V4, P1.
   TIMONEY JF, 1978, APPL ENVIRON MICROB, V36, P465.
   VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111.
   VIMY MJ, 1985, J DENT RES, V64, P1069, DOI 10.1177/00220345850640080901.
   VIMY MJ, 1985, J DENT RES, V64, P1072, DOI 10.1177/00220345850640081001.
   WHO, 1991, ENV HLTH CRIT, V118.
   WIREMAN J, 1996, UNPUB APPL ENV MICRO.
   WOODS JS, 1993, J TOXICOL ENV HEALTH, V40, P235, DOI 10.1080/15287399309531791.}},
Number-of-Cited-References = {{69}},
Times-Cited = {{6}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Metal Ions Biol. Syst.}},
Doc-Delivery-Number = {{BH23E}},
Unique-ID = {{ISI:A1997BH23E00015}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996VY09600014,
Author = {Fitch, MW and Weissman, D and Phelps, P and Georgiou, G and Speitel, GE},
Title = {{Trichloroethylene degradation by Methylosinus trichosporium OB3b mutants
   in a sequencing biofilm reactor}},
Journal = {{WATER RESEARCH}},
Year = {{1996}},
Volume = {{30}},
Number = {{11}},
Pages = {{2655-2664}},
Month = {{NOV}},
Abstract = {{Methylosinus trichosporium OB3b was used in a sequencing biofilm reactor
   to degrade trichloroethylene (TCE) in water at approximately 100 mu g/l
   influent concentration. The reactor consisted of biofilms grown on
   diatomaceous earth pellets or glass beads, and was sequenced between
   growth cycle, in which methane and air were fed in a gas phase, and
   degradation cycle, in which the column was completely liquid-filled.
   Biomass loading on the support media was only 10 mg cell dry weight/g
   support media, giving a calculated biofilm thickness of 0.04 cm.
   Apparent pseudo-first order degradation rate constants in the system
   were improved by more than an order of magnitude, from 0.008 l/mg d to
   0.1 l/mg d, through the use of antibiotic-resistant strains of
   copper-resistant organisms that express only the soluble methane
   monooxygenase, the enzyme responsible for trichloroethylene degradation.
   Also, biomass accumulation was improved through the use of a cationic
   coagulating polymer. However, TCE degradation was sustained only for
   sort times, and cycling back to growth mode did not completely
   regenerate TCE degradation ability. Thus, biofilms of Methylosinus
   trichosporium OB3b did not give rise to sustained high degradation
   rates. Copyright (C) 1996 Elsevier Science Ltd}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV TEXAS,DEPT CIVIL ENGN,AUSTIN,TX 78712.
   UNIV MISSOURI,DEPT CIVIL ENGN,ROLLA,MO 65409.
   UNIV TEXAS,DEPT CHEM ENGN,AUSTIN,TX 78712.}},
DOI = {{10.1016/S0043-1354(96)00178-9}},
ISSN = {{0043-1354}},
Keywords = {{Methylosinus trichosporium OB3b; methanotroph; trichloroethylene;
   co-metabolism; biodegradation}},
Keywords-Plus = {{SOLUBLE METHANE MONOOXYGENASE; HALOGENATED ALIPHATIC-COMPOUNDS;
   CHLORINATED SOLVENTS; TOXICITY; OXIDATION; BIOTRANSFORMATION;
   BIODEGRADATION; BIOREACTOR; KINETICS; AQUIFER}},
Research-Areas = {{Engineering; Environmental Sciences \& Ecology; Water Resources}},
Web-of-Science-Categories  = {{Engineering, Environmental; Environmental Sciences; Water Resources}},
Cited-References = {{ALVAREZ-COHEN L, 1991, ENVIRON SCI TECHNOL, V25, P1381, DOI 10.1021/es00020a003.
   ALVAREZ-COHEN L, 1991, APPL ENVIRON MICROB, V57, P228.
   BARBASH J, 1986, J WATER POLLUT CON F, V58, P343.
   BIRD RB, 1960, TRANSPORT PHENOMENA, P515.
   Bowman John P., 1994, Biodegradation, V5, P1.
   CHRISTENSEN BE, 1990, BIOFILMS.
   COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395.
   CORNISH A, 1984, J GEN MICROBIOL, V130, P2565.
   ENSLEY BD, 1991, ANNU REV MICROBIOL, V45, P283.
   FENNELL DE, 1992, BIOTECHNOL BIOENG, V40, P1218, DOI 10.1002/bit.260401012.
   Fitch MW, 1996, APPL ENVIRON MICROB, V62, P1124.
   FITCH MW, 1993, APPL ENVIRON MICROB, V59, P2771.
   FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013.
   HENRY SM, 1991, APPL ENVIRON MICROB, V57, P236.
   LAZARONE NA, 1990, GROUND WATER, V28, P910.
   LIDSTROMOCONNOR ME, 1983, J GEN MICROBIOL, V129, P3136.
   MAYER KP, 1988, WAT SCI TECHNOL, V20, P173.
   OLDENHUIS R, 1991, APPL ENVIRON MICROB, V57, P7.
   OLDENHUIS R, 1989, APPL ENVIRON MICROB, V57, P7.
   PHELPS PA, 1992, APPL ENVIRON MICROB, V58, P3701.
   RITTMANN BE, 1981, J ENV ENG DIV-ASCE, V107, P831.
   RITTMANN BE, 1982, BIOTECHNOL BIOENG, V24, P1341, DOI 10.1002/bit.260240609.
   ROSLEV P, 1994, APPL ENVIRON MICROB, V60, P2602.
   SHONNARD DR, 1994, WATER RESOUR RES, V30, P25, DOI 10.1029/93WR02402.
   SPEITEL GE, 1993, WATER RES, V27, P15, DOI 10.1016/0043-1354(93)90190-S.
   SPEITEL GE, 1992, WATER ENVIRON RES, V64, P712, DOI 10.2175/WER.64.5.8.
   STRAND SE, 1991, RES J WATER POLLUT C, V63, P859.
   STRANDBERG GW, 1989, ENVIRON SCI TECHNOL, V23, P1422, DOI 10.1021/es00069a016.
   TAYLOR RT, 1993, HYDROLOG SCI J, V38, P323, DOI 10.1080/02626669309492678.
   TREVORS JT, 1982, MICROBIAL ECOL, V8, P163, DOI 10.1007/BF02010449.
   UCHIYAMA H, 1992, BIOTECHNOL LETT, V14, P619, DOI 10.1007/BF01023952.
   VOGEL TM, 1987, ENVIRON SCI TECHNOL, V21, P722, DOI 10.1021/es00162a001.
   WILSON JT, 1985, APPL ENVIRON MICROB, V49, P242.}},
Number-of-Cited-References = {{33}},
Times-Cited = {{29}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Water Res.}},
Doc-Delivery-Number = {{VY096}},
Unique-ID = {{ISI:A1996VY09600014}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996UX58300036,
Author = {Mahon, BE and Mintz, ED and Greene, KD and Wells, JG and Tauxe, RV},
Title = {{Reported cholera in the United States, 1992-1994 - A reflection of
   global changes in cholera epidemiology}},
Journal = {{JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION}},
Year = {{1996}},
Volume = {{276}},
Number = {{4}},
Pages = {{307-312}},
Month = {{JUL 24}},
Abstract = {{Objective.-To describe US cholera surveillance data from 1992 to 1994
   and the domestic impact of the epidemics of Vibrio cholerae O1 in Latin
   America and V cholerae O139 in Asia.
   Design, Setting, and Participants.-Retrospective review of surveillance
   data from all cases of cholera reported to the Centers for Disease
   Control and Prevention (CDC) from January 1, 1992, through December 31,
   1994, in the United States and its territories.
   Main Outcome Measures.-Clinical, epidemiologic, and laboratory
   surveillance data.
   Results.-From 1992 through 1994, 160 cases of cholera were reported to
   CDC by 20 states and 1 territory. This is a marked increase: only 136
   cases were reported from 1965 through 1991. Outbreaks affecting 75
   passengers on an airplane from Latin America and 5 passengers on a
   cruise ship in Southeast Asia accounted for 50\% of cases. Vibrio
   cholerae O139 caused 6 cases (4\%). The proportion of V cholerae O1
   isolates resistant to at least 1 antimicrobial agent rose from 3\% in
   1992 to 93\% in 1994. Of 158 patients whose location of exposure was
   known, 151 (96\%) acquired infection abroad (125 in Latin America, 26 in
   Asia). Of 105 persons whose reason for travel was known, 31 (30\%) were
   US residents who had returned to their country of origin to visit family
   or friends, and 65 (62\%) were non-US residents visiting the United
   States from cholera-affected countries. The cholera rate among persons
   arriving in the United States from cholera-affected regions was 0.27
   case per 100 000 air travelers, not substantially increased from earlier
   estimates.
   Conclusions.-Cholera has increased in the United States since 1991,
   reflecting global changes in cholera epidemiology, and is now primarily
   travel associated and antimicrobial resistant. Most travelers were not
   traditional tourists; reaching them with prevention measures may be
   difficult. The risk of cholera to the individual traveler remains
   extremely low.}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60610}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Mahon, BE (Reprint Author), CTR DIS CONTROL \& PREVENT,FOODBORNE \& DIARRHEAL DIS BRANCH,DIV BACTERIAL \& MYCOT DIS,ATLANTA,GA 30333, USA.}},
DOI = {{10.1001/jama.276.4.307}},
ISSN = {{0098-7484}},
Keywords-Plus = {{VIBRIO-CHOLERAE; OUTBREAK; AMERICA; STRAIN; VCA-3}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{ALBERT MJ, 1993, LANCET, V341, P704.
   ALMEIDA RJ, 1992, J CLIN MICROBIOL, V30, P300.
   BART KJ, 1970, J INFECT DIS, V121, pS17, DOI 10.1093/infdis/121.Supplement.S17.
   BESSER RE, 1994, JAMA-J AM MED ASSOC, V272, P1203, DOI 10.1001/jama.272.15.1203.
   BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601.
   BOYCE TG, 1995, J INFECT DIS, V172, P1401, DOI 10.1093/infdis/172.5.1401.
   {*}CDCP, 1995, HLTH INF INT TRAV 19.
   CHONGSANGUAN M, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92841-G.
   EberhartPhillips J, 1996, EPIDEMIOL INFECT, V116, P9, DOI 10.1017/S0950268800058891.
   EVINS GM, 1995, J INFECT DIS, V172, P173, DOI 10.1093/infdis/172.1.173.
   FINELLI L, 1992, J INFECT DIS, V166, P1433, DOI 10.1093/infdis/166.6.1433.
   GOLDBERG S, 1983, INFECT IMMUN, V42, P224.
   JOHNSTON JM, 1983, NEW ENGL J MED, V309, P523, DOI 10.1056/NEJM198309013090903.
   KLONTZ KC, 1987, ANN INTERN MED, V107, P846, DOI 10.7326/0003-4819-107-6-846.
   Levine Myron M., 1994, P395.
   LOWRY PW, 1989, ARCH INTERN MED, V149, P2079, DOI 10.1001/archinte.149.9.2079.
   MACPHERSON DW, 1992, CAN MED ASSOC J, V146, P1947.
   MEKALANOS JJ, 1994, SCIENCE, V265, P1387, DOI 10.1126/science.8073279.
   {*}NAT COMM CLIN LAB, 1993, M2A5 NAT COMM CLIN L.
   RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5.
   SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2.
   SHIMADA T, 1993, LANCET, V341, P1347.
   SNYDER JD, 1982, JAMA-J AM MED ASSOC, V247, P2268, DOI 10.1001/jama.1982.03320410050031.
   SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495.
   TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388.
   TAYLOR JL, 1993, J INFECT DIS, V167, P1330, DOI 10.1093/infdis/167.6.1330.
   {*}US DEP TRANSP, 1995, INT AIR TRAV STAT 19.
   WEBER JT, 1994, ARCH INTERN MED, V154, P551, DOI 10.1001/archinte.154.5.551.
   WEISSMAN JB, 1975, AM J EPIDEMIOL, V100, P487.
   {*}WHO, 1991, WHO PROGR CONTR DIAR.
   WOODWARD WE, 1970, J INFECT DIS, V121, pS10, DOI 10.1093/infdis/121.Supplement.S10.
   1991, MMWR-MORBID MORTAL W, V40, P516.
   1991, MMWR-MORBID MORTAL W, V40, P108.
   1995, WKLY EPIDEMIOL REC, V70, P201.
   1977, MMWR-MORBID MORTAL W, V26, P307.
   1995, EPIDEMIOL B PAN AM H, V16, P11.
   1993, LANCET, V342, P387.
   1990, MMWR-MORBID MORTAL W, V39, P9.
   1993, MMWR-MORBID MORTAL W, V42, P501.
   1995, MMWR-MORBID MORTAL W, V44, P385.
   1992, MMWR-MORBID MORTAL W, V41, P664.
   1977, MMWR-MORBID MORTAL W, V26, P302.
   1988, MMWR-MORBID MORTAL W, V37, P617.
   1995, MMWR-MORBID MORTAL W, V44, P215.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JAMA-J. Am. Med. Assoc.}},
Doc-Delivery-Number = {{UX583}},
Unique-ID = {{ISI:A1996UX58300036}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996UY66900002,
Author = {Donald, PR and Parkin, DP and Seifart, HI and Schoeman, JF and vanZyl,
   LE},
Title = {{Drug treatment of tuberculosis meningitis in children - A practical
   guide}},
Journal = {{CNS DRUGS}},
Year = {{1996}},
Volume = {{6}},
Number = {{1}},
Pages = {{12-22}},
Month = {{JUL}},
Abstract = {{Tuberculosis meningitis is the most serious extrapulmonary complication
   of tuberculosis and the commonest cause of death in childhood as a
   result of tuberculosis. Appropriate treatment must be started as soon as
   a diagnosis of tuberculosis meningitis is suspected.
   The main aims of the drug treatment of tuberculosis meningitis are the
   eradication of the causative organism Mycobacterium tuberculosis, the
   control of raised intracranial pressure, and modulation of the immune
   processes causing cerebral vasculitis and the associated exudate at the
   base of the brain,
   Isoniazid, rifampicin (rifampin) and pyrazinamide are essential drugs in
   the treatment of tuberculosis meningitis in dosages of 20 mg/kg/day, 20
   mg/kg/day and 40 mg/kg/day, respectively. Lower dosages of isoniazid (10
   mg/kg/day) and rifampicin (10 mg/kg/day) can be used if infectious
   hepatitis is a recognised problem in a particular geographical area, but
   a reduction in the dose of rifampicin may compromise its sterilising
   capacity, If it is possible that the disease is caused by drug-resistant
   organisms, the above regimen should br augmented by ethionamide 20
   mg/kg/day or streptomycin 20 to 40 mg/kg/day. Treatment must be
   continued for a minimum of 6 months, but should be extended to 9 or 12
   months if rifampicin cannot be used throughout and if pyrazinamide
   cannot be used for the first 2 months of treatment.
   Hydrocephalus and raised intracranial pressure frequently complicate
   stage II and stage III tuberculosis meningitis. In the presence of
   communicating hydrocephalus, confirmed on air encephalogram by the
   appearance of air in the ventricles, furosemide (frusemide) 1 mg/kg/day
   and acetazolamide 100 mg/kg/day given in 6- or 8-hourly divided doses
   will expedite the normalisation of intracranial pressure in the majority
   of cases. Ventriculo-peritoneal shunting should be undertaken
   immediately in those children with non-communicating hydrocephalus,
   demonstrated on air encephalogram by the presence of air at the base of
   the brain but not in the ventricles, and in those children who do not
   respond satisfactorily to medical management.
   Corticosteroids, in the form of prednisone or dexamethasone, have been
   shown to improve both morbidity and mortality in tuberculosis
   meningitis. These drugs should be given for the first month of
   treatment.}},
Publisher = {{ADIS INTERNATIONAL LTD}},
Address = {{41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW
   ZEALAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Donald, PR (Reprint Author), UNIV STELLENBOSCH,DEPT PAEDIAT \& CHILD HLTH,POB 19063,ZA-7505 TYGERBERG,SOUTH AFRICA.
   TYGERBERG HOSP,DEPT PAEDIAT \& CHILD HLTH,TYGERBERG,SOUTH AFRICA.
   TYGERBERG HOSP,DEPT PHARMACOL,TYGERBERG,SOUTH AFRICA.}},
DOI = {{10.2165/00023210-199606010-00002}},
ISSN = {{1172-7047}},
Keywords-Plus = {{SHORT-COURSE CHEMOTHERAPY; EARLY BACTERICIDAL ACTIVITY;
   CEREBROSPINAL-FLUID; CHILDHOOD TUBERCULOSIS; PULMONARY TUBERCULOSIS;
   RIFAMPIN; THERAPY; HEPATOTOXICITY; PYRAZINAMIDE; HEPATITIS}},
Research-Areas = {{Neurosciences \& Neurology; Pharmacology \& Pharmacy; Psychiatry}},
Web-of-Science-Categories  = {{Clinical Neurology; Pharmacology \& Pharmacy; Psychiatry}},
Cited-References = {{ALARCON F, 1990, ARCH NEUROL-CHICAGO, V47, P1313, DOI 10.1001/archneur.1990.00530120057010.
   {[}Anonymous], 1991, AM REV RESPIR DIS, V143, P700.
   BACIEWICZ AM, 1987, ARCH INTERN MED, V147, P565, DOI 10.1001/archinte.147.3.565.
   BERGER JR, 1994, CURR OPIN NEUROL, V7, P191, DOI 10.1097/00019052-199406000-00004.
   BERMAN S, 1992, TUBERCLE LUNG DIS, V73, P349, DOI 10.1016/0962-8479(92)90039-M.
   BIDDULPH J, 1990, PEDIATR INFECT DIS J, V9, P794, DOI 10.1097/00006454-199011000-00003.
   Bishburg E., 1986, ANN MED INTERNE, V105, P201.
   BOBROWITZ ID, 1972, CHEST, V61, P629, DOI 10.1378/chest.61.7.629.
   BOBROWITZ ID, 1973, CHEST, V63, P648, DOI 10.1378/chest.63.4.648-a.
   Botha FJH, 1996, S AFR MED J, V86, P155.
   CHOTMONGKOL V, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P372.
   COTTON MF, 1991, PEDIATR INFECT DIS J, V10, P837, DOI 10.1097/00006454-199111000-00009.
   DONALD PR, 1987, AM J DIS CHILD, V141, P741, DOI 10.1001/archpedi.1987.04460070043019.
   DONALD PR, 1995, CLIN INFECT DIS, V21, P924, DOI 10.1093/clinids/21.4.924.
   DONALD PR, 1992, PEDIATRICS, V89, P247.
   DONALD PR, 1988, PEDIATR INFECT DIS J, V7, P469, DOI 10.1097/00006454-198807000-00003.
   DONALD PR, 1989, J PEDIATR-US, V115, P483, DOI 10.1016/S0022-3476(89)80862-5.
   ELLARD GA, 1987, BRIT MED J, V294, P284, DOI 10.1136/bmj.294.6567.284.
   ELLARD GA, 1993, AM REV RESPIR DIS, V148, P650, DOI 10.1164/ajrccm/148.3.650.
   ELLIOTT AM, 1995, TUBERCLE LUNG DIS, V76, P463, DOI 10.1016/0962-8479(95)90016-0.
   ESCOBAR JA, 1975, PEDIATRICS, V56, P1050.
   FREIMAN I, 1970, J PEDIATR-US, V76, P895, DOI 10.1016/S0022-3476(70)80372-9.
   GIRGIS NI, 1991, PEDIATR INFECT DIS J, V10, P179, DOI 10.1097/00006454-199103000-00002.
   Gordon A, 1972, BRIT J HOSP MED, V7, P651.
   GROSSET J, 1980, CLIN CHEST MED, V1, P231.
   GUNDERTREMY U, 1964, J CLIN PHARMACOL, V6, P133.
   HORNE N. W., 1966, ADVANCE TUBERC RESIN ADVANCES IN TUBERCULOSIS RESEARCH, V15, P1.
   HUGHES IE, 1962, LANCET, V1, P616.
   HUMPHRIES M, 1992, THORAX, V47, P577, DOI 10.1136/thx.47.8.577.
   HUMPHRIES MJ, 1990, TUBERCLE, V71, P161, DOI 10.1016/0041-3879(90)90069-K.
   ISEMAN MD, 1991, AM REV RESPIR DIS, V143, P697, DOI 10.1164/ajrccm/143.4\_Pt\_1.697.
   JACOBS RF, 1992, PEDIATR INFECT DIS J, V11, P194, DOI 10.1097/00006454-199203000-00004.
   JINDANI A, 1980, AM REV RESPIR DIS, V121, P939.
   KUMAR A, 1991, AM REV RESPIR DIS, V143, P1350, DOI 10.1164/ajrccm/143.6.1350.
   LINCOLN EM, 1963, TUBERCULOSIS CHILDRE, P161.
   LONG MW, 1979, AM REV RESPIR DIS, V119, P879.
   MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6.
   MOULDING TS, 1981, AM REV RESPIR DIS, V123, P262.
   NAUGHTEN E, 1981, LANCET, V2, P973.
   PHUAPRADIT P, 1987, Q J MED, V239, P249.
   PULSINELLI W, 1992, LANCET, V339, P533, DOI 10.1016/0140-6736(92)90347-6.
   RAHAJOE NN, 1979, TUBERCLE, V60, P245, DOI 10.1016/0041-3879(79)90006-0.
   RAMACHANDRAN P, 1986, TUBERCLE, V67, P17, DOI 10.1016/0041-3879(86)90028-0.
   RICH AR, 1993, B J HOPKINS HOSP, V52, P5.
   Rook G A, 1990, Bull Int Union Tuberc Lung Dis, V65, P23.
   SCHELD WM, 1985, PEDIATR INFECT DIS J, V4, P74, DOI 10.1097/00006454-198501000-00020.
   SCHOEMAN J, 1991, DEV MED CHILD NEUROL, V33, P396.
   SCHOEMAN JF, 1995, J CHILD NEUROL, V10, P320, DOI 10.1177/088307389501000417.
   SCHOEMAN JF, 1985, DEV MED CHILD NEUROL, V27, P644.
   SCHOEMAN JF, IN PRESS PEDIATRICS.
   SHAO PP, 1980, CHIN J TURBERC RESPI, V3, P131.
   SIRGEL FA, 1993, J ANTIMICROB CHEMOTH, V32, P867, DOI 10.1093/jac/32.6.867.
   TSAGAROPOULOUSTINGA H, 1985, PEDIATR INFECT DIS J, V4, P270, DOI 10.1097/00006454-198505000-00013.
   TURKTAS H, 1994, TUBERCLE LUNG DIS, V75, P58, DOI 10.1016/0962-8479(94)90104-X.
   World Health Organization, 1993, TREATM TUB GUID NAT.
   1994, AM J RESP CRIT CARE, V149, P1359.}},
Number-of-Cited-References = {{56}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{CNS Drugs}},
Doc-Delivery-Number = {{UY669}},
Unique-ID = {{ISI:A1996UY66900002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996UJ22800043,
Author = {Kim, AY and Thayer, DW},
Title = {{Mechanism by which gamma irradiation increases the sensitivity of
   Salmonella typhimurium ATCC 14028 to heat}},
Journal = {{APPLIED AND ENVIRONMENTAL MICROBIOLOGY}},
Year = {{1996}},
Volume = {{62}},
Number = {{5}},
Pages = {{1759-1763}},
Month = {{MAY}},
Abstract = {{Effects of irradiation and heating on survival of Salmonella typhimurium
   ATCC 14028 were examined by measuring DNA damage and the integrity of
   the cytoplasmic membrane, S. typhimurium cells fell into two distinct
   groups following heating: (i) heat-sensitive tells, which were rapidly
   inactivated at 65 degrees C and (ii) heat-resistant cells, which were
   only slowly inactivated at 65 degrees C. Radiation sensitivity of S.
   typhimurium was greater in the presence of air than in the presence of
   N-2 gas (radiation doses required to inactivate 90\% of the cells, 0.394
   +/- 0.029 in air and 0.561 +/- 0.035 in N-2), Recovery of the covalently
   closed circular form of plasmid pBR322 from S. typhimurium transformants
   (Amp(r) Tet(r)) was decreased by irradiation but not by heating, Heating
   prior to irradiation significantly decreased the recovery of plasmid DNA
   without affecting survival of S. typhimurium. Transformability of the
   recovered plasmid pBR322 was affected by neither irradiation nor
   heating, and mutation of antibiotic resistance genes was not detected in
   S. typhimurium. Heating, but not irradiation, caused destabilization of
   the cytoplasmic membrane, allowing penetration of hydrophobic dye, These
   results suggest that lethality of heating followed by irradiation for S.
   typhimurium was additive, reflecting irradiation-induced DNA damage and
   heat-induced membrane destabilization. When irradiation preceded heating
   in the absence of air, more cells were inactivated than was expected,
   because of heat-inactivating radiation-damaged DNA.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{USDA ARS,EASTERN REG RES CTR,PHILADELPHIA,PA 19118.}},
ISSN = {{0099-2240}},
Keywords-Plus = {{ESCHERICHIA-COLI; IONIZING-RADIATION; STRAND BREAKS; DNA;
   THERMORADIATION; MEMBRANE; CELLS}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Microbiology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Microbiology}},
Cited-References = {{BOREHAM DR, 1990, RADIAT RES, V123, P203, DOI 10.2307/3577546.
   BRIDGES BA, 1969, J GEN MICROBIOL, V58, P115, DOI 10.1099/00221287-58-1-115.
   DIKOMEY E, 1992, INT J RADIAT BIOL, V61, P221, DOI 10.1080/09553009214550851.
   DRIEDGER AA, 1970, CAN J MICROBIOL, V16, P881, DOI 10.1139/m70-149.
   DUBBERT WH, 1988, POULTRY SCI, V67, P944, DOI 10.3382/ps.0670944.
   FREUND RJ, 1986, SAS SYSTEM LINEAR MO.
   GOMEZ RF, 1977, ADV BIOCHEM ENG, V5, P50.
   Gould G. W., 1989, MECH ACTION FOOD PRE, P11.
   Horwitz W., 1980, OFFICIAL METHODS ANA.
   HURST A, 1977, CAN J MICROBIOL, V23, P935, DOI 10.1139/m77-139.
   KADOTA H, 1978, SPORES, V7, P27.
   KATSUI N, 1982, J BACTERIOL, V151, P1523.
   KIM A, 1994, RADIAT RES, V144, P36.
   KOW YW, 1991, RADIAT RES, V126, P357, DOI 10.2307/3577926.
   Maniatis T., 1982, MOL CLONING.
   MILLIGAN JR, 1993, RADIAT RES, V133, P151, DOI 10.2307/3578350.
   MUKHERJEE P, 1970, J GEN MICROBIOL, V60, P233, DOI 10.1099/00221287-60-2-233.
   PALLAS JE, 1976, APPL ENVIRON MICROB, V32, P250.
   RADOMYSKI T, 1994, J FOOD PROTECT, V57, P73, DOI 10.4315/0362-028X-57.1.73.
   SCHAFFNER DF, 1989, J FOOD SCI, V54, P902, DOI 10.1111/j.1365-2621.1989.tb07909.x.
   SCHEIE P, 1973, J BACTERIOL, V114, P814.
   SEDGWICK SG, 1972, J GEN MICROBIOL, V71, P191, DOI 10.1099/00221287-71-1-191.
   SIKPI MO, 1992, RADIAT RES, V130, P331, DOI 10.2307/3578378.
   THAYER DW, 1991, J FOOD PROTECT, V54, P718, DOI 10.4315/0362-028X-54.9.718.
   TSUCHIDO T, 1988, ANTIMICROB AGENTS CH, V32, P1680, DOI 10.1128/AAC.32.11.1680.
   Von Sonntag C, 1987, CHEM BASIS RAD BIOL.
   WATERS LC, 1991, RADIAT RES, V127, P190, DOI 10.2307/3577965.
   YATVIN MB, 1987, RADIAT PHYS CHEM, V30, P351.
   YATVIN MB, 1986, RADIAT RES, V106, P78, DOI 10.2307/3576563.
   1987, SAS STAT GUIDE PERSO.}},
Number-of-Cited-References = {{30}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Appl. Environ. Microbiol.}},
Doc-Delivery-Number = {{UJ228}},
Unique-ID = {{ISI:A1996UJ22800043}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996VR32700004,
Author = {Omura, Y and Shimotsuura, Y and Fukuoka, A and Fukuoka, H and Nomoto, T},
Title = {{Significant mercury deposits in internal organs following the removal of
   dental amalgam, \& development of pre-cancer on the gingiva and the
   sides of the tongue and their represented organs as a result of
   inadvertent exposure to strong curing light (used to solidify synthetic
   dental filling material) \& effective treatment: A clinical case report,
   along with organ representation areas for each tooth}},
Journal = {{ACUPUNCTURE \& ELECTRO-THERAPEUTICS RESEARCH}},
Year = {{1996}},
Volume = {{21}},
Number = {{2}},
Pages = {{133-160}},
Month = {{APR-JUN}},
Abstract = {{Because of the reduced effectiveness of antibiotics against bacteria
   (e.g. Chlamydia trachomatis, alpha-Streptococcus, Borrelia burgdorferi,
   etc.) and viruses (e.g. Herpes Family Viruses) in the presence of
   mercury, as well as the fact that the Ist author has found that mercury
   exists in cancer and pre-cancer cell nuclei, the presence of dental
   amalgam (which contains about 50\% mercury) in the human mouth is
   considered to be a potential hazard for the individual's health. In
   order to solve this problem, 3 amalgam fillings were removed from the
   teeth of the subject of this case study. In order to fill the newly
   created empty spaces in the teeth where the amalgams had formerly
   existed, a synthetic dental-filling substance was introduced and to
   solidify the synthetic substance, curing light (wavelength range
   reportedly between 400-520 nm) was radiated onto the substance in order
   to accelerate the solidifying process by photo-polymerization reaction.
   In spite of considerable care not to inhale mercury vapor or swallow
   minute particles of dental amalgam during the process of removing it by
   drilling, mercury entered the body of the subject. Precautions such as
   the use of a rubber dam and strong air suction, as well as frequent
   water suctioning and washing of the mouth were insufficient. Significant
   deposits of mercury, previously non-existent, were found in the lungs,
   kidneys, endocrine organs, liver, and heart with abnormal low-voltage
   ECGs (similar to those recorded 1-3 weeks after I.V. injection of
   radioisotope Thallium-201 for Cardiac SPECT) in all the limb leads and
   Vl(but almost normal ECGs in the precordial leads V2-V6) the day after
   the procedures were performed. Enhanced mercury evaporation by increased
   temperature and microscopic amalgam particles created by drilling may
   have contributed to mercury entering the lungs and G.I. system and then
   the blood circulation, creating abnormal deposits of mercury in the
   organs named above. Such mercury contamination may then contribute to
   intractable infections or pre-cancer. However, these mercury deposits,
   which commonly occur in such cases, were successfully eliminated by the
   oral intake of 100 mg tablet of Chinese parsley (Cilantro) 4 times a day
   (for average weight adults) with a number of drug-uptake enhancement
   methods developed by the Ist author, including different stimulation
   methods on the accurate organ representation areas of the hands (which
   have been mapped using the Bi-Digital O-Ring Test), without injections
   of chelating agents. ingestion of Chinese parsley, accompanied by
   drug-uptake enhancement methods, was initiated before the amalgam
   removal procedure and continued for about 2 to 3 weeks afterwards, and
   ECGs became almost normal. During the use of strong bluish curing light
   to create a photo-polymerization reaction to solidify the synthetic
   filling material, the adjacent gingiva and the side of the tongue were
   inadvertently exposed. This exposure to the strong bluish light was
   found to produce pre-cancerous conditions in the gingiva, the exposed
   areas of the tongue, as well as in the corresponding organs represented
   on those areas of the tongue, and abnormally increased enzyme levels in
   the liver. These abnormalities were also successfully reversed by the
   oral intake of a mixture of EPA with DHA and Chinese parsley, augmented
   by one of the non-invasive drug-uptake enhancement methods previously
   described by the Ist author, repeated 3 times each day for 2 weeks.}},
Publisher = {{COGNIZANT COMMUNICATION CORP}},
Address = {{3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Omura, Y (Reprint Author), HEART DIS RES FDN,NEW YORK,NY, USA.}},
DOI = {{10.3727/036012996816356915}},
ISSN = {{0360-1293}},
Keywords = {{dental amalgam; mercury; cardiac SPECT; antibiotic resistance; cancer;
   pre-cancer; leukoplakia; abnormal liver enzyme; Chinese parsley
   (Cilantro); drug-uptake enhancement; organ representation areas;
   Bi-digital O-Ring Test; EPA with DHA; ultraviolet; curing light;
   gingiva; tongue; teeth; oncogene C-fos Ab2; NO (nitric oxide); ECGs;
   chelating agents; radioisotope Thallium-201}},
Keywords-Plus = {{O-RING TEST; NITRIC-OXIDE SYNTHASE; SQUAMOUS-CELL CARCINOMA; QI-GONG
   ENERGY; C-FOS AB2; DRUG UPTAKE; MESO-2,3-DIMERCAPTOSUCCINIC ACID;
   MOLECULAR INFORMATION; ACCURATE LOCALIZATION; NEURO-TRANSMITTERS}},
Research-Areas = {{Integrative \& Complementary Medicine; Neurosciences \& Neurology}},
Web-of-Science-Categories  = {{Integrative \& Complementary Medicine; Neurosciences}},
Cited-References = {{Belles M, 1996, TOXICOLOGY, V106, P93, DOI 10.1016/0300-483X(95)03167-E.
   BERKOW R, 1992, MERCK MANUAL DIAGNOS.
   BONNER FT, 1996, SCI SPECTRA, V1, P32.
   Clarkson T W, 1992, Adv Dent Res, V6, P22.
   DEBELDER AJ, 1995, BRIT HEART J, V74, P426.
   DEPUEY EG, 1994, CARDIAC SPECT IMAGIN.
   Emilion G, 1996, BRIT J CANCER, V73, P809, DOI 10.1038/bjc.1996.142.
   FETNER T, 1991, DENT TODAY, V10, P14.
   FLORA SJS, 1995, FUND APPL TOXICOL, V25, P233, DOI 10.1006/faat.1995.1059.
   GALE GR, 1993, TOXICOLOGY, V81, P49, DOI 10.1016/0300-483X(93)90155-L.
   Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I.
   KILBOURN RG, 1995, CRIT CARE MED, V23, P1018, DOI 10.1097/00003246-199506000-00005.
   LORSCHEIDER FL, 1995, TOXICOLOGY, V97, P19, DOI 10.1016/0300-483X(94)02964-V.
   LUMERMAN H, 1995, ORAL SURG ORAL MED O, V79, P321, DOI 10.1016/S1079-2104(05)80226-4.
   Marcusson JA, 1996, TOXICOL LETT, V84, P113, DOI 10.1016/0378-4274(95)03623-7.
   OKABE T, 1994, J DENT RES, V73, P1711, DOI 10.1177/00220345940730110601.
   OMURA Y, 1995, ACUPUNCTURE ELECTRO, V20, P133, DOI 10.3727/036012995816357122.
   OMURA Y, 1991, ACUPUNCTURE ELECTRO, V16, P27, DOI 10.3727/036012991816358062.
   OMURA Y, 1986, ACUPUNCTURE ELECTRO, V11, P65, DOI 10.3727/036012986816359201.
   OMURA Y, 1994, ACUPUNCTURE ELECTRO, V19, P153, DOI 10.3727/036012994816357286.
   OMURA Y, 1988, ACUPUNCTURE ELECTRO, V13, P131, DOI 10.3727/036012988816358633.
   OMURA Y, 1990, ACUPUNCTURE ELECTRO, V15, P217, DOI 10.3727/036012990816358135.
   OMURA Y, 1995, ACUPUNCTURE ELECTRO, V20, P21.
   OMURA Y, 1985, ACUPUNCTURE ELECTRO, V10, P255, DOI 10.3727/036012985816714423.
   OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P125, DOI 10.3727/036012993816357494.
   OMURA Y, 1994, ACUPUNCTURE ELECTRO, V19, P39, DOI 10.3727/036012994816357394.
   OMURA Y, 1992, ACUPUNCTURE ELECTRO, V17, P107, DOI 10.3727/036012992816357774.
   OMURA Y, 1992, ACUPUNCTURE ELECTRO, V17, P29, DOI 10.3727/036012992816357855.
   Omura Y, 1995, ACUPUNCTURE ELECTRO, V20, P195, DOI 10.3727/036012995816357014.
   OMURA Y, 1993, ACUPUNCTURE ELECTRO, V18, P33, DOI 10.3727/036012993816357601.
   Omura Y., 1993, ACUPUNCTURE ELECTRO, V19, P248.
   OMURA Y, 1996, ACUPUNCTURE MED ITS.
   OMURA Y, 1991, CONST C INT SOC PATH, P52.
   OMURA Y, 1993, 1 INT S BID OR TEST, P42.
   Omura Y., 1996, 6 C JAP BID O RING T, P58.
   OMURA Y, 1994, P 4 ANN JAP BID O RI, P9.
   Omura Y., 1995, ICMART S 2 BULG AC C, P1.
   Omura Y., 1993, 3 WORLD C WORLD FED.
   OMURA Y, 1994, SAWARABI, P30.
   Omura Y., 1996, 6 C JAP BID OR TEST, P50.
   OMURA Y, 1993, 1 INT S BID OR TEST, P63.
   OSTERBLAD M, 1995, ANTIMICROB AGENTS CH, V39, P2499, DOI 10.1128/AAC.39.11.2499.
   PAPPAS JB, 1995, TOXICOL APPL PHARM, V133, P121, DOI 10.1006/taap.1995.1133.
   Peters E, 1995, J Can Dent Assoc, V61, P775.
   Pleva Jaro, 1994, Reviews on Environmental Health, V10, P1.
   Reinhardt J W, 1992, Adv Dent Res, V6, P110.
   ROSBE KW, 1995, OTOLARYNG HEAD NECK, V113, P541, DOI 10.1016/S0194-5998(95)70044-7.
   SCHWEINSBERG F, 1994, TOXICOL LETT, V72, P345, DOI 10.1016/0378-4274(94)90047-7.
   SHIMOTSUURA Y, 1987, ACUPUNCTURE ELECTRO, V12, P193, DOI 10.3727/036012987816358814.
   SHINTANI S, 1995, ANTICANCER RES, V15, P305.
   SUMMERS AO, 1993, ANTIMICROB AGENTS CH, V37, P825, DOI 10.1128/AAC.37.4.825.
   TOLINS JP, 1994, KIDNEY INT, V46, P230, DOI 10.1038/ki.1994.264.
   Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41.
   WILHELM M, 1992, CLIN INVESTIGATOR, V70, P728.
   Ziff M F, 1992, Adv Dent Res, V6, P131.}},
Number-of-Cited-References = {{55}},
Times-Cited = {{12}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{11}},
Journal-ISO = {{Acupunct. Electro-Ther. Res.}},
Doc-Delivery-Number = {{VR327}},
Unique-ID = {{ISI:A1996VR32700004}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996UX70400015,
Author = {Matsuhashi, M and Shindo, A and Ohshima, H and Tobi, M and Endo, S and
   Watanabe, H and Endoh, K and Pankrushina, AN},
Title = {{Cellular signals regulating antibiotic sensitivities of bacteria}},
Journal = {{MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE}},
Year = {{1996}},
Volume = {{2}},
Number = {{1}},
Pages = {{91-93}},
Month = {{SPR}},
Abstract = {{The effects of bacterial masses upon the drug resistance of neighboring
   bacteria were investigated, The experiments were performed with plastic
   Petri dishes divided into two identical compartments. A growing mass of
   Bacillus subtilis (signal emitter cell) in one compartment exerted
   enhancing effects upon the erythromycin and streptomycin resistance of
   Bacillus carboniphilus (signal recipient) cells, sparsely seeded in the
   other compartment, through the plastic wall and the air. These effects
   of the growing mass of cells are attributed to the emission of `'sonic''
   signals.}},
Publisher = {{MARY ANN LIEBERT INC PUBL}},
Address = {{2 MADISON AVENUE, LARCHMONT, NY 10538}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Matsuhashi, M (Reprint Author), TOKAI UNIV,DEPT BIOL SCI \& TECHNOL,317 NISHINO,NUMAZU 41003,JAPAN.
   MATSUSHITA RES INST TOKYO INC,RES DEV CORP JAPAN,ERATO,YOSHIMURA PI ELECTRON PROJECT,TAMA KU,KAWASAKI,KANAGAWA 214,JAPAN.}},
DOI = {{10.1089/mdr.1996.2.91}},
ISSN = {{1076-6294}},
Research-Areas = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Infectious Diseases; Microbiology; Pharmacology \& Pharmacy}},
Cited-References = {{Fujita T, 1996, INT J SYST BACTERIOL, V46, P116, DOI 10.1099/00207713-46-1-116.
   MATSUHASHI M, 1995, J BACTERIOL, V177, P688, DOI 10.1128/jb.177.3.688-693.1995.
   MATSUHASHI M, IN PRESS J GEN APPL.
   MATSUHASHI M, UNPUB J BACTERIOL.
   PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991.}},
Number-of-Cited-References = {{5}},
Times-Cited = {{7}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Microb. Drug Resist.-Mechan. Epidemiol. Dis.}},
Doc-Delivery-Number = {{UX704}},
Unique-ID = {{ISI:A1996UX70400015}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996TW86000005,
Author = {Pearce, RB},
Title = {{Effects of exposure to high ozone concentrations on stilbenes in Sitka
   spruce (Picea sitchensis (Bong) Carr) bark and on its lignification
   response to infection with Heterobasidion annosum (Fr) Bref}},
Journal = {{PHYSIOLOGICAL AND MOLECULAR PLANT PATHOLOGY}},
Year = {{1996}},
Volume = {{48}},
Number = {{2}},
Pages = {{117-129}},
Month = {{FEB}},
Abstract = {{The resistance of Sitka spruce (Picea sitchensis (Bong.) Carr.) stem
   bark tissues to the root and butt rot pathogen Heterobasidion annosum
   (Fr.) Bref. was reduced in trees grown for 275 days in an atmosphere
   supplemented with ozone (120 nmol mol(-1)) compared with those grown in
   charcoal-filtered or ambient air.
   Levels of the stilbene glucosides astringin and isorhapontin, the main
   constitutive antifungal compounds in the bark of P. sitchensis were not
   altered by the ozone treatment; neither was their accumulation in young
   stem tissues. However, the amount of induced lignification in living
   bark tissues at the margin of fungal lesions was reduced in stem lengths
   cut from ozone treated trees, following inoculation in vitro with H.
   annosum. The starch content in the xylem of these ozone fumigated trees
   was reduced in comparison with the other treatments. These results are
   discussed in relation to disease resistance and antimicrobial defence in
   P. sitchensis. (C) 1996 Academic Press Limited}},
Publisher = {{ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD}},
Address = {{24-28 OVAL RD, LONDON NW1 7DX, ENGLAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV OXFORD, OXFORD FORESTRY INST, DEPT PLANT SCI, OXFORD OX1 3RB, ENGLAND.}},
DOI = {{10.1006/pmpp.1996.0011}},
ISSN = {{0885-5765}},
Keywords-Plus = {{PINUS-SYLVESTRIS L; ABIES L KARST; SEPTORIA-NODORUM; PEACH BARK; ACID
   MIST; RESISTANCE; PLANTS; WHEAT; DECAY; SUSCEPTIBILITY}},
Research-Areas = {{Plant Sciences}},
Web-of-Science-Categories  = {{Plant Sciences}},
Cited-References = {{BARBER MS, 1988, PHYSIOL MOL PLANT P, V32, P185, DOI 10.1016/S0885-5765(88)80015-8.
   BEYER U, 1993, FORSTWISS CENTRALBL, V112, P251, DOI 10.1007/BF02742153.
   BIGGS AR, 1989, PHYTOPATHOLOGY, V79, P627, DOI 10.1094/Phyto-79-627.
   BIGGS AR, 1984, CAN J BOT, V62, P2814, DOI 10.1139/b84-375.
   BIRD PM, 1981, PHYSIOL PLANT PATHOL, V19, P289.
   BONELLO P, 1993, NEW PHYTOL, V124, P653, DOI 10.1111/j.1469-8137.1993.tb03855.x.
   Browning B. L., 1967, METHODS WOOD CHEM, VI.
   CAMPBELL MM, 1992, PHYTOCHEMISTRY, V31, P737.
   COOLEY DR, 1987, ENVIRON POLLUT, V47, P95, DOI 10.1016/0269-7491(87)90040-6.
   DARRALL NM, 1989, PLANT CELL ENVIRON, V12, P1, DOI 10.1111/j.1365-3040.1989.tb01913.x.
   DOSTER MA, 1988, PHYTOPATHOLOGY, V78, P473, DOI 10.1094/Phyto-78-473.
   ENEBAK SA, 1989, CAN J FOREST RES, V19, P225, DOI 10.1139/x89-031.
   ESCHRICH W., 1964, STAIN TECHNOL, V39, P303.
   GALLIANO H, 1993, PHYTOCHEMISTRY, V32, P557, DOI 10.1016/S0031-9422(00)95136-7.
   Grisebach H, 1981, BIOCH PLANTS, V7, P457.
   HAMMERSCHMIDT R, 1984, PHYSIOL PLANT PATHOL, V24, P33, DOI 10.1016/0048-4059(84)90071-7.
   HELLER W, 1990, ENVIRON POLLUT, V64, P353, DOI 10.1016/0269-7491(90)90057-J.
   HORN NM, 1985, EFFECTS AIR POLLUTIO, V20, P1.
   JAMES RL, 1982, PHYTOPATHOLOGY, V72, P1205, DOI 10.1094/Phyto-72-1205.
   JAMES RL, 1980, PHYTOPATHOLOGY, V70, P704, DOI 10.1094/Phyto-70-704.
   JAMES RL, 1980, PHYTOPATHOLOGY, V70, P560, DOI 10.1094/Phyto-70-560.
   JENSEN WA, 1962, BOTANICAL HISTOCHEMI.
   KARGIOLAKI H, 1991, J EXP BOT, V42, P1189, DOI 10.1093/jxb/42.9.1189.
   LINDBERG M, 1992, EUR J FOREST PATHOL, V22, P95.
   Luethy-Krause B, 1990, TREES-STRUCT FUNCT, V4, P107.
   McLaughlin S. B., 1980, PLANT DIS, P407.
   OSTROFSKY A, 1984, EUR J FOREST PATHOL, V14, P65.
   PARKER J, 1975, Canadian Journal of Forest Research, V5, P457, DOI 10.1139/x75-063.
   PEARCE RB, 1981, PHYSIOL PLANT PATHOL, V19, P359.
   PEARCE RB, 1990, EUR J FOREST PATHOL, V20, P275.
   PEARCE RB, 1989, ACS SYM SER, V399, P346.
   PEARCE RB, 1995, PLANT CELL ENVIRON, V18, P303, DOI 10.1111/j.1365-3040.1995.tb00365.x.
   PEARCE RB, 1986, STAIN TECHNOL, V61, P47, DOI 10.3109/10520298609110705.
   ROSEMANN D, 1991, PLANT PHYSIOL, V97, P1280, DOI 10.1104/pp.97.4.1280.
   SHAIN L, 1967, PHYTOPATHOLOGY, V57, P1034.
   TRESHOW M, 1980, USDA PSW43 FOR SERV, P103.
   TSENG EC, 1988, ENVIRON EXP BOT, V28, P37, DOI 10.1016/0098-8472(88)90044-5.
   UNDERWOOD CDT, 1991, EUR J FOREST PATHOL, V21, P279.
   UNDERWOOD CDT, 1992, PLANT PATHOL, V41, P722, DOI 10.1111/j.1365-3059.1992.tb02555.x.
   UNDERWOOD CDT, 1991, PHYTOCHEMISTRY, V30, P2183.
   VONTIEDEMANN A, 1993, PLANT PATHOL, V42, P287.
   Wargo P.M., 1991, USDA AGR HDB, V691, P88.
   WESTMAN WE, 1989, ENVIRON POLLUT, V57, P9, DOI 10.1016/0269-7491(89)90126-7.
   WOODWARD S, 1988, EUR J FOREST PATHOL, V18, P217.
   WOODWARD S, 1988, PHYSIOL MOL PLANT P, V33, P151, DOI 10.1016/0885-5765(88)90050-1.
   WOODWARD S, 1988, PHYSIOL MOL PLANT P, V33, P127, DOI 10.1016/0885-5765(88)90049-5.}},
Number-of-Cited-References = {{46}},
Times-Cited = {{8}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Physiol. Mol. Plant Pathol.}},
Doc-Delivery-Number = {{TW860}},
Unique-ID = {{ISI:A1996TW86000005}},
DA = {{2018-08-13}},
}

@article{ ISI:A1996VV53300012,
Author = {Veber, B},
Title = {{Pulmonary tuberculosis in 1996. Considerations for the
   anaesthesiologist.}},
Journal = {{ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION}},
Year = {{1996}},
Volume = {{15}},
Number = {{7}},
Pages = {{1080-1087}},
Abstract = {{Tuberculosis is one of the most widespread diseases, occurring in more
   than eight million persons, and about three million die annually of
   tuberculosis, in industrialized countries, the incidence has increased
   significantly over the last 10 years HIV infection is a main factor
   leading to this increase. Outbreaks of nosocomial tuberculosis among
   patients and healthcare workers have been reported. Tuberculosis is
   often caused by multidrug-resistant bacilli in patients with HIV
   infection. Physicians must be aware of this danger and careful adherence
   to guidelines is required to prevent further nosocomial spread of the
   disease. Airborne transmission by inhalation of infectious aerosol
   justifies appropriate measures for respiratory isolation to protect
   medical staff and other patients from the transmission of tuberculosis.
   In combination with some anaesthetic agents, antituberculous drugs may
   be responsible for hepatic toxicity. Influence of tuberculosis on
   regional anaesthesia and mechanical ventilation is also considered.}},
Publisher = {{EDITIONS SCIENTIFIQUES ELSEVIER}},
Address = {{141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE}},
Type = {{Article}},
Language = {{French}},
Affiliation = {{Veber, B (Reprint Author), HOP CHARLES NICOLLE,SERV REANIMAT CHIRURG,F-76031 ROUEN,FRANCE.}},
DOI = {{10.1016/S0750-7658(96)89478-0}},
ISSN = {{0750-7658}},
Keywords = {{tuberculosis; transmission; antituberculous agents; hepatotoxicity}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   HIV-INFECTION; NOSOCOMIAL TRANSMISSION; DISINFECTANTS; OUTBREAK}},
Research-Areas = {{Anesthesiology}},
Web-of-Science-Categories  = {{Anesthesiology}},
Cited-References = {{ALTMAN C, 1993, PRESSE MED, V22, P1212.
   BEST M, 1990, J CLIN MICROBIOL, V28, P2234.
   BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003.
   BOUVET E, 1991, B EPIDEMIOL HEBDOM, V45, P195.
   BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393.
   BRESLIN ABX, 1996, ANAESTH INTENSIVE CA, V24, P1769.
   BROWN BR, 1987, BRIT J ANAESTH, V59, P14, DOI 10.1093/bja/59.1.14.
   BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797.
   {*}CDC, 1990, MMWR-MORBID MORTAL W, V39, P369.
   {*}CDC, 1991, MMWR-MORBID MORTAL W, V40, P585.
   Centers for disease control, 1989, MMWR-MORBID MORTAL W, V38, p{[}256, 263].
   Centers for Disease Control, 1990, MMWR-MORBID MORTAL W, V39, P718.
   Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1, DOI DOI 10.HTTP://WWW.CDC.G0V/MMWR/PREVIEW/MMWRHTML/00032890.HTM.
   {*}CONF EXP, 1995, MED MAL INFECT S, V25, P3.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DESCAMPS JM, 1995, INFECT ACQUISE REANI, P269.
   DESPREZ R, 1990, PRINCIPLES PRACTICE, P2213.
   DIPERRI G, 1989, LANCET, V2, P1502.
   EDELIN BR, 1992, NEW ENGL J MED, V326, P1514.
   EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377.
   FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184.
   FLORENTIN A, 1994, B EPIDMEIOL HEBDOM, V5, P19.
   GOULLET D, 1995, ANTISEPSIE DISINFECT, P1212.
   GULLIFORD M, 1986, BRIT MED J, V292, P866, DOI 10.1136/bmj.292.6524.866.
   HEDLEY RM, 1992, ANAESTHESIA, V47, P414, DOI 10.1111/j.1365-2044.1992.tb02225.x.
   HOLTON J, 1994, INTENS CARE MED, V20, P233, DOI 10.1007/BF01704708.
   KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5.
   LEERS WD, 1980, CAN MED ASSOC J, V123, P275.
   NELSON KE, 1983, AM REV RESPIR DIS, V127, P97, DOI 10.1164/arrd.1983.127.1.97.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   PERONNE C, 1993, RES MICROBIOL, V144, P129.
   PERONNE C, 1994, PRESSE MED, V23, P731.
   PERRONNE C, 1992, ORG SOINS HOSP NOUVE, P49.
   PETERSEN GN, 1995, ASA NEWSLETTER, V59, P24.
   RODEN S, 1990, REV PNEUM CLIN, V16, P13.
   Rutala W. A., 1991, AM J MED, V91, P267.
   RUTALA WA, 1990, AM J INFECT CONTROL, V18, P99, DOI 10.1016/0196-6553(90)90089-B.
   SERVIN F, 1994, ANN FR ANESTH, V13, P477, DOI 10.1016/S0750-7658(05)80676-8.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   STEELE MA, 1991, CHEST, V99, P465, DOI 10.1378/chest.99.2.465.
   STEINER F, 1980, CAH ANESTHESIOL, V28, P1019.
   THOMAS MD, 1993, PRINCIPES MED INTERN, P637.
   VEBER B, 1995, ANN FR ANESTH REA S3, V14, pR106.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Ann. Fr. Anest. Reanim.}},
Doc-Delivery-Number = {{VV533}},
Unique-ID = {{ISI:A1996VV53300012}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995TJ74100045,
Author = {BATES, JH and NARDELL, E},
Title = {{INSTITUTIONAL CONTROL MEASURES FOR TUBERCULOSIS IN THE ERA OF
   MULTIPLE-DRUG RESISTANCE - ACCP/ATS CONSENSUS CONFERENCE}},
Journal = {{CHEST}},
Year = {{1995}},
Volume = {{108}},
Number = {{6}},
Pages = {{1690-1710}},
Month = {{DEC}},
Publisher = {{AMER COLL CHEST PHYSICIANS}},
Address = {{3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348}},
Type = {{Review}},
Language = {{English}},
DOI = {{10.1378/chest.108.6.1690}},
ISSN = {{0012-3692}},
Keywords = {{DRUG-RESISTANT TUBERCULOSIS; NOSOCOMIAL TUBERCULOSIS; OCCUPATIONAL
   TUBERCULOSIS}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY
   TUBERCULOSIS; HEALTH-CARE; NOSOCOMIAL TRANSMISSION; EXOGENOUS
   REINFECTION; AIR DISINFECTION; AIRBORNE SPREAD; INFECTION; ULTRAVIOLET}},
Research-Areas = {{General \& Internal Medicine; Respiratory System}},
Web-of-Science-Categories  = {{Critical Care Medicine; Respiratory System}},
Cited-References = {{ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306.
   ADAL KA, 1994, NEW ENGL J MED, V331, P1659.
   ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439.
   ALPERT ME, 1965, NEW ENGL J MED, V272, P718, DOI 10.1056/NEJM196504082721404.
   BADGER TL, 1949, AM REV TUBERC PULM, V60, P305.
   BARNHART S, 1995, ANN INTERN MED, V122, P70, DOI 10.7326/0003-4819-122-1-199501010-00020.
   Bass Jr JB, 1993, TUBERCULOSIS COMPREH, P139.
   BATES JH, 1993, MED CLIN N AM, V77, P1205, DOI 10.1016/S0025-7125(16)30188-2.
   BECKETT WS, 1995, ANN INTERN MED, V122, P70, DOI 10.7326/0003-4819-122-1-199501010-00022.
   BEEKMANN SE, 1993, INFECT CONT HOSP EP, V14, P228.
   BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228.
   BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665.
   Blum HF, 1942, J NATL CANCER I, V3, P211.
   BLUMBERG HM, 1993, INFECT CONT HOSP EP, V14, P414.
   Brahdy L, 1941, AM J PUBLIC HEALTH N, V31, P1040, DOI 10.2105/AJPH.31.10.1040.
   BRINDLE RJ, 1993, AM REV RESPIR DIS, V147, P958, DOI 10.1164/ajrccm/147.4.958.
   BROWN V, 1994, NEW ENGL J MED, V331, P1659.
   BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x.
   BURK JR, 1978, SOUTHERN MED J, V71, P7, DOI 10.1097/00007611-197801000-00004.
   CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559.
   CATANZARO A, 1995, LANCET, V345, P204, DOI 10.1016/S0140-6736(95)90216-3.
   CAUTHEN CM, 1994, AM J RESP CRIT CARE, V149, P1597.
   CHEN CC, 1992, AM IND HYG ASSOC J, V53, P566, DOI 10.1202/0002-8894(1992)053<0566:APTFFA>2.0.CO;2.
   CHEN CC, 1990, AM IND HYG ASSOC J, V51, P632, DOI 10.1202/0002-8894(1990)051<0632:FALPCO>2.0.CO;2.
   CHEN SK, 1994, AM J INFECT CONTROL, V22, P65, DOI 10.1016/0196-6553(94)90116-3.
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698.
   COUNSELL SR, 1989, ARCH INTERN MED, V149, P1274, DOI 10.1001/archinte.149.6.1274.
   CROWLE AJ, 1990, INFECT IMMUN, V58, P632.
   DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689.
   DEMARCHAYUELA P, 1990, AM REV RESPIR DIS, V141, P815, DOI 10.1164/ajrccm/141.4\_Pt\_1.815.
   DUNLAP NE, 1994, CHEST, V106, P658, DOI 10.1378/chest.106.3.658.
   DUTT AK, 1989, AM REV RESPIR DIS, V139, P867, DOI 10.1164/ajrccm/139.4.867.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377.
   FAGAN MJ, 1994, ANN INTERN MED, V120, P930, DOI 10.7326/0003-4819-120-11-199406010-00005.
   FORBES P.D., 1974, FED COSMET TOXICOL, V13, P335.
   FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623.
   GERBERDING JL, 1993, INFECT CONT HOSP EP, V14, P686.
   GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010.
   Heimbeck J, 1928, ARCH INTERN MED, V41, P336, DOI 10.1001/archinte.1928.00130150043002.
   HIERHOLZER WJ, 1987, PREVENTION CONTROL N, P61.
   HINDS WC, 1987, AM IND HYG ASSOC J, V48, P836, DOI 10.1202/0002-8894(1987)048<0836:PODRWF>2.0.CO;2.
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286.
   ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251.
   Israel HL, 1941, JAMA-J AM MED ASSOC, V117, P839, DOI {[}DOI 10.1001/JAMA.1941.02820360021007, 10.1001/jama.1941.02820360021007.].
   JARVIS WR, 1995, ANN INTERN MED, V122, P142, DOI 10.7326/0003-4819-122-2-199501150-00011.
   JEEVAN A, 1990, CELL IMMUNOL, V130, P32, DOI 10.1016/0008-8749(90)90159-O.
   JERNIGAN JA, 1994, AM J INFECT CONTROL, V22, P329, DOI 10.1016/0196-6553(94)90030-2.
   KEENEY RL, 1994, NEW ENGL J MED, V331, P193, DOI 10.1056/NEJM199407213310311.
   KOCHWESER D, 1993, CHEST, V103, P1641, DOI 10.1378/chest.103.6.1641.
   KUMARARATNE DS, 1992, IMMUNOLOGY HIV INFEC, P113.
   LINCOLN EDITH M., 1965, ADVANCES TUBERC RES, V14, P157.
   LUCKIESH M, 1946, APPL GERMICIDAL ERYT, P107.
   MACHER JM, 1993, INFECT CONT HOSP EP, V14, P723.
   MACHER JM, 1994, APPL OCCUP ENV HYG, V9, P462.
   Macher JM, 1992, APPL OCCUP ENV HYG, V7, P505.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   MARIER RL, 1993, INFECT CONT HOSP EP, V14, P700.
   MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002.
   MCLEAN RL, 1961, AM REV RESPIR DIS, V83, P36.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003.
   MUNGAI M, 1992, 8TH P INT C AIDS FLO.
   Myers JA, 1930, AM J NURS, V30, P1361, DOI 10.2307/3411236.
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502.
   NARDELL EA, 1993, INFECT CONT HOSP EP, V14, P681.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   NARDELL EA, 1992, WORLD C TUB BETH MD, P38.
   NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007.
   NETTLEMAN MD, 1995, ANN INTERN MED, V122, P70, DOI 10.7326/0003-4819-122-1-199501010-00023.
   NICAS M, 1993, INFECT CONT HOSP EP, V14, P619.
   NOLAN CM, 1994, ANN INTERN MED, V120, P964, DOI 10.7326/0003-4819-120-11-199406010-00009.
   NOTTEBART HC, 1987, PREVENTION CONTROL N, P26.
   PAGE MI, 1984, AM J MED, V77, P667, DOI 10.1016/0002-9343(84)90360-7.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   PERKINS JE, 1947, AJPH, V37, P529.
   PESANTI EL, 1994, AM J RESP CRIT CARE, V149, P1699, DOI 10.1164/ajrccm.149.6.7710481.
   Rabalais G, 1991, Lancet, V338, P826, DOI 10.1016/0140-6736(91)90719-6.
   RATCLIFFE HL, 1953, J EXP MED, V97, P61.
   RATCLIFFE HL, 1952, AM J HYG, V55, P36, DOI 10.1093/oxfordjournals.aje.a119504.
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046.
   RILEY EC, 1978, AM J EPIDEMIOL, V107, P421, DOI 10.1093/oxfordjournals.aje.a112560.
   RILEY RL, 1972, APPL MICROBIOL, V23, P1113.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P208, DOI 10.1080/00039896.1971.10665834.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1957, AM REV TUBERC PULM, V75, P420.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1994, INFECT CONT HOSP EP, V15, P324.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P200, DOI 10.1080/00039896.1971.10665833.
   RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V23, P35, DOI 10.1080/00039896.1971.10665951.
   RILEY RL, 1961, AIRBORNE INFECTION, P26.
   SCOTT B, 1994, ARCH INTERN MED, V154, P326, DOI 10.1001/archinte.154.3.326.
   SEGALMAURER S, 1994, CLIN INFECT DIS, V19, P299, DOI 10.1093/clinids/19.2.299.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012.
   SHAFER RW, 1991, 7TH P INT C AIDS, P79.
   SHERERTZ RJ, 1994, NEW ENGL J MED, V331, P1659.
   SLINEY DH, 1991, LIGHTS LASERS SYNCHR, P237.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   SOBEL E, 1994, NEW ENGL J MED, V331, P1658.
   STEAD W, 1993, J PRISON JAIL HLTH, V12, P13.
   STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837.
   STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702.
   STEAD WW, 1995, ANN INTERN MED, V122, P906, DOI 10.7326/0003-4819-122-12-199506150-00003.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587.
   URBACH F, 1991, DEC CONS M ULTR GERM.
   VANDENBRANDE P, 1992, CHEST, V101, P447, DOI 10.1378/chest.101.2.447.
   VARTERESIANKARA.L, 1988, NEW ENGL J MED, V319, P1018.
   VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D.
   Wallgren AJ., 1937, ACTA PAEDIATR SCAND, V22, P229.
   Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789.
   Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097.
   WELLS WF, 1948, AM J HYG, V47, P11, DOI 10.1093/oxfordjournals.aje.a119179.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   WHEELER AE, 1994, ASHRAE J, V36, P62.
   WINTERS RE, 1994, CLIN INFECT DIS, V19, P309, DOI 10.1093/clinids/19.2.309.
   ZMUDZKA BZ, 1990, PHOTOCHEM PHOTOBIOL, V52, P1153, DOI 10.1111/j.1751-1097.1990.tb08454.x.
   1990, MMWR-MORBID MORTAL W, V39, P1.
   1992, AM REV RESPIR DIS, V146, P1623.
   1989, MMWR-MORBID MORTAL W, V38, P256.
   1972, CRITERIA RECOMMENDED, P1.
   1988, J AM GERIATR SOC, V36, P77.
   1992, IARC MONOGRAPHS EVAL, V55, P227.
   1991, MMWR-MORBID MORTAL W, V41, P507.
   1982, B WORLD HEALTH ORGAN, V60, P555.
   1988, MMWR-MORBID MORTAL W, V37, P663.
   1994, TUBERCULOSIS CORRECT.
   1993, INFECT CONT HOSP EP, V14, P694.
   1990, AM REV RESPIR DIS, V142, P725.
   1994, MMWR-MORBID MORTAL W, V43, P1.
   ASHRAE621989 STAND.
   1993, MMWR-MORBID MORTAL W, V42, P696.
   1994, MMWR-MORBID MORTAL W, V43, P361.
   1994, FED REGISTER, V59, P58884.
   1990, MMWR-MORBID MORTAL W, V39, pRR17.
   1954, SPECIAL REPORT SERIE, V283.
   1993, MMWR-MORBID MORTAL W, V42, P703.
   1994, REPORTED TUBERCULOSI, P35.
   1992, MMWR-MORBID MORTAL W, V41, P61.
   1993, GUIDELINES CONSTRUCT, P1.
   1989, AM REV RESPIR DIS, V139, P871.
   1992, NIOSH RECOMMENDED GU, P1.}},
Number-of-Cited-References = {{144}},
Times-Cited = {{20}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Chest}},
Doc-Delivery-Number = {{TJ741}},
Unique-ID = {{ISI:A1995TJ74100045}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995TQ34800005,
Author = {Krapcho, AP and Maresch, MJ and Gallagher, CE and Hacker, MP},
Title = {{Synthesis of 4-hydroxy-6,9-difluorobenz{[}g]isoquinoline-5,10-diones and
   conversions to
   4-hydroxy-6,9-bis{[}(aminoalkyl)amino]-benz{[}g]isoquinoline-5,10-diones}},
Journal = {{JOURNAL OF HETEROCYCLIC CHEMISTRY}},
Year = {{1995}},
Volume = {{32}},
Number = {{6}},
Pages = {{1693-1702}},
Month = {{NOV-DEC}},
Abstract = {{Synthetic procedures have been developed which lead to
   4-hydroxy-6,9-difluorobenz{[}g]isoquinoline-5,10-dione (4a) and its
   3-methyl analogue 4b. Attempts to displace the fluorides from 4a with
   N,N-dimethylethylenediamine were unsuccessful. Analogue 4a on treatment
   with N-(t-butoxycarbonyl)ethylene diamine led to 15, formed from
   addition of the nucleophilic amine to C-3. On the other hand, analogue
   4b, on treatment with N,N-dimethylethylenediamine led to the anticipated
   difluoride displacement product 3c. The protection of the hydroxy group
   of 4a by benzylation with phenyldiazomethane led to 4c which on
   treatment with N-(t-butoxycarbonyl)ethylene diamine or
   N,N-dimethylethylenediamine led to the corresponding 6,9-bis-substituted
   analogues 18a and 18b, respectively. Reductive debenzylations of 18a and
   18b by hydrogenation over Pearlman's catalyst also effected partial
   reductions of the quinone. However, air oxidation of the over reduced
   products led to 3a and 3b, respectively. Treatment of 3a with hydrogen
   chloride gas led to the hydrochloride salt of 3d. Addition of
   O-p-Methoxybenzyl-N,N'-diisopropylurea to 4a led to the p-methoxybenzyl
   analogue 4d. Treatment of 4d with N,N-dimethylethylene diamine or
   N-(t-butoxycarbonyl)ethylene diamine led to displacements of the
   fluorides to yield 18c and 18d, respectively. Deprotection of 18c to 3b
   was accomplished using methanesulfonic acid. Treatment of 18d with
   trifluoroacetic acid followed by addition of maleic acid led to
   dimaleate salt of 3d.}},
Publisher = {{HETERO CORPORATION}},
Address = {{BOX 20285, TAMPA, FL 33622-0285}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{Krapcho, AP (Reprint Author), UNIV VERMONT,DEPT CHEM,BURLINGTON,VT 05405, USA.
   UNIV VERMONT,DEPT PHARMACOL,BURLINGTON,VT 05405.
   BOEHRINGER MANNHEIM ITALIA,RES CTR,I-20052 MONZA,ITALY.}},
DOI = {{10.1002/jhet.5570320605}},
ISSN = {{0022-152X}},
Keywords-Plus = {{MULTIDRUG-RESISTANCE; MITOXANTRONE; AGENTS; DNA; ANALOGS; CELLS}},
Research-Areas = {{Chemistry}},
Web-of-Science-Categories  = {{Chemistry, Organic}},
ResearcherID-Numbers = {{Wang, Rui/E-6585-2010
   }},
ORCID-Numbers = {{Oliva, Ambrogio/0000-0001-7397-9596}},
Cited-References = {{BADDELEY G, 1953, J CHEM SOC, P3969, DOI 10.1039/jr9530003969.
   BAGULEY BC, 1991, ANTI-CANCER DRUG DES, V6, P1.
   BHALLA K, 1993, BLOOD, V82, P3133.
   BRESLOW R, 1986, J AM CHEM SOC, V108, P1969, DOI 10.1021/ja00268a040.
   CHAUHAN MS, 1982, J CHROMATOGR, V237, P159, DOI 10.1016/S0021-9673(00)88285-0.
   CHENG CC, 1983, PROGR MED CHEM, V20, P83, DOI 10.1016/S0079-6468(08)70217-0.
   CLEARY X, 1984, ORG SYNTH, V64, P207.
   CORBETT TH, 1981, CANCER CHEMOTH PHARM, V6, P161.
   DENNY WA, 1990, ANTI-CANCER DRUG DES, V5, P189.
   DEVINE SE, 1994, J BIOL CHEM, V269, P6133.
   DOKTOROVA ND, 1969, TETRAHEDRON, V25, P3527, DOI 10.1016/S0040-4020(01)82888-X.
   DORR RT, 1991, ANTI-CANCER DRUG, V2, P27, DOI 10.1097/00001813-199102000-00003.
   FAULDS D, 1991, DRUGS, V41, P400, DOI 10.2165/00003495-199141030-00007.
   GADEKAR SM, 1962, J MED PHARMACEUT CH, V5, P531, DOI 10.1021/jm01238a013.
   GRIBBLE GW, 1992, J ORG CHEM, V57, P5891, DOI 10.1021/jo00048a022.
   Harris SA, 1940, J AM CHEM SOC, V62, P3198, DOI 10.1021/ja01868a086.
   Karpeiskii M. Y., 1969, RUSS CHEM REV, V38, P540.
   KORYTNYK W, 1977, J MED CHEM, V20, P745, DOI 10.1021/jm00216a002.
   KOZIKOWSKI AP, 1978, HETEROCYCLES, V9, P1271.
   KRAPCHO AP, 1991, J MED CHEM, V34, P2373, DOI 10.1021/jm00112a009.
   KRAPCHO AP, 1994, J MED CHEM, V37, P828, DOI 10.1021/jm00032a018.
   LAKHAN R, 1974, ADV OXAZOLE CHEM ADV, V17.
   MAEDA I, 1969, B CHEM SOC JPN, V42, P1435, DOI 10.1246/bcsj.42.1435.
   MATHIAS LJ, 1979, SYNTHESIS-STUTTGART, P561.
   MEIJERINGH MDJ, 1913, RECL TRAV CHIM PAY B, V32, P140.
   MURDOCK KC, 1979, J MED CHEM, V22, P1024, DOI 10.1021/jm00195a002.
   PAPA D, 1948, J AM CHEM SOC, V70, P3356, DOI 10.1021/ja01190a041.
   POTTS KT, 1986, J ORG CHEM, V51, P2011, DOI 10.1021/jo00361a014.
   SCHMIDT E, 1965, LIEBIGS ANN CHEM, V685, P161.
   SCHMIDTCHEN FP, 1977, J AM CHEM SOC, V99, P7014, DOI 10.1021/ja00463a041.
   Stiller ET, 1939, J AM CHEM SOC, V61, P1237, DOI 10.1021/ja01874a067.
   SUGIYAMA N, 1968, B CHEM SOC JPN, V41, P2219, DOI 10.1246/bcsj.41.2219.
   SUGIYAMA N, 1968, B CHEM SOC JPN, V41, P971, DOI 10.1246/bcsj.41.971.
   SYMES MO, 1993, INT J ONCOL, V3, P539.
   TUMMINELLO FM, 1987, CANCER TREAT REP, V71, P529.
   WHITE JD, 1989, J ORG CHEM, V54, P736, DOI 10.1021/jo00265a003.
   WIGLER PW, 1993, BIOCHIM BIOPHYS ACTA, V1154, P173, DOI 10.1016/0304-4157(93)90010-L.}},
Number-of-Cited-References = {{37}},
Times-Cited = {{9}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{J. Heterocycl. Chem.}},
Doc-Delivery-Number = {{TQ348}},
Unique-ID = {{ISI:A1995TQ34800005}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995TM33600004,
Author = {An, YH and Friedman, RJ and Draughn, RA and Smith, EA and Nicholson, JH
   and John, JF},
Title = {{Rapid quantification of staphylococci adhered to titanium surfaces using
   image analyzed epifluorescence microscopy}},
Journal = {{JOURNAL OF MICROBIOLOGICAL METHODS}},
Year = {{1995}},
Volume = {{24}},
Number = {{1}},
Pages = {{29-40}},
Month = {{NOV}},
Abstract = {{A method for rapid enumeration of S. epidermidis adhered to the surface
   of commercially pure titanium samples was developed using image analyzed
   epifluorescence microscopy. The method was used to determine the effects
   of different surface roughnesses of titanium samples and the influence
   of adsorbed human serum proteins on bacterial adherence. Bacterial
   suspension of S. epidermidis (VAS-11, concentration: 10(7) cfu/ml) were
   incubated with titanium samples (with different surface roughnesses and
   coated with human serum albumin or fibronectin) for 1 h at 37 degrees C
   with agitation. Thereafter they were washed, stained with propidium
   iodide, air dried, mounted onto microslides, and counted by using image
   analyzed epifluorescence microscopy. The results showed that: (1) this
   direct counting method is quick, simple, accurate, reproducible, and
   suitable for counting bacteria adhered to opaque surfaces such as metal,
   (2) the different roughnesses of the titanium surfaces (roughness: 1.25
   to 0.44 Ra) had no effect on the S. epidermidis adherence, and (3)
   adsorbed human serum albumin reduced the S. epidermidis adherence by
   more than 90\%, suggesting that precoating biomaterials with albumin may
   reduce the possibility of prosthesis or implant colonization by
   staphylococci. Conversely, human serum fibronectin had no effect on S.
   epidermidis adherence to a titanium surface.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{MED UNIV S CAROLINA, DEPT ORTHOPAED SURG, CHARLESTON, SC 29425 USA.}},
DOI = {{10.1016/0167-7012(95)00051-8}},
ISSN = {{0167-7012}},
EISSN = {{1872-8359}},
Keywords = {{image analyzed epifluorescence microscopy; Staphylococcus epiclermidis;
   bacterial adherence; albumin; fibronectin}},
Keywords-Plus = {{COAGULASE-NEGATIVE STAPHYLOCOCCI; FOREIGN-BODY INFECTION;
   ANTIBIOTIC-RESISTANCE; ADHESION; COLONIZATION; ATTACHMENT; INVITRO;
   AUREUS; EPIDERMIDIS; FIBRONECTIN}},
Research-Areas = {{Biochemistry \& Molecular Biology; Microbiology}},
Web-of-Science-Categories  = {{Biochemical Research Methods; Microbiology}},
Cited-References = {{ABSOLOM DR, 1983, APPL ENVIRON MICROB, V46, P90.
   AN YH, 1992, T ORTHOP RES SOC, V17, P577.
   BARTH E, 1989, BIOMATERIALS, V10, P325, DOI 10.1016/0142-9612(89)90073-2.
   BRUSASE BD, 1986, CLIN RHEUM DIS, V12, P523.
   CHANG CC, 1992, J BIOMED MATER RES, V26, P197, DOI 10.1002/jbm.820260206.
   CHANG TMS, 1970, T AM SOC ART INT ORG, V16, P141.
   CHAWLA A S, 1974, Biomaterials Medical Devices and Artificial Organs, V2, P157.
   DOMURADO D, 1978, J BIOENG, V2, P79.
   FALCIERI E, 1987, J INFECT DIS, V155, P524, DOI 10.1093/infdis/155.3.524.
   Fitzgerald R H Jr, 1989, Infect Dis Clin North Am, V3, P329.
   FLETCHER M, 1990, METHOD MICROBIOL, V22, P251.
   GOLOMB G, 1991, J BIOMED MATER RES, V25, P937, DOI 10.1002/jbm.820250803.
   GRAY ED, 1984, LANCET, V1, P365.
   GRISTINA AG, 1989, ANTIMICROB AGENTS CH, V33, P813, DOI 10.1128/AAC.33.6.813.
   GRISTINA AG, 1987, BIOMATERIALS, V8, P423, DOI 10.1016/0142-9612(87)90077-9.
   HARA M, 1967, AM J SURG, V113, P766, DOI 10.1016/0002-9610(67)90343-1.
   HERBERT RA, 1990, METHOD MICROBIOL, V22, P1.
   HERRMANN M, 1988, J INFECT DIS, V158, P693, DOI 10.1093/infdis/158.4.693.
   HOGT AH, 1983, J GEN MICROBIOL, V129, P2959.
   HOGT AH, 1985, J GEN MICROBIOL, V131, P2485.
   JOHN JF, 1993, CLIN INFECT DIS, V17, P380, DOI 10.1093/clinids/17.3.380.
   Krishan A, 1990, Methods Cell Biol, V33, P121.
   KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188.
   KUUSELA P, 1985, INFECT IMMUN, V50, P77.
   LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1.
   LOCCI R, 1981, ZBL BAKT MIK HYG B, V173, P285.
   MAXE I, 1986, INFECT IMMUN, V54, P695.
   MCDONALD DJ, 1987, ORTHOP T, V11, P462.
   Naylor P T, 1990, Clin Orthop Relat Res, P126.
   NAYLOR PT, 1989, T ORTHOP RES SOC, V14, P561.
   PARK K, 1986, J BIOMED MATER RES, V20, P589, DOI 10.1002/jbm.820200506.
   PETTIPHER GL, 1982, J APPL BACTERIOL, V53, P323, DOI 10.1111/j.1365-2672.1982.tb01278.x.
   PRATTTERPSTRA IH, 1987, J GEN MICROBIOL, V133, P3199.
   PRINGLE JH, 1986, APPL ENVIRON MICROB, V51, P1321.
   REYNOLDS EC, 1983, INFECT IMMUN, V39, P1285.
   SHETH NK, 1985, LANCET, V2, P1266.
   SIERACKI ME, 1985, APPL ENVIRON MICROB, V49, P799.
   SIPEHIA R, 1982, BIOMATER ARTIF CELL, V10, P229, DOI 10.3109/10731198209118783.
   SLIMANE S B, 1988, European Surgical Research, V20, P18.
   SPEIER JL, 1982, J COLLOID INTERF SCI, V89, P68, DOI 10.1016/0021-9797(82)90121-7.
   Sugarman B, 1989, Infect Dis Clin North Am, V3, P187.
   VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546.
   1985, F8676 ANN BOOK ASTM.}},
Number-of-Cited-References = {{43}},
Times-Cited = {{48}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{8}},
Journal-ISO = {{J. Microbiol. Methods}},
Doc-Delivery-Number = {{TM336}},
Unique-ID = {{ISI:A1995TM33600004}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995RU94000002,
Author = {MCGOWAN, JE},
Title = {{NOSOCOMIAL TUBERCULOSIS - NEW PROGRESS IN CONTROL AND PREVENTION}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{1995}},
Volume = {{21}},
Number = {{3}},
Pages = {{489-505}},
Month = {{SEP}},
Abstract = {{Nosocomial cases of tuberculosis have affected both health care workers
   and hospitalized patients, and each group has transmitted the infection
   to the other. This situation has been exacerbated by increases in the
   number of patients concurrently infected with human immunodeficiency
   virus and organisms resistant to multiple drugs; by inadequate
   implementation of procedures for the recognition, isolation, and
   treatment of patients with tuberculosis in health care and correctional
   facilities; and by a lack of practical engineering interventions for the
   control of airborne transmission, Epidemics at several hospitals have
   been controlled by the implementation of multiple measures listed in
   recent federal guidelines. Rapid recognition of cases and their
   effective isolation should be a priority at public hospitals, which can
   least afford the expensive engineering changes and personal respirators
   that are now mandated. Lacking are data on engineering controls
   (especially for retrofitting of existing facilities) and requirements
   for mask use that are both effective and financially practical. If
   relevant programs are to be developed, new methods are needed for the
   direct measurement of airborne transmission of tuberculosis.
   Fortunately, new federal guidelines allow individual hospitals and
   health care systems the flexibility to assess likely risk and to act in
   accordance with their findings to develop system-wide control programs.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{5720 S WOODLAWN AVE, CHICAGO, IL 60637}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{MCGOWAN, JE (Reprint Author), EMORY UNIV,GRADY MEM HOSP,SCH MED,DEPT PATHOL \& LAB MED,80 BUTLER ST,BOX 26248,ATLANTA,GA 30335, USA.
   EMORY UNIV,ROLLINS SCH PUBL HLTH,DEPT EPIDEMIOL,ATLANTA,GA 30322.}},
DOI = {{10.1093/clinids/21.3.489}},
ISSN = {{1058-4838}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; NEW-YORK-CITY;
   IMMUNODEFICIENCY-VIRUS INFECTION; HIV-INFECTION; PUBLIC-HEALTH;
   CORRECTIONAL FACILITIES; EXOGENOUS REINFECTION; HOSPITAL EMPLOYEES;
   DRUG-RESISTANCE; CARE FACILITIES}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
ResearcherID-Numbers = {{mcgowan jr, john/G-5404-2011}},
Cited-References = {{ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306.
   ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403.
   ANGLARET X, 1995, LANCET, V345, P867, DOI 10.1016/S0140-6736(95)93008-6.
   Arno P S, 1993, J Law Med Ethics, V21, P317, DOI 10.1111/j.1748-720X.1993.tb01256.x.
   BAILEY TC, 1995, ANN INTERN MED, V122, P580, DOI 10.7326/0003-4819-122-8-199504150-00004.
   BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BEEKMANN SE, 1993, INFECT CONT HOSP EP, V14, P228.
   BELLIN E, 1994, JAMA-J AM MED ASSOC, V271, P708, DOI 10.1001/jama.271.9.708.
   BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228.
   BENTLEY DW, 1990, INFECT CONT HOSP EP, V11, P42.
   BIERBAUM PJ, 1994, 94106 NAT I OCC SAF, P1.
   BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665.
   BLOCH AB, 1994, JAMA-J AM MED ASSOC, V272, P436, DOI 10.1001/jama.1994.03520060033026.
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003.
   BLUMBERG HM, 1993, INFECT CONT HOSP EP, V14, P414.
   BLUMENTHAL D, 1995, NEW ENGL J MED, V332, P465, DOI 10.1056/NEJM199502163320711.
   BREWER MA, 1994, J INFECT DIS, V170, P476, DOI 10.1093/infdis/170.2.476.
   BREWER TF, 1995, CLIN INFECT DIS, V20, P136, DOI 10.1093/clinids/20.1.136.
   CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535.
   CASTRO KG, 1993, INFECT CONT HOSP EP, V14, P65.
   CATANZARO A, 1995, LANCET, V345, P2004.
   CAUTHEN CM, 1994, AM J RESP CRIT CARE, V149, P1597.
   CIESIELSKI C, 1993, 33RD INT C ANT AG CH, P231.
   CLEVELAND JL, 1995, INFECT CONT HOSP EP, V16, P7.
   COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050.
   COMSTOCK GW, 1994, CLIN INFECT DIS, V19, P1015, DOI 10.1093/clinids/19.6.1015.
   CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052.
   DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689.
   DEMBRY LM, 1994, INFECT CONTROL HOS S, V15, P25.
   DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7.
   EARNEST MA, 1995, CLIN INFECT DIS, V20, P497, DOI 10.1093/clinids/20.3.497.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537.
   FAZAL BA, 1994, INFECT CONT HOSP EP, V15, P25.
   FELLA P, 1994, AM J INFECT CONTROL, V22, P100.
   FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   FRANKEL D, 1995, LANCET, V345, P783, DOI 10.1016/S0140-6736(95)90654-1.
   FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135.
   FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129.
   FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801.
   GOLDBERG MA, 1995, NEW ENGL J MED, V332, P742, DOI 10.1056/NEJM199503163321111.
   GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V273, P1223, DOI 10.1001/jama.273.15.1223.
   HAAS DW, 1994, AM J MED, V96, P439, DOI 10.1016/0002-9343(94)90171-6.
   HAAS WH, 1993, J CLIN MICROBIOL, V31, P1293.
   HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410.
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540.
   HORN DL, 1994, ANN INTERN MED, V121, P115, DOI 10.7326/0003-4819-121-2-199407150-00007.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968.
   HUEBNER RE, 1993, J CLIN MICROBIOL, V31, P771.
   HUTTON MD, 1993, PUBLIC HEALTH REP, V108, P305.
   IGLEHART JK, 1994, NEW ENGL J MED, V331, P63, DOI 10.1056/NEJM199407073310129.
   IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251.
   JACOBS RF, 1994, CLIN INFECT DIS, V19, P1, DOI 10.1093/clinids/19.1.1.
   JARVIS WR, 1995, AM J INFECT CONTROL, V23, P146, DOI 10.1016/0196-6553(95)90259-7.
   JARVIS WR, 1995, ANN INTERN MED, V122, P142, DOI 10.7326/0003-4819-122-2-199501150-00011.
   JERNIGAN JA, 1994, AM J INFECT CONTROL, V22, P329, DOI 10.1016/0196-6553(94)90030-2.
   JOHNSEN C, 1993, AM J INFECT CONTROL, V21, P1, DOI 10.1016/0196-6553(93)90199-E.
   JOHNSON JL, 1995, J INFECT DIS, V171, P1066, DOI 10.1093/infdis/171.4.1066.
   LANPHEAR BP, 1994, J INFECT DIS, V169, P703, DOI 10.1093/infdis/169.3.703-a.
   LOWENTHAL G, 1986, INFECT CONT HOSP EP, V7, P209, DOI 10.1017/S0195941700083958.
   LUMSDON K, 1992, HOSPITALS, V66, P24.
   MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306.
   McGowan J E Jr, 1995, J Med Assoc Ga, V84, P215.
   MCGOWAN JE, 1995, J HOSP INFECT, V30, P282, DOI 10.1016/0195-6701(95)90031-4.
   MCGOWAN JE, 1993, RES MICROBIOL, V144, P122, DOI 10.1016/0923-2508(93)90026-X.
   MCGOWAN JE, 1995, J HOSP INFECT, V30, P76, DOI 10.1016/0195-6701(95)90009-8.
   MCGOWAN JE, 1995, AM J INFECT CONTROL, V23, P141, DOI 10.1016/0196-6553(95)90258-9.
   MCGOWAN JE, 1994, INFECT CONT HOSP EP, V15, P510.
   MCGOWAN JE, 1992, INFECT CONT HOSP EP, V13, P575.
   MCGOWAN JE, 1980, INFECT CONT HOSP EP, V1, P147, DOI 10.1017/S0195941700052851.
   MCGOWAN JE, 1995, INFECT CONT HOSP EP, V16, P67.
   MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606.
   MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206.
   MIKOL EX, 1952, AM REV TUBERC PULM, V66, P16.
   MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003.
   MORRIS JT, 1993, CLIN INFECT DIS, V17, P538.
   NAGLIE G, 1995, INFECT CONT HOSP EP, V16, P148.
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502.
   NARDELL EA, 1995, AM J INFECT CONTROL, V23, P156, DOI 10.1016/0196-6553(95)90261-9.
   NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2.
   NARDELL EA, 1994, INFECT CONT HOSP EP, V15, P326, DOI 10.1017/S0195941700009656.
   NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007.
   NETTLEMAN MD, 1995, ANN INTERN MED, V122, P70, DOI 10.7326/0003-4819-122-1-199501010-00023.
   NOBLE RC, 1981, AM J INFECT CONTROL, V9, P6, DOI 10.1016/S0196-6553(81)80003-X.
   NOLAN CM, 1994, ANN INTERN MED, V120, P964, DOI 10.7326/0003-4819-120-11-199406010-00009.
   Nolte Frederick S., 1995, P400.
   NOORDHOEK GT, 1994, J CLIN MICROBIOL, V32, P277.
   NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1.
   OCONNOR PG, 1994, NEW ENGL J MED, V331, P450, DOI 10.1056/NEJM199408183310707.
   PASSANNANTE MR, 1994, CHEST, V106, P431, DOI 10.1378/chest.106.2.431.
   PELLETIER AR, 1993, ARCH INTERN MED, V153, P2692, DOI 10.1001/archinte.153.23.2692.
   POMERANTZ M, 1991, ANN THORAC SURG, V52, P1108, DOI 10.1016/0003-4975(91)91289-8.
   RAMIREZ JA, 1992, INFECT CONT HOSP EP, V13, P579.
   REICHMAN LB, 1993, AM J PUBLIC HEALTH, V83, P639, DOI 10.2105/AJPH.83.5.639.
   REICHMAN LB, 1994, NEW ENGL J MED, V330, P437.
   RILEY LW, 1993, CLIN INFECT DIS, V17, pS442, DOI 10.1093/clinids/17.Supplement\_2.S442.
   ROSELLE GA, 1993, CLIN INFECT DIS, V17, P573.
   ROSENBLUM LS, 1994, ANN INTERN MED, V121, P786, DOI 10.7326/0003-4819-121-10-199411150-00009.
   RUDNICK J, 1992, 1ST P WORLD C TUB RO.
   RUPP ME, 1994, J INFECT DIS, V169, P1174, DOI 10.1093/infdis/169.5.1174.
   SALFINGER M, 1994, AM J CLIN PATHOL, V101, pS6.
   SANTIN M, 1995, CLIN INFECT DIS, V20, P652, DOI 10.1093/clinids/20.3.652.
   SCOTT B, 1994, ARCH INTERN MED, V154, P326, DOI 10.1001/archinte.154.3.326.
   SEGALMAURER S, 1994, CLIN INFECT DIS, V19, P299, DOI 10.1093/clinids/19.2.299.
   SEPKOWITZ KA, 1994, CLIN INFECT DIS, V18, P755, DOI 10.1093/clinids/18.5.755.
   SEPKOWITZ KA, 1995, CLIN INFECT DIS, V20, P232, DOI 10.1093/clinids/20.2.232.
   SEPKOWITZ KA, 1995, CLIN MICROBIOL REV, V8, P180.
   SHAFER RW, 1995, J INFECT DIS, V171, P170, DOI 10.1093/infdis/171.1.170.
   SHARP V, 1994, LANCET, V343, P1431, DOI 10.1016/S0140-6736(94)92555-0.
   SHULKIN DJ, 1995, AM J INFECT CONTROL, V23, P1, DOI 10.1016/0196-6553(95)90001-2.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402.
   SOBEL E, 1994, NEW ENGL J MED, V331, P1658.
   STRATTON CW, 1993, INFECT CONT HOSP EP, V14, P481.
   STROUD LA, 1995, INFECT CONT HOSP EP, V16, P141.
   Tapper M L, 1995, Infect Control Hosp Epidemiol, V16, P125.
   TELZAK EE, 1994, CLIN INFECT DIS, V19, P627.
   TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767.
   USSERY XT, 1995, INFECT CONT HOSP EP, V16, P160.
   VOELKER R, 1993, JAMA-J AM MED ASSOC, V270, P1903.
   WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702.
   WEISS IK, 1995, LANCET, P345.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   WILCOX MH, 1995, J HOSP INFECT, V29, P165, DOI 10.1016/0195-6701(95)90325-9.
   WILLIAMS J, 1995, AM J INFECT CONTROL, V23, P152, DOI 10.1016/0196-6553(95)90260-0.
   WINTERS RE, 1994, CLIN INFECT DIS, V19, P309, DOI 10.1093/clinids/19.2.309.
   WOODS GL, 1993, ARCH PATHOL LAB MED, V117, P876.
   WOODS GL, 1995, ARCH PATHOL LAB MED, V119, P17.
   WOODS GL, 1994, AM J CLIN PATHOL, V101, P679, DOI 10.1093/ajcp/101.6.679.
   ZAZA S, 1992, 1992 WORLD C TUB BET.
   ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455.
   1993, OTAH574 PUBL.
   1979, CDC798371 PUBL, P1.
   1994, TUBERCULOSIS CONTROL, P1.
   1993, JAMA-J AM MED ASSOC, V270, P1525.
   1994, MMWR-MORBID MORTAL W, V43, P417.
   1991, MMWR-MORBID MORTAL W, V40, P585.
   1994, AM J RESP CRIT CARE, V149, P1359.
   1992, MMWR MORB MORT SRR11, V41, P61.
   1990, MMWR MORB MORT SRR17, V39, P1.
   1995, FED REG         0608, V60, P30336.
   1994, LANCET, V344, P277.
   1994, MMWR MORB MORT SRR13, V43, P1.
   1994, REPORTED TUBERCULOSI, P1.
   1969, AM REV RESPIR DIS, V99, P631.}},
Number-of-Cited-References = {{153}},
Times-Cited = {{56}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{RU940}},
Unique-ID = {{ISI:A1995RU94000002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995RN61600008,
Author = {CASTRO, KG},
Title = {{TUBERCULOSIS AS AN OPPORTUNISTIC DISEASE IN PERSONS INFECTED WITH
   HUMAN-IMMUNODEFICIENCY-VIRUS}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{1995}},
Volume = {{21}},
Number = {{1}},
Pages = {{S66-S71}},
Month = {{AUG}},
Abstract = {{Tuberculosis, a bacterial disease caused by the Mycobacterium
   tuberculosis complex, is becoming an increasingly common opportunistic
   disease in persons infected with the human immunodeficiency virus (HIV).
   M. tuberculosis is transmitted from person-to-person by airborne droplet
   nuclei, Persons who are exposed to these droplet nuclei in poorly
   ventilated environments are at risk of becoming infected with M.
   tuberculosis. HIV infection is probably the most significant risk factor
   associated with progression from latent M. tuberculosis infection to
   active disease. Thus, HIV-infected persons should avoid exposure to M.
   tuberculosis, they should be screened for evidence of latent infection
   with the tuberculin skin test, and they should be offered preventive
   therapy. Because many severely immunosuppressed anergic HIV-infected
   persons have been found to have an increased risk of developing active
   tuberculosis, decisions to use preventive therapy should be
   individualized on the basis of the local prevalence of tuberculosis and
   drug-resistance patterns. Persons with active tuberculosis should
   receive at least 6 months of treatment with recommended regimens,
   preferably with directly observed therapy, to ensure adequate
   bacteriologic response, completion of therapy, and cure. Chronic
   suppressive therapy after completion of therapy is currently not
   recommended.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{5720 S WOODLAWN AVE, CHICAGO, IL 60637}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{CASTRO, KG (Reprint Author), CTR DIS CONTROL \& PREVENT,DIV TUBERCULOSIS ELIMINAT,1600 CLIFTON RD,MAILSTOP E-10,ATLANTA,GA 30333, USA.}},
DOI = {{10.1093/clinids/21.Supplement\_1.S66}},
ISSN = {{1058-4838}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTION; ACTIVE
   TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; DEVELOPING-COUNTRIES; PREVENTIVE
   THERAPY; CLINICAL-FEATURES; UNITED-STATES; SYNDROME AIDS; DRUG-USERS}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Cited-References = {{BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BOUDES P, 1989, JAMA-J AM MED ASSOC, V262, P2386, DOI 10.1001/jama.1989.03430170046020.
   BRAILEY M, 1937, AM REV TUBERC, V36, P347.
   BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501.
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745.
   BURWEN DR, 1995, IN PRESS ARCH INTERN.
   CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535.
   CASTRO KG, 1993, CLIN INFECT DIS, V17, P802, DOI 10.1093/clinids/17.4.802.
   CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96.
   CHAULK CP, 1994, JAMA-J AM MED ASSOC, V271, P103, DOI 10.1001/jama.1994.03510260027017.
   COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407.
   COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397.
   COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8.
   Crawford J T, 1989, Semin Respir Infect, V4, P171.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.268.12.1581.
   DIPERRI G, 1989, LANCET, V2, P1502.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   ELLNER PD, 1988, J CLIN MICROBIOL, V26, P1349.
   FEREBEE SH, 1962, AM REV RESPIR DIS, V85, P490.
   FEREBEE SH, 1969, ADV TUBERC RES, V17, P28.
   FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184.
   Hopewell P C, 1989, Semin Respir Infect, V4, P111.
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540.
   HOUDE C, 1988, PEDIATR INFECT DIS J, V7, P810.
   HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968.
   HUEBNER RE, 1993, J CLIN MICROBIOL, V31, P771.
   JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987.
   KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0.
   LECOEUR HF, 1989, AM REV RESPIR DIS, V140, P1189, DOI 10.1164/ajrccm/140.5.1189.
   MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65.
   MANCHESTER K, 1984, MED HIST, V28, P162, DOI 10.1017/S0025727300035705.
   MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003.
   MOULDING T, 1994, TUBERCULOSIS, P41.
   MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N.
   ONORATO I, 1993, 33RD INT C ANT AG CH.
   PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204.
   PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393.
   RAVIGLIONE MC, 1992, B WORLD HEALTH ORGAN, V70, P515.
   REYNES J, 1989, J INFECT DIS, V160, P727, DOI 10.1093/infdis/160.4.727.
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046.
   RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B.
   SCHIEFFELBEIN CW, 1988, ARCH INTERN MED, V148, P1843, DOI 10.1001/archinte.148.8.1843.
   SCHUTZE GE, 1993, SEMIN PEDIAT INFECT, V4, P269.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504.
   SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503.
   STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304.
   STYBLO K, 1991, EPIDEMIOLOGY TUBERCU, V24, P55.
   SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362.
   TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767.
   VILLARINO M E, 1992, Morbidity and Mortality Weekly Report, V41, P59.
   WALLGREN A, 1948, Tubercle, V29, P245, DOI 10.1016/S0041-3879(48)80033-4.
   WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43.
   WALLIS RS, 1986, J IMMUNOL, V136, P193.
   WAYNE LG, 1984, MYCOBACTERIA SOURC A, P25.
   WEIS SE, 1994, NEW ENGL J MED, V330, P1179, DOI 10.1056/NEJM199404283301702.
   1992, MMWR-MORBID MORTAL W, V41, P5.
   1994, HIV AIDS SURVEILLANC, V5, P16.
   1991, MMWR-MORBID MORTAL W, V40, P27.
   1993, HIV AIDS SURVEILLANC, P1.
   1993, MMWR-MORBID MORTAL W, V42, P696.
   1987, ANN INTERN MED, V106, P254.
   1994, AM J RESP CRIT CARE, V149, P1359.
   1994, MMWR MORTAL WKLY REP, V43, P1.
   1994, MMWR-MORBID MORTAL W, V43, P361.
   1987, MMWR MORB MORTAL S1, V36, pS1.}},
Number-of-Cited-References = {{71}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{RN616}},
Unique-ID = {{ISI:A1995RN61600008}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995RJ16300005,
Author = {RUTALA, WA and JONES, SM and WORTHINGTON, JM and REIST, PC and WEBER, DJ},
Title = {{EFFICACY OF PORTABLE FILTRATION UNITS IN REDUCING AEROSOLIZED PARTICLES
   IN THE SIZE RANGE OF MYCOBACTERIUM-TUBERCULOSIS}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{1995}},
Volume = {{16}},
Number = {{7}},
Pages = {{391-398}},
Month = {{JUL}},
Abstract = {{OBJECTIVE: To evaluate engineering control measures to prevent
   nosocomial transmission of diseases such as tuberculosis, we studied
   four portable high-efficiency air filtration units, including three
   high-efficiency particulate air (HEPA) filtration units, for their
   ability to remove aerosolized particles.
   DESIGN:Studies were conducted in either a nonventilated aerosol chamber
   or in a hospital isolation room that met CDC guidelines for TB control
   (negative pressure, greater than or equal to 6 air changes per hour, air
   exhausted directly to the outside). The rooms were challenged with
   aerosolized mineral oil in the size range of 0.3 to 5.0 mu m at levels
   10 to 20 times the normal airborne particle load in the room at
   baseline. Airborne particles were counted with a laser counter capable
   of simultaneously measuring sizes greater than or equal to 0.3, greater
   than or equal to 0.5, greater than or equal to 1.0, and greater than or
   equal to 5.0 mu m. Experimental runs were conducted with the filtration
   units in the center or corner of the chamber or room, and the particle
   counter in the center of the room or at the exhaust vent.
   RESULTS: Portable filtration units were effective in accelerating the
   removal of aerosolized submicron particles. In the nonventilated room,
   time required by the various portable filtration units for removal of
   90\% of aerosolized particles (greater than or equal to 0.3 mu m) ranged
   from a low of 5 to 6 minutes to a high of 18 to 31 minutes, compared to
   the control (no filtration unit), >171 minutes. In the hospital room,
   individual filtration units removed 90\% of aerosolized particles
   (greater than or equal to 0.3 mu m) in times ranging from 5 to 8 minutes
   to 9 to 12 minutes, compared to the control (no filtration unit), 12 to
   16 minutes. The location of the portable filtration unit (center versus
   corner) did not affect the clearance rate of airborne particles.
   CONCLUSION: Our data indicate that portable filtration units can rapidly
   reduce levels of airborne particles similar in size to infectious
   droplet nuclei and, therefore, may aid in reducing the risk of
   tuberculosis exposure (Infect Control Hosp Epidemiol 1995;16:391-398).}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{RUTALA, WA (Reprint Author), UNIV N CAROLINA,DIV INFECT DIS,547 BURNETT WOMACK BLDG,CB 7030,CHAPEL HILL,NC 27599, USA.
   UNC HOSP,DEPT HOSP EPIDEMIOL,CHAPEL HILL,NC.
   UNIV N CAROLINA,HLTH \& SAFETY OFF,CHAPEL HILL,NC 27599.
   UNIV N CAROLINA,DEPT ENVIRONM SCI \& ENGN,CHAPEL HILL,NC 27599.}},
ISSN = {{0899-823X}},
Keywords-Plus = {{IMMUNODEFICIENCY-VIRUS INFECTION; MULTIDRUG-RESISTANT TUBERCULOSIS;
   NOSOCOMIAL TRANSMISSION; OUTBREAK; PENETRATION; WORKERS; PATIENT;
   LEAKAGE; MASKS; RISK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{{[}Anonymous], 1993, ENFORCEMENT POLICY P.
   BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   BROWN V, 1994, NEW ENGL J MED, V331, P1659.
   CHEN CC, 1992, AM J INFECT CONTROL, V20, P177, DOI 10.1016/S0196-6553(05)80143-9.
   CHEN CC, 1992, AM IND HYG ASSOC J, V53, P533, DOI 10.1202/0002-8894(1992)053<0533:COFSLI>2.0.CO;2.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   GARNER JS, 1983, INFECT CONTROL, V4, P248.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   MARIER RL, 1993, INFECT CONT HOSP EP, V14, P700.
   MOLLER AR, 1992, PUBLIC HLTH PREVENTI, P523.
   OPAL SM, 1986, J INFECT DIS, V153, P634, DOI 10.1093/infdis/153.3.634.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   PIERCE JR, 1992, CHEST, V101, P581, DOI 10.1378/chest.101.2.581.
   RHAME FS, 1984, AM J MED, V76, P42, DOI 10.1016/0002-9343(84)90243-2.
   RILEY RL, 1993, PLANT TECHNOLOGY SAF, P25.
   SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503.
   WEBER A, 1993, AM J INFECT CONTROL, V21, P167, DOI 10.1016/0196-6553(93)90027-2.
   1992, MMWR-MORBID MORTAL W, V41, P13.
   1990, MMWR-MORBID MORTAL W, V39, P1.
   1990, MMWR-MORBID MORTAL W, V32, P718.
   1991, MMWR-MORBID MORTAL W, V40, P585.
   1993, MMWR-MORBID MORTAL W, V42, P696.
   1994, FED REGISTER, V59, P54242.
   1993, MMWR-MORBID MORTAL W, V42, P1.
   1992, MMWR-MORBID MORTAL W, V41, P1.}},
Number-of-Cited-References = {{27}},
Times-Cited = {{32}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{RJ163}},
Unique-ID = {{ISI:A1995RJ16300005}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995QP89000031,
Author = {WILLIAMS, JW and HOLLEMAN, DR and SAMSA, GP and SIMEL, DL},
Title = {{RANDOMIZED CONTROLLED TRIAL OF 3 VS 10 DAYS OF
   TRIMETHOPRIM-SULFAMETHOXAZOLE FOR ACUTE MAXILLARY SINUSITIS}},
Journal = {{JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION}},
Year = {{1995}},
Volume = {{273}},
Number = {{13}},
Pages = {{1015-1021}},
Month = {{APR 5}},
Abstract = {{Objective.-To compare 14-day outcomes and relapse and recurrence rates
   among patients with acute maxillary sinusitis randomized to 3-day (3D)
   vs 10-day (10D) treatment with trimethoprim/sulfamethoxazole (TMP/SMX).
   Setting.-University-affiliated Veterans Affairs general medical and
   acute care clinics.
   Patients.-Consecutive patients with sinus symptoms and radiographic
   evidence of maxillary sinusitis (complete opacity, air-fluid level, or
   greater than or equal to 6 mm of mucosal thickening). Patients were
   excluded for antibiotic use within the past week, TMP/ SMX allergy,
   symptoms for more than 30 days, or previous sinus surgery.
   Methods.-All subjects (n=80) received oxymetazoline nasal spray 0.05\%,
   two sprays twice daily for 3 days. Subjects were randomly assigned to
   TMP/SMX double strength: one tablet twice daily for 10 days or one
   tablet twice daily for 3 days followed by 7 days of placebo, At 7 and 14
   days, patients rated their overall sinus symptoms on a Likert scale.
   Radiographs were scored at baseline and 14 days by radiologists masked
   to clinical symptoms and treatment assignment. The primary outcome was
   number of days to `'cure'' or `'much improvement'' in sinus symptoms.
   Patients who were clinical successes by day 14 were assessed for
   symptomatic relapse or recurrence at 30 and 60 days, respectively,
   Results.-Groups were comparable at randomization: male, 100\%; black,
   53\%; median age, 48 years (interquartile range, 41 to 63 years);
   symptom duration, 10 days (interquartile range, 6 to 17 days); bilateral
   maxillary disease, 51\%; and radiograph score, 4 (interquartile range, 2
   to 4). Outcome assessment was completed in 95\% of patients at day
   14(n=76). Medication side effects and use of nonstudy sinus medications
   were equal between groups. By 14 days, 77\% of 3D subjects and 76\% of
   10D subjects rated their sinus symptoms as cured or much improved (95\%
   confidence interval for difference, -15\% to 17\%). Median days to
   cure/much improvement were 5.0 and 4.5 for the 3D and 10D groups,
   respectively; distributions of time to cure were not different (P=.34).
   Radiograph scores improved in both groups compared with baseline (2
   points; P<.001), but improvement did not differ between groups (P=.31).
   Eight percent of 3D subjects and 13\% of 10D subjects missed work due to
   sinus symptoms. Of the 52 patients who were clinical successes at 14
   days and completed follow-up, three (11\%) of 27 3D subjects and one
   (4\%) of 25 10D subjects relapsed symptomatically by day 30; one (4\%)
   of 27 3D subjects and one (4\%) of 25 10D subjects suffered symptomatic
   recurrence between days 30 and 60 (P=.45 for the relapse and recurrence
   rates combined).
   Conclusion.-At the 2-week follow-up, clinical symptoms and radiograph
   scores improved equally following 3 or 10 days of TMP/SMX plus
   oxymetazoline nasal spray. Symptomatic relapse and recurrence were
   similar between groups. Three days of antibiotics were as effective as
   10 days and, because of the high disease prevalence, hold the potential
   for substantial cost savings.}},
Publisher = {{AMER MEDICAL ASSOC}},
Address = {{515 N STATE ST, CHICAGO, IL 60610}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{WILLIAMS, JW (Reprint Author), AUDIE L MURPHY MEM VET ADM MED CTR,AMBULATORY CARE SERV 11C,7400 MERTON MINTON BLVD,SAN ANTONIO,TX 78284, USA.
   AUDIE L MURPHY MEM VET ADM MED CTR,DIV GEN INTERNAL MED,SAN ANTONIO,TX.
   UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX.
   LEXINGTON VET HOSP,MED SERV,LEXINGTON,KY.
   LEXINGTON VET HOSP,DIV GEN INTERNAL MED,LEXINGTON,KY.
   UNIV KENTUCKY,LEXINGTON,KY.
   VET AFFAIRS MED CTR,HLTH SERV RES FIELD PROGRAM,DURHAM,NC.
   VET AFFAIRS MED CTR,DIV GEN INTERNAL MED,DURHAM,NC.
   DUKE UNIV,MED CTR,DURHAM,NC.}},
DOI = {{10.1001/jama.273.13.1015}},
ISSN = {{0098-7484}},
Keywords-Plus = {{ANTIMICROBIAL RESISTANCE; AMOXICILLIN-CLAVULANATE;
   HAEMOPHILUS-INFLUENZAE; COMPARATIVE EFFICACY; CEFUROXIME AXETIL;
   THERAPY; CLARITHROMYCIN; EQUIVALENCE; AMOXYCILLIN; BOOTSTRAP}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
ResearcherID-Numbers = {{Williams, Jr., John/A-3696-2008}},
ORCID-Numbers = {{Williams, Jr., John/0000-0002-5267-5558}},
Cited-References = {{ALTMAN DG, 1989, STAT MED, V8, P771, DOI 10.1002/sim.4780080702.
   AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861.
   AXELSSON A, 1988, ANN OTO RHINOL LARYN, V92, P75.
   AXELSSON A, 1970, ACTA OTOLARYNGOL STO, V69, P802.
   BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017.
   BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831.
   CAMACHO AE, 1992, AM J MED, V93, P271, DOI 10.1016/0002-9343(92)90232-Z.
   CASIANO RR, 1991, AM J MED, V91, pS27, DOI 10.1016/0002-9343(91)90398-H.
   DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709.
   DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457.
   EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844.
   EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502.
   Fascenelli F W, 1969, Arch Otolaryngol, V90, P190.
   FLEISS JL, 1981, STATISTICAL METHODS.
   GARLASCHI ML, 1993, EUR J EPIDEMIOL, V9, P64, DOI 10.1007/BF00463092.
   GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105.
   GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68.
   HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197.
   HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856.
   KARMA P, 1991, J ANTIMICROB CHEMOTH, V27, P83, DOI 10.1093/jac/27.suppl\_A.83.
   KAYSER FH, 1990, EUR J CLIN MICROBIOL, V9, P810, DOI 10.1007/BF01967379.
   KIRSHNER B, 1991, J CLIN EPIDEMIOL, V44, P839, DOI 10.1016/0895-4356(91)90139-Z.
   MARCHI E, 1990, CURR MED RES OPIN, V12, P19, DOI 10.1185/03007999009111487.
   MATTHEWS BL, 1993, SOUTHERN MED J, V86, P329, DOI 10.1097/00007611-199303000-00016.
   MATTUCCI KF, 1986, ARCH OTOLARYNGOL, V112, P73.
   MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N.
   Mooney C.Z., 1993, SERIES QUANTITATIVE, P07.
   MOSS AJ, 1986, VITAL HLTH STAT 10, V160, P66.
   NIELSEN RW, 1992, AM J MED, V92, pS70, DOI 10.1016/0002-9343(92)90611-E.
   NYFFENEGGER R, 1991, CLIN THER, V13, P589.
   ROVNER S, 1993, WASHINGTON POST 1130, P10.
   RUBIN RH, 1980, NEW ENGL J MED, V303, P426.
   SANFORD JP, 1993, GUIDE ANTIMICROBIAL, P29.
   SCHELD WM, 1986, ANTIMICROB AGENTS CH, V30, P350, DOI 10.1128/AAC.30.3.350.
   SYDNOR A, 1989, ARCH OTOLARYNGOL, V115, P1430.
   VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684.
   WALD ER, 1986, PEDIATRICS, V77, P795.
   WILLIAMS JW, 1992, J GEN INTERN MED, V7, P481, DOI 10.1007/BF02599447.
   WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705.
   WILLIAMS JW, 1993, CLIN RES, V41, pA566.
   WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507.
   1989, NATIONAL DISEASE THE, P487.
   1993, J ANTIMICROB CHEMOTH, V31, P949.
   1990, SAS STAT USERS GUIDE, P1027.
   1992, P229 SAS I INC TECHN, P435.
   1995, JAMA-J AM MED ASSOC, V273, P776.
   1994, JAMA-J AM MED ASSOC, V272, P1926.
   1994, REDBOOK DRUG TOPICS.}},
Number-of-Cited-References = {{48}},
Times-Cited = {{96}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{JAMA-J. Am. Med. Assoc.}},
Doc-Delivery-Number = {{QP890}},
Unique-ID = {{ISI:A1995QP89000031}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995QT79700002,
Author = {FRIDKIN, SK and MANANGAN, L and BOLYARD, E and JARVIS, WR},
Title = {{SHEA-CDC TB SURVEY .1. STATUS OF TB INFECTION-CONTROL PROGRAMS AT MEMBER
   HOSPITALS, 1989-1992}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{1995}},
Volume = {{16}},
Number = {{3}},
Pages = {{129-134}},
Month = {{MAR}},
Abstract = {{OBJECTIVE: To determine trends in Mycobacterium tuberculosis infection
   in healthcare workers, tuberculosis (TB) control measures, and
   compliance with the 1990 Centers for Disease Control and Prevention
   (CDC) guideline for preventing transmission of TB in healthcare
   facilities.
   DESIGN: Voluntary questionnaire sent to all members of the Society for
   Healthcare Epidemiology of America, representing 359 hospitals.
   RESULTS: Respondents' hospitals (210 {[}58\%]) had a median of 2,400
   healthcare workers (range, 396 to 13,745), 437 beds (range, 48 to
   1,250), 5.6 patients with TB per year (range, 0 to 499), and 0
   multidrug-resistant (MDR) TB patients per year (range, 0 to 33). Of 166
   respondents' hospitals for which data were provided for 1989 through
   1992, the number caring for MDR-TB patients increased from 10 (6\%) in
   1989 to 49 (30\%) in 1992. Reported policies for routine healthcare
   worker tuberculin skin testing varied. The median skin-test positivity
   rate for healthcare workers at the time of hire increased from 0.54\% in
   1989 to 0.81\% in 1992, but the median conversion rate during routine
   testing remained similar: 0.35\% in 1989 and 0.33\% in 1992. Among 196
   hospitals with reported data on respiratory protection use for 1989
   through 1992, the use of either surgical submicron, dust-mist, or
   dust-fume-mist respirators for healthcare workers increased from 9 (5\%)
   in 1989 to 85 (43\%) in 1992. Of 181 hospitals with reported data, 113
   (62\%) had acid-fast bacilli isolation facilities consistent with the
   1990 CDC guideline (ie, a single patient room, negative air pressure
   relative to the hallway, air exhausted directly outside, and greater
   than or equal to 6 air exchanges per hour).
   CONCLUSIONS: While the number of surveyed hospitals caring for TB and
   MDR-TB patients increased during 1989 through 1992, TB infection control
   measures at many hospitals still did not meet the 1990 CDC guideline
   recommendations}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{FRIDKIN, SK (Reprint Author), CTR DIS CONTROL \& PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP E-69,1600 CLIFTON RD,ATLANTA,GA 30333, USA.
   SOC HEALTHCARE EPIDEMIOL AMER,W DEPTFORD,NJ.}},
ISSN = {{0899-823X}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; OUTBREAK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   JARVIS WR, 1993, RES MICROBIOL, V144, P117, DOI 10.1016/0923-2508(93)90025-W.
   MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RUDNICK J, 1992, 1ST WORLD C TUB ROCK.
   SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203.
   STROUD L, 1993, 3RD ANN M SOC HEALTH.
   WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7.
   1990, MMWR-MORBID MORTAL W, V39, P1.
   1992, RECOMMENDED GUIDELIN.
   1991, MMWR-MORBID MORTAL W, V40, P585.
   1993, MMWR-MORBID MORTAL W, V42, P696.
   1988, PC SAS RELEASE 6 03.
   1993, MEMORANDUM REGIONAL.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{43}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{QT797}},
Unique-ID = {{ISI:A1995QT79700002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995QT79700006,
Author = {IKEDA, RM and BIRKHEAD, GS and DIFERDINANDO, GT and BORNSTEIN, DL and
   DOOLEY, SW and KUBICA, GP and MORSE, DL},
Title = {{NOSOCOMIAL TUBERCULOSIS - AN OUTBREAK OF A STRAIN RESISTANT TO 7 DRUGS}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{1995}},
Volume = {{16}},
Number = {{3}},
Pages = {{152-159}},
Month = {{MAR}},
Abstract = {{OBJECTIVE: To evaluate nosocomial transmission of multidrug-resistant
   (MDR) tuberculosis (TB).
   DESIGN: Outbreak investigation: review of infection control practices
   and skin test results of healthcare workers (HCWs); medical records of
   hospitalized TB patients and mycobacteriology reports; submission of
   specimens for restriction fragment length polymorphism (RFLP) typing;
   and an assessment of the air-handling system.
   SETTING: A teaching hospital in upstate New York.
   RESULTS: Skin-test conversions occurred among 46 (6.6\%) of 696 HCWs
   tested from August through October 1991. Rates were highest on two units
   (29\% and 20\%); HCWs primarily assigned to these units had a higher
   risk for conversion compared with HCWs tested following previous
   incidents of exposure to TB (relative risk {[}RR]=53.4, 95\% confidence
   interval {[}CI95]=6.9 to 411.1; and RR=37.4, CI95=5.0 to 277.3,
   respectively). The likely source patient was the only TB patient
   hospitalized on both units during the probable exposure period. This
   patient appeared clinically infectious, was associated with a higher
   risk of conversion among HCWs providing direct care (RR=2.37; CI95=1.05
   to 5.34), and was a prison inmate with TB resistant to seven
   antituberculosis agents. The MDR-TB strain isolated from this patient
   also was isolated from other inmate and noninmate patients, and a prison
   correctional officer exposed in the hospital. Mycobacterium tuberculosis
   isolates from all of these patients had matching RFLP patterns.
   Infection control practices closely followed established guidelines;
   however, several rooms housing TB patients had marginal negative
   pressure with variable numbers of air changes per hour, and directional
   airflow was disrupted easily.
   CONCLUSIONS: These data strongly suggest nosocomial transmission of
   MDR-TB to HCWs, patients, and a prison correctional officer working in
   the hospital. Factors contributing to transmission apparently included
   prolonged infectiousness of the likely source patient and inadequate
   environmental controls. Continued urgent attention to TB infection
   control is needed}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{CTR DIS CONTROL \& PREVENT,DIV FIELD EPIDEMIOL,EPIDEM INTELLIGENCE SERV,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341.
   CTR DIS CONTROL \& PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341.
   NEW YORK STATE DEPT HLTH,BUR COMMUNICABLE DIS CONTROL,ALBANY,NY 12201.
   SUNY ALBANY,SCH PUBL HLTH,DEPT EPIDEMIOL,ALBANY,NY 12222.
   SUNY SYRACUSE,HLTH SCI CTR,SYRACUSE,NY 13210.}},
ISSN = {{0899-823X}},
Keywords-Plus = {{HIV-INFECTED PATIENTS; MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DIPERRI G, 1989, LANCET, V2, P1502.
   DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623.
   NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151.
   VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222.
   VILLARINO M E, 1992, Morbidity and Mortality Weekly Report, V41, P59.
   1990, MMWR-MORBID MORTAL W, V39, P1.
   1991, MMWR-MORBID MORTAL W, V40, P129.
   1989, MMWR-MORBID MORTAL W, V38, P313.
   1985, MMWR-MORBID MORTAL W, V34, P429.
   1991, MMWR-MORBID MORTAL W, V40, P585.
   1990, MMWR-MORBID MORTAL W, V39, P9.
   1989, MMWR-MORBID MORTAL W, V38, P325.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{50}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{QT797}},
Unique-ID = {{ISI:A1995QT79700006}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995QT79700007,
Author = {USSERY, XT and BIERMAN, JA and VALWAY, SE and SEITZ, TA and
   DIFERDINANDO, GT and OSTROFF, SM},
Title = {{TRANSMISSION OF MULTIDRUG-RESISTANT MYCOBACTERIUM-TUBERCULOSIS AMONG
   PERSONS EXPOSED IN A MEDICAL EXAMINERS OFFICE, NEW-YORK}},
Journal = {{INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY}},
Year = {{1995}},
Volume = {{16}},
Number = {{3}},
Pages = {{160-165}},
Month = {{MAR}},
Abstract = {{OBJECTIVE: To determine the prevalence of and risk factors for having a
   positive tuberculin skin test (TST) result among employees at a medical
   examiner's office (MEO).
   DESIGN: Cohort study, environmental investigation.
   SETTING: Several employees at a medical examiner's office were found to
   have positive TST results after autopsies were performed on persons with
   multidrug-resistant tuberculosis (MDR-TB).
   PARTICIPANTS: Employees of the MEO.
   RESULTS: Of 18 MEO employees, 5 (28\%) had a positive TST result; 2 of
   these 5 had TST conversions. We observed a trend between TST conversion
   and participation in autopsies on persons with MDR-TB (2 of 2 converters
   versus 3 of 13 employees with negative TST; relative risk=4.3; 95\%
   confidence interval 1.61 to 11.69; P=0.10). The environmental
   investigation revealed that the autopsy room was at positive pressure
   relative to the rest of the MEO and that air from the autopsy room mixed
   throughout the facility.
   CONCLUSIONS: A systematic approach to preventing transmission of
   Mycobacterium tuberculosis in autopsy suites should include effective
   environmental controls and routine tuberculin skin testing of employees}},
Publisher = {{SLACK INC}},
Address = {{6900 GROVE RD, THOROFARE, NJ 08086}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{CTR DIS CONTROL \& PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333.
   CTR DIS CONTROL \& PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL \& MYCOT DIS,ATLANTA,GA 30333.
   CTR DIS CONTROL \& PREVENT,NIOSH,DIV SURVEILLANCE HAZARDS EVALUAT \& FIELD STUDIES,CINCINNATI,OH.
   NEW YORK STATE DEPT HLTH,ALBANY,NY 12201.}},
ISSN = {{0899-823X}},
Keywords-Plus = {{IMMUNODEFICIENCY-VIRUS INFECTION; PULMONARY TUBERCULOSIS; IMPACT}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q.
   COMSTOCK GW, 1993, TUBERCULOSIS COMPREH, P23.
   ELLIOTT AM, 1993, AIDS, V7, P981.
   Heinsohn PA, 1991, APPL OCCUP ENV HYG, V6, P773.
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540.
   IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152.
   KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5.
   KENT PT, 1985, PUBLIC HLTH MYCOBACT, P166.
   KLAUSNER JD, 1993, J INFECT DIS, V168, P106, DOI 10.1093/infdis/168.1.106.
   LUNDGREN R, 1987, TUBERCLE, V68, P147, DOI 10.1016/0041-3879(87)90032-8.
   NUNN P, 1994, TUBERCLE LUNG DIS, V75, P25, DOI 10.1016/0962-8479(94)90098-1.
   SLOAN R. A., 1942, New York State Journal of Medicine, V42, P133.
   SUGITA M, 1990, ACTA PATHOL JAPON, V40, P116.
   VALWAY S, 1994, AM J EPIDEMIOL, V140, P13.
   1991, ASHRAE APPLICATIONS.
   1992, AM REV RESPIR DIS, V146, P1623.
   1972, NIOSH HSM73110009 NA.
   1990, AM REV RESPIR DIS, V142, P725.
   1994, MMWR-MORBID MORTAL W, V43, P1.
   1992, NIOSH HETA921712255.
   1992, MMWR-MORBID MORTAL W, V41, P59.
   1993, GUIDELINES CONSTRUCT.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{24}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Infect. Control Hosp. Epidemiol.}},
Doc-Delivery-Number = {{QT797}},
Unique-ID = {{ISI:A1995QT79700007}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995QU56200017,
Author = {DAUTZENBERG, B},
Title = {{TUBERCULOSIS - ISOLEMENT, HYGIENE AND PREVENTIVE MEASURES}},
Journal = {{MEDECINE ET MALADIES INFECTIEUSES}},
Year = {{1995}},
Volume = {{25}},
Number = {{3}},
Pages = {{392-401}},
Month = {{MAR}},
Note = {{Experts Conference on Tuberculosis in France - How to Stop the
   Epidemies, PARIS, FRANCE, DEC   15, 1994}},
Organization = {{SOC PATHOL INFECTIEUSE LANGUE FRANCAISE; SOC PNEUMOL LANGUE FRANCAISE}},
Abstract = {{Isolement, hygiene and preventive measures implemented before
   antibiotics era for tuberculosis remain effective. Isolation in one
   person room may concern potential contaminator (AFB+) or potential
   receiver (children or HIV+) patients as soon as tuberculosis diagnosis
   was suspected. Contamination risk decrease gradually as soon as the
   antituberculous treatment was initiated. Except for MDR-TB a 3 days to 3
   weeks isolation was recommended. In isolation room, negative pressure
   and 6 air replacement by hour was recommanded. UV light 254 nm inactive
   65 \% of bacilli. Visitor and nurse mask were not effective. Surgical
   mask give law protection. Anti projection mask gave a convenient
   protection for more 99 \% of particle of 1 mu, particular mask was
   recommended in USA. For patient treated at home, a separation from
   receptive subject was need. No specific isolation measure were need as
   soon treatment was initiated. In case of multidrug resistant
   tuberculosis isolation measures had to be strictly applied. Risk
   assessment and risk management studies were need before the adoption of
   precise guidelines for decreasing the risk of TB in Health Care Workers
   at reasonable level.}},
Publisher = {{SOC FRANCAISE EDITION MED}},
Address = {{22-24 RUE DU CHATEAU RENTIERS, 75013 PARIS, FRANCE}},
Type = {{Article; Proceedings Paper}},
Language = {{French}},
Affiliation = {{DAUTZENBERG, B (Reprint Author), GRP HOP PITIE SALPETRIERE,SERV PNEUMOL,47-83 BLD HOP,F-75651 PARIS 13,FRANCE.}},
DOI = {{10.1016/S0399-077X(05)80602-X}},
ISSN = {{0399-077X}},
Keywords = {{TUBERCULOSIS; PREVENTION; ISOLEMENT MEASURES; PROTECTIVE MASK}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Med. Mal. Infect.}},
Doc-Delivery-Number = {{QU562}},
Unique-ID = {{ISI:A1995QU56200017}},
DA = {{2018-08-13}},
}

@article{ ISI:A1995QM06100004,
Author = {LAROCHELLE, DR and CARLSON, EV},
Title = {{PROTECTING THE PROVIDER FROM TUBERCULOSIS EXPOSURE}},
Journal = {{NURSING CLINICS OF NORTH AMERICA}},
Year = {{1995}},
Volume = {{30}},
Number = {{1}},
Pages = {{13-22}},
Month = {{MAR}},
Abstract = {{The resurgence of tuberculosis (TB), especially the new
   multidrug-resistant strain of TB, is a potential health hazard for
   caregivers in hospital settings. This article discusses the
   comprehensive multidisciplinary evaluation of one medical center's
   policies and procedures related to the control of infectious airborne
   pathogens.}},
Publisher = {{W B SAUNDERS CO}},
Address = {{INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA
   19106-3399}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{LAROCHELLE, DR (Reprint Author), RUSH UNIV,RUSH PRESBYTERIAN ST LUKES MED CTR,HOSP MED,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.
   RUSH UNIV,RUSH PRESBYTERIAN ST LUKES MED CTR,JRB HOSP,CHICAGO,IL 60612.
   RUSH UNIV,RUSH PRESBYTERIAN ST LUKES MED CTR,JOHNSTON R BOWMAN HLTH CTR ELDERLY,CHICAGO,IL 60612.
   RUSH UNIV,RUSH PRESBYTERIAN ST LUKES MED CTR,COLL NURSING,DEPT MED NURSING,CHICAGO,IL 60612.}},
ISSN = {{0029-6465}},
Keywords-Plus = {{DRUG-RESISTANT TUBERCULOSIS}},
Research-Areas = {{Nursing}},
Web-of-Science-Categories  = {{Nursing}},
Cited-References = {{CHAWLA PK, 1992, AM REV RESPIR DIS, V146, P280, DOI 10.1164/ajrccm/146.2.280.
   {*}CTR DIS CONTR, 1991, COR CURR TUB.
   FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801.
   HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410.
   MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65.
   SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011.
   1993, FED REGISTER, V58, P52809.
   1991, JAMA-J AM MED ASSOC, V266, P1483.}},
Number-of-Cited-References = {{8}},
Times-Cited = {{2}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Nurs. Clin. North Am.}},
Doc-Delivery-Number = {{QM061}},
Unique-ID = {{ISI:A1995QM06100004}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994PW85200006,
Author = {BAYOUMI, RAL and BABIKER, HA and ARNOT, DE},
Title = {{UPTAKE AND EFFLUX OF CHLOROQUINE BY CHLOROQUINE-RESISTANT
   PLASMODIUM-FALCIPARUM CLONES RECENTLY ISOLATED IN AFRICA}},
Journal = {{ACTA TROPICA}},
Year = {{1994}},
Volume = {{58}},
Number = {{2}},
Pages = {{141-149}},
Month = {{NOV}},
Abstract = {{In recently isolated African Plasmodium falciparum clones, the
   intracellular chloroquine concentration at steady-state, under standard
   culture conditions, could not differentiate chloroquine-sensitive from
   resistant parasites. However, under an atmosphere of air the
   chloroquine-resistant P. falciparum clones released pre-accumulated
   {[}H-3]chloroquine more rapidly than sensitive clones. The very fast
   efflux of the preaccumulated drag from chloroquine-resistant (CQR)
   parasites resulted in a differential in the drug retained by resistant
   and sensitive parasites. The chloroquine-sensitive parasites retained
   2-3 times more chloroquine than resistant parasites. The steady-state
   uptake of {[}H-3]chloroquine appeared to be enhanced by verapamil and
   desipramine in the chloroquine-resistant clones, while the opposite was
   observed with sensitive clones. This confirmed the suggestion that
   verapamil inhibits the rapid efflux in CQR parasites resulting in a
   readily detectable increase in chloroquine accumulation. These
   observations indicate that the biochemical phenotypes of African
   chloroquine-resistant P. falciparum are similar to those reported from
   S.E. Asia and Latin America and are consistent with a common molecular
   basis for the phenomenon.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{BAYOUMI, RAL (Reprint Author), UNITED ARAB EMIRATES UNIV, FAC MED \& HLTH SCI, DEPT BIOCHEM, POB 17666, AL AIN, U ARAB EMIRATES.
   UNIV EDINBURGH, INST CELL ANIM \& POPULAT BIOL, EDINBURGH, MIDLOTHIAN, SCOTLAND.
   UNIV KHARTOUM, FAC MED, KHARTOUM, SUDAN.}},
DOI = {{10.1016/0001-706X(94)90053-1}},
ISSN = {{0001-706X}},
EISSN = {{1873-6254}},
Keywords = {{PLASMODIUM FALCIPARUM; CHLOROQUINE RESISTANCE; AFRICAN CLONES}},
Keywords-Plus = {{DRUG-RESISTANCE; EASTERN SUDAN; GENETIC DIVERSITY; MALARIA;
   ERYTHROCYTES; VILLAGE; CULTURE; MODE; PH}},
Research-Areas = {{Parasitology; Tropical Medicine}},
Web-of-Science-Categories  = {{Parasitology; Tropical Medicine}},
ORCID-Numbers = {{Bayoumi, Riad/0000-0001-8177-8129}},
Funding-Acknowledgement = {{Wellcome Trust}},
Cited-References = {{BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P572, DOI 10.1016/0035-9203(91)90347-2.
   BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P578, DOI 10.1016/0035-9203(91)90349-4.
   BAYOUMI RA, 1989, ACTA TROP, V46, P157, DOI 10.1016/0001-706X(89)90032-6.
   BAYOUMI RAL, 1993, T ROY SOC TROP MED H, V87, P454, DOI 10.1016/0035-9203(93)90034-N.
   BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N.
   FERRARI V, 1991, BIOCHEM PHARMACOL, V42, P67.
   FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289.
   FITCH CD, 1983, CIBA F SYMP, V94, P222.
   FOOTE SJ, 1994, ACTA TROP, V56, P157, DOI 10.1016/0001-706X(94)90061-2.
   GEARY TG, 1986, BIOCHEM PHARMACOL, V35, P3805, DOI 10.1016/0006-2952(86)90668-4.
   GEARY TG, 1990, BIOCHEM PHARMACOL, V40, P685, DOI 10.1016/0006-2952(90)90302-2.
   GINSBURG H, 1988, PARASITOL TODAY, V4, P209, DOI 10.1016/0169-4758(88)90159-7.
   GINSBURG H, 1991, BIOCHEM PHARMACOL, V41, P1463, DOI 10.1016/0006-2952(91)90562-J.
   GINSBURG H, 1992, BIOCHEM PHARMACOL, V43, P63, DOI 10.1016/0006-2952(92)90662-3.
   GLUZMAN IY, 1990, AM J TROP MED HYG, V42, P521, DOI 10.4269/ajtmh.1990.42.521.
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0.
   JENSEN JB, 1977, J PARASITOL, V63, P883, DOI 10.2307/3279900.
   KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830.
   MESHNICK SR, 1990, PARASITOL TODAY, V6, P77, DOI 10.1016/0169-4758(90)90215-P.
   SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0.
   VERDIER F, 1985, ANTIMICROB AGENTS CH, V27, P561, DOI 10.1128/AAC.27.4.561.
   Warhurst D.C., 1988, Parasitology Today, V4, P211, DOI 10.1016/0169-4758(88)90160-3.
   YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Acta Trop.}},
Doc-Delivery-Number = {{PW852}},
Unique-ID = {{ISI:A1994PW85200006}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994PP79300006,
Author = {HERMANSSON, M and LINBERG, C},
Title = {{GENE-TRANSFER IN THE MARINE-ENVIRONMENT}},
Journal = {{FEMS MICROBIOLOGY ECOLOGY}},
Year = {{1994}},
Volume = {{15}},
Number = {{1-2}},
Pages = {{47-54}},
Month = {{NOV}},
Note = {{4th Symposium on Bacterial Genetics and Ecology, WAGENINGEN,
   NETHERLANDS, NOV 21-24, 1993}},
Abstract = {{This review summarises the literature on bacterial gene transfer in
   marine ecosystems. Relevant experiments carried out in model systems are
   also included. Prerequisites for the main gene transfer mechanisms,
   transformation, transduction and conjugation are discussed, such as
   concentrations of extracellular DNA in marine waters, numbers of
   bacteriophages in sea water and frequency of plasmids in marine
   bacteria. Transfer of chromosomal genes as well as plasmids are
   considered. We also discuss the possibility that gene transfer is more
   frequent in surface-associated bacterial communities. Examples of
   relevant studies using various solid surfaces and from the air-water
   interface are summarised. We suggest that there is a higher `flow-rate'
   of genetic information through surface-associated communities compared
   to bulk water communities.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{HERMANSSON, M (Reprint Author), GOTHENBURG UNIV,DEPT GEN \& MARINE MICROBIOL,MEDICINAREGATAN 9C,S-41390 GOTHENBURG,SWEDEN.}},
DOI = {{10.1111/j.1574-6941.1994.tb00228.x}},
ISSN = {{0168-6496}},
Keywords = {{GENE TRANSFER; BACTERIA; MARINE ENVIRONMENT; AIR-WATER INTERFACE; SOLID
   SURFACE; GMMO}},
Keywords-Plus = {{AIR-WATER-INTERFACE; NATURAL TRANSFORMATION; PLASMID TRANSFER;
   DRUG-RESISTANCE; AQUATIC ENVIRONMENTS; ESCHERICHIA-COLI; BACTERIA; DNA;
   SEDIMENT; VIBRIO}},
Research-Areas = {{Microbiology}},
Web-of-Science-Categories  = {{Microbiology}},
Cited-References = {{AARDEMA BW, 1983, APPL ENVIRON MICROB, V46, P417.
   ANGLES ML, 1993, APPL ENVIRON MICROB, V59, P843.
   BARNHARDT BJ, 1963, BIOCHIM BIOPHYS ACTA, V89, P25.
   BAROSS JA, 1978, APPL ENVIRON MICROB, V36, P492.
   BAYA AM, 1986, APPL ENVIRON MICROB, V51, P1285.
   BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0.
   BRADLEY DE, 1980, J BACTERIOL, V143, P1466.
   DEFLAUN MF, 1986, APPL ENVIRON MICROB, V52, P654.
   DELONG EF, 1993, LIMNOL OCEANOGR, V38, P924, DOI 10.4319/lo.1993.38.5.0924.
   FRISCHER ME, 1993, J GEN MICROBIOL, V139, P753, DOI 10.1099/00221287-139-4-753.
   FRY JC, 1990, BACTERIAL GENETICS N.
   GAUTHIER MJ, 1985, APPL ENVIRON MICROB, V50, P38.
   GOODMAN AE, 1994, FEMS MICROBIOL ECOL, V15, P55, DOI 10.1111/j.1574-6941.1994.tb00229.x.
   GOODMAN AE, 1993, APPL ENVIRON MICROB, V59, P1035.
   HADA HS, 1981, APPL ENVIRON MICROB, V41, P199.
   HARA T, 1981, AGR BIOL CHEM TOKYO, V11, P1104.
   HERMANSSON M, 1985, MICROB ECOL, V11, P91, DOI 10.1007/BF02010482.
   HERMANSSON M, 1983, MICROBIAL ECOL, V9, P317, DOI 10.1007/BF02019021.
   HERMANSSON M, 1987, APPL ENVIRON MICROB, V53, P2338.
   HERMANSSON M, 1990, BIOL PARTICLES AQUAT, P145.
   HUNTER KA, 1982, LIMNOL OCEANOGR, V27, P322, DOI 10.4319/lo.1982.27.2.0322.
   JEFFREY WH, 1990, MICROBIAL ECOL, V19, P259, DOI 10.1007/BF02017170.
   KEYNAN A, 1974, J VIROL, V14, P330.
   KJELLEBERG S, 1987, ANNU REV MICROBIOL, V41, P25, DOI 10.1146/annurev.mi.41.100187.000325.
   KOKJOHN TA, 1989, GENE TRANSFER ENV, P73.
   LEVY SB, 1989, GENE TRANSFER ENV.
   LORENZ MG, 1981, MAR BIOL, V64, P225, DOI 10.1007/BF00397113.
   LORENZ MG, 1987, APPL ENVIRON MICROB, V53, P2945.
   Paul JH, 1992, MOL ECOL, V1, P37, DOI 10.1111/j.1365-294X.1992.tb00153.x.
   PAUL JH, 1991, APPL ENVIRON MICROB, V57, P1509.
   PAUL JH, 1987, APPL ENVIRON MICROB, V53, P170.
   Power K., 1988, Biofouling, V1, P163.
   SANDAA RA, 1992, CAN J MICROBIOL, V38, P1061, DOI 10.1139/m92-174.
   SAYE DJ, 1987, APPL ENVIRON MICROB, V53, P987.
   SIMONSEN L, 1990, J GEN MICROBIOL, V136, P1001, DOI 10.1099/00221287-136-6-1001.
   SIZEMORE RK, 1977, ANTIMICROB AGENTS CH, V12, P373, DOI 10.1128/AAC.12.3.373.
   STEWART GJ, 1991, FEMS MICROBIOL ECOL, V85, P1.
   STEWART GJ, 1990, APPL ENVIRON MICROB, V56, P1818.
   STEWART GJ, 1992, GENETIC INTERACTIONS, P216.
   STEWART GJ, 1988, 1ST INT C REL GEN EN.
   STEWART KR, 1980, MAR POLLUT BULL, V11, P130, DOI 10.1016/0025-326X(80)90075-2.
   WELLINGTON EMH, 1992, GENETIC INTERACTIONS.
   WOMMACK KE, 1992, APPL ENVIRON MICROB, V58, P2965.
   WORTMAN AT, 1988, APPL ENVIRON MICROB, V54, P1284.}},
Number-of-Cited-References = {{44}},
Times-Cited = {{17}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{9}},
Journal-ISO = {{FEMS Microbiol. Ecol.}},
Doc-Delivery-Number = {{PP793}},
Unique-ID = {{ISI:A1994PP79300006}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994PQ41000017,
Author = {DANNENBERG, AM},
Title = {{ROLES OF CYTOTOXIC DELAYED-TYPE HYPERSENSITIVITY AND
   MACROPHAGE-ACTIVATING CELL-MEDIATED-IMMUNITY IN THE PATHOGENESIS OF
   TUBERCULOSIS}},
Journal = {{IMMUNOBIOLOGY}},
Year = {{1994}},
Volume = {{191}},
Number = {{4-5}},
Pages = {{461-473}},
Month = {{OCT}},
Note = {{Robert Koch Symposium 1993 on Progress in Tuberculosis Research, BERLIN,
   GERMANY, 1993}},
Abstract = {{The tubercle bacillus is a facultative intracellular parasite that grows
   well in non-activated macrophages. When large numbers of these bacilli
   have grown intracellularly within such macrophages, a cytotoxic immune
   response, herein called tissue-damaging (or necrotizing) delayed-type
   hypersensitivity (DTH), kills the macrophages (and usually some of the
   surrounding tissue), forming the caseous center of the developing
   tubercle. In solid caseum, tubercle bacilli may survive, but do not
   multiply.
   When bacilli escape from the edge of the caseum, they are rapidly
   ingested by nearby viable macrophages. If these macrophages have not
   been activated, the bacilli again multiply intracellularly, and the
   cytotoxic immune response kills the bacilli-laden macrophages (and
   surrounding tissue), thus enlarging the caseous center. In hosts that
   develop poor activation of macrophages, this process is repeated until
   much of the lung is destroyed.
   In hosts that can develop good activation of macrophages (by cytokines
   from antigen-specific T cells), herein called cell-mediated immunity
   (CMI), the caseous centers become surrounded by these activated
   macrophages, which ingest and destroy the bacilli escaping from the
   caseum. This process can arrest the disease.
   Unfortunately, the caseous center may liquefy in such resistant hosts.
   In the liquefied menstruum, the bacilli may grow extracellularly (for
   the first time during the course of the disease), reaching tremendous
   numbers. The cytotoxic immune response to these numerous bacilli and
   their tuberculin-like products causes much tissue necrosis, including
   erosion of the walls of small bronchi, which results in cavity
   formation. From such cavities, the bacilli spread to other parts of the
   lung and to the environment. The extracellular multiplication of
   tubercle bacilli in the liquefied caseum is the main reason why
   tuberculosis perpetuates itself in mankind. It is also the reason why
   antimicrobial drug-resistant bacillary strains develop.
   To elucidate the various mechanisms involved in macrophage activation,
   caseation, and liquefaction is a major challenge for tuberculosis
   researchers today.}},
Publisher = {{GUSTAV FISCHER VERLAG}},
Address = {{VILLENGANG 2, D-07745 JENA, GERMANY}},
Type = {{Article; Proceedings Paper}},
Language = {{English}},
Affiliation = {{DANNENBERG, AM (Reprint Author), JOHNS HOPKINS UNIV,SCH HYG \& PUBL HLTH,DEPT ENVIRONM HLTH SCI,615 N WOLFE ST,BALTIMORE,MD 21205, USA.
   JOHNS HOPKINS UNIV,SCH HYG \& PUBL HLTH,DEPT MOLEC MICROBIOL \& IMMUNOL,BALTIMORE,MD.
   JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205.}},
DOI = {{10.1016/S0171-2985(11)80452-3}},
ISSN = {{0171-2985}},
Keywords-Plus = {{EXPERIMENTAL AIRBORNE TUBERCULOSIS; HOST-PARASITE RELATIONSHIPS;
   GUINEA-PIGS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS;
   INFECTION}},
Research-Areas = {{Immunology}},
Web-of-Science-Categories  = {{Immunology}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI-27165]; NHLBI NIH HHS {[}HL-10342]; NIEHS NIH HHS
   {[}ES-03819]}},
Cited-References = {{BALASUBRAMANIAN V, 1992, INFECT IMMUN, V60, P4762.
   Dannenberg A.M., 1988, PULMONARY DISEASES D, V3, P1821.
   DANNENBERG AM, 1990, RES MICROBIOL, V141, P262.
   DANNENBERG AM, 1993, HOSP PRACT, V28, P51, DOI 10.1080/21548331.1993.11442738.
   DANNENBERG AM, 1989, REV INFECT DIS, V11, pS369.
   DANNENBERG AM, 1990, RES MICROBIOL, V141, P192, DOI 10.1016/0923-2508(90)90030-T.
   DANNENBERG AM, 1991, IMMUNOL TODAY, V12, P228, DOI 10.1016/0167-5699(91)90035-R.
   DANNENBERG AM, 1976, AM REV RESPIR DIS, V113, P257.
   DANNENBERG AM, 1993, HOSP PRACT, V28, P33.
   Dannenberg Arthur M. Jr., 1994, P459.
   Dannenberg Jr A. M., 1984, MICROBIOLOGY 1984, P344.
   Dannenberg Jr AM, 1994, TUBERCULOSIS, P17.
   Francis J., 1958, TUBERCULOSIS ANIMALS.
   LOCKSLEY RM, 1991, IMMUNOPARASITOL TODA, V3, pA58.
   Lurie M. B, 1964, RESISTANCE TUBERCULO.
   PAL PG, 1992, INFECT IMMUN, V60, P4781.
   PELLETIER M, 1982, J IMMUNOL, V129, P2179.
   SMITH DW, 1970, AM REV RESPIR DIS, V102, P937.
   STANFORD JL, 1990, VACCINE, V8, P525, DOI 10.1016/0264-410X(90)90002-4.
   WEISS C, 1953, AMA ARCH PATHOL, V55, P516.
   WIEGESHAUS EH, 1970, AM REV RESPIR DIS, V102, P422.
   YAMAMURA Y, 1974, AM REV RESPIR DIS, V109, P594.
   YAMAMURA Y, 1958, ADV TUBERC RES, V9, P13.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{69}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{Immunobiology}},
Doc-Delivery-Number = {{PQ410}},
Unique-ID = {{ISI:A1994PQ41000017}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994PB65500009,
Author = {SEGALMAURER, S and KALKUT, GE},
Title = {{ENVIRONMENTAL-CONTROL OF TUBERCULOSIS - CONTINUING CONTROVERSY}},
Journal = {{CLINICAL INFECTIOUS DISEASES}},
Year = {{1994}},
Volume = {{19}},
Number = {{2}},
Pages = {{299-308}},
Month = {{AUG}},
Abstract = {{The incidence of tuberculosis-and, more important, that of
   multidrug-resistant tuberculosis-have risen drastically in the past
   decade. Nosocomial outbreaks have alerted health-care workers to the
   hazards of the spread of tuberculosis. The use of environmental control
   modalities (e.g., ventilation, air filtration, and ultraviolet
   irradiation) and personal protective devices has been explored in the
   medical, legislative, and public forums. New regulations and legislation
   have created controversy over the recommendations and their
   interpretation. In this review we present the theory behind the rational
   selection of environmental-control modalities and personal protective
   devices. We also offer suggestions about the application of specific
   control techniques and the revision of existing facilities to comply
   with new standards.}},
Publisher = {{UNIV CHICAGO PRESS}},
Address = {{5720 S WOODLAWN AVE, CHICAGO, IL 60637}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{N CENT BRONX HOSP,MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,BRONX,NY 10467.}},
DOI = {{10.1093/clinids/19.2.299}},
ISSN = {{1058-4838}},
Keywords-Plus = {{HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS;
   ULTRAVIOLET AIR DISINFECTION; NOSOCOMIAL TRANSMISSION; EXOGENOUS
   REINFECTION; HIV-INFECTION; OUTBREAK; RISK; EPIDEMIOLOGY; PERFORMANCE}},
Research-Areas = {{Immunology; Infectious Diseases; Microbiology}},
Web-of-Science-Categories  = {{Immunology; Infectious Diseases; Microbiology}},
Cited-References = {{{[}Anonymous], 1993, ENFORCEMENT POLICY P.
   BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33.
   BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055.
   BROMBERG.B, 1969, AM REV RESPIR DIS, V99, P279.
   BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745.
   Cantazaro A, 1982, AM REV RESPIR DIS, V125, P559.
   CHEN CC, 1992, AM IND HYG ASSOC J, V53, P566, DOI 10.1202/0002-8894(1992)053<0566:APTFFA>2.0.CO;2.
   CHEN CC, 1990, AM IND HYG ASSOC J, V51, P632, DOI 10.1202/0002-8894(1990)051<0632:FALPCO>2.0.CO;2.
   COBLENTZ CW, 1957, REFRIGERATING AIR CO, V63, pA477.
   COLINS FM, 1971, APPL MICROBIOL, V21, P411.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DAVID HL, 1973, AM REV RESPIR DIS, V108, P1175.
   DAVIES WEA, 1971, J PHYS D APPL PHYS, V4, P318, DOI 10.1088/0022-3727/4/2/318.
   DAVIS WT, 1991, AM J INFECT CONTROL, V19, P16, DOI 10.1016/0196-6553(91)90156-7.
   DECKER HM, 1963, AM J PUBLIC HEALTH N, V53, P1982, DOI 10.2105/AJPH.53.12.1982.
   DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689.
   DIPERRI G, 1989, LANCET, V2, P1502.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312.
   GERBERDING JL, 1993, INFECT CONT HOSP EP, V14, P686.
   HATCH TF, 1961, BACTERIOL REV, V25, P237.
   HINDS WC, 1987, AM IND HYG ASSOC J, V48, P836, DOI 10.1202/0002-8894(1987)048<0836:PODRWF>2.0.CO;2.
   HOPEWELL PC, 1992, CLIN INFECT DIS, V15, P540, DOI 10.1093/clind/15.3.540.
   HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011.
   HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P4, DOI 10.1080/00039896.1968.10665007.
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286.
   HYATT E C, 1963, Am Ind Hyg Assoc J, V24, P295.
   ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251.
   JANSSEN JE, 1984, ANN AM C GOVT IND HY, V10, P59.
   LAROCCA PT, 1985, PHARM MANUFACTUR MAR, P47.
   LOUDON RG, 1967, AM REV RESPIR DIS, V95, P435.
   LOUDON RG, 1969, AM REV RESPIR DIS, V100, P165.
   LOWELL JD, 1988, ARCHIT DESIGN, P154.
   LOWRY PL, 1977, AM IND HYG ASSOC J, V38, P462, DOI 10.1080/0002889778507652.
   MACHER JM, 1993, INFECT CONT HOSP EP, V14, P723.
   Macher JM, 1992, APPL OCCUP ENV HYG, V7, P505.
   MALASKY C, 1990, AM REV RESPIR DIS, V142, P505, DOI 10.1164/ajrccm/142.3.505.
   MARIER RL, 1993, INFECT CONT HOSP EP, V14, P700.
   MCNALL PE, 1975, ARCH ENVIRON HEALTH, V30, P552, DOI 10.1080/00039896.1975.10666774.
   MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201.
   NAGY R, 1964, IND HYGIENE J, V25, P274.
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502.
   Nardell E. A., 1988, ARCHIT DESIGN, P296.
   NARDELL EA, 1993, INFECT CONT HOSP EP, V14, P681.
   NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302.
   NYKA W, 1962, AM REV RESPIR DIS, V85, P33.
   OPAL SM, 1986, J INFECT DIS, V153, P634, DOI 10.1093/infdis/153.3.634.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641.
   RHAME FS, 1984, AM J MED, V76, P42, DOI 10.1016/0002-9343(84)90243-2.
   RILEY RL, 1972, APPL MICROBIOL, V23, P1113.
   RILEY RL, 1974, AM J MED, V57, P466, DOI 10.1016/0002-9343(74)90140-5.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P208, DOI 10.1080/00039896.1971.10665834.
   RILEY RL, 1976, AM REV RESPIR DIS, V113, P413.
   RILEY RL, 1957, AM REV TUBERC PULM, V75, P420.
   RILEY RL, 1972, J CHRON DIS, V25, P421, DOI 10.1016/0021-9681(72)90204-4.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P551, DOI 10.1080/00039896.1971.10665899.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V22, P200, DOI 10.1080/00039896.1971.10665833.
   RILEY RL, 1962, AM REV RESPIR DIS, V85, P511.
   RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069.
   RILEY RL, 1971, ARCH ENVIRON HEALTH, V23, P35, DOI 10.1080/00039896.1971.10665951.
   RILEY RL, 1988, ARCHIT DESIGN, P174.
   RILEY RL, 1961, AIRBORNE INFECTION T, P126.
   SAMET J, 1987, AM REV RESPIR DIS, V137, P221.
   SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   SHERERTZ RJ, 1987, AM J MED, V83, P709, DOI 10.1016/0002-9343(87)90902-8.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   SOEIRO R, 1994, AIDS S1, V8, pS239.
   SPENDLOVE JC, 1983, PUBLIC HEALTH REP, V98, P229.
   STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a.
   SULTAN L, 1960, AM REV RESPIR DIS, V82, P358.
   Wells W. F., 1955, AIRBORNE CONTAGION.
   Wells WF, 1942, AM J HYG, V35, P97, DOI 10.1093/oxfordjournals.aje.a118789.
   Wells WF, 1938, AM J PUBLIC HEALTH N, V28, P343, DOI 10.2105/AJPH.28.3.343.
   Woods JE, 1988, ARCHIT DESIGN, P123.
   YEAGER H, 1967, AM REV RESPIR DIS, V95, P998.
   1990, MMWR-MORBID MORTAL W, V39, P1.
   1973, 209B GEN SERV ADM FE, P1.
   1972, NIOSH HSM73110009 NA.
   1993, FED REGISTER, V58, P52810.
   1991, HVAC1991 AM SOC HEAT.
   1980, AM NATIONAL STANDARD, P1.
   1987, GUIDELINES CONSTRUCT, P1.
   1990, AM REV RESPIR DIS, V142, P725.
   1990, USING UV RAD VENTILA, P1.
   1992, RECOMMENDED GUIDELIN, P1.
   1993, MMWR-MORBID MORTAL W, V42, P696.
   1967, AM REV RESPIR DIS, V96, P836.
   1988, IND VENTILATION MANU, P1.
   1973, IND ENV ITS EVALUATI, P95.
   1990, MMWR-MORBID MORTAL W, V39, P718.
   1988, 49 NAT SAN F NAT SAN, P1.
   1992, MMWR-MORBID MORTAL W, V41, P1.}},
Number-of-Cited-References = {{98}},
Times-Cited = {{35}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Clin. Infect. Dis.}},
Doc-Delivery-Number = {{PB655}},
Unique-ID = {{ISI:A1994PB65500009}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994NW79700006,
Author = {ADAL, KA and ANGLIM, AM and PALUMBO, CL and TITUS, MG and COYNER, BJ and
   FARR, BM},
Title = {{THE USE OF HIGH-EFFICIENCY PARTICULATE AIR-FILTER RESPIRATORS TO PROTECT
   HOSPITAL WORKERS FROM TUBERCULOSIS - A COST-EFFECTIVENESS ANALYSIS}},
Journal = {{NEW ENGLAND JOURNAL OF MEDICINE}},
Year = {{1994}},
Volume = {{331}},
Number = {{3}},
Pages = {{169-173}},
Month = {{JUL 21}},
Abstract = {{Background. After outbreaks of multidrug-resistant tuberculosis, the
   Centers for Disease Control and Prevention proposed the use of
   respirators with high-efficiency particulate air filters (HEPA
   respirators) as part of isolation precautions against tuberculosis,
   along with a respiratory-protection program for health care workers that
   includes medical evaluation, training, and tests of the fit of the
   respirators. Each HEPA respirator costs between \$7.51 and \$9.08, about
   10 times the cost of respirators currently used.
   Methods. We conducted a cost-effectiveness analysis using data from the
   University of Virginia Hospital on exposure to patients with
   tuberculosis and rates at which the purified-protein-derivative (PPD)
   skin test became positive in hospital workers. The costs of a
   respiratory-protection program were based on those of an existing
   program for workers dealing with hazardous substances.
   Results. During 1992, 11 patients with documented tuberculosis were
   admitted to our hospital. Eight of 3852 workers (0.2 percent) had PPD
   tests that became positive. Five of these conversions were believed to
   be due to the booster phenomenon; one followed unprotected exposure to a
   patient not yet in isolation; the other two occurred in workers who had
   never entered a tuberculosis isolation room. These data suggest that it
   will take more than one year for the use of HEPA respirators to prevent
   a single conversion of the PPD test. Assuming that one conversion is
   prevented per year, however, it would take 41 years at our hospital to
   prevent one case of occupationally acquired tuberculosis, at a cost of
   \$1.3 million to \$18.5 million.
   Conclusions. Given the effectiveness of currently recommended measures
   to prevent nosocomial transmission of tuberculosis, the addition of HEPA
   respirators would offer negligible protective efficacy at great cost.}},
Publisher = {{MASSACHUSETTS MEDICAL SOC}},
Address = {{WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV VIRGINIA, HLTH SCI CTR, CHARLOTTESVILLE, VA 22908 USA.}},
DOI = {{10.1056/NEJM199407213310306}},
ISSN = {{0028-4793}},
EISSN = {{1533-4406}},
Keywords-Plus = {{RESISTANT MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION;
   HIV-INFECTION; OUTBREAK; PERSONNEL; BACILLI; RISK}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}T32AI07046]}},
Cited-References = {{{[}Anonymous], 1993, MMWR-MORBID MORTAL W, V42, P1.
   ATUK N O, 1971, Journal of the American Medical Association, V218, P1795, DOI 10.1001/jama.218.12.1795.
   BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009.
   BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280.
   Centers for Disease Control, 1990, MMWR-MORBID MORTAL W, V39, P718.
   CRAVEN RB, 1975, ANN INTERN MED, V82, P628, DOI 10.7326/0003-4819-82-5-628.
   Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1.
   DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801.
   FRIEDEN TR, 1993, NEW ENGL J MED, V329, P148.
   GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245.
   GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802.
   HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204.
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286.
   KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RILEY LW, 1993, CLIN INFECT DIS, V17, pS442, DOI 10.1093/clinids/17.Supplement\_2.S442.
   WEISSLER JC, 1993, AM J MED SCI, V305, P52, DOI 10.1097/00000441-199301000-00009.
   1993, FED REGISTER, V58, P52810.
   1982, B WORLD HEALTH ORGAN, V60, P555.
   1991, MMWR-MORBID MORTAL W, V40, P585.
   1990, AM REV RESPIR DIS, V142, P725.
   1990, AM REV RESPIR DIS, V142, P1470.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{78}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{N. Engl. J. Med.}},
Doc-Delivery-Number = {{NW797}},
Unique-ID = {{ISI:A1994NW79700006}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994NR24400008,
Author = {VANEER, MY and KROON, FP and VANFURTH, R},
Title = {{PREVENTION OF NOSOCOMIAL SPREAD OF MULTIDRUG-RESISTANT TUBERCLE-BACILLI}},
Journal = {{NETHERLANDS JOURNAL OF MEDICINE}},
Year = {{1994}},
Volume = {{44}},
Number = {{6}},
Pages = {{220-226}},
Month = {{JUN}},
Abstract = {{Outbreaks of multidrug-resistant Mycobacterium tuberculosis
   (multidrug-resistant tuberculosis; MDR-TB have recently been reported in
   hospitals in the United States. Rapid spread of these bacilli and a high
   mortality among immunocompromised patients, i.e. HIV-infected
   individuals and AIDS patients, were observed. Factors that play a role
   in these outbreaks and the prevention of MDR-TB are discussed in this
   article. Awareness of a possible M. tuberculosis infection and the early
   introduction of measures to reduce the spread of these micro-organisms
   are steps that can prevent a nosocomial outbreak. The use of more rapid
   methods for culturing mycobacteria and determining their sensitivity to
   antimicrobial drugs can accelerate the diagnostic process and the
   recognition of multiresistance. In view of the poor results of treatment
   of MDR-TB, prevention should be the first requirement.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{UNIV HOSP LEIDEN,DEPT INFECT DIS,POB 9600,2300 RC LEIDEN,NETHERLANDS.}},
ISSN = {{0300-2977}},
Keywords = {{TUBERCULOSIS; DRUG RESISTANCE; HIV INFECTION; AIDS}},
Keywords-Plus = {{ULTRAVIOLET AIR DISINFECTION; HEALTH-CARE WORKERS;
   MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTION; TRANSMISSION; OUTBREAK;
   COMPLEX; GAMMA; RISK}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{BERMUDEZ LEM, 1988, J IMMUNOL, V140, P3006.
   Broekmans J F, 1993, Ned Tijdschr Geneeskd, V137, P636.
   BUSSILLO CP, 1992, CHEST, V102, P797.
   CHAWLA PK, 1992, AM REV RESPIR DIS, V146, P280, DOI 10.1164/ajrccm/146.2.280.
   CITRON KM, 1993, BRIT MED J, V306, P222, DOI 10.1136/bmj.306.6872.222.
   CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362.
   COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397.
   DAVID HL, 1980, CLIN CHEST MED, V1, P227.
   DIPERRI G, 1992, LANCET, V340, P682.
   DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   FELLA P, 1992, 8 INT C AIDS AMST, V2, pB99.
   FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184.
   FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177.
   HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051.
   ISEMAN MD, 1993, NEW ENGL J MED, V329, P784.
   JENNY E, 1992, 8 INT C AIDS 3 STD W, V2, pB101.
   LASLO A, 1983, J CLIN MICROBIOL, V18, P1335.
   MORRIS JT, 1992, CHEST, V102, P802, DOI 10.1378/chest.102.3.802.
   PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601.
   SQUIRES KE, 1992, J INFECT DIS, V166, P686, DOI 10.1093/infdis/166.3.686.
   STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a.
   TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767.
   Vandenbroucke-Grauls C M, 1993, Ned Tijdschr Geneeskd, V137, P642.
   VANKLINGEREN B, 1989, RIVM, P284.
   WADHAWAN D, 1993, 7TH P INT C AIDS FLO.
   1992, AM REV RESPIR DIS, V146, P1623.
   1988, MMWR-MORBID MORTAL W, V37, P663.
   1992, PREVENTIE BESMETTING.
   1991, MMWR-MORBID MORTAL W, V40, P585.
   1993, RICHTLIJNEN MET BETR.
   1992, CLIN PHARM, V11, P991.
   1992, CLIN PHARM, V11, P999.
   1986, AM REV RESPIR DIS, V134, P355.
   1992, CLIN PHARM, V11, P994.
   1993, MMWR-MORBID MORTAL W, V42, P1.
   1992, MMWR-MORBID MORTAL W, V41, P507.
   1992, MMWR-MORBID MORTAL W, V41, P1.}},
Number-of-Cited-References = {{40}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Neth. J. Med.}},
Doc-Delivery-Number = {{NR244}},
Unique-ID = {{ISI:A1994NR24400008}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994NT35600009,
Author = {WILKINS, D and WOOLCOCK, AJ and COSSART, YE},
Title = {{TUBERCULOSIS - MEDICAL-STUDENTS AT RISK}},
Journal = {{MEDICAL JOURNAL OF AUSTRALIA}},
Year = {{1994}},
Volume = {{160}},
Number = {{7}},
Pages = {{395-397}},
Month = {{APR 4}},
Abstract = {{In 1979 an outbreak of tuberculosis occurred in medical students at the
   University of Sydney. Eight of 35 Mantoux-negative students who attended
   the autopsy of an immunosuppressed patient with unsuspected active
   tuberculosis became infected and one developed clinical disease. A
   report of the incident was prepared for publication because it supported
   the then controversial University policy of recommending BCG vaccination
   to medical and dental students in a country where the reported
   prevalence of tuberculosis is very low. The report was never published,
   mainly in order to protect the privacy of the individual students
   involved, but also because it was felt by the administration of the time
   that it might undermine confidence in infection control procedures in
   the autopsy room.
   The original report, updated and reproduced here, suggested that
   tuberculosis might be an emerging nosocomial problem. This has been all
   too clearly realised since its re-emergence as an opportunistic
   infection in AIDS patients. Worldwide, the problem of antibiotic
   resistance in Mycobacterium tuberculosis(1,2) provides an added risk of
   a return to the situation which prevailed early this century when
   tuberculosis was a major occupational risk for young health care
   workers. Infection often restricted career choices, even in those whose
   disease was relatively benign. Our purpose in bringing this incident to
   light after so many years is to point out the relevance of the extensive
   studies of the problem which were conducted in the 1930s and 1940s to
   the current situation and to suggest that health care students are
   vulnerable to airborne infections as well as those spread by inoculation
   injuries. In retrospect, our 1979 conclusions about prospects for
   preventing nosocomial tuberculosis appear optimistic.}},
Publisher = {{AUSTRALASIAN MED PUBL CO LTD}},
Address = {{LEVEL 1, 76 BERRY ST, SYDNEY NSW 2060, AUSTRALIA}},
Type = {{Note}},
Language = {{English}},
Affiliation = {{UNIV SYDNEY,DEPT INFECT DIS,SYDNEY,NSW 2006,AUSTRALIA.
   UNIV SYDNEY,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA.
   UNIV SYDNEY,STUDENT HLTH SERV,SYDNEY,NSW 2006,AUSTRALIA.}},
ISSN = {{0025-729X}},
Keywords-Plus = {{OUTBREAK}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{ABRUZZI WA, 1953, NEW ENGL J MED, V248, P722, DOI 10.1056/NEJM195304232481705.
   ALPERSTEIN G, 1994, MED J AUSTRALIA, V160, P197.
   ALPERT ME, 1965, NEW ENGL J MED, V272, P718, DOI 10.1056/NEJM196504082721404.
   {[}Anonymous], 1993, MMWR, V42.
   BARRETTCONNOR E, 1979, JAMA-J AM MED ASSOC, V241, P33, DOI 10.1001/jama.241.1.33.
   BREAN HP, 1946, NEW ENGL J MED, V235, P315, DOI 10.1056/NEJM194609052351001.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377.
   EIKENHOFF TC, 1977, ANNU REV MED, V28, P411.
   ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537.
   Hetherington HW, 1935, ARCH INTERN MED, V55, P709, DOI 10.1001/archinte.1935.00160230002001.
   JONES JS, 1982, LANCET, V1, P1060.
   Koch R., 1882, BERL KLIN WOCHENSCHR, V19, P221.
   LEVY MH, 1993, MED J AUSTRALIA, V159, P840.
   MEADE GM, 1948, AM REV TUBERC PULM, V58, P675.
   1989, MMWR-MORBID MORTAL W, V38, P236.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{15}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Med. J. Aust.}},
Doc-Delivery-Number = {{NT356}},
Unique-ID = {{ISI:A1994NT35600009}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994NJ77000003,
Author = {CHEN, SK and VESLEY, D and BROSSEAU, LM and VINCENT, JH},
Title = {{EVALUATION OF SINGLE-USE MASKS AND RESPIRATORS FOR PROTECTION OF
   HEALTH-CARE WORKERS AGAINST MYCOBACTERIAL AEROSOLS}},
Journal = {{AMERICAN JOURNAL OF INFECTION CONTROL}},
Year = {{1994}},
Volume = {{22}},
Number = {{2}},
Pages = {{65-74}},
Month = {{APR}},
Abstract = {{Background: The recent increase in multidrug-resistant tuberculosis has
   spawned a major controversy concerning the degree of respiratory
   protection needed by health care workers, particularly during
   sputum-inducing procedures. The objective of this study was to measure
   the filtration efficiencies of a single-use submicron surgical mask, two
   disposable dust/mist respirators, a dust/mist/fume respirator, and a
   high-efficiency particulate air respirator against aerosolized
   mycobacteria. Facial fit was not addressed.
   Methods: In a specially designed enclosed test apparatus, an aerosol was
   generated with a Collison nebulizer from a known concentration of
   Mycobacteria chelonae, used as a surrogate for Mycobacterium
   tuberculosis. Aerosol concentrations were measured with Andersen
   samplers upstream and downstream of the test masks and respirators,
   which were heat sealed to a metal plate.
   Results: Mean efficiencies ranged from approximately 97\% for the
   surgical mask and a dust/mist respirator to more than 99.99\% for the
   high-efficiency particulate air respirator. Measurements of filter
   efficiency with an Aerodynamic Particle Sizer for the M. chelonae
   aerosol and independent challenge tests with latex spheres correlated
   closely with measurements of M. Chelonae collection efficiency
   determined with Andersen samplers.
   Conclusions: Analysis of variance and Tukey's method for multiple
   comparisons indicated that the dust/mist/fume respirator and the HEPA
   respirator collected M. chelonae with significantly greater efficiency
   than did either the surgical mask or the dust/mist respirator. Even the
   least efficient mask tested, however, had a filter efficiency of more
   than 97\% against particles averaging less than 1 mum in aerodynamic
   diameter.}},
Publisher = {{MOSBY-YEAR BOOK INC}},
Address = {{11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV MINNESOTA,SCH PUBL HLTH,DIV ENVIRONM \& OCCUPAT HLTH,BOX 807 MAYO,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455.}},
DOI = {{10.1016/0196-6553(94)90116-3}},
ISSN = {{0196-6553}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{67}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{10}},
Journal-ISO = {{Am. J. Infect. Control}},
Doc-Delivery-Number = {{NJ770}},
Unique-ID = {{ISI:A1994NJ77000003}},
DA = {{2018-08-13}},
}

@article{ ISI:A1994NE04600040,
Author = {GOBERT, JM and REMINGTON, KM and ZHU, YA and NORTH, TW},
Title = {{MULTIPLE-DRUG-RESISTANT MUTANTS OF FELINE IMMUNODEFICIENCY VIRUS
   SELECTED WITH 2',3'-DIDEOXYINOSINE ALONE AND IN COMBINATION WITH
   3'-AZIDO-3'-DEOXYTHYMIDINE}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{1994}},
Volume = {{38}},
Number = {{4}},
Pages = {{861-864}},
Month = {{APR}},
Abstract = {{Mutants of feline immunodeficiency virus (FIV) were selected in cell
   culture in the continuous presence of 10 muM (each)
   3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxyinosine (ddI). These
   mutants (AIR-1 and AIR-3) displayed a 13-fold resistance to AZT but had
   less than a 2-fold decrease in susceptibility to ddI. Interestingly, the
   AIR mutants were cross-resistant to phosphonoformate (PFA) and were
   hypersensitive to 2',3'-dideoxycytidine (ddC). Mutants of FIV were also
   selected in the presence of 10 muM ddI alone (DIS-1, DIS-2c), and these
   displayed a two- to fourfold decrease in susceptibility to ddI. Like the
   mutants selected with the combination of AZT plus ddI, DIS-1 and DIS-2c
   were cross-resistant to PFA and were hypersensitive to ddC. However,
   they remained as susceptible as wild-type FIV to AZT. Thus, the mutants
   selected with the combination of AZT plus ddI have phenotypes which
   reflect those obtained by selection with these drugs individually.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171}},
Type = {{Note}},
Language = {{English}},
Affiliation = {{UNIV MONTANA,DIV BIOL SCI,MISSOULA,MT 59812.}},
DOI = {{10.1128/AAC.38.4.861}},
ISSN = {{0066-4804}},
Keywords-Plus = {{REVERSE-TRANSCRIPTASE; IMMUNE DYSFUNCTION; CATS; INFECTION; VARIANTS;
   TYPE-1; MODEL}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
Funding-Acknowledgement = {{NIAID NIH HHS {[}AI28189]; NIGMS NIH HHS {[}GM15556-02]}},
Cited-References = {{ACKLEY CD, 1990, J VIROL, V64, P5652.
   BARLOUGH JE, 1993, ANTIVIR RES, V22, P259, DOI 10.1016/0166-3542(93)90036-I.
   BARLOUGH JE, 1991, J ACQ IMMUN DEF SYND, V4, P219.
   CRONN RC, 1992, BIOCHEM PHARMACOL, V44, P1375, DOI 10.1016/0006-2952(92)90539-U.
   ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1480, DOI 10.1128/AAC.37.7.1480.
   GAO Q, 1992, J VIROL, V66, P12.
   GAO Q, 1993, ANTIMICROB AGENTS CH, V37, P130, DOI 10.1128/AAC.37.1.130.
   ISHIDA T, 1990, JPN J VET SCI, V52, P645.
   NORTH TW, 1990, J BIOL CHEM, V265, P5121.
   NORTH TW, 1989, ANTIMICROB AGENTS CH, V33, P915, DOI 10.1128/AAC.33.6.915.
   NORTH TW, 1990, ANTIMICROB AGENTS CH, V34, P1505, DOI 10.1128/AAC.34.8.1505.
   NOVOTNEY C, 1990, AIDS, V4, P1213, DOI 10.1097/00002030-199012000-00005.
   PEDERSEN NC, 1991, J AM VET MED ASSOC, V199, P1298.
   PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650.
   REMINGTON KM, 1991, J VIROL, V65, P308.
   REMINGTON KM, 1994, J VIROL, V68, P632.
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788.
   TALBOTT RL, 1989, P NATL ACAD SCI USA, V86, P5743, DOI 10.1073/pnas.86.15.5743.
   TORTEN M, 1991, J VIROL, V65, P2225.
   YAMAMOTO JK, 1988, AM J VET RES, V49, P1246.
   ZHU Y, UNPUB.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{13}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{NE046}},
Unique-ID = {{ISI:A1994NE04600040}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:A1993MB17300015,
Author = {ZWEYGARTH, E and MOLOO, SK and KAMINSKY, R},
Title = {{TRYPANOSOMA-SIMIAE - IN-VITRO STUDIES ON DRUG SUSCEPTIBILITY}},
Journal = {{ACTA TROPICA}},
Year = {{1993}},
Volume = {{54}},
Number = {{3-4}},
Pages = {{301-308}},
Month = {{SEP}},
Abstract = {{Two Trypanosoma simiae stocks were initiated in culture with
   tsetse-derived metacyclics. They were propagated axenically as
   trypomastigote forms at 35-degrees-C in 4\% CO2 in air. Populations of
   trypanosomes were incubated with various concentrations of
   antitrypanosomal compounds. Growth was monitored after 24 h of
   incubation and the growth inhibition was calculated. Diminazene
   aceturate, quinapyramine sulphate, DL-alpha-difluoromethylomithine, and
   Ro 15-0216 showed activity against the stocks. Suramin and Mel Cy showed
   little effect upon the growth of the parasite populations. Isometamidium
   chloride gave questionable results in the 24 h growth inhibition test,
   but the results of a long-term viability assay indicated some degree of
   drug resistance (or drug tolerance). The results obtained herein
   correlate with observations obtained from in vivo studies in pigs. It is
   thus concluded that in many cases the cryptic nature of T. simiae rather
   than drug resistance is responsible for the failure of chemotherapy of
   simiaetrypanosomiasis in pigs.}},
Publisher = {{ELSEVIER SCIENCE BV}},
Address = {{PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{INT LAB RES ANIM DIS,NAIROBI,KENYA.
   KETRI,KIKUYU,KENYA.}},
DOI = {{10.1016/0001-706X(93)90102-H}},
ISSN = {{0001-706X}},
Keywords = {{TRYPANOSOMA-SIMIAE; TRYPOMASTIGOTE; IN-VITRO CULTIVATION; AXENIC
   CULTIVATION; DRUG SUSCEPTIBILITY; DIMINAZENE ACETURATE; ISOMETAMIDIUM
   CHLORIDE; QUINAPYRAMINE SULFATE; SURAMIN; MEL CY;
   DL-ALPHA-DIFLUOROMETHYLORNITHINE; DFMO; RO 15-0216}},
Keywords-Plus = {{DL-ALPHA-DIFLUOROMETHYLORNITHINE; SEMI-DEFINED MEDIUM; BLOOD-STREAM
   FORMS; BRUCEI-BRUCEI; NANNOMONAS SIMIAE; RO 15-0216; CULTIVATION;
   GAMBIENSE; EVANSI; PIGS}},
Research-Areas = {{Parasitology; Tropical Medicine}},
Web-of-Science-Categories  = {{Parasitology; Tropical Medicine}},
Cited-References = {{BALTZ T, 1985, EMBO J, V4, P1273.
   BAUER F, 1955, Z Tropenmed Parasitol, V6, P129.
   DENNIG HK, 1989, INT SCI COUNCIL TRYP, V115, P489.
   DUSZENKO M, 1985, J EXP MED, V162, P1256, DOI 10.1084/jem.162.4.1256.
   KAMINSKY R, 1989, ANTIMICROB AGENTS CH, V33, P881, DOI 10.1128/AAC.33.6.881.
   KAMINSKY R, 1989, EXP PARASITOL, V69, P281, DOI 10.1016/0014-4894(89)90074-X.
   MAHAGA MT, 1981, INT SCI COUNCIL TRYP, V112, P284.
   NOBLE NM, 1958, B EPIZOOT DIS AFR, V6, P379.
   Raynaud J. P., 1989, INT SCI COUNCIL TRYP, V115, P334.
   STEEL ED, 1968, INT SCI COUNCIL TRYP, V102, P119.
   Stephen L. E., 1960, Annals of Tropical Medicine and Parasitology, V54, P493.
   STEPHEN LE, 1966, REV SERIES COMMONWEA, V8, P33.
   VANNIEUWENHOVE S, 1985, T ROY SOC TROP MED H, V79, P692, DOI 10.1016/0035-9203(85)90195-6.
   WATSON H. J. C., 1958, ANN TROP MED AND PARASITOL, V52, P72.
   YABU Y, 1989, PARASITOL RES, V76, P93, DOI 10.1007/BF00930828.
   ZWEYGARTH E, 1990, TROP MED PARASITOL, V41, P208.
   ZWEYGARTH E, 1992, ACTA TROP, V52, P79, DOI 10.1016/0001-706X(92)90009-M.
   ZWEYGARTH E, 1990, ANN SOC BELG MED TR, V70, P269.
   ZWEYGARTH E, 1987, TROP MED PARASITOL, V38, P175.
   ZWEYGARTH E, 1991, ACTA TROP, V48, P223, DOI 10.1016/0001-706X(91)90050-T.
   ZWEYGARTH E, 1987, Z PARASITENKD, V73, P479.}},
Number-of-Cited-References = {{21}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Acta Trop.}},
Doc-Delivery-Number = {{MB173}},
Unique-ID = {{ISI:A1993MB17300015}},
DA = {{2018-08-13}},
}

@article{ ISI:A1993MD34300020,
Author = {BAUDON, D},
Title = {{MALARIA AND TRAVELERS - PRACTICAL ASPECTS}},
Journal = {{TROPICAL MEDICINE AND PARASITOLOGY}},
Year = {{1993}},
Volume = {{44}},
Number = {{3}},
Pages = {{246-249}},
Month = {{SEP}},
Abstract = {{As international air travel becomes more and more common, we are
   witnessing an increase in the incidence of imported malaria caused by
   Plasmodium falciparum, a fatal variety resistant to antimal-arial drugs.
   With the development of drug resistance, travelers can no longer rely on
   chemoprophylaxis alone for absolute protection against malaria; they
   need to take a number of complementary measures. The most important
   among these are steps to prevent mosquito bites (mosquito screens and
   nets impregnated with insecticide, insecticides and repellents in
   various formulations; nocturnal air-conditioning) which can be
   instituted anywhere. Chemoprophylaxis must be adapted in each case with
   regard to individual characteristics (laboratory and medical status),
   the drug used (contraindications, side effects) and the travel itinerary
   (departure date, places to be visited, duration of journey). The back-up
   treatment prescribed for a traveler before his departure is intended as
   cover in the event that the chemoprophylaxis used should prove to be
   ineffective. If people planning trips to malarious regions are to apply
   preventive measures, they have to be informed, aware and motivated.
   Information is an integral part of prevention. Objective, scientifically
   accurate information is provided by specialized centres and official
   bodies in the form of recommendations subject to regular updating. A
   recommendation of a nonmedical nature must be given by travel agents and
   tour operators, by airlines and shipping companies, embassies and
   consulates, and also by the media at peak periods of travel to the
   tropics. Information disseminated on this scale will produce the
   required degree of awareness, and the travelers targeted will then
   probably consult a doctor for the chemoprophylaxis they need.}},
Publisher = {{GEORG THIEME VERLAG KG}},
Address = {{RUDIGERSTR 14, D-70469 STUTTGART, GERMANY}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{BAUDON, D (Reprint Author), CIESPAC, POB 14513, Brazzaville, REP CONGO.}},
ISSN = {{0177-2392}},
Keywords-Plus = {{PROPHYLAXIS; MEFLOQUINE}},
Research-Areas = {{Parasitology; Tropical Medicine}},
Web-of-Science-Categories  = {{Parasitology; Tropical Medicine}},
Cited-References = {{BAUDON D, 1992, ANN SOC BELG MED TR, V72, P263.
   Bourgeade A, 1990, Med Trop (Mars), V50, P125.
   GENTILINI M, 1990, B ACAD NAT MED PARIS, V174, P147.
   HOFFMAN SL, 1991, JAMA-J AM MED ASSOC, V265, P398, DOI 10.1001/jama.265.3.398.
   LOBEL HO, 1991, JAMA-J AM MED ASSOC, V265, P361, DOI 10.1001/jama.265.3.361.
   PHILLIPSHOWARD PA, 1990, BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499.
   RINGWALD P, 1990, T ROY SOC TROP MED H, V84, P348, DOI 10.1016/0035-9203(90)90311-2.
   WERNSDORFER WH, 1990, MED TROP, V50, P120.
   1993, INT TRAVEL HLTH VACC.
   1992, ACTUALISATION RECOMM, V28, P127.
   1991, CONSEILS VOYAGEURS G.}},
Number-of-Cited-References = {{11}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Trop. Med. Parasitol.}},
Doc-Delivery-Number = {{MD343}},
Unique-ID = {{ISI:A1993MD34300020}},
DA = {{2018-08-13}},
}

@article{ ISI:A1993KV99100036,
Author = {SUMMERS, AO and WIREMAN, J and VIMY, MJ and LORSCHEIDER, FL and
   MARSHALL, B and LEVY, SB and BENNETT, S and BILLARD, L},
Title = {{MERCURY RELEASED FROM DENTAL SILVER FILLINGS PROVOKES AN INCREASE IN
   MERCURY-RESISTANT AND ANTIBIOTIC-RESISTANT BACTERIA IN ORAL AND
   INTESTINAL FLORAS OF PRIMATES}},
Journal = {{ANTIMICROBIAL AGENTS AND CHEMOTHERAPY}},
Year = {{1993}},
Volume = {{37}},
Number = {{4}},
Pages = {{825-834}},
Month = {{APR}},
Abstract = {{In a survey of 640 human subjects, a subgroup of 356 persons without
   recent exposure to antibiotics demonstrated that those with a high
   prevalence of Hg resistance in their intestinal floras were
   significantly more likely to also have resistance to two or more
   antibiotics. This observation led us to consider the possibility that
   mercury released from amalgam (''silver'') dental restorations might be
   a selective agent for both mercury- and antibiotic-resistant bacteria in
   the oral and intestinal floras of primates. Resistances to mercury and
   to several antibiotics were examined in the oral and intestinal floras
   of six adult monkeys prior to the installation of amalgam fillings,
   during the time they were in place, and after replacement of the amalgam
   fillings with glass ionomer fillings (in four of the monkeys). The
   monkeys were fed an antibiotic-free diet, and fecal mercury
   concentrations were monitored. There was a statistically significant
   increase in the incidence of mercury-resistant bacteria during the 5
   weeks following installation of the amalgam fillings and during the 5
   weeks immediately following their replacement with glass ionomer
   fillings. These peaks in incidence of mercury-resistant bacteria
   correlated with peaks of Hg elimination (as high as 1 mM in the feces)
   immediately following amalgam placement and immediately after
   replacement of the amalgam fillings. Representative mercury-resistant
   isolates of three selected bacterial families (oral streptococci,
   members of the family Enterobacteriaceae, and enterococci) were also
   resistant to one or more antibiotics, including ampicillin,
   tetracycline, streptomycin, kanamycin, and chloramphenicol. While such
   mercury- and antibiotic-resistant isolates among the staphylococci, the
   enterococci, and members of the family Enterobacteriaceae have been
   described, this is the first report of mercury resistance in the oral
   streptococci. Many of the enterobacterial strains were able to transfer
   mercury and antibiotic resistances together to laboratory bacterial
   recipients, suggesting that the loci for these resistances are
   genetically linked. Our findings indicate that mercury released from
   amalgam fillings can cause An enrichment of mercury resistance plasmids
   in the normal bacterial floras of primates. Many of these plasmids also
   carry antibiotic resistance, implicating the exposure to mercury from
   dental amalgams in an increased incidence of multiple antibiotic
   resistance plasmids in the normal floras of nonmedicated subjects.}},
Publisher = {{AMER SOC MICROBIOLOGY}},
Address = {{1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{SUMMERS, AO (Reprint Author), UNIV GEORGIA,DEPT MICROBIOL,ATHENS,GA 30602, USA.
   UNIV GEORGIA,DEPT STAT,ATHENS,GA 30602.
   UNIV CALGARY,HLTH SCI CTR,DEPT MED,CALGARY T2N 4N1,AB,CANADA.
   UNIV CALGARY,HLTH SCI CTR,DEPT MED PHYSIOL,CALGARY T2N 4N1,AB,CANADA.
   TUFTS UNIV,SCH MED,DEPT MOLEC BIOL \& MICROBIOL,BOSTON,MA 02111.}},
DOI = {{10.1128/AAC.37.4.825}},
ISSN = {{0066-4804}},
Keywords-Plus = {{ORGANOMERCURIAL LYASE; STAPHYLOCOCCUS-AUREUS; TOOTH FILLINGS; AIR
   MERCURY; PLASMID; AMALGAM; DNA}},
Research-Areas = {{Microbiology; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Microbiology; Pharmacology \& Pharmacy}},
ORCID-Numbers = {{Summers, Anne/0000-0003-4258-9696}},
Cited-References = {{BARKAY T, 1987, APPL ENVIRON MICROB, V53, P2725.
   Bauer J G, 1982, CDA J, V10, P47.
   BEGLEY TP, 1986, BIOCHEMISTRY-US, V25, P7186, DOI 10.1021/bi00370a063.
   BEGLEY TP, 1986, BIOCHEMISTRY-US, V25, P7192, DOI 10.1021/bi00370a064.
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513.
   BLOOM NS, 1983, MAR CHEM, V14, P49, DOI 10.1016/0304-4203(83)90069-5.
   BOYD ND, 1991, AM J PHYSIOL, V261, pR1010.
   COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050.
   CORPET DE, 1993, NEW ENGL J MED, V318, P1206.
   DANSCHER G, 1990, EXP MOL PATHOL, V52, P291, DOI 10.1016/0014-4800(90)90070-T.
   DRASAR BS, 1974, HUMAN INTESTINAL FLO.
   FRYKHOLM KD, 1957, ACTA ODONTOL SCA S22, V15, P84.
   GILBERT MP, 1988, PLASMID, V20, P127, DOI 10.1016/0147-619X(88)90015-7.
   GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I.
   HAHN LJ, 1990, FASEB J, V4, P3256.
   HAHN LJ, 1989, FASEB J, V3, P2641.
   HAMLETT NV, 1986, APPL ENVIRON MICROB, V52, P915.
   KHESIN RB, 1984, MOL GEN GENET, V197, P280, DOI 10.1007/BF00330974.
   LEVY SB, 1988, ANTIMICROB AGENTS CH, V32, P1801, DOI 10.1128/AAC.32.12.1801.
   MALMSTROM C, 1992, J TRACE ELEM EXP MED, V5, P122.
   MARSHALL B, 1981, MOL BIOL PATHOGENICI, P630.
   MILLAR MR, 1987, EPIDEMIOL INFECT, V99, P343, DOI 10.1017/S0950268800067819.
   MILLER RV, 1989, GENE TRANSFER ENV, P405.
   MISRA TK, 1992, PLASMID, V27, P4, DOI 10.1016/0147-619X(92)90002-R.
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064.
   OBRIEN TF, 1985, SCIENCE, V230, P87, DOI 10.1126/science.2994226.
   OBRIEN TF, 1991, APUA NEWS, V9, P1.
   PATTERSON JE, 1985, B ENVIRON CONTAM TOX, V34, P459, DOI 10.1007/BF01609761.
   PHILLIPS RW, 1982, SKINNERS SCI DENTAL, P348.
   PORTER FD, 1982, ANTIMICROB AGENTS CH, V22, P852, DOI 10.1128/AAC.22.5.852.
   REINHARDT JW, 1988, J PUBLIC HEALTH DENT, V48, P172, DOI 10.1111/j.1752-7325.1988.tb03188.x.
   ROLLAND RM, 1985, APPL ENVIRON MICROB, V49, P791.
   Snedecor G. W., 1980, STATISTICAL METHODS.
   SUMMERS AO, 1986, ANNU REV MICROBIOL, V40, P607, DOI 10.1146/annurev.micro.40.1.607.
   SUMMERS AO, 1992, J BACTERIOL, V174, P3097, DOI 10.1128/jb.174.10.3097-3101.1992.
   SUMMERS AO, 1978, MICROBIOLOGY 1978, P128.
   SUMMERS AO, UNPUB.
   SUMMERS AO, 1989, GENE TRANSFER ENV, P287.
   SUMMERS AO, IN PRESS 93RD GEN M.
   SVARE CW, 1981, J DENT RES, V60, P1668, DOI 10.1177/00220345810600090601.
   TYNECKA Z, 1981, J BACTERIOL, V147, P313.
   VIMY M J, 1990, Journal of Trace Elements in Experimental Medicine, V3, P111.
   VIMY MJ, 1985, J DENT RES, V64, P1069, DOI 10.1177/00220345850640080901.
   VIMY MJ, 1985, J DENT RES, V64, P1072, DOI 10.1177/00220345850640081001.
   1991, ENV HLTH CRITERIA, V118, P35.}},
Number-of-Cited-References = {{45}},
Times-Cited = {{145}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{Antimicrob. Agents Chemother.}},
Doc-Delivery-Number = {{KV991}},
Unique-ID = {{ISI:A1993KV99100036}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:A1993KG07700049,
Author = {MUSTONEN, P and KINNUNEN, PKJ},
Title = {{ON THE REVERSAL BY DEOXYRIBONUCLEIC-ACID OF THE BINDING OF ADRIMYCIN TO
   CARDIOLIPIN-CONTAINING LIPOSOMES}},
Journal = {{JOURNAL OF BIOLOGICAL CHEMISTRY}},
Year = {{1993}},
Volume = {{268}},
Number = {{2}},
Pages = {{1074-1080}},
Month = {{JAN 15}},
Abstract = {{The binding of the cytotoxin adriamycin (doxorubicin) to phospholipids,
   DNA, and RNA was investigated using (i) fluorescence quenching by this
   drug of liposomes containing pyrene-labeled phospholipids and (ii)
   monomolecular cardiolipin films on an air/water interface. In accordance
   with previous studies, our fluorescence experiments revealed that the
   acidic phospholipids, phosphatidylglycerol, phosphatidylmethanol, and
   phosphatidic acid all have high and comparable affinities to adriamycin
   mainly due to electrostatic interactions whereas binding to
   phosphatidylcholine was much weaker. Highest affinity, however, was
   possessed by cardiolipin. Addition of 4 mM CaCl2 reduced the binding of
   adriamycin to the above lipids. Moreover, in the presence of calcium the
   affinity of the drug to the different lipids was similar. Ca2+
   concentrations > 100 muM began to reverse the binding of adriamycin to
   cardiolipin-containing liposomes whereas lower concentrations had only
   an insignificant effect. The association of adriamycin with DNA, RNA,
   and cardiolipin was then compared by observing the reversal of the
   cytotoxin-cardiolipin association by nucleic acids. The affinity of
   adriamycin was found to decrease in the sequence DNA > cardiolipin > RNA
   with relative affinities of 7.8, 2.3, and 1, respectively. Penetration
   of the drug into cardiolipin monolayers spread on an air/water interface
   resulted in an increase in surface pressure pi whereas only a very weak
   increase was observed using dimyristoylphosphatidylcholine films.
   Removal of adriamycin from lipid monolayers was achieved by adding DNA
   into the aqueous subphase. Similar to the fluorescence quenching studies
   increase in pi after the inclusion of adriamycin into the aqueous
   subphase was significantly reduced in the presence of Ca2+
   concentrations > 100 muM, whereas lower concentrations had only an
   insignificant effect. Residual drug-phospholipid interactions in the
   lipid monolayer observed in the presence of Ca2+ were also reversed by
   DNA.}},
Publisher = {{AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC}},
Address = {{9650 ROCKVILLE PIKE, BETHESDA, MD 20814}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{UNIV HELSINKI, DEPT MED CHEM, SILTAVUORENPENGER 10A, SF-00170 HELSINKI 17, FINLAND.}},
ISSN = {{0021-9258}},
Keywords-Plus = {{MEMBRANE LIPID-PEROXIDATION; RESONANCE ENERGY-TRANSFER;
   MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; DNAA PROTEIN; TUMOR-CELLS;
   RAT-LIVER; PHOSPHATIDYLCHOLINE BILAYERS; MITOCHONDRIAL-MEMBRANES;
   ADRIAMYCIN RESISTANCE}},
Research-Areas = {{Biochemistry \& Molecular Biology}},
Web-of-Science-Categories  = {{Biochemistry \& Molecular Biology}},
Cited-References = {{BARABAS K, 1992, J BIOL CHEM, V267, P9437.
   BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2.
   BERMAN HM, 1981, ANNU REV BIOPHYS BIO, V10, P87, DOI 10.1146/annurev.bb.10.060181.000511.
   BURKE TG, 1985, BIOCHEMISTRY-US, V24, P1768, DOI 10.1021/bi00328a030.
   CANAVES JM, 1991, BIOCHEM J, V279, P413, DOI 10.1042/bj2790413.
   CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3927, DOI 10.1021/bi00260a004.
   CONSTANTINIDES PP, 1990, BIOPHYS CHEM, V35, P259, DOI 10.1016/0301-4622(90)80013-W.
   CONSTANTINIDES PP, 1986, J BIOL CHEM, V261, P196.
   DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3.
   DEWOLF FA, 1991, BIOCHIM BIOPHYS ACTA, V1096, P67.
   DIETEL M, 1990, CANCER RES, V50, P6100.
   DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210.
   DRAKE JM, 1991, SCIENCE, V251, P1574, DOI 10.1126/science.2011737.
   DUPOUCEZANNE L, 1989, EUR J BIOCHEM, V181, P695, DOI 10.1111/j.1432-1033.1989.tb14779.x.
   EILERS M, 1989, J BIOL CHEM, V264, P2945.
   ESCRIBA PV, 1990, BIOCHEMISTRY-US, V29, P7275, DOI 10.1021/bi00483a017.
   FAN D, 1990, CANCER RES, V50, P3619.
   FERRERMONTIEL AV, 1988, BIOCHIM BIOPHYS ACTA, V937, P379, DOI 10.1016/0005-2736(88)90260-X.
   FIALLO MML, 1986, BIOCHIM BIOPHYS ACTA, V854, P143.
   FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265.
   FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016.
   FREZARD F, 1991, BIOCHEMISTRY-US, V30, P5038, DOI 10.1021/bi00234a028.
   FULLFORD AJC, 1980, BIOCHIM BIOPHYS ACTA, V598, P237.
   Gianni L, 1983, REV BIOCHEM TOXICOL, V5, P1.
   GOORMAGHTIGH E, 1987, BIOCHEMISTRY-US, V26, P1789, DOI 10.1021/bi00380a043.
   GOORMAGHTIGH E, 1982, BIOCHEM BIOPH RES CO, V104, P314, DOI 10.1016/0006-291X(82)91976-3.
   GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5.
   GRIFFIN EA, 1986, BIOCHEMISTRY-US, V25, P7875, DOI 10.1021/bi00372a013.
   HENRY N, 1985, BIOCHEMISTRY-US, V24, P7085, DOI 10.1021/bi00346a010.
   HIRAI H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P191, DOI 10.1016/0167-4781(91)90054-P.
   HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9.
   HUART P, 1984, BIOCHIM BIOPHYS ACTA, V799, P199, DOI 10.1016/0304-4165(84)90296-4.
   HUBNER W, 1991, BIOCHIM BIOPHYS ACTA, V1066, P166, DOI 10.1016/0005-2736(91)90183-9.
   KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015.
   KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059.
   KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159.
   KONTTILA R, 1988, BIOCHEMISTRY-US, V27, P7443, DOI 10.1021/bi00419a040.
   LEMMETYINEN H, 1989, J PHYS CHEM-US, V93, P7170, DOI 10.1021/j100357a029.
   MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050.
   MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V857, P123, DOI 10.1016/0005-2736(86)90105-7.
   MIMNAUGH EG, 1985, BIOCHEM PHARMACOL, V34, P847, DOI 10.1016/0006-2952(85)90766-X.
   MIMNAUGH EG, 1985, CANCER RES, V45, P3296.
   MIMNAUGH EG, 1981, TOXICOL APPL PHARM, V61, P313, DOI 10.1016/0041-008X(81)90352-5.
   MIZUSHIMA T, 1992, BIOCHEM J, V285, P503, DOI 10.1042/bj2850503.
   MONTAUDON D, 1986, CANCER RES, V46, P5602.
   MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006.
   MUSTONEN P, 1991, J BIOL CHEM, V266, P6302.
   NEIDLE S, 1977, CANCER TREAT REP, V61, P928.
   NICOLAY K, 1987, BIOCHIM BIOPHYS ACTA, V892, P320, DOI 10.1016/0005-2728(87)90236-2.
   NICOLAY K, 1984, BIOCHIM BIOPHYS ACTA, V778, P359, DOI 10.1016/0005-2736(84)90380-8.
   NICOLAY K, 1985, BIOCHIM BIOPHYS ACTA, V819, P55, DOI 10.1016/0005-2736(85)90195-6.
   POHLE W, 1990, BIOPHYS CHEM, V35, P213, DOI 10.1016/0301-4622(90)80010-5.
   POSADA J, 1989, CANCER RES, V49, P6634.
   RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8.
   ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095.
   SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131.
   SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136.
   SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339.
   SIEGFRIED JM, 1983, CANCER BIOCHEM BIOPH, V6, P137.
   SINHA BK, 1984, CANCER RES, V44, P2892.
   STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131.
   TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249.
   THUREN T, 1990, CHEM PHYS LIPIDS, V53, P129, DOI 10.1016/0009-3084(90)90039-T.
   TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561.
   TSURUO T, 1983, CANCER RES, V43, P2905.
   YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305.
   YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202.
   YUSA K, 1989, CANCER RES, V49, P5002.
   ZWELLING LA, 1982, CANCER RES, V42, P2687.}},
Number-of-Cited-References = {{69}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Biol. Chem.}},
Doc-Delivery-Number = {{KG077}},
Unique-ID = {{ISI:A1993KG07700049}},
DA = {{2018-08-13}},
}

@article{ ISI:A1993MH45000001,
Author = {HEDIN, G},
Title = {{STAPHYLOCOCCUS-EPIDERMIDIS - HOSPITAL EPIDEMIOLOGY AND THE DETECTION OF
   METHICILLIN RESISTANCE}},
Journal = {{SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES}},
Year = {{1993}},
Number = {{90}},
Pages = {{3-59}},
Abstract = {{Infections in immunocompromised patients and in patients with indwelling
   prosthetic devices are often caused by hospital strains of
   Staphylococcus epidermidis resistant to methicillin.
   Tests for the detection of methicillin resistance, indicating resistance
   to all beta-lactam antibiotics, were evaluated in order to define a
   suitable screening test. A broth tube breakpoint test with a large
   inoculum, 107 colony forming units (cfu), gave the highest recovery of
   resistant strains. False resistance due to hyperproduction of
   beta-lactamase was excluded. The results correlated completely with the
   detection of the resistance gene, mecA, by the polymerase chain
   reaction. In 2/3 of the resistant strains tested the expression of the
   methicillin resistance was heterogeneous, only one cell in 10(2) to
   10(4) expressed the resistance within 72 h in broth. In broth screening
   tests an inoculum of at least 10(6) cfu therefore was required to detect
   all resistant strains within 24 h. Using agar dilution, 48 h incubation
   must be considered. In disc diffusion tests reliable results were
   obtained after only 16 h of incubation when discs containing cephradine
   5 and 30 mug, oxacillin 1 mug or cephalexin 30 gg were used, and the
   first disc is recommended for routine work.
   The epidemiology of S. epidermidis strains resistant to ciprofloxacin
   and/or gentamicin was studied in an isolation unit for patients
   undergoing bone marrow transplantation. Antibiograms and plasmids were
   used for typing and 31 such strains were found. Of 54 staff members 10
   were colonized in the nares only, two in the nares and perineum and one
   in the nares and stool. In ambient air and on the clothes of staff a few
   of the strains predominated quantitatively. These strains colonized the
   skin of some of the patients who seemed to be the main dispersers.
   Possible routes of cross-infection were indirect contact transfer via
   the hands and clothes of staff (82\% of the clothes were contaminated),
   and direct as well as indirect airborne transmission.
   To study the effects of chlorhexidine on skin bacteria, ten nurses
   washed one arm with chlorhexidine-detergent every morning for 3 weeks;
   the other arm served as control. The depression of the normal skin flora
   did nol lead to a colonization with more antibiotic-resistant hospital
   strains. During the wash period the counts of antibiotic-resistant S.
   epidermidis on the treated arms were significantly reduced compared with
   the control arms, as also were the number of different strains. However,
   some antibiotic-resistant strains could not be eradicated from the arms
   with chlorhexidine-detergent, probably because they colonized deeper
   layers of the skin. Many strains were only transient skin colonizers.
   In an experimental study, strains of S. epidermidis were inoculated on
   the skin of volunteers. An epidemic strain had an enhanced ability to
   colonize skin compared with non-epidemic strains, which may be of
   importance for its epidemic properties.}},
Publisher = {{SCANDINAVIAN UNIVERSITY PRESS}},
Address = {{PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO,
   NORWAY}},
Type = {{Review}},
Language = {{English}},
Affiliation = {{HEDIN, G (Reprint Author), UNIV HOSP UPPSALA,DEPT CLIN MICROBIOL,S-75185 UPPSALA,SWEDEN.}},
ISSN = {{0036-5548}},
Keywords = {{STAPHYLOCOCCUS-EPIDERMIDIS; METHICILLIN; RESISTANCE; CIPROFLOXACIN
   CROSS-INFECTION; AIRBORNE ROUTE; CLOTHES; BONE MARROW TRANSPLANTATION;
   CHLORHEXIDINE; SKIN}},
Keywords-Plus = {{COAGULASE-NEGATIVE STAPHYLOCOCCI; PROSTHETIC VALVE ENDOCARDITIS;
   PENICILLIN-BINDING PROTEIN; POLYMERASE CHAIN-REACTION; AMBULATORY
   PERITONEAL-DIALYSIS; CLINICALLY SIGNIFICANT STRAINS; BONE-MARROW
   TRANSPLANTATION; CEREBROSPINAL-FLUID SHUNTS; PLASMID-PATTERN-ANALYSIS;
   INTENSIVE-CARE UNIT}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Cited-References = {{ACAR JF, 1971, ANTIMICROB AGENTS CH, V10, P280.
   ALY R, 1976, APPL ENVIRON MICROB, V31, P931.
   Annear D I, 1968, Med J Aust, V1, P444.
   ARCHER GL, 1982, INFECT IMMUN, V35, P627.
   ARCHER GL, 1980, J INFECT DIS, V142, P725, DOI 10.1093/infdis/142.5.725.
   ARCHER GL, 1990, ANTIMICROB AGENTS CH, V34, P1720, DOI 10.1128/AAC.34.9.1720.
   ARCHER GL, 1983, J INFECT DIS, V147, P642, DOI 10.1093/infdis/147.4.642.
   ARCHER GL, 1978, ANTIMICROB AGENTS CH, V14, P353, DOI 10.1128/AAC.14.3.353.
   ARCHER GL, 1984, J INFECT DIS, V149, P913, DOI 10.1093/infdis/149.6.913.
   BABB JR, 1983, J HOSP INFECT, V4, P149, DOI 10.1016/0195-6701(83)90044-0.
   BARBER M, 1961, J CLIN PATHOL, V14, P385, DOI 10.1136/jcp.14.4.385.
   BARBER M, 1964, J GEN MICROBIOL, V35, P183, DOI 10.1099/00221287-35-2-183.
   BARRY AL, 1987, J CLIN MICROBIOL, V25, P1897.
   BAUMGART S, 1983, AM J DIS CHILD, V137, P461, DOI 10.1001/archpedi.1983.02140310043012.
   BENDER JW, 1980, JOHNS HOPKINS MED J, V146, P13.
   BENNETT PM, 1986, J ANTIMICROB CHEMOTH, V18, P123, DOI 10.1093/jac/18.Supplement\_C.123.
   BERRY AJ, 1986, ANTIMICROB AGENTS CH, V29, P748, DOI 10.1128/AAC.29.5.748.
   BIALKOWSKAHOBRZANSKA H, 1990, J CLIN MICROBIOL, V28, P269.
   BIRNBAUM D, 1991, INFECT CONT HOSP EP, V12, P319.
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513.
   BOR DH, 1983, REV INFECT DIS, V5, P885.
   BOYCE JM, 1990, J INFECT DIS, V161, P493, DOI 10.1093/infdis/161.3.493.
   BOYCE JM, 1984, J CLIN MICROBIOL, V19, P813.
   BOYCE JM, 1991, ANTIMICROB AGENTS CH, V35, P1495, DOI 10.1128/AAC.35.7.1495.
   BROWN DFJ, 1986, EUR J CLIN MICROBIOL, V5, P726, DOI 10.1007/BF02013313.
   BROWN E, 1989, J INFECT DIS, V160, P644, DOI 10.1093/infdis/160.4.644.
   BRUMFITT W, 1985, LANCET, V1, P1442.
   BRUN Y, 1978, J CLIN MICROBIOL, V8, P503.
   BUNT TJ, 1983, SURGERY, V93, P733.
   BURNIE JP, 1988, J CLIN PATHOL, V41, P103, DOI 10.1136/jcp.41.1.103.
   CANAWATI HN, 1982, ANTIMICROB AGENTS CH, V21, P173, DOI 10.1128/AAC.21.1.173.
   CARLOS CC, 1991, J HOSP INFECT, V19, P201, DOI 10.1016/0195-6701(91)90224-V.
   CHAMBERS HF, 1987, ANTIMICROB AGENTS CH, V31, P1982, DOI 10.1128/AAC.31.12.1982.
   CHAMBERS HF, 1987, ANTIMICROB AGENTS CH, V31, P1919, DOI 10.1128/AAC.31.12.1919.
   CHAMBERS HF, 1989, ANTIMICROB AGENTS CH, V33, P424, DOI 10.1128/AAC.33.4.424.
   CHRISTENSEN GD, 1982, INFECT IMMUN, V37, P318.
   CHRISTENSEN GD, 1983, J CLIN MICROBIOL, V18, P258.
   CLINK J, 1987, J MED MICROBIOL, V23, P41, DOI 10.1099/00222615-23-1-41.
   COOKSON BD, 1991, ANTIMICROB AGENTS CH, V35, P1997, DOI 10.1128/AAC.35.10.1997.
   COOKSON BD, 1992, J MED MICROBIOL, V36, P414, DOI 10.1099/00222615-36-6-414.
   COUDRON PE, 1986, J CLIN MICROBIOL, V24, P764.
   CROSSLEY KB, 1985, J HOSP INFECT, V6, P179.
   CULLIFORD AT, 1976, J THORAC CARDIOV SUR, V72, P714.
   DAVENPORT DS, 1986, J INFECT DIS, V153, P332, DOI 10.1093/infdis/153.2.332.
   DAVIES AJ, 1986, EUR J CLIN MICROBIOL, V5, P277, DOI 10.1007/BF02017781.
   DAVIES RR, 1962, LANCET, V2, P1295.
   De Lencastre H., 1993, European Journal of Clinical Microbiology and Infectious Diseases, V12, pS13.
   DELENCASTRE H, 1991, ANTIMICROB AGENTS CH, V35, P632, DOI 10.1128/AAC.35.4.632.
   DELEON SP, 1984, AM J MED, V77, P639, DOI 10.1016/0002-9343(84)90354-1.
   DESAXE MJ, 1981, ZENTRALBLATT BAK 1 S, V10.
   DIAZMITOMA F, 1987, J INFECT DIS, V156, P555.
   DILLON LK, 1984, J CLIN MICROBIOL, V19, P473.
   DRYDEN MS, 1992, J HOSP INFECT, V109, P97.
   DUNNE WM, 1987, PEDIATR INFECT DIS J, V6, P1031.
   EDMISTON CE, 1989, INFECT CONT HOSP EP, V10, P111.
   ETIENNE J, 1990, J MED MICROBIOL, V32, P115, DOI 10.1099/00222615-32-2-115.
   EVANS CA, 1980, J INVEST DERMATOL, V75, P140, DOI 10.1111/1523-1747.ep12521658.
   FASS RJ, 1986, ANTIMICROB AGENTS CH, V30, P545, DOI 10.1128/AAC.30.4.545.
   FREEMAN DJ, 1991, REV MED MICROBIOL, V2, P98.
   FREEMAN J, 1991, AM J EPIDEMIOL, V132, P1130.
   FREEMAN R, 1991, J MED MICROBIOL, V34, P245, DOI 10.1099/00222615-34-5-245.
   FRENCH GL, 1987, J ANTIMICROB CHEMOTH, V20, P599, DOI 10.1093/jac/20.4.599.
   GAHRNHANSEN B, 1982, SCAND J THORAC CARD, V16, P269.
   GEMMEL CG, 1990, REV MED MICROBIOL, P213.
   GIGER O, 1984, J CLIN MICROBIOL, V19, P68.
   GOERING RV, 1992, J CLIN MICROBIOL, V30, P577.
   HALL SL, 1991, PEDIATR INFECT DIS J, V10, P57, DOI 10.1097/00006454-199101000-00012.
   HAMBRAEU.A, 1973, J HYG-CAMBRIDGE, V71, P799, DOI 10.1017/S0022172400023068.
   HAMBRAEUS A, 1990, J HOSP INFECT, V16, P19, DOI 10.1016/0195-6701(90)90045-P.
   HAMBRAEUS A, 1973, J HYG-CAMBRIDGE, V71, P787, DOI 10.1017/S0022172400023056.
   HAMILTONMILLER JMT, 1985, J MED MICROBIOL, V19, P217, DOI 10.1099/00222615-19-2-217.
   HANSENNORD M, 1988, APMIS, V96, P133, DOI 10.1111/j.1699-0463.1988.tb05280.x.
   HARSTEIN AI, 1991, DIAGN MICROBIOL INFE, V14, P275.
   HARSTEINE AJ, 1987, J CLIN MICROBIOL, V25, P589.
   HARTMAN BJ, 1984, J BACTERIOL, V158, P513.
   HARTMAN BJ, 1986, ANTIMICROB AGENTS CH, V29, P85, DOI 10.1128/AAC.29.1.85.
   HERWALDT LA, 1992, INFECT CONT HOSP EP, V13, P86.
   HINDLER JA, 1985, J CLIN MICROBIOL, V21, P205.
   HIRAI Y, 1991, J HOSP INFECT, V19, P191, DOI 10.1016/0195-6701(91)90223-U.
   HORN WA, 1988, INFECT CONT HOSP EP, V9, P189.
   HOUANG ET, 1985, J HOSP INFECT, V8, P224.
   HOVELIUS B, 1984, REV INFECT DIS, V6, P328.
   ISHAK MA, 1985, J CLIN MICROBIOL, V22, P1025.
   IVERT TSA, 1984, CIRCULATION, V69, P223, DOI 10.1161/01.CIR.69.2.223.
   IZARD NC, 1992, J CLIN MICROBIOL, V30, P817.
   JARLOV JO, 1992, J MED MICROBIOL, V37, P195, DOI 10.1099/00222615-37-3-195.
   JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a.
   JOHN JF, 1980, ANTIMICROB AGENTS CH, V17, P179, DOI 10.1128/AAC.17.2.179.
   JOHNSON GM, 1986, INFECT IMMUN, V54, P13.
   JORGENSEN JH, 1991, INFECT CONT HOSP EP, V12, P14.
   KAMME C, 1981, CLIN ORTHOP RELAT R, V154, P201.
   KARCHMER AW, 1983, ANN INTERN MED, V98, P447, DOI 10.7326/0003-4819-98-4-447.
   KERNODLE DS, 1988, ANTIMICROB AGENTS CH, V32, P202, DOI 10.1128/AAC.32.2.202.
   KINGDOM JCP, 1983, J HOSP INFECT, V4, P75, DOI 10.1016/0195-6701(83)90069-5.
   KLIGMAN AM, 1976, J INVEST DERMATOL, V67, P160, DOI 10.1111/1523-1747.ep12513007.
   KLOOS WE, 1981, CAN J MICROBIOL, V27, P271, DOI 10.1139/m81-043.
   KLOOS WE, 1975, INT J SYST BACTERIOL, V25, P62, DOI 10.1099/00207713-25-1-62.
   KLOOS WE, 1975, APPL MICROBIOL, V30, P381.
   KNIGHT V, 1954, J CLIN INVEST, V33, P1190, DOI 10.1172/JCI102992.
   KOTILAINEN P, 1990, J CLIN MICROBIOL, V28, P2779.
   KOTILAINEN P, 1990, J INFECT DIS, V161, P41, DOI 10.1093/infdis/161.1.41.
   KOTILAINEN P, 1991, SCAND J INFECT DIS, V23, P325, DOI 10.3109/00365549109024318.
   KOTILAINEN P, 1991, J CLIN MICROBIOL, V29, P315.
   Lacey R W, 1984, Scand J Infect Dis Suppl, V42, P64.
   LAW D, 1992, J ANTIMICROB CHEMOTH, V30, P603, DOI 10.1093/jac/30.5.603.
   LIDWELL OM, 1971, J HYG-CAMB, V69, P113, DOI 10.1017/S002217240002132X.
   LIDWELL OM, 1975, J HYG-CAMBRIDGE, V75, P445, DOI 10.1017/S0022172400024505.
   LIDWELL OM, 1974, J APPL BACTERIOL, V37, P649, DOI 10.1111/j.1365-2672.1974.tb00489.x.
   LIDWELL OM, 1950, J HYG-CAMBRIDGE, V48, P21, DOI 10.1017/S0022172400014868.
   LIDWELL OM, 1972, LANCET, V1, P347.
   LIGOZZI M, 1991, ANTIMICROB AGENTS CH, V35, P575, DOI 10.1128/AAC.35.3.575.
   LOWBURY EJL, 1973, BRIT MED J, V1, P510, DOI 10.1136/bmj.1.5852.510.
   LOWY FD, 1983, ANN INTERN MED, V99, P834, DOI 10.7326/0003-4819-99-6-834.
   LOWY FD, 1983, J CLIN MICROBIOL, V18, P1122.
   LUDLAM HA, 1989, J MED MICROBIOL, V30, P161, DOI 10.1099/00222615-30-3-161.
   LUDLAM HA, 1989, J MED MICROBIOL, V30, P167, DOI 10.1099/00222615-30-3-167.
   MAKI D, 1984, AM J INFECT CONTROL, V12, P257.
   Maniatis T., 1982, MOL CLONING.
   MARPLES RR, 1969, APPL MICROBIOL, V18, P228.
   MARPLES RR, 1971, ARCH DERMATOL, V103, P148, DOI 10.1001/archderm.103.2.148.
   MARPLES RR, 1992, CURR OPIN INFECT DIS, V5, P530, DOI 10.1097/00001432-199208000-00006.
   MARPLES RR, 1980, INT C S SER R SOC ME, V23, P57.
   MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9.
   MASKELL R, 1974, LANCET, V1, P1155.
   MASSANARI RM, 1988, J INFECT DIS, V158, P702, DOI 10.1093/infdis/158.4.702.
   MAY KR, 1973, 6 INT S AER UTRECHT.
   MCDOUGAL LK, 1984, J CLIN MICROBIOL, V19, P482.
   MCDOUGAL LK, 1986, J CLIN MICROBIOL, V23, P832.
   MENZIES RE, 1987, ANTIMICROB AGENTS CH, V31, P42, DOI 10.1128/AAC.31.1.42.
   MICKELSEN PA, 1985, J INFECT DIS, V152, P50, DOI 10.1093/infdis/152.1.50.
   MILNE LM, 1987, J CLIN PATHOL, V40, P1178, DOI 10.1136/jcp.40.10.1178.
   MONTANARI MP, 1990, ANTIMICROB AGENTS CH, V34, P911, DOI 10.1128/AAC.34.5.911.
   MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319.
   MOUTON RP, 1984, EUR J CLIN MICROBIOL, V3, P144, DOI 10.1007/BF02014333.
   MUNSON DP, 1982, J PEDIATR-US, V101, P602, DOI 10.1016/S0022-3476(82)80718-X.
   MURAKAMI K, 1991, J CLIN MICROBIOL, V29, P2240.
   NOBLE WC, 1975, BRIT J DERMATOL, V93, P477, DOI 10.1111/j.1365-2133.1975.tb06527.x.
   Noble WC, 1974, MICROBIOLOGY HUMAN S.
   Nystrom B, 1981, J Hosp Infect, V2, P167, DOI 10.1016/0195-6701(81)90025-6.
   Ogston A., 1984, REV INFECT DIS, V6, P122, DOI DOI 10.1093/CLINIDS/6.1.122.PMID.
   OJAJARVI J, 1977, J HYG-CAMBRIDGE, V79, P107, DOI 10.1017/S0022172400052906.
   OLSSONLILJEQUIS.B, 1993, EUR J CLIN MICROBIOL, V12.
   OPPENHEIM BA, 1989, BRIT MED J, V299, P294, DOI 10.1136/bmj.299.6694.294.
   ORTQVIST A, 1987, EPIDEMIOL INFECT, V98, P231.
   PARISI JT, 1980, J INFECT DIS, V141, P637, DOI 10.1093/infdis/141.5.637.
   PARISI JT, 1985, MICROBIOL REV, V49, P126.
   PASCOLI L, 1986, EUR J CLIN MICROBIOL, V5, P669, DOI 10.1007/BF02013298.
   PETERS G, 1988, J ANTIMICROB CHEMOTH, V21, P139, DOI 10.1093/jac/21.suppl\_C.139.
   PETERS G, 1982, J INFECT DIS, V146, P479, DOI 10.1093/infdis/146.4.479.
   PFALLER M A, 1988, Clinical Microbiology Reviews, V1, P281.
   PFALLER MA, 1988, AM J CLIN PATHOL, V89, P120.
   PIERRE J, 1990, ANTIMICROB AGENTS CH, V34, P1691, DOI 10.1128/AAC.34.9.1691.
   POWELL M, 1987, J HOSP INFECT, V9, P48, DOI 10.1016/0195-6701(87)90095-8.
   PREDARI SC, 1991, ANTIMICROB AGENTS CH, V35, P2568, DOI 10.1128/AAC.35.12.2568.
   Price PB, 1938, J INFECT DIS, V63, P301, DOI 10.1093/infdis/63.3.301.
   RENAUD F, 1988, J CLIN MICROBIOL, V26, P1729.
   RICHARDSON JF, 1982, J MED MICROBIOL, V15, P475, DOI 10.1099/00222615-15-4-475.
   RICKETTS CR, 1951, CLIN SCI, V10, P89.
   ROSDAHL VT, 1990, APMIS, V98, P299, DOI 10.1111/j.1699-0463.1990.tb01036.x.
   RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6.
   RYLANDER M, 1991, SVENSKA LAKARESALLSK, P229.
   SANZEN L, 1988, J HOSP INFECT, V12, P103, DOI 10.1016/0195-6701(88)90132-6.
   SCHANZLIN DJ, 1980, BRIT J OPHTHALMOL, V64, P684, DOI 10.1136/bjo.64.9.684.
   Schleifer K. H., 1990, Journal of Applied Bacteriology Symposium Supplement, p9S.
   SCHLEIFER KH, 1975, INT J SYST BACTERIOL, V25, P50, DOI 10.1099/00207713-25-1-50.
   SCHLEIFER KH, 1986, BERGEYS MANUAL SYSTE, P999.
   SCHOENBAUM SC, 1975, J INFECT DIS, V131, P543, DOI 10.1093/infdis/131.5.543.
   SCHUMACHERPERDREAU F, 1988, EUR J CLIN MICROBIOL, V7, P270, DOI 10.1007/BF01963100.
   SELWYN S, 1972, BMJ-BRIT MED J, V1, P136, DOI 10.1136/bmj.1.5793.136.
   SHARPE AN, 1972, APPL MICROBIOL, V24, P175, DOI 10.1361/105497103770330811.
   SHETH NK, 1985, LANCET, V2, P1266.
   SIMPSON RA, 1986, J HOSP INFECT, V7, P108, DOI 10.1016/0195-6701(86)90053-8.
   SMITH JA, 1987, J CLIN MICROBIOL, V25, P1741.
   SPEERS R, 1969, LANCET, V2, P233.
   SPIERS ASD, 1990, J HYG CAMB, V84, P457.
   STEVENS DL, 1984, J CLIN MICROBIOL, V20, P977.
   STEWART GC, 1980, J BACTERIOL, V144, P1200.
   Sugarman B, 1989, Infect Dis Clin North Am, V3, P187.
   TALBOT HW, 1976, J CLIN MICROBIOL, V3, P519.
   TESCH W, 1988, ANTIMICROB AGENTS CH, V32, P1494, DOI 10.1128/AAC.32.10.1494.
   THORE M, 1990, EPIDEMIOL INFECT, V105, P95, DOI 10.1017/S0950268800047695.
   THORNSBERRY C, 1973, ANTIMICROB AGENTS CH, V4, P263, DOI 10.1128/AAC.4.3.263.
   THORNSBERRY C, 1983, J CLIN MICROBIOL, V18, P1084.
   TOMASZ A, 1991, ANTIMICROB AGENTS CH, V35, P124, DOI 10.1128/AAC.35.1.124.
   TOMASZ A, 1989, ANTIMICROB AGENTS CH, V33, P1869, DOI 10.1128/AAC.33.11.1869.
   UBUKATA K, 1990, ANTIMICROB AGENTS CH, V34, P170, DOI 10.1128/AAC.34.1.170.
   UBUKATA K, 1992, J CLIN MICROBIOL, V30, P1728.
   UBUKATA K, 1989, ANTIMICROB AGENTS CH, V33, P1624, DOI 10.1128/AAC.33.9.1624.
   UNAL S, 1992, J CLIN MICROBIOL, V30, P685.
   USHIJIMA T, 1984, CAN J MICROBIOL, V30, P647, DOI 10.1139/m84-096.
   UTSUI Y, 1985, ANTIMICROB AGENTS CH, V28, P397, DOI 10.1128/AAC.28.3.397.
   VALVANO MA, 1988, PEDIATR INFECT DIS J, V7, P116, DOI 10.1097/00006454-198802000-00010.
   VANDENBROEK PJ, 1985, BRIT MED J, V291, P949, DOI 10.1136/bmj.291.6500.949.
   VAZQUEZ GJ, 1980, ANTIMICROB AGENTS CH, V17, P280, DOI 10.1128/AAC.17.2.280.
   VERNON G N, 1976, Journal of Antimicrobial Chemotherapy, V2, P41, DOI 10.1093/jac/2.1.41.
   VONGRAEVENITZ A, 1992, CLIN MICROBIOL REV, V5, P36.
   WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503.
   WATANAKUNAKORN C, 1985, EUR J CLIN MICROBIOL, V4, P68, DOI 10.1007/BF02148668.
   WATSON JG, 1983, J CLIN PATHOL, V36, P683, DOI 10.1136/jcp.36.6.683.
   WATTS JL, 1991, J CLIN MICROBIOL, V29, P59.
   WILSON CR, 1978, APPL ENVIRON MICROB, V36, P368.
   WILSON WR, 1982, MAYO CLIN PROC, V57, P155.
   WILTON J, 1992, EUR J CLIN MICROBIOL, V11, P515, DOI 10.1007/BF01960806.
   WILTON J, 1991, J HOSP INFECT, V19, P287, DOI 10.1016/0195-6701(91)90250-C.
   WINSTON DJ, 1983, ARCH INTERN MED, V143, P32, DOI 10.1001/archinte.143.1.32.
   WOODS GL, 1986, J CLIN MICROBIOL, V24, P349.
   YAMANE N, 1991, DIAGN MICR INFEC DIS, V14, P451, DOI 10.1016/0732-8893(91)90073-O.
   YOUNGER JJ, 1987, J INFECT DIS, V156, P548, DOI 10.1093/infdis/156.4.548.
   1990, M2A4 NAT COMM CLIN L.
   1990, M4A2 NAT COMM CLIN L.}},
Number-of-Cited-References = {{210}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Scand. J. Infect. Dis.}},
Doc-Delivery-Number = {{MH450}},
Unique-ID = {{ISI:A1993MH45000001}},
DA = {{2018-08-13}},
}

@article{ ISI:A1992JF30400013,
Author = {ISEMAN, MD},
Title = {{A LEAP OF FAITH - WHAT CAN WE DO TO CURTAIL INTRAINSTITUTIONAL
   TRANSMISSION OF TUBERCULOSIS}},
Journal = {{ANNALS OF INTERNAL MEDICINE}},
Year = {{1992}},
Volume = {{117}},
Number = {{3}},
Pages = {{251-253}},
Month = {{AUG 1}},
Abstract = {{Large-scale, epidemic transmission of tuberculosis to patients,
   nonprofessional staff, nurses, and physicians has been documented
   recently in hospitals, clinics, acquired immunodeficiency syndrome
   (AIDS) residencies, and correctional facilities. Prominent factors in
   these outbreaks have included human immunodeficiency virus (HIV)
   infection and AIDS, delayed diagnosis of tuberculosis,
   multidrug-resistant strains of tuberculosis that resulted in protracted
   shedding of mycobacteria, and ventilation patterns in buildings that
   resulted in the accumulation of infectious particles. Multiple deaths
   from tuberculosis have resulted.
   Various strategies, including vaccines, masks, augmented ventilation,
   air filters, and ultraviolet irradiation have been proposed to control
   this situation. Although no well-controlled studies exist to document
   the utility of any of these modalities, ultraviolet germicidal
   irradiation seems both the best theoretical model and the most practical
   tactic. Ultraviolet systems should be widely deployed throughout
   high-risk institutions.}},
Publisher = {{AMER COLL PHYSICIANS}},
Address = {{INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA}},
Type = {{Editorial Material}},
Language = {{English}},
Affiliation = {{ISEMAN, MD (Reprint Author), NATL JEWISH CTR IMMUNOL \& RESP MED, DIV INFECT DIS, CLIN MYCOBACTERIOL SERV, 1400 JACKSON ST, DENVER, CO 80206 USA.
   UNIV COLORADO, SCH MED, DENVER, CO 80202 USA.}},
DOI = {{10.7326/0003-4819-117-3-251}},
ISSN = {{0003-4819}},
EISSN = {{1539-3704}},
Keywords = {{TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTION CONTROL;
   ULTRAVIOLET RAYS; CROSS INFECTION}},
Keywords-Plus = {{ULTRAVIOLET AIR DISINFECTION}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
Cited-References = {{CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DIPERRI G, 1989, LANCET, V2, P1502.
   EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302.
   Ferebee SH, 1969, ADV TUBERC RES, V17, P28.
   GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490.
   PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4.
   Riley R. L., 1961, AIRBORNE INFECTION T, P1961.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a.
   THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555.
   TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030.
   1991, MMWR, V40, P585.
   1980, B INT UNION TUBERC, V55, P14.
   1991, MMWR, V40, P129.
   1990, MMWR, V39, P1.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{52}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{Ann. Intern. Med.}},
Doc-Delivery-Number = {{JF304}},
Unique-ID = {{ISI:A1992JF30400013}},
DA = {{2018-08-13}},
}

@article{ ISI:A1992HW97200002,
Author = {EDLIN, BR and TOKARS, JI and GRIECO, MH and CRAWFORD, JT and WILLIAMS, J
   and SORDILLO, EM and ONG, KR and KILBURN, JO and DOOLEY, SW and CASTRO,
   KG and JARVIS, WR and HOLMBERG, SD},
Title = {{AN OUTBREAK OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG
   HOSPITALIZED-PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME}},
Journal = {{NEW ENGLAND JOURNAL OF MEDICINE}},
Year = {{1992}},
Volume = {{326}},
Number = {{23}},
Pages = {{1514-1521}},
Month = {{JUN 4}},
Abstract = {{Background. Since 1990 several clusters of multidrug-resistant
   tuberculosis have been identified among hospitalized patients with the
   acquired immunodeficiency syndrome (AIDS). We investigated one such
   cluster in a voluntary hospital in New York.
   Methods. We compared exposures among 18 patients with AIDS in whom
   tuberculosis resistant to isoniazid and streptomycin was diagnosed from
   January 1989 through April 1990 (the case patients) with exposures among
   30 control patients who had AIDS and tuberculosis susceptible to
   isoniazid, streptomycin, or both. We also compared exposures among the
   14 case patients hospitalized during the six months before the diagnosis
   of tuberculosis (the exposure period) with those among 44 control
   patients with AIDS matched for duration of hospitalization.
   Mycobacterium tuberculosis isolates were typed with analysis of
   restriction-fragment-length polymorphism (RFLP).
   Results. Case patients with drug-resistant tuberculosis were
   significantly more likely than controls with drug-susceptible
   tuberculosis to have been hospitalized during their exposure periods (14
   of 18 vs. 10 of 30) (odds ratio, 7.0; 95 percent confidence interval,
   1.6 to 36; P = 0.006). Case patients hospitalized during their exposure
   periods were significantly more likely to have been hospitalized on the
   same ward as a patient with infectious drug-resistant tuberculosis than
   were either controls with drug-susceptible tuberculosis hospitalized
   during their exposure periods or controls matched for duration of
   hospitalization (13 of 14 vs. 2 of 10 and 23 of 44) (odds ratio, 52; 95
   percent confidence interval, 3.1 to 2474; P < 0.001; and odds ratio,
   infinity; 95 percent confidence interval, 2.4 to infinity; P = 0.005,
   respectively). Among those hospitalized on the same ward, the rooms of
   case patients were closer to that of the nearest patient with infectious
   tuberculosis than were the rooms of controls matched for duration of
   hospitalization. M. tuberculosis isolates from 15 of 16 case patients
   had identical patterns on RFLP analysis. Of 16 patients' rooms tested
   with air-flow studies, only 1 had the recommended negative-pressure
   ventilation.
   Conclusions. Multidrug-resistant tuberculosis is readily transmitted
   among hospitalized patients with AIDS. Physicians must be alert to this
   danger and must enforce adherence to the measures recommended to prevent
   nosocomial transmission of tuberculosis.}},
Publisher = {{MASS MEDICAL SOC}},
Address = {{10 SHATTUCK, BOSTON, MA 02115}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{EDLIN, BR (Reprint Author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-45,ATLANTA,GA 30333, USA.
   CTR DIS CONTROL,HOSP INFECT PROGRAM,ATLANTA,GA 30333.
   CTR DIS CONTROL,NATL CTR INFECT DIS DIV BACTERIAL \& MYCOT DIS,ATLANTA,GA 30333.
   CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333.
   COLUMBIA UNIV COLL PHYS \& SURG,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032.}},
DOI = {{10.1056/NEJM199206043262302}},
ISSN = {{0028-4793}},
Keywords-Plus = {{VIRUS-INFECTION; ASSOCIATION; SHELTER}},
Research-Areas = {{General \& Internal Medicine}},
Web-of-Science-Categories  = {{Medicine, General \& Internal}},
ORCID-Numbers = {{Edlin, Brian/0000-0001-8172-8797}},
Cited-References = {{BARNES PF, 1991, NEW ENGL J MED, V324, P1644.
   BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393.
   CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q.
   DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404.
   DESPREZ RM, 1990, PRINCIPLES PRACTICE, P1881.
   DIPERRI G, 1989, LANCET, V2, P1502.
   ISEMAN MD, 1989, CLIN CHEST MED, V10, P341.
   Kent PT, 1985, PUBLIC HLTH MYCOBACT, P159.
   LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8.
   MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c.
   MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798.
   MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K.
   PELLETIER AR, 1991, 40TH ANN C EP INT SE, P43.
   SALOMON N, 1991, 31ST INT C ANT AG CH, P152.
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901.
   SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007.
   TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030.
   VALWAY SE, 1992, 41ST ANN C EP INT SE, P30.
   1985, MMWR, V34, P429.
   1991, MMWR, V40, P585.
   1986, AM REV RESPIR DIS, V134, P355.
   1991, MMWR, V40, P129.
   1990, MMWR S, V39, pRR17.}},
Number-of-Cited-References = {{23}},
Times-Cited = {{717}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{13}},
Journal-ISO = {{N. Engl. J. Med.}},
Doc-Delivery-Number = {{HW972}},
Unique-ID = {{ISI:A1992HW97200002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1992HQ41700018,
Author = {KOPFMAIER, P and KOLON, B},
Title = {{AN ORGANOID CULTURE ASSAY (OCA) FOR DETERMINING THE DRUG SENSITIVITY OF
   HUMAN TUMORS}},
Journal = {{INTERNATIONAL JOURNAL OF CANCER}},
Year = {{1992}},
Volume = {{51}},
Number = {{1}},
Pages = {{99-107}},
Month = {{APR 22}},
Abstract = {{A model for testing chemotherapeutic agents in vitro is described. It is
   based on an organoid culture method which allows human carcinomas to
   grow in vitro and to maintain many typical in vivo properties, including
   3-dimensional architecture, growth of multiple cell types, expression of
   morphological differentiation and formation of histotypical structures.
   The preservation of drug sensitivity and resistance under the conditions
   of our organoid culture assay (OCA) was demonstrated by investigating 3
   strains of a human hypopharynx carcinoma which differed by different
   sensitivity to cisplatin in in vivo conditions. These differences were
   retained in vitro and the modified neutral-red (NR) assay was especially
   suitable for revealing drug-induced cytotoxic damage in OCA. On the
   basis of our findings, the following approach is proposed for the in
   vitro testing of cytostatic drugs before they are administered to
   patients. (1) Removal of carcinomas from patients; (2) dense cell
   suspensions of these carcinomas to be dropped on membrane filters at the
   air-medium interface, resulting in growth of solid nodules of organized
   carcinoma tissues; (3) addition of cytostatic drugs to the growth medium
   for 2 or 3 days; (4) detachment and bisection of the culture nodules;
   (5) determination of viable cells by NR uptake and total cell mass by
   the sulforhodamin B (SRB) assay; (6) determination of quotient NR:SRB
   absorbance, related as percentage to control value: this indicates the
   fraction of viable cells and gives a measure of the cytotoxic injury
   caused by the applied cytotoxic drug. Thus, the OCA seems to be suitable
   for defining the patterns of drug sensitivity and resistance of
   individual human carcinomas in vitro within a few days.}},
Publisher = {{WILEY-LISS}},
Address = {{DIV JOHN WILEY \& SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{KOPFMAIER, P (Reprint Author), FREE UNIV BERLIN,INST ANAT,KONIGIN LUISE STR 15,W-1000 BERLIN 33,GERMANY.}},
DOI = {{10.1002/ijc.2910510119}},
ISSN = {{0020-7136}},
Keywords-Plus = {{SCREENING SYSTEM; ANTICANCER DRUGS; INVITRO; GROWTH; CANCER; COLLAGEN;
   CELLS; MODEL}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3.
   BRAAKHUSI BBJ, 1985, HEAD NECK CANCER, V1, P421.
   DAIDONE MG, 1987, INVEST NEW DRUG, V5, P245.
   DURAND R E, 1990, British Journal of Cancer, V62, P947, DOI 10.1038/bjc.1990.415.
   DURKIN WJ, 1979, CANCER RES, V39, P402.
   FIEBIG HH, 1984, BEHRING I MITT, V74, P434.
   FREEMAN AE, 1986, P NATL ACAD SCI USA, V83, P2694, DOI 10.1073/pnas.83.8.2694.
   JACKEL M, 1991, CANCER CHEMOTH PHARM, V27, P464, DOI 10.1007/BF00685161.
   KAO JWY, 1989, CANCER INVEST, V7, P303, DOI 10.3109/07357908909039855.
   KOFPMAIER P, 1991, CELL TISSUE RES, V266, P563.
   KOPFMAIER P, 1991, CELL TISSUE RES, V264, P563, DOI 10.1007/BF00319046.
   KOPFMAIER P, 1990, ANTICANCER RES, V10, P161.
   LAWSON AH, 1986, J UROLOGY, V135, P1061, DOI 10.1016/S0022-5347(17)45975-1.
   MILLER BE, 1985, CANCER RES, V45, P4200.
   MINAFRA IP, 1986, J SUBMICR CYTOL PATH, V18, P795.
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757.
   ROSENBERG B, 1979, CANCER TREAT REP, V63, P1433.
   SALMON SE, 1984, CANCER TREAT REP, V68, P117.
   SALMON SE, 1980, CLONING HUMAN TUMOR, P223.
   SCHEITHAUER W, 1986, CANCER RES, V46, P2703.
   SHEA WK, 1989, PROSTATE, V15, P157, DOI 10.1002/pros.2990150209.
   SHOEMAKER RH, 1984, BEHRING I MITT, V74, P262.
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107.
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290.
   ZIMMERMANN B, 1987, DIFFERENTIATION, V36, P86, DOI 10.1111/j.1432-0436.1987.tb00183.x.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{10}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{3}},
Journal-ISO = {{Int. J. Cancer}},
Doc-Delivery-Number = {{HQ417}},
Unique-ID = {{ISI:A1992HQ41700018}},
DA = {{2018-08-13}},
}

@article{ ISI:A1992HQ39700007,
Author = {KOPFMAIER, P},
Title = {{A NEW APPROACH FOR REALIZING THE ANTIONCOGRAM}},
Journal = {{LIFE SCIENCES}},
Year = {{1992}},
Volume = {{50}},
Number = {{22}},
Pages = {{1711-1718}},
Abstract = {{On the basis of an organoid culture method which allows organoid
   reorganization and histotypical growth of human carcinomas under in
   vitro conditions, we propose in the present study an organoid culture
   assay (OCA) as ``antioncogram{''}, i.e., as in vitro model for testing
   the drug sensitivity and resistance of individual patients' carcinomas
   previous to clinical chemotherapy. At the beginning of the assay,
   specimens of human carcinomas are disaggregated to dense single cell
   suspensions and dropped on a filter sheet at the air-medium interface.
   Organoid culture nodules develop within several days to weeks. They are
   exposed to cytostatics by adding the drugs for 2-3 days to the growth
   medium below the filter sheet. At the end of the exposure period, the
   cytotoxic effects are estimated by determining the fraction of viable
   cells, measured by the uptake of neutral red in relation to the total
   cell mass. In the present study we could show that this assay actually
   reflects the different levels of experimentally induced resistance of
   three human carcinoma strains of an epidermoid hypopharynx carcinoma to
   the cytostatic drug cisplatin and is obviously suited to predict the
   response of individual human carcinomas to chemotherapy in a rapid and
   feasible manner.}},
Publisher = {{PERGAMON-ELSEVIER SCIENCE LTD}},
Address = {{THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{KOPFMAIER, P (Reprint Author), FREE UNIV BERLIN,INST ANAT,KONIGIN LUISE STR 15,W-1000 BERLIN 33,GERMANY.}},
DOI = {{10.1016/0024-3205(92)90426-P}},
ISSN = {{0024-3205}},
Keywords-Plus = {{HUMAN-TUMORS; ASSAY; INVITRO; GROWTH; TOXICITY; CULTURE; LINES; CELLS}},
Research-Areas = {{Research \& Experimental Medicine; Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Medicine, Research \& Experimental; Pharmacology \& Pharmacy}},
Cited-References = {{BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3.
   BORENFREUND E, 1984, J TISSUE CULTURE MET, V9, P7.
   BORG M, 1984, SABOURAUDIA, V22, P357.
   DAIDONE MG, 1987, INVEST NEW DRUG, V5, P245.
   DURAND R E, 1990, British Journal of Cancer, V62, P947, DOI 10.1038/bjc.1990.415.
   DURKIN WJ, 1979, CANCER RES, V39, P402.
   FREEMAN AE, 1986, P NATL ACAD SCI USA, V83, P2694, DOI 10.1073/pnas.83.8.2694.
   HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061.
   HOLMSTROM T, 1975, HUMAN TUMOR CELLS IN, P161.
   JACKEL M, 1991, CANCER CHEMOTH PHARM, V27, P464, DOI 10.1007/BF00685161.
   KOPFMAIER P, 1991, CELL TISSUE RES, V264, P563, DOI 10.1007/BF00319046.
   LAWSON AH, 1986, J UROLOGY, V135, P1061, DOI 10.1016/S0022-5347(17)45975-1.
   MILLER BE, 1985, CANCER RES, V45, P4200.
   MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757.
   ROFSTAD EK, 1985, RADIAT RES, V102, P324, DOI 10.2307/3576708.
   RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113.
   SALMON SE, 1984, CANCER TREAT REP, V68, P117.
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107.
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290.
   VESCIO RA, 1987, P NATL ACAD SCI USA, V84, P5029, DOI 10.1073/pnas.84.14.5029.
   VESCIO RA, 1990, P NATL ACAD SCI USA, V87, P691, DOI 10.1073/pnas.87.2.691.
   WOLFF E, 1975, HUMAN TUMOR CELLS IN, P207.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{4}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Life Sci.}},
Doc-Delivery-Number = {{HQ397}},
Unique-ID = {{ISI:A1992HQ39700007}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991GN19200002,
Author = {SAKATA, K and KWOK, TT and MURPHY, BJ and LADEROUTE, KR and GORDON, GR
   and SUTHERLAND, RM},
Title = {{HYPOXIA-INDUCED DRUG-RESISTANCE - COMPARISON TO
   P-GLYCOPROTEIN-ASSOCIATED DRUG-RESISTANCE}},
Journal = {{BRITISH JOURNAL OF CANCER}},
Year = {{1991}},
Volume = {{64}},
Number = {{5}},
Pages = {{809-814}},
Month = {{NOV}},
Abstract = {{In this report, we investigate several examples of hypoxia-induced drug
   resistance and compare them with P-glycoprotein associated multidrug
   resistance (MDR).  EMT6/Ro cells exposed to drugs in air immediately
   after hypoxic treatment developed resistance to adriamycin,
   5-fluorouracil, and actinomycin D.  However, these cells did not develop
   resistance to colchicine, vincristine or cisplatin.  When the cells were
   returned to a normal oxygen environment, they lost resistance.  There
   was no correlation between the content of adriamycin and the development
   of adriamycin resistance induced by hypoxia.  There was no difference
   between the efflux of adriamycin from aerobic cells and that from
   hypoxia-treated cells.  The mRNA for P-glycoprotein was not detected in
   the hypoxia-treated cells.  These results suggest that hypoxia-induced
   drug resistance is different from P-glycoprotein associated multidrug
   resistance.}},
Publisher = {{STOCKTON PRESS}},
Address = {{HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{SRI INT,DIV LIFE SCI,CELL \& MOLEC BIOL LAB,MENLO PK,CA 94025.}},
DOI = {{10.1038/bjc.1991.405}},
ISSN = {{0007-0920}},
Keywords-Plus = {{CHINESE-HAMSTER CELLS; ASCITES TUMOR-CELLS; MULTIDRUG RESISTANCE;
   REGULATED PROTEINS; ENHANCED SYNTHESIS; CYTO-TOXICITY; OVARY CELLS;
   ADRIAMYCIN; DAUNORUBICIN; OXYGEN}},
Research-Areas = {{Oncology}},
Web-of-Science-Categories  = {{Oncology}},
Cited-References = {{BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6.
   GARMAN D, 1983, BIOCHEM PHARMACOL, V32, P3633, DOI 10.1016/0006-2952(83)90315-5.
   HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264.
   HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0.
   HUGHES CS, 1989, CANCER RES, V42, P4452.
   INABA M, 1979, CANCER RES, V39, P2200.
   KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059.
   KARTNER N, 1983, CANCER RES, V43, P4413.
   KINGSTON RE, 1988, CURRENT PROTOCOLS MO.
   LOFFLER M, 1983, FEBS LETT, V156, P72, DOI 10.1016/0014-5793(83)80251-8.
   RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0.
   RIORDAN JR, 1979, J BIOL CHEM, V254, P2701.
   SELDEN RF, 1988, CURRENT PROTOCOLS MO.
   SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278.
   SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284.
   SIROTNAK FM, 1986, J CELL PHYSIOL, V126, P266, DOI 10.1002/jcp.1041260217.
   SKOVSGAARD T, 1978, CANCER RES, V38, P4722.
   SMITH E, 1980, BRIT J CANCER, V41, P568.
   STREETER DG, 1986, CANCER CHEMOTH PHARM, V16, P247, DOI 10.1007/BF00293986.
   SUTHERLAND RM, 1982, INT J RADIAT ONCOL, V8, P745, DOI 10.1016/0360-3016(82)90726-X.
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290.
   SUTHERLAND RM, 1979, INT J RADIAT ONCOL, V5, P1225, DOI 10.1016/0360-3016(79)90643-6.
   TEICHER BA, 1981, CANCER RES, V41, P73.
   TEICHER BA, 1985, J NATL CANCER I, V75, P1129.
   THELANDER L, 1982, BIOCHEM BIOPH RES CO, V110, P859.
   ULLMAN B, 1979, MOL PHARMACOL, V15, P357.
   VALERIOTE F, 1984, PHARMACOL THERAPEUT, V24, P107, DOI 10.1016/0163-7258(84)90030-5.
   WILSON RE, 1989, J NATL CANCER I, V81, P1235, DOI 10.1093/jnci/81.16.1235.
   WILSON RE, 1989, INT J RADIAT ONCOL, V16, P957, DOI 10.1016/0360-3016(89)90895-X.}},
Number-of-Cited-References = {{29}},
Times-Cited = {{82}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{5}},
Journal-ISO = {{Br. J. Cancer}},
Doc-Delivery-Number = {{GN192}},
Unique-ID = {{ISI:A1991GN19200002}},
OA = {{gold\_or\_bronze}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991GN64300005,
Author = {FLEURETTE, J},
Title = {{STAPHYLOCOCCAL COMMUNITY-ACQUIRED RESPIRATORY-TRACT INFECTIONS}},
Journal = {{MEDECINE ET MALADIES INFECTIEUSES}},
Year = {{1991}},
Volume = {{21}},
Number = {{SI}},
Pages = {{27-33}},
Month = {{SEP}},
Note = {{SYMP ON ORAL ANTIBIOTHERAPY OF COMMUNITY ACQUIRED PULMONARY INFECTIONS :
   THE ROLE OF CEFUROXIME AXETIL, LONDON, ENGLAND, FEB 05-06, 1991}},
Abstract = {{Staphylococcus aureus is a causative agent of community-acquired
   respiratory tract infections.  Rhinopharyngeal carriage is relatively
   common and this must be taken into account in the microbiological
   diagnosis.  The frequency of pharyngitis and rhinopharyngitis due to S.
   aureus is therefore difficult to evaluate but is probably significant. 
   S. aureus is the most frequently encountered organism in paediatric
   bacterial tracheitis and is responsible for 2-7.5 \% of cases of acute
   sinusitis and 9 \% in acute otitis media.  Its involvement in pneumonia
   is increasing, particularly in the elderly and immunodepressed subject
   (1-14 \%, mean 4-5 \%).  Whether S. aureus is blood- or airborne is
   unknown, but it often superinfects viral lesions.  A number of cases of
   toxic shock syndrome have been reported during both benign and severe
   respiratory tract infections due to S. aureus.  Strains acquired in the
   community are generally sensitive to penicillinase-resistant antibiotics
   such as cefuroxime axetil.}},
Publisher = {{SOC FRANCAISE EDITION MED}},
Address = {{22-24 RUE DU CHATEAU RENTIERS, 75013 PARIS, FRANCE}},
Type = {{Article; Proceedings Paper}},
Language = {{French}},
Affiliation = {{FLEURETTE, J (Reprint Author), FAC MED ALEXIS CARREL,CTR NATL REFERENCE STAPHYLOCOQUES,RUE GUILLAUME PARADIN,F-69372 LYONS 08,FRANCE.}},
DOI = {{10.1016/S0399-077X(05)80470-6}},
ISSN = {{0399-077X}},
Keywords = {{STAPHYLOCOCCI; COMMUNITY-ACQUIRED RESPIRATORY TRACT INFECTIONS; TOXIC
   SHOCK-SYNDROME}},
Research-Areas = {{Infectious Diseases}},
Web-of-Science-Categories  = {{Infectious Diseases}},
Number-of-Cited-References = {{0}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Med. Mal. Infect.}},
Doc-Delivery-Number = {{GN643}},
Unique-ID = {{ISI:A1991GN64300005}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991EX24500010,
Author = {NOLAN, CM and ELARTH, AM and BARR, H and SAEED, AM and RISSER, DR},
Title = {{AN OUTBREAK OF TUBERCULOSIS IN A SHELTER FOR HOMELESS MEN - A
   DESCRIPTION OF ITS EVOLUTION AND CONTROL}},
Journal = {{AMERICAN REVIEW OF RESPIRATORY DISEASE}},
Year = {{1991}},
Volume = {{143}},
Number = {{2}},
Pages = {{257-261}},
Month = {{FEB}},
Abstract = {{An outbreak of tuberculosis at a shelter for homeless men was studied in
   detail to further the understanding of the epidemiology of tuberculosis
   in this setting.  The shelter provides evening accommodations for men
   aged 50 yr and older.  The capacity is approximately 200 clients, and
   the client pool is approximately 1,000 men/yr.  During a 6-wk period in
   December 1986 and January 1987, seven cases of tuberculosis were
   diagnosed in shelter clients.  Nine cases were reported in clients
   during the preceding 12 months, and four cases in the year previous to
   that.  The majority of outbreak cases were pulmonary tuberculosis,
   sputum smear positive.  Drug resistance was rare.  Phage typing of 15
   Mycobacterium tuberculosis isolates revealed one predominant type and
   four other types.  The goals of the control plan (and the steps taken to
   achieve them) were to render known infectious cases noninfectious
   (directly observed therapy); to find undiagnosed infectious cases
   (repetitive mass screenings); to protect exposed clients (repetitive
   tuberculin skin testing and isoniazid preventive therapy); and to make
   the shelter environment safe (exclude infectious, noncompliant clients
   and improve the shelter's ventilation system).  Implementation of this
   plan rapidly terminated the outbreak; following the first mass screening
   in January 1987, at which six asymptomatic cases were detected, only
   five additional cases occurred in shelter clients during a 2-yr period
   of follow-up.  The investigation suggested that the outbreak evolved
   during 1986 as a result of the presence at the shelter of an increasing
   number of men with undiagnosed infectious pulmonary tuberculosis. 
   Factors favoring disease transmission at the shelter were a relatively
   stable client pool, of which many were susceptible to tuberculosis;
   close proximity of bedding; and a closed ventilation system that
   provided extensive air recirculation during the winter months.  Clients
   with prior tuberculosis infection and disease were not protected from
   involvement in this outbreak.  The study suggests that at emergency
   shelters with a pattern of regular client usage, a program of ongoing
   tuberculosis control should be implemented to detect endemic cases, to
   limit the pool of clients with undiagnosed, infectious tuberculosis, and
   to prevent such outbreaks.}},
Publisher = {{AMER LUNG ASSOC}},
Address = {{1740 BROADWAY, NEW YORK, NY 10019}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{NOLAN, CM (Reprint Author), SEATTLE KING CTY DEPT PUBL HLTH,1200 PUBL SAFETY BLDG,SEATTLE,WA 98104, USA.
   UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195.
   UNIV WASHINGTON,SCH PUBL HLTH \& COMMUNITY MED,SEATTLE,WA 98195.}},
DOI = {{10.1164/ajrccm/143.2.257}},
ISSN = {{0003-0805}},
Keywords-Plus = {{UNITED-STATES}},
Research-Areas = {{Respiratory System}},
Web-of-Science-Categories  = {{Respiratory System}},
Funding-Acknowledgement = {{PHS HHS {[}CCU000510-04]}},
Cited-References = {{BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487.
   KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P150.
   MANTEL N, 1959, J NATL CANCER I, V22, P719.
   NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502.
   NAZAR V, 1990, American Review of Respiratory Disease, V141, pA438.
   PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7.
   RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385.
   RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286.
   SCHELLELBEIN CW, 1988, ARCH INTERN MED, V148, P1843.
   SHERMAN MN, 1980, NY MED Q, V2, P39.
   SLUTKIN G, 1986, PUBLIC HEALTH REP, V101, P481.
   SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436.
   SNIDER DE, 1984, AM REV RESPIR DIS, V130, P1095.
   SNIDER DE, 1989, PUBLIC HEALTH REP, V104, P646.
   Sommers HM, 1985, MANUAL CLIN MICROBIO, P216.
   STEAD WW, 1967, AM REV RESPIR DIS, V95, P729.
   STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304.
   SUTHERLAND I, 1972, B US TUBERCULOSIS, V47, P123.
   1987, MMWR, V36, P267.
   1985, MMWR, V34, P429.
   1989, MMWR, V38, P236.
   1989, MMWR, V38, P243.
   1981, AM REV RESPIR DIS, V123, P343.
   1981, AM REV RESPIR DIS, V124, P356.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{79}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{2}},
Journal-ISO = {{Am. Rev. Respir. Dis.}},
Doc-Delivery-Number = {{EX245}},
Unique-ID = {{ISI:A1991EX24500010}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991EZ43700003,
Author = {HEDIN, G and HAMBRAEUS, A},
Title = {{MULTIPLY ANTIBIOTIC-RESISTANT STAPHYLOCOCCUS-EPIDERMIDIS IN PATIENTS,
   STAFF AND ENVIRONMENT - A ONE-WEEK SURVEY IN A BONE-MARROW TRANSPLANT
   UNIT}},
Journal = {{JOURNAL OF HOSPITAL INFECTION}},
Year = {{1991}},
Volume = {{17}},
Number = {{2}},
Pages = {{95-106}},
Month = {{FEB}},
Publisher = {{W B SAUNDERS CO LTD}},
Address = {{24-28 OVAL RD, LONDON, ENGLAND NW1 7DX}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{HEDIN, G (Reprint Author), UNIV UPPSALA HOSP,DEPT CLIN BACTERIOL,BOX 552,S-75122 UPPSALA,SWEDEN.}},
DOI = {{10.1016/0195-6701(91)90173-6}},
ISSN = {{0195-6701}},
Keywords = {{STAPHYLOCOCCUS-EPIDERMIDIS; CROSS-INFECTION; AIRBORNE ROUTE; BONE MARROW
   TRANSPLANTATION; ANTIBIOGRAM}},
Keywords-Plus = {{COAGULASE-NEGATIVE STAPHYLOCOCCI; NASAL ACQUISITION; INFECTION; AUREUS;
   BACTEREMIA; OUTBREAK}},
Research-Areas = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Web-of-Science-Categories  = {{Public, Environmental \& Occupational Health; Infectious Diseases}},
Cited-References = {{BABB JR, 1983, J HOSP INFECT, V4, P149, DOI 10.1016/0195-6701(83)90044-0.
   BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513.
   CRUMPLIN GC, 1990, REV MED MICROBIOL, V1, P67.
   DAVIES RR, 1962, LANCET, V2, P1295.
   HAMBRAEU.A, 1973, J HYG-CAMBRIDGE, V71, P799, DOI 10.1017/S0022172400023068.
   HAMBRAEUS A, 1973, J HYG-CAMBRIDGE, V71, P787, DOI 10.1017/S0022172400023056.
   HARSTEINE AJ, 1987, J CLIN MICROBIOL, V25, P589.
   KINGDOM JCP, 1983, J HOSP INFECT, V4, P75, DOI 10.1016/0195-6701(83)90069-5.
   KNAPP CC, 1989, J CLIN MICROBIOL, V27, P2624.
   LIDWELL OM, 1971, J HYG-CAMB, V69, P113, DOI 10.1017/S002217240002132X.
   LIDWELL OM, 1975, J HYG-CAMBRIDGE, V75, P445, DOI 10.1017/S0022172400024505.
   LIDWELL OM, 1972, LANCET, V1, P347.
   LUDLAM HA, 1989, J MED MICROBIOL, V30, P161, DOI 10.1099/00222615-30-3-161.
   MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9.
   MICKELSEN PA, 1985, J INFECT DIS, V152, P50, DOI 10.1093/infdis/152.1.50.
   MORTIMER EA, 1966, BMJ-BRIT MED J, V1, P319, DOI 10.1136/bmj.1.5483.319.
   OPPENHEIM BA, 1989, BRIT MED J, V299, P294, DOI 10.1136/bmj.299.6694.294.
   SPEERS R, 1969, LANCET, V2, P233.
   STEVENS DL, 1984, J CLIN MICROBIOL, V20, P977.
   WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503.
   WATSON JG, 1983, J CLIN PATHOL, V36, P683, DOI 10.1136/jcp.36.6.683.
   WINSTON DJ, 1983, ARCH INTERN MED, V143, P32, DOI 10.1001/archinte.143.1.32.}},
Number-of-Cited-References = {{22}},
Times-Cited = {{25}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Hosp. Infect.}},
Doc-Delivery-Number = {{EZ437}},
Unique-ID = {{ISI:A1991EZ43700003}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991GT64800009,
Author = {ARREDONDOGARCIA, JL},
Title = {{THERAPEUTIC CONCEPTS IN DRUG PRESCRIBING FOR RESPIRATORY-TRACT INFECTION}},
Journal = {{DRUG INVESTIGATION}},
Year = {{1991}},
Volume = {{3}},
Number = {{3}},
Pages = {{33-37}},
Abstract = {{Respiratory tract infection (RTI) poses a serious threat to the health
   of patients in all age groups. Low birthweight, poor nutritional status,
   smoking, overcrowding and breathing polluted air may predispose one to
   the development of this disorder. While viruses are the main pathogens,
   different bacteria are involved in upper and lower RTI. When identifying
   the offending bacterial pathogen, one must take into account local
   antimicrobial resistance patterns. Selection of an appropriate
   antibiotic requires consideration of pharmacokinetic and pharmacodynamic
   properties and antibacterial activity to ensure the use of drugs that
   will aid patient compliance with the prescribed regimen. Additional
   factors in the decision of which antimicrobial to use include in vitro
   susceptibility, proven efficacy in controlled clinical trials, low cost,
   safety and good oral absorption. In this regard, macrolides,
   particularly the newer agents such as roxithromycin, may be considered
   effective therapy in RTI.}},
Publisher = {{ADIS INTERNATIONAL LTD}},
Address = {{41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW
   ZEALAND}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{ARREDONDOGARCIA, JL (Reprint Author), INST NACL PERINATOL,DEPT INFECT DIS \& IMMUNOL,MONTES URALES,800 5 PISO LOMAS VIRREYES,MEXICO CITY 11000,MEXICO.}},
DOI = {{10.1007/BF03258333}},
ISSN = {{0114-2402}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
ORCID-Numbers = {{Arredondo-Garcia, Jose Luis/0000-0001-6560-046X}},
Number-of-Cited-References = {{0}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{GT648}},
Unique-ID = {{ISI:A1991GT64800009}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991GT50400002,
Author = {HAYAKAWA, M and SADAKATA, T and KAJIURA, T and NONOMURA, H},
Title = {{NEW METHODS FOR THE HIGHLY SELECTIVE ISOLATION OF MICROMONOSPORA AND
   MICROBISPORA FROM SOIL}},
Journal = {{JOURNAL OF FERMENTATION AND BIOENGINEERING}},
Year = {{1991}},
Volume = {{72}},
Number = {{5}},
Pages = {{320-326}},
Abstract = {{Two plate culture methods for the highly selective isolation of the soil
   actinomycetes Micromonospora and Microbispora, are described, which
   utilize the differential antibiotic resistance of these microbes and the
   superior ability of their spores to withstand deleterious agents. (i) To
   isolate micromonosporae, a water suspension of air-dried soil is first
   treated with 1.5\% phenol, diluted with water and then cultured on HV
   agar supplemented with both tunicamycin and nalidixic acid. (ii) To
   isolate microbisporae, air-dried soil is heated in a hot-air oven at
   120-degrees-C for 1 h. A water suspension of the heated sample is then
   treated with a solution of 1.5\% phenol and 0.03\% chlorhexidine
   gluconate (CG), diluted and cultured on HV agar supplemented with
   nalidixic acid. The phenol pretreatment of the soil killed bacteria and
   streptomycetes in the samples, while keeping micromonosporae and
   microbisporae alive. The use of tunicamycin suppressed the growth of the
   remaining microbisporae on HV agar isolation plates, thereby
   facilitating the intensive isolation of micromonosporae. On the other
   hand, the dry heat treatment of the soil drastically reduced the number
   of bacteria in the sample and significantly reduced the numbers of
   streptomycetes and micromonosporae, without reducing the microbisporae
   content. Further treatment with a mixture of phenol and CG eliminated
   dry heat-resisting actinomycetes apart from microbisporae. Dilution
   plating of samples subjected to heat and the phenol-CG treatment
   resulted in the intensive isolation of microbisporae on HV agar. From
   various field soils (vegetable, orchard, corn, and rice paddy), the
   methods described above always enabled the highly selective isolation of
   micromonosporae and microbisporae, respectively, as each group accounted
   for more than 90\% of the total number of colonies recovered.}},
Publisher = {{SOC FERMENTATION BIOENGINEERING, JAPAN}},
Address = {{OSAKA UNIV, FACULTY ENGINEERING, 2-1 YAMADAOKA, SUITA, OSAKA 565, JAPAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{HAYAKAWA, M (Reprint Author), YAMANASHI UNIV,FAC ENGN,DEPT FERMENTAT TECHNOL,TAKEDA 4,KOFU,YAMANASHI 400,JAPAN.}},
DOI = {{10.1016/0922-338X(91)90080-Z}},
ISSN = {{0922-338X}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Cited-References = {{ANDERSON TF, 1951, T NEW YORK ACAD SCI, V13, P130, DOI 10.1111/j.2164-0947.1951.tb01007.x.
   Cross T., 1981, The prokaryotes. A handbook on habitats, isolation, and identification of bacteria. Volumes I and II, P2091.
   CROSS T, 1982, DEV IND MICROBIOL, V23, P1.
   GOODFELLOW M, 1988, ACTINOMYCETOLOGICA, V2, P13.
   HAYAKAWA M, 1982, HAKKOKOGAKU KAISHI, V60, P1.
   HAYAKAWA M, 1988, J FERMENT BIOENG, V66, P367, DOI 10.1016/0385-6380(88)90001-5.
   HAYAKAWA M, 1987, J FERMENT BIOENG, V65, P501, DOI 10.1016/0385-6380(87)90108-7.
   Hayakawa M., 1989, ACTINOMYCETOLOGICA, V3, P95.
   HO WC, 1986, J GEN MICROBIOL, V132, P2807.
   KALAKOUTSKII LV, 1973, ACTINOMYCETALES CHAR, P155.
   LAWRENCE C. H., 1956, CANADIAN JOUR BOT, V34, P44.
   Lechevaller H, 1981, PROKARYOTES HDB HABI, P1915.
   LYLOID AB, 1969, J GEN MICROBIOL, V56, P165.
   MAYFIELD C I, 1972, Soil Biology and Biochemistry, V4, P79, DOI 10.1016/0038-0717(72)90045-4.
   MIYADOH S, 1989, INT J SYST BACTERIOL, V39, P152, DOI 10.1099/00207713-39-2-152.
   NONOMURA H, 1969, J FERMENT TECHNOL, V47, P701.
   NONOMURA H, 1971, J FERMENT TECHNOL, V49, P895.
   NONOMURA H, 1969, J FERMENT TECHNOL, V47, P463.
   Nonomura H, 1960, J FERMENT TECHNOL, V38, P401.
   NONOMURA H, 1960, J FERMENT TECHNOL, V38, P405.
   ORCHARD VA, 1980, SOIL BIOL BIOCHEM, V12, P477, DOI 10.1016/0038-0717(80)90083-8.
   PISANO MA, 1987, APPL MICROBIOL BIOT, V27, P214.
   ROWBOTHAM TJ, 1977, J GEN MICROBIOL, V100, P231, DOI 10.1099/00221287-100-2-231.
   SPEER J R, 1969, Transactions of the Illinois State Academy of Science, V62, P265.
   WAKISAKA Y, 1982, J ANTIBIOT, V35, P822, DOI 10.7164/antibiotics.35.822.
   WILLIAMS ST, 1970, J GEN MICROBIOL, V62, P67, DOI 10.1099/00221287-62-1-67.}},
Number-of-Cited-References = {{26}},
Times-Cited = {{68}},
Usage-Count-Last-180-days = {{1}},
Usage-Count-Since-2013 = {{6}},
Journal-ISO = {{J. Ferment. Bioeng.}},
Doc-Delivery-Number = {{GT504}},
Unique-ID = {{ISI:A1991GT50400002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991GT50400003,
Author = {HAYAKAWA, M and KAJIURA, T and NONOMURA, H},
Title = {{NEW METHODS FOR THE HIGHLY SELECTIVE ISOLATION OF STREPTOSPORANGIUM AND
   DACTYLOSPORANGIUM FROM SOIL}},
Journal = {{JOURNAL OF FERMENTATION AND BIOENGINEERING}},
Year = {{1991}},
Volume = {{72}},
Number = {{5}},
Pages = {{327-333}},
Abstract = {{Two methods for the isolation of the rare actinomycetes
   Streptosporangium and Dactylosporangium in soil, are described. The
   methods use the ability of both the sporangiospores of Streptosporangium
   and tee globose bodies (the) of Dactylosporangium to withstand dry
   heating and treatment with benzethonium chloride (BC). In addition, the
   differential antibiotic resistance of these actinomycetes is also
   utilized. (i) To isolate streptosporangia, an air-dried soil sample is
   first subjected to dry heat treatment (120-degrees-C, 1 h). A water
   suspension of the heated sample is then treated with 0.01\% BC, diluted
   and cultured on HV agar supplemented with nalidixic acid and leucomycin.
   (ii) To isolate dactylosporangia, a water suspension of a soil sample
   given dry heat and 0.03\% BC treatment is cultured on HV agar
   supplemented with nalidixic acid and tunicamycin. The dry heat and BC
   treatment drastically eliminated bacteria and unwanted actinomycetes
   contaminants, including streptomycetes, from the isolation plates,
   thereby facilitating the selective isolation of streptosporangia and
   dactylosporangia. Nalidixic acid in HV agar was useful to suppress the
   growth of dry heat- and BC-resistant bacteria. The use of leucomycin and
   tunicamycin increased the selectivity of HV agar for streptosporangia
   and dactylosporangia, respectively, through elimination of the growth of
   unwanted actinomycetes which remained after the employment of
   pretreatments. From various field soils (vegetable, orchard, corn, and
   rice paddy), the methods described above consistently achieved the
   highly selective isolation of streptosporangia and dactylosporangia,
   respectively, as each group accounted for more than 20\% of the total
   number of colonies recovered.}},
Publisher = {{SOC FERMENTATION BIOENGINEERING, JAPAN}},
Address = {{OSAKA UNIV, FACULTY ENGINEERING, 2-1 YAMADAOKA, SUITA, OSAKA 565, JAPAN}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{HAYAKAWA, M (Reprint Author), YAMANASHI UNIV,FAC ENGN,DEPT FERMENTAT TECHNOL,TAKEDA 4,KOFU,YAMANASHI 400,JAPAN.}},
DOI = {{10.1016/0922-338X(91)90081-Q}},
ISSN = {{0922-338X}},
Research-Areas = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Web-of-Science-Categories  = {{Biotechnology \& Applied Microbiology; Food Science \& Technology}},
Cited-References = {{Cross T., 1973, Actinomycetales: characteristics and practical importance., P11.
   CROSS T, 1982, DEV IND MICROBIOL, V23, P1.
   ENSIGN JC, 1978, ANNU REV MICROBIOL, V32, P185, DOI 10.1146/annurev.mi.32.100178.001153.
   GOODFELLOW M, 1988, ACTINOMYCETOLOGICA, V2, P13.
   HAYAKAWA M, 1982, HAKKOKOGAKU KAISHI, V60, P1.
   HAYAKAWA M, 1988, J FERMENT BIOENG, V66, P367, DOI 10.1016/0385-6380(88)90001-5.
   HAYAKAWA M, 1987, J FERMENT BIOENG, V65, P501, DOI 10.1016/0385-6380(87)90108-7.
   Hayakawa M., 1989, ACTINOMYCETOLOGICA, V3, P95.
   HENSSEN A, 1971, International Journal of Systematic Bacteriology, V21, P29.
   HO WC, 1986, J GEN MICROBIOL, V132, P2807.
   KAWAMOTO I, 1975, J ANTIBIOT, V28, P358, DOI 10.7164/antibiotics.28.358.
   MAYFIELD C I, 1972, Soil Biology and Biochemistry, V4, P79, DOI 10.1016/0038-0717(72)90045-4.
   NONOMURA H, 1969, J FERMENT TECHNOL, V47, P701.
   NONOMURA H, 1969, J FERMENT TECHNOL, V47, P463.
   NONOMURA H, 1979, HAKKOKOGAKU KAISHI, V57, P79.
   NONOMURA H, 1989, BERGEYS MANUAL SYSTE, V4, P2545.
   OKUDA T, 1966, J ANTIBIOT, V19, P121.
   SHOMURA T, 1980, J ANTIBIOT, V33, P924, DOI 10.7164/antibiotics.33.924.
   SHOMURA T, 1985, INT J SYST BACTERIOL, V35, P1, DOI 10.1099/00207713-35-1-1.
   TAMURA A, 1971, J ANTIBIOT, V24, P270, DOI 10.7164/antibiotics.24.270.
   THIEMAN J. E., 1970, The Actinomycetales{''}. Jena International Symposium on Taxonomy, 1968., P245.
   Vobis G, 1989, BERGEYS MANUAL SYSTE, P2437.
   WAKSMAN SA, 1961, ACTINOMYCETES, P328.
   WILLIAMS ST, 1982, BIOACTIVE MICROBIAL, P9.}},
Number-of-Cited-References = {{24}},
Times-Cited = {{31}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{1}},
Journal-ISO = {{J. Ferment. Bioeng.}},
Doc-Delivery-Number = {{GT504}},
Unique-ID = {{ISI:A1991GT50400003}},
DA = {{2018-08-13}},
}

@article{ ISI:A1991GJ39900002,
Author = {JONES, GW and BAINES, L and GENTHNER, FJ},
Title = {{HETEROTROPHIC BACTERIA OF THE FRESH-WATER NEUSTON AND THEIR ABILITY TO
   ACT AS PLASMID RECIPIENTS UNDER NUTRIENT DEPRIVED CONDITIONS}},
Journal = {{MICROBIAL ECOLOGY}},
Year = {{1991}},
Volume = {{22}},
Number = {{1}},
Pages = {{15-25}},
Abstract = {{Significantly higher numbers of Gram-negative heterotrophic bacteria
   were present at the air-water interface (neuston) of freshwater lakes
   than in the bulk water.  Neuston bacteria were distinguished as a
   population distinct from bacteria in the bulk water by a higher
   incidence of pigmented colony types and significantly greater levels of
   multiple resistance to antibiotics and heavy metals.  The incidence of
   plasmids in 236 neuston and 229 bulk water strains were similar (14 and
   16.2\%, respectively).  Nine of 168 plasmid-free strains and 2 of 14
   plasmid carrying strains, isolated from both bulk water and neuston,
   acted as recipients of plasmid R68.45 in plate matings with a
   Pseudomonas aeruginosa donor strain PAO4032 at 21-degrees-C, but at
   frequencies below that of matings with a restriction-minus recipient
   strain of P. aeruginosa, strain PAO1168.  In a model system composed of
   nutrient-free synthetic lake water, plasmid R68.45 was shown to transfer
   between P. aeruginosa strains at frequencies between 10(-3) and 10(-5). 
   Transconjugants were detected about 100 times more frequently at the
   interface than in the bulk water, which in part reflected a greater
   enrichment of the donor at this site.  None of the aquatic isolates were
   able to act as recipients of plasmid R68.45 in this model system with
   strain PAO4032 as donor.  The results suggest that under nutrient
   deprived conditions, the spread of plasmid R68.45 and similar plasmids
   by lateral transfer into this particular aquatic population would be a
   rare event.}},
Publisher = {{SPRINGER VERLAG}},
Address = {{175 FIFTH AVE, NEW YORK, NY 10010}},
Type = {{Article}},
Language = {{English}},
Affiliation = {{JONES, GW (Reprint Author), UNIV MICHIGAN,DEPT MICROBIOL \& IMMUNOL,ANN ARBOR,MI 48109, USA.
   US EPA,ENVIRONM RES LAB,MICROBIAL ECOL \& BIOTECHNOL BRANCH,GULF BREEZE,FL 32561.}},
DOI = {{10.1007/BF02540210}},
ISSN = {{0095-3628}},
Keywords-Plus = {{PSEUDOMONAS-AERUGINOSA; WATER; STRAINS; RIVER; ENVIRONMENT; RESISTANCE;
   ENRICHMENT; DROPS}},
Research-Areas = {{Environmental Sciences \& Ecology; Marine \& Freshwater Biology;
   Microbiology}},
Web-of-Science-Categories  = {{Ecology; Marine \& Freshwater Biology; Microbiology}},
Cited-References = {{BALE MJ, 1988, APPL ENVIRON MICROB, V54, P972.
   BALE MJ, 1987, J GEN MICROBIOL, V133, P3099.
   BLANCHARD DC, 1981, LIMNOL OCEANOGR, V26, P961, DOI 10.4319/lo.1981.26.5.0961.
   BLANCHARD DC, 1982, APPL ENVIRON MICROB, V43, P1001.
   BRADLEY DE, 1985, J GEN MICROBIOL, V131, P2665.
   BURTON NF, 1982, APPL ENVIRON MICROB, V44, P1026.
   COLLINS VERA G., 1963, PROC SOC WATER TREATMENT AND EXAMINATION, V12, P40.
   GEALT MA, 1985, APPL ENVIRON MICROB, V49, P836.
   GENTHNER FJ, 1988, APPL ENVIRON MICROB, V54, P115.
   HAAS D, 1976, MOL GEN GENET, V144, P243, DOI 10.1007/BF00341722.
   HERMANSSON M, 1987, APPL ENVIRON MICROB, V53, P2338.
   JONES JG, 1986, J APPL BACTERIOL, V60, P443, DOI 10.1111/j.1365-2672.1986.tb05090.x.
   KADO CI, 1981, J BACTERIOL, V145, P1365.
   KING EO, 1954, J LAB CLIN MED, V44, P301.
   KJELLEBERG S, 1982, APPL ENVIRON MICROB, V43, P1166.
   KJELLEBERG S, 1987, ANNU REV MICROBIOL, V41, P25, DOI 10.1146/annurev.mi.41.100187.000325.
   KJELLEBERG S, 1979, MAR BIOL, V53, P21, DOI 10.1007/BF00386525.
   KJELLEBERG S, 1985, BACTERIAL ADHESION M, P163.
   KLEIN TM, 1986, APPL ENVIRON MICROB, V52, P114.
   Krieg N. R., 1984, BERGEYS MANUAL SYSTE, V1.
   NORKRANS B, 1980, ADV MICROB ECOL, V4, P51.
   OMORCHOE SB, 1988, APPL ENVIRON MICROB, V54, P1923.
   RAND MC, 1975, STANDARD METHODS EXA.
   ROSSMANN R, 1980, Journal of Great Lakes Research, V6, P47.
   STEWART KR, 1980, MAR POLLUT BULL, V11, P130, DOI 10.1016/0025-326X(80)90075-2.}},
Number-of-Cited-References = {{25}},
Times-Cited = {{27}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{4}},
Journal-ISO = {{Microb. Ecol.}},
Doc-Delivery-Number = {{GJ399}},
Unique-ID = {{ISI:A1991GJ39900002}},
DA = {{2018-08-13}},
}

@article{ ISI:A1980JP17200099,
Author = {CHAPON, JL and PITTELOUD, JJ and DUCEL, G},
Title = {{OCCURRENCE AND DRUG-RESISTANCE PATTERN OF AIR-BORNE GRAM-NEGATIVE
   BACILLI IN 2 HOSPITAL UNITS}},
Journal = {{EXPERIENTIA}},
Year = {{1980}},
Volume = {{36}},
Number = {{4}},
Pages = {{493}},
Publisher = {{BIRKHAUSER VERLAG AG}},
Address = {{PO BOX 133 KLOSTERBERG 23, CH-4010 BASEL, SWITZERLAND}},
Type = {{Meeting Abstract}},
Language = {{English}},
Affiliation = {{INST MICROBIOL APPL,CH-1203 GENEVE,SWITZERLAND.
   HOP CANTONAL,UNITE HYG HOSPIT LIERE,CH-1211 GENEVA 4,SWITZERLAND.}},
ISSN = {{0014-4754}},
Research-Areas = {{Science \& Technology - Other Topics}},
Web-of-Science-Categories  = {{Multidisciplinary Sciences}},
Number-of-Cited-References = {{0}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Journal-ISO = {{Experientia}},
Doc-Delivery-Number = {{JP172}},
Unique-ID = {{ISI:A1980JP17200099}},
DA = {{2018-08-13}},
}

@article{ ISI:A1972N056100015,
Author = {BAROYAN, OV and SHAGINYA.IA and ZUEVA, VS},
Title = {{ROLE OF ANTIBIOTICS USED UNDER VARIOUS CONDITIONS OF AIR SEMINATION WITH
   DRUG RESISTANT STAPHYLOCOCCI IN FORMATION OF RESISTANT MICROBIAL
   POPULATIONS IN MEN}},
Journal = {{ANTIBIOTIKI}},
Year = {{1972}},
Volume = {{17}},
Number = {{7}},
Pages = {{647-\&}},
Publisher = {{IZD VO MEDITSINA}},
Address = {{PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA}},
Type = {{Article}},
Language = {{Russian}},
ISSN = {{0301-5408}},
Research-Areas = {{Pharmacology \& Pharmacy}},
Web-of-Science-Categories  = {{Pharmacology \& Pharmacy}},
Cited-References = {{AOKAWA H, 1966, EXCEPTA MED INT C 19, P35.
   BARBER M, 1960, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.5165.11.
   BAROYAN OV, 1970, ANTIBIOTIKI, P845.
   CANETTI G, 1960, AM REV RESPIR DIS, V82, P295.
   CHISTOVICH GN, 1969, SANITARNAYA MIKROBIO, P263.
   CHISTOVICH GN, 1961, PATOGENEZ STAFILOKOK.
   CHORDI A, 1965, REV MED U NAVARRA, V9, P133.
   EHRENKRANTZ NJ, 1964, NEW ENGL J MED, V271, P225, DOI 10.1056/NEJM196407302710503.
   ERIKSEN KR, 1964, ACTA PATHOL MIC SC, V61, P154, DOI 10.1111/apm.1964.61.1.154.
   HELDELMANN G, 1966, DTSCH GESUNDH WES, V21, P294.
   LEBEDEVA MN, 1963, RUKOVODSTVO PRAKTICH, P135.
   NESTOPESCI N, 1961, ARCH ROUM PATH EXP, V3, P381.
   ROMANOVSKII VI, 1947, PRIMENENIYA MATEMATI.
   STEWART G T, 1963, Br Med J, V1, P308.
   STEWART GT, 1961, BRIT MED J, V1, P863, DOI 10.1136/bmj.1.5229.863.
   STILLE E, 1964, MUNCH MED WSCHR, V106, P1528.}},
Number-of-Cited-References = {{16}},
Times-Cited = {{0}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{N0561}},
Unique-ID = {{ISI:A1972N056100015}},
DA = {{2018-08-13}},
}

@article{ ISI:A1971K563600007,
Author = {BRETEY, J and JAHAN, MT},
Title = {{AIR TIGHT CULTURES OF MYOBACTERIA IN LIQUID MEDUM FOR ESTMATION OF
   ANTIBIOTIC RESISTANCE}},
Journal = {{ANNALES DE L INSTITUT PASTEUR}},
Year = {{1971}},
Volume = {{121}},
Number = {{3}},
Pages = {{349-\&}},
Publisher = {{MASSON EDITEUR}},
Address = {{120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE}},
Type = {{Article}},
Language = {{French}},
Research-Areas = {{General \& Internal Medicine; Microbiology}},
Web-of-Science-Categories  = {{Medicine, General \& Internal; Microbiology}},
Cited-References = {{ARMSTRONG AR, 1960, AM REV RESPIR DIS, V82, P881.
   BARCLAY WR, 1953, AM REV TUBERC PULM, V67, P490.
   BARTMANN K, 1966, B UN INT TUBERC, V37, P189.
   Bercea O, 1968, Tubercle, V49, P310, DOI 10.1016/0041-3879(68)90052-4.
   BOGDANESCU V, 1966, 9 C NAT TUB, P156.
   Bretey J, 1970, Bull Acad Natl Med, V154, P95.
   BRETEY J, 1945, ANN I PASTEUR PARIS, V71, P233.
   Bronfenbrenner J, 1939, J BACTERIOL, V37, P583.
   Burk D, 1934, J BACTERIOL, V27, P325.
   CANETTI G, 1963, Rev Tuberc Pneumol (Paris), V27, P217.
   COLETSOS PJ, 1951, PRESSE MED, V82, P1772.
   COLETSOS PJ, 1940, REV TUBERC PNEEMOL, V13, P344.
   CRONE P. B., 1963, MONTHLY BULL MIN HEALTH AND PUBL HEALTH LAB SERV, V22, P44.
   Ely JO, 1939, J BACTERIOL, V38, P391.
   ENGBAEK HC, 1967, SCAND J RESPIR DIS, V48, P268.
   FENNER F, 1951, AM REV TUBERC PULM, V64, P353.
   FISHER MW, 1952, AM REV TUBERC PULM, V66, P758.
   FISHER MW, 1952, J BACT, V62, P319.
   GINSBURG B, 1957, AM REV TUBERC PULM, V75, P688.
   Greig ME, 1941, J BACTERIOL, V41, P557.
   HOFFMANN FG, 1926, Z ANGEW CHEM, V39, P23.
   Jennison MW, 1940, J BACTERIOL, V39, P389.
   LAMENSANS A, 1967, ANN I PASTEUR PARIS, V112, P342.
   Le Lirzin M, 1969, Tubercle, V50, P182, DOI 10.1016/0041-3879(69)90024-5.
   Lefford M J, 1966, Tubercle, V47, P250, DOI 10.1016/S0041-3879(66)80003-X.
   LEGAM M, 1970, ANN I PASTEUR PARIS, V118, P158.
   LYON RH, 1961, AM REV RESPIR DIS, V83, P255.
   Meyerhof O, 1928, Z PHYS CHEM-STOCH VE, V139, P117.
   MONOD J, 1949, ANNU REV MICROBIOL, V3, P371, DOI 10.1146/annurev.mi.03.100149.002103.
   SCHAEFFER P, 1949, CR HEBD ACAD SCI, V228, P277.
   Schlayer C, 1936, J BACTERIOL, V31, P181.
   TSUKAMURA M, 1963, Kekkaku, V38, P166.
   WILSON, 1935, 206 MED RES COUN SPE.
   1965, B UN INT TUBERC, P189.}},
Number-of-Cited-References = {{34}},
Times-Cited = {{1}},
Usage-Count-Last-180-days = {{0}},
Usage-Count-Since-2013 = {{0}},
Doc-Delivery-Number = {{K5636}},
Unique-ID = {{ISI:A1971K563600007}},
DA = {{2018-08-13}},
}
